<SEC-DOCUMENT>0001193125-21-295543.txt : 20211008
<SEC-HEADER>0001193125-21-295543.hdr.sgml : 20211008
<ACCEPTANCE-DATETIME>20211008163853
ACCESSION NUMBER:		0001193125-21-295543
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		57
FILED AS OF DATE:		20211008
DATE AS OF CHANGE:		20211008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aura Biosciences, Inc.
		CENTRAL INDEX KEY:			0001501796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				320271970
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260156
		FILM NUMBER:		211315750

	BUSINESS ADDRESS:	
		STREET 1:		85 BOLTON STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		(617)500-8864

	MAIL ADDRESS:	
		STREET 1:		85 BOLTON STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d209588ds1.htm
<DESCRIPTION>S-1
<TEXT>
<HTML><HEAD>
<TITLE>S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October 8, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>Under </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>The Securities Act of 1933
</I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>AURA BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">32-0271970</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>85 Bolton Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, MA 02140 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">500-8864</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Elisabet de los Pinos, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>85
Bolton Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, MA 02140 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">500-8864</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Stuart Cable, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Danielle Lauzon, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Stephanie A. Richards,
Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>100 Northern
Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Boston, MA 02210</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Richard Segal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Divakar Gupta</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>500 Boylston Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Boston, MA
02116-3736</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">937-2300</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration statement.
</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the
Securities Act of 1933, as amended, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is
filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant
to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to
Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148;
&#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Accelerated&nbsp;Filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;Reporting&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of each Class&nbsp;of<BR>Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Offering&nbsp;Price(1)(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Registration Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common Stock, par value $0.00001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$100,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$9,270</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of
1933, as amended. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes the offering price of shares that the underwriters may purchase pursuant to an option to purchase additional
shares. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant
shall file&nbsp;a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this registration statement
shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#d6284a">The information in this preliminary prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#d6284a"><B>PRELIMINARY PROSPECTUS </B></FONT></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#d6284a"><B>SUBJECT TO COMPLETION, DATED OCTOBER&nbsp;8, 2021 </B></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g00c36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This is the
initial public offering of shares of our common stock.&nbsp;We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. Prior to this offering, there has been no public market for our common
stock. We have applied to list our common stock on the Nasdaq Global Market under the symbol &#147;AURA.&#148; We expect that the initial public offering price of our common stock will be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; under applicable Securities and Exchange Commission rules and will be subject
to reduced public company reporting requirements for this prospectus and future filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our business and investment in our common stock involves significant
risks. These risks are described under the caption &#147;<A HREF="#toc209588_4">Risk Factors</A>&#148; beginning on page&nbsp;13 of this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Neither
the Securities and Exchange Commission nor any state securities commission approved or disapproved of the securities that may be offered under this prospectus, nor have any of these organizations determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>Per&nbsp;Share</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>Total</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Public offering price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Underwriting discounts and commissions(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Proceeds, before expenses, to Aura Biosciences, Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See the section titled &#145;&#145;Underwriting&#146;&#146; for additional information regarding compensation payable to
the underwriters. We have agreed to reimburse the underwriters for certain expenses in connection with the offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have granted the
underwriters an option for a period of 30 days to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock from us at the public offering price, less the underwriting discounts and
commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the ordinary shares against payment on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Lead Manager </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>BTIG </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_2">THE OFFERING </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_3">SUMMARY FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_4">RISK FACTORS </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_8">CAPITALIZATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_9">DILUTION </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_11">MANAGEMENT &#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_12">BUSINESS </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_13">MANAGEMENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_14">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_15"><FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR
COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_16">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_17">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_18">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_19">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_20">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT STYLE="white-space:nowrap">NON-U.S.&nbsp;HOLDERS
</FONT> OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_21">UNDERWRITING </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_22">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_23">EXPERTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_24">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc209588_25">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than those contained in
this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to
the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information
contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business,
financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For investors outside the United States: We have not,
and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United
States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental
publications, reports by market research </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys, and studies generally indicate that their information has been
obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this prospectus, and we believe that these sources are
reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as
they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled &#147;Risk Factors&#148; and elsewhere in this
prospectus. Some data are also based on our good faith estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes included elsewhere in this prospectus. You should also consider, among
other things, the matters described under &#147;Business,&#148; &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case appearing elsewhere in this prospectus.
Unless the context otherwise requires, the terms &#147;Aura,&#148; &#147;Aura Biosciences,&#148; &#147;the Company,&#148; &#147;the Registrant,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; in this prospectus refer to Aura Biosciences,
Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biotechnology
company leveraging our novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Our proprietary platform enables the targeting of a broad
range of solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. Our VDCs are largely agnostic to tumor type and can recognize a surface marker,
known as heparan sulfate proteoglycans, or HSPGs, that are specifically modified and broadly expressed on many tumors. <FONT STYLE="white-space:nowrap">AU-011,</FONT> our first VDC candidate, is being developed for the first line treatment of
primary choroidal melanoma, a rare disease with no drugs approved. We have completed a Phase 1b/2 trial using intravitreal administration that has demonstrated a statistically significant growth rate reduction in patients with prior active growth
and high levels of tumor control with visual acuity preservation in a majority of patients, as assessed using clinical endpoints in alignment with feedback from the U.S. Food and Drug Administration, or the FDA. These data supported advancement into
a Phase 2 dose escalation trial, where we are currently evaluating suprachoroidal, or SC, administration of <FONT STYLE="white-space:nowrap">AU-011.</FONT> We plan to present six to twelve month safety and efficacy data from this trial in 2022, and,
if favorable, initiate a pivotal trial in the second half of 2022.<B><I> </I></B>We are also developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications and plan to file an IND in the United States in second
half of 2022 for choroidal metastases. Leveraging our VDCs&#146; broad tumor targeting capabilities, we also plan to initiate a Phase 1a trial in <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer, or NMIBC, our first <FONT
STYLE="white-space:nowrap">non-ophthalmic</FONT> solid tumor indication, in the second half of 2022.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our VDC Platform </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">VDCs are a novel class of drugs with a dual mechanism of action that promotes cancer cell death by both the delivery of the cytotoxic payload to generate
acute necrosis and by activating a secondary immune mediated response. VDCs are analogous to antibody-drug conjugates, or ADCs, another technology that employs a targeting moiety and a cytotoxic payload. We believe that our VDC platform has the
potential to serve as a backbone for a broad portfolio of targeted oncology therapeutics and has the following potential key advantages: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">A single VDC can deliver hundreds of cytotoxic molecules conjugated to its capsid proteins. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on the ability of VLPs to selectively recognize specifically modified and overexpressed HSPGs present on a large
number of tumor types, VDCs have the potential to be used broadly across a wide range of cancers with limited <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The VDCs have a high number of HSPG binding sites and this multi-valency permits the strong and selective binding to
tumor cells. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">VDCs have a dual mechanism of action, first by acute necrosis of the tumor cells, and subsequently by creating a highly
immunogenic milieu that induces an antitumor specific immune response leading to a more robust and durable therapy. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our goal is to leverage our platform to develop a new class of targeted therapies that bring therapeutic benefit to multiple cancer indications,
initially focusing on the field of ocular oncology. Our next area of focus, bladder cancer, is one of the most expensive cancers to treat on a per patient basis, and global market for bladder cancer is expected to reach $4.0 billion by 2028 across
the United States, EU5, and Japan. To date, we have produced a VDC, <FONT STYLE="white-space:nowrap">AU-011,</FONT> which we are advancing in multiple indications, as shown in the pipeline below. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g02x80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Solution &#150; <FONT STYLE="white-space:nowrap">AU-011</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">AU-011</FONT> consists of an <FONT STYLE="white-space:nowrap">HPV-derived</FONT> VLP conjugated to hundreds of infrared
laser-activated molecules. The VDC is designed in a way that prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. Laser activation of <FONT
STYLE="white-space:nowrap">AU-011</FONT> is designed to result in precise tumor cell killing with minimal damage to surrounding healthy tissues. In the absence of <FONT STYLE="white-space:nowrap">AU-011</FONT> activation or binding to the tumor cell
membrane, there is no cytotoxic effect. Multiple laser treatments, following a single dose of <FONT STYLE="white-space:nowrap">AU-011,</FONT> increase antitumor activity because of the reoxygenation of the tumor and the photostability of <FONT
STYLE="white-space:nowrap">AU-011.</FONT> Finally, acute necrosis triggers immunogenic cell death leading to the generation of an adaptive, long-term antitumor immune response. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">AU-011</FONT> for Ocular Oncology </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are initially developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of primary choroidal melanoma, a vision- and
life-threatening ocular cancer for which there are currently no drugs approved. Choroidal melanoma is the most common intraocular cancer in adults, with an incidence of 11,000 patients/year in the United States and Europe. It is estimated that 96%
of patients are diagnosed early without clinical evidence of metastatic disease. However, despite the current treatments with radiotherapy the long-term prognosis is poor with death occurring in more than 50% of cases. We intend to develop <FONT
STYLE="white-space:nowrap">AU-011</FONT> as a first line therapy to treat early-stage disease which includes small melanomas and indeterminate lesions representing approximately 9,000 patients/year in the United States and Europe. <FONT
STYLE="white-space:nowrap">AU-011</FONT> has been granted Orphan Drug designation for treatment of uveal melanoma and Fast Track designation for the treatment of choroidal melanoma by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In our completed Phase 1b/2 trial, <FONT STYLE="white-space:nowrap">AU-011,</FONT> administered by intravitreal injection, was well-tolerated and
demonstrated high levels of local tumor control while preserving vision at twelve months in patients that had prior active tumor growth. The therapeutic regimen of <FONT STYLE="white-space:nowrap">AU-011</FONT> achieved tumor shrinkage or a
near-zero growth rate in majority of patients and was associated with preservation of visual acuity in 71% of patients at twelve months. We are currently conducting a Phase&nbsp;2 dose escalation trial of
<FONT STYLE="white-space:nowrap">AU-011</FONT> with SC administration. We intend to initiate the first pivotal trial in the second half of 2022. Because our mechanism of action preserves key ocular structures, we also intend to develop <FONT
STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications, beginning with choroidal metastases. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">AU-011</FONT> for NMIBC </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we are developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of NMIBC. Bladder cancer is the most common malignancy
involving the urinary system and is the eighth most common cause of cancer death in men in the United States. While metastatic bladder cancer has several approved therapies, there are very limited options for the treatment of NMIBC. We are planning
to initiate clinical development of <FONT STYLE="white-space:nowrap">AU-011</FONT> with intramural administration, a novel route of administration, for the treatment of patients with intermediate and high-risk bladder cancer lesions. This novel
route of administration is intended to place high levels of the drug at the base of the tumor where laser activation of <FONT STYLE="white-space:nowrap">AU-011</FONT> can cause necrosis and prevent residual tumor cells from further growth and
recurrence. We have generated preclinical <I>in vivo</I> data that supports that our dual mechanism of action can lead to cytotoxicity and long-term antitumor immunity which may further reduce the risk of metastases. We believe this immune response
can play an even larger role in bladder cancer, given that bladder cancer has a well-documented response to immune activation. We are conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with
<FONT STYLE="white-space:nowrap">AU-011</FONT> and intend to begin clinical trials in second half of 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our goal is to leverage our proprietary platform to develop a new class of targeted therapies that bring therapeutic benefit to a broad range of cancer
indications with high unmet need where we believe we can establish a new standard of care. The key elements of our strategy include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Advance <FONT STYLE="white-space:nowrap">AU-011</FONT> through late-stage clinical development and, if approved,
commercialization for the first line treatment of primary choroidal melanoma. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Continue developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications, starting
with choroidal metastases. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Pursue development of <FONT STYLE="white-space:nowrap">AU-011</FONT> for our first
<FONT STYLE="white-space:nowrap">non-ophthalmic</FONT> solid tumor indication in NMIBC. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Broaden the application of our proprietary technology platform to expand our pipeline of product candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Evaluate and selectively enter into strategic collaborations to maximize the potential of our pipeline and accelerate the
development of our programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our team has extensive experience in the development of drugs in oncology and ophthalmology. Our CEO and founder, Elisabet de los Pinos, PhD, MBA, was
previously part of the marketing team that led the European commercialization of Alimta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of lung cancer at Eli Lilly. Cadmus Rich, MD, MBA, CPE, our Chief Medical Officer, a
board-certified ophthalmologist, has extensive experience in leading ophthalmology research and development at companies including Inotek, IQVIA and Alcon/Novartis. Julie Feder, our CFO, previously served as CFO at Verastem Oncology, the Clinton
Health Access Initiative and was instrumental in the integration of Genzyme and Sanofi. Mark De Rosch, PhD, our COO, was previously the Chief Regulatory Officer at Epizyme during which time Epizyme received FDA accelerated approval of its first
product in two oncology indications. Christopher Primiano, our CBO, led multiple strategic transactions during his prior tenure as CBO and General Counsel at Karyopharm Therapeutics, Inc., a commercial oncology company. The Chairman of our Board of
Directors is David Johnson, the former Chief Executive Officer at VelosBio Inc., a clinical-stage oncology company developing novel ADCs and bispecific antibodies that was acquired by Merck in 2020 for $2.75&nbsp;billion. Prior to founding VelosBio
Inc. he was the Chief Executive Officer at Acerta Pharma B.V. leading to its acquisition by AstraZeneca plc for $7&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since our
inception, we have raised approximately $218.5&nbsp;million from leading investors that include among others, Matrix Capital Management, Surveyor Capital (a Citadel company), </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Velosity Capital, Medicxi, Advent Life Sciences, Lundbeckfond Invest A/S, Arix Bioscience, Chiesi Ventures, Ysios Capital and Columbus Venture Partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to implement
our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in the section titled &#147;Risk Factors,&#148; immediately following this prospectus summary.
These risks include the following, among others: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are heavily dependent on the success of <FONT STYLE="white-space:nowrap">AU-011,</FONT> our only product candidate to
date. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the
foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for <FONT
STYLE="white-space:nowrap">AU-011,</FONT> we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if this offering is successful, we will require substantial additional capital to finance our operations. If we are
unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or terminate one or more of our research and development programs, future commercialization efforts, product development or other operations.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve our objectives
relating to the discovery, development and commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have not yet successfully initiated or completed any pivotal clinical trials nor commercialized any pharmaceutical
products, which may make it difficult to evaluate our future prospects. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we fail to develop additional product candidates, our commercial opportunity could be limited. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">AU-011</FONT> is a biologic that requires the use of a device, which may result in
additional regulatory risks. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Interim, <FONT STYLE="white-space:nowrap">&#147;top-line,&#148;</FONT> and preliminary data from our clinical trials that
we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates may cause or reveal significant adverse
events, toxicities or other undesirable side effects which may delay or prevent marketing approval. In addition, if we obtain approval for any of our product candidates, significant adverse events, toxicities or other undesirable side effects may be
identified during post-marketing surveillance, which could result in regulatory action or negatively affect our ability to market the product. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the
development and commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or a similar pandemic, epidemic, or outbreak of an
infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing,
and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even
recall or market </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory
requirements. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of <FONT
STYLE="white-space:nowrap">AU-011</FONT> and may continue to rely on CMOs for the production of commercial supply of <FONT STYLE="white-space:nowrap">AU-011,</FONT> if approved. This reliance on CMOs increases the risk that we will not have
sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or
commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates do not achieve broad market acceptance,
the revenue that we generate from their sales may be limited, and we may never become profitable. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our business operations and current and future relationships with investigators, healthcare professionals, consultants,
third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our ability to compete may decline if we do not adequately protect our proprietary rights, and our proprietary rights do
not necessarily address all potential threats to our competitive advantage. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to
become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of product candidates, prohibit our use of proprietary
technology or sale of potential products or put our patents and other proprietary rights at risk. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to pursue
our business strategy will be impaired, could result in loss of markets or market share and could make us less competitive. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to present a substantial
public health and economic challenge around the world, and to date has led to the implementation of various responses, including government-imposed quarantines,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stay-at-home</FONT></FONT> orders, travel restrictions, mandated business closures and other public health safety measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We continue to closely monitor the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on all aspects of our business, including how
it has and will continue to impact our operations and the operations of our suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition,
we have taken steps to minimize the current environment&#146;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of our employees and
families, we have introduced enhanced safety measures for scientists to be present in our labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. To date, we&#146;ve only
encountered minor delays in our manufacturing process due to a supply chain constraint with one of our vendors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Beyond the impact on our pipeline,
the extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> ultimately impacts our business, results of operations and financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with
confidence, such as the duration of the outbreak, the emergence of new variants, new information that may emerge concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the effectiveness of actions taken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, including vaccination campaigns, among others. If we or any of the third
parties with whom we engage, however, were to experience any additional shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively
affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> it is possible
that our clinical development timelines could be negatively affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which could materially and adversely affect our business, financial condition and results of operations. See &#147;Risk
Factors&#148; for a discussion of the potential adverse impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate History </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were incorporated under the laws of the
State of Delaware in January 2009. Our principal corporate office is located at 85 Bolton Street, Cambridge, MA 02140, and our telephone number is (617) <FONT STYLE="white-space:nowrap">500-8864.</FONT> Our website address is
www.aurabiosciences.com. We do not incorporate the information on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We own various U.S. federal trademark applications and unregistered trademarks, including our company name. All other trademarks or trade names referred
to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended. As an emerging growth
company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being permitted to only disclose two years of audited financial statements in addition to any required unaudited interim
financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden
parachute arrangements not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, in
the assessment of our internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may take advantage of these exemptions until the fifth
anniversary of our initial public offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which
we have total annual gross revenue of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than
$1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the last day of the fiscal year in which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which
means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the prior June&nbsp;30th. We may choose to take advantage of
</P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the
information you receive from other public companies in which you hold stock. We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an
emerging growth company, we may rely on certain of these exemptions, including without limitation, providing an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404(b) of the
Sarbanes-Oxley Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148; as defined under the Securities Act and Exchange Act. We may continue to be
a smaller reporting company so long as either (i)&nbsp;the market value of shares of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than
$100&nbsp;million during the most recently completed fiscal year and the market value of shares of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting company
at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to
present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and have reduced disclosure obligations regarding executive compensation, and, similar to
emerging growth companies, if we are a smaller reporting company under the requirements of (ii)&nbsp;above, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered
public accounting firm. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their over-allotment option in full). </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Over-allotment option </P></TD>
<TD>We have granted the underwriters an option, exercisable for 30 days after the date of this prospectus, to purchase up to&nbsp;additional shares from us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that our net proceeds to us from the sale of shares of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise in full their over-allotment option, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is
the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering
to fund clinical development of our initial product candidate, <FONT STYLE="white-space:nowrap">AU-011,</FONT> continued investment in our platform and for working capital and general corporate purposes. See &#147;Use of Proceeds&#148; for
additional information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD>AURA </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on 315,235,788&nbsp;shares of our
common stock outstanding as of June&nbsp;30, 2021, which assumes the automatic conversion of all of our outstanding shares of preferred stock into an aggregate of 308,946,244 shares of common stock upon the completion of this offering, and excludes:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">39,848,939 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2021, at a
weighted average exercise price of $0.34 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
reserved for future issuance under our 2021<B> </B>Stock Option and Incentive Plan, or 2021 Plan, which will become effective in connection with the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
reserved for future issuance under our 2021<B> </B>Employee Stock Purchase Plan, or ESPP, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Except as otherwise indicated, all information in this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the conversion of all Class&nbsp;A common stock and Class&nbsp;B common stock into shares of common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 308,946,244 shares of our
common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance of 173,827 shares of Series B convertible preferred stock upon the exercise of the outstanding preferred stock
warrants subsequent to June&nbsp;30, 2021, which will convert into 173,827 shares of our common stock upon completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance and sale of 50,000 shares of common stock on August 2, 2021 to Elisabet de los Pinos, our CEO, pursuant to an
option exercise, with an exercise price of $0.40 per common share. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance and sale of 30,000 and 20,000 shares of common stock on October&nbsp;5, 2021 to a holder of our convertible
preferred stock, pursuant to an option exercise, with an exercise price of $0.42 and $0.40 per share of common stock, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">except as expressly outlined above, no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise by the underwriters of their option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT> reverse split of our common stock, which will become effective
prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing of our tenth amended and restated certificate of incorporation and the adoption of our amended and restated
bylaws, which will occur immediately prior to the completion of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_3"></A>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">You should read the following summary financial data together with our financial statements and the related notes appearing elsewhere in this prospectus
and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. We have derived the statement of operations data for the years ended December&nbsp;31, 2020 and 2019 from our
audited financial statements appearing elsewhere in this prospectus. The statement of operations data for the six months ended June&nbsp;30, 2021 and 2020 and the balance sheet data as of June&nbsp;30, 2021 have been derived from our unaudited
financial statements appearing elsewhere in this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited data reflect all adjustments, consisting only of normal recurring
adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of results that should be expected in any future period, and our results for any interim period are
not necessarily indicative of results that should be expected for any full year. The summary financial data included in this section are not intended to replace the audited financial statements and the related notes included elsewhere in this
prospectus and are qualified in their entirety by the financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six Months<BR>Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income (expense), including amortization of discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net loss and comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average shares used to compute net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,741,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,872,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,031,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,634,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share of common stock attributable to common stockholders (unaudited), basic
and<BR>diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted average shares of common stock (unaudited), basic and diluted(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,051,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,345,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See Note 13 to our financial statements appearing elsewhere in this prospectus for details on the calculation of basic
and diluted net loss per share. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The unaudited pro forma basic and diluted weighted-average shares of common stock outstanding used in the calculation of
unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the six months ended June&nbsp;30, 2021 and year ended December&nbsp;31, 2020 have been prepared to reflect (i)&nbsp;the issuance of 173,827 shares of
Series&nbsp;B convertible preferred stock upon the exercise of the outstanding preferred stock warrants subsequent to June&nbsp;30, 2021, and (ii)&nbsp;the automatic conversion of all shares of our convertible preferred stock, including the
preferred stock warrants described above in (i), into common stock immediately prior to the closing of this offering, as if this offering had occurred on the later of the beginning of each period or the issuance date of the convertible preferred
stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth summary balance sheet data as of June&nbsp;30, 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the automatic conversion of all outstanding shares of our preferred stock
into an aggregate of 308,946,244 shares of common stock immediately prior to the completion of this offering; (ii)&nbsp;the issuance of 173,827 shares of Series&nbsp;B convertible preferred stock upon the exercise of the outstanding preferred stock
warrants subsequent to June&nbsp;30, 2021, which will convert into 173,827 shares of our common stock upon completion of this offering; (iii)&nbsp;the issuance and sale of 50,000 shares of common stock on August&nbsp;2, 2021 to Elisabet de los
Pinos, our CEO, pursuant to an option exercise, with an exercise price of $0.40 per share; (iv)&nbsp;the issuance and sale of 30,000 and 20,000 shares of common stock on October&nbsp;5, 2021 to a holder of our convertible preferred stock, pursuant
to an option exercise, with an exercise price of $0.42 and $0.40 per share of common stock, respectively; and (v)&nbsp;the filing and effectiveness of our tenth amended and restated certificate of incorporation upon the closing of this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give effect to (i)&nbsp;the pro forma adjustments described above and (ii)&nbsp;our
issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma as<BR>Adjusted<BR>(unaudited)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount
of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; deficit by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares
offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
expenses payable by us. A 1.0&nbsp;million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro
forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; deficit by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming
no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. This information is illustrative only and will depend on the actual
initial public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully read and consider all of the risks described below, as well as the
other information in this prospectus, including our financial statements and the related notes and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; before deciding whether to
invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. Unless otherwise indicated, references to our business being
harmed in these risk factors will include harm to our business, reputation, financial condition, results of operations and future prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your
investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Financial Position, and Additional Capital Needs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Investment in biotechnology product development is highly speculative because it entails substantial upfront capital expenditures and significant risk
that a product candidate will fail to gain regulatory approval or fail to become commercially viable. Our net losses were $14.8&nbsp;million and $13.7&nbsp;million for the six months ended June&nbsp;30, 2021 and 2020, respectively, and
$22.2&nbsp;million and $24.2&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively. As of June&nbsp;30, 2021, we had an accumulated deficit of $131.7&nbsp;million. Substantially all of our net losses have resulted from costs
incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our research and development expenses to increase significantly as we continue clinical development
for <FONT STYLE="white-space:nowrap">AU-011</FONT> and continue to discover and develop additional product candidates. In addition, if we obtain regulatory approval for our product candidates, we will incur significant sales, marketing and
manufacturing expenses. After this offering, we will incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of
the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. We have no products approved for commercial sale and
therefore have never generated any revenue from product sales, and we do not expect to in the foreseeable future. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from any product sales. We
have no products approved for commercial sale, and do not anticipate generating any revenue from product sales until after we have received marketing approval for the commercial sale of a product candidate, if ever. Our ability to generate revenue
and achieve profitability depends significantly on our success in achieving a number of goals, including:&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiating and completing research regarding, and preclinical and clinical development of,
<FONT STYLE="white-space:nowrap">AU-011</FONT> in primary choroidal melanoma and, additional oncology indications, other research programs from our VDC technology platform and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining marketing approval for <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates for which
we complete clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">transferring our manufacturing process to a commercial contract development and manufacturing organization for <FONT
STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates, including establishing and maintaining commercially viable supply and manufacturing relationships with third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">launching and commercializing <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates for which we
obtain marketing approvals, either directly or with a collaborator or distributor; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining market acceptance of <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates as viable
treatment options; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying, assessing, acquiring and developing new product candidates from our VDC technology platform;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining, maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade
secrets, and <FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">attracting, hiring, and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates that we develop are approved for commercial sale, we anticipate
incurring significant costs associated with commercializing any such product candidate. Our expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities to change our manufacturing processes
or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we are successful
in obtaining regulatory approvals to market <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain marketing
approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication
approved by regulatory authorities is narrower than we expect, the labels for <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates contain significant safety warnings, regulatory authorities impose burdensome or
restrictive distribution requirements, or the reasonably accepted patient population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if
approved. If we are not able to generate revenue from the sale of any approved products, we could be prevented from or significantly delayed in achieving profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and
remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our operations. A decline in
the value of our company could also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if this offering is successful, we will require substantial
additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or terminate one or more of our research and development programs, future commercialization
efforts, product development or other operations. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since our inception, we have used substantial amounts of cash to fund our operations, and
our expenses will increase substantially in the foreseeable future in connection with our ongoing activities, particularly as we continue the research and development of, initiate and complete clinical trials of, and seek marketing approval for <FONT
STYLE="white-space:nowrap">AU-011.</FONT> Identifying and developing pharmaceutical products, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Even if one or more of
<FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with sales, marketing, manufacturing and distribution activities.
Our expenses could increase beyond expectations if we are required by the FDA, the EMA, or other regulatory agencies to perform clinical trials or preclinical studies in addition to those that we are currently conducting or anticipate. Other
unanticipated costs may also arise. Because the design and outcome of our current and planned clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully
complete the development and commercialization of <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates that we develop. Following this offering, we also expect to incur additional costs associated with operating as a
public company. Accordingly, we will need to obtain substantial additional funding in order to continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on our current
operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditures
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Advancing the development of <FONT STYLE="white-space:nowrap">AU-011</FONT> and other research programs will require a significant amount of
capital. The net proceeds from this offering, together with our existing cash and cash equivalents, will not be sufficient to fund <FONT STYLE="white-space:nowrap">AU-011</FONT> through regulatory approval, and we anticipate needing to raise
additional capital to complete the development of and commercialize <FONT STYLE="white-space:nowrap">AU-011.</FONT> Our estimate as to how long we expect our existing cash and cash equivalents, together with the net proceeds from this offering, to
fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume
capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will be required to
obtain further funding through public or private equity financings, debt financings, collaborative agreements, licensing arrangements or other sources of financing, which may dilute our stockholders or restrict our operating activities. We do not
have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Any additional fundraising efforts may divert our management from their day to day activities, which may adversely
affect our ability to develop and commercialize product candidates. Disruptions in financial markets in general or more recently due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may make equity and debt financing more difficult
to obtain and may have a material adverse effect on our ability to meet our fundraising needs. To the extent that we raise additional capital through the sale of equity or convertible debt securities, each investor&#146;s ownership interests will be
diluted, and the terms may include liquidation or other preferences that adversely affect each investor&#146;s rights as a stockholder. Debt financing may result in imposition of debt covenants, increased fixed payment obligations or other
restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or
grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.
Attempting to secure additional financing may divert our management from our day to day activities, which may adversely affect our ability to commercialize <FONT STYLE="white-space:nowrap">AU-011</FONT> if and when approved and develop our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our
ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our clinical trials, research and development programs, future commercialization efforts or other operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require
us to relinquish proprietary rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not have any committed external source of funds or
other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may
never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we
raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#146; rights. Further, to the extent that we raise additional
capital through the sale of common stock or securities convertible or exchangeable into common stock, existing stockholder ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations and execute our
business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or
licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also
could be required to seek commercial or development partners for our lead products or any future product candidate at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise
would seek to develop or commercialize ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve
our objectives relating to the discovery, development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We rely on our team&#146;s expertise
in drug discovery, translational research and patient-driven precision medicine to develop our product candidates. Our business depends significantly on the success of this engine and the development and commercialization of the product candidates
that we discover with this engine. We have no products approved for commercial sale and do not anticipate generating any revenue from product sales in the near term, if ever. Our ability to generate revenue and achieve profitability depends
significantly on our ability to achieve several objectives, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful and timely completion of preclinical and clinical development of <FONT STYLE="white-space:nowrap">AU-011</FONT>
in primary choroidal melanoma and additional oncology indications, other research programs from our VDC technology platform, and any other future programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for the
clinical development of <FONT STYLE="white-space:nowrap">AU-011,</FONT> other research programs from our VDC technology platform, and any other future programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we
successfully complete clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Transferring our manufacturing process to a commercial CDMO, including obtaining finished products that are appropriately
packaged for sale; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide
adequate, in both amount and quality, products and services to support clinical development and meet the market demand for our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful commercial launch following any marketing approval, including the development of a commercial infrastructure,
whether <FONT STYLE="white-space:nowrap">in-house</FONT> or with one or more collaborators; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a continued acceptable safety profile following any marketing approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">commercial acceptance of our product candidates by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfying any required post-marketing approval commitments to applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying, assessing and developing new product candidates from our VDC technology platform; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the
United States and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">defending against third-party interference or infringement claims, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to
develop, manufacture or commercialize our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining coverage and adequate reimbursement by third-party payors for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">addressing any competing therapies and technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve
profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability
to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to
the Discovery and Development of our Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are heavily dependent on the success of <FONT STYLE="white-space:nowrap">AU-011,</FONT> our
only product candidate to date. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently have no products that are approved for commercial sale and may never be able to develop
marketable products. We expect that a substantial portion of our efforts and expenditures over the next several years will be devoted to development of <FONT STYLE="white-space:nowrap">AU-011</FONT> in multiple oncology indications, which is
currently our only product candidate. Accordingly, our business currently depends heavily on the successful development, regulatory approval, and commercialization of <FONT STYLE="white-space:nowrap">AU-011.</FONT> We can provide no assurance that <FONT
STYLE="white-space:nowrap">AU-011</FONT> will receive regulatory approval or be successfully commercialized even if we receive regulatory approval. If we were required to discontinue development of <FONT STYLE="white-space:nowrap">AU-011</FONT> or
if <FONT STYLE="white-space:nowrap">AU-011</FONT> does not receive regulatory approval or fails to achieve significant market acceptance, we would be delayed by many years in our ability to achieve profitability, if ever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The research, testing, manufacturing, safety, efficacy, recordkeeping, labeling, approval, licensure, sale, marketing, advertising, promotion and
distribution of <FONT STYLE="white-space:nowrap">AU-011</FONT> is, and will remain, subject to comprehensive regulation by the FDA and foreign regulatory authorities. Failure to obtain regulatory approval for
<FONT STYLE="white-space:nowrap">AU-011</FONT> in the United States, Europe and other major markets around the world will prevent us from commercializing and marketing <FONT STYLE="white-space:nowrap">AU-011</FONT> in such jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if we were to successfully obtain approval from the FDA and foreign regulatory authorities for <FONT STYLE="white-space:nowrap">AU-011,</FONT> any
approval might contain significant limitations related to use, including limitations on the stage or type of cancer <FONT STYLE="white-space:nowrap">AU-011</FONT> is approved to treat, as well as restrictions for specified age groups, warnings,
precautions or contraindications, or requirement for a risk evaluation and mitigation strategy, or REMS. Any such limitations or restrictions could similarly impact any supplemental marketing approvals we may obtain for <FONT
STYLE="white-space:nowrap">AU-011.</FONT> Furthermore, even if we obtain regulatory approval for <FONT STYLE="white-space:nowrap">AU-011,</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we will still need to develop a commercial infrastructure or develop relationships with collaborators to commercialize, establish a commercially viable pricing structure and obtain coverage and
adequate reimbursement from third-party payors, including government healthcare programs. If we, or any future collaborators, are unable to successfully commercialize <FONT STYLE="white-space:nowrap">AU-011,</FONT> we may not be able to generate
sufficient revenue to continue our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for <FONT
STYLE="white-space:nowrap">AU-011,</FONT> we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety,
efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities
in other countries. Before we can commercialize any of our product candidates, we must obtain marketing approval. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction and it is
possible that none of our product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. We, as a company, have no experience in filing and supporting the applications necessary to gain
regulatory approvals and have had to, and expect to continue to have to, rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical
data and supporting information to the various regulatory authorities for each therapeutic indication to establish the drug candidate&#146;s safety and efficacy. Securing regulatory approval also requires the submission of information about the drug
manufacturing process to, and inspection of manufacturing facilities and clinical sites by the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or
unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are
required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development
period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted Investigational New Drug application, or IND, Premarket Approval, or PMA, biologics license application, or BLA, or
equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may
decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Because the activity of <FONT STYLE="white-space:nowrap">AU-011</FONT> in ocular melanoma requires a drug delivery device and
activation by a laser, the regulatory complexity of the product candidate is greater than for products that don&#146;t utilize a device, which creates uncertainties in the requirements for regulatory approval. Our product candidates could be delayed
in receiving, or fail to receive, regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product
candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign
regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies
or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an BLA
or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or those
of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Of the large number of drugs in development, only a small
percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process, as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory
approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our VDC product
candidates are based on a technology that we are in the process of developing. We expect the novel nature of such product candidates to create further challenges in obtaining regulatory approval. As a result, our ability to develop product
candidates and obtain regulatory approval may be significantly impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA may also require a panel of experts, referred to as an Advisory
Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain approval of any product candidates that
we develop based on the completed clinical trials. Additionally, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the conduct of Advisory Committee meetings may be disrupted or delayed and the impact that may have on the overall
timing of regulatory approvals is uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product
candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product
candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for
our product candidates may be harmed and our ability to generate revenues will be materially impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have not yet successfully initiated or completed
any pivotal clinical trials nor commercialized any pharmaceutical products, which may make it difficult to evaluate our future prospects. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our operations to date have been limited to financing and staffing our company, developing our technology and conducting preclinical research and Phase 1
and Phase 2 clinical trials for our product candidates, primarily related to our <FONT STYLE="white-space:nowrap">AU-011</FONT> program. We have not yet demonstrated an ability to successfully initiate or complete pivotal clinical trials, obtain
marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Furthermore, we may conduct our first
pivotal trial based on an adaptive design, which could increase the time spent on or costs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
associated with this trial. We are in the process of transferring our intended commercial manufacturing process to our intended external contract development and manufacturing organization, or
CDMO, commercial manufacturing site. During this transfer process, some modifications may be needed to ensure manufacturability and ability to <FONT STYLE="white-space:nowrap">scale-up</FONT> the process to commercial batch sizes. We intend to
perform an analytical comparability assessment between the current clinical process and the intended commercial process, however, if this analytical process comparability assessment is unsuccessful, clinical comparability may be required, which may
result in delayed regulatory approval. We do not anticipate a change in formulation. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by clinical-stage
biopharmaceutical companies such as ours. Any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing
pharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to develop additional product candidates, our commercial opportunity could be limited. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect to focus our resources on the development of <FONT STYLE="white-space:nowrap">AU-011</FONT> in the near term. Developing, obtaining marketing
approval for, and commercializing any future product candidates will require substantial additional funding and will be subject to the risks of failure inherent in drug product development. We cannot assure you that we will be able to successfully
advance any future product candidates through the development process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if we obtain approval from the FDA or comparable foreign regulatory
authorities to market any future product candidates for any indication, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially
available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may
be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">AU-011</FONT> is a biologic that requires the use of a device, which may result in additional
regulatory risks. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">AU-011</FONT> is a novel biologic for which the intended use requires activation by a
laser, which is regulated as a medical device. We plan to file a single BLA for the review and approval of this combination in our initial target indication of choroidal melanoma, but subsequent indications and delivery systems may require different
or additional applications for marketing authorization. There may be additional regulatory risks for biologic-device combination products. We may experience delays in obtaining regulatory approval of <FONT STYLE="white-space:nowrap">AU-011</FONT>
given the increased complexity of the review process when approval of the product and a delivery device is sought under a single marketing application. In the United States, each component of a combination product is subject to the requirements
established by the FDA for that type of component, whether a drug, biologic or device. The laser component will be subject to FDA design control device requirements which comprise among other things, design verification, design validation, and
testing to assess performance, cleaning, and robustness. Delays in or failure of the studies conducted by us, or failure of our company, our collaborators, if any, or our third-party providers or suppliers to maintain compliance with regulatory
requirements could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in <FONT STYLE="white-space:nowrap">AU-011</FONT> reaching the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common
that various aspects of the development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
program, such as manufacturing methods and formulation, may be altered along the way in an effort to optimize processes and results. For example, we are planning to use Phase 2 drug product to
initiate our first pivotal study and transitioning to the intended commercial drug product as soon as it available to conduct the second planned pivotal study. Such changes to a product candidate carry the risk that they will not achieve the
intended objectives of optimizing the performance of the candidate. Any such changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the
materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay or prevent completion of clinical trials, require conducting bridging clinical trials or the
repetition of one or more clinical trials, increase clinical trial costs, delay or prevent approval of our product candidates and jeopardize our ability to commence sales and generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or
prevented. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a
sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities, or as needed to provide appropriate statistical power for a given trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, our competitors may in the future commence clinical trials for product candidates that treat the same indications as our product
candidates, and patients who would otherwise be eligible for our clinical trials may choose instead to enroll in clinical trials of our competitors. Furthermore, our ability to enroll patients may be significantly delayed by the evolving <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and we cannot accurately predict the extent and scope of such delays at this point. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit or
enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and
availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies and
obtaining regulatory approval of potential products may be delayed. Our lead indication of Choroidal Melanoma is a rare disease and as such clinical trial recruitment estimates may be inaccurate and such recruitment may take longer than expected.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Patient enrollment may be affected by other factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinicians&#146; and patients&#146; awareness of, and perceptions as to the potential advantages and risks of <FONT
STYLE="white-space:nowrap">AU-011</FONT> in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efforts to obtain and maintain patient consents and facilitate timely enrollment in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">competing studies or trails with similar eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reporting of the preliminary results of any of our clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">factors we may not be able to control, including the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, that may limit patients, principal investigators or staff or clinical site availability. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may in the future conduct clinical trials for current or future product candidates outside the United States,
and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may in the future choose to conduct one
or more clinical trials outside the United States, including in Europe. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be
subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on
the basis of foreign data alone unless (i)&nbsp;the data are applicable to the U.S. population and U.S. medical practice; (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to Good Clinical Practices,
or GCP, regulations; and (iii)&nbsp;the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate
the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as
support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign
regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any
comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for
additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we receive marketing approval for our current or future product candidates in the United States, we may never receive regulatory approval to market our
current or future product candidates outside of the United States. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We plan to seek regulatory approval of our current or future product
candidates outside of the U.S. Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For example, even if the FDA grants marketing approval of a product candidate, we may not obtain approvals in other jurisdictions, and comparable
regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining marketing approval in one
jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among countries and can involve additional product candidate testing and administrative review periods different from those in the United
States. The time required to obtain approvals in other countries might differ substantially from that required to obtain FDA approval. The marketing approval processes in other countries generally implicate all of the risks detailed above regarding
FDA approval in the U.S. as well as other risks. In particular, in many countries outside of the U.S., products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can result in
substantial delays in bringing products to market in such countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Obtaining foreign regulatory approvals and establishing and maintaining
compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with
regulatory requirements in international markets or fail to receive applicable marketing approvals, it would reduce the size of our potential market, which could have a material adverse impact on our business, results of operations and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The results of preclinical studies and early clinical trials may not be predictive of future results.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials. <FONT
STYLE="white-space:nowrap">AU-011</FONT> and any other product candidates we may develop may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through
initial clinical trials. For example, <FONT STYLE="white-space:nowrap">AU-011</FONT> may not be effective at slowing or arresting tumor growth or may not preserve visual acuity in later stage trials.&nbsp;Even if
<FONT STYLE="white-space:nowrap">AU-011</FONT> successfully slows or arrests tumor growth, this may not result in overall improved patient survival. Additionally, any positive results generated in our ongoing clinical trials and preclinical studies
would not ensure that we will achieve similar results in larger, pivotal clinical trials or in clinical trials of <FONT STYLE="white-space:nowrap">AU-011</FONT> in broader patient populations. Many companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials, and we cannot be certain that we will not face similar setbacks. Moreover,
preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed
to obtain marketing approval of their products. Furthermore, the failure of any product candidate to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of any other product candidates then under development
and/or cause the FDA or other regulatory authorities to require additional testing before approving any other product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>As an organization, we have
never conducted pivotal clinical trials, and we may be unable to do so for any product candidates we may develop. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will need to
successfully complete pivotal clinical trials in order to obtain the approval of the FDA, the EMA, or other regulatory agencies to market <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidate. Carrying out later-stage
clinical trials is a complicated process. As an organization, we have not previously conducted any later stage or pivotal clinical trials. In order to do so, we will need to expand our clinical development and regulatory capabilities, and we may be
unable to recruit and train qualified personnel. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to approval of <FONT STYLE="white-space:nowrap">AU-011</FONT> or
future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned
clinical trials, could prevent us from or delay us in commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interim,
<FONT STYLE="white-space:nowrap">&#147;top-line,&#148;</FONT> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time, we may publicly disclose preliminary, interim or <FONT
STYLE="white-space:nowrap">top-line</FONT> data from our clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more
comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and
carefully evaluate all data. As a result, the <FONT STYLE="white-space:nowrap">top-line</FONT> results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once
additional data have been received and fully evaluated. <FONT STYLE="white-space:nowrap">Top-line</FONT> data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary
data we previously published. As a result, <FONT STYLE="white-space:nowrap">top-line</FONT> data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all
endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patient data become available. Adverse differences between interim data and final data could materially affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may
interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. Further, additional disclosure of
interim data by us or by our potential competitors in the future could result in volatility in the price of our common stock. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically
selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose
may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or <FONT STYLE="white-space:nowrap">top-line</FONT> data
that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could
materially affect our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, we may utilize
&#147;open-label&#148; trial designs or open-label extensions to our clinical trials in the future. An &#147;open-label&#148; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational
product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to
various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#147;patient bias&#148; where patients perceive
their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological
outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial or extension may not be predictive
of future clinical trial results with <FONT STYLE="white-space:nowrap">AU-011</FONT> when studied in a controlled environment with a placebo or active control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates may cause or reveal significant adverse events, toxicities or other undesirable
side effects which may delay or prevent marketing approval. In addition, if we obtain approval for any of our product candidates, significant adverse events, toxicities or other undesirable side effects may be identified during post-marketing
surveillance, which could result in regulatory action or negatively affect our ability to market the product. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Adverse events or other
undesirable side effects caused by or associated with treatment by <FONT STYLE="white-space:nowrap">AU-011</FONT> or our future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result
in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities. Although <FONT STYLE="white-space:nowrap">AU-011</FONT> has been evaluated in clinical trials, unexpected
side effects may still arise in our ongoing or any future clinical trials. These side effects have included pigmentary changes around the tumor margin and vision loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the conduct of clinical trials, subjects report changes in their health, including illnesses, injuries, and discomforts, to their study doctor.
Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product
candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are
only detectable after investigational products are tested in large-scale, pivotal clinical trials or, in some cases, after they are made available to subjects on a commercial scale after approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse
events caused by such products, a number of potentially significant negative consequences could result, including but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may withdraw approvals of such product or require additional warnings on the label;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">additional clinical trials or post-approval studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects
for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may require additional warnings or limitations in the labeling, such as a contraindication,
limitation of use, or a boxed warning, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be subject to regulatory investigations and government enforcement actions; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, if <FONT STYLE="white-space:nowrap">AU-011</FONT> or any of our future product candidates is associated with undesirable or unexpected side
effects in clinical trials, we may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a
risk-benefit perspective, which may limit the commercial expectations for the product candidate, even if it is approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any of these events could
prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could materially affect our business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the development and commercialization of our
product candidates. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may experience delays in initiating or completing our preclinical studies or clinical trials, including as a result
of delays in obtaining, or failure to obtain, the FDA&#146;s clearance to initiate clinical trials under future INDs. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will not require
redesign, will enroll an adequate number of subjects on time, or will be completed on schedule, if at all. We may experience numerous unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent
our ability to receive regulatory approval or commercialize our product candidates, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may receive feedback from regulatory authorities that require us to modify the design or implementation of our
preclinical studies or clinical trials or to delay or terminate a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators or institutional review boards, or IRBs, or ethics committees may delay or may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and
prospective clinical research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preclinical studies or clinical trials of our product candidates may fail to show safety or efficacy or otherwise produce
negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, or we may decide to abandon product research or development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preclinical studies or clinical trials of our product candidates may not produce differentiated or clinically significant
results across tumor types or indications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment
in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our third party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, be
unable to provide us with sufficient product supply to conduct or complete preclinical studies or clinical trials, fail to meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or
drop out of the trial, which may require that we add new clinical trial sites or investigators; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or terminate
clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our clinical trials are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical trials of our product candidates may be delayed due to complications associated with the evolving <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product
candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our
investigators, regulators or IRBs or ethics committees to suspend or terminate the trials, or reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we
anticipate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions at
which such trials are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or clinical hold due to a number of factors,
including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, adverse findings upon an inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities,
unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors
that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA may disagree with our clinical trial design or our
interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, principal investigators for our trials involving <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future clinical trials may serve as
scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory
authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
investigator has created a conflict of interest or otherwise affected the interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of
the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign
regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future
clinical trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant preclinical study or clinical trial delays, including those caused
by <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market
before we do, which would impair our ability to successfully commercialize our product candidates and may significantly harm our business, operating results, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review,
which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated
safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging,
distribution, import, export, adverse event reporting, storage, advertising, promotion, monitoring, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, establishment registration and listing, compliance with applicable product tracking and tracing requirements, as well as continued compliance with current Good Manufacturing Practices, or cGMPs, and
GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the
conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. The FDA may also require a REMS in order to approve
our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may
result in, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or
mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring
remediation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications
or other safety information, including boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">imposition of a REMS which may include distribution or use restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to conduct additional post-market clinical trials to assess the safety of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical trial holds; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, warning letters or other regulatory enforcement action; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or
revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, the FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are
marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other regulatory agencies impose stringent restrictions on manufacturers&#146; communications regarding <FONT
STYLE="white-space:nowrap">off-label</FONT> use. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved labeling. If we do not market our
medicines for their approved indications, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice.
Violation of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and
state healthcare fraud and abuse laws and state consumer protection laws. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> use and
has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is
changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be enacted that could prevent, limit
or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
regulatory approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may
be unable to obtain orphan drug designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease
or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or
biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. In the United States, orphan drug designation entitles a party to
financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. After the FDA grants orphan drug designation, the generic identity of the drug
and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which
it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances such
as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition
for which the drug was designated. As a result, even if our current product candidates and any future product candidates receive orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating
the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have obtained orphan designation for <FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of uveal melanoma, and we may seek additional
orphan drug designations for some or all of our current or future product candidates in orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing
rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA may
reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on
what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A breakthrough therapy designation or
fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product
candidates will receive regulatory approval in the United States. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may seek breakthrough therapy designation for some of our product
candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence
indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates
that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in
ineffective control regimens. Products designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if
we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a
product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more
of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have obtained fast track designation for <FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of choroidal melanoma, and we may seek
additional fast track designations for other product candidates we may develop. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the drug or biologic demonstrates the potential to address unmet
medical needs for this condition, the sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we
cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is
no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review
or approval process and it does not increase the likelihood that our product candidates will receive&nbsp;regulatory&nbsp;approval. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may
seek accelerated approval of our current or future product candidates using the FDA&#146;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a
meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA requires that a sponsor of a drug or biologic receiving accelerated approval perform adequate and
well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires as a condition for accelerated
<FONT STYLE="white-space:nowrap">approval&nbsp;pre-approval&nbsp;of</FONT> promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a
faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks
Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to rely on third parties to conduct our clinical trials and some aspects of our research and
preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and
clinical investigators, to conduct some aspects of our research, preclinical testing and clinical trials. We plan to use a clinical CRO for at least part of the potentially pivotal trial for <FONT STYLE="white-space:nowrap">AU-011</FONT> for the
treatment of choroidal melanoma. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, our product development activities would be
delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our reliance on these third parties for research and development activities reduces our control over these activities, but does not
relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial, as well as the applicable legal,
regulatory and scientific standards. Moreover, the FDA requires us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that
the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any
of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA may require us to perform additional clinical trials before approving our marketing
applications. We are also required to register ongoing clinical trials and to post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and
civil and criminal sanctions. Due to the rarity of ocular melanomas, we may engage clinical trial sites that have little experience in the conduct of clinical trials under GCPs. Even though we train the clinical trial sites, monitor the activities,
and perform quality audits to assess and ensure compliance, we cannot ensure such compliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, these third parties may also have relationships with other entities, some of which may be
our competitors, for whom they may also be conducting clinical trials or other biological product development activities that could harm our competitive position. If these third parties do not successfully carry out their contractual duties, meet
expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and
will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also expect to rely on other third parties
to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our
medicines, producing additional losses and depriving us of potential product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently rely on third-party contract manufacturing organizations,
or CMOs, for the production of clinical supply of <FONT STYLE="white-space:nowrap">AU-011</FONT> and may continue to rely on CMOs for the production of commercial supply of <FONT STYLE="white-space:nowrap">AU-011,</FONT> if approved. This reliance
on CMOs increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could
delay, prevent, or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently do not have any manufacturing facilities and have no
plans to build our own clinical or commercial scale manufacturing capabilities. Instead, we expect to rely on third parties for the manufacture of our product candidates and related raw materials
<FONT STYLE="white-space:nowrap">for&nbsp;future&nbsp;pre-clinical&nbsp;and&nbsp;clinical</FONT> development, as well as for commercial manufacture if any of our product candidates receive marketing approval. We are currently reliant on a single
source for each of our regulatory starting materials, drug substance and drug product manufacturing for <FONT STYLE="white-space:nowrap">AU-011.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We or our third-party suppliers or manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredient, or API, necessary to <FONT
STYLE="white-space:nowrap">produce&nbsp;AU-011</FONT> and future product candidates we may develop in the quantities needed for our clinical trials or, <FONT STYLE="white-space:nowrap">if&nbsp;AU-011</FONT> or any future product candidates we may
develop are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or APIs, including shortages caused by the
purchase of such raw materials or API, by our competitors or others. Even if raw materials or API are available, we may be unable to obtain sufficient quantities at an acceptable cost or quality. The failure by us or our third-party suppliers or
manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities <FONT STYLE="white-space:nowrap">of&nbsp;AU-011</FONT> or any future product candidates we may develop could delay, prevent or impair our development
efforts and may have a material adverse effect on our business. To date, we have only encountered minor delays in our manufacturing process due to a supply chain constraint with one of our vendors </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Reliance on third party manufacturers may expose us to different risks than if we were to manufacture clinical or commercial supply of our product
candidates ourselves. The facilities used by third-party manufacturers to manufacture <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates must be authorized by the FDA pursuant to inspections that will be conducted after
we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of drug products and other laws and regulations. If these
third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and maintain regulatory approval for their
manufacturing facilities. Some of our contract manufacturers may not have produced a commercially-approved product and therefore may not have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
obtained the requisite FDA approvals to do so. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified
personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#146;s time and focus. In addition, there is typically a
transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the
clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product
candidates. Additionally, any changes implemented by a new CMO could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial
costs, delay approval of <FONT STYLE="white-space:nowrap">AU-011</FONT> and future product candidates and jeopardize our ability to commence product sales and generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the intellectual
property and proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes, misappropriates or otherwise violates the intellectual property or proprietary rights of others in the course of
providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against applicable claims, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our
product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result
in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect supplies of our products. In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to manufacture our product according to our specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">lack of qualified backup suppliers for those components or materials that are currently purchased from a sole or single
source supplier; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to manufacture our product according to our schedule or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">production difficulties caused by unforeseen events that may delay the availability of one or more of the necessary raw
materials or delay the manufacture of <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates for use in clinical trials or for commercial supply, including as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">supply or service disruptions or increased costs that are beyond our control; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">misappropriation of our proprietary information, including our trade secrets and
<FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">AU-011</FONT> and any other product candidates that we may develop
may compete with other product candidates and products for access to manufacturing facilities. Additionally, three vaccines for <FONT STYLE="white-space:nowrap">COVID-19</FONT> were granted Emergency Use Authorization by the FDA in late 2020 and
early 2021, and more may be authorized in the future. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make
it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. Any performance failure on the part of our existing or future manufacturers could delay
clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in
the manufacture of our product candidates. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or on terms acceptable to us. Our
current and anticipated future dependence upon others for the manufacture of <FONT STYLE="white-space:nowrap">AU-011</FONT> or any other future product candidates or products may adversely affect our future profit margins and our ability to
commercialize any products that receive marketing approval on a timely and competitive basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Commercialization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates do not achieve broad market acceptance, the revenue that we generate from their
sales may be limited, and we may never become profitable. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never commercialized a product candidate for any indication. Even if <FONT
STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the
medical community. If any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we may not generate significant revenue and may not become profitable or may be significantly delayed in
achieving profitability. Market acceptance of <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our
control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch, from existing therapies even when new and potentially more effective or safer treatments enter the market. If public perception
is influenced by claims that the use of virus-like drug conjugates, or VDCs, is unsafe, whether related to our or our competitors&#146; products, our products may not be accepted by the general public or the medical community. In addition, training
clinicians to properly use AU-011 or any future product candidate that requires a similar laser and microinjector may create reluctance by clinicians to adopt our products, potentially adversely affecting our future sales and marketing efforts.
Furthermore, such training increases our costs to generate sales associated with any such product. Future adverse events in targeted oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling
requirements and potential regulatory delays in the testing or approvals of our product candidates. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of
influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#146; organizations, hospitals, other healthcare providers, government agencies or private insurers
will determine that our product is safe, therapeutically effective and cost effective as compared with competing treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Efforts to educate the
medical community and third-party payors on the benefits of <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates may require significant resources and may not be successful. If
<FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates are approved but do not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of market acceptance of any of <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates will depend on a number of factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy of <FONT STYLE="white-space:nowrap">AU-011</FONT> and our virus-like particle, or VLP, technology, and any
future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of adverse events associated with <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future
product candidates or those products with which they may be <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the clinical indications for which <FONT STYLE="white-space:nowrap">AU-011</FONT> are approved and the approved claims that
we may make for the products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations or warnings contained in the product&#146;s <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling or
those of comparable foreign regulatory authorities, including potential limitations or warnings for <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates that may be more restrictive than other competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the standard of care for the targeted indications for <FONT STYLE="white-space:nowrap">AU-011</FONT> and any
future product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the relative convenience and ease of administration of <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future
product candidates and any products with which they are <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of adequate coverage or reimbursement by third party payors, including government healthcare programs such
as Medicare and Medicaid and other healthcare payors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the price concessions required by third-party payors to obtain coverage; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the perception of physicians, patients, third-party payors and others in the medical community of the relative safety,
efficacy, convenience, effect on quality of life and cost effectiveness of <FONT STYLE="white-space:nowrap">AU-011</FONT> compared to those of other available treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of adequate coverage and reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent and strength of our marketing and distribution of <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that
may later be approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to <FONT
STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates or to which we agree as part of a REMS or voluntary risk management plan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of market introduction of <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates, as
well as competitive products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to offer <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates for sale at
competitive prices; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent and strength of our third-party manufacturer and supplier support; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the publicity concerning our <FONT STYLE="white-space:nowrap">AU-011</FONT> or competing products and treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the actions of companies that market any products with which <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future
product candidates may be <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the approval of other new products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse publicity about <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates or any products
with which they are <FONT STYLE="white-space:nowrap">co-administered,</FONT> or favorable publicity about competitive products; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential product liability claims. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently have no marketing and sales organization and have no experience in marketing products. If we are
unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never commercialized a product candidate and we currently have no sales, marketing or distribution capabilities and have no experience in
marketing products. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring the rights to our product candidate and undertaking preclinical studies and clinical trials of our
product candidate. We intend to develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with
other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. We may not be successful in transitioning from a company with a development focus to a company capable of supporting commercial
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to establishing internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements
regarding the sales and marketing of our products, however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue
we receive will depend upon the efforts of such third parties, which may not be successful. Further, if we enter into arrangements with third parties to perform sales and marketing services, our product revenues, if any, may be lower than if we were
to market and sell any products that we develop ourselves. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product
candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product
candidate. We may not be able to build an effective sales and marketing organization in the United States, the EU or other key global markets. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for
the commercialization of our product candidate, we may have difficulties generating revenue from them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There can be no assurance that we will be
able to develop <FONT STYLE="white-space:nowrap">in-house</FONT> sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may face competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The biopharmaceutical industry is characterized by intense competition and rapid innovation. While we are not aware of anyone currently developing a
treatment for choroidal melanoma, in the future our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results than us. There are multiple companies that have drugs in clinical development for the
treatment of NMIBC that are unresponsive to Bacillus Calmette-Guerin, such as Sesen Bio, Inc., FerGene, Inc., UroGen Pharma Ltd., CG Oncology, Inc. and ImmunityBio, Inc. Our potential competitors include major multinational pharmaceutical companies,
established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our potential competitors have substantially greater financial, technical and other resources, such as larger research
and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to
treating disease indications that our product candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to
<FONT STYLE="white-space:nowrap">in-license</FONT> novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and
greater availability of capital for investment in these industries. Our competitors, either alone or with collaboration partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more
effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products, which may reduce or
eliminate our commercial opportunity. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and
reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if we obtain regulatory approval of our product candidates, the availability and price of our potential future
competitors&#146; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the
reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For
additional information regarding our competition, see &#147;Business&#151;Competition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we are able to commercialize any product candidates,
such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with
their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize any products that we
may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government
authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited
than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to
follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs, or VA, hospitals,
and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that
drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if
reimbursement is available, that the level of reimbursement will be sufficient. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best
price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either
in the United States, particularly in light of the most recent presidential election, or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain
regulatory compliance, our product candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If the market opportunity for <FONT STYLE="white-space:nowrap">AU-011</FONT> is smaller than we estimate or if any regulatory approval that we obtain is based on
a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The incidence and prevalence for target patient populations of <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates has not
been established with precision. <FONT STYLE="white-space:nowrap">AU-011</FONT> is a virus-like drug conjugate product candidate being developed for the first line treatment of primary choroidal melanoma. Our projections of both the number of people
who have choroidal melanoma, as well as additional ocular oncology and bladder cancer indications, are based on our estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The total
addressable market opportunity will ultimately depend upon, among other things, the patient criteria included in the final label, the indications for which <FONT STYLE="white-space:nowrap">AU-011</FONT> is approved for sale, acceptance by the
medical community and patient access, product pricing and reimbursement. The number of patients with choroidal melanoma, choroidal metastases and NMIBC for which <FONT STYLE="white-space:nowrap">AU-011</FONT> may be approved as treatment may turn
out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and
our business. <FONT STYLE="white-space:nowrap">AU-011</FONT> is our only product candidate and therefore our business is dependent on the market opportunity for our product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations
and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our business operations and
current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws. These laws may
constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include, but are not limited to:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully
soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchase, lease, order, arrangement, or
recommendation of any good, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to
have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration
involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal civil and criminal false claims laws and Civil Monetary Penalties Law, such as the federal False Claims Act,
which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment
that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly
concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors
if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging
violations of the federal False Claims Act and to share in any monetary recovery; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal
statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money
or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or
making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the federal Anti-Kickback
Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business
associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security
and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys
general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, there may be additional
federal, state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not
have the same effect, thus complicating compliance efforts;</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the United States Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of
drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors), certain other health care professionals beginning in 2022 (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists&nbsp;&amp; anesthesiologist assistants, and
certified nurse-midwives), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate
and timely manner to government programs; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and
regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and False Claims Act, and may apply to our
business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> payors, including
private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical
Research and Manufacturers of America&#146;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and
require the registration of pharmaceutical sales representatives. State and foreign laws, including for example the European Union General Data Protection Regulation, which became effective May 2018 also govern the privacy and security of health
information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state
requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other
in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The scope and enforcement of each of these laws is
uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have increased their scrutiny of interactions
between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our internal operations and future business arrangements with
third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations,
agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may
apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment,
reputational harm, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in
defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they
may be subject to criminal, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results
of operations could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Current and future healthcare legislative reform measures may have a material adverse effect on our business and
results of operations. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The United States and many foreign jurisdictions have enacted and/or proposed legislative and regulatory changes
affecting the healthcare system that could prevent or delay regulatory approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell a
product for which we obtain regulatory approval. Changes in laws, regulations, statutes or the interpretation of existing laws and regulations could impact our business in the future by requiring, for example: (i)&nbsp;changes to our manufacturing
arrangements, (ii)&nbsp;additions or modifications to product labeling, (iii)&nbsp;the recall or discontinuation of our products or (iv)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect
the operation of our business. In the United States, there have been, and continue to be, a significant number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education and Reconciliation Act, or collectively, the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the United States
pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid
managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70%
pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries
during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part&nbsp;D. Since then, the ACA risk adjustment program payment parameters have been updated annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since its enactment, there have been numerous judicial, administrative, executive, and&nbsp;legislative challenges to certain aspects of the ACA. On
June&nbsp;17, 2021, the U.S. Supreme Court dismissed on procedural grounds the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#146;s
decision, President Biden issued an Executive Order that initiated a special enrollment period from February&nbsp;15, 2021 through August&nbsp;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive
Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work
requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future.&nbsp;It is
unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or replace the ACA, will impact our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare,
review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, President Biden signed an Executive
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Order on July&nbsp;9, 2021 affirming the administration&#146;s policy to (i)&nbsp;support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing
Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii)&nbsp;support the enactment of a public health insurance option. Among other
things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price
gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the
FDA&#146;s implementing regulations. FDA released such implementing regulations on September&nbsp;24, 2020, which went into effect on November&nbsp;30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada.
On September&nbsp;25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section&nbsp;1927 of the Social Security Act and manufacturers would not report these drugs for &#147;best price&#148; or
Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Further, on November&nbsp;20, 2020 CMS issued an
Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for
Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and would have applied to all U.S. states and territories for a
seven-year period beginning January&nbsp;1, 2021, and ending December&nbsp;31, 2027. On December&nbsp;28, 2020, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction against implementation of the
interim final rule. On January&nbsp;13, 2021, in a separate lawsuit brought by industry groups in the U.S. District of Maryland, the government defendants entered a joint motion to stay litigation on the condition that the government would not
appeal the preliminary injunction granted in the U.S. District Court for the Northern District of California and that performance for any final regulation stemming from the MFN Model interim final rule shall not commence earlier than sixty
(60)&nbsp;days after publication of that regulation in the Federal Register. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented, importation of drugs from Canada and the MFN
Model may materially and adversely affect the price we receive for any of our product candidates. Additionally, on December&nbsp;2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical
manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November&nbsp;30, 2020, HHS published a
regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule
also creates a new safe harbor for price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit
managers and manufacturers. Further, implementation of this change and new safe harbors for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> reductions in price for prescription pharmaceutical products
and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. Although a number of these and other proposed measures may require authorization through additional legislation to
become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that it will continue to seek new legislative measures to control drug costs. For example, based
on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other legislative changes have been proposed and adopted in the United States since the ACA was
enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2%
per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030,&nbsp;unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES
Act, as well as subsequent legislation, these reductions have been suspended from May&nbsp;1, 2020 through December&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, on May&nbsp;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients
to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in
clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its product candidates available to eligible patients as a result of the Right to Try Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in
their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal
and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. In particular any policy changes through CMS as well as local
state Medicaid programs could have a significant impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our revenue prospects could be affected by changes in healthcare spending
and policy in the U.S. and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of
delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There have been,
and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives
that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or
reduce costs of healthcare and/or impose price controls may adversely affect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the demand for our current or future product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain coverage and reimbursement approval for a product;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may
adversely affect our future profitability. Further, it is possible that additional governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to compete may
decline if we do not adequately protect our proprietary rights, and our proprietary rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our commercial success depends upon obtaining and maintaining proprietary rights to our intellectual property estate, including rights relating to our
technology platform using <FONT STYLE="white-space:nowrap">HPV-derived</FONT> virus-like particles to target tumors and VDCs like <FONT STYLE="white-space:nowrap">AU-011,</FONT> as well as successfully defending these rights against third-party
challenges and successfully enforcing these rights to prevent third-party infringement. We will only be able to protect <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate derived from our platform from unauthorized use by
third parties to the extent that valid and enforceable patents cover it. Our ability to maintain patent protection for <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate is uncertain due to a number of factors, including
that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may design around our patent claims to produce competitive technologies, products or methods that fall outside of
the scope of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not obtain patent protection in all jurisdictions that may eventually provide us a significant business opportunity;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any patents issued to us may be successfully challenged by third parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even with our patents covering <FONT STYLE="white-space:nowrap">AU-011,</FONT> we may still not be able to make use or sell <FONT
STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate because of the patent rights of others. Others may have filed patent applications covering compositions, products or methods that are similar or identical to ours, which could
materially affect our ability to successfully commercialize <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in
loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and
products, or limit the duration of the patent protection of our technology and products. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions
may be available; however, the life of a patent, and the protection it affords, is limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Obtaining and maintaining a patent portfolio entails
significant expense, including periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and patent applications. These expenditures can be at numerous stages of prosecuting patent applications and over the
lifetime of maintaining and enforcing issued patents. We may or may not choose to pursue or maintain protection for particular intellectual property in our portfolio. If we choose to forgo patent protection or to allow a patent application or patent
to lapse purposefully or inadvertently, our competitive position could suffer. Furthermore, we employ reputable law firms and other professionals to help us comply with the various procedural, documentary, fee payment and other similar provisions
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we are subject to and, in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Legal action that may be required to enforce our patent rights can be expensive and may involve the diversion of significant management time. There can
be no assurance that we will have sufficient financial or other resources to file and pursue infringement claims, which typically last for years before they are concluded. In addition, these legal actions could be unsuccessful and result in the
invalidation of our patents, a finding that they are unenforceable or a requirement that we enter into a licensing agreement with or pay monies to a third party for use of technology covered by our patents. We may or may not choose to pursue
litigation or other actions against those that have infringed on our patents, or have used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to successfully protect or enforce
our intellectual property rights, our competitive position could suffer, which could harm our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may need to license intellectual
property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A third party
may hold intellectual property rights, including patent rights, that are important or necessary to the development of <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates. It may be necessary for us to use the patented or
proprietary technology of third parties to commercialize <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be
available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable terms, our business could be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use third-party
proprietary rights. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any such proprietary rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to
obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to
develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to
obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and
resources to develop or license replacement technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely on intellectual property licensed from third parties. We face risks with respect to such
reliance, including the risk that, if we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our
licensors, we could lose license rights that are important to our business. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a party to a number of intellectual property license
agreements that are important to our business. Our existing license agreements impose on us various diligence, milestone payment, royalty and other obligations. If we fail to comply with any of our obligations under these agreements, or we are
subject to a bankruptcy, our licensors may have the right to terminate the license, in which event we would not be able to market any products covered by the license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Disputes may also arise between us and our licensors regarding intellectual property subject to a
license agreement, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of rights granted and related obligations under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our licensor&#146;s right to license or sublicense patent and other rights to us, and whether and the extent to which the
right is retained by a third party; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether and the extent to which our technology infringes on intellectual property of the licensor that is not subject to
the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of <FONT STYLE="white-space:nowrap">AU-011</FONT> or any future product candidates, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use
of intellectual property by our licensors and us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If disputes over intellectual property that we have licensed prevent or impair
our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, disputes may arise regarding the payment of the royalties due to licensors in connection with our exploitation of the rights we license
from them. Licensors may contest the basis of royalties we retained and claim that we are obligated to make payments under a broader basis. Such disputes may be costly to resolve and may divert management&#146;s attention away from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities. In addition to the costs of any litigation we may face, any legal action against us could increase our payment obligations under the respective
agreement and require us to pay interest and potentially damages to such licensors. If disputes over intellectual property that we have licensed from third parties prevent or impair our ability to maintain our licensing arrangements on acceptable
terms, we or our collaborators may be unable to successfully manufacture and commercialize <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we fail to comply with our obligations under the license agreements, our licensors may have the right to terminate these agreements, in which event
we might not be able to manufacture or market <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to
negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our <FONT
STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate, thereby potentially extending the term of marketing exclusivity for such product, our business may be harmed. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug or biologic may be eligible for a term extension
designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more
of our owned, <FONT STYLE="white-space:nowrap">co-owned,</FONT> or <FONT STYLE="white-space:nowrap">in-licensed</FONT> U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of
1984, or the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
maximum of one patent to be extended per <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product as compensation for the patent term lost during the FDA regulatory review process. A patent
term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be
extended. In the European Union, <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we
fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our
request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may
obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patents and
patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The patent positions of biopharmaceutical and biotechnology companies and other actors in our fields of business can be highly uncertain and typically
involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in some patents covering biopharmaceutical compositions may be uncertain and difficult to determine and are often affected
materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the U.S. Patent and Trademark Office, or the USPTO, and its foreign counterparts are sometimes uncertain and could
change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference or
derivation proceedings, and U.S. patents may be subject to reexamination proceedings, post-grant review and/or <I>inter partes</I> review in the USPTO. International patents may also be subject to opposition or comparable proceedings in the
corresponding international patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such
interference, derivation, reexamination, post-grant review, <I>inter partes</I> review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products
or processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, even if not challenged, our patents and patent applications may not prevent others from designing their products to
avoid being covered by our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate is threatened, it could dissuade
companies from collaborating with us to develop, and could threaten our or their ability to successfully commercialize, <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use our discoveries
or to develop and commercialize our technology without providing any compensation to us, may limit the scope of patent protection that we are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent
as U.S. laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we
may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of product candidates, prohibit our use of
proprietary technology or sale of potential products or put our patents and other proprietary rights at risk. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our commercial success depends
upon our ability to develop, manufacture, market and sell <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights
of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the biotechnology industry is common, including patent infringement lawsuits, interferences, oppositions, reexamination
proceedings, post-grant review, and/or <I>inter partes</I> review before the USPTO and corresponding international patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and
other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage
over their competitors. As a result of any patent infringement claims, or in order to avoid any potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require payment of substantial
royalties or fees, or require us to grant a cross-license under our intellectual property rights. These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be
nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing <FONT STYLE="white-space:nowrap">AU-011</FONT>
or a future product candidate, or forced to modify <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate, or to cease some aspect of our business operations, which could harm our business significantly. We might also be forced
to redesign or modify our technology or product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or
technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities
relating to <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate that is the subject of the suit may be delayed or terminated. In addition, defending such claims may cause us to incur substantial expenses and, if successful,
could cause us to pay substantial damages if we are found to be infringing a third party&#146;s patent rights. These damages potentially could include increased damages and attorneys&#146; fees if we are found to have infringed such rights
willfully. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent
holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. In addition, if the breadth or strength of protection provided by the patents and patent applications we own or <FONT
STYLE="white-space:nowrap">in-license</FONT> is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may in the future be subject to third-party claims and similar adversarial proceedings or litigation in other jurisdictions regarding our
infringement of the patent rights of third parties. Even if such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be
able to block our ability to further develop or commercialize <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally
determined to be invalid or unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we or one of our licensors were to initiate legal proceedings against a third party to enforce a
patent covering our technology or a product candidate, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and Europe, defendant counterclaims alleging invalidity or
unenforceability are common. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> The outcome
of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the
patent examiner were unaware during prosecution, but that an adverse third party may identify and submit in support of such assertions of invalidity. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would
lose at least part of the patent protection on <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will not seek to protect our
intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Filing, prosecuting and defending patents on <FONT STYLE="white-space:nowrap">AU-011</FONT> or a future product candidate in all countries and
jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In addition, the laws of some foreign
countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have and have
applied for patents in those countries where we intend to make, have made, use, offer for sale or sell products and where we assess the risk of infringement to justify the cost of seeking patent protection. Competitors may use our technologies in
jurisdictions where we do not pursue and obtain patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection, but where our ability to enforce our patent rights is not as
strong as in the United States. These products may compete with any products that we may develop, and our patents or other intellectual property rights may not be effective or sufficient to prevent such competition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The laws of some other countries do not protect intellectual property rights to the same extent as the laws of the United States. For example, European
patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Patent protection must ultimately be sought on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we chose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property
protection, especially those relating to biopharmaceuticals or biotechnologies. As a result, many companies have encountered significant difficulties in protecting and defending intellectual property rights in certain jurisdictions outside the
United States. Such issues may make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention
from other aspects of our business, subject our patents to the risk of being invalidated or interpreted narrowly, subject our patent applications to the risk of not issuing or provoke third parties to assert claims against us. We may not prevail in
any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
commercially meaningful, while the damages and other remedies we may be ordered to pay such third parties may be significant. Accordingly, our efforts to enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we or our
licensors are unable to protect the confidentiality of the proprietary information related to our product or process, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and our licensors rely on confidentiality agreements to protect unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other
proprietary information related to our product and process, to maintain our competitive position. For example, our licensor Li-Cor maintains its manufacture of IRDye 700DX<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> dye molecules (used
in <FONT STYLE="white-space:nowrap">AU-011)</FONT> as a trade secret. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. In particular, the trade secrets and
<FONT STYLE="white-space:nowrap">know-how</FONT> in connection with our development programs and other proprietary technology we may develop may over time be disseminated within the industry through independent development, the publication of
journal articles describing the methodology and the movement of personnel with scientific positions in academic and industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We seek to protect
our proprietary information, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific
collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties
may breach the agreements and disclose our proprietary information. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will
be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information is difficult, expensive and time-consuming, and the
outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or are unwilling to protect trade secrets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may be subject to claims that third parties have an ownership interest in our trade secrets. For example, we may have disputes arise from conflicting
obligations of our employees, consultants or others who are involved in developing <FONT STYLE="white-space:nowrap">AU-011.</FONT> Litigation may be necessary to defend against these and other claims challenging ownership of our trade secrets. If we
fail in defending any such claims, in addition to paying monetary damages, we may lose valuable trade secret rights, such as exclusive ownership of, or right to use, trade secrets that are important to our therapeutic programs and other proprietary
technologies we may develop. Such an outcome could have a materially adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and
other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, our competitors may independently develop knowledge, methods and <FONT STYLE="white-space:nowrap">know-how</FONT>
equivalent to our proprietary information. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of
our proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any
of our proprietary information were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have
confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the
outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no
right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to our Business and Industry </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we lose key management
personnel, or if we fail to recruit additional highly skilled personnel, our ability to pursue our business strategy will be impaired, could result in loss of markets or market share and could make us less competitive. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to compete in the highly competitive biopharmaceutical industries depends upon our ability to attract, manage, motivate and retain highly
qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical
advisors, and our inability to find suitable replacements for these individuals could harm our business. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and
development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we
are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Competition for
skilled personnel in our industry is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, in a timely manner or at all. In particular, we have experienced a very competitive hiring environment in
Cambridge, Massachusetts, where we are headquartered. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry
than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. To induce valuable employees to remain
at our company, in addition to salary and cash incentives, we have provided equity incentive awards that vest over time. The value to employees of restricted stock awards and stock options that vest over time may be significantly affected by
movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and
development teams are <FONT STYLE="white-space:nowrap">at-will</FONT> employees and may terminate their employment with us on short notice. We do not maintain &#147;key man&#148; insurance policies on the lives of these individuals or the lives of
any of our other employees. Given the stage of our programs and our plans to expand operations, our success also depends on our ability to continue to attract, retain and motivate highly skilled junior,
<FONT STYLE="white-space:nowrap">mid-level</FONT> and senior personnel across our organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Public health crises such as pandemics or similar outbreaks could adversely impact our business. Recently, a novel strain of a virus named <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes <FONT STYLE="white-space:nowrap">COVID-19</FONT> has spread to most countries across
the world, including all 50 states within the U.S., including Cambridge, Massachusetts, where our primary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
office and laboratory space is located. The coronavirus pandemic is evolving, and has led to the implementation of various responses, including government-imposed quarantines, travel restrictions
and other public health safety measures. The extent to which the coronavirus impacts our operations or those of our third party partners, including our preclinical studies or clinical trial operations, will depend on future developments, which are
highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus, the emergence of new variance, acceptance of vaccines and the actions to
contain the coronavirus or treat its impact, among others. The continued spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> globally could adversely impact our preclinical or clinical trial operations in the U.S., including our ability to
recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT STYLE="white-space:nowrap">COVID-19</FONT> if an outbreak occurs in their geography. For example, similar to
other biopharmaceutical companies, we may experience delays in initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, protocol deviations, enrolling our clinical trials, or dosing of patients in our clinical trials as well as in
activating new trial sites. <FONT STYLE="white-space:nowrap">COVID-19</FONT> may also affect employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. Any negative impact <FONT
STYLE="white-space:nowrap">COVID-19</FONT> has to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory
approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, timely enrollment in planned clinical trials is dependent upon clinical trial sites which could be adversely affected by global health
matters, such as pandemics. We plan to conduct clinical trials for our product candidates in geographies which are currently being affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Some factors from the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic that will delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns,
including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and
monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or
contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> meetings and other interactions with potential partners,
any of which could delay or adversely impact the conduct or progress of our prospective clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential negative affect on the operations of our third-party manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption in global shipping affecting the transport of clinical trial materials, such as drug product and conditioning
drugs and other supplies used in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees
working from home, disruptions to or delays in ongoing laboratory experiments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our
business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which
may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval
timelines. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have taken temporary precautionary measures intended to help minimize the risk of the virus to our
employees, including temporarily requiring certain of our employees to work remotely, suspending all <FONT STYLE="white-space:nowrap">non-essential</FONT> travel worldwide for our employees and discouraging employee attendance at industry events and
<FONT STYLE="white-space:nowrap">in-person</FONT> work-related meetings, which could negatively affect our business. We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and
government agencies, such as the Securities and Exchange Commission, or the SEC, or FDA. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance,
bioresearch monitoring and <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic
inspections. As of May 2021, certain inspections, such as foreign preapproval, surveillance, and <FONT STYLE="white-space:nowrap">for-cause</FONT> inspections that are not deemed mission-critical, remain temporarily postponed. In April 2021, the FDA
issued guidance for industry formally announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates and in May 2021 announced plans to continue progress toward resuming standard
operational levels. Should FDA determine that an inspection is necessary for approval of and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to
be adequate, the agency has stated that it generally intends to issue a complete response letter or defer action on the application until an inspection can be completed. In 2020 and 2021, a number of companies announced receipt of complete response
letters due to the FDA&#146;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience delays in their regulatory activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These and other factors arising from <FONT
STYLE="white-space:nowrap">COVID-19</FONT> could worsen in countries that are already afflicted with <FONT STYLE="white-space:nowrap">COVID-19</FONT> or could continue to spread to additional countries. Any of these factors, and other factors
related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operation and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the
economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a
material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to numerous environmental, health and safety laws and regulations,
including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and
radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In
the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or
criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to
injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be
asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in tax laws or in their implementation or interpretation may adversely affect us or our investors.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have
been made and changes are likely to continue to occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">It cannot be predicted whether, when, in what form, or with what effective
dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our shareholders&#146; tax liability or require changes in the manner in
which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our internal information
technology systems, or those of our third-party CROs, contractors, consultants or others who process sensitive information on our behalf, may fail or suffer security incidents, loss or leakage of data and other compromises, any of which could result
in a material disruption of our product candidates&#146; development programs, compromise sensitive information related to our business or prevent us from accessing such information, expose us to liability or otherwise adversely affect our business.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the ordinary course of our business, we may collect, store and transmit confidential information, including intellectual property,
proprietary business information and personal information (including health information). It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such information. We also have outsourced
certain of our operations to third parties, and as a result we manage a number of third parties who have access to our information. Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third
parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyberattacks by sophisticated nation-state and nation-state supported actors or by malicious third parties (including the deployment of harmful malware
(such as malicious code, viruses and worms)), natural disasters, global pandemics, fire, terrorism, war and telecommunication and electrical failures, , fraudulent activity, as well as security incidents from inadvertent or intentional actions (such
as error or theft) by our employees, contractors, consultants, business partners, and/or other third parties, phishing attacks, ransomware,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service&nbsp;attacks,</FONT></FONT> social engineering schemes and other means that affect service reliability and threaten the confidentiality, integrity and availability
of information), which may compromise our system infrastructure as well as lead to unauthorized access, disclosure or acquisition of information. Cyberattacks are increasing in their frequency, sophistication and intensity. The techniques used to
sabotage or to obtain unauthorized access to our information technology systems or those upon whom we rely to process our information change frequently, and we may be unable to anticipate such techniques or implement adequate preventative measures
or to stop security incidents in all instances. The recovery systems, security protocols, network protection mechanisms and other security measures that we have integrated into our information technology systems, which are designed to protect
against, detect and minimize security breaches, may not be adequate to prevent or detect service interruption, system failure or data loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Significant disruptions of our information technology systems or security incidents could adversely affect our business operations and/or result in the
loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information
including health information), and could result in financial, legal, business and reputational harm to us.&nbsp;If such disruptions were to occur and cause interruptions in our operations, it could result in a material
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
disruption of our product development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. Further, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in a significant number of our employees and partners working remotely, which
increases the risk of a data breach or issues with data and cybersecurity. To the extent that any disruption or security incident results in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or
proprietary information, we could incur liability and the further development of our future product candidates could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may also be
required to comply with laws, regulations, rules, industry standards, and other legal obligations that require us to maintain the security of personal data. We may also have contractual and other legal obligations to notify collaborators, our
clinical trial participants, or other relevant stakeholders of security incidents. Failure to prevent or mitigate cyberattacks could result in unauthorized access to data, including personal data.&nbsp;Most jurisdictions have enacted laws requiring
companies to notify individuals, regulatory authorities, and others of security breaches involving certain types of data. Such disclosures are costly, could lead to negative publicity, may cause our collaborators or other relevant stakeholders to
lose confidence in the effectiveness of our security measures and require us to expend significant capital and other resources to respond to and/or alleviate problems caused by the actual or perceived security breach. In addition, the costs to
respond to a cybersecurity event or to mitigate any identified security vulnerabilities could be significant, including costs for remediating the effects of such an event, paying a ransom, restoring data from backups, and conducting data analysis to
determine what data may have been affected by the breach. In addition, our efforts to contain or remediate a security incident or any vulnerability exploited to cause an incident may be unsuccessful, and efforts and any related failures to contain
or remediate them could result in interruptions, delays, harm to our reputation, and increases to our insurance coverage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, litigation
resulting from security breaches may adversely affect our business.&nbsp;Unauthorized access to our information technology systems could result in litigation with our collaborators, our clinical trial participants, or other relevant
stakeholders.&nbsp;These proceedings could force us to spend money in defense or settlement, divert management&#146;s time and attention, increase our costs of doing business, or adversely affect our reputation.&nbsp;We could be required to
fundamentally change our business activities and practices in response to such litigation, which could have an adverse effect on our business.&nbsp;If a security breach were to occur and the confidentiality, integrity or availability of our data or
the data of our collaborators were disrupted, we could incur significant liability, which could negatively affect our business and damage our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, we may not have adequate insurance coverage or otherwise protect us from, or adequately mitigate, liabilities or damages.&nbsp;The
successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or <FONT
STYLE="white-space:nowrap">co-insurance</FONT> requirements), could have an adverse effect on our business.&nbsp;In addition, we cannot be sure that our existing insurance coverage and coverage for errors and omissions will continue to be available
on acceptable terms or that our insurers will not deny coverage as to any future claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are, or may become, subject to stringent and changing privacy and information security laws, regulations,
standards, policies and contractual obligations related to data privacy and security. Our actual or perceived failure to comply with such data privacy and security obligations could lead to government enforcement actions (which could include civil
or criminal fines or penalties), a disruption of our clinical trials or commercialization of our products, private litigation, changes to our business practices, increased costs of operations, and adverse publicity that could otherwise negatively
affect our operating results and business. Compliance or the failure to comply with such obligations could increase the costs of our products, could limit their use or adoption, and could otherwise negatively affect our operating results and
business. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Regulation of data (including personal and clinical trial data) is evolving, as federal, state, and foreign governments continue
to adopt new, or modify existing, laws and regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of data. These new or proposed laws and regulations are subject to differing interpretations and
may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data. Moreover, we are subject to the terms of our privacy
and security policies, representations, certifications, standards, publications, contracts and other obligations to third parties related to data privacy, security and processing. These and other requirements could require us or our collaborators to
incur additional costs to achieve compliance, limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use, store, transfer, and process data, impact our or our collaborators&#146;
ability to process or use data in order to support the provision of our products, affect our or our collaborators&#146; ability to offer our products in certain locations, cause regulators to reject, limit or disrupt our clinical trial activities,
result in increased expenses, reduce overall demand for our products, and make it more difficult to meet expectations of relevant stakeholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
and any potential collaborators may be subject to federal, state and foreign data protection laws and regulations including, without limitation, laws that regulate personal data such as health data. For example, in the United States, numerous
federal and state laws and regulations, including federal health information privacy laws, state personal information laws (e.g., the California Consumer Privacy Act of 2018, or CCPA), state data breach notification laws, state health information
privacy laws and federal and state consumer protection laws and regulations (e.g., Section&nbsp;5 of the Federal Trade Commission Act), govern the collection, use, disclosure and protection of health-related and other personal data. These laws and
regulations could apply to our operations, the operations of our collaborators, or other relevant stakeholders upon whom we depend. In addition, we may obtain personal data (including health information) from third parties (including research
institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic and
Clinical Health Act, or HITECH. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPPA. Additionally, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually
identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The CCPA became
effective on January&nbsp;1, 2020 and gives California residents expanded rights to access and delete their personal data, opt out of certain personal data sharing and receive detailed information about how their personal data is used. The CCPA
requires covered businesses to provide new disclosures to California residents. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.
Although there are limited exemptions for clinical trial data and the CCPA&#146;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, the CCPA may increase our compliance costs and potential
liability. It is anticipated that the CCPA will be expanded on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
January&nbsp;1, 2023, when the California Privacy Rights Act of 2020, or CPRA, becomes operative. The CPRA will, among other things, give California residents the ability to limit use of certain
sensitive information, establish restrictions on the retention of personal data, expand the types of data breaches subject to the CCPA&#146;s private right of action and establish a new California Privacy Protection Agency to implement and enforce
the new law. In addition, other states have enacted or proposed data privacy laws. For example, Virginia recently passed its Consumer Data Protection Act and Colorado recently passed the Colorado Privacy Act, both of which differ from the CPRA and
go into effect in 2023. These laws demonstrate our vulnerability to the evolving regulatory environment related to personal data. As we expand our operations, these and similar laws may increase our compliance costs and potential liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Foreign data protection laws, such as, without limitation, the EU&#146;s GDPR and EU member state implementing legislation, may also apply to
health-related and other personal data that we process, including, without limitation, personal data relating to clinical trial participants. European data protection laws impose strict obligations on the ability to process health-related and other
personal data of European data subjects, including in relation to security (which requires the adoption of administrative, physical and technical safeguards designed to protect such information), collection, use and transfer or personal data.
European data protection laws may affect our use, collection, analysis, and transfer (including cross-border transfer) of such personal data. These include, without limitation, several requirements relating to transparency related to communications
with data subjects regarding the processing of their personal data, obtaining the consent of the individuals to whom the personal data relates, limitations on the retention of personal data, increased requirements pertaining to health data,
establishing a legal basis for processing, notification of data processing obligations or security incidents to the competent national data protection authorities and/or data subjects, the security and confidentiality of the personal data, various
rights that data subjects may exercise with respect to their personal data, and strict rules and restrictions on the transfer of personal data outside of Europe (including from the European Economic Area (EEA), Switzerland and United Kingdom). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">European data protection laws prohibit, without an appropriate legal basis, the transfer of personal data to countries outside of Europe, such as to the
United States, which are not considered relevant authorities to provide an adequate level of data protection. A decision by the Court of Justice of the European Union, or the &#147;Schrems II&#148; ruling, invalidated the <FONT
STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield Framework, and raised questions about whether the European Commission&#146;s Standard Contractual Clauses, or SCCs, one of the primary alternatives to the Privacy Shield, can lawfully be used
for personal data transfers from Europe to the United States or most other countries. Similarly, the Swiss Federal Data Protection and Information Commissioner recently opined that the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy
Shield is inadequate for transfers of personal data from Switzerland to the United States. The United Kingdom, whose data protection laws are similar to those of the European Union, has similarly determined that the
<FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield is not a valid mechanism for lawfully transferring personal data from the United Kingdom to the United States. Use of the SCCs must now be assessed on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis taking into account the legal regime applicable in the destination country, in particular, applicable surveillance laws and rights of individuals and additional measures and/or contractual
provisions may need to be put in place. However, the nature of these additional measures is currently uncertain. Additionally, the European Commission recently adopted new SCCs that will repeal the SCCs adopted under the Data Protection Directive.
This means we may need to update our contracts that involve the transfer of personal data outside of the EEA to the new SCCs. As supervisory authorities issue further guidance on personal data export mechanisms, including on the new SCCs, and/or
start taking enforcement action, our compliance costs could increase, we may be subject to complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in
which we conduct clinical trials, this could negatively impact our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, the UK&#146;s decision to leave the EU, often referred to as Brexit, and ongoing developments
in the UK have created uncertainty regarding data protection regulation in the UK. Following December&nbsp;31, 2020, and the expiry of transitional arrangements between the UK and EU, the data protection obligations of the GDPR continue to apply to <FONT
STYLE="white-space:nowrap">UK-related</FONT> Processing of personal data in substantially unvaried form under the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;UK GDPR&#148; (i.e., the GDPR as it continues to form part of UK law by virtue
of section 3 of the EU (Withdrawal) Act 2018, as amended). However, going forward, there is increasing risk for divergence in application, interpretation and enforcement of the data protection laws as between the UK and EEA. Furthermore, the
relationship between the UK and the EEA in relation to certain aspects of data protection law remains uncertain, including with respect to regulation of data transfers between EU member states and the UK. On June&nbsp;28, 2021, the European
Commission issued an adequacy decision under the GDPR which allows transfers (other than those carried out for the purposes of United Kingdom immigration control) of personal data from the EEA to the UK to continue without restriction for a period
of four years ending June&nbsp;27, 2025. After that period, the adequacy decision may be renewed, but, only if the UK continues to ensure an adequate level of data protection. During these four years, the European Commission will continue to monitor
the legal situation in the UK and could intervene at any point if the UK deviates from the level of data protection in place at the time of issuance of the adequacy decision. If the adequacy decision is withdrawn or not renewed, transfers of
personal data from the EEA to the UK will require a valid &#145;transfer mechanism&#146; and we may be required to implement new processes and put new agreements in place, such as SCCs, to enable transfers of personal data from the EEA to the UK to
continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The increase of foreign privacy and security legal frameworks with which we must comply, increases our compliance burdens and exposure to
substantial fines and penalties <FONT STYLE="white-space:nowrap">for&nbsp;non-compliance.</FONT> For example, under the GDPR, entities that violate the GDPR can face fines of up to the greater of 20&nbsp;million euros or 4% of their worldwide annual
turnover (revenue). Additionally, regulators could prohibit our use of personal data subject to the GDPR. The GDPR has increased our responsibility and potential liability in relation to personal data that we process, requiring us to put in place
additional mechanisms to comply with the GDPR and other foreign data protection requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may also publish privacy policies and other
documentation regarding our collection, processing, use and disclosure of personal data and/or other confidential information. Although we endeavor to comply with our published policies and documentation, we may at times fail to do so or may be
perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees or contractors fail to comply with our published policies and documentation.&nbsp;Such failures can subject us to
potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Compliance with U.S. federal and state as well as foreign data protection laws and regulations could require us to take on more onerous obligations in
our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure, or perceived failure, to comply with federal, state and foreign data protection laws and
regulations could result in government enforcement actions (which could include civil or criminal penalties, fines or penalties), private litigation, a diversion of management attention, adverse publicity and negative effects on our operating
results and business. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages if we fail to comply with applicable data protection laws,
privacy policies or data protection obligations related to information security or security breaches. Moreover, clinical trial participants or subjects about whom we or our collaborators obtain information, as well as the providers who share this
information with us, may limit our ability to use and disclose the information. Claims that we have violated individuals&#146; privacy rights, failed to comply with data protection laws, contracts or privacy notices or breached other obligations,
even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. Compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
with data protection laws may be time consuming, require additional resources and could result in increased expenses, reduce overall demand for our products and make it more difficult to meet
expectations of or commitments to our relevant stakeholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Business disruptions could seriously harm our future revenue and financial condition and
increase our costs and expenses. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our operations, and those of our contractors and consultants, could be subject to earthquakes, power
shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, pandemics and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business
interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to
produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other
business interruption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any future acquisitions, <FONT STYLE="white-space:nowrap">in-licensing</FONT> or strategic partnerships may increase our capital
requirements, dilute our stockholders, divert our management&#146;s attention, cause us to incur debt or assume contingent liabilities and subject us to other risks. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual
property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the assumption of indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance of our equity securities which would result in dilution to our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">assimilation of operations, intellectual property, products and product candidates of an acquired company, including
difficulties associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the diversion of our management&#146;s attention from our existing product candidates and initiatives in pursuing such an
acquisition or strategic partnership; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">spend substantial operational, financial and management resources in integrating new businesses, technologies and products;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and
their existing products or product candidates and regulatory approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our
objectives or even to offset the associated transaction and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, if we undertake such a transaction,
we may incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire intangible assets that could result in significant future amortization expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not
adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Natural disasters could severely disrupt our operations and have a material adverse effect on
our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure,
such as the manufacturing facilities on which we rely, or that otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we
have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse
effect on our business. For example, following Hurricane Maria, shortages in production and delays in a number of medical supplies produced in Puerto Rico resulted, and any similar interruption due to a natural disaster affecting us or any of our
third-party manufacturers could materially delay our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to significantly expand our organization, including building sales and marketing
capability and creating additional infrastructure to support our operations as a public company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of sales and
marketing and finance and accounting. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified
personnel. Due to our limited financial resources and our limited experience in managing such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The
expansion of our operations may lead to significant costs and may divert or stretch our management and business development resources in a way that we may not anticipate. Any inability to manage growth could delay the execution of our business plans
or disrupt our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any
current or future product candidates that we may develop. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will face an inherent risk of product liability exposure related to the testing
of our current or future product candidates in human clinical trials and will face an even greater risk if we commercially sell any current or future product candidates that we may develop. Claims could also be asserted under the state consumer
production acts. If we cannot successfully defend ourselves against claims that our current or future product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result
in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased demand for any current or future product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a diversion of management&#146;s time and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a decline in our stock price; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize any current or future product candidates that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not yet maintain product liability insurance, and we anticipate that we will need to increase our insurance coverage when we begin clinical trials
and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain product liability insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that
may arise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees and independent contractors, including principal investigators, consultants, commercial
collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future
commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate
the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; United States federal and state
fraud and abuse laws, data privacy and security laws and other similar <FONT STYLE="white-space:nowrap">non-United</FONT> States laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities
subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product,
which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may
not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are
subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from
participation in Medicare, Medicaid and other United States federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance,</FONT> imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability
to operate our business and our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Common Stock and This Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on shares outstanding as of June&nbsp;30, 2021, upon completion of this offering, we will have outstanding a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. Of these shares, only&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock sold in this offering,
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the public market immediately after
this offering. Each of our officers and directors and substantially all our stockholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters that restrict their ability to sell or transfer their shares.
The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, the representatives of our underwriters may, in their sole discretion, permit our officers,
directors and other current stockholders who are subject to the contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. After the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements expire, based on shares outstanding as of June&nbsp;30, 2021, up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be eligible
for sale in the public market, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of which are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144
under the Securities Act of 1933, as amended, or Securities Act. In addition,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock that are subject to outstanding options as of June&nbsp;30, 2021
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock that are subject to options granted after June&nbsp;30, 2021 will become eligible for sale in the public market to the extent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
permitted by the provisions of various vesting agreements, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rules 144 and 701 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After this offering, the holders of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our outstanding
common stock as of June&nbsp;30, 2021 will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our
stockholders. We also intend to register shares of common stock that we may issue under our equity incentive plans. Once we register these shares, they will be able to be sold freely in the public market upon issuance, subject to the <FONT
STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above and in the section entitled &#147;Underwriting.&#148; The
representatives of the underwriters may release some or all of the shares of common stock subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time and without notice, which would allow for earlier sales of shares in the
public market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on
the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options or warrants, or the perception that such sales may occur, could
adversely affect the market price of our common stock, even if our business is doing well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also expect that significant additional capital may
be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. To the
extent that the additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. These sales, or the perception in the market that the holders of a large number of
shares intend to sell shares, could reduce the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities or industry analysts do not publish research or publish
inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The trading market for our common
stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our
business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to
stockholder approval. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the beneficial ownership of our common stock as of June&nbsp;30, 2021, prior to this offering, our executive
officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 76.2% of our voting stock and, upon the completion of this offering, that same group will hold
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock (assuming no exercise of the underwriters&#146; option to purchase additional shares, no exercise of
outstanding options and no purchases of shares in this offering by any of this group), in each case assuming the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock and the net exercise
of warrants outstanding that would otherwise expire upon the completion of this offering. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder
approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these
stockholders may not be the same as or may even conflict with your interests. For example, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an
opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the
trading price of our common stock due to investors&#146; perception that conflicts of interest may exist or arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If you purchase our common stock in this
offering, you will incur immediate and substantial dilution in the book value of your shares. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">You will suffer immediate and substantial
dilution in the net tangible book value of the common stock you purchase in this offering. Assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the
midpoint of the price range set forth on the cover page of this prospectus, and assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and that the underwriters do not exercise their
option to acquire additional common stock in this offering, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share in net tangible book value of the
common stock, representing the difference between the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and our pro forma as adjusted net tangible book value
per share as of June&nbsp;30, 2021. In addition, investors purchasing common stock in this offering will contribute&nbsp;&nbsp;&nbsp;&nbsp;% of the total amount invested by stockholders since inception but will only own&nbsp;&nbsp;&nbsp;&nbsp;% of
the shares of common stock outstanding. In the past, we issued options and other securities to acquire common stock at prices significantly below the initial public offering price. To the extent these outstanding securities are ultimately exercised,
investors purchasing common stock in this offering will sustain further dilution. In addition, if the underwriters exercise their option to purchase additional shares, or outstanding options and warrants are exercised, you could experience further
dilution. See &#147;Dilution&#148; for a more detailed description of the dilution you will experience immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad
discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will have considerable discretion in the application of the net proceeds of this offering. We intend to use the net proceeds from this offering to
fund clinical development of <FONT STYLE="white-space:nowrap">AU-011</FONT> and to fund new and ongoing research activities, working capital and other general corporate purposes, which may include funding for the hiring of additional personnel,
capital expenditures and the costs of operating as a public company. As a result, investors will be relying upon management&#146;s judgment with only limited information about our specific intentions for the use of the balance of the net proceeds of
this offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not
produce income or that loses value. For a further description of the use of proceeds from this offering, please refer to the section entitled &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership change&#148;
(generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity over a three year period), the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss
carryforwards and certain other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in
the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside our control. Our net operating losses and tax credits may also be impaired or restricted under state law. As of December&nbsp;31, 2020, we
had federal net operating loss carryforwards of approximately $106.1 million, and state net operating loss carryforwards of $89.3 million. Furthermore, our ability to utilize our NOLs or credits is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As a result, the amount of the net operating loss and tax credit carryforwards presented in our
financial statements could be limited and may expire unutilized. Under current law, unused U.S. federal net operating loss carryforwards generated in taxable years beginning after December&nbsp;31, 2017 are not subject to expiration and may be
carried forward indefinitely. For taxable years beginning after December&nbsp;31, 2020, however, the deductibility of such U.S. federal net operating losses is limited to 80% of our taxable income in such taxable years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of
gain. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any,
to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for
the foreseeable future. For a further description of our dividend policy, please refer to the section entitled &#147;Dividend Policy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject
to securities litigation, which is expensive and could divert management attention. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The market price of our common stock may be volatile
and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us
could result in substantial costs and divert our management&#146;s attention from other business concerns, which could seriously harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our
quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">variations in the level of expense related to the ongoing development of AU-011 or future development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or existing or
future collaborators or licensing partners; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or
receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may
become involved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic
investments or changes in business strategy; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand
for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory developments affecting our product candidates or those of our competitors; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in general market and economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline
substantially. Furthermore, any quarterly fluctuations in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and
should not be relied upon as an indication of our future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our amended and restated bylaws to be effective upon the consummation of this offering
designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to our amended and restated bylaws that will become effective upon the completion of this offering, unless we consent in writing to the
selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of
breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or our amended and
restated certificate of incorporation or our amended and amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine (the
Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws will further provide that unless we consent in writing to the
selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the Federal Forum Provision). In
addition, our amended and restated bylaws that will become effective upon the completion of this offering will provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice
of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs
on stockholders in pursuing any such claims. Additionally, these forum selection clauses in our amended and restated bylaws may limit our stockholders&#146; ability to bring a claim in a judicial forum that they find favorable for disputes with us
or our directors, officers or employees, which may discourage the filing of such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware
Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#147;facially valid&#148; under Delaware law, there is uncertainty as to whether other
courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation
costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other
courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in
an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Anti-takeover provisions in our amended and restated certificate of incorporation and bylaws and under Delaware
law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and, therefore, decrease the trading price of our common stock.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our fourth amended and restated certificate of incorporation and amended and restated bylaws, which are to become effective at or prior to
the completion of this offering, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board
will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a
meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a requirement that special meetings of the stockholders may be called only by the board of directors acting pursuant to a
resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and,
in addition to any other vote required by law, upon the approval of not less <FONT STYLE="white-space:nowrap">than&nbsp;two-thirds&nbsp;(2/3)</FONT> of all outstanding shares of our voting stock then entitled to vote in the election of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a requirement of approval of not less than a majority of all outstanding shares of our voting stock to amend any bylaws by
stockholder action and not less <FONT STYLE="white-space:nowrap">than&nbsp;two-thirds&nbsp;(2/3)</FONT> of all outstanding shares of our voting stock to amend specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without
stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding
voting stock. These anti-takeover provisions and other provisions in our fourth amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control
of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests
and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors
could cause the market price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General Risks </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face
serious consequences for violations. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control,
sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or
anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of
contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also
expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we
can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in
2008, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and the <FONT STYLE="white-space:nowrap">current&nbsp;COVID-19&nbsp;pandemic</FONT> has caused significant volatility and uncertainty in
U.S. and international markets. See &#147;Risks Related to our Business and Industry<I>&#151;</I><FONT STYLE="white-space:nowrap">The&nbsp;COVID-19&nbsp;pandemic,</FONT> or a similar pandemic, epidemic, or outbreak of an infectious disease may
materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.&#148; A severe or prolonged economic downturn could result in a variety of risks to our business,
including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or
cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees, independent contractors, consultants, academic collaborators, partners and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to the risk of employee fraud or other
illegal activity by our employees, independent contractors, consultants, academic collaborators, partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws of the
FDA, EMA and comparable foreign regulatory authorities, provide true, complete and accurate information to the FDA, EMA and comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with healthcare
fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin
commercializing those products in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our
current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter
misconduct by our employees, independent contractors, consultants, academic collaborators, partners and vendors, and the precautions we take to detect and prevent such activities may not be effective in controlling unknown or unmanaged risks or
losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful in defending ourselves or
asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, disgorgement, possible exclusion from participation in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>An active and liquid trading market for our common stock may not develop and you may not be able to resell your shares of common stock at or above the public
offering price. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to this offering, no market for shares of our common stock exists and an active trading market for our shares may
never develop or be sustained following this offering. The initial public offering, or IPO, price for our common stock will be determined through negotiations with the underwriters and the negotiated price may not be indicative of the market price
of our common stock after this offering. The market value of our common stock may decrease from the IPO price. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the IPO price. The lack of
an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive
market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; and we cannot be certain if the reduced reporting requirements
applicable to &#147;emerging growth companies&#148; and &#147;smaller reporting companies&#148; will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. For as long as we continue to
be an &#147;emerging growth company,&#148; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&nbsp;not being required to comply
with the independent auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley Act, (2)&nbsp;reduced disclosure obligations regarding executive compensation in our periodic reports and
proxy statements and (3)&nbsp;exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not approved previously. In addition, as an
&#147;emerging growth company,&#148; we are only required to provide two years of audited financial statements and two years of selected financial data in our periodic reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will remain an &#147;emerging growth company&#148; until the earlier of (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth
anniversary of the closing of our IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a &#147;large accelerated filer,&#148; which requires the market value of our common
stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to exceed $700.0&nbsp;million as of the prior June&nbsp;30, and (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even after we no longer qualify as an
&#147;emerging growth company,&#148; we may still qualify as a &#147;smaller reporting company,&#148; which would&nbsp;allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply
with&nbsp;the independent auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations&nbsp;regarding executive compensation in our periodic reports and proxy statements. We cannot predict if
investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result,&nbsp;there may be a less active trading market for our common stock and our share
price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the JOBS Act, &#147;emerging growth companies&#148; can also delay adopting new or revised accounting standards
until such time as those standards apply to private companies. We have elected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised
accounting standards. Until the date that we are no longer an &#147;emerging growth company&#148; or affirmatively and irrevocably opt out of the exemption provided by Section&nbsp;7(a)(2)(B) of the Securities Act, upon issuance of a new or revised
accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for <FONT STYLE="white-space:nowrap">non-emerging</FONT>
growth companies and the date on which we will adopt the recently issued accounting standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting company,&#148;
meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year. We may
continue to be a &#147;smaller reporting company&#148; until (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than
$100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million as of the prior June 30th. If we are a &#147;smaller
reporting company&#148; at the time we cease to be an &#147;emerging growth company,&#148; we may continue to rely on exemptions from certain disclosure requirements that are available to &#147;smaller reporting companies.&#148; Specifically, as a
&#147;smaller reporting company&#148; we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies,
&#147;smaller reporting companies&#148; have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The market price of our stock may be volatile,
and you could lose all or part of your investment. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The trading price of our common stock following this offering is likely to be highly
volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public offering price. The market
price for our common stock may be influenced by many factors, including the other risks described in this section of the prospectus entitled &#147;Risk Factors&#148; and the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results of preclinical studies and results or enrollment of clinical trials of
<FONT STYLE="white-space:nowrap">AU-011</FONT> or our future product candidates, or those of our potential future competitors or our existing or future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our employees, trials, collaboration
partners, suppliers, our results of operations, liquidity and financial condition; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations
applicable to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success of future competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the
timing of these introductions or announcements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actions taken by regulatory agencies with respect to our products, clinical trials, manufacturing process or sales and
marketing terms; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success of our efforts to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional technologies,
products or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments concerning any future collaborations, including but not limited to those with our sources of manufacturing
supply and our commercialization partners; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital
commitments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our
ability to obtain patent protection for <FONT STYLE="white-space:nowrap">AU-011</FONT> or our future product candidates and products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability or inability to raise additional capital and the terms on which we raise it; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common
stock, other comparable companies or our industry generally; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our failure or the failure of our competitors to meet analysts&#146; projections or guidance that we or our competitors may
give to the market; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcement and expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">speculation in the press or investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of our common stock by us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the concentrated ownership of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in accounting principles; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">terrorist acts, acts of war or periods of widespread civil unrest; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">natural disasters, pandemics and other calamities; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic, industry and market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced
extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our
actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#147;Risk Factors&#148; section, could have a dramatic and adverse impact on the market price of our
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against public companies following declines in the market
price of their securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent years. If we face such litigation, it could result insubstantial costs and a diversion
of management&#146;s attention and our resources, which could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have incurred and will continue to incur increased costs as a result of
operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a public
company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, the
Dodd-Frank Wall Street Reform and Consumer Protection Act and rules implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and
will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. We cannot predict or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain
qualified persons to serve on our board of directors, our board committees or as executive officers. The increased costs may require us to reduce costs in other areas of our business or increase the prices of our products once commercialized.
Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and
governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section 404, we will be required to furnish a report by our management on our
internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an &#147;emerging growth company,&#148; we
will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. In addition, for as long as we are a &#147;smaller reporting company&#148; with less than
$100&nbsp;million in annual revenue, we would be exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section&nbsp;404(b) of the of the Sarbanes-Oxley Act of 2002. To
achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to
continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as
appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor
our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in
the financial markets due to a loss of confidence in the reliability of our financial statements. In additional, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will become subject to the periodic reporting requirements of the Securities Exchange Act of 1934, or the Exchange
Act. We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed,
summarized and reported within the time periods specified in the rules and forms of the SEC. However, any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system will be met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available
to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown
risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.
Forward-looking statements in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and future
preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our
research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to efficiently develop our existing product candidates and discover new product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully manufacture our drug substances and product candidates for preclinical use, for clinical trials
and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability and willingness of our third-party strategic collaborators to continue research and development activities
relating to our development candidates and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and commercialization of our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to commercialize our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the implementation of our business model, and strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or
arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">future agreements with third parties in connection with the commercialization of product candidates and any other approved
product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our use of the proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> including mitigation efforts and
economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials and any future studies or trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;should,&#148; &#147;expects,&#148;
&#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. These
statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could
materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. If one or
more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a
guarantee of future performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read
this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration statement, of which this prospectus forms a part, completely and with the understanding
that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking
statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent
to the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, statements that &#145;&#145;we believe&#146;&#146; and similar statements reflect our beliefs and
opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or
incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not
to unduly rely upon these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus also contains estimates, projections and other information concerning our industry, our
business and the markets for our programs and product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may
differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
business, market, and other data from our own internal estimates and research as well as from reports, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and
similar sources. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and
uncertainties and are subject to change based on various factors, including those discussed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that our net proceeds from the sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise in
full their option to purchase additional shares, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set
forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our net proceeds from this
offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A 1.0&nbsp;million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would
increase (decrease) our net proceeds from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per share and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. This information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined
at pricing. We do not expect that a change in the initial price to the public or the number of shares by these amounts would have a material effect on uses of the proceeds from this offering, although a decrease in the initial offering price without
a corresponding increase in the number of shares offered may accelerate the time at which we will need to seek additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently
expect to use our net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance our initial product candidate, AU-011 through
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to develop our platform; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remaining proceeds for general corporate purposes, which may include the hiring of additional personnel, capital
expenditures and the costs of operating as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our expected use of the net proceeds from this offering represents
our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the
amounts that we will actually spend on the uses set forth above and we expect that we will require additional funds in order to fully accomplish the specified uses of the proceeds of this offering. We may also use a portion of the net proceeds to <FONT
STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses or technologies to continue to build our pipeline, research and development capabilities and our intellectual property position, although we currently have
no agreements, commitments, or understandings with respect to any such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on our current plans, we believe that our existing cash
and cash equivalents, together with the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The expected net proceeds from this offering will not be sufficient for us to fund any of our product candidates through regulatory approval, and
we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Due to the many inherent uncertainties in the development of our programs and product candidates, the
amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our research and development, the timing of patient enrollment and evolving regulatory requirements, the timing and success
of preclinical studies, our ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions, any strategic alliances that we may enter into with third parties for our product candidates or strategic
opportunities that become available to us, and any unforeseen cash needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pending our use of the net proceeds from this offering, we intend to
invest the net proceeds in a variety of capital preservation instruments, including short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict
whether the proceeds invested will yield a favorable return. Our management will retain broad discretion in the application of the net proceeds we receive from our initial public offering, and investors will be relying on the judgment of our
management regarding the application of the net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to
fund the growth and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will
depend on our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of
receiving cash dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and our capitalization as of June&nbsp;30, 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the conversion of all outstanding shares of our preferred stock into an
aggregate of 308,946,244 shares of common stock immediately prior to the completion of this offering (ii)&nbsp;the issuance of 173,827 shares of Series&nbsp;B convertible preferred stock upon the exercise of the outstanding preferred stock warrants
subsequent to June&nbsp;30, 2021, which will convert into 173,827 shares of our common stock upon completion of this offering (iii)&nbsp;the issuance and sale of 50,000 shares of common stock on August&nbsp;2, 2021 to Elisabet de los Pinos, our CEO,
pursuant to an option exercise, with an exercise price of $0.40 per share (iv)&nbsp;the issuance and sale of 30,000 and 20,000 shares of common stock on October&nbsp;5, 2021 to a holder of our convertible preferred stock, pursuant to an option
exercise, with an exercise price of $0.42 and $0.40 per share of common stock, respectively and (v)&nbsp;the filing and effectiveness of our tenth amended and restated certificate of incorporation upon the closing of this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give effect to (i)&nbsp;the pro forma adjustments described above and (ii)&nbsp;our
sale in this offering of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table should be read together with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Description of Capital Stock,&#148; and the financial statements and related notes appearing elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;Actual&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;Pro&nbsp;Forma&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;Pro&nbsp;Forma&nbsp;&nbsp;&nbsp;</B><br><B>&nbsp;&nbsp;&nbsp;As&nbsp;Adjusted(1)&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock (Series A, <FONT STYLE="white-space:nowrap">A-1,</FONT> <FONT
STYLE="white-space:nowrap">A-2,</FONT> B, <FONT STYLE="white-space:nowrap">C-1,</FONT> <FONT STYLE="white-space:nowrap">C-2,</FONT> <FONT STYLE="white-space:nowrap">D-1,</FONT> <FONT STYLE="white-space:nowrap">D-2,</FONT> E), $0.00001 par value,
308,506,707 shares authorized, 308,332,857 shares issued and outstanding, actual; 10,000,000 authorized, issued and outstanding, pro forma&nbsp;and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock (Class A and B), $0.00001 par value, 470,183,383 shares authorized, 6,015,717 issued and
outstanding, actual; 470,183,383 shares authorized, 315,235,788 issued and outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
increase (decrease) the pro forma as adjusted amount of cash and cash equivalents, common stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146;
deficit, and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us, as set forth on the cover page of this
prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A 1.0&nbsp;million share increase (decrease) in the number of shares offered by us would increase
(decrease) the pro forma as adjusted amount of cash and cash equivalents, common stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; deficit and total capitalization by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, which is the midpoint of the price range set forth on the cover page of this prospectus, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. This information is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering
determined at pricing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The actual, pro forma, and pro forma as adjusted information set forth in the table excludes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">39,848,939 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2021, at a
weighted average exercise price of $0.34 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock
reserved for future issuance under our 2021<B> </B>Plan, which will become effective in connection with the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock
reserved for future issuance under our ESPP, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_9"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the
initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our historical net tangible book value (deficit) as of June&nbsp;30, 2021 was $(124.3)&nbsp;million, or $(20.67)&nbsp;per share of our common stock. Our
historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and preferred stock, which are not included within stockholders&#146; equity (deficit). Historical net tangible book value (deficit)
per share represents our historical net tangible book value (deficit) divided by the 6,015,717 shares of our common stock outstanding as of June&nbsp;30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our pro forma net tangible book value as of June&nbsp;30, 2021 was $91.3&nbsp;million, or $0.29&nbsp;per share of our common stock. Pro forma net
tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 308,946,244 shares of common
stock immediately prior to the completion of this offering, the issuance of 173,827 shares of Series B convertible preferred stock upon the exercise of the outstanding preferred stock warrants subsequent to June&nbsp;30, 2021, which will convert
into 173,827 shares of our common stock upon completion of this offering, the issuance and sale of 50,000 shares of common stock on August&nbsp;2, 2021 to Elisabet de los Pinos, our CEO, pursuant to an option exercise, with an exercise price of
$0.40&nbsp;per share and the issuance and sale of 30,000 and 20,000 shares of common stock on October&nbsp;5, 2021 to a holder of our convertible preferred stock, pursuant to an option exercise, with an exercise price of $0.42 and $0.40 per share of
common stock, respectively. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares outstanding as of June&nbsp;30, 2021, after giving effect to the automatic conversion of all
outstanding shares of our preferred stock into common stock immediately prior to the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After giving further effect to
our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2021 would have been
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate
increase in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to existing stockholders and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering. Dilution per share to new
investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the assumed initial public offering price per share paid by new investors. The following table illustrates this dilution on a per
share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value per share as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma increase in net tangible book value per share as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value per share as of June&nbsp;30, 2021, before giving effect to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma net tangible book value per share attributable to investors purchasing shares in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution in pro forma as adjusted net tangible book value per share to new investors purchasing shares in
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, our pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp; and dilution per share to new investors purchasing shares in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. A 1.0&nbsp;million share increase in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value per share after
this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and decrease the dilution per share to new investors participating in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. A 1.0&nbsp;million share decrease in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this
offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and increase the dilution per share to new investors participating in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net
tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing an immediate increase in pro forma as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to new investors purchasing common stock in this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. If any shares are issued upon exercise of outstanding options or warrants, you will experience further dilution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes, on the pro forma as adjusted basis described above, the differences between the number of shares of common stock
purchased from us, the total consideration paid to us and the average price per share paid by existing stockholders and by new investors purchasing shares of common stock in this offering. The calculation below is based on an assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price<BR>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315,235,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">218,548,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If
the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock
outstanding after this offering, and the number of shares of common stock held by new investors participating in the offering would be increased to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on 315,235,788 shares of our common stock
outstanding as of June&nbsp;30, 2021, which assumes the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
automatic conversion of all of our outstanding preferred stock into 308,946,244 shares of common stock immediately prior to the completion of this offering, the issuance of 173,827 shares of
Series&nbsp;B convertible preferred stock upon the exercise of the outstanding preferred stock warrants subsequent to June&nbsp;30, 2021, which will convert into 173,827 shares of our common stock upon completion of this offering, the issuance and
sale of 50,000 shares of common stock on August&nbsp;2, 2021 to Elisabet de los Pinos, our CEO, pursuant to an option exercise, with an exercise price of $0.40&nbsp;per share, the issuance and sale of 30,000 and 20,000 shares of common stock on
October&nbsp;5, 2021 to a holder of our convertible preferred stock, pursuant to an option exercise, with an exercise price of $0.42&nbsp;and $0.40 per share of common stock, respectively and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">39,848,939 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2021, at a
weighted average exercise price of $0.34&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
reserved for future issuance under our 2021<B> </B>Plan, which will become effective in connection with the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
reserved for future issuance under our ESPP, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To
the extent that outstanding options are exercised or shares are issued under our 2021 Plan, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we
believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities may result in further dilution to
our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together
with our financial statements and the related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans,
strategies, objectives, expectations and intentions for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#147;Risk
Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by these forward-looking statements. Please also see the section entitled &#147;Special Note Regarding Forward-Looking
Statements.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a clinical-stage
biotechnology company leveraging our novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Our proprietary platform enables the
targeting of a broad range of solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. Our VDCs are largely agnostic to tumor type and can
recognize a surface marker, known as heparin sulfate proteoglycans, or HSPGs, that are specifically modified and broadly expressed on many tumors. We are focusing our initial development of VDCs to treat tumors of high unmet need in ocular and
urologic oncology. We are focusing our initial development of VDCs to treat tumors of high unmet need in ocular and urologic oncology. <FONT STYLE="white-space:nowrap">AU-011,</FONT> our first VDC candidate, is being developed for the first line
treatment of primary choroidal melanoma, a rare disease with no drugs approved. We have completed a Phase 1b/2 trial using intravitreal administration that has demonstrated a statistically significant growth rate reduction in patients with prior
active growth and high levels of tumor control with visual acuity preservation in a majority of patients, as assessed using clinical endpoints in alignment with feedback from the FDA. These data supported advancement into a Phase 2 dose escalation
trial, where we are currently evaluating suprachoroidal, or SC, administration of <FONT STYLE="white-space:nowrap">AU-011.</FONT> We plan to present six to twelve month safety and efficacy data from this trial in 2022, and, if favorable, initiate a
pivotal trial in the second half of 2022. We are also developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications and plan to file an IND in the United States in the second half of 2022 for choroidal
metastases. Leveraging our VDCs&#146; broad tumor targeting capabilities, we also plan to initiate a Phase 1a trial in <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer, or NMIBC, our first
<FONT STYLE="white-space:nowrap">non-ophthalmic</FONT> solid tumor indication, in the second half of 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were incorporated as a Delaware
corporation in 2009 and our headquarters is located in Cambridge, Massachusetts. Since our inception, we have focused our efforts on identifying and developing potential product candidates, conducting preclinical studies and clinical trials,
organizing and staffing our company, business planning, establishing our intellectual property portfolio, raising capital, conducting discovery, research and development activities and providing general and administrative support for these
operations. We do not have any product candidates approved for sale and have not generated any revenue to date. We have funded our operations primarily through the sale of convertible preferred stock, common stock, and convertible debt. From
inception through June&nbsp;30, 2021, we have raised an aggregate of approximately $218.5&nbsp;million of gross proceeds primarily from private placements of our equity and convertible debt securities as well as through the issuance of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have incurred significant operating losses in every year since our inception in 2009 and have not generated any revenue. We expect to
continue to incur significant expenses and operating losses for the foreseeable future. Our ability to generate product revenue sufficient to achieve profitability will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
depend on the successful development and commercialization of one or more of our product candidates. Our net losses were $14.8&nbsp;million and $13.7&nbsp;million for the six months ended
June&nbsp;30, 2021 and 2020, respectively, and $22.2&nbsp;million and $24.2&nbsp;million for the&nbsp;years ended December&nbsp;31, 2020 and 2019, respectively. As of June&nbsp;30, 2021, we had an accumulated deficit of $131.7&nbsp;million. In
addition, our losses from operations may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our clinical trials and our expenditures on other research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We anticipate that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly as we
advance the preclinical studies and clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company following the completion of this offering. We expect that our expenses and
capital requirements will increase substantially if and as we: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">conduct our current and future clinical trials of <FONT STYLE="white-space:nowrap">AU-011;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">progress the preclinical and clinical development of new indications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish our manufacturing capability, including developing our contract development and manufacturing relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek to identify and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory approval of our current and future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expand our operational, financial, and management systems and increase personnel, including personnel to support our
preclinical and clinical development, manufacturing and commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand and protect our intellectual property portfolio; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated
with operating as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a result, we will need substantial additional funding to support our continuing operations
and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations or other strategic transactions. We
may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly
delay, scale back or discontinue the development and commercialization of one or more of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will not generate revenue from
product sales unless and until we successfully complete clinical development and obtain marketing approval for our product candidates. The lengthy process of securing marketing approvals for new drugs requires the expenditure of substantial
resources. Any delay or failure to obtain regulatory approvals would materially adversely affect the development efforts of our product candidates and our business overall. Because of the numerous risks and uncertainties associated with product
development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail
to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2021, we had cash and cash equivalents of $92.2&nbsp;million. We believe that the anticipated net proceeds from this offering,
together with our existing cash and cash equivalents. will enable us to fund our operating expenses and capital expenditure requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have
based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and Capital Resources&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Pandemic </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to present substantial public health and economic challenges around the world,
and to date has led to the implementation of various responses, including government-imposed quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stay-at-home</FONT></FONT> orders, travel restrictions, mandated business
closures and other public health safety measures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We continue to closely monitor the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic on all aspects of our business, including how it has and will continue to impact our operations and the operations of our suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required
by federal, state or local authorities. In addition, we have taken steps to minimize the current environment&#146;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service
providers. For the safety of our employees and families, we have introduced enhanced safety measures for scientists to be present in our labs and increased the use of third party service providers for the conduct of certain experiments and studies
for research programs. To date, we&#146;ve only encountered minor delays in our manufacturing process due to a supply chain constraint with one of our vendors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Beyond the impact on our pipeline, the extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> ultimately impacts our business, results of
operations and financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, new information that may emerge
concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or the effectiveness of actions taken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, including vaccination campaigns, among others. If we
or any of the third parties with whom we engage, however, were to experience any additional shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be
materially or negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. Although to date, our business has not been materially impacted by
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> it is possible that our clinical development timelines could be negatively affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which could materially and adversely affect our business,
financial condition and results of operations. See &#147;Risk Factors&#148; for a discussion of the potential adverse impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since inception, we have not
generated any revenue and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for one or more of our product candidates are successful and result in regulatory approval, or if we
enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements. We cannot predict if, and when, or to what extent, we
will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Research and
Development Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery
efforts and the development of our <FONT STYLE="white-space:nowrap">AU-011</FONT> program, and include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">employee-related expenses, including salaries, related-benefits and stock-based compensation expense for employees engaged
in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fees paid to consultants for services directly related to our product development and regulatory efforts;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses associated with conducting preclinical studies performed by ourselves, outside vendors or academic collaborators;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses incurred under agreements with contract research organizations, or CROs, as well as consultants that conduct and
provide supplies for our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of manufacturing <FONT STYLE="white-space:nowrap">AU-011,</FONT> including the potential cost of CMOs that
manufacture product for use in our preclinical studies and clinical trials and perform analytical testing, <FONT STYLE="white-space:nowrap">scale-up</FONT> and other services in connection with our development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs associated with preclinical activities and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs associated with our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs related to compliance with regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">allocated expenses for utilities and other facility-related costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress
to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our
financial statements as prepaid or accrued research and development expenses. We allocate our direct external research and development costs across the entire <FONT STYLE="white-space:nowrap">AU-011</FONT> program. Preclinical expenses consist of
external research and development costs associated with activities to support our current and future clinical programs, but are not allocated by specific indications due to the overlap of the potential benefit of those efforts across the entire <FONT
STYLE="white-space:nowrap">AU-011</FONT> program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development activities are central to our business. We expect that our research and
development expenses will increase for the foreseeable future as we continue clinical development for <FONT STYLE="white-space:nowrap">AU-011</FONT> and continue to discover and develop additional product candidates. If any of our product candidates
enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General
and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive and finance functions. General and administrative expenses also include professional fees for
legal, accounting, auditing, tax and consulting services; travel expenses; and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs not included in research and development.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect that our general and administrative expenses will increase in the near-term as we continue to build a team to support our administrative,
accounting and finance, communications, legal and business development efforts. Following this offering, we expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax
compliance services; director and officer insurance costs; and investor and public relations costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Other Income (Expense) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our other income (expense) consists of changes in the fair value of our warrant liability and derivative, gain/loss on disposal of fixed assets, interest
expense on outstanding debt, and interest income on our invested cash balances. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Income Taxes </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our earned
research and development tax credits, due to the uncertainty of realizing a benefit from those items. As of December&nbsp;31, 2020, we had federal and state gross operating loss carryforwards of $106.1&nbsp;million and $89.3&nbsp;million,
respectively, which may be used to offset future taxable income, if any. Federal gross operating loss carryforwards of $44.2&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
begin to expire in 2029 and go through 2037 and federal gross operating loss carryforwards of $61.9&nbsp;million do not expire. The state gross operating loss carryforwards begin to expire in
2030. As of December&nbsp;31, 2020, we had federal and state research and development tax credit carryforwards of $3.8&nbsp;million and $1.1&nbsp;million, respectively, which may be used to offset future income tax liabilities and begin to expire in
2029 and 2027, respectively. Due to the degree of uncertainty related to the ultimate use of the deferred tax assets, we have fully reserved these tax benefits, as the determination of the realization of the deferred tax benefits was not determined
to be more likely than not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2021 and 2020 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the six months ended June&nbsp;30, 2021 and 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income (expense), including amortization of discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our research and development expenses for the six months ended June&nbsp;30, 2021 and 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Direct research and development expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Phase 1b/2 IVT Study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SC Dose Escalation Study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Registry Study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Manufacturing Development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Unallocated expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel expenses(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Includes stock-based compensation of $0.1&nbsp;million for the six months ended June&nbsp;30, 2021 and 2020.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses were $10.8&nbsp;million for the six months ended June&nbsp;30, 2021,
compared to $11.6&nbsp;million for the six months ended June&nbsp;30, 2020. The decrease of $0.8&nbsp;million was primarily due to decreases of $1.2&nbsp;million in preclinical expense and $0.4&nbsp;million in expenses for the continued development
and the advancement of clinical trials, offset by an increase of $0.8&nbsp;million in personnel expenses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General and administrative expenses were $3.9&nbsp;million for the six months ended June&nbsp;30, 2021, compared to $2.0&nbsp;million for the
six months ended June&nbsp;30, 2020. The increase of $1.9&nbsp;million was primarily due to increases in legal and professional fees of $1.3&nbsp;million and personnel expenses of $0.6&nbsp;million which was primarily due to an increase in
stock-based compensation expense. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2020 and 2019 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the years ended December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense, including amortization of discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our research and development expenses for the years ended December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Direct research and development expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Phase 1b/2 IVT Study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(794</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SC Dose Escalation Study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Registry Study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Manufacturing Development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Unallocated expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel expenses(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Includes stock-based compensation of $0.2&nbsp;million for the years ended December&nbsp;31, 2020 and 2019.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses were $18.0&nbsp;million for the year ended December&nbsp;31, 2020,
compared to $19.6&nbsp;million for the year ended December&nbsp;31, 2019. The decrease of $1.6&nbsp;million was primarily due to $3.4&nbsp;million decrease in manufacturing development expenses offset by an increase of $0.3&nbsp;million in expenses
for the continued development and the advancement of clinical trials, $0.6&nbsp;million in preclinical expenses, $0.7&nbsp;million in personnel expenses, and $0.2&nbsp;million in facility and other expenses related to office space. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General
and administrative expenses were $4.2&nbsp;million for the year ended December&nbsp;31, 2020, compared to $4.5&nbsp;million for the year ended December&nbsp;31, 2019. The decrease of $0.3&nbsp;million was primarily due to a decrease in legal and
professional fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To
date we have funded our operations primarily through the sale of convertible preferred stock, common stock, and convertible debt. Through June&nbsp;30, 2021, we have raised an aggregate of approximately $218.5&nbsp;million of gross proceeds
primarily from private placements of our equity and convertible debt securities and warrants, as well as through the issuance of our common stock. As of June&nbsp;30, 2021, we had cash and cash equivalents of $92.2&nbsp;million and an accumulated
deficit of $131.7&nbsp;million. Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized our product
candidate for any of its multiple indications, which is in various phases of preclinical and clinical development, depending on the indication, and we do not expect to generate revenue from sales of any products for the foreseeable future, if at
all. Since our inception we have incurred losses and negative cash flows from operations and expect these conditions to continue for the foreseeable future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table
summarizes our cash flows for each of the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Operating Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2021, net cash used in operating activities was $11.6&nbsp;million, primarily due to our net loss of
$14.8&nbsp;million offset by increases in our operating assets and liabilities of $2.3&nbsp;million and in <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.9&nbsp;million. Increases in our operating assets and liabilities consisted
primarily of a $1.6&nbsp;million in accounts payable, $0.4 million in prepaid expenses and other assets and $0.3&nbsp;million in accrued expenses and other liabilities. Our <FONT STYLE="white-space:nowrap">non-cash</FONT> charges consisted primarily
of $0.5&nbsp;million in stock-based compensation and $0.4&nbsp;million in depreciation expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2020, net
cash used in operating activities was $14.0&nbsp;million, primarily due to our net loss of $13.7&nbsp;million and a decrease in our operating assets and liabilities of $1.0&nbsp;million, partially offset by
<FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.7&nbsp;million. Decreases in our operating assets and liabilities consisted primarily of $2.1&nbsp;million in accrued expenses and other liabilities and $0.2&nbsp;million in prepaid
expenses and other assets offset by $1.3&nbsp;million in accounts payable. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">non-cash</FONT> charges consisted primarily of $0.3&nbsp;million in stock-based compensation and $0.4&nbsp;million in depreciation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2020, net cash used in operating activities was $24.3&nbsp;million, primarily due to our net loss of
$22.2&nbsp;million and decreases in our operating assets and liabilities of $3.7&nbsp;million and partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.6&nbsp;million. Decreases in our operating assets and liabilities
consisted primarily of $1.7&nbsp;million in accounts payable, $1.8&nbsp;million in accrued expenses and other liabilities and $0.2&nbsp;million in prepaid expenses and other assets. Our <FONT STYLE="white-space:nowrap">non-cash</FONT> charges
consisted primarily of $0.8&nbsp;million in stock-based compensation and $0.8&nbsp;million in depreciation expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended
December&nbsp;31, 2019, net cash used in operating activities was $20.7&nbsp;million, primarily due to our net loss of $24.2&nbsp;million partially offset by increases in our operating assets and liabilities of $2.5&nbsp;million and <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges of $1.0&nbsp;million. Increases in our operating assets and liabilities consisted primarily of a $1.0&nbsp;million increase in accounts payable and $1.6&nbsp;million increase in accrued expenses and
other liabilities partially offset by a decrease of $0.1&nbsp;million in prepaid expenses and other assets. Our <FONT STYLE="white-space:nowrap">non-cash</FONT> charges consisted primarily of $0.5&nbsp;million in stock-based compensation and
$0.5&nbsp;million in depreciation expense. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Investing Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash used in investing activities during the six months ended June&nbsp;30, 2021 and 2020 was $0.7&nbsp;million and $0.5&nbsp;million, respectively,
and for the years ended December&nbsp;31, 2020 and 2019 was $0.8&nbsp;million and $2.2&nbsp;million, respectively, due to purchases of property and equipment. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months
ended June&nbsp;30, 2021, net cash provided by financing activities was $87.2&nbsp;million from the $80.2&nbsp;million net proceeds from the sale of Series E convertible preferred stock, $7.0&nbsp;million net proceeds from the sale of Series <FONT
STYLE="white-space:nowrap">D-2</FONT> convertible preferred stock, and $0.3&nbsp;million proceeds from stock options exercises, offset by $0.3&nbsp;million of payments made for deferred offering costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2020, net cash provided by financing activities was $0.1&nbsp;million from the $0.1&nbsp;million proceeds from
stock options exercises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2020, net cash provided by financing activities was $10.0&nbsp;million from the
$9.9&nbsp;million net proceeds from the sale of Series <FONT STYLE="white-space:nowrap">D-2</FONT> convertible preferred stock and $0.1&nbsp;million proceeds from stock options exercises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2019, net cash provided by financing activities was $39.7&nbsp;million from the net proceeds from the sale of
Series <FONT STYLE="white-space:nowrap">D-1</FONT> convertible preferred stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our plan of operation is to continue implementing our business strategy, continue research and development of
<FONT STYLE="white-space:nowrap">AU-011</FONT> and any other product candidates we may acquire or develop and continue to expand our research pipeline and our internal research and development capabilities. We expect our expenses to increase
substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our current and future product candidates. In addition, we expect to incur additional costs associated with
operating as a public company following the completion of this offering. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive
terms, we would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
be forced to delay, reduce or terminate our research and development programs or future commercialization efforts. Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, timing, progress, costs, and results of discovery, preclinical development, and clinical trials for our current
and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of clinical trials required for regulatory approval of our current and future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our current and future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of manufacturing clinical and commercial supplies of our current and future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution,
for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual
property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses to attract, hire and retain, skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">addressing any potential interruptions or delays resulting from factors related to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs
and timing associated with the development of that product candidate. As of June&nbsp;30, 2021, we had cash and cash equivalents of $92.2&nbsp;million. Based on our research and development plans, we believe that the net proceeds from this offering,
together with our existing cash and cash equivalents, will be sufficient to fund our operations through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that
may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Until such time as we can generate significant
revenue from product sales, if ever, we expect to finance our operations from the sale of additional equity or debt financings, or other capital which comes in the form of strategic collaborations, licensing, or other arrangements. In the event that
additional financing is required, we may not be able to raise it on terms acceptable to us, or at all. If we raise additional funds through the issuance of equity or convertible debt securities, it may result in dilution to our existing
stockholders. Debt financing or preferred equity financing, if available, may result in increased fixed payment obligations, and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we
could become subject to covenants that would restrict our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we raise funds through strategic collaboration, licensing or other arrangements, we may relinquish
significant rights or grant licenses on terms that are not favorable to us. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the
credit and financial markets in the United States and worldwide resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and otherwise. If we are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market
ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations and Commitments </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
following table summarizes our contractual obligations and commitments as of December 31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease commitments(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Amounts in the table above reflect payments due for our lease of office space in Cambridge, Massachusetts that expires
July 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Except as disclosed in the table above, we have no long-term debt or finance leases and no material <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> purchase commitments with service providers, as we have generally contracted on a cancelable, purchase-order basis. We enter into contracts in the normal course of business with equipment and reagent
vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manufacturing services. These contracts are cancelable by us upon prior notice. Payments due upon cancellation consist only of payments for
services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the preceding table as the amount and timing of such payments are not known.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our management&#146;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been
prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and
liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis.
Our actual results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">While our significant accounting policies are
described in greater detail in Note 2 to our financial statements appearing elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our
financial statements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expense all costs in performing research and development activities in the periods in which they are incurred. Research and development expenses
include salaries and benefits, stock-based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
compensation expense, lab supplies and facility costs, as well as fees paid to nonemployees and entities that conduct certain research and development activities on our behalf and expenses
incurred in connection with license agreements. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods or services that will be used for rendered or future research and development activities are deferred and amortized
over the period that the goods are delivered, or the related services are performed, subject to an assessment of recoverability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As part of the
process of preparing our financial statements, we are required to estimate our accrued research and development expenses. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and
circumstances known to us at that time. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over
which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses
accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary
and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We account
for our stock-based compensation as expense in the statements of operations and comprehensive loss based on the awards&#146; grant date fair values. We account for forfeitures as they occur by reversing any expense recognized for unvested awards.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs
based on certain subjective assumptions, including (a)&nbsp;the expected stock price volatility, (b)&nbsp;the calculation of expected term of the award, (c)&nbsp;the risk-free interest rate and (d)&nbsp;expected dividends. Due to the lack of a
public market for our common stock and a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The
historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar
characteristics to us, including stage of product development and life science industry focus. We use the simplified method as allowed by the Securities and Exchange Commission, or SEC, Staff Accounting Bulletin, or SAB, No. 107,<I>&nbsp;Share-Based
Payment</I>, to calculate the expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is based on a
treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock. The fair
value of stock-based payments is recognized as expense over the requisite service period which is generally the vesting period. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Determination of
the Fair Value of Common Stock </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As there has been no public market for our common stock to date, the estimated fair value of our common stock has
been determined by our board of directors, with input from management, considering third-party valuations of our common stock as well as our board of directors&#146; assessment of additional objective and subjective factors that it believed were
relevant and which may have changed from the date of the most recent third-party valuation through the date of the option grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of
Certified Public Accountants&#146; Accounting and Valuation Guide,<I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Our common stock valuations were prepared using either an option pricing method, or OPM, or
a hybrid method, both of which used market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approaches to estimate our enterprise value. The hybrid method is a probability-weighted expected return method, or PWERM, where the equity value in one or more of the scenarios is calculated
using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the probability-weighted
present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at
an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common
stock. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#146;s securities
changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a
merger. These third-party valuations were performed at various dates, which resulted in valuations of our common stock of $0.31 per share as of December&nbsp;6, 2019, $0.32 per share as of August&nbsp;25, 2020 and December&nbsp;31, 2020, $0.40 per
share as of March&nbsp;15, 2021 and $0.70 as of August&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to considering the results of these third-party valuations, our
board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prices at which we sold shares of preferred stock and the superior rights and preferences of the preferred stock
relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the progress of our research and development programs, including the status and results of preclinical studies for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our stage of development and commercialization and our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">external market conditions affecting the biotechnology industry and trends within the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our financial position, including cash on hand, and our historical and forecasted performance and operating results;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of an active public market for our common stock and our preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the likelihood of achieving a liquidity event, such as an initial public offering, or sale of our company in light of
prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the analysis of initial public offerings and the market performance of similar companies in the biotechnology industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The assumptions underlying these valuations represented management&#146;s best estimate, which involved inherent uncertainties
and the application of management&#146;s judgment. As a result, if we had used different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, the fair value of our common stock will be determined based on the quoted market price of our common stock on
the date of option grant. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Options Granted </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth, by grant date, the number of shares subject to options granted from January&nbsp;1, 2020 through the date of this
prospectus, the per share exercise price of the options, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
fair value of common stock per share on each grant date, and the per share estimated fair value of the options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Common<BR>Shares Subject<BR>to Options Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price per<BR>Common&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value<BR>per&nbsp;Common&nbsp;Share<BR>at Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;per<BR>Share Fair<BR>Value of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">March&nbsp;16, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,498,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">September&nbsp;17, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">December&nbsp;14, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,830,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">February&nbsp;2, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">March&nbsp;23, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">815,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">May&nbsp;14, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">June&nbsp;28, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,320,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">September&nbsp;22, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,105,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not entered into any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements and do not have any holdings in variable interest
entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We early
adopted ASU No.&nbsp;2016-02, Leases (Topic&nbsp;842) effective January&nbsp;1, 2021 as disclosed in Note&nbsp;2 to our financial statements appearing elsewhere in this prospectus. The adoption of ASC&nbsp;842 resulted in the recognition of
operating lease liabilities of $0.6&nbsp;million and operating lease right-of-use assets of $0.5&nbsp;million and the derecognition of deferred rent liabilities of $0.02&nbsp;million on our balance sheet as of January&nbsp;1, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A description of recently issued accounting pronouncements not yet adopted that may potentially impact our financial position and results of operations
is also disclosed in Note&nbsp;2 to our financial statements appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures about Market Risks
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivity, which is
affected by changes in the general level of U.S. interest rates. As of June&nbsp;30, 2021, our cash and cash equivalents of $92.2&nbsp;million consisted of money market funds that invest in U.S. Treasury obligations and government funds with
commercial banks and financial institutions. Our exposure to interest rate sensitivity is impacted by changes in the underlying U.S. bank interest rates but is minimal. We have not entered into investments for trading or speculative purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Jumpstart Our Business
Startups Act of 2012, or the JOBS Act, permits that an &#147;emerging growth company&#148; may take advantage of the extended transition period to comply with new or revised accounting standards applicable to public companies until those standards
would otherwise apply to private companies. We have elected to use the extended transition period under the JOBS Act. However, we did early adopt ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> Leases (<I>Topic 842</I>) effective
January&nbsp;1, 2021 as disclosed in Note 2 to our financial statements appearing elsewhere in this prospectus. Accordingly, our financial statements may not be comparable to the financial statements of public companies that comply with such new or
revised accounting standards. The JOBS Act also exempts us from having to provide an auditor attestation of internal control over financial reporting under Sarbanes-Oxley Act Section&nbsp;404(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will remain an &#147;emerging growth company&#148; until the earliest of: the last day of the fiscal year in which we have more than
$1.07&nbsp;billion in annual revenue; the date we qualify as a &#147;large accelerated filer,&#148; with at least $700.0&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> the issuance, in any
three-year period, by us of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; or the last day of the fiscal year ending after the fifth anniversary of our initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biotechnology company
leveraging our novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Our proprietary platform enables the targeting of a broad range of
solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. Our VDCs are largely agnostic to tumor type and can recognize a surface marker, known as
heparan sulfate proteoglycans, or HSPGs, that are specifically modified and broadly expressed on many tumors. <FONT STYLE="white-space:nowrap">AU-011,</FONT> our first VDC candidate, is being developed for the first line treatment of primary
choroidal melanoma, a rare disease with no drugs approved. We have completed a Phase 1b/2 trial using intravitreal administration that has demonstrated a statistically significant growth rate reduction in patients with prior active growth and high
levels of tumor control with visual acuity preservation in a majority of patients, as assessed using clinical endpoints in alignment with the feedback from U.S. Food and Drug Administration, or the FDA. These data supported advancement into a Phase
2 dose escalation trial, where we are currently evaluating suprachoroidal, or SC, administration of <FONT STYLE="white-space:nowrap">AU-011.</FONT> We plan to present six to twelve month safety and efficacy data from this trial in 2022 and, if
favorable, initiate a pivotal trial in the second half of 2022.<B><I> </I></B>We are also developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications and plan to file an IND in the United States in the second
half of 2022 for choroidal metastases. Leveraging our VDCs&#146; broad tumor targeting capabilities, we also plan to initiate a Phase 1a trial in <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer, or NMIBC, our first <FONT
STYLE="white-space:nowrap">non-ophthalmic</FONT> solid tumor indication, in the second half of 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">VDCs are a novel class of drugs with a dual
mechanism of action that promotes cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and by activating a secondary immune mediated response. VDCs are analogous to ADCs, another technology that employs a
targeting moiety and a cytotoxic payload. In contrast to the limited tumor specificity of individual ADCs, the tumor targeting specificity of VDCs is driven by the selective binding of the VLPs to modified HSPGs expressed on the tumor cell membrane.
This targeting mechanism enables the delivery of multiple types of cytotoxic payloads directly to a wide range of solid tumors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g01z01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 1. Structure of our VDCs and HSPG Targeted Tumor Binding. The cytotoxic drug payload is covalently bound to
the VLP to form the VDC. The capsid proteins that make up the VLP can recognize HSPGs modified by tumor cells and function analogously to the antibody of an ADC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that our VDC platform has the potential to serve as a backbone for a broad portfolio of targeted oncology therapeutics and has the following
potential key advantages: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">A single VDC can deliver hundreds of cytotoxic molecules conjugated to its capsid proteins. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on the ability of VLPs to selectively recognize specifically modified and overexpressed HSPGs present on a large
number of tumor types, VDCs have the potential to be used broadly across a wide range of cancers with limited <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The VDCs have a high number of HSPG binding sites and this multi-valency permits the strong and selective binding to
tumor cells. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">VDCs have a dual mechanism of action, first by acute necrosis of the tumor cells, and subsequently by creating a highly
immunogenic milieu that induces an antitumor specific immune response potentially leading to a more robust and durable therapy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our goal is to leverage our platform to develop a new class of targeted therapies that bring therapeutic benefit to multiple cancer indications,
initially focusing on the field of ocular oncology, a field representing a potential $1.5 billion market opportunity. Our next area of focus, bladder cancer, is one of the most expensive cancers to treat on a per patient basis, and the global market
for bladder cancer is expected to reach $4.0 billion by 2028 across the United States, EU5 and Japan. To date, we have produced a VDC, <FONT STYLE="white-space:nowrap">AU-011,</FONT> that we are advancing in multiple indications, as shown in the
pipeline below. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g02x80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are initially developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of primary choroidal
melanoma, a vision- and life-threatening ocular cancer for which there are currently no drugs approved. Choroidal melanoma is the most common intraocular cancer in adults, with an incidence of 11,000 patients/year in the United States and Europe. It
is estimated that 96% of patients are diagnosed early without clinical evidence of metastatic disease. However, despite the current treatments with radiotherapy the long-term prognosis is poor with death occurring in more than 50% of cases and
irreversible vision loss within 5 to 10 years in approximately 70% of cases. We intend to develop <FONT STYLE="white-space:nowrap">AU-011</FONT> as a first line therapy to treat early-stage disease which includes small melanomas and indeterminate
lesions representing approximately 9,000 patients/year in the United States and Europe. <FONT STYLE="white-space:nowrap">AU-011</FONT> has been granted Orphan Drug designation for treatment of uveal melanoma and Fast Track designations for the
treatment of choroidal melanoma by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">AU-011</FONT> consists of an
<FONT STYLE="white-space:nowrap">HPV-derived</FONT> VLP conjugated to hundreds of infrared laser-activated molecules. The VDC is designed in a way that prevents the conjugation from interfering with tumor binding enabling its selectivity to
specifically modified HSPGs on tumor cells but not to normal cells. Laser activation of <FONT STYLE="white-space:nowrap">AU-011</FONT> is designed to result in precise tumor cell killing with minimal damage to surrounding healthy tissues. In the
absence of <FONT STYLE="white-space:nowrap">AU-011</FONT> activation or binding to the tumor cell membrane, there is no cytotoxic effect. Multiple laser treatments, following a single dose of <FONT STYLE="white-space:nowrap">AU-011,</FONT> increase
antitumor activity because of the reoxygenation of the tumor and the photostability of <FONT STYLE="white-space:nowrap">AU-011.</FONT> Finally, acute necrosis triggers immunogenic cell death leading to the generation of an adaptive, long-term
antitumor immune response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In our completed Phase 1b/2 trial, <FONT STYLE="white-space:nowrap">AU-011,</FONT> administered by intravitreal
injection, was well-tolerated and demonstrated high levels of local tumor control while preserving vision at twelve months in patients that had prior active tumor growth. The therapeutic regimen of <FONT STYLE="white-space:nowrap">AU-011</FONT>
achieved tumor shrinkage or a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
near-zero growth rate in the majority of patients and was associated with preservation of visual acuity in 71% of patients at twelve months. We are currently conducting a Phase 2 dose escalation
trial of <FONT STYLE="white-space:nowrap">AU-011</FONT> with SC administration. We intend to initiate the first pivotal trial in 2022. Because our mechanism of action preserves key ocular structures, we also intend to develop <FONT
STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications, beginning with choroidal metastases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we are
developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of NMIBC. Bladder cancer is the most common malignancy involving the urinary system and is the eighth most common cause of cancer death in men in the United States. While
metastatic bladder cancer has several approved therapies, there are very limited options for the treatment of NMIBC. We are planning to initiate clinical development of <FONT STYLE="white-space:nowrap">AU-011</FONT> with intramural administration, a
novel route of administration, for the treatment of patients with intermediate and high-risk bladder cancer lesions. This novel route of administration is intended to place high levels of the drug at the base of the tumor where laser activation of <FONT
STYLE="white-space:nowrap">AU-011</FONT> can cause necrosis and prevent residual tumor cells from further growth and recurrence. We have generated preclinical <I>in vivo</I> data that supports that our dual mechanism of action can lead to
cytotoxicity and long-term antitumor immunity which may further reduce the risk of metastases. We believe this immune response can play an even larger role in bladder cancer, given that bladder cancer has a well-documented response to immune
activation. We are conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with <FONT STYLE="white-space:nowrap">AU-011</FONT> and intend to begin clinical trials in the second half of 2022. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Our team and investors </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our team
consists of biopharmaceutical experts who have extensive experience in the development of drugs in oncology and ophthalmology. Our CEO and founder, Elisabet de los Pinos, PhD, MBA, was previously part of the marketing team that led the European
commercialization of Alimta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of lung cancer at Eli Lilly. Cadmus Rich, MD, MBA, CPE, our Chief Medical Officer, a board-certified ophthalmologist, has extensive experience in
leading ophthalmology research and development at companies including Inotek, IQVIA and Alcon/Novartis. He has led or participated in over 75 development programs including the submission and approval over ten devices and pharmaceutical products in
the United States, Europe, China, Japan and Latin America. Julie Feder, our CFO, previously served as CFO at Verastem Oncology, the Clinton Health Access Initiative and was instrumental in the integration of Genzyme and Sanofi. Mark De Rosch, PhD,
our COO, was previously the Chief Regulatory Officer at Epizyme during which time Epizyme received FDA accelerated approval of its first product in two oncology indications. Dr.&nbsp;De Rosch also led Regulatory Affairs at Nightstar Therapeutics, a
gene therapy company developing treatments for inherited retinal diseases prior to Nightstar&#146;s acquisition by Biogen in 2019. Christopher Primiano, our CBO, led multiple strategic transactions during his prior tenure as CBO and General Counsel
at Karyopharm Therapeutics, Inc., a commercial oncology company. The Chairman of our Board of Directors is David Johnson, a biopharmaceutical business leader with more than 25 years of experience in drug development and the former Chief Executive
Officer at VelosBio Inc., a clinical-stage oncology company developing novel ADCs and bispecific antibodies that was acquired by Merck in 2020 for $2.75&nbsp;billion. Prior to founding VelosBio Inc. he was the Chief Executive Officer at Acerta
Pharma B.V. leading to its acquisition by AstraZeneca plc for $7&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since our inception, we have raised approximately
$218.5&nbsp;million from leading investors that include among others, Matrix Capital Management, Surveyor Capital (a Citadel company), Velosity Capital, Medicxi, Advent Life Sciences, Lundbeckfond Invest A/S, Arix Bioscience, Chiesi Ventures, Ysios
Capital and Columbus Venture Partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
goal is to leverage our proprietary platform to develop a new class of targeted therapies that deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care.
The key elements of our strategy include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Advance <FONT STYLE="white-space:nowrap">AU-011</FONT> through late-stage clinical development and, if approved,
commercialization for the first line treatment of primary choroidal melanoma. </B>In our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
Phase&nbsp;1b/2 trial for <FONT STYLE="white-space:nowrap">AU-011</FONT> using intravitreal administration, we observed in patients that had prior active tumor growth high levels of local tumor
control while preserving vision at twelve months. We are currently evaluating SC administration of <FONT STYLE="white-space:nowrap">AU-011</FONT> in a Phase 2 trial in patients with choroidal melanoma and we plan to present the six to 12 month
safety and efficacy data from this trial in 2022. We believe SC administration will increase tumor exposure to the drug while reducing exposure in the vitreous. If the Phase 2a portion of this trial is successful, we expect to initiate the Phase 2b
randomized portion of this pivotal trial in 2022. We have received orphan drug designation for treatment of uveal melanoma and fast track designation from the FDA for the treatment of choroidal melanoma and have aligned with FDA and EMA on the
design and endpoints of this trial. If approved, this would represent the first therapy for primary choroidal melanoma as a first line treatment option, reserving radiotherapy for a second line treatment option. If approved, we intend to
independently commercialize <FONT STYLE="white-space:nowrap">AU-011</FONT> in ocular cancers using a limited sales force to target the approximately 50 ocular oncologists in the United States and approximately 50 in Europe, who are a focused call
point that treat most patients. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Continue developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications, starting
with choroidal metastases</B>. We intend to be at the forefront of ocular oncology innovation and believe we can apply our mechanism of action for <FONT STYLE="white-space:nowrap">AU-011,</FONT> which has the potential to treat tumors while
preserving key ocular structures, to multiple other ocular oncology indications. Beyond small primary choroidal melanoma, we intend to develop <FONT STYLE="white-space:nowrap">AU-011</FONT> in multiple other ocular oncology indications, starting
with choroidal metastases. We plan to file an IND with the FDA in the second half of 2022 for choroidal metastases. In addition, we plan to develop <FONT STYLE="white-space:nowrap">AU-011</FONT> for tumors of the ocular surface, including both
melanomas and squamous cell carcinomas. Every year, approximately 4,500 patients are diagnosed with cancers of ocular surface. We believe that we can leverage the sales force infrastructure we intend to build for primary choroidal melanoma for these
additional ocular oncology indications. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Pursue development of <FONT STYLE="white-space:nowrap">AU-011</FONT> for our first
<FONT STYLE="white-space:nowrap">non-ophthalmic</FONT> solid tumor indication in NMIBC.</B> Our novel approach has the potential benefit of treating early-stage solid tumors, particularly NMIBC, while generating long-term antitumor immunity to
prevent metastasis. We believe that local administration into the bladder, and the ability to use a focused laser to activate <FONT STYLE="white-space:nowrap">AU-011,</FONT> provides the opportunity to apply our technology platform to this area of
high unmet medical need. Bladder cancer represents an attractive indication given its sensitivity to immune response and high unmet medical need. <FONT STYLE="white-space:nowrap">AU-011&#146;s</FONT>
<FONT STYLE="white-space:nowrap">pro-immunogenic</FONT> mechanism of action has shown robust activity in preclinical models as a single agent and synergy with checkpoint inhibitors in this indication. Our preclinical data supports initiation of a
Phase 1a clinical trial, which we expect to begin in the second half of 2022, subject to FDA acceptance of our IND. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Broaden the application of our proprietary technology platform to expand our pipeline of product candidates.</B> Due to
the expression of specifically modified HSPGs across a wide range of solid tumors, we plan to evaluate our technology platform in other oncology indications. We also plan to expand the use of our proprietary technology platform by continuing to
explore the potential to deliver other therapeutic agents, including nucleic acid therapies and <FONT STYLE="white-space:nowrap">non-light</FONT> activated molecules, to broadly treat solid tumors. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Evaluate and selectively enter into strategic collaborations to maximize the potential of our pipeline and accelerate
the development of our programs.</B> While we continue to retain worldwide rights to <FONT STYLE="white-space:nowrap">AU-011,</FONT> we may opportunistically evaluate and enter into strategic collaborations around
<FONT STYLE="white-space:nowrap">AU-011</FONT> or future product candidates, geographies, or disease areas. We believe our technology platform has the potential to enable the development of a broad scope of product candidates that reaches beyond <FONT
STYLE="white-space:nowrap">AU-011.</FONT> By selectively entering into collaborations, we believe our potential to expand and accelerate the development of our programs and maximize worldwide commercial potential may be enhanced.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Targeting a broad range of solid tumors with our proprietary technology platform </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our technology platform represents a novel approach of targeting a broad range of solid tumors using VLPs that can be loaded or conjugated with drugs
creating a new class of targeted therapies. Our VDCs are analogous to ADCs, another technology that employs a targeting moiety and a payload. ADCs typically utilize a monoclonal antibody to traffic a cytotoxic payload preferentially to tumor cells.
There are currently 11 <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ADCs, six of which have gained regulatory approval since 2019. The class achieved approximately $4&nbsp;billion in sales in 2020 and is expected to garner over
$27&nbsp;billion in sales in 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Despite the successful adoption of this modality, there remains room for improvement. Key challenges related to
ADCs include the limited number of payloads that can be conjugated onto the ADC along with toxicities that have been reported. Only two to five toxin drug conjugate molecules per antibody can be delivered, potentially reducing potency, which can
necessitate higher doses of toxic drug to be delivered. These higher doses and the expression of ADC target receptors on healthy tissue can lead to systemic toxicity. We believe our VDCs can expand upon the foundation built by ADCs, given VDCs are
endowed with specific attributes designed to overcome the shortcomings of ADCs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The key finding that launched our technology development efforts
was the observation that human papilloma virus, or HPV, binds to specifically modified HSPGs on the tumor cell membrane. HSPGs are a large family of molecules found in the extracellular matrix and on the membranes of cells. Tumors specifically
modify HSPGs with key sulfation modifications that provide high binding specificity to a number of ligands. Tumor modified HSPGs regulate many aspects of tumor progression, including proliferation, invasion, angiogenesis and metastases. Our
scientific founder, John Schiller, PhD, and his colleagues at the National Institutes of Health, or NIH, identified that these specific modifications enable HSPG-selective binding of HPV on tumor cells, as illustrated below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g03w03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 2. VDCs bind to specifically modified HSPGs on the tumor cell surface with multivalent binding and do not
bind to normal healthy cells. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This NIH team discovered that HSPG-selective binding of HPV was determined by the properties of the
proteins that make up the viral capsid, or shell, not by the nucleic acids contained within the shell. Dr.&nbsp;Schiller pioneered the development of VLPs into a highly effective HPV vaccine to prevent cancer, work for which he received the
Lasker-DeBakey Clinical Medical Research Award. He discovered that these capsid proteins could be recombinantly manufactured and could self-assemble into empty VLPs without any viral genome. Our technology platform is based on variants of these VLPs
that were further engineered to reduce cross-reactivity with <FONT STYLE="white-space:nowrap">pre-existing</FONT> immunity against HPV, enabling the use of VLPs as oncology therapeutics. This platform leverages the tumor-specific targeting mechanism
of HPV VLPs to enable their use to deliver cytotoxic payloads directly to a wide range of solid tumors. VLPs have also demonstrated the ability to deliver nucleic acids, potentially expanding our platform on which to base a novel class of oncology
therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our first VDC, <FONT STYLE="white-space:nowrap">AU-011,</FONT> covalently conjugates approximately 200 molecules of an infrared
light-activated molecule, IRDye<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 700DX, to the VLP in a way that is designed not to interfere with tumor binding. IRDye<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 700DX, a
photosensitizer that received conditional marketing approval in Japan as part of an ADC (Akalux), is activated with near infrared light at 689 nm. <FONT STYLE="white-space:nowrap">AU-011</FONT> is activated using a laser produced by a third party
which has the same wavelength and intensity as that used in the activation of Visudyne<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, an approved therapy for the treatment of complications due to exudative
<FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration. The main difference between current commercial ophthalmic lasers and the laser used for AU-011 is in the software. Current commercial ophthalmic lasers use a single pulse of
light, whereas the laser used with <FONT STYLE="white-space:nowrap">AU-011</FONT> provides multiple pulses of light to ensure complete coverage of the tumor. We utilize lasers that we purchased from two separate manufacturers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">AU-011</FONT> given by SC administration uses the SCS Microinjector&reg; developed by Clearside Biomedical, Inc., or
Clearside, which requires minimal training for the clinicians to use properly, and the procedure is performed in the ophthalmologist&#146;s office. The SCS Microinjector&reg; was developed by Clearside to support the administration of their
ophthalmic steroid product XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension). We have an exclusive license with Clearside for use of the SCS Microinjector&reg; for ocular oncology indications. Assuming marketing approval of <FONT
STYLE="white-space:nowrap">AU-011,</FONT> we plan to provide the SCS Microinjector&reg; to the ocular oncologist&#146;s office along with the <FONT STYLE="white-space:nowrap">AU-011</FONT> drug product. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g04a00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 3. VDC structure and mechanism of light activation with generation of singlet oxygen. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Activation of the dye leads to light absorption, excitation of electrons and generation of highly reactive singlet oxygen, which has little or no
opportunity to diffuse away from where it is generated due to its half-life in aqueous solution of less than 4 microseconds. As a result of the VDC&#146;s targeted binding to the tumor cell, the generation of singlet oxygen in very close proximity
to the tumor cell membrane causes a physical disruption of the cell membrane that leads to acute cellular necrosis. Physical ablation of the tumor cell membrane is an especially potent modality for cancer cell killing because, unlike many other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
therapeutic mechanisms, there is minimal potential to trigger specific mutations, pathway alterations or other compensatory mechanisms or for tumors to develop resistance. In addition, this mode
of cell killing leads to acute necrosis, as opposed to apoptosis. Necrosis is highly <FONT STYLE="white-space:nowrap">pro-immunogenic</FONT> since the contents of the cell, including tumor-specific neoantigens and damage-associated molecular
patterns, or DAMPs, are exposed to the immune system triggering the activation of both the innate and adaptive immune systems and generating long-term antitumor activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that our technology platform has the potential to serve as a backbone for a broad portfolio of therapeutics. There are four key potential
advantages of VDCs compared to ADCs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">A single VDC can deliver hundreds of cytotoxic molecules conjugated to its capsid proteins. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The VDCs have a high number of HSPG binding sites and, it is this multi-valency that permits the strong binding of the
VDCs with tumor cells. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Based on the ability of VLPs to selectively recognize specifically modified and overexpressed HSPGs present on a large
number of tumor types, VDCs have the potential to be used broadly across a wide range of cancers with limited <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Tumor treatment with VDCs results in a dual mechanism of action, both directly with acute necrosis of the tumor cells,
and indirectly by creating a highly immunogenic milieu inducing an antitumor specific immune response leading to a more robust and durable therapy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our wholly owned product pipeline, which is
based on our first VDC, <FONT STYLE="white-space:nowrap">AU-011,</FONT> is summarized below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g02x80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of ocular cancers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">AU-011,</FONT> our first VDC candidate, is a VLP conjugated with approximately 200 molecules of a novel laser activated
cytotoxin, IRDye<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 700DX, and is being developed for the first-line treatment of primary choroidal melanoma. <FONT STYLE="white-space:nowrap">AU-011</FONT> is designed to be administered into
the eye by intravitreal or SC administration, and then activated by an ophthalmic laser. We have completed a Phase 1b/2 trial using intravitreal administration that has demonstrated a statistically significant growth rate reduction in patients with
active growth and high levels of tumor control with visual acuity preservation in a majority of patients. We are currently evaluating SC administration of <FONT STYLE="white-space:nowrap">AU-011</FONT> in a Phase 2 trial in patients with choroidal
melanoma. We plan to present six to twelve month safety and efficacy data from this trial in 2022. If favorable, we expect to initiate the Phase 2b randomized portion of this pivotal trial using the optimal dose and route of administration in the
second half of 2022. Beyond primary choroidal melanoma, we are developing <FONT STYLE="white-space:nowrap">AU-011</FONT> in multiple ocular oncology indications, starting with choroidal metastases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Choroidal melanoma overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Choroidal melanoma is the most common intraocular cancer in adults, with an incidence of 11,000 patients/year in the United States and Europe. This
comprises approximately 90% of all cases of uveal melanoma, consisting of melanomas in the choroid, ciliary body and iris, which are collectively referred to as the uvea. It is estimated that 96% of patients are diagnosed early without clinical
evidence of metastatic disease. There are approximately 2,000 new cases treated each year in the United States and 1,600 new cases treated each year in Europe. However, despite the current treatments with radiotherapy, the long-term prognosis is
poor with death occurring in more than 50% cases and irreversible vision loss within 5 to 10 years in approximately 70% of cases. We intend to develop <FONT STYLE="white-space:nowrap">AU-011</FONT> as a first line therapy to treat early-stage
disease which includes small melanomas and indeterminate lesions representing approximately 9,000 patients in the United States and Europe. Most cases are found in adults with a median age of 55, light eye color and fair skin. It is often discovered
in patients who are asymptomatic, although some patients report decreased vision or <FONT STYLE="white-space:nowrap">non-specific</FONT> visual symptoms such as flashes, floaters, blurry or distorted vision or visual field defects. Most choroidal
melanomas result from transformation of a benign choroidal nevus. In early stage lesions, most of the tumor is composed of benign nevi cells with a small cluster of malignant melanoma cells. Benign choroidal nevi are found in approximately 5% of
adults in the United States 40 years or older. There are 3,900 patients every year in the United States that are diagnosed with indeterminate melanocytic lesions that have risk factors and that are referred to the ocular oncologist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There has been great progress in the early diagnosis of choroidal melanoma in the last 30 years with the identification of risk factors that can
differentiate benign choroidal nevi from high-risk melanocytic lesions. These risk factors are diagnosed by the ocular oncologists with an ophthalmic exam and specialized imaging equipment that can determine the size of the lesion, pigmentation, the
presence of subretinal fluid, active growth in tumor height and diameter, decreased vision, visual symptoms and ultrasound hollowness. Early melanocytic lesions are typically managed by a conservative &#147;watch and wait&#148; period to confirm the
change in risk factors or early signs of growth which confirms malignant transformation before treatment with radiotherapy is recommended. We believe that the availability of a safe and effective therapy has the potential to change the treatment
paradigm for these early tumors, reducing the risk of development of metastatic disease. There are currently no FDA approved therapies for primary choroidal melanoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Choroidal melanoma is of grave concern for patients based on this potential to develop into metastatic disease with a high rate of mortality. At the
time of diagnosis, less than 4% of patients with choroidal melanoma have detectable metastatic disease. However, the proportion of patients who develop metastases increases with the size of the primary tumor and patient age. A tumor that is less
than 2 mm thick has a 10% chance of being associated with metastatic disease, but that risk increases to 24% with tumors that are 4.5 mm and greater than 50% chance in tumors greater than 8 mm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The risk of lethal metastatic disease also increases with lesion size. Patients face an 80% mortality risk within one year of diagnosis and a 92%
mortality risk within two years. Overall survival for patients with metastatic disease is less than a year and there are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs to treat metastatic disease. This drives a strong desire to treat
patients with early stage disease, comprised of patients with either small melanoma or high-risk indeterminate lesions, with the hope of preventing metastasis and ultimately increasing the probability of saving the patients&#146; lives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our goal is to develop <FONT STYLE="white-space:nowrap">AU-011</FONT> as a first line treatment option that can enable early treatment intervention of
primary choroidal melanoma while preserving vision and reserving radiotherapy for a second line treatment option. Earlier diagnosis and early treatment intervention of lesions in the eye before the onset of metastatic disease may dramatically change
outcomes for patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Current treatment options for choroidal melanoma </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies for choroidal melanoma. There are three primary treatments that are routinely
used for local control of choroidal melanoma: plaque brachytherapy; proton beam irradiation; and enucleation, or removal of the affected eye, each of which represent invasive surgical procedures. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g05c00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 4. Three primary treatments for choroidal melanoma. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Plaque brachytherapy has been a standard treatment to treat intraocular tumors for decades. In this procedure, a metal carrier, typically a thin sheet
of gold, is coated on the inner surface with radioactive seeds, normally <FONT STYLE="white-space:nowrap">iodine-125,</FONT> or <SUP STYLE="font-size:85%; vertical-align:top">125</SUP>I, and surgically placed over the tumor where it can irradiate
the tumor for up to seven days, after which a second surgery is performed to remove the plaque. Patients are followed every three to six months to observe tumor response and to treat radiation related comorbidities. Plaque brachytherapy is an
operating room procedure that requires the ocular oncologist to coordinate with the radiation oncologist and medical physicist to identify the precise location and dimensions of the lesion to be treated, calculation of the proper radiation dose to
be delivered, and the design of the plaque. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Plaque brachytherapy has demonstrated local tumor control in approximately 85% of cases. However, there
is no evidence that plaque brachytherapy is effective in reducing the rate of development of metastasis, especially because metastasis may have occurred before the primary tumor was treated. Because radiotherapy lacks tumor tissue specificity,
plaque brachytherapy is associated with the irreversible loss of vision over time in many patients. This loss of vision represents a negative outcome related to damage caused by the radiotherapy to key ocular structures and in particular to the
retinal blood vessels. A large, randomized, long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> trial, known as COMS, was conducted to investigate the benefit of plaque brachytherapy versus enucleation. In this trial, vision loss was defined
as a loss of visual acuity of more than six lines on an eye chart. It was discovered that by one year, 18% of patients, by two years, 34% of patients and by three years, 49% of patients, with medium tumors undergoing plaque brachytherapy had severe
vision loss. Additionally, 47% of patients at three years had 20/200 or worse vision, the legal definition of blindness in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g06q74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 5. Visual Acuity declines in patients treated with plaque brachytherapy. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other than vision loss, plaque brachytherapy is associated with significant posterior segment complications, like scleral necrosis, and potential
disfiguration due to complications of the surgery, as well as other adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A second method of treating choroidal melanoma with similar
efficacy as plaque brachytherapy is proton beam therapy, which also deploys a form of ionizing radiation that causes DNA damage and cell death by apoptosis both to tumor and healthy cells. In this procedure, patients undergo surgery to place
tantalum markers, which are tiny metal rings, to demarcate the edges of the tumor. After the inflammation due to the surgery has diminished, tumors are irradiated once daily, typically for up to seven days. However, the use of proton beam therapy is
limited by the availability of very expensive proton therapy centers. There are less than thirty centers that offer proton therapy in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since the radiation typically enters the front of the eye, eyelash loss, eyelid damage, corneal damage, dry eye, glaucoma and cataracts are common after
treatment with proton beam therapy. Some of these effects occur within weeks of treatment. Like plaque brachytherapy, patients also may suffer from progressive and irreversible vision loss after proton beam therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Enucleation was previously the standard treatment for ocular cancers. Now, enucleation is reserved either for patients whose tumors are too large or too
diffuse to be treated with other treatments; or for use after side effects of radioactive treatments occur. Approximately 10% to 15% of patients treated with radiation therapy end up with an enucleation due to local recurrence of their tumor or to
the devastating side effects from radiation treatment. Based on the results from the COMS trial, over a period of at least twelve years, there was no survival difference between patients whose tumors were treated with <SUP
STYLE="font-size:85%; vertical-align:top">125</SUP>I brachytherapy and those treated with enucleation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The limited options available to treat
patients with choroidal melanoma pose challenges to clinicians and patients. The existing treatments are far from innocuous: all of them are invasive procedures that are associated with irreversible loss of visual acuity and other deleterious side
effects. Because choroidal melanoma tends to metastasize early, even with radical treatments such as enucleation, metastatic disease still occurs, which results in a high degree of mortality. We believe that there is an urgent unmet medical need for
an effective vision preserving therapy and that the availability of such a therapy may encourage treatment of early stage ocular lesions and increase the awareness of the importance of early diagnosis for this life-threatening disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Our solution <FONT STYLE="white-space:nowrap">AU-011</FONT> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">AU-011</FONT> is a VDC consisting of an <FONT STYLE="white-space:nowrap">HPV-derived</FONT> VLP and IRDye 700DX, a laser
activated cytotoxic payload. Our VLP was created using the capsid proteins of HPV that have been genetically modified to avoid cross-reactivity with <FONT STYLE="white-space:nowrap">pre-existing</FONT> immunity against the virus and bind with high
affinity to specifically modified HSPGs found on the surface of tumors cells, including ocular melanoma cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Five observations from our
preclinical experiments supported the advancement of <FONT STYLE="white-space:nowrap">AU-011</FONT> into clinical development for the treatment of choroidal melanoma: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">AU-011</FONT> was shown to selectively bind to HSPGs on human ocular melanoma cells (and
other tumor cells) and not to normal cells. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Infrared light activation of <FONT STYLE="white-space:nowrap">AU-011</FONT> using an ophthalmic laser resulted in precise
tumor cell killing with minimal damage to surrounding tissues. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In the absence of light activation or binding to the tumor cell membrane, there was no cytotoxic effect.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Multiple laser treatments, following a single dose of <FONT STYLE="white-space:nowrap">AU-011,</FONT> increased antitumor
activity because of the reoxygenation of the tumor and the photostability of <FONT STYLE="white-space:nowrap">AU-011.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Acute necrosis triggered immunogenic cell death, which releases neoantigens and DAMPs, leading to the generation of an
adaptive, long-term antitumor immune response. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g01a88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 6. <FONT STYLE="white-space:nowrap">AU-011,</FONT> administered by intraocular injection, binds to tumor
cells. Activation using an ophthalmic laser leads to rupture of the tumor cell membrane, acute necrosis and a secondary immune activation leading to long term antitumor immunity. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I><U>Goal of Treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT></U> </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In ocular oncology, the goal of early stage local treatment is to achieve tumor control&#151;to prevent the tumor from growing further while preserving
the delicate ocular structures such as the retina. We believe that treatment early in the disease course can also limit the risk of metastasis for patients. After treatment, if tumors do not have an increase in thickness by ultrasound or an increase
in diameter as evaluated with digital photography, it is believed that the malignant cells have been killed, tumor control has been achieved and the treatment is considered successful. Ocular oncologists measure the antitumor activity after plaque
brachytherapy by evaluating tumor control as well as systemic disease to detect the presence of metastasis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on preclinical experiments, we
believe that early treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> will selectively kill the malignant cells that are localized in the lesion and leave the benign melanocytes and other surrounding cells unaffected. In addition, we
believe our treatment is highly <FONT STYLE="white-space:nowrap">pro-immunogenic,</FONT> meaning </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
that the necrotic tumor cells would trigger the infiltration of immune cells. The inflammatory process has the potential to transform the lesion into a fibrotic scar, resulting in long-term tumor
control and potentially an antitumor response that prevents the onset of metastases. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g08n95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 7. Goal of treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> is local tumor control with
targeted killing of melanoma cells. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that patients with earlier stage tumors stand to derive the most benefit from <FONT
STYLE="white-space:nowrap">AU-011.</FONT> These tumors are not only the most likely to respond to our therapy but, based on historic data, these patients also have the highest likelihood of not having already developed life-threatening metastatic
disease, and as such, <FONT STYLE="white-space:nowrap">AU-011</FONT> has the potential to confer the greatest long-term benefit. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Phase 1b/2
clinical trial design </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have completed a Phase 1b/2 clinical trial of <FONT STYLE="white-space:nowrap">AU-011</FONT> for the first-line
treatment of patients with a clinical diagnosis of choroidal melanoma. <FONT STYLE="white-space:nowrap">AU-011</FONT> was administered locally in the eye using two intravitreal injections and then activated with two focused laser treatments
approximately six hours after administration and thirty minutes apart per treatment day, as illustrated below. We refer to one cycle of treatment as three treatment days of the course of two weeks (e.g., on days 1, 8 and 15). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g48m20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 8. Treatment regimen of <FONT STYLE="white-space:nowrap">AU-011</FONT> with intravitreal administration and
laser activation in choroidal melanoma. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our Phase 1b/2 clinical trial of <FONT STYLE="white-space:nowrap">AU-011</FONT> included 57 adult
patients with a clinical diagnosis of primary choroidal melanoma, tumor thickness of 0.5&nbsp;mm <FONT STYLE="white-space:nowrap">-</FONT> 3.4&nbsp;mm, a largest basal diameter, or LBD, of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT></FONT>16 mm with risk factors and/or documented growth. The trial included single and multiple dose
escalation cohorts and two dose expansion cohorts. <FONT STYLE="white-space:nowrap">AU-011</FONT> was initially administered to patients starting with a single
20&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT></FONT>g dose followed by a single laser treatment, then the dose was increased to 40 <FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT></FONT>g and then 80&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT></FONT>g, followed in each case by two laser administrations. The dose escalation phase was
completed without any dose limiting toxicities or clinically significant adverse events observed. In the first expansion cohort, patients were treated with one cycle of treatment. In the second expansion cohort, a second cycle of treatment three
months after the initial cycle was added with the goal of optimizing antitumor activity and preventing tumor recurrence. Patients who failed <FONT STYLE="white-space:nowrap">AU-011</FONT> therapy were eligible to be treated with standard of care
radiotherapy treatment as determined by the clinical investigator. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g10b55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 9. Phase 1b/2 clinical trial design of <FONT STYLE="white-space:nowrap">AU-011</FONT> with intravitreal
administration in choroidal melanoma. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ocular oncologists evaluate tumor control after radiotherapy primarily by ultrasound measurements of the
tumor thickness, which are highly accurate to detect submillimeter differences in thickness and detect changes in the tumor diameter with either fundus photography measurements or ultrasound measurements. In our Phase 1b/2 trial, tumor control with <FONT
STYLE="white-space:nowrap">AU-011</FONT> was evaluated using the same methodology. In addition to tumor control, the growth rate of the tumor was also evaluated before and after treatment in those tumors that had active growth at study entry. By
focusing on such active tumors with active growth, we believe we have a greater ability to measure the clinical activity of <FONT STYLE="white-space:nowrap">AU-011</FONT> in terms of both reducing the rate of tumor growth needed to see a
statistically significant response and positively impacting the tumor control rate while implementing a smaller trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on communications with
the FDA, during our Phase 1b/2 trial, we evaluated the effectiveness of <FONT STYLE="white-space:nowrap">AU-011</FONT> in terms of tumor control and visual acuity preservation using the endpoints and thresholds in the table below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g11q01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Not judged by the Investigator to be due to inflammation/swelling, hemorrhage or pigmentary changes </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 10. Efficacy endpoints for our clinical trials in choroidal melanoma. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Phase 1b/2 demonstrated robust antitumor activity </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A total of 56 patients out of 57 patients enrolled with a clinical diagnosis of choroidal melanoma were treated with
<FONT STYLE="white-space:nowrap">AU-011,</FONT> due to one patient not having met predefined active growth criteria. Tumor growth measurements were obtained by one centralized reading center. Most patients (53 out of 56) had small tumors between 1
mm and 3 mm in height and a diameter less than 10 mm. Twenty patients had small tumors with active growth of 0.3 mm or greater in tumor height within the two years prior to enrollment, a sign that the tumors were actively growing prior to treatment
with <FONT STYLE="white-space:nowrap">AU-011.</FONT> Fourteen of the 20 patients with active growth were treated with two cycles of <FONT STYLE="white-space:nowrap">AU-011,</FONT> which was the highest dose and most frequent regimen examined in this
trial. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g10d10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 11. Patient disposition in the Phase 1b/2 trial. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In our Phase 1b/2 trial, the tumor control rate at twelve months across all treatment doses and initial tumor sizes was 54% based on the predefined
criteria of tumor control failure as an increase in thickness of greater than 0.5 mm or an increase in diameter of more than 1.0 mm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the
conduct of our trial, and based on feedback from key opinion leaders and ocular oncology experts, we amended the protocol and statistical analysis plan for the trial to analyze certain subgroups. The key two subgroups were patients with
well-documented active growth (n=20) and those with well-documented active growth treated at the highest therapeutic regimen (n=14). The 20 patients with well-documented active growth treated at all doses had a tumor control rate of 60%. The 14
patients with well-documented active growth treated at the highest therapeutic regimen had a tumor control rate of 64%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Data from the 14 patients
with small tumors treated with two cycles of <FONT STYLE="white-space:nowrap">AU-011</FONT> showed that nine patients had tumor control, of which six patients had some degree of tumor thickness reduction measured at twelve months. Five patients did
not realize tumor control, of which three patients had tumor control failure based on an increase in tumor thickness and LBD, one patient had tumor failure based on an increase in LBD and one patient was treated with radiation therapy early by the
investigator before the treatment failure criteria were met. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="border-bottom:1.00pt solid #000000" ALIGN="right">


<IMG SRC="g209588g22s22.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000">


<IMG SRC="g209588g23s23.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 12. Change from baseline in tumor thickness over 12 months and tumor control rates at 12
months. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g24s24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 13. Change in tumor thickness at twelve months or at the last measurement before administration of standard
of care for the 14 patients with actively growing tumors treated with two cycles of <FONT STYLE="white-space:nowrap">AU-011.</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">When
compared to each patient&#146;s rate of tumor growth within the prior two years before enrollment, the growth rate after treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> at any dose demonstrated a statistically significant reduction
both when assessing patients with active growth in all dose cohorts as well as patients on the therapeutic regimen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">


<IMG SRC="g209588g57a22.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000">


<IMG SRC="g209588g25s25.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 14. Tumor growth rates in <FONT STYLE="white-space:nowrap">AU-011</FONT> treated patients were
reduced compared to their growth rates prior to enrollment. The growth rate reduction at 12 months was statistically significant. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Phase 1b/2
demonstrated preservation of visual acuity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that showing preservation of visual acuity will be critical in our application for
regulatory approval of <FONT STYLE="white-space:nowrap">AU-011</FONT> to show that it can both halt tumor growth and preserve visual acuity. Visual acuity was measured at regular intervals as a key efficacy endpoint. In the Phase 1b/2 trial we
defined the loss of visual acuity as the loss of three lines of vision, or 15 letters, using best corrected visual acuity, or BCVA, which the FDA considers a clinically meaningful vision loss. We found moderate loss of visual acuity immediately
following treatment, which we believe was associated with short-term reversible adverse events such as ocular inflammation and corneal abrasions. Upon resolution of the short-term adverse events, visual acuity recovered in the majority of patients,
and we observed a vision preservation rate of 86% across all 56 treated patients in the trial over the twelve months follow up period and 71% for the 14 patients enrolled with active growth and treated with two cycles of <FONT
STYLE="white-space:nowrap">AU-011</FONT> therapy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g11i11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 15. Visual acuity was maintained after treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> in a
majority of patients with 12 months follow up. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Only four out of 14 patients with small tumors with active growth had a long-term loss of more than 15
letters of vision that did not recover back to less than the 15 letters at 12 months. These were related to persistent adverse events, such as pigmentary changes, macular edema or subretinal fluid. Of the four patients that had persistent vision
loss, two lost greater than 30 letters and the other two had a loss of 17 and 18 letters which is close to the threshold of 15 letters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Importantly, 17 of the 20 patients with small tumors with active growth had tumors close to the fovea or optic nerve and were considered high risk for
severe vision loss with radiotherapy. In this patient population, the vision preservation rate was 76% (13/17 patients) highlighting a potential important benefit <FONT STYLE="white-space:nowrap">AU-011</FONT> may have over the current standard of
care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Phase 1b/2 safety and tolerability data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> was generally reported to be well-tolerated at all doses including when two cycles of
therapy were administered. Adverse events were generally mild or moderate, transient and manageable with standard of care treatments in most patients. Expected AEs of vitreous inflammation, anterior chamber inflammation and increased intraocular
pressure were manageable with steroid treatment and ocular antihypertensives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Intraocular inflammation represented the most common treatment
related AE, which was expected given the viral-like component of our drug and the <FONT STYLE="white-space:nowrap">pro-immunogenic</FONT> mechanism of action. These inflammatory events included anterior chamber inflammation in approximately 71% of
patients and posterior inflammation in 91% of patients. Posterior inflammation originated in and around the tumor, suggesting that this inflammation may, at least in part, be related to potential antitumor activity of
<FONT STYLE="white-space:nowrap">AU-011.</FONT> This inflammation was not prophylactically treated, which allowed the immune response to initiate before starting steroid therapy. Cases of anterior inflammation were treated with topical steroid
drops, while posterior inflammation was treated with topical, oral, intravitreal or periocular steroids. Approximately 46% of patients also had transient increases in intraocular pressure that were managed with topical anti-hypertensives. One
patient had a Grade III vitreous opacity that was removed with surgery. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g22i22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 16. Adverse events among all 56 patients treated with <FONT STYLE="white-space:nowrap">AU-011.</FONT>
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The rate of treatment related AEs in the 14 patients with active tumor growth dosed with two cycles of
<FONT STYLE="white-space:nowrap">AU-011</FONT> were similar to those reported in the overall treated population. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g18c00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 17. Adverse events reported among the 14 patients with active tumor growth treated with two cycles of <FONT
STYLE="white-space:nowrap">AU-011.</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Adverse events of pigmentary changes around the tumor margin were reported in approximately 38% of
patients and were the cause of the only two drug-related serious adverse events, or SAEs, of vision loss. In these two subjects the edge of the tumor was within 1.0 mm of the fovea and the pigmentary changes occurred in the fovea causing the vision
loss of greater than 30 letters. Other pigmentary changes around the tumor outside of the fovea had minimal clinical impact and did not cause a loss of visual acuity, which suggests that the location of the tumor was in part responsible for the two
SAEs. While the cause of these pigmentary changes is unknown, we believe that based on clinical observations they may be related to an immune response. A risk mitigation strategy that was included as a protocol amendment after the first SAE occurred
was to limit the dose of laser in the fovea to only one laser activation per treatment, instead of two activations which is the dose given otherwise. Two SAEs that were not related to treatment were reported in two patients, one event each of
papillary renal cell carcinoma and diverticulitis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A high proportion of patients (43/56; 77%) in the trial were at high risk for vision loss with
radiotherapy because their tumors were close to the fovea or optic disk (&lt;3.0 mm). If these patients had been treated with radiotherapy, historical studies suggest that a large proportion would have a worse visual acuity prognosis, with many
having vision of &lt;20/200 or legal blindness within five years. Approximately 90&nbsp;percent of high-risk patients with tumors near the fovea or optic nerve had a significant vision loss with plaque brachytherapy as the plaque led to irreversible
damage to the fovea or optic nerve. In contrast, most of the high-risk patients in our trial were successfully treated with <FONT STYLE="white-space:nowrap">AU-011</FONT> without a significant impact on their visual acuity, highlighting the
potential benefit relative to the current standard of care. A cross trial comparison of patients treated with AU-011 and patients treated with plaque brachytherapy highlights the stark differences in the adverse event profiles between current
standard of care therapy and <FONT STYLE="white-space:nowrap">AU-011.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g19p20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 18. Treatment related adverse event rates with plaque brachytherapy </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g02b95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:30%; font-size:6pt; font-family:ARIAL">* 77% (43/56) of patients in Ph1b/2 IVT trial were at high risk for vision </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:30%; font-size:6pt; font-family:ARIAL">loss; 2/43= 4.6% </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 19. Treatment related
(AU-011 or laser) adverse event rates with AU-011 with IVT administration </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that <FONT STYLE="white-space:nowrap">AU-011</FONT> has
the potential to deliver meaningful clinical benefit to patients with early-stage choroidal melanoma as a first-line treatment while decreasing the likelihood of irreversible loss of visual acuity and other severe comorbidities that are often
associated with radiotherapy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Preclinical data </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In preclinical studies, we observed that <FONT STYLE="white-space:nowrap">AU-011</FONT> was able to bind potently to multiple ocular melanoma human cell
lines with over half of cells being bound at <FONT STYLE="white-space:nowrap">AU-011</FONT> concentrations below 100 pM. This binding was observed in 92.1, MP41 and MP46 cell lines, which represents a range of genetic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
profiles. These findings are consistent with binding of <FONT STYLE="white-space:nowrap">AU-011</FONT> to extracellular tumor-specific HSPGs independently of the genetic alteration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Activation of <FONT STYLE="white-space:nowrap">AU-011</FONT> by laser illumination resulted in potent cell killing at a picomolar level across cancer
cell lines. These data support that <FONT STYLE="white-space:nowrap">AU-011&#146;s</FONT> physical mechanism of action to cause acute cellular necrosis may be independent of the particular mutation of the melanoma. No cell killing was observed with <FONT
STYLE="white-space:nowrap">AU-011</FONT> in the absence of laser-activation, which supports our hypothesis that <FONT STYLE="white-space:nowrap">AU-011</FONT> only gains cytotoxicity upon activation with near infrared light when bound to the tumor
cell. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g209588g10p12.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g209588g10p13.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 20.
<FONT STYLE="white-space:nowrap">AU-011</FONT> leads to laser-activation-dependent killing of multiple ocular melanoma cell lines. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
investigated the efficacy of <FONT STYLE="white-space:nowrap">AU-011</FONT> in an orthotopic rabbit ocular melanoma model that closely mimics human disease and uses the 92.1 human choroidal melanoma cells. We administered <FONT
STYLE="white-space:nowrap">AU-011</FONT> by intravitreal injection or SC administration and laser activation in the exact same manner as in clinical practice. We observed dose-dependent tumor necrosis. At a dose of 50 <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT></FONT>g, laser-activated <FONT STYLE="white-space:nowrap">AU-011</FONT> given twice weekly by intravitreal administration, on day 1 and day 8, resulted in 80% (four
of five) of eyes with complete tumor necrosis. Importantly, this was in large tumors with thickness up to approximately 5&nbsp;mm to 10 mm, which is three to four times larger than what we are targeting in our clinical trials. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g04d78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 21. <FONT STYLE="white-space:nowrap">AU-011</FONT> caused dose dependent response and tumor necrosis
confirmed by histopathology in rabbit ocular melanoma model. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Suprachoroidal delivery </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As part of our overall development strategy, we are evaluating and developing the SC route of administration to optimize the delivery of <FONT
STYLE="white-space:nowrap">AU-011</FONT> to the choroid where the tumor is located. The suprachoroidal space, or SCS, is a potential space bound between the external surface of the choroid and the internal surface of the sclera, and encompasses the
full circumference of the full posterior segment of the eye. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g47x49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 22. Suprachoroidal administration with SCS
Microinjector<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our preclinical data supports the SCS as an attractive site for
intraocular drug delivery for choroidal melanoma for multiple reasons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Optimization of the therapeutic index due to increased bioavailability at the tumor and lower exposure to key ocular
structures as seen below in Figure 23. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In a rabbit choroidal melanoma model, we observed five times higher tumor exposure was obtained with SC versus
intravitreal administration. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We also observed lower levels in the vitreous, which may translate into lower risk of intraocular inflammation and may
lead to less vision loss. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Optimization of the treatment duration in the clinic reduces the time between the injection and the laser activation due to
faster distribution. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Injection procedure which requires minimal training. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We believe increased bioavailability may enable treatment of a broader range of patients with <FONT
STYLE="white-space:nowrap">medium-sized</FONT> choroidal tumors, including melanomas and choroidal metastases. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g37c50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 23. Suprachoroidal administration in a rabbit tumor model led to increased drug concentrations in tumors and
lower concentrations in vitreous than intravitreal administration. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Phase 2 suprachoroidal administration trial </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are currently conducting a Phase 2 dose escalation trial of <FONT STYLE="white-space:nowrap">AU-011</FONT> with SC administration in 18 patients with
choroidal melanoma. The primary objective of this portion of the trial is to determine the maximum tolerated dose and treatment regimen. We believe SC administration can result in a better target product profile with reduced inflammation because of
significantly lower exposure of the drug to the vitreous and potentially higher clinical activity than intravitreal administration because of increased drug exposure to the tumor in the choroid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The results from the initial patient cohorts with an average of six months <FONT STYLE="white-space:nowrap">follow-up</FONT> demonstrated that SC
administration was generally well tolerated with no serious treatment related adverse events reported. To date, drug and laser related adverse events have included three patients with mild anterior uveitis, two patients each with both punctate
keratitis and eye pain, and one patient with conjunctiva hyperemia, conjunctival edema, eyelid edema, pupils unequal retinal pigment epitheliopathy, and salivary gland enlargement. One moderate adverse event of anterior scleritis related to the
injection procedure was also observed. All of the events were resolved spontaneously with standard of care treatment. Of note, minimal inflammation in the vitreous has been observed in this trial through the two cycles of the highest tested dose (40
&micro;g). Given the tolerability profile with the 40 &micro;g dose, we increased the highest dose to 80 &micro;g per treatment and plan to explore a new treatment regimen with three cycles of treatment. We plan to present the six to 12 month safety
and efficacy data from this trial in 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g30a00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 24. Adverse events among the 13 patients enrolled in the Phase 2 suprachoroidal trial to date. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g24f55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 25. Phase 2 clinical trial design with suprachoroidal administration. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Dose escalation cohorts. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Pivotal trial plan
in choroidal melanoma </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In alignment with the FDA and EMA, we plan on conducting two pivotal trials with
<FONT STYLE="white-space:nowrap">AU-011.</FONT> The first pivotal trial will be the Phase 2b portion of the ongoing SC administration trial. We anticipate initiating this portion in the second half of 2022 in patients with high-risk indeterminate
lesions and small choroidal melanoma who have active growth prior to enrollment. We intend to randomize a minimum of 70 patients in this trial to three arms 2:1:2 to receive therapeutic regimen <FONT STYLE="white-space:nowrap">AU-011,</FONT> low
dose regimen <FONT STYLE="white-space:nowrap">AU-011</FONT> or a sham control. Patients will be selected based on having a small amount of active growth within two years of trial enrollment, and a tumor size of 0.5 mm to 3.0 mm in thickness and less
than 10 mm in diameter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><B>Pivotal Trial </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g01q72.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 26. Preliminary design of the pivotal trial. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The key primary endpoint agreed with the FDA is contemplated to be the tumor thickness growth rate over 12&nbsp;months, comparing the growth rates
between the <FONT STYLE="white-space:nowrap">AU-011</FONT> high dose group and the sham group<I>. </I>The first key secondary endpoint will be a composite time to event analysis that will evaluate the number of events of disease progression or
visual acuity failure between the <FONT STYLE="white-space:nowrap">AU-011</FONT> high dose group and the sham group. We will also evaluate time to disease progression and change from baseline in BCVA letter score. There will be a minimum follow up
for all patients of 12&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The trial has a power of &gt;95% to meet the primary and the first key secondary endpoint. Since there is no
drug approved for the treatment of choroidal melanoma, we have agreed with FDA that a statistically significant difference on these endpoints will provide support from a regulatory perspective to meet the requirement of clinical effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Given that choroidal melanoma is a rare disease and, based on the limited natural history data of the growth rate of these early-stage tumors, this
trial will follow an adaptive design with the ability to perform a sample size <FONT STYLE="white-space:nowrap">re-estimation.</FONT> With this adaptive design, the sample size will be increased if either (1)&nbsp;the observed growth rate in the
sham arm is lower than assumed or (2)&nbsp;the estimated treatment effect comparing the sham arm and the high dose arm is less than expected. With this strategy, we believe we will improve the probability of success of the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also plan to conduct a second pivotal trial, which will be a Phase 3 randomized trial, that will start enrolling when the first pivotal trial
completes enrollment. This Phase 3 trial is planned to be an identical design to the Phase&nbsp;2b pivotal trial described above with the same primary and secondary endpoints. The final sample size of this second pivotal trial will be determined by
the final sample size of the Phase&nbsp;2b pivotal trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If warranted by the data, we plan to submit the results of the Phase&nbsp;2b pivotal
trial to support approval of <FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of primary indeterminate lesions and small choroidal melanoma. Based on the results of the Phase&nbsp;2b pivotal trial, if positive, and the fact that
there are no therapies approved for the treatment of this rare disease, the FDA and EMA may agree to grant approval based on the first pivotal trial with the condition that the second Phase&nbsp;3 pivotal trial should be completed as a post-approval
commitment. However, the FDA and/or EMA may require both trials for approval, which will be addressed subsequent to submission of the data from the first pivotal trial. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Registry Trial </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have agreement with
the FDA that we will monitor all patients for a total of five years after dosing to evaluate the long-term tumor response, visual acuity preservation and safety, as well as the risk of metastatic disease and mortality, which we are doing in a
Phase&nbsp;4 registry trial. To date, all 57 patients in the Phase&nbsp;1b/2 trial with intravitreal administration have completed the Phase 1b/2 trial and 41 (72%) have entered the registry trial. The data collected with an average follow up of two
or more years from initial enrollment in the Phase 1b/2 trial and follow up in the registry demonstrates durability of tumor control, visual acuity preservation and related safety profile from treatment of
<FONT STYLE="white-space:nowrap">AU-011.</FONT> All </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
subjects in the registry trial treated only with AU-011 had stable vision and no local progression of disease after up to two years of follow-up. For those patients who progressed in tumor size
in the Phase 1b/2 trial and who received standard of care with radiotherapy, two patients lost visual acuity and one additional patient had to have their eye enucleated because of tumor recurrence after radiotherapy, reaffirming our belief that
there is a high unmet medical need in this patient population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Only one of 40 patients in the registry had onset of metastatic disease which is an
encouraging result as usually the metastatic risk for small melanomas is approximately 12% up to 10 years&#146; follow up. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Matched case
control studies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ability to demonstrate tumor control with long term visual acuity preservation could provide a favorable benefit-risk
profile of <FONT STYLE="white-space:nowrap">AU-011</FONT> for the first line treatment of patients with early-stage choroidal melanoma compared to an invasive radiotherapy procedure. To demonstrate the long-term value of visual acuity preservation
for patients treated with <FONT STYLE="white-space:nowrap">AU-011,</FONT> we are conducting two Matched Case Control, or MCC, studies that will provide data comparing <FONT STYLE="white-space:nowrap">AU-011</FONT> to radiotherapy. A retrospective
MCC study has been performed to provide an estimate of the vision benefit of <FONT STYLE="white-space:nowrap">AU-011</FONT> versus radiotherapy and to help estimate the treatment effect and powering of the prospective MCC study that is expected to
start in 2021. These studies are discussed below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Retrospective matched case control study analysis </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To estimate the vision preservation of <FONT STYLE="white-space:nowrap">AU-011</FONT> compared to radiotherapy we are conducting a retrospective MCC
analysis comparing the group of patients in our Phase 1b/2 trial with small tumors with active growth (n=14) to patients with tumors of similar size and location previously treated with radiotherapy at the Wills Eye Hospital Ocular Oncology Service
led by Dr.&nbsp;Carol Shields. This analysis will match up to 5:1 patients using the key baseline characteristics that impact long term visual acuity &#150; tumor location, tumor size and baseline visual acuity &#150; and will compare the visual
acuity after treatment with each therapy in terms of a change from baseline in vision and absolute vision at years one, two and three. Results from our Phase 1b/2 trial with intravitreal administration show visual acuity preservation in a majority
of patients after two cycles of treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> at twelve months. In addition, data from our ongoing registry trial to date do not show a change or decline in vision for patients treated with <FONT
STYLE="white-space:nowrap">AU-011</FONT> with long term follow up, while two patients that failed treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> and were treated with radiotherapy are having vision loss. We believe that the results of
the retrospective study will further validate these results and strengthen our thesis that the mechanism of <FONT STYLE="white-space:nowrap">AU-011</FONT> enables durable preservation of visual acuity providing an important advantage to
radiotherapy. The results of the retrospective study will be published with Dr.&nbsp;Carol Shields in the first half of 2022 and will be used to estimate the assumptions to power a prospective Matched Case Control study that we plan to start shortly
thereafter. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Prospective matched case control study </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the results of the retrospective MCC analysis we are initiating a prospective matched case control trial where we will compare, after one, two,
and three years, the visual acuity of patients treated with <FONT STYLE="white-space:nowrap">AU-011</FONT> versus patients treated with radiotherapy. Like the retrospective MCC analysis, patients will be matched based on similar tumor size,
location, and baseline vision at the beginning of the trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g26a95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure&nbsp;27. Matched case control prospective trial comparing visual acuity outcomes after treatment with <FONT
STYLE="white-space:nowrap">AU-011</FONT> or plaque radiotherapy. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The patients are planned to be matched on average 3:1 (Radiotherapy: <FONT
STYLE="white-space:nowrap">AU-011)</FONT> to increase the power. The matching and analysis will be masked and performed independently. The objective is to show the vision benefit of <FONT STYLE="white-space:nowrap">AU-011</FONT> compared to
radiotherapy using prospective data for both groups. Based on initial results in the retrospective MCC study, we believe these results may support the benefit/risk discussion of our regulatory submission and to serve as support for pricing and
reimbursement discussions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Choroidal metastases from other tumors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We can apply our mechanism of action for <FONT STYLE="white-space:nowrap">AU-011,</FONT> which we believe has the ability to preserve key ocular
structures, in multiple other ocular oncology indications. Beyond primary choroidal melanoma, we are developing <FONT STYLE="white-space:nowrap">AU-011</FONT> in additional ocular oncology indications, starting with choroidal metastases. Choroidal
metastases are a common intraocular malignancy that are caused by multiple primary cancers in the body that metastasize to the eye due to the high blood flow and perfusion that provides an environment receptive to metastases and tumor growth.
Approximately 22,000 patients have choroidal metastases globally every year. and approximately half (~47%) of the patients with choroidal metastases have primary breast tumors. Other common primary cancers include lung (approximately 21%),
gastrointestinal (4%), kidney (2%), cutaneous melanoma (2%) and prostate cancer (2%), and approximately 17% of cases with an unknown primary tumor type. The majority of these malignancies are solitary small tumors in the choroid associated with
subretinal fluid and, as opposed to choroidal melanoma, they can occur in and adversely affect vision in both eyes. These lesions are typically treated with radiation, which has the same comorbidities as previously described for the treatment of
choroidal melanoma. Given their poor prognosis, the quality of life and, in particular, maintenance of vision, for patients with metastatic cancer is critical and as such there is a significant unmet need for an effective vision sparing ocular
treatment that enables patients to avoid additional surgical interventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have observed in preclinical experiments that treatment with <FONT
STYLE="white-space:nowrap">AU-011</FONT> led to HSPG-dependent tumor cell binding and laser-activation-dependent cell killing of multiple cell lines in each of the common primary tumors listed above as well as multiple other primary solid tumors. We
believe this versatility makes <FONT STYLE="white-space:nowrap">AU-011</FONT> a good potential treatment option for choroidal metastasis. <FONT STYLE="white-space:nowrap">AU-011&#146;s</FONT> mechanism of action does not depend on specific mutations
in the genetic profile of the tumor or on the expression of a particular type of growth factor receptor, but rather on the ubiquitously expressed tumor modified HSPGs on the cell membrane of solid tumors. For example, in a mouse <FONT
STYLE="white-space:nowrap">EMT-6</FONT> breast cancer model, treatment with a single intravenous administration of 100 &micro;g dose of <FONT STYLE="white-space:nowrap">AU-011</FONT> followed twelve hours later by laser activation led to significant
reduction in tumor growth rate compared to placebo controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g01n05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 28. Single dose of <FONT STYLE="white-space:nowrap">AU-011</FONT> treatment led to significant reduction in
tumor growth in an <FONT STYLE="white-space:nowrap">EMT-6</FONT> breast cancer model. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the results we observed in our choroidal
melanoma Phase 1b/2 trial and the preclinical results we have observed with <FONT STYLE="white-space:nowrap">AU-011</FONT> in these multiple cancers <I>in vitro</I> and <I>in vivo</I>, we believe that <FONT STYLE="white-space:nowrap">AU-011</FONT>
has the potential to treat choroidal metastases and preserve vision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are planning to initiate clinical development in this indication in the
second half of 2022, subject to FDA acceptance of an IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of
<FONT STYLE="white-space:nowrap">non-muscle-invasive</FONT> bladder cancer </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for
the treatment of NMIBC. We are planning to initiate clinical development with <FONT STYLE="white-space:nowrap">AU-011</FONT> with intramural administration, a novel route of administration for the treatment of patients with intermediate and
high-risk bladder cancer lesions. This novel route of administration is based on the direct administration of <FONT STYLE="white-space:nowrap">AU-011</FONT> into the lamina propria of the bladder wall at the tumor edge. It is intended to place high
levels of <FONT STYLE="white-space:nowrap">AU-011</FONT> at the base of the tumor where laser activation can cause localized necrosis preventing residual tumor cells from further growth and recurrence. We are conducting <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies with <FONT STYLE="white-space:nowrap">AU-011</FONT> to demonstrate the feasibility of this approach and intend to begin clinical trials in the second half of 2022. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Bladder cancer disease background </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Bladder
cancer is the most common malignancy involving the urinary system and is the eighth most common cause of cancer death in men in the United States. Estimates are that there will be 61,300 new cases of bladder cancer and 17,000 deaths in 2021 in the
United States. Globally, bladder cancer accounts for approximately 570,000 cases, with 422,000 cases comprised of NMIBC, and 165,000 deaths each year. Patients with bladder cancer classically present with painless blood in the urine, however,
because this symptom is like those of benign disorders such as urinary tract infections, cystitis, prostatitis and the passage of kidney stones, the diagnosis of bladder cancer is often delayed while these other, more common, conditions are ruled
out. Furthermore, symptoms are often intermittent. Delays in diagnosis can lead to a worsened prognosis due to the presence of more advanced stage disease by the time a confirmation of bladder cancer is made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g60l12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 29. Cross section of the bladder wall and staging of bladder cancer. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Bladder cancer is classified into two broad categories: NMIBC, where the primary cancer is restricted to the urothelial layer of cells or the connective
tissue under this layer in the bladder; and muscle-invasive bladder cancer, or MIBC, which is a more advanced cancer that has invaded deeper into the bladder wall and has a higher potential to metastasize. Approximately 70% of newly diagnosed cases
of primary bladder cancer are NMIBC. The five-year survival for patients with early stage disease is 88%. For patients with metastatic disease or cancer that has spread to other parts of the body, however, the five-year survival drops to 15%. We
believe that early treatment intervention would significantly improve the outcomes for these patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Early stage NMIBC is characterized by a lack
of first-line treatment options. It is typically treated by surgical removal of the tumor through a procedure known as transurethral resection of bladder tumor, or TURBT, in which an endoscope is inserted through the urethra into the bladder
allowing tumor removal without requiring incisions. Depending on the stage of the tumor, this is followed by local chemotherapy or Bacillus Calmette-Guerin, or BCG, that is instilled into the bladder. Despite this treatment many of these cancers
recur and spread throughout the bladder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For high risk and intermediate risk patients, the most common
<FONT STYLE="white-space:nowrap">non-surgical</FONT> therapy used today is intravesical immunotherapy with BCG, a live attenuated form of <I>Mycobacterium</I> <I>bovis</I> that has been used to treat bladder cancer for over forty years. While the
exact mechanism of action of BCG is unknown, it is believed that infection of the bladder with BCG triggers a local immune response and the accompanying heightened activation of the immune system improves its ability to recognize and destroy
cancerous cells. BCG reduces tumor recurrence and progression of disease as defined by the need for surgery or additional chemotherapy. However, 30 to 40% of patients do not respond to this therapy and are at risk of developing advanced disease. The
recommended treatment for these patients is radical cystectomy, which is a surgical procedure where the entire bladder and other local structures are removed. In men, this procedure typically includes removal of the prostate and seminal vesicles. In
women, radical cystectomy also involves removal of the uterus, ovaries, and part of the vagina. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g10p11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 30. NMIBC is categorized and treated based on risk stratification, determined by combination of tumor grade,
stage, size, recurrence history and focality. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Beginning in January 2019, Merck&nbsp;&amp; Co., the world&#146;s only manufacturer of BCG,
announced a global shortage of BCG for the foreseeable future due to its growing use and supply constraints. In response to this shortage, urological cancer advocacy groups advised that BCG not be used for
<FONT STYLE="white-space:nowrap">low-risk</FONT> patients. They also advised that if the standard dose is unavailable due to supply constraints, high-risk patients only receive <FONT STYLE="white-space:nowrap">one-half</FONT> to <FONT
STYLE="white-space:nowrap">one-third</FONT> the standard dose in order to postpone surgical intervention or to slow progression of disease. These alterations in guidelines that limit available BCG for patients have resulted in suboptimal patient
care. This has driven clinicians to evaluate alternative therapeutics to ensure adequate patient care which underscores the need for continued innovation in NMIBC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The most common treatment for patients diagnosed with advanced or metastatic bladder cancer is chemotherapy with platinum-based drugs such as
carboplatin or cisplatin in combination with gemcitabine. Patients with metastatic disease that progresses during or after platinum-based chemotherapy are increasingly being treated with checkpoint immunotherapy. Several agents targeting the
programmed cell <FONT STYLE="white-space:nowrap">death-1,</FONT> or <FONT STYLE="white-space:nowrap">PD-1,</FONT> pathway have been approved by the FDA for use in refractory metastatic bladder cancer. Objective response rates for advanced metastatic
bladder cancer reported in clinical trials with checkpoint inhibitors have been between 23% and 33%. The historical median overall survival of patients with advanced or metastatic bladder cancer from the start of initial therapy is 12.7 months.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that a targeted therapy for the primary tumor directed specifically to bind to and
kill bladder cancer cells and subsequently activate the immune system has the potential to generate long-term antitumor immunity that may prevent recurrence in patients with early-stage disease. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Our solution <FONT STYLE="white-space:nowrap">AU-011</FONT> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are currently developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for the treatment of NMIBC with
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and plan to initiate a Phase 1a trial in the second half of 2022, subject to FDA acceptance of an IND, to evaluate the feasibility of intramural administration and to assess distribution,
safety and initial proof of mechanism with evaluation of local acute cellular necrosis after laser activation. We believe <FONT STYLE="white-space:nowrap">AU-011</FONT> represents a potential targeted therapy that can be activated using a similar
laser as that currently utilized in our choroidal melanoma program, following a well-characterized approach with commercially available devices used by urologists. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g01n02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 31. <FONT STYLE="white-space:nowrap">AU-011</FONT> is administered in the lamina propria close to the base
of the tumor where it selectively binds tumor cells. Upon laser activation, <FONT STYLE="white-space:nowrap">AU-011</FONT> leads to acute tumor cell necrosis and immune activation preventing tumor cells at the base of the tumor from further growth
and recurrence. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">AU-011</FONT> has been observed to be highly selective, through both its specific binding to
modified HSPGs on cancer cells, combined with focused laser activation leading to cytotoxicity and subsequent immune activation. We believe the immune response could play an even larger role in bladder cancer, given that bladder cancer has a
well-documented response to immune activation. This immune sensitivity is substantiated by the effectiveness of immune modulatory agents like BCG. We have observed in preclinical experiments that <FONT STYLE="white-space:nowrap">AU-011</FONT> was
able to target bladder cancer cells in both <I>in vitro</I> and <I>in vivo</I> tumor models. Laser activation of <FONT STYLE="white-space:nowrap">AU-011</FONT> resulted in cell killing of bladder tumor cells while sparing other normal surrounding
cells as a single agent. This cell killing induced a <FONT STYLE="white-space:nowrap">pro-immunogenic</FONT> antitumor response that resulted in complete elimination of tumors in a mouse xenograft model and durable responses as well as the
prevention of tumor <FONT STYLE="white-space:nowrap">re-implantation.</FONT> This highlights the value of <FONT STYLE="white-space:nowrap">AU-011</FONT> to generate antitumor immunity and prevent tumor recurrence. Based on our preclinical data, <FONT
STYLE="white-space:nowrap">AU-011</FONT> was also observed to be highly synergistic with checkpoint inhibitors that have already been approved for the treatment of a subset of NMIBC and metastatic bladder cancer patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:9%" ALIGN="center">


<IMG SRC="g209588g30s33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 32. Overview of <FONT STYLE="white-space:nowrap">AU-011&#146;s</FONT> dual mechanism of action with acute
tumor cell necrosis and secondary antitumor immunity. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Preclinical data </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In preclinical studies <FONT STYLE="white-space:nowrap">AU-011</FONT> demonstrated binding with high affinity to multiple bladder cancer cell lines at
very low concentrations of less than 100 pM. This robust multivalent binding was dependent on the presence of HSPGs on the cancer cell surface. To show the specificity of binding to HSPGs on tumor cells, we
<FONT STYLE="white-space:nowrap">pre-incubated</FONT> <FONT STYLE="white-space:nowrap">AU-011</FONT> with heparin, which blocked the heparin binding sites on <FONT STYLE="white-space:nowrap">AU-011</FONT> and prevented it from binding to HSPGs on
the tumor cell membrane. Furthermore, no cytotoxicity was observed. In contrast, without the presence of heparin, laser activation of <FONT STYLE="white-space:nowrap">AU-011</FONT> led to killing of cells from all four bladder cancer cell lines
tested. This highlights the requirement of HSPGs binding to tumor cells in order to initiate a potent cytotoxic effect, suggesting that not only is the cytotoxic payload inert when free, but that <FONT STYLE="white-space:nowrap">AU-011</FONT> is
required to be bound to be effective. We believe that these attributes will help limit <FONT STYLE="white-space:nowrap">off-target</FONT> and <FONT STYLE="white-space:nowrap">off-tumor</FONT> toxicity, which may limit the local and systemic toxicity
observed in other treatments like BCG, and ultimately may result in patients not requiring cystectomy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g01n04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 33. <FONT STYLE="white-space:nowrap">AU-011</FONT> is effective in killing multiple bladder cancer cell
lines. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have generated <I>in vivo</I> data in immunocompetent murine tumor models of bladder cancer that
show a dose-dependent cytotoxic response of <FONT STYLE="white-space:nowrap">AU-011</FONT> with an upregulation of markers of immunogenic cell death, such as calreticulin and HSP70, which are DAMP molecules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A single systemic dose administration of <FONT STYLE="white-space:nowrap">AU-011</FONT> in the MB49 syngeneic bladder cancer model led to cell death and
elimination of the primary tumors, resulting in complete responses in 80% of animals. Combination with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> immune checkpoint inhibitor antibody improved
therapeutic activity resulting in a 100% complete response rate and survival that was durable at least 100 days post-treatment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g34w34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 34. <FONT STYLE="white-space:nowrap">AU-011</FONT> in vivo effect on tumor growth and survival in a bladder
cancer model. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In this model, we observed that treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> was able to generate a long-term
immune response that further prevented the establishment of new bladder tumors on <FONT STYLE="white-space:nowrap">re-challenge</FONT> 100 days after the single administration of <FONT STYLE="white-space:nowrap">AU-011.</FONT> 80% of the mice
treated with AU-011 as a single agent or in combination with an <FONT STYLE="white-space:nowrap">anti-PD1</FONT> antibody remained tumor free after 100 days, demonstrating a durable antitumor immunity, while mice that were not previously treated
with <FONT STYLE="white-space:nowrap">AU-011</FONT> experienced tumor growth within days and poor survival after rechallenge. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g49v09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 35. <FONT STYLE="white-space:nowrap">AU-011</FONT> induced an antitumor immune response that protected mice
against tumor <FONT STYLE="white-space:nowrap">re-challenge</FONT> at day 100 in a MB49 bladder cancer model. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the resistance to tumor <FONT STYLE="white-space:nowrap">re-challenge</FONT> was due
to the generation of a cellular immune response following the treatment of the initial tumor 100 days earlier. Depletion of CD4+ or CD8+ <FONT STYLE="white-space:nowrap">T-cells</FONT> at the time of <FONT STYLE="white-space:nowrap">AU-011</FONT>
treatment or at the time of tumor <FONT STYLE="white-space:nowrap">re-challenge</FONT> confirmed the involvement of both cell populations in the mechanism of action of <FONT STYLE="white-space:nowrap">AU-011</FONT> and the promotion of long-lasting
antitumor immunity. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Clinical plans in NMIBC </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to conduct a Phase 1a trial in intermediate and high risk NMIBC patients that are either candidates for TURBT or cystectomy beginning in the
second half of 2022, subject to FDA acceptance of our IND. We plan to evaluate the safety, tolerability and feasibility of <FONT STYLE="white-space:nowrap">AU-011</FONT> using the intramural route of administration. After removal of the tumors, we
plan to further assess the tumor tissue with histopathology to evaluate the presence of acute cellular necrosis as an early sign of antitumor response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a &#147;window of opportunity&#148; trial, this trial is designed to evaluate <FONT STYLE="white-space:nowrap">AU-011</FONT> as a treatment before
planned standard of care with TURBT or cystectomy. We believe this intramural approach could be a significant benefit as the key problem leading to tumor recurrence after TURBT is that live cancerous cells may be left in the base of the resected
tumor when patients undergo the surgical procedure. In fact, researchers have recently observed that circulating tumor cells can be detected in the systemic circulation after TURBT. We believe that a neoadjuvant therapy to TURBT that could kill
tumor cells at the base of the lesion while generating antitumor immunity may reduce tumor recurrence, and further prevent live circulating tumor cells, which may reduce the risk of metastatic disease. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g84p49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 36. Treatment with <FONT STYLE="white-space:nowrap">AU-011</FONT> may reduce tumor recurrence by preventing
residual live tumor cells at the base of the tumor after resection with TURBT. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also believe that including a group of high risk, BCG unresponsive
<FONT STYLE="white-space:nowrap">pre-cystectomy</FONT> patients may enable us to evaluate <FONT STYLE="white-space:nowrap">AU-011&#146;s</FONT> potential to confer antitumor responses in the lesions directly treated with <FONT
STYLE="white-space:nowrap">AU-011</FONT> and in other lesions in the bladder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g34y88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 37. Phase 1a window of opportunity trial to establish route of administration and tumor necrosis. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In this Phase 1a trial, we intend to evaluate the tumor distribution of <FONT STYLE="white-space:nowrap">AU-011</FONT> after intramural administration
in intermediate to high-risk subjects with NMIBC. In cohort 1, we will assess <FONT STYLE="white-space:nowrap">AU-011</FONT> local and systemic exposure without laser activation. In cohorts 2 and 3 we will assess
<FONT STYLE="white-space:nowrap">AU-011</FONT> and laser activation in patients with intermediate risk that are planned to receive TURBT and high risk patients that are unresponsive to BCG and that are planned to receive cystectomy. In these
cohorts, we plan to administer <FONT STYLE="white-space:nowrap">AU-011</FONT> followed by laser activation, and one week later the tumor will be removed by TURBT (cohort 2) or the entire bladder by cystectomy (cohort 3), and we will assess tumor
response in the form of necrosis and the immune response by pathology and immunohistochemistry. This Phase 1a trial is planned to be conducted in association with the National Cancer Institute at approximately three selected private sites in the
United States and is planned to be initiated in the second half of 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Shortly after this initial trial, we are planning to conduct a Phase 1b/2
dose escalation and expansion trial in the treatment of NMIBC. We believe this Phase 1b/2 trial will help establish the treatment regimen and we are planning to involve multiple leading sites in the treatment of bladder cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other HSPG-Expressing Tumors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our <FONT
STYLE="white-space:nowrap">HPV-derived</FONT> VLPs have a unique tropism towards cancer cells based on their multivalent binding to modified HSPGs that are specifically found in tumor cells. <I>In vitro</I>, we have observed our VLPs bind to
multiple cancer cell lines. <I>In vivo, </I>we have also observed binding using our <FONT STYLE="white-space:nowrap">HPV-derived</FONT> VLPs using xenografts of human tumor cell lines and allografts of murine tumor cell lines, like lung, ovarian,
bladder, melanoma and colon.&nbsp;These results help to corroborate the thesis that multiple tumors appear to consistently express and specifically modify HSPGs. Accordingly, we believe we may be able treat a broad spectrum of solid tumors. We plan
to select our next solid tumor indication for clinical development with <FONT STYLE="white-space:nowrap">AU-011</FONT> based on its status as a tumor type with high HSPG expression, such as cutaneous melanoma. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g12k55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 38. Binding of VLPs to diverse tumor types uses an HSPG-sensitive mechanism which is demonstrated by its
inhibition with heparin. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition</B> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
biotechnology and pharmaceutical industries are characterized by rapid innovation of new technologies, fierce competition and strong defense of intellectual property. While we believe that <FONT STYLE="white-space:nowrap">AU-011</FONT> and our
knowledge, experience and scientific resources provide us with competitive advantages, we may face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research
institutions, among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We compete in the segments of the pharmaceutical, biotechnology, and companies focusing on developing therapies in the
oncology field. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. Any product candidates that we successfully develop and commercialize will compete with currently approved therapies
and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets that pursue oncology therapeutics. Key product features that would affect our ability to effectively compete with
other therapeutics include the efficacy, safety and convenience of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our competitors may obtain regulatory approval of their products
more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize <FONT STYLE="white-space:nowrap">AU-011</FONT> and any future product candidates. Our competitors may
also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Ocular oncology </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently we are not
aware of any other company that has a drug in clinical development for the treatment of primary choroidal melanoma or for the treatment of choroidal metastases, which are our first two ocular oncology indications. The standard of care as a first
line treatment for patients is plaque brachytherapy or proton beam therapy. Verteporfin (Visudyne) is currently used off label in some cases of early stage disease alone or in combination with transpupillary thermotherapy. It is possible that there
may be other companies with compounds in pre-clinical development but we are not aware of any data that has been published or presented at any conference. Given our stage of development, we believe we are the furthest along in development. Our focus
in ocular oncology is the treatment of the primary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
cancer in the eye before it metastasizes. We are aware of other companies like Immunocore Holdings PLC, or Immunocore, that has a drug in development for metastatic uveal melanoma.
Immunocore&#146;s drug is solely developed to treat metastatic disease and has not been developed to treat the early stage disease in the eye. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Urologic oncology </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently, we are not aware
of any other company that has a drug in clinical development as a neoadjuvant therapy to TURBT. Currently patients receive systemic chemotherapy after TURBT with a platinum based drug +/- Gemcitabine. There are multiple companies that have drugs in
clinical development for the treatment of NMIBC patients that are unresponsive to BCG. ImmunityBio, Inc. has presented Phase&nbsp;2/3 data for their drug Anktiva in combination with BCG in patients with BCG unresponsive high grade NMIBC and they
plan to submit a BLA in 2021. Sesen Bio, Inc. presented Phase&nbsp;3 data for their lead candidate, Viceneum, as a treatment for BCG-unresponsive NMIBC, but in August 2021 the FDA rejected its application and sent Sesen Bio, Inc. a complete Response
Letter. FerGene, Inc. announced positive data of their pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, for the treatment of high-grade, BCG-unresponsive NMIBC, however, they have
announced delays due to chemistry, manufacturing and controls problems, so it is uncertain when they marketing application will be submitted. UroGen Pharma Ltd. has a drug Jelmyto, a gel reformulation of mytomicin that is currently approved to treat
low grade upper tract urothelial cancer, which is currently in Phase 3 development for the treatment of NMIBC. CG Oncology, Inc. has a drug (CG0070) that is being investigated in a global Phase 3 clinical trial as a monotherapy for the treatment of
BCG-unresponsive NMIBC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our License Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>NIH</I><B><I> </I></B><I>Patent License Agreement </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2013, we entered into an exclusive patent license agreement, or the NIH License Agreement, with the NIH for certain intellectual property
rights, as amended in September 2015, August 2018 and April 2019. Under the NIH License Agreement, NIH granted us a worldwide, exclusive, sublicensable license to certain patent rights related to VLPs and papilloma pseudovirus for our development
and use in combination with our proprietary nanoparticle encapsulation technology both (1)&nbsp;for the treatment, diagnosis and imaging of cancer tumors and metastases as well as their respective <FONT STYLE="white-space:nowrap">pre-cursor</FONT>
dysplasia states and (2)&nbsp;conjugated with light activated drugs for the diagnosis and treatment of cancer tumors and metastases as well as their respective <FONT STYLE="white-space:nowrap">pre-cursor</FONT> dysplasia states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the NIH License Agreement, we are required to use commercially reasonable efforts to develop the licensed products using the licensed
processes to make the licensed products available to the United States public on reasonable terms, including by adhering to a commercial development plan and meeting specified benchmarks with regards to specified deadlines for regulatory filings,
initiation of clinical trials, and gaining regulatory approval for the licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In consideration of the rights granted under the NIH
License Agreement, we paid NIH a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $0.1&nbsp;million. We are required to make low single-digit percentage royalty payments based on specified levels of annual net sales of licensed
products subject to certain specified reductions. We are required to make development and regulatory milestone payments up to $0.7&nbsp;million in the aggregate and sales milestone payments up to $0.6&nbsp;million in the aggregate. We are also
required to pay NIH a <FONT STYLE="white-space:nowrap">mid-single</FONT> to low teen-digit percentage of any sublicensing revenue we receive. Additionally, our payment obligations to NIH are subject to an annual minimum royalty payment of low five
figures. As of June&nbsp;30, 2021, we have paid NIH approximately $0.4&nbsp;million in aggregate milestones under the NIH License Agreement. In addition to milestones under the agreement, we reimburse the NIH for any patent prosecution costs
incurred. As of June&nbsp;30, 2021, we have reimbursed the NIH approximately $0.3&nbsp;million in aggregate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The NIH License Agreement will terminate upon the last expiration of the patent rights or we may
terminate the entirety of the agreement upon written notice thereof to NIH. The expiry of the last to expire patent licensed under the agreement is September 2034. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2020 and 2019, we paid $0.02&nbsp;million and $0.2&nbsp;million, respectively, in fees associated with the NIH
License Agreement. During the six months ended June&nbsp;30, 2021 and 2020, we didn&#146;t pay any fees associated with the license. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I><FONT
STYLE="white-space:nowrap">LI-COR</FONT> Exclusive License and Supply Agreement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2014, we entered into an Exclusive License and
Supply Agreement, or the <FONT STYLE="white-space:nowrap">LI-COR</FONT> Exclusive License Agreement, with <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc., or <FONT STYLE="white-space:nowrap">LI-COR,</FONT> for the license of IRDye 700DX and
related licensed patents for the treatment and diagnosis of ocular cancers, ocular <FONT STYLE="white-space:nowrap">pre-cancer</FONT> and indeterminate lesions in humans, and as amended in January 2016, July 2017, April 2018 and April 2019. The <FONT
STYLE="white-space:nowrap">LI-COR</FONT> Exclusive License Agreement required a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront license issue fee of $0.1&nbsp;million and requires aggregate milestone payments of up to $0.2&nbsp;million upon
certain regulatory and development milestones. We are also required to pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> <FONT STYLE="white-space:nowrap">low-single</FONT> digit royalties on net sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The term of the <FONT STYLE="white-space:nowrap">LI-COR</FONT> Exclusive Agreement expires on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the longer of (i)&nbsp;ten years from the first commercial sale of a licensed product in such country and (ii)&nbsp;the last to expire valid claim in such country. The expiry
of the last to expire patent licensed under the agreement is December 2023. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Clearside License Agreement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2019, we entered into a license agreement, or the Clearside License Agreement, with Clearside Biomedical, Inc., or Clearside, for the license of
Clearside&#146;s suprachoroidal microinjector technology. Upon execution of the Clearside License Agreement, we paid Clearside a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $0.1&nbsp;million. Under the Clearside License
Agreement, we are required to pay milestones up to $21.0&nbsp;million in the aggregate to Clearside upon the achievement of specified regulatory and development milestones, and upon the achievement of certain commercial sales milestones. We are also
required to pay low to <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalties on net sales. If we sublicense a product for which royalties are payable, then we are required to pay the greater of 20% received or low single digit royalties
on net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Clearside License Agreement expires on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of the last to expire patent or ten years from the date of the first commercial sale of a product. The expiry of the last to
expire patent licensed under the agreement is August 2034. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our success depends in part on our abilities to (1)&nbsp;obtain and maintain proprietary protection for our lead virus-like drug conjugate product
candidate belzupacap sarotalacan <FONT STYLE="white-space:nowrap">(AU-011),</FONT> (2) defend and enforce our intellectual property rights, in particular, our patent rights, (3)&nbsp;preserve the confidentiality of our
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to, for example, certain manufacturing steps, material components and characteristics of our formulations, and (4)&nbsp;operate without infringing valid and enforceable intellectual property
rights of others. We seek to protect our proprietary position by, among other things, exclusively licensing United States and certain foreign patents and patent applications and filing United States and certain foreign patent applications related to
<FONT STYLE="white-space:nowrap">AU-011,</FONT> where patent protection is available. We also rely on <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and confidential information as well as pursue licensing
opportunities to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our proprietary technology, in part, by
confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and others who may have access to proprietary information, under which they are bound to assign to us
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
inventions made during the term of their employment or term of service. We also seek to preserve the integrity and confidentiality of our data by maintaining physical security of our premises and
physical and electronic security of our information technology systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot be sure that patents will be granted with respect to any patent
applications we have licensed or filed or may license or file in the future, and we cannot be sure that any patents we have licensed or which have been granted to us, or patents that may be licensed or granted to us in the future, will not be
challenged, invalidated or circumvented or that such patents will be commercially useful in protecting our technology. For more information regarding the risks related to our intellectual property, see &#147;Risk factors&#151;Risks related to our
intellectual property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our patent portfolio includes a combination of issued patents and pending patent applications that are owned by us, <FONT
STYLE="white-space:nowrap">co-owned</FONT> by us or licensed by us from third parties. As of September 16, 2021, we have an exclusive license (with regard to ocular cancers) and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license (with
regard to solid tumors in humans for a specific indication) from LI-COR under one issued United States patent; an exclusive license from NIH under four issued United States patents and three issued foreign patents; an exclusive license from
INSERM-TRANSFERT (Inserm) under three issued United States patents, and six granted foreign patents; and exclusive rights under a Cooperative Research and Development Agreement (CRADA) with the United States Department of Health and Human Services
(DHHS), as represented by the National Cancer Institute, and Institute, Center, or Division of the NIH, under three issued United States patents, two pending <FONT STYLE="white-space:nowrap">non-provisional</FONT> United States patent applications,
eight foreign patents, and eleven pending foreign patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, as of September&nbsp;16, 2021, we solely own four issued United
States patents, one pending United States provisional application, and one pending international Patent Cooperation Treaty patent application. We intend to pursue, when possible, additional patent protection, including composition of matter, method
of use and process claims related to <FONT STYLE="white-space:nowrap">AU-011.</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Patent families </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We license one patent family from LI-COR and one patent family from the NIH, <FONT STYLE="white-space:nowrap">co-own</FONT> and license one patent family
from Inserm, <FONT STYLE="white-space:nowrap">co-own</FONT> two patent families with DHHS/NIH and have exclusive rights under a CRADA, and solely own two patent families, all of which are generally directed to the
<FONT STYLE="white-space:nowrap">AU-011</FONT> product and related methods of use and production. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The first family, licensed from LI-COR, includes
one issued United States patent. This patent includes claims directed to (1)&nbsp;fluorescent phthalocyanine dyes and (2)&nbsp;processes for making the dyes (e.g., the IRDye 700DX<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> dye
molecules used in <FONT STYLE="white-space:nowrap">AU-011).</FONT> This patent has a standard expiration date of October&nbsp;23, 2023, subject to potential extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The second family, licensed from NIH, includes four issued United States patents, one issued European patent, and one issued patent in each of Australia
and Canada. Patents in this family include claims directed to (1)&nbsp;methods for inhibiting the proliferation of and/or killing cancer cells using a therapeutic agent formulated with a papilloma virus-like particle, (2)&nbsp;methods that include
administering to a subject (e.g., a subject having a melanoma) a papilloma virus-like particle having a fluorescent dye and exposing the dye to an excitation wavelength of light, and (3)&nbsp;methods for detecting cancer cells using a papilloma
virus-like particle having a detectable label. This patent has a standard expiration date of May&nbsp;1, 2028, subject to potential extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
third family, which we <FONT STYLE="white-space:nowrap">co-own</FONT> with and license from Inserm, includes three issued United States patents, two issued European patents, an issued patent in each of Canada, Hong Kong, India and Japan. Patents in
this family include claims directed to (1)&nbsp;a modified papillomavirus (HPV16) L1 protein having reduced immunogenicity relative to wild-type HPV16 L1 protein and an FG loop having </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the specific amino acid sequence that is present in <FONT STYLE="white-space:nowrap">AU-011,</FONT> (2) nanoparticles comprising the modified L1 protein, (3)&nbsp;methods of using the modified L1
protein to deliver therapeutic agents, and/or (4)&nbsp;methods of producing nanoparticles comprising the modified L1 protein. This patent has a standard expiration date of July&nbsp;24, 2029, subject to potential extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The fourth patent family, which we own, includes four issued United States patents. Patents in this family include claims directed to
(1)&nbsp;codon-optimized nucleic acids having the particular nucleotide sequence that encodes the modified papillomavirus (HPV16) L1 protein present in <FONT STYLE="white-space:nowrap">AU-011,</FONT> (2) methods of producing nanoparticles that
include the modified HPV16 L1 protein encoded by the codon-optimized nucleic acids, and (3)&nbsp;methods of using the nanoparticles that include the modified HPV16 L1 protein encoded by the codon-optimized nucleic acids to deliver a therapeutic
agent to a subject having cancer. This patent has a standard expiration date of February&nbsp;7, 2033, subject to potential extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The fifth
patent family, which we <FONT STYLE="white-space:nowrap">co-own</FONT> with DHHS/NIH and have exclusive rights under a CRADA, includes three issued United States patents, one issued European patent, an issued patent in each of Australia, Canada,
Hong Kong, Republic of Korea and Mexico, two issued patents in Japan, and one pending patent application in each of the United States, Australia, Brazil, China and Europe. Patents in this family include claims directed to (1)&nbsp;tumor-targeting
papilloma virus-like particles containing near infrared phthalocyanine dye molecules that become toxic or produce a toxic molecule upon light activation, (2)&nbsp;methods that include delivering the papilloma virus-like particles to an ocular tumor,
and/or (3)&nbsp;methods of producing tumor-targeting bioconjugates that include the papilloma virus-like particles and near infrared phthalocyanine dye molecules. This patent has a standard expiration date of September&nbsp;18, 2034, subject to
potential extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The sixth patent family, which we own, includes a pending international Patent Cooperation Treaty application with claims
directed to an ophthalmic composition that includes a near-isotonic solution of virus-like particle drug conjugates in suspension. Patents issuing from national stage applications based on this international application would have a standard
expiration date of March&nbsp;25, 2040, subject to potential extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The seventh patent family, which we
<FONT STYLE="white-space:nowrap">co-own</FONT> with DHHS/NIH and have exclusive rights under a CRADA, includes a pending patent application in each of the United States, Australia, Brazil, Canada, China, Europe, Israel and Japan. Patent applications
in this family include claims to a combination therapy that uses (1)&nbsp;tumor-targeting papillomavirus nanoparticles containing photosensitive molecules and (2)&nbsp;a checkpoint inhibitor. Patents issuing from this family would have a standard
expiration date of April&nbsp;11, 2038, subject to potential extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The eighth patent family, which we own, includes a pending United States
provisional application with claims directed to a method for treating a bladder tumor by administering a therapeutic agent to a region of the lamina propria of the bladder wall that is proximate to the bladder tumor. Patents issuing from
applications claiming priority to this provisional application would have a standard expiration date of September 2042 (assuming an international PCT application claiming priority to this U.S. provisional application is filed in September 2022).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA and other regulatory
authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with our vendors, collaboration partners, contract
research organizations, or CROs, and contract manufacturers, will be required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek
approval of our product candidate. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and
financial resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, where we initially focused our product development, the FDA regulates biologics under the FDCA and the
Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state and local statutes and regulations. Our product candidate, <FONT STYLE="white-space:nowrap">AU-011,</FONT> has not been
approved by the FDA for marketing in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The process required by the FDA before any product candidates we develop are approved for
therapeutic indications and may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in
accordance with Good Laboratory Practice, or GLP, requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually
or when significant changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approval by an Institutional Review Board, or IRB, or independent ethics committee at each clinical trial site before each
trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">performance of adequate and well-controlled clinical trials in accordance with Good Clinical Practice, or GCP, requirements
and other clinical trial-related regulations to establish the safety, purity and potency of the proposed biological product candidate for its intended purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparation and submission to the FDA of a BLA after completion of all pivotal trials, accompanied by payment of FDA user
fees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of the
manufacturing facility or facilities where the product will be produced to assess compliance with current Good Manufacturing Practice requirements, or cGMPs, to assure that the facilities, methods and controls are adequate to preserve the biological
product&#146;s continued safety, purity and potency; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential FDA audit of the clinical trial sites that generated the data in support of the BLA; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee, prior to any
commercial marketing or sale of the biologic in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Preclinical and clinical trials for biologics
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Before testing any drug or biologic in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include
laboratory evaluations of chemistry, formulation and stability, as well as<I></I><I>&nbsp;in vitro</I>&nbsp;and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is
subject to federal and state regulations and requirements, including GLP requirements for safety and toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data must be submitted to the FDA
as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and it must become effective before clinical trials may begin. The central focus of an IND submission is on the protocol(s) for
the initial clinical study and the general investigational plan. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product; chemistry,
manufacturing and controls information; and any available human data or literature to support the use of the investigational product. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA, within the <FONT
STYLE="white-space:nowrap">30-day</FONT> time period, raises concerns or questions about </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a clinical hold. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical trial can begin. Some long-term preclinical testing may continue after the IND is submitted. Accordingly, submission of an IND may or may not result in FDA authorization to begin a
trial. A separate protocol submission to an existing IND must also be made for each successive clinical trial conducted in the United States, each of which may begin following a 30 day period unless the FDA issues a clinical hold on the clinical
trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for
their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria
to be used in monitoring safety and evaluating effectiveness. Each protocol to be conducted in the United States, and any subsequent amendments to the protocol, must be submitted to the FDA as an amendment to the IND. Furthermore, each clinical
trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted, or by a central IRB, to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable
related to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. The FDA, the IRB, or
the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Some studies also include oversight by an independent group of qualified
experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt
the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There also are requirements governing the reporting of ongoing clinical trials and completed clinical
trials to public registries. Information about applicable clinical trials, including clinical trials results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">While we plan to conduct any international clinical trials under our INDs, a sponsor who wishes to conduct a clinical trial outside of the United States
under its IND may need to obtain waivers for certain regulatory compliance requirements such as those requiring IRB review and approval. However, the FDA does not require that all foreign clinical trials be conducted under United States INDs. The
FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed
necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Clinical trials to evaluate therapeutic indications to support BLAs for marketing approval are typically conducted in three sequential
phases, which phases may overlap or be conducted in combination. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;1</I>&#151;Phase&nbsp;1 clinical trials involve initial introduction of the investigational
product into healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans,
evaluate the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;2</I>&#151;Phase&nbsp;2 clinical trials typically involve administration of the investigational
product to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&nbsp;2 clinical
trials may be conducted to obtain information prior to beginning larger and more expensive Phase&nbsp;3 clinical trials. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;3</I>&#151;Phase&nbsp;3 clinical trials typically involve administration of the investigational
product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These
clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the
FDA for approval of a BLA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase&nbsp;4 clinical trials, may be conducted after
initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a
clinical setting. In certain instances, the FDA may mandate the performance of Phase&nbsp;4 clinical trials as a condition of approval of a BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND
safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal
or<I></I><I>&nbsp;in vitro</I>&nbsp;testing that suggest a significant risk for human participants exposed to the biologic and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or
investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#146;s initial receipt of the
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information
about the biological characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently
producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and
tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life and to identify appropriate storage conditions for the product candidate. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Expanded Access </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Expanded access,
sometimes called &#147;compassionate use,&#148; is the use of investigational products outside of intended clinical development to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or
satisfactory alternative treatment options. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes for the following expanded access requests: individual patients
(single-patient IND applications for treatment in emergency settings and <FONT STYLE="white-space:nowrap">non-emergency</FONT> settings); <FONT STYLE="white-space:nowrap">intermediate-size</FONT> patient populations; and larger populations for use
of the investigational product under a treatment protocol or treatment IND application. There is no requirement for a company to provide expanded access to its investigational product. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>BLA Submission and Review by the FDA </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to seek data exclusivity or market exclusivity for our product candidates. Assuming successful completion of the required clinical testing, the
results of the preclinical studies and clinical trials, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of a biologics
license application, or BLA. A BLA is a request for approval to market a new biologic for one or more specified indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or
ambiguous results as well as positive findings, together with detailed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data may come from company-sponsored clinical trials intended to test the
safety and efficacy of a product&#146;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety,
purity and potency of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of
the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. A sponsor who is planning to
submit a marketing application for a biological product that includes a new clinically active component, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (PSP) within sixty
days after an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological
product for an indication for which orphan designation has been granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA reviews all submitted BLAs before it accepts them for filing, and
may request additional information rather than accepting the BLA for filing. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is
accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review of the BLA. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent and whether the facility in
which it is manufactured, processed, packaged or held meets standards designed to assure the product&#146;s continued safety, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA,
the FDA targets ten months from the filing date in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA filed for priority review. The FDA does not always meet
its PDUFA goal dates for standard or priority BLAs, and the review process is often extended by FDA requests for additional information or clarification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, under PDUFA, as amended, each BLA must be accompanied by a user fee, and the sponsor of an approved BLA is also subject to an annual program
fee. FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions may be available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees
are assessed on BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA may refer an application for a biologic to an advisory committee. An advisory committee is a panel of independent experts, including clinicians
and other scientific experts, which reviews, evaluates and provides a recommendation, for example, as to whether the biologic is sufficiently safe and efficacious in a given indication for a given population and under what conditions. The FDA is not
bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making marketing approval decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a
BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, as a
condition for approving the BLA to ensure that the benefits of the product outweigh its risks. The REMS could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted
distribution methods, patient registries, or other risk-minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After evaluating the BLA and all related information, including the
advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter
indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter will usually describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA
determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling.
In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA will typically issue an approval letter. An
approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if the FDA
approves a product, depending on the specific risk(s) to be addressed, the FDA may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that
post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess a product&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other
conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product
based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further
testing requirements and FDA review and approval. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Expedited development and review programs for biologics </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs and biologics to address unmet medical needs
in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, priority review and Accelerated Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A new biologic is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the
potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. Fast Track designation provides increased
opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed, meaning that the FDA may consider for review sections of the BLA
on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the
sponsor pays any required user fees upon submission of the first section of the BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, a new drug or biological product may be eligible
for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
evidence indicates that the biologic, alone or in combination with or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient development
program beginning as early as Phase&nbsp;1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for
additional FDA programs intended to expedite the review and approval process, including priority review and Accelerated Approval. A product is eligible for priority review if it is intended to treat a serious or life-threatening disease or
condition, and if approved, would provide a significant improvement in safety or effectiveness. For original BLAs, priority review designation means the FDA&#146;s goal is to take action on the marketing application within six months of the <FONT
STYLE="white-space:nowrap">60-day</FONT> filing date (compared with ten months under standard review). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A product intended to treat serious or
life-threatening diseases or conditions may receive Accelerated Approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be
measured earlier than on irreversible morbidity or mortality which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition
and the availability or lack of alternative treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Accelerated Approval is usually contingent on a sponsor&#146;s agreement to conduct
additional post-approval studies to verify and describe the product&#146;s clinical benefit. The FDA may withdraw approval of a drug or biologic approved under Accelerated Approval if, for example, the sponsor fails to conduct the confirmatory
trials in a timely manner or the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, unless otherwise informed by the FDA, the FDA currently requires, as a condition for Accelerated Approval, that all
advertising and promotional materials that are intended for dissemination or publication within 120&nbsp;days following marketing approval be submitted to the agency for review during the <FONT STYLE="white-space:nowrap">pre-approval</FONT> review
period, and that after 120&nbsp;days following marketing approval, all advertising and promotional materials must be submitted at least 30&nbsp;days prior to the intended time of initial dissemination or publication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Fast Track designation, Breakthrough Therapy designation, priority review and Accelerated Approval do not change the scientific or medical standards for
approval or the quality of evidence necessary to support approval but may expedite the development or review process. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Post-approval
requirements for biologics </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Drugs and biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing
regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising
requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;) and limitations on industry-sponsored scientific and educational
activities. Although physicians may prescribe approved products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, including not only by company employees but also by agents of the company or those speaking on the company&#146;s behalf, and a company that is found to have
improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective
advertising and potential civil and criminal penalties, including liabilities under the False Claims Act where products carry reimbursement under federal health care </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
programs. Promotional materials for approved biologics must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the
product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the development of additional data or
preclinical studies and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA may impose a number of post-approval requirements as a condition of approval of a BLA. For
example, the FDA may require post-market testing, including Phase&nbsp;4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, drug and biologics manufacturers and their subcontractors involved in the manufacture and distribution of approved products are required to
register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP, which impose certain
procedural and documentation requirements upon us and our contract manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented.
FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time,
money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with statutory and regulatory requirements can subject a manufacturer to possible legal or
regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual program fee for any marketed product. The FDA may withdraw approval
if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new
safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety
information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">mandated modification of promotional materials and labeling and issuance of corrective information; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">holds on clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs.
</P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Orphan Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant orphan drug designation, or ODD, to a drug or biologic intended to treat a rare disease or condition,
defined as a disease or condition with either a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patient population of fewer than 200,000 individuals in the United States, or a patient population greater of than 200,000 individuals in the United States when there is no reasonable expectation
that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States of that drug or biologic. ODD must be requested before submitting a BLA. After the FDA grants ODD, the
generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a product that has received ODD and
subsequently receives the first FDA approval for a particular clinically active component for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other
applications, including a full BLA, to market the same biologic for the same indication for seven years from the approval of the BLA, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug
exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the
drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of ODD
are tax credits for certain research and a waiver of the BLA application user fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A designated orphan drug may not receive orphan drug exclusivity
if it is approved for a use that is broader than the indication for which it received ODD. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was
materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Biosimilars and Exclusivity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Patent
Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act, or BPCIA, which
created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. The FDA has issued several guidance documents
outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be
shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same
clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered
without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the BPCIA, an
application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA
until 12&nbsp;years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if
the FDA approves a full BLA for the competing product containing that applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also
created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are
governed by state pharmacy law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric
exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted
based on the voluntary completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the <FONT
STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact,
implementation, and regulatory interpretation of the BPCIA remain subject to significant uncertainty. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Regulation of Combination Products in
the United States </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain products may be comprised of components, such as biologic components and device components, that would normally be
regulated under different types of regulatory authorities, and by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and
produced as a single entity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">two or more separate products packaged together in a single package or as a unit and comprised of drug and device products,
device and biological products, or biological and drug products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a drug, or device, or biological product packaged separately that according to its investigational plan or proposed
labeling is intended for use only with an approved individually specified drug, device or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of
the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration or significant change in dose; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any investigational drug, device or biological product packaged separately that according to its proposed labeling is for
use only with another individually specified investigational drug, device or biological product where both are required to achieve the intended use, indication or effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a
combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA component for combination products, although it does not preclude consultations by the lead center with other components
of FDA. The determination of which center will be the lead center is based on the &#147;primary mode of action&#148; of the combination product. Thus, if the primary mode of action of a biologic-device combination product is attributable to the
biologic product, the FDA center responsible for premarket review of the biologic product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding
combination products and provide more certainty to the regulatory review process. That office is responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has
primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A combination product with a biologic
primary mode of action generally would be reviewed and approved pursuant to FDA&#146;s biologic approval processes. In reviewing the BLA application for such a product, however, FDA reviewers in the biologics center could consult with their
counterparts in the device center to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regulations, combination products are subject to applicable current GMP requirements for drugs, biologics and devices, including the Quality System regulations applicable to medical devices. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Other Regulatory Matters </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Manufacturing, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also
subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human Services, or
HHS, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and
local governments and governmental agencies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with
their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates
will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if
coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private
health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is also
significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In
the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within the DHHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private
payors tend to follow CMS to a substantial degree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, millions of
individuals have lost/will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our products. It is unclear what effect, if any, the American Rescue Plan will have on the number of covered individuals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Factors payors consider in determining reimbursement are based on whether the product is: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future
relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts
from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In
addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory
discounts or rebates required by government healthcare programs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Health Care Laws and Regulations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and
foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization.
Such laws include, without limitation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment
may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal false claims and civil monetary penalties laws, including the False Claims Act and Civil Monetary Penalties
Law, prohibit individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay
money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False
Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability
for, among other things, executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or
payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal physician payment transparency requirements, sometimes referred to as the &#147;Sunshine Act&#148; under the
ACA require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report to HHS information related to physician (defined to include
doctors, dentists, optometrists, podiatrists and chiropractors) payments and other transfers of value and the ownership and investment interests of such physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting
obligations will extend to include payments and other transfers of value made in the previous year to certain nonphysician providers, including physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants,
certified registered nurse anesthetists and certified nurse midwives; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing
regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of
individually identifiable health information, as well as their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or
marketing arrangements and claims involving healthcare items or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, and may be broader in scope than their federal equivalents; some
state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to
report information related to payments to physicians and other health care providers or marketing expenditures; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">state laws governing the privacy and security of health information in certain circumstances, many of which differ from
each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts, and analogous foreign laws and regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to significant
penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations and exclusion from participation in
federal and state healthcare programs, and responsible individuals may be subject to imprisonment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Health Care Legislative Updates
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare
costs, and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. In both the United States and certain foreign jurisdictions, there have
been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the ACA was enacted, which, among other things, subjected biologic products to
potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;
increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations;
subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan
Budget Act of 2018, effective as of January&nbsp;1, 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their
coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since its enactment, there have been numerous judicial, administrative, executive, and&nbsp;legislative challenges to certain aspects of the ACA. On
June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states on procedural grounds without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect
in its current form. Prior to the Supreme Court&#146;s decision, President Biden issued an Executive Order that initiated a special enrollment period from February&nbsp;15, 2021 through August&nbsp;15, 2021 for purposes of obtaining health insurance
coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to
judicial or Congressional challenges in the future.&nbsp;It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011,
among other things, created measures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through
2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year and, due to
subsequent legislative amendments, will remain in effect through 2030&nbsp;unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, as well as subsequent
legislation, these reductions have been suspended from May&nbsp;1, 2020 through December&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients
to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical
trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.
Specifically, there have been several recent Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review
the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. For example, at the federal level, in a recent executive order, the Biden administration expressed its intent to
pursue certain policy initiatives to reduce drug prices. At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing,
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. Further, it is possible that additional governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulation in the European Union </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Drug Development
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the European Union, our product candidates may be subject to extensive regulatory requirements. As in the United States, medicinal
products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Similar to the United States,
the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC, or the Directive, has sought to harmonize the EU clinical trials
regulatory framework, setting out common rules for the control and authorization of clinical trials in the European Union, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant
variations in the Member State regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the national competent authority,
or CA, and one or more independent ethics committees, or ECs. Under the current regime, all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the CA and ECs of the
Member State where they occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and
streamlining clinical trial authorization, simplifying adverse-event reporting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
procedures, improving the supervision of clinical trials and increasing their transparency. In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, or the Regulation,
which is set to replace the current Clinical Trials Directive 2001/20/EC. It is expected that the new Regulation will become fully applicable at the end of January 2022. The new Regulation will be directly applicable in all Member States (and so
does not require national implementing legislation in each Member State), and aims at simplifying and streamlining the approval of clinical studies in the EU, for instance by providing for a streamlined application procedure via a single point and
strictly defined deadlines for the assessment of clinical study applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are in the process of applying to renew our status with EMA as a
small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprise, or SME. If we obtain SME status with EMA, it will provide access to administrative, regulatory and financial support, including fee reductions for scientific advice and
regulatory procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Much like the Anti-Kickback Statue prohibition in the United States, the provision of benefits or advantages to physicians
to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to induce or reward improper performance
generally is usually governed by the national anti-bribery laws of European Union Member States, and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the
EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered
or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from
the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often
must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the
national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Drug Review and Approval </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the
European Economic Area, or EEA, which is comprised of the Member States of the European Union together with Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a marketing authorization, or MA. There are
two types of marketing authorizations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The centralized MA is issued by the European Commission through the centralized procedure, based on the opinion of the
Committee for Medicinal Products for Human Use, or CHMP, of the EMA, and is valid throughout the entire territory of the EEA. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan
medicinal products, advanced-therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative
disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases, and we therefore consider our product candidates would fall within the mandatory scope of the centralized procedure. The centralized procedure is optional for
products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union. Under
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
the centralized procedure the maximum timeframe for the evaluation of a MA application by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided
by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of a MA application considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with
supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#146;s recommendation. Accelerated assessment might be granted by the CHMP in
exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MA application under the accelerated assessment
procedure is of 150 days, excluding stop-clocks, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated
assessment. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective
territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this national MA can be recognized in other Member
States through the mutual recognition procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the
EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As part of its marketing authorization process, the EMA may grant MAs for certain categories of medicinal products on the basis of less complete data
than is normally required, where the benefit of immediate availability of the medicine outweighs the risk inherent in the fact that additional data are still required or in the interests of public health. In such cases, it is possible for the CHMP
to recommend the granting of an MA, subject to certain specific obligations to be reviewed annually, which is referred to as a conditional marketing authorization. This may apply to medicinal products for human use that fall under the jurisdiction
of the EMA, including those that aim at the treatment, the prevention, or the medical diagnosis of seriously debilitating or life-threatening diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety and efficacy
of the medicinal product have not been supplied, all the following requirements are met: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the risk-benefit balance of the medicinal product is positive; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is likely that the applicant will be in a position to provide the comprehensive clinical data post-authorization;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unmet medical needs will be fulfilled; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the
risk inherent in the fact that additional data is still required. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The granting of a conditional marketing authorization is
restricted to situations in which only the clinical part of the application is not yet fully complete. Incomplete preclinical or quality data may only be accepted if duly justified and only in the case of a product intended to be used in emergency
situations in response to public health threats. Conditional marketing authorizations are valid for one year, on a renewable basis. The MA holder will be required to complete ongoing trials or to conduct
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
new trials with a view to confirming that the benefit-risk balance is positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance data. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Compassionate Use </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Compassionate use
program allow for the use of unauthorized medicines for a specific group of patients under strict conditions. The EMA provides recommendations on how a medicine should be used in a compassionate use program and the type of patient who may benefit
from treatment, however the individual Member States implement their own rules in respect of the administration of such programs. Competent authorities of the Member States can also ask the EMA for an opinion on how to administer, distribute and use
certain medicines for compassionate use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Compassionate use programs are only available for a group of patients with a chronically or seriously
debilitating disease or whose disease is considered to be life-threatening, and who cannot be treated satisfactorily by an authorized medicinal product. The medicinal product provided through a compassionate use program must either be the subject of
an MA application or must be undergoing clinical trials. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>New Chemical Entity Exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the EEA, new chemical entities (including both small molecules and biological medicinal products), sometimes referred to as new active substances,
qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#146;s <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization, for a period of eight years from the date on which the
reference product was first authorized in the EU. During the additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#146;s data
may be referenced, no generic or biosimilar product can be marketed until the expiration of the market exclusivity period. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period will be extended to a maximum of 11 years if, during the
first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a significant
clinical benefit in comparison with currently approved therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained a marketing
authorization based on an application with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Orphan Designation and Exclusivity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
the EEA, the EMA&#146;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating
conditions with either (i)&nbsp;affect not more than 5 in 10,000 persons in the European Union, or (ii)&nbsp;where it is unlikely that the marketing of the medicine would generate sufficient return in the EU to justify the necessary investment in
its development. In each case, no satisfactory method of diagnosis, prevention or treatment of the condition must have been authorized (or, if such a method exists, the product in question would be of significant benefit to those affected by the
condition). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the EEA, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of
market exclusivity is granted following marketing approval for the orphan product. This period may be reduced to six years if, at the end of the fifth year, it is established that the orphan drug designation criteria are no longer met, including
where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. During the period of market exclusivity, marketing authorization may only be granted to a &#147;similar medicinal product&#148; for the
same therapeutic indication if: (i)&nbsp;a second applicant can establish that its product, although similar to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
authorized product, is safer, more effective or otherwise clinically superior; (ii)&nbsp;the marketing authorization holder for the authorized product consents to a second orphan medicinal
product application; or (iii)&nbsp;the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active
substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug
designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Pediatric Investigation
Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the EEA, companies developing a new medicinal product must agree upon a pediatric investigation plan, or PIP, with the EMA&#146;s
Pediatric Committee, or PDCO, and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which
marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further,
the obligation to provide pediatric clinical trial data can be waived by the PDCO when this data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is
intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Products that are granted a marketing authorization with the results of the
pediatric clinical trials conducted in accordance with the PIP (even where such results are negative) are eligible for six months&#146; supplementary protection certificate, or SPC, extension, provided an application for such extension is made at
the same time as filing the SPC application for the product, or at any point up to two&nbsp;years before the SPC expires. In the case of orphan medicinal products, a two year extension of the orphan market exclusivity may be available. This
pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>PRIME Designation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2016, the
EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of
unmet medical need and provides accelerated assessment of products representing substantial innovation, where the marketing authorization application will be made through the centralized procedure. Eligible products must target conditions for which
where is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the European Union or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to
address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises may qualify for earlier entry into the PRIME scheme than
larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development
program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the EMA&#146;s CHMP or Committee for Advanced Therapies are appointed early in
PRIME scheme facilitating increased understanding of the product at EMA&#146;s Committee level. A <FONT STYLE="white-space:nowrap">kick-off</FONT> meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to
provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Similar to
the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regulatory authorities of the Member States. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is
responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All new MA applications must include a risk management plan, or RMP, describing the risk management system that the company will put in place and
documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may
include additional safety monitoring, more frequent submission of PSURs, or the conducting of additional clinical trials or post-authorization safety studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians,
misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in the European Union.
Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each Member State and can differ from one country to another. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Pricing and Reimbursement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the
European Union, pricing and reimbursement schemes vary widely from country to country. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is
almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of
products in that context. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular
product candidate to currently available therapies <FONT STYLE="white-space:nowrap">(so-called</FONT> health technology assessments) in order to obtain reimbursement or pricing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The European Union provides options for its Member States to restrict the range of products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. European Union Member States may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company
placing the product on the market. Other Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the
European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many
countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political,
economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union Member States and parallel trade
(arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced Member States) can further reduce prices. Special pricing and reimbursement rules may apply to orphan drugs. Inclusion of orphan drugs in reimbursement systems
tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any drug. Acceptance of any medicinal product for reimbursement may come with cost, use and often volume restrictions, which
again can vary by country. In addition, results-based rules of reimbursement may apply. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>European Union Data Collection </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The collection and use of personal data, including clinical trial data, in the European Economic Area, or the EEA, governed by the GDPR, which became
effective May&nbsp;25, 2018. The GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EU or the
monitoring of the behavior of data subjects in the European Union. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures
about how personal data is used, requirements to conduct privacy impact assessments for &#147;high risk&#148; processing, limitations on retention of personal data, special provisions for &#147;sensitive information&#148; including health and
genetic information of data subjects, mandatory data breach notification and &#147;privacy by design&#148; requirements and direct obligations on service providers acting as data processors. The GDPR also imposes strict rules and restrictions on the
transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA Member
States may result in fines up to 20&nbsp;million euros or 4% of a company&#146;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the GDPR grants data subjects the right to request deletion of personal
information in certain circumstances, and claim material and <FONT STYLE="white-space:nowrap">non-material</FONT> damages resulting from infringement of the GDPR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulation in the United Kingdom </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Brexit and the
Regulatory Framework in the United Kingdom </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The UK&#146;s withdrawal from the EU on January&nbsp;31, 2020, commonly referred to as Brexit,
has created significant uncertainty concerning the future relationship between the UK and the EU. The impact of Brexit on the ongoing validity in the UK of current EU authorizations for medicinal products, whether granted through the centralized
procedure, decentralized procedure or mutual recognition, and on the future process for obtaining marketing authorization for pharmaceutical products manufactured or sold in the UK remains uncertain. On December&nbsp;24, 2020, the EU and UK reached
an agreement in principle on the framework for their future relationship, the <FONT STYLE="white-space:nowrap">EU-UK</FONT> Trade and Cooperation Agreement, or the Agreement. The Agreement primarily focuses on ensuring free trade between the EU and
the UK in relation to goods, including medicinal products. Although the body of the Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex
provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extended to procedures such as batch release certification. Among the changes that will now
occur are that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. As part of the Agreement, the EU and the UK will
recognize Good Manufacturing Practice (GMP) inspections carried out by the other party and the acceptance of official GMP documents issued by the other party. The Agreement also encourages, although it does not oblige, the parties to consult one
another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to accept EU batch testing
and batch release for a period of at least two years until January&nbsp;1, 2023. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are
tested and released in the UK must be retested and <FONT STYLE="white-space:nowrap">re-released</FONT> when entering the EU market for commercial use. As regards marketing authorizations, Great Britain will have a separate regulatory submission
process, approval process and a separate national MA. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the European Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The UK has implemented Directive 2001/20/EC into national law through the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended), and
therefore UK legislation currently is broadly aligned with the position in the European Union, where Member State regimes are derived from Directive 2001/20/EC. The extent to which the regulation of clinical trials in the UK will mirror the new
European Union Regulation once that comes into effect is unknown at present. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Great Britain Marketing Authorizations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a result of the Northern Irish Protocol, centralized European Union MAs will continue to be recognized in Northern Ireland. A separate MA is, however,
required in order to place medicinal products on the market in Great Britain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On January&nbsp;1, 2021, all medicinal products with a current
centralized MA were automatically converted to Great Britain MAs. For a period of two years from January&nbsp;1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, the UK medicines regulator, may rely on a decision taken by the
European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain MA. This is known as the EC Decision Reliance Procedure, or ECDRP. Under the ECDRP, submission of
an MA application can be submitted to the MHRA at any time after the approval of a European Union MA; however, a delay in submission may affect the delivery of a decision within the specified timelines. Where a submission is made within five days of
a positive opinion issued by the CHMP, the MHRA will aim to determine the Great Britain MA as soon as possible after European Commission approval, and by day 67 at the latest provided that the European Commission decision has been received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The MHRA also offers a <FONT STYLE="white-space:nowrap">150-day</FONT> assessment timeline for all high quality applications for a UK, Great Britain or
Northern Ireland MA. The 150-day timeline does not include a <FONT STYLE="white-space:nowrap">&#147;clock-off&#148;</FONT> period which may occur if issues arise or points require clarification following an initial assessment of the application.
Such issues should be addressed within a <FONT STYLE="white-space:nowrap">60-day</FONT> period, although extensions may be granted in exceptional cases. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Early Access to Medicines Scheme </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Early Access to Medicines Scheme, or EAMS, applies in relation to patients with life threatening or seriously debilitating conditions and aims to give such patients access to unauthorized medicines, when there is a clear unmet medical need. Under
EAMS, the MHRA will undertake a <FONT STYLE="white-space:nowrap">two-step</FONT> evaluation process of a medicine, which includes a promising innovative medicine designation (an indication that a product may be eligible for EAMS based on early
clinical data) and a scientific opinion on the risks and benefits of the medicine based on data gathered from the patients who will benefit from the medicine. A positive EAMS scientific opinion is valid for one year (which can be renewed) and
regular updates must be provided to the MHRA following such positive opinion. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Orphan Designation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since January&nbsp;1, 2021, a separate process for orphan drug designation to the European Union process has applied Great Britain. There is now no <FONT
STYLE="white-space:nowrap">pre-marketing</FONT> authorization orphan designation (as there is in the European Union) in Great Britain and the application for orphan designation will be reviewed by the MHRA at the time of an application for a UK or
Great Britain MA. The criteria for orphan designation remain the same as in the European Union, save that they apply to Great Britain only (e.g. there must be no satisfactory method of diagnosis, prevention or treatment of the condition concerned in
Great Britain, as opposed to the European Union). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Data Privacy and Security Laws and Regulations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We collect, store, transmit and process sensitive and confidential data and information, including health information, and personal data. As we seek to
expand our business, we are, and will increasingly become, subject to numerous state, federal and foreign laws, regulations, rules and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
government and industry standards relating to the collection, use, retention, security, disclosure, transfer and other processing of sensitive and personal information in the jurisdictions in
which we operate. The regulatory framework for data privacy, data security and data transfers worldwide is rapidly evolving, and there has been an increasing focus on privacy and data protection issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are numerous U.S. federal and state laws and regulations related to the privacy and security of health information. HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act (HITECH Act), and their implementing regulations impose obligations on covered entities, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as
business associates that provide services involving the use or disclosure of personal health information to or on behalf of covered entities. These obligations, such as mandatory contractual terms, relate to safeguarding the privacy and security of
protected health information. Many states also have laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA. In addition,
many states and foreign countries in which we operate have laws that protect the privacy and security of sensitive and personal information. Certain of these laws may be more stringent or broader in scope, or offer greater individual rights, with
respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and human
capital resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of October&nbsp;8, 2021, we had 42 full-time employees, of which eleven have M.D. (or its equivalent) Ph.D. or J.D.
degrees. Within our workforce, 32 employees are engaged in research and development and ten are engaged in business development, finance, legal and general management and administration. None of our employees are represented by labor unions or
covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our human capital resources objectives
include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel
through the granting of equity-based compensation awards in order to increase shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our corporate headquarters are located in
Cambridge, Massachusetts, where we lease and occupy approximately 14,354 square feet of office space at 85 Bolton St, Cambridge, MA 02140. The current term of our Cambridge lease expires in July 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that our facilities are adequate for our current needs and for the foreseeable future. To meet the future needs of our business, we may lease
additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time, we may become involved
in litigation or other legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our
business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executives and directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth the
name, age and position of each of our executives and directors as of October&nbsp;1, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Elisabet de los Pinos, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Julie Feder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cadmus Rich, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Medical Officer and Head of Research and Development</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Mark De Rosch, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">58</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Operating Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Christopher Primiano</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Business Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Johnson(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chairman and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Giovanni Mariggi, Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Raj Parekh, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">61</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sapna Srivastava, Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Karan Takhar(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">30</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Antony Mattessich(1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Audit Committee. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Compensation Committee. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the Nominating and Corporate Governance Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each executive officer serves at the discretion of our board of directors and holds office until his or her successor is duly elected and qualified or
until his or her earlier resignation or removal. There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Executive
Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Elisabet de los Pinos, Ph.D.</I></B> is our founder and Chief Executive Officer. Since our founding in January 2010,
Dr.&nbsp;de los Pinos has led our strategy and operations and has spearheaded our fundraising efforts. Prior to founding Aura, she was a brand manager in Eli Lilly&nbsp;&amp; Co.&#146;s oncology business unit, where she was part of the leadership
team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Dr.&nbsp;de los Pinos worked as a post-doctoral fellow at the Institute of Cancer Research at the University of London. She
previously completed research fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine of New York University and at the Georgetown School of Medicine. She is a member of the board of overseers at the Museum of Science,
Boston. Dr.&nbsp;de los Pinos has been named to Boston Business Journal&#146;s 2009 &#147;Top 40 under 40&#148; list; as a Mass High Tech &#147;Woman to Watch&#148; in 2010; as a &#147;Technology Pioneer&#148; by the World Economic Forum in 2010;
and as one of Goldman Sachs&#146;s &#147;100 Most Intriguing Entrepreneurs&#148; in 2014. Dr.&nbsp;de los Pinos holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an M.B.A. from IE Business School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Julie Feder</I></B> has served as our Chief Financial Officer since August 2018. Prior to this role, Ms.&nbsp;Feder served as Chief Financial
Officer at Verastem Oncology, or Verastem, from July 2017 to June 2018, where she was responsible for developing the company&#146;s strategic financial plan and overseeing a rapid financial and staff growth. Prior to joining Verastem, Ms.&nbsp;Feder
served as the Chief Financial Officer at the Clinton Health Access Initiative, Inc., or CHAI, from September 2011 to July 2017. At CHAI, Ms.&nbsp;Feder was responsible for managing a global team across multiple departments and developed the global
finance strategy and internal audit, treasury and global payroll functions. Prior to joining CHAI, Ms.&nbsp;Feder spent three years at Genzyme Corporation, as Vice President of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Internal Audit and later as Finance Integration Leader. In these roles, she managed the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of
Genzyme&#146;s global internal audit function, while leading the Genzyme Global Finance integration following Sanofi&#146;s acquisition of Genzyme. Ms.&nbsp;Feder began her career at Deloitte&nbsp;&amp; Touche LLP, where she was Senior Manager of
Audit, Consulting and Enterprise Risk Services. Ms.&nbsp;Feder holds a B.S. in Accounting from Yeshiva University&#146;s Sy Syms School of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Cadmus Rich, M.D., M.B.A.</I></B> has served as our Chief Medical Officer and Head of Research and Development since June 2019, having previously
served as our Senior Vice President, Chief Medical Officer from October 2017 to May 2019. Before joining us, Dr.&nbsp;Rich was Vice President of Clinical Development and Medical Affairs at Inotek Pharmaceuticals from May 2015 to September 2017. He
previously held several senior positions at Alcon Laboratories, Inc., or Alcon, including overseeing the pipeline strategy and R&amp;D projects for Alcon&#146;s intraocular lens product line and leading global pharmaceutical clinical trial
management. Dr.&nbsp;Rich has extensive experience in R&amp;D, having led or participated in nearly 75 development programs, including the submission and approval of multiple devices and pharmaceutical products in the United States, European Union,
China, Japan and Brazil/Latin America. He has directly led or participated in over 150 clinical trials across multiple ophthalmology and systemic indications as an executive leader, medical director, medical monitor and principal investigator.
Dr.&nbsp;Rich has served on the board of directors of the North Carolina Specialty Hospital and is currently a member of the board of directors and treasurer of Prevent Blindness, the nation&#146;s longest-acting volunteer eye health and safety
organization, and Sustained Nanosystems, LLC, a company developing extended release technologies for drugs. Dr.&nbsp;Rich holds an M.D. from the University of North Carolina at Chapel Hill School of Medicine, an M.B.A. from Regis University, a
Certified Physician Executive Certification from the American Association for Physician Leadership and a B.A. in Psychology from Case Western Reserve University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Mark De Rosch, Ph.D.</I></B> has served as our Chief Operating Officer since March 2021. In this role, Dr.&nbsp;De Rosch is responsible for
leading our global operations and regulatory strategy. Prior to joining us, Dr.&nbsp;De Rosch served as Chief Regulatory Officer of Epizyme, Inc., or Epizyme, from September 2019 to March 2021 and led regulatory efforts for their first approved
product, TAZVERIK<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (tazemetostat). Prior to Epizyme, Dr.&nbsp;De Rosch served as Senior Vice President, Regulatory Affairs and Quality Assurance for Nightstar Therapeutics, or Nightstar,
(acquired by Biogen in 2019) from April 2018 to September 2019, where he developed and implemented global regulatory roadmaps for their gene therapy programs in choroideremia and retinitis pigmentosa. Prior to Nightstar, he served as Senior Vice
President, Regulatory Affairs, Quality Assurance and Chemistry, Manufacturing and Controls at Akebia Therapeutics, Inc. from August 2014 to February 2018. Dr.&nbsp;De Rosch holds a Ph.D. and an M.S. in Inorganic Chemistry from the University of
California, San Diego and a B.S. in Chemistry/Biochemistry from the University of Wisconsin-Parkside. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B></B><B><I>Christopher
Primiano</I></B><B></B> has served as our Chief Business Officer since September 2021. Prior to joining us, from March 2014 to December 2020, Mr. Primiano served in roles with increasing responsibility at Karyopharm Therapeutics, Inc., most recently
as Executive Vice President, Chief Business Officer, General Counsel and Secretary. In this role, Mr. Primiano was responsible for leading Karyopharm&#146;s business development, operations and legal departments. Prior to joining Karyopharm, Mr.
Primiano worked at multiple international law firms and led internal legal and business development departments. He was a counsel at Wilmer Cutler Pickering Hale and Dorr LLP, a full-service multinational law firm, and he served as Vice President,
Corporate Development, General Counsel and Secretary of GlassHouse Technologies, Inc., an information technology consulting company, where he led global legal operations and managed asset and subsidiary acquisition and sale activity. Mr. Primiano
began his career at Gunderson Dettmer Stough Villeneuve Franklin &amp; Hachigian LLP, a global law firm focused on venture capital and the emerging technology marketplace. Mr.&nbsp;Primiano received an M.B.A. from the Boston College Carroll School
of Management, a J.D. from Boston College Law School and a B.A. in Political Economy and English from Georgetown University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>David Johnson </I></B>has served as a member of our board of directors since January 2021. Mr.&nbsp;Johnson has more than 25 years of experience in
biopharmaceuticals and is currently the Chief Executive Officer of Solve Therapeutics, a biologics company focused on developing novel cancer therapeutics, which he founded in January&nbsp;2021. Prior to founding Solve Therapeutics, Mr.&nbsp;Johnson
founded VelosBio, an oncology-focused clinical stage biopharmaceutical company focused on novel antibody drug conjugates and bispecific antibodies, and served as the Chief Executive Officer from December&nbsp;2017 to December&nbsp;2020. While at
VelosBio, Mr.&nbsp;Johnson raised approximately $200&nbsp;million in capital, and the company filed an IND for its lead ROR1-directed ADC <FONT STYLE="white-space:nowrap">VLS-101</FONT> in Q4 2018 and started enrolling patients in a Phase 1 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial in Q1 2019. In December 2020, VelosBio was acquired by Merck for $2.75&nbsp;billion. Prior to founding VelosBio, Mr.&nbsp;Johnson was the Chief
Executive Officer at Acerta Pharma, or Acerta, from May 2013 to March 2016, where he led Acerta through a critical phase of growth from approximately 40 to over 150 employees and from a signal-seeking, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial to more than 20 active clinical studies. His tenure included the regulatory negotiation and launch of three registration-directed trials, including two global Phase 3 trials for
acalabrutinib. Mr.&nbsp;Johnson and his leadership team ultimately led the acquisition of Acerta by AstraZeneca in a deal valued at up to $7&nbsp;billion. Earlier in his career, Mr.&nbsp;Johnson served in roles spanning from <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development to all phases of clinical development through product launch. He has extensive experience in fundraising and deal making and has made significant contributions to drugs ultimately garnering
NDA/sNDA approval, including acalabrutinib, idelalisib, romidepsin and bortezomib. Mr.&nbsp;Johnson has served on the board of directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), or Zentalis, since January 2020. Mr.&nbsp;Johnson received a
bachelor&#146;s degree in Economics from Indiana University. We believe that Mr.&nbsp;Johnson&#146;s experience as a pharmaceutical business leader provides him with the appropriate set of skills to serve as a member of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Giovanni Mariggi, Ph.D.</I></B> has served as a member of our board of directors since April 2019. Dr.&nbsp;Mariggi is a member of the <FONT
STYLE="white-space:nowrap">co-founding</FONT> team at Medicxi, having served as a Partner since October 2018 and a Principal from February 2016 to September 2018. Prior to Medicxi, Dr.&nbsp;Mariggi served in multiple roles at Index Ventures, or
Index, over four years, ultimately serving as a Principal from January 2015 to January 2016. Prior to joining Index, Dr.&nbsp;Mariggi worked at Cancer Research UK&#146;s London Research Institute (now the Crick Institute) conducting research on
vascular biology and angiogenesis, whilst also performing competitive intelligence projects as an independent consultant to various biopharma companies. He currently serves on the boards of a number of portfolio companies, including Gadeta B.V.
Dr.&nbsp;Mariggi holds a Ph.D. in Biochemistry and Molecular Biology from University College London and a B.Sc. in Biochemistry from Imperial College London. We believe Dr.&nbsp;Mariggi&#146;s experience and background in the biopharmaceutical
industry provides him with the appropriate set of skills to serve as a member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Raj Parekh, Ph.D. </I></B>has served
as a member of our board of directors since 2015. Dr.&nbsp;Parekh joined Advent Life Sciences as a General Partner in 2005, bringing over 20 years of experience in biomedical research and as an entrepreneur and investor. Since joining Advent, he has
been involved with portfolio companies primarily engaged in the discovery of new medicines, including Avila Therapeutics, Inc., EUSA Pharma, Inc. and Thiakis Limited. Earlier in his career, Dr.&nbsp;Parekh
<FONT STYLE="white-space:nowrap">co-founded</FONT> Oxford GlycoSciences, which was sold to <FONT STYLE="white-space:nowrap">UCB-Celltech,</FONT> and then served as Chairman of Galapagos NV, a member of the Supervisory Board of the Novartis Venture
Fund and a founding director of Celldex Therapeutics. Dr.&nbsp;Parekh currently serves on the boards of directors of several portfolio companies, including Arrakis and Levicept. Dr.&nbsp;Parekh holds a Ph.D. in Molecular Medicine and an M.A. in
Biochemistry from Oxford University. We believe Dr.&nbsp;Parekh&#146;s experience and background provides him with the appropriate set of skills to serve as a member of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Sapna Srivastava, Ph.D. </I></B>has served as a member of our board of directors since May 2021.
Dr.&nbsp;Srivastava is currently the Chief Financial Officer at eGenesis, Inc., or eGenesis, a position she has held since March 2021. Prior to eGenesis, she held similar roles as the Chief Financial and Strategy Officer at Abide Therapeutics, Inc.
(acquired by Lundbeck) from September 2017 to January 2019 and at Intellia Therapeutics, Inc., or Intellia, from April 2015 to December 2016. In these positions, she has played a key role in equity financings including a successful initial public
offering, strategic alliances, mergers and acquisitions and shaping the strategic direction of the companies. Before Intellia, Dr.&nbsp;Srivastava spent more than a decade as a senior biotechnology analyst for Goldman Sachs&nbsp;&amp; Co. LLC,
Morgan Stanley&nbsp;&amp; Co. LLC and ThinkEquity Partners. She has served on the board of VelosBio Inc., and currently serves on the boards of directors for Talaris Therapeutics, Inc. (NASDAQ: TALS), Nuvalent, Inc. (NASDAQ: NUVL), SQZ
Biotechnologies Company (NASDAQ: SQZ) and Social Capital Suvretta Holdings Corp. II (NASDAQ: DNAB), a special purpose acquisition corporation. Dr.&nbsp;Srivastava holds a Ph.D. in Neuroscience from the New York University School of Medicine and a
B.S. in Microbiology from St. Xavier&#146;s College at the University of Mumbai. We believe Dr.&nbsp;Srivastava&#146;s experience as an executive officer in the biopharmaceutical industry and investment banking provides her with the appropriate set
of skills to serve as a member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Karan Takhar </I></B>has served as a member of our board of directors since March
2021. Since 2013, Mr.&nbsp;Takhar has held roles of increasing responsibility at Matrix Capital Management, L.P., or Matrix, an investment fund focused on technology and life sciences. He currently serves as a Senior Managing Director and the head
of Life Sciences investing, a position he has held since February 2021. He previously served as a Managing Director from January 2017 to January 2021 and as a Vice President from January 2016 to December 2016. Mr. Takhar has served as a member of
the board of directors of Zentalis since December 2017. Mr.&nbsp;Takhar received a B.S. in Economics and Mathematics from the Massachusetts Institute of Technology. We believe Mr.&nbsp;Takhar&#146;s experience investing in life sciences companies
provides him with the appropriate set of skills to serve as a member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B></B><B><I>Antony Mattessich</I></B><B></B> has
served as a member of our board of directors since September 2021. Mr.&nbsp;Mattessich is currently the Chief Executive Officer of Ocular Therapeutix, a position he has held since August 2017. Prior to Ocular Therapeutix, beginning in 2009, he
served in roles of increasing responsibility at Mundipharma International, including serving as Managing Director from May 2011 to August 2017. Previous to his time at Mundipharma, Mr.&nbsp;Mattessich ran the U.S. respiratory, dermatology and
pediatrics group at Novartis AG, or Novartis. Before Novartis, Mr. Mattessich held several positions at Bristol-Myers Squibb, among them, Managing Director roles in Malaysia/Singapore and The Netherlands, and Head of Operations for the International
Medicines Group. Mr. Mattessich holds a Masters in International Affairs from Columbia University and a B.A. from the University of California at Berkeley. We believe Mr.&nbsp;Mattessich&#146;s leadership experience in biotech and pharmaceuticals
provides him with the appropriate set of skills to serve as a member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Composition of our board of directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board consists of six<B> </B>members, each of whom are members pursuant to the board composition provisions of our certificate of incorporation and
agreements with our stockholders, and is chaired by Mr.&nbsp;Johnson. These board composition provisions will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations
regarding the election of our directors. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and
corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is identification of persons who will further the interests of our stockholders through their established record of professional
accomplishment, the ability to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences, and expertise
relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. Our tenth amended and restated certificate of incorporation that will become
effective upon the closing of this offering and amended and restated bylaws that will become effective upon the effectiveness of the registration statement of which this prospectus is a part, also provide that our directors may be removed only for
cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of
directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Director independence </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied
to list our common stock on The Nasdaq Global Market. Under the Nasdaq listing rules, independent directors must comprise a majority of a listed company&#146;s board of directors within twelve months from the date of listing. In addition, the Nasdaq
listing rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and governance committees be independent within twelve months from the date of listing. Audit committee members
must also satisfy additional independence criteria, including those set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation committee members must
also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that
company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board
committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (2)&nbsp;be an affiliated person of the listed
company or any of its subsidiaries. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the board of directors must consider, for each member of a compensation committee of a listed company, all
factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member,
including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its
subsidiaries or affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has determined that all members of the board of directors, except Dr.&nbsp;de los Pinos, are
independent directors, including for purposes of the rules of The Nasdaq Global Market and the SEC. In making such independence determinations, our board of directors considered the relationships that each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. In considering the independence of the directors listed above, our board of directors considered the association of our directors with the holders of more than 5% of our common
stock. Upon the completion of this offering, we expect that the composition and functioning of our board of directors and each of our committees will comply with all applicable requirements of The Nasdaq Global Market and the rules and regulations
of the SEC. There are no family relationships among any of our directors or executive officers. Dr.&nbsp;de los Pinos<B> </B>is not an independent director under these rules because she is our President and Chief Executive Officer. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Staggered board </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In accordance with the
terms of our tenth amended and restated certificate of incorporation that will become effective upon the closing of this offering and amended and restated bylaws that will become </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
effective upon the effectiveness of the registration statement of which this prospectus is a part, our board of directors will be divided into three staggered classes of directors and each will
be assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will
expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2022 for Class&nbsp;I directors, 2023 for Class&nbsp;II directors and 2024 for Class&nbsp;III directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our Class&nbsp;I directors will be Giovanni Mariggi, Raj Parekh and Elisabet de los Pinos; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our Class&nbsp;II directors will be David Johnson and Karan Takhar; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our Class&nbsp;III directors will be Sapna Srivastava and Antony Mattessich. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our tenth amended and restated certificate of incorporation that will become effective upon the closing of this offering and amended and restated <FONT
STYLE="white-space:nowrap">by-laws</FONT> that will become effective upon the effectiveness of the registration statement of which this prospectus is a part provide that the number of our directors shall be fixed from time to time by a resolution of
the majority of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The division of our board of directors into three classes with staggered three-year terms may delay or
prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board leadership structure and board&#146;s role in risk oversight
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently, the role of chairman of our board of directors is separated from the role of Chief Executive Officer. Our Chief Executive Officer is
responsible for recommending strategic decisions and capital allocation to the board of directors and to ensure the execution of the recommended plans. The chairman of our board of directors is responsible for leading the board of directors in its
fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that the Chief Executive Officer is required to devote to her position in the current business
environment, as well as the commitment required to serve as our chairman, particularly as the board of directors&#146; oversight responsibilities continue to grow. While our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> and
corporate governance guidelines will not require that our chairman and Chief Executive Officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and
demonstrates our commitment to good corporate governance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Risk is inherent with every business, and how well a business manages risk can ultimately
determine its success. We face a number of risks, including the four risks more fully discussed in the section entitled &#147;Business&#148; appearing elsewhere in this prospectus. Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of
directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of directors, as
disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a particular committee)
discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairman of
the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk oversight role,
particularly with respect to risk interrelationships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Committees of our board of directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which
will operate pursuant to a charter adopted by our board of directors and that will be effective upon the effectiveness of the registration statement of which this prospectus is a part. The board of directors may also establish other committees from
time to time to assist us and our board of directors. Upon the effectiveness of the registration statement of which this prospectus is a part, the composition and functioning of all of our committees will comply with all applicable requirements of
the Sarbanes-Oxley Act of 2002, Nasdaq and SEC rules and regulations, if applicable. Upon our listing on The Nasdaq Global Market, each committee&#146;s charter will be available on our website at www.aurabiosciences.com. The reference to our
website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be part of this prospectus. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Audit committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Sapna Srivastav and
Giovanni Mariggi currently serve on the audit committee and, upon the effectiveness of the registration statement of which this prospectus forms a part, Sapna Srivastava, Giovanni Mariggi and Antony Mattessich serve on the audit committee, which is
chaired by Sapna Srivastava. Our board of directors has determined that&nbsp;each are &#147;independent&#148; for audit committee purposes as that term is defined by the rules of the SEC and Nasdaq, and that each has sufficient knowledge in
financial and auditing matters to serve on the audit committee. Our board of directors has determined that Sapna Srivastava qualifies as an &#147;audit committee financial expert,&#148; as defined under the applicable rules of the SEC. The audit
committee&#146;s responsibilities include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appointing, approving the compensation of, and assessing the independence of, our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recommending, based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Compensation committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">David Johnson
and Karan Takhar serve on the compensation committee, which is chaired by David Johnson. Our board of directors has determined that each member of the compensation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
committee is &#147;independent&#148; as defined in the applicable Nasdaq rules. The compensation committee&#146;s responsibilities include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">annually reviewing and determining the corporate goals and objectives relevant to the compensation of our Chief Executive
Officer; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and, based on
such evaluation, determining the cash compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">determining the cash compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation
of compensation matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retaining and approving the compensation of any compensation advisors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving the grant of equity-based awards; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and recommending to the board of directors the compensation of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy
statement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each member of our compensation committee is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as
defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Nominating and corporate governance committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Antony Mattessich, David Johnson and Karan Takhar serve on the nominating and corporate governance committee, which is chaired by Antony Mattessich. Our
board of directors has determined that a majority of the nominating and corporate governance committee is &#147;independent&#148; as defined in the applicable Nasdaq rules. The nominating and corporate governance committee&#146;s responsibilities
include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate
skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and recommending to the board of directors appropriate corporate governance guidelines; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing the evaluation of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation committee interlocks and insider participation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2020, the compensation committee consisted of George Golumbeski, Giovanni Mariggi, and Arthur Pappas. None of the members of our compensation
committee has at any time during the prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
three years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation
committee of any entity that has one or more executive officers serving on our board of directors or compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors intends to adopt a Code of Business Conduct and Ethics in connection with this offering. The Code of Business Conduct and
Ethics will apply to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions. Upon the completion of this
offering, the full text of our Code of Business Conduct and Ethics will be posted on our website at www.aurabiosciences.com. The information on our website is deemed not to be incorporated in this prospectus or to be a part of this prospectus. If we
make any substantive amendments to, or grant any waivers from, our Code of Business Conduct and Ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form <FONT
STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations on Liability and Indemnification Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As permitted by Delaware law, provisions in our tenth amended and restated certificate of incorporation, which will become effective immediately prior to
the closing of this offering, and amended and restated bylaws, which will become effective upon the effectiveness of this registration statement, limit or eliminate the personal liability of directors for a breach of their fiduciary duty of care as
a director. The duty of care generally requires that, when acting on behalf of the corporation, a director exercise an informed business judgment based on all material information reasonably available to him or her. Consequently, a director will not
be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payments of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek
<FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, such as injunctive relief or rescission. These provisions will not alter a director&#146;s liability under other laws, such as the federal securities laws or other state or federal laws.
Our tenth amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under
Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As permitted by Delaware law, our amended and restated bylaws to be effective upon the effectiveness of this registration statement
will provide that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other agents, in
connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal
liability of a director or officer, then the liability of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure
insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our bylaws permit such indemnification. We have obtained such
insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to the indemnification that will be provided for in our tenth amended and restated certificate of incorporation and amended
and restated bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law.
These indemnification agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts incurred by a director or
executive officer in any action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and
agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This description of the
indemnification provisions of our tenth amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as
an exhibit to the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed
in the Securities Act, and is, therefore, unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is no pending litigation or proceeding naming any of our directors or officers as to
which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations
regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As an emerging growth company, we have opted to comply with the executive compensation disclosure rules applicable to &#147;smaller reporting
companies,&#148; as such term is defined in the rules promulgated under the Securities Act. The compensation provided to our named executive officers for the fiscal year ended December, 31, 2020 is detailed in the 2020 Summary Compensation Table and
accompanying footnotes and narrative that follow. Our named executive officers are: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Elisabet de los Pinos, Ph.D, our Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Julie Feder, our Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Cadmus Rich, M.D., our Chief Medical Officer and Head of Research and Development. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, the compensation of our named executive officers has consisted of a combination of base salary, cash bonuses and long-term incentive
compensation in the form of stock options. Our named executive officers, like all full-time employees, are eligible to participate in our health and welfare benefit plans. As we transition from a private company to a publicly traded company, we
intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2020 Summary Compensation Table
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table shows the total compensation earned by, or paid to, our named executive officers for services rendered to us in all
capacities during the fiscal year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and principal position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Elisabet de los Pinos, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">394,890</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">148,913</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">533,997</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">17,100</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,094,900</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Julie Feder</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">343,216</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">113,249</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">95,877</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">552,342</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cadmus Rich, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><I>Chief Medical Officer and Head of Research and Development</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">377,280</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">124,488</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">113,498</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">17,100</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">632,366</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Amounts represent discretionary cash bonuses paid to our named executive officers based on performance in 2020.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Amounts represent the aggregate grant date fair value of the option awards granted to our named executive officers during
our fiscal year ended December&nbsp;31, 2020, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 9 to our financial statements for the year ended
December&nbsp;31, 2020, included elsewhere in this prospectus. This amount does not correspond to the actual value that may be recognized by the named executive officer upon exercise of the applicable award or sale of the underlying shares of stock.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amounts reported represent matching contributions made by the Company under the Company&#146;s 401(k) plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>2020 salaries </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our named executive
officers each receive a base salary to compensate them for services rendered to our company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set,
experience, role and responsibilities. Base salaries are reviewed annually, typically in connection with our annual performance review process, approved by our board of directors or the compensation committee, and may be adjusted from time to time
to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For fiscal year 2020,
the annual base salary for each of Dr.&nbsp;de los Pinos, Ms.&nbsp;Feder and Dr.&nbsp;Rich were $391,875, $340,596 and $374,400, respectively. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>2020 bonuses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the fiscal year ended
December&nbsp;31, 2020, each of our named executive officers was eligible to earn an annual cash bonus based on performance as determined at the discretion of our board of directors. The target annual bonuses for Dr.&nbsp;de los Pinos,
Ms.&nbsp;Feder and Dr.&nbsp;Rich for the fiscal year ended December&nbsp;31, 2020 were 40%, 35% and 35% of annual base salary, respectively. The discretionary cash bonus paid to each named executive officer with respect to the fiscal year ended
December&nbsp;31, 2020 is reported in the &#147;Bonus&#148; column of the &#147;2020 Summary Compensation Table&#148; above. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Equity-based
compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, we
believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote
executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors or our compensation committee periodically review the equity incentive compensation of our
named executive officers and may grant equity incentive awards to them from time to time. In March 2020, we granted Dr.&nbsp;de los Pinos, Ms.&nbsp;Feder and Dr.&nbsp;Rich options to purchase 2,669,984, 479,385 and 567,488 shares of our common
stock, respectively, with an exercise price per share equal to the fair market value of our common stock on the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at 2020 Fiscal Year End </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table lists all outstanding equity awards held by our named executive officers as of December&nbsp;31, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Elisabet de los Pinos, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/28/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/1/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/2/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/11/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,696</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/7/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,541,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,458,356</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">471,597</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">556,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113,744</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/15/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Julie Feder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">716,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511,810</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/3/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,424</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,515</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/15/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cadmus Rich, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,342</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/11/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">779,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,848</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/21/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,424</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449,268</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/15/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Each of the outstanding equity awards in the table above was granted pursuant to our Amended and Restated 2009 Stock
Incentive Plan, as amended, or the 2009 Plan, or our 2018 Equity Incentive Plan, as amended, or the 2018 Plan. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months
following April 12, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months
following February 21, 2018. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months
following February 6, 2019. If the executive&#146;s employment is terminated without &#147;cause&#148; (as defined in the 2018 Plan) within 12 months following a &#147;change of control&#148; (as defined in the applicable option award agreement) all
unvested shares will immediately accelerate and vest. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months
following February 6, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of August 13, 2018
with the remainder vesting thereafter pro-rata in 36 monthly installments. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of February 6, 2019
with the remainder vesting thereafter pro-rata in 36 monthly installments. If the executive&#146;s employment is terminated without &#147;cause&#148; (as defined in the 2018 Plan) within 12 months following a &#147;change of control&#148; (as
defined in the applicable option award agreement) all unvested shares will immediately accelerate and vest. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 23, 2017
with the remainder vesting thereafter pro-rata in 36 monthly installments. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of February 21, 2018
with the remainder vesting thereafter pro-rata in 36 monthly installments. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Compensation Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this offering, we intend to enter into new employment agreements with each of Dr. de los Pinos, Ms. Feder and Dr. Rich. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Employment Arrangements in Place Prior to the Offering for Named Executive Officers </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Elisabet de los Pinos, Ph.D. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
entered into an employment agreement with Dr.&nbsp;de los Pinos, who serves as our Chief Executive Officer, in January 2015, which we amended in October 2017, or as amended, the de los Pinos Employment Agreement. The de los Pinos Employment
Agreement provides for Dr.&nbsp;de los Pinos&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, base salary and annual target bonus. Dr.&nbsp;de los Pinos is also eligible to participate in the employee benefit plans available to our
employees, subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the de los Pinos Employment Agreement, in the event that Dr.&nbsp;de los Pinos&#146;s
employment is terminated by us without &#147;cause&#148; or by Dr.&nbsp;de los Pinos for &#147;good reason&#148; (as defined in the de los Pinos Employment Agreement), subject to the execution and effectiveness of a release within 60 days of such
termination, she will be entitled to receive (i) 12 months of base salary continuation and a <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of any bonus for which Dr.&nbsp;de los Pinos was eligible, (ii)&nbsp;continued vesting of stock
options for 12 months and (iii)&nbsp;subject to the Dr.&nbsp;de los Pinos&#146;s timely election to continue COBRA health coverage and copayment of premium amounts at the applicable active employees&#146; rate, we will continue to pay the share of
the premiums that we would have paid to provide health insurance to Dr.&nbsp;de los Pinos for the 12 month severance period. In the event that such termination occurs within nine months after a &#147;change of control&#148; (as defined in the de los
Pinos Employment Agreement), Dr.&nbsp;de los Pinos will, subject to the execution and effectiveness of a release within 60 days of such termination, be entitled to receive a lump sum payment equal to 12 months of base salary as of the date of
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The de los Pinos Employment Agreement contains <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> provisions that apply during Dr.&nbsp;de los Pinos&#146;s employment with us and for one year thereafter. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Julie B. Feder </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2018, we
entered into an employment offer letter, or the Feder Offer Letter, with Ms.&nbsp;Feder who serves as our Chief Financial Officer. The Feder Offer Letter provides for Ms.&nbsp;Feder&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment,
base salary and target annual bonus. Ms.&nbsp;Feder is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pursuant to the Feder Offer Letter, in the event that Ms.&nbsp;Feder&#146;s employment is terminated by us without &#147;cause&#148; (as defined in the Feder Offer
Letter), subject to her execution of a release within 60 days of such termination, Ms.&nbsp;Feder will be entitled to (i)&nbsp;continuation of her base salary for nine months and (ii)&nbsp;provided Ms.&nbsp;Feder has properly elected to continue her
healthcare coverage pursuant to COBRA, the continuation of healthcare coverage premiums on the same premium-sharing basis for nine months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ms.&nbsp;Feder has also entered into a Confidential Information, <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> and Invention Assignment
Agreement with us that contains <FONT STYLE="white-space:nowrap">non-disclosure</FONT> provisions that apply during and for 12 months following her employment with us. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Cadmus Rich, M.D. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2017, we
entered into an employment offer letter, or the Rich Offer Letter, with Dr.&nbsp;Rich, who serves as our Senior Vice President and Chief Medical Officer. The Rich Offer Letter provides for Dr.&nbsp;Rich&#146;s
<FONT STYLE="white-space:nowrap">at-will</FONT> employment, base salary and target annual bonus. Dr.&nbsp;Rich is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the Rich Offer Letter, in the event that Dr.&nbsp;Rich&#146;s employment is terminated by us without &#147;cause&#148; (as defined in the
Rich Offer Letter), subject to his execution of a release within 60 days of such termination, he will be entitled to receive (i)&nbsp;continuation of his annual base salary for nine&nbsp;months and (ii)&nbsp;subject to Dr.&nbsp;Rich&#146;s timely
election to continue COBRA health coverage and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
copayment of premium amounts at the applicable active employees&#146; rate, a monthly cash payment equal to the amount that we would have paid to provide health insurance to Dr.&nbsp;Rich for
nine months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dr.&nbsp;Rich has also entered into an Confidentiality, Intellectual Property, <FONT STYLE="white-space:nowrap">Non-Competition</FONT>
and <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement with us that contains <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> provisions that apply during and for one
year following his employment with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employee Benefit and Equity Compensation Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Amended and Restated 2009 Stock Option and Restricted Stock Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our 2009 Plan was adopted by our board of directors on January&nbsp;15, 2009, approved by our stockholders on January&nbsp;16, 2009, and most recently
amended in September 2018. Under the 2009 Plan, we reserved for issuance an aggregate of 17,311,397 shares of our common stock. The number of shares of common stock reserved for issuance shall be equitably adjusted by the our board of directors in
the event of any merger, consolidation, sale of all or substantially all of our assets, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in capitalization or event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the adoption of our 2018 Plan, no awards have been granted under the 2009 Plan and the shares of common stock underlying awards under the 2009
Plan that are terminated, surrendered or cancelled are forfeited in whole or in part or otherwise result in shares of common stock not being issued are currently added to the shares of common stock available for issuance under the 2018 Plan.
Following this offering, such shares will be added to the shares of common stock available for issuance under the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors
has acted as administrator of the 2009 Plan. The administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, and to determine the specific terms and conditions of each
award, subject to the provisions of the 2009 Plan. Persons eligible to participate in the 2009 Plan are employees, officers and directors of, and consultants and advisors to, our company as selected from time to time by the administrator in its
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2009 Plan permits the granting of (1)&nbsp;options to purchase common stock intended to qualify as incentive stock options under
Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, or the Code, and (2)&nbsp;options that do not so qualify. The per share exercise price of each option is determined by our board of directors but may not be less than 100% of the
fair market value of the common stock on the date of grant. The term of each option is fixed by our board of directors but may not exceed ten years from the date of grant. Our board of directors determines at what time or times each option may be
exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the 2009 Plan permits the granting of restricted shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2009 Plan provides that upon the expectation of the occurrence of a &#147;acquisition event,&#148; as defined in the 2009 Plan, (i)&nbsp;all then
unvested outstanding options shall terminate immediately prior to the consummation of such acquisition event, and (ii)&nbsp;the administrator shall take any one or more or none of the following actions with respect to all then vested outstanding
options: (a)&nbsp;provide that such vested outstanding options shall be assumed or equivalent options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); (b) upon written notice to the optionees, provide that
all then vested outstanding options will terminate immediately prior to the consummation of the acquisition event, except to the extent exercised by the optionee prior to the consummation; (c)&nbsp;in the event of a merger under the terms of which
holders of common stock will receive a cash or stock payment for each share surrendered in the merger, the &#147;merger price,&#148; provide for a cash or stock payment to each optionee equal to (A)&nbsp;the merger price, times the number of shares
of common stock issuable to that optionee upon the exercise by that optionee of such of that optionee&#146;s vested outstanding options which the optionee actually elects to exercise less (B)&nbsp;the aggregate exercise price of all such outstanding
options which the optionee actually exercises in exchange for the termination of all outstanding options; (d)&nbsp;terminate each such vested outstanding option in exchange for a cash payment equal to the amount by which the value of the common
stock issuable upon exercise exceeds the exercise price with respect to such common stock; or (e)&nbsp;provide for a combination of any one or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
more of the foregoing options or any other plan which would be equitable in the good faith judgment of the administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The board of directors may amend or discontinue the 2009 Plan at any time, subject to stockholder approval where such approval is required by applicable
law. The administrator of the 2009 Plan may also amend or cancel any outstanding award, provided that no amendment to an award may materially adversely affect a participant&#146;s rights without his or her consent. The administrator of the 2009 Plan
is specifically authorized to exercise its discretion to reduce the exercise price of outstanding awards or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2009 Plan terminated on the day prior to the tenth anniversary of the date of its adoption. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>2018 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2018
Plan was adopted by our board of directors on December&nbsp;12, 2018, approved by our stockholders on December&nbsp;12, 2018. Under the 2018 Plan, we have reserved for issuance an aggregate number of shares equal to the sum of (i) 55,034,270 shares
of our common stock and (ii)&nbsp;any shares of common stock underlying awards granted under the 2009 Plan that are forfeited, expire or are cancelled without delivery of shares after December&nbsp;12, 2018. The number of shares of common stock
reserved for issuance shall be equitably adjusted by the our board of directors in the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares,
<FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization or event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares of common stock underlying awards
that are terminated, surrendered or cancelled, are forfeited in whole or in part or otherwise result in shares of common stock not being issued are currently added back to the shares of common stock available for issuance under the 2018 Plan.
Following this offering, such shares will be added to the shares of common stock available for issuance under the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors
has acted as administrator of the 2018 Plan. The administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, and to determine the specific terms and conditions of each
award, subject to the provisions of the 2018 Plan. Persons eligible to participate in the 2018 Plan are employees, directors of, and consultants to, our company or its affiliates, as selected from time to time by the administrator in its discretion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2018 Plan permits the granting of (1)&nbsp;options to purchase common stock intended to qualify as incentive stock options under
Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, or the Code, and (2)&nbsp;options that do not so qualify. The per share exercise price of each option is determined by our board of directors but may not be less than 100% of the
fair market value of the common stock on the date of grant. The term of each option is fixed by our board of directors but may not exceed 10 years from the date of grant. Our board of directors determines at what time or times each option may be
exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the 2018 Plan permits the granting of restricted shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2018 Plan provides that upon the occurrence of a &#147;corporate transaction,&#148; as defined in the 2018 Plan, the administrator shall, as to
outstanding options, either (i)&nbsp;make appropriate provisions for the continuation of such options by such options by substituting on an equitable basis for the shares then subject to such options either the consideration payable with respect to
the outstanding shares of common stock in connection with the corporate transaction or securities of any successor or acquiring entity; or (ii)&nbsp;upon written notice to the participants, provide that such options must be exercised (either to the
extent then exercisable or, at the discretion of the administrator, any such options being made </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
partially or fully exercisable), within a specified number of days of the date of such notice, at the end of which period such options which have not been exercised shall terminate; or
(iii)&nbsp;terminate such options in exchange for payment of an amount equal to the consideration payable upon consummation of such corporate transaction to a holder of the number of shares of common stock into which such option would have been
exercisable (either to the extent then exercisable, or, at the discretion of the administrator, any such options being made partially or fully exercisable) less the aggregate exercise price thereof. With respect to any grants of restricted stock,
the administrator shall provide for the continuation or substitution of such awards or provide for the termination of such awards in exchange for the payment of consideration equal to the consideration payable upon consummation of the transaction to
a holder of the number of shares of common stock underlying such award (to the extent no longer subject to forfeiture or repurchase or, at the administrator&#146;s discretion, with all forfeiture and repurchase rights being waived in the corporate
transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The board of directors may amend or discontinue the 2018 Plan at any time, subject to stockholder approval where such approval is
required by applicable law. The administrator of the 2018 Plan may also amend or cancel any outstanding award, provided that no amendment to an award may materially adversely affect a participant&#146;s rights without his or her consent. The
administrator of the 2018 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding awards or effect the repricing of such awards through cancellation and
<FONT STYLE="white-space:nowrap">re-grants.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2018 Plan will automatically terminate upon the earlier of ten years from the date on which
the 2018 Plan was initially adopted by our board of directors or ten years from the date the 2018 Plan was initially approved by our stockholders. As of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021, options to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock were outstanding under the 2018 Plan. Our board of directors has determined not to make any further
awards under the 2018 Plan following the closing of this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>2021 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2021 Plan was adopted by our board of directors on October&nbsp;7, 2021, approved by our stockholders
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 and will become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is part is
declared effective by the SEC. The 2021 Plan will replace the 2018 Plan as our board of directors has determined not to make additional awards under the 2018 Plan following the closing of our initial public offering. However, the 2018 Plan will
continue to govern outstanding equity awards granted thereunder. The 2021 Plan allows us to make equity-based and cash-based incentive awards to our officers, employees, directors and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have initially reserved&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock for
the issuance of awards under the 2021 Plan, or the Initial Limit. The 2021 Plan provides that the number of shares reserved and available for issuance under the 2021 Plan will automatically increase on January&nbsp;1, 2022 and each January&nbsp;1
thereafter, by 5% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by our compensation committee, or the Annual Increase. The number of shares
reserved under the 2021 Plan subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares
we issue under the 2021 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards under the 2021 Plan, the 2018 Plan and the 2009 Plan that are forfeited, cancelled, held back upon
exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the
shares of common stock available for issuance under the 2021 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The maximum number of shares of common stock that may be issued in the form of incentive stock options
shall not exceed the Initial Limit, cumulatively increased on January&nbsp;1, 2022 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The grant date fair value
of all awards made under our 2021 Plan and all other cash compensation paid by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director shall not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; provided, however, that such amount shall be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to the
board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2021 Plan will be administered by our compensation committee. Our compensation committee has the full power to select, from
among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the exercisability or vesting of
any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2021 Plan. Persons eligible to participate in the 2021 Plan will be those full or part-time officers, employees, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2021 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the
Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date of grant unless the option is
granted (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code or (ii)&nbsp;to individuals who are not subject to U.S. income tax. The term of each option will be fixed by our compensation
committee and may not exceed ten years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may award stock appreciation rights under the 2021 Plan subject to such conditions and restrictions as it may determine.
Stock appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right may not be less than 100% of
the fair market value of our common stock on the date of grant. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed ten years from the date of grant. Our compensation committee will determine at
what time or times each stock appreciation right may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may award restricted shares of common stock and
restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a
specified vesting period. Our compensation committee may also grant shares of common stock that are free from any restrictions under the 2021 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid
consideration and may be issued in lieu of cash compensation due to such participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may grant dividend equivalent
rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may grant cash bonuses under the 2021 Plan to participants, subject to the achievement of certain performance goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2021 Plan provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2021
Plan, an acquirer or successor entity may assume, continue or substitute outstanding awards under the 2021 Plan. To the extent that awards granted under the 2021 Plan are not assumed or continued or substituted by the successor entity, upon the
effective time of the sale event, such awards shall terminate. In such case, except as may be otherwise provided in the relevant award certificate, all awards with time-based vesting, conditions or restrictions shall become fully vested and
nonforfeitable as of the effective time of the sale event and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a sale event in the
administrator&#146;s discretion or to the extent specified in the relevant award certificate. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise such options and stock
appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind, to participants holding vested and exercisable options and stock
appreciation rights equal to the difference between the per share consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights and we may make or provide for a payment, in cash or in
kind, to participants holding other vested awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors may amend or discontinue the 2021 Plan and our compensation committee may
amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2021 Plan require
the approval of our stockholders. The administrator of the 2021 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards
through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. No awards may be granted under the 2021 Plan after the date that is ten years from the effective date of the 2021 Plan. No awards under the 2021
Plan have been made prior to the date of this prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>2021 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ESPP was adopted by our board of directors on October&nbsp;7, 2021, approved by our stockholders
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 and will become effective on the date immediately preceding the date on which the registration statement of which this prospectus forms a part
is declared effective by the SEC. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. The ESPP initially reserves and authorizes the issuance of up to a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will
automatically increase on January&nbsp;1, 2022 and each January&nbsp;1 thereafter through January&nbsp;1, 2031, by the least of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common
stock, (ii) 1% of the outstanding number of shares of common stock on the immediately preceding December&nbsp;31 or (iii)&nbsp;such lesser number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved
under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All employees who are
customarily employed by us or one of our designated subsidiaries for more than 20 hours per week and who we have employed for at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;days are eligible
to participate in the ESPP. However, any employee who owns&nbsp;5% or more of the total combined voting power or value of all classes of our stock will not be eligible to purchase shares of common stock under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may make one or more offerings each year to our employees to purchase shares under the ESPP. Offerings will usually begin on
each&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and will continue for <FONT
STYLE="white-space:nowrap">six-month</FONT> periods, referred to as offering periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least&nbsp;15&nbsp;business days before the applicable offering
date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing
payroll deductions of up to 15% of his or her eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of
our common stock on the last business day of the offering period at a price equal to&nbsp;85% of the fair market value of the shares of our common stock on the first business day or the last business day of the offering period, whichever is lower,
provided that no more than $25,000 worth of common stock (or such other lesser maximum number of shares as may be established by the administrator) may be purchased by any one employee during any offering period. Under applicable tax rules, an
employee may purchase no more than $25,000 worth of shares of our common stock, valued at the start of the purchase period, under the ESPP in any calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An employee&#146;s
rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ESPP may
be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Senior Executive Cash Incentive Bonus Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On October&nbsp;7, 2021 our board of directors adopted the Senior Executive Cash Incentive Bonus Plan, or the Bonus Plan. The Bonus Plan provides for
annual cash bonus payments based upon the attainment of company and individual performance targets established by our compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our
company, or the Corporate Performance Goals, as well as individual performance objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may select Corporate
Performance Goals from among the following: research and development, publication, clinical and/or regulatory milestones; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before
interest, taxes, depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of our common stock; economic value-added; acquisitions or strategic
transactions, including collaborations, joint ventures or promotion arrangements; operating income (loss); return on capital assets, equity, or investment; stockholder returns; return on sales; gross or net profit levels; productivity; expense
efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss) per share of our common stock; bookings, new bookings or renewals; sales or market shares; number of customers, number of new customers or customer
references; operating income and/or net annual recurring revenue; or any other performance goal as selected by the compensation committee, any of which may be measured in absolute terms, as compared to any incremental increase, in terms of growth,
as compared to results of a peer group, against the market as a whole, compared to applicable market indices and/or measured on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus
formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The Corporate Performance Goals will be measured at the end of each performance period after our financial reports have been
published or such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and individual performance objectives are met, payments will be made as soon as practicable following the end of each performance
period, but no later than 74 days after the end of the fiscal year in which such performance period ends. Subject to the rights contained in any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
agreement between the executive officer and us, an executive officer must be employed by us on the bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the
compensation committee to approve additional bonuses to executive officers in its sole discretion. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>401(k) plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility
requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. Our 401(k) plan is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code, and
contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. We believe that providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though our 401(k) plan
adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_15"></A>NON-EMPLOYEE DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table presents the total compensation for each person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our
board of directors during the year ended December&nbsp;31, 2020. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT>
awards to, or pay any other compensation to any of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors in 2020. We reimburse <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of
directors for reasonable travel and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in attending meetings of our board of directors and committees of our board of directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or&nbsp;Paid<BR>in Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Johnson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George S. Golumbeski, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Raj Parekh, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joel Jean-Mairet, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Giovanni Mariggi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arthur Pappas</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Casper Breum</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Christian Schetter, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Amounts represent the aggregate grant date fair value of the option awards granted to our directors during our fiscal
year ended December&nbsp;31, 2020, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 9 to our financial statements for the year ended December&nbsp;31,
2020, included elsewhere in this prospectus. This amount does not correspond to the actual value that may be recognized by the director upon exercise of the applicable award or sale of the underlying shares of stock. Except as noted below, none of
our directors held options to purchase our common stock or any other stock awards as of December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Amount was paid pursuant to a board offer letter dated November 13, 2019, pursuant to which Dr. Golumbeski is entitled to
receive $50,000 annually for his board service, to be paid on a quarterly basis, as well as a one-time option grant for 2,081,000 shares. This compensation arrangement will be replaced by the non-employee director compensation policy we intend to
adopt in connection with this offering. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Number of<BR>Shares<BR>Subject to<BR>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Johnson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">George Golumbeski</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,081,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this offering, we have adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that will become
effective upon the completion of this offering and will be designed to enable us to attract and retain, on a long-term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each director who is not
an employee will be paid cash compensation from and after the completion of this offering, as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional retainer for non-executive chair</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the non-employee director compensation policy provides that, upon initial election to our board of
directors, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted an option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, or Initial Grant. The Initial Grant
will vest in equal installments on the first, second, and third anniversaries of the grant date, subject to continued service through the applicable vesting date. Furthermore, on the date of each annual meeting of stockholders following the
completion of this offering, each non-employee director who continues as a non-employee director following such meeting will be granted an annual option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock, or Annual Grant. The Annual Grant will vest in full on the earlier of (i)&nbsp;the first anniversary of the grant date or (ii)&nbsp;our next annual meeting of stockholders, subject to continued service through the applicable
vesting date. Such awards are subject to full accelerated vesting upon the sale of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will reimburse all
reasonable&nbsp;out-of-pocket&nbsp;expenses incurred by directors for their attendance at meetings of our board of directors or any committee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Employee directors will receive no additional compensation for their service as a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_16"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following is a description of transactions or series of transactions since January&nbsp;1, 2018, to which we were or will be a party, in which: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the amount involved in the transaction exceeds, or will exceed, the lesser of $120,000 or one percent of the average of the
Company&#146;s total assets for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in which any of our executive officers, directors or holders of five percent or more of any class of our capital stock,
including their immediate family members or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Compensation arrangements for our named executive officers and our directors are described elsewhere in this prospectus under &#147;Executive
Compensation,&#148; &#147;Director <FONT STYLE="white-space:nowrap">Compensation&#151;Non-Employee</FONT> Director Compensation&#148; and Director Compensation&#151;Consulting Agreement with Dr.&nbsp;Golumbeski.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Private Placements of Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock Financing </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2019, with a subsequent closing in December 2019, we
sold an aggregate of 57,878,742 shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock at a purchase price of $0.6911 per share for aggregate proceeds of $40.0&nbsp;million. The following table summarizes purchases
of our Series <FONT STYLE="white-space:nowrap">D-1</FONT> preferred stock by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series <FONT STYLE="white-space:nowrap">D-1</FONT><BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Medicxi(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,151,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,000,001.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Advent Life Sciences(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,170,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,999.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lundbeckfond Invest A/S(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,877,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,062,050.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arix Bioscience Holdings Limited(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,489,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,484,987.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chiesi Ventures, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,600,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,488,248.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Belinda A. Termeer(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,445,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,380,965.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ysios Biofund II Innvierte, F.C.R.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,893,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,999,999.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Columbus Innvierte, F.C.R.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,161,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,185,076.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Medicxi collectively beneficially own more than five percent of our outstanding capital stock.
Giovanni Mariggi, Ph.D. is a member of Medicxi and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Advent Life Sciences collectively beneficially own more than five percent of our outstanding
capital stock. Raj Parekh, Ph.D. is a member of Advent Life Sciences and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Lundbeckfond Invest A/S beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Arix Bioscience Holdings Limited beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Chiesi Ventures, LP beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Belinda A. Termeer beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Ysios Biofund II Innvierte, F.C.R. beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Columbus Innvierte, F.C.R. beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock Financing
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2020, with a subsequent closing in March 2021, we sold an aggregate of 24,598,481 shares of Series
<FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock at a purchase price of $0.6911 per share for aggregate proceeds of $17.0&nbsp;million. The following table summarizes purchases of our Series
<FONT STYLE="white-space:nowrap">D-2</FONT> preferred stock by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series <FONT STYLE="white-space:nowrap">D-2</FONT><BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Medicxi(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,240,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,621,386.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Advent Life Sciences(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,881,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,991,390.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lundbeckfond Invest A/S(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,762,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,909,088.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arix Bioscience Holdings Limited(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590,216.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chiesi Ventures, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,204,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,523,369.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Belinda A. Termeer(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,109,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457,688.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ysios Biofund II Innvierte, F.C.R.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,954,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350,616.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Columbus Innvierte, F.C.R.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,337,760.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Medicxi collectively beneficially own more than five percent of our outstanding capital stock.
Giovanni Mariggi, Ph.D. is a member of Medicxi and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Advent Life Sciences collectively beneficially own more than five percent of our outstanding
capital stock. Raj Parekh, Ph.D. is a member of Advent Life Sciences and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Lundbeckfond Invest A/S beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Arix Bioscience Holdings Limited beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Chiesi Ventures, LP beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Belinda A. Termeer beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Ysios Biofund II Innvierte, F.C.R. beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Columbus Innvierte, F.C.R. beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Series E Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2021, we sold an aggregate of 102,671,041 shares of Series E Convertible Preferred Stock at a purchase price of $0.7839 per share for aggregate
proceeds of $80.5&nbsp;million. The following table summarizes purchases of our Series E preferred stock by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series E<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Matrix Capital Management Master Fund, LP(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,891,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000,000.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Citadel-Multi Strategy Equities Master Fund Ltd.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,513,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Medicxi(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,528,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,765,638.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Advent Life Sciences(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,241,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,757,105.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lundbeckfond Invest A/S(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,148,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,684,489.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arix Bioscience Holdings Limited(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,284,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,790,606.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chiesi Ventures, LP(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,188,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,335.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Belinda A. Termeer(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,039,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,599,103.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ysios Biofund II Innvierte, F.C.R.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,520,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,191,719.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Velosity Capital Management LLC(10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,913,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,999.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Columbus Innvierte, F.C.R.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,921,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,506,337.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Karan Takhar is an affiliate of Matrix Capital Management Master Fund, LP and a member of our board of directors.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Citadel-Multi Strategy Equities Master Fund Ltd. beneficially owns more than five percent of our outstanding capital
stock. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Medicxi collectively beneficially own more than five percent of our outstanding capital stock.
Giovanni Mariggi, Ph.D. is an affiliate of Medicxi and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Entities affiliated with Advent Life Sciences collectively beneficially own more than five percent of our outstanding
capital stock. Raj Parekh, Ph.D. is an affiliate of Advent Life Sciences and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Lundbeckfond Invest A/S beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Arix Bioscience Holdings Limited beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Chiesi Ventures, LP beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Belinda A. Termeer beneficially owns more than five percent of our outstanding capital stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Ysios Biofund II Innvierte, F.C.R. beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">David Johnson is an affiliate of Velosity Capital Management LLC. David Johnson is a member of our board of directors.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Columbus Innvierte, F.C.R. beneficially owns more than five percent of our outstanding capital stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Agreements with Our Stockholders </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with our Series E convertible preferred stock financing, we entered into investors&#146; rights, voting and right of first refusal <FONT
STYLE="white-space:nowrap">and&nbsp;co-sale&nbsp;agreements</FONT> containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of our preferred stock and certain holders of
our common stock. These stockholder agreements will terminate upon the closing of this offering, except for the registration rights granted under our investors&#146; rights agreement, as more fully described in &#147;Description of Capital
Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify
these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services
undertaken by such person on our behalf or that person&#146;s status as a member of our board of directors to the maximum extent allowed under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies for Approval of Related Party Transactions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
board of directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party. Prior to this offering, the material facts as to the related
party&#146;s relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the transaction is not considered approved by our board of directors unless a majority of the
directors who are not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#146;s relationship or interest in the
transaction are disclosed to the stockholders, who must approve the transaction in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this offering, we have adopted a
written related party transactions policy that such transactions must be approved by our audit committee. This policy will become effective on the date on which the registration statement of which this prospectus is part is declared effective by the
SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_17"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of September&nbsp;30, 2021, as
adjusted to reflect the sale of common stock offered by us in this offering, for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person or group of affiliated persons known by us to be the beneficial owner of more than five percent of our capital
stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power with respect to the securities as well as any shares of common stock that the individual or entity
has the right to acquire within 60 days of September&nbsp;30, 2021 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of
computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where
applicable, we believe, based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each individual or entity shown on the table has furnished information with respect to beneficial ownership. Unless otherwise indicated, the address for
each beneficial owner is c/o Aura Biosciences,&nbsp;Inc., 85 Bolton St., Cambridge, MA 02140. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The percentage of beneficial ownership prior to this
offering in the table below is based on 315,235,788 shares of common stock deemed to be outstanding as of&nbsp;September 30, 2021, assuming the conversion of all outstanding shares of our preferred stock immediately prior to the completion of this
offering, and the percentage of beneficial ownership at this offering in the table below is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock assumed to be outstanding
after the closing of the offering. The information in the table below assumes no exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Outstanding<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Medicxi(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,919,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Matrix Capital Management Master Fund, LP(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,891,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Citadel-Multi Strategy Equities Master Fund Ltd.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,513,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Advent Life Sciences(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,260,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lundbeckfond Invest A/S(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,216,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arix Bioscience Holdings Limited(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,666,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chiesi Ventures, LP(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,797,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Belinda A. Termeer(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,795,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Columbus Innvierte, F.C.R.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,385,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ysios Biofund II Innvierte, F.C.R.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,132,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Outstanding<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Elisabet de los Pinos, Ph.D.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,764,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cadmus Rich(12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,030,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Julie Feder(13)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,558,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Johnson(14)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,746,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Giovanni Mariggi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Raj Parekh, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sapna Srivastava, Ph.D.(15)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Karan Takhar</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Antony Mattessich(16)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">All executive officers and directors as a group (10 persons)(17)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,223,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 22,614,268 shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock,
5,118,420 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock and 3,446,180 shares of Series E Convertible Preferred Stock held by Medicxi Growth I LP, a Jersey limited partnership (&#147;Medicxi Growth I&#148;)
and 537,232 shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, 121,613 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock and 81,870 shares of Series E Convertible
Preferred Stock held by Medicxi Growth <FONT STYLE="white-space:nowrap">Co-Invest</FONT> I LP, a Jersey limited partnership (&#147;Medicxi Growth <FONT STYLE="white-space:nowrap">Co-Invest</FONT> I&#148;, and together with Medicxi Growth I, the
&#147;Medicxi Funds&#148;). Medicxi Growth I GP Limited, a Jersey limited liability company (&#147;MGI GP&#148;), is the sole managing general partner of the Medicxi Funds, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability
company (&#147;Medicxi Manager&#148;), is the sole manager of the Medicxi Funds. MGI GP and Medicxi Manager may be deemed to have voting and dispositive power over the shares held by the Medicxi Funds. The share ownership reported by the Medicxi
Funds does not include any shares beneficially owned by Index Ventures Life VI (Jersey) LP and Yucca (Jersey) SLP, and each of the Medicxi Funds and their affiliates disclaim beneficial ownership of the securities beneficially owned by Index
Ventures Life VI (Jersey) LP, Yucca (Jersey) SLP and their affiliates. Giovanni Mariggi, Ph.D. is a member of Medicxi and a member of our board of directors. The address of the principal business office of each of the Medicxi Funds is c/o Intertrust
Fund Services (Jersey) Limited, 44 Esplanade, St. Helier, Jersey JE4 9WG. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 31,891,823 shares of Series E Convertible Preferred Stock held by Matrix Capital Management Master Fund, LP
(&#147;Matrix&#148;). Karan Takhar, a member of our board of directors, is a Senior Managing Director of Matrix and may be deemed to have voting and dispositive power over the shares held by Matrix. The mailing address for Matrix is 1000 Winter
Street, Suite 4500, Waltham, Massachusetts 02451. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 25,513,458 shares of Series E Convertible Preferred Stock held of record by Citadel Multi-Strategy Equities
Master Fund Ltd. (&#147;Citadel&#148;). Citadel Advisors LLC (&#147;Citadel Advisors&#148;) is the portfolio manager of Citadel. Citadel Advisors Holdings LP (&#147;CAH&#148;) is the sole member of Citadel Advisors. Citadel GP LLC (&#147;CGP&#148;)
is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&nbsp;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or
to direct the disposition of, the shares held by Citadel. The foregoing should not be construed as an admission that Mr.&nbsp;Griffin or any of the Citadel related entities is the beneficial owner of any of our securities other than the securities
actually owned by such person (if any). The address for Citadel is 601 Lexington Ave., New York, NY 10022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 6,791,176 shares of Series B Convertible Preferred Stock, 4,601,603 shares of
<FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> Convertible Preferred Stock, 5,847,462 shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT> Convertible Preferred Stock, 2,082,606 shares of Series
<FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, 173,356 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock and 122,403 shares of Series E Convertible Preferred Stock held by Advent Life
Sciences Fund I LP, 286,457 shares of Series B Convertible Preferred Stock, 194,098 shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Convertible Preferred Stock, 246,651 shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT>
Convertible Preferred Stock, 87,846 shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, 7,312 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;D-2</FONT> Convertible Preferred Stock and 5,163 shares of
Series E Convertible Preferred Stock held by Advent Life Sciences LLP (&#147;ALS&#148;), 1,954,176 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock and 1,541,788 shares of Series E Convertible Preferred Stock
held by Advent Life Sciences Fund III LP, 83,584 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock and 65,944 shares of Series&nbsp;E Convertible Preferred Stock held by ALS III Carry and <FONT
STYLE="white-space:nowrap">Co-Invest</FONT> LP and 663,051 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;D-2</FONT> Convertible Preferred Stock and 506,194 shares of Series E Convertible Preferred Stock held by Advent-Harrington Impact Fund
LP. (collectively, the &#147;Advent Funds&#148;). ALS is the manager of the Advent Funds and has voting and dispositive power over the shares held by the Advent Funds. Rajesh Parekh, Ph.D., a member of our board of directors, is a General Partner of
ALS, and may be deemed to have voting and dispositive power over the shares held by ALS. The address of each of the entities is 27 Fitzroy Square, London, United Kingdom W1T 6ES. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 13,427,967 shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Convertible Preferred Stock,
5,877,660 shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, 2,762,391 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock and 2,148,857 shares of Series E Convertible
Preferred Stock held by Lundbeckfond Invest A/S, or Lundbeckfond. Lundbeckfond is wholly-owned by the Lundbeck Foundation, and the board of directors of the Lundbeckfond Foundation consists of J&oslash;rgen Huno Rasmussen, Steffen Kragh, Lars
Holmqvist, Susanne Kr&#252;ger Kj&aelig;r, Michael Kj&aelig;r, Peter Sch&#252;tze, Gunhild Waldemar, Ludovic Tranholm Otterbein, Vagn Flink M&oslash;ller Pedersen, Henrik Villsen Andersen and Peter Adler W&#252;rtzen. The board of directors of the
Lundbeck Foundation serve as the board members of Lundbeckfond. No individual member of the Lundbeckfond board of directors is deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by Lundbeckfond. The board of
directors of Lundbeckfond makes decisions with respect to investments made by Lundbeckfond, and the board of directors of Lundbeckfond and Lene Skole, the chief executive officer of Lunbeckfonden, may be deemed to share voting and investment
authority over the shares held by Lundbeckfond. Mette Kirstine Agger, a current member of our board of directors, is a Managing Partner at Lundbeckfond Ventures, which is an affiliate of Lundbeckfond. The address of Lundbeckfond Invest A/S is
Scherfigsvej 7 <FONT STYLE="white-space:nowrap">DK-2100,</FONT> Copenhagen &Oslash;, Denmark. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 9,591,405 shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Convertible Preferred Stock, 6,489,636
shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, 2,300,993 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock and 2,284,228 shares of Series E Convertible Preferred
Stock. The securities are held by Arix Bioscience Holdings Limited (&#147;Arix Ltd.&#148;). Arix Bioscience Plc is the sole owner and parent of Arix Ltd. and may be deemed to indirectly beneficially own the shares held by Arix Ltd. The Arix
Investment Committee, composed of Mark Chin, Peregrine Moncreiffe, Isaac Kohlberg and Maureen O&#146;Connell, may be deemed to share voting and investment power over the shares held by Arix Ltd. The address of Arix Ltd. is 20&nbsp;Berkeley Square,
London, W1J 6EQ, United Kingdom. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 4,044,364 shares of Series B Convertible Preferred Stock, 4,277,921 shares of
<FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> Convertible Preferred Stock, 3,482,351 shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT> Convertible Preferred Stock, 3,600,418 shares of Series
<FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, 2,204,268 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;D-2</FONT> Convertible Preferred Stock and 2,188,207 shares of Series E Convertible Preferred Stock. Chiesi
Ventures, Inc., or Chiesi, as General Partner of Chiesi Ventures, LP, or Chiesi Ventures, may be deemed to have voting and investment authority over the shares held by Chiesi Ventures, LP., and Mr.&nbsp;Giacomo Chiesi is President of, and may be
deemed to have control of, Chiesi. By virtue of their respectively relationships with Chiesi Ventures, each of Chiesi and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Mr.&nbsp;Chiesi may be deemed to indirectly beneficially own the shares of which Chiesi Ventures is the record owner. The address of Chiesi Ventures, LP is 1 Broadway #14, Cambridge, MA 02142.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 225,000 shares of Common Stock, 60,369 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Convertible Preferred Stock, 612,250 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Convertible Preferred Stock, 1,919,867 shares of Series B Convertible Preferred Stock, 2,750,797 shares of Series
<FONT STYLE="white-space:nowrap">C-1</FONT> Convertible Preferred Stock, 6,625,004 shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT> Convertible Preferred Stock, 3,445,182 shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT>
Convertible Preferred Stock, 2,109,229 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock and 2,039,933 shares of Series E Convertible Preferred Stock. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 248,966 shares of Series B Convertible Preferred Stock, 7,577,210 shares of
<FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> Convertible Preferred Stock, 2,540,168 shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT> Convertible Preferred Stock, 3,161,738 shares of Series
<FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, 1,935,697 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;D-2</FONT> Convertible Preferred Stock and 1,921,594 shares of Series E Convertible Preferred Stock. Columbus
Innvierte, F.C.R. is administered and managed by Columbus Venture Partnes SGEIC, S.A.U., whose board of directors makes decisions with respect to investments made by Columbus Innvierte, F.C.R. The board of directors of Columbus Venture Partnes
SGEIC, S.A.U., composed of Javier Garc&#314;a Cogorro, Dami&#225; Tormo Carulla and Neil Collen, may be deemed to share voting and investment authority over the shares held by Columbus Innvierte, F.C.R. The address of Columbus Innvierte, F.C.R. is
Jose Abascal&nbsp;58, 7D 28003, Madrid, Spain. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 3,033,272 shares of Series B Convertible Preferred Stock, 5,119,115 shares of
<FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> Convertible Preferred Stock, 2,611,762 shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT> Convertible Preferred Stock, 2,893,936 shares of Series
<FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, 1,954,299 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;D-2</FONT> Convertible Preferred Stock and 1,520,244 shares of Series E Convertible Preferred Stock. Jo&#235;l
Jean-Mairet, Julia Salaverria and Karen Wagner, managing Partners at Ysios Capital Partners SGEIC, SAU, management company of Ysios Biofund II Innvierte FCR, may be deemed to share voting and investment authority over the shares held by Ysios
Biofund II Innvierte FCR. The address of Ysios Biofund II Innvierte, F.C.R. is Avenida de la Libertad 25, 4th Floor 20004 San Sebasti&aacute;n, Spain. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 1,800,364 shares of common stock held of record by EdlP Revocable Trust and (ii)&nbsp;7,964,515 shares of
common stock that the person has the right to acquire within 60 days of September&nbsp;30, 2021 through the exercise of stock options. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of shares of common stock that the person has the right to acquire within 60 days of September&nbsp;30, 2021
through the exercise of stock options. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of shares of common stock that the person has the right to acquire within 60 days of September&nbsp;30, 2021
through the exercise of stock options. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 1,913,509 shares of Series E Convertible Preferred Stock held by Velosity Capital Management LLC, an
entity that Mr.&nbsp;Johnson is the sole member of, and (ii) 833,335 shares of common stock that the person has the right to acquire within 60 days of September&nbsp;30, 2021 through the exercise of stock options, which is held individually by
Mr.&nbsp;Johnson. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of shares of common stock that the person has the right to acquire within 60 days of September&nbsp;30, 2021
through the exercise of stock options. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of shares of common stock that the person has the right to acquire within 60 days of September 30, 2021 through
the exercise of stock options. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;3,713,873&nbsp;shares of common stock and (ii)&nbsp;12,509,620&nbsp;shares of common stock that the
persons have the right to acquire within 60&nbsp;days of September&nbsp;30, 2021 through the exercise of stock options. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_18"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>The following descriptions are summaries of the material terms of our tenth amended and restated certificate of incorporation, which will be
effective upon the closing of this offering and amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this prospectus is a part. The descriptions of the common stock and preferred stock
give effect to changes to our capital structure that will occur immediately prior to the completion of this offering. We refer in this section to our tenth amended and restated certificate of incorporation as our certificate of incorporation, and we
refer to our amended and restated bylaws as our bylaws. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, our authorized capital stock will consist of 150,000,000 shares of common stock, par value $0.00001 per share, and
10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock will be undesignated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of
June&nbsp;30, 2021, 6,015,717 shares of our common stock were outstanding and held by 102 stockholders of record. This amount assumes the conversion of all outstanding shares of our preferred stock into common stock, which will occur immediately
prior to the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to
receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion
rights or other subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of our liquidation, dissolution or winding up, holders
of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be,
when issued and paid for, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Immediately prior to the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock.
Upon the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences,
privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or
the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will
receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our Company or other corporate action. Immediately after
consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering,
the holders of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion of preferred stock, will be entitled to rights with respect to
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
registration of these securities under the Securities Act. These rights are provided under the terms of our Investor Rights Agreement between us and the holders of our preferred stock. The
Investor Rights Agreement includes demand registration rights, short-form registration rights, and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling
expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Demand
registration rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Beginning six months after the completion of this offering, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion of shares of our preferred stock upon closing of this offering, will be
entitled to demand registration rights. Under the terms of the Investor Rights Agreement, we will be required, upon the written request of a majority of holders of the registrable securities then outstanding that would result in an aggregate
offering price of at least $5.0&nbsp;million, to file a registration statement and to use commercially reasonable efforts to effect the registration of all or a portion of these shares for public resale. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Short-form registration rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon
the completion of this offering, the holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion of shares of our preferred stock
upon closing of this offering, are also entitled to short-form registration rights. Pursuant to the Investor Rights Agreement, if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written
request from any such holder to sell registrable securities at an aggregate price of at least $3.0&nbsp;million, we will be required to use commercially reasonable efforts to effect a registration of such shares. We are required to effect only two
registrations in any twelve-month period pursuant to this provision of the investor rights agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Piggyback registration rights
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion of shares of our preferred stock upon closing of this offering, are entitled
to piggyback registration rights. If we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain
exceptions contained in the Investor Rights Agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not
jeopardize the success of the offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Investor Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable
securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Expiration of registration rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
demand registration rights and short-form registration rights granted under the Investor Rights Agreement will terminate on the fifth anniversary of the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-takeover effects of our certificate of incorporation and bylaws and Delaware Law </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party
from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT>
takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Board composition and filling vacancies </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one
class being elected each year. Our certificate of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of <FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the
shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a
majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to
change the composition of our board of directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>No written consent of stockholders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special
meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by
our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Meetings of stockholders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special
meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of
stockholders to those matters properly brought before the meeting. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Advance notice requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or
new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken.
Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as
to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Amendment to certificate of incorporation and bylaws </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our
certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment
of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and
not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to
any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions
relating to notice of stockholder business and nominations and special meetings must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority
of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Undesignated preferred stock
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, our certificate of incorporation will provide for 10,000,000 authorized shares of preferred stock. The
existence of authorized but unissued shares of preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its
fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one
or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad
power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common
stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exclusive Forum </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws to be
adopted upon the completion of this offering will provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for:
(1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers and employees to us or our stockholders; (3)&nbsp;any action asserting a
claim arising pursuant to the Delaware General Corporation Law or our certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (including the interpretation, validity or enforceability thereof); or (4)&nbsp;any action
asserting a claim that is governed by the internal affairs doctrine; provided, however, that this provision shall not apply to any causes of action arising under the Securities Act or the Exchange Act. In addition, our amended and restated bylaws
will provide that, unless we consent to an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action under the Securities Act (the Federal Forum
Provision). Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to these forum provisions. These forum provisions may impose additional costs on stockholders and may
limit our stockholders&#146; ability to bring a claim in a forum they find favorable, and the designated courts may reach different judgements or results than other courts. In addition, there is uncertainty as to whether our Federal Forum Provision
will be enforced, which may impose additional costs on us and our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general,
Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested
stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers,
and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of
the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share
of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, Section&nbsp;203 defines an interested stockholder as any entity or
person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nasdaq Global Market listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied to list our
common stock on The Nasdaq Global Market under the trading symbol &#147;AURA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer agent and registrar </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is
250&nbsp;Royall Street, Canton, Massachusetts 02021, and its telephone number is (800)&nbsp;962-4284. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_19"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the availability of
such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal
restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to
raise equity capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of June&nbsp;30, 2021, upon the completion of this offering,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of
outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in
compliance with the limitations described below, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock are restricted shares of common stock subject to time-based vesting
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, a person who has
beneficially owned restricted stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a
sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or
any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the number of shares
outstanding as of June&nbsp;30, 2021; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks preceding
the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">provided, in each case, that we are subject to the Exchange Act
periodic reporting requirements for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice
provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Rule&nbsp;701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without
compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive officers, or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on
the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90 days after the effectiveness of the registration statement of which this prospectus forms a part before selling their shares. However,
substantially all Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and under &#147;Underwriting&#148; included elsewhere in this prospectus and will become eligible for sale upon the
expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or
exchangeable for our capital stock have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any of our common stock or any securities
convertible into or exercisable or exchangeable for common stock for a period of not less than 180&nbsp;days from the date of this prospectus without the prior written consent of the representatives, subject to certain exceptions. See the section
entitled &#147;Underwriting&#148; appearing elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, certain of our officers, directors and significant stockholders may adopt written plans, known as <FONT
STYLE="white-space:nowrap">Rule&nbsp;10b5-1&nbsp;trading</FONT> plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under <FONT
STYLE="white-space:nowrap">these&nbsp;10b5-1&nbsp;trading</FONT> plans, a broker may execute trades pursuant to parameters established by the officer, director or stockholder when entering into the plan, without further direction from such officer,
director or stockholder. Such sales would not commence until the expiration of the <FONT STYLE="white-space:nowrap">applicable&nbsp;lock-up&nbsp;agreements</FONT> entered into by such officer, director or stockholder in connection with this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon completion of this
offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities Act.&nbsp;Registration of these shares under the Securities Act would result in these shares becoming
fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration statement.&nbsp;See the section entitled &#147;Description of Capital Stock&#151;Registration rights&#148; appearing elsewhere in this
prospectus for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity incentive plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register our
shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC.
Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions
described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_20"></A>MATERIAL U.S. FEDERAL INCOME TAX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSIDERATIONS <FONT STYLE="white-space:nowrap">FOR&nbsp;NON-U.S.&nbsp;HOLDERS</FONT> OF COMMON STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following discussion is a summary of material U.S. federal income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. For purposes of this discussion,
a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is, for U.S. federal income tax purposes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation or any other organization taxable as a corporation for U.S. federal income tax purposes that is created or
organized in or under laws other than the laws of the United States, any state thereof, or the District of Columbia;</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is not subject to U.S. federal income tax on a net income basis; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust that (1) (a) has not made an election to be treated as a U.S. person under applicable U.S. Treasury regulations and
(b)&nbsp;either (i) is not subject to the primary supervision of a court within the United States or (ii)&nbsp;is not subject to the substantial control of one or more U.S. persons or (2)&nbsp;the income of which is not subject to U.S. federal
income tax on a net income basis. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion does not address the tax treatment of partnerships or other entities or
arrangements that are treated as pass-through entities for U.S. federal income tax purposes or persons that hold their shares of our common stock through partnerships or such other pass-through entities. The tax treatment of a partner in a
partnership or other entity or arrangement that is treated as a pass-through entity for U.S. federal income tax purposes generally will depend upon the status of the partner and the activities of the partnership. A partner in a partnership or an
investor in any other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through
entity, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion is based on current provisions of the Internal Revenue Code, or the Code, existing and proposed U.S.
Treasury regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive
effect. Any such change or differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. We have not sought and will not seek any rulings from the Internal Revenue
Service, or the IRS, regarding the matters discussed below and there can be no assurance that the IRS will not challenge one or more of the tax consequences described herein or that any such challenge would not be sustained by a court. We assume in
this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code, which is generally property held for investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances, including the alternative minimum tax, the Medicare tax on net investment income, the
special tax accounting rules under Section&nbsp;451(b) of the Code, the rules relating to &#147;qualified small business stock,&#148; any U.S. federal tax other than the income tax (including, for example, the estate or gift tax), or any aspects of
U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address
the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code or entities wholly owned by
a &#147;qualified foreign pension fund&#148;; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">persons that own, or are deemed to own, more than 5% of our capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other
integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">persons that hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">U.S. expatriates and former citizens or long-term residents of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local, estate and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions on our common stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As described
in the &#147;Dividend Policy&#148; section above, we do not intend to pay any dividends in cash or property on our common stock to our stockholders in the foreseeable future. Distributions of cash or property, if any, on shares of our common stock
generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and
accumulated earnings and profits, the excess will be treated as a return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s adjusted tax basis in the shares of common stock (not below zero).
Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &#147;Gain on sale, exchange or other taxable disposition of shares of our common stock.&#148; Any such distributions will also be subject to the
discussion below under the section titled &#147;Withholding and information reporting requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to the discussion in
the following two paragraphs in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower
rate specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of shares of our common stock who claims the benefit of an applicable
income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or a successor form) to the applicable withholding agent and satisfy applicable certification and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult
their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may
generally obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dividends that are treated
as effectively connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment
or a fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder delivers a properly executed IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are so connected and satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is
taxed at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also,
under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on sale, exchange or other taxable disposition of shares of our common stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to the discussion below under &#147;Withholding and information reporting requirements&#151;FATCA,&#148; a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder&#146;s sale, exchange or other taxable disposition of shares of our common stock unless: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a
U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of
residence) may also apply as described above in &#147;Distributions on our common stock&#148; also may apply; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the
United States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax
(or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the gain derived from the disposition, which may be offset by certain U.S. source capital losses of
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S.
federal income tax returns with respect to such losses, if any; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market, within the meaning of the
relevant provisions of the Code, and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the five-year period
ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not
apply, then the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on its gain derived from the disposition at the U.S. federal income tax rates applicable to United States persons (as defined in the Code). Generally, a
corporation is a &#147;U.S. real property holding corporation&#148; only if the fair market value of its &#147;U.S. real property interests&#148; (as defined in the Code and applicable U.S. Treasury regulations) equals or exceeds 50% of the sum of
the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a &#147;U.S. real property holding
corporation&#148; for U.S. federal income tax purposes, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules
described above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Backup withholding and information reporting </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on shares of
our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is
not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on shares of our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will comply
with such procedures if it provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or
<FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or other applicable IRS Form <FONT STYLE="white-space:nowrap">W-8),</FONT> or otherwise meets documentary evidence requirements for establishing that it is a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, or otherwise establishes an exemption. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal income tax, as described above in
&#147;Distributions on our common stock,&#148; generally will be exempt from U.S. backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Information reporting and backup withholding
will generally apply to the proceeds of a disposition of shares of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or
<FONT STYLE="white-space:nowrap">non-U.S.,</FONT> unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally,
information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or
operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the
information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated
under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded
or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Withholding and information reporting requirements&#151;FATCA </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax at a rate of 30% on payments of dividends on our
common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the
foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Such withholding may also apply to payments of
gross proceeds of sales or other dispositions of shares of our common stock, although under proposed U.S. Treasury regulations (the preamble to which specifies that taxpayers, including withholding agents, are generally permitted to rely on them
pending finalization), no withholding will apply to payments of gross proceeds. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An
intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the
possible implications of this legislation on their investment in our common stock and the entities through which they hold our shares of common stock, including, without limitation, the process and deadlines for meeting the applicable requirements
to prevent the imposition of the 30% withholding tax under FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>The preceding discussion of material U.S. federal tax considerations is for
prospective investors&#146; information only. It is not tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax
consequences of purchasing, holding, and disposing of our common stock, including the consequences of any proposed changes in applicable laws, as well as tax consequences arising under any state, local,
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> or U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax laws such as estate and gift tax or under any applicable tax treaty. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_21"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and Cowen and Company, LLC, SVB Leerink LLC and Evercore Group, L.L.C., as the representatives of the several underwriters for the offering named
below, have entered into an underwriting agreement with respect to the common stock being offered. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally, and not jointly, agreed to purchase from us the
number of shares of our common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Evercore Group, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">BTIG, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent
and that the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the option to purchase additional shares
described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to
contribute to payments the underwriters may be required to make in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters are offering the shares, subject to prior
sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the
public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares</B>. &nbsp;&nbsp;&nbsp;&nbsp;We have granted to the
underwriters an option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock at the public offering price, less the underwriting discounts and
commissions. This option is exercisable for a period of 30 days. To the extent that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Discounts and Commissions</B>. &nbsp;&nbsp;&nbsp;&nbsp;The following table shows the public offering price, underwriting discounts and
commissions and proceeds, before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With Full<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that the total expenses of the offering, excluding underwriting discounts and commissions,
will be approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and are payable by us. We also have agreed to reimburse the underwriters for up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters propose to offer the shares of our common stock to the public at the public offering price set forth on the cover page of this
prospectus. The underwriters may offer the shares of our common stock to securities dealers at the public offering price less a concession not in excess
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Discretionary Accounts</B>. &nbsp;&nbsp;&nbsp;&nbsp;The underwriters do not intend to confirm sales of the shares to any accounts over which they
have discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Market Information</B>. &nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for shares
of our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In addition to prevailing market conditions, the factors to be considered in these negotiations will
include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the history of, and prospects for, our company and the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our past and present financial information; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an assessment of our management; its past and present operations, and the prospects for, and timing of, our future
revenues; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the present state of our development; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in activities
similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">An active trading market for the shares may not develop. It is also possible that after the offering the shares
will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied to list our common stock on the Nasdaq Global
Market under the symbol &#147;AURA&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Stabilization</B>. &nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, the underwriters may
engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Stabilizing transactions permit bids to purchase shares of our common stock so long as the stabilizing bids do not exceed a
specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Overallotment transactions involve sales by the underwriters of shares of our common stock in excess of the number of
shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is
not greater than the number of shares that they may purchase pursuant to the option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares that the underwriters have the option to
purchase. The underwriters may close out any short position by exercising their option to purchase additional shares and/or purchasing shares in the open market. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been
completed in order to cover syndicate short positions. In determining </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price
at which they may purchase shares through exercise of the option to purchase additional shares. If the underwriters sell more shares than could be covered by exercise of the option to purchase additional shares and, therefore, have a naked short
position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares
in the open market that could adversely affect investors who purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock
originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our
common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor
the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Passive Market
Making</B>. &nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on Nasdaq in accordance with Rule 103 of Regulation M under the
Exchange Act, as amended, during a period before the commencement of offers or sales of common stock and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest
independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, such bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</B>. &nbsp;&nbsp;&nbsp;&nbsp;Pursuant to certain
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, we and our executive officers, directors and substantially all of our other securityholders, have agreed, subject to certain exceptions, not to, and not to cause or direct any
affiliates to, offer, sell, lend, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement (including, without
limitation, the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) that transfers, in whole or in part, directly or
indirectly, the economic consequence of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file with the SEC a registration statement under the Securities Act relating
to, any common stock or securities convertible into or exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC, SVB Leerink LLC and Evercore Group, L.L.C. for a period of 180 days after the date
of the pricing of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to securities
convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of
disposition. The exceptions permit us, among other things and subject to restrictions, to: (i)&nbsp;issue common stock or options pursuant to employee benefit plans, (ii)&nbsp;issue common stock upon exercise of outstanding options or warrants,
(iii)&nbsp;issue securities in connection with acquisitions or similar transactions or (iv)&nbsp;file registration statements on Form <FONT STYLE="white-space:nowrap">S-8.</FONT> The exceptions permit parties to the
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, among other things and subject to restrictions, to: (i)&nbsp;convert outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
convertible preferred stock into shares of common stock in connection with this offering, (ii)&nbsp;if a natural person, transfer as a bona fide gift, by will or intestate succession,
(iii)&nbsp;if a business entity, transfer to an equityholder, if not for value, (iv)&nbsp;if a business entity, in connection with a sale or bona fide transfer in a single transaction of all or substantially all equity interests or to an affiliate,
(v)&nbsp;transfer pursuant to change in control, (vi)&nbsp;if a trust, distribute to beneficiaries of a trust, (vii)&nbsp;transfer pursuant to agreements in effect as of the date of execution where we have an option to repurchase shares upon
termination of the signatory, (viii)&nbsp;enter into transactions related to common stock sold in this offering, (ix)&nbsp;enter into a <FONT STYLE="white-space:nowrap">10b5-1(c)</FONT> trading plan, provided the plan does not permit sales during
the lock-up period, (x)&nbsp;transfer to satisfy tax withholding obligations pursuant to arrangements disclosed herein and (xi)&nbsp;transfer pursuant to a court order or order of regulatory agency. In addition, the
<FONT STYLE="white-space:nowrap">lock-up</FONT> provision will not restrict broker-dealers from engaging in market making and similar activities conducted in the ordinary course of their business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC, SVB Leerink LLC, and Evercore Group, L.L.C., in their sole discretion, may release our common stock and other securities subject
to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. When determining whether or not to release our common stock and other securities from <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements, Cowen and Company, LLC, SVB Leerink LLC, and Evercore Group, L.L.C. will consider, among other factors, the holder&#146;s reasons for requesting the release, the number of shares for which the release is being requested and market
conditions at the time of the request. In the event of such a release or waiver for one of our directors or officers, Cowen and Company, LLC, SVB Leerink LLC and Evercore Group, L.L.C. shall provide us with notice of the impending release or waiver
at least three business days before the effective date of such release or waiver and we will announce the impending release or waiver by issuing a press release at least two business days before the effective date of the release or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Electronic Offer, Sale and Distribution of Shares</B>. &nbsp;&nbsp;&nbsp;&nbsp;A prospectus in electronic format may be made available on the
websites maintained by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. Cowen and Company,
LLC, SVB Leerink LLC and Evercore Group, L.L.C. may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and
selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of
which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Other Relationships</B>. &nbsp;&nbsp;&nbsp;&nbsp;Certain of the underwriters and their affiliates have provided, and may in the future provide,
various investment banking, commercial banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Canada</B>.
&nbsp;&nbsp;&nbsp;&nbsp;The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus
Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations.
Any resale of the common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities
legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to
Section&nbsp;3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT
STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>United Kingdom</B>.
&nbsp;&nbsp;&nbsp;&nbsp;No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct
Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or
supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any form
and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation
(EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Switzerland</B>.
&nbsp;&nbsp;&nbsp;&nbsp;The securities will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the
Swiss Federal Code of Obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>European Economic Area</B>. &nbsp;&nbsp;&nbsp;&nbsp;In relation to each member state of the European Economic
Area, each a member state, no shares have been offered or will be offered pursuant to the offering to the public in that member state prior to the publication of a prospectus in relation to the shares which has been approved by the competent
authority in that member state or, where appropriate, approved in another member state and notified to the competent authority in that member state, all in accordance with the Prospectus Regulation, except that shares may be made to the public in
that member state at any time: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of the underwriters; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">provided that no such offer of shares shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the public&#148; in relation to shares in any member state means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so
as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Hong Kong</B>. &nbsp;&nbsp;&nbsp;&nbsp;The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any
document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances
which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, the CO, or which do not constitute an offer to the public within the meaning
of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the
contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Singapore</B>.
&nbsp;&nbsp;&nbsp;&nbsp;Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold
any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not
circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any
person in Singapore other than: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore,
as modified or amended from time to time, or the SFA) pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any
person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Where the shares are purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">securities or securities-based derivatives contracts (each term as
defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (however described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares
pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based
Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Singapore SFA Product Classification &#150; In connection with Section&nbsp;309B of the
SFA and the CMP Regulations 2018, unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets
products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT
STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Israel</B>. &nbsp;&nbsp;&nbsp;&nbsp;In the State
of Israel this prospectus shall not be regarded as an offer to the public to purchase shares under the Israeli Securities Law, 5728 - 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies
with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728 - 1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed
Investors; or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 - 1968, subject to certain conditions, collectively, the Qualified Investors. The
Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require it to
publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 - 1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our shares to any person within the State of
Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Qualified Investors may have to submit written evidence that they meet
the definitions set out in the First Addendum to the Israeli Securities Law, 5728 - 1968. In particular, we may request, as a condition to be offered shares, that Qualified Investors will each represent, warrant and certify to us and/or to anyone
acting on our behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 - 1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities
Law, 5728 - 1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728 - 1968 and the regulations promulgated thereunder in connection with the offer to be
issued shares; (iv)&nbsp;that the shares that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 - 1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view
to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 - 1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have
to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than offers
made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further
offer of shares on our behalf or on behalf of the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_22"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. The
underwriters are being represented by Cooley LLP, Boston, Massachusetts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_23"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements at December&nbsp;31, 2019 and
December&nbsp;31, 2020, and for each of the two years in the period ended December&nbsp;31, 2020, as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the registration statement in reliance on
Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_24"></A>WHERE YOU
CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File
Number <FONT STYLE="white-space:nowrap">333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</FONT> under the Securities Act with respect to the common stock we are offering by this prospectus. This
prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference
in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other
document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, we will be subject to the informational requirements of the Exchange Act and will file annual,
quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at www.aurabiosciences.com.
Upon completion of this offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and any amendment to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished
to, the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc209588_25"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Index to Financial Statements as of and for the Years Ended December&nbsp;31, 2020 and 2019 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><U>Page</U></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-2</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-3</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_3">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-4</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_4">Statements of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-5</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-6</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-7</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Index to Unaudited Interim Condensed Financial Statements as of June&nbsp;30, 2021 and for the Six&nbsp;Months Ended June&nbsp;30,
2021 and 2020 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><U>Page</U></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_7">Condensed Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-28</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_8">Condensed Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-30</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_9">Condensed Statements of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-31</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_10">Condensed Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-32</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin209588_11">Notes to Condensed Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-33</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">To the Stockholders and the Board of Directors of Aura Biosciences, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have audited the accompanying balance
sheets of Aura Biosciences, Inc. (the Company) as of December&nbsp;31, 2020 and 2019, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#146; deficit and cash flows for the years then ended,
and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2020 and 2019,
and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for
Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test
basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2016. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">August&nbsp;9, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_2"></A>Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Restricted cash and deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Restricted cash and deposits, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 37,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Liabilities, Convertible Preferred Stock, and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Equipment promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Equipment promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Commitments and Contingencies (Note 12)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series A convertible preferred stock, $0.00001 par value, 1,701,141 shares authorized, issued and outstanding
at December&nbsp;31, 2020 and 2019, respectively, and a liquidation preference of $3,403 at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, $0.00001 par value, 3,298,732
shares authorized, issued, and outstanding at December&nbsp;31, 2020 and 2019, respectively, and a liquidation preference of $8,196 at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, $0.00001 par value, 4,325,021
shares authorized, and 4,324,998 shares issued and outstanding at December&nbsp;31, 2020 and 2019, respectively, and a liquidation preference of 5,373 at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series B convertible preferred stock, $0.00001 par value, 22,705,646 shares authorized, and 22,531,819 shares
issued and outstanding at December&nbsp;31, 2020 and 2019, respectively, and a liquidation preference of $37,429 and $35,464 at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock, $0.00001 par value,
58,109,711 shares authorized, issued and outstanding at December&nbsp;31, 2020 and 2019, respectively, and a liquidation preference of $36,150 and $34,023 at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">C-2</FONT> convertible preferred stock, $0.00001 par value,
33,218,192 shares authorized, issued and outstanding at December&nbsp;31, 2020 and 2019, respectively, and a liquidation preference of $14,697 and $13,847 at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">D-1</FONT> convertible preferred stock, $0.00001 par value,
57,878,742 shares authorized, issued and outstanding at December&nbsp;31, 2020 and 2019, respectively, and a liquidation preference of $43,908 and $41,101 at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">D-2</FONT> convertible preferred stock, $0.00001 par value,
24,598,481 shares authorized, and 14,469,710 issued and outstanding at December&nbsp;31, 2020, and a liquidation preference of $10,176 at December&nbsp;31, 2020; no shares authorized, issued or outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Stockholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common stock, $0.00001 par value, 232,697,999 and 208,099,518 shares authorized at December&nbsp;31, 2020 and
2019, respectively, 5,221,829 and 4,466,436 shares issued and outstanding at December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Total Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Total Liabilities, Convertible Preferred Stock, and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 37,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_3"></A>Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands except for share and per share data) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Operating Expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense, including amortization of discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">(Loss) gain from disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,031,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,634,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of
these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_4"></A>Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share data) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="46" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> and <FONT STYLE="white-space:nowrap">C-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">D-1</FONT> and <FONT STYLE="white-space:nowrap">D-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,701,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,298,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,324,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,531,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,327,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,514,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(70,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL">Issuance of Series D convertible preferred stock, net of issuance costs of $314</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,878,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL">Stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,701,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,298,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,324,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,531,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,327,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,878,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,666,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(87,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL">Issuance of Series D convertible preferred stock, net of issuance costs of $93</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,469,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL">Stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:6.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,701,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,298,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,324,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,531,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,327,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,348,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,221,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(116,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:150pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of
these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_5"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payment of issuance costs for Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of Series D convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payments made on equipment promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net (decrease) increase in cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash, cash equivalents and restricted cash at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash, cash equivalents and restricted cash at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental Disclosure of Cash Flow Information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense related to equipment promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">C-1</FONT> issuance costs unpaid at year end</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series D issuance costs unpaid at year end</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of
these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_6"></A>Notes to Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Years Ended December&nbsp;31, 2020 and 2019 </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Description
of Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Aura Biosciences, Inc. (the &#147;Company&#148; or &#147;Aura&#148;) is a clinical-stage biotechnology company leveraging its novel
targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. The Company&#146;s proprietary platform enables the targeting of a broad range of solid
tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. The Company&#146;s VDCs are largely agnostic to tumor type and can recognize a surface marker,
known as HSPGs, that are specifically modified and more broadly expressed on many tumors. The Company is developing <FONT STYLE="white-space:nowrap">AU-011,</FONT> its first VDC product candidate for the first line treatment of primary choroidal
melanoma, a rare disease with no drugs approved. The Company is also developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications and in non-muscle invasive bladder cancer. Aura&#146;s team combines expertise
in cancer cell biology, ophthalmology, and targeted therapies together with experience in the development and commercialization of orphan products for significant unmet medical needs. Aura&#146;s headquarters are located in Cambridge, Massachusetts.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s operations to date have consisted primarily of conducting research and development and raising capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, the successful development and
commercialization of products, fluctuations in operating results and financial risks, need for additional financing or alternative means of financial support or both to fund its current operating plan, protection of proprietary technology and patent
risks, compliance with government regulations, dependence on key personnel and collaborative partners, competition, customer demand, management of growth, and the effectiveness of marketing by the Company. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Liquidity and Going Concern </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Through
December&nbsp;31, 2020, the Company has funded its operations primarily with proceeds from the initial closing and additional closings of its convertible preferred stock financings and through its license agreements. The Company has incurred
recurring losses and negative operating cash flows from operations since its inception, including net losses of $22.2&nbsp;million and $24.2&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively. As of December&nbsp;31,
2020, the Company had cash of $17.4&nbsp;million and an accumulated deficit of $116.9&nbsp;million. The Company expects to continue to generate operating losses for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of the issuance date of these financial statements for the year ended December&nbsp;31, 2020, the Company has raised an additional $87.5&nbsp;million
through convertible preferred stock financings in 2021 and expects that its cash will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the financial statements. The
future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Impact of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2019, a novel strain of coronavirus, which causes the disease known as <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> was reported to have surfaced. Since then, <FONT STYLE="white-space:nowrap">COVID-19</FONT> coronavirus has spread globally. In March 2020, the World Health Organization declared the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak a pandemic and the U.S. government-imposed travel restrictions on travel between the United States, Europe and certain other countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as certain worker shortages have occurred, supply
chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on the Company&#146;s business and operations are uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is monitoring the potential impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on its business and financial statements. The effects
of the public health directives and the Company&#146;s work-from-home policies may negatively impact productivity, disrupt its business, and delay clinical programs and timelines and future clinical trials, the magnitude of which will depend, in
part, on the length and severity of the restrictions and other limitations on its ability to conduct business in the ordinary course. These and similar, and perhaps more severe, disruptions in the Company&#146;s operations could negatively impact
business, results of operations and financial condition, including its ability to obtain financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, the Company has not incurred
impairment losses in the carrying values of its assets as a result of the pandemic and are not aware of any specific related event or circumstance that would require the Company to revise its estimates reflected in the financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will be on its business and
prospects. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or indirectly impact its business, results of operations, financial condition, and liquidity, including planned and future clinical trials and
research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain or treat
it, and the duration and intensity of the related effects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accompanying
financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Use of Estimates
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and
assumptions include the useful lives of property and equipment, deferred tax assets and liabilities and related valuation allowance, fair value of common stock and stock-based compensation, warrant liability and accrued research and development
costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Segment Information </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Operating segments
are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The
Company views its operations and manages its business in one operating segment operating exclusively in the United States. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Cash and Restricted
Cash </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cash consists of standard checking accounts. As of December&nbsp;31, 2020, and 2019, the restricted cash account is comprised of a
$0.1&nbsp;million security deposit held by the lessor for the Company&#146;s facility lease, and a $0.02&nbsp;million deposit that is collateral for the Company&#146;s corporate credit card. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Accounting Standards Codification 820, Fair Value Measurement (&#147;ASC 820&#148;), establishes a fair value hierarchy for instruments measured at fair
value that distinguishes between assumptions based on market data (observable inputs) and the Company&#146;s own assumptions (unobservable inputs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the
circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes
between the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Level&nbsp;1&#151;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Level&nbsp;2&#151;Inputs are inputs other than quoted prices included within Level&nbsp;1 that are observable for the asset
or liability, either directly or indirectly. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Level&nbsp;3&#151;Inputs are unobservable inputs that reflect the Company&#146;s own assumptions about the assumptions
market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value
requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on
the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in
bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Property and
equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the assets. Upon sale or retirement, the cost and accumulated depreciation is eliminated from their respective accounts and the resulting
gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. The estimated useful lives of the Company&#146;s respective assets are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Useful&nbsp;Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equipment capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs for capital assets not yet placed into service are capitalized as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">construction-in-progress</FONT></FONT> and depreciated in accordance with the above guidelines once placed into service. Upon retirement or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
disposal of property and equipment, the cost and related accumulated depreciation are removed from the balance sheet and any gain or loss is reflected in the statements of operations and
comprehensive loss. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company reviews all long-lived assets for impairment whenever events or circumstances indicate the carrying amount of such assets may not be
recoverable. Recoverability of assets to be held and used is measured by comparison of the carrying value of the assets to the future undiscounted net cash flows expected to be generated by the asset. If such asset is considered to be unrecoverable,
the impairment recognized is measured by the difference between the estimated fair value of the asset and its carrying value. The Company did not recognize any material impairments during the years ended December&nbsp;31, 2020 or 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and
development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation,
third-party license fees, and external costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials. The Company accrues costs for clinical trial
activities and contract manufacturers based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations, clinical study sites, contract manufacturers, laboratories,
consultants, or other vendors that perform the activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-refundable</FONT> prepayments for goods or services
that will be used or rendered for future research and development activities are deferred. Such amounts are expensed as the goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered,
or the services rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs incurred in obtaining technology licenses are recognized as research and development expense as incurred if the
technology licensed has not reached technological feasibility and has no alternative future uses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Patent and Trademark Costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All patents and trademark related costs incurred in connection with filing and prosecuting patent and trademark applications are expensed as incurred due
to uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Leases are classified at their
inception as either operating or capital leases. The Company recognizes rent expense for its facility lease, which is classified as an operating lease, on a straight-line basis over the respective lease term, inclusive of rent escalation provisions
and rent holidays. The difference between rent payments made and straight-line rent expense is recorded as deferred rent. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the
Company&#146;s financial statements and/or tax returns. Deferred tax assets and liabilities are based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit
carryforwards using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all the
deferred tax asset will not be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company provides reserves related to uncertain tax positions when management determines the related
tax benefit is not more likely than not to be realized. The determination as to whether the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as the consideration of the available facts and circumstances. The Company has no
reserves related to uncertain tax positions as of December&nbsp;31, 2020 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest and penalty charges, if any, related to uncertain tax
positions would be classified as income tax expense in the accompanying statements of operations and comprehensive loss. As of December&nbsp;31, 2020, and 2019, the Company had no accrued interest related to uncertain tax positions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Deferred Offering Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company
capitalizes certain legal, professional accounting and other third-party fees that are directly associated with <FONT STYLE="white-space:nowrap">in-process</FONT> preferred stock or common stock financings as deferred offering costs until such
financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible preferred stock or in stockholders&#146; deficit as a reduction of additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of
operations and comprehensive loss. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Convertible Preferred Stock Classification </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company records all convertible preferred stock upon issuance at its respective fair value or original issuance price less issuance costs. The
Company classifies its convertible preferred stock outside of stockholders&#146; deficit as the redemption of such shares is outside the Company&#146;s control. The Company does not adjust the carrying values of the convertible preferred stock to
redemption value unless and until it becomes probable that the instrument will become redeemable. As of December&nbsp;31, 2020, and 2019, the Company&#146;s convertible preferred stock was not adjusted to redemption value. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company
recognizes stock-based compensation expense for all stock-based awards based on their grant date fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company recognizes compensation
expense over the requisite service period, which is generally the vesting period of the award. For awards that include performance-based vesting conditions, expense is recognized using the accelerated attribution method when the performance
condition is deemed to be probable of being satisfied. The Company accounts for forfeitures as they occur. The Company determines the fair value of restricted stock awards in reference to the fair value of its common stock less any applicable
purchase price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which
requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and the
Company&#146;s expected dividend yield. As there is no public market for its common stock, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline companies that have issued options
with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. The Company expects to continue to do so until such time as it has
adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#146;s stock options granted to employees has been determined utilizing the &#147;simplified&#148; method, using the midpoint between
the vesting date and the contractual term. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.
The Company has not paid, and does not anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company classifies stock-based compensation expense in its statements of operations and
comprehensive loss in the same manner in which the award recipient&#146;s cash compensation costs are classified. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Determination of the Fair
Value of Common Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock. The
Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the
&#147;Practice Aid&#148;), to estimate the fair value of its common stock. The common stock valuation is based on the Company&#146;s enterprise value determined utilizing various methods including the option-pricing method (&#147;OPM&#148;) or a
hybrid of the probability-weighted expected return method (&#147;PWERM&#148;) and the OPM. Each valuation methodology includes estimates and assumptions that require the Company&#146;s judgment. These estimates and assumptions include a number of
objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#146;s common stock at the time of, and
the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company accounts for
warrants on capital stock based on guidelines provided in ASC Topic 815, Derivatives and Hedging&#151;Contracts in Entity&#146;s Own Equity (&#147;ASC 815&#148;), which provides guidance on contracts that are settled in the Company&#146;s own shares
as either a liability or as an equity instrument depending on the warrant agreement. The Company uses the Black-Scholes pricing model, depending on the applicable terms of the warrant agreement, to value the warrants. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Net Loss per Share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net loss per share
attributable to common stockholders is computed by using the <FONT STYLE="white-space:nowrap">two-class</FONT> method, which is an earnings allocation formula that determines loss per share for the holders of the Company&#146;s common stock and
participating securities. All series of preferred stock contain participation rights in any dividend declared or accumulated by the Company and are deemed to be participating securities. Income available to common stockholders and participating
convertible preferred stock is allocated to each share on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual
obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Diluted net income per share is computed using the more dilutive of (a)&nbsp;the <FONT STYLE="white-space:nowrap">two-class</FONT> method, or
(b)&nbsp;the <FONT STYLE="white-space:nowrap">if-converted</FONT> method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The
weighted-average number of common stock included in the computation of diluted loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, and convertible preferred stock. Common stock
equivalent shares are excluded from the computation of diluted loss per share if their effect is antidilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s convertible
preferred stock contractually entitles the holders of such shares to participate in dividends. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the
Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed
to have been issued if their effect is anti-dilutive. The Company reported a net loss to common stockholders for the years ended December&nbsp;31, 2020 and 2019, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <FONT
STYLE="white-space:nowrap">non-owner</FONT> sources. For the years ended December&nbsp;31, 2020 and 2019, comprehensive loss was equal to net loss. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value Measurement (Topic 820): Disclosure Framework
&#150; Changes to the Disclosure Requirements for Fair Value Measurement (&#147;ASU <FONT STYLE="white-space:nowrap">2018-13&#148;).</FONT> The new standard removes certain disclosures, modifies certain disclosures and adds additional disclosures
related to fair value measurement. The Company adopted this pronouncement on January 1, 2020, which did not have a material impact on the Company&#146;s financial statements. </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Recently Issued Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I> <I>(Topic 842) (&#147;ASC 842</I>&#148;<I>)</I>,
which amends the existing accounting standards for leases. The guidance requires lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding leasing arrangements. In July
2018, the FASB issued additional guidance, which offers a transition option to entities adopting the new lease standard. Under the transition option, entities can elect to apply the new guidance using a modified retrospective approach at the
beginning of the year in which the new lease standard is adopted, rather than to the earliest comparative period presented in their financial statement and provides for certain practical expedients. The guidance is effective for reporting periods
beginning after December&nbsp;15, 2020 for private companies with early adoption permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has completed its assessment of the impact
ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will have on its financial position, results of operations, and related footnotes. The adoption of the new standard will result in the recognition of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities of approximately $0.5&nbsp;million and $0.6&nbsp;million, respectively, on the Company&#146;s balance sheet as of January&nbsp;1, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments &#151; Credit Losses (Topic 362):
Measurement of Credit Losses on Financial Statements</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value
increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC <FONT STYLE="white-space:nowrap">825-10,</FONT> Financial Instruments-Overall, applied on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">instrument-by-instrument</FONT></FONT> basis for eligible instruments. For public entities that are Securities and Exchange Commission (&#147;SEC&#148;) filers, excluding entities
eligible to be smaller reporting companies, ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> is effective for annual periods beginning after December&nbsp;15, 2019, including interim periods within those fiscal years. For all other entities, ASU <FONT
STYLE="white-space:nowrap">2016-13</FONT> is effective for annual periods beginning after December&nbsp;15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect this standard to have a
material impact on its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Income
Taxes-Simplifying the Accounting for Income Taxes </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> eliminates certain exceptions related to the approach for intraperiod tax
allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted
changes in tax laws or rates and clarifies the accounting for transactions that result in a <FONT STYLE="white-space:nowrap">step-up</FONT> in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020
and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
changes to be made retrospectively. The Company is currently assessing the impact of this standard on its financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Fair Value of Assets and Liabilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table
presents information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&nbsp;31, 2020 and
December&nbsp;31, 2019 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;prices<BR>active&nbsp;markets<BR>for identical<BR>assets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Liability</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrant Liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;prices<BR>active&nbsp;markets<BR>for identical<BR>assets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Liability</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrant Liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2020, the fair value of the warrant liability was determined based on Level&nbsp;3 inputs and
utilizing the Black-Scholes option pricing model (see Note 10). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2020 and 2019, there were no transfers
into or out of Level&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table set forth a summary of changes in the fair value of the (&#147;Series B Warrants&#148;), which
represents a recurring fair value measurement that is classified within Level&nbsp;3 of the fair value hierarchy. Changes in fair value are recognized in other (expense) income as &#147;Change in fair value of warrant liability&#148; in the
Company&#146;s statements of operations and comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><U>Series B Warrants (173,827 warrants)</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Property and Equipment, Net </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2020 and 2019, property and equipment consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assets under construction</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equipment capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less&#151;accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the years ended December&nbsp;31, 2020 and 2019, depreciation expense was $0.8&nbsp;million and $0.5&nbsp;million,
respectively. For the years ended December&nbsp;31, 2020 and 2019, $0.02&nbsp;million of depreciation expense was attributable to the equipment capital lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Prepaid Expenses and Other Current Assets </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At
December&nbsp;31, 2020 and 2019, prepaid expenses and other current assets consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid insurance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid license agreements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2020 and 2019, accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Convertible Preferred Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company had 1,701,141 authorized, issued and outstanding shares of Series A convertible preferred stock (&#147;Series
A&#148;), 3,298,732 authorized, issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">A-1&#148;),</FONT> 4,325,021 authorized shares and
4,324,998 issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">A-</FONT> 2&#148;) and, 22,705,646 authorized shares and 22,531,819 issued and
outstanding shares of Series B convertible preferred stock (&#147;Series B&#148;), 58,109,711 authorized, issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">C-1&#148;),</FONT> 33,218,192 authorized, issued and outstanding shares of Series
<FONT STYLE="white-space:nowrap">C-2</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">C-2&#148;,</FONT> together with Series <FONT STYLE="white-space:nowrap">C-1,</FONT> &#147;Series C&#148;), 57,878,742 authorized,
issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">D-1&#148;)</FONT> and 24,598,481 authorized shares and 14,469,710 issued and outstanding
shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">D-2&#148;,</FONT> together with Series <FONT STYLE="white-space:nowrap">D-1,</FONT> &#147;Series D,&#148; and
together with the Series C and Series B, collectively the &#147;Senior Preferred Stock&#148;). All series of convertible preferred stock are collectively referred to as Preferred Stock, each with a par value of $0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, the Company had 1,701,141 authorized, issued and outstanding shares of Series A stock, 3,298,732 authorized, issued and
outstanding shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> stock, 4,325,021 authorized shares and 4,324,998 issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> stock, 22,705,646 authorized shares and
22,531,819 issued and outstanding shares of Series B stock, 58,109,711 authorized, issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> stock, 33,218,192 authorized, issued and outstanding shares of Series <FONT
STYLE="white-space:nowrap">C-2</FONT> stock, and 57,878,742 authorized, issued and outstanding shares of Series D stock, each with a par value of $0.00001 per share. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Series <FONT STYLE="white-space:nowrap">D-2</FONT> Offering </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;25, 2020, the Company entered into the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Purchase Agreement (&#147;Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Agreement&#148;) with certain investors to sell up to 24,598,481 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> stock at a purchase price of $0.6911 per share. The Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Agreement provides for two closings, the first on October&nbsp;1, 2020 and the second upon the achievement or waiver of certain milestone events. The Company sold 14,469,710 shares of Series <FONT
STYLE="white-space:nowrap">D-2</FONT> stock on October&nbsp;1, 2020 at the first tranche closing for gross proceeds of $10.0&nbsp;million. The second tranche closing, contingent upon the achievement or waiver of certain milestones, has occurred in
2021 (see Note 16). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs incurred in connection with the Series <FONT STYLE="white-space:nowrap">D-2</FONT> offering totaled $0.1&nbsp;million
during the year ended December&nbsp;31, 2020 and were recorded as a reduction to Series <FONT STYLE="white-space:nowrap">D-2</FONT> convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company evaluated the tranche rights pursuant to the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Agreement and determined the tranche rights
did not represent a freestanding financial instrument as they are not legally detachable from the Series <FONT STYLE="white-space:nowrap">D-2</FONT> shares issued in the first tranche. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The rights and privileges of the Company&#146;s Preferred Stock are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><U>Voting</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Except as otherwise required by law or
by other provisions, holders of the Preferred Stock vote together with the holders of common stock as a single class. Holders of Preferred Stock may cast the number of votes equal to the number of shares of common stock to which such shares of
Preferred Stock are convertible into. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Series C and D Dividends: </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From and after the
date of the issuance of any shares of Series <FONT STYLE="white-space:nowrap">C-1,</FONT> Series <FONT STYLE="white-space:nowrap">C-2,</FONT> Series <FONT STYLE="white-space:nowrap">D-1</FONT> and Series <FONT STYLE="white-space:nowrap">D-2,</FONT>
dividends at the annual rate of seven percent (7%) per annum of the original share price per share accrue on such shares of Series <FONT STYLE="white-space:nowrap">C-1,</FONT> Series <FONT STYLE="white-space:nowrap">C-2,</FONT> Series <FONT
STYLE="white-space:nowrap">D-1,</FONT> and Series <FONT STYLE="white-space:nowrap">D-2.</FONT> Dividends accrue from day to day, whether or not declared, and are cumulative, but not compounding. Such dividends are only payable when and if declared
by the Board or in the event of a Deemed Liquidation Event (as defined in the amended and restated Certificate of Incorporation). No other dividends may be declared or paid on any other class of stock unless the holders of the shares of Series D
then outstanding first receive, or simultaneously receive, their applicable dividend. For the year ended December&nbsp;31, 2020, $5.9&nbsp;million, $2.6&nbsp;million, $3.9&nbsp;million and $0.2&nbsp;million of cumulative dividends on Series <FONT
STYLE="white-space:nowrap">C-1,</FONT> Series <FONT STYLE="white-space:nowrap">C-2,</FONT> Series <FONT STYLE="white-space:nowrap">D-1</FONT> and Series <FONT STYLE="white-space:nowrap">D-2,</FONT> respectively, are included in the liquidation
preference amount indicated on the balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Series B Dividends: </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From and after the date of the issuance of any shares of Series B, dividends at the annual rate of $0.0869645 per share accrue on such shares of Series
B. Dividends accrue from day to day, whether or not declared, and are cumulative, but not compounding. Such dividends are only payable when and if declared by the Company&#146;s Board or in the event of a Deemed Liquidation Event (as defined in the
amended and restated Certificate of Incorporation). No other dividends may be declared or paid on any other class of stock unless the holders of the shares of Series B then outstanding first receive, or simultaneously receive, their applicable
dividend. For the year ended December&nbsp;31, 2020, $9.4&nbsp;million of cumulative dividends on Series B are included in the liquidation preference amount indicated on the balance sheet. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Series A Dividends </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From and after the date of
the issuance of Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> and Series <FONT STYLE="white-space:nowrap">A-2,</FONT> if the Company declares, pays or sets aside, on the same date, a dividend on shares of more than one class or
series of capital stock of the Company, the dividend payable to the holders of Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock shall be calculated based
upon the dividend on the class or series of capital stock that would result in the highest dividend. No other dividends, or dividends on common stock payable in shares of common stock, may be declared or paid unless the holders of Series A, Series <FONT
STYLE="white-space:nowrap">A-1,</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> then outstanding first receive, or simultaneously receive, their applicable dividend. As of December&nbsp;31, 2020, no dividends have been declared on the
common stock or the convertible preferred stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of a Deemed Liquidation Event, as defined in the Company&#146;s amended and restated Certificate of Incorporation, the assets of the Company
will be distributed first to the holders of Series D. The holders of Series D will receive, in preference to all other stockholders, an amount equal to the sum of the Series D original issue price (equal to the cash price paid per share of $0.6911),
plus unpaid dividends on such shares. Next, the holders of Series C will receive, in preference to all stockholders other than the Series D holders, an amount equal to the sum of the Series C original issue price plus unpaid dividends on such
shares. Next, the holders of Series B will receive, in preference to the holders of Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series <FONT STYLE="white-space:nowrap">A-2</FONT> and common stock, an amount equal to the sum of the
Series B original issue price plus unpaid dividends on such shares. Next, the holders of Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> will receive, in preference to the holders
of common stock, an amount equal to the greater of their applicable liquidation preference or what they would have received had their shares converted into common stock. If the proceeds available are not sufficient to satisfy the full liquidation
preference, the entire proceeds are to be distributed <FONT STYLE="white-space:nowrap">pro-rata</FONT> among the Series D holders in proportion to the full preferential amount the Series D holders are entitled to receive. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Conversion </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Senior Preferred Stock
converts into common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. Each share of Series B, Series <FONT STYLE="white-space:nowrap">C-1,</FONT> Series
<FONT STYLE="white-space:nowrap">C-2,</FONT> Series <FONT STYLE="white-space:nowrap">D-1,</FONT> and Series <FONT STYLE="white-space:nowrap">D-2</FONT> is convertible into the number of shares of common stock as is determined by dividing the
respective original issue price by the conversion price in effect at the time of conversion. The Series <FONT STYLE="white-space:nowrap">D-1</FONT> and Series <FONT STYLE="white-space:nowrap">D-2</FONT> conversion price is set at $0.6911 per share,
Series <FONT STYLE="white-space:nowrap">C-1</FONT> conversion price is set at $0.5213 per share, the Series <FONT STYLE="white-space:nowrap">C-2</FONT> conversion price is set at $0.36491 per share and the Series B conversion price is set at
$1.24235 per share; none represents a beneficial conversion feature. Subject to certain exceptions, the Senior Preferred Stock has the benefit of anti-dilution protection on a weighted-average basis in the event that the Company sells stock at less
than the applicable conversion price per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each share of Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> was originally
convertible into the number of shares of common stock determined by dividing the respective Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> original issue price by the conversion price in effect at the time of conversion. The Series
A conversion price was originally equal to $2.00 per share and the Series <FONT STYLE="white-space:nowrap">A-1</FONT> conversion price was originally equal to $2.4847 per </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
share. As Series <FONT STYLE="white-space:nowrap">A-2</FONT> was sold at $1.24235 per share, less than the per share prices of Series A and Series <FONT STYLE="white-space:nowrap">A-1,</FONT>
anti-dilution protections were triggered. Pursuant to the anti-dilution protection terms, on February&nbsp;24, 2015, the Series A conversion price was reduced from $2.00 to $1.8191 per share of common stock and the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> conversion price was reduced from $2.4847 to $2.1898 per share of common stock and, therefore, the Series A conversion ratio was changed from 1:1 to 1:1.099 and the Series
<FONT STYLE="white-space:nowrap">A-1</FONT> conversion ratio was changed from 1:1 to 1:1.135. The Company evaluated Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> with the updated conversion ratios and determined that there was no
beneficial conversion feature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-2</FONT> converts into common stock on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. The Series <FONT STYLE="white-space:nowrap">A-2</FONT> conversion price is set at $1.24235 per share and does not represent a beneficial conversion feature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">According to the terms of the Company&#146;s amended and restated certificate of incorporation, in the event that the applicable conversion price for
any series of Senior Preferred Stock is reduced, then the applicable conversion price for each series of Series A convertible preferred stock shall be uniformly and concurrently reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each share of Preferred Stock will automatically convert into common stock upon (a)&nbsp;the occurrence of an event, specified by vote or written
consent of certain stockholders or (b)&nbsp;the completion of a public stock offering involving a price per share of common stock of not less than $1.554975 per share, subject to certain adjustments, where such offering results in aggregate gross
proceeds to the Company of at least $50.0&nbsp;million and the common stock is listed for trading on either the New York Stock Exchange or the Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company must reserve and keep available out of its authorized but unused capital stock such number of authorized shares of common stock to
sufficiently effect the conversion of all outstanding Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In considering the features of the convertible preferred stock, the Company
determined that none of the features, including the conversion features, requires bifurcation during 2020 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has 232,697,999 and 208,099,518 authorized shares of common stock, par value $0.00001 per share, of which 5,221,829 and 4,666,436 shares were
issued and outstanding as of December&nbsp;31, 2020 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Stock-Based Compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On January&nbsp;15, 2009, the Company&#146;s Board adopted the 2009 Long-Term Incentive Stock Option Plan (the &#147;2009 Plan&#148;) for the issuance of
stock-based compensation to both employees and <FONT STYLE="white-space:nowrap">non-</FONT> employees. The awards under this plan typically vest over a 24, 36 or <FONT STYLE="white-space:nowrap">48-month</FONT> period depending on the option
agreement and have a <FONT STYLE="white-space:nowrap">10-year</FONT> term. On December 12, 2018, the 2009 Plan expired, and the Company adopted the Aura Biosciences, Inc. 2018 Equity Incentive Plan (the &#147;2018 Plan&#148; and collectively with
the 2009 Plan, &#147;the Plans&#148;). No options were modified in conjunction with the expiration of the 2009 Plan. The options granted under the 2009 Plan continue to be outstanding in accordance with their original terms. The 2018 Plan will
expire in 2028. Under the 2018 Plan, Aura may grant incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted and unrestricted stock awards and stock rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Board is authorized to administer the 2018 Plan. In accordance with the provisions of the 2018 Plan, the Board determines the terms of Aura options
and other awards issued pursuant thereto, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">which employees, directors and consultants shall be granted awards; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares of common stock subject to options and other awards; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the exercise price of each option, which generally shall not be less than fair market value of the common stock on the date
of grant; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the termination or cancellation provisions applicable to options; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms and conditions of other awards, including conditions for repurchase, termination or cancellation, issue price and
repurchase price; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all other terms and conditions upon which each award may be granted in accordance with the 2018 Plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the Board or any committee to which the Board delegates authority may, with the consent of the affected plan
participants, <FONT STYLE="white-space:nowrap">re-price</FONT> or otherwise amend outstanding awards consistent with the terms of the 2018 Plan. On December 12, 2018, the Board approved an increase to the 2018 Plan available option pool of 51,759
options. With this increase and the transfer of the available options from the 2009 Plan, there were 309,839 options available for grant under the 2018 Plan at December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes stock option activity under the 2018 Plan for the year ended December&nbsp;31, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,073,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,378,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(555,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cancelled/Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,178,857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding at December&nbsp;31,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,717,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,426,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The weighted-average grant date fair value of stock options granted during the years ended December 31, 2020 and 2019
was $0.20 and $0.18 per share, respectively. The total intrinsic value of options exercised was $0.02&nbsp;million and $0 for the years ended December&nbsp;31, 2020 and 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, the total fair value of stock options vested during the years ended December 31, 2020 and 2019 was $0.7&nbsp;million and $0.5&nbsp;million,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has elected to use the Black-Scholes option pricing model to determine the fair value of options granted and generally
recognizes the compensation cost of stock-based awards on a straight-line basis over the vesting period of the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The determination of the fair
value of stock-based payment awards utilizing the Black-Scholes option pricing model is affected by the estimated fair value of the Company&#146;s common stock and a number of other assumptions, including expected volatility, expected life,
risk-free interest rate, and expected dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The fair value of the stock options issued as of December&nbsp;31, 2020 and 2019 was measured with
the following weighted-average assumptions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility of the underlying stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.04</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.52</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company recorded stock-based compensation as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2020, there was $1.9&nbsp;million of unrecognized compensation expense related to stock options,
which is expected to be recognized over a weighted-average period of 1.89 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Series B Warrants </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2015 and May 2015, the Company issued warrants to purchase 1,650,098 and 887,536 shares of Series B convertible preferred stock,
respectively, at an exercise price of $1.24235 per share. Each Series B Warrant was immediately exercisable and expires ten years from the original date of issuance. Pursuant to FASB ASC Topic 480, <I>Distinguishing Liabilities from Equity</I>, the
Series B Warrants were classified as a liability and are <FONT STYLE="white-space:nowrap">re-measured</FONT> to fair value at each balance sheet date and immediately prior to exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A total of 173,827 of the Series B Warrants remained outstanding at December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The warrants were valued using the Black-Scholes option pricing model. The estimated fair value of the warrants and the significant assumptions used
were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series B Warrants</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.69</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January
2012, the Company adopted the Aura Biosciences 401(K) Profit Sharing Plan and Trust (the &#147;401(k) Plan&#148;) for its employees, which is designed to be qualified under Section&nbsp;401(k) of the Internal Revenue Code. Eligible employees are
permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company makes matching contributions of 100% of the first 6% of employee contributions. The Company made matching contributions in the amount of
$0.2&nbsp;million and $0.2&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. Commitments and Contingencies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Lease Commitments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company leases
its facility under a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease and there is a security deposit of $0.1&nbsp;million held by the lessor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company recognizes rent expense, including escalation charges, on a straight-line basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On October 17, 2019, the Company executed an amendment to the facility lease to extend the lease term by a period of 30 months from February&nbsp;1,
2020 to July&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Rent expense under this operating lease was $0.3&nbsp;million for each of the years ended December&nbsp;31, 2020 and
2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Future minimum payments under the remaining term of the lease as of December&nbsp;31, 2020, are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total minimum payments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Laser Purchasing Commitment </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On April&nbsp;5, 2019, the Company entered into a purchase agreement for equipment with future commitments payable in three installments of <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>0.2&nbsp;million each. The first two installments of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.2&nbsp;million were paid by the Company in April 2019 and August 2019, respectively. The
last installment of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.2&nbsp;million will be due upon shipment of the initial order, which is expected to occur in 2021. The Company will receive 20 laser systems upon completion of the final
installment payment. Upon receipt of the laser systems, the Company will assess whether the laser systems have an alternative future use and, if so, will capitalize the lasers as a component of fixed assets.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>License Agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has
entered into the following key agreements that relate to the core technology under development: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">LI-COR</FONT>
Exclusive License and Supply Agreement </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2014, the Company entered into an Exclusive License and Supply Agreement, or the <FONT
STYLE="white-space:nowrap">LI-COR</FONT> Exclusive License Agreement with <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc. <FONT STYLE="white-space:nowrap">(&#147;LI-COR&#148;)</FONT> for the license of IRDye 700DX and related licensed patents
for the treatment and diagnosis of ocular cancers in humans, and as amended in January 2016, July 2017, April 2018 and April 2019. <FONT STYLE="white-space:nowrap">LI-COR</FONT> is a related party owning shares of the Company&#146;s capital stock.
The <FONT STYLE="white-space:nowrap">LI-COR</FONT> Exclusive License Agreement required a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront license issue fee of $0.1&nbsp;million and requires aggregate milestone payments of up to
$0.2&nbsp;million upon certain regulatory and development milestones. The Company is also required to pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> <FONT STYLE="white-space:nowrap">low-single</FONT> digit royalties on net sales. The term of the
<FONT STYLE="white-space:nowrap">LI-COR</FONT> Exclusive Agreement expires on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the longer of (i)&nbsp;ten years from the first
commercial sale of a licensed product in such country and (ii)&nbsp;the last to expire valid claim in such country The Company recognized $0.2&nbsp;million and $0.8&nbsp;million of expenses related to this agreement and related amendments for the
years ended December&nbsp;31, 2020 and 2019, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">LI-COR</FONT>
<FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License and Supply Agreement </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2014, the Company entered into a <FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> License Agreement (the &#147;2014 <FONT STYLE="white-space:nowrap">Non-</FONT> Exclusive Agreement&#148;) for <FONT STYLE="white-space:nowrap">LI-COR</FONT> to supply IRDye 700DX to the Company for the
treatment and diagnosis of <FONT STYLE="white-space:nowrap">non-ocular</FONT> cancers in humans. Under the 2014 <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Agreement, the Company paid a license issue fee of $0.03&nbsp;million on the
effective date. The Company must also pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> a <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.03&nbsp;million per each licensed
product upon <FONT STYLE="white-space:nowrap">pre-IND</FONT> designation, as defined, of such licensed product. During the term, the Company must pay LI-COR a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
low-single digit percentage royalty on net sales. <FONT STYLE="white-space:nowrap">LI-COR</FONT> receives 10% of all sublicensee income within 30 days of the Company&#146;s receipt from the
sublicensee. The 2014 <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Agreement also required the Company to make certain payments upon the achievement of specified development and commercial milestones of up to $0.4 million in the aggregate.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Life Technologies Corporation </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
December 2014, the Company entered into a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual license agreement with Life Technologies Corporation (&#147;Life Technologies&#148;), which allows for five licensed products. Under this
agreement the Company is required to pay an initial license fee of $0.1&nbsp;million for each product. An annual development fee of $0.1&nbsp;million is due within a year from the payment of the initial license fee and due annually until the earlier
of (i)&nbsp;payment of a commercialization fee or (ii)&nbsp;all development work is terminated. The commercialization fee is a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT
STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.3&nbsp;million due upon receipt of approval of a licensed product. In the event of a change of control, there will be a change of control fee of $0.2&nbsp;million. During each of the years
ended December&nbsp;31, 2020 and 2019, the Company recognized $0.1&nbsp;million of expenses related to this agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>National Institute of
Health (NIH)-Biologic Materials License Agreement </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2010, the Company entered into a Biologic Materials License Agreement with
National Institutes of Health (the &#147;NIH&#148;) for a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to use materials described in Schiller et al., Virology 2004 Apr.10, <FONT STYLE="white-space:nowrap">321(2):205-16,</FONT> which
required a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issuance fee of $0.02&nbsp;million. No future milestone payments or royalties are due under this agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>National Institute of Health (NIH)-Collaboration Research and Development Agreement </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2011, the Company entered into a Collaboration Research and Development Agreement (&#147;CRADA&#148;) with Dr.&nbsp;John Schiller at the NIH, for
a period of two years with the rights to an exclusive license to all technology generated within the collaboration. Under the agreement, the Company was required to make annual payments each year to fund the research activities, with the first
payment due within 30 days of the effective date and subsequent payments due within 30 days of the anniversary date. This agreement was further amended in 2012, 2013, 2014, 2015, 2016, 2018 and most recently in September of 2020. From 2011-2020, the
Company paid an aggregate of $0.3&nbsp;million in research collaboration fees, $0.04&nbsp;million of which was paid in 2020 and $0.04&nbsp;million was paid in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2020, the Company executed the seventh amendment to the CRADA agreement. In this amendment the term of this agreement is extended until
September&nbsp;30, 2022, and the Company must pay $0.03&nbsp;million on the tenth anniversary of the CRADA agreement which will occur in September of 2021. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>National Institute of Health (NIH)-Exclusive Patent License Agreement </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2013, the Company entered into an exclusive patent license agreement (the &#147;NIH Exclusive License Agreement&#148;) with the NIH that required the
Company to pay a license issue royalty fee of $0.1&nbsp;million and reimburse the NIH for any patent expenses incurred. Under the agreement, the Company is required to make low single-digit percentage royalty payments based on specified levels of
annual net sales of licensed products subject to certain specified reductions. The Company is required to make development and regulatory milestone payments up to $0.7&nbsp;million in the aggregate and sales milestone payments up to
$0.6&nbsp;million in the aggregate. The Company is also required to pay NIH a <FONT STYLE="white-space:nowrap">mid-single</FONT> to low teen-digit percentage of any sublicensing revenue the Company receives. Additionally, the Company&#146;s payment
obligations to NIH are subject to an annual minimum royalty payment of low five figures. As of December&nbsp;31, 2020, the Company has paid NIH approximately $0.3&nbsp;million in aggregate milestones under the NIH Exclusive License Agreement. In
addition to milestones under the agreement, the Company reimburses the NIH for any patent prosecution costs incurred. As of December&nbsp;31, 2020, the Company has reimbursed the NIH approximately $0.3&nbsp;million in aggregate. The Company accrued
$0.02&nbsp;million and $0.02&nbsp;million in patent licensing reimbursement fees for 2020 and 2019, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Inserm </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In November 2009, the Company entered into an exclusive, royalty-bearing license agreement with Inserm-Transfert of France for use of its patents. The
agreement expires on a country by country basis based on the last to expire of any patent encompassed within the scope of the patent rights or 10 years from the date of the first commercial sale by the Company, whichever is later. There are
potential milestone payments of up to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.5&nbsp;million (up to $0.5&nbsp;million at December&nbsp;31, 2020) in the aggregate associated with this agreement. The IND filing milestone of <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>0.01&nbsp;million was accrued in 2016 and paid in 2017 by the Company. The milestones for the successful Phase I, II and III clinical trials are based on receiving a final report and achieving the
primary endpoints defined in that trial and those milestones have not been achieved as of December 31, 2020. Upon the sublicense by the Company of a product for which royalties are payable under this agreement, low- to mid-single-digit royalty
payments would be due by the Company. If the Company sublicenses the delivery platform for use with multiple drugs, low- to mid-teen payments on receipts would be due by the Company. The <FONT STYLE="white-space:nowrap">non-milestone</FONT> payments
in this agreement are subject to an anti-stacking clause. The Company did not incur any expense in the years ended December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Clearside </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2019, the Company entered
into a License Agreement with Clearside Biomedical, Inc. (&#147;Clearside&#148;) for the license of Clearside&#146;s Suprachorodial Microneedle Technology for use in an upcoming clinical trial expected to begin in 2020. Upon execution of the License
Agreement, the Company paid Clearside an upfront payment of $0.1&nbsp;million which was expensed as incurred. Under the Clearside License Agreement, the Company is required to pay milestones up to $21.0&nbsp;million in the aggregate to Clearside
upon the achievement of specified regulatory and development milestones, and upon the achievement of certain commercial sales milestones The Company is also required to pay low to <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalties on
net sales. If the Company sublicenses a product for which royalties are payable, then the Company is required to pay the greater of 20% received or low single digit royalties on net sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Clearside License Agreement expires on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis
upon the later of the last to expire patent or ten years from the date of the first commercial sale of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Net Loss Per Share </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common
stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are
antidilutive given the net loss of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has calculated basic and diluted loss per share for the years ended December&nbsp;31, 2020
and 2019 as follows (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: Accruals of dividends of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,031,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,634,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following potentially dilutive securities were excluded from the computation of the diluted net loss per share for
the periods presented because their effect would have been antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preferred stock on an if converted basis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,146,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,676,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,717,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,073,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrants to purchase preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total potential dilutive shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217,037,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198,923,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company
has not recorded any net tax provision for the periods presented due to the losses incurred and the need for a full valuation allowance on net deferred tax assets. The difference between the income tax expense at the U.S. federal statutory rate and
the recorded provision is primarily due to the valuation allowance provided on all deferred tax assets. The Company&#146;s loss before income tax for the periods presented was generated entirely in the United States: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A reconciliation of the federal statutory income tax rate to the Company&#146;s effective tax rate as of December&nbsp;31, 2020 and 2019 is as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tax provision at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Permanent Items</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">US tax rate change</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease in valuation reserve</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Temporary differences that give rise to significant deferred tax assets (liabilities) as of
December&nbsp;31, 2020 and 2019 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 27,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 21,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Capitalized research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciable Assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company had federal gross operating loss carryforwards of approximately
$106.1&nbsp;million which may be available to offset future taxable income, of which $44.2&nbsp;million begin to expire in 2029 and go through 2037 and $61.9&nbsp;million do not expire. The Company had state gross operating loss carryforwards of
$89.3&nbsp;million, which may be available to offset future taxable income, and which would begin to expire in 2030. As of December&nbsp;31, 2020, the Company had federal and state research and experimentation credit carryforwards of
$3.8&nbsp;million and $1.1&nbsp;million, respectively, which may be available to offset future income tax liabilities and which would begin to expire in 2029 and 2027, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s ability to use its operating loss carryforwards and tax credit carryforwards to offset taxable income is subject to restrictions
under Sections 382 and 383 of the United States Internal Revenue Code (the &#147;Internal Revenue Code&#148;). Under the Internal Revenue Code provisions, certain substantial changes in the Company&#146;s ownership, including the sale of the Company
or significant changes in ownership due to sales of equity, have limited and may limit in the future, the amount of net operating loss carryforwards which could be used annually to offset future taxable income. The Company has not yet completed an
analysis of ownership changes. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership, some of which may be outside the Company&#146;s control. As a result, the Company&#146;s ability
to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to the Company. In addition, at the state level,
there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. All Federal NOLs generated post tax reform have an indefinite life, are not subject to carryback
provisions, and limited to 80% of income in any year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has not conducted a study of its research and development credit carryforwards. A
study may result in an adjustment to the Company&#146;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts will be presented as an uncertain tax position. A full valuation
allowance has been provided against the Company&#146;s research and development credit carryforwards and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to
the balance sheet or statement of operations at this time, if an adjustment were required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Management has evaluated the positive and negative
evidence bearing upon the realizability of its deferred tax assets, which are principally comprised of NOL carryforwards and tax credit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
carryforwards. Management has determined that it is more likely than not that the Company will not realize the benefits of its deferred tax assets, and as a result, a valuation allowance of
$33.4&nbsp;million has been recorded at December&nbsp;31, 2020. The increase in the valuation allowance of $6.6&nbsp;million during the year ended December&nbsp;31, 2020 was primarily due to the increase in net operating loss generated by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2020, and 2019, the Company had no unrecognized tax benefits. The Company does not expect any significant change
in its uncertain tax positions in the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company files income tax returns in the United States federal tax jurisdiction and
several state tax jurisdictions. Since the Company is in a loss carryforward position, it is generally subject to examination by federal and state tax authorities for all tax years in which a loss carryforward is available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. Related Parties </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During 2020 and 2019, the Company
incurred $0 and $0.3&nbsp;million in expenses to a legal firm whose partner is also an investor and former officer of the Company. As of December&nbsp;31, 2020, and 2019, none of these amounts were included in accounts payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During 2020 and 2019, the Company incurred $0.5&nbsp;million and $0.3&nbsp;million in expenses to a shareholder that provided research and development
related services. Of these amounts, $0.1&nbsp;million and $0.01&nbsp;million were in accrued expenses as of December&nbsp;31, 2020 and 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During 2020 and 2019, two members of the Board received compensation from the Company while also consulting for other equity shareholders. Payment to
the members was $0.1&nbsp;million in 2020 and $0.02&nbsp;million in 2019. The Board members resigned from the Board in September of 2019 and March of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During 2020 and 2019, the Company incurred $0.01&nbsp;million and $0.01&nbsp;million in expense to a consultant who is also a spouse of an employee at
the Company. As of December&nbsp;31, 2020, and 2019, de minimis amounts were included in accounts payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. Subsequent Events </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has evaluated subsequent events from the balance sheet date through August&nbsp;9, 2021, the date at which the financial statements were
available to be issued, and identified the following subsequent events: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On March&nbsp;5, 2021, the Company completed the second tranche of Series <FONT STYLE="white-space:nowrap">D-2</FONT> offering and issued 10,128,771
shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Stock, $0.00001 par value per share, at a purchase price of $0.6911 per share for aggregate proceeds of $7.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On March&nbsp;18, 2021, the Company completed its Series E Stock offering and issued 102,671,041 shares of Series E Stock, $0.00001 par value per share,
at a purchase price of $0.7839 per share for aggregate proceeds of $80.5&nbsp;million. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Cambridge Lease Modification </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On March&nbsp;31, 2021, the Company executed an amendment to the facility lease which included an extension of the expiration date of the original leased
premises, the addition of 4,516 square feet of laboratory space with an expected commencement date of May&nbsp;1, 2021, and the addition of 1,000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
square feet of laboratory space with an expected commencement date of June&nbsp;15, 2021. The lease term for the original and new spaces will expire on July&nbsp;31, 2023, with an option to renew
for an additional 12 months. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On March&nbsp;18, 2021, the Company&#146;s 2018 Plan was amended to increase the number of shares of common stock reserved for issuance under the 2018
Plan from 22,890,945&nbsp;shares to 55,034,270 shares in the aggregate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From January&nbsp;1, 2021 through August&nbsp;9, 2021, the board of
directors approved and granted stock options to purchase 21,699,200 shares of the common stock under the 2018 Plan. 21,329,200 of these stock options vest over four years and 370,000 of these stock options vest over one year with exercise prices
ranging from $0.32 to $0.40&nbsp;per share. The weighted-average fair value of these stock options is $0.26 per share and the related stock compensation expense of these stock options of $5.6&nbsp;million will be recognized over a weighted-average
period of 3.95 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From January 1, 2021 through August&nbsp;9, 2021, 843,888 stock options were exercised at exercise prices ranging from $0.20
to $0.69 per share for gross proceeds of $0.3 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_7"></A>Condensed Balance Sheets (Unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash and deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash and deposits, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease right of use assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities, Convertible Preferred Stock, and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Commitments and Contingencies (Note 12)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A convertible preferred stock, $0.00001 par value, 1,701,141 shares authorized, issued and
outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively, and a liquidation preference of $3,403 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, $0.00001 par value,
3,298,732 shares authorized, issued, and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively, and a liquidation preference of $8,196 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, $0.00001 par value,
4,325,021 shares authorized, and 4,324,998 shares issued and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively, and a liquidation preference of $5,373 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B convertible preferred stock, $0.00001 par value, 22,705,646 shares authorized, and 22,531,819
shares issued and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively, and a liquidation preference of $38,400 and $37,429 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock, $0.00001 par value,
58,109,711 shares authorized, issued and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively, and a liquidation preference of $37,201 and $36,150 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">C-2</FONT> convertible preferred stock, $0.00001 par value,
33,218,192 shares authorized, issued and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively, and a liquidation preference of $15,118 and $14,697 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">D-1</FONT> convertible preferred stock, $0.00001 par value,
57,878,742 shares authorized, issued and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively, and a liquidation preference of $45,297 and $43,908 at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">D-2</FONT> convertible preferred stock, $0.00001 par value,
24,598,481 shares authorized, and 24,598,481 and 14,469,710 issued and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively, and a liquidation preference of $17,682 and $10,176 at June&nbsp;30, 2021 and December&nbsp;31, 2020,
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series E convertible preferred stock, $0.00001 par value, 102,671,041 shares authorized, issued and
outstanding at June&nbsp;30, 2021, and a liquidation preference of $82,105 at June&nbsp;30, 2021; no shares authorized, issued or outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Stockholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.00001 par value, 470,183,383 and 232,697,999 shares authorized at June&nbsp;30, 2021 and
December&nbsp;31, 2020, respectively, and 6,015,717 and 5,221,829 shares issued and outstanding at June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total Liabilities, Convertible Preferred Stock, and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:180pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of
these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_8"></A>Condensed Statements of Operations and Comprehensive Loss (Unaudited)
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands except for share and per share data) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Operating Expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income (expense), including amortization of discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">(Loss) gain from disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted (Note&nbsp;13)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,741,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,872,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of
these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_9"></A>Condensed Statements of Convertible Preferred Stock and Stockholders&#146; Deficit (Unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share data) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="54" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Convertible Preferred Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B></FONT><br><FONT STYLE="font-size:5pt"><B>Capital</B>
</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Accumulated</B></FONT><br><FONT STYLE="font-size:5pt"><B>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Total<BR>Stockholders&#146;</B></FONT><br><FONT STYLE="font-size:5pt"><B>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Series A</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Series B</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> and <FONT STYLE="white-space:nowrap">C-2</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Series <FONT STYLE="white-space:nowrap">D-1</FONT> and <FONT STYLE="white-space:nowrap">D-2</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Series E</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Shares </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Shares </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Shares </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Shares </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Shares </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Shares </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Shares </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Shares </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:5pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">1,701,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">3,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">3,298,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">7,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">4,324,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">5,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">22,531,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">20,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">91,327,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">41,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">57,878,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">39,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">4,666,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">7,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(94,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(87,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL">Stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">445,693</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(13,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(13,668 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL"><B>Balance, June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">1,701,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">3,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">3,298,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">7,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">4,324,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">5,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">22,531,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">20,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">91,327,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">41,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">57,878,742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">39,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">5,112,129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">7,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(108,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(100,578</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">1,701,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">3,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">3,298,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">7,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">4,324,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">5,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">22,531,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">20,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">91,327,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">41,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">72,348,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">49,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">5,221,829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">8,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(116,886</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(108,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL">Issuance of Series D Tranche 2, convertible preferred stock, net of issuance costs of $18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">10,128,771</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">6,982</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL">Issuance of Series E convertible preferred stock, net of issuance costs of $237</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">102,671,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">80,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL">Stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">793,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(14,779</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(14,779</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:5pt; font-family:ARIAL"><B>Balance, June&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">1,701,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">3,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">3,298,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">7,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">4,324,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">5,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">22,531,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">20,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">91,327,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">41,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">82,477,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">56,575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">102,671,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">80,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">6,015,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">8,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(131,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:5pt">(122,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of
these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Aura Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin209588_10"></A>Condensed Statements of Cash Flows (Unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">(Loss) gain on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from financing activities</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of Series D convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of Series E convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payments made for deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payments made for deferring financing costs related to issuance of Series
<FONT STYLE="white-space:nowrap">D-2</FONT> preferred</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net (decrease) increase in cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash, cash equivalents and restricted cash at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash, cash equivalents and restricted cash at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental Disclosure of Cash Flow Information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment in accounts payable and accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial measurement of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities for operating lease</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">536 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Remeasurement of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities for lease modification</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets obtained
in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred financing costs in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred offering costs in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><A NAME="fin209588_11"></A>1. Description of Business </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Aura Biosciences, Inc. (the &#147;Company&#148; or &#147;Aura&#148;) is a clinical-stage biotechnology company leveraging its novel targeted oncology
platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. The Company&#146;s proprietary platform enables the targeting of a broad range of solid tumors using
Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. The Company&#146;s VDCs are largely agnostic to tumor type and can recognize a surface marker, known as
HSPGs, that are specifically modified and more broadly expressed on many tumors. The Company is developing <FONT STYLE="white-space:nowrap">AU-011,</FONT> its first VDC product candidate for the first line treatment of primary choroidal melanoma, a
rare disease with no drugs approved. The Company is also developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for additional ocular oncology indications and in <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer.
Aura&#146;s team combines expertise in cancer cell biology, ophthalmology, and targeted therapies together with experience in the development and commercialization of orphan products for significant unmet medical needs. Aura&#146;s headquarters are
located in Cambridge, Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s operations to date have consisted primarily of conducting research and development and
raising capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, the successful
development and commercialization of products, fluctuations in operating results and financial risks, need for additional financing or alternative means of financial support or both to fund its current operating plan, protection of proprietary
technology and patent risks, compliance with government regulations, dependence on key personnel and collaborative partners, competition, customer demand, management of growth, and the effectiveness of marketing by the Company. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Liquidity and Going Concern </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Through
June&nbsp;30, 2021, the Company has funded its operations primarily with proceeds from the initial closing and additional closings of its convertible preferred stock financings. The Company has incurred recurring losses and negative cash flows from
operations since its inception, including net losses of $14.8&nbsp;million and $13.7&nbsp;million for the six months ended June&nbsp;30, 2021 and 2020, respectively. As of June&nbsp;30, 2021, the Company had cash and cash equivalents of
$92.2&nbsp;million and an accumulated deficit of $131.7&nbsp;million. The Company expects to continue to generate operating losses for the foreseeable future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of October 8, 2021, the issuance date of these condensed financial statements, the Company expects that its cash and cash equivalents will be
sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the condensed financial statements. The future viability of the Company beyond that point is dependent on its ability to
raise additional capital to finance its operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2019, a novel strain of coronavirus, which causes the disease known as <FONT STYLE="white-space:nowrap">COVID-19,</FONT> was reported to have
surfaced. Since then, <FONT STYLE="white-space:nowrap">COVID-19</FONT> coronavirus has spread globally. In March 2020, the World Health Organization declared the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak a pandemic and the U.S.
government- imposed travel restrictions on travel between the United States, Europe and certain other countries. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on businesses and
commerce, as certain worker shortages have occurred, supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on the Company&#146;s business and operations are
uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is monitoring the potential impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on its business and condensed
financial statements. The effects of the public health directives and the Company&#146;s work-from-home </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
policies may negatively impact productivity, disrupt its business, and delay clinical programs and timelines and future clinical trials, the magnitude of which will depend, in part, on the length
and severity of the restrictions and other limitations on its ability to conduct business in the ordinary course. These and similar, and perhaps more severe, disruptions in the Company&#146;s operations could negatively impact business, results of
operations and financial condition, including its ability to obtain financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, the Company has not incurred impairment losses in the
carrying values of its assets as a result of the pandemic and are not aware of any specific related event or circumstance that would require the Company to revise its estimates reflected in the condensed financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will be on its business and
prospects. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or indirectly impact its business, results of operations, financial condition, and liquidity, including planned and future clinical trials and
research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain or treat
it, and the duration and intensity of the related effects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accompanying
unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). In management&#146;s opinion, the accompanying unaudited condensed
financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company&#146;s financial position, results of operations, and cash flows. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accompanying condensed balance sheet as of June&nbsp;30, 2021, the condensed statements of operations and comprehensive loss, condensed statement of
convertible preferred stock and stockholders&#146; deficit and the condensed statements of cash flows for the six months ended June&nbsp;30, 2020 and 2021 are unaudited. The unaudited interim financial statements have been prepared on the same basis
as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#146;s financial position as of June&nbsp;30,
2021 and the results of its operations and its cash flows for the six months ended June&nbsp;30, 2020 and 2021. The financial data and other information disclosed in these notes related to the six months ended June&nbsp;30, 2020 and 2021 are also
unaudited. The unaudited condensed results of operations are not necessarily indicative of the operating results that may occur for the full fiscal year. Certain information and footnote disclosures normally included in annual financial statements
prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#147;SEC&#148;). Management believes that the disclosures provided here are
adequate to make the information presented not misleading when these unaudited condensed financial statements are read in conjunction with the audited financial statements and notes thereto as of and for the year ended December&nbsp;31, 2020. The
condensed balance sheet data as of December&nbsp;31, 2020 was derived from the Company&#146;s audited financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Significant Accounting Policies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company&#146;s significant accounting policies are disclosed in the audited financial statements for the year ended December&nbsp;31, 2020, included elsewhere in this prospectus. Since the date of those financial statements, there have been no
changes to its significant accounting policies except as noted below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Cash Equivalents </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cash equivalents are highly liquid investments with an original maturity of 90 days or less at the date of purchase and consist of time deposits and
investments in money market funds that invest in U.S. Treasury obligations and government funds with commercial banks and financial institutions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to January&nbsp;1, 2021,
the Company accounted for leases in accordance with ASC 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent
escalation, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was charged to deferred rent. The Company presented lease incentives as deferred rent and
amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified deferred rent as current and noncurrent liabilities based on the portion of the deferred rent that was scheduled to mature
within the proceeding twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective January&nbsp;1, 2021, the Company accounts for leases in accordance with ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic 842) (&#147;ASC 842&#148;)</I>. At contract inception, the Company determines if an arrangement is or contains a lease. A lease conveys the right to control the use of an
identified asset for a period of time in exchange for consideration. If determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on
which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. For each lease with a term greater than twelve months, the Company records a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company adopted the new leasing standard effective
January&nbsp;1, 2021, using the modified retrospective transition approach which uses the effective date, or January&nbsp;1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance
in ASC 840. ASC 842 provides several optional practical expedients in transition. The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the
lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the
obligation to make lease payments arising from the lease. The Company elected the practical expedient to not separate lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for all classes of underlying assets and therefore measures
each lease payment as the total of the fixed lease and associated <FONT STYLE="white-space:nowrap">non-lease</FONT> components. Lease liabilities are measured at lease commencement and calculated as the present value of the future lease payments in
the contract using the rate implicit in the contract, when available. If an implicit rate is not readily determinable, the Company uses an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized
basis, a commensurate loan in the same currency over a period consistent with the lease term at the commencement date. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are measured as the lease
liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor. The lease term is measured as the noncancelable period in the contract, adjusted for any options to extend or terminate when it is
reasonably certain the Company will extend the lease term via such options based on an assessment of economic factors present as of the lease commencement date. The Company elected the practical expedient to not recognize leases with a lease term of
twelve months or less. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Components of a lease are split into three categories: lease components, <FONT STYLE="white-space:nowrap">non-lease</FONT>
components, and <FONT STYLE="white-space:nowrap">non-components.</FONT> The fixed and <FONT STYLE="white-space:nowrap">in-substance</FONT> fixed contract consideration (including any consideration related to
<FONT STYLE="white-space:nowrap">non-components)</FONT> are allocated, based on the respective relative fair values, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the lease components and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. The Company has elected to account for lease and <FONT STYLE="white-space:nowrap">non-lease</FONT>
components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s operating leases are presented in the condensed balance sheet as operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent liabilities. Operating lease expense is recognized on a straight-line basis over the
lease term. Variable costs associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Deferred Offering
Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with <FONT
STYLE="white-space:nowrap">in-process</FONT> preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the
carrying value of convertible preferred stock or in stockholders&#146; equity (deficit) as a reduction of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should a planned equity financing be
abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations. As of June&nbsp;30, 2021, the Company had deferred offering costs of $0.3&nbsp;million. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Derivative Liability </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Derivative
financial instruments, as defined in ASC 815<I>, Accounting for Derivative Financial Instruments and Hedging Activities</I>, consist of financial instruments or other contracts that contain a notional amount and one or more underlyings (e.g.
interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial
instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company does not
use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company did have a license agreement that included a change of control fee (see Note 12). As required by ASC 815, in certain
instances, these instruments are required to be carried as derivative liabilities, at fair value, in the financial statements (see Note 3). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon adoption of ASC 842, the Company recorded lease liabilities and their corresponding
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets based on the present value of lease payments over the remaining lease term. The adoption of ASC 842 resulted in the recognition of operating lease
liabilities of $0.6&nbsp;million and operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets of $0.5&nbsp;million and the derecognition of deferred rent liabilities of $0.02&nbsp;million on
the Company&#146;s balance sheet as of January&nbsp;1, 2021. The adoption impact relates to the Company&#146;s existing operating lease for operating and laboratory space. The adoption of ASC 842 did not have a material impact on the Company&#146;s
statements of operations and comprehensive loss or statements of cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Fair Value of Assets and Liabilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table presents information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis and
indicates the level of the fair value hierarchy utilized to determine such fair values as of June&nbsp;30, 2021 and December&nbsp;31, 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;prices<BR>active&nbsp;markets<BR>for identical<BR>assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Assets</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Liability</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;prices<BR>active&nbsp;markets<BR>for identical<BR>assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>other<BR>observable<BR>inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Liability</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At June&nbsp;30, 2021, the Company&#146;s cash equivalents include investments in money market funds that invest in U.S.
Treasury obligations and government funds, the fair value of which is valued using level 1 inputs. The fair value of the warrant liability was determined based on Level&nbsp;3 inputs and utilizing the Black-Scholes option pricing model (see Note
10). The fair value of the derivative liability was determined by utilizing assumptions including the probability of payment factors and discount rate used in the most current common stock valuation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2021 and 2020, there were no transfers into or out of Level&nbsp;3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table set forth a summary of changes in the fair value of the derivative liability, which represents a recurring fair value measurement
that is classified within Level&nbsp;3 of the fair value hierarchy. Changes in fair value are recognized in other (expense) income as &#147;Change in fair value of derivative liability&#148; in the Company&#146;s condensed statements of operations
and comprehensive loss (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Derivative Liability</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at June 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at June 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table set forth a summary of changes in the fair value of the (&#147;Series B
Warrants&#148;), which represents a recurring fair value measurement that is classified within Level&nbsp;3 of the fair value hierarchy. Changes in fair value are recognized in other (expense) income as &#147;Change in fair value of warrant
liability&#148; in the Company&#146;s condensed statements of operations and comprehensive loss (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series B Warrants (173,827 warrants)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at June 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value at June 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Property and Equipment, Net </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Property and equipment, net, consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assets under construction</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">IT equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less&#151;accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the six months ended June&nbsp;30, 2021 and 2020, depreciation expense was $0.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Prepaid Expenses and Other Current Assets </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prepaid
expenses and other current assets consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid insurance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid license agreements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Convertible Preferred Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2021, the Company had 1,701,141 authorized, issued and outstanding shares of Series A convertible preferred stock (&#147;Series
A&#148;), 3,298,732 authorized, issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">A-1&#148;),</FONT> 4,325,021 authorized shares and
4,324,998 issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">A-</FONT> 2&#148;), and 22,705,646 authorized shares and 22,531,819 issued and
outstanding shares of Series B convertible preferred stock (&#147;Series B&#148;), 58,109,711 authorized, issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred stock (&#147;Series <FONT
STYLE="white-space:nowrap">C-1&#148;),</FONT> 33,218,192 authorized, issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">C-2&#148;,</FONT>
together with Series <FONT STYLE="white-space:nowrap">C-1,</FONT> &#147;Series C&#148;), 57,878,742 authorized, issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> convertible preferred stock (&#147;Series <FONT
STYLE="white-space:nowrap">D-1&#148;)</FONT> and 24,598,481 authorized, issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">D-2&#148;,</FONT>
together with Series <FONT STYLE="white-space:nowrap">D-1,</FONT> &#147;Series D,&#148;) 102,671,041 authorized, issued, and outstanding shares of Series E convertible preferred stock (&#147;Series E&#148;, and together with the Series D, Series C
and Series B, collectively the &#147;Senior Preferred Stock&#148;). All series of convertible preferred stock are collectively referred to as Preferred Stock, each with a par value of $0.00001 per share. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Series <FONT STYLE="white-space:nowrap">D-2</FONT> Offering </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;25, 2020, the Company entered into the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Purchase Agreement (&#147;Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Agreement&#148;) with certain investors to sell up to 24,598,481 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> stock at a purchase price of $0.6911 per share. The Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Agreement provides for two closings, the first on October 1, 2020, and the second upon the achievement or waiver of certain milestone events. The Company sold 14,469,710 shares of Series <FONT
STYLE="white-space:nowrap">D-2</FONT> stock on October 1, 2020 at the first tranche closing for gross proceeds of $10.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On March 5,
2021, the Company completed the second tranche of Series <FONT STYLE="white-space:nowrap">D-2</FONT> offering and issued 10,128,771 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Stock, $0.00001 par value per share, at a purchase price
of $0.6911 per share for gross proceeds of $7.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs incurred in connection with the Series
<FONT STYLE="white-space:nowrap">D-2</FONT> offering totaled $0.1&nbsp;million and were recorded as a reduction to Series <FONT STYLE="white-space:nowrap">D-2</FONT> convertible preferred stock. The majority of offering costs were incurred during
the year ended December&nbsp;31, 2020. Offering costs incurred during the six months ended June&nbsp;30, 2021 was $0.02&nbsp;million. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Series E
Offering </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On March 18, 2021, the Company completed its Series E Stock offering and issued 102,671,041 shares of Series E Stock, $0.00001 par
value per share, at a purchase price of $0.7839 per share for gross proceeds of $80.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs incurred in connection with the Series E
offering totaled $0.2&nbsp;million during the six months June&nbsp;30, 2021 and were recorded as a reduction to Series E convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The rights and privileges of the Company&#146;s Preferred Stock are as follows: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Except as otherwise required by
law or by other provisions, holders of the Preferred Stock vote together with the holders of common stock as a single class. Holders of Preferred Stock may cast the number of votes equal to the number of shares of common stock to which such shares
of Preferred Stock are convertible into. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Series C, D, and E Dividends: </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From and after
the date of the issuance of any shares of Series <FONT STYLE="white-space:nowrap">C-1,</FONT> Series <FONT STYLE="white-space:nowrap">C-2,</FONT> Series <FONT STYLE="white-space:nowrap">D-1,</FONT> Series <FONT STYLE="white-space:nowrap">D-2,</FONT>
and Series E, dividends at the annual rate of seven percent (7%) per annum of the original </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
share price per share accrue on such shares of Series <FONT STYLE="white-space:nowrap">C-1,</FONT> Series <FONT STYLE="white-space:nowrap">C-2,</FONT> Series
<FONT STYLE="white-space:nowrap">D-1,</FONT> Series <FONT STYLE="white-space:nowrap">D-2,</FONT> and Series E. Dividends accrue from day to day, whether or not declared, and are cumulative, but not compounding. Such dividends are only payable when
and if declared by the Board or in the event of a Deemed Liquidation Event (as defined in the amended and restated Certificate of Incorporation). No other dividends may be declared or paid on any other class of stock unless the holders of the shares
of Series E then outstanding first receive, or simultaneously receive, their applicable dividend. As of June&nbsp;30, 2021, $6.9&nbsp;million, $3.0&nbsp;million, $5.3&nbsp;million, $0.7&nbsp;million, and $1.6&nbsp;million of cumulative dividends on
Series <FONT STYLE="white-space:nowrap">C-1,</FONT> Series <FONT STYLE="white-space:nowrap">C-2,</FONT> Series <FONT STYLE="white-space:nowrap">D-1,</FONT> Series <FONT STYLE="white-space:nowrap">D-2,</FONT> and Series E respectively, are included
in the liquidation preference amount indicated on the balance sheet. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Series B Dividends: </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From and after the date of the issuance of any shares of Series B, dividends at the annual rate of $0.0869645 per share accrue on such shares of Series
B. Dividends accrue from day to day, whether or not declared, and are cumulative, but not compounding. Such dividends are only payable when and if declared by the Company&#146;s Board or in the event of a Deemed Liquidation Event (as defined in the
amended and restated Certificate of Incorporation). No other dividends may be declared or paid on any other class of stock unless the holders of the shares of Series B then outstanding first receive, or simultaneously receive, their applicable
dividend. As of June&nbsp;30, 2021, $10.4&nbsp;million of cumulative dividends on Series B are included in the liquidation preference amount indicated on the balance sheet. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Series A Dividends </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From and after the date of
the issuance of Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> and Series <FONT STYLE="white-space:nowrap">A-2,</FONT> if the Company declares, pays or sets aside, on the same date, a dividend on shares of more than one class or
series of capital stock of the Company, the dividend payable to the holders of Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock shall be calculated based
upon the dividend on the class or series of capital stock that would result in the highest dividend. No other dividends, or dividends on common stock payable in shares of common stock, may be declared or paid unless the holders of Series A, Series <FONT
STYLE="white-space:nowrap">A-1,</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> then outstanding first receive, or simultaneously receive, their applicable dividend. As of June&nbsp;30, 2021, no dividends have been declared on the
common stock or the convertible preferred stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of a Deemed Liquidation Event, as defined in the Company&#146;s amended and restated Certificate of Incorporation, the assets of the Company
will be distributed first to the holders of Series&nbsp;E. The holders of Series E will receive, in preference to all other stockholders, and amount equal to the sum of the Series E original issue price (equal to the cash price paid per share of
$0.783900), plus unpaid dividends on such shares. Next, the holders of Series D will receive, in preference to all other stockholders other than Series E, an amount equal to the sum of the Series D original issue price, plus unpaid dividends on such
shares. Next, the holders of Series C will receive, in preference to all stockholders other than the Series E and D holders, an amount equal to the sum of the Series C original issue price plus unpaid dividends on such shares. Next, the holders of
Series B will receive, in preference to the holders of Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series <FONT STYLE="white-space:nowrap">A-2</FONT> and common stock, an amount equal to the sum of the Series B original issue price
plus unpaid dividends on such shares. Next, the holders of Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> will receive, in preference to the holders of common stock, an amount
equal to the greater of their applicable liquidation preference or what they would have received had their shares converted into common stock. If the proceeds available are not sufficient to satisfy the full liquidation preference, the entire
proceeds are to be distributed <FONT STYLE="white-space:nowrap">pro-rata</FONT> among the Series E holders in proportion to the full preferential amount the Series E holders are entitled to receive. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Conversion </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Senior Preferred Stock
converts into common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. Each share of Series B, Series <FONT STYLE="white-space:nowrap">C-1,</FONT> Series
<FONT STYLE="white-space:nowrap">C-2,</FONT> Series <FONT STYLE="white-space:nowrap">D-1,</FONT> Series <FONT STYLE="white-space:nowrap">D-2,</FONT> and Series E is convertible into the number </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of shares of common stock as is determined by dividing the respective original issue price by the conversion price in effect at the time of conversion. The Series E conversion price is set at
$0.7839 per share, the Series <FONT STYLE="white-space:nowrap">D-1</FONT> and Series <FONT STYLE="white-space:nowrap">D-2</FONT> conversion price is set at $0.6911 per share, the Series <FONT STYLE="white-space:nowrap">C-1</FONT> conversion price is
set at $0.5213 per share, the Series <FONT STYLE="white-space:nowrap">C-2</FONT> conversion price is set at $0.36491 per share, and the Series B conversion price is set at $1.24235 per share; none represents a beneficial conversion feature. Subject
to certain exceptions, the Senior Preferred Stock has the benefit of anti- dilution protection on a weighted-average basis in the event that the Company sells stock at less than the applicable conversion price per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each share of Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> was originally convertible into the number of shares of common stock
determined by dividing the respective Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> original issue price by the conversion price in effect at the time of conversion. The Series A conversion price was originally equal to $2.00 per
share and the Series <FONT STYLE="white-space:nowrap">A-1</FONT> conversion price was originally equal to $2.4847 per share. As Series <FONT STYLE="white-space:nowrap">A-2</FONT> was sold at $1.24235 per share, less than the per share prices of
Series A and Series <FONT STYLE="white-space:nowrap">A-1,</FONT> anti-dilution protections were triggered. Pursuant to the anti-dilution protection terms, on February&nbsp;24, 2015, the Series A conversion price was reduced from $2.00 to $1.8191 per
share of common stock and the Series <FONT STYLE="white-space:nowrap">A-1</FONT> conversion price was reduced from $2.4847 to $2.1898 per share of common stock and, therefore, the Series A conversion ratio was changed from 1:1 to 1:1.099 and the
Series <FONT STYLE="white-space:nowrap">A-1</FONT> conversion ratio was changed from 1:1 to 1:1.135. The Company evaluated Series A and Series <FONT STYLE="white-space:nowrap">A-1</FONT> with the updated conversion ratios and determined that there
was no beneficial conversion feature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-2</FONT> converts into common stock on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. The Series <FONT STYLE="white-space:nowrap">A-2</FONT> conversion price is set at $1.24235 per share and does not represent a beneficial conversion feature.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">According to the terms of the Company&#146;s amended and restated certificate of incorporation, in the event that the applicable conversion price
for any series of Senior Preferred Stock is reduced, then the applicable conversion price for each series of Series A convertible preferred stock shall be uniformly and concurrently reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each share of Preferred Stock will automatically convert into common stock upon (a)&nbsp;the occurrence of an event, specified by vote or written
consent of certain stockholders or (b)&nbsp;the completion of a public stock offering involving a price per share of common stock of not less than $1.554975 per share, subject to certain adjustments, where such offering results in aggregate gross
proceeds to the Company of at least $50.0&nbsp;million and the common stock is listed for trading on either the New York Stock Exchange or the Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company must reserve and keep available out of its authorized but unused capital stock such number of authorized shares of common stock to
sufficiently effect the conversion of all outstanding Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In considering the features of the convertible preferred stock, the Company
determined that none of the features, including the conversion features, requires bifurcation during the six months ended June&nbsp;30, 2021 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Common
Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company had 470,183,383 and 232,697,999 authorized shares of common stock, par value $0.00001 per share, of which 6,015,717 and
5,221,829 shares were issued and outstanding as of June&nbsp;30, 2021 and December&nbsp;31, 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Stock-Based Compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On January&nbsp;15, 2009, the Company&#146;s Board adopted the 2009 Long-Term Incentive Stock Option Plan (the &#147;2009 Plan&#148;) for the issuance of
stock-based compensation to both employees and non-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
employees. The awards under this plan typically vest over a 24, 36 or <FONT STYLE="white-space:nowrap">48-month</FONT> period depending on the option agreement and have a <FONT
STYLE="white-space:nowrap">10-year</FONT> term. On December&nbsp;12, 2018, the 2009 Plan expired, and the Company adopted the Aura Biosciences, Inc. 2018 Equity Incentive Plan (the &#147;2018 Plan&#148; and collectively with the 2009 Plan, &#147;the
Plans&#148;). No options were modified in conjunction with the expiration of the 2009 Plan. The options granted under the 2009 Plan continue to be outstanding in accordance with their original terms. The 2018 Plan will expire in 2028. Under the 2018
Plan, Aura may grant incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted and unrestricted stock awards and stock rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Board is authorized to administer the 2018 Plan. In accordance with the provisions of the 2018 Plan, the Board determines the terms of Aura options
and other awards issued pursuant thereto, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">which employees, directors and consultants shall be granted awards; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares of common stock subject to options and other awards; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the exercise price of each option, which generally shall not be less than fair market value of the common stock on the date
of grant; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the termination or cancellation provisions applicable to options; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms and conditions of other awards, including conditions for repurchase, termination or cancellation, issue price and
repurchase price; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all other terms and conditions upon which each award may be granted in accordance with the 2018 Plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the Board or any committee to which the Board delegates authority may, with the consent of the affected plan
participants, <FONT STYLE="white-space:nowrap">re-price</FONT> or otherwise amend outstanding awards consistent with the terms of the 2018 Plan. On March 18, 2021, the Board approved an increase to the 2018 Plan available option pool of 32,143,325
options. With this increase and the transfer of the available options from the 2009 Plan, there were 12,477,612 options available for grant under the 2018 Plan at June&nbsp;30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes stock option activity under the 2018 Plan for the six months ended June&nbsp;30, 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding at December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,717,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,699,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(793,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,773,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding at June 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,848,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable at June 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,943,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The weighted-average grant date fair value of stock options granted during the six months ended June&nbsp;30, 2021 was
$0.26 and $0.20 per share, respectively. The total intrinsic value of options exercised was $0.01&nbsp;million and $0.02&nbsp;million for the six months ended June&nbsp;30, 2021 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has elected to use the Black-Scholes option pricing model to determine the fair value of options granted and generally recognizes the
compensation cost of stock-based awards on a straight-line basis over the vesting period of the award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The determination of the fair value of stock-based payment awards utilizing the Black-Scholes option
pricing model is affected by the estimated fair value of the Company&#146;s common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate, and expected dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The fair value of the stock options issued for the six months ended June&nbsp;30, 2021 and 2020 was measured with the following weighted-average
assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.07</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility of the underlying stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company recorded stock-based compensation as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2021, there was $6.7&nbsp;million of unrecognized compensation expense related to stock options,
which is expected to be recognized over a weighted-average period of 2.73 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Series B Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2015 and May 2015, the Company issued warrants to purchase 1,650,098 and 887,536 shares of Series B convertible preferred stock,
respectively, at an exercise price of $1.24235 per share. Each Series B Warrant was immediately exercisable and expires ten years from the original date of issuance. Pursuant to FASB ASC Topic 480, <I>Distinguishing Liabilities from Equity</I>, the
Series B Warrants were classified as a liability and are <FONT STYLE="white-space:nowrap">re-measured</FONT> to fair value at each balance sheet date and immediately prior to exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A total of 173,827 of the Series B Warrants remained outstanding at June&nbsp;30, 2021 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The warrants were valued using the Black-Scholes option pricing model. The estimated fair value of the warrants and the significant assumptions used
were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series B Warrants</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;31, 2020 the change in fair value of the warrant liability was deemed immaterial.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2012, the Company adopted
the Aura Biosciences 401(K) Profit Sharing Plan and Trust (the &#147;401(k) Plan&#148;) for its employees, which is designed to be qualified under Section&nbsp;401(k) of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company makes matching contributions of 100% of the first 6%
of employee contributions. The Company made matching contributions in the amount of $0.1&nbsp;million for the six months ended June&nbsp;30, 2021 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12.
Commitments and Contingencies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Lease Commitments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has historically entered into lease arrangements for its facilities. As of December&nbsp;31, 2020, the Company had one operating lease for
its office and lab facility with required future minimum payments. The lease does not contain any options to renew, terminate, or purchase the underlying asset, and was set to expire on July&nbsp;31, 2022. As part of its adoption of ASC 842, the
Company recorded a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and operating lease liability for this lease as of the effective date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On March 31, 2021, the Company executed an amendment to the facility lease which included an extension of the expiration date of the original leased
premises, the addition of 4,516 square feet of laboratory space with an expected commencement date of May 1, 2021, and the addition of 1,000 square feet of laboratory space with an expected commencement date of June&nbsp;15, 2021. The lease term for
the original and new spaces will expire on July&nbsp;31, 2023, with an option to renew for an additional 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the execution of the
amendment, which was deemed to be a lease modification, the Company <FONT STYLE="white-space:nowrap">re-evaluated</FONT> the assumptions made at the original lease commencement date. The Company determined the amendment consists of two separate
contracts under ASC 842. One contract is related to the modification of term for the original space, and the other is related to a new <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> for the two
additional spaces, which are to be accounted for as new leases. The Company remeasured the lease liability and corresponding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for the original space as
of the effective date of the amendment to reflect the extended term and recorded in the second quarter of 2021 an additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liability upon
lease commencement of each of the additional space. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company also leases office and laboratory equipment for which the related expense is
immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the
Company&#146;s leases for the six months ended June&nbsp;30, 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Lease Cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financing lease costs:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Amortization of finance right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest on finance lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Short-term lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Variable lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total Lease Costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for amounts included in the measurement of lease liability&#151;finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid for amounts included in the measurement of lease liability&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average remaining lease term&#151;finance leases (years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average remaining lease term&#151;operating leases (years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average discount rate&#151;finance leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.94</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average discount rate&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table reconciles the future minimum commitments to the Company&#146;s operating lease
liabilities at June&nbsp;30, 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating&nbsp;lease&nbsp;payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021 (excluding six months ended June&nbsp;30, 2021)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: present value adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating lease liabilities at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: current portion of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2021, the Company paid in full its finance lease. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Laser Purchasing Commitment </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On April
5, 2019, the Company entered into a purchase agreement for equipment with future commitments payable in three installments of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.2&nbsp;million each. The first two installments of <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>0.2&nbsp;million were paid by the Company in April 2019 and August 2019, respectively. The last installment of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.2&nbsp;million will be due upon
shipment of the initial order, which is expected to occur in 2021. The Company will receive 20 laser systems upon completion of the final installment payment. Upon receipt of the laser systems, the Company will assess whether the laser systems have
an alternative future use and, if so, will capitalize the lasers as a component of fixed assets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>License Agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has entered into the following key agreements that relate to the core technology under development: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">LI-COR</FONT> Exclusive License and Supply Agreement </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2014, the Company entered into an Exclusive License and Supply Agreement (the <FONT STYLE="white-space:nowrap">&#147;LI-COR</FONT> Exclusive
License Agreement&#148;) with <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc. <FONT STYLE="white-space:nowrap">(&#147;LI-COR&#148;)</FONT> for the license of IRDye 700DX and related licensed patents for the treatment and diagnosis of ocular
cancers in humans, and as amended in January 2016, July 2017, April 2018 and April 2019. <FONT STYLE="white-space:nowrap">LI-COR</FONT> is a related party owning shares of the Company&#146;s capital stock. The
<FONT STYLE="white-space:nowrap">LI-COR</FONT> Exclusive License Agreement required a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront license issue fee of $0.1&nbsp;million and requires aggregate milestone payments of up to
$0.2&nbsp;million upon certain regulatory and development milestones. The Company is also required to pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> <FONT STYLE="white-space:nowrap">low-single</FONT> digit royalties on net sales. The term of the
<FONT STYLE="white-space:nowrap">LI-COR</FONT> Exclusive Agreement expires on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the longer of (i)&nbsp;ten years from the first
commercial sale of a licensed product in such country and (ii)&nbsp;the last to expire valid claim in such country. The Company recognized zero and $0.1&nbsp;million of expenses related to this agreement and related amendments for the six months
ended June&nbsp;30, 2021 and 2020, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">LI-COR</FONT>
<FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License and Supply Agreement </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2014, the Company entered into a <FONT
STYLE="white-space:nowrap">Non-Exclusive</FONT> License Agreement (&#147;the 2014 <FONT STYLE="white-space:nowrap">Non-</FONT> Exclusive Agreement&#148;) for <FONT STYLE="white-space:nowrap">LI-COR</FONT> to supply IRDye 700DX to the Company for the
treatment and diagnosis of <FONT STYLE="white-space:nowrap">non-ocular</FONT> cancers in humans. Under the 2014 <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Agreement, the Company paid a license issue fee of $0.03&nbsp;million on the
effective date. The Company must also pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> a <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.03&nbsp;million per each licensed
product upon <FONT STYLE="white-space:nowrap">pre-IND</FONT> designation, as defined, of such licensed product. During the term, the Company must pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> the following royalty on net sales: 1% for sales up
to $0.1&nbsp;million per year; 1.25% for sales between $0.1&nbsp;million and $0.5&nbsp;million; 1.75% for sales between $0.5&nbsp;million and $1.0&nbsp;million; 2.25% for sales between $1.0&nbsp;million and $2.0&nbsp;million; and 2.75% for sales
greater than $2.0&nbsp;million. <FONT STYLE="white-space:nowrap">LI-COR</FONT> receives 10% of all sublicensee income within 30 days of the Company&#146;s receipt from the sublicensee. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
2014 <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Agreement also required the Company to make certain payments upon the achievement of specified development and commercial milestones
relating to a Phase III clinical trial with NDA submitted for approval to the Food and Drug Administration (the &#147;FDA&#148;) ($0.1 million), first commercial sale of a Licensed product for clinical
<FONT STYLE="white-space:nowrap">(non-research)</FONT> human in vivo use in the United&nbsp;States ($0.1 million), Marketing Authorization Application (&#147;MAA&#148;) approval in the first country in the European Union ($0.1 million) and MAA (or
equivalent) approval in first country outside of the United States or European Union ($0.1 million). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Life Technologies Corporation </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2014, the Company entered into a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual license agreement with Life Technologies
Corporation (&#147;Life Technologies&#148;), which allows for five licensed products. Under this agreement the Company is required to pay an initial license fee of $0.1&nbsp;million for each product. An annual development fee of $0.1&nbsp;million is
due within a year from the payment of the initial license fee and due annually until the earlier of (i)&nbsp;payment of a commercialization fee or (ii)&nbsp;all development work is terminated. The commercialization fee is a <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.3&nbsp;million due upon receipt of approval of a licensed product. In the event of a
change of control, there will be a change of control fee of $0.2&nbsp;million. The Company recorded a derivative liability due an increased probability of payment assessed this quarter to account for the change of control fee (see Note 3). The
derivative liability existed prior to June 2021 but was considered insignificant. During the six months ended June&nbsp;30, 2021 and 2020, the Company recognized $0.03&nbsp;million of expenses related to this agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>National Institute of Health (NIH)-Biologic Materials License Agreement </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2010, the Company entered into a Biologic Materials License Agreement with National Institutes of Health (the &#147;NIH&#148;), for a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> right to use materials described in Schiller et al., Virology 2004 Apr.10, <FONT STYLE="white-space:nowrap">321(2):205-16,</FONT> which required a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT
STYLE="white-space:nowrap">non-refundable</FONT> license issuance fee of $0.02&nbsp;million. No future milestone payments or royalties are due under this agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>National Institute of Health (NIH)-Collaboration Research and Development Agreement </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2011, the Company entered into a Collaboration Research and Development Agreement (&#147;CRADA&#148;) with Dr.&nbsp;John Schiller at the NIH, for
a period of two years with the rights to an exclusive license to all technology generated within the collaboration. Under the agreement, the Company was required to make annual payments each year to fund the research activities, with the first
payment due within 30 days of the effective date and subsequent payments due within 30 days of the anniversary date. This agreement was further amended in 2012, 2013, 2014, 2015, 2016, 2018 and most recently in September of 2020. From 2011-2020, the
Company paid an aggregate of $0.3&nbsp;million in research collaboration fees, $0.04&nbsp;million of which was paid in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2020, the
Company executed the seventh amendment to the CRADA agreement. In this amendment the term of this agreement is extended until September&nbsp;30, 2022, and the Company must pay $0.03&nbsp;million on the tenth anniversary of the CRADA agreement which
will occur in September of 2021. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>National Institute of Health (NIH)-Exclusive Patent License Agreement </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2013, the Company entered into an exclusive patent license agreement that required the Company to pay a license issue royalty fee of $0.1&nbsp;million
and reimburse the NIH for any patent expenses incurred. Under the agreement, the Company is required to make low single-digit percentage royalty payments based on specified levels of annual net sales of licensed products subject to certain specified
reductions. The Company is required to make development and regulatory milestone payments up to $0.7&nbsp;million in the aggregate and sales milestone payments up to $0.6&nbsp;million in the aggregate. The Company is also required to pay NIH a <FONT
STYLE="white-space:nowrap">mid-single</FONT> to low teen-digit percentage of any sublicensing revenue the Company receives. Additionally, the Company&#146;s payment obligations to NIH are subject to an annual minimum royalty payment of low five
figures. As of June&nbsp;30, 2021, the Company has paid NIH approximately $0.4&nbsp;million in aggregate milestones under the NIH License </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Agreement. In addition to milestones under the agreement, the Company reimburses the NIH for any patent filing costs incurred. As of June&nbsp;30, 2021, the Company has reimbursed the NIH
approximately $0.3&nbsp;million in aggregate. The Company accrued $0.02&nbsp;million in patent licensing reimbursement fees as of June&nbsp;30, 2021 and December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2015, 2018 and 2019, the Company amended its exclusive patent license to include updates on the status of the commercial development and
update/expand the list of licensed patents and patent applications. Each of those amendments required a $0.03&nbsp;million payment that the Company paid. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Inserm </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In November 2009, the Company entered
into an exclusive, royalty-bearing license agreement with Inserm-Transfert of France for use of its patents. The agreement expires on a country by country basis based on the last to expire of any patent encompassed within the scope of the patent
rights or 10 years from the date of the first commercial sale by the Company, whichever is later. There are potential milestone payments of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.5&nbsp;million ($0.5&nbsp;million at
December&nbsp;31, 2020) in the aggregate associated with this agreement. The milestones are as follows: IND Filing (<FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.01 million), successful Phase I clinical trial final report (<FONT
STYLE="font-family:Times New Roman">&#128;</FONT>0.03 million), successful Phase II clinical trial final report (<FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.1 million), successful Phase III clinical trial final report (<FONT
STYLE="font-family:Times New Roman">&#128;</FONT>0.1 million), and approval by the FDA or CHMP for each clinical candidate (<FONT STYLE="font-family:Times New Roman">&#128;</FONT>0.3 million). The IND filing milestone of <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>0.01&nbsp;million was accrued in 2016 and paid in 2017 by the Company. The milestones for the successful Phase I, II and III clinical trials are based on receiving a final report and achieving the
primary endpoints defined in that trial and those milestones have not been achieved as of June&nbsp;30, 2021. Upon the sublicense by the Company of a product for which royalties are payable under this agreement, royalty payments due Inserm-Transfert
would equal 5% of Aura receipts prior to commencement of a proof of principle Phase I clinical trial, 3% of receipts prior to commencement of a proof of principle Phase II clinical trial, and 1.5% of receipts prior to commencement of a proof of
principle Phase III clinical trial. If Aura sublicenses the delivery platform for use with multiple drugs, the payment to Inserm-Transfert would be 15% of receipts prior to commencement of Phase I clinical trial, 10% of receipts prior to
commencement of Phase II clinical trial, and 6% of receipts prior to commencement of Phase III clinical trial. The <FONT STYLE="white-space:nowrap">non-milestone</FONT> payments in this agreement are subject to an anti-stacking clause. The Company
did not incur any expense in the period ended June&nbsp;30, 2021 and 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Clearside </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2019, the Company entered into a license agreement with Clearside Biomedical, Inc. (&#147;Clearside&#148;) for the license of Clearside&#146;s
Suprachorodial Microneedle Technology for use in an upcoming clinical trial expected to begin in 2020. Upon execution of the license agreement, the Company paid Clearside an upfront payment of $0.1&nbsp;million which was expensed as incurred. Under
the Clearside License Agreement, the Company is required to pay milestones up to $21.0&nbsp;million in the aggregate to Clearside upon the achievement of specified regulatory and development milestones, and upon the achievement of certain commercial
sales milestones The Company is also required to pay low to <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalties on net sales. If the Company sublicenses a product for which royalties are payable, then the Company is required to pay
the greater of 20% received or low single digit royalties on net sales. The Company has made no milestone or royalty payments as of June&nbsp;30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Clearside license agreement expires on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis
upon the later of the last to expire patent or ten years from the date of the first commercial sale of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Net Loss Per Share </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common
stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are
antidilutive given the net loss of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has calculated basic and diluted net loss per share for the six months ended June&nbsp;30,
2021 and 2020 as follows (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: Accruals of dividends of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,741,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,872,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following potentially dilutive securities were excluded from the computation of the diluted net loss per share for
the periods presented because their effect would have been antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preferred stock on an if converted basis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308,946,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,676,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,848,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,207,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Warrants to purchase preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total potential dilutive shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,969,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,057,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company
estimates an annual effective tax rate of 0% for the year ending December&nbsp;31, 2021 as the Company incurred losses for the six months ended June&nbsp;30, 2021 and is forecasting additional losses through the remainder of fiscal year ending
December&nbsp;31, 2021, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December&nbsp;31, 2021. Therefore, no federal or state income taxes are expected and none have been recorded at this time.
Income taxes have been accounted for using the liability method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Due to the Company&#146;s history of losses since inception, there is not enough
evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation
allowance, since the Company does not currently believe that realization of its deferred tax assets is more likely than not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30,
2021, the Company had no unrecognized income tax benefits that would reduce the Company&#146;s effective tax rate if recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15. Related Parties </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2021 and 2020, the Company incurred $0.04&nbsp;million and $0&nbsp;million in expenses to a legal firm whose
partner is also an investor and former officer of the Company. As of June&nbsp;30, 2021, and 2020, none of these amounts were included in accounts payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2021 and 2020, the Company incurred $0.3&nbsp;million and $0.1&nbsp;million in expenses to a shareholder that
provided research and development related services. Of these amounts, no amounts were in accrued expenses as of June&nbsp;30, 2021 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2021 and 2020, the Company incurred $0.01&nbsp;million in
expense to a consultant who is also a spouse of an employee at the Company. As of June&nbsp;30, 2021, and 2020, no amounts were included in accounts payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16. Subsequent Events </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has evaluated subsequent
events from the balance sheet date through October&nbsp;8, 2021, the date at which the condensed financial statements were available to be issued, and has identified the following subsequent events: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock-based compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On August&nbsp;2, 2021, Elisabet de
los Pinos, our CEO, exercised options for 50,000 shares of common stock, with an exercise price of $0.40 per common share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On October 5, 2021, a
holder of our convertible preferred stock exercised options for 30,000 and 20,000 shares of common stock, with exercise prices of $0.42 and $0.40 per share of common stock, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On September 22, 2021, the board of directors approved and granted stock options to purchase 4,105,000 shares of the common stock under the 2018 Plan.
4,060,000 of these stock options vest over four years and 45,000 of these stock options vest over one year with exercise prices of $0.70 per share. The weighted-average fair value of these stock options is $0.45 per share and the related stock
compensation expense of these stock options of $1.8 million will be recognized over a weighted-average period of 3.97 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g209588g00c36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-Running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Lead Manager </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>BTIG </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (25 days after the commencement of this
offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus
when acting as underwriters and with respect to their unsold allotments or subscriptions. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Information Not Required in Prospectus </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13.
Other Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth the fees and expenses, other than underwriting discounts and
commissions, payable in connection with the registration of the common stock hereunder. All amounts are estimates except the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>to&nbsp;be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and mailing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">To be completed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the Delaware General Corporation Law, or DGCL, authorizes a corporation to indemnify its directors and officers against liabilities
arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses
(including attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145 permits corporations to pay
expenses (including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain
insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the
power to indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have adopted provisions in our tenth amended and
restated certificate of incorporation to be in effect upon the closing of this offering and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> to be in effect upon the effectiveness of this registration statement of which this
prospectus forms a part that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or
our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These limitations of liability do not alter director liability under the federal securities laws and
do not affect the availability of equitable remedies such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the
<FONT STYLE="white-space:nowrap">by-laws</FONT> to be in effect upon the effectiveness of this registration statement provide that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to enter into indemnification agreements with each of our directors and executive officers. These agreements will provide that we will
indemnify each of our directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146; fees (but excluding judgments, fines and
settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of
that person&#146;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance
provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director referenced herein. Nonetheless, we will agree
in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities
incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will maintain general liability insurance which covers certain liabilities of our directors and
officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended, or the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriting agreement filed as Exhibit&nbsp;1.1 to this registration statement provides for indemnification of us and our directors and officers by
the underwriters against certain liabilities under the Securities Act and the Securities Exchange Act of 1934. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered
Securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the three years preceding the filing of this registration statement, we have issued the following securities that were not
registered under the Securities Act: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>(a) Issuances of Capital Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Set forth below is information regarding securities we have issued within the past three years that were not registered under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2019, with a subsequent closing in December 2019, an aggregate of 57,878,742 shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT>
Convertible Preferred Stock was sold at a purchase price of $0.6911 per share for aggregate proceeds of $40.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2020, with a
subsequent closing in March 2021, an aggregate of 24,598,481 shares of Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock at a purchase price of $0.6911 per share was sold for aggregate proceeds of $17.0&nbsp;million.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2021, an aggregate of 102,671,041 shares of Series E Convertible Preferred Stock at a
purchase price of $0.7839 per share was sold for aggregate proceeds of $80.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing sales of
securities. Unless otherwise stated, the sales of securities described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act, including Regulation&nbsp;D and Rule&nbsp;506 promulgated thereunder, as
transactions by an issuer not involving a public offering. All of the purchasers in these transactions represented to us in connection with their purchase that they were acquiring the securities for investment and not distribution, that they could
bear the risks of the investment and could hold the securities for an indefinite period of time. Such purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made
pursuant to a registration or an available exemption from such registration. All of the foregoing securities are deemed restricted securities for the purposes of the Securities Act. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>(b) Grants and Exercises of Stock Options </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Through September 30, 2021, we have granted stock options to purchase an aggregate of 53,723,418 shares of our common stock, with an exercise price of
$0.20 to $0.70 per share, to employees, directors and consultants pursuant to the 2009 Plan and 2018 Plan. Since January&nbsp;1, 2018, 1,833,479 shares of common stock have been issued upon the exercise of stock options pursuant to the 2009 Plan and
the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The issuances of the securities described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the
Securities Act or Rule&nbsp;701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. The shares of common stock issued upon the exercise of options are deemed to be restricted securities for purposes of the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">(a) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex31.htm">Ninth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Tenth Amended and Restated Certificate of Incorporation of Registrant, to be in effect immediately prior to the completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex33.htm">Bylaws of Registrant, as currently in effect. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of Registrant, to be in effect upon the effectiveness of this registration statement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Common Stock Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex42.htm">Fifth Amended and Restated Investors&#146; Rights Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Goodwin Procter LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex101.htm">2009 Amended and Restated Stock Option and Restricted Stock Plan, and form of award agreements thereunder. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex102.htm">2018 Equity Incentive Plan, and form of award agreements thereunder.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Stock Option and Incentive Plan, and form of award agreements thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Employee Stock Purchase Plan.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Executive Cash Bonus Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement between the Registrant and Elisabet de los Pinos, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement between the Registrant and Julie Feder, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement between the Registrant and Cadmus Rich, to be in effect upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex1011.htm">Exclusive Patent License Agreement with the National Institutes of Health, dated September&nbsp;3, 2013 as amended. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex1012.htm">Exclusive License and Supply Agreement with <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc., dated January&nbsp;31, 2014, as amended. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex1013.htm">License Agreement with Clearside Biomedical, Inc., dated July&nbsp;3, 2019. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex1014.htm">Lease Agreement with Bolton Street Partners, LLC, dated June 9, 2011, as amended. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex211.htm">List of Subsidiaries of Registrant.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d209588dex231.htm">Consent of Ernst&nbsp;&amp; Young, independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Goodwin Procter LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#ii209588_sig">Power of Attorney (included on signature page)</A>.</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Previously filed </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit (indicated by asterisks) will be omitted in accordance with the rules of the Securities and
Exchange Commission. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">(b) Financial Statements Schedules: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Schedules have
been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17.
Undertakings. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Act, may be permitted to
directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person
of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of
such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Registrant hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL">(a) For purposes of determining any liability under the Act, the information omitted from a form of prospectus filed as part of this registration
statement in reliance upon Rule&nbsp;430A and contained in the form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Act, shall be deemed to be part of this registration statement as of the time
it was declared effective. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL">(b) For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="ii209588_sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the 8th&nbsp;day of October, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AURA BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/&nbsp;&nbsp;Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Name: Elisabet de los Pinos, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Title: President and Chief
Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>POWER OF ATTORNEY AND SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each individual whose signature appears below hereby constitutes and appoints Elisabet de los Pinos, Ph.D. and Julie Feder as such person&#146;s true
and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent with full power of substitution and resubstitution, for such person in such person&#146;s name, place and stead, in any and all
capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement (or any Registration Statement for the same offering that is to be effective upon filing pursuant to Rule&nbsp;462(b) under the
Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully
to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or any substitute
or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement and power of attorney have been signed by the following persons in the capacities and on the date indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/&nbsp;&nbsp;Elisabet de los Pinos</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Elisabet de los Pinos, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Principal Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October&nbsp;8,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/&nbsp;&nbsp;Julie Feder</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Julie Feder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Principal Financial Officer and Principal Accounting Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">October&nbsp;8,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/&nbsp;&nbsp;David Johnson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">David Johnson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">October&nbsp;8,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/&nbsp;&nbsp;Giovanni Mariggi, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Giovanni Mariggi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">October&nbsp;8,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/&nbsp;&nbsp;Antony Mattessich</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Antony Mattessich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">October&nbsp;8,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/&nbsp;&nbsp;Raj Parekh, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Raj Parekh, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">October&nbsp;8,&nbsp;2021</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/&nbsp;&nbsp;Sapna Srivastava, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Sapna Srivastava, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">October&nbsp;8,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/&nbsp;&nbsp;Karan Takhar</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Karan Takhar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">October&nbsp;8,&nbsp;2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d209588dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NINTH AMENDED AND RESTATED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AURA BIOSCIENCES, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections 242 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aura Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State
of Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;That the name of this corporation is Aura Biosciences, Inc., and that this corporation was originally incorporated
pursuant to the General Corporation Law on January&nbsp;13, 2009 under the name Aura Biosciences, Inc., and that an Amended and Restated Certificate of Incorporation was filed on February&nbsp;3, 2009, and further amended on July&nbsp;14, 2009, and
that a Second Amended and Restated Certificate of Incorporation was filed on May&nbsp;10, 2011, and further amended on August&nbsp;29, 2012, and that a Third Amended and Restated Certificate of Incorporation was filed on March&nbsp;26, 2014, and
further amended on June&nbsp;19, 2014, and that a Fourth Amended and Restated Certificate of Incorporation was filed on February&nbsp;23, 2015, and further amended on March&nbsp;31, 2016, and that a Fifth Amended and Restated Certificate of
Incorporation was filed on September&nbsp;15, 2016, and further amended on October&nbsp;19, 2017, and that a Sixth Amended and Restated Certificate of Incorporation was filed on December&nbsp;20, 2017, and further amended on October&nbsp;4, 2018,
that a Seventh Amended and Restated Certificate of Incorporation was filed on March&nbsp;29, 2019 and that an Eighth Amended and Restated Certificate of Incorporation was filed on June&nbsp;25, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;That the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation
of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders
therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Certificate of
Incorporation of this corporation be amended and restated in its entirety to read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>: The name of this corporation
is Aura Biosciences, Inc. (the &#147;<B>Corporation</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>: The address of the registered office of the Corporation in
the State of Delaware is Corporation Trust Center, 1209 Orange Street, in Wilmington, DE 19801, County of New Castle. The name of its registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIRD</B>: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOURTH</B>: The total number of shares of all classes of stock which the Corporation
shall have authority to issue is (i) 367,512,342 shares of Class&nbsp;A Common Stock, $0.00001 par value per share (&#147;<B>Class</B><B></B><B>&nbsp;A Common Stock</B>&#148;), (ii) 102,671,041 shares of Class&nbsp;B common stock, $0.00001 par value
per share (&#147;<B>Class</B><B></B><B>&nbsp;B</B> <B>Common Stock</B>&#148; and collectively with the Class&nbsp;A Common Stock, &#147;<B>Common Stock</B>&#148;) and (iii) 308,506,707 shares of Preferred Stock, $0.00001 par value per share
(&#147;<B>Preferred Stock</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the acceptance of this Ninth Amended and Restated Certificate of Incorporation (the
&#147;<B>Certificate of Incorporation</B>&#148;) for filing with the Secretary of State of the State of Delaware (the time of acceptance shall be referred to herein as the &#147;<B>Effective Time</B>&#148;), each share of Common Stock of the
Corporation outstanding immediately prior to the Effective Time shall, without any further action by any stockholder, be reclassified as, and shall become, one share of Class&nbsp;A Common Stock. Any stock certificate that immediately prior to the
Effective Time represented shares of the Corporation&#146;s Common Stock shall, from and after the Effective Time, be deemed to represent the same number of shares of Class&nbsp;A Common Stock, without the need for surrender or exchange thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the shares of Preferred Stock authorized, 1,701,141 shares shall be designated as Series A Convertible Preferred Stock
(&#147;<B>Series A Preferred Stock</B>&#148;), 3,298,732 shares shall be designated as Series <FONT STYLE="white-space:nowrap">A-1</FONT> Convertible Preferred Stock (&#147;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock</B>&#148;), 4,325,021 shares shall be designated as Series <FONT STYLE="white-space:nowrap">A-2</FONT> Convertible Preferred Stock (&#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</B>&#148; and, with the Series A
Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, collectively the &#147;<B>Junior Preferred Stock</B>&#148;), 22,705,646 shares shall be designated as Series B Convertible Preferred Stock (&#147;<B>Series B
Preferred Stock</B>&#148;), 58,109,711 shares shall be designated as Series <FONT STYLE="white-space:nowrap">C-1</FONT> Convertible Preferred Stock (&#147;<B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock</B>&#148;) and
33,218,192 shares shall be designated as Series <FONT STYLE="white-space:nowrap">C-2</FONT> Convertible Preferred Stock (&#147;<B>Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock</B>&#148;, and with the Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, collectively the &#147;<B>Series C Preferred Stock</B>&#148;), 57,878,742 shares shall be designated as Series <FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock
(&#147;<B>Series <FONT STYLE="white-space:nowrap">D-1</FONT> Preferred Stock</B>&#148;), 24,598,481 shares shall be designated as Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock (&#147;<B>Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Preferred Stock</B>,&#148; with the Series <FONT STYLE="white-space:nowrap">D-1</FONT> Preferred Stock, collectively the &#147;<B>Series D Preferred Stock</B>&#148;) and 102,671,041 shares shall be designated as
Series E Convertible Preferred Stock (&#147;<B>Series E Preferred Stock</B>&#148; together with the Series D Preferred Stock, Series C Preferred Stock and the Series B Preferred Stock, collectively the &#147;<B>Senior Preferred Stock</B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or
restrictions thereof in respect of each class of capital stock of the Corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;COMMON STOCK </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. The voting, dividend and liquidation rights of the holders of the Class&nbsp;A Common Stock and
Class&nbsp;B Common Stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting</U>. The holders of the Class&nbsp;A Common Stock are entitled to one vote for each share of Class&nbsp;A
Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Class&nbsp;A Common Stock, as such, shall not be entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of
Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation or pursuant to the General Corporation
Law. Except as otherwise required by law, holders of Class&nbsp;B Common Stock shall not be entitled to vote on any matter on which the holders of Class&nbsp;A Common Stock or Preferred Stock shall be entitled to vote, and shares of Class&nbsp;B
Common Stock shall not be included in determining the number of shares of Common Stock voting or entitled to vote on any such matters. The number of authorized shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock may be increased or
decreased (but not below the number of shares thereof then outstanding) or the number of shares thereof reserved for issuance pursuant to Section&nbsp;1.5 of the Purchase Agreement by (in addition to any vote of the holders of one or more series of
Preferred Stock that may be required by the terms of the Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of
capital stock of the Corporation entitled to vote, voting together as a single class, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal Status</U>. Except as expressly set forth in this Article Fourth with respect to voting rights and the
conversion rights set forth in Article Fourth, Part D, Section&nbsp;1, the Class&nbsp;B Common Stock shall have the same rights and powers of, rank equally to, share ratably with, and be identical in all respects and as to all matters to, the
Class&nbsp;A Common Stock. If the Corporation in any manner subdivides or combines the shares of Class&nbsp;A Common Stock, then the shares of Class&nbsp;B Common Stock will be subdivided or combined in the same proportion and manner, and if the
Corporation in any manner subdivides or combines the shares of Class&nbsp;B Common Stock, then the shares of Class&nbsp;A Common Stock will be subdivided or combined in the same proportion and manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;PREFERRED STOCK </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance and Reissuance</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preferred Stock may be issued from time to time in one or more series, each of such series to consist of such number of shares and to have such
terms, rights, powers, and preferences, and the qualifications and limitations with respect thereto, as stated or expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;SERIES A PREFERRED STOCK, SERIES <FONT STYLE="white-space:nowrap">A-1</FONT> PREFERRED STOCK, SERIES <FONT
STYLE="white-space:nowrap">A-2</FONT> PREFERRED STOCK, SERIES B PREFERRED STOCK, SERIES <FONT STYLE="white-space:nowrap">C-1</FONT> PREFERRED STOCK, SERIES <FONT STYLE="white-space:nowrap">C-2</FONT> PREFERRED STOCK, SERIES <FONT
STYLE="white-space:nowrap">D-1</FONT> PREFERRED STOCK, SERIES <FONT STYLE="white-space:nowrap">D-2</FONT> PREFERRED STOCK AND SERIES E PREFERRED STOCK </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Preferred Stock have the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless
otherwise indicated, references to &#147;Sections&#148; or &#147;Subsections&#148; in this Part C of this Article Fourth refer to sections and subsections of Part C of this Article Fourth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;From and after the date of the issuance of any shares of Series E Preferred Stock, dividends at the rate of seven
percent (7%) per annum of the Series E Original Issue Price (as defined below) shall accrue on such shares of Series E Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Series E Preferred Stock (the &#147;<B>Series E Accruing Dividends</B>&#148;). Series E Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative, but not compounding;
<U>provided</U>, <U>however</U>, that except as set forth below and in <U>Section</U><U></U><U>&nbsp;2</U>, such Series E Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under
no obligation to pay such Series E Accruing Dividends. The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock
payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series E Preferred Stock then outstanding shall first receive, or simultaneously
receive, a dividend on each outstanding share of Series E Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series E Accruing Dividends then accrued on such share of Series E Preferred Stock and not
previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series E Preferred Stock as would equal the product of (1)&nbsp;the dividend payable
on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series E
Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of
Series E Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the applicable Series E Original Issue
Price; provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Series E Preferred Stock
pursuant to this <U>Subsection 1.1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series E Preferred Stock dividend. The &#147;<B>Series E Original Issue Price</B>&#148; shall
mean $0.7839 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series E Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;From and after (x)&nbsp;the original date of issuance pursuant to the Series D Purchase Agreement with respect to
any shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Preferred Stock, dividends at the rate of seven percent (7%) per annum of the Series <FONT STYLE="white-space:nowrap">D-1</FONT> Original Issue Price (as defined below) shall accrue on
such shares of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Preferred Stock (the &#147;<B>Series <FONT STYLE="white-space:nowrap">D-1</FONT> Accruing Dividends</B>&#148;) and (y)&nbsp;the date of issuance of any shares of Series
<FONT STYLE="white-space:nowrap">D-2</FONT> Preferred Stock, dividends at the rate of seven percent (7%) per annum of the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Original Issue Price (as defined below) shall accrue on such shares of
Series <FONT STYLE="white-space:nowrap">D-2</FONT> Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Preferred Stock (the &#147;<B>Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Accruing Dividends</B>&#148; and together with the Series <FONT STYLE="white-space:nowrap">D-1</FONT> Accruing Dividends, the &#147;<B>Series D Accruing Dividends</B>&#148;). Series D Accruing Dividends shall
accrue from day to day, whether or not declared, and shall be cumulative, but not compounding; <U>provided</U>,<U> however</U>, that except as set forth below and in <U>Section</U><U></U><U>&nbsp;2</U>, such Series D Accruing Dividends shall be
payable only when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series D Accruing Dividends. The Corporation shall not declare, pay or set aside any dividends on shares of any other class
or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock or the Series E Accruing Dividends)) unless (in addition to the obtaining of any consents required elsewhere in the
Certificate of Incorporation) the holders of the Series D Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series D Preferred Stock in an amount at least equal to the greater of
(i)&nbsp;the amount of the aggregate Series D Accruing Dividends then accrued on such share of Series D Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible
into Common Stock, that dividend per share of Series D Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been
converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series D Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend
or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series D Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or
series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such
class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the applicable Series D Original Issue Price; provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class
or series of capital stock of the Corporation, the dividend payable to the holders of Series D Preferred Stock pursuant to this <U>Subsection 1.2</U> shall be calculated based upon the dividend on the class or series of capital stock that would
result in the highest Series D Preferred Stock dividend. The &#147;<B>Series <FONT STYLE="white-space:nowrap">D-1</FONT> Original Issue Price</B>&#148; shall mean $0.6911 per share, subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">D-1</FONT> Preferred Stock. The &#147;<B>Series <FONT STYLE="white-space:nowrap">D-2</FONT> Original Issue
Price</B>&#148; shall mean $0.6911 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">D-2</FONT>
Preferred Stock. The Series <FONT STYLE="white-space:nowrap">D-1</FONT> Original Issue Price and Series <FONT STYLE="white-space:nowrap">D-2</FONT> Original Issue Price shall be referred to in the aggregate as the &#147;<B>Series D Original Issue
Price</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp;From and after the date of the issuance of any shares of Series C Preferred Stock, dividends
at the rate of seven percent (7%) per annum of (y)&nbsp;the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price (as defined below) shall accrue on such shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock
(subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock (the &#147;<B>Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Accruing Dividends</B>&#148;) and (z)&nbsp;the Series <FONT STYLE="white-space:nowrap">C-2</FONT> Original Issue Price (as defined below) shall accrue on such shares of Series
<FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series
<FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock (the &#147;<B>Series <FONT STYLE="white-space:nowrap">C-2</FONT> Accruing Dividends</B>&#148; and together with the Series <FONT STYLE="white-space:nowrap">C-1</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Accruing Dividends, the &#147;<B>Series C Accruing Dividends</B>&#148;). Series C Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative, but not
compounding; <U>provided</U>, <U>however</U>, that except as set forth below and in <U>Section</U><U></U><U>&nbsp;2</U>, such Series C Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors and the Corporation
shall be under no obligation to pay such Series C Accruing Dividends. The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of
Common Stock payable in shares of Common Stock, the Series D Accruing Dividends or the Series E Accruing Dividends) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the
Series C Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series C Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series C
Accruing Dividends then accrued on such share of Series C Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of
Series C Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the
number of shares of Common Stock issuable upon conversion of a share of Series C Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any
class or series that is not convertible into Common Stock, at a rate per share of Series C Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original
issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying
such fraction by an amount equal to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price; provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series
of capital stock of the Corporation, the dividend payable to the holders of Series C Preferred Stock pursuant to this <U>Subsection 1.3</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the
highest Series C Preferred Stock dividend. The &#147;<B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price</B>&#148; shall mean $0.5213 per share, subject to appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock. The &#147;<B>Series <FONT STYLE="white-space:nowrap">C-2</FONT> Original Issue Price</B>&#148; shall mean
$0.36491 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.4&nbsp;&nbsp;&nbsp;&nbsp;From and after the date of the issuance of any shares of Series B Preferred Stock, dividends at the rate per annum
of $0.0869645 per share shall accrue on such shares of Series B Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred
Stock) (the &#147;<B>Series B Accruing Dividends</B>&#148;). Series B Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative, but not compounding; <U>provided</U>, <U>however</U>, that except as set forth
below and in <U>Section</U><U></U><U>&nbsp;2</U>, such Series B Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series B Accruing Dividends.
The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock, the Series C Accruing Dividends, the Series D Accruing Dividends or the Series E Accruing Dividends) unless (in addition to the obtaining of any consents required elsewhere in the
Certificate of Incorporation) the holders of the Series B Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series B Preferred Stock in an amount at least equal to the greater of
(i)&nbsp;the amount of the aggregate Series B Accruing Dividends then accrued on such share of Series B Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible
into Common Stock, that dividend per share of Series B Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been
converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series B Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend
or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series B Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or
series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such
class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the Series B Original Issue Price (as defined below); provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than
one class or series of capital stock of the Corporation, the dividend payable to the holders of Series B Preferred Stock pursuant to this <U>Subsection 1.4</U> shall be calculated based upon the dividend on class or series of capital stock that
would result in the highest Series B Preferred Stock dividend. The &#147;<B>Series B Original Issue Price</B>&#148; shall mean $1.24235 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or
other similar recapitalization with respect to the Series B Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.5&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall not
declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock or as provided in <U>Subsections 1.1</U>,
<U>1.2</U>, <U>1.3</U> <U>1.4</U> or <U>Section</U><U></U><U>&nbsp;2</U>) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Junior Preferred Stock then outstanding shall
first receive, or simultaneously receive, a dividend on each outstanding share of each series of Junior Preferred Stock in an amount at least equal to (i)&nbsp;in the case of a dividend on Common Stock or any class or series that is convertible into
Common Stock, that dividend per share of a series of Junior Preferred Stock as would equal the product of (A)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had
been converted into Common Stock and (B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of that series of Junior Preferred Stock, in each case calculated on the record date for determination of holders entitled to
receive such dividend or (ii)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of a series of Junior Preferred Stock determined by (A)&nbsp;dividing the amount of the dividend
payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to such class or series) and (B)&nbsp;multiplying such fraction by an amount equal to, in the case of Series A Preferred Stock, the Series A Original Issue Price (as defined below) or, in the case of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price (as defined below) or, in the case of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, the Series
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price (as defined below); provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more
than one class or series of capital stock of the Corporation, the dividend payable to the holders of Junior Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on class or series of
capital stock that would result in the highest Junior Preferred Stock dividend. The &#147;<B>Series A Original Issue Price</B>&#148; shall mean $2.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A Preferred Stock. The &#147;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price</B>&#148; shall mean $2.4847 per share, subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. The &#147;<B>Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price</B>&#148; shall mean $1.24235 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect
to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Liquidation, Dissolution or Winding
Up; Certain Mergers, Consolidations and Asset Sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Series E Liquidation Preference</U>. In the event of
any Deemed Liquidation Event (as defined below), either voluntary or involuntary, the holders of shares of Series E Preferred Stock then outstanding shall be entitled to receive, prior and in preference to any distribution of the proceeds of such
Deemed Liquidation Event (the &#147;<B>Proceeds</B>&#148;) to the holders of all Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Junior Preferred Stock and Common Stock by reason of their ownership thereof an amount per
share equal to the sum of the Series E Original Issue Price plus the Series E Accruing Dividend, plus any other declared but unpaid dividends on such share (the &#147;<B>Series E Liquidation Preference</B>&#148;). If, upon the occurrence of such
event, the Proceeds thus distributed among the holders of the Series E Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid Series E Liquidation Preference, then the entire Proceeds legally available for
distribution shall be distributed ratably among the holders of the Series E Preferred Stock in proportion to the full preferential amount that each such holder is otherwise entitled to receive under this <U>Subsection 2.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Series D Liquidation Preference</U>. Upon the completion of the distribution required by <U>Subsection 2.1</U>
above, in the event of any Deemed Liquidation Event (as defined below), either voluntary or involuntary, the holders of shares of Series D Preferred Stock then outstanding shall be entitled to receive, prior and in preference to any distribution of
Proceeds to the holders of all Series C Preferred Stock, Series B Preferred Stock, Junior Preferred Stock and Common Stock by reason of their ownership thereof an amount per share equal to the sum of (1)&nbsp;in the case of the Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">D-1</FONT> Original Issue Price plus the Series <FONT STYLE="white-space:nowrap">D-1</FONT> Accruing Dividend, plus any other declared but unpaid
dividends on such share (the &#147;<B>Series <FONT STYLE="white-space:nowrap">D-1</FONT> Liquidation Preference</B>&#148;), and (2)&nbsp;in the case of the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Preferred Stock, the Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Original Issue Price plus the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Accruing Dividend, plus any other declared but unpaid dividends on such share (the &#147;<B>Series
<FONT STYLE="white-space:nowrap">D-2</FONT> Liquidation Preference</B>&#148;). If, upon the occurrence of such event, the Proceeds thus distributed among the holders of the Series D Preferred Stock shall be insufficient to permit the payment to such
holders of the full aforesaid Series D Liquidation Preference, then the entire Proceeds legally available for distribution to the holders of shares of Series D Preferred Stock shall be distributed ratably among the holders of the Series D Preferred
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock in proportion to the full preferential amount that each such holder is otherwise entitled to receive under this <U>Subsection 2.2</U>. For the avoidance of doubt, the Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Liquidation Preference and the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Liquidation Preference shall be paid to the holders of the Series D Preferred Stock <I>pari passu</I> and shall be referred to in
the aggregate as the &#147;<B>Series D Liquidation Preference</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Series C Liquidation
Preference</U>. Upon the completion of the distribution required by <U>Subsection 2.1</U> and <U>2.2</U> above, in the event of any Deemed Liquidation Event (as defined below), either voluntary or involuntary, the holders of shares of Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Stock then outstanding shall be entitled to receive, prior and in preference to any distribution of the Proceeds thereof to the holders of all Series B Preferred Stock, Junior Preferred Stock and
Common Stock by reason of their ownership thereof an amount per share equal to the sum of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price (as defined above) plus the Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Accruing Dividend, plus any other accrued or declared but unpaid dividends on such share (the &#147;<B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Liquidation Preference</B>&#148;), and the holders of shares of Series <FONT
STYLE="white-space:nowrap">C-2</FONT> Preferred Stock then outstanding shall be entitled to receive, prior and in preference to any distribution of the Proceeds thereof to the holders of all Series B Preferred Stock, Junior Preferred Stock and
Common Stock by reason of their ownership thereof an amount per share equal to the sum of the Series <FONT STYLE="white-space:nowrap">C-2</FONT> Original Issue Price (as defined below) plus the Series <FONT STYLE="white-space:nowrap">C-2</FONT>
Accruing Dividend, plus any other accrued or declared but unpaid dividends on such share (the &#147;<B>Series <FONT STYLE="white-space:nowrap">C-2</FONT> Liquidation Preference</B>&#148;). If, upon the occurrence of such event, the Proceeds thus
distributed among the holders of the Series C Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid Series <FONT STYLE="white-space:nowrap">C-1</FONT> Liquidation Preference and Series <FONT
STYLE="white-space:nowrap">C-2</FONT> Liquidation Preference, then the entire Proceeds legally available for distribution to the holders of Series C Preferred Stock shall be distributed ratably among the holders of the Series C Preferred Stock in
proportion to the full preferential amount that each such holder is otherwise entitled to receive under this <U>Subsection 2.3</U>. For the avoidance of doubt, the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Liquidation Preference and the
Series <FONT STYLE="white-space:nowrap">C-2</FONT> Liquidation Preference shall be paid to the holders of the Series C Preferred Stock <I>pari passu</I> and shall be referred to in the aggregate as the &#147;<B>Series C Liquidation
Preference</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Series B Liquidation Preference</U>. Upon the completion of the distributions
required by <U>Subsections 2.1</U>, <U>2.2</U> and <U>2.3</U> above, in the event of any Deemed Liquidation Event, either voluntary or involuntary, the holders of shares of Series B Preferred Stock then outstanding shall be entitled to receive,
prior and in preference to any distribution of the Proceeds thereof to the holders of all Junior Preferred Stock and Common Stock by reason of their ownership thereof an amount per share equal to the sum of the Series B Original Issue Price (as
defined above) plus the Series B Accruing Dividends, plus any other accrued or declared but unpaid dividends on such share (the &#147;<B>Series B Liquidation Preference</B>&#148;). If, upon the occurrence of such event, the Proceeds thus distributed
among the holders of the Series B Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid Series B Liquidation Preference, then the entire Proceeds legally available for distribution to the holders of Series
B Preferred Stock shall be distributed ratably among the holders of the Series B Preferred Stock in proportion to the full preferential amount that each such holder is otherwise entitled to receive under this <U>Subsection 2.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Junior Preferred Stock Liquidation Preference</U>. Upon the completion of the distributions required by
<U>Subsections 2.1</U>, <U>2.2</U>, <U>2.3 and 2.4</U> above, in the event of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Deemed Liquidation Event, either voluntary or involuntary, the holders of shares of Junior Preferred Stock shall be entitled to receive on a pari passu basis, prior and in preference to any
distribution of the Proceeds to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the following: (i)&nbsp;the holders of shares of Series A Preferred Stock then outstanding shall be entitled to receive an
amount per share equal to the greater of (A)&nbsp;the Series A Original Issue Price, plus any dividends declared but unpaid thereon, or (B)&nbsp;such amount per share as would have been payable had all shares of Series A Preferred Stock been
converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the &#147;<B>Series A Liquidation
Preference</B>&#148;); (ii) the holders of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then outstanding shall be entitled to receive an amount per share equal to the greater of (A)&nbsp;the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Original Issue Price, plus any dividends declared but unpaid thereon, or (B)&nbsp;such amount per share as would have been payable had all shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the &#147;<B>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Liquidation Preference</B>&#148;); and (iii)&nbsp;the holders of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock then outstanding shall be entitled to receive an amount per share
equal to the greater of (A)&nbsp;the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price, plus any dividends declared but unpaid thereon, or (B)&nbsp;such amount per share as would have been payable had all shares of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter
referred to as the &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Liquidation Preference</B>&#148;). If upon any Deemed Liquidation Event, the Proceeds shall be insufficient to pay the holders of shares of Junior Preferred Stock the
full amount to which they shall be entitled under this <U>Subsection 2.5</U>, the holders of shares of such Junior Preferred Stock shall share ratably in the distribution of the Proceeds remaining after completion of the distributions required by
<U>Subsections 2.1</U>, <U>2.2</U>, <U>2.3 and 2.4</U> in proportion to the full preferential amount that each such holder is otherwise entitled to receive under this <U>Subsection 2.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Distribution Waterfall After Liquidation Preferences</U>. Upon the completion of the distributions required by
<U>Subsections 2.1</U>, <U>2.2</U>, <U>2.3</U>, <U>2.4</U> and 2.5 above, in the event of any Deemed Liquidation Event, either voluntary or involuntary, all of the remaining Proceeds available for distribution to stockholders (&#147;<B>Remaining
Proceeds</B>&#148;) shall be distributed among the holders of the shares of Senior Preferred Stock and Common Stock, pro rata based on the number of shares of Common Stock that each such holder would hold if all shares of Senior Preferred Stock had
been converted to Common Stock pursuant to the terms of this Certificate of Incorporation immediately prior to such Deemed Liquidation Event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definition</U>. Each of the following events shall be considered a &#147;<B>Deemed Liquidation Event</B>&#148;
unless holders of at least sixty percent (60%) of the outstanding Senior Preferred Stock, voting together as a single class (as determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) (the &#147;<B>Required
Preferred Holders</B>&#148;) and, if the proceeds per share distributed to the holders of Series E Preferred Stock would be less than the Series E Original Issue Price, the holders of a majority of the outstanding shares of Series E Preferred Stock
(the &#147;<B>Required Series E Holders</B>&#148;), elect otherwise by written notice sent to the Corporation at least 10 days prior to the effective date of any such event: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;liquidation, dissolution or a winding up of the Corporation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;a merger or consolidation in which </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger or consolidation, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger or consolidation involving the Corporation or a subsidiary in which
the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or
consolidation, at least a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately
following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related
transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one
or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other
disposition is to a wholly owned subsidiary of the Corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.7.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Effecting a Deemed Liquidation
Event</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in
<U>Subsection&nbsp;2.7.1(d)(i)</U> unless the agreement or plan of merger or consolidation for such transaction (the &#147;<B>Merger Agreement</B>&#148;) provides that the consideration payable to the stockholders of the Corporation shall be
allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U>, <U>2.2</U>, <U>2.3</U>, <U>2.4,</U> <U>2.5</U> and <U>2.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Deemed Liquidation Event referred to in <U>Subsection 2.7.1(b)(ii)</U> or <U>2.7.1(c)</U> if the
Corporation does not effect a dissolution of the Corporation under the General Corporation Law within 90 days after such Deemed Liquidation Event, then (1)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later
than the 90th day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following <U>clause (ii)</U>&nbsp;to require the redemption of such shares
of Preferred Stock, and (ii)&nbsp;if the Required Preferred Holders so request in a written instrument delivered to the Corporation not later than 120 days after such Deemed Liquidation Event, the Corporation shall use the consideration received by
the Corporation from such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation), together with any other assets of the Corporation available for distribution to its stockholders (the &#147;<B>Available Proceeds</B>&#148;), to the extent legally available
therefor, on the 150th day (&#147;<B>Redemption Date</B>&#148;) after such Deemed Liquidation Event, to redeem all outstanding shares of Preferred Stock at a price per share equal to the amount that such holders would have received if the Available
Proceeds were distributed to such holders in connection with the Deemed Liquidation Event pursuant to <U>Subsections 2.1</U>, <U>2.2</U>, <U>2.3</U>, <U>2.4, 2.5</U> and <U>2.6</U> above. Notwithstanding the foregoing, in the event of a redemption
pursuant to the preceding sentence where the Available Proceeds are less than the aggregate Series E Liquidation Preference plus the aggregate Series D Liquidation Preference, plus the aggregate Series C Liquidation Preference, plus the aggregate
Series B Liquidation Preference, plus the aggregate Series A Liquidation Preference, plus the aggregate Series <FONT STYLE="white-space:nowrap">A-1</FONT> Liquidation Preference, plus the aggregate Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Liquidation Preference, the Corporation shall redeem the Preferred Stock as follows in the following order: (i)&nbsp;if the Available Proceeds equal or exceed the Series E Liquidation Preference, multiplied by the then-outstanding number of shares
of Series E Preferred Stock, then (v)&nbsp;first, all of the Series E Preferred Stock shall be redeemed at a price per share equal to the Series E Liquidation Preference; (w)&nbsp;second, all of the Series D Preferred Stock shall be redeemed, in the
case of a share of Series <FONT STYLE="white-space:nowrap">D-1</FONT> Preferred Stock, at a price per share equal to the Series <FONT STYLE="white-space:nowrap">D-1</FONT> Liquidation Preference; and in the case of a share of Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Preferred Stock, at a price per share equal to the Series <FONT STYLE="white-space:nowrap">D-2</FONT> Liquidation Preference; (x)&nbsp;third, all of the Series C Preferred Stock shall be redeemed, in the case of
a share of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, at a price per share equal to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Liquidation Preference; and in the case of a share of Series <FONT
STYLE="white-space:nowrap">C-2</FONT> Preferred Stock, at a price per share equal to the Series <FONT STYLE="white-space:nowrap">C-2</FONT> Liquidation Preference, (y)&nbsp;fourth, all of the Series B Preferred Stock shall be redeemed at a price per
share equal to the Series B Liquidation Preference, and (z)&nbsp;fifth, the remaining Available Proceeds shall be used to redeem a pro rata portion of the then-outstanding Junior Preferred Stock from all holders of Junior Preferred Stock, in the
case of a share of Series A Preferred Stock, at a price per share equal to the Series A Liquidation Preference; in the case of a share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, at a price per share equal to the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Liquidation Preference; and, in the case of a share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, at a price per share equal to the Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Liquidation Preference and (ii)&nbsp;if the Available Proceeds are less than or equal to the Series E Liquidation Preference, multiplied by the then-outstanding number of shares of Series E Preferred Stock, then the Available Proceeds shall all be
used to redeem a pro rata portion of the Series E Preferred Stock from all of the holders of Series E Preferred Stock, at a price per share equal to the Series E Liquidation Preference. For the avoidance of doubt, the intent of the foregoing
sentence is to redeem only a portion of the Preferred Stock at the full preferential amount per share that the holders of such redeemed Preferred Stock are entitled to receive under <U>Sections 2.1</U>, <U>2.2</U>, <U>2.3</U>, <U>2.4</U> and
<U>2.5</U> above and, after such redemption, certain shares of Preferred Stock will remain outstanding to the extent of the shortfall in Available Proceeds, but the Corporation shall redeem all remaining shares of Preferred Stock in accordance with
this <U>Subsection 2.7.2(b)</U> as soon after the Corporation has funds legally available therefor as it may lawfully do so under Delaware law. Prior to the distribution or redemption provided for in this <U>Subsection 2.7.2(b)</U>, the Corporation
shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Corporation is required to redeem the Preferred Stock pursuant to <U>Subsection
2.7.2(b)</U>, the Corporation shall send written notice of the mandatory redemption (the &#147;<B>Redemption Notice</B>&#148;) to each holder of record of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock not less than 40 days prior to the Redemption Date. Each Redemption Notice shall state: (i)&nbsp;the number of shares of Preferred Stock held by the holder that the Corporation
shall redeem on the Redemption Date specified in the Redemption Notice; (ii)&nbsp;the Redemption Date and the price per share of Preferred Stock to be paid by the Corporation (the &#147;<B>Redemption Price</B>&#148;); (iii) the date upon which the
holder&#146;s right to convert such shares terminates (as determined in accordance with <U>Subsection 4.1</U>); and (iv)&nbsp;that the holder is to surrender to the Corporation, in the manner and at the place designated, his, her or its certificate
or certificates representing the shares of Preferred Stock to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;On or before the Redemption Date,
each holder of shares of Preferred Stock to be redeemed on such Redemption Date, unless such holder has exercised his, her or its right to convert such shares as provided in <U>Section</U><U></U><U>&nbsp;4</U>, shall surrender the certificate or
certificates representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation
against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the Redemption
Price for such shares shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. In the event less than all of the shares of Preferred Stock represented by a certificate are redeemed, a
new certificate representing the unredeemed shares of Preferred Stock shall promptly be issued to such holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;If the Redemption Notice shall have been duly given, and if on the applicable Redemption Date the Redemption Price
payable upon redemption of the shares of Preferred Stock to be redeemed on such Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding
that the certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, dividends with respect to such shares of Preferred Stock shall cease to accrue after such Redemption Date and all rights
with respect to such shares shall forthwith after the Redemption Date terminate, except only the right of the holders to receive the Redemption Price without interest upon surrender of their certificate or certificates therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its
subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred
Stock following redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that (i)&nbsp;the consideration payable to the stockholders of the
Corporation in a SPAC Transaction (as defined in the Purchase Agreement) or Deemed Liquidation Event includes shares of a class of voting capital stock of the acquirer in a SPAC Transaction or Deemed Liquidation Event or any successor or parent
corporation that is registered under Section&nbsp;12(b) or 12(g) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;) and the rules and regulations promulgated thereunder, and (ii)&nbsp;at the time of the
consummation of such SPAC Transaction or Deemed Liquidation Event, there is one or more Electing Investor (as defined in the Purchase Agreement), then, as a condition to the effectiveness of such SPAC Transaction or Deemed Liquidation Event, the
Merger Agreement (or such other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement to effect such SPAC Transaction or Deemed Liquidation Event) shall provide that the consideration payable to the Electing Investor shall be subject to, and comply with, the Limitation
(as defined in the Purchase Agreement), <I>mutatis mutandis</I>, such that no Electing Investor would, after consummation, become in the aggregate, directly or indirectly, the beneficial owner(s) of more than the Limitation of such class of voting
stock of such acquirer, SPAC, successor or parent corporation, with the balance of any shares to be issued in <FONT STYLE="white-space:nowrap">non-voting</FONT> stock that is economically equivalent to, and convertible into, voting stock of such
acquirer, SPAC, successor or parent corporation on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">share-for-share</FONT></FONT> basis, with appropriate conversion limitations. The term &#147;beneficial owner&#148; (and its
correlates &#147;beneficially own&#148; and &#147;beneficial ownership&#148;) shall have the meaning given such terms in Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.7.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock
of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or
the acquiring person, firm or other entity. The value of such property, rights or securities shall be determined in good faith by the Board of Directors of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.7.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to
<U>Subsection 2.7.1(d)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<B>Additional Consideration</B>&#148;), the Merger Agreement shall
provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B>Initial Consideration</B>&#148;) shall be allocated among the holders of capital stock of the Corporation in accordance with
<U>Subsections 2.1</U>, <U>2.2</U>, <U>2.3</U>, <U>2.4</U>, <U>2.5</U> and <U>2.6</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration
which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U>, <U>2.2</U>, <U>2.3</U>,
<U>2.4</U>, <U>2.5</U> and <U>2.6</U> after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Subsection 2.7.4</U>, consideration placed into escrow or retained as
holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at
any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of
Class&nbsp;A Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the
Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Class&nbsp;A Common Stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Class&nbsp;A Common Stock basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Election of Directors</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Board Composition.</U> The size of the Board shall be set and remain at no more than seven (7)&nbsp;directors
(or such higher number as may be approved with the written consent of the Required Preferred Holders): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;as
long as any shares of Series E Preferred Stock are outstanding, the holders of record of shares of Series E Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;person (the &#147;<B>Series E
Director</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;as long as any shares of Series D Preferred Stock are outstanding, the holders of record
of shares of Series D Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;person (the &#147;<B>Series D Director</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;as long as any shares of Series C Preferred Stock are outstanding, the holders of record of shares of Series C
Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;person (the &#147;<B>Series C Director</B>&#148; and together with the Series D Director and the Series E Director, the &#147;<B>Preferred
Directors</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;the holders of record of shares of Class&nbsp;A Common Stock, voting together as a
separate class, shall be entitled to elect one (1)&nbsp;person (the &#147;<B>CEO Director</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of record of the shares of Class&nbsp;A
Common Stock and of any other class or series of voting stock (including the Preferred Stock but excluding the Class&nbsp;B Common Stock), exclusively and voting together as a single class, shall be entitled to elect the balance of the total number
of directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum</U>. At any meeting held for the purposes of electing a Series E
Director, the presence in person or by proxy of stockholders holding a majority of the Series E Preferred Stock shall constitute a quorum for the purpose of electing such director. At any meeting held for the purposes of electing a Series D
Director, the presence in person or by proxy of stockholders holding a majority of the Series D Preferred Stock shall constitute a quorum for the purpose of electing such director. At any meeting held for the purposes of electing a Series C
Director, the presence in person or by proxy of stockholders holding a majority of the Series C Preferred Stock shall constitute a quorum for the purpose of electing such directors. At any meeting held for the purposes of electing a CEO Director,
the presence in person or by proxy of stockholders holding a majority of the Class&nbsp;A Common Stock shall constitute a quorum for the purpose of electing such director. At any meeting held for the purposes of electing a director other than the
Series E Director, Series D Director, a Series C Director or a CEO Director, the presence in person or by proxy of the holders of (i)&nbsp;a majority of the outstanding shares of Class&nbsp;A Common Stock and the Preferred Stock, voting together as
a single class, and (ii)&nbsp;the Required Preferred Holders shall constitute a quorum for the purpose of electing directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Series E Preferred Stock Protective Provisions</U>. At any time when originally issued shares of Series E
Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following, or permit or cause any of its subsidiaries to do any of the following, without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent
or affirmative vote of the Required Series E Holders, given in writing or by vote at a meeting, consenting or voting (as the case may be) together as a single class: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1&nbsp;&nbsp;&nbsp;&nbsp;amend, alter, or change the rights, preferences or privileges of the Series E Preferred Stock so as to affect
the Series E Preferred Stock adversely; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2&nbsp;&nbsp;&nbsp;&nbsp; increase or decrease the authorized number of shares of the Series
E Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3&nbsp;&nbsp;&nbsp;&nbsp;amend, waive or modify the Series E Original Issue Price, the Series E Conversion Price
(including any anti-dilution rights with respect thereto) or the Series E Liquidation Preference; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4&nbsp;&nbsp;&nbsp;&nbsp;purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any
distribution on, any shares of capital stock of the Corporation prior to the Series E Preferred Stock other than (i)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the
Corporation or any subsidiary in connection with the cessation of such employment or service at the lower of the fair market value and original purchase price, or (ii)&nbsp;purchases of stock from stockholders of the Corporation in connection with
the Corporation&#146;s exercise of its right of first refusal or similar right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Series D Preferred Stock
Protective Provisions</U>. At any time when originally issued shares of Series D Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following
without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of holders of at least seventy percent (70%) of the outstanding Series D Preferred Stock (as determined on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) (the &#147;<B>Required Series D Holders</B>&#148;), given in writing or by vote at a meeting, consenting or voting (as the case may be) together as a single class: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.1&nbsp;&nbsp;&nbsp;&nbsp;amend, alter or change the rights, preferences or privileges of the Series D Preferred Stock so as to affect the
Series D Preferred Stock adversely; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.2&nbsp;&nbsp;&nbsp;&nbsp; increase or decrease the authorized number of shares of the Series D
Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.3&nbsp;&nbsp;&nbsp;&nbsp;convert the Series D Preferred Stock into Common Stock (unless all shares of Preferred
Stock are converted into Common Stock); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.4&nbsp;&nbsp;&nbsp;&nbsp;take any action resulting in the redemption of any shares of
Series D Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Senior Preferred Stock Protective Provisions</U>. At any time when shares of
Senior Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following, or permit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or cause any subsidiary of the Corporation to do any of the following, without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or
affirmative vote of the Required Preferred Holders, given in writing or by vote at a meeting, consenting or voting (as the case may be) together as a single class: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.1&nbsp;&nbsp;&nbsp;&nbsp;liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of the
Corporation, effect any merger, consolidation, sale or license of all or part of the assets (including intellectual property rights) or shares of the Corporation (except where such sale, lease, transfer, exclusive license or other disposition is to
a wholly owned subsidiary of the Corporation) or any other Deemed Liquidation Event, or consent to any of the foregoing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.2&nbsp;&nbsp;&nbsp;&nbsp;amend, alter, or repeal any provision of the Certificate of Incorporation or Bylaws of the Corporation, or
permit any subsidiary to amend, alter or repeal any provision of its Certificate of Incorporation, Bylaws or other governing documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.3&nbsp;&nbsp;&nbsp;&nbsp;create, or authorize the creation of, any additional class or series of capital stock unless the same ranks
junior to the Senior Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends, and rights of redemption, or increase or decrease the authorized number of
shares of the Common Stock, Junior Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock, Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">D-2</FONT> Preferred Stock or Series E Preferred Stock or increase the authorized number of shares of any additional class or series of capital stock
unless the same ranks junior to the Senior Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends, and rights of redemption; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.4&nbsp;&nbsp;&nbsp;&nbsp;reclassify, alter or amend any existing security of the Corporation or any of its subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.5&nbsp;&nbsp;&nbsp;&nbsp;purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any
distribution on, any shares of capital stock of the Corporation other than (i)&nbsp;dividends or other distributions to the holders of Preferred Stock in accordance with the terms of this Certificate of Incorporation, (ii)&nbsp;repurchases of stock
from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service, which repurchase has been approved in advance by
the Board of Directors of the Corporation or (iii)&nbsp;purchases of stock from stockholders of the Corporation in connection with the Corporation&#146;s exercise of its right of first refusal or similar right, which purchase has been approved in
advance by the Board of Directors of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.6&nbsp;&nbsp;&nbsp;&nbsp;create, or authorize the creation of, or issue, or
authorize the issuance of any debt security, or permit any subsidiary to take any such action with respect to any debt security, if the aggregate indebtedness of the Corporation and its subsidiaries for borrowed money following such action would
exceed $250,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.7&nbsp;&nbsp;&nbsp;&nbsp;create, or hold capital stock in, any subsidiary that is not wholly owned (either directly
or through one or more other subsidiaries) by the Corporation, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively
license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.8&nbsp;&nbsp;&nbsp;&nbsp;create, or authorize the creation of or issuance of any additional equity securities by the Corporation or any
of its subsidiaries, exclusive of option plans approved by the Board of Directors of the Corporation (and options and stock issued thereunder); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.9&nbsp;&nbsp;&nbsp;&nbsp;amend, alter or change the rights, preferences and privileges of the Series B Preferred Stock (which also
requires the consent of holders of a majority of the Series B Preferred Stock), the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock (which also requires the consent of holders of a majority of the Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Stock), or the Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock (which also requires the consent of holders of a majority of the Series <FONT STYLE="white-space:nowrap">C-2</FONT>
Preferred Stock) so as to adversely affect the Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, or Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock, as the case may be; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.10&nbsp;&nbsp;&nbsp;&nbsp;increase or decrease the authorized number of directors comprising the Board or alter the mechanisms or
procedures for designating or electing members of the Board, except as provided in <U>Section</U><U></U><U>&nbsp;3.2</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.11&nbsp;&nbsp;&nbsp;&nbsp;change the current business of the Corporation, add a material new line of business of the Corporation or
abandon a material existing line of the current business of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.12&nbsp;&nbsp;&nbsp;&nbsp;undertake any underwritten
initial public offering other than a Qualified Public Offering (as defined below); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.13&nbsp;&nbsp;&nbsp;&nbsp;increase the number
of shares reserved for issuance to employees and consultants, whether or not pursuant to an equity incentive plan adopted by the Corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Optional Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;Each holder of a share of Preferred Stock shall have the right to convert such Preferred Stock at its option as set
forth in this Section&nbsp;4 (the &#147;<B>Conversion Rights</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion Ratio</U>. Unless otherwise specified herein, each share of Preferred Stock shall be convertible,
at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable shares of Class&nbsp;A Common Stock and/or
Class&nbsp;B Common Stock, as applicable, as is determined by dividing (i)&nbsp;in the case of Series A Preferred Stock, the Series A Original Issue Price by the Series A Conversion Price (as defined below) in effect at the time of conversion,
(ii)&nbsp;in the case of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price by the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price (as
defined below) in effect at the time of conversion, (iii)&nbsp;in the case of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price (as defined below) in effect at the time of conversion, (iv)&nbsp;in the case of Series B Preferred Stock, the Series B
Original Issue Price by the Series B Conversion Price (as defined below) in effect at the time of conversion, (v)&nbsp;in the case of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, the Series
<FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price by the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Conversion Price (as defined below) in effect at the time of conversion, (vi)&nbsp;in the case of Series <FONT
STYLE="white-space:nowrap">C-2</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">C-2</FONT> Original Issue Price by the Series <FONT STYLE="white-space:nowrap">C-2</FONT> Conversion Price (as defined below) in effect at the time of
conversion, (vii)&nbsp;in the case of Series D Preferred Stock, the Series D Original Issue Price by the Series D Conversion Price (as defined below) in effect at the time of conversion and (viii)&nbsp;in the case of Series E Preferred Stock, the
Series E Original Issue Price by the Series E Conversion Price (as defined below) in effect at the time of conversion; provided that a holder of Series E Preferred Stock may waive such holder&#146;s option to convert upon written notice to the
Corporation. The &#147;<B>Series A Conversion Price</B>&#148;, as of the Filing Date (as defined in <U>Subsection 4.4</U> below), is equal to $1.8191. The &#147;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price</B>&#148;, as of
the Filing Date, is equal to $2.1898. The &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price</B>&#148;, as of the Filing Date, is equal to $1.24235. The &#147;<B>Series B Conversion Price</B>&#148;, as of the Filing Date,
is equal to $1.24235. The &#147;<B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Conversion Price</B>&#148;, as of the Filing Date, is equal to $0.5213. The &#147;<B>Series <FONT STYLE="white-space:nowrap">C-2</FONT> Conversion Price</B>&#148;,
as of the Filing Date, is equal to $0.36491. The &#147;<B>Series <FONT STYLE="white-space:nowrap">D-1</FONT> Conversion Price</B>&#148; and the &#147;<B>Series <FONT STYLE="white-space:nowrap">D-2</FONT> Conversion Price</B>&#148;, as of the Filing
Date, in each case is equal to $0.6911. The &#147;<B>Series E Conversion Price</B>&#148;, as of the Filing Date, is equal to $0.7839 (and with the Series A Conversion Price, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series B Conversion Price, Series <FONT STYLE="white-space:nowrap">C-1</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">C-2</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">D-2</FONT> Conversion Price, each a &#147;<B>Conversion Price</B>&#148; and collectively the &#147;<B>Conversion Prices</B>&#148;). Such Conversion
Prices, and the rate at which shares of such Preferred Stock may be converted into shares of Class&nbsp;A Common Stock and/or Class&nbsp;B Common Stock, as applicable, shall be subject to adjustment as provided below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Conversion Rights</U>. In the event of a notice of redemption of any shares of Preferred Stock
pursuant to <U>Section</U><U></U><U>&nbsp;2.7.2</U>, the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding the Redemption Date. In the event of a Deemed Liquidation
Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock; provided that the foregoing
termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with Sections 2.1 through 2.5 to holders of Preferred Stock pursuant to such liquidation, dissolution or winding up of the Corporation or a
Deemed Liquidation Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon
conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined
in good faith by the Board of Directors of the Corporation. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time
converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred
Stock into shares of Common Stock, such holder shall surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate
affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the
transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent), together with written notice that such holder elects to convert all or any number of the shares of the
Preferred Stock represented by such certificate or certificates and, if applicable, any event on which such conversion is contingent. Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the
certificate or certificates for shares of Common Stock to be issued. If required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to
the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer
agent) of such certificates (or lost certificate affidavit and agreement) and notice shall be the time of conversion (the &#147;<B>Conversion Time</B>&#148;), and the shares of Common Stock issuable upon conversion of the shares represented by such
certificate shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time, (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a
certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the
surrendered certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash such amount as provided in <U>Subsection 4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;pay
all declared but unpaid dividends on the shares of Preferred Stock converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation of Shares</U>.
The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its
duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to
effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be
sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Before taking any action which would cause an
adjustment reducing any of the Conversion Prices below the then par value of the shares of Common Stock issuable upon conversion of the applicable series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of
its counsel, be necessary in order that the Corporation may validly and legally issue fully paid, and nonassessable shares of Common Stock at such adjusted Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as
herein provided shall no longer be deemed to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock
in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in <U>Subsection 4.2</U> and to receive payment of any dividends declared but unpaid thereon. Any shares of Preferred
Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the
authorized number of shares of Preferred Stock accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4&nbsp;&nbsp;&nbsp;&nbsp;<U>No Further Adjustment</U>. Upon any such
conversion, no adjustment to the applicable Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect
of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax which may be payable in respect
of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person
or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments to Conversion Prices for Diluting Issues</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions shall apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Option</B>&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire
Common Stock or Convertible Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Filing Date</B>&#148; shall mean the date on which this
Ninth Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Convertible Securities</B>&#148; shall mean any evidences of indebtedness, shares or other securities
directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Purchase Agreement</B>&#148; shall mean that certain Series E Convertible Preferred Stock Purchase
Agreement entered into on or about the Filing Date by and among the Corporation and the Investors therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Investor</B>&#148; shall have the meaning ascribed to such term in the Purchase Agreement, unless
otherwise defined herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Required</B> <B>Series B</B> <B>Holders</B>&#148; shall
mean holders of at least fifty-seven percent (57%) of the shares of the Series B Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series D Purchase Agreement</B>&#148; shall mean the Series D Convertible Preferred Stock Purchase
Agreement entered into on April&nbsp;1, 2019 by and among the parties listed therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Additional
Shares of Common Stock</B>&#148; shall mean all shares of Common Stock issued (or, pursuant to <U>Subsection 4.4.3</U> below, deemed to be issued) by the Corporation after the Filing Date, other than (1)&nbsp;the following shares of Common Stock and
(2)&nbsp;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#147;<B>Exempted Securities</B>&#148;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock issuable upon conversion of Preferred Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares issued in connection with the exercise of warrants to purchase shares of Series B Preferred Stock, the
shares of Series B Preferred Stock issued prior to the Filing Date and shares of Common Stock issuable upon conversion of such Series B Preferred Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Preferred
Stock in accordance with the terms of this Certificate of Incorporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Subsection 4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4&nbsp;8</U>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Corporation (including a majority of the Preferred Directors); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to customers, banks, equipment lessors or
other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board of Directors of the Corporation (including a majority of the Preferred Directors,
which must include the Series E Preferred Director); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the
acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement; provided that such issuances are approved by the Board of Directors of the
Corporation (including a majority of the Preferred Directors, which must include the Series E Preferred Director); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors of the Corporation (including a majority of the Preferred Directors, which must include the
Series E Preferred Director). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>No Adjustment of Conversion Prices</U>. No adjustment in
the Series A Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least a majority of the then outstanding shares of
Series A Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion
Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least a majority of the then outstanding shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock agreeing that no such adjustment shall be made as the result </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price shall be made as the result
of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least a majority of the then outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred
Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series B Conversion Price shall be made as the result of the issuance or deemed
issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Required Series B Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of
Common Stock. No adjustment in the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice
from the holders of at least a majority of the outstanding Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock (which majority must include either LV or Arix, as such terms are defined in that certain Amended and Restated Series C
Convertible Stock Purchase Agreement by and among the Corporation and the Investors therein, dated as of December&nbsp;20, 2017) agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional
Shares of Common Stock. No adjustment in the Series <FONT STYLE="white-space:nowrap">C-2</FONT> Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written
notice from the holders of at least a majority of the then outstanding shares of Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of
such Additional Shares of Common Stock. No adjustment in the Series D Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Required
Series D Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series E Conversion Price shall be made as the result of the issuance or
deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Required Series E Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional
Shares of Common Stock. Notwithstanding the foregoing, if there is an issuance or a deemed issuance of Additional Shares of Common Stock at a price per share less than the Series E Original Issue Price, then the Required Series E Holders can waive
the adjustment for all, but not less than all, of the Conversion Prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Deemed Issue of Additional
Shares of Common Stock</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Corporation at any time or from time to time after the Filing Date shall
issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such
Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without
regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible
Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If the terms of any Option or Convertible Security, the issuance
of which resulted in an adjustment to a Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible
Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock
issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective
upon such increase or decrease becoming effective, such Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Conversion
Price as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this <U>clause (b)</U>&nbsp;shall have the
effect of increasing a Conversion Price to an amount which exceeds the lower of (i)&nbsp;the Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or
(ii)&nbsp;the Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security)
between the original adjustment date and such readjustment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If the terms of any Option or Convertible
Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to a Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U> (either because the
consideration per share (determined pursuant to <U>Subsection 4.4.6</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the Conversion Price then in effect, or because such Option or Convertible Security was
issued before the Filing Date), are revised after the Filing Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms
pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or
Convertible Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock
subject thereto (determined in the manner provided in <U>Subsection 4.4.3(a)</U>) shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security
(or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to a Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, such Conversion Price shall be readjusted to the
Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or
Convertible Security, or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to
adjustment based upon subsequent events, any adjustment to a Conversion Price provided for in this <U>Subsection&nbsp;4.4.3</U> shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration
without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b)&nbsp;and (c) of this <U>Subsection 4.4.3</U>). If the number of shares of Common Stock issuable upon the
exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security
is issued or amended, any adjustment to a Conversion Price that would result under the terms of this <U>Subsection 4.4.3</U> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of
consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Conversion Price that such issuance or amendment took place at the time such calculation can first be made.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.5.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment of Senior Preferred Conversion Price Upon Issuance of Additional Shares of Common Stock</U>.
In the event the Corporation shall at any time on or after the Filing Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Subsection 4.4.3</U>), without consideration or for a
consideration per share less than the Conversion Price applicable to any series of Senior Preferred Stock in effect immediately prior to such issue, then the applicable Conversion Price or Conversion Prices of such applicable series of Senior
Preferred Stock shall be reduced, concurrently with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> = CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>* (A + B) &divide; (A
+ C). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>&#148; shall mean the applicable Conversion Price
in effect immediately after such issue of Additional Shares of Common Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;CP<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148; shall mean the applicable Conversion Price in effect immediately prior to such issue of Additional Shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;&#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately prior to such issue of
Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issue or upon conversion or exchange of Convertible Securities (including
the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional
Shares of Common Stock had been issued at a price per share equal to CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB>); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;&#147;C&#148; shall mean the number of such Additional Shares of
Common Stock issued in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.5.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment of Series A, Series
<FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Prices Upon Adjustment of Senior Preferred Conversion Price</U>. In the event the Series B Conversion Price shall be reduced pursuant to
<U>Subsection 4.4.4</U>, then the Series A Conversion Price, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price and the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price shall be uniformly reduced, concurrently
with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB> = CP<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> - (CP<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB> &#150; CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing
formula, CP<SUB STYLE="font-size:85%; vertical-align:bottom">1 </SUB>and CP<SUB STYLE="font-size:85%; vertical-align:bottom">2 </SUB>shall equal the amounts set forth in <U>Subsection 4.4.4</U> as applicable to the Series B Preferred Stock. The
following definitions shall apply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB>&#148;
shall, for any series of Junior Preferred Stock, mean such applicable Conversion Price in effect immediately after the reduction of the Series B Conversion Price in connection with <U>Subsection 4.4.4</U>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>&#148; shall, for any series of Junior Preferred
Stock, mean such applicable Conversion Price in effect immediately prior to the reduction of the Series B Conversion Price in connection with <U>Subsection 4.4.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any adjustment to the Series B Conversion Price pursuant to <U>Subsection 4.4.4</U> is subsequently reversed (in whole or in part) pursuant to
<U>Subsection&nbsp;4.4.3</U>, then there shall be a corresponding adjustment pursuant to <U>Subsection 4.4.3</U> to the Series A Conversion Price, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price and the Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Conversion Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.5.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Determination of Consideration</U>. For purposes
of this <U>Subsection 4.4</U>, the consideration received by the Corporation for the issue of any Additional Shares of Common Stock shall be computed as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cash and Property</U>: Such consideration shall: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issue, as determined in good faith by the Board of Directors of the Corporation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="31%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
for consideration which covers both, be the proportion of such consideration so received, computed as provided in <U>clauses (i)</U>&nbsp;and <U>(ii)</U> above, as determined in good faith by the
Board of Directors of the Corporation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Options and Convertible Securities</U>. The
consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <U>Subsection 4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the total amount, if any, received or receivable by the Corporation as consideration for the issue of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration)
payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the
conversion or exchange of such Convertible Securities, by </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.5.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares
of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to a Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, then, upon the final such issuance, such Conversion
Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period). </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment for Stock Splits and Combinations</U>. If the
Corporation shall at any time or from time to time after the Filing Date effect a subdivision of the outstanding Common Stock, the Conversion Prices in effect immediately before that subdivision shall be proportionately decreased so that the number
of shares of Common Stock issuable on conversion of each share of each series of Preferred Stock shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or
from time to time after the Filing Date combine the outstanding shares of Common Stock, the Conversion Prices in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on
conversion of each share of each series of Preferred Stock shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of
business on the date the subdivision or combination becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment for Certain Dividends
and Distributions</U>. In the event the Corporation at any time or from time to time after the Filing Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other
distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Conversion Prices in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a
record date shall have been fixed, as of the close of business on such record date, by multiplying each Conversion Price then in effect by a fraction: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately
prior to the time of such issuance or the close of business on such record date, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;the denominator of which
shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or
distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such
distribution is not fully made on the date fixed therefor, the Conversion Prices shall be recomputed accordingly as of the close of business on such record date and thereafter the Conversion Prices shall be adjusted pursuant to this subsection as of
the time of actual payment of such dividends or distributions; and (b)&nbsp;that no such adjustment shall be made if the holders of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal
to the number of shares of Common Stock as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to
time after the Filing Date shall make or issue, or fix a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of
Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock
shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have
received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Subsection 2</U>, if there
shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property
(other than a transaction covered by <U>Subsection 4.4</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of the Common
Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of Preferred Stock
immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the
Board of Directors of the Corporation) shall be made in the application of the provisions in this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the
provisions set forth in this <U>Section</U><U></U><U>&nbsp;4</U> (including provisions with respect to changes in and other adjustments of the Conversion Prices) shall thereafter be applicable, as nearly as reasonably may be, in relation to any
securities or other property thereafter deliverable upon the conversion of the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of a Conversion
Price pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than 10 days thereafter, compute such adjustment or readjustment in accordance with
the terms hereof and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which the Preferred Stock is convertible) and
showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than 10
days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the Conversion Price or Conversion Prices then in effect for that or those series of Preferred Stock then held by such holder, and (ii)&nbsp;the
number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of such series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at
the time issuable upon conversion of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of
any class or any other securities, or to receive any other security; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;of any capital reorganization of the
Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;of the voluntary or involuntary dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> of
the Corporation, then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the
amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or
<FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion
of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer,
dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least 10 days prior to the
record date or effective date for the event specified in such notice. Notwithstanding the foregoing, the provision of the notice required under this <U>Section</U><U></U><U>&nbsp;4.10</U> may be waived in writing by the Required Preferred Holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.12&nbsp;&nbsp;&nbsp;&nbsp; Beneficial Ownership Limitations. Any capitalized but undefined term used in this Section&nbsp;4.12 shall
have the meaning ascribed to such term in the Purchase Agreement. Notwithstanding anything to the contrary herein, no Electing Investor shall be entitled to receive, and the Corporation shall not deliver to the Electing Investor, shares of
Class&nbsp;A Common Stock upon conversion of the Series E Preferred Stock to the extent (but only to the extent) that, after such receipt, such converting Electing Investor would beneficially own shares of Class&nbsp;A Common Stock in excess of the
Limitation (such shares above the Limitation, the &#147;<B>Excess Securities</B>&#148;), and in lieu of the Excess Securities, the Corporation shall deliver to the Electing Investor the number of shares of Class&nbsp;B Common Stock equal to the
number of the Excess Securities in book-entry form. Any conversion notice provided by a converting Electing Investor under Section&nbsp;4.3 shall constitute the converting Electing Investor&#146;s acknowledgement and confirmation that (i)&nbsp;after
the acquisition of the shares of Class&nbsp;A Common Stock sought in the conversion, such Electing Investor will not be in the aggregate, directly or indirectly, the beneficial owner of more shares of Class&nbsp;A Common Stock than permitted by the
Limitation and (ii)&nbsp;any Excess Securities to which the Electing Holder would otherwise be entitled will be satisfied solely by the delivery of Class&nbsp;B Common Stock equal to the number of such Excess Securities. Any purported delivery of
shares of Class&nbsp;A Common Stock upon conversion of Series E Preferred Stock shall be void <I>ab initio</I> and shall have no effect to the extent (but only to the extent) that such delivery would result in the converting Electing Investor
becoming in the aggregate, directly or indirectly, the beneficial owner of more shares of Class&nbsp;A Common Stock than permitted by the Limitation, it being understood that the Corporation shall only deliver shares of Class&nbsp;B Common Stock to
the Electing Investor on account of any Excess Securities. Within two (2)&nbsp;business days of any request by a holder of Series E Preferred Stock, the Corporation shall inform such holder in writing of the then current number of outstanding shares
of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Trigger Events</U>. Upon either (a)&nbsp;the date and time, or the occurrence of an event, specified by vote or
written consent of, (i)&nbsp;in the case of the Preferred Stock that is not Series E Preferred Stock, the Required Preferred Holders and (ii)&nbsp;in the case of the Series E Preferred Stock, the Required Series E Holders or (b)&nbsp;the closing of
the sale of shares of Common Stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, provided that (1)&nbsp;the price per share of the Common
Stock in such public offering is at least $1.17585 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock) and such offering results in at
least $75,000,000 of gross proceeds to the Corporation and (2)&nbsp;the Common Stock is listed for trading on either the New York Stock Exchange or the Nasdaq Stock Market (a &#147;<B>Qualified Public Offering</B>&#148;) (the time of such closing of
a Qualified Public Offering or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the &#147;<B>Mandatory Conversion Time</B>&#148;), then (i)&nbsp;all outstanding shares of the
applicable series of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate and (ii)&nbsp;such shares may not be reissued by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedural Requirements</U>. All holders of record of shares of Preferred Stock shall be sent written notice of
the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such notice need not be sent in advance of the occurrence of the Mandatory
Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or
destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such
certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to <U>Subsection 5.1</U>, including the rights, if
any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender the certificates at or prior to such time), except
only the rights of the holders thereof, upon surrender of their certificate or certificates (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Subsection 5.2</U>. As soon as
practicable after the Mandatory Conversion Time and the surrender of the certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall issue and deliver to such holder, or to his, her or its
nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof, together with cash as provided in <U>Subsection 4.2</U> in lieu of any fraction of a share of
Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without
the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Beneficial Ownership Limitation</U>. Notwithstanding anything to the contrary herein, in connection with any
mandatory conversion pursuant to this Section&nbsp;5, no Electing Investor shall be entitled to receive, and the Corporation shall not deliver to the Electing Investor, any Excess Securities, and in lieu of the Excess Securities, the Corporation
shall deliver to the Electing Investor the number of shares of Class&nbsp;B Common Stock equal to the number of the Excess Securities in book-entry form. Any purported delivery of shares of Class&nbsp;A Common Stock upon conversion of Series E
Preferred Stock shall be void <I>ab initio</I> and shall have no effect to the extent (but only to the extent) that, after such delivery, the converting Electing Investor would be in the aggregate, directly or indirectly, the beneficial owner of
more shares of Class&nbsp;A Common Stock than permitted by the Limitation, it being understood that the Corporation shall only deliver shares of Class&nbsp;B Common Stock to the Electing Investor on account of any Excess Securities. Within two
(2)&nbsp;business days of any request by a holder of Series B Preferred Stock, the Corporation shall inform such holder in writing of the then current number of outstanding shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;Waiver. Any provision in this Certificate of Incorporation (i)&nbsp;related to the limitations on the conversion of
an Electing Holder&#146;s Series E Preferred Stock into shares of Class&nbsp;A Common Stock and the issuance of Class&nbsp;B Common Stock in lieu thereof, (ii)&nbsp;related to the rights of an Electing Holder to convert shares of such Electing
Holder&#146;s Class&nbsp;B Common Stock into Class&nbsp;A Common Stock (including any limitation on any such conversion), or (iii)&nbsp;related to the limitations on the issuance to an Electing Holder of a class of voting capital stock of any
successor or parent corporation that is subject to the periodic reporting requirements of Section&nbsp;12 or 15(d) of the Exchange Act in connection with a Deemed Liquidation Event or SPAC Transaction and the issuance of such other
corporation&#146;s <FONT STYLE="white-space:nowrap">non-voting</FONT> securities in lieu thereof, in each case in accordance with this Certificate of Incorporation, may be amended, modified or waived without the consent of (1)&nbsp;such Electing
Holder for so long as such Electing Holder either owns Class&nbsp;B Common Stock or Series E Preferred Stock and (2)&nbsp;each other holder of Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notice required or permitted by the provisions of this Article Fourth to be given to a holder of
shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be
deemed sent upon such mailing or electronic transmission. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp;Conversion Rights of the Class&nbsp;B Common Stock.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion of Class</U><U></U><U>&nbsp;B Common Stock</U>. Subject to the terms of this Section&nbsp;1,
shares of Class&nbsp;B Common Stock shall be convertible into a corresponding number of Class&nbsp;A Common Stock upon written notice by the holder thereof. Any capitalized but undefined term used in this Section&nbsp;1 shall have the meaning
ascribed to such term in the Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary herein (but subject to
Section&nbsp;1.2), no holder of Class&nbsp;B Common Stock shall be entitled to receive, and the Corporation shall not deliver to any such holder, any Class&nbsp;A Common Stock upon conversion of the Class&nbsp;B Common Stock to the extent (but only
to the extent) that, after such receipt, such converting holder and its Affiliates (as defined in the Purchase Agreement) (together, the &#147;<B>Related Holders</B>&#148;) would beneficially own in the aggregate, directly or indirectly, shares of
Class&nbsp;A Common Stock in excess of 9.9% of such shares outstanding at such time (the &#147;<B>Section</B><B></B><B>&nbsp;16 Limitation</B>&#148;). For avoidance of doubt, in the event that the Related Holders beneficially own in the aggregate,
directly or indirectly, shares of Class&nbsp;A Common Stock in excess of the Section&nbsp;16 Limitation without taking account the conversion of Class&nbsp;B Common Stock, then none of the Class&nbsp;B Common Stock shall be convertible until such
time as the Related Holders no longer beneficially own in the aggregate, directly or indirectly, shares of Class&nbsp;A Common Stock in excess of the Section&nbsp;16 Limitation. Any conversion notice provided by a converting holder under this
Section&nbsp;1 shall constitute the converting holder&#146;s acknowledgement and confirmation to the Corporation that (i)&nbsp;the acquisition of the shares of Class&nbsp;A Common Stock sought in the conversion notice will not result in Related
Holders becoming in the aggregate, directly or indirectly, the beneficial owner of more shares of Class&nbsp;A Common Stock than permitted by the Section&nbsp;16 Limitation and (ii)&nbsp;any Class&nbsp;A Common Stock to which the Electing Holder
would be entitled but for the Section&nbsp;16 Limitation will remain Class&nbsp;B Common Stock. Any purported delivery of shares of Class&nbsp;A Common Stock upon conversion of Class&nbsp;B Common Stock shall be void <I>ab initio</I> and shall have
no effect to the extent (but only to the extent) that such delivery would result in the Related Holders becoming in the aggregate, directly or indirectly, the beneficial owner of more shares of Class&nbsp;A Common Stock than permitted by the
Section&nbsp;16 Limitation. Before any holder shall be entitled to exchange any shares of such Class&nbsp;B Common Stock pursuant to this provision, such holder shall give written notice to the Corporation at its principal corporate office, of the
election to exchange the same and shall state therein the name or names in which the certificate or certificates for shares of Class&nbsp;A Common Stock are to be issued. The Corporation shall, as soon as practicable thereafter, issue and deliver to
the Electing Investor, or to the nominee or nominees of such holder, a certificate or certificates for the number of shares of Class&nbsp;A Common Stock to which such holder shall be entitled as aforesaid (unless shares of Class&nbsp;A Common Stock
are then maintained in book-entry form, in which event such number of shares of Class&nbsp;A Common Stock shall be issued in book-entry form). Such exchange shall be deemed to have been made immediately prior to the close of business on the date of
such written notice, and the person or persons entitled to receive the shares of Class&nbsp;A Common Stock issuable upon such exchange shall be treated for all purposes as the record holder or holders of such shares of Class&nbsp;A Common Stock as
of such date. Each share of Class&nbsp;B Common Stock that is exchanged pursuant to this Section&nbsp;1.1 shall be retired by the Corporation and shall not be available for reissuance. Within two (2)&nbsp;business days of any request by a holder of
Class&nbsp;B Common Stock, the Corporation shall inform such holder in writing of the then current number of outstanding shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;Any shares of Class&nbsp;B Common Stock shall be exchanged for a corresponding number of fully paid and
nonassessable shares of Class&nbsp;A Common Stock promptly upon request following a <FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Transfer. A &#147;<B><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Transfer</B>&#148; shall mean a
transfer of shares of Class&nbsp;B Common Stock to any person that is not an Affiliate of a holder of the Class&nbsp;B Common Stock immediately following the issuance thereof. The Corporation shall, upon the request of each such holder and a
certification from such transferee holder of such holder&#146;s <FONT STYLE="white-space:nowrap">non-affiliation</FONT> with the original holder of such Class&nbsp;B Common Stock, issue and deliver </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to such holder new certificates (unless shares of Class&nbsp;A Common Stock are then maintained in book-entry form) representing such <FONT STYLE="white-space:nowrap">non-Affiliate</FONT>
holder&#146;s shares of Class&nbsp;A Common Stock. Such exchange shall be deemed to have been made immediately prior to the close of business on the date of such request and certification, and the person or persons entitled to receive the shares of
Class&nbsp;A Common Stock issuable upon such exchange shall be treated for all purposes as the record holder or holders of such shares of Class&nbsp;A Common Stock as of such date. Each share of Class&nbsp;B Common Stock that is exchanged pursuant
to this section shall be retired and canceled by the Corporation and shall not be available for reissuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH</B>: Subject to any
additional vote required by the Certificate of Incorporation or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of
the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH</B>: Subject to any additional vote required by the Certificate of Incorporation, the number of
directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH</B>: Elections of
directors need not be by written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH</B>: Meetings of stockholders
may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of
Directors or in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH</B>: To the fullest extent permitted by law, a director of the Corporation shall
not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders
of this Article Ninth to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the
General Corporation Law as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this Article Ninth by the stockholders
of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director
occurring prior to, such repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH</B>: To the fullest extent permitted by applicable law, the Corporation is
authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw
provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions of this Article Tenth
shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH</B>: The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in
being offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B>Excluded Opportunity</B>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the
possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or agent of
any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, &#147;<B>Covered Persons</B>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed
by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation. Any repeal or modification of this Article Eleventh will only be prospective and will not
affect the rights under this Article Eleventh in effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Certificate of Incorporation, the
affirmative vote of the Required Preferred Holders will be required to amend or repeal, or to adopt any provisions inconsistent with this Article Eleventh. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH</B>: Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of
Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of
fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees
arising pursuant to any provision of the Delaware General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees
governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery
(and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or
for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article Twelfth shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason
whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article Twelfth (including, without limitation, each portion of
any sentence of this Article Twelfth containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and
circumstances shall not in any way be affected or impaired thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;That the foregoing amendment and restatement was approved by the
holders of the requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;That this Ninth Amended and Restated Certificate of Incorporation, which restates and integrates and further amends
the provisions of this corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General. Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE NEXT PAGE IS THE SIGNATURE PAGE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Ninth Amended and Restated Certificate of Incorporation has
been executed by a duly authorized officer of this corporation on this 17<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of March, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Elisabet de los Pinos, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>d209588dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BY-LAWS</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aura Biosciences,
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(the &#147;Corporation&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article I - Stockholders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Meeting.</U> The annual meeting of stockholders shall be held for the election of directors each year at
such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting is established or said meeting is not held on the date established as
provided above, a special meeting in lieu thereof may be held or there may be action by written consent of the stockholders on matters to be voted on at the annual meeting, and such special meeting or written consent shall have for the purposes of
these <FONT STYLE="white-space:nowrap">By-laws</FONT> or otherwise all the force and effect of an annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Meetings.</U> Special meetings of stockholders may be called by the Chief Executive Officer, if one is
elected, or, if there is no Chief Executive Officer, a President, by the Board of Directors, or by the holders of at least twenty-five percent (25%) of the Corporation&#146;s then outstanding Preferred Stock, $0.001 par value per share, but such
special meetings may not be called by any other person or persons. The call for the meeting shall state the place, date, hour and purposes of the meeting. Only the purposes specified in the notice of special meeting shall be considered or dealt with
at such special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Meetings.</U> Whenever stockholders are required or permitted to take any
action at a meeting, a notice stating the place, if any, date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present and vote at such meeting, and, in the case of a
special meeting, the purpose or purposes of the meeting, shall be given by the Secretary (or other person authorized by these <FONT STYLE="white-space:nowrap">By-laws</FONT> or by law) not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days
before the meeting to each stockholder entitled to vote thereat and to each stockholder who. under the Certificate of Incorporation or under these <FONT STYLE="white-space:nowrap">By-laws</FONT> is entitled to such notice. If mailed, notice is given
when deposited in the mail, postage prepaid, directed to such stockholder at such stockholder&#146;s address as it appears in the records of the Corporation. Without limiting the manner by which notice otherwise may be effectively given to
stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the Delaware General Corporation Law (the &#147;DGCL&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place, if any, and the
means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken, except that if the adjournment is
for more than thirty (30)&nbsp;days, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum.</U> The holders of a majority in interest of all stock issued, outstanding and entitled to vote at a
meeting, present in person or represented by proxy, shall constitute a quorum. Any meeting may be adjourned from time to time by a majority of the votes properly cast upon the question, whether or not a quorum is present. The stockholders present at
a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting and Proxies.</U> Except as otherwise provided by the
Certificate of Incorporation or by law, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of stock held by such stockholder which has voting power upon the matter in question. Each
stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by either written proxy or by a
transmission permitted by Section&nbsp;212(c) of the DGCL, but no proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period or is irrevocable and coupled with an interest. Proxies shall be
filed with the Secretary of the meeting, or of any adjournment thereof. Except as otherwise limited therein, proxies shall entitle the persons authorized thereby to vote at any adjournment of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Action at Meeting.</U> When a quorum is present, any matter before the meeting shall be decided by vote of the
holders of a majority of the shares of stock voting on such matter except where a larger vote is required by law, by the Certificate of Incorporation or by these <FONT STYLE="white-space:nowrap">By-laws.</FONT> Any election of directors by
stockholders shall be determined by a plurality of the votes cast, except where a larger vote is required by law, by the Certificate of Incorporation or by these <FONT STYLE="white-space:nowrap">By-laws.</FONT> The Corporation shall not directly or
indirectly vote any share of its own stock; provided, however, that the Corporation may vote shares which it holds in a fiduciary capacity to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Presiding Officer.</U> Meetings of stockholders shall be presided over by the Chairman of the Board, if one is
elected, or in his or her absence, the Vice Chairman of the Board, if one is elected, or if neither is elected or in their absence, a President. The Board of Directors shall have the authority to appoint a temporary presiding officer to serve at any
meeting of the stockholders if the Chairman of the Board, the Vice Chairman of the Board or a President is unable to do so for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Conduct of Meetings.</U> The Board of Directors may adopt by resolution such rules and regulations for the
conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the presiding officer of any meeting of stockholders shall have the right
and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the
Board of Directors or prescribed by the presiding officer of the meeting, may include, without limitation, the following: (i)&nbsp;the establishment of an agenda or order of business for the meeting; (ii)&nbsp;rules and procedures for maintaining
order at the meeting and the safety of those present; (iii)&nbsp;limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the
chairman of the meeting shall determine; (iv)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v)&nbsp;limitations on the time allotted to questions or comments by participants. Unless and to the
extent determined by the Board of Directors or the presiding officer of the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Action without a Meeting.</U> Unless otherwise provided in the
Certificate of Incorporation, any action required or permitted by law to be taken at any annual or special meeting of stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting
forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were
present and voted and shall be delivered to the Corporation by delivery to its registered office, by hand or by certified mail, return receipt requested, or to the Corporation&#146;s principal place of business or to the officer of the Corporation
having custody of the minute book. Every written consent shall bear the date of signature and no written consent shall be effective unless, within sixty (60)&nbsp;days of the earliest dated consent delivered pursuant to these <FONT
STYLE="white-space:nowrap">By-laws,</FONT> written consents signed by a sufficient number of stockholders entitled to take action are delivered to the Corporation in the manner set forth in these <FONT STYLE="white-space:nowrap">By-laws.</FONT>
Prompt notice of the taking or the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder Lists.</U> The officer who has charge of the stock ledger of the Corporation shall prepare and make,
at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in
the name of each stockholder. Nothing contained in this Section&nbsp;10 shall require the Corporation to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any
stockholder, for any purpose germane to the meeting, for a period of at least ten (10)&nbsp;days prior to the meeting in the manner provided by law. The list shall also be open to the examination of any stockholder during the whole time of the
meeting as provided by law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article II - Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Powers.</U> The business of the Corporation shall be managed by or under the direction of a Board of Directors
who may exercise all the powers of the Corporation except as otherwise provided by law, by the Certificate of Incorporation or by these <FONT STYLE="white-space:nowrap">By-laws.</FONT> In the event of a vacancy in the Board of Directors, the
remaining directors, except as otherwise provided by law, may exercise the powers of the full Board until the vacancy is filled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Number and Qualification.</U> Unless otherwise provided in the Certificate of Incorporation or in these <FONT
STYLE="white-space:nowrap">By-laws,</FONT> the number of directors which shall constitute the whole board shall be determined from time to time by resolution of the Board of Directors. Directors need not be stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies; Reduction of Board.</U> A majority of the directors then in office, although less than a quorum, or a
sole remaining Director, may fill vacancies in the Board of Directors occurring for any reason and newly created directorships resulting from any increase in the authorized number of directors. In lieu of filling any vacancy, the Board of Directors
may reduce the number of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenure.</U> Except as otherwise provided by law. by the Certificate of
Incorporation or by these <FONT STYLE="white-space:nowrap">By-laws,</FONT> directors shall hold office until their successors arc elected and qualified or until their earlier resignation or removal. Any director may resign at any time upon notice
given in writing or by electronic transmission to the Corporation. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal.</U> To the extent permitted by law, a director may be removed from office with or without cause by vole
of the holders of a majority of the shares of stock entitled to vote in the election of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Meetings.</U> Regular meetings of the Board of Directors may be
held without notice at such time, date and place as the Board of Directors may from time to time determine. Special meetings of the Board of Directors may be called, orally or in writing, by the Chief Executive Officer, if one is elected, or, if
there is no Chief Executive Officer, the President, by two or more Directors, or by the holders of at least twenty-five percent (25%) of the Corporation&#146;s then outstanding Preferred Stock, $0.001 par value per share, designating the time, date
and place thereof. Directors may participate in meetings of the Board of Directors by means of conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation
in a meeting in accordance herewith shall constitute presence in person at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of
Meetings.</U> Notice of the time, date and place of all special meetings of the Board of Directors shall be given to each director by the Secretary, or Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by
the officer or one of the directors calling the meeting. Notice shall be given to each director in person, by telephone, or by facsimile, electronic mail or other form of electronic communications, sent to such director&#146;s business or home
address at least twenty-four (24)&nbsp;hours in advance of the meeting, or by written notice mailed to such director&#146;s business or home address at least forty-eight (48)&nbsp;hours in advance of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum.</U> At any meeting of the Board of Directors, a majority of the total number of directors shall
constitute a quorum for the transaction of business. Less than a quorum may adjourn any meeting from time to time and the meeting may be held as adjourned without further notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Action at Meeting.</U> At any meeting of the Board of Directors at which a quorum is present, unless otherwise
provided in the following sentence, a majority of the directors present may take any action on behalf of the Board of Directors, unless a larger number is required by law, by the Certificate of Incorporation or by these <FONT
STYLE="white-space:nowrap">By-laws.</FONT> So long as there are two (2)&nbsp;or fewer Directors, any action to be taken by the Board of Directors shall require the approval of all Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Action by Consent</U> Any action required or permitted to be taken al any meeting of the Board of Directors may
be taken without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the records of the meetings of the
Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Committees.</U> The Board of Directors may, by resolution passed by a majority of the whole Board of Directors,
establish one or more committees, each committee to consist of one or more directors. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting
of the committee. In the absence or disqualification of a member or a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously
appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such
committee, to the extent permitted by law and to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the
Corporation, and may authorize the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seal of the Corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to the following: (i)&nbsp;approving or adopting, or
recommending to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval or (ii)&nbsp;adopting, amending or repealing any provision of these <FONT STYLE="white-space:nowrap">By-laws.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but in the
absence of such rules its business shall be conducted so far as possible in the same manner as is provided in these <FONT STYLE="white-space:nowrap">By-laws</FONT> for the Board of Directors. All members of such committees shall hold their committee
offices at the pleasure of the Board of Directors, and the Board may abolish any committee at any time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article III - Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enumeration.</U> The officers of the Corporation shall consist of one or more Presidents (who, if there is more
than one, shall be referred to as <FONT STYLE="white-space:nowrap">Co-Presidents),</FONT> a Treasurer, a Secretary, and such other officers, including, without limitation, a Chief Executive Officer and one or more Vice Presidents (including
Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and Assistant Secretaries, as the Board of Directors may determine. The Board of Directors may elect from among its members a Chairman of the Board
and a Vice Chairman of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Election.</U> The Presidents, Treasurer and Secretary shall be elected
annually by the Board of Directors al their first meeting following the annual meeting of stockholders. Other officers may be chosen by the Board of Directors at such meeting or at any other meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Qualification</U>. No officer need be a stockholder or Director. Any two or more offices may be held by the same
person. Any officer may be required by the Board of Directors to give bond for the faithful performance of such officer&#146;s duties in such amount and with such sureties as the Board of Directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenure.</U> Except as otherwise provided by the Certificate of Incorporation or by these <FONT
STYLE="white-space:nowrap">By-laws,</FONT> each of the officers of the Corporation shall hold office until the first meeting of the Board of Directors following the next annual meeting of stockholders and until such officer&#146;s successor is
elected and qualified or until such officer&#146;s earlier resignation or removal. Any officer may resign by delivering his or her written resignation to the Corporation, and such resignation shall be effective upon receipt unless it is specified to
be effective at some other time or upon the happening of some other event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal.</U> The Board of
Directors may remove any officer with or without cause by a vote of a majority of the directors then in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies.</U> Any vacancy in any office may be filled for the unexpired portion of the term by the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Chairman of the Board and Vice Chairman.</U> Unless otherwise provided by the Board of Directors,
the Chairman of the Board of Directors, if one is elected, shall preside, when present, at all meetings of the stockholders and the Board of Directors. The Chairman of the Board shall have such other powers and shall perform such duties as the Board
of Directors may from time to time designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by the Board of Directors, in the absence of the Chairman of the
Board, the Vice Chairman of the Board, if one is elected, shall preside, when present, at all meetings of the stockholders and the Board of Directors. The Vice Chairman of the Board shall have such other powers and shall perform such duties as the
Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Chief Executive Officer.</U> The Chief Executive
Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Presidents.</U> The Presidents shall, subject to the direction of the Board of Directors, each have general
supervision and control of the Corporation&#146;s business and any action that would typically be taken by a President may be taken by any <FONT STYLE="white-space:nowrap">Co-President.</FONT> If there is no Chairman of the Board or Vice Chairman of
the Board, a President shall preside, when present, at all meetings of stockholders and the Board of Directors. The Presidents shall have such other powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vice Presidents and Assistant Vice Presidents.</U> Any Vice President (including any Executive Vice President or
Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Treasurer and Assistant Treasurers.</U> The Treasurer shall, subject to the direction of the Board of Directors,
have general charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody of all funds, securities, and valuable documents of the Corporation, except as the Board of
Directors may otherwise provide. The Treasurer shall have such other powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Assistant Treasurer shall have such powers and perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary and Assistant Secretaries.</U> The Secretary shall record the proceedings of all meetings of the
stockholders and the Board of Directors (including committees of the Board) in books kept for that purpose. In the absence or the Secretary from any such meeting an Assistant Secretary, or if such person is absent, a temporary secretary chosen at
the meeting, shall record the proceedings thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation) and shall have such other duties and powers as may be designated
from time to time by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Assistant Secretary shall have such powers and perform such duties as the Board of
Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Powers and Duties.</U> Subject to these <FONT
STYLE="white-space:nowrap">By-laws,</FONT> each officer of the Corporation shall have in addition to the duties and powers specifically set forth in these <FONT STYLE="white-space:nowrap">By-laws,</FONT> such duties and powers as arc customarily
incident to such officer&#146;s office, and such duties and powers as may be designated from time to time by the Board of Directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article IV - Capital Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificates of Stock</U>. Each stockholder shall be entitled to a certificate of the capital stock of the
Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by a President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant
Secretary. Such signatures may be a facsimile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or registrar
before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the lime of its issue. Every certificate for shares of stock which are subject to any
restriction on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of stock shall contain such legend with respect thereto as is required by law. The Corporation shall be permitted to issue
fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfers.</U> Subject to any restrictions on transfer, shares of stock may be
transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate therefor properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps
(if necessary) affixed, and with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Record Holders.</U>&nbsp;Except as may otherwise be required by law, by the Certificate of Incorporation or by
these <FONT STYLE="white-space:nowrap">By-laws,</FONT> the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner or such stock for all purposes, including the payment of dividends and the right to vote
with respect thereto, regardless of any transfer, pledge or other disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these
<FONT STYLE="white-space:nowrap">By-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall be the duty of each stockholder to notify the Corporation of such
stockholder&#146;s post office address. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Record Date</U>. In order that the Corporation may determine the
stockholders entitled to notice of or to vole at any meeting of stockholders or any adjournment thereof, or to consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or
allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not precede
the dale on which it is established, and which shall not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting, more than ten (10)&nbsp;days after the date on which the record date for stockholder consent
without a meeting is established, nor more than sixty (60)&nbsp;days prior to any other action. In such case only stockholders of record on such record date shall be so entitled notwithstanding any transfer of stock on the books of the Corporation
after the record date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no record date is fixed, (a)&nbsp;the record date for determining stockholders entitled to notice of or to vole
at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held, (b)&nbsp;the
record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is necessary, shall be the first date on which a signed written consent setting forth the
action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in this state, to its principal place of business, or to an officer or agent of the Corporation having custody of the book in which proceedings
of meetings of stockholders are recorded, and (c)&nbsp;the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Lost Certificates</U>. The Corporation may issue a new
certificate of stock in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or his legal representative, to
give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article V - Indemnification </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp; <U>Definitions.</U> For purposes of this Article V: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Corporate Status&#148; describes the status of a person who is serving or has served
(i)&nbsp;as a Director of the Corporation, (ii)&nbsp;as an Officer of the Corporation, or (iii) as a director, partner, trustee, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other
enterprise which such person is or was serving at the request of the Corporation. For purposes of this Section 1(a), an Officer or Director of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or agent
of a Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, &#147;Corporate Status&#148; shall not include the status of a person who is serving or has served as a director, officer, employee or
agent of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such person&#146;s activities prior to said transaction, unless specifically authorized by the Board of Directors or the
stockholders of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Director&#148; means any person who serves or has served
the Corporation as a director on the Board of Directors of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Disinterested
Director&#148; means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Expenses&#148; means all reasonable attorney&#146;s fees, retainers, court costs, transcript
costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of
demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements,
costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(e)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Non-Officer</FONT> Employee&#148; means any person who serves
or has served as an employee or agent of the Corporation, but who is no! or was no! a Director or Officer; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Officer&#148; means any person who serves or has served the Corporation as an officer
appointed by the Board of Directors of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Proceeding&#148; means any
threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism. inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;&#147;Subsidiary&#148; shall mean any
corporation, partnership, limited liability company, joint venture, trust or other entity of which the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i)&nbsp;a general partner, managing
member or other similar interest or (ii) (A) 50% or more of the voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B) 50% or more of the outstanding
voting capital stock or other voting equity interests of such corporation, partnership, limited liability company, joint venture or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification of Directors and Officers.</U> Subject to the operation of Section&nbsp;4 of this Article V of
these <FONT STYLE="white-space:nowrap">By-laws,</FONT> each Director and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case
of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment) against any and all Expenses, judgments,
penalties, fines and amounts reasonably paid in settlement that arc incurred by such Director or Officer or on such Director&#146;s or Officer&#146;s behalf in connection with any threatened, pending or completed Proceeding or any claim, issue or
matter therein, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#146;s or Officer&#146;s Corporate Status, if such Director or Officer acted in good faith and in a manner such
Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification
provided by this Section&nbsp;2 shall continue as to a Director or Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives.
Notwithstanding the foregoing, the Corporation shall indemnify any Director or Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding was authorized by the Board of Directors of
the Corporation, unless such Proceeding was brought to enforce an Officer or Director&#146;s rights to indemnification or, in the case of Directors, advancement of Expenses under these <FONT STYLE="white-space:nowrap">By-laws</FONT> in accordance
with the provisions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification of <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employees.</U> Subject to the operation of Section&nbsp;4 of this Article V of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> each <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee may, in the discretion of the Board of Directors
of the Corporation, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses, judgments, penalties, fines and amounts reasonably paid in settlement
that arc incurred by such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee or on such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee&#146;s behalf in connection with any threatened, pending or completed Proceeding, or any
claim, issue or matter therein, which such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee is, or is threatened to be made, a party to or participant in by reason of such <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employee&#146;s Corporate Status, if such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee acted in good faith and in a manner such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee reasonably believed to be in or not opposed
to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section&nbsp;3 shall exist as to a <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Employee after he or she has ceased to be a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee and shall inure to the benefit of his or her heirs, personal representatives, executors and
administrators. Notwithstanding the foregoing, the Corporation may indemnify any <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee seeking indemnification in connection with a Proceeding initiated by such
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee only if such Proceeding was authorized by the Board of Directors of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Good Faith.</U> Unless ordered by a court, no indemnification
shall be provided pursuant to this Article V to a Director, to an Officer or to a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee unless a determination shall have been made that such person acted in good faith and in a manner such
person reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be
made by (a)&nbsp;a majority vote of the Disinterested Directors, even though less than a quorum of the Board of Directors, (b)&nbsp;a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the
Disinterested Directors (even though less than a quorum), (c) if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion, or (d)&nbsp;by the stockholders of
the Corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Advancement of Expenses to Directors Prior to Final Disposition.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection
with any Proceeding in which such Director is involved by reason of such Director&#146;s Corporate Status within ten (10)&nbsp;days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances
from time to lime, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf
of such Director to repay any Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If a claim for advancement of Expenses hereunder by a Director is not paid in full by the
Corporation within 10 days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if
successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or
stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to the action and shall not create a presumption that such advancement is not permissible. The burden of
proving that a Director is not entitled to an advancement of expenses shall be on the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms
of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Advancement of Expenses to Officers and <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employees Prior to
Final Disposition.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Corporation may, at the discretion of the Board of Directors of the
Corporation, advance any or all Expenses incurred by or on behalf of any Officer and <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee in connection with any Proceeding in which such is involved by reason of the Corporate Status of such
Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee upon the receipt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
by the Corporation of a statement or statements from such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee requesting such advance or advances from time to time, whether
prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer and <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee and shall be preceded or
accompanied by an undertaking by or on behalf of such to repay any Expenses so advanced if it shall ultimately be determined that such Officer or Non-Officer Employee is not entitled to be indemnified against such Expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms
of an undertaking. the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee has not met any applicable standard for indemnification set
forth in the DGCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Contractual Nature of Rights.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The foregoing provisions of this Article V shall be deemed to be a contract between the Corporation
and each Director and Officer entitled to the benefits hereof at any time while this Article V is in effect, and any repeal or modification thereof shall not affect any rights or obligations then existing with respect to any state of facts then or
theretofore existing or any Proceeding theretofore or thereafter brought based in whole or in part upon any such state of facts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If a claim for indemnification hereunder by a Director or Officer is not paid in full by the
Corporation within 60 days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful
in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or
stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to the action and shall not create a presumption that such indemnification is not permissible. The burden of
proving that a Director or Officer is not entitled to indemnification shall be on the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it
shall be a defense that such Director or Officer has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Exclusivity of Rights</U>. The rights to indemnification and advancement of Expenses set forth in this
Article V shall not be exclusive of any other right which any Director, Officer, or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee may have or hereafter acquire under any statute, provision of the Certificate or these <FONT
STYLE="white-space:nowrap">By-laws,</FONT> agreement, vote of stockholders or Disinterested Directors or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance.</U> The Corporation may maintain insurance, at its expense, to protect itself and any Director,
Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employee, or arising out of any such person&#146;s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or the provisions of this Article V. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Indemnification</U>. The Corporation&#146;s obligation,
if any, to indemnify any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust,
employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification from such other corporation, partnership, joint venture, trust, employee benefit plan or enterprise. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Article VI - Miscellaneous Provisions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Fiscal Year.</U> Except as otherwise determined by the Board of Directors, the fiscal year of the Corporation
shall end on December 31 of each year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Seal</U>. The Board of Directors shall have power to adopt and alter
the seal of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution of Instruments.</U> Subject to any limitations which may be set forth
in a resolution of the Board of Directors, all deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the Corporation in the ordinary course of its business without director action may be executed on behalf of
the Corporation by, a President, or by any other officer, employee or agent of the Corporation as the Board of Directors may authorize. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting of Securities.</U> Unless the Board of Directors otherwise provides, a President, any Vice President or
the Treasurer may waive notice of and act on behalf of this Corporation, or appoint another person or persons to act as proxy or attorney in fact for this Corporation with or without discretionary power and/or power of substitution, at any meeting
of stockholders or shareholders of any other corporation or organization, any of whose securities arc held by this Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Resident Agent.</U> The Board of Directors may appoint a resident agent upon whom legal process may be served in
any action or proceeding against the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate Records.</U> The original or attested copies of
the Certificate of Incorporation, <FONT STYLE="white-space:nowrap">By-laws</FONT> and records of all meetings of the incorporators, stockholders and the Board of Directors and the stock and transfer records, which shall contain the names of all
stockholders, their record addresses and the amount of stock held by each, shall be kept at the principal office of the Corporation, at the office of its counsel, or at an office of its transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate of Incorporation</U>. All references in these <FONT STYLE="white-space:nowrap">By-laws</FONT> to the
Certificate of Incorporation shall be deemed to refer to the Certificate of Incorporation of the Corporation, as amended and in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments.</U> These <FONT STYLE="white-space:nowrap">By-laws</FONT> may be altered, amended or repealed, and
new <FONT STYLE="white-space:nowrap">By-laws</FONT> may be adopted, by the stockholders or by the Board of Directors; provided, that (a)&nbsp;the Board of Directors may not alter, amend or repeal any provision of these
<FONT STYLE="white-space:nowrap">By-laws</FONT> which by law, by the Certificate of Incorporation or by these <FONT STYLE="white-space:nowrap">By-laws</FONT> requires action by the stockholders and (b) any alteration, amendment or repeal of these <FONT
STYLE="white-space:nowrap">By-laws</FONT> by the Board of Directors and any new <FONT STYLE="white-space:nowrap">By-law</FONT> adopted by the Board of Directors may be altered, amended or repealed by the stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of Notice.</U> Whenever notice is required to be given
under any provision of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or alter the time of the
event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting al
the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at. nor the purpose of, any meeting needs to be specified in any written waiver or any
waiver by electronic transmission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>d209588dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIFTH AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;18, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>Page<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REGISTRATION RIGHTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Demand Registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses of Registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registration Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information by Holder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Restrictions on Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rule 144 Reporting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT> Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delay of Registration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limitations on Subsequent Registration Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination of Registration Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COVENANTS OF THE COMPANY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Basic Financial Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Inspection Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Matters Requiring Preferred Director Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Board Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Observer Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Successor Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses of Counsel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Properties, Business and Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Right to Conduct Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FCPA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defense Production Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination of Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Material Non-Public Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RIGHT OF FIRST REFUSAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Right of Refusal of the Investors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION 5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Investors; Successor and Assigns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delays or Omissions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Titles and Subtitles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Execution and Delivery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Aggregation of Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect on Prior Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIFTH AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS FIFTH AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;) is made as of March&nbsp;18, 2021,
by and among Aura Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;) and the persons and entities listed on Schedule A hereto (each, an &#147;<B>Investor</B>&#148; and collectively, the &#147;<B>Investors</B>&#148;). Unless
otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section&nbsp;1. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, certain of the Investors (the &#147;<B>Existing Investors</B>&#148;) hold shares of Series A Convertible Preferred
Stock of the Company, par value $0.00001 per share (&#147;<B>Series A Preferred Stock</B>&#148;), Series <FONT STYLE="white-space:nowrap">A-1</FONT> Convertible Preferred Stock of the Company, par value $0.00001 per share (&#147;<B>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</B>&#148;), Series <FONT STYLE="white-space:nowrap">A-2</FONT> Convertible Preferred Stock of the Company, par value $0.00001 per share (&#147;<B>Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</B>&#148;), Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock, Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Preferred Stock and/or Series <FONT STYLE="white-space:nowrap">D-2</FONT> Preferred Stock and possess registration rights, information rights, rights of first offer, and other rights pursuant to a Fourth Amended
and Restated Investors&#146; Rights Agreement dated as of April&nbsp;1, 2019 by and among the Company and such Investors, as amended on June&nbsp;25, 2020 (the &#147;<B>Prior Agreement</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Existing Investors include holders who constitute the Required Holders (as defined in the Prior Agreement) and who hold a
majority of the outstanding shares of Junior Preferred Stock and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior
Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, certain of the Investors are parties to that certain Series E Convertible Preferred Purchase Agreement,
under which certain of the Company&#146;s and such Investors&#146; obligations are conditioned upon the execution and delivery of this Agreement by such Investors, the Existing Investors described above and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the Existing Investors hereby agree that the Prior Agreement shall be amended and restated in its entirety by this
Agreement, and the parties to this Agreement further agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
<I>Certain Definitions</I>. As used in this Agreement, the following terms shall have the meanings set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
&#147;<B>Affiliate</B>&#148; shall mean, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner,
limited partner, managing member, member, employee, officer or director of such Person or any venture capital or other investment fund now or hereafter existing that is controlled by or under common control with one or more general partners or
managing members of, or shares the same management or advisory company with, such Person. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Affiliated Fund</B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.8(a)(iii)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Board</B>&#148; or &#147;<B>Board of Directors</B>&#148; shall mean
the board of directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Commission</B>&#148; shall mean the U.S. Securities and Exchange Commission or any
other federal agency at the time administering the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Class</B><B></B><B>&nbsp;A Common Stock</B>&#148; shall
mean the Company&#146;s Class&nbsp;A Common Stock, par value $0.00001 per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Class</B><B></B><B>&nbsp;B
Common Stock</B>&#148; means shares of the Company&#146;s Class&nbsp;B common stock, par value $0.00001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Common
Stock</B>&#148; means, collectively, shares of the Company&#146;s Class&nbsp;A Common Stock and Class&nbsp;B Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
&#147;<B>Derivative Securities</B>&#148; means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly)<B>,</B> Common Stock, including options and warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Exchange Act</B>&#148; shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and
the rules and regulations thereunder, all as the same shall be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Exempted Registration</B>&#148;
shall mean a registration relating solely to employee benefit plans, a registration relating to the offer and sale of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities, a registration relating to a corporate reorganization or
other Rule 145 transaction, or a registration on any registration form that does not permit secondary sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Fund
Investor</B>&#148; shall mean each of Advent Life Sciences Fund III LP, ALS III Carry and <FONT STYLE="white-space:nowrap">Co-Invest</FONT> LP, Advent-Harrington Impact Fund LP, and Advent Life Sciences LLP, Advent Life Sciences Fund I LP
(collectively, &#147;<B>Advent</B>&#148;), Chiesi Ventures, LP (&#147;<B>Chiesi</B>&#148;), Columbus Innvierte Life Science F.C.R. (&#147;<B>Columbus</B>&#148;), Ysios BioFund II Innvierte F.C.R. (&#147;<B>Ysios</B>&#148;), Lundbeckfond Invest A/S
(&#147;<B>LV</B>&#148;), Arix Bioscience Holdings Limited (&#147;<B>Arix</B>&#148;), Medicxi Growth I LP, Medicxi Growth Co Invest I LP (together with Medicxi Growth I LP, &#147;<B>Medicxi</B>&#148;), Citadel Multi-Strategy Equities Master Fund Ltd.
(together with its Affiliates, &#147;<B>Surveyor</B>&#148;), Matrix Capital Management Master Fund, LP (&#147;<B>Matrix</B>&#148;), Rock Springs Capital Master Fund LP, Four Pines Master Fund LP and their respective Affiliates (including Affiliated
Funds). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>GAAP</B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.1(a)</U> hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Holder</B>&#148; shall mean: (i)&nbsp;any Investor that holds Registrable
Securities and (ii)&nbsp;any holder of Registrable Securities to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with <U>Section</U><U></U><U>&nbsp;5.1</U> of this Agreement;
<U>provided</U>, <U>however</U>, that for purposes of this Agreement, a record holder of shares of Preferred Stock convertible into such Registrable Securities shall be deemed to be the Holder of such Registrable Securities; <U>provided</U>,
<U>further</U>, that the Company shall in no event be obligated to register shares of Preferred Stock, and <U>also</U> <U>provided</U> that Holders of Registrable Securities will not be required to convert their shares of Preferred Stock into Common
Stock in order to exercise the registration rights granted hereunder until immediately before the closing of the offering to which the registration relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B>Indemnified Party</B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.6(c)</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) &#147;<B>Indemnifying Party</B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.6(c)</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) &#147;<B>Initial Public Offering</B>&#148; shall mean the closing of the Company&#146;s first firm commitment underwritten public offering
of Common Stock registered under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) &#147;<B>Initiating Holders</B>&#148; shall mean, collectively, Holders who
properly initiate a registration request under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) &#147;<B>Investors</B>&#148; shall mean the persons and entities
listed on <U>Schedule A</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) &#147;<B>Junior Preferred Investor</B>&#148; shall mean the holders of Junior Preferred Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) &#147;<B>Junior Preferred Nonpurchasing Holder</B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.1(d)</U>
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) &#147;<B>Junior Preferred Overallotment Notice</B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.1(d)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) &#147;<B>Junior Preferred Purchasing Holder</B>&#148; shall have the meaning set
forth in <U>Section</U><U></U><U>&nbsp;4.1(d)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) &#147;<B>Junior Preferred Stock</B>&#148; shall mean collectively, all
shares of Series A Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) &#147;<B>Key Employee</B>&#148; shall mean any executive-level employee (including division director and vice-president-level positions)
as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Series E Purchase Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) &#147;<B>Major Investor</B>&#148; shall mean any Investor that, individually or together
with such Investor&#146;s Affiliates, holds at least 500,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) and each
Person to whom any of the rights of any such Investor are assigned pursuant to Section&nbsp;5.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) &#147;<B>New Securities</B>&#148;
shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.1(f)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<B>Person</B>&#148; shall mean any
individual, corporation, partnership, trust, limited liability company, association or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<B>Preferred
Director</B>&#148; shall mean the (1)&nbsp;director elected by the holders of the outstanding Series C Preferred Stock (the &#147;<B>Series C Director</B>&#148;), the one (1)&nbsp;director elected by the holders of the outstanding Series D Preferred
Stock (the &#147;<B>Series D Director</B>&#148;) and the one (1)&nbsp;director elected by the holders of the outstanding Series E Preferred Stock pursuant to the Voting Agreement (the &#147;<B>Series E Director</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<B>Preferred Director Majority</B>&#148; shall mean the majority of the Preferred Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<B>Preferred Stock</B>&#148; shall mean, collectively, all shares of Junior Preferred Stock and Senior Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee) &#147;<B>Qualified Public Offering</B>&#148; shall have the meaning set forth in the Restated Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff) &#147;<B>Registrable Securities</B>&#148; shall mean: (i)&nbsp;shares of Common Stock issuable or issued pursuant to the conversion of
the Shares, (ii)&nbsp;shares of Common Stock issued or issuable (directly or indirectly) upon conversion of any capital stock of the Company owned or later acquired by the Investors and (iii)&nbsp;any Common Stock issued as a dividend or other
distribution with respect to or in exchange for or in replacement of the shares referenced in (i)&nbsp;or (ii) above; <U>provided</U>, <U>however</U>, that Registrable Securities shall not include any shares of Common Stock described in clauses (i),
(ii) or (iii)&nbsp;above (A) which have previously been registered, and sold to the public through a registration statement, (B)&nbsp;which have been sold in a transaction exempt from the registration and prospectus delivery requirements of the
Securities Act so that all transfer restrictions and restrictive legends with respect thereto were able to be removed upon the consummation of such sale or (C)&nbsp;which have been sold in a private transaction in which the transferor&#146;s rights
under this Agreement are not validly assigned in accordance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg) The terms &#147;<B>register</B>,&#148;
&#147;<B>registered</B>&#148; and &#147;<B>registration</B>&#148; shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the
declaration or ordering of the effectiveness of such registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(hh) &#147;<B>Registration Expenses</B>&#148; shall mean all
expenses incurred by the Company in effecting any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, accounting fees, escrow fees, fees and disbursements of
counsel for the Company, fees and disbursements of one special counsel for the Holders (selected by the Required Preferred Holders), blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such
registration, but shall not include Selling Expenses, fees and disbursements of other counsel for the Holders and the compensation of regular employees of the Company, which shall be paid in any event by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<B>Required Preferred Holders</B>&#148; means the holders of at least sixty
percent (60%) of the outstanding Senior Preferred Stock of the Company voting together as a single class (as determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(jj) &#147;<B>Restated Certificate</B>&#148; shall mean the Company&#146;s Ninth Amended and Restated Certificate of Incorporation, as such
may be further amended and restated from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(kk) &#147;<B>Restricted Securities</B>&#148; shall mean any Registrable
Securities required to bear the first legend set forth in <U>Section</U><U></U><U>&nbsp;2.8(b)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ll) &#147;<B>Rock
Springs</B>&#148; shall mean Rock Springs Capital Master Fund LP and Four Pines Master Fund LP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(mm) &#147;<B>Rule 144</B>&#148; shall
mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(nn) &#147;<B>Rule 145</B>&#148; shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended
from time to time, or any similar successor rule that may be promulgated by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(oo) &#147;<B>Securities Act</B>&#148; shall
mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(pp) &#147;<B>Selling Expenses</B>&#148; shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the
sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of one special counsel to the Holders included in Registration Expenses). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(qq) &#147;<B>Senior Preferred Investor</B>&#148; shall mean the holders of Senior Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(rr) &#147;<B>Senior Preferred Nonpurchasing Holder</B>&#148; shall have the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.1(b)</U>
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ss) &#147;<B>Senior Preferred Overallotment Notice</B>&#148; shall have the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.1(b)</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(tt) &#147;<B>Senior Preferred Purchasing Holder</B>&#148; shall have the meaning set
forth in <U>Section</U><U></U><U>&nbsp;4.1(b)</U> hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(uu) &#147;<B>Senior Preferred Stock</B>&#148; shall mean collectively, all shares of Series
B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vv) &#147;<B>Series B Preferred
Stock</B>&#148; shall mean Series B Convertible Preferred Stock of the Company, par value $0.00001 per share, and shares of Series B Convertible Preferred Stock issuable (whether or not yet issued) upon exercise of the Warrants (as defined in the
Series B Purchase Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ww) &#147;<B>Series B Purchase Agreement</B>&#148; shall mean that certain Amended and Restated Series B
Convertible Preferred Stock Purchase Agreement, dated on or about March&nbsp;31, 2016, by and among the Company and the Investors named therein, as such may be amended, modified, supplemented or rested from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx) &#147;<B>Series C Preferred Stock</B>&#148; shall mean, collectively: the (i)&nbsp;Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Stock and (ii)&nbsp;Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(yy) &#147;<B>Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Stock</B>&#148; means shares of the Company&#146;s Series <FONT STYLE="white-space:nowrap">C-1</FONT> Convertible Preferred Stock, par value $0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(zz) &#147;<B>Series <FONT STYLE="white-space:nowrap">C-2</FONT> Preferred Stock</B>&#148; means shares of the Company&#146;s Series <FONT
STYLE="white-space:nowrap">C-2</FONT> Convertible Preferred Stock, par value $0.00001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aaa) &#147;<B>Series C Purchase
Agreement</B>&#148; shall mean that certain Series C Convertible Preferred Stock Purchase Agreement, dated as of December&nbsp;20, 2017, by and among the Company and the Investors named therein, as such may be amended, modified, supplemented or
rested from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bbb) &#147;<B>Series D Preferred Stock</B>&#148; means collectively, the (i)&nbsp;Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Preferred Stock and (ii)&nbsp;Series <FONT STYLE="white-space:nowrap">D-2</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ccc) &#147;<B>Series <FONT STYLE="white-space:nowrap">D-1</FONT> Preferred Stock</B>&#148; means shares of the Company&#146;s Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock, par value $0.00001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ddd) &#147;<B>Series <FONT
STYLE="white-space:nowrap">D-1</FONT> Purchase Agreement</B>&#148; shall mean that certain Series <FONT STYLE="white-space:nowrap">D-1</FONT> Convertible Preferred Stock Purchase Agreement, dated as of April&nbsp;1, 2019, by and among the Company
and the Investors named therein, as such may be amended, modified, supplemented or rested from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(eee) &#147;<B>Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Preferred Stock</B>&#148; means shares of the Company&#146;s Series <FONT STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock, par value $0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(fff) &#147;<B>Series <FONT STYLE="white-space:nowrap">D-2</FONT> Purchase Agreement</B>&#148; shall mean that certain Series <FONT
STYLE="white-space:nowrap">D-2</FONT> Convertible Preferred Stock Purchase Agreement, dated as of June&nbsp;25, 2020, by and among the Company and the Investors named therein, as such may be amended, modified, supplemented or rested from time to
time </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ggg) &#147;<B>Series E Preferred Stock</B>&#148; shall mean Series E Convertible Preferred Stock of the Company, par value $0.00001
per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(hhh) &#147;<B>Series E Purchase Agreement</B>&#148; shall mean that certain Series E
Convertible Preferred Stock Purchase Agreement, dated as of March&nbsp;18, 2021, by and among the Company and the Investors named therein, as such may be amended, modified, supplemented or rested from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<B>Shares</B>&#148; shall mean: (i)&nbsp;the Preferred Stock and (ii)&nbsp;any securities issued with respect to the foregoing
upon any stock split, stock dividend, recapitalization, or similar event or upon any conversion of the Preferred Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 2
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <I>Demand Registration</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Demand for Registration</U>. Subject to the conditions set forth in this <U>Section</U><U></U><U>&nbsp;2.1</U>, if the Company shall
receive from Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to at least twenty-five percent (25%) of the Registrable Securities having an aggregate offering price to the
public of not less than Five Million Dollars ($5,000,000) (such request shall state the number of shares of Registrable Securities to be disposed of by such Initiating Holders), the Company shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) within ten (10)&nbsp;days give written notice of the proposed registration to all other Holders; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) as soon as practicable, file and effect such registration (including, without limitation, filing post-effective amendments, appropriate
qualifications under applicable blue sky or other state securities laws, and appropriate compliance with the Securities Act) and to permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified
in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request received by the Company within twenty (20)&nbsp;days after such written notice
from the Company is mailed; <U>provided</U> that the Company shall file the registration statement within sixty (60)&nbsp;days of the receipt of the request from the Initiating Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Limitations on Demand Registration</U>. The Company shall not be obligated to effect, or to take any action to effect, any such
registration pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Prior to the earlier of: (a)&nbsp;three (3) years after the date
of this Agreement, or (b)&nbsp;six (6) months following the closing of the Initial Public Offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) In any particular jurisdiction
in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and except as may be
required by the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) After the Company has initiated two (2)&nbsp;such registrations pursuant to this
<U>Section</U><U></U><U>&nbsp;2.1</U> (counting for these purposes only registrations which have been declared or ordered effective and pursuant to which not less than all of the Registrable Securities that Holders have requested to be included in
such registrations are actually included and sold in such registrations); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) During the period starting with the date sixty (60)&nbsp;days prior to the
Company&#146;s good faith estimate of the date of filing of, and ending on a date one hundred eighty (180)&nbsp;days after the effective date of, a Company-initiated registration; <U>provided</U> that the Company is actively employing, in good
faith, commercially reasonable efforts to cause such registration statement to become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Deferral</U>. If: (i)&nbsp;in the
good faith judgment of the Board of Directors, the filing of a registration statement covering the Registrable Securities would be materially detrimental to the Company and the Board of Directors concludes, as a result, that it is in the best
interests of the Company to defer the filing of such registration statement at such time, and (ii)&nbsp;the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the
Board of Directors, it would be materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration statement,
then (in addition to, the limitations set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(iv)</U> above), the Company shall have the right to defer such filing for a period of not more than sixty (60)&nbsp;days after receipt of the request of the
Initiating Holders, and, <U>provided</U> <U>further</U>, that the Company shall not defer its obligation in this manner more than once in any twelve month period and <U>provided</U> <U>further</U>, the Company shall not register any securities for
its own account or that of any other stockholder during such sixty (60)&nbsp;day period other than an Exempted Registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
<U>Underwriting</U>. If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this
<U>Section</U><U></U><U>&nbsp;2.1</U> and the Company shall include such information in the written notice referred to in <U>Section</U><U></U><U>&nbsp;2.1(a)(i)</U>. In such event, the right of any Holder to include all or any portion of its
Registrable Securities in a registration pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U> shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities to the
extent provided herein. If the Company shall request inclusion in any registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> of securities being sold for its own account, or if other persons shall request inclusion in any registration
pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, the Initiating Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall be conditioned upon the participation of the Company or such other
persons in such underwriting and the inclusion of the Company&#146;s and such person&#146;s other securities of the Company and their acceptance of the further applicable provisions of this Section (including <U>Section</U><U></U><U>&nbsp;2.10</U>).
The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such
underwriting by the Initiating Holders, subject to the reasonable approval of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this
<U>Section</U><U></U><U>&nbsp;2.1</U>, if the underwriters advise the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so included
shall be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. In no event shall Registrable
Securities be excluded from such registration unless all other stockholders&#146; securities (including securities for the account of the Company) have been first excluded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a person who has requested inclusion in such registration as provided above does not
agree to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriters or the Initiating Holders. The securities so excluded shall also be withdrawn from registration. Any
Registrable Securities or other securities excluded or withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration
was previously reduced as a result of marketing factors pursuant to this <U>Section</U><U></U><U>&nbsp;2.1(d)</U>, then the Company shall then offer to all Holders who have retained rights to include securities in the registration the right to
include additional Registrable Securities in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders requesting additional inclusion, as set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <I>Company Registration</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Company Registration</U>. If the Company shall determine to register any of its securities either for its own account or the account of
a security holder or holders, other than a registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or <U>2.3</U> or an Exempted Registration, the Company shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) within ten (10)&nbsp;days give written notice of the proposed registration to all Holders; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) include in such registration (and any related qualification under blue sky laws or other compliance), except as set forth in
<U>Section</U><U></U><U>&nbsp;2.2(b)</U> below, and in any underwriting involved therein, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders received by the Company within twenty
(20)&nbsp;days after such written notice from the Company is delivered. Such written request may specify all or a part of a Holder&#146;s Registrable Securities. If a Holder decides not to include all of its Registrable Securities in any
registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the
Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Underwriting</U>. If the
registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to <U>Section</U><U></U><U>&nbsp;2.2(a)(i)</U>. In
such event, the right of any Holder to registration pursuant to this <U>Section</U><U></U><U>&nbsp;2.2(b)</U> shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable
Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other holders of securities of the Company with registration rights
to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this <U>Section</U><U></U><U>&nbsp;2.2</U>, if the
underwriters advise the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) limit the number of Registrable Securities to be
included in the registration and underwriting. In no event shall any Registrable Securities be excluded from such registration and underwriting unless all other stockholders&#146; securities have been first excluded. In the event that the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such registration and underwriting, then the Registrable Securities that are included in such registration and underwriting shall
be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no
event shall the amount of securities of the selling Holders included in the registration and underwriting be reduced below thirty percent (30%) of the total amount of securities included in such registration and underwriting (other than in the case
of the Initial Public Offering). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a person who has requested inclusion in such registration as provided above does not agree to the
terms of any such underwriting, such person shall also be excluded therefrom by written notice from the Company or the underwriter. The securities so excluded shall also be withdrawn from such registration. Any Registrable Securities or other
securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Right to Terminate
Registration</U>. The Company shall have the right to terminate or withdraw any registration initiated by it under this <U>Section</U><U></U><U>&nbsp;2.2</U> prior to the effectiveness of such registration whether or not any Holder has elected to
include securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with <U>Section</U><U></U><U>&nbsp;2.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <I>Registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT></I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Request for Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration</U>. If the Company is then qualified for the use of Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> in addition to the rights contained in the foregoing provisions of this Section&nbsp;2 and subject to the conditions set forth in this <U>Section</U><U></U><U>&nbsp;2.3</U>, if the Company shall receive from
Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or any similar short form registration statement with respect to all or part of the
Registrable Securities (such request shall state the number of shares of Registrable Securities to be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">disposed-of-and</FONT></FONT> the intended methods of disposition of such shares
by such Holder or Holders), the Company will take all such action with respect to such Registrable Securities as required by <U>Section</U><U></U><U>&nbsp;2.1(a)(i)</U> and <U>(ii)</U>; provided, that in the case of a registration pursuant to this
<U>Section</U><U></U><U>&nbsp;2.3</U>, the Company shall file the registration statement within forty-five (45)&nbsp;days of the receipt of the request from the Initiating Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Limitations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration</U>. The Company shall not be obligated to effect, or take
any action to effect, any such registration pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the circumstances described in
either <U>Sections 2.1(b)(ii)</U> or <U>2.1(b)(iv)</U>; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the Initiating Holders, together with the holders of any other securities of the
Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) on Form <FONT STYLE="white-space:nowrap">S-3</FONT> at an aggregate price to the public of less than Three Million Dollars
($3,000,000); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) If the Company has effected two (2)&nbsp;registrations pursuant to <U>Section</U><U></U><U>&nbsp;2.3</U> at any
time within the twelve (12)&nbsp;month period immediately preceding the date of the written request from the Initiating Holders described in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Deferral</U>. The provisions of <U>Section</U><U></U><U>&nbsp;2.1(c)</U> shall apply to any registration pursuant to this
<U>Section</U><U></U><U>&nbsp;2.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Underwriting</U>. If the Initiating Holders requesting registration under this
<U>Section</U><U></U><U>&nbsp;2.3</U> intend to distribute the Registrable Securities covered by their request by means of an underwriting, the provisions of <U>Section</U><U></U><U>&nbsp;2.1(d)</U> shall apply to such registration. Notwithstanding
anything contained herein to the contrary, registrations effected pursuant to this <U>Section</U><U></U><U>&nbsp;2.3</U> shall not be counted as requests for registration or registrations effected pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <I>Expenses of Registration</I>. All Registration Expenses incurred in connection with registrations pursuant to <U>Sections 2.1</U>,
<U>2.2</U> and <U>2.3</U> hereof shall be borne by the Company; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to <U>Sections 2.1</U> and <U>2.3</U> if
the registration request is subsequently withdrawn at the request of the Holders of at least a majority of the Registrable Securities to be registered or because a sufficient number of Holders shall have withdrawn so that the minimum offering
conditions set forth in <U>Sections 2.1</U> and <U>2.3</U> are no longer satisfied (in which case all participating Holders shall bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so
registered), unless the Holders of at least a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1(a)</U>; and <U>provided</U> <U>further</U>, <U>however</U>,
that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with
reasonable promptness after learning of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> or <U>2.3</U>. All Selling
Expenses shall be borne pro rata by the selling Holders based on the number of Registrable Securities requested to be so registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5
<I>Registration Procedures</I>. In the case of each registration effected by the Company pursuant to <U>Section</U><U></U><U>&nbsp;2</U>, the Company will keep each Holder advised in writing as to the initiation of each registration and as to the
completion thereof. At its expense, the Company shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Prepare and file with the Commission a registration statement with respect to
such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and keep such registration effective for a period ending on the earlier of the date which is one hundred twenty
(120)&nbsp;days from the effective date of the registration statement or such time as the Holder or Holders have completed the distribution described in the registration statement relating thereto; <U>provided</U>, <U>however</U>, that (i)&nbsp;such
one hundred twenty (120)&nbsp;day period shall be extended for a period of time equal to the period the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii)&nbsp;in the case of any
registration of Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable Commission rules, such one hundred twenty
(120)&nbsp;day period shall be extended for up to 12 months, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection (a)&nbsp;above;
<U>provided</U> <U>further</U> that in connection with any registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> pursuant to <U>Section</U><U></U><U>&nbsp;2.3</U> above, the Company agrees to timely file all reports required under the
Exchange Act in order to maintain the right to continue to use such Form <FONT STYLE="white-space:nowrap">S-3</FONT> and to maintain such registration in effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Furnish such number of prospectuses, including any preliminary prospectuses, and other documents incident thereto, including any amendment
of or supplement to the prospectus as required by the Securities Act and other documents, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Use commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; <U>provided</U>, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notify each seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification promptly prepare and furnish to such Holder a
reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each
securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Otherwise use its
commercially reasonable efforts to comply with all applicable rules and regulations of the Commission; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In connection with any
underwritten offering pursuant to a registration statement filed pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> hereof, enter into an underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock,
<U>provided</U> such underwriting agreement contains reasonable and customary provisions, and <U>provided</U> <U>further</U>, that each Holder participating in such underwriting shall also enter into and perform its obligations under such an
agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Use its reasonable best efforts to furnish, at the request of any Holder requesting registration of Registrable Securities
pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, if such securities
are being sold through underwriters, (i)&nbsp;an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public
offering and reasonably satisfactory to a majority in interest of Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities, and (ii)&nbsp;a letter dated such date,
from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering and reasonably satisfactory to a majority
in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Promptly make available for inspection by the selling Holders, any underwriter participating in any disposition pursuant to such
registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the
Company&#146;s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent in connection with any such registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) After such
registration statement becomes effective, notify each selling Holder of any request by the Commission that the Company amend or supplement such registration statement or prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#146;s directors may implement a trading program under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <I>Indemnification</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, each of its officers, directors,
stockholders, members and partners, legal counsel, and accountants and each person controlling such Holder within the meaning of the Securities Act or the Exchange Act, with respect to which registration, qualification, or compliance has been
effected pursuant to this <U>Section</U><U></U><U>&nbsp;2</U>, and each underwriter, if any, and each person who controls within the meaning of the Securities Act or the Exchange Act any underwriter, against all expenses, claims, losses, damages,
and liabilities (or actions, proceedings, or settlements in respect thereof) arising out of or based on: (i)&nbsp;any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus,
offering circular, or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification, or compliance; (ii)&nbsp;any omission (or alleged omission) to state therein a material
fact required to be stated therein or necessary to make the statements therein not misleading; or (iii)&nbsp;any violation (or alleged violation) by the Company or any of its agents or affiliates of the Securities Act, the Exchange Act, any state
securities laws or any rule or regulation thereunder applicable to the Company, and the Company will reimburse each such Holder, each of its officers, directors, stockholders, members, partners, legal counsel, and accountants and each person
controlling such Holder, each such underwriter, and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage,
liability, or action as they are incurred; <U>provided</U> that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission based
upon written information furnished to the Company and stated to be specifically for use therein by such Holder, any of such Holder&#146;s officers, directors, partners, legal counsel or accountants, any person controlling such Holder, such
underwriter or any person who controls any such underwriter; and <U>provided</U> <U>further</U> that, the indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;2.6(a)</U> shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, each selling Holder, severally and not jointly, if Registrable Securities held by such Holder are included
in the securities as to which such registration, qualification, or compliance is being effected, will indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel, and accountants and each underwriter, if any, of
the Company&#146;s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section&nbsp;15 of the Securities Act, each other selling Holder, and each of their officers,
directors, stockholders, members and partners, and each person controlling each other selling Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on: (i)&nbsp;any untrue statement (or
alleged untrue statement) of a material fact contained or incorporated by reference in any such registration statement, prospectus, offering circular, or other document (including any related registration statement, notification, or the like)
incident to any such registration, or (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be stated therein or necessary to make the statements therein not misleading, and such Holder will reimburse the Company and other selling Holders, directors, officers, stockholders, members,
partners, legal counsel, and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action as they are
incurred, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular, or other document in
reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein; <U>provided</U>, <U>however</U>, that the obligations of such Holder hereunder shall not apply to amounts
paid in settlement of any such claims, losses, damages, or liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and <U>provided</U> that in
no event shall any indemnity or contribution under this <U>Section</U><U></U><U>&nbsp;2.6</U> exceed the net proceeds from the offering received by such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each party entitled to indemnification under this <U>Section</U><U></U><U>&nbsp;2.6</U> (the &#147;<B>Indemnified Party</B>&#148;) shall
give notice to the party required to provide indemnification (the &#147;<B>Indemnifying Party</B>&#148;) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying
Party to assume the defense of such claim or any litigation resulting therefrom; <U>provided</U> that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the
Indemnified Party (whose approval shall not be unreasonably withheld); <U>provided</U>, <U>further</U>, <U>however</U>, that an Indemnified Party (together with all other Indemnified Parties that may be represented without conflict by one counsel)
shall have the right to retain one separate counsel, with the fees and expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual
or potential differing interests between such Indemnified Party and any other party represented by such counsel in such proceeding; and <U>provided</U> <U>further</U> that the failure of any Indemnified Party to give notice as provided herein shall
not relieve the Indemnifying Party of its obligations under this <U>Section</U><U></U><U>&nbsp;2.6</U>, to the extent such failure is not materially prejudicial to the Indemnifying Party&#146;s ability to defend such action. No Indemnifying Party,
in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably
request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
In any case in which either: (i)&nbsp;any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section</U><U></U><U>&nbsp;2.6</U> but it is judicially determined (by the entry of a final
judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
<U>Section</U><U></U><U>&nbsp;2.6</U> provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
<U>Section</U><U></U><U>&nbsp;2.6</U>, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative
fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable
considerations; <U>provided</U>, <U>however</U>, that no contribution by any Holder, when combined with any amounts paid by such Holder pursuant to <U>Section</U><U></U><U>&nbsp;2.6(b)</U>, shall exceed the net proceeds from the offering received by
such Holder. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; <U>provided</U>,
<U>however</U>, that, in any such case (x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement,
and (y)&nbsp;no Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this <U>Section</U><U></U><U>&nbsp;2.6</U> shall survive the completion of any offering of Registrable Securities in a registration statement, and otherwise shall survive the termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <I>Information by Holder</I>. Each Holder of Registrable Securities shall furnish to the Company such information regarding such Holder
and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance referred to in this
<U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <I>Restrictions on Transfer</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Holder of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all respects with the
provisions of this <U>Section</U><U></U><U>&nbsp;2.8</U>. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and
until (x)&nbsp;the transferee thereof has agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in this Agreement, including, without
limitation, this <U>Section</U><U></U><U>&nbsp;2.8</U> and <U>Section</U><U></U><U>&nbsp;2.10</U>, and (y): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) There is then in effect a
registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Such Holder shall have given prior written notice to the Company of such Holder&#146;s
intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, and, if requested by the Company, such Holder shall have furnished the Company, at such
Holder&#146;s expense, with (A)&nbsp;an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition will not require registration of such Restricted Securities under the Securities Act or (B)&nbsp;a &#147;no
action&#148; letter from the Commission to the effect that the transfer of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto or (C)&nbsp;any other
evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the holder of such Restricted
Securities shall be entitled to transfer such Restricted Securities in accordance with the terms of the notice delivered by the Holder to the Company. It is agreed that the Company will not require opinions of counsel or &#147;no action&#148;
letters for transactions made pursuant to Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Notwithstanding the provisions of subsections (a)(i) and (a)(ii)&nbsp;above,
no such registration statement or opinion of counsel or &#147;no action&#148; letter shall be necessary for: (A)&nbsp;a transfer by a Holder to any of its Affiliates (including an affiliated fund managed by the same manager or managing member or
general partner or management company or by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management company, each an &#147;<B>Affiliated Fund</B>&#148;); (B) a transfer by a
Holder that is a partnership, limited liability company or corporation to a partner, limited partner, retired partner, member, retired member or stockholder of a Holder; (C)&nbsp;a transfer by gift, will or intestate succession of any partner to his
or her spouse or to the siblings, lineal descendants or ancestors of such partner or his or her spouse; (D)&nbsp;any transfer by a Holder in connection with a Sale of the Company (as defined in the Fifth Amended and Restated Voting Agreement of even
date herewith by and among the Investors, the holders of Common Stock party thereto and the Company (the &#147;<B>Voting Agreement</B>&#148;)); or (E)&nbsp;the transfer by a Holder exercising its <FONT STYLE="white-space:nowrap">co-sale</FONT>
rights under the Fifth Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement of even date herewith by and among the Company and the Investors and certain other stockholders named therein (the
&#147;<B>ROFR and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement</B>&#148;), if in each transfer under clauses (A), (B) or (C), the prospective transferee agrees in all such instances in writing to be subject to the terms hereof to the
same extent as if he or she were an original Holder hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each certificate representing Registrable Securities shall (unless
otherwise permitted by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;), OR UNDER THE
SECURITIES LAWS OF CERTAIN STATES. THESE SHARES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
THEREFROM. THE ISSUER OF THESE SHARES MAY REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND
ANY APPLICABLE STATE SECURITIES LAWS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE, INCLUDING A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD OF UP TO 180 DAYS (SUBJECT TO EXTENSION) IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTOR RIGHTS AGREEMENT, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL
OFFICE OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holders consent to the Company making a notation on its records and giving instructions to any transfer agent
of the Restricted Securities in order to implement the restrictions on transfer established in this <U>Section</U><U></U><U>&nbsp;2.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The first legend referring to federal and state securities laws identified in <U>Section</U><U></U><U>&nbsp;2.8(b)</U> hereof stamped on a
certificate evidencing the Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted Securities shall be removed and the Company shall issue a certificate without such legend to the holder of such
Restricted Securities if (i)&nbsp;such securities are registered under the Securities Act; or (ii)&nbsp;such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a public sale or transfer of
such securities may be made without registration under the Securities Act; or (iii)&nbsp;such holder provides the Company with reasonable assurances, which may, at the option of the Company, include an opinion of counsel reasonably satisfactory to
the Company, that such securities can be sold pursuant to Rule 144 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <I>Rule 144 Reporting</I>. With a view
to making available the benefits of certain rules and regulations of the Commission that may permit the sale of the Restricted Securities to the public without registration or pursuant to a registration on Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> the Company agrees to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Make and keep available adequate current public information
regarding the Company available as those terms are understood and defined in Rule 144 under the Securities Act, at all times from and after the effective date of the first registration under the Securities Act filed by the Company for an offering of
its securities to the general public; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Use commercially reasonable efforts to file with the Commission in a timely manner all reports
and other documents required of the Company under the Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) So long as a Holder owns any Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90)&nbsp;days following the effective date of the first registration statement filed by the Company for an offering of its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant
whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so
filed by the Company and such other information as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration (at any time after it has become
subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 <I>Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT> Agreement</I>. If requested by the Company and the managing underwriter of
Common Stock (or other securities) of the Company, each Holder hereby agrees that such Holder shall not sell or otherwise transfer, make any short sale of grant any option for the purchase of, or enter into any hedging or similar transaction with
the same economic effect as a sale, of any Common Stock (or other securities) of the Company held by such Holder immediately prior to the effective date for the registration statement for the Initial Public Offering (other than any shares included
in the registration) during the one hundred and eighty (180)&nbsp;day period following the effective date of the Initial Public Offering. The foregoing provisions of this <U>Section</U><U></U><U>&nbsp;2.10</U> shall not apply to transactions
(including, without limitation, any swap, hedge or similar agreement or arrangement) or announcements, in each case, relating to securities acquired in the Initial Public Offering or securities acquired in open market or other transactions from and
after the Initial Public Offering or that otherwise that do not involve or relate to shares of Common Stock owned by a Holder prior to the IPO, shall be applicable to the Holders only if all officers, directors, and stockholders individually and
together with their Affiliates owning one percent (1%) or more of the outstanding Common Stock are subject to the same restrictions and <U>provided</U>, in addition, the Company will use commercially reasonable efforts to obtain the consent of the
managing underwriter for earlier release of market <FONT STYLE="white-space:nowrap">stand-off</FONT> and transfer restrictions on a portion of the Holders&#146; Common Stock and if the Company or any underwriter of the Initial Public Offering waives
or terminates any market <FONT STYLE="white-space:nowrap">stand-off</FONT> or transfer restrictions imposed on any holder of securities of the Company, then such waiver or termination shall be granted to all Holders subject to market <FONT
STYLE="white-space:nowrap">stand-off</FONT> or transfer restrictions hereby, pro rata based on the number of shares of Common Stock beneficially held by such other holder and the Holders hereby. The underwriters in connection with such registration
are intended third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;2.10</U> and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. The Company may impose stop-transfer
instructions and may stamp each such certificate with the second legend set forth in <U>Section</U><U></U><U>&nbsp;2.8(b)</U> hereof with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end
of such one hundred eighty (180)&nbsp;day period. Each Holder agrees to execute a market standoff agreement with said underwriters in customary form consistent with the provisions of this <U>Section</U><U></U><U>&nbsp;2.10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 <I>Delay of Registration</I>. No Holder shall have any right to take any action to restrain, enjoin, or otherwise delay any registration
as the result of any controversy that might arise with respect to the interpretation or implementation of this <U>Section</U><U></U><U>&nbsp;2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 <I>Limitations on Subsequent Registration Rights</I>. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Required Preferred Holders, enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder any registration rights the terms of which are pari passu
with or senior to the registration rights granted to the Holders hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13 <I>Termination of Registration Rights</I>. The right of any Holder to request
registration or inclusion in any registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, <U>2.2</U> or <U>2.3</U> shall terminate on the earlier of: (i)&nbsp;five (5) years after the closing of the Company&#146;s Initial Public Offering;
(ii)&nbsp;the closing of a Deemed Liquidation Event, as such term is defined in the Company&#146;s Certificate of Incorporation, in which the consideration received by the Investors in such Deemed Liquidation Event is in the form of cash and/or
publicly traded securities, or if the Investors receive registration rights from the acquiring company or other successor to the Company reasonably comparable to those set forth in <U>this Section</U><U></U><U>&nbsp;2</U>; and (iii)&nbsp;such time
as Rule 144 or another similar exemption under the Securities Act is available for the sale of all such Holder&#146;s shares without limitation during a three-month period without registration. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS OF
THE COMPANY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby covenants and agrees, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <I>Basic Financial Information</I>. Provided that any of the Preferred Stock originally issued by the Company or the Registrable Securities
remain outstanding, the Company shall deliver to each Major Investor the following financial information: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) as soon as practicable, but
in any event within ninety (90)&nbsp;days after the end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder&#146;s equity as of the end of such year, and a
statement of cash flows for such year, plus, where applicable, comparisons to the annual budget and operating plan approved by the Board of Directors; such <FONT STYLE="white-space:nowrap">year-end</FONT> financial reports to be in reasonable
detail, prepared in accordance with generally accepted accounting principles in the United States (&#147;<B>GAAP</B>&#148;), and audited and certified by an independent public accounting firm selected by the Board of Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) as soon as practicable, but in any event within thirty (30)&nbsp;days after the end of each of the first three quarters of each fiscal
year of the Company, an unaudited income statement, a statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, plus, where applicable, quarterly comparisons to the annual budget and
operating plan approved by the Board of Directors; such unaudited financial statements to be prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the exception of footnotes that may be required by GAAP)
and that fairly present the financial condition of the Company and its results of operation for the period specified, subject to <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) as soon as practicable, but in any event within thirty (30)&nbsp;days of the end of each month, an unaudited income statement and
statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders&#146; equity as of the end of such month, plus, where applicable, monthly comparisons to the annual budget and operating plan approved by the Board
of Directors; such unaudited financial statements to be prepared in accordance with GAAP and that fairly present the financial condition of the Company and its results of operation for the period specified, subject to
<FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustment; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) as soon as practicable, but in any event within the thirty (30)&nbsp;day period prior to
the commencement of each new fiscal year of the Company, an annual budget and operating plan for such fiscal year as approved by the Board of Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) as soon as practicable, but in any event within thirty (30)&nbsp;days of the end of each fiscal quarter, an updated capitalization table,
certified by the Treasurer of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) such other information relating to the financial condition, business, prospects, or
corporate affairs of the Company as any Major Investor may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be obligated under this <U>Section</U><U></U><U>&nbsp;3.1</U> to provide information
(i)&nbsp;that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii)&nbsp;the disclosure of which
would adversely affect the attorney-client privilege between the Company and its counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, for any period, the Company has any
subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the
Company and all such consolidated subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <I>Inspection Rights</I>. Provided that any of the Preferred Stock originally issued
by the Company or the Registrable Securities remain outstanding, the Company will afford to each Major Investor reasonable access during normal business hours to all of the Company&#146;s properties, books and records. Major Investors may exercise
their rights under this <U>Section</U><U></U><U>&nbsp;3.2</U> only for purposes reasonably related to their interests as a stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <I>Confidentiality</I>. The Company shall not be required to comply with any inspection rights of <U>Section</U><U></U><U>&nbsp;3</U> in
respect of any Holder whom the Company reasonably determines to be a competitor or an officer, employee, director or holder of more than ten percent (10%) of a competitor (<U>provided</U> that neither the Fund Investors nor a financial investment
firm or collective investment vehicle (including any venture capital fund) shall be deemed to be a competitor of the Company by virtue of its ownership of a portfolio company that competes with the Company), nor shall the Company be obligated to
disclose any information which the Board of Directors determines in good faith is attorney-client privileged and should not, therefore, be disclosed. Each Holder agrees that it will not use any information received by it pursuant to this Agreement
in violation of the Exchange Act or reproduce, disclose or disseminate such information to any other person other than (i)&nbsp;its employees, agents or partners having a need to know the contents of such information, and its attorneys, consultants,
and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii)&nbsp;to any prospective purchaser of any Registrable Securities from such Holder, if such prospective
purchaser agrees to be bound by the provisions of this <U>Section</U><U></U><U>&nbsp;3.3</U>; (iii) to any existing partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, <U>provided</U> that
such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information, (iv)&nbsp;to the extent required in connection with any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
routine or periodic examination or similar process by any regulatory or self-regulatory body or authority not specifically directed at the Company or the confidential information obtained from
the Company pursuant to the terms of this Agreement, including, without limitation, quarterly or annual reports or (v)&nbsp;as may otherwise be required by law, <U>provided that</U>, with respect to clauses (iii)&nbsp;and (v), the Holder promptly
notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure; provided further that with respect to clause (iv), the Holder takes reasonable steps to minimize the extent of any such
required disclosure, unless such information (a)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this <U>Section</U><U></U><U>&nbsp;3.3</U> by such Holder), (b) is or has been independently developed or
conceived by the Holder without use of the Company&#146;s confidential information, or (c)&nbsp;is or has been made known or disclosed to the Holder by a third party without a breach of any obligation of confidentiality such third party may have to
the Company. The Company acknowledges that certain of the Investors are in the business of investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises that may have products or
services that compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise, regardless of whether such enterprise
has products or services that compete with those of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <I>Insurance.</I> The Company shall use its commercially reasonable
efforts to cause to be maintained, from financially sound and reputable insurers, Directors and Officers liability insurance and term <FONT STYLE="white-space:nowrap">&#147;key-person&#148;</FONT> insurance on such executives determined by the
Preferred Director Majority, in the amount of at least $5,000,000 and on terms and conditions satisfactory to the Board of Directors, until such time as the Preferred Director Majority determines that such insurance should be discontinued. The <FONT
STYLE="white-space:nowrap">key-person</FONT> policy shall name the Company as loss payee, and neither policy shall be cancelable by the Company without prior approval by the Preferred Director Majority. Each Key Holder (as defined in the ROFR and <FONT
STYLE="white-space:nowrap">Co-Sale</FONT> Agreement) hereby covenants and agrees that, to the extent such Key Holder is named under such <FONT STYLE="white-space:nowrap">key-person</FONT> policy, such Key Holder will execute and deliver to the
Company, as reasonably requested, a written notice and consent form with respect to such policy. Prior to commencing any clinical trial, the Company shall use its commercially reasonable efforts to obtain, from financially sound and reputable
insurers clinical trial and/or product liability insurance in an amount and on terms and conditions satisfactory to the Preferred Director Majority, and will use commercially reasonable efforts to cause such insurance policy to be maintained until
such time as the Board of Directors determines that such insurance should be discontinued. Immediately prior to the Company&#146;s Initial Public Offering, and subject to further approval by the Preferred Director Majority, the Company will use its
commercially reasonable efforts to increase the coverage amount of its Directors and Officers liability insurance and term <FONT STYLE="white-space:nowrap">&#147;key-person&#148;</FONT> insurance to an amount commensurate with that of similarly
situated companies in the determination of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <I>Employee Agreements</I>. The Company will cause (i)&nbsp;each
person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and
proprietary rights assignment agreement; and (ii)&nbsp;each Key Employee to enter into a one (1)&nbsp;year nonsolicitation agreement in a form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or
otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the Preferred Director Majority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <I>Employee </I><I>Stock.</I> Unless otherwise approved by the Preferred Director
Majority, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company&#146;s capital stock after the date hereof shall be required to execute restricted stock or option
agreements, as applicable, providing for (i)&nbsp;vesting of shares over a four (4)&nbsp;year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12)&nbsp;months of continued employment or service, and the
remaining shares vesting in equal monthly, quarterly or annual installments over the following three (3)&nbsp;years, and (ii)&nbsp;a market <FONT STYLE="white-space:nowrap">stand-off</FONT> provision substantially similar to that in
<U>Section&nbsp;2.10</U>. In addition, unless otherwise approved by the Preferred Director Majority, the<B> </B>Company shall retain a &#147;right of first refusal&#148; on employee transfers until the Company&#146;s Initial Public Offering and
shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 <I>Matters
Requiring Preferred Director Approval</I>. So long as the holders of Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock are entitled to elect a Series C Director, Series D Director or a Series E Director, respectively,
the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Preferred Director Majority: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership, or other entity unless it is wholly owned by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) make, or permit any subsidiary to make, any loan
or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan
approved by the Board of Directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly,
any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) make any
investment inconsistent with any investment policy approved by the Board of Directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) otherwise enter into or be a party to any
transaction with any director, officer, or employee of the Company or any &#147;associate&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Exchange Act) of any such Person, including without limitation
any &#147;management bonus&#148; or similar plan providing payments to employees in connection with a Deemed Liquidation Event, except for transactions contemplated by this Agreement and the Series E Purchase Agreement and transactions made in the
ordinary course of business and pursuant to reasonable requirements of the Company&#146;s business and upon fair and reasonable terms that are approved by a majority of the Board of Directors; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) hire, terminate, or change the compensation of the executive officers, including
approving any option grants or stock awards to executive officers; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) change the principal business of the Company, enter new lines of
business, or exit the current line of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) sell, assign, license, pledge, or encumber material technology or intellectual
property, other than licenses granted in the ordinary course of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) enter into any corporate strategic relationship involving
the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $100,000; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) purchase,
lease, license or otherwise acquire for value, or agree or commit to purchase, lease, license or otherwise acquire for value, (i)&nbsp;any material ownership interest, or right to acquire a material ownership interest, in another corporation,
partnership, limited liability company or other entity or (ii)&nbsp;all or substantially of the assets of any (A)&nbsp;such other corporation, partnership, limited liability company or other entity or (B)&nbsp;line of business, division or material
portion of any such other corporation, partnership, limited liability company or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8 <I>Board Matters</I>. Unless otherwise
determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses incurred (consistent with the Company&#146;s travel policy) in connection with attending meetings of the Board of Directors. The Company shall
cause to be established, as soon as practicable after such request, and will maintain, an audit and compensation committee, each of which shall consist solely of <FONT STYLE="white-space:nowrap">non-management</FONT> directors. Each Committee of the
Board shall be a maximum size of three individuals and shall be comprised solely of Preferred Directors and Independent Directors (as defined in the Voting Agreement). The Series E Director may serve on each Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.9 <I>Observer Rights</I>. The Company shall permit each of Surveyor and LV (each of the foregoing, an &#147;<B>Observer Investor</B>&#148;),
so long as each Observer Investor continues to hold at least twenty-five percent (25%) of the shares (if any) of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock it purchased pursuant to the
Series B Purchase Agreement, Series C Purchase Agreement, Series <FONT STYLE="white-space:nowrap">D-1</FONT> Purchase Agreement, Series <FONT STYLE="white-space:nowrap">D-2</FONT> Purchase Agreement and Series E Purchase Agreement, respectively, to
designate a designee to attend in person meetings of the Board of Directors (and any committee thereof) in a <FONT STYLE="white-space:nowrap">non-voting,</FONT> observer capacity (&#147;<B>Observer Rights</B>&#148;). As an observer, notice will be
given to the designee of any scheduled meeting of the Board of Directors (or any committee thereof) at the same time the members of the Board of Directors (or any committee thereof) are given notice, but no change of schedule will be necessary if
the designee is unavailable. Such designee shall be entitled to receive, prior to each meeting of the Board of Directors (or any committee thereof) and at the same time and in the same manner as directors of the Company receive such materials, all
materials sent to members of the Board of Directors (or any committee thereof), subject to the terms of this <U>Section</U><U></U><U>&nbsp;3.10</U>. Notwithstanding the foregoing, the Company reserves the right to exclude such designee from access
to a meeting of the Board of Directors (or any committee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof), any portion thereof, or to any material if the Company believes such exclusion is reasonably necessary (a)&nbsp;to protect the attorney-client privilege, (b)&nbsp;to avoid a potential
conflict of interest on the part of an Observer Investor or (c)&nbsp;to preserve the proper functioning of the Board or the exercise of its fiduciary duties. Each Observer Investor agrees, on behalf of itself and any of its representatives,
including the designee, to hold in confidence and to not use (other than in connection with such Observer Investor&#146;s evaluation of its investment in the Company) or disclose any information provided to or learned by it in connection with its
Observer Rights. This <U>Section</U><U></U><U>&nbsp;3.10</U> may not be amended or waived as to any Observer Investor without the written consent of such Observer Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10 <I>Successor Indemnification</I>. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company&#146;s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may
be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11 <I>Expenses of Counsel</I>. In the event of a transaction which is a Sale of the Company, the reasonable fees and disbursements
of one counsel for the Senior Preferred Investors (&#147;<B>Investor Counsel</B>&#148;), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would constitute a
Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel&#146;s clients) and shall share the confidential information (including, without limitation, the initial and all subsequent drafts of
memoranda of understanding, letters of intent and other transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or
when aggregated with others, would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company&#146;s counsel and investment bankers to share) such materials when distributed to the Company&#146;s executives
and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the
parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and
substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in
order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to
negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.12 <I>Indemnification
Matters</I>. The Company hereby acknowledges that one (1)&nbsp;or more of the Preferred Directors nominated to serve on the Board of Directors by the Senior Preferred Investors (each a &#147;<B>Fund Director</B>&#148;) may have certain rights to
indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the &#147;<B>Fund Indemnitors</B>&#148;).&nbsp;The Company hereby agrees (a)&nbsp;that it is the
indemnitor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of first resort (<I>i.e.</I>, its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same
expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties,
fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Company&#146;s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such
Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and (c)&nbsp;that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for
contribution, subrogation or any other recovery of any kind in respect thereof.&nbsp;The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund
Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such
Fund Director against the Company. The Fund Directors and the Fund Indemnitors are intended third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;3.13</U> and shall have the right, power and authority to enforce the provisions of this
<U>Section</U><U></U><U>&nbsp;3.13</U> as though they were a party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.13 <I>Properties, Business and Insurance</I>. The
Company and its subsidiaries shall maintain as to their respective properties and business, with financially sound and reputable insurers, insurance against such casualties and contingencies and of such types and in such amounts as is customary for
companies similarly situated, which insurance shall be deemed by the Company to be sufficient. For so long as any Preferred Director serves on the Board, and for a period of at least six (6)&nbsp;years thereafter, the Company hereby agrees to
(i)&nbsp;provide in the certificate of incorporation and bylaws of the Company for indemnification and reimbursement of expenses of directors and officers to the fullest extent permitted by the General Corporation Law of the State of Delaware or the
general corporation law of the state of its incorporation, as applicable; and (ii)&nbsp;maintain director and officer insurance in an amount described in <U>Section</U><U></U><U>&nbsp;3.4</U> on behalf of any person who is or was a director or an
officer of the Company, or is or was serving at the request of the Company as a director or an officer of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by
him or her in any such capacity, or arising out of his or her status as such. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.14 <I>Right to Conduct
Activities</I>.<B></B><B>&nbsp;</B>The Company hereby agrees and acknowledges that<B> </B>each Fund Investor is a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the
Company&#146;s business (as currently conducted or as currently propose to be conducted).&nbsp;The Company hereby agrees that, to the extent permitted under applicable law, each Fund Investor shall not be liable to the Company for any claim arising
out of, or based upon, (i)&nbsp;the investment by such Fund Investor in any entity competitive with the Company, or the evaluation of a potential investment in any such entity, or (ii)&nbsp;actions taken by any partner, officer or other
representative of such Fund Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect
on the Company; <U>provided</U> that the foregoing shall not relieve (x)&nbsp;any of the Investors from liability associated with the unauthorized disclosure of the Company&#146;s confidential information obtained pursuant to this Agreement, or
(y)&nbsp;any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.15 <I>FCPA</I>. The Company represents that it shall not (and shall not permit any of its
subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to,
directly or indirectly, to any third party, including any <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147;<B>FCPA</B>&#148;)), in each case,
in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their
respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the
FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law.&nbsp;The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including,
but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law.&nbsp;Upon request, the Company agrees to provide
responsive information and/or certifications concerning its compliance with applicable anti-corruption laws.&nbsp;The Company shall promptly notify each Investor if the Company becomes aware of any allegation, voluntary disclosure, investigation,
prosecution or other enforcement action related to the FCPA or any other anti-corruption law.&nbsp;The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to
comply with the FCPA.&nbsp;The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.16 <I>Defense Production Act</I>. To the extent that the Company engages in the design, fabrication, development, testing, production or
manufacture of critical technologies within the meaning of the DPA (as defined in the Purchase Agreement), whether because of a new categorization of technology by the U.S. government or otherwise, the Company shall promptly provide written notice
to Surveyor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.17 <I>Termination of Covenants</I>. The covenants set forth in this <U>Section</U><U></U><U>&nbsp;3</U>, except for
<U>Sections 3.11</U> and <U>3.13</U>, shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the Initial Public Offering or (ii)&nbsp;when the Company first becomes subject to the periodic reporting
requirements of Section&nbsp;12 or 15(d) of the Exchange Act, or (iii)&nbsp;upon a Deemed Liquidation Event, whichever event occurs first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.18 <I>Material <FONT STYLE="white-space:nowrap">Non-Public</FONT> Information</I>. The Company understands and acknowledges that in the
regular course of Surveyor&#146;s and Rock Springs&#146; businesses, Surveyor and Rock Springs (and their respective Affiliates) will invest in companies that have issued securities that are publicly traded (each, a &#147;<B>Public
Company</B>&#148;). Accordingly, the Company covenants and agrees that before providing any material <FONT STYLE="white-space:nowrap">non-public</FONT> information about a Public Company (&#147;<B>Public Company Information</B>&#148;) to Surveyor,
Rock Springs or their representatives (or any of their respective Affiliates), the Company shall provide written notice of such Public Company Information to Surveyor&#146;s compliance officer at SCComplianceAppvl@citadel.com and to Jill
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Seidman at Rock Springs at jill@rockspringscapital.com, respectively, describing such Public Company Information in reasonable detail. The Company shall not disclose Public Company Information to
Surveyor, Rock Springs or their representatives (or any of their respective Affiliates) without prior written authorization from Surveyor&#146;s and Rock Springs&#146; compliance officer listed above. In addition, the Company acknowledges and agrees
that in no event shall Surveyor&#146;s or Rock Springs&#146; (or their respective representatives&#146;) confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations hereunder (including, without limitation, pursuant to
Section&nbsp;3.9) in any manner be deemed or construed as limiting Surveyor, or Rock Springs&#146;, or their respective representatives (or any of their respective Affiliates) ability to trade any security of a Public Company or any other Person.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHT OF
FIRST REFUSAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <I>Right of Refusal of the Investors</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Provided that any Senior Preferred Stock originally issued by the Company or any of the Registrable Securities remain outstanding, the
Company hereby grants to each Senior Preferred Investor that is a Major Investor a right of first refusal to purchase its pro rata share of New Securities which the Company may, from time to time, propose to sell and issue after the date of this
Agreement. A Major Investor&#146;s pro rata share, for purposes of this right of first refusal, is equal to the ratio of (i)&nbsp;the number of shares of Senior Preferred Stock (as determined on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) then owned (or subject to warrants owned by) by such Major Investor to (ii)&nbsp;the total number of shares of Senior Preferred Stock (as determined on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) then outstanding immediately prior to issuance of the New Securities, including shares of Series B Preferred Stock subject to outstanding warrants). A Major Investor who chooses
to exercise its right of first refusal may designate as purchasers under such right itself and/or its partners or Affiliates (including Affiliated Funds), in such proportions as it deems appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event the Company proposes to undertake an issuance of New Securities, it shall give each Major Investor written notice of its
intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes to issue the same. Each Major Investor shall have twenty (20)&nbsp;days after any such notice is mailed or delivered to agree to
purchase such Holder&#146;s pro rata share of such New Securities for the price and upon the terms specified in the notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased. If any Major
Investor fails to so agree in writing within such twenty (20)&nbsp;day period to purchase such Holder&#146;s full pro rata share of an offering of New Securities (a &#147;<B>Senior Preferred Nonpurchasing Holder</B>&#148;), then such Senior
Preferred Nonpurchasing Holder shall forfeit the right hereunder to purchase that part of such Senior Preferred Nonpurchasing Holder&#146;s pro rata share of such New Securities that such Senior Preferred Nonpurchasing Holder did not so agree to
purchase. The Company shall promptly give each Major Investor who has timely agreed to purchase such Holder&#146;s full pro rata share of such offering of New Securities (a &#147;<B>Senior Preferred Purchasing Holder</B>&#148;) written notice of the
failure of any Senior Preferred Nonpurchasing Holder to purchase such Senior Preferred Nonpurchasing Holder&#146;s full pro rata share of such offering of New Securities (the &#147;<B>Senior Preferred Overallotment Notice</B>&#148;). Each Senior
Preferred Purchasing Holder shall have a right </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of overallotment such that such Senior Preferred Purchasing Holder may agree to purchase a portion of the Senior Preferred Nonpurchasing Holders&#146; unpurchased pro rata shares of such offering
on a pro rata basis according to the relative pro rata shares of the Senior Preferred Purchasing Holders, at any time within five (5)&nbsp;days after receiving the Senior Preferred Overallotment Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company hereby grants to each Junior Preferred Investor, a right of second refusal to purchase its pro rata share of any New
Securities not so purchased by the Major Investors. A Junior Preferred Investor&#146;s pro rata share, for purposes of this right of first refusal: is equal to the ratio of (i)&nbsp;the number of shares of Common Stock then owned by such Junior
Preferred Investor (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) to (ii)&nbsp;the total number of shares of Common Stock then owned by all Junior Preferred Investors (on an <FONT STYLE="white-space:nowrap">as-converted</FONT>
basis). A Junior Preferred Investor who chooses to exercise its right of second refusal may designate as purchasers under such right itself and/or its partners or Affiliates (including Affiliated Funds), in such proportions as it deems appropriate.
Any such sale to such Junior Preferred Investors shall be at a price and upon terms no more favorable than specified in the Company&#146;s notice to Senior Preferred Investors delivered pursuant to <U>Section</U><U></U><U>&nbsp;4.1(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the event the Major Investors fail to exercise fully the right of first refusal within the periods described in this
<U>Section</U><U></U><U>&nbsp;4.1(b)</U>, the Company shall give each Junior Preferred Investor written notice of its intention to issue New Securities, describing the type of New Securities, and their price and the general terms upon which the
Company proposes to issue the same. Each Junior Preferred Investor shall have ten (10)&nbsp;days after any such notice is mailed or delivered to agree to purchase such Holder&#146;s pro rata share of such New Securities not purchased by the Major
Investors for the price and upon the terms specified in the notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased. If any Junior Preferred Investor fails to so agree in writing within such
ten (10)&nbsp;day period to purchase such Holder&#146;s full pro rata share of an offering of New Securities not purchased by the Senior Preferred Investors (a &#147;<B>Junior Preferred Nonpurchasing Holder</B>&#148;), then such Junior Preferred
Nonpurchasing Holder shall forfeit the right hereunder to purchase that part of such Junior Preferred Nonpurchasing Holder&#146;s pro rata share of such New Securities that such Junior Preferred Nonpurchasing Holder did not so agree to purchase. The
Company shall promptly give each Junior Preferred Investor who has timely agreed to purchase such Holder&#146;s full pro rata share of such offering of New Securities (a &#147;<B>Junior Preferred Purchasing Holder</B>&#148;) written notice of the
failure of any Junior Preferred Nonpurchasing Holder to purchase such Junior Preferred Nonpurchasing Holder&#146;s full pro rata share of such offering of New Securities (the &#147;<B>Junior Preferred Overallotment Notice</B>&#148;). Each Junior
Preferred Purchasing Holder shall have a right of overallotment such that such Junior Preferred Purchasing Holder may agree to purchase a portion of the Junior Preferred Nonpurchasing Holders&#146; unpurchased pro rata shares of such offering on a
pro rata basis according to the relative pro rata shares of the Junior Preferred Purchasing Holders, at any time within five (5)&nbsp;days after receiving the Junior Preferred Overallotment Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In the event the Junior Preferred Investors fail to exercise fully the right of second refusal within the periods described in
<U>Section</U><U></U><U>&nbsp;4.1(d)</U> (the &#147;<B>Election Period</B>&#148;), the Company shall have forty-five (45)&nbsp;days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be
closed, if at all, within forty-five (45) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
days from the date of said agreement) to sell to any Person or Persons any or all New Securities which have not been subscribed by Investors pursuant to their right of first refusal option set
forth in this <U>Section</U><U></U><U>&nbsp;4.1</U>. Any such sale to such Person or Persons shall be at a price and upon terms no more favorable to the purchasers thereof than specified in the Company&#146;s notice to Investors delivered pursuant
to <U>Section</U><U></U><U>&nbsp;4.1</U>. In the event the Company has not sold such unsubscribed New Securities within such forty-five (45)&nbsp;day period following the Election Period, or such forty-five (45)&nbsp;day period following the date of
said agreement, the Company shall not thereafter issue or sell such New Securities without first again offering such New Securities first, to the Major Investors, and second, to the Junior Preferred Investors, in the manner provided in this
<U>Section</U><U></U><U>&nbsp;4.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>New Securities</B>&#148; shall mean any capital stock (including Common Stock and/or
Preferred Stock) of the Company whether now authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and securities of any type whatsoever (including debt securities) that are, or may become,
exercisable or convertible into capital stock; <U>provided</U> that the term &#147;<B>New Securities</B>&#148; does not include: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the
Shares or any shares of Common Stock issuable upon conversion thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Exempted Securities as defined in Article FOURTH, Part C,
Section&nbsp;4.4.1(h)(i) to (ix)&nbsp;of the Restated Certificate, as such provision is amended, modified, supplemented or replaced; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the issuance of Series E Preferred Stock pursuant to the Series E Purchase Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) shares issued pursuant to an Initial Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Notwithstanding anything to the contrary in this Agreement, this <U>Section</U><U></U><U>&nbsp;4.1</U> (including, without limitation,
Sections 4.1(c) and (d)) may be amended or waived by a written instrument referencing this Agreement and signed by the Company and the Required Preferred Holders; <U>provided</U> that, in the event of any such waiver and subsequent purchase of New
Securities by an existing Major Investor, then all Major Investors shall have the right, but not the obligation, to purchase such holder&#146;s pro rata share (determined pursuant to <U>Section</U><U></U><U>&nbsp;4.1(b)</U>) of such New Securities
for the same price and upon the same terms. In addition to the preceding sentence, <U>Section</U><U></U><U>&nbsp;4.1(c)</U> and <U>(d)</U>&nbsp;may be waived by a written instrument referencing this Agreement and signed by the Company and a majority
of the holders of the Junior Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The right of first refusal granted under this Agreement shall expire and be of no
further force or effect (i)&nbsp;immediately before the consummation of the Initial Public Offering or (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, or
(iii)&nbsp;upon a Deemed Liquidation Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<I>Additional Investors; Successor and Assigns</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary herein, if the Company shall issue
additional shares of its Series E Preferred Stock, any purchaser of such shares may become a party to this Agreement by executing and delivering an adoption agreement to this Agreement, in the form of <U>Attachment A</U> (the &#147;<B>Adoption
Agreement</B>&#148;) and shall be deemed, an &#147;Investor&#148; hereunder and <U>Schedule A</U> shall be amended to include such Investor or permitted transferee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The rights under this Agreement may be<B> </B>assigned (but only with all related obligations) by a Holder to a transferee of Registrable
Securities that: (a)&nbsp;after such transfer, holds at least five percent (5%) of the transferring Investor&#146;s shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends,
reverse stock splits, and the like); (b) is an Affiliate of such Holder (including an Affiliated Fund) or a subsidiary, parent, partner, limited partner, retired partner, member, retired member or stockholder of a Holder; or (c)&nbsp;is a family
member of such Holder or trust for the benefit of a such Holder or such Holder&#146;s family members; <U>provided</U> that, in each case, (i)&nbsp;any such transfer or assignment of Registrable Securities is effected in accordance with the terms of
<U>Section</U><U></U><U>&nbsp;2.8</U> hereof, and applicable securities laws; (ii)&nbsp;the Company is given written notice prior to said transfer or assignment, stating the name and address of the transferee or assignee and identifying the
securities with respect to which such registration rights are intended to be transferred or assigned; (iii)&nbsp;the transferee or assignee of such rights assumes in writing the obligations of such Holder under this Agreement, including without
limitation the obligations set forth in <U>Section</U><U></U><U>&nbsp;2.10</U>; and (iv)&nbsp;any such transferee is not engaged in competition with the Company as reasonably determined by the Board of Directors (<U>provided</U> that any such
transferee that is a Fund Investor or a financial investment firm or collective investment vehicle (including any venture capital or other investment fund) shall not be deemed to be engaged in competition with the Company by virtue of its ownership
of a portfolio company that competes with the Company). The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <I>Amendment; Waiver</I>. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended,
waived, discharged or terminated other than by a written instrument referencing this Agreement and signed by the Company and the Required Preferred Holders; <U>provided</U> that (i)&nbsp;if such amendment, waiver, discharge or termination (other
than a waiver of Section&nbsp;4) adversely affects the holders of Junior Preferred Stock in a manner in which the holders of Senior Preferred Stock are not similarly affected, such amendment, modification or waiver shall also require the written
consent of Investors holding at least a majority of the outstanding Junior Preferred Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), (ii) if such amendment, waiver, discharge or termination adversely affects
the holders of the Series E Preferred Stock in a manner in which the holders of other Senior Preferred Stock are not similarly affected, such amendment, modification or waiver shall also require the written consent of the holders of a majority of
the shares of Series E Preferred Stock then outstanding, (iii)&nbsp;if such amendment, waiver, discharge or termination adversely affects the holders of the Series D Preferred Stock in a manner in which the holders of other Senior Preferred Stock
are not similarly affected, such amendment, modification or waiver shall also require the written consent of the holders of at least seventy percent (70%) of the shares of Series D Preferred Stock then
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding, (iv)&nbsp;if such amendment, modification or waiver adversely affects the holders of the Series C Preferred Stock in a manner in which the holders of other Senior Preferred Stock are
not similarly affected, such amendment, modification or waiver shall also require the written consent of holders of a majority of the Series C Preferred Stock then outstanding, which majority must include either LV or Arix, and (v)&nbsp;if such
amendment, modification or waiver adversely affects the holders of the Series B Preferred Stock in a manner in which the holders of other Senior Preferred Stock are not similarly affected, such amendment, modification or waiver shall also require
the written consent of holders of at least fifty-seven percent (57%) of the shares of the Company&#146;s Series B Preferred Stock then outstanding. For the avoidance of doubt, the issuance by the Company of any new series of Preferred Stock that
constitutes Senior Preferred Stock or any additional shares of an existing series of Senior Preferred Stock in compliance with <U>Section</U><U></U><U>&nbsp;4.1</U> shall not be deemed to adversely affect the holders of Junior Preferred Stock in a
manner in which the holders of Senior Preferred Stock are not similarly affected. Any such amendment, waiver, discharge or termination effected in accordance with this paragraph shall be binding upon each Holder and each future holder of all such
securities of the Holder. Each Holder acknowledges that by the operation of this paragraph, the Required Preferred Holders will have the right and power to diminish or eliminate all rights of such Holder under this Agreement, including rights under
<U>Section</U><U></U><U>&nbsp;4</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <I>Notices</I>. All notices and other communications required or permitted hereunder
shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or email or otherwise delivered by hand or by messenger addressed: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if to an Investor, one copy should be sent to the Investor, at the Investor&#146;s address, facsimile number or email address as shown in
the Company&#146;s records, as may be updated in accordance with the provisions hereof, with copies to Edwin C. Pease and Steven Hoffman, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 and Brian P.
Lenihan and Tobin P Sullivan, Choate Hall&nbsp;&amp; Stewart LLP, Two International Place, Boston MA 02110; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if to the Company, one
copy should be sent to Aura Biosciences, Inc., 85 Bolton Street, Cambridge, MA 02140 or at such other address as the Company shall have furnished to the Investors, with a copy to Goodwin Procter LLP, 100 Northern Avenue, Boston MA 02210, Attn:
Danielle Lauzon, Esq. (DLauzon@goodwinlaw.com). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each such notice or other communication shall for all purposes of this Agreement be
treated as effective or having been given when delivered if delivered personally, or, if sent by mail, at the earlier of its receipt or <FONT STYLE="white-space:nowrap">seventy-two</FONT> (72)&nbsp;hours after the same has been deposited in a
regularly maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid or, if sent by facsimile, upon confirmation of facsimile transfer or, if sent by email, upon confirmation of delivery when directed to the
email address as shown in the Company&#146;s records, as may be updated in accordance with the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <I>Governing
Law</I>. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance
with the internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <I>Entire Agreement</I>. This Agreement and the Schedules hereto constitute the full and
entire understanding and agreement between the parties with regard to the subjects hereof and supersedes all prior written or oral agreements and understandings relating to such subject matter. No party hereto shall be liable or bound to any other
party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <I>Delays or Omissions</I>. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to
any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party, nor shall it be construed to be a
waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or
thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement,
must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement, shall be cumulative and not alternative.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <I>Severability</I>. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such illegal, void or unenforceable provision of this Agreement with a
valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance of this Agreement shall be enforceable in accordance with its
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <I>Titles and Subtitles</I>. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and schedules attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <I>Counterparts</I>. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties
that execute such counterparts, and all of which together shall constitute one instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <I>Execution and Delivery</I>. A
facsimile, PDF or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party
can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile,
PDF or other reproduction hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <I>Further Assurances</I>. Each party hereto agrees to execute and deliver, by the
proper exercise of its corporate, limited liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <I>Aggregation of Stock</I>. All shares of Registrable Securities held or acquired by affiliated entities or persons or entities under
common investment management or control shall be aggregated together for the purpose of determining the availability of any rights or obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <I>Effect on Prior Agreement</I>. Upon the execution and delivery of this Agreement by the Company, the Required Holders (as defined in
the Prior Agreement) and a majority of the outstanding shares of Junior Preferred Stock, the Prior Agreement automatically shall terminate and be of no further force and effect and shall be amended and restated in its entirety as set forth in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Left Blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U><B>COMPANY</B></U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AURA BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Elisabet de los Pinos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Elisabet de los Pinos, Ph.D., President and CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MATRIX CAPITAL MANAGEMENT<BR>MASTER FUND, LP</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Goel</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Goel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing General Partner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Shellane Mulcahy</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Shellane Mulcahy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROCK SPRINGS CAPITAL MASTER FUND LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rock Springs General Partner LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mark Bussard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark Bussard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Member</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FOUR PINES MASTER FUND LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Four Pines General Partner LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mark Bussard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark Bussard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Member</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U><B>INVESTORS</B></U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDICXI GROWTH <FONT STYLE="white-space:nowrap">CO-INVEST</FONT> I LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">its manager Medicxi Ventures Management (Jersey) Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew Jeanne&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Director</B></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDICXI GROWTH I LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">its manager Medicxi Ventures Management (Jersey) Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew Jeanne&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Director</B></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LUNDBECKFOND INVEST A/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mette Kirstine Agger</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mette Kirstine Agger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Managing Partner,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lundbeckfonden Ventures</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Lene Skole</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lene Skole</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lundbeckfonden Invest A/S</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U><B>INVESTORS</B></U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARIX BIOSCIENCE HOLDINGS LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Lyne</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Robert Lyne</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><U>INVESTORS</U>:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ADVENT LIFE SCIENCES LLP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ADVENT LIFE SCIENCES FUND III LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: <U>/s/ Kaasim Mahmood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: Advent Life Science LLP, its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Kaasim Mahmood</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: <U></U><U>/s/ Kaasim Mahmood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: General Partner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name: Kaasim Mahmood</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>ADVENT LIFE SCIENCES FUND I LP</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title: General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: Advent Life Science LLP, its manager</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>ADVENT-HARRINGTON IMPACT FUND LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: <U>/s/ Kaasim Mahmood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: Advent Life Science LLP, its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Kaasim Mahmood</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: <U>/s/ Kaasim Mahmood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: General Partner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name: Kaasim Mahmood</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>ALS III CARRY AND <FONT STYLE="white-space:nowrap">CO-INVEST</FONT> LP</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title: General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: Advent Life Science LLP, its manager</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: <U>/s/ Kaasim Mahmood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Kaasim Mahmood</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: General Partner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>YSIOS BIOFUND II INNVIERTE, F.C.R.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">YSIOS CAPITAL PARTNERS S.G.E.I.C.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>S.A., its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Joes Jean Mairet</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joel Jean Mairet</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attorney-in-fact</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U><B>INVESTORS</B>:</U></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CHIESI VENTURES, LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Chiesi Ventures, Inc., its General Partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Pappas Capital, LLC, its Management Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Arthur M. Pappas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Arthur M. Pappas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: CEO &amp; Managing Partner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BELINDA A. TERMEER</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Belinda A. Termeer</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Belinda A. Termeer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COLUMBUS INNVIERTE LIFE SCIENCE F.C.R.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Javier Garcia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Javier Garcia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GARCIA-ATANCE LAFUENTE SALVADOR.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Salvador Garcia-Atance</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Salvador Garcia-Atance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MERCURY CAPITAL, S.L.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Nicolas Ayuso</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Nicolas Ayuso</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JV RISK TECHNOLOGIES, S.L.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Antonio Vila Casa</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Antonio Vila Casa</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Administrador Solidario</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ALEXANDRIA VENTURE INVESTMENTS, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ALEXANDRIA REAL ESTATE</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EQUITIES, INC.,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Maryland corporation, managing member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Aaron Jacobson</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aaron Jacobson</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VP &#150; Corporate Counsel</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ William W. Biggs<U></U></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">William W. Biggs</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Gregory L. Biggs</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Gregory L. Biggs</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ADAGE CAPITAL PARTNERS, LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Adage Capital Partners, GP, LLC, it&#146;s General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dan Lehan</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dan Lehan</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Roy Dunbar</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Roy Dunbar</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Lewis J. Green</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lewis J. Green </P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Maraganore</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John Maraganore</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Diana Frazier</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Diana Frazier</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Gregory T. Winner <U></U></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Gregory T. Winner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Chew <U></U></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Robert Chew</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VELOCITY CAPITAL MANAGEMENT LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Johnson <U></U></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Johnson <U></U></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Partner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert S. Milligan <U></U></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Robert S. Milligan</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Carpenter</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Robert Carpenter</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Israel Ruiz</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Israel Ruiz</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Alan D. Solomont</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Alan D. Solomont</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JUDY C. SWANSON REVOCABLE TRUST</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Judy C. Swanson</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Judy C. Swanson</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMY M. WINSLOW 2011 REVOCABLE TRUST</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amy M. Winslow</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amy M. Winslow</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Alan E. Walts</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Alan E. Walts</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EDWARD C. WINSLOW 2011 REVOCABLE TRUST</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Edward C. Winslow</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Edward C. Winslow</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Edwina Wright</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Edwina Wright</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MYELIN LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Myelin Management LLC, Inc., its General Partner</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mat&iacute;as Nisenson</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mat&iacute;as Nisenson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PAGS GROUP, LLC</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Judy M. Pagliuca</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Judy M. Pagliuca</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Manager</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors&#146; Rights Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>INVESTORS</U>:</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter Elliot, PH.D.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Elliot, PH.D.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signature Page to
Fifth Amended and Restated Investors&#146; Rights Agreement </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule of Investors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salvador Garcia-Atance </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVENT LIFE SCIENCES LLP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVENT LIFE SCIENCES FUND I LP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVENT LIFE SCIENCES FUND III LP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVENT-HARRINGTON IMPACT FUND LP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALS III CARRY AND <FONT STYLE="white-space:nowrap">CO-INVEST</FONT> LP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALEXANDRIA VENTURE INVESTMENTS, LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOSE RAMON ARCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARIX
BIOSCIENCE HOLDINGS LIMITED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LAWRENCE C. BEST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GREGORY L. BIGGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WILLIAM W. BIGGS </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JESUS CAINZOS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DR. JOSE CARLOS MONTILLA CANIS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROBERT CARPENTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROBERT CHEW </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHIESI
VENTURES, LP </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CARLOS GARCIA COGORRO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLUMBUS INNVIERTE LIFE SCIENCE F.C.R. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELISABET DE LOS PINOS REVOCABLE TRUST u/d/t dated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">04-08-2016</FONT></FONT>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MATHIAS D&Ouml;PFNER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DROIA S.A. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROY DUNBAR
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELICTA LLC </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PETER ELLIOTT, PH.D. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PETER B. FINN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIANA
FRAZIER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANTONIO GALINDEZ </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JAVIER GARCIA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARIA
GARIN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEWIS J. GEFFEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PEDRO P. GRANADILLO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANDREW AND EILEEN HOLTVEDT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JAZZYA INVESTMENTS, S.L. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JV RISK TECHNOLOGIES S.L. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LANDA, LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">LI-COR</FONT> OF LINCOLN LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LUNDBECKFOND INVEST A/S </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOHN MARAGANORE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEILI TRUST DTD JULY 13, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MERCURY CAPITAL, S.L. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROBERT S. MILLIGAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LAURA B. MORSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EDMUNDO
MUNIZ </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAROL NULMAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE CAROL NULMAN TRUST DTD 10/3/2003 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAGS GROUP, LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE
RICHARD H. PETERS TRUST OF 2004 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DR. RICHARD PILNIK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MICHAEL DENNIS PRICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CARLOS ROBLES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PABLO
RODRIGUEZ </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ISRAEL RUIZ </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EDUARDO SANCHIZ </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EDUARDO SANCHIZ&nbsp;&amp; MARIA GARIN SANCHIZ </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAOLA MARRI MALACRIDA SANTINI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAN D. SOLOMONT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MICHAEL A. STELLER 401(k), OPPENHEIMER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JUDY C. SWANSON REVOCABLE TRUST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BELINDA A. TERMEER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UBS
F/B/O TRAD. IRA (GREGORY T. WINNER) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GREGORY T. WINNER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAN E. WALTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMY M.
WINSLOW 2011 REVOCABLE TRUST </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EDWARD C. WINSLOW 2011 REVOCABLE TRUST </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EDWINA WRIGHT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MICHAEL S. WYZGA REVOCABLE TRUST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YSIOS BIOFUND II INNVIERTE, F.C.R. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDICXI GROWTH I LP and MEDICXI GROWTH <FONT STYLE="white-space:nowrap">CO-INVEST</FONT> I LP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Medicxi Ventures Management (Jersey) Limited </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Matrix Capital Management Master Fund, LP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Velosity Capital Management LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Citadel Multi-Strategy Equities Master Fund Ltd. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adage Capital </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Rock
Springs Capital Master Fund LP </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Four Pines Master Fund LP </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A</B> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>d209588dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2009 STOCK OPTION AND RESTRICTED STOCK PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Purpose</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;15, 2009, the Directors of Aura Biosciences, Inc. (the &#147;Corporation&#148;) adopted the &#147;Aura Biosciences 2009
Long-Term Incentive Stock Option Plan&#148; (&#147; Original Plan&#148;). The Original Plan was approved by the stockholders of the Corporation on January&nbsp;16, 2009. In accordance with Article 10 of the Original Plan, the Directors hereby amend
the Original Plan in certain respects, and restate the Original Plan, as so amended, in its entirety, as herein set forth (the Original Plan, as so amended and restated, the &#147; Plan&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Plan is to secure for and its shareholders the benefits arising from capital stock ownership by employees, officers and
directors of, and consultants or advisors to, the Corporation who are expected to contribute to the Corporation&#146;s future growth and success. Except where the context otherwise requires, the term &#147;Corporation&#148; shall include all future
subsidiaries of the Corporation as defined in Section&nbsp;424(&pound;) of the Internal Revenue Code of 1986, as amended or replaced from time to time (the &#147;Code&#148;). Those provisions of the Plan which make express reference to
Section&nbsp;422 shall apply only to Incentive Stock Options (as that term is defined in the Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan is intended to be a written
compensatory benefit plan within the meaning of Rule 701 of the federal Securities Act of 1933, as amended, and is intended to qualify under similar provisions of applicable State Blue Sky laws. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Type of Options, Restricted Stock Grants. and Administration</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Types of Options</U>. Options granted pursuant to the Plan shall be authorized by action of the Administrator (as defined below) and may
be either incentive stock options (&#147;Incentive Stock Options&#148;) meeting the requirements of Section&nbsp;422 of the Code or non-statutory options which are not intended to meet the requirements of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Restricted Stock</U>. Shares of the Corporation&#146;s $0.01 par value common stock (&#147;Common Stock&#148;) issued pursuant to the
Plan and subject to restrictions as the Administrator shall determine (&#147;Restricted Stock&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Administration</U>. The Plan
will be administered by the Administrator, whose construction and interpretation of the terms and provisions of the Plan shall be final and conclusive. The Administrator may, in its sole discretion, (i)&nbsp;grant options to purchase shares Common
Stock and issue shares upon exercise of such options as provided in the Plan and (ii)&nbsp;issue Restricted Stock. The Administrator shall have authority, subject to the express provisions of the Plan, to determine the optionees; to set exercise
prices, the number of shares subject to each option grant, and the vesting or other schedule by which any option may be exercisable; to construe, amend, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminate the respective option agreements; to determine the terms and provisions of the respective option agreements, which need not be identical; to determine, subject to Section&nbsp;3 hereof.
the persons who will be issued Restricted Stock pursuant to the Plan. the price to be paid for any such shares, the method of payment for such shares. and the restrictions to which such shares will be subject; to construe and interpret the Plan; to
prescribe. amend and rescind rules and regulations relating to the Plan; and to make all other determinations in the judgment of the Administrator necessary or desirable for the administration of the Plan and the agreements entered into pursuant to
the Plan. The Administrator may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any option agreement in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the
sole and final judge of such expediency. No director or person acting pursuant to authority delegated by the Administrator shall be liable for any action or determination under the Plan made in good faith. To the extent permitted by applicable law,
the Administrator may delegate any or all of its powers under the Plan to the Compensation Committee (the &#147;Committee&#148;). If and when the Common Stock is registered under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) the
Administrator shall appoint one such Committee of two members, each member of which shall be an &#147;outside director&#148; within the meaning of Section&nbsp;162(m) of the Code and a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT>
director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act). All references in the Plan to the term &#147; Administrator &#147; shall mean either the Corporation&#146;s Board of Directors or
the Compensation Committee thereof, to the extent the Compensation Committee is at the time responsible for the administration of the Plan). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Eligibility</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Restricted Stock may be issued, and Options may be granted, to persons who are, at the time of issuance or grant, employees, officers
or directors of, or consultants or advisors to, the Corporation, or any subsidiary; <U>provided</U>, that the class of employees to whom Incentive Stock Options may be granted shall be limited to all employees of the Corporation, or any subsidiary.
A person who has been granted an option may, if he or she is otherwise eligible, be granted additional options if the Administrator shall so determine. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Stock Subject to Plan</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment as provided in Section&nbsp;15 below, the maximum number of shares of Common Stock of the Corporation which may be issued
and sold under the Plan is Seven Hundred <FONT STYLE="white-space:nowrap">Twenty-Six</FONT> Thousand Three Hundred Thirty-Four (726,334) shares. If an option granted under the Plan shall expire or terminate for any reason without having been
exercised in full, the unpurchased shares subject to such option shall again be available for subsequent option grants under the Plan. If shares issued upon exercise of an option under the Plan are tendered to the Corporation in payment of the
exercise price of an option granted under the Plan, such tendered shares shall again be available for subsequent option grants under the Plan; provided, that in no event shall such shares be made available pursuant to exercise of Incentive Stock
Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Forms of Option Agreements; Restricted Stock</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition to any grant under the Plan, each recipient shall execute: (a)&nbsp;an option or Restricted Stock agreement (as the case may be)
in such form not inconsistent with the Plan as may be approved by the Administrator and (b)&nbsp;a joinder agreement and limited power of attorney, each in forms attached to a stockholders agreement if applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Purchase Price</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The purchase price per share of Common Stock deliverable upon the exercise an option shall be determined by the
Administrator, <U>provided, however</U>, that the exercise price shall not be less than 100% of the fair value of such stock, as determined by the Administrator, at the time of grant of such option, or less than 110% of such fair market value in the
case of options described in Section&nbsp;11(b). The purchase price per share of Restricted Stock to be issued to a recipient hereunder shall be determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Payment of Purchase Price</U>. Options granted under the Plan may provide for the payment of the exercise price by (i)&nbsp;delivery of
cash or a check to the order of the Corporation in an amount equal to the exercise price of such options, or, to the extent provided in the applicable option agreement, (ii)&nbsp;by delivery to the Corporation of shares of Common Stock of the
Corporation already owned by the optionee having a fair market value equal in amount to the exercise price of the options being exercised, (iii)&nbsp;by any other means which the Administrator determines are consistent with the purpose of the Plan
and with applicable laws and regulations (including, without limitation, the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> and Regulation T promulgated by the Federal Reserve Board) or (iv)&nbsp;by any combination of such methods
of payment. The fair market value of any shares of the Corporation&#146;s Common Stock or other <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration which may be delivered upon exercise of an option or which may be delivered pursuant to a
Restricted Stock agreement shall be determined by the Administrator. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Option Period</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each option and all rights thereunder shall expire on such date as shall be set forth in the applicable option agreement, except that, in the
case of an Incentive Stock Option, such date shall not be later than ten years after the date on which the option is granted and, in all cases, options shall be subject to earlier termination as provided in the Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exercise of Options</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each option granted under the Plan shall be exercisable either in full or in installments at such time or times and during such period as shall
be set forth in the agreement evidencing such option, subject to the provisions of the Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Nontransferability of Options</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as the Administrator may otherwise determine or provide in the applicable option agreement, options shall not be assignable or
transferable by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the optionee, shall be exercisable only by the optionee; provided,
however, that <FONT STYLE="white-space:nowrap">non-statutory</FONT> options may be transferred pursuant to a qualified domestic relations order (as defined in Code Section&nbsp;414(p)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Effect of Termination of Employment or Other Relationship</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Plan, the Administrator shall determine the period of time during which an optionee may exercise an option
following (i)&nbsp;the termination of the optionee&#146;s employment or other relationship with the Corporation, or any subsidiary, or (ii)&nbsp;the death or disability of the optionee. Such periods shall be set forth in the agreement evidencing
such option. For the purposes of the Plan, employment shall not be deemed to be terminated solely because an optionee is transferred from the Corporation to any subsidiary thereof or to an acquiring or succeeding corporation (or an affiliate
thereof). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Incentive Stock Options</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted under the Plan which are intended to be Incentive Stock Options shall be subject to the following additional terms and
conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Express Designation</U>. All Incentive Stock Options granted under the Plan shall, at the time of grant, be
specifically designated as such in the option agreement covering such Incentive Stock Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>10% Shareholder</U>. If any
employee to whom an Incentive Stock Option is to be granted under the Plan is, at the time of the grant of such option, the owner of stock possessing more than 10% of the total combined voting power of all classes of stock of the Corporation (after
taking into account the attribution of stock ownership rules of Section&nbsp;424(d) of the Code), then the following special provisions shall be applicable to the Incentive Stock Option granted to such individual: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the purchase price per share of the Common Stock subject to such Incentive Stock Option shall not be less than 110% of the
fair market value of one share of Common Stock at the time of grant; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the option exercise period shall not exceed
five years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Dollar Limitation</U>. For so long as the Code shall so provide, options granted to any
employee under the Plan (and any other incentive stock option plans of the Corporation) which are intended to constitute Incentive Stock Options shall not constitute Incentive Stock Options to the extent that such options, in the aggregate, become
exercisable for the first time in any one calendar year for shares of Common Stock with an aggregate fair market value (determined as of the respective date or dates of grant) of more than $100,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Employment, Death or Disability</U>. No Incentive Stock Option may be
exercised unless, at the time of such exercise, the optionee is, and has been continuously since the date of grant of his or her option, employed by the Corporation, or any subsidiary, except that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an Incentive Stock Option may be exercised within the period of three months after the date the optionee ceases to be an
employee of the Corporation, or any subsidiary (or within such lesser period as may be specified in the applicable option agreement); <U>provided</U>, that the agreement with respect to such option may designate a longer exercise period and that any
exercise after such three-month period shall be treated as the exercise of a <FONT STYLE="white-space:nowrap">non-statutory</FONT> option under the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if the optionee dies while in the employ of the Corporation, or any subsidiary, or within three months after the optionee
ceases to be such an employee, the Incentive Stock Option may be exercised by the person to whom it is transferred by will or the laws of descent and distribution within the period of one year after the date of death (or within such lesser period as
may be specified in the applicable option agreement); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if the optionee becomes disabled (within the meaning of
Section&nbsp;22(e)(3) of the Code or any successor provision thereto) while in the employ of the Corporation, or any subsidiary, the Incentive Stock Option may be exercised within the period of one year after the date the optionee ceases to be such
an employee because of such disability (or within such lesser period as may be specified in the applicable option agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all
purposes of the Plan and any option granted hereunder, &#147;employment&#148; shall be defined in accordance with the provisions of Section <FONT STYLE="white-space:nowrap">l.421-7(h)</FONT> of the Income Tax Regulations (or any successor
regulations) and shall include employment by the Corporation, or any subsidiary. Employment shall not be deemed to be terminated because an optionee is transferred from one of the Corporation, or any subsidiary to another one of the Corporation, or
any subsidiary. Notwithstanding the foregoing provisions, no Incentive Stock Option may be exercised after its expiration date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Provisions</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Additional Option Provisions</U>. The Administrator may, in its sole discretion, include additional provisions in option agreements
covering options granted under the Plan, including, without limitation, restrictions on transfer, repurchase rights, commitments to pay cash bonuses, to make, arrange for or guaranty loans or to transfer other property to optionees upon exercise of
options, or such other provisions as shall be determined by the Administrator; <U>provided</U> that such additional provisions shall not be inconsistent with any other term or condition of the Plan and such additional provisions shall not cause any
Incentive Stock Option granted under the Plan to fail to qualify as an Incentive Stock Option within the meaning of Section&nbsp;422 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Acceleration, Extension, Etc</U>. The Administrator may, in its sole discretion,
(i)&nbsp;accelerate the date or dates on which all or any particular option or options granted under the Plan may be exercised or (ii)&nbsp;extend the dates during which all, or any particular, option or options granted under the Plan may be
exercised; <U>provided, however</U>, that no such extension shall be permitted if it would cause the Plan to fail to comply with Section&nbsp;422 of the Code. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General Restrictions</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Investment Representations</U>. The Corporation may require any person to whom an option is granted, or any shares of Restricted Stock
are being issued, as a condition of exercising such option or acquiring such shares, to give written assurances in substance and form satisfactory to the Corporation to the effect that such person is acquiring the Common Stock for his or her own
account for investment and not with any present intention of selling or otherwise distributing the same, and to such other effects as the Corporation deems necessary or appropriate in order to comply with federal and applicable state securities
laws, or with covenants or representations made by the Corporation in connection with any public offering of its Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Compliance With Securities Laws</U>. Each option shall be subject to the requirement that if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject to such option upon any
securities exchange or under any state or federal law, or the consent or approval of any governmental or regulatory body, or that the disclosure of <FONT STYLE="white-space:nowrap">non-public</FONT> information or the satisfaction of any other
condition is necessary as a condition of, or in connection with, the issuance or purchase of shares thereunder, such option may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or approval, or
satisfaction of such condition shall have been effected or obtained on conditions acceptable to the Administrator. Nothing herein shall be deemed to require the Corporation to apply for or to obtain such listing, registration or qualification, or to
satisfy such condition. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Rights as a Shareholder</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of an option shall have no rights as a shareholder with respect to any shares covered by the option (including, without limitation,
any rights to receive dividends or <FONT STYLE="white-space:nowrap">non-cash</FONT> distributions with respect to such shares) until the <I>date </I>of issue of a stock certificate to him or her for such shares. No adjustment shall be made for
dividends or other rights for which the record date is prior to the date such stock certificate is issued. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Adjustment Provisions for Recapitalizations and Related Transactions</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. If, through or as a result of any merger, consolidation, sale of all or substantially all of the assets of the Corporation,
reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar transaction, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the outstanding shares of Common Stock are increased, decreased or exchanged for a different number or kind of shares or
other securities of the Corporation, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) additional shares or new or different shares or other securities of the
Corporation or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such shares of Common Stock or other securities, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">an appropriate and proportionate adjustment shall be made in (x)&nbsp;the maximum number and kind of shares
reserved for issuance under the Plan, (y)&nbsp;the number and kind of shares or other securities subject to any then outstanding options under the Plan, and (z)&nbsp;the price for each share subject to any then outstanding options under the Plan,
without changing the aggregate purchase price as to which such options remain exercisable. Notwithstanding the foregoing, no adjustment shall be made pursuant to this Section&nbsp;15 if such adjustment would cause the Plan to fail to comply with
Section&nbsp;422 of the Code. If this Section&nbsp;15 applies and Section&nbsp;16 also applies to any event, then Section&nbsp;16 shall be applicable to such event and this Section&nbsp;15 shall not be applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Authority to Make Adjustments</U>. Any adjustments under this Section&nbsp;15 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued under the Plan on account of any such adjustments. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Merger. Consolidation, Asset Sale, Liquidation, etc</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Subject to Section&nbsp;16(b), if an Acquisition Event (as defined below) is expected to occur, (A)&nbsp;all then unvested
Outstanding Options (which term shall include all vested and unvested, but unexercised Options specified in all issued, outstanding and then currently binding Stock Option Agreements) shall terminate immediately prior to the consummation of such
Acquisition Event, and (B)&nbsp;the Administrator shall take any one or more or none of the following actions with respect to all then vested Outstanding Options: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) provide that such vested Outstanding Options shall be assumed, or equivalent options shall be substituted, by the acquiring
or succeeding corporation (or an affiliate thereof), <U>provided</U> that any such options substituted for Outstanding Incentive Stock Options shall meet the requirements of Section&nbsp;424(a) of the Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) upon written notice to the optionees, provide that all then vested Outstanding Options will terminate immediately prior to
the consummation of such Acquisition Event, except to the extent exercised by the optionees before the consummation of such Acquisition Event; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) in the event of a merger under the terms of which holders of the Common Stock of the Corporation will receive upon
consummation thereof a cash or stock payment for each share surrendered in the merger (the &#147;Merger Price&#148; ), make or provide for a cash or stock payment to each optionee equal to (A)&nbsp;the Merger Price times the number of shares of
Common Stock issuable to that Optionee upon the exercise by that Optionee of such of that Optionee&#146;s vested Outstanding Options (whether or not then exercisable at prices not in excess of the Merger Price) which that Optionee actually elects to
exercise, less (B)&nbsp;the aggregate exercise price of all such Outstanding Options which the Optionee actually exercises in exchange for the termination of all of that Optionee&#146;s Outstanding Options; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) terminate each such vested Outstanding Option in exchange for a cash payment equal to the amount by which the value of the
Common Stock issuable upon exercise of such Outstanding Option exceeds the exercise price with respect to such Common Stock; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) provide for a combination of any one or more of the foregoing options or
any other plan which would be equitable, in the good faith judgment of the Administrator, to the holders of vested Outstanding Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An
&#147;Acquisition Event&#148; shall mean: (A)&nbsp;any merger or consolidation which results in the voting securities of the Corporation outstanding immediately prior thereto representing immediately thereafter (either by remaining outstanding or by
being converted into voting securities of the surviving or acquiring entity) less than 50% of the combined voting power of the voting securities of the Corporation or such surviving or acquiring entity outstanding immediately after such merger or
consolidation, (B)&nbsp;any sale of all or substantially all of the assets of the Corporation, or (C)&nbsp;the complete liquidation of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Substitute Options</U>. The Corporation may grant options under the Plan in substitution for options held by employees of another
corporation who become employees of the Corporation, or a subsidiary of the Corporation, as the result of a merger or consolidation of the employing corporation with the Corporation or a subsidiary of the Corporation, or as a result of the
acquisition by the Corporation, or one of its subsidiaries, of property or stock of the employing corporation. The Corporation may direct that substitute options be granted on such terms and conditions as the Administrator considers appropriate in
the circumstances. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Special Employment Rights</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing contained in the Plan or in any option shall confer upon any optionee any right with respect to the continuation of his or her
employment by the Corporation or interfere in any way with the right of the Corporation at any time to terminate such employment or to increase or decrease the compensation of the optionee. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Other Employee Benefits</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as to plans which by their terms include such amounts as compensation, the amount of any compensation deemed to be received by an
employee as a result of the exercise of an option or the sale of shares received upon such exercise will not constitute compensation with respect to which any other employee benefits of such employee are determined, including, without limitation,
benefits under any bonus, pension, profit-sharing, life insurance or salary continuation plan, except as otherwise specifically determined by the Administrator. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment of the Plan</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Administrator may at any time, and from time to time, modify or amend the Plan in any respect, except that if at any time the approval
of the shareholders of the Corporation is required under Section&nbsp;422 of the Code or any successor provision with respect to Incentive Stock Options, the approval of the shareholders shall be required to ratify such modification or amendment.
Amendments shall become effective as described in Section&nbsp;22(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The termination or any modification or amendment of the Plan shall not, without the
consent of an optionee, affect his or her rights under an option previously granted to him or her. With the consent of the optionee affected, the Administrator may amend outstanding option agreements in a manner not inconsistent with the Plan. The
Administrator shall have the right to amend or modify the terms and provisions of the Plan and of any outstanding Incentive Stock Options granted under the Plan to the extent necessary to qualify any or all such options for such favorable federal
income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section&nbsp;422 of the Code. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Withholding</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall have the right to deduct from payments of any kind otherwise due to the optionee any federal, state or local taxes of any
kind required by law to be withheld with respect to any shares issued upon exercise of options under the Plan, or any Restricted Stock issued under the Plan. Subject to the prior approval of the Corporation, which may be withheld by the Corporation
in its sole discretion, the optionee may elect to satisfy such obligations, in whole or in part, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) by causing the
Corporation to withhold shares of Common Stock otherwise issuable pursuant to the exercise of an option, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) by
delivering to the Corporation shares of Common Stock already owned by the optionee. The shares so delivered or withheld shall have a fair market value equal to such withholding obligation. The fair market value of the shares used to satisfy such
withholding obligation shall be determined by the Corporation as of the date that the amount of tax to be withheld is to be determined. An optionee who has made an election pursuant to this Section&nbsp;20(a) may only satisfy his or her withholding
obligation with shares of Common Stock which are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cancellation and New Grant of Options. Etc</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator or the Directors shall have the authority to effect, at any time and from time to time, with the consent of the affected
optionees, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the cancellation of any or all outstanding options under the Plan and the grant in substitution therefor of
new options under the Plan covering the same or different numbers of shares of Common Stock and having an option exercise price per share which may be lower or higher than the exercise price per share of the cancelled options, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the amendment of the terms of any and all outstanding options under the Plan to provide an option exercise price per share
which is higher or lower than the then current exercise price per share of such outstanding options. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Effective Date and Duration of the Plan</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Effective Date</U>. The Plan is intended to be effective retroactive to January&nbsp;15, 2009, to the extent not inconsistent with
applicable law or with the terms of any Award (as defined in the Original Plan) outstanding on the date of adoption of this (amended and restated) Plan, the amendment of which would require the written consent of the holder of the Award. Amendments
to the Plan not requiring shareholder approval shall become effective when </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adopted by the Administrator or as otherwise specified by the Administrator or set forth in the instrument of amendment. Amendments to the Plan requiring shareholder approval (as provided in
Section&nbsp;19) shall become effective when so approved, retroactive to the date of adoption by the Administrator. No Incentive Stock Option granted after the date of such amendment shall become exercisable (to the extent that such amendment to the
Plan was required to enable the Corporation to grant such Incentive Stock Option to a particular optionee) unless and until such amendment shall have been approved by the Corporation&#146;s shareholders, and if such shareholder approval is not
obtained within twelve months of the Administrator&#146;s adoption of such amendment, any Incentive Stock Options granted on or after the date of such amendment shall terminate to the extent that such amendment to the Plan was required to enable the
Corporation to grant such option to a particular optionee. Subject to this limitation, options may be granted under the Plan at any time after the effective date and before the date fixed for termination of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. Unless sooner terminated in accordance with Section&nbsp;16, the Plan shall terminate, with respect to Incentive Stock
Options, upon the earlier of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the close of business on the day next preceding the tenth
anniversary of the date of its adoption by the Administrator, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the date on which all shares available for issuance
under the Plan shall have been issued pursuant to the exercise or cancellation of options granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the date of termination is
determined under (i)&nbsp;above, then options outstanding on such date shall continue to have force &middot;and effect in accordance with the provisions of the instruments evidencing such options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless sooner terminated in accordance with Section&nbsp;16, the Plan shall terminate with respect to options which are not Incentive Stock
Options on the date specified in (ii)&nbsp;above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Provision for Foreign Participants</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may, without amending the Plan, modify awards or options granted to participants who are foreign nationals or employed
outside the United States to recognize differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AURA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Elisabet de los Pinos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Elisabet de los Pinos, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC. <U> </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INCENTIVE STOCK OPTION AGREEMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. Effective as of [&#149;] (&#147;Date of Grant&#148;), AURA BIOSCIENCES, INC., a Delaware corporation (the
&#147;Corporation&#148;), hereby grants to [NAME] (the &#147;Optionee&#148;), an option, pursuant to the Corporation&#146;s 2009 Amended and Restated Stock Option and Restricted Stock Plan, as further amended, (the &#147;Plan&#148;), to purchase an
aggregate of [&#149;] shares of the Corporation&#146;s $0.00001 par value common stock (&#147;Common Stock&#148;) at a price of [&#149;] per share, purchasable as set forth in and subject to the terms and conditions of this option and the Plan.
Except where the context otherwise requires, the term &#147;Corporation&#148; shall include all present and future subsidiaries of the Corporation as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or replaced
from time to time (the &#147;Code&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Incentive Stock Option</U>. This option is intended to qualify as an incentive stock
option (&#147;Incentive Stock Option&#148;) within the meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of Option and Provisions
for Termination</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Vesting Schedule</U>. Except as otherwise provided in this Agreement, this option may be exercised prior to
the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the Date of Grant (hereinafter the &#147;Expiration Date&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This option shall vest as follows: [on [&#149;], a total of [&#149;] shares shall be deemed fully vested and thereafter, commencing as of
[&#149;], an additional [&#149;] shares shall vest monthly on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day of each consecutive monthly anniversary during the term of the Optionee&#146;s employment by the Corporation for
the next <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;months so long as the Optionee is employed by the Corporation and in accordance with the terms of this Incentive Stock Option Agreement]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Optionee&#146;s employment is terminated by the Corporation without Cause (as defined in Section&nbsp;3(f)) within twelve
(12)&nbsp;months after a Sale Event (as defined in Section&nbsp;3(g)), then all of the Optionee&#146;s unvested options will accelerate and vest immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of exercise shall be cumulative so that if the option is not exercised to the maximum extent permissible during any exercise period,
it shall be exercisable, in whole or in part, with respect to all shares not so purchased at any time prior to the Expiration Date or the earlier termination of this option. This option may not be exercised at any time on or after the Expiration
Date, except as otherwise provided in Section&nbsp;3(e) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Procedure</U>. Subject to the conditions set forth in this
Agreement, this option shall be exercised by the Optionee&#146;s delivery of a written notice of exercise in the form of attached hereto and marked as <U>Exhibit 1</U> to the Treasurer of the Corporation, specifying the number of shares to be
purchased and the purchase price to be paid therefor and accompanied by payment in full in accordance with Section&nbsp;4, and a joinder agreement and limited power of attorney, each in form attached to that certain Stockholders Agreement defined in
the Plan. Such exercise shall be effective upon receipt by the Treasurer of the Corporation of such written notice together with the required payment and the said joinder agreement and limited power of attorney executed by the Optionee. The Optionee
may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Continuous Employment Required</U>. Except as otherwise provided in this
Section&nbsp;3, this option may not be exercised unless the Optionee, at the time he or she exercises this option, is, and has been at all times since the Date of Grant of this option, an employee of the Corporation or any subsidiary. For all
purposes of this option, (i) &#147;employment&#148; shall be defined in accordance with the provisions of <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-7(h)</FONT> of the Income Tax Regulations or any successor regulations and shall include
employment by the Corporation or any subsidiary, and (ii) if this option shall be assumed or a new option substituted therefor in a transaction to which Section&nbsp;424(a) of the Code applies, employment by such assuming or substituting corporation
(hereinafter called the &#147;Successor Corporation&#148;) shall be considered for all purposes of this option to be employment by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all purposes under this Agreement, Optionee&#146;s employment shall not be deemed to be terminated because Optionee&#146;s employment is
transferred from one of the Corporation or any subsidiary to another one of the Corporation or any subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Period
Upon Termination of Employment</U>. If the Optionee ceases to be employed by the Corporation or any subsidiary for any reason, then, except as provided in paragraphs (e)&nbsp;and (f) below, the right to exercise this option shall terminate three
(3)&nbsp;months after such cessation (but in no event after the Expiration Date), <U>provided that</U> this option shall be exercisable only to the extent that the Optionee was entitled to exercise this option on the date of such cessation. The
Corporation&#146;s obligation to deliver shares upon the exercise of this option shall be subject to the satisfaction of all applicable federal, state and local income and employment tax withholding requirements, arising by reason of this option
being treated as a <FONT STYLE="white-space:nowrap">non-statutory</FONT> option or otherwise. Notwithstanding the foregoing, if the Optionee, prior to the Expiration Date, materially violates the
<FONT STYLE="white-space:nowrap">non-competition</FONT> or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Optionee and the Corporation or any subsidiary, the right to
exercise this option shall terminate immediately upon written notice to the Optionee from the Corporation or any subsidiary describing such violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise Period Upon Death or Disability</U>. If the Optionee dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of
the Code) prior to the Expiration Date while he or she is an employee of the Corporation or any subsidiary, or if the Optionee dies within three months after the Optionee ceases to be an employee of the Corporation or any subsidiary (other than as
the result of a discharge for &#147;cause&#148; as specified in paragraph (f)&nbsp;below), this option shall be exercisable within the period of one year following the date of death or disability of the Optionee (but in no event after the Expiration
Date), by the Optionee or by the person to whom this option is transferred by will or the laws of descent and distribution, provided that this option shall be exercisable only to the extent this option was exercisable by the Optionee on the date of
his or her death or disability. Except as otherwise indicated by the context, the term &#147;Optionee,&#148; as used in this option, shall be deemed to include the estate of the Optionee or any person who acquires the right to exercise this option
by bequest or inheritance or otherwise by reason of the death of the Optionee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Discharge for Cause</U>. If the Optionee, prior to the Expiration Date, is discharged
by the Corporation or any subsidiary for Cause (as defined below), the right to exercise this option shall terminate immediately upon the Optionee being given notice of such cessation of employment whether the actual cessation of employment is
immediate or occurs at a later date. &#147;Cause&#148; shall mean (i)&nbsp;dishonest statements or acts by the Optionee with respect to the Corporation or any affiliate or subsidiary of the Corporation, or any of the Corporation&#146;s current or
prospective customers, suppliers vendors or other third parties with which such entity does business; (ii)&nbsp;the Optionee&#146;s commission of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud;
(iii)&nbsp;failure to perform to the reasonable satisfaction of the Board of Directors of the Corporation (the &#147;Board&#148;) the Optionee&#146;s duties and responsibilities assigned by the Board which failure continues, in the reasonable
judgment of the Board, after written notice given to the Optionee by the Board; (iv)&nbsp;gross negligence, willful misconduct or insubordination by the Optionee with respect to the Corporation or any affiliate or subsidiary of the Corporation; or
(v)&nbsp;a violation of any provision of any agreement(s) between the Optionee and the Corporation relating to noncompetition, nondisclosure and/or assignment of inventions. The Optionee shall be considered to have been discharged for Cause if the
Corporation or any subsidiary determines, within 30 days after the Optionee&#146;s resignation, that discharge for Cause was warranted. In the event Optionee&#146;s employment relationship with the Corporation is suspended pending investigation of
whether such relationship shall be terminated for Cause, all Optionee&#146;s rights under this option, including the right to exercise this option, shall be suspended during the investigation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Sale Event</U>. &#147;Sale Event&#148; means the consummation of (i)&nbsp;the dissolution or liquidation of the Corporation,
(ii)&nbsp;the sale of all or substantially all of the assets of the Corporation on a consolidated basis to an unrelated person or entity (a &#147;Person&#148;), (iii) a merger, reorganization or consolidation involving the Corporation in which the
shares of the Corporation&#146;s voting equity outstanding immediately prior to such transaction represent or are converted into or exchanged for securities of the surviving or resulting entity immediately upon completion of such transaction which
represent less than fifty percent (50%) of the outstanding voting power of such surviving or resulting entity, (iv)&nbsp;the acquisition of all or a majority of the outstanding voting equity of the Corporation in a single transaction or a series of
related transactions by a Person or a group of Persons, or (v)&nbsp;any other acquisition of the business of the Corporation, as determined by the Board; provided, however, that the Corporation&#146;s initial public offering, any subsequent public
offering or another capital raising event, or a merger effected solely to change the Corporation&#146;s domicile shall not constitute a &#147;Sale Event.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Payment of Purchase Price</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Method of Payment</U>. Payment of the purchase price for shares purchased upon exercise of this option shall be made (i)&nbsp;by
delivery to the Corporation of cash or a check to the order of the Corporation in an amount equal to the purchase price of such shares, (ii)&nbsp;subject to the consent of the Corporation, by delivery to the Corporation of shares of Common Stock of
the Corporation then owned by the Optionee having a fair market value equal in amount to the purchase price of such shares, (iii)&nbsp;by any other means which the Administrator (as that term is defined in the Plan) determines are consistent with
the purpose of the Plan and with applicable laws and regulations (including, without limitation, the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Securities Exchange Act of 1934 and Regulation T promulgated by the
Federal Reserve Board), or (iv)&nbsp;by any combination of such methods of payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Valuation of Shares or Other <FONT STYLE="white-space:nowrap">Non-Cash</FONT>
Consideration Tendered in Payment of</U><U> </U><U>Purchase Price</U>. For the purposes hereof, the fair market value of any share of the Corporation&#146;s Common Stock or other <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration which
may be delivered to the Corporation in exercise of this option shall be determined in good faith by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delivery of
Shares Tendered in Payment of Purchase Price</U>. If the Optionee exercises options by delivery of shares of Common Stock of the Corporation, the certificate or certificates representing the shares of Common Stock of the Corporation to be delivered
shall be duly executed in blank by the Optionee or shall be accompanied by a stock power duly executed in blank suitable for purposes of transferring such shares to the Corporation. Fractional shares of Common Stock of the Corporation will not be
accepted in payment of the purchase price of shares acquired upon exercise of this option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Restrictions on Use of Option
Stock</U>. Notwithstanding the foregoing, no shares of Common Stock of the Corporation may be tendered in payment of the purchase price of shares purchased upon exercise of this option if the shares to be so tendered were acquired within twelve
(12)&nbsp;months before the date of such tender through the exercise of an option granted under the Plan or any other stock option or restricted stock plan of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Delivery of Shares; Compliance With Securities Laws, Etc.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Corporation shall, upon payment of the option price for the number of shares purchased and paid for, make prompt
delivery of such shares to the Optionee, <U>provided</U> that if any law or regulation requires the Corporation to take any action with respect to such shares before the issuance thereof, then the date of delivery of such shares shall be extended
for the period necessary to complete such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Listing, Qualification, Etc</U>. This option shall be subject to the requirement
that if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject hereto upon any securities exchange or under any state or federal law, or the consent or approval of any
governmental or regulatory body, or that the disclosure of <FONT STYLE="white-space:nowrap">non-public</FONT> information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase of
shares hereunder, this option may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or approval, disclosure or satisfaction of such other condition shall have been effected or obtained on terms
acceptable to the Administrator. Nothing herein shall be deemed to require the Corporation to apply for, effect or obtain such listing, registration, qualification, or disclosure, or to satisfy such other condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Nontransferability of Option</U>. Except as provided in paragraph (e)&nbsp;of Section&nbsp;3, this option is personal and no rights
granted hereunder may be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise), nor shall any such rights be subject to execution, attachment or similar process. Upon any attempt to transfer, assign,
pledge, hypothecate or otherwise dispose of this option or of such rights contrary to the provisions hereof, or upon the levy of any attachment or similar process upon this option or such rights, this option and such rights shall, at the election of
the Corporation, become null and void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Special Employment Rights</U>. Nothing contained in the Plan or this option shall
be construed or deemed by any person under any circumstances to bind the Corporation or any subsidiary to continue the employment of the Optionee for the period within which this option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Rights as a Shareholder</U>. The Optionee shall have no rights as a shareholder with respect to any shares which may be purchased by
exercise of this option (including, without limitation, any rights to receive dividends or <FONT STYLE="white-space:nowrap">non-cash</FONT> distributions with respect to such shares) unless and until a certificate representing such shares is duly
issued and delivered to the Optionee. No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Adjustment Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. In the event of a transaction described in Section&nbsp;15(a) of the Plan, the Optionee shall, with respect to this option
or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in Section&nbsp;15(a) of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Authority to Make Adjustments</U>. Any adjustments under this Section&nbsp;9 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued pursuant to this option on account of any such adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Limits on Adjustments</U>. No adjustment shall be made under this Section&nbsp;9 which would, within the meaning of any applicable
provision of the Code, constitute a modification, extension or renewal of this option or a grant of additional benefits to the Optionee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Mergers, Consolidation, Distributions, Liquidations Etc.</U> In the event of a merger, consolidation, distribution, liquidation or
other similar event described in Section&nbsp;16(a) of the Plan, the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in
Section&nbsp;16(a) of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Withholding Taxes</U>. The Corporation&#146;s obligation to deliver shares upon the exercise of
this option shall be subject to the Optionee&#146;s satisfaction of all applicable federal, state and local income and employment tax withholding requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Limitations on Disposition of Incentive Stock Option Shares</U>. It is understood and intended that this option shall qualify as an
&#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code. Accordingly, the Optionee understands that in order to obtain the benefits of an incentive stock option under Section&nbsp;422 of the Code, no sale or other disposition
may be made of any shares acquired upon exercise of the option within one year after the day of the transfer of such shares to the Optionee, nor within two years after the grant of the option. If the Optionee intends to dispose, or does dispose
(whether by sale, exchange, gift, transfer or otherwise), of any such shares within said periods, he or she will notify the Corporation in writing within ten days after such disposition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Investment Representations; Legends</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations</U>. The Optionee represents, warrants and covenants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Any shares purchased upon exercise of this option shall be acquired for the Optionee&#146;s account for investment only and
not with a view to, or for sale in connection with, any distribution of the shares in violation of the Securities Act of 1933 (the &#147;Securities Act&#148;) or any rule or regulation under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Optionee has had such opportunity as he or she has deemed adequate to obtain from representatives of the Corporation
such information as is necessary to permit the Optionee to evaluate the merits and risks of his or her investment in the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Optionee is able to bear the economic risk of holding shares acquired pursuant to the exercise of this option for an
indefinite period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Optionee understands that (A)&nbsp;the shares acquired pursuant to the exercise of this option
will not be registered under the Securities Act and are &#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act; (B)&nbsp;such shares cannot be sold, transferred or otherwise disposed of unless they are subsequently
registered under the Securities Act or an exemption from registration is then available; (C) in any event, an exemption from registration under Rule 144 or otherwise under the Securities Act may not be available for at least two years and even then
will not be available unless a public market then exists for the Common Stock, adequate information concerning the Corporation is then available to the public and other terms and conditions of Rule 144 are complied with; and (D)&nbsp;there is now no
registration statement on file with the Securities and Exchange Commission with respect to any stock of the Corporation and the Corporation has no obligation or current intention to register any shares acquired pursuant to the exercise of this
option under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Optionee agrees that, if the Corporation offers any of its Common Stock for sale
pursuant to a registration statement under the Securities Act, the Optionee will not, without the prior written consent of the Corporation, directly or indirectly offer, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant for the sale of or otherwise dispose of or transfer any shares purchased upon exercise of this option, for such period not to exceed (a)&nbsp;one hundred eighty (180)&nbsp;days following
the effective date of the relevant registration statement filed under the Securities Act in connection with the Corporation&#146;s initial public offering of Registrable Securities, or (b)&nbsp;ninety (90) days following the effective date of the
relevant registration statement in connection with any other public offering of Registrable Securities; <U>provided</U>, <U>however</U>, that all officers and directors of the Corporation and all 1% or greater stockholders of the Corporation enter
into similar agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By making payment upon exercise of this option, the Optionee shall be deemed to have reaffirmed, as of the date
of such payment, the representations made in this Section&nbsp;13. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Legends on Stock Certificates</U>. All stock certificates representing shares of
Common Stock issued to the Optionee upon exercise of this option shall have affixed thereto legends substantially in the following forms, in addition to any other legends required by applicable state law: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate have not been registered under the Securities Act of 1933 and may not be transferred,
sold or otherwise disposed of in the absence of an effective registration statement with respect to the shares evidenced by this certificate, filed and made effective under the Securities Act of 1933, or an opinion of counsel satisfactory to the
Corporation to the effect that registration under such Act is not required.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this
certificate are subject to certain restrictions on transfer contained in an Option Agreement, a copy of which will be furnished upon request by the issuer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
Except as provided herein, this option may not be amended or otherwise modified unless evidenced in writing and signed by the Corporation and the Optionee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All notices under this option shall be mailed or delivered by hand or overnight courier to the parties at their respective addresses set
forth beneath their names below or at such other address as may be designated in writing by either of the parties to one another. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
This option shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page Follows
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DATED effective as of the Date of Grant. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">AURA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and CEO</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hereunto Duly Authorized</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OPTIONEE&#146;S ACCEPTANCE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges
receipt of a copy of the Corporation&#146;s Amended and Restated 2009 Stock Option and Restricted Stock Plan, as further amended. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">OPTIONEE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[NAME]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 1 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Notice of Option Exercise </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: The Treasurer of AURA BIOSCIENCES, INC.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, in accordance with the provisions of a Stock Option Agreement (&#147;Agreement&#148;) between AURA BIOSCIENCES, INC.
(&#147;Corporation&#148;) and the undersigned, hereby gives notice pursuant to Section&nbsp;3(b) of the Agreement of the undersigned&#146;s exercise of the option pursuant to the Agreement to purchase
(#)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>common shares of the Corporation for the aggregate payment for said shares of
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>(&#147;Price&#148;) payable as follows (please check one): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the tender of a check for immediately available funds for the entire Price (enclose check made payable to &#147;AURA BIOSCIENCES, INC.&#148;);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">subject to the consent of the Corporation, by tendering (#)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>shares of the Corporation&#146;s
(type)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>stock;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">subject to the consent of the Corporation, by tendering $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>in cash (enclose check made payable to
&#147;AURA BIOSCIENCES, INC.&#148;) and (#) shares of the Corporation&#146;s
(type)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>stock; or</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by alternative means approved by the Corporation&#146;s Administrator as follows:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants to the Corporation that all of the representations and
warranties set forth in Section&nbsp;13(a) of the Agreement are true and correct as of the date of this Notice. The undersigned hereby (a)&nbsp;agrees that the undersigned is acquiring Stock of the Corporation subject to the terms and conditions of
the Voting Agreement and ROFR Agreement; (b) agrees that the Stock acquired by the undersigned shall be bound by and subject to the terms of the Voting Agreement and ROFR Agreement; (c)&nbsp;adopts the Voting Agreement and ROFR Agreement with the
same force and effect as if the undersigned were originally a party thereto; (d) agrees that any notice required or permitted by the Voting Agreement or ROFR Agreement shall be given to the undersigned at the address listed below the
undersigned&#146;s signature below; (e) agrees to be bound by (i)&nbsp;the Voting Agreement as a &#147;Common Holder&#148; thereunder and (ii)&nbsp;the ROFR Agreement as a &#147;Key Holder&#148; thereunder irrespective of whether the undersigned
will or will not hold one percent (1%) or more of the Corporation&#146;s Stock (as defined in the ROFR Agreement); (f) agrees that a copy of this document may be used as a counterpart signature page or adoption agreement to each of the Voting
Agreement and the ROFR Agreement; and (g)&nbsp;agrees to execute and deliver to the Corporation additional or alternative adoption agreements (in forms acceptable to the Corporation) to each of the Voting Agreement and ROFR Agreement if so required
by the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants to the Corporation that all of the representations
and warranties set forth in Section&nbsp;13(a) of the Agreement are true and correct as of the date of this Notice. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Social Security Number:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">NON-STATUTORY</FONT> STOCK OPTION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. Effective [&#149;] (&#147;Date of Grant&#148;), AURA BIOSCIENCES, INC., a Delaware corporation (the
&#147;Corporation&#148;), hereby grants to [NAME] (the &#147;Optionee&#148;) an option, pursuant to the Corporation&#146;s Amended and Restated 2009 Stock Option and Restricted Stock Plan (the &#147;Plan&#148;), to purchase an aggregate of [&#149;]
shares of the Corporation&#146;s $0.00001 par value common stock (&#147;Common Stock&#148;) at a price of [&#149;] per share, purchasable as set forth in and subject to the terms and conditions of this option and the Plan (the &#147;Shares&#148;).
Except where the context otherwise requires, the term &#147;Corporation&#148; shall include the all present and future subsidiaries of the Corporation as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or
replaced from time to time (the &#147;Code&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U><FONT STYLE="white-space:nowrap">Non-Statutory</FONT></U><U> </U><U>Stock</U><U>
</U><U>Option</U>. This option is not intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise</U><U> </U><U>of</U><U> </U><U>option</U><U> </U><U>and</U><U> </U><U>Provisions</U><U> </U><U>for</U><U>
</U><U>Termination</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Vesting Schedule</U>. Except as otherwise provided in this Agreement, this option may be exercised prior
to the tenth (10th) anniversary of the Date of Grant (hereinafter the &#147;Expiration Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This option shall vest as follows:
The Shares shall vest [equally on an annual basis with the first vesting occurring on [DATE] and thereafter, on the second and third anniversary dates]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right of exercise shall be cumulative so that if the option is not exercised to the maximum extent permissible during any exercise period,
it shall be exercisable, in whole or in part, with respect to all shares not so purchased at any time prior to the Expiration Date or the earlier termination of this option. This option may not be exercised at any time on or after the Expiration
Date, except as otherwise provided in Section&nbsp;3(e) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Procedure</U>. Subject to the conditions set forth in this
Agreement, this option shall be exercised by the Optionee&#146;s delivery of a written notice of exercise in the form attached hereto and marked as <U>Exhibit 1</U> to the Treasurer of the Corporation, specifying the number of shares to be purchased
and the purchase price to be paid therefor and accompanied by payment in full in accordance with Section&nbsp;4. Such exercise shall be effective upon receipt by the Treasurer of the Corporation of such written notice together with the required
payment. The Optionee may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten (10)&nbsp;whole shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Continuous</U><U> </U><U>Relationship</U><U> </U><U>with</U><U> </U><U>the</U><U> </U><U>Corporation</U>. Except as otherwise provided
in this Section&nbsp;3, this option may not be exercised unless the Optionee, at the time it exercises this option, is, and has been at all times since the date of grant of this option, an employee, officer or director of, or consultant or advisor
to, the Corporation or any subsidiary (an &#147;Eligible Optionee&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Period Upon Termination of Relationship with the Corporation</U>. If the
Optionee ceases to be an Eligible Optionee for any reason, then, except as <U>provided</U> in paragraphs (e)&nbsp;and (f) below, the right to exercise this option shall terminate three (3)&nbsp;months after such cessation (but in no event after the
Expiration Date), <U>provided</U> that this option shall be exercisable only to the extent that the Optionee was entitled to exercise this option on the date of such cessation. The Corporation&#146;s obligation to deliver shares upon the exercise of
this option shall be subject to the satisfaction of all applicable federal, state and local income and employment tax withholding requirements. Notwithstanding the foregoing, if the Optionee, prior to the Expiration Date, materially violates the
noncompetition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Optionee and the Corporation or any subsidiary, the right to exercise this option shall terminate
immediately upon written notice to the Optionee from the Corporation or any subsidiary describing such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise</U><U>
</U><U>Period</U><U> </U><U>Upon</U><U> </U><U>Death</U><U> </U><U>or</U><U> </U><U>Disability</U>. If the Optionee dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3) of the Code) prior to the Expiration Date while it is an
Eligible Optionee, or if the Optionee dies within three (3)&nbsp;months after the Optionee ceases to be an Eligible Optionee (other than as the result of a termination of such relationship by the Corporation or any subsidiary for &#147;cause&#148;
as specified in paragraph (t)&nbsp;below), this option shall be exercisable, within the period of one (1)&nbsp;year following the date of death or disability of the Optionee (whether or not such exercise occurs before the Expiration Date), by the
Optionee or by the person to whom this option is transferred by will or the laws of descent and distribution, provided that this option shall be exercisable only to the extent that this option was exercisable by the Optionee on the date of his death
or disability. Except as otherwise indicated by the context, the term &#147;Optionee,&#148; as used in this option, shall be deemed to include the estate of the Optionee or any person who acquires the right to exercise this option by bequest or
inheritance or otherwise by reason of the death of the Optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Discharge for Cause</U>. If the Optionee, prior to the Expiration
Date, is discharged by the Corporation or any subsidiary for Cause (as defined below), the right to exercise this option shall terminate immediately upon such cessation of employment. &#147;Cause&#148; shall mean (i)&nbsp;dishonest statements or
acts by the Optionee with respect to the Corporation or any affiliate or subsidiary of the Corporation, or any of the Corporation&#146;s current or prospective customers, suppliers vendors or other third parties with which such entity does business;
(ii)&nbsp;the Optionee&#146;s commission of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;failure to perform to the reasonable satisfaction of the Board of Directors of the
Corporation (the &#147;Board&#148;) the Optionee&#146;s duties and responsibilities assigned by the Board which failure continues, in the reasonable judgment of the Board, after written notice given to the Optionee by the Board; (iv)&nbsp;gross
negligence, willful misconduct or insubordination by the Optionee with respect to the Corporation or any affiliate or subsidiary of the Corporation; or (v)&nbsp;a violation of any provision of any agreement(s) between the Optionee and the
Corporation relating to noncompetition, nondisclosure and/or assignment of inventions. The Optionee shall be considered to have been discharged for Cause if the Corporation or any subsidiary determines, within thirty (30)&nbsp;days after the
Optionee&#146;s resignation, that discharge for Cause was warranted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Payment</U><U> </U><U>of</U><U> </U><U>Purchase</U><U> </U><U>Price</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Method of Payment</U>. Payment of the purchase price for shares purchased upon exercise of this option shall be made: (i)&nbsp;by
delivery to the Corporation of cash or a check to the order of the Corporation in an amount equal to the purchase price of such shares, (ii)&nbsp;subject to the consent of the Corporation, by delivery to the Corporation of shares of Common Stock of
the Corporation then owned by the Optionee having a fair market value equal in amount to the purchase price of such shares, (iii)&nbsp;by any other means which the Administrator (as that term is defined in the Plan) determines are consistent with
the purpose of the Plan and with applicable laws and regulations (including, without limitation, the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Securities Exchange Act of 1934 and Regulation T promulgated by the
Federal Reserve Board), or (iv)&nbsp;by any combination of such methods of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Valuation</U><U> </U><U>of</U><U>
</U><U>Shares</U><U> </U><U>or</U><U> </U><U>Other</U><U> </U><U><FONT STYLE="white-space:nowrap">Non-Cash</FONT></U><U> </U><U>Consideration</U><U> </U><U>Tendered</U><U> </U><U>in</U> <U>Payment of Purchase Price</U>. For the purposes hereof, the
fair market value of any share of the Corporation&#146;s Common Stock or other <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration which may be delivered to the Corporation in exercise of this option shall be determined in good faith by
the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Delivery</U><U> </U><U>of</U><U> </U><U>Shares</U><U> </U><U>Tendered</U><U> </U><U>in</U><U>
</U><U>Payment</U><U> </U><U>of</U><U> </U><U>Purchase</U><U> </U><U>Price</U>. If the Optionee exercises this option by delivery of shares of Common Stock of the Corporation, the certificate or certificates representing the shares of Common Stock
of the Corporation to be delivered shall be duly executed in blank by the Optionee or shall be accompanied by a stock power duly executed in blank suitable for purposes of transferring such shares to the Corporation. Fractional shares of Common
Stock of the Corporation will not be accepted in payment of the purchase price of shares acquired upon exercise of this option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
<U>Restrictions on Use of Option Stock</U>. Notwithstanding the foregoing, no shares of Common Stock of the Corporation may be tendered in payment of the purchase price of shares purchased upon exercise of this option if the shares to be so tendered
were acquired within twelve (12)&nbsp;months before the date of such tender through the exercise of an option granted under the Plan or any other stock option or restricted stock plan of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Delivery</U><U> </U><U>of</U><U> </U><U>Shares;</U><U> </U><U>Compliance</U><U> </U><U>With</U><U> </U><U>Securities Laws,</U><U>
</U><U>Etc</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Corporation shall, upon payment of the option price for the number of shares purchased and paid
for, make prompt delivery of such shares to the Optionee, provided that if any law or regulation requires the Corporation to take any action with respect to such shares before the issuance thereof, then the date of delivery of such shares shall be
extended for the period necessary to complete such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Listing, Qualification, Etc</U>. This option shall be subject to the
requirement that if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject hereto upon any securities exchange or under any state or federal law, or the consent or approval of
any governmental or regulatory body, or that the disclosure of <FONT STYLE="white-space:nowrap">non-public</FONT> information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase
of shares hereunder, this option may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval, disclosure or satisfaction of such other condition shall have been effected or obtained on terms acceptable to the Administrator. Nothing herein shall be deemed to require the
Corporation to apply for, effect or obtain such listing, registration, qualification or disclosure, or to satisfy such other condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Nontransferability</U><U> of Option</U>. Except as provided in paragraph (e)&nbsp;of Section&nbsp;3, this option is personal and no
rights granted hereunder may be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) nor shall any such rights be subject to execution, attachment or similar process, except that this option may be
transferred: (i)&nbsp;by will or the laws of descent and distribution or (ii)&nbsp;pursuant to a qualified domestic relations order as defined in Section&nbsp;414(p) of the Code. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise
dispose of this option or of such rights contrary to the provisions hereof, or upon the levy of any attachment or similar process upon this option or such rights, this option and such rights shall, at the election of the Corporation, become null and
void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Special Employment or Similar Rights</U>. Nothing contained in the Plan or this option shall be construed or deemed by any
person under any circumstances to create or to bind the Corporation or any subsidiary to enter into or continue any relationship (whether employment, independent contractor, agency, or other) of the Optionee with the Corporation or any subsidiary
for the period within which this option may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Rights as a Shareholder</U>. The Optionee shall have no rights as a
shareholder with respect to any shares which may be purchased by exercise of this option (including, without limitation, any rights to receive dividends or <FONT STYLE="white-space:nowrap">non-cash</FONT> distributions with respect to such shares)
unless and until a certificate representing such shares is duly issued and delivered to the Optionee. No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Adjustment</U><U> </U><U>Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. In the event of a merger, consolidation, sale of all or substantially all of the securities or assets, or reorganization,
recapitalization, etc. the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to an appropriate adjustment of the shares to be issued pursuant to this option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Authority to Make Adjustments</U>. Any adjustments under this Section&nbsp;9 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued pursuant to this option on account of any such adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Mergers, Consolidation, Distributions, Liquidations Etc</U>. In the event of a merger, consolidation, distribution, liquidation or
other similar event, the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in Article 9 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Withholding Taxes</U>. The Corporation&#146;s obligation to deliver shares upon the exercise of this option shall be subject to the
Optionee&#146;s satisfaction of all applicable federal, state and local income and employment tax withholding requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Investment</U><U> </U><U>Representations,</U><U> </U><U>Legends</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations</U>. The Optionee represents, warrants and covenants that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Any shares purchased upon exercise of this option shall be acquired for the Optionee&#146;s account for investment only,
and not with a view to, or for sale in connection with, any distribution of the shares in violation of the Securities Act of 1933 (the &#147;Securities Act&#148;), or any rule or regulation under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Optionee has had such opportunity as it has deemed adequate to obtain from representatives of the Corporation such
information as is necessary to permit the Optionee to evaluate the merits and risks of his investment in the Corporation, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The Optionee is able to bear the economic risk of holding such shares acquired pursuant to the exercise of this option
for an indefinite period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) The Optionee understands that: (A)&nbsp;the shares acquired pursuant to the exercise of
this option will not be registered under the Securities Act and are &#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act; (B)&nbsp;such shares cannot be sold, transferred or otherwise disposed of unless they arc
subsequently registered under the Securities Act or an exemption from registration is then available; (C) in any event, an exemption from registration under Rule 144 or otherwise under the Securities Act may not be available for at least two years
and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Corporation is then available to the public, and other terms and conditions of Rule 144 are complied with; and
(D)&nbsp;there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Corporation and the Corporation has no obligation or current intention to register any shares acquired pursuant to
the exercise of this option under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) The Optionee agrees that, if the Corporation offers any of his
Common Stock for sale pursuant to a registration statement under the Securities Act, the Optionee will not, without the prior written consent of the Corporation, directly or indirectly offer, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of or otherwise dispose of or transfer any shares purchased upon exercise of this option, for such period not to exceed (a)&nbsp;one hundred eighty
(180)&nbsp;days following the effective date of the relevant registration statement filed under the Securities Act in connection with the Company&#146;s initial public offering of Registrable Securities, or (b)&nbsp;ninety (90) days following the
effective date of the relevant registration statement in connection with any other public offering of Registrable Securities; <U>provided</U>, <U>however</U>, that all officers and directors of the Company and all one percent (1%) percent or greater
stockholders of the Company enter into similar agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By making payment upon exercise of this option, the Optionee shall be deemed
to have reaffirmed, as of the date of such payment, the representations made in this Section&nbsp;12. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Legends on Stock Certificate</U>. All stock certificates representing shares of
Common Stock issued to the Optionee upon exercise of this option shall have affixed thereto legends substantially in the following forms, in addition to any other legends required by applicable state Law: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate have not been registered under the Securities Act or 1933 and may not be
transferred, sold or otherwise disposed of in the absence of an effective registration statement with respect to the shares evidenced by this certificate, filed and made effective under the Securities Act of 1933, or an opinion of counsel
satisfactory to the Corporation to the effect that registration under such Act is not required.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock
represented by this certificate are subject to certain restrictions on transfer contained in an Option Agreement, a copy of which will be furnished upon request by the, issuer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Except as provided herein, this option may not be amended or otherwise modified unless evidenced in writing and signed by the Corporation and the Optionee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All notices under this option shall be mailed or delivered by hand or overnight courier to the parties at their respective addresses set
forth beneath their names below or at such other address as may be designated in writing by either of the parties to one another. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
This option shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Page 6 Ends Here</I>.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DATED: Effective as of the Date of Grant. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;AURA BIOSCIENCES, INC.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; CEO</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hereunto Duly Authorized</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OPTIONEE&#146;S ACCEPTANCE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges
receipt of a copy of the Corporation&#146;s Amended and Restated 2009 Stock Option and Restricted Stock Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">OPTIONEE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[NAME]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>Address</U>:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Notice of Option Exercise</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: The Treasurer of AURA BIOSCIENCES, INC.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, in accordance with the provisions of a Stock Option Agreement (&#147;Agreement&#148;) between AURA BIOSCIENCES, INC.
(&#147;Corporation&#148;) and the undersigned, hereby gives notice pursuant to Section&nbsp;3(b) of the Agreement of the undersigned&#146;s exercise of the option pursuant to the Agreement to purchase
(#)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>common shares of the Corporation for the aggregate payment for said shares of
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (&#147;Price&#148;) payable as follows (please check one): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">by the tender of a check for immediately available funds for the entire Price (enclose check made payable to &#147;AURA BIOSCIENCES, INC.&#148;);</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">subject to the consent of the Corporation, by tendering (#)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>shares of the Corporation&#146;s
(type)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>stock;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">subject to the consent of the Corporation, by tendering $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>in cash (enclose check made payable to
&#147;AURA BIOSCIENCES, INC.&#148;) and <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of the Corporation&#146;s
(type)<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>stock; or</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">by alternative means approved by the Corporation&#146;s Administrator as follows:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned represents and warrants to the Corporation that all of the representations and
warranties set forth in Section&nbsp;12(a) of the Agreement are true and correct as of the date of this Notice. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Social Security Number:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit 1 &#150; 1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>d209588dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Aura Biosciences, Inc. 2018 Equity
Incentive Plan, have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Administrator</U> means the Board of Directors, unless it has delegated power to act on
its behalf to the Committee, in which case the Administrator means the Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Affiliate</U> means a corporation which, for purposes
of Section&nbsp;424 of the Code, is a parent or subsidiary of the Company, direct or indirect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Agreement</U> means an agreement between
the Company and a Participant delivered pursuant to the Plan and pertaining to a Stock Right, in such form as the Administrator shall approve. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Board of Directors</U> means the Board of Directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Cause</U> means, with respect to a Participant (a)&nbsp;dishonesty with respect to the Company or any Affiliate, (b)&nbsp;insubordination,
substantial malfeasance or nonfeasance of duty, (c)&nbsp;unauthorized disclosure of confidential information, (d) breach by a Participant of any provision of any employment, consulting, advisory, nondisclosure,
<FONT STYLE="white-space:nowrap">non-competition</FONT> or similar agreement between the Participant and the Company or any Affiliate, and (e)&nbsp;conduct substantially prejudicial to the business of the Company or any Affiliate; provided, however,
that any provision in an agreement between a Participant and the Company or an Affiliate, which contains a conflicting definition of Cause for termination and which is in effect at the time of such termination, shall supersede this definition with
respect to that Participant. The determination of the Administrator as to the existence of Cause will be conclusive on the Participant and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Code</U> means the United States Internal Revenue Code of 1986, as amended including any successor statute, regulation and guidance thereto.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Committee</U> means the committee of the Board of Directors to which the Board of Directors has delegated power to act under or
pursuant to the provisions of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Common Stock</U> means shares of the Company&#146;s common stock, $0.00001 par value per share.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Company</U> means Aura Biosciences, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Consultant</U> means any natural person who is an advisor or consultant that provides bona fide services to the Company or its Affiliates,
provided that such services are not in connection with the offer or sale of securities in a capital raising transaction, and do not directly or indirectly promote or maintain a market for the Company&#146;s or its Affiliates&#146; securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Disability</U> or <U>Disabled</U> means permanent and total disability as defined in Section&nbsp;22(e)(3) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Employee</U> means any employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an
officer or director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Fair Market Value</U> of a Share of Common Stock means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Common Stock is listed on a national securities exchange or traded in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and sales prices are regularly reported for the Common Stock, the closing or, if not applicable, the last price of the Common Stock on the
composite tape or other comparable reporting system for the trading day on the applicable date and if such applicable date is not a trading day, the last market trading day prior to such date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Common Stock is not traded on a national securities exchange but is traded on the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, if sales prices are not regularly reported for the Common Stock for the trading day referred to in clause (1), and if bid and asked prices for the
Common Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market for the
trading day on which Common Stock was traded on the applicable date and if such applicable date is not a trading day, the last market trading day prior to such date; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Common Stock is neither listed on a national securities exchange nor traded in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, such value as the Administrator, in good faith, shall determine. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>ISO</U> means an option intended to qualify as an incentive stock option under Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option</U> means an option which is not intended to qualify as an ISO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Option</U> means an ISO or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option granted under the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Participant</U> means an Employee, director or Consultant of the Company or an Affiliate
to whom one or more Stock Rights are granted under the Plan. As used herein, &#147;Participant&#148; shall include &#147;Participant&#146;s Survivors&#148; where the context requires. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Plan</U> means this Aura Biosciences, Inc. 2018 Equity Incentive Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Securities Act</U> means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Shares</U> means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital
stock into which the Shares are changed or for which they are exchanged within the provisions of Paragraph 3 of the Plan. The Shares issued under the Plan may be authorized and unissued shares or shares held by the Company in its treasury, or both.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Stock Grant</U> means a grant by the Company of Shares under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Stock Right</U> means a right to Shares or the value of Shares of the Company granted pursuant to the Plan &#151; an ISO, a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Option or a Stock Grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Survivor</U> means a deceased Participant&#146;s legal
representatives and/or any person or persons who acquired the Participant&#146;s rights to a Stock Right by will or by the laws of descent and distribution. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PURPOSES</B><B> </B><B>OF</B><B> </B><B>THE</B><B> </B><B>PLAN.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan is intended to encourage ownership of Shares by Employees and directors of and certain Consultants to the Company and its Affiliates
in order to attract and retain such people, to induce them to work for the benefit of the Company or of an Affiliate and to provide additional incentive for them to promote the success of the Company or of an Affiliate. The Plan provides for the
granting of ISOs, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options or Stock Grants. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHARES</B><B> </B><B>SUBJECT</B><B> </B><B>TO</B><B> </B><B>THE</B><B> </B><B>PLAN.</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The number of Shares which may be issued from time to time pursuant to this Plan shall be the sum of: (i) 2,943,764
shares of Common Stock and (ii)&nbsp;any shares of Common Stock that are represented by awards granted under the Company&#146;s 2009 Amended and Restated Stock Option and Restricted Stock Plan that are forfeited, expire or are cancelled without
delivery of shares of Common Stock or which result in the forfeiture of shares of Common Stock back to the Company on or after December&nbsp;12, 2018, or the equivalent of such number of Shares after the Administrator, in its sole discretion, has
interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance with Paragraph 24 of this Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If an Option ceases to be &#147;outstanding&#148;, in whole or in part (other than by
exercise), or if the Company shall reacquire (at not more than its original issuance price) any Shares issued pursuant to a Stock Grant, or if any Stock Right expires or is forfeited, cancelled, or otherwise terminated or results in any Shares not
being issued, the unissued or reacquired Shares which were subject to such Stock Right shall again be available for issuance from time to time pursuant to this Plan. Notwithstanding the foregoing, if a Stock Right is exercised, in whole or in part,
by tender of Shares or if the Company or an Affiliate&#146;s tax withholding obligation is satisfied by withholding Shares, the number of Shares deemed to have been issued under the Plan for purposes of the limitation set forth in Paragraph 3(a)
above shall be the number of Shares that were subject to the Stock Right or portion thereof, and not the net number of Shares actually issued. However, in the case of ISOs, the foregoing provisions shall be subject to any limitations under the Code.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ADMINISTRATION</B><B> </B><B>OF</B><B> </B><B>THE</B><B> </B><B>PLAN.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator of the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the
Committee, in which case the Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Interpret the provisions of the Plan and all Stock Rights and to make all rules and determinations which it deems necessary or advisable
for the administration of the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Determine which Employees, directors and Consultants shall be granted Stock Rights; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Determine the number of Shares for which a Stock Right or Stock Rights shall be granted; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Specify the terms and conditions upon which a Stock Right or Stock Rights may be granted; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Make changes to any outstanding Stock Right, including, without limitation, to reduce or increase the exercise price or purchase price,
accelerate the vesting schedule or extend the expiration date, provided that no such change shall impair the rights of a Participant under any grant previously made without such Participant&#146;s consent; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Buy out for a payment in cash or Shares, a Stock Right previously granted and/or cancel any such Stock Right and grant in substitution
therefor other Stock Rights, covering the same or a different number of Shares and having an exercise price or purchase price per share which may be lower or higher than the exercise price or purchase price of the cancelled Stock Right, based on
such terms and conditions as the Administrator shall establish and the Participant shall accept; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Adopt any <FONT
STYLE="white-space:nowrap">sub-plans</FONT> applicable to residents of any specified jurisdiction as it deems necessary or appropriate in order to comply with or take advantage of any tax or other laws applicable to the Company, any Affiliate or to
Participants or to otherwise facilitate the administration of the Plan, which <FONT STYLE="white-space:nowrap">sub-plans</FONT> may include additional restrictions or conditions applicable to Stock Rights or Shares issuable pursuant to a Stock
Right; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that all such interpretations, rules, determinations, terms and conditions shall be made
and prescribed in the context of not causing any adverse tax consequences under Section&nbsp;409A of the Code and preserving the tax status under Section&nbsp;422 of the Code of those Options which are designated as ISOs. Subject to the foregoing,
the interpretation and construction by the Administrator of any provisions of the Plan or of any Stock Right granted under it shall be final, unless otherwise determined by the Board of Directors, if the Administrator is the Committee. In addition,
if the Administrator is the Committee, the Board of Directors may take any action under the Plan that would otherwise be the responsibility of the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent permitted under applicable law, the Board of Directors or the Committee may allocate all or any portion of its responsibilities
and powers to any one or more of its members and may delegate all or any portion of its responsibilities and powers to any other person selected by it. The Board of Directors or the Committee may revoke any such allocation or delegation at any time.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ELIGIBILITY</B><B> </B><B>FOR</B><B> </B><B>PARTICIPATION.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator will, in its sole discretion, name the Participants in the Plan; provided, however, that each Participant must be an
Employee, director or Consultant of the Company or of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the Administrator may authorize the grant of a Stock Right to a person not then an Employee, director or
Consultant of the Company or of an Affiliate; provided, however, that the actual grant of such Stock Right shall be conditioned upon such person becoming eligible to become a Participant at or prior to the time of the execution of the Agreement
evidencing such Stock Right. ISOs may be granted only to Employees who are deemed to be residents of the United States for tax purposes. <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options and Stock Grants may be granted to any Employee,
director or Consultant of the Company or an Affiliate. The granting of any Stock Right to any individual shall neither entitle that individual to, nor disqualify him or her from, participation in any other grant of Stock Rights or any grant under
any other benefit plan established by the Company or any Affiliate for Employees, directors or Consultants. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMS</B><B> </B><B>AND</B><B> </B><B>CONDITIONS</B><B> </B><B>OF</B><B> </B><B>OPTIONS.</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option shall be set forth in writing in an Option Agreement, duly executed by the Company and, to the extent
required by law or requested by the Company, by the Participant. The Administrator may provide that Options be granted subject to such terms and conditions, consistent with the terms and conditions specifically required under this Plan, as the
Administrator may deem appropriate including, without limitation, subsequent approval by the shareholders of the Company of this Plan or any amendments thereto. The Option Agreements shall be subject to at least the following terms and conditions:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options</U>: Each Option intended to be a
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option shall be subject to the terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards for
any such <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exercise Price</U>: Each Option Agreement shall state the exercise price (per share) of the Shares covered
by each Option, which exercise price shall be determined by the Administrator and shall be at least equal to the Fair Market Value per share of Common Stock on the date of grant of the Option. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Number</U><U> </U><U>of</U><U> </U><U>Shares</U>: Each Option Agreement shall state the number of Shares to
which it pertains. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Option Periods</U>: Each Option Agreement shall state the date or dates on which it first is exercisable and
the date after which it may no longer be exercised, and may provide that the Option rights accrue or become exercisable in installments over a period of months or years, or upon the occurrence of certain conditions or the attainment of stated goals
or events. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Option Conditions</U>: Exercise of any Option may be conditioned upon the Participant&#146;s execution of a
Share purchase agreement in form satisfactory to the Administrator providing for certain protections for the Company and its other shareholders, including requirements that: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Participant&#146;s or the Participant&#146;s Survivors&#146; right to sell or transfer the Shares may be restricted; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Participant or the Participant&#146;s Survivors may be required to execute letters of investment intent and must also acknowledge that the
Shares will bear legends noting any applicable restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>ISOs</U>: Each Option intended to be an ISO shall be issued only to
an Employee who is deemed to be a resident of the United States for tax purposes, and shall be subject to the following terms and conditions, with such additional restrictions or changes as the Administrator determines are appropriate but not in
conflict with Section&nbsp;422 of the Code and relevant regulations and rulings of the Internal Revenue Service: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Minimum standards</U>: The ISO shall meet the minimum standards required of
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options, as described in Paragraph 6(a) above, except clause (i)&nbsp;thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exercise Price</U>: Immediately before the ISO is granted, if the Participant owns, directly or by reason of
the applicable attribution rules in Section&nbsp;424(d) of the Code: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">10% <U>or less</U> of the total combined voting power of all classes of stock of the Company or an Affiliate,
the exercise price per share of the Shares covered by each ISO shall not be less than 100% of the Fair Market Value per share of the Common Stock on the date of grant of the Option; or </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">More than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate, the
exercise price per share of the Shares covered by each ISO shall not be less than 110% of the Fair Market Value per share of the Common Stock on the date of grant of the Option. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Term</U><U> </U><U>of</U><U> </U><U>Option</U>: For Participants who own: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">10% <U>or</U><U> </U><U>less</U> of the total combined voting power of all classes of stock of the Company or
an Affiliate, each ISO shall terminate not more than ten years from the date of the grant or at such earlier time as the Option Agreement may provide; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">More than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate, each
ISO shall terminate not more than five years from the date of the grant or at such earlier time as the Option Agreement may provide. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Limitation on Yearly Exercise</U>: The Option Agreements shall restrict the amount of ISOs which may become
exercisable in any calendar year (under this or any other ISO plan of the Company or an Affiliate) so that the aggregate Fair Market Value (determined on the date each ISO is granted) of the stock with respect to which ISOs are exercisable for the
first time by the Participant in any calendar year does not exceed $100,000. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMS</B><B> </B><B>AND</B><B> </B><B>CONDITIONS</B><B> </B><B>OF</B><B> </B><B>STOCK</B><B>
</B><B>GRANTS.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Stock Grant to a Participant shall state the principal terms in an Agreement duly executed by
the Company and, to the extent required by law or requested by the Company, by the Participant. The Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be
appropriate and in the best interest of the Company, subject to the following minimum standards: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Agreement shall state the
purchase price per share, if any, of the Shares covered by each Stock Grant, which purchase price shall be determined by the Administrator but shall not be less than the minimum consideration required by the Delaware General Corporation Law, if any,
on the date of the grant of the Stock Grant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Agreement shall state the number of Shares to which the Stock Grant pertains; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Agreement shall include the terms of any right of the Company to restrict or reacquire the Shares subject to the Stock Grant,
including the time and events upon which such rights shall accrue and the purchase price therefor, if any. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[INTENTIONALLY</B><B> </B><B>OMITTED].</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXERCISE</B><B> </B><B>OF</B><B> </B><B>OPTIONS</B><B> </B><B>AND</B><B> </B><B>ISSUE</B><B>
</B><B>OF</B><B> </B><B>SHARES.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Option (or any part or installment thereof) shall be exercised by giving written
notice to the Company or its designee (in a form acceptable to the Administrator, which may include electronic notice), together with provision for payment of the aggregate exercise price in accordance with this Paragraph for the Shares as to which
the Option is being exercised, and upon compliance with any other condition(s) set forth in the Option Agreement. Such notice shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to
the Administrator), shall state the number of Shares with respect to which the Option is being exercised and shall contain any representation required by the Plan or the Option Agreement. Payment of the exercise price for the Shares as to which such
Option is being exercised shall be made (a)&nbsp;in United States dollars in cash or by check, or (b)&nbsp;at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative
accounting treatment) having a Fair Market Value equal as of the date of the exercise to the aggregate cash exercise price for the number of Shares as to which the Option is being exercised, or (c)&nbsp;at the discretion of the Administrator, by
having the Company retain from the Shares otherwise issuable upon exercise of the Option, a number of Shares having a Fair Market Value equal as of the date of exercise to the aggregate exercise price for the number of Shares as to which the Option
is being exercised, or (d)&nbsp;at the discretion of the Administrator (after consideration of applicable securities, tax and accounting implications), by delivery of the grantee&#146;s personal recourse note bearing interest payable not less than
annually at no less than 100% of the applicable Federal rate, as defined in Section&nbsp;1274(d) of the Code, or (e)&nbsp;at the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage
firm, and approved by the Administrator, or (f)&nbsp;at the discretion of the Administrator, by any combination of (a), (b), (c), (d) and (e)&nbsp;above or (g)&nbsp;at the discretion of the Administrator, by payment of such other lawful
consideration as the Administrator may determine. Notwithstanding the foregoing, the Administrator shall accept only such payment on exercise of an ISO as is permitted by Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall then reasonably promptly deliver the Shares as to which such Option was exercised to the Participant (or to the
Participant&#146;s Survivors, as the case may be). In determining what constitutes &#147;reasonably promptly,&#148; it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law
or regulation (including, without limitation, state securities or &#147;blue sky&#148; laws) which requires the Company to take any action with respect to the Shares prior to their issuance. The Shares shall, upon delivery, be fully paid, <FONT
STYLE="white-space:nowrap">non-assessable</FONT> Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator shall have the right to accelerate the date of exercise of any
installment of any Option; provided that the Administrator shall not accelerate the exercise date of any installment of any Option granted to an Employee as an ISO (and not previously converted into a
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option pursuant to Paragraph 27) without the prior approval of the Employee if such acceleration would violate the annual vesting limitation contained in Section&nbsp;422(d) of the Code, as
described in Paragraph 6(b)(iv). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may, in its discretion, amend any term or condition of an outstanding
Option provided (i)&nbsp;such term or condition as amended is permitted by the Plan, (ii)&nbsp;any such amendment shall be made only with the consent of the Participant to whom the Option was granted, or in the event of the death of the Participant,
the Participant&#146;s Survivors, if the amendment is adverse to the Participant, and (iii)&nbsp;any such amendment of any Option shall be made only after the Administrator determines whether such amendment would constitute a
&#147;modification&#148; of any Option which is an ISO (as that term is defined in Section&nbsp;424(h) of the Code) or would cause any adverse tax consequences for the holder of any Option including, but not limited to, pursuant to Section&nbsp;409A
of the Code. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ACCEPTANCE</B><B> </B><B>OF</B><B> </B><B>STOCK</B><B> </B><B>GRANTS</B><B> </B><B>AND</B><B>
</B><B>ISSUE</B><B> </B><B>OF</B><B> </B><B>SHARES.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Stock Grant (or any part or installment thereof) shall be
accepted by executing the applicable Agreement and delivering it to the Company or its designee, together with provision for payment of the purchase price, if any, in accordance with this Paragraph for the Shares as to which such Stock Grant is
being accepted, and upon compliance with any other conditions set forth in the applicable Agreement. Payment of the purchase price for the Shares as to which such Stock Grant is being accepted shall be made (a)&nbsp;in United States dollars in cash
or by check, or (b)&nbsp;at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) and having a Fair Market Value equal as of the date of
acceptance of the Stock Grant to the purchase price of the Stock Grant, or (c)&nbsp;at the discretion of the Administrator (after consideration of applicable securities, tax and accounting implications), by delivery of the grantee&#146;s personal
recourse note bearing interest payable not less than annually at no less than 100% of the applicable Federal rate, as defined in Section&nbsp;1274(d) of the Code, or (d)&nbsp;at the discretion of the Administrator, by any combination of (a), (b) and
(c)&nbsp;above; or (e)&nbsp;at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall then, if required by the applicable Agreement, reasonably promptly deliver the Shares as to which such Stock Grant was
accepted to the Participant (or to the Participant&#146;s Survivors, as the case may be), subject to any escrow provision set forth in the applicable Agreement. In determining what constitutes &#147;reasonably promptly,&#148; it is expressly
understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities or &#147;blue sky&#148; laws) which requires the Company to take any
action with respect to the Shares prior to their issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may, in its discretion, amend any term or condition of an
outstanding Stock Grant or applicable Agreement provided (i)&nbsp;such term or condition as amended is permitted by the Plan, (ii)&nbsp;any such amendment shall be made only with the consent of the Participant to whom the Stock Grant was made, if
the amendment is adverse to the Participant, and (iii)&nbsp;any such amendment shall be made only after the Administrator determines whether such amendment would cause any adverse tax consequences to the Participant, including, but not limited to,
pursuant to Section&nbsp;409A of the Code. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHTS AS A SHAREHOLDER.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Participant to whom a Stock Right has been granted shall have rights as a shareholder with respect to any Shares covered by such Stock
Right, except after due exercise of the Option or acceptance of the Stock Grant or as set forth in any Agreement, and tender of the aggregate exercise or purchase price, if any, for the Shares being purchased pursuant to such exercise or acceptance
and registration of the Shares in the Company&#146;s share register in the name of the Participant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNABILITY</B><B> </B><B>AND</B><B> </B><B>TRANSFERABILITY</B><B> </B><B>OF</B><B> </B><B>STOCK</B><B>
</B><B>RIGHTS.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By its terms, a Stock Right granted to a Participant shall not be transferable by the Participant
other than (i)&nbsp;by will or by the laws of descent and distribution, or (ii)&nbsp;as approved by the Administrator in its discretion and set forth in the applicable Agreement provided that no Stock Right may be transferred by a Participant for
value. Notwithstanding the foregoing, an ISO transferred except in compliance with clause (i)&nbsp;above shall no longer qualify as an ISO. The designation of a beneficiary of a Stock Right by a Participant, with the prior approval of the
Administrator and in such form as the Administrator shall prescribe, shall not be deemed a transfer prohibited by this Paragraph. Except as provided above, a Stock Right shall only be exercisable or may only be accepted, during the
Participant&#146;s lifetime, by such Participant (or by his or her legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or
similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of any Stock Right or of any rights granted thereunder contrary to the provisions of this Plan, or the levy of any attachment or similar process upon a
Stock Right, shall be null and void. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> </B><B>ON</B><B> </B><B>OPTIONS</B><B> </B><B>OF</B><B> </B><B>TERMINATION</B><B>
</B><B>OF</B><B> </B><B>SERVICE</B><B> </B><B>OTHER</B><B> </B><B>THAN</B><B> </B><B>FOR </B><B></B><B>CAUSE</B><B> </B><B>OR</B><B> </B><B>DEATH OR</B><B> </B><B>DISABILITY.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s Option Agreement, in the event of a termination of service (whether as an Employee,
director or Consultant) with the Company or an Affiliate before the Participant has exercised an Option, the following rules apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A
Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate (for any reason other than termination for Cause, Disability, or death for which events there are special rules in Paragraphs 14, 15, and 16,
respectively), may exercise any Option granted to him or her to the extent that the Option is exercisable on the date of such termination of service, but only within such term as the Administrator has designated in a Participant&#146;s Option
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as provided in Subparagraph (c)&nbsp;below, or Paragraph 15 or 16, in no event may an Option intended to be an ISO,
be exercised later than three months after the Participant&#146;s termination of employment. The provisions of this Paragraph, and not the provisions of Paragraph 15 or 16, shall apply to a Participant who subsequently becomes Disabled or dies after
the termination of employment, director status or consultancy; provided, however, in the case of a Participant&#146;s Disability or death within three months after the termination of employment, director status or consultancy, the Participant or the
Participant&#146;s Survivors may exercise the Option within one year after the date of the Participant&#146;s termination of service, but in no event after the date of expiration of the term of the Option. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything herein to the contrary, if subsequent to a Participant&#146;s
termination of employment, termination of director status or termination of consultancy, but prior to the exercise of an Option, the Administrator determines that, either prior or subsequent to the Participant&#146;s termination, the Participant
engaged in conduct which would constitute Cause, then such Participant shall forthwith cease to have any right to exercise any Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) A Participant to whom an Option has been granted under the Plan who is absent from the Company or an Affiliate because of temporary
disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated
such Participant&#146;s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide; provided, however, that, for ISOs, any leave of absence granted by the
Administrator of greater than three months, unless pursuant to a contract or statute that guarantees the right to reemployment, shall cause such ISO to become a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option on the date that is six
months following the commencement of such leave of absence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Except as required by law or as set forth in a Participant&#146;s Option
Agreement, Options granted under the Plan shall not be affected by any change of a Participant&#146;s status within or among the Company and any Affiliates, so long as the Participant continues to be an Employee, director or Consultant of the
Company or any Affiliate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> </B><B>ON</B><B> </B><B>OPTIONS</B><B> </B><B>OF</B><B> </B><B>TERMINATION</B><B>
</B><B>OF</B><B> </B><B>SERVICE FOR</B><B> </B><B>CAUSE.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s Option
Agreement, the following rules apply if the Participant&#146;s service (whether as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause prior to the time that all his or her outstanding Options have been
exercised: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All outstanding and unexercised Options as of the time the Participant is notified his or her service is terminated for Cause
will immediately be forfeited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cause is not limited to events which have occurred prior to a Participant&#146;s termination of service,
nor is it necessary that the Administrator&#146;s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&#146;s termination of service but prior to the exercise of an Option, that either prior or
subsequent to the Participant&#146;s termination the Participant engaged in conduct which would constitute Cause, then the right to exercise any Option is forfeited. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> </B><B>ON</B><B> </B><B>OPTIONS</B><B> </B><B>OF</B><B> </B><B>TERMINATION</B><B>
</B><B>OF</B><B> </B><B>SERVICE FOR</B><B> </B><B>DISABILITY.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s
Option Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of
Disability may exercise any Option granted to such Participant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent that the Option has become exercisable but has not been exercised on the date of the
Participant&#146;s termination of service due to Disability; and </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the
date of the Participant&#146;s termination of service due to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of days
accrued in the current vesting period prior to the date of the Participant&#146;s termination of service due to Disability. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) A Disabled Participant may exercise the Option only within the period ending one year after the date of the Participant&#146;s termination
of service due to Disability, notwithstanding that the Participant might have been able to exercise the Option as to some or all of the Shares on a later date if the Participant had not become Disabled and had continued to be an Employee, director
or Consultant or, if earlier, within the originally prescribed term of the Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Administrator shall make the determination
both of whether Disability has occurred and the date of its occurrence (unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such
determination). If requested, the Participant shall be examined by a physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> </B><B>ON</B><B> </B><B>OPTIONS</B><B> </B><B>OF</B><B> </B><B>DEATH</B><B>
</B><B>WHILE</B><B> </B><B>AN</B><B> </B><B>EMPLOYEE,</B><B> </B><B>DIRECTOR</B><B> </B><B>OR</B><B> </B><B>CONSULTANT.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s Option Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate,
such Option may be exercised by the Participant&#146;s Survivors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent that the Option has become exercisable but has not been exercised on the date of death; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the
date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant&#146;s
date of death. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Participant&#146;s Survivors wish to exercise the Option, they must take all
necessary steps to exercise the Option within one year after the date of death of such Participant, notwithstanding that the decedent might have been able to exercise the Option as to some or all of the Shares on a later date if he or she had not
died and had continued to be an Employee, director or Consultant or, if earlier, within the originally prescribed term of the Option. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> </B><B>OF</B><B> </B><B>TERMINATION</B><B> </B><B>OF</B><B> </B><B>SERVICE</B><B>
</B><B>ON</B><B> </B><B>UNACCEPTED</B><B> </B><B>STOCK</B><B> </B><B>GRANTS.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a termination of
service (whether as an Employee, director or Consultant) with the Company or an Affiliate for any reason before the Participant has accepted a Stock Grant, such offer shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Paragraph 17 and Paragraph 18 below, a Participant to whom a Stock Grant has been offered and accepted under the Plan who
is absent from work with the Company or with an Affiliate because of temporary disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any
such absence, be deemed, by virtue of such absence alone, to have terminated such Participant&#146;s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, for purposes of this Paragraph 17 and Paragraph 18 below, any change of employment or other service within or among the Company
and any Affiliates shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues to be an Employee, director or Consultant of the Company or any Affiliate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> </B><B>ON</B><B> </B><B>STOCK</B><B> </B><B>GRANTS</B><B> </B><B>OF</B><B>
</B><B>TERMINATION</B><B> </B><B>OF</B><B> </B><B>SERVICE</B><B> </B><B>OTHER</B><B> </B><B>THAN</B><B> </B><B>FOR</B><B> </B><B>CAUSE OR</B><B> </B><B>DEATH </B><B>OR</B><B> </B><B>DISABILITY.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a Participant&#146;s Stock Grant Agreement, in the event of a termination of service (whether as an Employee,
director or Consultant), other than termination for Cause, Disability, or death for which events there are special rules in Paragraphs 19, 20, and 21, respectively, before all forfeiture provisions or Company rights of repurchase shall have lapsed,
then the Company shall have the right to cancel or repurchase that number of Shares subject to a Stock Grant as to which the Company&#146;s forfeiture or repurchase rights have not lapsed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> </B><B>ON</B><B> </B><B>STOCK</B><B> </B><B>GRANTS</B><B> </B><B>OF</B><B>
</B><B>TERMINATION</B><B> </B><B>OF</B><B> </B><B>SERVICE</B><B> </B><B>FOR</B><B> </B><B>CAUSE.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise
provided in a Participant&#146;s Stock Grant Agreement, the following rules apply if the Participant&#146;s service (whether as an Employee, director or Consultant) with the Company or an Affiliate is terminated for Cause: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All Shares subject to any Stock Grant that remain subject to forfeiture provisions or as to which the Company shall have a repurchase right
shall be immediately forfeited to the Company as of the time the Participant is notified his or her service is terminated for Cause. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Cause is not limited to events which have occurred prior to a Participant&#146;s
termination of service, nor is it necessary that the Administrator&#146;s finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&#146;s termination of service, that either prior or subsequent to the
Participant&#146;s termination the Participant engaged in conduct which would constitute Cause, then all Shares subject to any Stock Grant that remained subject to forfeiture provisions or as to which the Company had a repurchase right on the date
of termination shall be immediately forfeited to the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> </B><B>ON</B><B> </B><B>STOCK</B><B> </B><B>GRANTS</B><B> </B><B>OF</B><B>
</B><B>TERMINATION</B><B> </B><B>OF</B><B> </B><B>SERVICE</B><B> </B><B>FOR</B><B> </B><B>DISABILITY.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
otherwise provided in a Participant&#146;s Stock Grant Agreement, the following rules apply if a Participant ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of Disability: to the extent the forfeiture
provisions or the Company&#146;s rights of repurchase have not lapsed on the date of Disability, they shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions
or rights shall lapse to the extent of a pro rata portion of the Shares subject to such Stock Grant through the date of Disability as would have lapsed had the Participant not become Disabled. The proration shall be based upon the number of days
accrued prior to the date of Disability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator shall make the determination both as to whether Disability has occurred and
the date of its occurrence (unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the Participant shall
be examined by a physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT</B><B> ON</B><B> STOCK</B><B> GRANTS</B><B> OF</B><B> DEATH</B><B> WHILE</B><B> AN</B><B>
EMPLOYEE,</B><B> </B><B>DIRECTOR</B><B> </B><B>OR</B><B> </B><B>CONSULTANT.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a
Participant&#146;s Stock Grant Agreement, the following rules apply in the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate: to the extent the forfeiture provisions or
the Company&#146;s rights of repurchase have not lapsed on the date of death, they shall be exercisable; provided, however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall
lapse to the extent of a pro rata portion of the Shares subject to such Stock Grant through the date of death as would have lapsed had the Participant not died. The proration shall be based upon the number of days accrued prior to the
Participant&#146;s date of death. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PURCHASE</B><B> </B><B>FOR</B><B> </B><B>INVESTMENT.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the offering and sale of the Shares to be issued upon the particular exercise or acceptance of a Stock Right shall have been effectively
registered under the Securities Act, the Company shall be under no obligation to issue the Shares covered by such exercise unless and until the following conditions have been fulfilled: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The person who exercises or accepts such Stock Right shall warrant to the Company, prior to the receipt of such Shares, that such person is
acquiring such Shares for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person acquiring such Shares shall be bound by the provisions of the
following legend (or a legend in substantially similar form) which shall be endorsed upon the certificate evidencing the Shares issued pursuant to such exercise or such grant: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any
person, including a pledgee, unless (1)&nbsp;either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b)&nbsp;the Company shall have received an opinion of counsel
satisfactory to it that an exemption from registration under such Act is then available, and (2)&nbsp;there shall have been compliance with all applicable state securities laws.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued upon such
particular exercise or acceptance in compliance with the Securities Act without registration thereunder. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISSOLUTION</B><B> </B><B>OR</B><B> </B><B>LIQUIDATION</B><B> </B><B>OF</B><B> </B><B>THE</B><B>
</B><B>COMPANY.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the dissolution or liquidation of the Company, all Options granted under this Plan which as of
such date shall not have been exercised and all Stock Grants which have not been accepted will terminate and become null and void; provided, however, that if the rights of a Participant or a Participant&#146;s Survivors have not otherwise terminated
and expired, the Participant or the Participant&#146;s Survivors will have the right immediately prior to such dissolution or liquidation to exercise or accept any Stock Right to the extent that the Stock Right is exercisable or subject to
acceptance as of the date immediately prior to such dissolution or liquidation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ADJUSTMENTS.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of any of the following events, a Participant&#146;s rights with respect to any Stock Right granted to him or her hereunder
shall be adjusted as hereinafter provided, unless otherwise specifically provided in a Participant&#146;s Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock
Dividends and Stock Splits</U>. If (i)&nbsp;the shares of Common Stock shall be subdivided or combined into a greater or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common
Stock, or (ii)&nbsp;additional shares or new or different shares or other securities of the Company or other non- cash assets are distributed with respect to such shares of Common Stock, the number of shares of Common Stock deliverable upon the
exercise of an Option or acceptance of a Stock Grant shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made including, in the exercise or purchase price per share, to reflect such events. The number
of Shares subject to the limitations in Paragraph 3(a) shall also be proportionately adjusted upon the occurrence of such events. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Corporate Transactions</U>. If the Company is to be consolidated with or acquired by
another entity in a merger, consolidation, or sale of all or substantially all of the Company&#146;s assets other than a transaction to merely change the state of incorporation (a &#147;Corporate Transaction&#148;), the Administrator or the board of
directors of any entity assuming the obligations of the Company hereunder (the &#147;Successor Board&#148;), shall, as to outstanding Options, either (i)&nbsp;make appropriate provision for the continuation of such Options by substituting on an
equitable basis for the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity; or
(ii)&nbsp;upon written notice to the Participants, provide that such Options must be exercised (either (A)&nbsp;to the extent then exercisable or, (B)&nbsp;at the discretion of the Administrator, any such Options being made partially or fully
exercisable for purposes of this Subparagraph), within a specified number of days of the date of such notice, at the end of which period such Options which have not been exercised shall terminate; or (iii)&nbsp;terminate such Options in exchange for
payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock into which such Option would have been exercisable (either (A)&nbsp;to the extent then
exercisable or, (B)&nbsp;at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes of this Subparagraph) <U>less</U><U> </U><U>the</U><U> </U><U>aggregate</U> exercise price thereof. For purposes
of determining the payments to be made pursuant to Subclause (iii)&nbsp;above, in the case of a Corporate Transaction the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair
value thereof as determined in good faith by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to outstanding Stock Grants, the Administrator or the
Successor Board, shall make appropriate provision for the continuation of such Stock Grants on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock Grants either the consideration payable with
respect to the outstanding Shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Corporate Transaction, the Administrator may provide
that, upon consummation of the Corporate Transaction, each outstanding Stock Grant shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number
of shares of Common Stock comprising such Stock Grant (to the extent such Stock Grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being
waived upon such Corporate Transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In taking any of the actions permitted under this Paragraph 24(b), the Administrator shall not
be obligated by the Plan to treat all Stock Rights, all Stock Rights held by a Participant, or all Stock Rights of the same type, identically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Recapitalization</U><U> </U><U>or</U><U> </U><U>Reorganization</U>. In the event of a recapitalization or reorganization of the Company
other than a Corporate Transaction pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant upon exercising an Option or accepting a Stock Grant after the
recapitalization or reorganization shall be entitled to receive for the price paid upon such exercise or acceptance if any, the number of replacement securities which would have been received if such Option had been exercised or Stock Grant accepted
prior to such recapitalization or reorganization. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) [Intentionally Omitted]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Modification of Options</U>. Notwithstanding the foregoing, any adjustments made pursuant to Subparagraph (a), (b) or (c)&nbsp;above
with respect to Options shall be made only after the Administrator determines whether such adjustments would constitute a &#147;modification&#148; of any ISOs (as that term is defined in Section&nbsp;424(h) of the Code) or would cause any adverse
tax consequences for the holders of Options, including, but not limited to, pursuant to Section&nbsp;409A of the Code. If the Administrator determines that such adjustments made with respect to Options would constitute a modification or other
adverse tax consequence, it may refrain from making such adjustments, unless the holder of an Option specifically agrees in writing that such adjustment be made and such writing indicates that the holder has full knowledge of the consequences of
such &#147;modification&#148; on his or her income tax treatment with respect to the Option. This paragraph shall not apply to the acceleration of the vesting of any ISO that would cause any portion of the ISO to violate the annual vesting
limitation contained in Section&nbsp;422(d) of the Code, as described in Paragraph 6(b)(iv). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ISSUANCES</B><B> </B><B>OF</B><B> </B><B>SECURITIES.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock
of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Stock Rights. Except as expressly provided herein, no adjustments shall be made for dividends paid in cash or in
property (including without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FRACTIONAL</B><B> </B><B>SHARES.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares shall be issued under the Plan and the person exercising a Stock Right shall receive from the Company cash in lieu of such
fractional shares equal to the Fair Market Value thereof. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONVERSION</B><B> </B><B>OF</B><B> </B><B>ISOS</B><B> </B><B>INTO</B><B> </B><B><FONT
STYLE="white-space:nowrap">NON-QUALIFIED</FONT></B><B> </B><B>OPTIONS;</B><B> </B><B>TERMINATION</B><B> </B><B>OF</B><B> </B><B>ISOS.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator, at the written request of any Participant, may in its discretion take such actions as may be necessary to convert such
Participant&#146;s ISOs (or any portions thereof) that have not been exercised on the date of conversion into <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options at any time prior to the expiration of such ISOs, regardless of whether the
Participant is an Employee of the Company or an Affiliate at the time of such conversion. At the time of such conversion, the Administrator (with the consent of the Participant) may impose such conditions on the exercise of the resulting <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Options as the Administrator in its discretion may determine, provided that such conditions shall not be inconsistent with this Plan. Nothing in the Plan shall be deemed to give any Participant the
right to have such Participant&#146;s ISOs converted into <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options, and no such conversion shall occur until and unless the Administrator takes appropriate action. The Administrator, with the
consent of the Participant, may also terminate any portion of any ISO that has not been exercised at the time of such conversion. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WITHHOLDING.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any federal, state, or local income taxes, employment taxes, Federal Insurance Contributions Act (&#147;F.I.C.A.&#148;)
withholdings or other amounts are required by applicable law or governmental regulation to be withheld from the Participant&#146;s salary, wages or other remuneration in connection with the exercise or acceptance of a Stock Right or in connection
with a Disqualifying Disposition (as defined in Paragraph 29) or upon the lapsing of any forfeiture provision or right of repurchase or for any other reason required by law, the Company may withhold from the Participant&#146;s compensation, if any,
or may require that the Participant advance in cash to the Company, or to any Affiliate of the Company which employs or employed the Participant, the statutory minimum amount of such withholdings unless a different withholding arrangement, including
the use of shares of the Company&#146;s Common Stock or a promissory note, is authorized by the Administrator (and permitted by law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll withholding shall be
determined in the manner set forth under the definition of Fair Market Value provided in Paragraph 1 above, as of the most recent practicable date prior to the date of exercise. If the Fair Market Value of the shares withheld is less than the amount
of payroll withholdings required, the Participant may be required to advance the difference in cash to the Company or the Affiliate employer. The Administrator in its discretion may condition the exercise of an Option for less than the then Fair
Market Value on the Participant&#146;s payment of such additional withholding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICE</B><B> </B><B>TO</B><B> </B><B>COMPANY</B><B> </B><B>OF</B><B> </B><B>DISQUALIFYING</B><B>
</B><B>DISPOSITION.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Employee who receives an ISO must agree to notify the Company in writing immediately after
the Employee makes a Disqualifying Disposition of any Shares acquired pursuant to the exercise of an ISO. A Disqualifying Disposition is defined in Section&nbsp;424(c) of the Code and includes any disposition (including any sale or gift) of such
Shares before the later of (a)&nbsp;two years after the date the Employee was granted the ISO, or (b)&nbsp;one year after the date the Employee acquired Shares by exercising the ISO, except as otherwise provided in Section&nbsp;424(c) of the Code.
If the Employee has died before such Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION</B><B> </B><B>OF</B><B> </B><B>THE</B><B> </B><B>PLAN.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will terminate on December 12, 2028, the date which is ten years from the <U>earlier</U> of the date of its adoption by the Board of
Directors and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the shareholders or the Board of Directors of the Company; provided, however, that any such earlier termination shall
not affect any Agreements executed prior to the effective date of such termination. Termination of the Plan shall not affect any Stock Rights theretofore granted. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT</B><B> </B><B>OF</B><B> </B><B>THE</B><B> </B><B>PLAN</B><B> </B><B>AND</B><B>
</B><B>AGREEMENTS.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan may be amended by the shareholders of the Company. The Plan may also be amended by the
Administrator, including, without limitation, to the extent necessary to qualify any or all outstanding Stock Rights granted under the Plan or Stock Rights to be granted under the Plan for favorable federal income tax treatment as may be afforded
incentive stock options under Section&nbsp;422 of the Code (including deferral of taxation upon exercise), and to the extent necessary to qualify the shares issuable upon exercise or acceptance of any outstanding Stock Rights granted, or Stock
Rights to be granted, under the Plan for listing on any national securities exchange or quotation in any national automated quotation system of securities dealers. Any amendment approved by the Administrator which the Administrator determines is of
a scope that requires shareholder approval shall be subject to obtaining such shareholder approval. Any modification or amendment of the Plan shall not, without the consent of a Participant, adversely affect his or her rights under a Stock Right
previously granted to him or her. With the consent of the Participant affected, the Administrator may amend outstanding Agreements in a manner which may be adverse to the Participant but which is not inconsistent with the Plan. In the discretion of
the Administrator, outstanding Agreements may be amended by the Administrator in a manner which is not adverse to the Participant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">32.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EMPLOYMENT</B><B> </B><B>OR</B><B> </B><B>OTHER</B><B> </B><B>RELATIONSHIP.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this Plan or any Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment, consultancy or
director status of a Participant, nor to prevent a Participant from terminating his or her own employment, consultancy or director status or to give any Participant a right to be retained in employment or other service by the Company or any
Affiliate for any period of time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">33.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNING</B><B> </B><B>LAW.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall be construed and enforced in accordance with the law of the State of Delaware. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NO. 1 TO THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA
BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Aura Biosciences, Inc. (the &#147;Company&#148;) maintains the Aura Biosciences, Inc. 2018 Equity Incentive Plan (the
&#147;Plan&#148;), which was previously adopted by the Board of Directors of the Company (the &#147;Board&#148;) and approved by the stockholders of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Board desires to amend certain provisions of the Plan related to a sale of the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Section&nbsp;31 of the Plan provides that the Board may amend the Plan at any time, subject to certain conditions set forth
therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Section 1 of the Plan is hereby amended by adding the following definitions to the definitions set forth in Section&nbsp;1 of the Plan: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Initial Public Offering</U> means the consummation of the first firm commitment underwritten public offering pursuant to an
effective registration statement under the Securities Act covering the offer and sale by the Company of its equity securities, as a result of or following which the Shares shall be publicly held. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Person</U> shall mean any individual, corporation, partnership (limited or general), limited liability company, limited
liability partnership, association, trust, joint venture, unincorporated organization or any similar entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Sale
Event</U> means the consummation of (i)&nbsp;the dissolution or liquidation of the Company, (ii)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (iii)&nbsp;a merger,
reorganization or consolidation pursuant to which the holders of the Company&#146;s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the surviving or resulting entity (or its
ultimate parent, if applicable), (iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transactions by a Person or group of Persons, or (v)&nbsp;any other acquisition
of the business of the Company, as determined by the Board of Directors; <I>provided, however, </I>that the Company&#146;s Initial Public Offering, any subsequent public offering or another capital raising event, or a merger effected solely to
change the Company&#146;s domicile shall not constitute a &#147;Sale Event.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Section&nbsp;23 of the Plan is hereby deleted in its
entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Upon a Sale Event (solely as defined in section (i)&nbsp;of &#147;Sale
Event&#148;), all Options granted under this Plan which as of such date shall not have been exercised and all Stock Grants which have not been accepted will terminate and become null and void; provided, however, that if the rights of a Participant
or a Participant&#146;s Survivors have not otherwise terminated and expired, the Participant or the Participant&#146;s Survivors will have the right immediately prior to such dissolution or liquidation to exercise or accept any Stock Right to the
extent that the Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution or liquidation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Section 24(b) and (c)&nbsp;of the Plan are hereby deleted in their entirety and replaced
with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Sale Events</U>. In the event of a Sale Event (other than as defined in section (i)&nbsp;of
&#147;Sale Event&#148;), the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the &#147;Successor Board&#148;), shall, as to outstanding Options, either (i)&nbsp;make appropriate provision for
the continuation of such Options by substituting on an equitable basis for the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Sale Event or
securities of any successor or acquiring entity; or (ii)&nbsp;upon written notice to the Participants, provide that such Options must be exercised (either (A)&nbsp;to the extent then exercisable or, (B)&nbsp;at the discretion of the Administrator,
any such Options being made partially or fully exercisable for purposes of this Subparagraph), within a specified number of days of the date of such notice, at the end of which period such Options which have not been exercised shall terminate; or
(iii)&nbsp;terminate such Options in exchange for payment of an amount equal to the consideration payable upon consummation of such Sale Event to a holder of the number of shares of Common Stock into which such Option would have been exercisable
(either (A)&nbsp;to the extent then exercisable or, (B)&nbsp;at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes of this Subparagraph) <U>less the aggregate</U> exercise price thereof. For
purposes of determining the payments to be made pursuant to Subclause (iii)&nbsp;above, in the case of a Sale Event the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair
value thereof as determined in good faith by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to outstanding Stock Grants, the
Administrator or the Successor Board, shall make appropriate provision for the continuation of such Stock Grants on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock Grants either the
consideration payable with respect to the outstanding Shares of Common Stock in connection with the Sale Event or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Sale Event, the Administrator may
provide that, upon consummation of the Sale Event, each outstanding Stock Grant shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such Sale Event to a holder of the number of shares of
Common Stock comprising such Stock Grant (to the extent such Stock Grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being waived upon
such Sale Event). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In taking any of the actions permitted under this Paragraph 24(b), the Administrator shall not be
obligated by the Plan to treat all Stock Rights, all Stock Rights held by a Participant, or all Stock Rights of the same type, identically. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Recapitalization or Reorganization</U>. In the event of a
recapitalization or reorganization of the Company other than a Sale Event pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant upon exercising an
Option or accepting a Stock Grant after the recapitalization or reorganization shall be entitled to receive for the price paid upon such exercise or acceptance if any, the number of replacement securities which would have been received if such
Option had been exercised or Stock Grant accepted prior to such recapitalization or reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Effective Date of
Amendment</U>. This Amendment to the Plan shall become effective upon the date that it is approved by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Other
Provisions.</U> Except as set forth above, all other provisions of the Plan shall remain unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Amendment
No.&nbsp;1 to the Plan has been adopted by the Board of Directors of the Company this 14th day of May 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Option
No.<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA
BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stock Option Grant Notice </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stock Option Grant under the Company&#146;s 2018 Equity Incentive Plan </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name and Address of Participant:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date of Option Grant:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Type of Grant [ISO or NQO]:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Maximum Number of Shares for which this Option is exercisable:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exercise (purchase) price per share:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Option Expiration Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vesting Start Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vesting Schedule:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the first anniversary of the Vesting Start Date (the &#147;Initial Vesting Date&#148;), 25% of the Shares
shall be vested; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the Initial Vesting Date, an additional 6.25% of the Shares shall vest ratably in twelve consecutive
equal (rounded up or down to the next highest whole number of shares) quarterly installments, commencing on<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 201X and ending
on<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 201X; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>[NOTE: include &#147;double trigger&#148; acceleration for employees only] </I>[If the Participant&#146;s
employment is terminated by the Company without Cause (as defined in the Company&#146;s 2018 Equity Incentive Plan) within twelve (12)&nbsp;months after a Change of Control occurs, then all of the Participant&#146;s unvested options will accelerate
and vest immediately. As used herein, &#147;Change of Control&#148; means the occurrence of any of the following events: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The dissolution or liquidation of the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated
person or entity (a &#147;Person&#148;); or </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A merger, reorganization or consolidation involving the Company in which the shares of the Company&#146;s
voting equity outstanding immediately prior to such transaction represent or are converted into or exchanged for securities of the surviving or resulting entity immediately upon completion of such transaction which represent less than fifty percent
(50%) of the outstanding voting power of such surviving or resulting entity; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other acquisition of the business of the Company&#146;s, as determined by the Board; provided, however,
that the Company&#146;s initial public offering, any subsequent public offering or another capital raising event, or a merger effected solely to change the Company&#146;s domicile shall not constitute a &#147;Change of Control.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For clarity, &#147;Change of Control&#148; shall be interpreted, if applicable, in a manner, and limited to the
extent necessary, so that it will not cause adverse tax consequences under Section&nbsp;409A of the Code.] </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vesting
is further subject to the other terms and conditions of this Agreement and the Company&#146;s 2018 Equity Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and
the Participant acknowledge receipt of this Stock Option Grant Notice and agree to the terms of the Stock Option Agreement attached hereto and incorporated by reference herein, the Company&#146;s 2018 Equity Incentive Plan and the terms of this
Option Grant as set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AURA BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Participant Name:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGREEMENT made as of the date of grant set forth in the Stock Option Grant Notice by and between Aura Biosciences, Inc. (the
&#147;Company&#148;), a Delaware corporation, and the individual whose name appears on the Stock Option Grant Notice (the &#147;Participant&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to grant to the Participant an Option to purchase shares of its common stock, $0.00001 par value per share (the
&#147;Shares&#148;), under and for the purposes set forth in the Company&#146;s 2018 Equity Incentive Plan (the &#147;Plan&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the same meanings as in the
Plan; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Participant each intend that the Option granted herein shall be of the type set forth in the Stock
Option Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable
consideration, the parties hereto agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>GRANT OF OPTION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the Participant the right and option to purchase all or any part of an aggregate of the number of Shares set forth
in the Stock Option Grant Notice, on the terms and conditions and subject to all the limitations set forth herein, under United States securities and tax laws, and in the Plan, which is incorporated herein by reference. The Participant acknowledges
receipt of a copy of the Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>EXERCISE PRICE</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The exercise price of the Shares covered by the Option shall be the amount per Share set forth in the Stock Option Grant Notice, subject to
adjustment, as provided in the Plan, in the event of a stock split, reverse stock split or other events affecting the holders of Shares after the date hereof (the &#147;Exercise Price&#148;). Payment shall be made in accordance with Paragraph 9 of
the Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>EXERCISABILITY OF OPTION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in this Agreement and the Plan, the Option granted hereby shall become vested and exercisable as
set forth in the Stock Option Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>TERM OF OPTION</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Option shall terminate on the Option Expiration Date as specified in the Stock Option Grant Notice and, if this Option is designated in
the Stock Option Grant Notice as an ISO and the Participant owns as of the date hereof more than 10% of the total combined voting power of all classes of capital stock of the Company or an Affiliate, such date may not be more than five years from
the date of this Agreement, but shall be subject to earlier termination as provided herein or in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the Participant ceases to
be an Employee, director or Consultant of the Company or of an Affiliate for any reason other than the death or Disability of the Participant, or termination of the Participant for Cause (the &#147;Termination Date&#148;), the Option to the extent
then vested and exercisable pursuant to Section&nbsp;3 hereof as of the Termination Date, and not previously terminated in accordance with this Agreement, may be exercised within three months after the Termination Date, or on or prior to the Option
Expiration Date as specified in the Stock Option Grant Notice, whichever is earlier, but may not be exercised thereafter except as set forth below. In such event, the unvested portion of the Option shall not be exercisable and shall expire and be
cancelled on the Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If this Option is designated in the Stock Option Grant Notice as an ISO and the Participant ceases to
be an Employee of the Company or of an Affiliate but continues after termination of employment to provide service to the Company or an Affiliate as a director or Consultant, this Option shall continue to vest in accordance with Section&nbsp;3 above
as if this Option had not terminated until the Participant is no longer providing services to the Company. In such case, this Option shall automatically convert and be deemed a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option as of the
date that is three months from termination of the Participant&#146;s employment and this Option shall continue on the same terms and conditions set forth herein until such Participant is no longer providing service to the Company or an Affiliate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event of the Participant&#146;s Disability or death within three months after the Termination Date,
the Participant or the Participant&#146;s Survivors may exercise the Option within one year after the Termination Date, but in no event after the Option Expiration Date as specified in the Stock Option Grant Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the event the Participant&#146;s service is terminated by the Company or an Affiliate for Cause, the Participant&#146;s right to exercise
any unexercised portion of this Option even if vested shall cease immediately as of the time the Participant is notified his or her service is terminated for Cause, and this Option shall thereupon terminate. Notwithstanding anything herein to the
contrary, if subsequent to the Participant&#146;s termination, but prior to the exercise of the Option, the Administrator determines that, either prior or subsequent to the Participant&#146;s termination, the Participant engaged in conduct which
would constitute Cause, then the Participant shall immediately cease to have any right to exercise the Option and this Option shall thereupon terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the event of the Disability of the Participant, as determined in accordance with the Plan, the Option shall be exercisable within one year
after the Participant&#146;s termination of service due to Disability or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event, the Option shall be exercisable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that the Option has become exercisable but has not been exercised as of the date of the
Participant&#146;s termination of service due to Disability; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the
date of the Participant&#146;s termination of service due to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of days
accrued in the current vesting period prior to the date of the Participant&#146;s termination of service due to Disability. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the event of the death of the Participant while an Employee, director or Consultant of the Company or of an Affiliate, the Option shall be
exercisable by the Participant&#146;s Survivors within one year after the date of death of the Participant or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event, the Option shall be
exercisable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that the Option has become exercisable but has not been exercised as of the date of death; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the
date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant&#146;s
date of death. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>METHOD OF EXERCISING OPTION.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of this Agreement, the Option may be exercised by written notice to the Company or its designee, in
substantially the form of <U>Exhibit A</U> attached hereto (or in such other form acceptable to the Company, which may include electronic notice). Such notice shall state the number of Shares with respect to which the Option is being exercised and
shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to the Company). Payment of the Exercise Price for such Shares shall be made in accordance with Paragraph 9 of the Plan. The
Company shall deliver such Shares as soon as practicable after the notice shall be received, provided, however, that the Company may delay issuance of such Shares until completion of any action or obtaining of any consent, which the Company deems
necessary under any applicable law (including, without limitation, state securities or &#147;blue sky&#148; laws). The Shares as to which the Option shall have been so exercised shall be registered in the Company&#146;s share register in the name of
the person so exercising the Option (or, if the Option shall be exercised by the Participant and if the Participant shall so request in the notice exercising the Option, shall be registered in the Company&#146;s share register in the name of the
Participant and another person jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person exercising the Option. In the event the Option shall be exercised, pursuant to Section&nbsp;4
hereof, by any person other than the Participant, such notice shall be accompanied by appropriate proof of the right of such person to exercise the Option. All Shares that shall be purchased upon the exercise of the Option as provided herein shall
be fully paid and nonassessable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>PARTIAL EXERCISE</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Exercise of this Option to the extent above stated may be made in part at any time and from time to time within the above limits, except that
no fractional share shall be issued pursuant to this Option. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">NON-ASSIGNABILITY</FONT></U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Option shall not be transferable by the Participant otherwise than by will or by the laws of descent and distribution. If this Option is a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Option then it may also be transferred pursuant to a qualified domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act or the rules thereunder. Except
as provided above in this paragraph, the Option shall be exercisable, during the Participant&#146;s lifetime, only by the Participant (or, in the event of legal incapacity or incompetency, by the Participant&#146;s guardian or representative) and
shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition
of the Option or of any rights granted hereunder contrary to the provisions of this Section&nbsp;7, or the levy of any attachment or similar process upon the Option shall be null and void. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NO RIGHTS AS STOCKHOLDER UNTIL EXERCISE</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Participant shall have no rights as a stockholder with respect to Shares subject to this Agreement until registration of the Shares in the
Company&#146;s share register in the name of the Participant. Except as is expressly provided in the Plan with respect to certain changes in the capitalization of the Company, no adjustment shall be made for dividends or similar rights for which the
record date is prior to the date of such registration. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>ADJUSTMENTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Plan contains provisions covering the treatment of Options in a number of contingencies such as stock splits and mergers. Provisions in the
Plan for adjustment with respect to stock subject to Options and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>TAXES</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Participant acknowledges and agrees that (i)&nbsp;any income or other taxes due from the Participant with respect to this Option or the
Shares issuable upon exercise of this Option shall be the Participant&#146;s responsibility; (ii)&nbsp;the Participant was free to use professional advisors of his or her choice in connection with this Agreement, has received advice from his or her
professional advisors in connection with this Agreement, understands its meaning and import, and is entering into this Agreement freely and without coercion or duress; (iii)&nbsp;the Participant has not received and is not relying upon any advice,
representations or assurances made by or on behalf of the Company or any Affiliate or any Employee of or counsel to the Company or any Affiliate regarding any tax or other effects or implications of the Option, the Shares or other matters
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated by this Agreement and (iv)&nbsp;neither the Administrator, the Company, its Affiliates, nor any of its officers or directors, shall be held liable for any applicable costs, taxes, or
penalties associated with the Option if, in fact, the Internal Revenue Service were to determine that the Option constitutes deferred compensation under Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If this Option is designated in the Stock Option Grant Notice as a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option or if the
Option is an ISO and is converted into a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option and such Non- Qualified Option is exercised, the Participant agrees that the Company may withhold from the Participant&#146;s remuneration, if any,
the minimum statutory amount of federal, state and local withholding taxes attributable to such amount that is considered compensation includable in such person&#146;s gross income. At the Company&#146;s discretion, the amount required to be
withheld may be withheld in cash from such remuneration, or in kind from the Shares otherwise deliverable to the Participant on exercise of the Option. The Participant further agrees that, if the Company does not withhold an amount from the
Participant&#146;s remuneration sufficient to satisfy the Company&#146;s income tax withholding obligation, the Participant will reimburse the Company on demand, in cash, for the amount under-withheld. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>PURCHASE FOR INVESTMENT</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless the offering and sale of the Shares to be issued upon the particular exercise of the Option shall have been effectively registered under
the Securities Act of 1933, as now in force or hereafter amended (the &#147;1933 Act&#148;), the Company shall be under no obligation to issue the Shares covered by such exercise unless the Company has determined that such exercise and issuance
would be exempt from the registration requirements of the 1933 Act and until the following conditions have been fulfilled: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The person(s) who exercise the Option shall warrant to the Company, at the time of such exercise, that such
person(s) are acquiring such Shares for their own respective accounts, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person(s) acquiring such Shares shall be bound by
the provisions of the following legend which shall be endorsed upon any certificate(s) evidencing the Shares issued pursuant to such exercise: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any
person, including a pledgee, unless (1)&nbsp;either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b)&nbsp;the Company shall have received an opinion of counsel
satisfactory to it that an exemption from registration under such Act is then available, and (2)&nbsp;there shall have been compliance with all applicable state securities laws;&#148; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(b) If the Company so requires, the Company shall have received an opinion of its counsel that the Shares may be issued upon such particular
exercise in compliance with the 1933 Act without registration thereunder. Without limiting the generality of the foregoing, the Company may delay issuance of the Shares until completion of any action or obtaining of any consent, which the Company
deems necessary under any applicable law (including without limitation state securities or &#147;blue sky&#148; laws). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>RESTRICTIONS ON TRANSFER OF SHARES; JOINDER TO</U> <U>STOCKHOLDER AGREEMENTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1 As a condition precedent to the exercise of the Option granted hereby, the grant of the Option or the delivery of certificates for Shares
issued upon exercise of the Option, the Participant must execute any and all agreements as may be requested by the Administrator, including, without limitation, a shareholders&#146; agreement, voting agreement, and right of first refusal and <FONT
STYLE="white-space:nowrap">co-sale</FONT> agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2 The Shares acquired by the Participant pursuant to the exercise of the Option
granted hereby shall not be transferred by the Participant except as permitted herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3 It shall be a condition precedent to the
validity of any sale or other transfer of any Shares by the Participant that the following restrictions be complied with (except as otherwise provided in this Section&nbsp;12): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Shares owned by the Participant may be sold, pledged or otherwise transferred (including by gift or devise)
to any person or entity, voluntarily, or by operation of law, except in accordance with the terms and conditions hereinafter set forth. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Before selling or otherwise transferring all or part of the Shares, the Participant shall give written notice
of such intention to the Company, which notice shall include the name of the proposed transferee, the proposed purchase price per share, the terms of payment of such purchase price and all other matters relating to such sale or transfer and shall be
accompanied by a copy of the binding written agreement of the proposed transferee to purchase the Shares of the Participant. Such notice shall constitute a binding offer by the Participant to sell to the Company such number of the Shares then held
by the Participant as are proposed to be sold in the notice at the monetary price per share designated in such notice, payable on the terms offered to the Participant by the proposed transferee (provided, however, that the Company shall not be
required to meet any <FONT STYLE="white-space:nowrap">non-monetary</FONT> terms of the proposed transfer, including, without limitation, delivery of other securities in exchange for the Shares proposed to be sold). The Company shall give written
notice to the Participant as to whether such offer has been accepted in whole by the Company within 60 days after its receipt of written notice from the Participant. The Company may only accept such offer in whole and may not accept such offer in
part. Such acceptance notice shall fix a time, location and date for the Closing on such purchase (&#147;Closing Date&#148;) which shall not be less than ten nor more than sixty days after the giving of the acceptance notice, provided, however, if
any of the Shares to be sold pursuant to this Section&nbsp;12.3 have been held by the Participant for less than six months, then the Closing Date may be extended by the Company until no more than ten days after such Shares have been held by the
Participant for six months if required under applicable accounting rules in effect at the time. The place </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
for such Closing shall be at the Company&#146;s principal office. At such Closing, the Participant shall accept payment as set forth herein and shall deliver to the Company in exchange therefor
certificates for the number of Shares stated in the notice accompanied by duly executed instruments of transfer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company shall fail to accept any such offer, the Participant shall be free to sell all, but not less
than all, of the Shares set forth in his or her notice to the designated transferee at the price and terms designated in the Participant&#146;s notice, provided that (i)&nbsp;such sale is consummated within six months after the giving of notice by
the Participant to the Company as aforesaid, and (ii)&nbsp;the transferee first agrees in writing to be bound by the provisions of this Section&nbsp;12 so that such transferee (and all subsequent transferees) shall thereafter only be permitted to
sell or transfer the Shares in accordance with the terms hereof. After the expiration of such six months, the provisions of this Section&nbsp;12.3 shall again apply with respect to any proposed voluntary transfer of the Participant&#146;s Shares.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The restrictions on transfer contained in this Section&nbsp;12.3 shall not apply to (a)&nbsp;transfers by the
Participant to his or her spouse or children or to a trust for the benefit of his or her spouse or children, (b)&nbsp;transfers by the Participant to his or her guardian or conservator, and (c)&nbsp;transfers by the Participant, in the event of his
or her death, to his or her executor(s) or administrator(s) or to trustee(s) under his or her will (collectively, &#147;Permitted Transferees&#148;); provided however, that in any such event the Shares so transferred in the hands of each such
Permitted Transferee shall remain subject to this Agreement, and each such Permitted Transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such transfer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Section&nbsp;12.3 may be waived by the Company. Any such waiver may be unconditional or
based upon such conditions as the Company may impose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4 In the event that the Participant or his or her successor in
interest fails to deliver the Shares to be repurchased by the Company under this Agreement, the Company may elect (a)&nbsp;to establish a segregated account in the amount of the repurchase price, such account to be turned over to the Participant or
his or her successor in interest upon delivery of such Shares, and (b)&nbsp;immediately to take such action as is appropriate to transfer record title of such Shares from the Participant to the Company and to treat the Participant and such Shares in
all respects as if delivery of such Shares had been made as required by this Agreement. The Participant hereby irrevocably grants the Company a power of attorney which shall be coupled with an interest for the purpose of effectuating the preceding
sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.5 If the Company shall pay a stock dividend or declare a stock split on or with respect to any of its Common Stock, or
otherwise distribute securities of the Company to the holders of its Common Stock, the number of shares of stock or other securities of the Company issued with respect to the shares then subject to the restrictions contained in this Agreement shall
be added to the Shares subject to the Company&#146;s rights to repurchase pursuant to this Agreement. If the Company shall distribute to its stockholders shares of stock of another corporation, the shares of stock of such other corporation,
distributed with respect to the Shares then subject to the restrictions contained in this Agreement, shall be added to the Shares subject to the Company&#146;s rights to repurchase pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.6 If the outstanding shares of Common Stock of the Company shall be subdivided into a
greater number of shares or combined into a smaller number of shares, or in the event of a reclassification of the outstanding shares of Common Stock of the Company, or if the Company shall be a party to a merger, consolidation or capital
reorganization, there shall be substituted for the Shares then subject to the restrictions contained in this Agreement such amount and kind of securities as are issued in such subdivision, combination, reclassification, merger, consolidation or
capital reorganization in respect of the Shares subject immediately prior thereto to the Company&#146;s rights to repurchase pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.7 The Company shall not be required to transfer any Shares on its books which shall have been sold, assigned or otherwise transferred in
violation of this Agreement, or to treat as owner of such Shares, or to accord the right to vote as such owner or to pay dividends to, any person or organization to which any such Shares shall have been so sold, assigned or otherwise transferred, in
violation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.8 The provisions of Sections 12.1 and 12.3 shall terminate upon the effective date of the registration of
the Shares pursuant to the Securities Exchange Act of 1934. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.9 The Participant agrees that in the event the Company proposes to offer
for sale to the public any of its equity securities and such Participant is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting the sale or other transfer of Shares,
then it will promptly sign such agreement and will not transfer, whether in privately negotiated transactions or to the public in open market transactions or otherwise, any Shares or other securities of the Company held by him or her during such
period as is determined by the Company and the underwriters, not to exceed 180 days following the closing of the offering, plus such additional period of time as may be required to comply with NASD Rule 2711 or similar rules thereto (such period,
the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;). Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company and such underwriter and pursuant to customary and prevailing terms and
conditions. Notwithstanding whether the Participant has signed such an agreement, the Company may impose stop-transfer instructions with respect to the Shares or other securities of the Company subject to the foregoing restrictions until the end of
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.10 In the event that the Initiating Holders (as defined below) approve a
Sale of the Company (as defined below) then the Participant hereby agrees with respect to the Shares and any other shares of Common Stock that the Participant holds and any other Company securities over which the Participant otherwise exercises
dispositive power (the &#147;Drag Along&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event such transaction requires the approval of stockholders, (1)&nbsp;if the matter is to be brought to
a vote at a stockholder meeting, after receiving proper notice of any meeting of stockholders of the Company to vote on the approval of a Sale of the Company, to be present, in person or by proxy, as a holder of Shares, at all such meetings and be
counted for the purposes of determining the presence of a quorum at such meetings; and (2)&nbsp;to vote (in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
person, by proxy or by action by written consent, as applicable) all Shares in favor of such Sale of the Company and in opposition of any and all other proposals that could reasonably be expected
to delay or impair the ability of the Company to consummate such Sale of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to refrain from exercising any dissenters&#146; rights or rights of appraisal under applicable law at any time
with respect to such Sale of the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to execute and deliver all related documentation and take such other action in support of the Sale of the
Company as shall reasonably be requested by the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the following terms shall have the following
respective meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Initiating Holders&#148; means Persons holding not less than 50.1% of the shares of Common
Stock of the Company then outstanding, determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis (and including, for this purpose, any and all shares of Common Stock issued or issuable upon conversion of the Company&#146;s
convertible preferred stock, but specifically excluding, for this purpose, any then outstanding options and warrants). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Sale of the
Company&#148; means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a merger or consolidation in which (A)&nbsp;the Company is a constituent party or (B)&nbsp;a subsidiary of the
Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Company or a subsidiary in which the shares of capital stock of the
Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by
voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the
parent corporation of such surviving or resulting corporation (<U>provided that</U>, for the purpose of this clause (i)&nbsp;all shares of Common Stock issuable upon exercise of options or warrants outstanding immediately prior to such merger or
consolidation or upon conversion of convertible securities immediately prior to such merger or consolidation shall be deemed to be outstanding immediately prior to such merger or consolidation and, if applicable, converted or exchanged in such
merger or consolidation on the same terms as the actual outstanding shares of Common Stock are converted or exchanged); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any transaction or series of related transactions to which the Company is a party in which in excess of fifty
percent (50%) of the Company&#146;s voting power is transferred such that the stockholders of the Company immediately prior to the transaction or series of related transactions do not own a majority of the voting power of the surviving or acquiring
entity following such transaction or series of transactions; other than any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or any successor or indebtedness of the
Company is cancelled or converted or a combination thereof; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale, lease, transfer, exclusive license (other than an exclusive license that is approved by the Board of
Directors, or other disposition, in a single transaction or series of related transactions, by the Company or any subsidiary of the Company of all or substantially all the assets of the Company and its subsidiaries taken as a whole, or the sale or
disposition (whether by merger or otherwise) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale,
lease, transfer, exclusive license (other than an exclusive license that is approved by the Board of Directors or other disposition is to a wholly owned subsidiary of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.11 The Participant acknowledges and agrees that neither the Company, its shareholders nor its directors and officers, has any duty or
obligation to disclose to the Participant any material information regarding the business of the Company or affecting the value of the Shares before, at the time of, or following a termination of the service of the Participant by the Company,
including, without limitation, any information concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another firm or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.12 All certificates representing the Shares to be issued to the Participant pursuant to this Agreement shall have endorsed thereon a legend
substantially as follows: &#147;The shares represented by this certificate are subject to restrictions set forth in a Stock Option Agreement dated as the date of the Stock Option Grant Notice between the Participant and the Company, a copy of which
Agreement is available for inspection at the offices of the Company or will be made available upon request.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NO OBLIGATION TO MAINTAIN RELATIONSHIP</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Participant acknowledges that: (i)&nbsp;the Company is not by the Plan or this Option obligated to continue the Participant as an Employee,
director or Consultant of the Company or an Affiliate; (ii)&nbsp;the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (iii)&nbsp;the grant of the Option is a
<FONT STYLE="white-space:nowrap">one-time</FONT> benefit which does not create any contractual or other right to receive future grants of options, or benefits in lieu of options; (iv)&nbsp;all determinations with respect to any such future grants,
including, but not limited to, the times when options shall be granted, the number of shares subject to each option, the option price, and the time or times when each option shall be exercisable, will be at the sole discretion of the Company;
(v)&nbsp;the Participant&#146;s participation in the Plan is voluntary; (vi)&nbsp;the value of the Option is an extraordinary item of compensation which is outside the scope of the Participant&#146;s employment or consulting contract, if any; and
(vii)&nbsp;the Option is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IF OPTION IS INTENDED TO BE AN ISO</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If this Option is designated in the Stock Option Grant Notice as an ISO so that the Participant (or the Participant&#146;s Survivors) may
qualify for the favorable tax treatment provided to holders of Options that meet the standards of Section&nbsp;422 of the Code then any provision of this Agreement or the Plan which conflicts with the Code so that this Option would not be deemed an
ISO is null and void and any ambiguities shall be resolved so that the Option qualifies as an ISO. The Participant should consult with the Participant&#146;s own tax advisors regarding the tax effects of the Option and the requirements necessary to
obtain favorable tax treatment under Section&nbsp;422 of the Code, including, but not limited to, holding period requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>Notwithstanding the foregoing, to the extent that the Option i</U>s designated in the Stock Option Grant Notice as an ISO and is not deemed
to be an ISO pursuant to Section&nbsp;422(d) of the Code because the aggregate Fair Market Value (determined as of the Date of Option Grant) of any of the Shares with respect to which this ISO is granted becomes exercisable for the first time during
any calendar year in excess of $100,000, the portion of the Option representing such excess value shall be treated as a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option and the Participant shall be deemed to have taxable income measured
by the difference between the then Fair Market Value of the Shares received upon exercise and the price paid for such Shares pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Neither the Company nor any Affiliate shall have any liability to the Participant, or any other party, if the Option (or any part thereof)
that is intended to be an ISO is not an ISO or for any action taken by the Administrator, including without limitation the conversion of an ISO to a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Option. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION OF AN ISO</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If this Option is designated in the Stock Option Grant Notice as an ISO then the Participant agrees to notify the Company in writing
immediately after the Participant makes a Disqualifying Disposition of any of the Shares acquired pursuant to the exercise of the ISO. A Disqualifying Disposition is defined in Section&nbsp;424(c) of the Code and includes any disposition (including
any sale) of such Shares before the later of (a)&nbsp;two years after the date the Participant was granted the ISO or (b)&nbsp;one year after the date the Participant acquired Shares by exercising the ISO, except as otherwise provided in
Section&nbsp;424(c) of the Code. If the Participant has died before the Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NOTICES</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized courier service, facsimile,
registered or certified mail, return receipt requested, addressed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aura Biosciences</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cambridge, MA 02140</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Participant at the address set forth on the Stock Option Grant Notice or to such other address or
addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given upon the earlier of receipt, one business day following delivery to a recognized courier service or three business days
following mailing by registered or certified mail. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>GOVERNING LAW</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflict
of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, the parties hereby consent to exclusive jurisdiction in the Commonwealth of Massachusetts and agree that such litigation shall be conducted in the
state and federal courts sitting in Massachusetts. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>BENEFIT OF AGREEMENT</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Plan and the other provisions hereof, this Agreement shall be for the benefit of and shall be binding upon the
heirs, executors, administrators, successors and assigns of the parties hereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>ENTIRE AGREEMENT</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Agreement, together with the Plan, embodies the entire agreement and understanding between the parties hereto with respect to the subject
matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be
used to interpret, change or restrict, the express terms and provisions of this Agreement, provided, however, in any event, this Agreement shall be subject to and governed by the Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>MODIFICATIONS AND AMENDMENTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The terms and provisions of this Agreement may be modified or amended as provided in the Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>WAIVERS AND CONSENTS</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only
by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement,
whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>DATA PRIVACY</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">By entering into this Agreement, the Participant: (i)&nbsp;authorizes the Company and each Affiliate, and any agent of the Company or any
Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of options
and the administration of the Plan; and (ii)&nbsp;authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF EXERCISE OF STOCK OPTION </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Form for Unregistered Shares] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To:&nbsp;&nbsp;&nbsp;&nbsp;Aura Biosciences, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby exercise my Stock Option to
purchase<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>shares (the &#147;Shares&#148;) of the common stock, $0.00001 par value, of Aura Biosciences, Inc. (the &#147;Company&#148;), at the
exercise price of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>per share, pursuant to and subject to the terms of that certain Stock Option Agreement between the undersigned and the Company
dated<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 201_. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am aware that the
Shares have not been registered under the Securities Act of 1933, as amended (the &#147;1933 Act&#148;), or any state securities laws. I understand that the reliance by the Company on exemptions under the 1933 Act is predicated in part upon the
truth and accuracy of the statements by me in this Notice of Exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby represent and warrant that (1)&nbsp;I have been furnished
with all information which I deem necessary to evaluate the merits and risks of the purchase of the Shares; (2)&nbsp;I have had the opportunity to ask questions concerning the Shares and the Company and all questions posed have been answered to my
satisfaction; (3)&nbsp;I have been given the opportunity to obtain any additional information I deem necessary to verify the accuracy of any information obtained concerning the Shares and the Company; and (4)&nbsp;I have such knowledge and
experience in financial and business matters that I am able to evaluate the merits and risks of purchasing the Shares and to make an informed investment decision relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby represent and warrant that I am purchasing the Shares for my own personal account for investment and not with a view to the sale or
distribution of all or any part of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I understand that because the Shares have not been registered under the 1933 Act, I must
continue to bear the economic risk of the investment for an indefinite time and the Shares cannot be sold unless the Shares are subsequently registered under applicable federal and state securities laws or an exemption from such registration
requirements is available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I agree that I will in no event sell or distribute or otherwise dispose of all or any part of the Shares
unless (1)&nbsp;there is an effective registration statement under the 1933 Act and applicable state securities laws covering any such transaction involving the Shares or (2)&nbsp;the Company receives an opinion of my legal counsel (concurred in by
legal counsel for the Company) stating that such transaction is exempt from registration or the Company otherwise satisfies itself that such transaction is exempt from registration. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit <FONT
STYLE="white-space:nowrap">A-1</FONT> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I consent to the placing of a legend on my certificate for the Shares stating that the
Shares have not been registered and setting forth the restriction on transfer contemplated hereby and to the placing of a stop transfer order on the books of the Company and with any transfer agents against the Shares until the Shares may be legally
resold or distributed without restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I understand that at the present time Rule 144 of the Securities and Exchange Commission (the
&#147;SEC&#148;) may not be relied on for the resale or distribution of the Shares by me. I understand that the Company has no obligation to me to register the sale of the Shares with the SEC and has not represented to me that it will register the
sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I understand the terms and restrictions on the right to dispose of the Shares set forth in the 2019 Equity Incentive
Plan and the Stock Option Agreement, both of which I have carefully reviewed. I consent to the placing of a legend on my certificate for the Shares referring to such restriction and the placing of stop transfer orders until the Shares may be
transferred in accordance with the terms of such restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I have considered the Federal, state and local income tax implications of
the exercise of my Option and the purchase and subsequent sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am paying the option exercise price for the Shares as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please issue the
Shares (check one): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; to me; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; to me
and<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, as joint tenants with right of survivorship
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and mail the certificate to me at the following address: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">My mailing address for shareholder communications, if different from the address listed
above is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Participant (signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Social Security Number</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-3 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit B</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>NOTICE OF EXERCISE OF STOCK OPTION </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Form for Shares <U>Registered</U> in the United States] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To:&nbsp;&nbsp;&nbsp;&nbsp;Aura Biosciences, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMPORTANT
NOTICE: This form of Notice of Exercise may only be used at such time as the Company has filed a Registration Statement with the Securities and Exchange Commission under which the issuance of the Shares for which this exercise is being made is
registered and such Registration Statement remains effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby exercise my Stock Option to
purchase<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>shares (the &#147;Shares&#148;) of the common stock, $0.00001 par value, of Aura Biosciences, Inc. (the &#147;Company&#148;), at the
exercise price of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>per share, pursuant to and subject to the terms of that Stock Option Grant Notice
dated<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 201_. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I understand the nature of the investment I am making and the financial risks thereof. I am aware that it is my responsibility to have
consulted with competent tax and legal advisors about the relevant national, state and local income tax and securities laws affecting the exercise of the Option and the purchase and subsequent sale of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I am paying the option exercise price for the Shares as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please issue the Shares (check one): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; to me; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; to
me
and<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, as joint tenants with right of survivorship, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">at the following address: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-1 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">My mailing address for shareholder communications, if different from the address listed
above, is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participant (signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Social Security Number</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-2 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AGREEMENT made as of the<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>day
of<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U> (the &#147;Grant Date&#148;), between AURA BIOSCIENCES, INC. (the &#147;Company&#148;), a Delaware corporation, and
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <U></U>(the &#147;Participant&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Company has adopted the Aura Biosciences, Inc. 2018 Equity Incentive Plan (the &#147;Plan&#148;) to promote the interests of the Company by providing an incentive for Employees, directors and Consultants of the Company or its Affiliates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the provisions of the Plan, the Company desires to offer to the Participant shares of the Company&#146;s common stock,
$0.00001 par value per share (&#147;Common Stock&#148;), in accordance with the provisions of the Plan, all on the terms and conditions hereinafter set forth; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Participant wishes to accept said offer; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties hereto understand and agree that any terms used and not defined herein have the meanings ascribed to such terms in the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Terms of
Grant</U>. The Participant hereby accepts the offer of the Company to issue to the Participant, in accordance with the terms of the Plan and this Agreement,
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>) Shares of the Company&#146;s
Common Stock (such shares, subject to adjustment pursuant to Section&nbsp;24 of the Plan and Subsection 2.1(f) hereof, the &#147;Granted Shares&#148;) at a per share purchase price of $0.00001 (the &#147;Purchase Price&#148;), or an aggregate of $
receipt of which is hereby acknowledged by the Company<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1. <U>Lapsing Forfeiture Right</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Lapsing Forfeiture Right</U>. Except as set forth in Subsections 2.1(b), [(f)] or (g)&nbsp;hereof, in the event that for any reason the
Participant is no longer an Employee, director or Consultant of the Company or an Affiliate (the &#147;Termination&#148;) prior to<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, the
Participant (or the Participant&#146;s Survivor) shall, on the date of Termination, immediately forfeit to the Company (or its designee) all of the Granted Shares which have not yet vested in accordance with the schedule set forth below (the
&#147;Lapsing Forfeiture Right&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Lapsing Forfeiture Right is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">On the first anniversary of the Vesting Start Date, 25% of the Shares shall be vested; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the Participant&#146;s Termination is on or
after<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, but prior to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>,
then 6.25% of Granted Shares shall vest ratably in twelve consecutive equal (rounded up or down to the next highest whole number of shares) quarterly installments over the next quarters, commencing on
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> and ending on________, 20___. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Effect of Termination for Disability or upon Death</U>. The following rules apply to the Company&#146;s Lapsing Forfeiture Right if the
Participant&#146;s Termination is by reason of Disability or death: to the extent the Company&#146;s Lapsing Forfeiture Right has not lapsed as of the date of Termination due to Disability or death, as the case may be, the Participant shall forfeit
to the Company any or all of the Granted Shares subject to such Lapsing Forfeiture Right; provided, however, that the Company&#146;s Lapsing Forfeiture Right shall be deemed to have lapsed to the extent of a pro rata portion of the Granted Shares
through the date of Termination due to Disability or death, as would have lapsed had the Participant not been terminated due to Disability or death, as the case may be. The proration shall be based upon the number of days accrued in such current
vesting period prior to the Participant&#146;s date of Termination due to Disability or death, as the case may be. In the case of death all Granted Shares which are no longer subject to the Company&#146;s Lapsing Forfeiture Right shall be issued to
the Participant&#146;s Survivor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Escrow</U>. The Granted Shares issued to the Participant hereunder which from time to time are
subject to the Lapsing Forfeiture Right shall be held in escrow by the Company as provided in this Subsection 2.1(c). Promptly following receipt by the Company of a written request from the Participant, the Company shall release from escrow and
deliver to the Participant the Granted Shares, if any, as to which the Company&#146;s Lapsing Forfeiture Right has lapsed. In the event of forfeiture to the Company of Granted Shares subject to the Lapsing Forfeiture Right, the Company shall release
from escrow and cancel the number of Granted Shares so forfeited. Any securities distributed in respect of the Granted Shares held in escrow, including, without limitation, shares issued as a result of stock splits, stock dividends or other
recapitalizations (&#147;<U>Retained</U><U> </U><U>Distributions</U>&#148;) also be held in escrow in the same manner as the Granted Shares and all Retained Distributions shall be forfeited to the Company or released from escrow and delivered to the
Participant, as the case may be, at such time and in such manner as the Granted Shares to which such Retained Distributions so relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Prohibition on Transfer</U>. The Participant recognizes and agrees that all Granted Shares and Retained Distributions which are subject
to the Lapsing Forfeiture Right may not be sold, transferred, assigned, hypothecated, pledged, encumbered or otherwise disposed of, whether voluntarily or by operation of law, other than to the Company (or its designee). However, the Participant,
with the approval of the Administrator, may transfer the Granted Shares and Retained Distributions for no consideration to or for the benefit of the Participant&#146;s Immediate Family (including, without limitation, to a trust for the benefit of
the Participant&#146;s Immediate Family or to a partnership or limited liability company for one or more members of the Participant&#146;s Immediate Family), subject to such limits as the Administrator may establish, and the transferee shall remain
subject to all the terms and conditions applicable to this Agreement prior to such transfer and each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such transfer. The term &#147;Immediate Family&#148; shall mean the Participant&#146;s spouse,
former spouse, parents, children, stepchildren, adoptive relationships, sisters, brothers, nieces and nephews and grandchildren (and, for this purpose, shall also include the Participant. The Company shall not be required to transfer any Granted
Shares or Retained Distributions on its books which shall have been sold, assigned or otherwise transferred in violation of this Subsection 2.1(d), or to treat as the owner of such Granted Shares or Retained Distributions, or to accord the right to
vote as such owner or to pay dividends to, any person or organization to which any such Granted Shares or Retained Distributions shall have been so sold, assigned or otherwise transferred, in violation of this Subsection 2.1(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Failure to Deliver Granted Shares to be Forfeited</U>. In the event that the Granted Shares to be forfeited to the Company under this
Agreement are not in the Company&#146;s possession pursuant to Subsection 2.1(e) above or otherwise and the Participant or the Participant&#146;s Survivor fails to deliver such Granted Shares to the Company (or its designee), the Company may
immediately take such action as is appropriate to transfer record title of such Granted Shares from the Participant to the Company (or its designee) and to treat the Participant and such Granted Shares in all respects as if delivery of such Granted
Shares had been made as required by this Agreement. The Participant hereby irrevocably grants the Company a power of attorney which shall be coupled with an interest for the purpose of effectuating the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) [<U>Change of Control</U>. Upon the closing of a Change in Control (as defined below) of the Company, the vesting schedule of the Granted
Shares shall be accelerated in full and the Company&#146;s Lapsing Forfeiture Right shall have lapsed as to all Granted Shares upon the closing of such Change of Control.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Adjustments</U>. The Plan contains provisions covering the treatment of Shares in a number of contingencies such as stock splits and
mergers. Provisions in the Plan for adjustment with respect to the Granted Shares and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) [<U>Certain Definition</U>. As used herein, a &#147;<U>Change of Control</U>&#148; means the occurrence of any of the following
events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any &#147;Person&#148; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the
&#147;Beneficial Owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the
Company&#146;s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its Affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related
transactions which the Board of Directors does not approve; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A) A merger or consolidation of the Company whether or not approved by the Board of Directors, other than a
merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of the surviving entity or the parent of such entity) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such
corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B)&nbsp;the sale or disposition by the Company of all or substantially all of the Company&#146;s assets in a transaction requiring stockholder approval;
or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A change in the composition of the Board of Directors, as a result of which less than a majority of the
directors are Incumbent Directors. &#147;Incumbent Directors&#148; shall mean directors who either (A)&nbsp;are directors of the Company as of January&nbsp;1, 2019, or (B)&nbsp;are elected, or nominated for election, to the Board of Directors with
the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating
to the election of directors to the Company). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For clarity, &#147;Change of Control&#148; shall be interpreted, if applicable, in a manner, and limited to the
extent necessary, so that it will not cause adverse tax consequences under Section&nbsp;409A of the Code.] </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2
<U>General Restrictions on Transfer of Granted Shares</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Limitations on Transfer</U>. In addition to the restrictions set forth
above in Section&nbsp;2.1, the Granted Shares issued to the Participant hereunder and no longer subject to the Lapsing Forfeiture Right described in Section&nbsp;2.1 herein (the &#147;Vested Shares&#148;) shall not be transferred by the Participant
except as permitted herein, shall be subject to the provisions of Sections 2.1(d), (e) and (f)&nbsp;above and shall be subject to the repurchase rights described in this Section&nbsp;2.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Right to Repurchase following Termination of Service</U>. In the event of the Participant&#146;s Termination for any reason, including
due to death or Disability, then the Company shall have the option to repurchase the Vested Shares not previously forfeited to the Company in accordance with the provisions of Section&nbsp;2.1 of this Agreement as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company&#146;s option to repurchase the Vested Shares in the event of Termination under this Section&nbsp;2.2(b) shall
be valid for a period of one year commencing with the date of such Termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) In the event the Company shall be
entitled to and shall elect to exercise its option to repurchase the Vested Shares under this Section&nbsp;2.2(b), the Company shall notify the Participant, or in case of death, his or her Survivor, in writing of its intent to repurchase the Vested
Shares. Such written notice may be mailed by the Company up to and including the last day of the time period provided for in Section&nbsp;2.2(b)(i) for exercise of the Company&#146;s option to repurchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The written notice to the Participant shall specify the address at,
and the time and date on, which payment of the Repurchase Price (as hereinafter defined) is to be made (the &#147;Post-Termination Repurchase Closing&#148;). The date specified shall not be less than ten days nor more than 60 days from the date of
the mailing of the notice, and the Participant or the Participant&#146;s Survivor with respect to the Vested Shares shall have no further rights as the owner thereof from and after the date specified in the notice. At the Post-Termination Repurchase
Closing, the Repurchase Price shall be delivered to the Participant or the Participant&#146;s Survivor and the Vested Shares being purchased, duly endorsed for transfer, shall, to the extent that they are not then in the possession of the Company,
be delivered to the Company by the Participant or the Participant&#146;s Survivor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) The price paid per share for any
Vested Shares repurchased hereunder (the &#147;Repurchase Price&#148;) shall equal the Fair Market Value of such Vested Shares determined in accordance with the Plan as of the date of Termination, provided, however, in the event of a Termination for
Cause, the Repurchase Price of the Vested Shares to be repurchased by the Company upon exercise of its option under this Section&nbsp;2.2(b) shall be equal to $0.00001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Right to Repurchase on Proposed Transfer</U>. It shall be a condition precedent to the validity of any sale or other transfer of any
Vested Shares by the Participant that the following restrictions be complied with (except as hereinafter otherwise provided): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) No Vested Shares owned by the Participant may be sold, pledged or otherwise transferred (including by gift or devise) to
any person or entity, voluntarily, or by operation of law, except in accordance with the terms and conditions hereinafter set forth. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Before selling or otherwise transferring all or part of the Vested Shares, the Participant shall give written notice of
such intention to the Company which notice shall include the name of the proposed transferee, the proposed purchase price per share, the terms of payment of such purchase price and all other matters relating to such sale or transfer and shall be
accompanied by a copy of the binding written agreement of the proposed transferee to purchase the Vested Shares of the Participant. Such notice shall constitute a binding offer by the Participant to sell to the Company such number of the Vested
Shares then held by the Participant as are proposed to be sold in the notice at the monetary price per share designated in such notice, payable on the terms offered to the Participant by the proposed transferee (provided, however, that the Company
shall not be required to meet any <FONT STYLE="white-space:nowrap">non-monetary</FONT> terms of the proposed transfer, including, without limitation, delivery of other securities in exchange for the Vested Shares proposed to be sold). The Company
shall give written notice to the Participant as to whether such offer has been accepted in whole by the Company within 60 days after its receipt of written notice from the Participant. The Company may only accept such offer in whole and may not
accept such offer in part. Such acceptance notice shall fix a time, location and date for the closing on such purchase (the &#147;Transfer Repurchase Closing&#148;) which shall not be less than ten nor more than 60 days after the giving of the
acceptance notice, provided, however, if any of the Vested Shares to be sold pursuant to this Section&nbsp;2.2(c) have been held by the <B>Participant </B>for less than six months, then the Transfer Repurchase Closing may be extended by the Company
until no more than ten days after such Vested Shares have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
held by the <B>Participant </B>for six months. At the Transfer Repurchase Closing, the Participant shall accept payment as set forth herein and shall deliver to the Company in exchange therefor
the Vested Shares being repurchased, duly endorsed for transfer, to the extent that they are not then in the possession of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) If the Company shall fail to accept any such offer, the Participant shall be free to sell all, but not less than all, of
the Vested Shares set forth in his or her notice to the designated transferee at the price and terms designated in the Participant&#146;s notice, provided that (a)&nbsp;such sale is consummated within six months after the giving of notice by the
Participant to the Company as aforesaid, and (b)&nbsp;the transferee first agrees in writing to be bound by the provisions of this Section&nbsp;2.2(c) so that he or she (and all subsequent transferees) shall thereafter only be permitted to sell or
transfer the Vested Shares in accordance with the terms hereof. After the expiration of such six months, the provisions of this Section&nbsp;2.2(c) shall again apply with respect to any proposed voluntary transfer of the Vested Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) The provisions of this Section&nbsp;2.2(c) may be waived by the Company. Any such waiver may be unconditional or based
upon such conditions as the Company may impose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) The restrictions on transfer contained in this Section&nbsp;2.2(c)
shall not apply to (a)&nbsp;transfers by the Participant to his or her spouse or children or to a trust for the benefit of his or her spouse or children, (b)&nbsp;transfers by the Participant to his or her guardian or conservator, or
(c)&nbsp;transfers by the Participant, in the event of his or her death, to his or her executor(s) or administrator(s) or to trustee(s) under his or her will (collectively, &#147;Permitted Transferees&#148;); provided however, that in any such event
the Vested Shares so transferred in the hands of each such Permitted Transferee shall remain subject to this Agreement, and each such Permitted Transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such
transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The provisions of Section&nbsp;2.2(a) through (c)&nbsp;shall terminate upon the effective date of the registration of the
Shares pursuant to the Exchange Act consummation of a public offering of any of the Company&#146;s securities pursuant to a registration statement filed with the Securities and Exchange Commission pursuant to the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Participant agrees that in the event the Company proposes to offer for sale to the public any of its equity securities and such
Participant is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting the sale or other transfer of Shares, then it will promptly sign such agreement and will not
transfer, whether in privately negotiated transactions or to the public in open market transactions or otherwise, any Shares or other securities of the Company held by him or her during such period as is determined by the Company and the
underwriters, not to exceed 180 days following the closing of the offering, plus such additional period of time as may be required to comply with NASD Marketplace Rule 2711 or similar rules thereto (such period, the
<FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;). Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company and such underwriter and pursuant to customary and prevailing terms and
conditions. Notwithstanding whether the Participant has signed such an agreement, the Company may impose stop-transfer instructions with respect to the Shares or other securities of the Company subject to the foregoing restrictions until the end of
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Participant acknowledges and agrees that neither the Company, its shareholders nor
its directors and officers, has any duty or obligation to disclose to the Participant any material information regarding the business of the Company or affecting the value of the Shares before, at the time of, or following the Participant&#146;s
Termination, including, without limitation, any information concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another firm or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Purchase for Investment; Securities Law Compliance</U>. The Participant hereby represents and warrants that he or she is acquiring the
Granted Shares for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Granted Shares. The Participant specifically acknowledges and agrees that any sales of Granted Shares
shall be made in accordance with the requirements of the Securities Act, in a transaction as to which the Company shall have received an opinion of counsel satisfactory to it confirming such compliance. The Participant shall be bound by the
provisions of the following legend which shall be endorsed upon the certificate(s) evidencing the Granted Shares: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES
REPRESENTED BY THIS CERTIFICATE HAVE BEEN TAKEN FOR INVESTMENT AND THEY MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1)&nbsp;EITHER (A) A REGISTRATION STATEMENT WITH RESPECT TO SUCH SHARES SHALL BE EFFECTIVE
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)&nbsp;THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO IT THAT AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT IS THEN AVAILABLE, AND (2)&nbsp;THERE SHALL HAVE BEEN COMPLIANCE
WITH ALL APPLICABLE STATE SECURITIES LAWS.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Legend</U>. In addition to any legend required pursuant to the Plan, all
certificates representing the Granted Shares issued to the Participant pursuant to this Agreement shall have endorsed thereon a legend substantially as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS SET FORTH IN A RESTRICTED STOCK AGREEMENT DATED AS
OF<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U> WITH THIS COMPANY, A COPY OF WHICH AGREEMENT IS AVAILABLE FOR INSPECTION AT THE
OFFICES OF THE COMPANY OR WILL BE MADE AVAILABLE UPON REQUEST.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Rights as a Stockholder</U>. The Participant shall have all
the rights of a stockholder with respect to the Granted Shares, including voting and dividend rights, subject to the transfer and other restrictions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Incorporation of the Plan</U>. The Participant specifically understands and agrees that the Granted Shares issued under the Plan are
being sold to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has read and understands and by which Plan he or she agrees to be bound. The provisions of the Plan are incorporated herein by reference.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax Liability of the Participant and Payment of Taxes</U>. The Participant
acknowledges and agrees that any income or other taxes due from the Participant with respect to the Granted Shares issued pursuant to this Agreement, including, without limitation, the Lapsing Forfeiture Right, shall be the Participant&#146;s
responsibility. Without limiting the foregoing, the Participant agrees that, to the extent that the lapsing of restrictions on disposition of any of the Granted Shares or the declaration of dividends on any such shares before the lapse of such
restrictions on disposition results in the Participant&#146;s being deemed to be in receipt of earned income under the provisions of the Code, the Company shall be entitled to immediate payment from the Participant of the amount of any tax required
to be withheld by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of this Agreement, the Participant may file an election under Section&nbsp;83 of the Code
in substantially the form attached as <U>Exhibit A</U>. The Participant acknowledges that if he or she does not file such an election, as the Granted Shares are released from the Lapsing Forfeiture Right in accordance with Section&nbsp;2.1, the
Participant will have income for tax purposes equal to the Fair Market Value of the Granted Shares at such date, less the price paid for the Granted Shares by the Participant. The Participant has been given the opportunity to obtain the advice of
his or her tax advisors with respect to the tax consequences of the purchase of the Granted Shares and the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Participant has not filed an election under Section&nbsp;83 of the Code, the Participant shall be required to deposit with the Company
an amount of cash equal to the amount determined by the Company to be required with respect to the statutory minimum of the Participant&#146;s estimated total federal, state and local tax obligations associated with the termination of the Lapsing
Forfeiture Right with respect to the Granted Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Equitable Relief</U>. The Participant specifically acknowledges and agrees
that in the event of a breach or threatened breach of the provisions of this Agreement or the Plan, including the attempted transfer of the Granted Shares by the Participant in violation of this Agreement, monetary damages may not be adequate to
compensate the Company, and, therefore, in the event of such a breach or threatened breach, in addition to any right to damages, the Company shall be entitled to equitable relief in any court having competent jurisdiction. Nothing herein shall be
construed as prohibiting the Company from pursuing any other remedies available to it for any such breach or threatened breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>No
Obligation to Maintain Relationship</U>. The Participant acknowledges that: (i)&nbsp;the Company is not by the Plan or this Agreement obligated to continue the Participant as an Employee, director or Consultant of the Company or an Affiliate;
(ii)&nbsp;the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (iii)&nbsp;the grant of the Granted Shares is a <FONT STYLE="white-space:nowrap">one-time</FONT> benefit which does not create any
contractual or other right to receive future grants of Shares, or benefits in lieu of Shares; (iv)&nbsp;all determinations with respect to any such future grants, including, but not limited to, the times when Shares shall be granted, the number
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Shares to be granted, the purchase price, and the time or times when each Share shall be free from a lapsing repurchase or forfeiture right, will be at the sole discretion of the Company;
(v)&nbsp;the Participant&#146;s participation in the Plan is voluntary; (vi)&nbsp;the value of the Granted Shares is an extraordinary item of compensation which is outside the scope of the Participant&#146;s employment contract, if any; and
(vii)&nbsp;the Granted Shares are not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar
payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized
courier service, facsimile, registered or certified mail, return receipt requested, addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aura Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">85 Bolton
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Participant: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address or addresses of which notice in the same
manner has previously been given. Any such notice shall be deemed to have been given on the earliest of receipt, one business day following delivery by the sender to a recognized courier service, or three business days following mailing by
registered or certified mail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Benefit of Agreement</U>. Subject to the provisions of the Plan and the other provisions hereof,
this Agreement shall be for the benefit of and shall be binding upon the heirs, executors, administrators, successors and assigns of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Governing Law</U>. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving
effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in Massachusetts and agree that such
litigation shall be conducted in the state courts of Massachusetts or the federal courts of the United States for the First District. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.
<U>Severability</U>. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and
enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality and enforceability of the rest of this Agreement shall not be affected thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Entire Agreement</U>. This Agreement, together with the Plan, constitutes the entire
agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict the express terms and provisions of this Agreement provided, however, in any event, this Agreement shall be subject to and
governed by the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Modifications and Amendments; Waivers and Consents</U>. The terms and provisions of this Agreement may be
modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the
benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall
be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Consent of Spouse/Domestic Partner</U>. If the Participant has a spouse or a domestic partner as of the date of this Agreement, the
Participant&#146;s spouse or domestic partner shall execute a Consent of Spouse/Domestic Partner in the form of <U>Exhibit B</U> hereto, effective as of the date hereof. Such consent shall not be deemed to confer or convey to the spouse or domestic
partner any rights in the Granted Shares that do not otherwise exist by operation of law or the agreement of the parties. If the Participant subsequent to the date hereof, marries, remarries or applies to the Company for domestic partner benefits,
the Participant shall, not later than 60 days thereafter, obtain his or her new spouse&#146;s/domestic partner&#146;s acknowledgement of and consent to the existence and binding effect of all restrictions contained in this Agreement by having such
spouse/domestic partner execute and deliver a Consent of Spouse/Domestic Partner in the form of <U>Exhibit B</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.
<U>Counterparts</U>. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Data Privacy</U>. By entering into this Agreement, the Participant: (i)&nbsp;authorizes the Company and each
Affiliate, and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall
request in order to facilitate the grant of Shares and the administration of the Plan; and (ii)&nbsp;authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[THE NEXT PAGE IS THE SIGNATURE PAGE] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AURA BIOSCIENCES, INC.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PARTICIPANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Print name:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>EXHIBIT A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Election to Include Gross Income in Year </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of Transfer Pursuant to Section&nbsp;83(b) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of the Internal Revenue Code of 1986, as amended </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Section&nbsp;83(b) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), the undersigned hereby elects to include in his
gross income as compensation for services the excess, if any, of the fair market value of the property (described below) at the time of transfer over the amount paid for such property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following sets forth the information required in accordance with the Code and the regulations promulgated thereunder: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The name, address and social security number of the undersigned are: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Name: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Address: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Social Security No.:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The description of the property with respect to which the election is being made is as follows:
</P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>) shares (the &#147;Shares&#148;) of Common Stock, $0.00001 par value per share, of AURA BIOSCIENCES, INC., a Delaware corporation (the &#147;Company&#148;). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This election is made for the calendar year 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, with respect to the transfer of
the property to the taxpayer on<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Description of restrictions: The property is subject to the following restrictions: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event the taxpayer&#146;s service with the Company or an affiliate of the Company is terminated (the &#147;Termination&#148;), the
taxpayer shall forfeit the Shares as set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If the Termination takes place
after<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, the number of Shares forfeited shall be <U></U><U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> minus 6.25%
for each full quarter elapsed after<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20__ that the taxpayer was employed by the Company or an affiliate of the Company or provided services as a consultant to or director
of the Company or an affiliate of the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair market value at the time of transfer (determined without regard to any restrictions other than
restrictions which by their terms will never lapse) of the property with respect to which this election is being made was not more than $.0001 per Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount paid by taxpayer for said property was $.0001 per Share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of this statement has been furnished to the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signed this<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>day
of<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000">Print Name:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>EXHIBIT B </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CONSENT OF SPOUSE/DOMESTIC PARTNER </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I,&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, spouse or domestic partner of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
acknowledge that I have read the RESTRICTED STOCK AGREEMENT dated as of<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20__ (the &#147;Agreement&#148;) to which this
Consent is attached as <U>Exhibit B</U> and that I know its contents. Capitalized terms used and not defined herein shall have the meanings assigned to such terms in the Agreement. I am aware that by its provisions the Granted Shares granted to my
spouse/domestic partner pursuant to the Agreement are subject to a Lapsing Forfeiture Right in favor of Aura Biosciences, Inc. (the &#147;Company&#148;) and that, accordingly, I may be required to forfeit to the Company any or all of the Granted
Shares of which I may become possessed as a result of a gift from my spouse/domestic partner or a court decree and/or any property settlement in any domestic litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby agree that my interest, if any, in the Granted Shares subject to the Agreement shall be irrevocably bound by the Agreement and
further understand and agree that any community property interest I may have in the Granted Shares shall be similarly bound by the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I agree to the Lapsing Forfeiture Right described in the Agreement and I hereby consent to the forfeiture of the Granted Shares to the Company
by my spouse/domestic partner or my spouse/domestic partner&#146;s legal representative in accordance with the provisions of the Agreement. Further, as part of the consideration for the Agreement, I agree that at my death, if I have not disposed of
any interest of mine in the Granted Shares by an outright bequest of the Granted Shares to my spouse/domestic partner, then the Company shall have the same rights against my legal representative to exercise its rights to the Granted Shares with
respect to any interest of mine in the Granted Shares as it would have had pursuant to the Agreement if I had acquired the Granted Shares pursuant to a court decree in domestic litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I AM AWARE THAT THE LEGAL, FINANCIAL AND RELATED MATTERS CONTAINED IN THE AGREEMENT ARE COMPLEX AND THAT I AM FREE TO SEEK INDEPENDENT
PROFESSIONAL GUIDANCE OR COUNSEL WITH RESPECT TO THIS CONSENT. I HAVE EITHER SOUGHT SUCH GUIDANCE OR COUNSEL OR DETERMINED AFTER REVIEWING THE AGREEMENT CAREFULLY THAT I WILL WAIVE SUCH RIGHT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dated as of the<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>day
of<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000">Print name:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>7
<FILENAME>d209588dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#147;[***]&#148;. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE NATIONAL INSTITUTES OF HEALTH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PATENT LICENSE AGREEMENT - </B><B><I>EXCLUSIVE</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COVER PAGE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <B>NIH </B>internal use
only: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>License Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013/0</FONT></FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">License Application Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A-098-2012</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Serial Number(s) of Licensed Patent(s) or Patent Application(s): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Licensee: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Aura Biosciences, Inc. 85 Bolton Street Cambridge, MA 02140 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Additional Remarks: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Public
Benefit(s): The treatment, diagnosis and imaging of cancer tumors and metastases as well as their respective <FONT STYLE="white-space:nowrap">pre-cursor</FONT> dysplasia states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Patent License Agreement, hereinafter referred to as the <B>&#147;Agreement&#148;, </B>consists of this Cover Page, an attached <B>Agreement, </B>a
Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty
Report), and Appendix G (Royalty Payment Options). The Parties to this <B>Agreement </B>are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The National Institutes of Health <B>(&#147;NIH&#148;), </B>an agency of the United States Public Health
Service within the Department of Health and Human Services <B>(&#147;HHS&#148;); </B>and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The person, corporation, or institution identified above or on the Signature Page, having offices at the
address indicated on the Signature Page, hereinafter referred to as the <B>&#147;Licensee&#148;.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <B>NIH </B>and the <B>Licensee
</B>agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>BACKGROUND</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the course of conducting biomedical and behavioral research, the NIH or the <B>FDA </B>investigators made
inventions that may have commercial applicability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By assignment of rights from <B>NIH </B>or <B>FDA </B>employees and other inventors, <B>HHS, </B>on behalf of
the <B>Government, </B>owns intellectual property rights claimed in any United States or foreign patent applications or patents corresponding to the assigned inventions. <B>HHS </B>also owns any tangible embodiments of these inventions actually
reduced to practice by the <B>NIH </B>of the <B>FDA.</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 1 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Secretary of <B>HHS </B>has delegated to the <B>NIH </B>the authority to enter into this <B>Agreement
</B>for the licensing of rights to these inventions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>desires to transfer these inventions to the private sector through commercialization licenses to
facilitate the commercial development of products and processes for public use and benefit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>DEFINITIONS</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Affiliate(s)&#148; </B>means a corporation or other business entity, which directly or indirectly is
controlled by or controls, or is under common control with the <B>Licensee. </B>For this purpose, the term &#147;control&#148; shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the corporation
or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Benchmarks&#148; </B>mean the <B>performance</B> milestones that are set forth in Appendix D.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Commercial Development Plan&#148; </B>means <B>the</B> written commercialization plan attached as
Appendix E. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;CRADA&#148; </B>means a <B>Cooperative</B> Research and Development Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;FDA&#148; </B>means the <B>Food</B> and Drug Administration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;First Commercial Sale&#148; </B>means the <B>initial</B> transfer by or on behalf of the <B>Licensee
</B>or its sublicensees of the <B>Licensed Products </B>or the initial practice of a <B>Licensed Process </B>by or on behalf of the <B>Licensee </B>or its sublicensees in exchange for cash or some equivalent to which value can be assigned for the
purpose of determining <B>Net Sales.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Government&#148; </B>means the <B>Government</B> of the United States of America.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Fields of Use&#148; </B>means the <B>fields</B> of use identified in Appendix B.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Patent Rights&#148; </B>shall <B>mean</B>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.9(a): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> of
2.9(a); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all divisions and continuations of these
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part;</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all patents issuing from these
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, and continuations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">priority patent application(s) of 2.9(a); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 2 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any reissues, reexaminations, and extensions of these patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.9(a): all counterpart foreign and U.S. patent applications and patents to 2.9(a) and 2.9(b), including those listed in Appendix A; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensed Patent Rights </B>shall <I>not</I> include 2.9(b) or 2.9(c) to the extent that they contain one or
more claims directed to new matter which is not the subject matter disclosed in 2.9(a). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Processes&#148; </B>means processes which, in the course of being practiced, would be within
the scope of one or more claims of the <B>Licensed Patent Rights </B>that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Products&#148; </B>means tangible materials which, in the course of manufacture, use, sale,
or importation, would be within the scope of one or more claims of the <B>Licensed Patent Rights </B>that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Territory&#148; </B>means the geographical area identified in Appendix B.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Net Sales&#148; </B>means [***] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Practical Application&#148; </B>means to manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or
<B>Government </B>regulations available to the public on reasonable terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Research License&#148; </B>means a nontransferable, nonexclusive license to make and to use the
<B>Licensed Products </B>or the <B>Licensed Processes </B>as defined by the <B>Licensed Patent Rights </B>for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>GRANT OF RIGHTS</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>hereby grants and the <B>Licensee </B>accepts, subject to the terms and conditions of this
<B>Agreement, </B>an exclusive license under the <B>Licensed Patent Rights </B>in the <B>Licensed Territory </B>to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any <B>Licensed Products </B>in the
<B>Licensed Fields of Use </B>and to practice and have practiced any <B>Licensed Process(es) </B>in the <B>Licensed Fields of Use.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This <B>Agreement </B>confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the <B>NIH </B>other than the <B>Licensed Patent Rights </B>regardless of whether these patents are dominant or subordinate to the <B>Licensed Patent Rights.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>SUBLICENSING</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon written approval, which shall include prior review of any sublicense agreement by the <B>NIH </B>and which
shall not be unreasonably withheld, the <B>Licensee </B>may enter into sublicensing agreements under the <B>Licensed Patent Rights.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees that any sublicenses granted by it shall provide that the obligations to the <B>NIH
</B>of Paragraphs <FONT STYLE="white-space:nowrap">5.1-5.4,</FONT> 8.1, 10.1, 10.2, 12.5, and <FONT STYLE="white-space:nowrap">13.8-13.10</FONT> of this <B>Agreement </B>shall be binding upon the sublicensee as if it were a party to this
<B>Agreement</B>. The <B>Licensee </B>further agrees to attach copies of these Paragraphs to all sublicense agreements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 3 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any sublicenses granted by the <B>Licensee </B>shall provide for the termination of the sublicense, or the
conversion to a license directly between the sublicensees and the NIH, at the option of the sublicensee, upon termination of this <B>Agreement </B>under Article 13. This conversion is subject to the NIH approval and contingent upon acceptance by the
sublicensee of the remaining provisions of this <B>Agreement</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to forward to the <B>NIH </B>a complete copy of each fully executed sublicense
agreement postmarked within [***] of the execution of the agreement. To the extent permitted by law, the <B>NIH </B>agrees to maintain each sublicense agreement in confidence. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">(a)&#8195;&#8201;&#8202;the <B>NIH </B>reserves on behalf of the <B>Government </B>an irrevocable,
nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed under the <B>Licensed Patent Rights </B>throughout the world by or on behalf of the <B>Government </B>and on behalf of any foreign government or
international organization pursuant to any existing or future treaty or agreement to which the <B>Government </B>is a signatory. Prior to the <B>First Commercial Sale, </B>the <B>Licensee </B>agrees to provide the <B>NIH </B>with reasonable
quantities of the <B>Licensed Products </B>or materials made through the <B>Licensed Processes </B>for NIH research use; and</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that the <B>Licensed Patent Rights </B>are Subject Inventions made under <B>CRADA, </B>the
<B>Licensee </B>grants to the <B>Government, </B>pursuant to <U>15 U.S.C. &#167;3710a(b)(l)(A)</U>, a nonexclusive, nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license to practice the <B>Licensed Patent Rights
</B>or have the <B>Licensed Patent Rights </B>practiced throughout the world by or on behalf of the <B>Government. </B>In the exercise of this license, the <B>Government </B>shall not publicly disclose trade secrets or commercial or financial
information that is privileged or confidential within the meaning of <U>5 U.S.C. &#167;552(b)(4)</U> or which would be considered as such if it had been obtained from a <FONT STYLE="white-space:nowrap">non-Federal</FONT> party. Prior to the <B>First
Commercial Sale, </B>the <B>Licensee </B>agrees to provide the <B>NIH </B>with reasonable quantities of the <B>Licensed Products </B>or materials made through the <B>Licensed Processes </B>for <B>NIH </B>research use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee</B> agrees that products used or sold in the United States embodying the <B>Licensed Products
</B>or produced through use of the <B>Licensed Processes </B>shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the <B>NIH.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>acknowledges that the <B>NIH </B>may enter into future <B>CRADAs </B>under the <U>Federal
Technology Transfer Act of 1986</U> that relate to the subject matter of this <B>Agreement. </B>The <B>Licensee </B>agrees not to unreasonably deny requests for a <B>Research License </B>from future collaborators with the <B>NIH </B>when acquiring
these rights is necessary in order to make a <B>CRADA </B>project feasible. The <B>Licensee </B>may request an opportunity to join as a party to the proposed <B>CRADA.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">(a)&#8195;&#8201;&#8202;in addition to the reserved license of Paragraph 5.1, the <B>NIH
</B>reserves the right to grant <B>Research Licenses </B>directly or to require the <B>Licensee </B>to grant <B>Research Licenses </B>on reasonable terms. The purpose of these <B>Research Licenses </B>is to encourage basic research, whether
conducted at an academic or corporate facility. In order to safeguard the <B>Licensed Patent Rights, </B>however, the <B>NIH </B>shall consult with the <B>Licensee </B>before granting to commercial entities a <B>Research License </B>or providing to
them research samples of materials made through the <B>Licensed Processes; </B>and</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 4 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in exceptional circumstances, and in the event that the <B>Licensed Patent Rights </B>are Subject Inventions
made under a <B>CRADA, </B>the <B>Government, </B>pursuant to <U>15 U.S.C. &#167;3710a(b)(T)(B)</U>, retains the right to require the <B>Licensee </B>to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to
use the <B>Licensed Patent Rights </B>in the <B>Licensed Field of Use </B>on terms that are reasonable under the circumstances, or if the <B>Licensee </B>fails to grant this license, the <B>Government </B>retains the right to grant the license
itself. The exercise of these rights by the <B>Government </B>shall only be in exceptional circumstances and only if the <B>Government </B>determines: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the action is necessary to meet health or safety needs that are not reasonably satisfied by the
<B>Licensee;</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the action is necessary to meet requirements for public use specified by Federal regulations, and these
requirements are not reasonably satisfied by the <B>Licensee; </B>o </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <B>Licensee </B>has failed to comply with an agreement containing provisions described in <U>15 U.S.C.
&#167;3710a(c)(4)(B)</U>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the determination made by the <B>Government </B>under this Paragraph 5.4 is subject to administrative appeal
and judicial review under <U>35 U.S.C. &#167;203(b).</U> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>ROYALTIES AND REIMBURSEMENT</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to pay the <B>NIH </B>a noncreditable, nonrefundable license issue royalty as set
forth in Appendix C. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to pay the <B>NIH </B>a nonrefundable minimum annual royalty as set forth in
Appendix C. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to pay the <B>NIH </B>earned royalties as set forth in Appendix C.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to pay the <B>NIH </B>benchmark royalties as set forth in Appendix C.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to pay the <B>NIH </B>sublicensing royalties as set forth in Appendix C.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A patent or patent <B>application</B> licensed under this <B>Agreement </B>shall cease to fall within the
<B>Licensed Patent Rights </B>for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the application has been abandoned and not continued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the patent expires or irrevocably lapses, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No multiple royalties shall be payable because any <B>Licensed Products </B>or <B>Licensed Processes </B>are
covered by more than one of the <B>Licensed Patent Rights.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On sales of the <B>Licensed Products </B>by the <B>Licensee </B>to sublicensees or on sales made in other than
an arms-length transaction, the value of the <B>Net Sales </B>attributed under this Article 6 to this transaction shall be that which would have been received in an arms-length transaction, based on sales of like quantity and quality products on or
about the time of this transaction. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 5 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the <B>Licensed Patent Rights </B>and paid by the <B>NIH </B>prior to the effective date of this <B>Agreement, </B>the <B>Licensee </B>shall pay the <B>NIH, </B>as an additional royalty, within
sixty (60)&nbsp;days of the <B>NIH&#146;s </B>submission of a statement and request for payment to the <B>Licensee, </B>an amount equivalent to [***] of these unreimbursed expenses previously paid by the NIH, [***] of the remaining balance due
ninety (90)<U></U>&nbsp;days from the NIH&#146;s initial submission of a statement and request for payment and the remaining balance (i.e. [***] due One Hundred Twenty (120)<U></U>&nbsp;days from the NIH&#146;s initial submission of a statement and
request for payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of
all patent applications and patents included within the <B>Licensed Patent Rights </B>and paid by the <B>NIH </B>on or after the effective date of this <B>Agreement, </B>the <B>NIH, </B>at its sole option, may require the <B>Licensee;</B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>agrees, upon written request, to provide the <B>Licensee </B>with summaries of patent
prosecution invoices for which the <B>NIH </B>has requested payment from the <B>Licensee </B>under Paragraphs 6.9 and 6.10. The <B>Licensee </B>agrees that all information provided by the <B>NIH </B>related to patent prosecution costs shall be
treated as confidential commercial information and shall not be released to a third party except as required by law or a court of competent jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>may elect to surrender its rights in any country of the <B>Licensed Territory </B>under any
of the <B>Licensed Patent Rights </B>upon ninety (90)&nbsp;days written notice to the <B>NIH </B>and owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after ninety (90)<U></U>&nbsp;days of the effective
date of the written notice. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>PATENT FILING, PROSECUTION, AND MAINTENANCE</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided in this Article 7, the <B>NIH </B>agrees to take responsibility for, but to
consult with, the <B>Licensee </B>in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the <B>Licensed Patent Rights </B>and shall furnish copies of relevant patent-related documents to
the <B>Licensee.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the <B>NIH&#146;s </B>written request, the <B>Licensee </B>shall assume the responsibility for the
preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the <B>Licensed Patent Rights </B>and shall, on an ongoing basis, promptly furnish copies of all patent-related documents to the <B>NIH.
</B>In this event, the <B>Licensee </B>shall, subject to the prior approval of the NIH, select registered patent attorneys or patent agents to provide these services on behalf of the <B>Licensee </B>and the <B>NIH. </B>The <B>NIH </B>shall provide
appropriate powers of attorney and other documents necessary to undertake this action to the patent attorneys or patent agents providing these services. The <B>Licensee </B>and its attorneys or agents shall consult with the <B>NIH </B>in all aspects
of the preparation, filing, prosecution and maintenance of patent applications and patents included within the <B>Licensed Patent Rights </B>and shall provide the <B>NIH </B>sufficient opportunity to comment on any document that the <B>Licensee
</B>intends to file or to cause to be filed with the relevant intellectual property or patent office. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any time, the <B>NIH </B>may provide the <B>Licensee </B>with written notice that the <B>NIH </B>wishes to
assume control of the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the <B>Licensed Patent Rights. </B>If the <B>NIH </B>elects to reassume these responsibilities, the <B>Licensee
</B>agrees to cooperate fully with the <B>NIH, </B>its attorneys, and agents in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the <B>Licensed Patent Rights </B>and to provide the
<B>NIH </B>with complete copies of any and all documents or other materials that the <B>NIH </B>deems necessary to undertake such responsibilities. The <B>Licensee </B>shall be responsible for all costs associated with transferring patent
prosecution responsibilities to an attorney or agent of the <B>NIH&#146;s </B>choice. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 6 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the <B>Licensed Patent Rights </B>and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the <B>Licensed Patent Rights,
</B>which comments and suggestions shall be considered by the other party. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>RECORD KEEPING</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to keep accurate and correct records of the <B>Licensed Products </B>made, used,
sold, or imported and the <B>Licensed Processes </B>practiced under this <B>Agreement </B>appropriate to determine the amount of royalties due the <B>NIH. </B>These records shall be retained for at least five (5)&nbsp;years following a given
reporting period and shall be available during normal business hours for inspection, at the expense of the NIH, by an accountant or other designated auditor selected by the <B>NIH </B>for the sole purpose of verifying reports and royalty payments
hereunder. The accountant or auditor shall be required to execute s a reasonable confidentiality agreement with <B>Licensee, </B>and shall only disclose to the NIH information relating to the accuracy of reports and royalty payments made under this
<B>Agreement. </B>If an inspection shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12)<U></U>&nbsp;month period, then the <B>Licensee </B>shall reimburse the <B>NIH </B>for the reasonable cost of the inspection
at the time the <B>Licensee </B>pays the unreported royalties, including any additional royalties as required by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within sixty (60)<U></U>&nbsp;days of the date the <B>NIH
</B>provides to the <B>Licensee </B>notice of the payment due. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to signing this <B>Agreement, </B>the <B>Licensee </B>has provided the <B>NIH </B>with the <B>Commercial
Development Plan </B>in Appendix E, under which the <B>Licensee </B>intends to bring the subject matter of the <B>Licensed Patent Rights </B>to the point of <B>Practical Application. </B>This <B>Commercial Development Plan </B>is hereby incorporated
by reference into this <B>Agreement. </B>Based on this plan, performance <B>Benchmarks </B>are determined as specified in Appendix D. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>shall provide written annual reports on [***] for each of the <B>Licensed Fields of Use
</B>within [***]. These progress reports shall include, but not be limited to: [***]. The <B>NIH </B>also encourages these reports to include information on any of the <B>Licensee&#146;s </B>public service activities that relate to the <B>Licensed
Patent Rights. </B>[***]<B>, </B>the <B>Licensee </B>shall [***]. In the annual report, the <B>Licensee </B>may [***]. The <B>Licensee </B>agrees to provide any additional information reasonably required by the <B>NIH </B>to evaluate the
<B>Licensee&#146;s </B>performance under this <B>Agreement. </B>The <B>Licensee </B>may amend the <B>Benchmarks </B>at any time upon written approval by the <B>NIH. </B>The <B>NIH </B>shall not unreasonably withhold approval of any request of the
<B>Licensee </B>to [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>shall report to the <B>NIH </B>the dates for achieving <B>Benchmarks </B>specified in
Appendix D and the <B>First Commercial Sale </B>in each country in the <B>Licensed Territory </B>within [***] of such occurrences. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>shall submit to the <B>NIH, </B>within [***] after each calendar half-year ending
June&nbsp;30 and December&nbsp;31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the <B>Licensed Products </B>sold or <B>Licensed Processes </B>practiced by or on behalf
of the <B>Licensee </B>in each country within the <B>Licensed Territory, </B>the <B>Net Sales, </B>and the amount of royalty accordingly due. With each royalty report, the <B>Licensee </B>shall submit payment of earned royalties due. If no earned
royalties are due to the <B>NIH </B>for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of the <B>Licensee </B>[***]. The royalty report shall also identify the site
of manufacture for the <B>Licensed Product(s) </B>sold in the United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 7 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to forward semi-annually to the <B>NIH </B>a copy of these reports received by the
<B>Licensee </B>from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to the <B>NIH </B>by the <B>Licensee </B>for activities under the sublicense. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in <I>The Wall Street Journal</I> on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the <B>Licensee. </B>The royalty report required by Paragraph 9.4 shall be mailed to the <B>NIH </B>at its address for <B>Agreement </B>Notices indicated on the
Signature Page. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>shall be solely responsible for determining if any tax on royalty income is owed outside
the United States and shall pay the tax and be responsible for all filings with appropriate agencies of foreign governments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional royalties may be assessed by the NIH on any payment that is more than ninety (90)&nbsp;days overdue
at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by the NIH of the overdue payment and additional royalties. The payment of any
additional royalties shall not prevent the NIH from exercising any other rights it may have as a consequence of the lateness of any payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All plans and reports required by this Article 9 and marked &#147;confidential&#148; by the <B>Licensee
</B>shall, to the extent permitted by law, be treated by the <B>NIH </B>as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the <B>NIH </B>under the
Freedom of Information Act (FOIA), <U>5 U.S.C. &#167;552</U> shall be subject to the predisclosure notification requirements of <U>45 C.F.R. &#167;5.65(d).</U> </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>PERFORMANCE</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>shall use its reasonable commercial efforts to bring the <B>Licensed Products </B>and the
<B>Licensed Processes </B>to <B>Practical Application. </B>&#147;Reasonable commercial efforts&#148; for the purposes of this provision shall include reasonable adherence to the <B>Commercial Development Plan </B>in Appendix E and performance of the
<B>Benchmarks </B>in Appendix D. The efforts of a sublicensee shall be considered the efforts of the <B>Licensee.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the <B>First Commercial Sale, </B>until the expiration or termination of this <B>Agreement, </B>the
<B>Licensee </B>shall use its reasonable commercial efforts to make the <B>Licensed Products </B>and the <B>Licensed Processes </B>reasonably accessible to the United States public. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees, after its <B>First Commercial Sale, </B>to use reasonable commercial efforts to
make reasonable quantities of the <B>Licensed Products </B>or materials produced through the use of the <B>Licensed Processes </B>available to patient assistance programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees, after its <B>First Commercial Sale </B>and as part of its marketing and product
promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the <B>Licensed Products </B>or medical aspects of the prophylactic and therapeutic uses of the <B>Licensed Products.</B>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 8 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to supply, to the Mailing Address for <B>Agreement </B>Notices indicated on the
Signature Page, the Office of Technology Transfer, <B>NIH </B>with inert samples of the <B>Licensed Products </B>or the <B>Licensed Processes </B>or their packaging for educational and display purposes only. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>INFRINGEMENT AND PATENT ENFORCEMENT</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>and the <B>Licensee </B>agree to notify each other promptly of each infringement or possible
infringement of the <B>Licensed Patent Rights, </B>as well as, any facts which may affect the validity, scope, or enforceability of the <B>Licensed Patent Rights </B>of which either party becomes aware. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to this <B>Agreement </B>and the provisions of 35 U.S.C. Chapter 29, the <B>Licensee </B>may:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the <B>Licensed Patent Rights;</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">settle any claim or suit for infringement of the <B>Licensed Patent Rights </B>provided, however, that the
<B>NIH </B>and appropriate <B>Government </B>authorities shall have the first right to take such actions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the <B>Licensee </B>desires to initiate a suit for patent infringement, the <B>Licensee </B>shall notify the
<B>NIH </B>in writing. If the <B>NIH </B>does not notify the <B>Licensee </B>of its intent to pursue legal action within ninety (90)&nbsp;days, the <B>Licensee </B>shall be free to initiate suit. The <B>NIH </B>shall have a continuing right to
intervene in the suit. The <B>Licensee </B>shall take no action to compel the <B>Government </B>either to initiate or to join in any suit for patent infringement. The <B>Licensee </B>may request the <B>Government </B>to initiate or join in any suit
if necessary to avoid dismissal of the suit. Should the <B>Government </B>be made a party to any suit, the <B>Licensee </B>shall reimburse the <B>Government </B>for any costs, expenses, or fees which the <B>Government </B>incurs as a result of the
motion or other action, including all costs incurred by the <B>Government </B>in opposing the motion or other action. In all cases, the <B>Licensee </B>agrees to keep the <B>NIH </B>reasonably apprised of the status and progress of any litigation.
Before the <B>Licensee </B>commences an infringement action, the <B>Licensee </B>shall notify the <B>NIH </B>and give careful consideration to the views of the <B>NIH </B>and to any potential effects of the litigation on the public health in
deciding whether to bring suit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that a declaratory judgment action alleging invalidity or
<FONT STYLE="white-space:nowrap">non-infringement</FONT> of any of the <B>Licensed Patent Rights </B>shall be brought against the <B>Licensee </B>or raised by way of counterclaim or affirmative defense in an infringement suit brought by the
<B>Licensee </B>under Paragraph 11.2, pursuant to this <B>Agreement </B>and the provisions of 35 U.S.C. Part 29 or other statutes, the <B>Licensee </B>may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
<B>Licensed Patent Rights;</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">settle any claim or suit for declaratory judgment involving the <B>Licensed Patent </B>Rights-provided,
however, that the <B>NIH </B>and appropriate <B>Government </B>authorities shall have the first right to take these actions and shall have a continuing right to intervene in the suit; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 9 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the <B>NIH </B>does not notify the <B>Licensee </B>of its intent to respond to the legal action within a
reasonable time, the <B>Licensee </B>shall be free to do so. The <B>Licensee </B>shall take no action to compel the <B>Government </B>either to initiate or to join in any declaratory judgment action. The <B>Licensee </B>may request the <B>Government
</B>to initiate or to join any suit if necessary to avoid dismissal of the suit. Should the <B>Government </B>be made a party to any suit by motion or any other action of the <B>Licensee, </B>the <B>Licensee </B>shall reimburse the <B>Government
</B>for any costs, expenses, or fees, which the <B>Government </B>incurs as a result of the motion or other action. If the <B>Licensee </B>elects not to defend against the declaratory judgment action, the NIH, at its option, may do so at its own
expense. In all cases, the <B>Licensee </B>agrees to keep the <B>NIH </B>reasonably apprised of the status and progress of any litigation. Before the <B>Licensee </B>commences an infringement action, the <B>Licensee </B>shall notify the <B>NIH
</B>and give careful consideration to the views of the <B>NIH </B>and to any potential effects of the litigation on the public health in deciding whether to bring suit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In any action under Paragraphs 11.2 or 11.3 the expenses including costs, fees, attorney fees, and
disbursements, shall be paid by the <B>Licensee. </B>The value of any recovery made by the <B>Licensee </B>through court judgment or settlement shall be treated as <B>Net Sales </B>and subject to earned royalties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>shall cooperate fully with the <B>Licensee </B>in connection with any action under Paragraphs
11.2 or 11.3. The <B>NIH </B>agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the <B>Licensee.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>NEGATION OF WARRANTIES AND INDEMNIFICATION</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>offers no warranties other than those specified in Article 1. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>does not warrant the validity of the <B>Licensed Patent Rights </B>and makes no representations
whatsoever with regard to the scope of the <B>Licensed Patent Rights, </B>or that the <B>Licensed Patent Rights </B>may be exploited without infringing other patents or other intellectual property rights of third parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">THE <B>NIH </B>MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE <B>LICENSED PATENT RIGHTS </B>OR TANGIBLE MATERIALS RELATED THERETO. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>does not represent that it shall commence legal actions against third parties infringing the
<B>Licensed Patent Rights.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>shall indemnify and hold the <B>NIH, </B>its employees, students, fellows, agents, and
consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the use by or on behalf of the <B>Licensee, </B>its sublicensees, directors, employees, or third parties of any
<B>Licensed Patent Rights; </B>or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the design, manufacture, distribution, or use of any <B>Licensed Products, Licensed Processes </B>or materials
by the <B>Licensee, </B>or other products or processes developed in connection with or arising out of the <B>Licensed Patent Rights.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to maintain a liability insurance program consistent with sound business practice.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 10 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>TERM, TERMINATION, AND MODIFICATION OF RIGHTS</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This <B>Agreement </B>is effective when signed by all parties, unless the provisions of Paragraph 14.16 are not
fulfilled, and shall extend to the expiration of the last to expire of the <B>Licensed Patent Rights </B>unless sooner terminated as provided in this Article 13. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the <B>Licensee </B>is in default in the performance of any material obligations under this
<B>Agreement, </B>including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90)&nbsp;days after the date of notice in writing of the default, the <B>NIH </B>may terminate this
<B>Agreement </B>by written notice and pursue outstanding royalties owed through procedures provided by the <U>Federal Debt Collection Act</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the <B>Licensee </B>becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a third party&#146;s intention to file an involuntary petition in bankruptcy, the <B>Licensee </B>shall immediately notify the <B>NIH </B>in writing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>shall have a unilateral right to terminate this <B>Agreement </B>or any licenses in any
country or territory by giving the <B>NIH </B>sixty (60)&nbsp;days written notice to that effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>shall specifically have the right to terminate or modify, at its option, this <B>Agreement,
</B>if the <B>NIH </B>determines that the <B>Licensee:</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not executing the <B>Commercial Development Plan </B>submitted with its request for a license and the
<B>Licensee </B>cannot otherwise demonstrate to the <B>NIH&#146;s </B>satisfaction that the <B>Licensee </B>has taken, or can be expected to take within a reasonable time, effective steps to achieve the <B>Practical Application </B>of the
<B>Licensed Products </B>or the <B>Licensed Processes;</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has not achieved the <B>Benchmarks </B>as may be modified under Paragraph 9.2; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has willfully made a false statement of, or willfully omitted a material fact in the license application or in
any report required by this <B>Agreement;</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has committed a material breach of a covenant or agreement contained in this <B>Agreement;</B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not keeping the <B>Licensed Products </B>or the <B>Licensed Processes </B>reasonably available to the public
after commercial use commences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cannot reasonably satisfy unmet health and safety needs; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless
waived. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In making the determination referenced in Paragraph 13.5, the <B>NIH </B>shall take into account the normal
course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the <B>Licensee </B>under Paragraph 9.2. Prior to invoking termination or modification of this
<B>Agreement </B>under Paragraph 13.5, the <B>NIH </B>shall give written notice to the <B>Licensee </B>providing the <B>Licensee </B>specific notice of, and a [***] opportunity to respond to, the NIH&#146;s concerns as to the items referenced in <FONT
STYLE="white-space:nowrap">13.5(a)-13.5(g).</FONT> If the <B>Licensee </B>fails to alleviate the <B>NIH&#146;s </B>concerns as to the items referenced in <FONT STYLE="white-space:nowrap">13.5(a)-13.5(g)</FONT> or fails to initiate corrective action
to the <B>NIH&#146;s </B>satisfaction, the <B>NIH </B>may terminate this <B>Agreement.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When the public health and safety so require, and after written notice to the <B>Licensee </B>providing the
<B>Licensee </B>a [***] opportunity to respond, the <B>NIH </B>shall have the right to require the <B>Licensee </B>to grant sublicenses to responsible applicants, on reasonable terms, in any <B>Licensed Fields of Use </B>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 11 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
under the <B>Licensed Patent Rights, </B>unless the <B>Licensee </B>can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of
the subject matter of the <B>Licensed Patent Rights. </B>The <B>NIH </B>shall not require the granting of a sublicense unless the responsible applicant has first negotiated in good faith with the <B>Licensee.</B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>reserves the right according to <U>35 U.S.C. 5209(d)(3)</U> to terminate or modify this
<B>Agreement </B>if it is determined that this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the
<B>Licensee.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within thirty (30)&nbsp;days of receipt of written notice of the <B>NIH&#146;s </B>unilateral decision to
modify or terminate this <B>Agreement, </B>the <B>Licensee </B>may, consistent with the provisions of <U>37 C.F.R. &#167;404.11</U>, appeal the decision by written submission to the designated <B>NIH </B>official. The decision of the designated the
<B>NIH </B>official shall be the final agency decision. The <B>Licensee </B>may thereafter exercise any and all administrative or judicial remedies that may be accessible. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within ninety (90)&nbsp;days of expiration or termination of this <B>Agreement </B>under this Article 13, a
final report shall be submitted by the <B>Licensee. </B>Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to the <B>NIH </B>shall become immediately
due and payable upon termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with the <B>NIH </B>pursuant to Paragraph 4.3. Unless otherwise specifically provided for
under this <B>Agreement, </B>upon termination or expiration of this <B>Agreement, </B>the <B>Licensee </B>shall return all <B>Licensed Products </B>or other materials included within the <B>Licensed Patent Rights </B>to the <B>NIH </B>or provide the
<B>NIH </B>with certification of the destruction thereof. The <B>Licensee </B>may not be granted additional <B>NIH </B>licenses if the final reporting requirement is not fulfilled. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>GENERAL PROVISIONS</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither party may waive or release any of its rights or interests in this <B>Agreement </B>except in writing.
The failure of the <B>Government </B>to assert a right hereunder or to insist upon compliance with any term or condition of this <B>Agreement </B>shall not constitute a waiver of that right by the <B>Government </B>or excuse a similar subsequent
failure to perform any of these terms or conditions by the <B>Licensee.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This <B>Agreement </B>constitutes the entire agreement between the parties relating to the subject matter of
the <B>Licensed Patent Rights, </B>the <B>Licensed Products </B>and the <B>Licensed Processes, </B>and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this
<B>Agreement.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this <B>Agreement </B>are severable, and in the event that any provision of this <B>Agreement
</B>shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this <B>Agreement.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If either party desires a modification to this <B>Agreement, </B>the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this <B>Agreement </B>or
their designees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The construction, validity, performance, and effect of this <B>Agreement </B>shall be governed by Federal law
as applied by the Federal courts in the District of Columbia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All <B>Agreement </B>notices required or permitted by this <B>Agreement </B>shall be given by prepaid, first
class, registered or certified mail or by an express/overnight delivery service provided by a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 12 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address as may be designated in writing by the other party.
<B>Agreement </B>notices shall be considered timely if the notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial
carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This <B>Agreement </B>shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) except to the <B>Licensee&#146;s Affiliate(s) </B>without the prior written consent of the NIH. The parties agree that the
identity of the parties is material to the formation of this <B>Agreement </B>and that the obligations under this <B>Agreement </B>are nondelegable. In the event that the <B>NIH </B>approves a proposed assignment, the <B>Licensee </B>shall pay the
<B>NIH, </B>as an additional royalty, one percent (1%) of the fair market value of any consideration received for any assignment of this <B>Agreement </B>within sixty (60)&nbsp;days of the assignment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees in its use of any <FONT STYLE="white-space:nowrap">NIH-supplied</FONT> materials to
comply with all applicable statutes, regulations, and guidelines, including NIH and HHS regulations and guidelines. The <B>Licensee </B>agrees not to use the materials for research involving human subjects or clinical trials in the United States
without complying with <U>21 C.F.R. Part 50</U> and <U>45 C.F.R. Part 46</U>. The <B>Licensee </B>agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying the NIH, in
writing, of the research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the NIH of research involving human subjects or clinical trials outside of the United States
shall be given no later than sixty (60)&nbsp;days prior to commencement of the research or trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the <U>Export Administration Act of 1979</U> and <U>Arms Export Control Act</U>) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of
these items may require a license from the appropriate agency of the U.S. <B>Government </B>or written assurances by the <B>Licensee </B>that it shall not export these items to certain foreign countries without prior approval of this agency. The
<B>NIH </B>neither represents that a license is or is not required or that, if required, it shall be issued. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>Licensee </B>agrees to mark the <B>Licensed Products </B>or their packaging sold in the United States
with all applicable U.S. patent numbers and similarly to indicate &#147;Patent Pending&#148; status. All the <B>Licensed Products </B>manufactured in, shipped to, or sold in other countries shall be marked in a manner to preserve the <B>NIH&#146;s
</B>patent rights in those countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By entering into this <B>Agreement, </B>the <B>NIH </B>does not directly or indirectly endorse any product or
service provided, or to be provided, by the <B>Licensee </B>whether directly or indirectly related to this <B>Agreement. </B>The <B>Licensee </B>shall not state or imply that this <B>Agreement </B>is an endorsement by the <B>Government, </B>the
<B>NIH, </B>any other <B>Government </B>organizational unit, or any <B>Government </B>employee. Additionally, the <B>Licensee </B>shall not use the names of the <B>NIH, </B>the <B>FDA </B>or the <B>HHS </B>or the <B>Government </B>or their employees
in any advertising, promotional, or sales literature without the prior written approval of the <B>NIH.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree to attempt to settle amicably any controversy or claim arising under this <B>Agreement </B>or
a breach of this <B>Agreement, </B>except for appeals of modifications or termination decisions provided for in Article 13. The <B>Licensee </B>agrees first to appeal any unsettled claims or controversies to the designated the NIH official, or
designee, whose decision shall be considered the final agency decision. Thereafter, the <B>Licensee </B>may exercise any administrative or judicial remedies that may be available. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 13 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to <U>37 C.F.R. Part 404</U> shall not be immunized from the operation of state or Federal law by reason of the
source of the grant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any formal recordation of this <B>Agreement </B>required by the laws of any <B>Licensed Territory </B>as a
prerequisite to enforceability of the <B>Agreement </B>in the courts of any foreign jurisdiction or for other reasons shall be carried out by the <B>Licensee </B>at its expense, and appropriately verified proof of recordation shall be promptly
furnished to the <B>NIH.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Paragraphs 4.3, 8.1, <FONT STYLE="white-space:nowrap">9.5-9.8,</FONT>
<FONT STYLE="white-space:nowrap">12.1-12.5,</FONT> 13.9, 13.10, 14.12 and 14.15 of this <B>Agreement </B>shall survive termination of this <B>Agreement.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms and conditions of this <B>Agreement </B>shall, at the <B>NIH&#146;s </B>sole option, be considered by
the <B>NIH </B>to be withdrawn from the <B>Licensee&#146;s </B>consideration and the terms and conditions of this <B>Agreement, </B>and the <B>Agreement </B>itself to be null and void, unless this <B>Agreement </B>is executed by the <B>Licensee
</B>and a fully executed original is received by the <B>NIH </B>within sixty (60)&nbsp;days from the date of the <B>NIH&#146;s </B>signature found at the Signature Page. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES BEGIN ON NEXT PAGE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 14 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NIH PATENT LICENSE AGREEMENT </U></B><B><I><U>-EXCLUSIVE</U></I></B><B><U> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE PAGE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <B>NIH:</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard U. Rodriguez</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">8/28/13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard U. Rodriguez</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Division of
Technology Development and Transfer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Technology Transfer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">National Institutes of Health</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mailing Address or <FONT STYLE="white-space:nowrap">E-mail</FONT> Address
for <B>Agreement </B>notices and reports: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief, Monitoring&nbsp;&amp; Enforcement Branch</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Technology Transfer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">National Institutes of Health</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6011 Executive Boulevard, Suite 325</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rockville, Maryland
20852-3804 U.S.A.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> LicenseNotices_Reports@mail.nih.gov</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any
statements of the Licensee made or referred to in this document are truthful and accurate.): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">9/3/13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature of Authorized Official</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Founder&nbsp;&amp; CEO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">I.&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Official and Mailing Address for Agreement notices:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Peter Finn.(Rubin&nbsp;&amp; Rudman LLP)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Counsel for Aura Biosciences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mailing Address</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>50 Rowes Wharf</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Boston, MA 02110</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 15 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email&nbsp;Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>pfinn@rubinrudman.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Phone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">II.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Official and Mailing Address for Financial notices (the <B>Licensee&#146;s</B> contact person for royalty payments)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Founder&nbsp;&amp; CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mailing Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email&nbsp;Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Phone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:4%; font-size:10pt; font-family:Times New Roman">Any false or misleading statements made, presented, or submitted to the <B>Government, </B>including any
relevant omissions, under this <B>Agreement </B>and during the course of negotiation of this <B>Agreement </B>are subject to all applicable civil and criminal statutes including Federal statutes <U>31 U.S.C.
</U><U>&#167;</U><U>&#167;</U><U>3801-3812</U> (civil liability) and <U>18 U.S.C. </U><U>&#167;</U><U>1001</U> (criminal liability including fine(s) or imprisonment). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 16 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX A - PATENT(S) OR PATENT APPLICATION(S) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 17 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 18 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX C - ROYALTIES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 19 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX D - BENCHMARKS AND PERFORMANCE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 20 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX E - COMMERCIAL DEVELOPMENT PLAN </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 21 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX F - EXAMPLE ROYALTY REPORT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 22 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX G - ROYALTY PAYMENT OPTIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NIH&nbsp;</B>Patent&nbsp;License&nbsp;Agreement&nbsp;&#150;<I>&nbsp;Exclusive</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 10-2005 (updated 8-2012) Page 23 of 31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[Final</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[Aura Biosciences]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[August 20, 2013]</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NATIONAL INSTITUTES OF HEALTH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FIRST AMENDMENT TO <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013/0</FONT></FONT> </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the first amendment <B>(&#147;First Amendment&#148;) </B>of the agreement by and between the National Institutes of Health <B>(&#147;NIH&#148;)
</B>within the Department of Health and Human Services <B>(&#147;HHS&#148;), </B>and Aura Biosciences, Inc. having an effective date of September&nbsp;3, 2013 and having <B>NIH </B>Reference Number <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">L-164-2013/0</FONT></FONT> <B>(&#147;Agreement&#148;). </B>This <B>First Amendment, </B>having <B>NIH </B>Reference Number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-l64-2013/1,</FONT></FONT> is
made between the <B>NIH </B>through the Office of Technology Transfer, <B>NIH, </B>having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852- 3804, U.S.A., and Aura Biosciences, Inc. having an office at 85 Bolton Street,
Cambridge, MA 02140 the <B>(&#147;Licensee&#148;). </B>This <B>First Amendment </B>includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Revised Commercial Development Plan), and 3) Attachment 2 (Royalty Payment
Information). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, the <B>NIH </B>and the <B>Licensee </B>desire that the <B>Agreement </B>be amended a first time as set forth below in order to
include <FONT STYLE="white-space:nowrap">co-owned</FONT> intellectual property&#146; to the <B>Licensed Patent Rights, </B>modify&#146; the <B>Licensed Field of Use, </B>and modify&#146; the commercial development plan (Appendix E). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the <B>NIH </B>and the <B>Licensee, </B>intending to be bound, hereby
mutually agree to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Cover Page&#146;s &#147;Serial Number(s) of Licensed Patent(s) or Patent Application(s)&#148; section and
Appendix A&#146;s Patent(s) or Patent Application(s)&#146;s section shall be deleted and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appendix B shall be deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appendix E shall be deleted in its entirety and replaced with the revised commercial development plan in
Attachment 1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within sixty (60)&nbsp;days of the execution of this <B>First Amendment, </B>the <B>Licensee </B>shall pay the
<B>NIH </B>an amendment issue royalty in the sum of [***], and payment options may be found in Attachment 2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event any provision(s) of the <B>Agreement </B>is/are inconsistent with Attachment 2, such provision(s)
is/are hereby amended to the extent required to avoid such inconsistency&#146; and to give effect to the payment information in such Attachment 2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All terms and conditions of the <B>Agreement </B>not herein amended remain binding and in effect.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms and conditions of this <B>First Amendment </B>shall, al the <B>NIH&#146;s </B>sole option, be
considered by the <B>NIH </B>to be withdrawn from the <B>Licensee&#146;s </B>consideration and the terms and conditions of this <B>First Amendment, </B>and the <B>First Amendment </B>itself, to be null and void, unless this <B>First Amendment </B>is
executed by the <B>Licensee </B>and a fully&#146; executed original is received by&#146; the <B>NIH </B>within sixty (60)&nbsp;day&#146;s from the date of tire <B>NIH&#146;s </B>signature found al the Signature Page. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This <B>First Amendment </B>is effective upon execution by all parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES BEGIN ON NEXT PAGE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>First </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 1 of 16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FIRST AMENDMENT TO
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013/0</FONT></FONT> </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE PAGE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Witness Whereof, the parties have executed this <B>First Amendment </B>on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <B>NIH</B>: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richard U. Rodriguez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director, Division of Technology Development and Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office of Technology Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">National Institutes of Health</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mailing Address or <FONT STYLE="white-space:nowrap">E-mail</FONT> Address for <B>Agreement </B>notices and reports: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief, Monitoring&nbsp;&amp; Enforcement Branch, DTDT </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of
Technology Transfer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">National Institutes of Health </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6011
Executive Boulevard, Suite 325 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rockville, Maryland 20852-3804 U.S.A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;LicenseNotices_Reports@mail.nih.gov</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <B>Licensee </B>(Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the Licensee made
or referred to in this document are truthful and accurate.): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature of Authorized Official</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos President and Chief Executive Officer Aura Biosciences Inc. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">I.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Official and Mailing Address for <B>Agreement</B> notices:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mailing Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Aura Biosciences Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">85 Bolton Street</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Cambridge, MA 02140</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Phone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>First </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 2 of 16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">With copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Alison Lawton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mailing Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aura Biosciences Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phone:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Official and Mailing Address for Financial notices (the <B>Licensee&#146;s</B> contact person for royalty payments):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Alison Lawton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mailing Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aura Biosciences Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:4%; font-size:10pt; font-family:Times New Roman">Any false or misleading statements made, presented, or submitted to the <B>Government, </B>including any
relevant omissions, under this <B>Agreement </B>and during the course of negotiation of this <B>Agreement </B>are subject to all applicable civil and criminal statutes including Federal statutes <U>31 U.S.C.
</U><U>&#167;</U><U>&#167;</U><U>3801-3812</U> (civil liability) and <U>18 U.S.C. </U><U>&#167;</U><U>1001</U> (criminal liability including fine(s) or imprisonment). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>First </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 3 of 16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTACHMENT 1 - REVISED COMMERCIAL DEVELOPMENT PLAN </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>First </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 4 of 16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTACHMENT 2 - ROYALTY PAYMENT OPTIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>First </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 5 of 16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NATIONAL INSTITUTES OF HEALTH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SECOND AMENDMENT TO
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013-0</FONT></FONT></FONT> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appendix B shall be deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX B - LICENSED FIELDS OF USE AND TERRITORY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appendix <FONT STYLE="white-space:nowrap">E-</FONT> Commercial Development Plan shall be appended with
Attachment 2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event any provision(s) of the <B>Agreement </B>is/are inconsistent with Attachment 1, such provision(s)
is/are hereby&#146; amended to the extent required to avoid such inconsistency and to give effect to the payment information in such Attachment 1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All terms and conditions of the <B>Agreement </B>not herein amended remain binding and in effect.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms and conditions of this <B>Second Amendment </B>shall, at the <B>NIH&#146;s </B>sole option, be
considered by the <B>NTH </B>to be withdrawn from the <B>Licensee&#146;s </B>consideration and the terms and conditions of this <B>Second Amendment, </B>and the <B>Second Amendment </B>itself, to be null and void, unless this <B>Second Amendment
</B>is executed by the <B>Licensee </B>and a fully executed original is received by the <B>NIH </B>within sixty (60)&nbsp;days from the date of the <B>NIH&#146;s </B>signature found at the Signature Page. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This <B>Second Amendment </B>is effective upon execution by all parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES BEGIN ON NEXT PAGE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 1 of 21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SECOND AMENDMENT TO <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">L-164-2013-0</FONT></FONT></FONT> </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE PAGE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Witness Whereof, the parties have executed this <B>Second Amendment </B>on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <B>NIH:</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name: Richard Rodriguez,
M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Associate Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office: Technology Transfer Center, National Cancer Institute</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">National Institutes of Health</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mailing Address or <FONT STYLE="white-space:nowrap">E-mail</FONT> Address for <B>Agreement </B>notices and reports: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">License Compliance and Administration Monitoring&nbsp;&amp; Enforcement Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard,
Suite 325 Rockville, Maryland 20852-3804 U.S.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;LicenseNotices_Reports@mail.nih.gov</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the Licensee Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the Licensee made or
referred to in this document are truthful and accurate.): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature of Authorized
Official</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Elisabet de los Pinos</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: President and Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">I.&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Official and Mailing Address for <B>Agreement</B> notices:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mailing Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Aura Biosciences Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 2 of 21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email&nbsp;Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Phone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fax:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">With copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Michele Keough</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Senior Vice President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mailing Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Aura Biosciences Inc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Cambridge. MA 02140</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email&nbsp;Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Phone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">II.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Official and Mailing Address for Financial notices (the <B>Licensee&#146;s</B> contact person for royalty payments):</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Kylie Reynolds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>VP. Finance</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mailing Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Aura Bioscience, Inc.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Cambridge. MA 02140</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Email&nbsp;Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Phone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 3 of 21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any false or misleading statements made, presented, or submitted to the <B>Government, </B>including any
relevant omissions, under this <B>Agreement </B>and during the course of negotiation of this <B>Agreement </B>are subject to all applicable civil and criminal statutes including Federal statutes <U>31 U.S.C. $$3801-3812</U> (civil liability) and
<U>18 U.S.C. $1001</U> (criminal liability including fine(s) or imprisonment). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 4 of 21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTACHMENT 1 - ROYALTY PAYMENT OPTIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 5 of 21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTACHMENT 2 - APPENDIX E ADDENDUM </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 6 of 21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NATIONAL INSTITUTES OF HEALTH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THIRD AMENDMENT TO
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013-0</FONT></FONT></FONT> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tax ID No: [***] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the third
amendment <B>(&#145;Third Amendment&#148;) </B>of the agreement by and between the National Institutes of Health <B>(&#147;NIH&#148;) </B>within the Department of Health and Human Services <B>(&#147;HHS&#148;), </B>and Aura Biosciences, Inc. having
an effective date of September&nbsp;3, 2013 and having <B>NIH </B>Reference Number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013-0,</FONT></FONT></FONT> its <B>First Amendment
</B>having an effective date of September&nbsp;28, 2015 and having <B>NIH </B>Reference Number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013-1,</FONT></FONT></FONT> and its <B>Second
Amendment, </B>having an effective date of August&nbsp;20, 2018 and having <B>N</B><B><U>TH</U></B><B> </B>Reference Number
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013-2</FONT></FONT></FONT> (collectively, <B>&#147;Agreement&#148;). </B>This <B>Third Amendment, </B>having <B>NIH </B>Reference Number <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L-164-2013-3,</FONT></FONT></FONT> is made between the <B>NIH </B>through the Office of Technology Transfer, <B>NIH, </B>having an address at 6011 Executive
Boulevard, Suite 325, Rockville, Maryland 20852- 3804, U.S.A., and Aura Biosciences, Inc., having an office at 85 Bolton Street, Cambridge MA 02140 (the <B>&#147;Licensee&#148;). </B>This <B>Third Amendment </B>includes, in addition to the
amendments made below, 1) a Signature Page, 2) Attachment 1 (Appendix <FONT STYLE="white-space:nowrap">E-</FONT> Commercial Development Plan Addition), and Attachment 2 (Royalty Payment Information). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, the <B>NIH </B>and the <B>Licensee </B>desire that the <B>Agreement </B>be amended a third time as set forth below in order to address combination
products in the <B>Agreement, </B>transfer control of the patent prosecution of the <B>Licensed Patent Rights, </B>update the <B>Benchmarks </B>in Appendix <B>D, </B>and update the <B>Commercial Development Plan </B>in Appendix E. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the NIH and the <B>Licensee, </B>intending to be bound, hereby
mutually agree to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 7 shall be deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>PATENT FILING. PROSECUTION. AND MAINTENANCE</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the <B>Licensed Patent Rights </B>and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the <B>Licensed Patent Rights,
</B>which comments and suggestions shall be considered by the other party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 11 shall be deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>INFRINGEMENT AND PATENT ENFORCEMENT</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>and the <B>Licensee </B>agree to notify each other promptly of each infringement or possible
infringement of the <B>Licensed Patent Rights, </B>as well as, any facts which may affect the validity, scope, or enforceability of the <B>Licensed Patent Rights </B>of which either party becomes aware. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to this <B>Agreement </B>and the provisions of 35 U.S.C. Chapter 29, the <B>Licensee </B>may:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">bring suit in its own name, at its own expense, and on its own behalf for. infringement of presumably valid
claims in the <B>Licensed Patent Rights;</B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 1 of 17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">settle any claim or suit for infringement of the <B>Licensed Patent Rights; </B>and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the <B>Licensee </B>desires to initiate a suit for patent infringement, the <B>Licensee </B>shall notify the
<B>NIH </B>in writing. If the <B>NIH </B>does not notify the <B>Licensee </B>of its intent to pursue legal action within ninety (90)&nbsp;days, the <B>Licensee </B>shall be free to initiate suit. The <B>NIH </B>shall have a continuing right to
intervene in the suit. The <B>Licensee </B>shall take no action to compel the <B>Government </B>either to initiate or to join in any suit for patent infringement. The <B>Licensee </B>may request the <B>Government </B>to initiate or join in any suit
if necessary, to avoid dismissal of the suit. Should the <B>Government </B>be made a party to any suit, the <B>Licensee </B>shall reimburse the <B>Government </B>for any costs, expenses, or fees which the <B>Government </B>incurs as a result of the
motion or other action, including all costs incurred by the <B>Government </B>in opposing the motion or other action. In all cases, the <B>Licensee </B>agrees to keep the <B>NIH </B>reasonably apprised of the status and progress of any litigation.
Before the <B>Licensee </B>commences an infringement action, the <B>Licensee </B>shall notify the <B>NIH </B>and give careful consideration to the views of the <B>NIH </B>and to any potential effects of the litigation on the public health in
deciding whether to bring suit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that a declaratory judgment action alleging invalidity or noninfringement of any of the
<B>Licensed Patent Rights </B>shall be brought against the <B>Licensee </B>or raised by way of counterclaim or affirmative defense in an infringement suit brought by the <B>Licensee </B>under Paragraph 11.2, pursuant to this <B>Agreement </B>and the
provisions of 35 U.S.C. Part 29 or other statutes, the <B>Licensee </B>may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
<B>Licensed Patent Rights;</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">settle any claim or suit for declaratory judgment involving the <B>Licensed Patent Rights,</B>-provided,
however, that the <B>NIH </B>shall have a continuing right to intervene in the suit; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">respond to the legal action within ninety (90)&nbsp;days. The <B>Licensee </B>shall take no action to compel
the <B>Government </B>either to initiate or to join in any declaratory judgment action. The <B>Licensee </B>may request the <B>Government </B>to initiate or to join any suit if necessary, to avoid dismissal of the suit. Should the <B>Government
</B>be made a party to any suit by motion or any other action of the <B>Licensee, </B>the <B>Licensee </B>shall reimburse the <B>Government </B>for any costs, expenses, or fees, which the <B>Government </B>incurs as a result of the motion or other
action. If the <B>Licensee </B>elects not to defend against the declaratory judgment action, the NIH, at its option, may do so at its own expense. In all cases, the <B>Licensee </B>agrees to keep the <B>NIH </B>reasonably apprised of the status and
progress of any litigation. Before the <B>Licensee </B>commences an infringement action, the <B>Licensee </B>shall notify the NIH and give careful consideration to the views of the <B>NIH </B>and to any potential effects of the litigation on the
public health in deciding whether to bring suit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In any action under Paragraphs 11.2 or 11.3, the expenses, including costs, fees, attorney fees, and
disbursements, shall be paid by the <B>Licensee. </B>The value of any recovery made by the <B>Licensee, </B>which exceeds the expenses incurred with prosecuting or defending any action therein, through court judgment or settlement, shall be treated
as <B>Net Sales </B>and subject to earned royalties. The <B>Licensee </B>shall provide an accounting of any expenses that are deducted from <B>Net Sales </B>under this Paragraph 11.4. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 2 of 17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <B>NIH </B>shall cooperate fully with the <B>Licensee </B>in connection with any action under Paragraphs
11.2 or 11.3. The <B>NIH </B>agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the <B>Licensee.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Paragraph 14.7 shall be deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This <B>Agreement </B>shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) without the prior written consent of the <B>NIH. </B>The parties agree that the identity of the parties is material to the
formation of this <B>Agreement </B>and that the obligations under this <B>Agreement </B>are nondelegable. [***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appendix C - Royalties, Paragraph III, shall be deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The <B>Licensee </B>agrees to pay the <B>NIH </B>earned royalties of [***]. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appendix D - Benchmarks and Performance, shall be deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The <B>Licensee </B>agrees to the following <B>Benchmarks </B>for its performance under this <B>Agreement </B>and,
within thirty (30)&nbsp;days of achieving a <B>Benchmark, </B>shall notify the <B>NIH </B>that the <B>Benchmark </B>has been achieved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Appendix E - Commercial Development Plan shall be appended with Attachment I. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event any provision(s) of the <B>Agreement </B>is/are inconsistent with Attachment 2, such provision(s)
is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the payment information in such Attachment 2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All terms and conditions of the <B>Agreement </B>not herein amended remain binding and in effect.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms and conditions of this <B>Third Amendment </B>shall, at the <B>NIH&#146;s </B>sole option, be
considered by the <B>NIH </B>to be withdrawn from the <B>Licensee&#146;s </B>consideration and the terms and conditions of this <B>Third Amendment, </B>and the <B>Third Amendment </B>itself, to be null and void, unless this <B>Third Amendment </B>is
executed by the <B>Licensee </B>and a fully executed original is received by the <B>NIH </B>within [***] days from the date of the <B>NIH&#146;s </B>signature found at the Signature Page. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This <B>Third Amendment </B>is effective upon execution by all parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES BEGIN ON NEXT PAGE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 3 of 17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THIRD AMENDMENT TO <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">L-164-2013-0</FONT></FONT></FONT> </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE PAGE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Witness Whereof, the parties have executed this <B>Third Amendment </B>on the dates set forth below. Any communication or notice to be given shall be
forwarded to the respective addresses listed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <B>NIH:</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Name: Richard U. Rodriguez</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: Associate Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office: National Cancer Institute</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">National Institutes of Health</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mailing Address or <FONT STYLE="white-space:nowrap">E-mail</FONT> Address for <B>Agreement </B>notices and reports: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">License Compliance and Administration </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monitoring&nbsp;&amp;
Enforcement </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Technology Transfer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">National
Institutes of Health </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6011 Executive Boulevard, Suite 325 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rockville, Maryland 20852-3804 U.S.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <B>Licensee </B>(Upon information and belief, the undersigned expressly certifies or affirms that
the contents of any statements of the <B>Licensee </B>made or referred to in this document are truthful and accurate.): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Signature of Authorized Official</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Date</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Elisabet de los Pinos Title: President and CEO </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I.&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Official and Mailing Address for <B>Agreement</B> notices:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mailing Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Cambridge. MA 02140</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 4 of 17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email&nbsp;Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Phone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fax:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">II.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Official and Mailing Address for Financial notices (the <B>Licensee&#146;s</B> contact person for royalty payments):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mailing Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">85 Bolton Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Cambridge. MA 02140</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email&nbsp;Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Phone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[***]<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fax:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any false or misleading statements made, presented, or submitted to the <B>Government, </B>including any relevant omissions, under this <B>Agreement </B>and
during the course of negotiation of this <B>Agreement </B>are subject to all applicable civil and criminal statutes including Federal statutes <U>31 U.S.C., $$3801-3812</U> (civil liability) and <U>18 U.S.C. $1001</U> (criminal liability including
fine(s) or imprisonment). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 5 of 17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTACHMENT 1 - ADDITION TO APPENDIX E -COMMERCIAL DEVELOPMENT PLAN </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 6 of 17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ATTACHMENT 2 - ROYALTY PAYMENT OPTIONS </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New Payment Options Effective March 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONFIDENTIAL &#150; NIH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Second </B>Amendment of L-164-2013/0</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">FINAL Aura Biosciences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">9-16-15</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Model 09-2006 (updated 8-20120</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Page 7 of 17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>8
<FILENAME>d209588dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#147;[***]&#148;. </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXCLUSIVE LICENSE AND SUPPLY AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated January&nbsp;31, 2014 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">LI-COR,</FONT> Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">And </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aura Biosciences, Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>DEFINITIONS</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>LICENSE</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Grant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sublicenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consideration for Expanded Field</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Implied Rights or Licenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>FEES, ROYALTIES, AND PAYMENTS</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>License Issue Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Royalty</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Method of Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Late Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>REPORTS, RECORDS, AND INSPECTIONS</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Records and Inspections</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 5<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>ADDITIONAL OBLIGATIONS OF THE PARTIES</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Due Diligence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Data Sharing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Prosecution, Maintenance, and Enforcement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Challenges</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Promotional Materials and Product Labeling</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Publicity and Use of Marks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;6<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>SUPPLY OFIR DYE 700DX</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Supply&nbsp;&amp; Exclusivity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Forecasting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Orders and Acceptance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Pricing and Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Delivery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Inspection and Rejection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Safety Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">6.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Secondary Supplier</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 7 <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>REPRESENTATIONS AND WARRANTIES</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Of Both Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Of <FONT STYLE="white-space:nowrap">LI-COR</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclaimer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 8 <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>CONFIDENTIALITY</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exceptions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Unauthorized Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Duration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 9 <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>TERM AND TERMINATION</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE&nbsp;10<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>INDEMNIFICATION</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice and Defense of Third-Party Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>INSURANCE </I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third-Party Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 12<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>LIMITATION OF LIABILITY</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 13<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>MISCELLANEOUS</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Force Majeure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law and Forum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General Interpretive Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waivers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Independent Contractors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third-Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Export Controls</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>US&nbsp;Dollars</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">13.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Dispute Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUSIVE LICENSE AND SUPPLY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Exclusive License and Supply Agreement (this &#147;<B>Agreement</B>&#148;)<B> </B>is dated January&nbsp;31, 2014 (&#147;<B>Effective
Date</B>&#148;)<B> </B>and is between <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc., a Nebraska corporation with a principal address of 4647&nbsp;Superior Street, Lincoln, Nebraska 68504
(&#147;<B><FONT STYLE="white-space:nowrap">LI-COR</FONT></B>&#148;),<B> </B>and Aura Biosciences, Inc., a Delaware corporation with a principal address of 85 Bolton Street, Cambridge, MA 02140 (&#147;<B>Aura</B>&#148;). <FONT
STYLE="white-space:nowrap">LI-COR</FONT> and Aura individually referred to herein as a &#147;<B>Party</B>&#148;<B> </B>and collectively as the &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B><FONT STYLE="white-space:nowrap">LI-COR</FONT> has developed a certain proprietary dye, IRDye 700DX, for use in targeted
imaging agents, as well as certain technology concerning the binding of such dye to an optical agent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>Aura desires to <FONT
STYLE="white-space:nowrap">license-in,</FONT> and <FONT STYLE="white-space:nowrap">LI-COR</FONT> is willing to grant such license to, such dye and technology, on an exclusive basis, for commercial use in the limited field of the treatment and
diagnosis of ocular cancers in humans using Aura&#146;s nanoparticles conjugated to such dye; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>in connection with such
license grant to Aura, Aura desires to have <FONT STYLE="white-space:nowrap">LI-COR</FONT> supply its requirements of such IR Dye 700DX, and <FONT STYLE="white-space:nowrap">LI-COR</FONT> is willing to supply such IR Dye 700DX, to Aura. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE, </B>in mutual consideration of the covenants and obligations set forth in this Agreement, the receipt and legal sufficiency
of which is hereby acknowledged, accepted and agreed to, the Parties, intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Definitions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the following capitalized terms, whether used in the singular or plural, have the respective meanings set
forth below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148;<B> </B>means, with respect to any given Person, any other Person at
the time directly or indirectly controlling, controlled by or under common control with that Person. &#147;Control&#148; means the possession of, directly or indirectly, of the power to direct or cause the direction of the management and policies of
a Person, whether through ownership of voting securities, by contract, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercially
Reasonable Efforts</B>&#148;<B> </B>means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidential Information</B>&#148;<B> </B>means any
and all confidential or proprietary information and materials of or concerning a Party or the Licensed Patent or <FONT STYLE="white-space:nowrap">Know-How,</FONT> including, but not limited to, commercial, financial, and technical information,
substances, formulations, techniques, methodologies, customer or client lists, programs, procedures, data, documents, <FONT STYLE="white-space:nowrap">know-how,</FONT> protocols, results of experimentation and testing, specifications, databases,
business plans, trade secrets, business arrangements, information regarding specific transactions, long-term plans and goals, and the terms and conditions of this Agreement. The Licensed Patent and <FONT STYLE="white-space:nowrap">Know-How</FONT>
will be treated as the Confidential Information of <FONT STYLE="white-space:nowrap">LI-COR.</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>EU</B>&#148;<B> </B>means the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>FDA</B>&#148;<B> </B>means the United States Food and Drug Administration, including all agencies under
its control, and any successor agency thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>First Commercial Sale</B>&#148;<B> </B>means the first
sale of a Licensed Product by Aura, an Affiliate or a Sublicensee to a Third Party, following Regulatory Approval of such Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Generic Product</B>&#148;<B> </B>means, with respect to a Licensed Product, a product that
(a)&nbsp;obtained Regulatory Approval solely by means an ANDA procedure (or any foreign equivalent thereto) under Section&nbsp;505 (j) of the Federal Food, Drug, and Cosmetic Act, in the United States for establishing equivalence to such Licensed
Product, with the Licensed Product as the reference listed drug, (b)&nbsp;is AB rated and legally substituted by pharmacies for such Licensed Product and (c)&nbsp;is legally marketed by an entity other than the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Improvements</B>&#148;<B> </B>means any changes, discoveries, improvements, developments, enhancements, or
modifications in the <FONT STYLE="white-space:nowrap">Know-How</FONT> or IRDye 700DX however arising and occurring at any time during the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Infringement</B>&#148;<B> </B>means any infringement as determined by applicable Law, including direct
infringement, contributory infringement, and any inducement to infringe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IRDye 700DX</B>&#148;<B>
</B>means <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> IRDye 700DX Carboxylate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT
STYLE="white-space:nowrap">Know-How</FONT></B>&#148;<B> </B>means any and all unpatented technical information, research data, designs, trade secrets, confidential information, methods, techniques, results, formulas, process information, clinical
data, or other information that: (a)&nbsp;is known to or acquired by <FONT STYLE="white-space:nowrap">LI-COR</FONT> during the Term; <FONT STYLE="white-space:nowrap">(b)&nbsp;LI-COR</FONT> has the right to license; (c)&nbsp;is outside the public
domain; and (d)&nbsp;is related to <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> (i)&nbsp;IR Dye 700DX, including but not limited to, chemical synthesis and conjugation methods or (ii)&nbsp;the formulation of IR Dye 700DX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Law</B>&#148;<B> </B>means any federal, state, local, municipal, foreign, international, multinational,
or other administrative order, constitute, law, ordinance, principle of common law, regulation, statute, or treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Field</B>&#148;<B> </B>means use in the treatment and diagnosis of ocular cancers in humans.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Patent</B>&#148;<B> </B>means the U.S. Patent No.&nbsp;7,005,518, entitled,
&#147;Phthalocyanine Dyes&#148;, which was issued on February&nbsp;28, 2006 and filed on October&nbsp;23, 2003, along with the inventions described and claimed therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Product</B>&#148;<B> </B>means nanoparticles conjugated with IR Dye 700DX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;Losses&#148;</B> means any and all losses, damages, liabilities judgments, costs, and expenses (including
reasonable attorneys&#146; fees) based on, arising out of, or incidental to any and all claims, actions, demands, suits, causes of action, brought or asserted against a Party by a Third Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>MAA</B>&#148; means any marketing authorization
application for a country or region in the Territory, requesting approval from the applicable Regulatory Authority for commercial sale (including the marketing, promotion and distribution) of a Licensed Product in such country or region in the
Territory, and any equivalent application submitted in any such country in the Territory, including all additions, deletions or supplements thereto, and as any and all such requirements may be amended, or supplanted, at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.18&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Minimum Royalty</B>&#148;<B> </B>means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.19&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>NDA</B>&#148;<B> </B>means a New Drug Application as defined in Title&nbsp;21 of the U.S. Code of Federal
Regulations, &#167;314.80 et seq., in accordance with the requirements of the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the regulations promulgated thereunder, and all amendments and supplements thereto, filed with the FDA,
including all documents, data, and other information that are necessary for gaining Regulatory Approval in the Territory, and all additions, supplements, extension and amendments thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.20&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Net Sales</B>&#148;<B> </B>means the gross sales revenues and fees billed or received by Aura, its
Affiliates and Sublicensees for sales of a Licensed Product to independent or unaffiliated Third Party purchasers of such Licensed Product, less deductions with respect to such gross amounts to the extent that such deductions are either included in
the billing as a line item as part of the gross amount invoiced, or otherwise specifically documented in accordance with generally acceptable accounting principles to be specifically attributable to actual sales of such Licensed Product: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of discounts on packages of
products or services which include Licensed Product in those countries in which such is legally permissible (&#147;<B>Packages</B>&#148;),<B> </B>the discount applied to Licensed Product within the Package shall be no greater than the smallest
discount of a product in the Package determined based on the list price of all such products. If a Licensed Product or another product in the Package does not have a list price, then the Parties will agree on the &#147;Fair Value&#148; of such
product in place of the list place for the purpose of calculating royalties hereunder. For clarity, a &#147;sale&#148; of a Licensed Product is deemed to occur upon the invoicing, or if no invoice is issued, upon the earlier of shipment or transfer
of title in the Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.21&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148;<B> </B>means any individual, corporation
(including any nonprofit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, governmental authority, or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.22&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase III Clinical Trial</B>&#148;<B> </B>means an expanded human clinical trial intended to gather
information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship and to provide an adequate basis for physician labeling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.23&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;Regulatory Approval&#148;</B> means any and all approvals (including any applicable governmental price
and reimbursement approvals), licenses, registrations or authorizations from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Regulatory Authority necessary for the use, storage, import, export, distribution, transport, promotion, marketing, commercialization and regular and continuance commercial sale (including
packaging and labeling) of the Licensed Product, NDA filings (or any foreign equivalents thereof) for the Licensed Product, and product license applications of the Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.24&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Authority</B>&#148;<B> </B>means any federal, national, multinational, regional, state,
provincial or local regulatory agency, department, bureau, commission, council or other governmental entity with authority to grant a Regulatory Approval or having jurisdiction over the manufacture, development or commercialization of the Licensed
Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.25&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Territory</B>&#148;<B> </B>means the entire world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.26&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148;<B> </B>means any party other than the Parties or either Party&#146;s Affiliates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.27&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party Royalties</B>&#148;<B> </B>means any royalties Aura owes to one or more Third Parties
pursuant to one or more licenses to intellectual property rights entered into by Aura to avoid Infringement of such rights that are reasonably necessary for the practice of the Licensed Patent in the manufacture, use, or sale of the IR Dye 700DX, or
to avoid infringement-related litigation with respect to the practice of the Licensed Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.28&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Unit</B>&#148;<B> </B>means a single unit of Licensed Product packaged for use in a single setting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.29&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Valid Claim</B>&#148;<B> </B>means an issued and unexpired claim of the Licensed Patent, that has not
been held unpatentable, invalid, or unenforceable by a final unappealable decision of a court or other government agency of competent jurisdiction, in an unappealed or unappealable decision, admitted to be invalid or unenforceable through reissue, <FONT
STYLE="white-space:nowrap">re-examination,</FONT> disclaimer, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.30&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Definitions</B>. The
following definitions have the meanings ascribed to them in the corresponding Section: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Definition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A.A.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.17(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aura</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diligence Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dispute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.17(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expanded Field</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forecast</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LI-COR</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milestone Payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Package</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.20</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Party(ies)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specifications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublicensee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supply Failure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.1</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>License </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Grant</B>. Subject to the terms and conditions of this Agreement, <FONT STYLE="white-space:nowrap">LI-COR</FONT>
hereby grants to Aura an exclusive, royalty-bearing, license (&#147;<B>License</B>&#148;)<B> </B>under the Licensed Patent, Improvements and <FONT STYLE="white-space:nowrap">Know-How</FONT> to research, develop, make, have made, use, have used,
market, sell, have sold, distribute, have distributed, export and have imported Licensed Product for the Licensed Field in the Territory during the Term. Notwithstanding the foregoing, such License does not include the right to make or have made IR
Dye 700DX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Sublicenses</B>. Subject to the terms and conditions of this Agreement, Aura shall have the
right to grant sublicenses under the License to (a)<U></U>&nbsp;to its Affiliates and (b)<U></U>&nbsp;to Third Parties (&#147;<B>Sublicensee</B>&#148;), to make, have made, market, sell and have sold Licensed Product in the Licensed Field in the
Territory. Aura shall remain responsible for complying with all terms and conditions of this Agreement regardless of any grant to a Sublicensee or Affiliate. In addition, Aura shall require that each of its Affiliates and Sublicensees accept all of
the relevant terms and conditions of this Agreement as if such Affiliates or Sublicensees were a party to this Agreement, and shall provide LI-COR with a copy of each agreement with a Sublicensee upon execution of such agreement. For clarity, Aura
shall have no right to grant a sublicense to its Affiliates or any Third Party under the Licensed Patent and <FONT STYLE="white-space:nowrap">Know-How</FONT> to make or have made IRDye 700DX in the Licensed Field in the Territory. Upon termination
or expiration of this Agreement for any reason, any Sublicensee not then in default under its agreement with Aura or an Affiliate shall have the right to seek a license directly from <FONT STYLE="white-space:nowrap">LI-COR.</FONT> <FONT
STYLE="white-space:nowrap">LI-COR</FONT> agrees to negotiate such license in good faith under reasonable terms and conditions consistent with this Agreement; provided, however, whether <FONT STYLE="white-space:nowrap">LI-COR</FONT> enters into any
such license shall be at the sole discretion of <FONT STYLE="white-space:nowrap">LI-COR.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Consideration for Expanded Field</B>. At any time during the Term,
<FONT STYLE="white-space:nowrap">LI-COR</FONT> hereby agrees to consider any request by Aura to negotiate a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing license under the Licensed Patent, Improvements and <FONT
STYLE="white-space:nowrap">Know-How</FONT> to research, develop, make, have made, use, have used, market, offer for sale, sell, have sold, distribute, have distributed, export and import products for the diagnosis and treatment of cancers in
indications other than ocular cancers (the &#147;<B>Expanded Field</B>&#148;)<B> </B>in the Territory; provided, that <FONT STYLE="white-space:nowrap">LI-COR</FONT> is not obligated to negotiate or grant any such license. It is understood generally
that the aggregate financial terms of a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license in the Expanded Field is likely to be less than financial terms of an exclusive license of an identical scope. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<B>No Implied Rights or Licenses</B>. Neither Party grants to the other Party any rights or licenses in or to any
patent, know-how or other intellectual property right, whether by implication, estoppel or otherwise, except to the extent expressly provided for under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Fees, Royalties, and Payments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<B>License Issue Fee</B>. In partial consideration for the license and rights granted to Aura under this Agreement,
Aura shall pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> the following <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> license issue fee of $[***] according to the following
schedule: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Issue Fee Portion</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date&nbsp;Due</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>***<B>]</B>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalty</B>. In partial consideration for the license and rights granted to Aura
under this Agreement, Aura shall, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, during the Term pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> the following royalty
(&#147;<B>Royalty</B>&#148;)<B> </B>on Net Sales. The Royalties due shall be calculated on an incremental basis and paid annually. [***]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Royalty due for any calendar quarter is less than the Minimum Royalty
applicable for such calendar quarter and the total amount of Royalty paid for each of the calendar quarters in the same calendar year as such calendar quarter is less than the total Minimum Royalty due in the aggregate for such calendar quarters,
Aura shall pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> the Royalty plus the difference between the Minimum Royalty and the Royalty for such calendar quarter, to be trued up at the end of each calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All such payments must be made quarterly, in accordance with Section&nbsp;4.1 (b)<U></U>&nbsp;and this
Article<U></U>&nbsp;3. In order to ensure <FONT STYLE="white-space:nowrap">LI-COR</FONT> the full royalty payments contemplated hereunder, Aura agrees that in the event any Licensed Product is sold to an Affiliate or a Sublicensee or to a
corporation, firm, or association with which Aura has any agreement, understanding, or arrangement with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving
division of profits or special rebates or allowances), the royalties to be paid hereunder for such Licensed Product will be based upon the greater of (x)&nbsp;the net selling price (per Net Sales) at which the purchaser of the Licensed Product
resells such product to the end user; (y)&nbsp;the fair market value of the Licensed Product; or (z)<U></U>&nbsp;the net selling price (per Net Sales) of Licensed Product paid by the purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event that, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the Licensed Product is not covered by a Valid Claim in a country and there is a Generic Product in such country, then the Royalty on Net Sales of Licensed Product in such country
due to <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall be reduced by [***]% for the remainder of the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Aura receives a communication from a Third Party alleging infringement of or notification of such
Third Party&#146;s patent rights as they relate to the research, development, manufacture, or use of IRDye 700DX, Aura shall notify <FONT STYLE="white-space:nowrap">LI-COR</FONT> of such communication, and Aura shall take into consideration <FONT
STYLE="white-space:nowrap">LI-COR&#146;s</FONT> comments regarding such communication. In the event that Aura is required to pay Third Party Royalties in order to license rights to the IRDye 700DX, then Aura may deduct [***]of the Third Party
Royalties paid by Aura in such calendar quarter from the Royalty due to <FONT STYLE="white-space:nowrap">LI-COR</FONT> for such calendar quarter, provided that in no event shall the Royalty due to <FONT STYLE="white-space:nowrap">LI-</FONT> COR be
reduced by more than [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Milestone Payments</B>. In partial consideration for the license and rights
granted to Aura under this Agreement, Aura shall pay to <FONT STYLE="white-space:nowrap">LI-COR</FONT> each of the following milestone payments (&#147;<B>Milestone Payments</B>&#148;)<B> </B>within [***] after the occurrence of the applicable
milestone (&#147;<B>Milestone</B>&#148;)<B> </B>only for the first achievement of the Milestone event below for each Licensed Product, whether such event results from the activities of Aura or its Affiliates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>***<B>]</B>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Milestone Payments are <FONT STYLE="white-space:nowrap">non-refundable</FONT> and
<FONT STYLE="white-space:nowrap">non-creditable</FONT> against any other royalties, fees, or payments hereunder. For clarity, Milestone Payments are owed on a Licensed Product by Licensed Product basis. Notwithstanding the foregoing, with respect to
the development of more than one candidate constituting a Licensed Product, if any milestone payments have been made with respect to a candidate the development of which is abandoned by Aura and Aura pursues the development of a subsequent candidate
constituting part of such Licensed Product, all milestone payments previously made with respect to such abandoned candidate shall be credited towards the milestones that would otherwise be due and payable with respect to one or more subsequent
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Method of Payment</B>. All payments to <FONT STYLE="white-space:nowrap">LI-COR</FONT> hereunder
shall be made by deposit of United States Dollars in the requisite amount to such bank account as <FONT STYLE="white-space:nowrap">LI-COR</FONT> may from time to time designate by written notice to Aura. With respect to sales not denominated in
United States Dollars, Aura shall convert applicable sales in foreign currency into United States Dollars based on the average of the conversion rate reported in The Wall Street Journal on the last working day of each month in the calendar quarter
of the applicable calendar quarter. Based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on the resulting sales in USD, the then applicable royalties shall be calculated. The Parties may vary the method of payment set forth herein at any time upon mutual written agreement, and any
change shall be consistent with the local Law at the place of payment or remittance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Late Payments</B>. In
the event that any payment (other than a payment disputed in good faith) hereunder is not made when due, the amount due will accrue interest calculated at the annual rate of the sum of (a)&nbsp;four percent<U></U>&nbsp;(4%) plus (b)<U></U>&nbsp;the
prime interest rate quoted by <U>The Wall Street Journal</U> on the date said payment is due, the interest being compounded on the last day of each calendar quarter; provided that in no event will said annual interest rate exceed the maximum
interest rate allowed by law. Each such payment when made must be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof will not negate or waive the right of <FONT STYLE="white-space:nowrap">LI-COR</FONT> to
seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment, including termination of this Agreement as set forth in Section&nbsp;9.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Taxes</B>. All fees, royalties, and other payments are exclusive of any national, state, and local sales, use,
value added, and other taxes, customs duties, or similar tariffs and fees which Aura may be required to collect or pay. Should any tax or levy be made, Aura agrees to pay such tax or levy and indemnify <FONT STYLE="white-space:nowrap">LI-COR</FONT>
against any claim for such tax or levy demanded. Aura shall pay any withholding taxes required by applicable Law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Reports, Records, and Inspections </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Reports</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Summary Reports</U>. Not less than once every six&nbsp;(6) months, Aura shall provide <FONT
STYLE="white-space:nowrap">LI-COR</FONT> with a summary report, which must describe a summary-level review and/or update of the research, development, and commercialization activities undertaken by Aura and its Affiliates and Sublicensees with
respect to Licensed Product during the period covered by the report and/or update since the last report. Each such report shall include a summary of work completed, a summary of work in progress, a current schedule of anticipated regulatory
approvals, sublicensing efforts, if any, and market plans for introduction of Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Royalty
Reports</U>. Aura shall provide <FONT STYLE="white-space:nowrap">LI-COR</FONT> with quarterly royalty reports, due within [***] after the end of each calendar quarter. Each such royalty report shall disclose the number of Units of Licensed Product
sold, the total Net Sales of such Licensed Product, and the resulting royalties due to <FONT STYLE="white-space:nowrap">LI-COR</FONT> as a result of either number of Units or Net Sales by Aura and its Affiliates and Sublicensees. Payment of any such
royalties due will accompany such royalty report. If no amounts are due <FONT STYLE="white-space:nowrap">LI-COR</FONT> for any calendar quarter, the report shall so state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Records and Inspections</B><B>. </B>Aura shall make and retain, for a period of three&nbsp;(3) years following
the period of each report required by Section<U></U>&nbsp;4.1, true and accurate records, files, and books of account containing all the data reasonably required for the full computation and verification of sales and other information required in
Section&nbsp;4.1. Such books and records will be in accordance with generally accepted accounting principles consistently applied. Subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the terms of the Confidentiality Agreement by and between the Parties, Aura will permit the inspection and copying of such records, files, and books of account by
<FONT STYLE="white-space:nowrap">LI-COR</FONT> or its agents during regular business hours upon [***] prior written notice to Aura. Aura may require that the inspection be performed by an independent certified public accountant (CPA) subject to a
confidentiality agreement reasonably acceptable to Aura. Inspections may not be made more than once each calendar year. All costs of each such inspection and copying will be paid by <FONT STYLE="white-space:nowrap">LI-COR;</FONT> provided that if
any such inspection reveals that an error has been made in Aura&#146;s favor in an amount equal to five percent&nbsp;(5%) or more of the amounts actually owed, all costs will be borne by Aura. Aura agrees to include in any agreement with its
Sublicensees which permits any such party to research, develop, use, offer for sale, sell, or have sold Licensed Product, a provision requiring such party to retain records of sales of Licensed Product and other information as required in
Section<U></U>&nbsp;4.1 and permit <FONT STYLE="white-space:nowrap">LI-COR</FONT> or its agents to inspect such records as required by this Section<U></U>&nbsp;4.2. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Additional
Obligations of the Parties </I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Due Diligence</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;General. Aura shall use Commercially Reasonable Efforts to develop and commercialize Licensed Product, and
thereafter it shall use Commercially Reasonable Efforts to keep Licensed Product readily available to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Key Diligence Obligations. Aura shall use Commercially Reasonable Efforts to achieve each of the following
diligence events (each, a &#147;<B>Diligence Event</B>&#148;)<B> </B>by the corresponding achievement date set forth below (&#147;<B>Achievement Date</B>&#148;). Notwithstanding the foregoing, Aura shall have the right and option to extend any
Achievement Date for a Diligence Event by six&nbsp;(6) month increments, but not more than three<U></U>&nbsp;(3) times per Diligence Event, by making a [***] payment to <FONT STYLE="white-space:nowrap">LI-COR</FONT> prior to the expiration of the
Achievement Date for such Diligence Event. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Diligence Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Achievement&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Aura fails to achieve any Diligence Event by the applicable Achievement Date, and Aura does
not elect to extend the applicable Achievement Date as permitted by this Section&nbsp;5.1(b), then this License shall automatically convert to a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Compliance with Law</B>. In all activities undertaken pursuant
to this Agreement, each Party covenants and agrees that it will comply in all material respects with applicable Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Data Sharing</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>By Aura</U>. Aura will provide <FONT STYLE="white-space:nowrap">LI-COR</FONT> with a right to reference
Aura&#146;s &#147;Drug Master File,&#148; or DMF, relating to each Licensed Product and with reasonable access to all data and other information resulting from Aura&#146;s research and development activities regarding IR Dye 700DX. Further, to the
extent required by <FONT STYLE="white-space:nowrap">LI-COR</FONT> with respect to its regulatory filings or manufacturing processes, Aura will provide <FONT STYLE="white-space:nowrap">LI-COR</FONT> reasonable access to the required raw or summary
data within the applicable DMF of Aura, subject to the confidentiality obligations herein and any applicable confidentiality obligations Aura may have to Third Parties. The Parties will cooperate in good faith in furtherance of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>By <FONT STYLE="white-space:nowrap">LI-COR</FONT></U>. <FONT STYLE="white-space:nowrap">LI-COR</FONT> will
provide Aura with a right to reference <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> DMF for IR Dye 700DX. Further, to the extent required by Aura with respect to its regulatory filings or manufacturing processes, <FONT
STYLE="white-space:nowrap">LI-COR</FONT> will provide Aura reasonable access to the required raw or summary data within such DMF of <FONT STYLE="white-space:nowrap">LI-COR,</FONT> subject to the confidentiality obligations herein and any applicable
confidentiality obligations <FONT STYLE="white-space:nowrap">LI-COR</FONT> may have to Third Parties. <FONT STYLE="white-space:nowrap">LI-COR</FONT> will reasonably assist Aura, upon its written request, with the CMC section of regulatory filings.
The Parties will cooperate in good faith in furtherance of the foregoing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Prosecution, Maintenance, and
Enforcement</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Prosecution and Maintenance</U>. <FONT STYLE="white-space:nowrap">LI-COR</FONT> will have
the sole right, in its sole discretion, to prepare, file, prosecute, and maintain the Licensed Patent and any patents or patent applications concerning any Improvements. Aura shall promptly inform <FONT STYLE="white-space:nowrap">LI-COR</FONT> as to
all matters that come to its attention that may affect the preparation, filing, prosecution or maintenance of the Licensed Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforcement</U>. <FONT STYLE="white-space:nowrap">LI-COR</FONT> and Aura shall notify each other promptly of
each infringement or possible infringement of the Licensed Patent, as well as any facts that may affect the validity, scope, or enforceability of the Licensed Patent, of which either Party becomes aware. Aura shall cooperate fully with <FONT
STYLE="white-space:nowrap">LI-COR</FONT> in connection with any action or defense relating to infringement, invalidity, or unenforceability. Aura shall promptly provide <FONT STYLE="white-space:nowrap">LI-COR</FONT> with access to all necessary
documents, and agrees to render reasonable assistance in response to a request by <FONT STYLE="white-space:nowrap">LI-COR.</FONT> Aura agrees not to take any action or compel <FONT STYLE="white-space:nowrap">LI-COR</FONT> either to initiate actions
for infringement or defend against allegations of invalidity or unenforceability of the Licensed Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Challenges</B>. If Aura or any of its Affiliates (a)&nbsp;brings any action for a declaratory judgment of the
invalidity, unenforceability, or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any of the Licensed Patent, (b)<U></U>&nbsp;initiates a <FONT STYLE="white-space:nowrap">re-examination</FONT> proceeding with respect to any Licensed
Patent, or (c)<U></U>&nbsp;asserts any other legal challenge to the ownership, infringement, validity or enforceability of any of the Licensed Patent or <FONT STYLE="white-space:nowrap">Know-How,</FONT> then in any case <FONT
STYLE="white-space:nowrap">LI-COR</FONT> may terminate this Agreement without notice. Aura shall reimburse <FONT STYLE="white-space:nowrap">LI-COR</FONT> for all costs and expenses it may have incidental to such a termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Promotional Materials and Product Labeling</B>. Subject to
Section&nbsp;5.7(b), Aura agrees that in all advertising, marketing, publicity, promotional, sales, product literature, and similar materials for public distribution or use concerning any Licensed Product, as well on all packaging for all Licensed
Product, Aura shall prominently identify such Licensed Product as using <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> IRDye 700DX &#147;under license from <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc.&#148; Aura further agrees that
all packaging for all Licensed Product will be marked with the number of the Licensed Patent in accordance with each country&#146;s patent laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7&nbsp;&nbsp;&nbsp;&nbsp;<B>Publicity and Use of Marks</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Publicity</U>. Except as provided in Section&nbsp;8.2(e), Aura may not publish or make known to others the
existence, terms, or subject matter of this Agreement without first obtaining the prior written approval of <FONT STYLE="white-space:nowrap">LI-COR;</FONT> provided that, notwithstanding anything to the contrary, Aura may disclose or reference the
existence of this Agreement and the existence of its rights under Section<U></U>&nbsp;2.1, but no other terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Use of Marks</U>. Aura and its Affiliates and Sublicensees may not use the name
<FONT STYLE="white-space:nowrap">&#147;LI-COR,&#148;</FONT> <FONT STYLE="white-space:nowrap">&#147;LI-COR</FONT> Biosciences&#148; &#147;IRDye,&#148; &#147;IRDye 700DX,&#148; or any other mark of <FONT STYLE="white-space:nowrap">LI-COR</FONT>
without the prior written consent from <FONT STYLE="white-space:nowrap">LI-COR,</FONT> such consent not to be unreasonably withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8&nbsp;&nbsp;&nbsp;&nbsp;<B>Improvements</B>. The Parties acknowledge and agree that <FONT STYLE="white-space:nowrap">LI-COR</FONT> will own
any Improvements developed by Aura or its Affiliates or Sublicensees. Aura hereby assigns to <FONT STYLE="white-space:nowrap">LI-COR</FONT> all right, title, and interest in and to such Improvements, and agrees to take all such actions, and execute
such documents, as <FONT STYLE="white-space:nowrap">LI-COR</FONT> may request to secure title to such Improvements in <FONT STYLE="white-space:nowrap">LI-COR.</FONT> Aura shall timely disclose to <FONT STYLE="white-space:nowrap">LI-COR</FONT> each
Improvement, and further shall provide <FONT STYLE="white-space:nowrap">LI-COR</FONT> all information concerning each such Improvement. All Improvements will automatically become licensed to Aura as part of the Licensed Patent or <FONT
STYLE="white-space:nowrap">Know-How</FONT> under this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Supply of IRDye 700DX </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Supply</B><B></B><B>&nbsp;&amp; Exclusivity</B>. <B><U></U></B>Subject to Section<U></U>&nbsp;6.8, Aura, its
Affiliates and Sublicensees shall during the Term, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, purchase all of their requirements of IRDye 700DX exclusively from <FONT
STYLE="white-space:nowrap">LI-COR.</FONT> <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall manufacture and supply Aura, its Affiliates and Sublicensees with <FONT STYLE="white-space:nowrap">non-cGMP</FONT> IRDye 700DX meeting the Forecast,
subject to the terms and conditions of this Agreement, and in accordance with the specifications (&#147;<B>Specifications</B>&#148;)<B> </B>set forth in <B>Exhibit</B><B><U></U></B><B>&nbsp;A</B>. In the event Aura, its Affiliates or Sublicensees
require cGMP IRDye 700DX to manufacture Licensed Product, Aura, its Affiliates and Sublicensees shall obtain their requirements of such from <FONT STYLE="white-space:nowrap">LI-COR.</FONT> The price for any cGMP IRDye 700DX supplied by <FONT
STYLE="white-space:nowrap">LI-COR</FONT> to Aura, its Affiliates or Sublicensees shall be reasonably determined by <FONT STYLE="white-space:nowrap">LI-COR.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Forecasting</B>. Commencing on the Effective Date, Aura shall provide LI-COR with a rolling, eighteen&nbsp;(18)
month forecast (&#147;<B>Forecast</B>&#148;)<B> </B>of anticipated quantities and order dates for IR Dye 700DX, with the first six<U></U>&nbsp;(6) months of each Forecast binding upon Aura. Such Forecast will be updated and submitted monthly, and
will be sent by mail or email to [***] ([***]), <FONT STYLE="white-space:nowrap">LI-COR</FONT> Biosciences, 4647<U></U>&nbsp;Superior Street, Lincoln, Nebraska 68504. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Orders and Acceptance</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Orders</U>. Aura shall place purchase orders for IRDye 700DX from time to time, provided that Aura shall at a
minimum place orders in accordance with the binding portion of the Forecast as set forth in Section&nbsp;6.2 hereof. Each purchase order will specify: (a)<U></U>&nbsp;the quantity of IRDye 700DX desired, which quantity shall not be less than
50<U></U>&nbsp;mg per purchase order; (b)<U></U>&nbsp;the desired delivery date(s); and (c)<U></U>&nbsp;the ship to address. No purchase order will be binding on the Parties unless and until accepted by
<FONT STYLE="white-space:nowrap">LI-COR.</FONT> Aura may cancel any purchase order if notice of cancellation is received by <FONT STYLE="white-space:nowrap">LI-</FONT> COR in advance of <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT>
acceptance of such purchase order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Acceptance</U>. <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall use
commercially reasonable efforts to accept each purchase order if it can deliver the IRDye 700DX on or before the requested delivery date. Each delivery of IRDye 700DX shall be made from either concurrently manufactured IRDye 700DX or from the safety
stock maintained by <FONT STYLE="white-space:nowrap">LI-COR</FONT> as required by Section&nbsp;6.7 hereof. Aura shall notify <FONT STYLE="white-space:nowrap">LI-COR</FONT> of its acceptance or rejection within [***] after receipt of each such
purchase order. Any notice of acceptance will include confirmation of the requested quantities, the delivery date, and the applicable prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Pricing and Payment</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>IRDye 700DX Pricing</U>. Aura, its Affiliates and Sublicensees shall pay
<FONT STYLE="white-space:nowrap">LI-COR</FONT> the following prices for <FONT STYLE="white-space:nowrap">non-cGMP</FONT> manufactured IR Dye 700DX: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Price Increases</U>. Commencing on January&nbsp;1, 2015, the prices in subsection (a)<U></U>&nbsp;may be
increased by <FONT STYLE="white-space:nowrap">LI-COR</FONT> from time to time, but not more than once per calendar year, to reflect reasonable increases in <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> manufacturing and supply costs
(including materials costs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment</U>. Aura shall pay for each accepted and undisputed purchase order
within [***] after the date of <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> invoice for the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Delivery</B>. Deliveries of IRDye 700DX will be made on the date specified in the accepted purchase order;
provided that <FONT STYLE="white-space:nowrap">LI-COR</FONT> will not be obligated to ship any IRDye 700DX if Aura (or any of its Affiliates or Sublicensees) is delinquent in any undisputed payment for (a)&nbsp;any previously shipped order or
(b)<U></U>&nbsp;any Royalties, Milestone Payments, or other fees owed to <FONT STYLE="white-space:nowrap">LI-COR.</FONT> The terms of delivery from <FONT STYLE="white-space:nowrap">LI-COR</FONT> to Aura will be
<FONT STYLE="white-space:nowrap">&#147;Ex-Works</FONT> Incoterms 2010 (EXW)&#148; <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> facility, and risk of loss and title will pass to Aura accordingly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Inspection and Rejection</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Inspection and Rejection</U>. Aura will have [***] after receipt of a shipment of IRDye 700DX to inspect such
product and notify <FONT STYLE="white-space:nowrap">LI-COR</FONT> if any such product fails to meet </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable specifications. Failure of Aura to provide notice within the aforesaid [***] period will cause such shipment to be deemed accepted. In the event Aura timely rejects any shipment of
product, it shall promptly return such nonconforming shipment to <FONT STYLE="white-space:nowrap">LI-COR</FONT> with a detailed explanation as to the reason(s) for nonconformance. Aura must immediately upon receipt of delivery store and maintain all
IRDye 700DX in accordance with <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> instructions and applicable Law; if Aura fails to so store and maintain such product, Aura will have no right to inspect (and reject) the same hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disputes</U>. In the event any shipment of IRDye 700DX is timely and properly rejected by Aura and <FONT
STYLE="white-space:nowrap">LI-COR</FONT> agrees that the IRDye 700DX does not conform to the applicable Specifications, <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall send a replacement shipment of IRDye 700DX within [***], after its
determination that the IRDye 700DX does not conform to the applicable Specifications. If <FONT STYLE="white-space:nowrap">LI-COR</FONT> disagrees as to whether or not the IRDye 700DX meets the Specifications, the Parties shall submit the IRDye 700DX
in question to an independent third party that has the capability of testing the IRDye 700DX to determine whether or not it complies with applicable Specifications. The losing Party will bear all costs and expenses related to such testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7&nbsp;&nbsp;&nbsp;&nbsp;<B>Safety Stock</B>. <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall, at all times during the Term, maintain a
minimum safety stock of the IRDye 700DX sufficient to meet at least eighteen (18)&nbsp;months demand based on Aura&#146;s Forecast. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8&nbsp;&nbsp;&nbsp;&nbsp;<B>Secondary Supplier</B>. In the event that <FONT STYLE="white-space:nowrap">LI-COR</FONT> fails to supply Aura
with IRDye 700DX meeting the Forecast for a period of six&nbsp;(6) consecutive months, and <FONT STYLE="white-space:nowrap">LI-COR</FONT> is unable to meet the Forecast after such six<U></U>&nbsp;(6) consecutive month period (&#147;<B>Supply
Failure</B>&#148;),<B> </B>Aura may secure a secondary supplier to supply Aura&#146;s Forecasted requirements of IRDye 700DX from such secondary supplier for such period that <FONT STYLE="white-space:nowrap">LI-COR</FONT> is unable to meet
Aura&#146;s Forecasted requirements. <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall use best efforts to assist Aura in providing <FONT STYLE="white-space:nowrap">Know-How</FONT> to such secondary supplier necessary to manufacture the IR Dye
700DX. In the event of a Supply Failure, and subject to the terms set forth in this Agreement, <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall grant to a secondary supplier a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> royalty-bearing
license under the Licensed Patent and <FONT STYLE="white-space:nowrap">Know-How</FONT> to make and have made IRDye 700DX on behalf of Aura for the Licensed Product for the Licensed Field in the Territory. Such license shall be limited to the period
of such Supply Failure and shall extend after such Supply Failure, provided, that after such Supply Failure such secondary supplier may supply up to twenty percent<U></U>&nbsp;(20%) of Aura&#146;s requirements of IR Dye 700DX. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Representations and Warranties </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Of Both Parties</B>. Each Party hereby represents and warrants to the other as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization</U>. Such Party is duly organized, validly existing, and in good standing under the laws of the
state or province of its incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority and Validity</U>. Such Party has all requisite corporate
power and authority to execute, deliver, and perform its obligations under this Agreement and to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consummate the transactions contemplated hereby. The execution, delivery, and performance by such Party of its obligations under this Agreement and the consummation of the transactions
contemplated hereby have been duly and validly authorized by all necessary action required on the part of such Party, and no other proceedings on the part of such Party are necessary to authorize this Agreement or for such Party to perform its
obligations under this Agreement. This Agreement constitutes the lawful, valid, and legally binding obligation of such Party, enforceable in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, or similar laws affecting the enforcement of creditors&#146; rights generally and general equitable principles, regardless of whether such enforceability is considered in a proceeding at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Violation or Conflict</U>. The execution, delivery, and performance of this Agreement and the transactions
contemplated hereby do not: (i)&nbsp;violate, conflict with, or result in the breach of any provision of the organizational documents of such Party; (ii)<U></U> conflict with or violate any Law applicable to such Party or any of its assets,
properties, or businesses; or (iii)<U></U>&nbsp;conflict with, result in any breach of, constitute a default (or event that with the giving of notice or lapse of time, or both, would become a default) under, require any consent which has not been
obtained under, or give to others any rights of termination, amendment, acceleration, suspension, revocation, or cancellation of, or result in the creation of any lien or encumbrance on any of the assets of such Party, pursuant to any note, bond,
mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise, or other instrument or arrangement to which such Party is a Party except, in the case of<U></U>&nbsp;(iii), to the extent that such conflicts, breaches,
defaults or other matters would not adversely affect the ability of such Party to carry out its obligations under, and to consummate the transactions contemplated by, this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governmental Consents and Approvals</U>. The execution, delivery, and performance of this Agreement by such
Party do not require any approval from a governmental authority that has not already been obtained, effected, or provided, except with respect to which the failure to so obtain or make could not reasonably be expected to have a material adverse
effect on the business, operations, properties, financial condition, assets or liabilities, results of operations or prospects of such Party or its ability to perform its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>. There are no actions by or against such Party pending before any governmental authority or, to
the knowledge of such Party, threatened to be brought by or before any governmental authority relating to the subject matter of this Agreement. There are no pending or, to the knowledge of such Party, threatened actions to which such Party is a
party (or threatened to be named as a party) to set aside, restrain, enjoin, or prevent the execution, delivery, or performance of this Agreement or the consummation of the transactions contemplated hereby by either Party. Such Party is not subject
to any order of a governmental authority (nor, to the knowledge of such Party, is there any such order threatened to be imposed by any governmental authority) relating to the subject matter of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Of <FONT STYLE="white-space:nowrap">LI-COR</FONT></B>. <FONT STYLE="white-space:nowrap">LI-COR</FONT> represents
and warrants that it owns the Licensed Patent and <FONT STYLE="white-space:nowrap">Know-How</FONT> free and clear, to its knowledge, of all ownership claims and has the freedom to practice and license all rights granted in Section&nbsp;2.1 and to
enter into this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Disclaime</B><B>r</B>. EXCEPT AS EXPRESSLY SET FORTH IN THIS
ARTICLE 7, <FONT STYLE="white-space:nowrap">LI-COR</FONT> MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO RESPONSIBILITY WHATSOEVER WITH RESPECT TO AURA&#146;S (OR ITS AFFILIATE&#146;S OR
SUBLICENSEE&#146;S) (A)&nbsp;USE OF THE LICENSED PATENTS, <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> OR IRDYE 700DX, ALL OF WHICH IS PROVIDED &#147;AS IS,&#148; OR (B)<U></U>&nbsp;RESEARCH OF, DEVELOPMENT OF, USE OF, OFFERING FOR SALE OF,
SELLING, OR HAVING SOLD ANY LICENSED PRODUCT. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES (X)<U></U>&nbsp;OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE OR (Y)<U></U>&nbsp;WITH RESPECT TO THE PERFORMANCE, SAFETY,
EFFECTIVENESS, OR COMMERCIAL VIABILITY OF THE LICENSED PRODUCT OR IRDYE 700DX, AND <FONT STYLE="white-space:nowrap">LI-COR</FONT> HEREBY DISCLAIMS ALL SUCH WARRANTIES. FURTHER, AURA MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND,
EXPRESS OR IMPLIED EXCEPT AS EXPRESSLY SET FORTH HEREIN. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Confidentiality </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality</B>. Each Party may disclose to the other Party certain Confidential Information in connection
with this Agreement. The recipient of such information shall maintain the Confidential Information as secret and confidential, such efforts to be no less than the degree of care employed by the recipient to preserve and safeguard its own
confidential information (but in no event less than a reasonable degree of care). Confidential Information of the other Party may not be used other than for the purposes of carrying out the Parties&#146; respective rights and obligations under this
Agreement, nor shall such information be disclosed or revealed to anyone except employees, advisors, consultants and representatives of the recipient who have a need to know the Confidential Information and who have each entered into a
confidentiality agreement with the recipient, under which such employees, advisors, consultants and representatives are required to maintain as confidential the confidential or proprietary information of the recipient. Such employees, advisors,
consultants and representatives must be advised by the recipient of the confidential nature of the Confidential Information and that the Confidential Information must be treated accordingly. The obligations in this Section&nbsp;8.1 apply to
Aura&#146;s Affiliates, as well as any Sublicensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Exceptions</B>. The recipient&#146;s obligations under
Section&nbsp;8.1 will not extend to any part of the Confidential Information: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;that can be demonstrated to have
been in the public domain or publicly known and readily available to the trade or the public prior to the date of the disclosure; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;that can be demonstrated, from the recipient&#146;s written records, to have been in the recipient&#146;s
possession; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;that becomes part of the public domain or publicly known by publication or otherwise, not due to
any unauthorized act by the recipient or any Third Party; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;that is demonstrated from the recipient&#146;s written records to
have been developed by or for the receiving Party without reference to Confidential Information disclosed by the disclosing Party; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;that is required to be disclosed by applicable Law; provided that the recipient notifies the other Party prior to
such disclosure and fully cooperates with the other Party in the event that the other Party elects to contest and avoid such disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Unauthorized Disclosure</B>. Each Party acknowledges and agrees that the Confidential Information of the other
Party constitutes proprietary information and trade secrets valuable to the other Party, and that the unauthorized use, loss, or disclosure of such Confidential Information may cause irreparable injury to the other Party, for which monetary damages
may not be a sufficient remedy, and that the other Party may be entitled, without waiving other rights or remedies, to obtain injunctive or equitable relief as may be deemed proper by a court of competent jurisdiction in the event of any actual or
threatened unauthorized use, loss, or disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Notification</B>. Each Party shall notify the other Party
promptly upon discovery of any unauthorized use or disclosure of the other Party&#146;s Confidential Information, and shall cooperate with the other Party in any reasonably requested fashion to assist the other Party to regain possession of such
Confidential Information and to prevent its further unauthorized use or disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Duration</B>. This
Article&nbsp;8 will survive termination or expiration of this Agreement and will continue for a period of [***] from the date of that termination or expiration. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Term and
Termination </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Term</B>. The term of this Agreement (&#147;<B>Term</B>&#148;)<B> </B>will commence on
the date of this Agreement and will continue, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the longer of (a)&nbsp;ten (10)<U></U>&nbsp;years from the First Commercial Sale of a
Licensed Product in such country and (b)<U></U>&nbsp;the last to expire Valid Claim in such country. Upon expiration of the license in a country, Aura shall have a fully paid license under Section<U></U>&nbsp;2.1 under the <FONT
STYLE="white-space:nowrap">Know-How</FONT> in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination</B>. This Agreement may be
terminated: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;by either Party upon [***] prior written notice for any material breach by the other Party of this
Agreement that remains uncured (other than with respect to late payments, which must be cured within [***]) at the end of such [***] period; provided, however, that if the breach is of such a nature that it cannot be cured within [***], then the
cure period shall continue, upon reasonable request by the breaching party, for up to [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;by either Party
immediately in the event that the other Party files or has filed against it a petition for bankruptcy, makes an assignment for the benefit of creditors, has a receiver appointed for it or a substantial part of its assets, or otherwise takes
advantage of any Law designed for relief of debtors; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;by <FONT STYLE="white-space:nowrap">LI-COR</FONT> in the event of
any violation or breach of Section&nbsp;5.5, without any notice or additional waiting periods; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;by either
Party upon [***] prior written notice, if Aura completely abandons the development of a nanoparticle product conjugated with a dye for the Licensed Field. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Effect of Termination</B>. In the event of any termination or expiration of this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The License will immediately terminate, and Aura will no longer have any rights under the Licensed Patent,
Improvements or <FONT STYLE="white-space:nowrap">Know-How</FONT> to research, develop, make, have made, use, have used, sell or have sold any Licensed Product, IRDye 700DX, or to make any other use of the Licensed Patent or <FONT
STYLE="white-space:nowrap">Know-How.</FONT> Further, both Parties will be released from all obligations and duties imposed or assumed hereunder to the extent so terminated, except as expressly provided to the contrary in this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Party will cease all use of the other Party&#146;s Confidential Information. Further, each Party shall
promptly return to the other Party all Confidential Information of the other Party in such Party&#146;s possession except for one&nbsp;(1) copy which may be maintained in a secure location for archival purposes only; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Aura shall assign (and hereby assigns) and deliver to <FONT STYLE="white-space:nowrap">LI-COR</FONT> any and all
regulatory files it may have concerning IR Dye 700DX; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Termination will not affect <FONT
STYLE="white-space:nowrap">LI-COR&#146;s</FONT> right to recover unpaid Royalties, fees, Milestone Payments, or other forms of financial compensation incurred prior to or on termination or expiration. Upon termination, Aura shall submit a final
royalty report to <FONT STYLE="white-space:nowrap">LI-COR,</FONT> and any Royalties, fees, Milestone Payments, and other financial compensation due <FONT STYLE="white-space:nowrap">LI-COR</FONT> will become immediately payable and shall be paid
concurrent with the submission of such final royalty report; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Upon termination of this Agreement by Aura
pursuant to Section&nbsp;9.2(a) due to a uncured material breach by LI-COR, Aura, its Affiliates and Sublicensees shall have the right to use, sell or have sold <FONT STYLE="white-space:nowrap">un-used</FONT> inventory of Licensed Product in its
possession for a period of three<U></U>&nbsp;(3) months subject to the terms and conditions set forth in this Agreement. All such sales by Aura, its Affiliates and Sublicensees shall be subject to the Royalty set forth in Section<U></U>&nbsp;3.2.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The following Articles and Sections will survive any termination of this Agreement: Sections&nbsp;3.4, 3.5,
3.6, 4.2, 5.3 (solely with respect to the right of reference), 5.8, and Article<U></U>&nbsp;8; Section<U></U>&nbsp;9.3; and Articles 10, 12, and 13. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>By <FONT STYLE="white-space:nowrap">LI-COR</FONT></U>. <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall
indemnify, defend, and hold harmless Aura, its Affiliates and Sublicensees, and their respective officers, directors, shareholders, employees, agents, contractors, and personnel from and against any and all Losses arising out of, based on, or
incidental to any breach of <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> representations and warranties in Article<U></U>&nbsp;7, except with respect to Losses for which <FONT STYLE="white-space:nowrap">LI-COR</FONT> is entitled to
indemnification under subsection&nbsp;(b). In no event shall <FONT STYLE="white-space:nowrap">LI-COR</FONT> be obligated to indemnify, defend, or hold harmless Aura, its Affiliates and Sublicensees, and their respective officers, directors,
shareholders, employees, agents, contractors, and personnel arising out of any claim related to the manufacture of IRDye 700DX in accordance with the Specifications, including, but not limited to, the manufacture of IRDye 700DX under <FONT
STYLE="white-space:nowrap">non-cGMP</FONT> conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>By Aura</U>. Aura shall indemnify, defend, and hold
harmless <FONT STYLE="white-space:nowrap">LI-COR,</FONT> its Affiliates, and its and their respective officers, directors, shareholders, employees agents, contractors, and personnel from and against any and all Losses arising out of, based on, or
incidental to any: (i)&nbsp;the research, development, manufacture, marketing, promotion, advertising, transportation, handling, storage, distribution, or commercialization with respect to any Licensed Product, including product liability, except to
the extent such Losses result from <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> gross negligence or willful misconduct; (ii)&nbsp;the research, development, manufacture, transportation, handling, storage, distribution, or commercialization
with respect to IRDye 700DX, except to the extent such Losses result from <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> gross negligence or willful misconduct; (iii)&nbsp;the practice or use of any the Licensed Patent, Improvements or <FONT
STYLE="white-space:nowrap">Know-How</FONT> by Aura, any of its Affiliates, or any of its or their Sublicensees, except to the extent such claim results from a breach by <FONT STYLE="white-space:nowrap">LI-COR</FONT> of its representations and
warranties in Section&nbsp;7.1 or 7.2; and (iv)&nbsp;any breach of this Agreement by Aura. The obligation of Aura to indemnify, defend, and hold harmless will continue after, and will not be affected by, any assignment, transfer, or sublicensing of
rights to any Affiliate or Sublicensee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Notice and Defense of Third-Party Claims</B>. In the event of a
claim by a Party for indemnification under this Article, such indemnified Party shall give the indemnifying Party prompt notice of the claim and copies of all papers served upon or received by the indemnified Party relating thereto. The indemnifying
Party will have the right to control the defense of such claim and all negotiations for its settlement or compromise; provided that the indemnifying Party (a)<U></U>&nbsp;will not have the right to bind the indemnified Party to any <FONT
STYLE="white-space:nowrap">non-financial</FONT> settlement, consent, or other agreement without the prior written consent of the indemnified Party, which consent may not be unreasonably withheld or delayed and (b)<U></U>&nbsp;shall keep the
indemnified Party fully informed in all respects concerning the defense and negotiation of the claim(s). The indemnified Party shall provide reasonable assistance to the indemnifying Party, at the indemnifying Party&#146;s expense, in connection
with the defense of any such claim. The indemnified Party shall have the right to participate in the defense of any such claim, at its expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Insurance </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Requirements</B>. Aura shall, at its sole cost and expense, procure and maintain insurance policies as follows:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;From the date of this Agreement and for a reasonable period after the last and final sale of any Licensed
Product (whether by Aura or its Sublicensee), comprehensive general liability insurance in an amount not less than $[***] per incident and $[***] in the annual aggregate. Such comprehensive general liability insurance must provide (i)&nbsp;product
liability coverage and (ii)<U></U>&nbsp;contractual liability coverage (covering, without limitation, Aura&#146;s indemnification obligations under this Agreement), pending confirmation of binding approval of 10.1(a)(ii) by Aura&#146;s insurer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;During all clinical trials and for a reasonable period after such trials, clinical trial insurance with per subject
coverage of $[***] and total study coverage in aggregate of $[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Obligations</B>. Aura shall name
<FONT STYLE="white-space:nowrap">LI-COR</FONT> as an additional insured in each policy obtained and maintained in accordance with Section&nbsp;11.1. Further, upon <FONT STYLE="white-space:nowrap">LI-COR</FONT><U>&#146;</U>s request, Aura shall
promptly furnish <FONT STYLE="white-space:nowrap">LI-COR</FONT> with written evidence of all such insurance policies. Aura shall provide <FONT STYLE="white-space:nowrap">LI-</FONT> COR with at least [***] prior written notice before the
cancellation, <FONT STYLE="white-space:nowrap">non-renewal,</FONT> or material change in any insurance policy. If Aura fails to obtain an applicable replacement insurance provision with comparable coverage within such [***] period, <FONT
STYLE="white-space:nowrap">LI-COR</FONT> will have the right to terminate this Agreement at the end of such [***] period, without any notice or additional waiting periods and without liability of any kind or nature to Aura. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Third-Party Requirements</B>. Aura shall require its Affiliates and Sublicensees to maintain insurance in favor
of <FONT STYLE="white-space:nowrap">LI-COR.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Limitation of Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN NO EVENT WILL EITHER PARTY BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND ARISING OUT OF OR IN
CONNECTION WITH THIS AGREEMENT, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; <U>PROVIDED</U> THAT THE FOREGOING LIMITATIONS WILL NOT APPLY WITH RESPECT TO (1)&nbsp;A PARTY&#146;S BREACH OF ITS CONFIDENTIALITY
OBLIGATIONS HEREUNDER; (2)&nbsp;A PARTY&#146;S INDEMNIFICATION OBLIGATIONS HEREUNDER AND ANY AND ALL AMOUNTS PAID IN CONNECTION THEREWITH; AND (3)&nbsp;A PARTY&#146;S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Miscellaneous </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Force Majeure</B>. If either Party fails to fulfill its obligations hereunder (other than an obligation for the
payment of money), when such failure is due to an act of God, or other circumstances beyond its reasonable control, including fire, flood, civil commotion, riot, war (declared and undeclared), revolution, or embargoes, then said failure will be
excused for the duration of such event and for such a time thereafter as is reasonable to enable the Parties to resume performance under this Agreement; provided that in no event will such time extend for a period of more than [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law and Forum</B>. This Agreement will be governed
by and construed in accordance with the laws of the State of Delaware, excluding any choice of law rules. Any action arising under or relating to this Agreement shall be brought in the U.S. District Court for the District of Nebraska, and the
Parties hereby consent to jurisdiction in such forum for any such action. To the extent permitted by applicable Law, each Party irrevocably waives all right of trial by jury in any action regarding or relating to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment</B>. Aura may not sell, assign, delegate, pledge, dispose of, or transfer this Agreement or any
rights or duties hereunder, by operation of law or otherwise, without the prior written consent of <FONT STYLE="white-space:nowrap">LI-COR</FONT> provided however, that no such consent will be required to assign, transfer or dispose of this
Agreement or any rights hereunder to a successor in connection with a merger, consolidation, business combination, sale, so long as Aura is not the surviving entity and the successor in interest agrees in writing to be bound by all the terms and
conditions hereof prior to such assignment. No assignment or other transfer will release Aura from responsibility for the performance of any accrued obligation of it hereunder (including payment obligations). This Agreement will be binding upon and
enforceable against each Party&#146;s successors and permitted assigns and transferees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Merger</B>. This
Agreement represents the entire agreement between the Parties with respect to the subject matter hereof and supersedes all previous proposals and arrangements, oral and written, relating to such subject matter, including the term sheet (and all
amendments thereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices</B>. All notices, communications and deliveries under this Agreement shall be
made in writing signed by or on behalf of the Party making the same, shall, as applicable, specify the Section under this Agreement pursuant to which it is given or being made, and shall be delivered personally or sent by registered or certified
mail (return receipt requested) or by overnight delivery (with evidence of delivery and postage and other fees prepaid) as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">If to <FONT STYLE="white-space:nowrap">LI-COR:</FONT> <BR><FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc. <BR>ATTN: <BR>Title: <BR>4647 Superior Street <BR>Lincoln, NE 68504 <BR>Phone: <BR>Email:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If to Aura: <BR>Aura Biosciences, Inc. <BR>ATTN: <BR>Title: <BR>85 Bolton Street <BR>Cambridge, MA 02140 <BR>Phone: <BR>Email:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a copy to: <BR>[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">With a copy to: <BR>Rubin and Rudman LLP <BR>ATTN: Peter B. Finn, Esq. <BR>50 Rowes Wharf <BR>Boston, MA 02110 <BR>Phone: [***] <BR>Email: [***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.6&nbsp;&nbsp;&nbsp;&nbsp;<B>General Interpretive Provisions</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The words &#147;hereof,&#148; &#147;herein,&#148; &#147;hereunder,&#148; and similar words refer to this Agreement
as a whole and not to any particular provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The term &#147;including&#148; (and
variations thereof) is not limiting and means &#147;including without limitation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The captions and
headings of this Agreement are for convenience of reference only and will not affect the interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.7&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability</B>. In the event a court of competent jurisdiction finds any provision herein illegal, invalid,
or unenforceable, that provision shall be enforced, if possible, to the greatest extent allowed by law in accordance with the Parties&#146; intent as reflected by this Agreement. If that provision cannot be enforced, the remainder of this Agreement
will be enforced to the greatest extent possible, and the offending provision will be treated as though not part of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.8&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendments</B>. This Agreement may not be amended or modified except by an instrument in writing signed by duly
authorized representatives of each Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.9&nbsp;&nbsp;&nbsp;&nbsp;<B>Waivers</B>. <U></U>The failure of either Party to enforce at
any time any of the provisions of this Agreement will in no way be construed to be a waiver of any such provision, nor in any way affect the validity of this Agreement or any part of it or the right of either Party after any such failure to enforce
each and every such provision. No waiver of any breach of this Agreement will be held to be a waiver of any other or subsequent breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.10&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts</B>. This Agreement may be executed in multiple counterparts, each of which will be deemed to be
an original and binding upon the Party who executed the same, but all of which together will constitute one and the same Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.11&nbsp;&nbsp;&nbsp;&nbsp;<B>Independent Contractors</B>. The relationship between the Parties is and shall be that of independent
contractors. This Agreement does not establish or create a partnership or joint venture between the Parties. Neither Party shall have any right or authority to bind, or enter into any contract on behalf of, the other Party, nor shall either Party
hold itself out as having such authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.12&nbsp;&nbsp;&nbsp;&nbsp;<B>Third-Party Beneficiaries</B>. Nothing expressed or implied in
this Agreement is intended, or shall be construed, to confer upon or give any person or entity (including any client, customer, employee, partner or other representative of the Parties) other than the Parties and their successors or permitted
assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, or result in such person or entity being deemed a third party beneficiary of this Agreement. All provisions hereof shall be personal solely among the
Parties to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.13&nbsp;&nbsp;&nbsp;&nbsp;<B>Construction</B>. This Agreement has been negotiated by the Parties and their
respective counsel in good faith and will be fairly interpreted in accordance with its terms and without any strict construction in favor of or against any Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.14&nbsp;&nbsp;&nbsp;&nbsp;<B>Export Controls</B>. Each Party acknowledges that it is
subject to United States laws and regulations controlling the export of compounds, technical data, and other commodities, and that Aura&#146;s rights under this Agreement are contingent on compliance with applicable United States export laws and
regulations. The transfer of certain technical data and commodities may require a license from an applicable agency of the United States government and written assurances by Aura that Aura shall not export data or commodities outside of the United
States without prior approval of such agency. Aura shall take all actions necessary to insure compliance with all such laws and regulations, orders or other restrictions on exports and further will not sell, license or
<FONT STYLE="white-space:nowrap">re-export</FONT> directly, or indirectly, the Licensed Product to any Person for use in any country or territory if such license or use would cause Aura or LI-COR to be in violation of such laws or regulations now or
hereafter in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.15&nbsp;&nbsp;&nbsp;&nbsp;<B>US Dollars</B>. All payment hereunder shall be made in United States Dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.16&nbsp;&nbsp;&nbsp;&nbsp;<B>Further Assurances</B>. Each Party shall, at the reasonable request of the other Party, execute and deliver to
the other such instruments and documents and shall take such actions as may be required to more effectively carry out the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.17&nbsp;&nbsp;&nbsp;&nbsp;<B>Dispute Resolution</B>. In the event of any dispute, controversy, disagreement, breach or claim arising out of
or relating to this Agreement or interpretation of any of the provisions (&#147;<B>Dispute</B>&#148;), such Dispute shall be submitted for resolution in accordance with the following procedures: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Parties initially shall attempt to settle any Dispute through good faith negotiations between representatives
from each Party in the spirit of mutual cooperation. If the representatives are unable to resolve such Dispute within [***], the Parties shall submit such Dispute to the Parties respective Executive Officers (the &#147;<B>Executives</B>&#148;)<B>
</B>for good faith discussion and attempted resolution. If the Executives are unable to resolve such Dispute within [***], then for such Dispute shall be settled by final and binding, <FONT STYLE="white-space:nowrap">non-appealable</FONT>
arbitration pursuant to Section<U></U>&nbsp;13.17(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If the Dispute has not been satisfactorily resolved (or
waived) pursuant to Section&nbsp;13.17(a), then the matter shall be referred to arbitration for resolution under the then commercial arbitration rules of the American Arbitration Association (the &#147;<B>A.A.A.</B>&#148;) and the decision of the
arbitrators shall be final and binding on the parties. Unless the Parties agree otherwise, the number of arbitrators shall be three, and all three shall be independent, neutral, and experienced in the biotechnology industry. One such arbitrator
shall be appointed by each Party within [***] of the initiation of arbitration under this Agreement, and the third such arbitrator shall be selected by mutual agreement of the two such arbitrators selected by the Parties. To the extent three such
arbitrators are not selected within [***] of the initiation of arbitration hereunder, such arbitrators shall be appointed by the A.A.A. Each Party shall be responsible for the filing fee and the arbitrator&#146;s fee; and otherwise, each Party shall
be responsible for its own costs and expenses, including but not limited to, travel, consultants, depositions, witnesses and attorneys&#146; fees and disbursements. The arbitrators shall be authorized to only interpret and apply the provisions of
this Agreement or any related agreements entered into under this Agreement and shall have no power or authority to modify or change any of the above in any manner. The arbitrators shall have no authority to award punitive or speculative
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
damages or any damages inconsistent with the Agreement. In addition to any monetary award, the arbitrators shall be empowered to award equitable relief, including an injunction and specific
performance of any obligation under this Agreement. The arbitrators shall, within [***] of the conclusion of the hearing, unless such time is extended by mutual agreement, notify the parties in writing of the decision, stating the reasons for such
decision and separately listing the findings of fact and conclusions of law. The arbitration shall be conducted in Chicago, Illinois and shall be governed by the laws of the State of Delaware, and the decision of the arbitrators may be entered in
any court of competent jurisdiction. The arbitration proceedings and the decision of the arbitrators will be kept confidential by the Parties and the arbitrators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>//SIGNATURE PAGE FOLLOWS// </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties are signing this License and Supply Agreement on the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="white-space:nowrap">LI-COR,</FONT> INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">AURA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ [***] <BR></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos <BR></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Name: [***] <BR>Title: [***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name: Elisabet de los Pinos, Ph. D. <BR>Title: President and CEO</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment to the Exclusive License and Supply Agreement (the &#147;<B>Amendment</B>&#148;)<B> </B>is entered into as of January&nbsp;26,
2016 (the &#147;<B>Effective Date</B>&#148;),<B> </B>by and between <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc., a Nebraska corporation with a principal address of 4647&nbsp;Superior Street, Lincoln, Nebraska 68504 (&#147;<B><FONT
STYLE="white-space:nowrap">LI-COR</FONT></B>&#148;),<B> </B>and Aura Biosciences, Inc. a Delaware corporation with a principal address of 85&nbsp;Bolton Street, Cambridge, MA 02140 (&#147;<B>Aura</B>&#148;). All defined terms used herein, but not
defined, shall have the meanings ascribed to such terms in the Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties entered into that
certain Exclusive License and Supply Agreement, dated as of January&nbsp;31, 2014 (the &#147;<B>Agreement</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Agreement set forth a procedure whereby Aura was granted a limited right and option to extend any Achievement Date for a Diligence Event by six&nbsp;(6) month increments by making a ten thousand dollar payment for each such extension; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Aura has <I>inter alia</I> requested an extension of two&nbsp;(2) Achievement Dates associated with certain Diligence Events; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to amend the Agreement to reflect the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be
legally bound, hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.15 of the Agreement is hereby amended and replaced in its entirely as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;&#147;<B>Licensed Product</B>&#148;<B> </B>means tumor binding or tumor targeting molecules (excluding antibodies, antibody fragments and
antibody-like constructs) conjugated with IRDye 700DX.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.1(b) of the Agreement is hereby
amended and replaced in its entirely as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Key Diligence Obligations</U>. Aura shall use Commercially Reasonable Efforts to
achieve each of the following diligence events (each , a &#147;<B>Diligence Event</B>&#148;)<B> </B>by the corresponding achievement date set forth below (&#147;<B>Achievement Date</B>&#148;). Notwithstanding the foregoing, Aura shall have the right
and option to extend any Achievement Date for a Diligence Event by six&nbsp;(6) month increments (but not more than two&nbsp;(2) times with respect to first and second Diligence Events, and not more than three&nbsp;(3) times with respect to the
third, fourth, and fifth Diligence Events) by making a [***] payment to <FONT STYLE="white-space:nowrap">LI-COR</FONT> prior to the expiration of the Achievement Date for such Diligence Event. In the event that Aura extends an Achievement Date for a
Diligence Event, the Achievement Dates for the remaining Diligence Events subsequent to such extended Achievement Date shall also be extended by six&nbsp;(6) month increments at no additional cost. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Diligence Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B>Achievement<BR>Date</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In the event that Aura fails to achieve any Diligence Event by the applicable Achievement Date, and Aura does
not elect to extend the applicable Achievement Date as permitted by this Section&nbsp;5.1(b), then this License shall automatically convert to a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments</U>. Aura shall pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;As partial consideration for the rights granted to Aura pursuant to Section&nbsp;1.1 of this Amendment, Aura shall
pay <FONT STYLE="white-space:nowrap">LI-COR:</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment in the amount of [***], and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT
STYLE="white-space:nowrap">non-creditable</FONT> payment in the amount of [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;As partial consideration for
the rights granted to Aura pursuant to Section&nbsp;1.2 of this Amendment, upon the Effective Date, Aura shall pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> a <FONT STYLE="white-space:nowrap">one-time,</FONT>
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment in the amount of [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>License</U>. The Parties acknowledge and agree that, notwithstanding the fact that Aura failed to achieve its first Diligence
Event by the applicable Achievement Date under the Agreement, and did not elect to extend such Achievement Date prior to such date, the License did not automatically convert to a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>General Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;All other terms and conditions of the Agreement shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;The captions to the paragraphs/sections in this Amendment are not a part of this Amendment or the Agreement, and
are included merely for convenience of reference only and shall not affect its meaning or interpretation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;This Amendment was drafted by all Parties concerned and thus any
rule of contract interpretation calling for documents to be construed against the drafter shall not apply to the construction of this Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4&nbsp;&nbsp;&nbsp;&nbsp;This Amendment, together with the Agreement, constitutes the entire agreement between the Parties with respect to
the subject matter hereof. In the event of a conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall prevail. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed this
Amendment as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">LI-COR,</FONT> INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>AURA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ ***</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: ***</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: ***</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Elisabet de los Pinos, Ph. D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: President and CEO</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT 2 TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment&nbsp;2 to the Exclusive License and Supply Agreement (the &#147;<B>Amendment</B>&#148;)<B> </B>is entered into as of
July&nbsp;27, 201 7 (the &#147;<B>Effective Date</B>&#148;),<B> </B>by and between <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc., a Nebraska corporation with a principal address of 4647&nbsp;Superior Street, Lincoln, Nebraska 68504 (&#147;<B><FONT
STYLE="white-space:nowrap">LI-COR</FONT></B>&#148;),<B> </B>and Aura Biosciences, Inc. a Delaware corporation with a principal address of 85&nbsp;Bolton Street, Cambridge, MA 02140 (&#147;<B>Aura</B>&#148;). All defined terms used herein, but not
defined, shall have the meanings ascribed to such terms in the Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties entered into that
certain Exclusive License and Supply Agreement, dated as of January&nbsp;31, 2014 (the &#147;<B>Agreement</B>&#148;);<B> </B>and further amended January&nbsp;26, 2016; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have requested clarification on several definitions in the Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, <FONT STYLE="white-space:nowrap">LI-COR</FONT> has agreed to provide Aura with an additional product under the Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, <FONT STYLE="white-space:nowrap">LI-COR</FONT> has requested Aura to assist with patent term extension under the Agreement; and
WHEREAS, pursuant to Section&nbsp;13.8 of the Agreement, the Parties desire to amend the Agreement to reflect the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.10 is deleted and is hereby amended and replaced with: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;1.10 &#147;<U>IRDye 700DX&#148;</U> means IRDye 700DX Carboxylate and any components, fragments, modifications, or derivatives of such
dye (&#147;<B>IRDye 700DX Carboxylate</B>&#148;) and any precursors of IRDye 700DX Carboxylate, such as IRDye 700DX Step&nbsp;D, as set forth in <B><U>Exhibit</U></B><B><U></U></B><B><U>&nbsp;B</U></B>.&#146;&#146; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.22 is deleted and is hereby amended and replaced with: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;1.22 &#147;Pivotal Clinical Trial&#148; means a clinical study on a sufficient number of subjects that is designed to establish that a
Licensed Product is safe and efficacious for its intended use and to determine warnings, precautions and adverse reactions that are associated with such Licensed Product in the dosage range to be prescribed, as more fully defined in 21 C.F.R.
&#167;312.21(c), as amended, such clinical study which is intended to support Regulatory Approval of such Licensed Product, including all tests and studies that are required by the FDA from time to time, pursuant to Applicable Law or otherwise an
expanded human clinical trial intended to gather information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship and to provide an adequate basis for physician labeling.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp;Each reference in the Agreement to the term &#147;Phase&nbsp;III
Clinical Trial is hereby deleted and replaced with the term &#147;Pivotal Clinical Trial.&#146;&#146; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.4&nbsp;&nbsp;&nbsp;&nbsp;The last
sentence of Section&nbsp;2.1 is deleted and is hereby amended and replaced with: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding the foregoing, such
License does not include the right to make or have made IRDye 700DX, other than modification of the IRDye 700DX Step D to perform the carboxylate processing of such IRDye 700DX Step D to make IRDye 700DX Carboxylate.&#146;&#146; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.5&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.1 (b) is hereby deleted and replaced in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(b) <U>Key Diligence Obligations</U>. Aura shall use Commercially Reasonable Efforts to achieve each of the following
diligence events (each, a &#147;<B>Diligence Event</B>&#148;)<B> </B>by the corresponding achievement date set forth below (&#147;<B>Achievement Date</B>&#148;). Notwithstanding the foregoing, Aura shall have the right and option to extend any
Achievement Date for a Diligence Event by six&nbsp;(6) months increments, but not more than three&nbsp;(3) times per Diligence Event, by making a [***] payment to <FONT STYLE="white-space:nowrap">LI-COR</FONT> prior to the expiration of the
Achievement Date for such Diligence Event. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Diligence Event</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Achievement<BR>Date</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that Aura fails to meet the Achievement Date for one or more of Diligence Events&nbsp;3, 4 or
5 referenced in the table above, then Aura shall by obligated to pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> as follows (each, a &#147;<B>Failure Payment</B>&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure to meet the Achievement Date for Diligence Event 3 or 4: Payment of the $[***] associated with
successful completion of the first Pivotal Clinical Trial with a NDA accepted by the FDA, as set forth in Section&nbsp;3.3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure to meet the Achievement Date for Diligence Event 5: Payment of the $[***] associated with the first
Commercial Sale of Licensed Product for clinical <FONT STYLE="white-space:nowrap">(non-research)</FONT> human <I>in vivo</I> use in the United States, as set forth in Section&nbsp;3.3. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Aura shall also provide a reasonably detailed written report demonstrating Aura&#146;s use of its Commercially Reasonable Efforts to achieve
the Diligence Event, and upon receipt of such report and Failure Payment for such Diligence Event, Aura shall be deemed by LI-</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
COR to have met all requirements associated with such Diligence Event. In addition, the full payment of a Failure Payment by Aura shall satisfy the applicable Milestone Payment in
Section&nbsp;3.3 and no additional payments shall be due to <FONT STYLE="white-space:nowrap">LI-COR</FONT> for the achievement of that Milestone. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Aura fails to achieve any Diligence Event by the applicable Achievement Date, and Aura has not
elected to either extend the applicable Achievement Date as permitted by this Section&nbsp;5.1 (b)&nbsp;and has not elected to proceed according to the provision in Section&nbsp;5.1(b)(i), then this License shall automatically convert to a
nonexclusive license.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.6&nbsp;&nbsp;&nbsp;&nbsp;To clearly identify the appropriate Drug Master File, the first sentence of
Section&nbsp;5.3(b) is deleted and is hereby amended and replaced as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(b) <U>By
<FONT STYLE="white-space:nowrap">LI-COR</FONT></U>. <FONT STYLE="white-space:nowrap">LI-COR</FONT> will provide Aura with a right to reference <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> DMF for IRDye 700DX Carboxylate.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.7&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.6 is hereby amended to include, after the last sentence in Section&nbsp;5.6, the following sentence:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding the foregoing, regulatory requirements for labeling and packaging in a region may overrule such requirement for Aura
to prominently display the <FONT STYLE="white-space:nowrap">LI-COR</FONT> name or patent information pertaining to the Licensed Product.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.8&nbsp;&nbsp;&nbsp;&nbsp;New Section&nbsp;5.9 is hereby added immediately after Section&nbsp;5.8 as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>5.9 Patent Term Extension</U>. The Parties shall reasonably cooperate with each other in obtaining patent term extension in any
country in the Territory under any statute or regulation equivalent or similar to 35 U.S.C. &#167; 156, where applicable to the Licensed Patents. If any election with respect to seeking such patent term extension is to be made in any country in the
Territory with respect to the Licensed Patents, then <FONT STYLE="white-space:nowrap">LI-COR,</FONT> in its sole discretion, shall make such election (including by filing supplementary protection certificates and any other extensions that are now or
in the future become available). Aura shall abide by such election and cooperate, as reasonably requested by <FONT STYLE="white-space:nowrap">LI-COR,</FONT> in connection with the foregoing (including by providing appropriate information and
executing appropriate documents).&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.9&nbsp;&nbsp;&nbsp;&nbsp;The last sentence of Section&nbsp;6.2 is deleted and is hereby amended
and replaced with: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Such Forecast will be updated and submitted quarterly, and will be sent by mail or email to [***] ([***]), <FONT
STYLE="white-space:nowrap">LI-COR</FONT> Biosciences, 4647&nbsp;Superior Street, Lincoln, Nebraska 68504.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.10&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.3 is hereby amended and replaced in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(a) <U>Orders</U>. Aura shall place purchase orders for IRDye 700DX from time to time, provided that it shall at a minimum place orders
in accordance with the binding portion of the Forecast. Each purchase order will specify: (a)&nbsp;the description of the product; (b)&nbsp;part number; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(c)&nbsp;the quantity of IRDye 700DX desired, which quantity shall not be less than 50&nbsp;mg per purchase order; (d)&nbsp;the desired delivery date(s); and (e)&nbsp;the ship to address. No
purchase order will be binding on (he Parties unless and until accepted by <FONT STYLE="white-space:nowrap">LI-COR.</FONT> Aura may cancel any purchase order if notice of cancellation is received by <FONT STYLE="white-space:nowrap">LI-COR</FONT> in
advance of <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> acceptance of such purchase order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Acceptance</U>. <FONT
STYLE="white-space:nowrap">LI-COR</FONT> shall use Commercially Reasonable Efforts to accept each purchase order if it can deliver the IRDye 700DX on or before the requested delivery date, and shall notify Aura of its acceptance or rejection within
[***] after receipt of each such purchase order. Any notice of acceptance will include confirmation of the requested quantities, the delivery date, and the applicable prices. If the order from Aura requires more than one batch or lot of material to
fulfill said order, <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall consult with Aura as to how to proceed.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.11&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.4(a) is hereby amended and replaced in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;(a)<U> IRDye 700DX Pricing</U>. Aura, its Affiliates and Sublicensees shall pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> in
accordance with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.12&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.1(b)(ii) is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;(ii) the research, development, manufacture, transportation, handling, storage, distribution, or commercialization with respect to IRDye
700DX and any modification of the IRDye 700DX Step D by Aura, its Affiliates or Sublicensees, except to the extent such Losses result from <FONT STYLE="white-space:nowrap">LI-COR&#146;s</FONT> gross negligence or willful misconduct;&#146;&#146; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.13&nbsp;&nbsp;&nbsp;&nbsp;To include the specifications for <FONT STYLE="white-space:nowrap">non-GMP</FONT> IRDye 700DX Carboxylate and IRDye
700DX Step D, Exhibit&nbsp;A (Specifications) of the Agreement is hereby amended and replaced in its entirety with Exhibit A attached hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.14&nbsp;&nbsp;&nbsp;&nbsp;New Exhibit B (IRDye 700DX) attached hereto, is hereby added immediately after Exhibit&nbsp;A (Specifications) to
the Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>General Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;All other terms and conditions of the Agreement shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;The captions to the paragraphs/sections in this Amendment are not a part of this Amendment or the Agreement, and
are included merely for convenience of reference only and shall not affect its meaning or interpretation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;This
Amendment was drafted by all Parties concerned and thus any rule of contract interpretation calling for documents to be construed against the drafter shall not apply to the construction of this Amendment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;This Amendment, together with the Agreement, constitutes the
entire agreement between the Parties with respect to the subject matter hereof. In the event of a conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;This Amendment may be executed in any number of counterparts, each of which shall be an original as against either
Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument. An executed facsimile or electronic copy of this Amendment shall have the same force and effect as an original. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed this Amendment as of the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">LI-COR,</FONT> INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>AURA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ [***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: [***]</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: [***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Specifications </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[</B>***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IRDye 700DX </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g161026g0916225457358.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 3 TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AND SUPPLY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;3 to License and Supply Agreement (&#147;<B>Amendment</B>&#148;) is entered into on April&nbsp;2018, (the
&#147;<B>Amendment Effective Date</B>&#148;) by and between <B><FONT STYLE="white-space:nowrap">LI-COR,</FONT> INC.</B> (D/B/A <FONT STYLE="white-space:nowrap">LI-COR</FONT> BIOSCIENCES), a Nebraska corporation with a principal address of
4647&nbsp;Superior Street, Lincoln, Nebraska 68504 (&#147;<B><FONT STYLE="white-space:nowrap">LI-COR</FONT></B>&#148;), and Aura Biosciences, Inc. a Delaware corporation with a principal address of 85&nbsp;Bolton Street, Cambridge, MA 02140
(&#147;<B>Aura</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, <FONT STYLE="white-space:nowrap">LI-COR</FONT> and Aura have entered into a License and Supply
Agreement dated January&nbsp;31, 2014, and amended January&nbsp;26, 2016, further amended July&nbsp;27, 2017 (the &#147;<B>Agreement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the parties now wish to amend the Agreement to reduce the pricing for IRDye 700DX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the premises and of the mutual covenants, representations and warranties set forth herein,
the parties agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Definitions; References</U></B>. Unless otherwise
specifically defined herein, each term used herein which is defined in the Agreement shall have the meaning assigned to such term in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Amendment of Section</U></B><B><U></U></B><B><U>&nbsp;6.4(a)</U></B>. Section&nbsp;6.4(a) of
the Agreement is hereby amended and replaced in its entirety as to read as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;6.4 <U>IRDye 700DX Pricing</U>. Aura, its
Affiliates, and Sublicensees shall pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> the following priced for <FONT STYLE="white-space:nowrap">non-cGMP</FONT> manufactured IRDye 700DX: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Lifetime quantity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">Non-GMP&nbsp;IRDye</FONT><BR>700DX&nbsp;Carboxylate<BR>&#147;Step D&#148; Pricing<BR>per gram</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">Non-GMP&nbsp;IRDye</FONT><BR>700DX<BR>Carboxylate <BR>&#147;Step F&#148; Pricing<BR>per gram</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECTION 11.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Construction of Agreement</U></B>. Except as amended and
supplemented hereby, all of the terms of the Agreement are incorporated herein by reference and shall remain and continue in full force and effect and are hereby ratified and confirmed in all respects. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have hereto caused their duly authorized
representatives to execute this Amendment as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">LI-COR,</FONT> INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">AURA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ [***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-15-18</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-30-18</FONT></FONT></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT 4 TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment&nbsp;4 (this &#147;<B>Amendment</B>&#148;)<B> </B>to the Exclusive License and Supply Agreement described below is entered into
as of April&nbsp;2, 2019 (the &#147;<B>Effective Date</B>&#148;),<B> </B>by and between <FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc., a Nebraska corporation with a principal address of 4647&nbsp;Superior Street, Lincoln, Nebraska 68504
(&#147;<B><FONT STYLE="white-space:nowrap">LI-COR</FONT></B>&#148;),<B> </B>and Aura Biosciences, Inc. a Delaware corporation with a principal address of 85&nbsp;Bolton Street, Cambridge, MA 02140 (&#147;<B>Aura</B>&#148;). All defined terms used
herein, but not defined, shall have the meanings ascribed to such terms in the Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties entered
into that certain Exclusive License and Supply Agreement, dated as of January&nbsp;31, 2014 (the &#147;<B>Agreement</B>&#148;);<B> </B>and further amended January&nbsp;26, 2016, July&nbsp;27, 2017 and April&nbsp;12, 2018; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have requested clarification on certain definitions and terms in the Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;13.8 of the Agreement, the Parties desire to amend the Agreement to reflect the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be
legally bound, hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendments</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;Section 1.13 is deleted and is hereby amended and replaced with: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;1.13 &#147;<U>Licensed Field</U>&#148; means use in the treatment and diagnosis of ocular cancer, including ocular <FONT
STYLE="white-space:nowrap">pre-cancer</FONT> and indeterminate lesions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.3 is amended by
deleting the phrase &#147;so long as Aura is not the surviving entity&#148; and inserting in its place the phrase &#147;so long as Aura is the surviving entity&#148;. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General Provisions</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;All other terms and conditions of the Agreement shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;The captions to the paragraphs/sections in this Amendment are not a part of this Amendment or the Agreement, and
are included merely for convenience of reference only and shall not affect its meaning or interpretation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;This
Amendment was drafted by all Parties concerned and thus any rule of contract interpretation calling for documents to be construed against the drafter shall not apply to the construction of this Amendment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;This Amendment, together with the Agreement, constitutes the
entire agreement between the Parties with respect to the subject matter hereof. In the event of a conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;This Amendment may be executed in any number of counterparts, each of which shall be an original as against either
Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument. An executed facsimile or electronic copy of this Amendment shall have the same force and effect as an original. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed this Amendment as of the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">LI-COR,</FONT> INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" NOWRAP>AURA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***] <BR>4/5/2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Name: Elisabet de Pinos<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Title: President and CEO</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">4/5/2019</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g161026g0916225940106.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap">LI-COR,</FONT> Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">4647 Superior Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Lincoln,
Nebraska </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">68504 USA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Phone:
[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Toll Free U.S. &amp; Canada: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">www.licor.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Email </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;5, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos, CEO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aura Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">85 Bolton Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exclusive License Agreement Between Aura Biosciences and <FONT STYLE="white-space:nowrap">LI-COR</FONT> dated
January&nbsp;31, 2014 (the &#147;Agreement&#148;); <FONT STYLE="white-space:nowrap">LI-COR</FONT> Agreement <FONT STYLE="white-space:nowrap">#2013-154</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Elisabet, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As mutually agreed between Aura Biosciences and
<FONT STYLE="white-space:nowrap">LI-COR,</FONT> Aura Biosciences shall pay <FONT STYLE="white-space:nowrap">LI-COR</FONT> [***] ($[***])] on or before June&nbsp;30, 2020 and [***] ($[***])] on or before May&nbsp;1, 2021 as Failure Payments under
Section&nbsp;5.1(b)(i)A and B of the Agreement. The timely receipt of the foregoing Failure Payments by <FONT STYLE="white-space:nowrap">LI-COR</FONT> shall satisfy Aura&#146;s obligations under the terms of Section&nbsp;5.1(b)(i) A and B of the
Agreement and no breach of the Agreement will have occurred on behalf of Aura, provided that Aura Bioscience remains in compliance of Section&nbsp;5.1(a) and the Agreement shall remain an exclusive Agreement unless Aura fails to timely pay the
Failure Payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreed and Accepted by Aura Biosciences</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CEO</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">6/5/2020</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>9
<FILENAME>d209588dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark &#147;[***]&#148;. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by
and between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CLEARSIDE BIOMEDICAL, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July&nbsp;3, 2019 </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Table of Contents </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>LICENSES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>2.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>License Grants</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>2.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Affiliates; Sublicenses</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>2.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>In-Licenses</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>2.4</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Licenses of Necessary Third Party IP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>2.5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Technology Transfer; Training</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>2.6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Retained Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>2.7</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Other Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>GOVERNANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>3.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Joint Steering Committee</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>3.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>JSC Authority</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>3.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>JSC Membership and Meetings</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>3.4</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>JSC Decision-Making</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>CERTAIN FINANCIAL TERMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Upfront Payment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Additional Payment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Milestone Payments</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.4</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Royalties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.5</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Reports</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.6</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Audits</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.7</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Payment Exchange Rate</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.8</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Registration</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Income Tax Withholding</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>4.10</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Late Payments</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>MANUFACTURE AND SUPPLY RESPONSIBILITIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>5.1</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Initial Supply Agreement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>5.2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Commercial Supply Agreement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>5.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Supply Failure</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>5.4</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Manufacturing License and Manufacturing Technology Transfer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;</TD>
<TD VALIGN="top" COLSPAN="4" NOWRAP>REGULATORY MATTERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>6.1</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Regulatory Filings and Interactions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>6.2</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Notice of Adverse Events Affecting Licensed Products and Clearside</B> <B>Suprachoroidal Microneedle Technology</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>6.3</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Rights of Reference</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;</TD>
<TD VALIGN="top" COLSPAN="4" NOWRAP>CONFIDENTIALITY AND PUBLICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>7.1</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Nondisclosure Obligation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>7.2</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Publicity</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;</TD>
<TD VALIGN="top" COLSPAN="4" NOWRAP>REPRESENTATIONS, WARRANTIES AND COVENANTS; INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>8.1</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Mutual Representations and Warranties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>8.2</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Additional Representations and Warranties of the Parties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>8.3</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Warranty Disclaimer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>8.4</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Certain Covenants</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>8.5</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Indemnification</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>8.6</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Limitation of Liability</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>8.7</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Insurance</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;</TD>
<TD VALIGN="top" COLSPAN="4" NOWRAP>INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>9.1</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Inventorship</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>9.2</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>9.3</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Prosecution and Maintenance of Patent Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>9.4</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Third Party Infringement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;</TD>
<TD VALIGN="top" COLSPAN="4" NOWRAP>TERM AND TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>10.1</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Term</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>10.2</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Termination Rights</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>10.3</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Effect of Expiration or Termination; Survival</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>&nbsp;</TD>
<TD VALIGN="top" COLSPAN="4" NOWRAP>MISCELLANEOUS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>11.1</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Assignment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B>11.2</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Governing Law</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><B>11.3</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Entire Agreement; Amendments</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><B>11.4</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Severability</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><B>11.5</B></TD>
<TD NOWRAP VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Headings</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Waiver of Rule of Construction</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>No Implied Waivers; Rights Cumulative</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Notices</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Compliance with Export Regulations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Force Majeure</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Dispute Resolution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Independent Contractors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Counterparts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Binding Effect; No Third Party Beneficiaries</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LICENSE AGREEMENT (the &#147;<B>Agreement</B>&#148;), effective as of July&nbsp;3, 2019 (the &#147;<B>Effective Date</B>&#148;), is by
and between Clearside Biomedical, Inc., a Delaware corporation having a principal place of business at 900 North Point Parkway, Suite 200, Alpharetta, GA 30005 (&#147;<B>Clearside</B>&#148;) and Aura Biosciences, Inc., a Delaware corporation having
its principal place of business at 85 Bolton Street, Cambridge, MA 02140 (&#147;<B>Aura</B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Aura owns or controls rights and technology useful to the research, development and commercialization of products and product
candidates to treat, diagnose or prevent neoplasms of the choroid of any size or disease stage, including, without limitation, choroidal melanoma, ocular metastases occurring in the choroid, and collectively, neoplasms known as ocular cancers; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Clearside controls a proprietary tissue targeting microinjection platform for the treatment of diseases of the eye and
delivery of pharmaceutical agents to specific portions of the eye, including the delivery of pharmaceutical compositions and formulations to the suprachoroidal space; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Aura desires to obtain an exclusive, worldwide license to the Clearside microinjection platform for the treatment of diseases
of the eye for the purpose of developing and commercializing Licensed Products (as defined herein); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Clearside desires
to grant such an exclusive, worldwide license to Aura, all on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in
consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective
meanings set forth below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means a corporation or <FONT
STYLE="white-space:nowrap">non-corporate</FONT> business entity that, directly or indirectly, controls, is controlled by, or is under common control with the Person specified, for so long as such control continues. An entity will be regarded as in
control of another entity if: (a)&nbsp;it owns, directly or indirectly, at least 50% of the voting securities or capital stock of such entity, or has other comparable ownership interest with respect to any entity other than a corporation; or
(b)&nbsp;it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or <FONT STYLE="white-space:nowrap">non-corporate</FONT> business entity, as applicable, whether through the
ownership or control of voting securities, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Applicable Law</B>&#148;
means all statutes, ordinances, regulations, rules, or orders of any Governmental Authority that may be in effect from time to time and applicable to the activities contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Aura Improvements</B>&#148; mean any
improvements, ideas, Inventions, developments, derivatives, modifications, technologies, discoveries, <FONT STYLE="white-space:nowrap">Know-How</FONT> and techniques, whether or not patentable, conceived or reduced to practice by Aura or its
Affiliates or Sublicensees during the Term of this Agreement that are Controlled by Aura and Cover or relate to any Licensed Product (excluding the Clearside Suprachoroidal Microneedle Technology component or aspect of any Licensed Product). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Background IP</B>&#148; of a Party means any and all discoveries, developments, improvements, <FONT
STYLE="white-space:nowrap">know-how,</FONT> combinations, formulations, compositions of matter, data, processes and other inventions, whether or not patentable, in such Party&#146;s ownership, possession or Control prior to the Effective Date or
made, conceived or reduced to practice by such Party outside the scope of the Agreement and without the use of any Background IP of the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business Day</B>&#148; means a day other than Saturday, Sunday or any day on which banks located in
Atlanta, Georgia or Boston, Massachusetts are authorized or obligated by Applicable Law to close. Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Calendar Quarter</B>&#148; means the respective periods of three (3)&nbsp;consecutive calendar
months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December 31; <U>provided,</U> that (a)&nbsp;the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of March&nbsp;31, June&nbsp;30,
September&nbsp;30 or December&nbsp;31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b)&nbsp;the first Calendar Quarter of a Royalty Term for the Licensed Product in a country shall begin on the First
Commercial Sale of the Licensed Product in such country and end on the first to occur of March&nbsp;31, June&nbsp;30, September&nbsp;30 or December&nbsp;31 thereafter and the last Calendar Quarter of a Royalty Term shall end on the last day of such
Royalty Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Calendar Year</B>&#148; means each successive period of twelve (12)&nbsp;months
commencing on January&nbsp;1 and ending on December 31; <U>provided,</U> that (a)&nbsp;the first Calendar Year of the Term shall begin on the Effective Date and end on the first December&nbsp;31 thereafter and the last Calendar Year of the Term
shall end on the last day of the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Change of Control</B>&#148; means any transaction or
series of related transactions which shall result in (a)&nbsp;direct or indirect ownership of more than fifty percent (50%) of the voting stock or assets of a Party or an Affiliate that controls such Party by Persons who are not shareholders of the
Party or the controlling Affiliate of such Party prior to such transaction or series related transactions, provided, however that a bona fide financing in which new shares of capital stock are sold shall not constitute a Change of Control,
(b)&nbsp;the merger of a Party with or into a Third Party in a transaction in which the shareholders of the merging Party prior to such transaction do not retain a majority interest in the entity surviving the merger, or (c)&nbsp;the sale of all or
substantially all of the assets of a Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Clearside</B><B> Improvements</B>&#148; mean any
improvements, ideas, Inventions, developments, derivatives, modifications, technologies, discoveries, <FONT STYLE="white-space:nowrap">Know-How</FONT> and techniques, whether or not patentable, conceived or reduced to practice by Clearside, its
Affiliates or its Third Party licensors party to a Clearside <FONT STYLE="white-space:nowrap">In-License</FONT> during the Term of this Agreement that are Controlled by Clearside or its Affiliates and Cover or relate to the Clearside Suprachoroidal
Microneedle Technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Clearside</B><B>
<FONT STYLE="white-space:nowrap">In-License</FONT></B>&#148; means (a)&nbsp;the Emory/GTRC License Agreement, and (b)&nbsp;any other agreement entered into between Clearside and a Third Party after the Effective Date under which, pursuant to
Section&nbsp;2.4, Aura has rights and obligations with respect to, or which otherwise Cover, the Licensed Product and is necessary to Develop, Commercialize and/or Manufacture such Licensed Product in the Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Clearside</B><B> Manufacturing Technology</B>&#148; means all Patent Rights, <FONT
STYLE="white-space:nowrap">Know-How</FONT> and Improvements owned or Controlled by Clearside or its Affiliates (including all technology and patent rights with respect to the manufacturing process) at any time during the term of the Supply
Agreement, which is necessary or useful for the Manufacture of the Clearside Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Clearside</B><B> </B><B>Suprachoroidal</B><B> Microneedle Technology</B>&#148; means
Clearside&#146;s suprachoroidal drug delivery platform and/or microinjectors and microneedles necessary or reasonably useful for the Development, Manufacture or Commercialization of Licensed Products in the Field, as in existence as of the Effective
Date and as further improved, modified, or enhanced during the Term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Clinical Trial</B>&#148; means a Phase I Clinical Trial, Phase II Clinical Trial, Phase III
Clinical Trial or Post-Approval Study, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Combination Product</B>&#148; means a
Licensed Product that is sold for a single price that includes (a)&nbsp;a compound, preparation, substance or formulation owned or Controlled by Aura in the Field (an &#147;<B>Aura Compound</B>&#148;) that is delivered to the suprachoroidal space
using the Clearside Suprachoroidal Microneedle Technology and (b)&nbsp;a laser or light source, system or device to activate such Aura Compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercialization</B>&#148; <B>or </B>&#147;<B>Commercialize</B>&#148; means any and all
activities directed to marketing, promoting, distributing, importing, exporting, using, offering to sell and/or selling the Licensed Product, including the conduct of Post-Approval Studies, and activities directed to obtaining pricing and
reimbursement approvals, as applicable. Aura shall not Commercialize any Licensed Products under the same or substantially similar name as any Clearside product and shall use a different active ingredient(s), trade dress and NDC number (in the US).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercially Reasonable Efforts</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidential Information</B>&#148; means any and all information and data, including without
limitation all scientific, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, regulatory, manufacturing, marketing, financial, trade secret and commercial information or data, whether communicated in writing or orally or by any other
method, which is provided by one Party to the other Party in connection with this Agreement. Licensed IP and Sublicensed IP are Confidential Information of Clearside. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Control</B>&#148;, &#147;<B>Controls</B>&#148; <B>or </B>&#147;<B>Controlled by</B>&#148; means
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Cost of Goods</B>&#148; means [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Cover</B>,&#148; &#147;<B>Covering</B>&#148;
<B>or </B>&#147;<B>Covers</B>&#148; means that in the absence of a license granted under a Valid Claim, the Development, Manufacture or Commercialization of the Licensed Product would or is reasonably likely to infringe such Valid Claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Development</B>,&#148; &#147;<B>Developing</B>&#148; <B>or </B>&#147;<B>Develop</B>&#148; means
the research and development activities related to the generation, characterization, optimization, construction, expression, use and production of the Licensed Product, any other research and development activities related to the <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing and qualification of the Licensed Product for clinical testing, and such other tests, studies and activities as may be required or recommended from time to time by any Regulatory Authority to
obtain Regulatory Approval of the Licensed Product, including toxicology studies, statistical analysis and report writing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing, Clinical Studies and regulatory affairs, product approval and
registration activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Emory/GTRC License Agreement</B>&#148; means that certain License
Agreement between Emory University, The Georgia Tech Research Foundation and Clearside dated as of the 4th day of July, 2012, as amended April&nbsp;2, 2014, December&nbsp;2, 2016 and April&nbsp;1, 2018, and as further amended from time to time in
accordance with Section&nbsp;2.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Field</B>&#148; means the treatment, prevention and
diagnosis of choroidal melanoma, including <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> cells and indeterminate lesions in the choroid, and choroidal metastases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>First Commercial Sale</B>&#148; means, with respect to a Licensed Product in a country, the first
sale for end use of such Licensed Product to a Third Party in such country after all required Regulatory Approvals have been granted by the Regulatory Authority of such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B>GAAP</B><B>&#148;</B><B> </B>means generally accepted accounting principles in the United
States, or internationally, as appropriate, consistently applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Generic Product</B>&#148;
means, with respect to a Licensed Product, any product other than a generic product authorized by Aura that contains the same compound, preparation, substance or formulation as such Licensed Product and that is approved by a Regulatory Agency for
administration to the suprachoroidal space and sold under an approved Marketing Authorization Application granted by a Regulatory Authority to a Third Party that is not a Sublicensee of Aura or its Affiliates and did not obtain such product in a
chain of distribution that includes any of Aura, its Affiliates, or Sublicensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Governmental Authority</B>&#148; means any court, commission, authority, department, ministry,
official or other instrumentality of, or being vested with public authority under any law of, any country, region, state or local authority, or any political subdivision thereof, or any association of countries, including without limitation any
Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IND</B>&#148; means an Investigational New Drug Application, Clinical
Trial Application or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initiate</B>&#148;, &#147;<B>Initiated</B>&#148; <B>or </B>&#147;<B>Initiation</B>&#148; means,
with respect to a Clinical Study, the administration of the first dose to the first subject in such study; <U>provided, however,</U> that in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case of a Clinical Study in which the protocol is a combination of a Phase I Clinical Trial and a Phase II Clinical Trial, the Phase II Clinical Trial portion of such Clinical Study shall be
deemed Initiated only upon commencement of the Phase II Study portion of such Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Invention</B>&#148; means any technical, scientific and other
<FONT STYLE="white-space:nowrap">know-how</FONT> and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs,
drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
<FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, safety, manufacturing and quality control data and information, including study designs and protocols, assays and biological methodology process, composition of matter, article of
manufacture, discovery or finding, patentable or otherwise, that is made, generated, conceived or otherwise invented as a result of a Party exercising its rights or carrying out its obligations under this Agreement, whether directly or via its
Affiliates, agents or independent contractors, including all rights, title and interest in and to the intellectual property rights therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all biological materials and
other tangible materials, inventions, practices, methods, protocols, formulas, knowledge, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, processes, assays, skills, experience, technology, prototypes, techniques and results of
experimentation and testing, including without limitation pharmacological, toxicological and <FONT STYLE="white-space:nowrap">pre-</FONT> clinical and clinical test data and stability, analytical and quality control data, patentable or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Knowledge</B>,&#148; with respect to a Party, means the actual knowledge of any of the
executive officers of such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all <FONT STYLE="white-space:nowrap">Know-How</FONT> that is Controlled by Clearside or its Affiliates (including the Sublicensed <FONT STYLE="white-space:nowrap">Know-How)</FONT> and
is useful or necessary in connection with the Development, Manufacture and Commercialization of a Licensed Product and, solely to the extent Section&nbsp;5.4 becomes applicable, the Manufacture of Clearside Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed IP</B>&#148; means Licensed Patent Rights, Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> and Clearside Improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Patent
Rights</B>&#148; means (a)&nbsp;the Patent Rights Covering the Clearside Suprachoroidal Microneedle Technology as set forth on <U>Schedule A,</U> (b)&nbsp;the Sublicensed Patent Rights and (c)&nbsp;all new Patent Rights Controlled by Clearside or
its Affiliates that are filed or issued with claims Covering or directed to the Clearside Suprachoroidal Microneedle Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Product</B>&#148; means any compound, preparation, substance or formulation owned or
Controlled by Aura in the Field that is delivered to the suprachoroidal space, in whole or in part, by means of or through the use of the Licensed IP, including Clearside&#146;s Suprachoroidal Microneedle Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Manufacturing</B>&#148; <B>or </B>&#147;<B>Manufacture</B>&#148; means, as applicable, all
activities associated with the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and storage of the Licensed Product, including process and formulation development,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process validation, stability testing, manufacturing <FONT STYLE="white-space:nowrap">scale-up,</FONT> <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and commercial manufacture
and analytical development, product characterization, quality assurance and quality control development, testing and release. For the avoidance of doubt, the term &#147;Manufacture&#148; does not include Aura&#146;s right to manufacture the
Clearside Product component of the Licensed Product except to the extent Section&nbsp;5.4 becomes applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Manufacture of </B><B>Clearside</B><B> Product</B>&#148; or &#147;<B>Manufacture
</B><B>Clearside</B><B> Product</B>&#148; means, as applicable, all activities associated with the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and storage of the Clearside Product, including process and
formulation development, process validation, stability testing, manufacturing scale- up, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and commercial manufacture and analytical development, product characterization, quality
assurance and quality control development, testing and release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>NDA/BLA</B>&#148; means a New
Drug Application, Biologics License Application or similar application or submission for approval to sell and market a new drug filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Necessary Third Party IP</B>&#148; means, with respect to any country, on a <FONT
STYLE="white-space:nowrap">country-by</FONT> country basis, <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patent Rights in such country owned or controlled by a Third Party that Cover the Development, Manufacturing and/or Commercialization of
the Licensed Product in or for such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Net Sales</B>&#148; means, with respect to any
Licensed Product, the gross amounts invoiced for sales or other dispositions of such Licensed Product (excluding transfer or dispositions of product at or below manufacturing cost, or without charge, for nonclinical or clinical purposes, research,
commercial samples, compassionate use, indigent programs and humanitarian and charitable donations) by or on behalf of Aura or its Affiliates (and with respect to Section&nbsp;4.4.3, its Sublicensees) to Third Parties, less the following deductions
to the extent consistent with GAAP and Aura&#146;s standard accounting practices and included in the gross invoiced sales price for such Licensed Product or otherwise paid or incurred by Aura or its Affiliates (and with respect to
Section&nbsp;4.4.3, its Sublicensees), as applicable, with respect to the sale or other disposition of such Licensed Product: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>NovaMedica</B><B> Agreement</B>&#148; means that certain License Agreement between Clearside and
NovaMedica LLC, dated August&nbsp;29, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Party</B>&#148; means Aura or Clearside;
&#147;<B>Parties</B>&#148; means Aura and Clearside. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Rights</B>&#148; means all
patents (including all reissues, extensions, substitutions, confirmations, <FONT STYLE="white-space:nowrap">re-registrations,</FONT> <FONT STYLE="white-space:nowrap">re-examinations,</FONT> invalidations, supplementary protection certificates and
patents of addition) and patent applications (including all provisional applications, requests for continuation, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> and divisions) and
all foreign equivalents of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means any individual, corporation,
company, partnership, trust, incorporated or unincorporated association, joint venture or other entity of any kind. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase 1 Clinical Trial</B>&#148; means a
Clinical Trial of a Licensed Product that generally meets the requirements of 21 CFR &#167; 312.21(a), as amended (or its successor regulation or comparable laws in countries outside of the United States) that is intended to support a preliminary
determination as to the metabolic and pharmacologic actions of the Licensed Product and whether it is safe in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase 2 Clinical Trial</B>&#148; means a Clinical Trial of a Licensed Product that generally meets
the requirements of 21 CFR &#167; 312.21(b), as amended (or its successor regulation or comparable laws in countries outside of the United States) that is intended to support a preliminary determination as to whether such Licensed Product is safe
for its intended use, and to provide preliminary information about such Licensed Product&#146;s efficacy, in order to permit the design of further Clinical Trial(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase 3 Clinical Trial</B>&#148; means a Clinical Trial of an Licensed Product in any country that
generally meets the requirements of 21 CFR &#167; 312.21(c), as amended (or its successor regulation or comparable laws in countries outside the United States) that, together with any other such clinical trials that are planned or have been
conducted, is intended to (i)&nbsp;serve as a primary basis for establishing that the Licensed Product is safe and efficacious for its intended use, (ii)&nbsp;provide an adequate basis to establish physician labeling, including contraindications,
warnings, precautions and adverse reactions and (iii)&nbsp;support marketing approval for such Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Post-Approval Study</B>&#148; means a Clinical Trial of the Licensed Product Initiated in a
country after receipt of Regulatory Approval for such Licensed Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Approval</B>&#148; means any and all approvals (including pricing and reimbursement
approvals), licenses, registrations or authorizations of any Regulatory Authority, necessary for the Development, Commercialization and Manufacture of the Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Authority</B>&#148; means any applicable government regulatory authority involved in
granting approvals for the Development, Manufacturing, Commercialization, reimbursement and/or pricing of the Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Royalty Term</B>&#148; means, on a Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and country- <FONT STYLE="white-space:nowrap">by-country</FONT> basis, the period beginning on the date of the First Commercial Sale of a Licensed Product in a country and ending
on the latest to occur of (a)&nbsp;the last date on which such Licensed Product is Covered by a Valid Claim within the Licensed Patent Rights in such country and (b)&nbsp;ten (10) years from the date of First Commercial Sale of such Product in such
country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sublicense Agreement</B>&#148; means a written agreement between Aura (or its
Affiliate) and a Third Party in which Aura grants a sublicense to such Third Party of some or all of the rights granted by Clearside to Aura pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sublicensee</B>&#148; means a Third Party to whom Aura or its Affiliate grants a sublicense under
the rights granted to Aura by Clearside hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sublicensed IP</B>&#148; means Sublicensed
Patent Rights and Sublicensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sublicensed
<FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means the <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by Clearside under the Emory/GTRC License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sublicensed Patent Rights</B>&#148; means the patents and patent applications licensed to
Clearside pursuant to the Emory/GTRC License Agreement, and all divisional, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> and foreign counterparts thereof, together with all
registrations, reissues, reexaminations, supplemental protection certificates, or extensions thereof, and any foreign counterparts thereof. For avoidance of doubt, the list of above mentioned patents and patent applications as of the Effective Date
is set forth on <U>Schedule B</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Territory</B>&#148; means worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148; means an entity other than a Party and its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>United States</B>&#148; means the United States of America and its territories, possessions and
commonwealths. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Valid Claim</B>&#148; means a claim (a)&nbsp;of any issued, unexpired patent
within the Licensed Patent Rights that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken
within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through recission, disclaimer, or otherwise or (b)&nbsp;of any patent application within the Licensed Patent Rights that was filed in
good faith and is being prosecuted actively and in good faith and has not been cancelled, withdrawn, or abandoned and has not been pending for more than five (5)&nbsp;years. If a claim of a patent application ceases to be a Valid Claim under item
(a)&nbsp;because of the passage of time and later issues as part of a patent within item (b), then it shall again be considered to be a Valid Claim effective as of the grant or issuance of such patent. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LICENSES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>License Grants</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Licensed IP</U></B>. Subject to the terms and conditions of this Agreement, Clearside hereby grants
Aura an exclusive (even as to Clearside), royalty-bearing license under and to the Licensed IP (other than the Sublicensed IP which is set forth in Section&nbsp;2.1.2), with the right to sublicense through multiple tiers (as set forth below), to
Develop and Commercialize Licensed Products in the Territory for use in the Field and, subject to Section&nbsp;5.4, to Manufacture Licensed Products in the Territory for use in the Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Sublicensed IP</U></B>. Subject to the terms and conditions of this Agreement and the Emory/GTRC
License Agreement, Clearside hereby grants Aura an exclusive (even as to Clearside), royalty-bearing sublicense under and to the Sublicensed IP, with the right to further sublicense through multiple tiers (as set forth below), to Develop and
Commercialize Licensed Products in the Territory for use in the Field and, subject to Section&nbsp;5.4, to Manufacture Licensed Products in the Territory for use in the Field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Affiliates; Sublicenses</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Affiliates</U></B>. The license grants in Section&nbsp;2.1 shall apply to an entity that is an Aura
Affiliate only for so long as such entity remains an Aura Affiliate and complies in all respects with the obligations of Aura under this Agreement. Aura hereby guarantees the full payment and performance of its Affiliates under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Sublicensing Terms</U></B>. Aura and its Affiliates shall be entitled to grant sublicenses (through
multiple tiers) of all or any portion of their rights under this Agreement; provided that each sublicense granted by Aura or its Affiliate pursuant to this Section&nbsp;2.2.2 shall be subject and subordinate to the terms and conditions of this
Agreement and the and the applicable terms and conditions of the Emory/GTRC License Agreement and shall contain terms and conditions consistent with those in this Agreement and the applicable terms and conditions in the Emory/GTRC License Agreement.
Within [***] of execution of a Sublicense Agreement or amendment to a Sublicense Agreement with any Sublicensee, Aura shall provide Clearside with a copy of the executed Sublicense Agreement or amendment, as applicable, which shall contain the
identity of the Sublicensee (and which may be redacted as to financial, economic and proprietary terms) and shall provide sufficient information to show that the following provisions have been imposed on the Sublicensee: (a)&nbsp;a requirement that
such Sublicensee submit applicable sales or other reports consistent with those required under this Agreement; (b)&nbsp;the audit requirement set forth in Section&nbsp;4.6; (c) a termination provision in the event the Sublicensee commences a legal
action challenging the validity, enforceability or scope of any Sublicensed Patent Rights; (d)&nbsp;indemnification and insurance requirements consistent with those set forth in the Emory/GTCR License Agreement; and (e)&nbsp;a requirement that such
Sublicensee comply with the confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> provisions of Article 7 with respect to both Parties&#146; Confidential Information. In the event Aura becomes aware of a material breach of any
Sublicense Agreement by a Sublicensee that has not been cured pursuant to the terms of such Sublicense Agreement Aura shall promptly notify Clearside of the particulars of same and shall enforce the terms of such sublicense. If Aura does not cause
the Sublicensee to comply with the terms of the Sublicense Agreement within [***] of Clearside&#146;s request, Aura shall, upon Clearside&#146;s written direction, terminate the Sublicense Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Liability</U></B>. Aura shall at all times be responsible for the performance of all obligations
under this Agreement, including all payment obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U><FONT STYLE="white-space:nowrap">In-Licenses</FONT></U></B>. All licenses and other rights granted to
Aura under this Agreement are subject to the rights and obligations of Clearside under the Clearside <FONT STYLE="white-space:nowrap">In-Licenses</FONT> and Aura shall comply with all Clearside <FONT STYLE="white-space:nowrap">In-Licenses</FONT> in
all material respects; <U>provided</U> that Aura shall not be obligated to make any payments to any Clearside or any Third Party licensor under a Clearside <FONT STYLE="white-space:nowrap">In-License</FONT> including, without limitation, under the
Emory/GTCR License Agreement (except to the extent Aura becomes a direct licensee of Emory University and The Georgia Tech Research Foundation pursuant to Section&nbsp;10.2.2(a)). During the Term, Clearside shall comply with and maintain the
Emory/GTRC License Agreement in full force and effect with respect to the rights granted to Aura under this Agreement. Clearside may not alter the terms of any Clearside <FONT STYLE="white-space:nowrap">In-License,</FONT> including the Emory/GTRC
License Agreement, in a manner that would have an adverse effect on Aura&#146;s rights hereunder in the Territory without the prior written consent of Aura. Clearside agrees to provide Aura with copies of any Clearside
<FONT STYLE="white-space:nowrap">In-Licenses</FONT> that are relevant to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights granted to Aura under this Agreement, and will promptly provide to Aura any notices received by Clearside and keep Aura fully apprised of circumstances arising under the Clearside <FONT
STYLE="white-space:nowrap">In-Licenses,</FONT> in each case that may affect the rights or obligations of Aura as a sublicensee thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Licenses of Necessary Third Party IP</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;During the Term, Aura may obtain, at its cost and expense, any licenses of any Necessary Third Party IP
for the Territory that it does not Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;If, during the Term, Clearside obtains a license to
Necessary Third Party IP for the Territory that relates to Clearside&#146;s Suprachoroidal Microneedle Technology and is not already Controlled by Aura or Clearside, then Clearside shall notify Aura in writing and include in such notification a
summary of such Necessary Third Party IP, the proposed commercial and sublicensing terms of the license, the Patent Rights and/or <FONT STYLE="white-space:nowrap">Know-How</FONT> included therein and any other relevant information, together with a
draft of the license agreement covering such Necessary Third Party IP and, if and to the extent requested by Aura, such requested Necessary Third Party IP shall be sublicensed to Aura hereunder or under a mutually agreed sublicense agreement between
Clearside and Aura; provided that Aura shall not be obligated to make any payments to any Third Party licensor of such Necessary Third Party IP and Aura shall not be obligated to pay Clearside any incremental compensation to Clearside under this
Agreement or such sublicense agreement. Upon inclusion herein or execution of such sublicense agreement, Clearside&#146;s license of such Necessary Third Party IP will be deemed a Clearside <FONT STYLE="white-space:nowrap">In-License</FONT> and
<U>Schedule A</U> will be updated accordingly. The Parties agree that this Section&nbsp;2.4.2 shall not apply to the Emory/GTRC License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Technology Transfer; Training</U></B>. As soon as practicable after the Effective Date, Clearside
shall (a)&nbsp;disclose to Aura all Licensed IP and Sublicensed IP in existence as of the Effective Date, and transfer to Aura copies of all tangible <FONT STYLE="white-space:nowrap">Know-How</FONT> included in the Licensed IP, including without
limitation all regulatory data and all regulatory documentation that the Parties mutually agree is reasonably necessary in order for Aura to prepare and submit an amendment to Aura&#146;s IND 121893 or as otherwise reasonably needed for regulatory
purposes; (b)&nbsp;provide Aura and its investigators for use at Aura&#146;s clinical sites all reasonably requested physical and electronic embodiments of such Licensed IP and Sublicensed IP as may be necessary for Aura and such investigators to
practice and incorporate Clearside&#146;s Suprachoroidal Microneedle Technology into Aura&#146;s preclinical and Clinical Trials; and (c)&nbsp;exercise commercially reasonable efforts, taking Clearside&#146;s ongoing business priorities into
consideration, to make appropriately trained personnel available for consultation and advice upon Aura&#146;s or such investigator&#146;s reasonable request to the extent reasonably necessary to (i)&nbsp;provide technical assistance necessary to
enable Aura or such investigator to practice and incorporate Clearside&#146;s Suprachoroidal Microneedle Technology into Aura&#146;s preclinical and Clinical Trials and (ii)&nbsp;provide regulatory assistance as reasonably necessary for Aura to
prepare and submit an amendment to Aura&#146;s IND 121893 to start a Phase I Clinical Trial using Clearside&#146;s Suprachoroidal Microneedle Technology. In addition, Clearside will provide [***] of training to Aura or its clinical sites, as
mutually agreed, for which Aura will reimburse Clearside for such training at a rate of $[***] per full time employee FTE, and Aura will reimburse Clearside for any regulatory assistance provided as mutually agreed at a rate of $[***] per FTE, in
each case following written invoices in reasonable detail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Retained Rights</U></B>. Notwithstanding the
exclusive licenses granted to Aura under Section&nbsp;2.1, Clearside expressly retains the right to use the Licensed IP in the Field in the Territory solely to perform its obligations under this Agreement. In addition, Clearside retains the right to
practice, license, and otherwise exploit the Licensed IP outside the scope of the licenses granted to Aura under Section&nbsp;2.1. Aura acknowledges and agrees that Emory and Georgia Tech retain the right to make, have made, use, import, and
transfer Licensed Products (as defined in the Emory/GTRC License Agreement) and practice Technology (as defined in the Emory/GTRC License Agreement) solely for research, educational, <FONT STYLE="white-space:nowrap">non-commercial</FONT> and
humanitarian clinical purposes subject to the limitations set forth in the Emory/GTRC License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Other Rights</U></B>. Except as otherwise expressly provided in this Agreement, under no
circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest or other right in any <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patent Rights of the other Party, including items owned, Controlled or
developed by the other Party, or provided by the other Party to the receiving Party at any time pursuant to this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNANCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Joint Steering Committee</U></B>. Within sixty (60)&nbsp;days after the Effective Date, the Parties
shall establish a joint steering committee (the &#147;<B>Joint Steering Committee</B>&#148; or the &#147;<B>JSC</B>&#148;), composed of two (2)&nbsp;representatives of Aura and two (2)&nbsp;representatives of Clearside, to coordinate the
Development, Manufacture and Commercialization of the Licensed Products in the Field in the Territory. Each JSC representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions
arising within the scope of the JSC&#146;s responsibilities. The JSC shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;serve as a forum for
discussing Development of the Licensed Products in the Field in the Territory including an annual review of Aura&#146;s Development plan which shall include a summary of tasks completed during the prior twelve (12)&nbsp;months as well as a summary
of tasks to be completed during the next twelve (12)&nbsp;months; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;serve as a forum for discussing the
Manufacture and supply of Licensed Products in the Field in the Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;serve as a forum for
discussing the Commercialization of Licensed Products in the Field in the Territory including an annual review of Aura&#146;s Commercial plan which shall include a summary of tasks completed during the prior twelve (12)&nbsp;months as well as a
summary of tasks to be completed during the next twelve (12)&nbsp;months; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;perform such other
functions as are set forth herein or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>JSC Authority</U></B>. The JSC shall have only such powers as are expressly assigned to it in this
Agreement, and such powers shall be subject to the terms and conditions of this Agreement. For clarity, the JSC shall not have any right, power or authority: (a)&nbsp;to determine any issue in a manner that would conflict with the express terms and
conditions of this Agreement; or (b)&nbsp;to modify or amend the terms and conditions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>JSC Membership and Meetings</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>JSC Members</U></B>. Aura&#146;s initial JSC representatives will be Elisabet de lose Pinos and
Cadmus Rich and Clearside&#146;s initial JSC representatives will be Dr.&nbsp;Rafael Andino and Dr.&nbsp;Thomas Ciulla. The chairmanship for each meeting shall rotate between Aura and Clearside, with one of each Party&#146;s JSC representatives
acting as chairperson of the JSC on a rotating basis. Each Party may replace its JSC representatives on written notice to the other Party, but each Party shall strive to maintain continuity. The JSC members shall jointly prepare and circulate the
meeting agenda at least ten (10)&nbsp;Business Days in advance of each meeting, and shall also promptly, but in no event later than thirty (30)&nbsp;days after such meeting, prepare and circulate for review and approval of the Parties the minutes of
such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>JSC Meetings</U></B>. The JSC will hold its first meeting within thirty
(30)&nbsp;days of establishment of the JSC pursuant to Section&nbsp;3.1. Thereafter, the JSC shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less frequently than once per Calendar Year. Meetings
may be held in person, or by audio or video teleconference; provided that all <FONT STYLE="white-space:nowrap">in-person</FONT> JSC meetings shall be held at locations mutually agreed upon by Aura and Clearside. Each Party shall be responsible for
all of its own expenses of participating in JSC meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.3.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U><FONT STYLE="white-space:nowrap">Non-Member</FONT> Attendance</U></B>. Each of Aura and Clearside
may from time to time invite a reasonable number of participants, in addition to its representatives, to attend JSC meetings in a <FONT STYLE="white-space:nowrap">non-voting</FONT> capacity; provided that, if either Aura or Clearside intends to have
any Third Party (including any consultant) attend such a meeting, such Party shall provide at least seven (7)&nbsp;days&#146; prior written notice to the other Party and obtain the other Party&#146;s approval for such Third Party to attend such
meeting, which approval shall not be unreasonably withheld or delayed. Such Party shall ensure that such Third Party is bound by confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations consistent with the terms of this
Agreement, and provide the other Party with a copy of such confidentiality agreement. The Party inviting any such Third Party shall be responsible for all of such Third Party&#146;s costs and expenses of participating in JSC meetings, unless such
invitation is mutually made by Aura and Clearside, in which case they shall equally share such costs and expenses. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>JSC Decision-Making</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Consensus and Escalation</U></B>. The JSC shall strive to make decisions solely relating to the
Field by consensus. If, after reasonable discussion and good faith consideration of each of their views on a particular matter before the JSC, the representatives of Aura and Clearside cannot reach an agreement as to such matter within five
(5)&nbsp;Business Days after such matter was brought to the JSC for resolution, such disagreement shall be resolved through escalation to the Chief Executive Officer of Aura (or his or her designee) and the Chief Executive Officer of Clearside (or
his or her designee) (collectively, the &#147;<B>Executive Officers</B>&#148;) for resolution, who shall use good faith efforts to resolve such matter within ten (10)&nbsp;Business Days after it is referred to them and, if such matter is resolved by
the Executive Officers, such resolution shall be implemented by and binding on the Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Final Decisions</U></B>. If the Executive Officers
are unable to reach consensus on any such matter during such (10)&nbsp;Business Day period, then the Executive Officer of Aura shall have the right to make the final decision; <U>provided</U> that the Executive Officer of Clearside must consent to
any final decision in connection with any disputed matter that would require or result in a change to Clearside&#146;s Suprachoroidal Microneedle Technology. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CERTAIN FINANCIAL TERMS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Upfront Payment</U></B>. Within thirty (30)&nbsp;days of the Effective Date, Aura shall pay to
Clearside [***] (the &#147;<B>Upfront Payment</B>&#148;) by wire transfer to an account designated by Clearside. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Additional Payment</U></B>. Aura shall pay to Clearside an additional [***] within [***] of the
earlier of [***] (the &#147;<B>Additional Payment</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Milestone Payments</U></B>. Aura
shall use its Commercially Reasonable Efforts to Develop, seek Regulatory Approval for a Licensed Product and, following Regulatory Approval of such Licensed Product, to Commercialize such Licensed Product. Upon the achievement of each milestone
event set forth below (a &#147;<B>Milestone Event</B>&#148;) (whether by Aura itself, an Affiliate or a Sublicensee), Aura shall become obligated to make the corresponding payment amount (&#147;<B>Milestone Payment</B>&#148;) to Clearside. Aura
shall notify Clearside in writing of the achievement of a Milestone Event (y)&nbsp;within thirty (30)&nbsp;days of achievement in the case of Milestone Events 1 through 5 and (z)&nbsp;within [***] of achievement in the case of Milestone Events 6
through 9, and Aura shall pay the corresponding Milestone Payment Amount to Clearside within [***] following such notification. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><I>Milestone&nbsp;Event</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Milestone<BR>Payment<BR>Amount</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="top">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Milestone Payment specified above for a clinical or commercial Milestone Event is only due once upon the first occurrence
of the respective Milestone Event for any Licensed Product, regardless of the applicable Clinical Trial triggering such payment or the number of Licensed Products achieving such Milestone Event. Aura understands that Clearside intends to treat the
Upfront Payment, the Additional Payment and Milestone Payment Amounts 1 through 4 set forth in the table above as partial reimbursement for actual costs incurred by Clearside in connection with research and development of Licensed Products and the
prosecution, maintenance, and enforcement of intellectual property rights Covering Licensed Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Royalties</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Royalties Payable on the Licensed Product</U></B>. Subject to the terms and conditions of this
Agreement, during the Royalty Term, Aura shall pay to Clearside on a quarterly basis royalties based on the aggregate Net Sales of all Licensed Products covered by a Valid Claim sold by Aura or its Affiliates in the Territory during a Calendar
Quarter at the rates set forth in the table below. The obligation to pay royalties will be imposed only once with respect to the same unit of a Licensed Product. Net Sales by Sublicensees are covered under Section&nbsp;4.4.3. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="27%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Calendar Year Net Sales (in Dollars)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">for all Licensed Products Sold by</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Aura or an Affiliate in the Territory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Royalty&nbsp;Rates&nbsp;as&nbsp;a&nbsp;Percentage<BR>(%)&nbsp;of&nbsp;Net&nbsp;Sales</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Necessary Third Party IP</U></B>. Any royalties and any fees,
milestones or other payments under all Clearside <FONT STYLE="white-space:nowrap">In-Licenses</FONT> of Necessary Third Party IP shall be borne exclusively by Clearside, except to the extent Aura becomes a direct licensee of Emory University and The
Georgia Tech Research Foundation pursuant to Section&nbsp;10.2.2(a). For clarity, any royalties and any fees, milestones or other payments under the Emory/GTRC License Agreement shall be borne exclusively by Clearside. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Sublicensee Royalty Revenue Percentage</U></B>. If Aura has entered into a Sublicense Agreement and
Net Sales of Licensed Products are achieved by such Sublicensee who is then obligated to make one or more royalty payments to Aura based directly or indirectly on Net Sales of Licensed Products covered by a Valid Claim sold by such Sublicensee, Aura
shall pay to Clearside, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, per Calendar Quarter, the greater of the following in respect of such Calendar Quarter: (a) [***] of the royalty
payments (based directly or indirectly on Net Sales of Licensed Products covered by a Valid Claim in such country) received by Aura from such Sublicensee during such Calendar Quarter or (b)&nbsp;royalties at the rates set forth in the table below
based on the aggregate Net Sales of all Licensed Products covered by a Valid Claim sold by such Sublicensee in such country during such Calendar Quarter. The greater of such amounts will be payable within [***] of receipt of such payments by Aura.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B><I>Calendar Year Net Sales (in Dollars)</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B><I>for all Licensed Products Sold by a</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><I>Sublicensee in the Territory</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Royalty&nbsp;Rates&nbsp;as&nbsp;a&nbsp;Percentage<BR>(%) of Net Sales</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.4.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U><FONT STYLE="white-space:nowrap">Know-How</FONT>
Based Royalty Percentage</U></B>. In the event that, during the Royalty Term, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, a Licensed Product ceases to be Covered by a Valid Claim within the Licensed Patent Rights in such country, then (a)&nbsp;the royalties payable by Aura or its Affiliates based on the
aggregate Net Sales of such Licensed Product in such country shall be equal to [***] of the Patent-Based Royalty Rates set forth in Section&nbsp;4.4.1 above and (b)&nbsp;the amounts otherwise payable pursuant Section&nbsp;4.4.3 with respect to
Licensed Product sold by a Sublicensee in such country shall be reduced by [***]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Royalty Adjustments and Limitations</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compulsory Licenses</U>. In the event that a court or a governmental agency of competent jurisdiction requires
Aura or any of its Affiliates or Sublicensees to grant a compulsory license to a Third Party permitting such Third Party to make and sell a Licensed Product in a country in the Territory, then, for the purposes of calculating the royalties payable
with respect to such Licensed Product, the royalty rate to be paid by Aura or any of its Affiliates or Sublicensees in such country shall be reduced to the rate payable by the compulsory licensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment for Generic Competition</U>. In the event that in any country in the Territory during the Royalty
Term for a Licensed Product, unit sales of all Generic Products of such Licensed Product in such country in a Calendar Quarter are equal to or greater than [***] of the sum of unit sales of such Licensed Product and all such Generic Products in such
country, then the royalty rate otherwise payable by Aura with respect to such Licensed Product in such country in such Calendar Quarter shall be reduced by [***]. Unit sales shall be measured by IQVIA (IMS Health and Quintiles) or, in the absence of
such data, an appropriate end user-level database mutually agreed by the Parties). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Third Party
Royalties</U>. If Aura, in its good faith judgment reasonably believes that it is necessary to obtain or maintain a license from any Third Party under any Patent or <FONT STYLE="white-space:nowrap">Know-How</FONT> in order to Develop, Manufacture or
Commercialize any Licensed Product (each, a &#147;<B>Third Party License</B>&#148;), then Aura will have the right to credit not more than [***] of any royalty payments actually paid by Aura or its Affiliates under such Third Party License in any
Calendar Quarter against any royalty payment payable to Clearside </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Limits on Royalty Adjustments</U>.
Notwithstanding the forgoing, in no event will the royalty reductions under this section reduce the royalty rates otherwise due to Clearside in any Calendar Year to less than [***] of such royalty rates otherwise due. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Reports</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Milestone Events; Sublicenses</U></B>. During the Term, Aura shall furnish to Clearside a written
report within [***] after the end of each Calendar Year showing the Milestone Events achieved and Sublicenses executed during the prior Calendar Year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Net Sales; Royalties</U></B>. During the Term and
after First Commercial Sale in each country in the Territory, Aura shall furnish to Clearside a written report within [***] after the end of each Calendar Quarter showing the quantity of Licensed Products sold in each country, the gross sales of
Licensed Product in each country, the itemized deductions for Licensed Products for each country included in the calculation of Net Sales, and the Net Sales in each country of the Licensed Products during the reporting period. In addition, Aura
shall prepare and deliver to Clearside any additional reports as required under the Clearside <FONT STYLE="white-space:nowrap">In-Licenses,</FONT> in each case within a time period sufficiently in advance to enable Clearside to comply with its
obligations under such Clearside <FONT STYLE="white-space:nowrap">In-Licenses.</FONT> Aura and its Affiliates and Sublicensees shall keep complete and accurate records in sufficient detail to enable the royalties and other payments payable hereunder
and to Third Parties under the Clearside <FONT STYLE="white-space:nowrap">In-Licenses</FONT> to be determined. Aura shall make all royalty payments due within [***] after the end of each Calendar Quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Financial Statements</U></B><U>.</U> During the Term, Aura shall furnish to Clearside a copy of
certified or audited financial statements and evidence of renewal of insurance within [***] of end of each fiscal year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Audits</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.6.1</B>&nbsp;&nbsp;&nbsp;&nbsp;Upon the written request of Clearside delivered at least thirty (30)&nbsp;days in advance and not more
than once in each Calendar Year, Aura and its Affiliates and Sublicensees shall permit an independent certified public accounting firm of internationally-recognized standing selected by Clearside or Emory/Georgia Tech and reasonably acceptable to
Aura, at Clearside&#146;s expense except as set forth below, to have access during normal business hours to such of the records of Aura and its Affiliates and Sublicensees as may be reasonably necessary to verify the accuracy of the royalty and
other reports hereunder for any year ending not more than [***] prior to the date of such request for the sole purpose of verifying the basis and accuracy of payments made under this Agreement. The independent public accountant shall disclose to
Clearside only (a)&nbsp;the accuracy of Net Sales reported and the basis for royalty and Milestone Payments made to Clearside under this Agreement and (b)&nbsp;the difference, if any, by which such reported and paid amounts vary from amounts
determined as a result of the audit and the details concerning such difference. Except as required by Applicable Law, no other information shall be provided to Clearside. No record may be audited more than once. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.6.2</B>&nbsp;&nbsp;&nbsp;&nbsp;If such accounting firm identifies in its written report a discrepancy made during such period, Aura shall
pay to Clearside any underpayment discovered by such audit within [***] after the accountant&#146;s report, plus interest as set forth in Section&nbsp;4.10 from the original due date. If the audit reveals an overpayment by Aura, then Aura may take a
credit for such overpayment against any future payments due to Clearside. The written report shall be binding upon the Parties. The fees charged by such accounting firm shall be paid by Clearside, unless such discrepancy represents an underpayment
by Aura of [***] or more of the total amounts due hereunder in the audited period, in which case such fees shall be paid by Aura. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.6.3</B>&nbsp;&nbsp;&nbsp;&nbsp;Aura shall comply with all applicable audit requirements in the Clearside
<FONT STYLE="white-space:nowrap">In-Licenses</FONT> and shall include in each sublicense granted by it pursuant to this Agreement a provision requiring the Sublicensee to make reports to Clearside, to keep and maintain records of sales made pursuant
to such sublicense and to grant access to such records by Clearside&#146;s independent accountant to the same extent required of Aura under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payment Exchange Rate</U></B>. All payments to be
made under this Agreement shall be made in United States dollars and shall be paid by bank wire transfer in immediately available funds to such bank account in the United States as may be designated in writing by Clearside from time to time. In the
case of Net Sales made or expenses incurred by Aura and its Affiliates and Sublicensees, the rate of exchange to be used in computing the amount of currency equivalent in United States dollars due shall be made at the rate of exchange utilized by
such Party in its worldwide accounting system and calculated in accordance with GAAP (or in accordance with Aura&#146;s accounting methods applied in the Territory consistent with Applicable Law), prevailing on the third to the last business day of
the month preceding the month in which such sales or expenses are recorded, as the case may be, but in any case consistent with the requirements of the Clearside <FONT STYLE="white-space:nowrap">In-Licenses.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Registration</U></B>. Aura will promptly make all filings with and submissions to all Governmental
Authorities and obtain and maintain all consents, permits, registrations and authorizations that are necessary or required in order for Aura to make timely payments under this Agreement, including, without limitation, any foreign exchange approvals
or requirements. Aura will promptly provide Clearside with evidence thereof upon Clearside&#146;s written request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Income Tax Withholding</U></B>. If laws, rules or regulations require withholding of income taxes or
other taxes imposed upon payments set forth in this Article 4, Aura shall make such withholding payments as required and subtract such withholding payments from the payments set forth in this Article 4. Aura shall submit appropriate proof of payment
of the withholding taxes to Clearside within a reasonable period of time. At the request of Clearside, Aura shall, at its cost, give Clearside such reasonable assistance, which shall include the provision of appropriate certificates of such
deductions made together with other supporting documentation as may be required by the relevant tax authority, to enable Clearside to claim exemption from such withholding or other tax imposed or obtain a repayment, reduction or credit and shall
upon request provide such additional documentation from time to time as is reasonably required to confirm the payment of tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Late Payments</U></B>. Any payments required to be paid hereunder that are not paid when due shall
bear interest at an annual rate equal to [***] points above the prime rate as published by <I>The Wall Street Journal</I> or any successor thereto on the first day of each Calendar Quarter in which such payments are overdue calculated on the number
of days such payment is delinquent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MANUFACTURE AND SUPPLY RESPONSIBILITIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Initial Supply Agreement</U></B>. The Parties agree to negotiate in good faith within sixty
(60)&nbsp;days after the Effective Date, or such later date as the Parties may agree, an initial agreement concerning the supply of Clearside Products for Aura&#146;s preclinical and/or clinical use (the &#147;<B>Initial Supply Agreement</B>&#148;),
with Aura&#146;s cost of the Clearside Products under the Initial Supply Agreement being equal to Clearside&#146;s Cost of Goods (reasonably documented to Aura) plus a reasonable direct markup amount to be negotiated after the Effective Date. The
Initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Supply Agreement shall require Aura to provide written notice to Clearside with rolling forecasts its preclinical and/or clinical needs promptly following its decision on initiating <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> experiments or Clinical Trials. In connection with the Initial Supply Agreement, the Parties shall also enter into a written quality agreement on reasonable and customary terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Commercial Supply Agreement</U></B>. Not later than six (6)&nbsp;months prior to Aura&#146;s filing of
an NDA/BLA covering a Licensed Product, upon Aura&#146;s written request, the Parties will negotiate in good faith and execute a manufacturing and supply agreement pursuant to which Clearside will supply Aura with its requirements of microinjectors
and microneedles (&#147;<B>Clearside</B><B> Products</B>&#148;) for Aura&#146;s commercial use in the Field (the &#147;<B>Supply Agreement</B>&#148;). Aura&#146;s cost of the Clearside Products under the Supply Agreement shall equal Clearside&#146;s
Cost of Goods (as defined) (reasonably documented to Aura) plus a reasonable direct markup amount to be negotiated at the time. The Supply Agreement shall require Aura to provide written notice to Clearside with rolling quarterly forecasts of its
commercial needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Supply Failure</U></B>. If during the term of the Supply Agreement, Clearside
fails to supply Aura with at least [***]% of the quantities of Clearside Product meeting the specifications which have been accepted by Clearside and which Clearside is obligated to supply, cumulatively, in any consecutive six (6)&nbsp;month period
for any reason other than due to a Force Majeure event or due to the material breach by Aura of the Supply Agreement (a &#147;<B>Supply Failure</B>&#148;), Aura may, at its discretion, upon not less than thirty (30)&nbsp;days&#146; written notice to
Clearside (a &#147;<B>Supply Failure Notice</B>&#148;): (a) require Clearside to supply the undelivered Clearside Product at a future date to be agreed upon by the Parties and/or (b)&nbsp;exercise its right to have one or more Third Parties
identified by Aura to Manufacture Clearside Product (an &#147;<B>Alternative Manufacturer Election</B>&#148;) and Aura shall covenant that it will require that its Third Party Manufacturer to only sell such Clearside Product in the Field, utilizing
trade dress, trade name(s), active ingredient(s) and NDC number(s) (in the US) that are different from Clearside&#146;s. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Manufacturing License and Manufacturing Technology Transfer</U></B>. Upon the occurrence of a Supply
Failure and an Alternative Manufacturer Election, Clearside shall (a)&nbsp;be deemed to have granted to Aura a worldwide, exclusive license in the Field, with the right to grant sublicenses (through multiple tiers), under the Clearside Manufacturing
Technology, to Manufacture Clearside Product and have Manufactured Clearside Product (the &#147;<B>Manufacturing License</B>&#148;) in the Field, and (b)&nbsp;transfer the Clearside Manufacturing Technology (the &#147;<B>Manufacturing Technology
Transfer</B>&#148;) to Aura and any Third Party Manufacturers identified by Aura as follows: Clearside shall (i)&nbsp;promptly disclose to Aura and any such Third Party Manufacturer all Clearside Manufacturing Technology; (ii)&nbsp;provide Aura or
any such Third Party Manufacturer with the training, documentation and other information relating to the use of the process for Manufacturing Clearside Product as may be necessary for Aura and such Third Party Manufacturers to exercise the
Manufacturing License and Manufacture Clearside Products; and (iii)&nbsp;make appropriately trained personnel available for consultation and advice upon Aura&#146;s reasonable request to the extent reasonably necessary to provide technical
assistance necessary to enable Aura or such Third Party Manufacturers to Manufacture Clearside Products. For clarity, Aura shall not be obligated to pay to Clearside the transfer price on quantities of Clearside Products so manufactured by or on
behalf of Aura by third parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY MATTERS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Regulatory Filings and Interactions</U></B>. Aura shall be responsible at its expense, for preparation
and submission of all regulatory filings for Licensed Products within the Territory. Aura will own any regulatory documents and applications submitted to the applicable Regulatory Authorities in the Territory with respect to the Licensed Product,
and will be identified as marketing authorization holder in the Territory. Aura shall: (a)&nbsp;oversee, monitor and coordinate all regulatory actions, communications and filings with, and submissions to, each Regulatory Authority; (b)&nbsp;be
responsible for interfacing, corresponding and meeting with each Regulatory Authority; and (c)&nbsp;be responsible for maintaining all regulatory filings. Aura shall provide Clearside with a draft of all regulatory submissions (or portions thereof)
that relate to the Clearside Suprachoroidal Microneedle Technology at least ten (10)&nbsp;Business Days prior to submission for review and comment by Clearside, and Aura shall consider in good faith any comments received from Clearside, and Aura
shall not submit such regulatory submissions relating to the Clearside Suprachoroidal Microneedle Technology without receipt of Clearside&#146;s prior written consent, not to be unreasonably withheld, conditioned or delayed. In addition, Aura shall
notify Clearside of any regulatory responses or communications (or portions thereof) relating to the Clearside Microneedle Technology received from any Regulatory Authority and shall provide Clearside with copies thereof within five (5)&nbsp;days
after receipt. Aura shall provide Clearside with prompt written notice of any meeting or discussion with any Regulatory Authority potentially related to the Clearside Microneedle Technology. Aura shall reasonably consider in good faith
Clearside&#146;s request to attend such meeting or discussion. Aura shall promptly provide Clearside with unredacted copies of the portion of any Regulatory Authority meeting minutes that pertain to the Clearside Suprachoroidal Microneedle
Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notice of Adverse Events Affecting Licensed Products and
</U></B><B><U>Clearside</U></B><B><U> </U></B><B><U>Suprachoroidal</U></B><B><U> Microneedle Technology</U></B>. Each Party will maintain a record of any and all complaints it or its Affiliates and Sublicensees receive with respect to the Licensed
Product. Each Party will notify the other Party in reasonable detail of any such complaints within sufficient time to allow the other Party and its Affiliates and Sublicensees (if applicable) to comply with any and all regulatory and other
requirements imposed upon them in any jurisdiction in which the Licensed Product utilizing the Clearside Suprachoroidal Microneedle Technology is being marketed or tested in Clinical Studies and/or Post-Approval Studies. Each Party will maintain at
its own expense an adverse event database for the Clearside Suprachoroidal Microneedle Technology or Licensed Product, as applicable, and the other Party will have access to all data in such adverse event database. Notwithstanding the foregoing,
each Party will report to the other Party the details around any adverse events and serious adverse events relating to the Licensed Product within the time periods for such reporting as specified in the Pharmacovigilance Agreement (defined below).
Each Party shall be responsible, at its own expense, for obtaining all adverse event information and safety data relating to the Clearside Suprachoroidal Microneedle Technology or Licensed Product, as applicable, from its Affiliates and Sublicensees
in a timely manner, and for submitting adverse event reports with respect to the Licensed Product to the applicable Regulatory Authorities in its own Territory. Upon the earlier of (a) 12 months after the Effective Date (or such other date as the
Parties may agree) and (b)&nbsp;the first patient dosed in a Clinical Trial, the Parties will develop and agree in writing upon a pharmacovigilance agreement (&#147;<B>Pharmacovigilance Agreement</B>&#148;) that will include safety data exchange
procedures governing the coordination of collection, investigation, reporting, and exchange of information concerning any adverse experiences, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any product quality and product complaints involving adverse experiences, related to the Licensed Product, sufficient to enable each Party to comply with its legal and regulatory obligations. In
addition, each Party shall promptly notify the other if such Party becomes aware of any information or circumstance that is likely to have a material adverse effect on the Development, Manufacture or Commercialization of Licensed Products utilizing
the Clearside Suprachoroidal Microneedle Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Rights of Reference</U></B>. Clearside shall
provide Aura in writing a letter of authorization, granting Aura (and its Affiliates and Sublicensees) the right of reference Clearside&#146;s device master file number 3069 for all purposes relating to Development, Manufacture or Commercialization
of Licensed Products. Such letter of authorization shall expressly permit Aura to transfer such rights to its Affiliates and Sublicensees and allow such entities the right of reference such device master file, and such rights of reference shall
expressly be binding on any assignee or transferee of Clearside&#146;s device master file. If any Regulatory Authority or Governmental Authority requires access to certain portions of any such filings, registrations and approvals related to a
Licensed Product for legal or regulatory purposes in connection with Aura&#146;s or its Affiliate&#146;s or Sublicensee&#146;s Development, Manufacture and/or Commercialization efforts, including without limitation, for filing patent-related
submissions, then Clearside shall reasonably cooperate with Aura and such Regulatory Authority or Governmental Authority and make such portions available to such Regulatory Authority or Governmental Authority and, if legally required for Aura to
submit or pursue an application for Regulatory Approval, to Aura (or its Affiliate or Sublicensee) solely for such purpose. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY AND PUBLICATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Nondisclosure Obligation</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;All Confidential Information disclosed by one Party to the other Party hereunder shall be maintained in
confidence by the receiving Party and shall not be disclosed to a Third Party or used for any purpose except as set forth herein without the prior written consent of the disclosing Party, except that the obligations set forth in this
Section&nbsp;5.1 shall not apply to Confidential Information to the extent that such Confidential Information: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;is known by the receiving Party at the time of its receipt, and not through a prior disclosure, directly or
indirectly, by the disclosing Party, as documented by the receiving Party&#146;s business records; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;is in the
public domain or otherwise available to the public by use and/or publication before its receipt from the disclosing Party, or thereafter enters the public domain or otherwise becomes available to the public through no fault of the receiving Party or
its Affiliates and Sublicensees; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;is subsequently disclosed to the receiving Party by a Third Party who may
lawfully do so and is not under an obligation of confidentiality to the disclosing Party; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;is developed by the receiving Party independently of
Confidential Information received from the disclosing Party, as documented by the receiving Party&#146;s business records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the obligations of confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT>
and nonuse set forth above and in Section&nbsp;7.2 below, a receiving Party may provide Confidential Information disclosed to it, and disclose the existence and terms of this Agreement as may be reasonably required in order to perform its
obligations and to exploit its rights under this Agreement, and specifically to (a)&nbsp;Affiliates and Sublicensees, and their employees, directors, agents, consultants, advisors and/or other Third Parties for the performance of its obligations
hereunder (or for such entities to determine their interest in performing such activities) in accordance with this Agreement in each case who are bound by confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT
STYLE="white-space:nowrap">non-use</FONT> obligations substantially similar to those set forth herein; (b)&nbsp;Governmental Authorities in order to obtain patents or perform its obligations or exploit its rights under this Agreement;
<U>provided,</U> that such Confidential Information shall be disclosed only to the extent reasonably necessary to do so, (c)&nbsp;the extent required by Applicable Law, including without limitation by the rules or regulations of the United States
Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or listing entity; provided that the receiving party shall be permitted at least five (5)&nbsp;Business Days to review
and comment upon, and reasonably approve, any such required disclosure, (d)&nbsp;any bona fide actual or prospective underwriters, investors, lenders or other financing sources and any bona fide actual or prospective collaborators or strategic
partners and to consultants and advisors of such Party, in each case who are bound by confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations substantially similar to
those set forth herein, and (e)&nbsp;Third Parties to the extent a Party is required to do so pursuant to the terms of an <FONT STYLE="white-space:nowrap">In-License.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;If a Party is required by judicial or administrative process to disclose Confidential Information that is
subject to the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> provisions of this Section&nbsp;7.1 or Section&nbsp;7.2, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other
Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality,
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-use</FONT> provisions of this Section&nbsp;7.1 and Section&nbsp;7.2, and the Party disclosing Confidential Information pursuant to law or court order
shall, at the other Party&#146;s expense, take all steps reasonably practical, including without limitation seeking an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information. In addition to the
foregoing restrictions on public disclosure, if either Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States, such
Party shall provide the other Party with a copy of this Agreement showing any sections as to which the Party proposes to request confidential treatment, will provide the other Party with an opportunity to comment on any such proposal and to suggest
additional portions of the Agreement for confidential treatment, and will take such Party&#146;s reasonable comments into consideration before filing the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Publicity</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in Section&nbsp;7.1 above and clause 7.2.2 below, the terms of this Agreement may not
be disclosed by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or disclosure relating to this Agreement or its subject matter, without the prior express
written permission of the other Party, except as may be required by law or expressly permitted by the terms hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;As soon as practicable after the execution of this Agreement by both Parties, the Parties shall use good
faith efforts to agree in writing upon a press release to be issued jointly by the Parties publicizing the execution of this Agreement. After such initial press release, neither Party shall issue a press release or public announcement relating to
this Agreement without the prior written approval of the other Party, which approval shall not be unreasonably withheld or delayed, except that a Party may (a)&nbsp;once a press release or other written statement is approved in writing by both
Parties, make subsequent public disclosure of the information contained in such press release or other written statement without the further approval of the other Party, and (b)&nbsp;issue a press release or public announcement as required, in the
reasonable judgment of such Party, by Applicable Law, including without limitation by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any
stock exchange or listing entity. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS; INDEMNIFICATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Mutual Representations and Warranties</U></B>. Each Party represents and warrants to the other Party
that as of the Effective Date of this Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;It is duly organized and validly existing under the
laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement, and to carry out the provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;It is duly authorized to execute and deliver this Agreement, and to perform its obligations hereunder, and
the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is legally binding upon it and enforceable in accordance with its terms. The execution,
delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party and by which it may be bound, or with its charter or
<FONT STYLE="white-space:nowrap">by-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;It has not granted, and will not grant, during the
Term, any right to any Third Party that would conflict with the rights granted to the other Party hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;Neither Party nor any of its Affiliates has been debarred or is subject to debarment and neither Party nor
any of its Affiliates will use in any capacity, in connection with the exercise of its rights and the performance of its obligations under this Agreement, any person or entity that has been debarred pursuant to Section&nbsp;306 of the United States
Federal Food, Drug, and Cosmetic Act or any similar law in any foreign jurisdiction, or that is the subject of a conviction described in such section or similar law in any foreign jurisdiction. Each Party agrees to inform the other Party in writing
immediately if it or any person or entity that is performing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activities under this Agreement, is debarred or is the subject of a conviction described in Section&nbsp;306 or similar law in any foreign jurisdiction, or if any action, suit, claim,
investigation or legal or administrative proceeding is pending or, to the best of the notifying Party&#146;s knowledge, is threatened, relating to the debarment or conviction of the notifying Party or any person or entity used in any capacity by
such Party or any of its Affiliates in connection with the performance of its obligations under this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Additional Representations and Warranties of the Parties</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;Additional Representations and Warranties of Clearside. Clearside represents and warrants to Aura that:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Clearside is the sole and exclusive owner of all right, title and interest in and to the Licensed IP (other
than the Sublicensed IP) in existence as of the Effective Date in the Territory, and Clearside is in Control of the Sublicensed IP. As of the Effective Date, to Clearside&#146;s Knowledge there are no claims challenging Clearside&#146;s Control of
the Licensed IP and Sublicensed IP in existence as of the Effective Date in the Territory or making any adverse claim of ownership of the Licensed IP or Sublicensed IP in existence as of the Effective Date in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Emory/GTRC License Agreement is the only Clearside <FONT STYLE="white-space:nowrap">in-license</FONT>
applicable to the Territory existing as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, (i)&nbsp;the
Emory/GTRC License Agreement is valid, binding and in full force and effect, (ii)&nbsp;Clearside is in compliance in all material respects with its material obligations under the Emory/GTRC License Agreement, (iii)&nbsp;to Clearside&#146;s
Knowledge, each Third Party is in compliance in all materials respects with its material obligations under the Emory/GTRC License Agreement and (iv)&nbsp;no party has claimed a breach of, or initiated any dispute resolution proceedings under, the
Emory/GTRC License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, Clearside has not received any written notice from
any Third Party asserting or alleging that any development or commercialization of Clearside Product or Manufacture of Clearside Product by Clearside prior to the Effective Date infringed or misappropriated the Patent Rights or other intellectual
property rights of such Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, to Clearside&#146;s Knowledge, there are no
Third Party rights that could interfere with or materially conflict with the grant of rights by Clearside to Aura under this Agreement, nor is there any Necessary Third Party IP applicable to the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Clearside&#146;s device master file number 3069 is, and, to Clearside&#146;s Knowledge, at all times during the
Term will be, complete and accurate in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;It will comply with all laws applicable to the
exercise of its rights and performance of its obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;Clearside shall exercise commercially reasonable efforts, at its
sole expense, to terminate the NovaMedica Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE
CONTRARY, CLEARSIDE MAKES NO REPRESENTATIONS OR WARRANTIES THAT ANY PATENT RIGHTS THAT COVER OR PURPORT TO COVER THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF LICENSED PRODUCT WILL ISSUE IN ANY COUNTRY IN THE TERRITORY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Additional Representations and Warranties of Aura</U></B>. Aura represents, warrants and covenants
to Clearside that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;It has or has the ability to obtain and will maintain as and when necessary the financial
and other capabilities reasonably necessary to discharge its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;It will comply
with all laws in the Territory applicable to the exercise of its rights and performance of its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Warranty Disclaimer</U></B>. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY
MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> AND FITNESS FOR A
PARTICULAR PURPOSE. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Certain Covenants</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Restrictive Covenants</U></B>. In furtherance of the exclusive license grants to Aura, during the
Term of the Agreement, Clearside shall not, and shall cause its Affiliates and their respective sublicensees, not to, directly or indirectly, Develop, Manufacture or Commercialize (or enable or assist any Person that is not a Party to the Agreement
to Develop, Manufacture or Commercialize) any compound, drug product, chemical substance, chemical entity, conjugate, biologic, biosimilar, intermediate or other drug substance intended to treat, prevent or diagnose any choroidal melanoma, including
<FONT STYLE="white-space:nowrap">pre-cancerous</FONT> cells and indeterminate lesions in the choroid, and choroidal metastases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Compliance</U></B>. Aura and its Affiliates and Sublicensees shall conduct the Development,
Manufacture (if applicable) and Commercialization of the Licensed Product in accordance with all applicable laws, rules and regulations, including without limitation current governmental regulations concerning good laboratory practices, good
clinical practices and good manufacturing practices (including but not limited the guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Employee Inventions</U></B>. Prior to performing any activities in connection with this Agreement,
the Parties shall ensure that its and its Affiliates&#146; employees, agents and consultants have executed valid and binding agreements with it that assign and otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectively vest in them any and all rights that such employees, agents and/or consultants might otherwise have in any invention including but not limited to Aura Improvements made by such
employees, agents and/or consultants. Should any royalties or other consideration become payable to such employees, agents and/or consultants, the respective Party shall remain solely responsible for making such payments. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Indemnification</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General Indemnification by Aura</U></B>. Aura shall indemnify, hold harmless, and defend Clearside,
its Affiliates and their respective directors, officers and employees and the Indemnitees (as defined in the Emory/GTRC License Agreement) (collectively, &#147;<B>Clearside Indemnitees</B>&#148;) from and against any and all Third Party claims,
suits, losses, liabilities, damages, costs, fees and expenses (including reasonable attorneys&#146; fees) (collectively, &#147;<B>Losses</B>&#148;) to the extent arising out of or resulting from, directly or indirectly, (a)&nbsp;any breach of this
Agreement by Aura, or (b)&nbsp;the gross negligence or willful misconduct by or of Aura or its Affiliates, and their respective directors, officers and employees, (c)&nbsp;the Development, Manufacture (subject to Sections 5.3 and 5.4) or
Commercialization of the Licensed Product (excluding any Clearside Product component of such Licensed Product manufactured by Clearside, an Affiliate or sublicensee), or (d)&nbsp;any (i) infringement, unauthorized use or misappropriation of any
Third Party intellectual property rights by a Licensed Product (excluding any Clearside Product component of such Licensed Product manufactured by Clearside, an Affiliate or sublicensee) or (ii)&nbsp;infringement, unauthorized use or
misappropriation of the intellectual property rights of Aura used in a Licensed Product by a Third Party where such infringement, unauthorized use or misappropriation is not related to any Clearside Product Component of such Licensed Product, in
each case except to the extent such Loss is caused by matters for which Clearside has an indemnification obligation pursuant to Section&nbsp;8.5.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General Indemnification by Clearside</U></B>. Clearside shall indemnify, hold harmless, and defend
Aura, its Affiliates, their Sublicensees and their respective directors, officers and employees (&#147;<B>Aura Indemnitees</B>&#148;) from and against any and all Losses to the extent arising out of or resulting from, directly or indirectly,
(a)&nbsp;any breach of this Agreement by Clearside, (b)&nbsp;any failure, absence, encumbrance or impairment of or upon Clearside&#146;s Control or the Licensed IP, (c)&nbsp;the development, commercialization or Manufacture of Clearside Products by
Clearside, an Affiliate or a sublicensee, (d)&nbsp;any (i) infringement, unauthorized use or misappropriation of any Third Party intellectual property rights by a Clearside Product, or (ii)&nbsp;infringement, unauthorized use or misappropriation of
the Licensed IP or Sublicensed IP by a Third Party where such infringement, unauthorized use or misappropriation is not related to any intellectual property rights of Aura used in a Licensed Product, (e)&nbsp;the gross negligence or willful
misconduct by or of Clearside, its Affiliates and Sublicensees, and their respective directors, officers, employees and agents, or (f)&nbsp;the NovaMedica Agreement or the termination thereof, in each case except to the extent such Loss is caused by
matters for which Aura has an indemnification obligation pursuant to Section&nbsp;8.5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Indemnification Procedure</U></B>. In the event of any such claim against any Aura Indemnitee or
Clearside Indemnitee (individually, an &#147;<B>Indemnitee</B>&#148;), the indemnified Party shall promptly notify the other Party in writing of the claim and the indemnifying Party shall manage and control, at its sole expense, the defense of the
claim and its settlement. The Indemnitee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall cooperate with the indemnifying Party and may, at its option and expense, be represented in any such action or proceeding. The indemnifying Party shall not be liable for any settlements,
litigation costs or expenses incurred by any Indemnitee without the indemnifying Party&#146;s written authorization. Notwithstanding the foregoing, if the indemnifying Party believes that it is not obligated to indemnify the Indemnitee, the
indemnifying Party shall promptly notify the Indemnitees, which shall then have the right to be represented in any such action or proceeding by separate counsel at their expense; <U>provided</U> that the indemnifying Party shall be responsible for
payment of such expenses if the Indemnitees are ultimately determined to be entitled to indemnification from the indemnifying Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Limitation of Liability</U></B>. NEITHER PARTY HERETO WILL BE LIABLE FOR SPECIAL, INDIRECT,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT AS A RESULT OF A PARTY&#146;S WILLFUL MISCONDUCT OR GROSS
NEGLIGENCE OR BREACH OF THE CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-USE</FONT> OBLIGATIONS IN ARTICLE 7. NOTHING IN THIS SECTION 8.6 SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Insurance</U></B>. At the time of commencement of the first Clinical Trial of a Licensed Product and
for [***] thereafter, Aura will procure and maintain in full force and effect commercial general liability insurance policies that protect and name the Indemnitees as additional insureds, at coverage levels no less than $[***] per incident and
$[***] in annual aggregate. Aura shall provide Clearside with written evidence of such insurance upon issuance and upon each annual renewal. Aura shall give Clearside at least thirty (30)&nbsp;days written notice prior to any cancellation, <FONT
STYLE="white-space:nowrap">non-renewal</FONT> or material change in such insurance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Inventorship</U></B>. Inventorship for patentable inventions conceived or reduced to practice during
the course of the performance of activities pursuant to this Agreement shall be determined in accordance with the principles that are used to determine inventorship under the patent laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Ownership</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Clearside</U></B>. Subject to the licenses granted by Clearside pursuant to this Agreement,
Clearside shall own the entire right, title and interest in and to all Clearside Background IP and, subject to Section&nbsp;9.2.4, all Clearside Improvements (and Patent Rights claiming patentable inventions therein) first made or discovered solely
by employees or consultants of Clearside or acquired solely by Clearside. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Aura</U></B>. Aura
shall own the entire right, title and interest in and to all Aura Background IP and, subject to Section&nbsp;9.2.4, all Aura Improvements (and Patent Rights claiming patentable inventions therein) first made or discovered solely by employees or
consultants of Aura or acquired solely by Aura. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.2.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Joint IP</U></B><B>. </B>Subject to
Section&nbsp;9.2.4, <B>t</B>he Parties shall jointly own any Inventions (and Patent Rights claiming patentable inventions therein) first made or discovered jointly by the Parties or their personnel during the Term (&#147;<B>Joint IP</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.2.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Certain Inventions.</U></B><B> </B>Notwithstanding anything in Sections 9.2.1 through 9.2.3 to the
contrary, (a)&nbsp;any Aura Improvement or Joint IP (and Patent Rights claiming patentable inventions therein) that relates solely to Clearside&#146;s Suprachoroidal Microneedle Technology shall be owned by Clearside and be included in the Clearside
Improvements, and (b)&nbsp;any Clearside Improvement or Joint IP (and Patent Rights claiming patentable inventions therein) that relates solely to Aura&#146;s viral nanoparticle (VLP) platform technology (including the viral nanoparticles,
formulations, dosages, volumes and delivery parameters), its choroidal cancer and <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> and <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> cell therapeutics or product candidates and its
near-infrared laser activated therapies, shall be owned by Aura. If Joint IP relates to both Parties&#146; technology, then the Parties shall (1)&nbsp;first, negotiate in good faith for one or both Parties to obtain ownership or an exclusive license
to the other Party&#146;s interest in all or a portion of such Joint IP and (2)&nbsp;subject to any transaction contemplated by the foregoing clause (1), neither Party shall be permitted to sublicense such Joint IP without the other Party&#146;s
prior written consent, not to be unreasonably withheld, delayed or conditioned. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Prosecution and Maintenance of Patent Rights</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Licensed Patent Rights</U></B>. Clearside has the sole right to, at Clearside&#146;s discretion,
file, conduct prosecution, and maintain (including without limitation the defense of any interference or opposition proceedings), all Licensed Patent Rights in the Territory and all Patent Rights that Cover Clearside Improvements, provided that,
Aura will have the opportunity to provide substantive review and comment on any such prosecution relating to the Field. The Parties acknowledge that the Sublicensed Patent Rights are being prosecuted and maintained pursuant to the Emory/GTRC License
Agreement. Clearside shall use commercially reasonable efforts to facilitate Emory University and The Georgia Tech Research Foundation to file, conduct prosecution and maintain (including without limitation the defense of any interference or
opposition proceedings) all Sublicensed Patent Rights in the Territory. If Clearside elects not to continue to seek or maintain any Licensed Patent Rights or Patent Rights that solely Cover Clearside Improvements in the Field and in any country in
the Territory (the &#147;<B>Abandoned Patents</B>&#148;), then: (a)&nbsp;if Aura is the sole exclusive licensee of such Abandoned Patents, Clearside will provide Aura with timely notice and will provide Aura with a reasonable opportunity to assume
responsibility for the continued prosecution and maintenance of such Abandoned Patents; or (b)&nbsp;if Aura is not the sole exclusive licensee of such Abandoned Patents, Clearside will provide Aura with timely notice and Aura and the other exclusive
licensees will negotiate in good faith regarding the assumption of responsibility for the continued prosecution and maintenance of such Abandoned Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Aura Technology</U></B>. Aura has the sole right to, at Aura&#146;s discretion and expense, file,
conduct prosecution, and maintain (including without limitation the defense of any interference or opposition proceedings), all Patent Rights comprising Aura Background Technology and Aura Improvements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Joint IP</U></B>. Subject to reasonable
consultation with Clearside and an opportunity for Clearside to timely review and comment on material documents, Aura has the sole right to, at Aura&#146;s discretion, file, conduct prosecution, and maintain (including without limitation the defense
of any interference or opposition proceedings), all Patent Rights comprising Joint IP in the Field, in the names of both Clearside and Aura. Clearside shall use commercially reasonable efforts to make available to Aura or its authorized attorneys,
agents or representatives, such of its employees, consultants or representatives as Aura in its reasonable judgment deems necessary in order to assist it in obtaining patent protection for such Joint IP. Each Party shall sign, or use commercially
reasonable efforts to have signed, all legal documents necessary to file and prosecute patent applications or to obtain or maintain patents in respect of such Joint IP, at its own cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Cooperation; Patent Challenges</U></B>. Each Party hereby agrees: (a)&nbsp;to make its employees,
agents and consultants reasonably available to the other Party (or to the other Party&#146;s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such Party to undertake patent prosecution; (b)&nbsp;to
provide the other Party with copies of all material correspondence pertaining to prosecution with the patent offices in the Territory; (c)&nbsp;to cooperate, if necessary, appropriate and consistent with the respective Party&#146;s intellectual
property and business strategies, with the other Party in gaining patent term extensions wherever applicable to the Patent Rights Covering the Licensed Product in Field in the Territory; and (d)&nbsp;to endeavor in good faith to coordinate its
efforts with the other Party to minimize or avoid interference with the prosecution and maintenance of the other Party&#146;s patent applications. Without limiting the foregoing, the Party prosecuting and maintaining the Patent Right shall furnish
to the other Party copies of substantive documents (<I>e.g.</I>, applications, office actions and responses) relevant to any such efforts in advance with sufficient time for such other Party to review and provide comments on such documents, and
shall in good faith take such comments into account. The Parties acknowledge that they have a shared community of legal interest in the development of products that can be manufactured, used, sold and otherwise commercialized without infringing the
intellectual property rights of any third party. The Parties may exchange confidential attorney-client communications to advance certain common legal interests in accordance with this Agreement, and shall not disclose such communications to a third
party, nor to employees of either party who do not have a need to know the content of such communication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Patent Expenses</U></B>. The patent filing, prosecution and maintenance expenses incurred after the
Effective Date with respect to Patent Rights shall be borne by each Party filing, prosecuting and maintaining such Patent Rights under this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Registration of licenses and sublicenses in the Territory</U></B>. Aura and Clearside will perform
all actions required to ensure that the licenses of the Licensed IP and sublicenses of the Sublicensed IP to Aura are approved, registered, recorded or noticed with the applicable Governmental Authorities in each applicable country in the Territory,
and that all other actions required under Applicable Law are taken to ensure that such licenses and sublicenses are fully effective and enforceable. Aura and Clearside shall each use all reasonable efforts to ensure that such actions are completed
as soon as practicable after the Effective Date. Clearside shall provide to Aura all such assistance as shall be reasonably required in connection with the above mentioned activities upon Aura&#146;s reasonable request, which request shall not be
unreasonably refused, withheld or delayed, and shall promptly provide Aura with all information and sign all documents required in order to complete activities mentioned above in this Section&nbsp;9.3.6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Third Party Infringement</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notices</U></B>. Each Party shall promptly report in writing to the other Party during the Term any
(a)&nbsp;known or suspected infringement of any Licensed IP, Sublicensed IP, Aura Improvements or Joint IP, or (b)&nbsp;unauthorized use or misappropriation of any Confidential Information, Licensed IP, Sublicensed IP, Aura Improvements or Joint IP
by a Third Party of which it becomes aware, and shall provide the other Party with all available evidence supporting such infringement, or unauthorized use or misappropriation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Rights to Enforce</U></B>. Clearside shall have the sole and exclusive right (but not obligation) to
initiate an infringement or other appropriate suit anywhere in the world against any Third Party who at any time has infringed or misappropriated, or is suspected of infringing or misappropriating, any Licensed IP or Sublicensed IP in the Field,
subject to Aura&#146;s rights below. Clearside will consider in good faith any request from Aura to initiate an infringement or other appropriate suit against any Third Party with respect to matters described in Section&nbsp;9.4.1 occurring in the
Territory in the Field; <U>provided, however,</U> that Clearside shall not be required to initiate any such suit. In the event that Clearside does not promptly initiate and diligently prosecute such a suit reasonably requested by Aura within three
(3)&nbsp;months of the request, then, subject to the Emory/GTRC License Agreement: (a)&nbsp;if Aura is the only exclusive licensee of such Licensed IP or Sublicensed IP, Aura shall have the right, at its expense, to initiate and conduct such suit in
the Territory, subject, as applicable to the terms of any Clearside <FONT STYLE="white-space:nowrap">In-License;</FONT> or (b)&nbsp;if Aura is not the only exclusive licensee of such Licensed IP or Sublicensed IP, Aura and the other exclusive
licensees shall negotiate in good faith regarding the initiation and conduct of such suit in the Territory and the allocation of such expenses among such exclusive licensees, subject, as applicable to the terms of any Clearside <FONT
STYLE="white-space:nowrap">In-License.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Procedures; Expenses and Recoveries</U></B>. The
Party having the right to initiate any infringement suit under Section&nbsp;9.4.2 above shall have the sole and exclusive right to select counsel for any such suit and shall pay all expenses of the suit, including but not limited to attorneys&#146;
fees and court costs and reimbursement of the other Party&#146;s reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expense in rendering assistance requested by the initiating Party. If required
under Applicable Law in order for the initiating Party to initiate and/or maintain such suit, or if either Party is unable to initiate or prosecute such suit solely in its own name or it is otherwise advisable to obtain an effective legal remedy, in
each case, the other Party shall join as a party to the suit and will execute and cause its Affiliates to execute all documents necessary for the initiating Party to initiate litigation to prosecute and maintain such action. In addition, at the
initiating Party&#146;s request, the other Party shall provide reasonable assistance to the initiating Party in connection with an infringement suit at no charge to the initiating Party except for reimbursement by the initiating Party of reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in rendering such assistance. The <FONT STYLE="white-space:nowrap">non-initiating</FONT> Party shall have the right to participate and be
represented in any such suit by its own counsel at its own expense. If the Parties obtain from a Third Party, in connection with such suit, any damages, license fees, royalties or other compensation (including but not limited to any amount received
in settlement of such litigation) (<B>&#147;Recoveries</B>&#148;), such amounts shall be allocated in all cases as follows regardless of which Party brings the enforcement action: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;first, to reimburse each Party for all expenses of the suit
incurred by such Party, including but not limited to attorneys&#146; fees and disbursements, travel costs, court costs and other litigation expenses; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;second, if such suit is related to the Sublicensed IP, any amounts required to be paid to Emory University and/or
Georgia Tech Research Corporation pursuant to the Emory/GTRC Licensed Agreement shall be so paid; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;third,
Aura shall be entitled to receive the remaining Recoveries as Net Sales of the Licensed Product in the Territory; provided that, Clearside shall be entitled to receive Aura Royalty Payments on such Net Sales pursuant to the terms of Section&nbsp;3.1
as if such Net Sales had occurred during the time period of the infringement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Term</U></B>. This Agreement shall be effective as of the Effective Date and, unless terminated
earlier pursuant to Section&nbsp;10.2 below, this Agreement shall continue in effect until expiration of the Royalty Term (&#147;<B>Term</B>&#148;). Upon expiration of the Term, all licenses of the Parties under Article 2 (including for clarity
Section&nbsp;5.4, if applicable) then in effect shall become fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> perpetual, irrevocable, exclusive licenses. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination Rights</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination for Cause</U></B>. This Agreement may be terminated at any time during the Term as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;by Clearside, upon written notice to Aura if Aura is in breach of its material obligations hereunder
and has not cured such breach within thirty (30)&nbsp;days in the case of a payment breach, or sixty (60)&nbsp;days in the case of all other breaches, after written notice requesting cure of the breach; however, such sixty (60)&nbsp;day period shall
be extended for an additional thirty (30)&nbsp;days if Clearside is acting diligently to cure any alleged breach. Aura may seek dispute resolution if there is a disagreement on whether or not a material breach has occurred, and pending final
resolution of the dispute, termination shall not be effective and Aura shall retain all its exclusive license rights hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;by Aura, upon written notice to Clearside if Clearside is in breach of its material obligations hereunder and has
not cured such breach within sixty (60)&nbsp;days after written notice requesting cure of the breach; however, such ninety (60)&nbsp;day period shall be extended for an additional thirty (30)&nbsp;days if Clearside is acting diligently to cure any
alleged breach; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;by Aura, at any time, upon at least sixty (60)&nbsp;days&#146; prior written notice to
Clearside; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or
receivership proceedings of the other Party, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; <U>provided, however,</U> that in the event of any involuntary bankruptcy or receivership
proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within sixty (60)&nbsp;days after the filing thereof; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;unless unenforceable under Applicable Law, by Clearside upon
written notice to Aura if Aura, its Affiliates, or Sublicensees, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or scope of any of the Licensed Patent Rights in a
court or other governmental agency of competent jurisdiction, including a reexamination or opposition proceeding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Effect of Termination</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination by Clearside</U></B>. Without limiting any other legal or equitable remedies that Clearside may
have, if Clearside terminates this Agreement in accordance with Section&nbsp;10.2.1 (a) or 10.2.1 (d) then, all Sublicense Agreements that are in compliance with the terms of Section&nbsp;2.2 shall be assigned by Aura to Clearside and shall continue
in full force and effect unless the Sublicensee is in material breach or has failed to remedy such breach pursuant to the provisions of the Sublicense Agreement, in which case such Sublicense Agreement shall automatically terminate; provided,
however, that Clearside shall not have any obligations under any Sublicense Agreement that are in addition to or inconsistent with this Agreement. In addition, if the Emory/GTRC License Agreement terminates for any reason, Aura shall, unless this
Agreement also terminates, from the effective date of such termination, become a direct licensee of Emory/GTRC with respect to the rights sublicensed to Aura by Clearside, in which case Aura shall have the rights and obligations of Clearside under
Emory/GTRC License Agreement, provided that Aura will not become a direct licensee of Emory/GTRC if Aura was the direct cause of the termination of the Emory/GTRC License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination upon Bankruptcy of a Party</U></B>. If this Agreement is terminated by either Party (the
&#147;<B><FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party</B>&#148;) pursuant to Section&nbsp;10.2.1(d) due to the rejection of this Agreement by or on behalf of the other Party (the &#147;<B>Bankrupt Party</B>&#148;) under
Section&nbsp;365 of the United States Bankruptcy Code (the &#147;<B>Code</B>&#148;) or an equivalent type of provision under a relevant law applicable to the Party in question, all licenses and rights to licenses granted under or pursuant to this
Agreement by the Bankrupt Party to the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the Code, licenses of rights to &#147;intellectual property&#148; as
defined under Section&nbsp;101(35A) of the Code. The Parties agree that the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and
elections under the Code, and that upon commencement of a bankruptcy proceeding by or against the Bankrupt Party under the Code, the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party shall be entitled to a complete duplicate of, or complete
access to (as the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party deems appropriate), any such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments thereof shall be
promptly delivered to the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party (i)&nbsp;upon any such commencement of a bankruptcy proceeding upon written request therefor by the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party,
unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement or (ii)&nbsp;if not delivered under (i)&nbsp;above, upon the rejection of this Agreement by or on behalf of the Bankrupt Party upon written request
therefor by the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party. The foregoing provisions are without prejudice to any rights the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party may have arising under the Code or other
Applicable Law. The Parties intend for the substance of this Section&nbsp;10.2.2(b) to apply worldwide, even if the Code does not expressly apply to the Bankrupt Party or to the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Effect of Expiration or Termination;
Survival</U></B>. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights
of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including without limitation the obligation to pay royalties for the Licensed Products sold prior to such expiration or termination. The
provisions of Articles 1, 7, 9 and 11 and Sections 4.6, 4.7, 4.9, 4.10, 6.2, 6.4 (but only with respect to filings and submissions made on or prior to such expiration or termination), 8.5, 8.6, 8.7, 10.2.2 and 10.3 shall survive any expiration or
termination of this Agreement (in each case in accordance with its terms, as applicable). Except as set forth in this Article 10, upon termination or expiration of this Agreement all other rights and obligations of the Parties under this Agreement
cease. Clearside shall exercise commercially reasonable efforts to continue any Sublicense that is not in default following the termination of the Agreement for any reason. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Assignment</U></B>. Except as provided in this Section&nbsp;11.1, this Agreement may not be assigned
or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party, not to be unreasonably withheld conditioned or delayed. However, either Party may, without the
other Party&#146;s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate or pursuant to or in connection with a Change of Control of such Party, provided that the assignee assumes the Agreement
and the obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Governing Law</U></B>. This Agreement shall be construed and the
respective rights of the Parties determined in accordance with the substantive laws of the State of New York, notwithstanding any provisions of New York law governing conflicts of laws to the contrary, and the patent laws of the relevant
jurisdiction without reference to any rules of conflict of laws. Notwithstanding the foregoing, the Parties acknowledge that the laws of the State of Georgia shall apply to matters related to the Sublicensed IP to the extent required by the
Emory/GTRC License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Entire Agreement; Amendments</U></B>. This Agreement contains the
entire understanding of the Parties with respect to the subject matter hereof, and supersedes all previous arrangements with respect to the subject matter hereof, whether written or oral. This Agreement (including the Schedules hereto) may be
amended, or any term hereof modified, only by a written instrument duly-executed by authorized representatives of both Parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Severability</U></B>. If any provision hereof should be held invalid, illegal or unenforceable in any
respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions, which valid provisions in their economic effect are sufficiently similar to the invalid,
illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invalid, illegal or unenforceable provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such
essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Headings</U></B>. The captions to the Articles and Sections hereof are not a part of this Agreement,
but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Waiver of Rule of Construction</U></B>. Each Party has had the opportunity to consult with counsel in
connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Implied Waivers; Rights Cumulative</U></B>. No failure on the part of Clearside or Aura to
exercise, and no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or
privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the
exercise of any other right, power, remedy or privilege. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notices</U></B>. All notices which are
required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile, sent by email, sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt
requested, addressed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If to Clearside, to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Clearside Biomedical, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>900 North Point Pkwy Suite 200</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Alpharetta, Georgia 30005</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attention: CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Email: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">With a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Clearside Biomedical, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>900 North Point Pkwy Suite 200</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Alpharetta, Georgia 30005</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attn: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Email: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If to Aura, to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Aura Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>85 Bolton Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cambridge, MA 02140</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attention: Elisabet de los Pinos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Email: [***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">With a copy to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>One Financial Center, 39th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Boston, MA 02111</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attention: Lewis J. Geffen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Email: [***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. Any such notice shall be deemed to have been given: (a)&nbsp;when delivered if personally delivered or sent by facsimile or email on a Business Day (or if delivered or sent on a
<FONT STYLE="white-space:nowrap">non-Business</FONT> Day, then on the next Business Day); (b) on receipt if sent by overnight courier; and/or (c)&nbsp;on receipt if sent by mail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Compliance with Export Regulations</U></B>. Neither Party shall export any technology licensed to it
by the other Party under this Agreement except in compliance with U.S. and all other applicable export laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Force Majeure</U></B>. Neither Party shall be held liable to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party,
potentially including without limitation embargoes, war, acts of war (whether war be declared or not), insurrections, terrorism, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts,
omissions or delays in acting by any Governmental Authority or the other Party. The affected Party shall notify the other Party of such <I>force majeure</I> circumstances as soon as reasonably practical, and shall promptly undertake all reasonable
efforts necessary to cure such <I>force majeure </I>circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Dispute Resolution</U></B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.11.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Disputes</U></B>. The Parties shall negotiate in good faith and use reasonable efforts to
settle any dispute, controversy or claim arising from, or related to, this Agreement or to the breach hereof (collectively, &#147;<B>Dispute</B>&#148;). In particular, the Chief Executive Officers of the Parties shall attempt to resolve all Disputes
in accordance with Section&nbsp;3.4.2. In the event that the Chief Executive Officers cannot reach an agreement regarding a Dispute in accordance with Section&nbsp;3.4.2, and a Party wishes to pursue the matter further, each such Dispute that is not
an &#147;Excluded Claim&#148; shall be finally resolved by binding arbitration under the then-current Rules of Arbitration of the American Arbitration Association (&#147;AAA&#148;) by three (3)&nbsp;arbitrators appointed in accordance with the said
Rules and Section&nbsp;11.11.2 below, and judgment on the arbitration award may be entered in any court having jurisdiction thereof. As used in this Section&nbsp;11.11.1, the term &#147;<B>Excluded Claim</B>&#148; shall mean a dispute that concerns
the validity or infringement of a patent, trademark or copyright. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.11.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Arbitration</U></B>. The
arbitration shall be conducted by a panel of three (3)&nbsp;persons experienced in the pharmaceutical business who are independent of both Parties and neutral with respect to the Dispute presented for arbitration. Within thirty (30)&nbsp;days after
initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within thirty (30)&nbsp;days of their appointment. If the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the AAA. The place of arbitration shall be New York, NY, and
all proceedings and communications shall be in English. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Either Party may apply to the arbitrators for interim injunctive relief until the
arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the
rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party&#146;s compensatory damages. Each Party shall bear its own costs and
expenses and attorneys&#146; fees, and the Party that does not prevail in the arbitration proceeding shall pay the arbitrators&#146; and any administrative fees of arbitration. Except to the extent necessary to confirm an award or as may be required
by law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal
or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Parties agree that, in the event of a Dispute over the nature or quality of performance under this Agreement,
neither Party may terminate this Agreement until final resolution of the Dispute through arbitration or other judicial determination. The Parties further agree that any payments made pursuant to this Agreement pending resolution of the Dispute shall
be refunded promptly if an arbitrator or court determines that such payments are not due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Parties hereby
agree that any disputed performance or suspended performances pending the resolution of the arbitration that the arbitrators determine to be required to be performed by a Party must be completed within a reasonable time period following the final
decision of the arbitrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Parties hereby agree that any monetary payment to be made by a Party pursuant
to a decision of the arbitrators shall be made in United States dollars, free of any tax or other deduction. The Parties further agree that the decision of the arbitrators shall be the sole, exclusive and binding remedy between them regarding
determination of the matters presented to the arbitrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Independent Contractors</U></B>. It
is expressly agreed that Clearside and Aura shall be independent contractors and that the relationship between Clearside and Aura shall not constitute a partnership, joint venture or agency. Clearside shall not have the authority to make any
statements, representations or commitments of any kind, or to take any action, which shall be binding on Aura, without the prior written consent of Aura, and Aura shall not have the authority to make any statements, representations or commitments of
any kind, or to take any action, which shall be binding on Clearside without the prior written consent of Clearside. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.13</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Counterparts</U></B>. The Agreement may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.14</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Binding Effect; No Third Party Beneficiaries</U></B>. As of the Effective Date, this Agreement shall
be binding upon and inure to the benefit of the Parties and their respective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permitted successors and permitted assigns. Except as expressly set forth in this Agreement, no person or entity other than the Parties and their respective Affiliates and permitted assignees
hereunder shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>remainder
of page intentionally blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>AURA BIOSCIENCES, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>CLEARSIDE BIOMEDICAL, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: <U>/s/ Elizabet de los
Pinos&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: <U>Elizabet de los
Pinos&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: <U>Chief Executive
Officer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: <U>/s/ George
Lasezkay&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: <U>George
Lasezkay&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:
<U>CEO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSED PATENT RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule A </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBLICENSED PATENT RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule B </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>10
<FILENAME>d209588dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED: AS OF
JUNE&nbsp;9, 2011 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOLTON STREET PARTNERS, LLC, LESSOR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AURA BIOSCIENCES, INC, LESSEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">85-95</FONT> BOLTON STREET, CAMBRIDGE, MASSACHUSETTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Reference Data</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Premises</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Premises</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Common Areas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>As Is</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lessor&#146;s Work</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>3.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Term; Commencement Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>4.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Rent</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Permitted Use</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Taxes; Operating Expenses; Electricity</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Operating Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Taxes, Operating Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Abatement of Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Utilities; Payment as Additional Rent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>7.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Insurance; Exculpation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Public Liability Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Casualty Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Business Interruption Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorized Insurers; Evidence of Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lessor&#146;s Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Subrogation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lessee&#146;s Acts, Effect on Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limitation of Lessor&#146;s Liability for Damage or Injury</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>8.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Assignment, Subletting and Relocation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>9.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Parking</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>10.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Late Payment of Rent</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>11.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Lessee&#146;s Covenants</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>12.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Building Security</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>13.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Casualty and Eminent Domain</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>14.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Defaults; Remedies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Defaults; Events of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival of Covenants; Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Right to Relet</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Right to Equitable Relief</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Performance by Lessor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>15.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Real Estate Broker</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>16.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Notices</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>17.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Hazardous Materials</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>17.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Prohibition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>17.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>17.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Hazardous Material Defined</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>17.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Testing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>17.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Decommissioning; Clean Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>18.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>No Waivers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>19.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Services Provided by Lessor</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>20.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Quiet Enjoyment; Ground Leases; Mortgages</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>20. l</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Quiet Enjoyment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>20.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights of Ground Lessors and Mortgagees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>20.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lease Subordinate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>21.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Security Deposit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>31</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>22.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Estoppel Certificates</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>23.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>Holding Over</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>24.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Force Majeure</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>25.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Independent Covenants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>26.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Entire Agreement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>27.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Applicable Law, Severability and Construction</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>28.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Successors and Assigns</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>29.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Authority</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>30.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>31.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OFAC Compliance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>32.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Use of Walden Square Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>33.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Extension Option </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom"><B>36</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>34.0</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Special Provisions Relating to the Special Equipment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>34.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Access to Special Equipment Located Within Premises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4l</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">EXHIBITS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT A - PREMISES</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EXHIBIT B - SITE
PLAN</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT C - SERVICES PROVIDED BY LESSEE</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT
D - SERVICES PROVIDED BY LESSOR</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT E - RULES AND REGULATIONS</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EXHIBIT F - CLEAN CERTIFICATE</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EXHIBIT G - PROPOSED 2011 OPERA TING EXPENSE BUDGET</TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LEASE is made as of the 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of June, 2011 by and between BOLTON STREET PARTNERS,
LLC, a Massachusetts limited liability corporation with a place of business at 126 North Washington Street, Suite 5, Boston, Massachusetts 02114 (&#147;Lessor&#148;), and Aura Biosciences, Inc., a Connecticut corporation, with a principal place of
business as of the date hereof at I Kendall Square, Building 600, Ste, B6101, Cambridge, MA 02139 (&#147;Lessee&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reference Data. The following terms shall have the definitions set forth in this Section&nbsp;1.0:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PREMISES AND RENTABLE AREA OF THE PREMISES:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 4,000 gross rentable square feet on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st </SUP>) floor of the Building (Lab 116 and 118) and on the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd
</SUP>) floor of the building (offices <FONT STYLE="white-space:nowrap">221-225)</FONT> as shown on Exhibit A. The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the rentable area of the Premises is as
stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENTABLE AREA OF BUILDING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">INITIAL TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An initial term commencing on the Commencement Date and expiring twenty four (24) calendar months from the Commencement Date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Initial Term and any proper extension thereof in accordance with the terms of this Lease.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RIGHT OF FIRST OFFER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Option A: </B>Landlord shall make available an additional 1,553 gross rentable square feet on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) floor of the Building (Lab 110 and 119) and on the second (2<SUP
STYLE="font-size:85%; vertical-align:top">nd </SUP>) floor of the building (offices 214 and 216) as shown on Exhibit A for an occupancy date to occur no earlier than January&nbsp;1, 2012. Tenant shall notify Landlord of its intent to take this space
no later than August&nbsp;1, 2011. In the event that</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenant does not lease the space at that time, Tenant shall have an ongoing right of first offer thereafter. Lessee must exercise such option to extend by giving Lessor written notice (the &#147;<U>Option A Notice</U>&#148;) on or
before August&nbsp;1, 2011, time being of the essence. Upon the timely giving of such notice, the Option A Term shall be deemed effective under and upon all of the terms and conditions of this Lease, except that (a)&nbsp;Basic Rent for Option A
shall be $24.50 per square feet of gross rentable square feet for the period from January l to June&nbsp;30, 2012 and $25.50 per square feet of gross rentable square feet for the period from July I, 2012 to June&nbsp;30, 2013. Lessor shall have no
obligation to provide a Lessee allowance or other Lessee inducement of any kind, (b)&nbsp;Lessor shall have no obligation to perform any Lessor&#146;s Work or to construct or renovate the Premises or make any decorations or improvements thereto and
(c) there shall be no further right or option to extend the Term other than as set forth in Section&nbsp;33.0. If Lessee fails to give timely notice, as aforesaid, Lessee shall have no further right to Option A. Notwithstanding the fact that
Lessee&#146;s proper and timely exercise of such Option A shall be self-executing, the parties shall promptly execute a lease amendment reflecting such Option A Terms after Lessee exercises such option. The execution of such lease amendment shall
not be deemed to waive any of the conditions to Lessee&#146;s exercise of its rights under this Section&nbsp;33.0.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Option B: </B>In the event that the current tenant vacated the space, Landlord shall offer Tenant the Right of First Offer on the second floor lab space. Building (Lab 238, 239 and 247) on the second (2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the building.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July l, 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENT COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July 1, 2011.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BASIC RENT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic&nbsp;Rent<BR>Per&nbsp;Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic&nbsp;Rent<BR>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July 1, 2011 to June 30, 2012;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,166.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July 1, 2012 to June 30, 2013;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,500.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE (TAXES)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE (OPERATING EXPENSES)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$39,500.00.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERMITTED USE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend
to more than forty (40%) percent of the floor area of the Premises. Other than the MWRA Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning variance,
zoning change, special permit or other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee. Notwithstanding the forgoing, no use involving the
presence, storage, generation or release of any radioactive or nuclear materials shall be permitted.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S REPRESENTATIVE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not Applicable</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Premises. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.1 Premises. Lessor hereby leases unto Lessee the Premises, together with the benefit of, and subject to (as the case may be) all rights,
easements, covenants, conditions, encumbrances, encroachments and restrictions of record as of the date of this Lease. Lessor shall have the right, without the necessity of obtaining Lessee&#146;s consent thereto or joinder therein, to grant,
permit, or enter into during the term of this Lease such additional rights, easements, covenants, conditions, encumbrances, encroachments and restrictions with respect to the Land as Lessor may deem appropriate, provided that no such rights,
easements, covenants, conditions, encumbrances, encroachments or restrictions shall materially affect Lessee&#146;s use of the Premises for the Permitted Use. Lessor further hereby reserves the right to install, maintain, use, repair and replace
pipes, ducts, wires, meters and any other equipment, machinery, apparatus and fixtures located within the Premises and serving other parts of the Building, provided that reasonable advance notice thereof is given to Lessee and that the exercise of
such rights shall not materially affect Lessee&#146;s use of the Premises for the Permitted Use. Lessee, its employees and invitees shall have access to the Premises twenty-four (24)&nbsp;hours per day, seven (7)&nbsp;days per week, subject to
Lessor&#146;s reasonable security procedures. Lessee shall be permitted to operate its business in the Premises outside of the Building hours (as set forth in Paragraph l of <U>Exhibit D</U> attached hereto), but Lessee shall pay to Lessor, as
Additional Rent, the cost of supplying HVAC and other services to the Premises, as described on <U>Exhibit D</U> at times other than such Building hours in the event that Lessee requests HVAC or other such services outside of Building hours, such
payment to be due and payable no later than thirty (30)&nbsp;days after Lessor gives written notice to Lessee of the amount of such charges. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.2 Common Areas. Lessor also grants to Lessee, and Lessee&#146;s invitees, the right, in common with others entitled thereto, to use for the
purposes for which they were designed, the common facilities of the Building, including but not limited to, all entrances, hallways, elevator foyers, stairwells and stairs, restrooms, passenger elevators, loading bays, parking areas (consistent with
Section&nbsp;9 of this Lease), drives, and walkways, a kitchen and eating area, the Special Equipment (as hereinafter defined) as also shown on <U>Exhibit A</U>, and at least two meeting rooms which may be reasonably shared and reserved by tenants
of the Building (collectively, the &#147;Common Areas&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.3 As Is. Lessee agrees to accept the Premises from Lessor in an &#147;as
is&#148; condition, with all faults and without any representation or warranty, express or implied, from Lessor except for the Lessor&#146;s Work (as said term is hereinafter defined). Except for the Lessor&#146;s Work, Lessor is not obligated to
perform, or pay for, any work in order to prepare the Premises for occupancy by Lessee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.4 Lessor&#146;s Work. Lessor agrees that it will
perform the following work (the &#147;Lessor&#146;s Work&#148;) in the Premises at Lessor&#146;s expense: Lessor will provide the Premises in broom clean condition, systems in good working order, including, but not limited to the chemical hoods in
the Premises, repair all ceiling tiles, polish or replace laboratory floors, replace damaged carpets, scrub clean laboratory benches, repaint walls and key </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
lock the space for the Lessee. Lessor will conduct the following work to the Second Floor Office Area of the Premises: Construct demising wall on second floor as outlined per mutually agreed upon
plan attached as Exhibit A; furnish and install electrical outlets and lighting in office area, construct one and a half glass entry doors with locking system for security and install 2 pieces of glass in the wall to create visual connection between
reception area and 2 offices across the common hallway. Tenant shall be responsible for the cost difference for any improvements to the second floor office area above the Landlord&#146;s base work. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Landlord&#146;s work at Tenant&#146;s cost will include:</I></B><B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Landlord shall install one (1) 220 electric outlet as Tenant expense. Landlord shall confirm installation costs with Tenant prior to work
commencement of the work. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Term; Commencement Date. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.1 Term. The Term of this Lease shall commence on the Commencement Date. As used in this Lease, the term &#147;Lease Year&#148; shall mean the
twelve (12)&nbsp;month period commencing on the Commencement Date. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rent. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.1 Rent. Lessee shall pay Lessor, without offset or deduction and without previous demand therefor, as items constituting rent (collectively,
&#147;Rent&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Basic Rent, at the rates set forth in Section&nbsp;1.0, in equal monthly installments, in advance, commencing
on the Rent Commencement Date and continuing thereafter on the first day of each calendar month or portion thereof during the Term; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From and after the Commencement Date, all other costs, charges, or expenses which Lessee in this Lease agrees
to pay, or which Lessor reasonably incurs as the result of a default by Lessee hereunder, including any penalty or interest which may be added for nonpayment or late payment thereof as provided in this Lease (collectively, &#147;Additional
Rent&#148;). All recurring payments of Additional <B>Rent, </B>including, without limitation, payments on account of &#147;Taxes&#148; and &#147;Operating Expenses&#148; (as these terms are hereinafter defined), shall be due and payable on the same
day on which Basic Rent is due. Unless otherwise specifically provided in this Lease, all <FONT STYLE="white-space:nowrap">non-recurring</FONT> items constituting Additional Rent shall be due and payable within thirty (30)&nbsp;days after demand
therefor by Lessor. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic Rent and Additional Rent shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for partial months
occurring at the beginning or the end of the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All payments shall be made to Lessor or such agent, and at such place, as Lessor shall, from time to
time, in writing designate, the following being now so designated: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bolton Street Partners, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o Peter Zagorianakos, Manager </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">126 North Washington Street, Unit 5 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Boston, MA 02114 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Permitted Use. The Premises may be used only for the Permitted Use as set forth in Section&nbsp;1.0 and for no
other use. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Taxes; Operating Expenses; Electricity. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.1 Taxes. Lessee shall pay as Additional Rent, in any tax year, all or a portion of which is included in the Term, Lessee&#146;s Share (Taxes)
(as defined below) of Taxes. As used herein the term &#147;Taxes&#148; shall mean collectively real estate taxes, special or general assessments, water rents, rates and charges, sewer rents and other impositions and charges imposed by governmental
authorities of every kind and nature whatsoever, excluding Taxes imposed by or as a result of Lessor&#146;s or its agents&#146;, representatives&#146; negligence or willful misconduct, extraordinary as well as ordinary and each and every installment
thereof which shall or may during the Term be charged, levied, laid, assessed, imposed, become due and payable or become liens upon or for or with respect to the Land or the Building or any appurtenances or equipment owned by Lessor thereon or
therein, or any part thereof , or on this Lease, and any tax based on a percentage fraction or capitalized value of the Rent (whether in lieu of or in addition to the taxes hereinbefore described), provided that all taxes and assessments shall be
paid over the longest period permitted by law. Taxes shall not include inheritance, estate, excise, succession, transfer, gift, franchise, income, gross receipt, or profit taxes except to the extent such are in lieu of or in substitution for Taxes
as now imposed on the Building, the Land, the Premises or this Lease nor (i)&nbsp;any environmental assessments, charges or liens arising in connection with the remediation of Hazardous Materials (as hereinafter defined) from the Premises or
Building, the causation of which arose prior to the Commencement Date of this Lease, or to the extent caused by Lessor, its agents, employees or contractors or any other tenant of the Building (other than Lessee or its sublessees or assignees); (ii)
costs or fees payable to public authorities in connection with any future construction, renovation and/or improvements to the Premises or Building other than the Work or improvements to the Premises made by or for Lessee, including fees for transit,
housing, schools, open space, child care, arts programs, traffic mitigation measures, environmental impact reports, traffic studies, and transportation system management plans and (iii)&nbsp;reserves for future Taxes. Additionally, interest and
penalties incurred as a result of Lessor&#146;s late payment shall not be included in the definition of Taxes. As used in this Agreement Lessee&#146;s Share of the taxes (Taxes) is the percentage set forth in Section&nbsp;1.0. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.2 Operating Expenses. Lessee shall pay as Additional Rent Lessee&#146;s Share (Operating Expenses) of Operating Expenses (as defined below)
for the Land and Building. &#147;Operating Expenses&#148; shall include, without limitation, all expenses, costs, and disbursements of every kind and nature which Lessor shall pay or become obligated to pay in connection with the ownership,
operation, repair and maintenance of the Building or the Land, including all facilities in operation on the Commencement Date and such additional facilities in subsequent years as may be determined by Lessor to be necessary or beneficial for the
operation of the Building or the Land or the provision of services to Lessees, including, but not limited to: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all salaries, wages, fringe benefits, payroll taxes and workmen&#146;s compensation insurance premiums related
thereto of and for employees engaged in the operation of the Building and the Land (or a reasonable allocation thereof for personnel who work in multiple buildings); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">painting, repairs, maintenance and cleaning of all Common Areas; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">common area utilities (including, without limitation, electricity, water, sewer, gas and steam) which are not
separately chargeable to the Lessee, including, without limitation, lighting of exterior areas, common areas and the parking area during any portion of the Tern when Lessee is not the sole lessee of the Building (&#147;Base Building Utility
Expenses&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintenance and repair of the Building heating and cooling systems, the plumbing systems, the fire detection
and suppression systems, the electrical system and the elevators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all maintenance, janitorial, and service agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all insurance, including the cost of casualty and liability insurance applicable to the parking area, the Land,
the Building and Lessor&#146;s personal property used in connection therewith; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintenance of landscaped areas and paved areas, and s ow removal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintenance of the Building security system, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commercially reasonable management fees and charges and the fair market value of office space for the manager
of the Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reasonable expenses incurred in pursuing an application for an abatement of Taxes, to the extent not deducted
from the abatement, if any, received; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">legal (excluding legal fees with respect to lease negotiations or disputes with lessees), accounting and other
professional fees and disbursements (excluding leasing commissions); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(I)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">services to be provided by Lessor as set forth on Exhibit &#147;D&#148; attached. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, &#147;Lessee&#146;s Share (Operating Expenses)&#148; is the percentage set forth in Section&nbsp;1.0. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event that the average occupancy rate for the Building is less than ninety-five (95%)
percent for any fiscal year, then for purposes of calculating Operating Expenses, the Operating Expenses for such fiscal year shall be increased by the additional costs and expenses that Lessor reasonably estimates would have been incurred if the
average occupancy rate had been ninety-five (95%) percent for such fiscal year (&#147;Expense Gross-Up&#148;). It is not the intent of this provision to permit Lessor to charge Lessee for any Operating Expenses attributable to unoccupied space, or
to seek reimbursement from Lessee for costs Lessor never incurred. Rather, the intent of this provision is to allow Lessor to recover only those increases in Operating Expenses properly attributable to occupied space in the Building, and this
provision is designed to calculate the actual cost of providing a variable operating expense service to the portions of the Building receiving such service. This <FONT STYLE="white-space:nowrap">&#147;gross-up&#148;</FONT> treatment shall be applied
only with respect to variable Operating Expenses arising from services provided to Utilities, Common Areas, for Special Equipment Costs and related expenses or to space in the Building being occupied by lessees in order to allocate equitably such
variable Operating Expenses to the lessees receiving the benefits thereof. This <FONT STYLE="white-space:nowrap">&#147;gross-up&#148;</FONT> treatment of any and all Special Equipment Costs and related expenses shall be applied using a base cost of
$0.00 and the variable costs being grossed up such that the Tenants occupying the Building shall pay l 00% of the Special equipment Costs and related expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.3 Payment of Taxes, Operating Expenses. Commencing on the Rent Commencement Date, Lessee shall pay to Lessor, as Additional Rent, on account
of its share of anticipated Operating Expenses and Taxes for the then-current year, 1/12th of the total annualized amount of Lessee&#146;s Share (Operating Expenses) of the projected Operating Expenses and Lessee&#146;s Share (Taxes) of the
projected Taxes. Within a reasonable time after the end of the fiscal year ending December&nbsp;31, 2011, and thereafter within a reasonable time after the end of each fiscal year (or portion thereof) included in the Term, Lessor shall deliver to
Lessee (i)&nbsp;a statement of actual Operating Expenses and Taxes for the fiscal year just ended, and (ii)&nbsp;a budget of Operating Expenses and Taxes for the then-current fiscal year based on the actual Operating Expenses and Taxes for the
preceding year and projected increases or decreases reasonably anticipated by Lessor, together with documentation in reasonable detail which evidence such Operating Expenses and Taxes (&#147;Annual Report&#148;). Upon delivery to Lessee of the
statement of actual Operating Expenses and Taxes for the preceding fiscal year, Lessor shall adjust Lessee&#146;s account accordingly. If the total amount paid by Lessee on account of the preceding fiscal year is less than the amount due hereunder,
Lessee shall pay the balance due within thirty (30)&nbsp;days after delivery by Lessor of such statement. If the total amount paid by Lessee on account of the preceding fiscal year exceeds the amount due hereunder, such excess shall be credited by
Lessor against the monthly installments of Additional Rent next falling due or refunded to Lessee upon the expiration or termination of this Lease (unless such expiration or termination is the result of an Event of Default). Lessor reserves the
right to revise the budget once during any fiscal year to cause it to more accurately reflect the actual Taxes or Operating Expenses being paid or incurred by Lessor, and upon any such revision the parties shall make adjustments in the same time and
manner as hereinabove provided for fiscal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments. Lessor&#146;s current fiscal year is January 1 - December 31, but Lessor reserves the right to change the fiscal year at any time during the
Term. Lessee and its designated agents shall have the right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
inspect and audit Lessor&#146;s books and records relative to the operation of the Building (including, but not limited to, all documents related to Expenses, Taxes, utility charges, payroll,
insurance, rental escalation, service contracts, and management information) (collectively, &#147;Lessor Records&#148;) during normal business hours within ninety (90)&nbsp;days following receipt from Lessor; and, unless Lessee shall take written
exception to any item in any such statement within such ninety (90)&nbsp;day period, the Annual Report shall be considered as final and accepted by Lessee. If Lessee shall timely dispute any specific item or items in an Annual Report and if such
dispute is not resolved between Lessor and Lessee within thirty (30)&nbsp;days after notice of such dispute from Lessee, then Lessee may refer such disputed item or items to reputable independent certified public accounting firm or lease audit firm
selected by Lessee for determination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.4 Abatement of Taxes. Lessor may at any time and from time to time make application to the
appropriate governmental authority for an abatement of Taxes. If (i)&nbsp;such an application is successful and (ii)&nbsp;Lessee has made any payment in respect of Taxes pursuant to Section&nbsp;6.3 for the period with respect to which the abatement
was granted, Lessor shall (a)&nbsp;deduct from the amount of the abatement all expenses incurred by it in connection with the application, (b)&nbsp;pay to Lessee Lessee&#146;s Share (Taxes) (adjusted for any period for which Lessee had made a
partial payment) of the abatement, with interest, if any, paid by the governmental authority on such abatement, and (c)&nbsp;retain the balance, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.5 Utilities; Payment as Additional Rent. The tenanted spaces occupied by the Lessee are not separately metered and therefore, subject to
adjustment as set forth below, utilities will be charged to Lessee as Additional Rent in the following manner: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Included in the Operating Expenses is Base Building Utility expenses. Lessee shall pay as an Additional Rent
Lessee&#146;s Share of all utilities OVER the Base Building Utility expenses (collectively &#147;Additional Utility Expenses&#148;) provided to the Building based on the Lessee&#146;s Share of the physically occupied space within the building.
Lessee will pay a share of Additional Utility Costs provided to the Building based on a fraction, the denominator of which will be the Physically Rented Area of the Building and the numerator of which will be the Lessee&#146;s Rentable area of the
Building. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this Lease, Lessor shall have the right to monitor the allocation of
charges for electricity and gas to all Lessees of the Building to ensure that the allocation method is appropriately related to Lessee&#146;s actual use of these services within or in connection with the Premises. If the current method of allocation
is materially inaccurate, Lessor may reasonably change the method of allocation during the term, as necessary, to correct the disproportionate charges. In addition, if Lessor determines in the course of its audit of the charges for electricity and
gas previously allocated that Lessee has underpaid or overpaid charges properly due for its use of either or both of these services, Lessor shall invoice Lessee for the amounts due (together with reasonable
<FONT STYLE="white-space:nowrap">back-up</FONT> documentation regarding the total charges and the method of allocating the charges to Lessee) and Lessee shall pay such additional amount, as additional rent hereunder, within thirty (30)&nbsp;days of
receipt of Lessor&#146;s invoice therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Commencing on the Commencement Date, Lessee shall pay to Lessor, as Additional Rent, on account of its share of
anticipated Additional Utility Expenses for the then-current fiscal year, 1/12th of the total annualized amount of Lessee&#146;s Share (Operating Expenses) of the Additional Utility Expenses as projected by Lessor. Within a reasonable time after the
end of the fiscal year ending December&nbsp;31, 2011, and thereafter within a reasonable time after the end of each fiscal year (or portion thereof) included in the Term, Lessor shall deliver to Lessee (i)&nbsp;a statement of actual Additional
Utility Expenses for the fiscal year just ended, and (ii)&nbsp;a budget of Additional Utility Expenses for the then-current fiscal year based on the actual Additional Utility Expenses for the preceding year and projected increases or decreases
reasonably anticipated by Lessor, together with documentation in reasonable detail which evidence such Additional Utility Expenses. Upon delivery to Lessee of the statement of actual Additional Utility Expenses for the preceding fiscal year, Lessor
shall adjust Lessee&#146;s account accordingly. If the total amount paid by Lessee on account of the preceding fiscal year is less than the amount due hereunder, Lessee shall pay the balance due within thirty (30)&nbsp;days after delivery by Lessor
of such statement. If the total amount paid by Lessee on account of the preceding fiscal year exceeds the amount due hereunder, such excess shall be credited by Lessor against the monthly installments of Additional Rent on account of Additional
Utility Expenses next falling due or (if the term has expired or terminated) refunded to Lessee upon the expiration or termination of this Lease. Lessor reserves the right to revise the Additional Utility Expenses budget during any fiscal year to
cause it to more accurately reflect the actual Additional Utility Expenses being paid or incurred by Lessor, and upon any such revision the parties shall make adjustments in the same time and manner as hereinabove provided for fiscal <FONT
STYLE="white-space:nowrap">year-end</FONT> adjustments. Lessor&#146;s current fiscal year is January 1 - December 31, but Lessor reserves the right to change the fiscal year at any time during the Term. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) Review of Apportionment. Notwithstanding any other provisions in section 6.5(a) and (b)&nbsp;of this lease, in the event that the Gas,
Electricity, and Water&nbsp;&amp; Sewer charges and Special Equipment Expenses (collectively &#147;the Expenses&#148;) billed to Lessee during any <FONT STYLE="white-space:nowrap">12-month</FONT> period exceeds the amounts contained in the Bolton
Street 2011 Budget (attached as Exhibit G to the lease) by more than 20%, Lessor, at Lessee&#146;s written request, agrees to review the utility usage by each tenant. If Lessor determines in the course of its audit of the charges for electricity,
gas, water and sewer and Special Equipment Expenses previously allocated that Lessee has underpaid or overpaid charges properly due for its use of these services, Lessor shall invoice or credit Lessee for the amounts due (together with reasonable <FONT
STYLE="white-space:nowrap">back-up</FONT> documentation regarding the total charges and the method of allocating the charges to Lessee) and Lessee shall pay or be credited such additional amount, as additional rent hereunder, within thirty
(30)&nbsp;days of receipt of Lessor&#146;s invoice therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insurance; Exculpation. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.1 Public Liability Insurance. Lessee shall procure, pay for and keep in force throughout the Term (and for so long thereafter as Lessee
remains in occupancy of the Premises) commercial general liability insurance insuring Lessee on an occurrence basis against all claims and demands for personal injury liability (including, without limitation, bodily injury, sickness, disease, and
death) or damage to property which may be claimed to have occurred from and after the time any of the Lessee or any of its officers, directors, contractors, servants and agents shall first enter the Premises, of not less than $2,000,000 with a
$1,000,000 per occurrence limit. Such policy shall also include contractual liability coverage covering Lessee&#146;s liability assumed under this Lease, including without limitation Lessee&#146;s indemnification obligations. Such insurance policy
(ies) shall name Lessor; Lessor&#146;s managing agent and persons claiming by, through or under them, if any, as additional insured&#146;s. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.2 Casualty Insurance. Lessee shall take out and maintain throughout the Term a policy of fire, vandalism, malicious mischief, extended
coverage and <FONT STYLE="white-space:nowrap">so-called</FONT> all risk coverage insurance insuring all (i) &#147;Alterations&#148; (as defined in paragraph (f)&nbsp;of Section&nbsp;11.0 below) which Lessee is by this Lease either entitled to or
required to remove upon </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the expiration or earlier termination of this Lease, and (ii) &#147;Lessee&#146;s Property&#148; (as defined in
paragraph (i)&nbsp;of Section&nbsp;11.0 below) for the benefit of Lessor and Lessee, as their respective interests may appear, in an amount equal to one hundred percent of the replacement value thereof, but not to exceed $1,000,000 in coverage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.3 Business Interruption Insurance. Lessee shall take out and maintain a policy of business interruption insurance throughout the Term
sufficient to cover at least twelve (12) months of Rent due hereunder and Lessee&#146;s business losses during such <FONT STYLE="white-space:nowrap">12-month</FONT> period. Irrespective of insurance coverage, other than as specifically set forth
herein, Lessor is not responsible for any business interruptions in the Lessee&#146;s business for any reasons whatsoever, except caused by Lessor&#146;s or its agents or representatives willful misconduct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.4 Authorized Insurers; Evidence of Insurance. The insurance required pursuant to Sections 7.1, 7.2 and 7.3 (collectively, &#147;Lessee&#146;s
Insurance Policies&#148;) shall be effected with insurers approved by Lessor, with a rating of not less than <B><FONT STYLE="white-space:nowrap">&#147;A-XI&#148;</FONT> </B>in the current Best&#146;s Insurance Reports, and authorized to do business
in the Commonwealth of Massachusetts under valid and enforceable policies. Lessee&#146;s Insurance Policies shall each provide that it shall not be canceled or modified without at least thirty (30)&nbsp;days&#146; prior written notice to each
insured named therein. On or before the date on which any of the Lessee or any of its officers, directors, contractors, servants and agents shall first enter the Premises and thereafter not less than fifteen (15)&nbsp;days prior to the expiration
date of each expiring policy, Lessee shall deliver to Lessor binders of Lessee&#146;s Insurance Policies issued by the respective insurers setting forth in full the provisions thereof. In the event of any claim, and upon Lessor&#146;s request,
Lessee shall deliver to Lessor complete copies of Lessee&#146;s Insurance Policies. Upon request of Lessor, Lessee shall deliver to any Mortgagee copies of the foregoing documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.5 Lessor&#146;s Insurance. Lessor shall take out and maintain in force throughout the
Term, in a company or companies authorized to do business in Massachusetts, casualty insurance on the Building (exclusive of &#147;Lessee&#146;s Property&#148; (as defined in paragraph (i)&nbsp;of Section&nbsp;11.0 below), and all items or
components of &#147;Alterations&#148; (as defined in paragraph (f)&nbsp;of Section&nbsp;11.0 below) as to which Lessee is required to maintain insurance pursuant to Section&nbsp;7.2 above) in an amount equal to the full replacement value of the
Building (exclusive of foundations and those items set forth in the preceding parenthetical in this sentence), covering all risks of direct physical loss or damage and so-called &#147;extended coverage&#148; risks. This insurance may be maintained
in the form of a blanket policy covering the Building as well as other properties owned by Lessor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.6 Waiver of Subrogation. To the
extent to which a waiver of subrogation clause is available, Lessor and Lessee shall obtain a provision in all insurance policies carried by such party covering the Premises, including but not limited to contents, fire and casualty insurance,
expressly waiving any right on the part of the insurer against the other party. If extra cost is chargeable for such provision, then the party benefiting from the provision shall pay such extra charge. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.7 Waiver of Rights. All claims, causes of action and rights of recovery for any damage to or destruction of property or business which shall
occur on or about the Premises, the Building or the Land, which result from any of the perils insured under any and all policies of insurance maintained by Lessor or Lessee, are waived by each party as against the other party, and the officers,
directors, employees, contractors, servants and agents thereof, regardless of cause, including the negligence of the other party and its respective officers, directors, employees, contractors, servants and agents, but only to the extent of recovery,
if any, under such policy or policies of insurance; provided, however, that (i)&nbsp;this waiver shall be null and void to the extent that any such insurance shall be invalidated by reason of this waiver, and (ii)&nbsp;with respect to such portion
of the Term during which Lessor elects to self-insure under Section&nbsp;7.5 above, then for purposes of this Section&nbsp;7.6, Lessor shall be deemed to have maintained fire and <FONT STYLE="white-space:nowrap">all-risk</FONT> coverage in an amount
equal to the full insurable value of the Building. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.8 Lessee&#146;s Acts, Effect on Insurance. Lessee shall not do or permit any of its
officers, directors, contractors, servants and agents to do any act or thing upon the Premises or elsewhere in the Building which will invalidate or be in conflict with any insurance policies covering the Building and the fixtures and property
therein; and shall not do, or permit to be done, any act or thing upon the Premises which shall subject Lessor to any liability or responsibility for injury to any person or persons or to property by reason of any business or operation being carried
on upon said Premises or for any other reason. If by reason of the failure of Lessee to comply with the provisions hereof the insurance rate applicable to any policy of insurance shall at any time thereafter be higher than it otherwise would be,
Lessee shall reimburse Lessor upon demand for that part of any insurance premiums which shall have been charged because of such failure by Lessee, together with interest at the rate of l - l /2% per month or the highest rate permitted by law,
whichever is less until paid in full, within ten (10)&nbsp;days after receipt of an invoice therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.9 Limitation of Lessor&#146;s Liability for Damage or Injury. Lessor shall not be liable
for any injury or damage to persons or property resulting from fire, explosion, falling plaster, steam, gas, air contaminants or emissions, electricity, electrical or electronic emanations or disturbance, water, rain or snow or leaks from any part
of the Building or from the pipes, appliances, equipment or plumbing works or from the roof, street or sub-surface or from any other place or caused by dampness, vandalism, malicious mischief or by any other cause of whatever nature, except to the
extent caused by or due to the negligence or willful misconduct of any of the Lessor or its officers, directors, contractors, servants and agents, and then, where notice and an opportunity to cure are appropriate (i.e., where Lessee has an
opportunity to know or should have known of such condition sufficiently in advance of the occurrence of any such injury or damage resulting therefrom as would have enabled Lessor to prevent such damage or loss had Lessee notified Lessor of such
condition) only after (i)&nbsp;notice to Lessor of the condition claimed to constitute negligence, and (ii)&nbsp;the expiration of thirty (30)&nbsp;days after such notice has been received by Lessor without Lessor having commenced to take all
reasonable and practicable means to cure or correct such condition; and pending such cure or correction by Lessor, Lessee shall take all reasonably prudent temporary measures and safeguards to prevent any injury, loss or damage to persons or
property. Notwithstanding the foregoing, in no event shall any of the Lessor or its officers, directors, contractors, servants and agents be liable for any loss which is covered by </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">insurance policies actually carried or required to be so carried by this Lease; nor shall any of the Lessor or its officers, directors,
contractors, servants and agents be liable for any such damage caused by other lessees or persons in the Building or caused by operations in construction of any private, public, or quasi-public work; nor shall any of the Lessor or its officers,
directors, contractors, servants and agents be liable for any latent defect in the Premises or in the Building. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">7.10 Indemnification. To
the fullest extent allowable by law, Lessee shall indemnify and save harmless, Lessor, its agents (including, without limitation, Lessor&#146;s managing agent) and employees (such agents and employees being referred to collectively as the
&#147;Lessor Related Parties&#148;) from and against any and all claims, liabilities or penalties asserted by or on behalf of any person, firm, corporation or public authority on account of injury, death, damage or loss to person, business or
property in or upon the Leased Premises and the Property arising out of the use or occupancy of the Leased Premises by Lessee or by any person claiming by, through or under Lessee (including, without limitation, all patrons, employees and customers
of Lessee), or arising out of any delivery to or service supplied to the Leased Premises, or on account of or based upon anything whatsoever done on the Leased Premises, except if the same was caused by the negligence, fault or willful misconduct of
Lessor or Lessor Related Parties. In respect of all of the foregoing, Lessee shall indemnify Lessor and the Lessor Related Parties from and against all costs, expenses (including reasonable attorneys&#146; fees), liabilities incurred in or in
connection with any such claim, action or proceeding brought thereon; and, in case of any action or proceeding brought against Lessor or the Lessor Related Parties by reason of any such claim, Lessee, upon notice from Lessor and at Lessee&#146;s
expense, shall resist or defend such action or proceeding and employ counsel therefor reasonably satisfactory to Lessor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assignment, Subletting and Relocation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessee shall not mortgage, pledge, hypothecate, grant a security interest in, or otherwise encumber this Lease
or any sublease hereinafter entered into by Lessee, or assign this Lease, or sublease the Premises or any portion thereof (the term &#147;sublease&#148; shall be deemed to include any arrangement pursuant to which a third party is permitted by
Lessee to occupy all or any portion of the Premises, except for temporary occupancies by consultants or collaborators providing services to Lessee and except as otherwise provided in paragraph (i)&nbsp;below), without obtaining, on each occasion,
the prior written consent of Lessor, which consent shall not be unreasonably withheld, conditioned, or delayed. Without limiting the standard of reasonableness set forth in this Section&nbsp;8.0(a), Lessor shall not be deemed to be unreasonably
withholding its consent to any proposed assignment or subleasing if: (a)&nbsp;the proposed assignee or subtenant (and each of its owners)&nbsp;(i) is not of good character and reputation or (ii)&nbsp;has ever been charged or convicted of any crime
or listed as a terrorist or suspected terrorist by governmental authority, or (b)&nbsp;the proposed assignee or subtenant does not possess adequate financial capability to perform the Lessee&#146;s obligations as and when due or required as
determined by Lessor, or (c)&nbsp;the assignee or subtenant proposes to use any part of the Premises (or part thereof) for a purpose other than the Permitted Uses applicable thereto, or (d)&nbsp;there shall be existing an Event of Default, or
(e)&nbsp;the proposed assignee or subtenant is unable to provide an OFAC Compliance Statement (as said term is hereinafter defined). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Lessee wishes to assign this Lease or sublease all or any portion of the Premises, Lessee shall so notify
Lessor in writing and request Lessor&#146;s consent thereto. Such notice shall include (i)&nbsp;the name of the proposed assignee or subtenant, (ii)&nbsp;a general description of the types of business conducted by the proposed assignee or subtenant
and a reasonably detailed description of the business operations proposed to be conducted in the Premises by such person or entity, (iii)&nbsp;such financial information concerning the proposed assignee or subtenant as Lessor may reasonably require,
and (iv)&nbsp;all terms and provisions upon which such assignment or sublease is proposed to be made, including a copy of the assignment or sublease agreement which Lessee proposes to execute. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Lessor consents to an assignment or sublease: (i)&nbsp;Lessee shall promptly deliver to Lessor a fully
executed copy of said assignment or sublease, which shall be in the form previously submitted to Lessor for review; (ii)&nbsp;after any such assignment or sublease, Lessee shall remain primarily liable to Lessor hereunder (which liability shall be
joint and several with the assignee or subtenant); and (iii)&nbsp;if the aggregate rent and other amounts received by Lessee under or in connection with a sublease, after deduction of the direct out of pocket third party costs reasonably incurred by
Lessee in entering into such sublease (such costs being limited to reasonable attorneys&#146; fees and expenses, brokerage commissions, and alteration </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs payable by the Lessee under the Sublease for the sublease premises) exceeds the Rent payable hereunder with respect to the portion of the Premises subject to such sublease, Lessee shall pay the Required Percentage
(as said term is hereinafter defined) of such excess to Lessor as Additional Rent immediately upon receipt thereof by Lessee. In the event Lessee shall assign its rights under this Lease, Lessee shall pay to Lessor as Additional Rent, the Required
Percentage of any net profit realized by Lessee as the result of such assignment after deduction of the costs reasonably incurred by Lessee in entering into such assignment (such costs being limited to reasonable attorneys&#146; fees and expenses,
brokerage commissions amortized on a straight line basis over the remaining term of the Lease, and alteration costs payable by the Lessee under the assignment). As used herein, the term &#147;Required Percentage&#148; shall mean fifty (50%) percent
so long as no Event of Default shall occur hereunder and one hundred (100%) percent after the occurrence of an Event of Default. Termination of the Lease shall terminate all rights of Lessee to any share or claim for any rent, additional rent or
other sums or charges payable under any sublease or assignment. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Lessor withholds its consent to such assignment or sublease in accordance with its rights under this Lease,
Lessee shall not enter into the proposed assignment or sublease with such person or entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Lessor elects, it shall have the right to consider Lessee&#146;s request for Lessor&#146;s consent to any
assignment of the Lease, or a request for Lessor&#146;s consent to a sublease as an offer to Lessor to release from this Lease the portion of the Premises which is proposed to be the subject of such sublease as well as all other space occupied by
Lessees other than the Lessee (but subject to such prior sublease agreements) or, in the case of a proposed assignment of this Lease, the entire Premises for the remainder of the term of this Lease. If Lessor accepts such offer, then (i)&nbsp;in the
case of a proposed sublease, this Lease shall be deemed to be amended as of the proposed effective date of such sublease so as to delete from the Premises all space proposed to be or presently occupied by lessees other than the Lessee (with a
commensurate adjustment in Rent and Lessee&#146;s Share (Taxes) and Lessee&#146;s Share (Operating Expenses) for the proposed term of sublease, or (ii) in the case of a proposed assignment, this Lease shall terminate as of the proposed effective
date of such assignment as if such date was the last day of the Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regardless of whether Lessor grants such consent, Lessee shall reimburse Lessor on demand, as Additional Rent,
for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including, without limitation, reasonable attorneys&#146; fees) reasonably incurred by Lessor in responding to a request for
such consent, not to exceed $1,500.00. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessee shall not be entitled to enter into any assignment or sublease, or to request Lessor&#146;s consent
thereto, during the continuance of an Event of Default hereunder by Lessee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any assignment or sublease entered into pursuant to this Section&nbsp;8.0 shall be subject to all of the terms
and provisions of this Lease, including without limitation this Section&nbsp;8.0. If Lessee enters into any such assignment or sublease, Lessor may, at any time and from time to time after the occurrence of an Event of Default hereunder, collect
rent from such assignee or subtenant, and apply the net amount collected against Lessee&#146;s obligations hereunder, but no such assignment or sublease or collection shall be deemed an acceptance by Lessor of such assignee or subtenant as a lessee
hereunder or as a release of the original named Lessee hereunder. No assignment or subletting shall in any way affect the uses permitted under this Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that Lessee desires to assign this Lease or to sublease the Premises (or any portion thereof) to
any corporation, partnership, association or other business organization directly or indirectly controlling or controlled by Lessee or under common control with Lessee, or to any successor by merger, consolidation or purchase of all or substantially
all of the assets of Lessee either directly or by operation of law (each a &#147;Lessee Affiliate&#148;), Lessee shall give at least fifteen (15)&nbsp;business days&#146; prior written notice thereof to Lessor (unless Lessee is prohibited by
applicable laws, codes, rules or regulations, or by the terms of the operative merger agreement or purchase and sale agreement from providing notice to Lessor at such time, in which event such notice shall be provided to Lessor as soon as Lessee is
no longer subject to such prohibition). No consent of Lessor shall be required for any such assignment or sublease and the provisions of Subsection 8.0(c) and (e)&nbsp;shall not apply to such assignment or sublease. Any assignee or subtenant which
claims an interest in this Lease pursuant to a transfer of the type described in this paragraph (i)&nbsp;shall be bound by all of the terms and conditions of this Lease. For the purpose of this Lease, the sale of Lessee&#146;s capital stock through
any public exchange shall not be deemed an assignment or sublease of the Lease or of the Premises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything contained in this Lease, Lessee shall not, either voluntarily or by operation of law,
make any transfer of this Lease or the Premises (or any portion thereof) which results in Lessee (or anyone claiming by, through or under Lessee) collecting in connection with the Premises any rental or other charge based on the net income or on the
profits of any person so as to render any part of the Rent due hereunder unrelated business taxable income of Lessor as described in Section&nbsp;512 of the Internal Revenue Code of 1986, as amended, and any such transfer shall be void.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parking. Lessee shall be entitled to utilize one (1)&nbsp;parking space(s) in the parking area on the premises
on a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> unreserved basis in common with others entitled thereto provided, however, and that Lessee shall not have the right to use any spaces that are marked &#147;handicapped&#148;. In no event
shall Lessor have any responsibility or liability to Lessee for any damage to any vehicles parked in the parking area nor for theft thereof or of items stored therein, unless directly caused by Lessor. Use of parking spaces shall be subject to such
rules and regulations as are from time to time promulgated by Lessor and the City of Cambridge. Parking spaces may be used only to park a passenger car, van or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">light truck having a maximum height no greater than the maximum height posted from time to time of such length and width such that it fits within a conventional parking space. The parking spaces may not be used for
parking commercial vehicles or as a staging area for commercial transportation, delivery or other services, except with Lessor&#146;s prior written consent. The parking spaces may not be used for storage of vehicles or other equipment. Any vehicle
or equipment remaining in the parking spaces for more than thirty (30)&nbsp;calendar days shall be deemed abandoned and may be removed from the parking area in which event Lessor shall have no liability to any person for loss or damage on account of
such removal. Lessee agrees that Lessor is not obligated to provide any security to or for parking spaces or vehicles parked thereon or elsewhere. To the fullest extent permitted by law, neither the Lessor, nor their respective officers, directors,
beneficiaries, agents, employees, successors and assigns, shall be responsible or liable to any extent for (i)&nbsp;damage to or theft of any vehicle or its contents due to fire, collision, vandalism or any other cause, (ii)&nbsp;injuries or
liabilities suffered by any person while using the parking spaces or parking area; or (iii)&nbsp;any losses or other damages incurred by any party by reason of that party&#146;s inability to use the parking spaces or parking area except as arises
due to such party&#146;s negligence or willful misconduct. In no event is the Lessor responsible for loss of items or valuables left in vehicles. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Late Payment of Rent. Lessee agrees that in the event that any payment of Basic Rent or Additional Rent shall
remain unpaid at the close of business on the fifteenth (15th) business day after the same is due and payable hereunder (without reliance on any applicable grace period), there shall become due to Lessor from Lessee, as Additional Rent, as
compensation for Lessor&#146;s extra administrative costs in investigating the circumstances of late Rent, a late charge of two (2%) percent of the amount overdue <B>per </B>calendar month (or portion thereof) during which such amount remains
outstanding. The assessment or collection of such a charge shall not be deemed to be a waiver by Lessor of any default by Lessee arising out of such failure to pay Rent when due. The foregoing charge shall not be imposed with respect to Operating
Expense charges under dispute between Lessor and Lessee where Lessee has a reasonable basis for its claim. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessee&#146;s Covenants. Lessee covenants, at its sole cost and expense, during the Term and such further time
as Lessee occupies any part of the Premises: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to pay when due the Basic Rent and all Additional Rent, and, if separately metered at any time during the Term,
all charges for electricity and other utilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">damage by fire or casualty and reasonable wear and tear only excepted, to keep the Premises in as good order,
repair and condition as the same are in at the commencement of the Term, or may be put in thereafter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to injure, overload or deface the Premises or the Building, nor to suffer or commit any waste therein, nor
to place a load upon any floor which exceeds the floor load which the floor was designed to carry, nor to connect any equipment or apparatus to any Building system (e.g., electrical, plumbing, mechanical) which exceeds the capacity of such system,
nor to permit on the Premises any auction sale or any nuisance or the emission therefrom of any objectionable vibration, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">noise, or odor, nor to permit the use of the Premises for any purpose other than the Permitted Use, nor any use thereof which is improper, offensive, or contrary to any laws, ordinances, codes, rules and regulations, or
the provisions of any license, permit or other governmental consent required for or applicable now or at any time during the Term to the Land, the Building, the Premises or Lessee&#146;s use thereof (collectively, &#147;Legal Requirements&#148;), or
which is liable to invalidate or increase the premiums for any insurance on the Building or its contents, or liable to render necessary any alterations or additions to the Building; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to obstruct in any manner any portion of the Building not hereby leased, or the sidewalks or approaches to
the Building, or any Common Areas, and to conform to all reasonable rules and regulations now or hereafter made by Lessor for the care and use of the Building, its facilities and approaches, the initial rules and regulations being attached hereto as
Exhibit E; provided that Lessor agrees not to discriminate against Lessee in the enforcement of rules and regulations against all lessees (including Lessee), and in the event of a conflict between any provision of Exhibit E and a provision of this
Lease, the provision of this Lease shall govern; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to comply with all Legal Requirements and all recommendations of Lessor&#146;s fire insurance rating
organization now or hereafter in effect provided in writing to Lessee; to keep the Premises equipped with all safety appliances specific to Lessee&#146;s equipment, and to procure (and maintain in full force and effect) all licenses and permits
required by any Legal Requirement or by the provisions of any applicable insurance policy because of the use made of the Premises by Lessee (without hereby intending to vary the Permitted Use), and, if requested by Lessor, to make all repairs,
alterations, replacements or additions so required in and to the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not, without on each occasion obtaining the prior written consent of Lessor, which consent shall not be
unreasonably withheld, conditioned or delayed, to make any alterations, renovations, improvements and/or additions to the Premises (collectively, &#147;Alterations&#148;) or the painting or placing of any signs, antennae, awnings, or the like,
visible from outside of the Premises. Lessee will coordinate with Lessor to minimize the size of any conduits installed to provide telecommunications services from floor to floor, and the location of any such conduits must first be approved by
Lessor which approval will not be unreasonably withheld or delayed. Prior to commencing any Alterations, Lessee shall: secure all necessary licenses, permits and other governmental consents; obtain the written approval of Lessor as to the plans and
specifications for such work (except where such approval is not required as provided in the preceding sentence); and obtain the written approval of Lessor as to the general contractor. Lessee shall cause each contractor and subcontractor to carry
worker&#146;s compensation insurance in statutory amounts covering all of their respective employees and comprehensive public liability insurance in amounts reasonably satisfactory to Lessor (such insurance to be written by companies reasonably
satisfactory to Lessor and insuring Lessee and Lessor as well as the contractor and subcontractors). All Alterations (other than Lessee&#146;s removable personal property </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">and trade fixtures) shall remain part of the Premises and shall not be removed upon the expiration or earlier termination of the Term except for those items which Lessor designates for removal in a notice given to
Lessee at the time that Lessee requests Lessor&#146;s approval of such Alteration. Lessee shall pay promptly when due the entire cost of such work. Lessee shall not cause or permit any liens for labor or materials performed or furnished in
connection therewith to attach to the Land, the Building or Premises, and shall discharge or bond any such liens which may be so filed or recorded within fifteen (15)&nbsp;days after the filing or recording thereof. All such work shall be performed
in a good and workmanlike manner and in compliance with all Legal Requirements and the provisions of all applicable insurance policies. Lessee shall indemnify and hold Lessor harmless from and against any and all suits, demands, causes of action,
claims, losses, debts, liabilities, damages, penalties or judgments, including, without limitation, reasonable attorneys&#146; fees, arising from injury to any person or property occasioned by or growing out of such work, except to the extent due to
the negligence or willful misconduct of the Lessor or its officers, agents, employees, servants or contractors, or the breach of Lessor&#146;s obligations under this Lease (such indemnity shall survive the expiration or termination of this Lease);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to save Lessor harmless and indemnified from any loss, cost and expense (including, without limitation,
reasonable attorneys&#146; fees) arising out of or relating to (i)&nbsp;Lessee&#146;s breach of any covenant or obligation under this Lease; (ii)&nbsp;a claim of injury or death to any person or damage to any property while on the Premises, if not
due to the negligence or willful misconduct of the Lessor or its officers, agents, employees, servants or contractors, or the breach of Lessor&#146;s obligations under this Lease; (iii)&nbsp;a claim of injury to any person or damage to any property
anywhere alleged to be occasioned by any omission, neglect or default of Lessee or of anyone claiming by, through, or under Lessee, or any officer, agent, employee, servant, contractor, or invitee of any of the foregoing, if not due to the
negligence or willful misconduct of the Lessor or its officers, agents, employees, servants or contractors, or the breach of Lessor&#146;s obligations under this Lease; or (iv) on account of or based upon any work or thing whatsoever done (other
than by Lessor or any of its officers, agents, employees, servants or contractors) at the Premises during the Term and during the period of time, if any, prior to the Commencement Date that any of the Lessee or any of its officers, agents,
employees, servants or contractors may have been given access to the Premises provided that in no case shall Lessee&#146;s liability from any claim, cause or damage exceed the dollar limits in the applicable insurance purchased by Lessee pursuant to
Article 7 hereof. The provisions of this clause (g)&nbsp;shall survive the expiration or termination of this Lease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to permit Lessor and Lessor&#146;s agents to examine the Premises at reasonable times, subject to Lessee&#146;s
reasonable security regulations (provided 24 hours&#146; notice is given to Lessee, except in case of emergency), and if Lessor shall so elect (without hereby imposing any obligation on Lessor to do so), after notice as aforesaid, to permit Lessor
to make any repairs or additions Lessor may deem necessary, provided that the same do not materially adversely affect Lessee&#146;s use of the Premises for the Permitted Use; and at Lessee&#146;s expense to remove any Alterations, signs, antennae,
awnings, flagpoles, or the like not consented to in writing; and to permit Lessor to show the Premises to prospective purchasers and Lessees and to keep affixed to any suitable part of the Premises, during the four (4) months preceding the
expiration of the Term, appropriate notices for letting or selling; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that all furniture, furnishings, fixtures and property of every kind of Lessee and of all persons claiming by,
through or under Lessee which may be on the Premises from time to time (&#147;Lessee&#146;s FF&amp;E&#148;) and any of Lessee&#146;s wiring, cables or other installations appurtenant thereto, for Lessee&#146;s computer, telephone, <FONT
STYLE="white-space:nowrap">tel-data</FONT> and other communication systems and equipment, or any other equipment, whether located in the Premises or in any other portion of the Building including, without limitation, those located in any risers or
chasers in the Building (collectively &#147;Lessee&#146;s Cable&#148;) (the Lessee&#146;s FF&amp;E and the Lessee&#146;s Cable are hereinafter collectively called &#147;Lessee&#146;s Property&#148;) shall be at the sole risk of Lessee, and Lessor
shall not be liable if the whole or any part thereof shall be destroyed or damaged by fire, water or otherwise, or by the leakage or bursting of water pipes, steam pipes, or other pipes, or by theft or from any other cause, except to the extent
caused by the negligence or willful misconduct of the Lessor or its officers, agents, employees, servants or contractors, or the breach of Lessor&#146;s obligations under this Lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to pay promptly when due, all taxes of any kind levied, imposed or assessed on Lessee&#146;s Property, which
taxes shall be the sole obligation of Lessee, whether the same is assessed to Lessee or to any other person and whether the property on which such tax is levied, imposed or assessed shall be considered part of the Premises or personal property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by the end of business on the last day of the Term (or the effective date of any earlier termination of this
Lease as herein provided), to remove (i)&nbsp;all of Lessee&#146;s Property, and (ii)&nbsp;the items or components of Alterations designated for removal as provided in paragraph (f)&nbsp;above (the items described in the foregoing clauses (i), and
(ii)&nbsp;are sometimes referred to, collectively, as &#147;Lessee&#146;s Removal Items&#148;), in each case whether the same be permanently affixed to the Premises or not, and to repair any damage caused by any such removal to Lessor&#146;s
reasonable satisfaction; and peaceably to yield up the Premises clean and in good order, repair and condition (reasonable wear and tear, and damage by fire or other casualty or taking only excepted); and to deliver the keys to the Premises to
Lessor; provided, however, that notwithstanding the foregoing, Lessor may, by notice in writing to Lessee, require that Lessee&#146;s Cable (as defined as Cable within the walls, ceilings, walls of the building or that is attached to the building in
any way) remain in the Premises and/or Building, in which case, Lessee&#146;s Cable shall become the property of Lessor upon expiration or earlier termination of the Lease. Any of Lessee&#146;s Removal Items which are not removed within thirty
(30)&nbsp;days following Lessee&#146;s surrender of the Premises shall be deemed abandoned and may be removed and disposed of by Lessor in such manner as Lessor may determine, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">and Lessee shall pay to Lessor on demand, as Additional Rent, the cost of such removal and disposition, together with the reasonable costs and expenses incurred by Lessor in making any incidental repairs and
replacements to the Premises necessitated by Lessee&#146;s failure to remove any of Lessee&#146;s Removal Items, or by any other failure of Lessee to comply with the terms of this Lease, and for use and occupancy during the period after the
expiration of the Term and prior to Lessee&#146;s performance of its obligations under this paragraph (k). Lessee shall further indemnify and hold Lessor harmless from and against any and all suits, demands, causes of action, claims, losses, debts,
liabilities, damages, penalties or judgments, including, without limitation, reasonable attorneys&#146; fees, resulting from Lessee&#146;s failure or delay in surrendering the Premises as above provided (such indemnity to survive the expiration or
termination of this Lease); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to pay Lessor&#146;s reasonable expenses, including reasonable attorneys&#146; fees, incurred in enforcing any
obligations of Lessee under this Lease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to comply in full with the requirements set forth in Section&nbsp;17.0 regulating the use and disposition of
Hazardous Materials and compliance with Environmental Laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to permit any officer, agent, employee, servant, contractor or visitor of Lessee, or of anyone claiming by,
through or under Lessee, to violate any covenant or obligation of Lessee hereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in case Lessee takes possession of the Premises prior to the Commencement Date, to perform and observe all of
Lessee&#146;s covenants from and after the date upon which Lessee takes possession except that no Rent shall accrue prior to the Rent Commencement Date, with respect to Basic Rent, and the Commencement Date, with respect to Additional Rent except as
defined in Paragraph 1.0 above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to provide and pay for the services outlined in Exhibit C attached hereto; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to make any alteration or repair to or to place or install any of Lessee&#146;s Property, or equipment in
the telephone and electric closets within the Premises without first obtaining the Lessor&#146;s approval which shall not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Building Security. Lessee acknowledges that, other than a card key access system Lessor does not provide
security services to the Building. Therefore, Lessee shall otherwise be responsible for security to its Premises or in any way related to its use or occupancy of the Premises. If there is more than one lessee occupying the Building, Lessee agrees to
cooperate with such other lessee(s) to ensure proper security for the common areas, entrances, exists, freight elevators, loading docks, elevators and parking areas serving the Property. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Casualty and Eminent Domain. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the entire Premises or Building, or any substantial part thereof, shall be taken by any
exercise of the right of eminent domain or shall receive any direct or consequential and substantial damages for which Lessor or Lessee or either of them shall be entitled to compensation by reason of anything lawfully done in pursuance of any
public or other authority during the Term, then this Lease shall terminate at the election of Lessor, which election may be made notwithstanding Lessor&#146;s entire interest may have been divested. If such taking or damage substantially reduces the
floor space of the Premises so as to render the Premises unusable for the Permitted Use after such taking, or if it affects the common areas or other parts of the Building in a manner that materially interferes with Lessee&#146;s use of the Premises
for the Permitted Use, Lessee shall have the right, effective when its possession is disturbed, to terminate this Lease by notice in writing to Lessor delivered within thirty (30)&nbsp;days of the first day on which Lessee&#146;s possession is so
disturbed. Lessor reserves and excepts all rights to damage to the Premises and Building and the leasehold hereby created, now accrued or hereafter accruing by reason of any exercise of eminent domain, or by reason of anything lawfully done in
pursuance of any public or other authority and, by way of confirmation, Lessee grants to Lessor all of Lessee&#146;s rights to such damages except for moving and relocation expenses and for Lessee&#146;s Property which Lessee is entitled or required
to remove upon termination of this Lease and covenants to execute and deliver such further instruments of assignment thereof as Lessor may from time to time request. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Building or any substantial part thereof shall be substantially damaged by fire or other casualty in any
respect (whether or not the Premises shall have been damaged) or if any mortgagee of the Building requires that insurance proceeds payable in connection with such casualty be used to retire the mortgage debt, either Lessor or Lessee may, at its
option, terminate this Lease by notifying the other party in writing of such termination within thirty (30)&nbsp;days after the date of such damage, in which event this Lease shall terminate on the date set forth in such notice, and Lessor shall
allow Lessee a fair diminution of Rent from and after the date of such damage to the date of such termination of this Lease to the extent the Premises are unusable for the permitted uses hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of damage to or taking of any portion of the Premises or any portion of the Building, if this Lease
is not terminated as a result thereof, Lessor shall diligently act to seek to restore the Building and the Premises (exclusive of all items or components of Alterations which Lessee is by this Lease either entitled to or required to remove upon the
expiration or earlier termination of this Lease, and Lessee&#146;s Property) or, in case of taking, what remains thereof, to substantially the condition in which they existed prior to the occurrence of such taking or casualty, provided, however,
that: (i)&nbsp;in no event shall Lessor be required to spend in connection with restoring the Premises more than the amount of insurance proceeds or taking award actually received and allocable thereto; (ii)&nbsp;Lessor shall not be required to
restore any Alterations which Lessee is by this Lease either entitled to or required to remove upon the expiration or earlier termination of this Lease; (iii)&nbsp;Lessor shall not be required to restore or replace any of Lessee&#146;s
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Property; and (iv)&nbsp;promptly upon completion of such work by Lessor, Lessee shall diligently act to restore and/or replace all Alterations which Lessor is not required to restore, if any, and to restore or replace
all of Lessee&#146;s Property, to substantially the same condition they were in prior to the occurrence of such taking or casualty; provided that, if Lessor reasonably determines that the work for which Lessee is hereby made responsible can more
effectively be performed as an integral part of the repair work on the Premises, Lessor may elect to perform such work at Lessee&#146;s expense, with the prior approval of Lessee as to the scope, cost and schedule of such work, which approval shall
not be unreasonably withheld or delayed. In the event that Lessor fails to substantially complete such restoration within two (2)&nbsp;months of the occurrence of such taking or casualty, Lessee shall have the option to terminate this Lease by
giving written notice to Lessor within forty-five (45)&nbsp;days after the expiration of such <FONT STYLE="white-space:nowrap">2-month</FONT> period. Such right of termination shall be Lessee&#146;s sole and exclusive remedy at law or in equity for
Lessor&#146;s failure to complete such restoration. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessor shall not be liable for any inconvenience or annoyance to Lessee or injury to the business of Lessee
resulting in any way from such taking or damage or the repair thereof, except that (i)&nbsp;Lessor shall allow Lessee a fair diminution of Rent during the time for the entire Premises if more than 30% are unusable for the Permitted Use or otherwise
to the extent the Premises are unusable for the Permitted Use but such abatement shall end if and when Lessor shall have substantially restored the Premises to the condition they were in prior to such damage (with an additional 15 days to permit
Lessee to complete any Alterations or improvements made by Lessee and exclusive of Lessee&#146;s Property), and (ii)&nbsp;in the event of a partial taking, a just proportion of Rent, similarly determined, shall be abated for the remainder of the
Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defaults; Remedies. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">14.1 Defaults; Events of Default. The following shall, if any requirement for notice or lapse of time or both has not been met, constitute
defaults hereunder, and, if such conditions have been met, constitute &#147;Events of Default&#148; hereunder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The failure of Lessee to perform or observe any of Lessee&#146;s covenants or agreements hereunder concerning
the payment of Rent for a period often (10)&nbsp;days after written notice thereof, provided, however, that Lessee shall not be entitled to such notice if Lessor has given notice to Lessee of one or more previous such failures within a twelve-month
period, in which event such failure shall constitute an Event of Default hereunder upon the expiration of ten (10)&nbsp;days after such payment was due; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The failure of Lessee, either (i)&nbsp;to maintain the insurance required hereunder in full force and effect,
or (ii)&nbsp;to deliver an estoppel certificate to Lessor within the time provided in Section&nbsp;22.0 below) for a period of ten (10)&nbsp;days after written notice thereof, provided, however, that Lessee shall not be entitled to such notice if
Lessor has given notice to Lessee of one or more previous such failures within a twelve-month period, in which event such failure shall constitute an Event of Default hereunder upon the expiration of ten ( I 0) days after such default;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution by Lessee of any assignment, sublease or other agreement without the prior written approval of
Lessor as required by Section&nbsp;8.0; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The failure of Lessee to perform or observe any of Lessee&#146;s other covenants or agreements hereunder for a
period of thirty (30)&nbsp;days after written notice thereof (provided that, in the case of defaults not curable in thirty (30)&nbsp;days through the exercise of reasonable diligence, such <FONT STYLE="white-space:nowrap">30-day</FONT> period shall
be extended so long as Lessee commences cure within such <FONT STYLE="white-space:nowrap">30-day</FONT> period and thereafter prosecutes such cure to completion with reasonable diligence, but such extended cure period shall not in any event exceed
ninety (90)&nbsp;days after Lessor&#146;s initial notice to Lessee); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the leasehold hereby created shall be taken on execution, or by other process of law, or if any assignment
shall be made of Lessee&#146;s property for the benefit of creditors, or if a receiver, guardian, conservator, trustee in bankruptcy or similar officer shall be appointed to take charge of all or any part of Lessee&#146;s assets by a court of
competent jurisdiction; or if a petition is filed by Lessee under any bankruptcy or insolvency law; or if a petition is filed against Lessee under any bankruptcy or insolvency law and the same shall not be dismissed within sixty (60) days from the
date upon which it is filed, or a lien or other involuntary encumbrance is filed against Lessee&#146;s leasehold (or against the Premises, the Building or the Land based on a claim against Lessee) and is not discharged or bonded within thirty
(30)&nbsp;days after the filing thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Termination. If an Event of Default shall occur, Lessor may, at its option, immediately or any time thereafter
pursuant to lawful process, and in accordance with law, enter upon the Premises or any part thereof in the name of the whole and repossess the same as of Lessor&#146;s former estate and dispossess Lessee and those claiming through or under Lessee
and remove their effects, forcibly if necessary, without being deemed guilty of any manner of trespass and without prejudice to any remedies which might otherwise be used for arrears of rent or preceding breach of covenant, and upon such entry this
Lease shall terminate. In lieu of making such entry, Lessor may terminate this Lease upon three (3)&nbsp;business days&#146; prior written notice to Lessee. Upon any termination of this Lease as the result of an Event of Default, Lessee shall quit
and peacefully surrender the Premises to Lessor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Survival of Covenants; Remedies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No such termination of this Lease shall relieve Lessee of its liability and obligations under this Lease and
such liability and obligations shall survive any such termination. Lessee shall indemnify and hold Lessor harmless from all loss, cost, expense, damage or liability arising out of or in connection with such termination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any such termination Lessee shall pay to Lessor the Rent up to the time of such termination.
Lessee shall remain liable for, and shall pay on the days originally fixed for such payment hereunder, the full amount of all Basic Rent and Additional Rent as if this Lease had not been terminated; provided, however, if Lessor relets the Premises,
there shall be credited against such obligation the amount actually received by Lessor each month from such lessee after first deducting all costs and expenses incurred by Lessor in connection with releting the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the option of Lessor at any time after such termination, in lieu of damages pursuant to paragraph
(b)&nbsp;above, Lessee shall pay to Lessor, on demand, as and for liquidated and agreed damages for Lessee&#146;s default, the present value, discounted at the then prime rate set forth in the Wall Street Journal, of amount by which:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">the aggregate Rent which would have been payable under this Lease by Lessee from the date of such termination until what
would have been the last day of the Term but for such termination, exceeds the fair and reasonable rental value of the Premises for the same period, less Lessor&#146;s reasonable estimate of expenses to be incurred in connection with releting the
Premises, including, without limitation, all repossession costs, brokerage commissions, legal expenses, reasonable attorneys&#146; fees, alteration costs, and expenses of preparation for such releting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">There shall be credited against Lessee&#146;s obligation under this paragraph (c)&nbsp;all amounts actually received by Lessor from Lessee
pursuant to paragraph (b)&nbsp;above or actually received by Lessor from releting the Premises. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Premises or any part thereof are relet by Lessor to an unrelated party in a bona fide lease transaction
for the period prior to what would have been the last day of the Term but for such termination, or any portion thereof, the amount of rent reserved upon such releting (excluding any free rent or concessions) shall be, prima facie, the fair and
reasonable rental value for the part or the whole of the Premises so relet during the term of the releting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">14.4 Right
to Relet. At any time or from time to time after any such termination, Lessor may relet the Premises or any part thereof for such a term (which may be greater or less than the period which would otherwise have constituted the balance of the Term)
and on such conditions (which may include concessions or free rent) as Lessor, in its reasonable discretion, may determine, and may collect and receive the rents therefor. Lessor shall in no way be responsible or liable for any failure to relet the
Premises or any part thereof, or for any failure to collect any rent due upon any such releting, provided that Lessor shall have used reasonable efforts to mitigate damages hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">14.5 Right to Equitable Relief. In the event there shall occur a default or threatened default hereunder, Lessor shall be entitled to enjoin
such default or threatened default and shall have the right to invoke any right and remedy allowed at law or in equity or by statute or otherwise as though <FONT STYLE="white-space:nowrap">re-entry</FONT> and other remedies were not provided for in
this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">14.6 Performance by Lessor. In the event of a default by Lessee hereunder which continues
beyond the expiration of the applicable grace period, Lessor shall have the right to perform such defaulted obligation of Lessee, including the right to enter upon the Premises to do so. Lessor shall notify Lessee of its intention to perform such
obligation. In the event of a default by Lessee hereunder which has not yet continued beyond the expiration of the applicable grace period but which Lessor determines constitutes an emergency threatening imminent injury to persons or damage to
property, Lessor shall have the right to perform such defaulted obligation of Lessee (including the right to enter upon the Premises to do so) after giving Lessee such notice (if any) as is reasonable under the circumstances. In either event, the
aggregate of (i)&nbsp;all sums so paid by Lessor, (ii)&nbsp;interest (at the rate of <FONT STYLE="white-space:nowrap">1-1/2%</FONT> per month or the highest rate permitted by law, whichever is less) on such sum, and (iii)&nbsp;all necessary
incidental costs and expenses in connection with the performance of any such act by Lessor, shall be deemed to be Additional Rent under this Lease and shall be payable to Lessor immediately upon demand. Lessor may exercise its rights under this
Section&nbsp;14.6 without waiving any other of its rights or releasing Lessee from any of its obligations under this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">14.7 Further
Remedies. Nothing in this Lease contained shall require Lessor to elect any remedy for a default or Event of Default by Lessee hereunder, and, except as specifically limited herein, all rights herein provided shall be cumulative with one another and
with any other rights and remedies which Lessor may have at law or in equity in the case of such a default or Event of Default. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Real Estate Broker. Lessor and Lessee each represent to the other that they have dealt with no broker in
connection with this Lease other than Newmark Knight Frank (&#147;NKF&#148; or &#147;Broker&#148;). If, and only if, this Lease is executed and delivered by both Lessor and Lessee, Lessor shall pay NKF a brokerage fee under a separate agreement with
NKF. Lessee agrees to indemnify and hold Lessor harmless from and against any claims for commissions or fees by any person other than the Broker by reason of any act of Lessee or its representatives. Lessor agrees to indemnify and hold Lessee
harmless from and against any claims for commissions or fees by any person by reason of any act of Lessor or its representatives. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notices. All notices, demands, approvals or other communications hereunder which shall or may be given either
to Lessor or to Lessee shall be in writing and shall be sent by hand delivery, or by registered or certified mail, postage prepaid, or by Federal Express or other similar overnight delivery service: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bolton Street Partners, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Peter Zagorianakos, Manager</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">181 Dudley
Road</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Newton, MA 02459</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bolton Street Partners, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">c/o Christopher
Argyrople, Manager</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">126 North Washington Street, Unit 5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02114</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">and to:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bruce I. Miller, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Pierce&nbsp;&amp; Atwood, LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">160 Federal Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston, Massachusetts 0211 0</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Aura Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attention:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">85 Bolton Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cambridge, MA 02139</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(except that prior to the Commencement Date,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">notice shall also be provided to Lessee at</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">and to:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Aura Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attention: Kevin McGovern, Chairman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1 0 Wall Street, 1<SUP STYLE="font-size:85%; vertical-align:top">st </SUP>Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Norwalk,, CT 06850</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any notice, demand, approval or other communication shall be effective upon receipt by or tender for
delivery to the intended recipient thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17.0 Hazardous Materials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">17.1 Prohibition. Except for (a)&nbsp;de minimis quantities of standard office supplies and cleaning materials used, generated and stored in
compliance with Environmental Laws (hereinafter defined) and any other Legal Requirements and in proper containers and (b)&nbsp;Hazardous Materials (as said term is hereinafter defined) which are not radioactive and are used in connection with
Lessee&#146;s business operations at the Premises within the limits of the Permitted Uses under this Lease and identified in writing to Lessor prior to commencement of any use, generation or storage thereof on the Premises and then only to the
extent any such use, generation and storage is in compliance with all Environmental Laws and any other Legal Requirements and so called &#147;best environmental practices&#148; and in proper containers, Lessee shall not, without the prior written
consent of Lessor, which shall not be unreasonably withheld, conditioned, or delayed, generate, store, use, bring or permit to be brought or kept in or on the Premises or elsewhere in the Building (i)&nbsp;any flammable, combustible or explosive
fluid, material, chemical or substance; or (ii)&nbsp;any Hazardous Material (hereinafter defined). Lessor shall have the right, from time to time upon three (3)&nbsp;business days&#146; prior notice (except in the case of emergency in which case no
prior notice shall be required), to inspect the Premises for compliance with the terms of this Section&nbsp;17.1 at Lessor&#146;s sole cost and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">expense unless the occasion for such inspection is a breach of this Section&nbsp;17.0 by
Lessee or discloses or reveals a breach in which event such inspection shall be at the sole cost and expense of Lessee. Any right of entry by Lessor hereunder shall be made using diligent efforts to minimize interference with Lessee&#146;s use and
enjoyment of the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">17.2 Environmental Laws. Lessee, at its sole cost and expense, shall comply with (i)&nbsp;an laws, statutes,
ordinances, rules and regulations of any local, state or federal governmental authority having jurisdiction concerning environmental, health and safety matters, including, without limitation, the laws listed in Section&nbsp;17.3 below (collectively,
&#147;Environmental Laws&#148;), including Environmental Laws that govern or prohibit any discharge by any of the Lessee Parties into the air, surface, water, sewers, soil or groundwater of any Hazardous Material, whether within or outside the
Premises or Building, and (ii)&nbsp;any rules, requirements and safety procedures of the Massachusetts Department of Environmental Protection, the City of Cambridge Fire Marshall and any insurer of the Building or the Premises with respect to
Lessee&#146;s use, storage and disposal of any Hazardous Materials. Without limiting any term or provision of this Article 17 to the contrary, Lessee (and shall require and cause all parties claiming by, through or under Lessee shall (including,
without limitation, any subtenant, <FONT STYLE="white-space:nowrap">sub-subtenant</FONT> (at any tier), licensee, assignee or other occupant of the Premises or any officer, agent, employee, servant, contractor, subcontractor, supplier or guest or
invitee of the foregoing (collectively, the &#147;Lessee Parties&#148; and each a &#147;Lessee Party&#148;)) to dispose of all Hazardous Materials from the Premises only to a properly approved disposal facility and only in compliance with any and
all applicable Environmental Laws and other Legal Requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">17.3 Hazardous Material Defined. As used herein, the term &#147;Hazardous
Material&#148; means any hazardous, radioactive or toxic chemical substance, material, contaminant, waste, gas emission or petroleum derivative, which is or becomes regulated by any Environmental Law. The term &#147;Hazardous Material&#148;
includes, without limitation, any material or substance which is defined (i)&nbsp;designated as a &#147;hazardous substance&#148; pursuant to Section&nbsp;1311 of the Federal Water Pollution Control Act (33 U.S.C. Section&nbsp;1317), (ii) defined as
a &#147;hazardous waste&#148; pursuant to Section&nbsp;1004 of the Federal Resource Conservation and Recovery Act, 42 U.S.C. Section&nbsp;6901 et seq. (42 U.S.C. Section&nbsp;6903), or (iii)&nbsp;defined as a &#147;hazardous substance&#148; pursuant
to Section&nbsp;101 of the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Section&nbsp;9601 et seq. (42 U.S.C. Section&nbsp;9601), or (iv)&nbsp;defined as &#147;hazardous substance&#148; or &#147;oil&#148; under
Chapter 21E of the General Laws of Massachusetts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">17.4 Testing. If at any time during the Term of the Lease, any Governmental Authority
requires testing or inspection of the Premises or any other part of the Property to determine whether there has been any release of Hazardous Materials by reason of, or in any way related to, the use of the Premises made by Lessee or anyone claiming
by, through or under Lessee (including, without limitation, any Lessee Party) then, without limiting any other right or remedy which Lessee may have on account thereof, Lessee shall reimburse Lessor, upon demand, as Additional Rent, for all costs
and expenses related thereto. If, in anticipation of the commencement of the Lease Term or at any time during the Lease Term, Lessee or anyone claiming by, through or under Lessee performs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">any testing to determine whether there has been any release of Hazardous Materials from the
Premises, Lessee shall promptly provide a copy of such report to Lessor at no charge to Lessor. Lessee shall execute such affidavits as may be requested by Lessor from time to time concerning Lessee&#146;s best knowledge and belief concerning the
presence, or threat of presence, of Hazardous Materials in or on the Premises or which may have been discharged from the Premises. Lessor reserves the right to enter the Premises at reasonable times (provided twenty four (24)&nbsp;hours notice is
given to Lessee, except in the case of emergency) and subject to Lessee&#146;s reasonable security precautions to inspect the same for Hazardous Materials. Without limiting any other term or provision of the Lease, Lessee shall indemnify, defend and
hold harmless Lessor and the holder of any mortgage on the Premises from time to time from and against any claim, cost, expense, liability, obligation or damage, including, without limitation, reasonable attorneys&#146; fees and the cost of
litigation, arising from, or relating to, the breach by Lessee of any of the provisions of this Article 17 and shall immediately discharge, or cause to be discharged, any lien imposed upon the Building, the Land or the Property or the Premises in
connection with any such claim. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">17.5 Decommissioning; Clean Certificate. Notwithstanding anything to the contrary contained in this Lease,
upon expiration or earlier termination of the Term, Lessee shall cause the Premises to be &#147;decommissioned&#148; in accordance with all applicable Legal Requirements and Environmental Laws and shall leave the Premises and the Property (and the
drains and lines and storage containers and basins serving the same and the Special Equipment) free of all chemicals, blood, germs, biological products and other Hazardous Materials. Without limiting the foregoing, upon expiration or earlier
termination of the Lease, Lessee shall provide Lessor, at Lessee&#146;s sole cost and expense, with a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Clean Certificate&#148; from a reputable, experienced third party industrial hygienist
first approved by Lessor (which approval will not be unreasonably withheld, conditioned or delayed), licensed to do business in the Commonwealth of Massachusetts, dated within fifteen (15)&nbsp;days after Lessee and all parties claiming by, through
and under Lessee, have vacated the Premises (but no earlier than the actual date Lessee and all parties claiming by, through and under Lessee, have vacated the Premises) certifying to the Lessor that (a)&nbsp;the Premises and the pipes, drains,
storage containers, basins (including, without limitation, the Special Equipment used by Lessee) are free from all such substances and other Hazardous Materials, (b)&nbsp;the Premises and the pipes and drains serving the Premises, the Special
Equipment used by Lessee has been completely sanitized, including, without limitation, all sanitization required in accordance with applicable Environmental Laws and other Legal Requirements, (c)&nbsp;any biological or chemical safety cabinets
located in the Premises have been completely decontaminated, including, without limitation, all decontamination required under all Environmental Laws and other Legal Requirements. Without limiting the generality of the foregoing, the so-called Clean
Certificate described hereinabove shall include at least the matters set forth in Exhibit F attached hereto and such other matters as Lessor may require which are in any way related to the use or occupancy of the Premises by Lessee or any Lessee
Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The provisions of this Article 17 shall expressly survive expiration or earlier termination of the Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Waivers. Failure of Lessor to complain of any act or omission on the part of Lessee, no matter how long the
same may continue, shall not be deemed to be a waiver by Lessor of any of its rights hereunder. No waiver by Lessor at any time, expressed or implied, of any breach of any provision of this Lease shall be deemed a waiver of a breach of any other
provision of this Lease or a consent to any subsequent breach of the same or any other provision. No acceptance by Lessor of any partial payment shall constitute an accord or satisfaction but shall only be deemed a partial payment on account; nor
shall any endorsement or statement on any check or any letter accompanying any check or payment be deemed an accord and satisfaction, and Lessor may accept such check or payment without prejudice to Lessor&#146;s right to recover the balance of such
installment or pursue any other remedy available to Lessor in this Lease or at law or in equity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Services Provided by Lessor. Lessor shall furnish the services described on Exhibit D attached hereto, the cost
of which shall be included in Operating Expenses or Additional Utility Expenses. Lessor shall not be liable in damages, nor in default hereunder, for any failure or delay in furnishing any service rendered customarily to the Premises or Building or
agreed to by the terms of this Lease, due to any accident, to the making of repairs, alterations or improvements, or to the occurrence of an event of &#147;Force Majeure&#148; as defined in Section&nbsp;24 below, or to any act or default of Lessee
hereunder. No such failure shall be held or pleaded as an eviction or disturbance in any manner whatsoever of Lessee&#146;s possession or give Lessee any right to terminate this Lease or give rise to any claim for
<FONT STYLE="white-space:nowrap">set-off</FONT> or any abatement of Rent or of any of Lessee&#146;s obligations under this Lease unless the failure or delay in furnishing any service is caused by Lessor&#146;s or its agents&#146; willful misconduct.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quiet Enjoyment; Ground Leases; Mortgages. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">20.1 Quiet Enjoyment. Lessor covenants that, provided that an Event of Default has not occurred and is not then continuing, Lessee shall
quietly have and enjoy the Premises during the Term, without hindrance or molestation from any person lawfully claiming by, through or under Lessor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">20.2 Rights of Ground Lessors and Mortgagees. No act or failure to act on the part of Lessor which would entitle Lessee under the terms of this
Lease, or by law, to be relieved of Lessee&#146;s obligations hereunder or to terminate this Lease, shall result in a release or termination of such obligations or a termination of this Lease unless (i)&nbsp;Lessee shall have first given written
notice to Lessor&#146;s ground lessors and mortgagees of record of the act or failure to act on the part of Lessor which Lessee claims as the basis of Lessee&#146;s rights; and (ii)&nbsp;such ground lessors and mortgagees, after receipt of such
notice, have failed or refused to correct or cure the condition within a reasonable time thereafter, including such time as necessary to obtain access to or possession of the Building, but nothing in this Lease shall be deemed to impose any
obligation on any such ground lessor or mortgagee to correct or cure any such condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">20.3 Lease Subordinate. This Lease is and shall be subject and subordinate to any ground
lease or mortgage hereafter on the Premises, and to all advances under any such mortgage and to all renewals, amendments, extensions and consolidations thereof, provided that no such subordination shall be effective unless Lessor shall obtain from
such ground lessor or mortgagee an agreement (a <FONT STYLE="white-space:nowrap">&#147;Non-Disturbance</FONT> Agreement&#148;) in commercially reasonable form whereby such ground lessor or mortgagee agrees not to disturb the possession of Lessee
under this Lease or to join Lessee in summary or foreclosure proceedings in the event such ground lessor terminates its ground lease or such mortgagee forecloses its interest against the Premises under its mortgage so long as Lessee duly and
promptly keeps and performs all of its obligations hereunder, and Lessee shall enter into such agreement and agree to attorn to such ground lessor or mortgagee as its landlord under this Lease in the event of such foreclosure. In confirmation of
such subordination, Lessee shall execute and deliver promptly a certificate in recordable form that Lessor or any ground lessor or any mortgagee may request. Notwithstanding the foregoing provisions of this Section, the holder of any mortgage on the
Premises may at any time subordinate its mortgage to this Lease by written notice to Lessee. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Security Deposit. Lessee shall, deposit with Lessor the Security Deposit as security for the full and faithful
payment and performance by Lessee of its obligations under this Lease, and not as a prepayment of Rent. The Security Deposit shall be deposited with Lessor simultaneously with the execution and delivery of this Lease. For purposes of this Lease, the
term &#147;Security Deposit&#148; shall mean and include all cash security deposited with Lessor pursuant to this Section. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any cash security held by Lessor pursuant to this section may be commingled with Lessor&#146;s other funds. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lessor shall assign and deliver the Security Deposit to any transferee of the Building and thereafter Lessor shall have no further
responsibility therefor. Upon the expiration (or earlier termination) of the Term of this Lease, Lessor shall inspect the Premises, make such deductions from the Security Deposit as may be required to cure any default by Lessee hereunder, and, if
Lessee is not then in default hereunder, return the cash security then held by Lessor to Lessee within thirty (30)&nbsp;days of such expiration or termination. If Lessee is in default at the time of such expiration or termination, the Lessor shall
be entitled to retain so much of the Security Deposit as Lessor reasonably estimates to be Lessee&#146;s liability to Lessor under this Lease and shall pay the balance, if any, to Lessee within such <FONT STYLE="white-space:nowrap">30-day</FONT>
period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event that Lessor applies all or any portion of the cash security, towards the cure of an Event of Default by Lessee
hereunder or towards damages payable by Lessee to Lessor by reason of the occurrence of an Event of Default by Lessee hereunder, Lessee shall pay to Lessor, as Additional Rent, the amount so expended by Lessor within thirty (30) business days of
notice given by Lessor so that at all times (subject to the thirty (30)-business day grace period herein referenced) Lessor shall be entitled to hold the full cash security required to be deposited with Lessor hereunder. Any failure of Lessee to
deliver to Lessor the cash security as prescribed herein or any amounts expended from the cash security within the time and manner specified in this Section shall constitute an Event of Default under the Lease and Lessor shall retain such cash
amounts (or the cash security, as appropriate) as a Security Deposit pursuant to the provisions of this Section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estoppel Certificates. From time to time during the Term, and without charge, either party shall, within
fifteen (15)&nbsp;days of request by the other party, certify by written instrument duly executed and acknowledged, to a lender or potential buyer of the (i)&nbsp;Land and Building with respect to a request by Lessee, or (ii)&nbsp;ownership interest
in Lessee with respect to a request by Lessor, regarding (a)&nbsp;the existence of any amendments or supplements to this Lease; (b)&nbsp;the validity and force and effect of this Lease; (c)&nbsp;the existence of any default; (d)&nbsp;the existence
of any offsets, counterclaims or defenses; (e)&nbsp;the Commencement Date and the expiration date of the Term; (f)&nbsp;the amount of Rent due and payable and the date to which Rent has been paid; and (g)&nbsp;any other matter reasonably requested
and commercially reasonable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Holding Over. If Lessee occupies the Premises after the day on which the Term expires (or the effective date of
any earlier termination as herein provided) without having entered into a new lease thereof with Lessor, Lessee shall be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Lessee-at-sufferance,</FONT></FONT> subject to all of the
terms and provisions of this Lease at 125% of the rate of the Basic Rent in effect on the last day of the Term. Such a holding over, even if with the consent of Lessor, shall not constitute an extension or renewal of this Lease.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Force Majeure. Lessor shall not be deemed to be in default hereunder and the time for performance of any of
Lessor&#146;s obligations hereunder shall be postponed for so long as the performance of such obligation is prevented by strike, <FONT STYLE="white-space:nowrap">lock-out,</FONT> act of God, absence of materials or any other matter not reasonably
within the control of the Lessor (collectively, &#147;Force Majeure&#148;), provided, however, that such Force Majeure shall not eliminate any right of rent abatement specifically provided for herein. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Independent Covenants. In no event shall Lessor&#146;s failure to perform its obligations under this Lease be
held or pleaded as an eviction or disturbance in any manner whatsoever of Lessee&#146;s possession or give Lessee any right to terminate this Lease or give rise to any claim for <FONT STYLE="white-space:nowrap">set-off</FONT> or any abatement of
Rent or of any of Lessee&#146;s obligations under this Lease other than as specifically provided for herein. Lessee&#146;s remedies hereunder being limited to an action for damages or injunctive relief in the event that such failure is the result of
Lessor&#146;s gross negligence or willful misconduct. Basic Rent, Additional Rent and other sums and charges payable by Lessee under this Lease (collectively called the &#147;Rent&#148; for purposes of this Section&nbsp;25) shall be paid without
notice or demand, and without setoff, counterclaim, defense, abatement, suspension, deferment, reduction or deduction. Lessee waives all rights (i)&nbsp;to any abatement, suspension, deferment, reduction or deduction of or from Rent, other than as
specifically provided for herein, and (ii)&nbsp;to quit, terminate or surrender this Lease or the Premises or any part thereof, except as expressly provided in this Lease. Lessee hereby acknowledges and agrees that the obligations of Lessee
hereunder shall be separate and independent covenants and agreements, that Rent shall continue to be payable in all events and that the obligations of Lessee hereunder shall continue unaffected, unless the requirement to pay or perform the same
shall have been terminated or abated pursuant to an express provision of this Lease. Lessor and Lessee each acknowledges and agrees that the independent nature of the obligations of Lessee hereunder represents fair, reasonable, and accepted
commercial practice with respect to the type of property subject to this Lease, and that this agreement is the product of free and informed negotiation during which both Lessor and Lessee </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">were represented by counsel skilled in negotiating and drafting commercial leases in
Massachusetts, and that the acknowledgements and agreements contained herein are made with full knowledge of the holding in Wesson v. Leone Enterprises, Inc., 437 Mass. 708 (2002). Such acknowledgements, AGREEMENTS AND WAIVERS by Lessee are a
material inducement to Lessor entering into this Lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entire Agreement. No oral statement or prior written matter shall have any force or effect. This Agreement
shall not be modified or canceled except by writing subscribed to by all parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Applicable Law, Severability and Construction. This Lease shall be governed by and construed in accordance with
the laws of Massachusetts and, if any provisions of this Lease shall to any extent be invalid, the remainder of this Lease, and the application of such provisions in other circumstances, shall not be affected thereby. The titles of the several
Sections contained herein are for convenience only and shall not be considered in construing this Lease. Whenever the singular is used and when required by the context it shall include the plural, and the neuter gender shall include the masculine
and feminine. The Exhibits attached to this Lease are incorporated into this Lease by reference. This Lease may be executed in several counterparts, each of which shall be an original, but all of which shall constitute one and the same instrument.
The term &#147;Lessor&#148; whenever used herein, shall mean only the owner at the time of Lessor&#146;s interest herein, and no covenant or agreement of Lessor, express or implied, shall be binding upon any person except for defaults occurring
during such person&#146;s period of ownership nor binding individually upon any agent, fiduciary, shareholder, officer, director or partner of Lessor, and the liability of Lessor, in any event, shall be limited to Lessor&#146;s interest in the
Building. Lessee shall neither assert nor seek to enforce any claim against Lessor or any of the Lessor&#146;s agents, employees, contractors, officers, directors, managers, members, shareholders, partners or limited partners (collectively,
&#147;Lessor Parties&#148;), or the assets of any of the Lessor Parties, for breach of this Lease or otherwise, other than against Lessor&#146;s interest in the Building and Lessee agrees to look solely to such interest for the satisfaction of any
liability of Lessor under, or in connection with, this Lease. Without limiting the generality of the foregoing, Lessee specifically agrees that in no event shall any officer, director, trustee, employee or representative of Lessor or any of the
other Lessor Parties ever be personally liable for any obligation under this Lease, nor shall Lessor or any of the other Lessor Parties be liable for consequential or incidental damages or for lost profits whatsoever in connection with this Lease.
If more than one person or entity executes this Lease as Lessee, the Lessee&#146;s obligations hereunder shall be the joint and several obligations of such persons or entities. Unless repugnant to the context, &#147;Lessor&#148; and
&#147;Lessee&#148; mean the person or persons, natural or corporate, named above as Lessor and as Lessee respectively, and their respective heirs, executors, administrators, successors and assigns. Lessor specifically agrees that in no event shall
any officer, director, trustee, employee or representative of Lessee or any Lessee Party ever be personally liable for any obligation under this Lease, nor shall Lessee or any of the other Lessee Parties be liable for consequential or incidental
damages or for lost profits whatsoever in connection with this Lease. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Successors and Assigns. The terms, covenants and conditions of this Lease shall run with the Land, and be
binding upon and inure to the benefit of Lessor and Lessee and their respective successors and permitted assigns. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">29.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Authority. Contemporaneously with the signing of this Lease, Lessee shall furnish to Lessor a certified copy of
the resolution of the Board of Directors or Managers of Lessee authorizing Lessee to enter into this Lease and authorizing the person executing this Lease on behalf of Lessee to do so. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30.0 Financial Statements. Lessee shall (from time to time upon request of Lessor) provide Lessor on an annual basis with an audited financial statement for
Lessee&#146;s most recent fiscal year (including both a balance sheet and operating statement) prepared in accordance with generally accepted accounting principles by an independent, certified public accountant (or if no audited statement is
prepared, then such statement may be prepared and certified by Lessor&#146;s Chief Financial Officer) within ninety (90)&nbsp;days after the end of Lessee&#146;s fiscal year. Lessor agrees that all such financial information shall be deemed the
confidential and proprietary information of Lessee and, accordingly, may only be accessed by and made available to personnel of Lessor who have a reasonable need to review such information and who are obligated (i)&nbsp;to treat it as confidential,
(ii)&nbsp;to use it only for the purposes of assessing Lessee&#146;s financial condition as a Building lessee and (iii)&nbsp;not to transfer or disclose it except to other Lessor personnel who meet these same requirements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31.0 OFAC Compliance. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessee represents and warrants that (a)&nbsp;each person or entity owning a 10% or greater interest in Lessee
is (i)&nbsp;not currently identified on the Specially Designated Nationals and Blocked Persons List maintained by the Office of Foreign Assets Control, Department of the Treasury (&#147;OFAC&#148;) and/or on any other similar list maintained by OFAC
pursuant to any authorizing statute, executive order or regulation (collectively, the &#147;List&#148;), and (ii)&nbsp;is not a person or entity with whom a citizen of the United States is prohibited to engage in transactions by any trade embargo,
economic sanction, or other prohibition of United States law, regulation, or Executive Order of the President of the United States, (b)&nbsp;none of the funds or other assets of Lessee constitute property of, or are beneficially owned, directly or
indirectly, by any Embargoed Person (as hereinafter defined), (c) no Embargoed Person has any interest of any nature whatsoever in Lessee (whether directly or indirectly), (d) none of the funds of Lessee have been derived from any unlawful activity
with the result that the investment in Lessee is prohibited by law or that the Lease is in violation of law, and (e)&nbsp;Lessee will use good faith efforts to implement procedures, and will consistently apply those procedures, to ensure the
foregoing representations and warranties remain true and correct at all times. The term &#147;Embargoed Person&#148; means any person, entity or government subject to trade restrictions under U.S . law, including but not limited to, the
International Emergency Economic Powers Act, 50 U.S.C. &#167;1701 et seq., The Trading with the Enemy Act, 50 U.S.C. App. I et seq., and any Executive Orders or regulations promulgated there under with the result that the investment in Lessee is
prohibited by law or Lessee is in violation of law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessee covenants and agrees (a)&nbsp;to comply with all requirements of law relating to money laundering,
anti-terrorism, trade embargos and economic sanctions, now or hereafter in effect, (b)&nbsp;to immediately notify Lessor in writing if any of the representations, warranties or covenants set forth in this paragraph or the preceding paragraph are no
longer true or have been breached or if Lessee has a reasonable basis to believe that they may no longer be true or have been breached, (c) not to use funds from any &#147;Prohibited Person&#148; (as such term is defined in the September 24, 2001
Executive Order Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism) to make any payment due to Lessor under the Lease and (d)&nbsp;at the request of Lessor, to provide such information as
may be requested by Lessor to determine Lessee&#146;s compliance with the terms hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessor represents and warrants that (a)&nbsp;each person or entity owning a 10% or greater interest in Lessor
is (i)&nbsp;not currently identified on the Specially Designated Nationals and Blocked Persons List maintained by the Office of Foreign Assets Control, Department of the Treasury (&#147;OFAC&#148;) and/or on any other similar list maintained by OFAC
pursuant to any authorizing statute, executive order or regulation (collectively, the &#147;List&#148;), and (ii)&nbsp;is not a person or entity with whom a citizen of the United States is prohibited to engage in transactions by any trade embargo,
economic sanction, or other prohibition of United States law, regulation, or Executive Order of the President of the United States, (b)&nbsp;none of the funds or other assets of Lessor constitute property of, or are beneficially owned, directly or
indirectly, by any Embargoed Person (as hereinafter defined), (c) no Embargoed Person has any interest of any nature whatsoever in Lessor (whether directly or indirectly), (d) none of the funds of Lessor have been derived from any unlawful activity
with the result that the investment in Lessor is prohibited by law or that the Lease is in violation of law, and (e)&nbsp;Lessor will use good faith efforts to implement procedures, and will consistently apply those procedures, to ensure the
foregoing representations and warranties remain true and correct at all times. The term &#147;Embargoed Person&#148; means any person, entity or government subject to trade restrictions under U.S. law, including but not limited to, the International
Emergency Economic Powers Act, 50 U.S.C. &#167;1701 et seq., The Trading with the Enemy Act, 50 U.S.C. App. 1 et seq., and any Executive Orders or regulations promulgated there under with the result that the investment in Lessor is prohibited by law
or Lessor is in violation of law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessor covenants and agrees (a)&nbsp;to comply with all requirements of law relating to money laundering,
anti-terrorism, trade embargos and economic sanctions, now or hereafter in effect, (b)&nbsp;to immediately notify Lessee in writing if any of the representations, warranties or covenants set forth in this paragraph or the preceding paragraph are no
longer true or have been breached or if Lessor has a reasonable basis to believe that they may no longer be true or have been breached, (c) not to use funds from any &#147;Prohibited Person&#148; (as such term is defined in the September&nbsp;24,
200 I Executive Order Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism) with respect to the Land or Building or in fulfilling any obligation under the Lease and (d)&nbsp;at the request
of Lessee, to provide such information as may be requested by Lessee to determine Lessor&#146;s compliance with the terms hereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">32.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Use of Walden Square Name. Lessee shall not use the name of Walden, Walden Square, Walden Square Science
Center, or any adaptation, abbreviation or derivative thereof, or any of Walden&#146;s associated seals, marks, symbols, logos, or photographic images, without the prior written permission of Bolton Street Partners LLC, which permission may be
granted or denied in the sole discretion of Bolton Street Partners LLC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">33.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Extension Option</U>. (a)&nbsp;Provided (i) no Event of Default nor an event which, with the passage of time
and/or the giving of notice would constitute an Event of Default remains uncured (1)&nbsp;as of the date of the Extension Notice (hereinafter defined), and (2)&nbsp;at the commencement of the Extension Term (hereinafter defined); and
(ii)&nbsp;Lessee&#146;s interest in this Lease shall not have been assigned and no part of the Premises shall have been sublet, Lessee shall have the right and option (which may not be separated or severed from this Lease) to extend the Term for one
(1)&nbsp;additional term of one (1)&nbsp;year (an &#147;<U>Extension Term</U>&#148;), commencing as of the expiration of the Initial Term. Lessee must exercise such option to extend by giving Lessor written notice (the &#147;<U>Extension
Notice</U>&#148;) on or before the date that is six (6)&nbsp;months prior to the expiration of the Initial Term of this Lease, time being of the essence. Upon the timely giving of such notice, the Initial Term shall be deemed extended upon all of
the terms and conditions of this Lease, except that (a)&nbsp;Basic Rent during each Extension Term shall be calculated in accordance with this Section&nbsp;33.0, Lessor shall have no obligation to provide a Lessee allowance or other Lessee
inducement of any kind, (b)&nbsp;Lessor shall have no obligation to perform any Lessor&#146;s Work or to construct or renovate the Premises or make any decorations or improvements thereto and (c)&nbsp;there shall be no further right or option to
extend the Term. If Lessee fails to give timely notice, as aforesaid, Lessee shall have no further right to extend the Term. Notwithstanding the fact that Lessee&#146;s proper and timely exercise of such option to extend the Term shall be
self-executing, the parties shall promptly execute a lease amendment reflecting such Extension Term after Lessee exercises such option. The execution of such lease amendment shall not be deemed to waive any of the conditions to Lessee&#146;s
exercise of its rights under this Section&nbsp;33.0 </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) The Basic Rent for each year during the Extension Term (the
&#147;<U>Extension Term Basic Rent</U>&#148;) shall be determined in accordance with the process described hereafter. Extension Term Basic Rent shall be the greater of (i)&nbsp;Basic Rent for the last twelve (12)&nbsp;month period of the Initial
Term, or (ii)&nbsp;the fair market rental value of the Premises then demised to Lessee as of the commencement of the Extension Term as determined in accordance with the process described below, for renewals of office/laboratory space in the
Cambridge, Massachusetts area of equivalent quality, size, utility and location, with the length of the Extension Term and the availability of parking and common use laboratory facilities of Lessor in the Building and to be taken into account.
Within thirty (30) days after receipt of the Extension Notice, Lessor shall deliver to Lessee written notice of its determination of the Extension Term Basic Rent for the Extension Term. Lessee shall, within thirty (30)&nbsp;days after receipt of
such notice, notify Lessor in writing whether Lessee accepts or rejects Lessor&#146;s determination of the Extension Term Basic Rent (&#147;<U>Lessee&#146;s Response Notice</U>&#148;). If Lessee fails timely to deliver Lessee&#146;s Response Notice,
Lessor&#146;s determination of the Extension Term Basic Rent shall be binding on Lessee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) If and only if Lessee&#146;s Response Notice is timely delivered to Lessor and indicates
both that Lessee rejects Lessor&#146;s determination of the Extension Term Basic Rent and that Lessee desires to submit the matter to arbitration, then the Extension Term Basic Rent shall be determined in accordance with the procedure set forth in
this Section&nbsp;33.0(c). In such event, within ten (10)&nbsp;days after receipt by Lessor of Lessee&#146;s Response Notice indicating Lessee&#146;s desire to submit the determination of the Extension Term Basic Rent to arbitration, Lessee and
Lessor shall each notify the other, in writing, of their respective selections of an appraiser (respectively, &#147;<U>Lessor&#146;s Appraiser</U>&#148; and &#147;<U>Lessee&#146;s Appraiser</U>&#148;). Lessor&#146;s Appraiser and Lessee&#146;s
Appraiser shall then jointly select a third appraiser (the &#147;<U>Third Appraiser</U>&#148;) within ten (10)&nbsp;days of their appointment. All of the appraisers selected shall be individuals with at least five (5)&nbsp;years&#146; commercial
appraisal experience in the area in which the Premises are located, shall be members of the Appraisal Institute (M.G.I.), and, in the case of the Third Appraiser, shall not have acted in any capacity for either Lessor or Lessee within five
(5)&nbsp;years of his or her selection. The three appraisers shall determine the Extension Term Basic Rent in accordance with the requirements and criteria set forth in Section&nbsp;33.0(b) above, employing the method commonly known as Baseball
Arbitration, whereby Lessor&#146;s Appraiser and Lessee&#146;s Appraiser each sets forth its determination of the Extension Term Basic Rent as defined above, and the Third Appraiser must select one or the other (it being understood that the Third
Appraiser shall be expressly prohibited from selecting a compromise figure). Lessor&#146;s Appraiser and Lessee&#146;s Appraiser shall deliver their determinations of the Extension Term Basic Rent to the Third Appraiser within five (5)&nbsp;days of
the appointment of the Third Appraiser and the Third Appraiser shall render his or her decision within ten (10)&nbsp;days after receipt of both of the other two determinations of the Extension Term Basic Rent. The Third Appraiser&#146;s decision
shall be binding on both Lessor and Lessee. Each party shall bear the cost of its own appraiser and shall share equally in the cost of the Third Appraiser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>After the initial 36 months of the initial lease term, should Landlord seek to redevelop the property, Landlord, at his sole discretion, may
terminate the lease upon six (6)&nbsp;months written notice. Any extension or extended lease term will continue to be subject to the redevelopment termination clause, after the initial 36 months of the initial lease term</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">34.0</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Special Provisions Relating to the Special Equipment. As used herein, the term &#147;Special Equipment&#148;
shall mean (i)&nbsp;the <FONT STYLE="white-space:nowrap">die-ionized</FONT> water system located on the first (1st) and second (2nd) floor of the Building; (ii)&nbsp;the acid neutralization tank in the greenhouse area of the Building; (iii)&nbsp;the
Hazardous Waste Storage/Disposal Area; (iv)&nbsp;the Autoclave glass washing system located on the second (2nd) floor of the Building; (v)&nbsp;the emergency generator system; (vi)&nbsp;the Laboratory vacuum system; (vii)&nbsp;the Medical Air
system; (viii)&nbsp;the hot/cold rooms and (ix)&nbsp;the specialize HVAC systems that supply the various specialized systems including the fume hoods through out the Building. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lessee shall have the right, in common with other lessees, subtenants, occupants and users from time to time, to use the Special Equipment, subject, however, to all the terms and conditions of this Lease and only in
compliance with all Environmental Laws and other Legal Requirements and the MWRA Permit (as said tennis hereinafter defined) and all Special Equipment Permits (as said tennis hereinafter defined). Lessee may only use the Special Equipment in
connection with its laboratory uses in the Premises and no use of the Special Equipment shall be permitted until (a)&nbsp;the MWRA Permit has been obtained by Lessor and (b)&nbsp;Lessee has first obtained all operational licenses, permits and other
approvals, if any (&#147;Special Equipment Permits&#148;) required for the use thereof (including, without limitation, any and all licenses, permits or approvals (other than the MWRA Permit) required in order to dispose or transmit any fluids or
other materials through Special Equipment into the MWRA or other sewer systems). Lessee shall promptly provide Lessor copies of all Special Equipment Permits (except the MWRA Permit (as said term is hereinafter defined). Without limiting the
generality of the foregoing or any other term or provision of this Lease, Lessee (including, without limitation, all Lessee Parties), in its use of the Special Equipment (and shall cause each party claiming by, through or under Lessee, in its use of
the Special Equipment, to comply with the MWRA Permit and the Special Equipment Permits and all Environmental Laws and other Legal Requirements and shall keep all Special Equipment Permits in full force and effect. Lessee shall indemnify and hold
Lessor harmless from and against any and all claims of any kind or nature in any way related to the use of the Special Equipment by Lessee or any other Lessee Party and shall cause each subtenant or other occupant of the Premises, prior to its
commencement of use thereof, to provide the Lessor with its certification that it has obtained all Special Equipment Permits (other than the MWRA Permit) required to make use thereof and/or to dispose of, or discharge fluids and other materials
through the Special Equipment into the MWRA or other public sewer system. All costs and expenses incurred by Lessee or any other Lessee Party in obtaining any such Special Equipment Permits or otherwise complying with Legal Requirements or other
provisions hereof or of the Lease shall be borne by Lessee at its sole cost and expense. Access by Lessee and those claiming by, through and under Lessee to any area (&#147;Leased Areas&#148;) of the Building which is leased to another Lessee and in
which the Special Equipment is located shall be permitted only at such times as the Lessee or occupant of the Leased Area shall permit and shall be subject to such restrictions and requirements as any Lessee leasing such Leased Area may require and
if and to the extent any of the Special Equipment is located within an area (a &#147;Building Special Equipment Area&#148;) of the Building which is not part of any Leased Area, access thereto shall be only at such times as Lessor may approve, which
approval will not be unreasonably withheld or delayed, and subject to such rules and regulations as the Lessor may reasonably promulgate from time to time. No access shall be permitted to a Leased Area for access to Special Equipment therein or to a
Building Area for access to Special Equipment therein, except to the extent such access is necessary for the use of the Special Equipment by Lessee. In the exercise of any right hereunder to access a Leased Area as permitted hereunder, Lessee shall
not interfere with the use of such Leased Area (or other related leased space) by the Lessee or occupants thereof and shall comply with all restrictions and requirements of the Lessee which the Lessee of such Leased Area requires. In the exercise of
any right hereunder to access a Building Special Equipment Area, Lessee shall not interfere with any use thereof by Lessor or any machinery, equipment, or building systems located therein and shall comply with all rules and regulations promulgated
by the Lessor with respect thereto. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lessee shall be solely responsible for all costs and expenses which Lessor may suffer or
incur or pay on account of or in any way related to the Lessee or any Lessee Party in their use of Special Equipment (including, without limitation, any damage caused to the Special Equipment). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Special Equipment Costs and Other Special Costs: As used herein, the term &#147;Special Equipment Costs&#148; shall mean all costs and expenses
incurred by Lessor from time to time to maintain, repair, waste disposal, consulting services and the regulatory compliance of the Special Equipment. Without limiting the generality of the foregoing, the Special Equipment Costs shall also include
Lessee&#146;s share of costs and expenses incurred under or in connection with the MWRA Permit or any Environmental Laws or other Legal Requirements related to the use, operation, repair, or maintenance of the Special Equipment and/or the discharge
of any liquids or other materials from the Special Equipment to the MWRA or other public sewer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Special Equipment Use Charges. Lessee
covenants and agrees to pay Lessor, in each case, within thirty (30)&nbsp;days of being billed therefor, as Additional Rent, a sum equal to the Special Equipment Use Charge (as said term is hereinafter defined). As used herein, the term
&#147;Special Equipment Use Charge&#148; shall be an amount equal to the product obtained by multiplying the total Special Equipment Costs by Lessee&#146;s Special Equipment Percentage (as said term is hereinafter defined). As used herein, the term
&#147;Lessee&#146;s Special Equipment Percentage&#148; shall mean the Lessee&#146;s Share, subject to Expense Gross Up under Section&nbsp;6.2. Notwithstanding the foregoing to the contrary, Lessee shall be responsible for one hundred (100%) percent
of the Special Equipment Use Charges which are attributable to any (a)&nbsp;damage caused to the Special Equipment by Lessee or any Lessee Party, (b)&nbsp;any failure of Lessee or any Lessee Party to comply with the MWRA Permit or Environmental Laws
or other Legal Requirements and all such costs and expenses shall be due and payable as Additional Rent within fifteen (15)&nbsp;days after being billed therefor by Lessor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this Lease, Lessor shall have the right to monitor the allocation of charges for Special Equipment
Charges to all Lessees of the Building to ensure that the allocation method is appropriately related to Lessee&#146;s actual use of these services within or in connection with the Premises. If the current method of allocation is materially
inaccurate, Lessor may change the method of allocation during the term, as necessary, to correct the disproportionate charges. In addition, if Lessor determines in the course of its audit of the charges for Special Equipment Charges previously
allocated that Lessee has underpaid charges properly due for its use of any these services, Lessor shall invoice Lessee for the amounts due (together with reasonable <FONT STYLE="white-space:nowrap">back-up</FONT> documentation regarding the total
charges and the method of allocating the charges to Lessee) and Lessee shall pay such additional amount, as additional rent hereunder, within thirty (30)&nbsp;days of receipt of Lessor&#146;s invoice therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MWRA Permit. Lessor shall use best efforts to apply for and obtain the MWRA Permit but if
Lessor shall be unable to obtain the MWRA Permit, Lessor shall not be subject to any liability for failure to do so nor shall such failure affect the validity of this Lease, give rise to any right on the part of Lessee to any offset, deduction,
abatement or credit against the Basic Rent, Additional Rent and other sums due under this Lease nor give rise to any right on the part of Lessee to terminate this Lease nor constitute an eviction (constructive or otherwise). Lessee agrees to
cooperate in good faith <B>with </B>Lessor in applying for and obtaining the MWRA Permit and shall furnish such information that Lessor may reasonably require or as the issuer of the MWRA Permit may require in connection therewith. As used herein,
the term &#147;MWRA Permit&#148; shall mean a sewer use discharge permit issued by the Massachusetts Water Resources Authority (the &#147;MWRA&#148;) under 360 CMR 10 relating to industrial waste water discharges from the Building&#146;s acid
neutralization system (comprising part of the Special Equipment) into the MWRA Sewer System. Lessor shall provide Lessee with a copy of the MWRA Permit when it is received. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Maintenance of Special Equipment.</U> Lessor shall be responsible for maintenance, repair and replacement of the Special Equipment to the
extent so provided in Paragraph 9 of Exhibit D hereof but in no event shall Lessor be responsible for any maintenance, repair or replacement of the Special Equipment at any time while an Event of Default has occurred and is continuing under this
Lease nor shall Lessor be responsible for the maintenance, repair or replacement of the Special Equipment to the extent the need therefor is caused by any failure of Lessee or any Lessee Party to observe, perform and comply with this Lease or by any
act or omission of the Lessee or any Lessee Party or by reason of any damage caused to the Special Equipment by Lessee or any Lessee Party. Without limiting any other term or provision of this Lease in no event shall Lessor have any obligation or
liability to Lessee on account of, or in any way related to, any use, non-use of, or damage to, or contamination of the Special Equipment nor any failure of the Special Equipment to operate or function caused by any other lessee, subtenant,
licensee, invitee, agent, servant, contractor or other party who may from time to time make use of the same nor on account of any failure of any such other lessee, subtenant, licensee, invitee, agent, servant, contractor or other party to comply
with the MWRA Permit or other applicable Environmental Laws or other Legal Requirements in any way related to the Special Equipment or the use thereof. Notwithstanding the foregoing, Lessor shall repair the Special Equipment to keep it in good
working order irrespective of the cause any damage to the Special Equipment; the cost of such repair being allocated as set forth in Section&nbsp;6 above. To the extent damage to the Special Equipment is caused by another lessee in the Building,
Lessor shall make good faith efforts to recover the costs of repairing such damage from the responsible lessee. Lessor shall use best efforts to maintain and renew the MWRA Permit and Lessee agrees to fully cooperate with Lessor in connection
therewith. In no event shall Lessor have any liability to Lessee for lost revenues, profits, damage to business or consequential damages on account of, or in any way related to, the failure of Lessor to maintain, repair or replace the Special
Equipment or for failure to obtain, maintain and/or renew the MWRA Permit nor for any failure of the Special Equipment to operate or function properly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lessor shall never be liable for any failure to perform maintenance or make repairs or
replacements which, under the provisions of this Section&nbsp;34.0 or any other provision of this Lease, Lessor is obligated to perform or make or for failure to obtain or maintain the MWRA Permit or any other permit, license or approval required
under Environmental Laws or other Legal Requirements for the use and operation of the Special Equipment or related to the disposal of fluids and other materials through the Special Equipment into the MWRA or other public sewer system or otherwise
unless Lessee has given notice thereof to Lessor of the need to perform such maintenance, make such repairs or replacements or obtain or maintain any such licenses, permits or approvals and Lessor has failed to commence to perform such maintenance
or to make such repairs or replacements or to obtain or maintain such licenses, permits or approvals within a reasonable time after actual receipt of such notice or Lessor fails to proceed with reasonable diligence to complete such maintenance,
repairs or replacements, or to attempt to obtain such MWRA Permit or other licenses, permits or approvals, after receipt of such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Without limiting any other term or provision of this Lease , Lessor reserves the right to curtail, suspend, interrupt and/or stop use of the
Special Equipment without thereby incurring any liability to Lessee or any Lessee Party when necessary by reason of accident or emergency, or for repairs, alterations, replacements or improvements in the judgment of Lessor desirable or necessary or
when required in order to comply with the MWRA Permit or other Environmental Laws or other Legal Requirements or when use thereof is interrupted, suspended or prevented under the MWRA Permit or Environmental Laws or other Legal Requirements (or by
any governmental authority having jurisdiction with respect to the MWRA Permit) or when the MWRA Permit expires or when the use thereof or the maintenance, repair or replacement thereof is prevented by strikes, lockouts, difficulty of obtaining
materials, accidents or any other cause beyond Lessor&#146;s control or by laws, orders or inability by exercise of reasonable diligence, to obtain electricity, water, gas, steam, coal, oil or other suitable fuel or power. No diminution or abatement
of rent or other compensation, nor any direct, indirect or consequential damages or claims for lost profits, or damage to business shall, or will be, claimed by Lessee (or any Lessee Party) as a result of, nor shall this Lease nor any of the
obligations of Lessee or any Lessee Party be affected or reduced by reason of any such interruption, curtailment, or suspension. Failure or omission on the part of Lessor to maintain, repair or replace the Special Equipment or to obtain or maintain
the MWRA Permit or otherwise comply with Environmental Laws or other Legal Requirements related to the Special Equipment shall not be construed as an eviction of Lessee, actual or constructive, or entitle Lessee to an abatement of Basic Rent, nor to
render the Lessor liable in damages, nor release Lessee from prompt fulfillment of any of its covenants under this Lease, but does entitle Lessee to terminate this Lease as a breach of the covenant of quiet enjoyment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">34.2 Access to Special Equipment Located Within Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A portion of the Special Equipment, namely (i)&nbsp;the
<FONT STYLE="white-space:nowrap">de-ionized</FONT> water system and related pipes, equipment and other appurtenances; (ii)&nbsp;the specialize HVAC systems that supply the various specialized systems including the hoods and (iii) the Autoclave glass
washing system located on the second (2nd) floor of the Building, is located within the Premises or elsewhere on the first and second floor of the Building (the foregoing, together with any other equipment, pipes and appurtenances related to the
Special Equipment which are located in the Premises or elsewhere on the first and second floor are collectively hereinafter called the <FONT STYLE="white-space:nowrap">&#147;Di-Ionizing</FONT> Special Equipment&#148;). Lessee agrees that it shall
not alter damage, relocate or remove the <FONT STYLE="white-space:nowrap">Di-Ionizing</FONT> Special Equipment or do anything within the Premises which could adversely affect the <FONT STYLE="white-space:nowrap">Di-Ionizing</FONT> Special Equipment
or the use, operation or maintenance thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each Approved User (as said term is hereinafter defined) shall, so long as it remains an
Approved User, have the right to make use of and/or inspect and/or test the Special Equipment within the Building and Lessee shall fully cooperate with each Approved User in the exercise by such Approved User of its rights hereunder. As used herein
the term &#147;Approved User&#148; shall mean (a)&nbsp;any other lessee, subtenant or occupant of all or any part of the Property which Lessor has designated as an Approved User by written notice to Lessee (an&#148; Approved User&#148;), (b) all
employees of any such Approved User and (c)&nbsp;any other person or entity which Lessor designated as an Approved User by written notice from Lessor to Lessee. Lessor shall have the right, from time to time, to terminate and/or renew or modify the
status of any person or entity as an Approved User by written notice to Lessee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In addition to all other rights of Lessor under the Lease,
there is reserved to the Lessor and each of the Lessor Parties, the right and easement to enter upon the Premises from time to time, upon 2 days written notice to Lessee, or otherwise provided in herein, in order to inspect, maintain, repair,
replace, test, alter or otherwise deal with any Special Equipment in accordance with the provisions of Section&nbsp;11(h) during reasonable hours, unless in an emergency situation, making it impracticable or impossible to provide advanced notice..
Lessee agrees to fully cooperate with Lessor in connection with the exercise by Lessor of its rights hereunder. Lessor agrees to use best efforts to minimize interference with Lessee&#146;s use of the Premises in connection with any maintenance,
repair, replacement or alteration of the Special Equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signatures on the following page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESS the execution hereof in duplicate under seal as of the day and year
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSOR:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">BOLTON STREET PARTNERS, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">its, Manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hereunto duly authorized</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">AURA BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos____</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hereunto duly authorized</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PREMISES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See attached
plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A certain
parcel of land shown as &#147;Map 203A LOT 70&#148; on ALTA/ACSM LAND TITLE SURVEY IN CAMBRIDGE, MASSACHUSETTS, Located in Cambridge Massachusetts&#148; Dated xxxxx by Dunn McKenzie Inc. - bounded and described as follows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning at a granite bound on the southerly sideline Bolton Street at northeast corner of N/F Demchak; thence </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S 78&deg; 02&#146; 29&#148; E,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the southerly sideline of Bolton Street; for a distance of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">60.12 feet to a corner; thence,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">N 11&deg; 57&#146; 31&#148; E,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the easterly sideline of Bolton Street; for a distance of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30.00 feet to a corner; thence,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">N 78&deg; 02&#146; 29&#148; W,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the northerly sideline of Bolton Street; for a distance of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">189.50 feet to a corner at the southeast corner of N/F</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bolton Street Condominium; thence,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">N 11&deg; 57&#146; 31&#148; E,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the easterly sideline of N/F Bolton Street Condominium,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">for a distance of 103.58 feet to a corner at the southerly side line</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Massachusetts Bay Transit Authority; thence</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S 78&deg; 02&#146; 29&#148; E,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the southerly sideline Massachusetts Bay Transit Authority;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">for a distance of 620.95 feet to a comer; thence</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S 11&deg; 10&#146; 24&#148; W,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the westerly sideline of N/F C.R.A., for a distance of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">122.45 feet to a comer; thence</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">N 79&deg; 25&#146; 42&#148; W,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the northerly sideline of N/F C.R.A., for a distance of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">52.97 feet to a comer; thence,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S 12&deg; 00&#146; 04&#148; W,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the westerly sideline of N/F C.R.A., for a distance of 60.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">feet to a corner; thence</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">N 79&deg; 59&#146; 17&#146;&#146; W,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the northerly sideline of Walden Square Road; for a</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">distance of 353.08 feet to a comer; thence,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">N 03&deg; 08&#146; 19&#148; W,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the westerly sideline of N/F C.R.A., for a distance of l 0.00</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">feet to a comer; thence</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">N 79&deg; 59&#146; 17&#146;&#146; W,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the northerly sideline of N/F C.R.A.; for a distance of 70.00</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">feet to a comer; thence</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">N 03&deg; 08&#146; 19&#148; W,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">along the easterly sideline of N/F Damchak, for a distance of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">56.84 feet to the point of beginning.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above describe parcel contains an area of 100,956 square feet (2.31 acres) more or less. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERVICES PROVIDED BY LESSEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Exhibit is incorporated by reference into the Lease by and between Bolton Street Partners, LLC, as Lessor, and Aura Biosciences, Inc., as
Lessee. Terms defined in or by reference in the Lease not otherwise defined herein shall have the same meaning herein as therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lessee shall provide
and pay for the following services (These services will be provided through Building management on a time and materials basis and billed to the Lessee): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All maintenance of and repairs to the Premises necessary to keep the Premises in good condition or in as good a
condition as the Premises were at the beginning of the Term or may be put in during the Term (damage from taking or casualty or reasonable wear and tear only excepted). Except to the extent otherwise specifically provided in Exhibit D to this Lease,
such repairs and maintenance shall include but not be limited to the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The maintenance and repair of any plumbing, heating, ventilation, and air conditioning systems or components
within the Premises (and serving solely the Premises), and the repair of any damage to the Premises or to the Building caused by the malfunction of any of the foregoing, except as set forth on Exhibit D; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The maintenance and repair of all electrical wiring, outlets, switches and light fixtures located entirely
within the Premises and serving solely the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The maintenance and repair of all hardware within the Premises; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The maintenance and repair of the surfaces of all walls, doors, ceilings, and floors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The replacement of fluorescent light tubes and ballasts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">F.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Security for the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">G.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cleaning for the Premises. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERVICES PROVIDED BY LESSOR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Exhibit is incorporated by reference into the Lease by and between Bolton Street Partners, LLC, as Lessor, and Aura Biosciences, Inc., as
Lessee. Terms defined in or by reference in the Lease not otherwise defined herein shall have the same meaning herein as therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lessor
shall provide the following services at the Building and the Lessee shall pay for the following services in accordance with this Lease: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">l.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Heating and air conditioning for the Premises as demised at the start of the Term for normal operations between
the hours of 8:00 a.m. and 6:00 p.m., Monday through Friday, and on Saturdays between the hours of 8:00 a.m. and 1:00 p.m., except on national or state holidays. At other times, heating and air conditioning for operational lab areas at a &#147;set
back&#148; temperature of no more than 75 degrees Fahrenheit in summer and no less than 60 degrees Fahrenheit in winter. After hours operation of the heating and air conditioning at normal operating temperatures shall be charged at Lessor&#146;s
standard rates which are currently $65.00 per hour. Excluded from such services are air conditioning requirements for (i)&nbsp;personal computers in excess of an average of one personal computer per person in occupancy of the Premises, or
(ii)&nbsp;exceptional or special office machinery or other equipment including, without limitation, servers and other business equipment having special power, HVAC or environmental requirements or (iii)&nbsp;computer rooms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maintenance of the following as necessary to keep the same in serviceable condition: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All Building heating equipment, electrical equipment, and plumbing systems in public areas and in all of the bathrooms located within the core
area of the Building (but not the plumbing in bathrooms in the Premises); all Building air conditioning equipment, excluding special air conditioning equipment installed by or at request of Tenant; all window frames and glass, unless the damage to
any of the above is caused by the willful neglect or misuse by Lessee. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Extermination of all public and leased areas of the Building, as the management of the Building deems
necessary. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cleaning of the common areas. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Structural maintenance of the Building. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lettering for the name of Lessee in the Building directory located in the main lobby, subject to a final
directory design to be determined by Lessor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One sign, similar to Lessor&#146;s standard signage, which lists Lessee&#146;s company name and suite number
and which shall be located adjacent to Lessee&#146;s main entrance to each floor of the Premises and which may be installed at Lessee&#146;s expense. One sign bearing Lessee&#146;s corporate logo which shall be located adjacent to Lessee&#146;s main
entrance to each floor of the Premises and which may be installed at Lessee&#146;s expense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Snow removal, and other services as deemed necessary by Lessor for the normal operation of the Building.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maintenance and repair of the Special Equipment as needed so as to keep the same in serviceable condition
(subject, however, to Section&nbsp;34.0 of the Lease and all other applicable provisions of the Lease). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Hot water for bathroom lavatory purposes and cold water (at temperatures provided by the City of Cambridge) for
drinking, bathroom, and lavatory and toilet purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Freight elevator service to the Premises through the existing freight elevator at times and subject to such
rules and regulations, as Lessor may establish from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Electricity to the Premises sufficient to operate normal lighting and business machines approved by Lessor
(exclusive, however, of Lessee&#146;s electrical needs for equipment having special power or environmental requirements); provided however that in no event shall Lessor ever be obligated to furnish electricity to supply a requirement of in excess of
6 watts per square feet of useable area in the Premises. Lessor shall not in any way be liable or responsible to Lessee for any loss, damage or expense which Lessee may sustain or incur if the quantity, character or supply of electricity is changed
or is no longer suitable or available for Lessee&#146;s requirements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RULES AND REGULATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Exhibit is incorporated by reference into the Lease by and between Bolton Street Partners, LLC, as Lessor, and Aura Biosciences, Inc., as
Lessee. Terms defined in or by reference in the Lease not otherwise defined herein shall have the same meaning herein as therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following rules and regulations shall apply, where applicable, to the Premises, the Building, the parking area associated therewith, the Land and the appurtenances thereto: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees and their employees, shall not in any way obstruct the sidewalks, halls, stairways, or elevators of the
Building, and shall use the same only as a means of passage to and from their respective offices. Lessees will not place or allow to be placed in the Building corridors or public stairways any waste paper, dust, refuse, or anything whatever. At no
time shall lessees permit their employees to loiter in Common Areas or elsewhere in and about the Building or the Land. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No signs, advertisements or notices shall be inscribed, painted or affixed where they can be seen from the
outside the leased premises without prior written consent of Building management. Management reserves the right to prohibit the posting of any sign which it finds objectionable and to remove any which has already been placed, at the lessee&#146;s
expense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All contractors, contractor&#146;s representatives, and installation technicians performing work in the
Building which modifies the Building in any way shall be subject to Lessor&#146;s prior approval which shall not be unreasonably withheld or delayed and shall be required to comply with Lessor&#146;s standard rules, regulations, policies and
procedures, as the same may be revised from time to time. Lessees shall be solely responsible for complying with all applicable laws, codes and ordinances pursuant to which said work shall be performed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All electric and telephone wiring shall be installed as directed by Lessor. No boring or cutting for wires
shall be executed and no new pipes or wires shall be introduced without the prior written consent of Lessor which shall not be unreasonably withheld or delayed. Lessor shall have the right to install a line for access as may be required by
Lessee&#146;s internet provided, subject however, to the prior approval of Lessor which will not be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall not install or use any machinery in the demised premises which may cause any noise, jar, or
tremor to the floors or walls, or which by its weight might damage the floors of the Building. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall not bring in or take out, position construct, install or move any safe, or business machine or
other heavy equipment weighing over 100 pounds without the prior written consent of Lessor which, subject to all other provisions of the Lease and these rules and regulations, will not be unreasonably withheld or delayed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All furniture, safes, equipment and freight shall be move into and out of the Building only at certain hours
approved by and under the supervision of Lessor and according to these rules and regulations. All damage to the Building caused by installing or removing any safe, furniture; equipment or other property shall be repaired at the expense of the
Lessee. Lessor will not be responsible for loss or damage to any furniture, equipment or freight from any cause. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Corridor doors, when not in use, shall be kept closed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessee, lessees&#146; agents and employees shall not: play any musical instruments, other than radio and
television; make or permit any improper noises in the Building; interfere with other lessees or those having business with them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No animals, except Seeing Eye dogs, shall be brought into or kept in, on or about the Premises.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The restroom fixtures shall be used only for the purpose for which they were constructed and no rubbish, ashes,
or other substances of any kind shall be thrown into them. Lessee will bear the expense of any damage resulting from misuse. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessee shall not place any additional lock or locks on any exterior door in the Premises or Building or on any
door in the Building core within the Premises, including doors providing access to the telephone and electric closets and the slop sink, without Lessor&#146;s prior written consent, which for doors in the Premises shall not be unreasonably withheld
or delayed. A reasonable number of keys to the locks on the doors in the Premises shall be furnished by Lessor to Lessee at the cost of Lessee, and Lessee shall not have any duplicate keys made. All keys shall be returned to Lessor at the expiration
or earlier termination of this Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The directory board in the entrance lobby of the Building is provided for the exclusive display of the name and
location of each lessee at the lessee&#146;s expense. Lessor reserves the right to allocate space in the directory and to design style of such identification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessor reserves the right to exclude or expel from the Building any persons who, in the judgment of Lessor, is
intoxicated under the influence of liquor or drugs, or shall do any act in violation of the rules and regulations of the Building. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rooms used in common by lessees shall be subject to such regulations as are posted therein.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessor reserves the right to close and keep locked all entrance and exit doors of the Building during the hours
Lessor may deem advisable for the adequate protection of the property. Use of the Building and the leased premises before 8 AM or after 6 PM, or any time during Sundays or legal holidays shall be allowed only to persons with a key/card key to the
premises or guests accompanied by such persons. At these times, all occupants and their guests must sign in at the concierge when entering and exiting the building. Any persons found in the Building after hours without such keys/card keys are
subject to the surveillance of building staff. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessor shall have the right to prohibit any advertising by an agent which, in Lessor&#146;s opinion, tends to
impair the reputation of the Building or its desirability as a Building for offices, and upon written notice from Lessor, such lessee shall refrain from or discontinue such advertising. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No lessee will install blinds, shades, awnings, or other form of inside or outside window covering, or window
ventilators or similar devices without the prior consent of Lessor (which, in the case of blinds in office and laboratory windows, will not be unreasonably withheld or delayed so long as they conform in type, color and appearance with the
Lessor&#146;s building standard blinds). Lessee will not interfere with or obstruct any perimeter heating, air conditioning or ventilating units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall give Lessor prompt notice of any accidents to or defects in water pipes, gas pipes, electric
lights and fixtures, heating apparatus, or any other service equipment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall not perform improvements or alterations within the Building or their premises, if the work has
the potential of disturbing the fireproofing which has been applied on the surfaces of structural steel members, without the prior written consent of Lessor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall not take any action which would violate Lessor&#146;s labor contracts affecting the Building or
which would cause any work stoppage, picketing, labor disruption or dispute, or any interference with the business of Lessor or any other lessee or occupant of the Building or with the right and privileges of any person lawfully in the Building.
Lessees shall take any actions necessary to resolve any such work stoppage, picketing, labor disruption, dispute or interference and shall have pickets removed and, at the request of Lessor, immediately terminate at any time any construction work
being performed in the Premises giving rise to such labor problems, until such time as Lessor shall have given its written consent for such work to resume. Lessees shall have no claim for damages of any nature against Lessor in connection therewith,
nor shall the date of the commencement of the Term be extended as a result as a result thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall utilize the termite and pest extermination service designated by Lessor to control termites and
pests in the Premises. Except as included in Lessor&#148; Services, lessees shall bear the cost and expense of such extermination services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall not install, operate or maintain in the Premises or in any other area of the Building, any
electrical equipment which does not bear the U/L (Underwriters Laboratories) seal of approval, or which would overload the electrical system or any part thereof beyond its capacity for proper, efficient and safe operation as determined by Lessor,
taking into consideration the overall electrical system and the present and future requirements therefor in the Building. Lessees shall not furnish any cooling or heating to the Premises, including, without limitation, the use of any electronic or
gas heating devices, without Lessor&#146;s prior written consent. Lessees shall not use more than its proportionate share of telephone lines available to service the Building. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall not operate or permit to be operated on the Premises any coin or token operated vending machine
or similar device (including, without limitation, telephones, lockers, toilets, scales, amusement devices and machines for sale of beverages food, candy, cigarettes or other goods), except for those vending machines or similar devices which are for
the sole and exclusive use of lessee&#146;s employees, and then only if such operation does not violate the lease of any other lessee of the Building. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bicycles and other vehicles are not permitted inside or on the walkways outside the Building, except in those
areas specifically designated by Lessor for such purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessor may from time to time adopt appropriate systems and procedures for the security or safety of the
Building, its occupants, entry and use, or its contents, provided that Lessee shall have access to the Building 24 hours per day, 7 days a week. Lessee, lessee&#146;s agents, employees, contractors, guests and invitees shall comply with
Lessor&#146;s reasonable requirements relative thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">27.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lessees shall carry out lessee&#146;s permitted repair, maintenance, alterations, and improvements in the
Premises only during times agreed to in advance by Lessor and in a manner which will not interfere with the rights of other lessees in the Building. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">28.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Canvassing, soliciting, and peddling in or about the Building is prohibited. Lessees shall cooperate and use
best efforts to prevent the same. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">29.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At no time shall Lessees permit or shall lessee&#146;s agents, employees, contractors, guests, or invitees
smoke in any Common Area of the Building, unless such Common Area has been declared a designated smoking area by Lessor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">30.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All deliveries to or from the Premises shall be made only at such times, in the areas and through the entrances
and exits designated for such purposes by Lessor. Lessee shall not permit the process of receiving deliveries to or from the Premises outside of said areas or in a manner, which may interfere with the use by any other lessee of its premises or of
any Common Areas, any pedestrian use of such area, or any use, which is inconsistent with good business practice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">31.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The work of cleaning personnel shall not be hindered by lessees after 5:30 PM, and such cleaning work may be
done at any time when the offices are vacant. Windows, doors and fixtures may be cleaned at any time. Lessees shall provide adequate waste and rubbish receptacles necessary to prevent unreasonable hardship to Lessor regarding cleaning service.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CLEAN CERTIFICATE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered Industrial
Hygienist Name: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building/Room Number: [Description of Sublet Premises to be inserted here] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the items below have been completed and are ready for the <FONT STYLE="white-space:nowrap">inspection/sign-off</FONT> by the approved Registered
Industrial Hygienist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1) Radioactive Materials: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X All
equipment that is or was used for holding, handling or shielding radioactives which is to remain in the Sublet Premises has been cleaned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X All
radioactive signage has been removed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X A termination survey has been completed and documented by a registered industrial hygienist and a copy is
attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I certify that the above tasks have been completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registered Industrial Hygienist </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registered Industrial Hygienist Approval </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biological Hazardous Materials </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X All equipment that contained
BIOHAZARDS was cleaned inside and out with an EPA approved disinfectant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X All BIOHAZARD labels have been-removed. X All BIOHAZARDS have been removed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X All countertop bench papers have been removed and counters wiped down with an EP A approved disinfectant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X Every surface, especially shelves, drawers and bench tops (and under benchtop equipment) has been cleaned for razor blades, needles, syringes, pipettes,
scalpels, microscope slides, cover slips and other sharp objects. These items have been properly disposed of in sharps containers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X The Sublet Premises
including the walls, floors, glass and other surfaces and all fixtures and equipment in or serving the Sublet Premises have been cleaned using an EP A approved disinfectant and all Hazardous Substances have been removed therefrom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I certify that the above tasks have been completed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registered Industrial Hygienist </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hazardous Materials </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X All containers of hazardous waste or
materials have been removed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X All Hazardous Substances (as said term is define in the Consent to which this is attached) in the Sublet Premises have been
removed from the Sublet Premises and the Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">X All FUME HOODS display certification of decontamination or suitable alternative as provided by the
undersigned Registered Industrial Hygienist. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I certificate that the above tasks have been completed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;Registered Industrial
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hygienist Date: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT G </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PROPOSED 2011 OPERATING EXPENSE BUDGET </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Projected Budget for 85 Bolton St., Cambridge, MA </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Base&nbsp;Op&nbsp;Ex</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Annually</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Per&nbsp;Sq&nbsp;Ft</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">RE Taxes<BR>Annually</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Util&nbsp;&amp;&nbsp;Spec&nbsp;Equip<BR>Exp Annually</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Per&nbsp;Sq&nbsp;Ft</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Expenses;</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Wages: </B>Superintendent + Labor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Electricity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Telephone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Water&nbsp;&amp; Sewer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janitorial Contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trash Removal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exterminating</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Security Contract/Systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fire Alarm Systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Snow Removal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General R&amp;M Supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plumbing Contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Electrical Contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HVAC Contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elevator Contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Autoclave/Glass wash service contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waste water treat plant mgmVtesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other service contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Medical Air system</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab vacuum system</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emegency Generator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RODI System</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IMndow Cleaning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RoofR&amp;M</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Misc. </B>Operating</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Landscaping</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sign Expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Building R&amp;M Interior</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Building R&amp;M Exterior</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sprinkler Systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operations Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operations Consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative Management Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R.E. Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,878.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License&nbsp;&amp; Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office Supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Environmental Compliance/Audit fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7 500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <B>Reimbursable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>344,900</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>102,878 </B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<B></B><B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>247</B><B>,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5.29</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <B>Operating Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2.20 </B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<B></B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5.29 </B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOLLOWING &#147;LEASE MODIFICATION&#148; DATED September 6, 2011, between Bolton Street Partners, LLC (LESSOR) and Aura Biosciences, Inc. (LESSEE). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Modification previously entered into a Lease dated June&nbsp;9, 2011, for certain premises at 85 Bolton Street, Cambridge, MA, which
premises is described in &#147;The Lease&#148; and are referred to therein, and will be referred to herein, as the &#147;Demised Premises&#148;. The parties hereto desire to renew and modify the Lease and to replace the Sections of Lease with these
modifications stated below and to make such other modifications as are expressly stated herein: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. &#147;Reference Data&#148;. The following terms shall
have the definitions set forth in this Section&nbsp;1.0: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PREMISES AND RENTABLE AREA OF THE PREMISES:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 4,000 gross rentable square feet on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st </SUP>) floor of the Building (Lab 116 and 118) and on the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd
</SUP>) floor of the building (offices <FONT STYLE="white-space:nowrap">221-225)</FONT> as shown on Exhibit A. It is agreed that on January&nbsp;1, 2012, Lab 110 of 370 gross rentable square feet shall be added to the gross rentable square for a
total of 4,370 gross rentable square feet. The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the rentable area of the Premises is as stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENT ABLE AREA OF BUILDING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">INITIAL TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An initial term commencing on the Commencement Date and expiring twenty four (24)&nbsp;calendar months from the Commencement Date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Initial Term and any proper extension thereof in accordance with the terms of this Lease.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RIGHT OF FIRST OFFER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Option B: </B>In the event that the current tenant vacated the space, Landlord shall offer Tenant the Right of First Offer on the second floor lab space. Building (Lab 238, 239 and 247) on the second (2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the building.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMMENCEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENT COMMENCEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">BASIC RENT </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Per Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<BR>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July I, 2011 to December 31, 2011:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,166.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from January I , 2012 to June 30, 2012:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,065.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,922.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July I, 2012 to June 30, 2013;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,435.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,286.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From July&nbsp;1, 2011 to December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 2012 to June&nbsp;30, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE (TAXES):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From July&nbsp;1, 2011 to December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 2012 to June&nbsp;30, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(OPERATING EXPENSES)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From July&nbsp;1, 2011 to December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 2012 to June&nbsp;30, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$39,500.00.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERMITTED USE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend
to more than forty (40%) percent of the floor area of the Premises. Other than the MWRA Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning variance,
zoning change, special permit or other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee. Notwithstanding the forgoing, no use involving the
presence, storage, generation or release of any radioactive or nuclear materials shall be permitted.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This LEASE MODIFICATION hereby incorporates as if set forth fully herein all other terms,
covenants and agreements contained in the LEASE together with all addendum&#146;s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>5. </I>This is legally binding agreement. Consult legal council if you do not understand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lessee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lessor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lessee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">9/26/11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOLLOWING &#147;LEASE MODIFICATION&#148; DATED October 17, 2011, between Bolton Street Partners , LLC (LESSOR) and Aura Biosciences, Inc. (LESSEE). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Modification previously entered into a Lease dated June 9, 2011, for certain premises at 85 Bolton Street, Cambridge, MA, which
premises is described in &#147;The Lease&#148; and are referred to therein, and will be referred to herein, as the &#147;Demised Premises&#148;. The parties hereto desire to renew and modify the Lease and to replace the Sections of Lease with these
modifications stated below and lo make such other modifications as are expressly stated here in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Reference Data&#148;. The following terms shall have the definitions set forth in this Section&nbsp;1.0:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PREMISES AND<BR>RENTABLE AREA OF<BR>THE PREMISES :</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 4,000 gross rentable square feet on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) floor of the Building (Lab 116 and 118) and on the second
(2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the building (offices <FONT STYLE="white-space:nowrap">221-225)</FONT> as shown on Exhibit A. It is agreed that on January&nbsp;1, 2012, Lab 110 of 370 gross rentable square feet
shall be added to the gross rentable square for a total of 4,370 gross rentable square feet. Additionally, it is agreed that on January&nbsp;1, 2012, Lab 119 of 910 gross rentable square feet shall be added to the gross rentable square for a total
of 5,280 gross rentable square feet. The payment of base rent for Lab 119 shall not begin until March&nbsp;1, 2012. The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the rentable area of the Premises is
as stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RENTABLE AREA OF</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BUILDING :</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">INITIAL TERM :</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An initial term commencing on the Commencement Date and expiring twenty four (24)&nbsp;calendar months from the Commencement Date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TERM :</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Initial Term and any proper extension thereof in accordance with the terms of this Lease .</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RIGHT OF FIRST OFFER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Option B: </B>In the event that the current tenant vacated the space, Landlord shall offer Tenant the Right of First Offer on the second floor lab space. Building (Lab 238, 239 and 247) on the second (2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the building.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMMENCEMENT<BR>DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENT COMMENCEMENT<BR>DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July 1, 2011.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BASIC RENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<BR>Per&nbsp;Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<BR>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July 1, 2011 to December 31. 2011:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">98,000.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">8,166.67</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from January 1, 2012 to February 28, 2012;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">107,065.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">8,922.08</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from March 1, 2012 to June 30, 2012;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">129,360.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">10,780.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July 1, 2012 to June 30, 2013;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">134,640.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">11,220.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From July&nbsp;1, 20 11 to December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 2012 to June&nbsp;30, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.29%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE (TAXES):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From July&nbsp;1, 2011 to December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.29%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 2012 to June&nbsp;30, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(OPERATING EXPENSES)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8.55%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From July&nbsp;1, 201 I to December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.29%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 20 I 2 to June&nbsp;30, 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$39,500.00.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERMITTED USE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend to more than forty (40%) percent of the
floor area of the Premises. Other than the <B>MWRA</B> Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning variance, zoning change, special permit or
other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee. Notwithstanding the forgoing, no use involving the presence, storage, generation or
release of any radioactive or nuclear materials shall be permitted.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This LEASE MODIFICATION hereby incorporates as if set forth fully herein
all other terms, covenants and agreements contained in the LEASE together with all addendum&#146;s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein . </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">5. This is legally binding agreement. Consult legal council if you do not understand . </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Illegible</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lessor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Lessee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">10/18/11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">10/18/11</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE MODIFICATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOLLOWING &#147;LEASE MODIFICATION&#148; DATED January 23, 2013, between Bolton Street Partners, LLC (LESSOR) and Aura Biosciences, Inc. (LESSEE). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Modification previously entered into a Lease dated June 9, 2011, and modified on September 16 and October 17, 2011 for certain
premises at 85 Bolton Street, Cambridge, MA, which premises is described in &#147;The Lease&#148; and are referred to therein, and will be referred to herein, as the &#147;Demised Premises&#148;. The parties hereto desire to renew and modify the
Lease and to replace the Sections of Lease with these modifications stated below and to make such other modifications as are expressly stated herein: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
&#147;Reference Data&#148;. The following terms shall have the definitions set forth in this Section&nbsp;1.0: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PREMISES AND</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RENTABLE AREA OF</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">THE PREMISES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 6,213 gross rentable square feet on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP><B>) </B>floor of the Building (Labs 116, 118, 119, 142, 150 and 110) and on the second (2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the building (Offices <FONT STYLE="white-space:nowrap">221-225).</FONT> The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the rentable area
of the Premises is as stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RENTABLE AREA OF</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BUILDING:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2013 to June&nbsp;30, 2014.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENT COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BASIC RENT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Per Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July 1, 2013 to June 30, 2014;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,644.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,720.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 2012 to June&nbsp;30, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">13.28%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE (TAXES):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 2012 to June&nbsp;30, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">13.28%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(OPERATING EXPENSES)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From January&nbsp;1, 2012 to June&nbsp;30, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">13.28%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$39,500.00.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERMITTED USE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend
to more than forty (40%) percent of the floor area of the Premises. Other than the MWRA Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning variance,
zoning change, special permit or other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee. Notwithstanding the forgoing, no use involving the
presence, storage, generation or release of any radioactive or nuclear materials shall be permitted.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This LEASE MODIFICATION hereby incorporates as if set forth fully herein
all other terms, covenants and agreements contained in the LEASE together with all addendum&#146;s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. This is legally binding agreement. Consult legal council if you do not understand </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Illegible</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">2/15/2013</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This LEASE MODIFICATION hereby incorporates as if set forth fully herein all other terms,
covenants and agreements contained in the LEASE together with all addendum&#146;s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. This is legally binding agreement. Consult legal council if you do not understand </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Illegible</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">2/15/13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">2/15/2013</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOLLOWING &#147;LEASE MODIFICATION&#148; DATED March 21, 2014, between Bolton Street Partners, LLC (LESSOR) and Aura Biosciences, Inc. (LESSEE). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Modification previously entered into a Lease dated June&nbsp;9, 2011, and modified on September 16 and October&nbsp;17, 2011 and
January 23, 2013, for certain premises at 85 Bolton Street, Cambridge, MA, which premises is described in &#145;The Lease&#148; and are referred to therein, and will be referred to herein, as the &#147;Demised Premises&#148;. The parties hereto
desire to renew and modify the Lease and to replace the Sections of Lease with these modifications stated below and to make such other modifications as are expressly stated herein: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. </B>&#147;Reference Data&#148;. The following terms shall have the definitions set forth in this Section&nbsp;1.0: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PREMISES AND RENTABLE</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">AREA OF THE
PREMISES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 5,302 gross rentable square feet on the first (1st) floor of the Building (Labs 116, 118, 119, and 110) and on the second (2nd) floor of the building (Offices 22 <FONT STYLE="white-space:nowrap">1-225).</FONT> The
rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the rentable area of the Premises is as stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NEW TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The term shall be from July 1, 2014 to June&nbsp;30, 2015 and the arrangement shall be a Tenant at Will arrangement shall commence on July&nbsp;1, 2014 and shall continue month to month; provided, however, the. Tenant may terminate
this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Tenant-at-Will</FONT></FONT> arrangement at any time with ninety (90) days advanced written notice to the Landlord. The Landlord may not exercise this early termination
right.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July 1, 2011</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Basic Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Per Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July 1, 2013 to June&nbsp;30, 2014;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,503.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,708.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from July 1, 2014 to June&nbsp;30, 2015 shall be month to month with a three (3) month
termination option by written notice to landlord;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,805.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,150.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LESSEE&#146;S SHARE: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October 1, 2013 to June 30, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE (TAXES):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October&nbsp;1, 2013 to June&nbsp;30, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(OPERATING EXPENSES)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October&nbsp;1, 2013 to June&nbsp;30, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$39,500.00</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERMITTED USE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend
to more than forty (40%) percent of the floor area of the Premises. Other than the MWRA Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning variance,
zoning change, special permit or other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee. Notwithstanding the forgoing, no use involving the
presence, storage, generation or release of any radioactive or nuclear materials shall be permitted.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This LEASE MODIFICATION hereby incorporates as if set forth fully herein all other terms, covenants and
agreements contained in the LEASE together with all addendum&#146;s, amendments, riders and exhibits, except as the same arc inconsistent with, or specifically modified by the provisions contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. This is legally binding agreement. Consult legal counsel if you do not understand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor: Bolton Street Partners, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lessee: Aura Biosciences, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:<U>/s/
Illegible&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">By: <U>/s/ Elisabet de los
Pinos&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(name) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(title)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(name) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(title) CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hereunto Duly Authorized</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hereunto Duly Authorized</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;27, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date: March&nbsp;27, 2014</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOLLOWING &#147;LEASE MODIFICATION&#148; DATED August&nbsp;5, 2015, between Bolton Street Partners, LLC (LESSOR) and Aura Biosciences, Inc . (LESSEE).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Modification previously entered into a Lease elated June&nbsp;9, 2011 , and modified on September 16 and October 17, 2011,
January 23, 2013 and March 21, 2014, for certain premises at 85 Bolton Street, Cambridge, MA. which premises is described in &#147;The Lease&#148; and arc referred to there in, and will be referred to herein, as the &#147;Demised Premises&#148;. The
parties hereto desire to renew and modify the Lease and to replace the Section; of Lease with these modifications stated below and to make such other modifications as am expressly stated herein: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Reference Data&#148;. The following terms shall have the definitions set forth in this Section&nbsp;1.0:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PREMISES AND RENTABLE AREA OF THE PREMISES:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 5,302 gross rentable square feet on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) floor of the Building (Labs 116, 118, 119, and 110) and on the second (2nd) floor of the building (Offices <FONT
STYLE="white-space:nowrap">221-225).</FONT> The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the rentable area of the Premises is as stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENTABLE AREA OF BUILDING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NEW TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The term shall be from August l, 2015 to June 30, 2016 and the arrangement shall be a Tenant at Will arrangement shall commence on August&nbsp;1, 2015 and shall continue month to month. The Landlord may terminate this Tenant at Will
arrangement at any time with 120 days advanced notice to the Tenant. The Tenant may terminate this Tenant at Will arrangement at any time with 120 days advanced notice from to the Landlord. The Tenant at Will arrangement may not be terminated before
December&nbsp;31, 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July l, 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENT COMMENCEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BASIC RENT</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic&nbsp;Rent<br>Per Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<BR>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from August 1, 2015 to December 31, 2015.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159,060.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,255.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from January&nbsp;1, 2016 to March&nbsp;31, 2016.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,664.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,138.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October&nbsp;1, 2013 lo June&nbsp;10,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2016 LESSEE&#146;S SHARE (TAXES):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October&nbsp;1, 2013 to June&nbsp;30, 20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IGLESSEE&#146;S SHARE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(OPERATING EXPENSES)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October&nbsp;1, 2013 lo June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">$39,500.00.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECURITY DEPOSIT:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PERMITTED USE:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend
to more than forty (40%) percent of the floor area of the Premises. Other than the MWRA Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning variance,
zoning change, special permit or other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee. Notwithstanding the forgoing, no use involving the
presence, storage, generation or release of any radioactive or nuclear materials shall be permitted.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This LEASE MODIFICATION hereby incorporates as if set forth fully herein
all other terms, covenants and agreements contained in the LEASE together with all addendum&#146;s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This is legally binding agreement. Consult legal council if you do not understand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Illegible</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;Elisabet de los Pinos/CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;8/18/15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;8/17/15</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOLLOWING &#147;LEASE MODIFICATION&#148; DATED December 14, 2015, between Bolton Street Partners, LLC (LESSOR) and Aura Biosciences, Inc. (LESSEE) . </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Modification previously entered into a Lease dated June 9, 2011, and modified on September 16 and October&nbsp;17, 2011, January 23,
2013, March&nbsp;21, 2014 and August 5, 2015, for certain premises at 85 Bolton Street, Cambridge, MA, which premises is described in &#147;The Lease&#148; and are referred to therein, and will be referred to herein, as the &#147;Demised
Premises&#148;. The parties hereto desire to renew and modify the Lease and to replace the Sections of Lease with these modifications stated below and to make such other modifications as are expressly stated herein: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. &#147;Reference Data&#148;. The following terms shall have the definitions set forth in this Section&nbsp;1.0: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PREMISES AND RENTABLE AREA OF THE PREMISES:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 5,302 gross rentable square feet on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) floor of the Building (Labs 116, 118, 119, and 110) and on the second (2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the building (Offices <FONT STYLE="white-space:nowrap">221-225).</FONT> It is agreed that Labs 130, 131 and 132 will be added on February&nbsp;1, 2016 for an agreed to be 8,074 gross
rentable square feet, and The Lessee shall the option to take Office <FONT STYLE="white-space:nowrap">210-215</FONT> and Office <FONT STYLE="white-space:nowrap">216-217</FONT> for an occupancy of November&nbsp;1, 2016 to March&nbsp;1, 2017 depending
on when <FONT STYLE="white-space:nowrap">N-12</FONT> vacates the space. Lessee gross square feet would increase 1,677 gross rental square feet or a total of 9,751 gross rentable square feet, if the option is exercised. Lessee must notify Lessor in
writing by written notice within 21 days of receiving written notice from Lessor that the space is becomes available. The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the rentable area of the Premises
is as stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENTABLE AREA OF BUILDING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NEW TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The new term shall be from January&nbsp;1, 2016 to January&nbsp;31, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENT COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BASIC RENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Per Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from January 1, 2016 to January 31, 2016.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,664.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,138.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from February 1, 2016 to January 31, 2017.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">282,590.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,549.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from February 1, 2017 to January 31, 2018.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,664.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,222.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October&nbsp;1, 2013 to January&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From February&nbsp;1, 2016 to January&nbsp;31, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">17.26%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If Option for Offices <FONT STYLE="white-space:nowrap">210-217</FONT> is exercised.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">20.85%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE (TAXES):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October&nbsp;1, 2013 to January&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From February&nbsp;1, 2016 to January&nbsp;31, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">17.26%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If Option for Offices <FONT STYLE="white-space:nowrap">210-217</FONT> is exercised.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">20.85%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LESSEE&#146;S SHARE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(OPERATING EXPENSES)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From October&nbsp;1, 2013 to January&nbsp;31, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11.34%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From February&nbsp;1, 2016 to January&nbsp;31, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">17.26%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If Option for Offices <FONT STYLE="white-space:nowrap">210-217</FONT> is exercised.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">20.85%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Current Security Deposit is $39,500 which will be increased to $75,000.00 by February&nbsp;1, 2016 .</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERMITTED USE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend
to more than forty (40%) percent of the floor area of the Premises. Other than the MWRA Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning variance,
zoning change, special permit or other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee Notwithstanding the forgoing, no use involving the
presence, storage, generation or release of any radioactive or nuclear materials shall be permitted</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2, This LEASE MODIFICATION hereby incorporates as if set forth fully herein
all other terms, covenants and agreements contained in the LEASE together with all addendum&#146;s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3_ This is legally binding agreement Consult legal council if you do not understand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Lessor&#146;s Work LESSOR agrees to complete the following work at LESSOR cost: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Paint the current labs (1 <FONT STYLE="white-space:nowrap">16-1</FONT> 19), The painting will be completed by
February 15, 2016. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Paint the new labs <FONT STYLE="white-space:nowrap">(130-132)</FONT> The painting work will be completed by
February l, 2016 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Remove and dispose of walls from Aura current open office space through lo offices 22 l and 222. Final scope of
work to be defined with a meeting between Lessor and Lessee. Repair drywall, carpet and lights and paint the reconfigured office space (22 <FONT STYLE="white-space:nowrap">l-225).</FONT> The work will be completed within 60 days of a mutually agreed
plan </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lessor shall complete any such punch-list items in a reasonably diligent manner, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Broker(s) to be paid by Lessor for the square feet of Lease for the term of February !, 2016 to January 18, 2018. Lessor and
Lessee each represent to the other that they have dealt with no broker in connection with this Lease other than Newmark Knight Frank and Transwestern/RBJ (the &#147;Broker(s)&#148;). If, and only if, this Lease is executed and delivered by both
Lessor and Lessee, Lessor shall pay the Broker a brokerage fee under a separate agreement with the Broker. Lessee agrees to indemnify and hold Lessor harmless from and against any claims for commissions or fees by any person other than the Broker by
reason of any act of Lessee or its representatives. Lessor agrees to indemnify and hold Lessee harmless from and against any claims for commissions or fees by any person by reason of any act of Lessor or its representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Illegible</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elisabet de los Pinos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lessor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lessee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">12/23/15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">12/18/15</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOLLOWING &#147;LEASE MODIFICATION&#148; DATED June&nbsp;19, 2017, between Bolton&nbsp;Street Partners, LLC (LESSOR) and Aura Biosciences, Inc. (LESSEE).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Modification previously entered into a Lease dated June&nbsp;9, 2011, and modified on September&nbsp;16 and October&nbsp;17,
2011, January&nbsp;23, 2013, March&nbsp;21, 2014, August&nbsp;5, 2015 and December&nbsp;14, 2015 for certain premises at 85 Bolton Street, Cambridge, MA, which premises is described in &#147;The Lease&#148; and are referred to therein, and will be
referred to herein, as the &#147;Demised Premises&#148;. The parties hereto desire to renew and modify the Lease and to replace the Sections of Lease with these modifications stated below and to make such other modifications as are expressly stated
herein: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. &#147;Reference Data&#148;. The following terms shall have the definitions set forth in this Section 1.0: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PREMISES AND RENTABLE AREA OF THE PREMISES:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 8,074 gross rentable square feet on the first (1st) floor of the Building (Labs 116, 118, 119, 130, 131, 132 and 110) and on the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the building
(Offices <FONT STYLE="white-space:nowrap">221-225).</FONT> It is agreed that Labs 116, 118, 130, 131, 132 and 110 will be relinquished on July&nbsp;31,2017 and It is agreed that Offices Labs 231 and Office
<FONT STYLE="white-space:nowrap">226-228</FONT> and 229 will be added on August&nbsp;1, 2017 for an agreed to be 7,657 gross rentable square feet. The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the
rentable area of the Premises is as stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENTABLE AREA OF BUILDING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NEW TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The new term shall be from August&nbsp;1, 2017 to January&nbsp;31, 2020.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COMMENCEMENT DATE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENT COMMENCEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;1, 2011.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BASIC RENT </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Per Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic<br>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent up July 31.2017.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,664.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.222.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from August&nbsp;1, 2017 to January&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">275,652.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,971.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from February&nbsp;1, 2018 to January&nbsp;31, 2019.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283,309.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,609.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from February&nbsp;1, 2019 to January&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,966.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,247.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LESSEE&#146;S SHARE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To July&nbsp;31, 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">18.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From August&nbsp;1, 2017 to January&nbsp;31, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">16.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LESSEE&#146;S SHARE (TAXES):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To July&nbsp;31,2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">18.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From August&nbsp;1, 2017 to January&nbsp;31, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">16.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LESSEE&#146;S SHARE</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(OPERATING
EXPENSES)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To July&nbsp;31, 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">18.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From August&nbsp;1, 2017 to January&nbsp;31,2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">16.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Current Security Deposit is $39,500 which was be increased to $75,000.00 by February&nbsp;1, 2016.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERMITTED USE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend
to more than forty (40%) percent of the floor area of the Premises. Other than the MWRA Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning variance,
zoning change, special permit or other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee. Notwithstanding the forgoing, no use involving the
presence, storage, generation or release of any radioactive or nuclear materials shall be permitted.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This LEASE MODIFICATION hereby incorporates as if set forth folly herein all other terms,
covenants and agreements contained in the LEASE together with all addendum s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Lessor agrees to conduct the maintenance and repair items attached in Exhibit A as part of its building maintenance program. The second
floor bathrooms and hallway carpet will be completed by December<U></U>&nbsp;31, 2017 and all work is to be completed by June<U></U><U>&nbsp;30, 2018.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The Lessee shall notify in writing the Lessor by November&nbsp;15, 2017 as to whether Lessee has closed Lessee&#146;s next round of
financing. If and only if Lessee has not closed Lessee&#146;s next round of financing then Lessee shall have the option of terminating the February&nbsp;1, 2018 to January<U></U> 31, 2020 portion of the lease term. If Lessor does not receive written
Notice by November<U></U>&nbsp;15, 2018, then the February<U></U>&nbsp;1, 2018 to January<U></U> 31, 2020 term shall be in full effect and binding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. This is legally binding agreement. Consult legal counsel if you do not understand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Illegible</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSOR</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elizabet de los Pinos</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSOR</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elizabet de los Pinos</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">8/10/17</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DATE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">8/3/17</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DATE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Exhibit A - 85 Bolton Street Improvements </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Hallway </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace carpet in the halls in 2nd floor common halls. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Large Conference Room # 201 </B>(to be completed by June 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2018) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Get longer conference table </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Remove the round table </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Get telecom phone </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace light bulbs </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Get new Matching chairs </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Small Conference Room #248 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Get telecom phone </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace recess light bulbs </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Remove glass tables in hallway and in conference room </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Get a 6&#146; x 2&#146; rectangular table for supplies, food etc. that would go against the wall
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace blinds </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ladies Bathroom #251 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shower tub to be cleaned at least once per week </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace tub mat </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lights in locker/tub area need to be fixed/ replaced </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace toilet bowls if stains cannot be removed </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sinks to be repaired, cleaned and any dirt, mold removed </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Broken faucets and rusty strainers to be replaced </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace floor tile </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The stall wall with holes in needs to be repaired/replaced </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace sanitary container with one that is sealed&nbsp;&amp; (professionally replaced on a regular basis
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace the paper towel dispenser to an automatic one or one that the towels fit so you can pull them out without
falling on the floor </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paint walls </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Men&#146;s Bathroom (#250) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Same upgrades as ladies room with the exception of sanitary container </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ladies&nbsp;&amp; Gents Bathrooms (#219 &amp; #220) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fix door stopper (#220) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace toilet bowls if stains cannot be removed </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace floor tile </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sinks to be repaired, cleaned&nbsp;&amp; dirt, mold removed. Replace broken faucets&nbsp;&amp; rusty strainers.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fix /reattach shelf below mirror (#220) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paint walls and doors </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Small Kitchen </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cupboard doors to be replaced </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Flooring to be replaced </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Replace stained ceiling tiles </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paint walls </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE EXTENSION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS EXTENSION AGREEMENT DATED October&nbsp;17, 2019, between Bolton Street Partners, LLC (LESSOR) and Aura Biosciences, Inc. (LESSEE). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Extension Agreement previously entered into a Lease dated June&nbsp;9, 2011, and modified on September&nbsp;16 and October&nbsp;17,
2011, January&nbsp;23, 2013, March&nbsp;21, 2014, August&nbsp;5, 2015 and December&nbsp;14, 2015 and June&nbsp;19, 2017 for certain premises at 85 Bolton&nbsp;Street, Cambridge, MA, which premises are described in &#147;The Lease&#148; and are
referred to therein, and will be referred to herein, as the &#147;Demised Premises&#148;. The parties hereto desire to expand the Premises, extend the lease term and modify the Lease and to replace the Sections of Lease with these modifications
stated below and to make such other modifications as are expressly stated herein: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. &#147;Reference Data&#148;. The following terms
shall have the definitions set forth in this Section<U></U> 1.0: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PREMISES AND</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RENTABLE AREA OF</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">THE PREMISES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 7,657 gross rentable square feet on the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the Building (Labs 23l and (Offices <FONT STYLE="white-space:nowrap">221-225</FONT> <FONT
STYLE="white-space:nowrap">226-229).</FONT> It is agreed that Labs 253,265, 266 and 253A will be added on February&nbsp;1,2020 for an agreed to be 8,838 gross rentable square feet. Tenant shall receive one and a half (1.5) months of abated base rent
on the Expansion Premises once they are delivered by the Landlord following completion of the improvements, targeted for December&nbsp;15, 2019. The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the
rentable area of the Premises is as stated herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EXPANSION:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenant shall have a Right of First Offer on the Novogy, LifeMine / Proclara Premises within 60&nbsp;days of written notice that the space will be vacating. The terms and conditions will be the same as this lease modification if
Tenant expands within the first six (6)&nbsp;months from the Lease Extension Commencement Date (February 1, 2020)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RENTABLE AREA OF BUILDING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet,</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NEW TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The extended term shall be from February&nbsp;1, 2020 to July&nbsp;31, 2022.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TERM EXTENSION COMMENCEMENT</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DATE:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;1, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TERM EXTENSION</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RENT COMMENCEMENT</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DATE:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;1, 2020</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BASIC RENT FOR EXTENSION TERM </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Per Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from February&nbsp;1, 2020 to April&nbsp;30, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353,520.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,460.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from May&nbsp;1, 2021 to July&nbsp;31, 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">362,358.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,196.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LESSEE&#146;S SHARE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From August&nbsp;1, 2017 to January&nbsp;31, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">16.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From February&nbsp;1, 2020 to July&nbsp;31, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">18.90%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LESSEE&#146;S SHARE (TAXES):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From August&nbsp;1, 2017 to January&nbsp;31, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">16.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From February&nbsp;1, 2020 to July&nbsp;31, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">18.90%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LESSEE&#146;S SHARE</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(OPERATING
EXPENSES)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From August&nbsp;1, 2017 to January&nbsp;31, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">16.37%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From February&nbsp;1, 2020 to July&nbsp;31, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">18.90%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Current Security Deposit is $75,000.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LANDLORD&#146;S WORK:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Landlord, at its sole expense, shall perform the following improvements to the Premises:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Demise the existing
office Premises by extending the hallway wall all the way to the deck.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Add HVAC temperature control to the &#147;Barcelona&#148; conference room</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Add HVAC venting and
temperature control to the &#147;City of Lights&#148; conference room</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Improve HVAC performance and temperature control in the existing office and lab areas.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Perform the
improvements to the lab areas (the existing lab 231 and new labs 253, 253A, and 256) as outlined on the attached spreadsheet.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BROKERAGE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Newmark represents both the Landlord (Ryan Weber and Joe Pearce) and Tenant (Dan Krysiak and David Townsend) in this transaction and will be paid a market fee by the Landlord.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PARKING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenant&#146;s allocation of parking spaces shall increase based upon the amount of additional space being leased in accordance with the building ratio.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PERMITTED USE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Office and laboratory uses, in each case, to the extent permitted as a matter of right under the zoning ordinance of the City of Cambridge and subject to all the provisions of this Lease. General Office use shall not extend
to more than forty&nbsp;(40%) percent of the floor area of the Premises. Other than the M WRA Permit, any and all local, state or federal operational permits shall be the sole responsibility of the Lessee. Any and all uses which require a zoning
variance, zoning change, special permit or other type of zoning approval relief shall be subject to the approval of the Lessor in its reasonable discretion and shall be the responsibility of the Lessee. Notwithstanding the forgoing, no use involving
the presence, storage, generation or release of any radioactive or nuclear materials shall be permitted.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This LEASE EXTENSION AGREEMENT hereby incorporates as if set forth fully herein all other terms, covenants
and agreements contained in the LEASE together with all addendum&#146;s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The Lessor agrees to conduct the maintenance and repair items attached in Exhibit A as part of its building maintenance program, which
included exterior paving, repainting and slatting exterior fencing and exterior painting. Build out for Labs 253, 253A, 256, and 231 attached in Exhibit B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Illegible</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSOR</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elizabet de los Pinos</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSOR</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Elizabet de los Pinos</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DATE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">10/17/19</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DATE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXHIBIT B </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Room 253</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install <FONT STYLE="white-space:nowrap">air-in</FONT> filters in ceiling to prevent contamination</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install &#147;emergency&#148; outlets 4/room</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install 220V Power
outlet for centrifuge</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install house airline (for bioreactor) install house vacuum line (for biosafety cabinet)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>install gas cylindar station outside of the room </B>(wall stands and thread nylon air hose through ceiling or wall)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install shelving</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install controllable thermostat</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">sink area with drain and foot pedals di water source</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Room 253A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install <FONT STYLE="white-space:nowrap">air-in</FONT> filters in ceiling to prevent contamination</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install &#147;emergency&#148; outlets 4/room</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install 220V Power
outlet for centrifuge</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install house air line</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install house
vacuum line Air exhaust</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Install shelving</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">di water
source</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Room 256</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Freezer and LN2 room</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install 208V 20A
Power outlet for <FONT STYLE="white-space:nowrap">-80c</FONT> freezer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Install oxygen sensor (safety)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Remove the sink and install in Room 253.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Room# 231</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>(current lab space)</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lock doors (side
panel missing pin, unable to securely lock doors at end of day)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ceiling panels- missing panels in lab, lots of debris from ceiling</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">locks for freezer chest</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">install &#147;emergency&#148; outlets
4/room</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">replace <FONT STYLE="white-space:nowrap">air-in</FONT> filter in current cell culture room</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOLLOWING &#147;LEASE MODIFICATION&#148; DATED March&nbsp;10, 2021, between Bolton Street Partners, LLC (LESSOR) and Aura Biosciences, Inc. (LESSEE). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties to this Lease Modification previously entered into a Lease dated June&nbsp;9, 2011, and modified on September&nbsp;16 and October&nbsp;17, 2011,
January&nbsp;23, 2013, March&nbsp;21, 2014, August&nbsp;5, 2015 and December&nbsp;14, 2015, June&nbsp;19, 2017 and October&nbsp;17, 2019 for certain premises at 85&nbsp;Bolton Street, Cambridge, MA, which premises is described in &#147;The
Lease&#148; and are referred to therein, and will be referred to herein, as the &#147;Demised Premises&#148;. The parties hereto desire to renew and modify the Lease and to replace the Sections of Lease with these modifications stated below and to
make such other modifications as are expressly stated herein: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. &#147;Reference Data&#148;. The following terms shall have the
definitions set forth in this Section<U></U>&nbsp;1.0: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PREMISES AND</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RENTABLE AREA OF</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">THE PREMISES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreed to be 8,838 gross rentable square feet on the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) floor of the Building (Labs 231, 253, 265, 266 and 253A and (Offices
<FONT STYLE="white-space:nowrap">221-225</FONT> <FONT STYLE="white-space:nowrap">226-229).</FONT> It is agreed that Labs 153, 122, 123 will be added on May&nbsp;1, 2021 for an agreed to be 13, 354 gross rentable square feet. It is agreed that Lab
124 will be added on June&nbsp;15, 2021 for an agreed to be 14, 354 gross rentable square feet. The rentable area of the Premises includes a common area factor and Lessor and Lessee agree that the rentable area of the Premises is as stated
herein.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BUILDING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The building located at <FONT STYLE="white-space:nowrap">85-95</FONT> Bolton Street, Cambridge, Massachusetts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RENTABLE AREA OF</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BUILDING:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">46,771 square feet.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LAND:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The parcel of land on which the Building is located more fully described on Exhibit B hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NEW TERM:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The new term shall be from May&nbsp;1, 2021 to July&nbsp;31, 2023.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BASIC RENT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Rental Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Per Annum</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Basic Rent<br>Monthly</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from May&nbsp;1, 2021 to June&nbsp;15, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">565,578.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,131.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from June&nbsp;15, 2021 to July&nbsp;31, 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">610,578.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,881.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from August&nbsp;1, 2022 to July&nbsp;31, 2023.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">645,930.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,827.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12 Month Extension Option if exercised.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent from August&nbsp;1, 2023 to July&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">688,992.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,416.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LESSEE&#146;S SHARE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From May&nbsp;1, 2021 to July&nbsp;31, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30.69%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LESSEE&#146;S SHARE (TAXES):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From May&nbsp;1, 2021 to July&nbsp;31, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30.69%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LESSEE&#146;S SHARE</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(OPERATING
EXPENSES)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">From May&nbsp;1, 2021 to July&nbsp;31, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30.69%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SECURITY DEPOSIT:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Current Security Deposit is $75,000 and will be brought up to $125,000 by May&nbsp;1, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PARKING:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenant&#146;s allocation of parking spaces shall increase based upon the amount of additional space being leased in accordance with the building ratio.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. LANDLORD&#146;S WORK: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Landlord, at its sole expense, shall perform the following improvements to the Premises: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Add a CO2, Oxygen, air and vac line to room 153. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Add (2)&nbsp;emergency power outlets to room 153. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Install HEPA filers to vents in room 153. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Add a CO2, Oxygen, air and vac line to office area&#151;room 153. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Add (2)&nbsp;emergency power outlets and (3) 220 v sockets to office area&#151;room 153. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Install HEPA filers to vents in office area&#151;room 153. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Remove one sink from room 153. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Add a CO2, Oxygen, and air lines to office area&#151;&#147;cell culture room&#148;. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This LEASE MODIFICATION hereby incorporates as if set forth fully herein all other terms, covenants and agreements contained in the LEASE
together with all addendum&#146;s, amendments, riders and exhibits, except as the same are inconsistent with, or specifically modified by the provisions contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This is legally binding agreement. Consult legal counsel if you do not understand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS HEREOF, the parties hereto executed this LEASE EXTENSION AGREEMENT as of the date set forth above, and by their own free will. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Zagorianakos</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSOR</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Julie B. Feder</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Peter Zagorianakos, CFA</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSOR</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Julie D. Feder, CFO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">LESSEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">3/31/2021</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DATE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">3/30/2021</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DATE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Triad Alpha Partners, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aura Biosciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>11
<FILENAME>d209588dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Subsidiaries of Registrant </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None.
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>d209588dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148;&nbsp;and to the use of our report dated August&nbsp;9, 2021, in the Registration
Statement (Form <FONT STYLE="white-space:nowrap">S-1)</FONT> and related Prospectus of Aura Biosciences, Inc. dated October&nbsp;8, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;8, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g161026g0916225457358.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g161026g0916225457358.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W *P# 2(  A$! Q$!_\0
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MHH **XK6/'7V#4YK6VCCE2([68@_>[]ZZ#P_J5SJVFB\N(5B5V_=@ C*^O-
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M],,49.2BD^I% 'B\4.KZQ(MNHN;@YSM8D@>_->G>&- &@Z<4<A[B4[I&';T
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6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g161026g0916225940106.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g161026g0916225940106.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X )H# 2(  A$! Q$!_\0
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M95C3BJ%/YGFX"C*K-XBIUV$E=(8VD=@J*"68G  KPGQ?XBD\1:RS(6^R0$K
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g209588g00c36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g00c36.jpg
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MNJ5"^>6#8RM6N])<>LJ?7:U+X](E+&04P,S.HZ-2%U;G3F^3C\=M\/S6P_\
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MY7"OQTE$=T7#NA69Y<SZP4T+%V)X_P#!W?BTS'A*LWT=9L4JI+(K7,-GD92
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M##N].YM-,Q$Q/;,\QI LEX*NH"KYKQ&YMI7L;+)A5N^W+XVY"^?0GT48O)J
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g209588g01a88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g01a88.jpg
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M 0$! 0$! 0$! 0$! 0'_P  1" #A B4# 1$  A$! Q$!_\0 'P   0,$ P$
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MPASVNZ-%TU,0UO\ ^(#3M;IVO:C_ +(/Q$_[]I_\ETO^N:Q;*Z4$ "37_O\
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M.-Q?#I>Y_)F%:#>K0=HI/6*->.I([%L#-J95"8DF1!1; 8X)%\AJD @!C;F
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MZ9E,?_\ 7C_YOZVUWQS^'I]OM]'F7_W]?;\OL^VE]J\A]N$__I[#_P"\9O\
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MGVVV_#8C[0,4/,J;ZXM8&^OG^C<@ZZVU OA 2:  )NG0=PV_*(;#MO\ ,.H
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MO+_^C_\ \]^G6F7^;]7K];X;8=4_\_ZW\W;K];4X].&J;CHN#1@PS&=,YTS
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M1PQ/#E67"L=7RJ&9<RKLP\>=&<>#723>#+,S*8520AY/+<\X;XTSJBRG]FO
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MNQKP:,&&PDW9"9DI;$9(J:B^-\CN2Q S--1.[(WLF,$S/RU]Y'*7^0*Q%P1
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M%^WF,.*<VY]+_5[?][N#CTY:I>.CX-&#'GCR;'/:[E;BU@UP.$B7)%XGFY5
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M5'Q)>.KJXUK:.M6HI:Z%:FGK8*^C>>BGBFBECECG]H$9+ 2<K<P547?@5IS
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M.D02>BI7AKYA)(O@R15$M8 J,ACITC8*8^9E?5O',TT;U=T^@HL+'$1-JI#
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MO8ABE+I/V*FV2$:QXO848@SB<3D7KH[)-*39%8Q(/T.1TDW=@ @\,T,Z Y%
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M%^L2'K)!2,+)PHH8TT G520/'-PUKS&N:8F ,3&&\1B&:S26[;+R@W)7?0=
M"^X&X86@C.;U45JF9&CI49"#% WUI-;MSS6L"!H@-B><VUFU9X@*K<CH3@F"
MI!4$FP'%+<.<"B;< .)0, =.@^@ZK<[ WYKVOL-K ]^GETOO:XQU"E1@ZLEM
MC:YV-K FWF.^IV\I(*J5]-\@:N+.%&0M&IE!>%,!R.Q1(9T4N_*(ID6YBIG$
M YR;"(%]82NCC+\L/,05%@;D\]K-:^IU^8.EMA>,EFF6/FJ@BNK,05(MR!KJ
M2.AY;7&]_6PE%CFP49G6GA982JS )**-Q(TW-S\HBDD0RZGE"'F<HJ=3@!1
MX%Y@V"+>"@2FE%2T2RV:Q9@S!K @<J"1M-R>6W]$<WNBWTM;F#5</LRRM 2M
MPH*IRWL26?PUYB#H+\Q(ULNN.K>:5/SJD4(DV*)CG,91LCR)AN.QQ5(Z3 @
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MD7'4 ]+V.WZ\O3%O*3)P:Q]9CDW"TI-O4C+@4BRI$&93<G,5%$ISK''?G H
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M!'J:F5W=FB$4C*K=(NKK-<FRUG>1#R%BTVJM6C6R\G"V9"8)[,YAUVS@Z[1
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M,-Q3U=/%4QDKRL8JB-98B5(N"4<>[H0W3%G$09W\1.HG<ODCM  _D(@4R0J
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MVUQ5L^R3,,\SJO1%CRG+^=7,8YF\4AE8N&"1J[*.<,; DE1RBQ)P\[$FE(J
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M 5;$',( 'T@M741 /_@Z'^/3[M2^4:-4'LB#KN2UMK6V/7%?S\@1TW?GDM\
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ML9>.2?2!.2)(Z=/1:D7(L^;K U!4GLY%'!2:W/5S2.8T1_&1#]52%NPTNS
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M</YK!65%#D29/FXIZB6GJ\E<4?BU0C)B$]&H6FK5>4JKQU <E6<AT8!AZ_\
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M'PTU]]N2]TL0%"EAL5L#8&^&_CZY7+2BY7=L9&*>';J+>;$RRC$C=1=15FS
MK=TC)QP('<-EDS'_ ,38B1)%8IB).!42W^VRJ1=B=;68<Q.QW4JQTV!N1J.F
MK5<M@DYB(Q&;7M$P0 DE5 1E=0"P()'(IMS"P:^&^L%#D&@*OJZ^/8HQDFBZ
M<_XH1"7BFZG*9'SXXSE47B:K!VT?++,P368-W#5>8C8PCA HN8JH, KGPV)L
M!<E6M?9K"Q)N+$!21968X93Y>Z^_%^^0"[$*%D0&Q4E+GF'*RM=#S*I!D2.X
MPT(O@5=BW>)%26,<BI' "?D7$")E\DIRE263,8QO*(F)N?83'3 H" G=:BQ[
M?X]#L;Z]KV[7C2!JI!N3\M"#V(.A.WG?6V.K]Q(M"$!1)!$GD*^7)$$JK8RR
M6P@FNLLCSI*G[$24 QS>5Y95E%% 4UD&8ZWT%KCYWL#UL._3TMBR!=" ;@@-
M;X[@ZC4:6V([83*UB5!<@.!]H$"@=8$A*("F4"AYPHJ))" '$Z9 )ML)A44)
M^++]100UP4UZG:VNQ^7KIMVP964 A]+BRVN+WWOOY["POJ=,7K.?;-G0$=M0
M<(K )2>0#5J9N<Q#&3.X.NB9IY1S?BN=0R)2',(F43 @G'>BKOS'3:UOMO>^
MGSVOUQ'U,CA3HJG4:A_> W"E"&OV O?8 WU=6N+K(1SR:BV;YC(Q;=XJ@^>O
M7QT6BH @V24:@S.YC@?@99%9D)%DN8X\R2Y@2.1)RA*K<$W .MR#V%B-B+BU
MK=]2,0,[+-+R,;JQ'NH@]X'F/O<P5RM@0UUV&HUUD%C7C;M>/W<O"6"/&RQR
MCI5HO)N$BNC+D9G.BW<*(+E;J.5R@'.<'3Y RA3*"0R"PG44LU'Q/.D<,,YD
M8P'D6HCE,<WA: KS'F4M;8W3H9 Q!O7ZO@VFD,L\'@H*@*[TTL*O )K!E;E'
M*;7U(M):YL5!"CK:N*-O9)F-LTA:XAVQ@';*2+4F%9>1[650;KF<^Z'#Y\+A
M=4@J*%Y@=.SL6BYO:4TU"MT2C)9=G&0Y'E;Y=E,>8&"*9JN#VVMJ:RH:KED$
MDLLE1523SR2%B0)))V9$LB$*% B\WR#B;B3.DS3.YLL6HF@6AJ#E^74=#3K1
M0Q&&"*&EHX:6GBB55#&*&F022<TD@:1F)F%4,E8&LD>E-5'(-8:N9&-:'>TM
MX_15FDEC)H.'4:@Q.*3UTLW=)""9%6R G42*HBL=$2+CT+*./*"IBIH*TAZM
MGO'/'/'$\;LI55D64QA6LS(SH61@3[M_=QRO/OV:YM25%5/0!TH%4I+!-32S
M1RQAU8O$\'BLRDA7$;\K(; M8!L.D@ZQ%,U6<4LEG0!BJT3]HA%3L6[R/D$U
MDSHK*D0>R2::J:0G3\@/-5$JIR&*)P*32YAQA 7B:-8 ])+(/:6E$ZO&5(:,
MA0I)+\IW4 @6 U.$RO@:JB2=7DJ/#K8HO^BI U,R2*ZLLP+'E"JG,".5K@Z\
MQ 4P[B\K.&5T<5]S:;2:ER*H VJM'<V*0@JQ LE&;!@K->[%BHN) R"?GR4F
MDV]H2<KG.1NLS6*U&DU'%4,.8(_*LA<M-)*D<4BI(W.=8@&4I<@>&2651];G
MM;H,/"<\F6R)SB(*BP1QSU#1/+$@0 "4V?QB$8F15"R$E2.06PK,C<0.&Z,X
MD64">:N=XCG2K-RV<M9U>+8'1,H5!-W*.%EN=4P( (%2<&$  2JM4%2F(1U+
M^T6HIH7AHCJR%"S4\2,LK J3S*O)R"Y95Y&9@ K$884O[+J>NFIZG,HQ&BR!
MU JI")858, (W?Q?$(]UI RQJ3S(&)OB".?\W9%RY/,7,XZ;P<&Q0.,;6H]
M&B#=58")OWT@=)(@.)%R=(4Q773*9LW2!JB5/E6,KR^3,,ZK8*=<XS!<PJ8
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M*(A]83")5 $#@0_(!.4"<VX&!4_7S&KR*IL-P;7O?0]KV N-K:[ ['$S'$Q
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MQHKL T=U5@5YF4A@'0@J&";<R68R/*H<TU.M558MI+2\KYI#@9^"A7"C%9<
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MVY"*F<-#IJ@110ZZ3GV@!$I3IG.#=PB3R157*!"E(B,9,3U(V.NA^?<7];[
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MB*FZKEOY:+F57%-PFS6<%9'317!<X-ZB6"KJN2 0WIV$%3S*QLZ*KL%)]P.
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M=L7<UR"GHEI&QDSB&(SHS3<*V1I&&</4,;2BL[*-VI%0CQC7S<RJRGD"KF4
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MJY*5HB)Q(',7F5]G12,J?<RH@4QP,J<YFB@[:<MP;6TOM<^MAZ:VUU-BD:-
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M"+4V #N!<@6-[XOFDN4@&4*H4RY^KF07,=5ZN.XG\AN8X%*R9%*(%(BT* &
M1,DH4YE%]2+4*9=%$9%DK:R=':G61XGR^D17>$S&*-YHZNJ62-V03OR1>Z:B
M!GM"K0YW)F4DPC9*&BA9%G,22IF%6S(LO@++(D+4=*Z2(LC0*))1S"GG53XK
M;L/"4X+T\YWMUE7(D*+O&M-4!1%D]2_Q&>L?U19L13$-E21Q#B[6Y!("*H(
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MV-CYC0=K8U?2%-RZPRAR;M9T*W)'-8<@.PL#>^NOED5>(&GINFSYO2IYRNT
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MU'J!1[C_ $!OOMOOTZ#UVTN%QP(;=_3;TZ;_ #_1OZCM\-]&#'.^W;8!V-V
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M]=@/*V_IV/\ #%KIP+KIH!H.WG]E][D;=L+!D.Y #X%^/P, _P!/[;ZC)#8
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M/OL'VC^W?Y#M\/ATZKOT.PV[Z#XW/QUPUF  TW!TZZ[$'UZD=.W2Q4V XAU
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MP-_$EB/X?][:F]OA_M+HY5_HKWV&_?;!XDG]8_\ >;\\'[G_  ,';"6(@_\
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M  8S'$.?C;/,X'IF=:/_ *^.P8LQB';'%##[*A7@_P"CM)]'T'^A4G^S0_\
M!A?\H^(1MGV<C_\ 5*[_ )^.?P6XR_BZHG\D:_\ J_2?1V7_ .@T?^S0?\&,
MO\I>(_\ M!G?_FM?_P _'/X+L9_Q=T7^2-?_ %?H^CLO_P!!H_\ 9H/^#!_E
M-Q)_V@SO_P UK_\ [C!^"_&?\7=%_DC ?J_1]'9?_H%'_LL'7?\ F87_ "GX
MD_[0YY_YM7__ '&#\%V,_P"+NB_R1@/U?I/H[+_] HO]E@_Y>#_*;B3_ +0Y
MYV_];5^W;_.,'X+L9_Q=T7^2,!^K]'T=E_\ H%%_LL'_ "\'^4_$G_:'//\
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M8L#Z#E Z=VU/IMUEU@KQ)F/$_P -O$7F?'V(L@8RE<2X43S#32Y/BVSNNVZ
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M5'D1&9+QH25/C9N]P[C5.(2DXD\7<H[)+65>N'35%C')O>WIW_7V8RY0-[W
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MG%>",H7'#EHR\%BQ]PP80AYFXWD6$5F'%:,TUN.=H_(]3@W;&5CV\;5ZTS=
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M%B*BK-)IEF7%6C&-=<2"L,U19$,)<VM<V_1^_7UQ(C1A,&C!@T8,&C!C4B/
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M[CC"&>3"9JBA1\92M;QS$8V%"K0U.CW3!A.-C!S;Z#7IK;MW^TW-]0;XHT_
M-(NW#_FOA>MO$.E0LPYTXL,UY&N"N)K0U93\5?9'*49Q*KXGKS*U1+92]5VO
MXB>X_JF6([W(O%6^GR5E3D CF5C%-J8+Z@V%@+"XTZBY\R;GUVQBZCX-W#S6
M<7Y)Q(ZO62YNKY+P=DS!$@KY&/*\^A(#)G$7D;B;=3M=9UBCQ%8C)FNY!R.]
M0K\:C7 IR$#"0<4[J[IL@Z3=& L3VW!Z]  .O8:XE-P]XBQ%P)T.O8N>Y#9N
M)7-N:Y@8N:FZKCN@N[_EJV5E[,IU^*@,85"HU\[Y"CXW="Q,\8OII>(JZQI&
M<?>S-R)&$U/38=+FP^-[#[,3/T83#8R;LA,R4MB,F1)1;'&1W)8@9VI(*/"(
M63&":D@6M.XM6\R9&)ETT#S4%,LJO"B_(RLT;(RD[5G,:O0^H_'X?K3KA.H]
M#VT_'7Y8<[287!HP8:?/6(H3B!P;F; UFDI6&KF;,4Y#Q)/S$$+0LW%0F1JC
M+T^5DH<T@V>L"RC%C,+N8\7K-VT!VDB+ELNCSI',*#8@CH0?EB&MG\-/&[N>
MLMMQIE+)^"+7/X9X?L/)R^)"4>#9D:</%YR#>(.8L59?5&3JV06U]4R++5K*
M5.OL/8*;;ZJV91RL,T=))R"9@YM@0#8DZWW8 'KY CSPR%8\-S@:X;KA@>6S
M7:J[?Y@LMQ4HU6#SE3\-HT"ZY,SLI5<_Y0M$-0XJ@0./J"\H50X>962K#&FQ
M%8A*[4$;>\D?>,D[=2:Q;X]<+S,00/+:_2X'W]>ML4LM^'-PN<9EXRLE7<_6
MYMC;)ENPKGK.&%J)"83ME'G[RA0(2)QMEBAV^]XIN=LQ5/7[%]8@X.?LV(;=
M#+V6J,0*U<0[R5E9"32V_G@#$= ="!>_>]M"+V.MC?4WP^E"X*,,\)6?N(3C
MMDLN6N$C['5LL6[)42[88_H^-HR$GIJ,R7<KK?6V/:95UL@S-(;U1=M5+E=C
M3%LA:P_L2,W,VB6DU)DBX+WL+#IZ]MR38>0L+],,ZEX1V#;E72ME,X9BLV,B
M0-W1P%6#FQP2&PW4\W9[QYQ/9";5>784)C8[FA:KECNJQL2^R-+VAY7J41:)
M8JJ2+A2:$P<Q!V (W^ (VZ:'#]9"X.,+/\0Y\X9)K+D[5'7&SFG(F6HYTI*4
MY"ZH7^35@LBRC#'$/*Q2K2P1]23H"$ZXC7D5-."0C>2/*.0;F!RB807O?M;[
M,1TMGAZ\)&:*YGN%NF<[Q<&5-R=Q62_$*[C'M5B7]9O7$YPS5&MY)CY0(JIE
M;PSRNXVG:QDBL-63%=%J]FF)I!"5B#!#Z,+S$6-AL+'R4Z?:-?3#RX\\/?#K
M[@DS;PU,,D6&S4OB[@['.VK*L#3L4T&POD<BT*M52)L,)#43'U8JZBT?5:]6
MSL'5E@IN6=^1[-(OU(M.-BHLP$FX) NIV-SL;ZZZ_/$<,A<"O#?8\WW"K9!X
MR<G.KU<+B:]VW%)(_%;))QF;BKX)<F<#Y\B*A&8S+-QCG(^-,=W2T5>NH3C6
MEPURIU@.VB@AW+>(:F%#&V@&@M?7;F#=^]OA\\2 F?"GP19%5TK#;<ARD/(7
MW'5YF87VN!9-I0N/."2T<"C>NJ.F4(B_:Q,WC&VR=CDUF;E&21N!4%XUZSB2
MGC#F$YCIL+=O[7-]^GH ,6^-O"RQ[2;AC7(=HS=F'*U]Q5<\"355LMQ;8RC%
M"4?AFQIF_&6(,:/8ND4&JQ#F+BF&?[_8I^S"Q+;;%9G#!RO+-8MBVB4C 6OT
M W\]3:YUZFP] !UUP_\ D?@_1NG$=%\2-4S?EG$E@>T_&./,I5FA!130>6:+
MAW(UFRA1*Y,R%GIU@LM523G[K<(FR/J/-0$A9*A8W\"Y<-U$V4BT,)?2V^]O
M(G<_(?8,1(PWX-& ,*#7$:W?;X[847(^&[K0D7-:Q!'2L!7\'VFZ6VH4*4MM
M>QQ#W"Z13A_=G;27E+=/2TFLPAX51B>/F#3\O/&%+$]!J"#\;?@!AT,B^&)B
MK(7!GP]\%KN\VAO2N'")HT33;5*5/%EQL4F-#H\G0HJ5DTK?1YAC"V%.-EG$
MJRLM!)3+'$SB#91C+%A59:#E3!S'F+=22>HWWV.WD<))GX3N/&%YKEI3X@N(
M"3@X"RX?O[NHV>2H-F-;,FX;X5'7!W"Y"M]VDZ*>_P Q.3>)5&KFQ-RV-K$R
M-S(_LJK 5'R+5@80F_0=?@";Z#I8W^!PH9GPO,<O<;X\Q[7\R9EI"F,>"V@<
M$E;M=4D:W&SZM!Q[<L771E89<Y*_[*^EK,XQ5&5V\0R:+6M62GV&UP"L6V2E
M"+MC"\QUT&I+==S\;^G7SPE,3^$U3,%3%7GL/\1^<\<RC!Q>&%X=5.*PO$ER
M'1[SQ 27$F\HJC!MBTL10(J+R!.V6+B'6,HVHNV=%LDG5T^7V>$D8<P%K[@=
M+;Z6%N_4 7\P/,%W>#?PY<2<%-PO%JQW9;!8$K-#N*K6XVR5C&#5Y2::ZN]@
MORU=2N=8HL#?;<F$S/$9).;I9IL"0\# $.V4FD92=ES"$WW_ %^'3I;$>L<>
M"5PLXNOLED&M6C*0RLA$9\ABLG\O!.8MHWS-4Y3&=141;^X2&44X?</V*TXE
MPP#A15."I-EEF$@21.OY@&%+DBQVT'IL3;U(!/F-+8=3'WA>XVQW?J5<XW+.
M3Y"-HF4.'7,4/4))O1ABCWSAUX0I7@OAW[J1:U5M.J,+;B]S#2MBC D2H-K;
M (R$&:,8R#^.5/QP<QUT&H(/Q/-WZ';$R>&G ]<X8<"8IX?:C,3<_6<2T^-I
ML+-60S T[),(P% 1=2AHQG'QXNU/,'S!:,FR/0.5(O71A";F^'QT83!HP8:[
M";PC_$N/GB<F29(XK$<H643GJA:"/0%+8%RV&@Q4'3)@!VV!]7(B/BUMN9NV
M(&^ZG<_Q_$D_/"+L/S!^T:8='287#'\1V"*YQ+8>LV&;9+S<# VB2I4F\E*Z
M9B67;K4>^5F_QZ;89)F_9@F[DJNS9O?-:J&%BX<@@9%P*2R9A0;&^-0[#PX>
M$;*>5L^0A.*R[90R5EF.S3CNU0EPJ^%,E/HQK4>(O%.>;=7+,O=L23IKL?%U
MOEZ/1F2%U?23JN8_GH"*I2E;GH-G:6YA;D6T V[]BO0Z$V)/4FYP\-)\&3!=
M(NN$[PCE3*MHD<3,,?,)E"_QN*\@DOB&)\T7W.^-6Q'MUQ[/RN.F%.M^1)B!
MA6V.7]><1E!AZ? 1+V-EJM&V0I@YCJ--;G2XW !V/6VH.AP\F3. \C/PYB\$
M6'9AQ+2%'KM"+BVR76SMZ:_)<,89/K>6*98Y6SPF/+U&Q<G%6RM1\LW<'QE:
MX5P^9MV\W5Y:)<R#18P<UVYCU)O;L=#;7H-M?CB!>+_")K65E[(XXF\W1TMQ
M+(Y)S%>\R5NFO,,9H2-B[B9N%-MT;4K^POV JY6V4_.&PV1[&V^KX:QQ')-Y
M.Y5^!A).%;1T@V,*6["PTMON!J=SO?7<'2^),YE\+?A9M4+'4S)F7;E7T<@W
M+C895%NYG:)$2DY?^-W,%7XI;1'U=O+5UPC89S&\]AI*:HL![OETG-1@K I<
MXRR1S5^NB8 Q[#^;W_FJ5'7J#KY[6QD>';P^N'R0H%>RMA_/%VGH_)G#EQ*8
M]K^7\71^,L9KRT!QB3N+KA+Y8I"N.*!6&4%<JFCBNIM<;V%-D[?-6:8.[&O8
MY-)N]2,(6.Q T(T-_P";<6L3YF_7M;"!C/"<P/AMI7#O^)>]5>=L^<IFR(S,
MFPPG6B7JY9:X84.%"SX]BX)O18R*<OKO0(CWRBK&-7-[<6HLY9W,U*R+R0?E
M,',>VPL-S8<W-W[]^_IAV$O"=PJTK:=?"YWV;:-KMA*^>P33J#;L9>0P1P9C
MP55V!EG$1!M9%& LE $UALZD8LVER6=99:$>QT<"<<4[^?Y ?AA.8[_K?F^_
M"'\.O@0XAL!.\ZR/$G>8>;^GW#YPU<,5&905Y@LHR5>H'#O&9IB63U2;-PW8
M#KXM'##*[-E!0\_0;C,+*04A,W2S3Z\Z,6P,*Q!T'=C?UMTN>W?X=[*D>"MA
M"ETHE(1S#EUS#M[5?K1'Q;!IC>IU"#5R!PMY<X4Y9&L8[J-(A:)4EG=2S%8+
ME-N*M 0R$]>HV$=.&+:OL4Z^!@+$WT&HL=[[AN_<:= /GBTSMX9-Q@9*C9;X
M3KC+%SG2;;A5Q&RUIR16\:F@ZCBKAGO7"_(I5R8>\.G$)6G<I<Z1<5 L#&SX
MRD$$G1U)BLS-;?13)C(F -WUTMJ"?YW-W'7K?;$:7WAE<*F"<(X5H7$OQ0DQ
M[FZB85P/<ALK)K3YJF,#\(>+IOAXO-I@*ID6C3;&RT5TCQ2>Z)<UMB_>3:5F
MZ/-QJ,(^;N&AS"EB22!H2>_5N;<==/L.-HF%?#ZQ;A%EFRJP=IM<SC'.V(<6
M8AMF-W\91("%91^,,-Q^"23E?7HE1J*L&\LU B(Q"4AHA%A5XN42<O*S"0C9
M=!@S,8EB;>1)OK?4WWQ&V7\&S$MXQE:\3Y:SYGO)]6O54X?L2VU:26QG4YF8
MX?\ A<4N$KA?#!I"@X]K";2+B[C<7-VM=P:-4;Q<)F-CF#N<9UOVR$=F%YC>
MXL-]NA;0[D[C3^.N$U:O"]LV2^(>_P"0,H34/>**WX#G?"G79&?N\BA;\[Y3
MGZ!=\;/\\Y@KU5QO7:UC>UP.-,EY#Q.G-T=[;9"Q5^YOY@D=6DXJ(K29OZ87
MF%@.O-?8:#L->X!M;IZXB]PZ>%E-\2%?R/?^(CB!93^1:]EJHTVFV_'-AQSG
M'Z+37#3B;('"?DNI79.U\+V&\:SB@.;!;8,L*7#H2M<EZI!6)_;YJ><3;=8P
MI:QT&F^HUUL0=R>@-[ZCI;&S"D>&;AG'UEJ5AK=JNK5*E9\P=GZ"A4FM(C(=
MO,X$X.&_!74:L2-K]3A8QA57>.VR5BD(^$81)&MI#RH(L/7"(P21C L3\K?_
M #%OO/RPI+1P!4JT\1DMQ"N\EW]NM,9PP7Q"N,?MVU/&L)9'P1BJQX<@W*$B
MK7#V<(B>ITZV"9BE)E0B<K$I/XY9H#IPAHPO,;6TV(^>(G3/A7\/6#DL5YNO
M7$GEN*QEP9Q]#RBV;W<^.Y2G5-G@.WWW*DK9B/G]&=2]&B+#'6V:0R6G17M?
M<61K 5MX\>#[G4:/C "=0!O<6%^MM+7^7\!C8WPC8$A^%[AQQ-@&LWJQY&J&
M+JLUJ]*M%L:UUM/+4IHHJ:IQK\:O#P42]-"0*C"(3E C47LHDR)(2)EGSAPJ
M8PA-R3M?M_&^'BOU\IV+:1;LDY#L,;4J)0JY,6ZXVF86%O$UVM5]@O)S4U)+
M@4XHL8V/;+NW*@$,)$4CF H[;:,)OM@J-[J%\3GU:A.LYU.KV20J$^=F"W+&
M66+;LG<A$KBLDES.&S>28JG,CYB(E<I\BIAY@*8,*W1@P:,&#1@QYCY_PC^-
M*6ELG24;;L45RW3.)<_X]D,T1^;LGO<A\1SO)O'!P^<2+)3(T;-XEEH?%;*U
M8,Q=9,"V@\2XR<A%)O8^/&&L]!8QD*T/U^OUKC9S+:Q!/U;BP %E(L-;[FX)
M]=[W=BL>%YQ70T=25TK[6&3Z&KF&H@S&;RW-6J2J</2_$UJ7%Y8,?P=JKN$L
M9,7M-C,(1$G2*K$M*= 1+"459X\:,FU$9,YY,PG,+[=&^96P.I/\[7?SWQQ?
M/"LXL92JYF@8O-\1/5^'RGCF"X;<?.;S/P+-[P?5_-MUSW<\/Y*GIW'^1(-&
MU34S?XB@LW$I0LBU>8HN <50EF;&CYRRE:F ,!TW!OH/K$6TU&@]1:YMMKC%
M/"4XEW^(LOQLEE9L[R])</'"=BW#=DF\VW.RO*T&-<F7BW\1>.']N+B:O0[.
MLY6QQ)U;"+*^%Q'+2#ZI,>6QTI2.8.8J>,',I.HZM>PMH0 .I.A!-KGUPW>2
MO".XOKABNNT0TIC>^(JXBMM)KL%E?B+OCEEPO6F7XH)G-:<YC)W1N'JI0-^9
M3V,)"(Q"O"JTK';&DPM5B*A"KSV/2JL%C &%[V^0U.@&NO<7ZW)N=<3!\1#@
M!X@>)K/Z64L/$Q:S]JX;87"E9R%:<IY$H-]P)D=MF]/([?.U#A:=1K)'7"9I
ML"DLWA861GZJYD9&0<1HS<9"NI@DH8%8 6-][V&Q%MCJ,*+@6PKE!GQE\7=^
MLBV2$.'/$%UR-CKA%C,A57(-&5=N\_W"(SGQ12\5 Y 80SR?I56RDRBL?XAO
M,1&N:G)4YC.-Z-,OJVL59P81K67:Y O;I;0>A(U(OKH2+XCDX\*[BAE&*4G-
M9 ICN[U*GTY+%\V3*63D2U+(4-XD.6N)R7M346]=;D0?*\.UYBL>L9D6CN2+
M(*SU(*1K4'*TM(F%YA:UN]]!K[H ^1N?*]QKC+8@\*K+U!MXO%H?#477\=3G
MB8W3$[5GD_+#B&L>5.);..*\I<*.2KW6X"!ISR*4QC5:[.T2VQ4=99Q]7SUR
M L51FI24G5%ZX8"PL;7U" [#ZJD$7N=]#]X[M11?"CXZJQA^WQ=6S%1L/Y2F
M,J1SFK&@LE6.UU6J8<R]PUP_#QQ013%.&Q#C.-9VTDVT0SIBQ1.J2+Q:_P!,
MIBMXNL].N+3<)HU_6OY8.9;@VV'06N0;CJ=.F^@VPX>6O"DSE+7>=LE#_!=+
ML([)'%BCB +5E'($3,XSQAFO@;PCP[XP?L9!&D6)0)VC9-Q7*STG76RI4%HR
M69SC2PK2KB28MS!S>MM+Z#4B]]/.^_V:XRC+PL>(:D<17#7>\<7YA&8XQ51>
M'M)TFWS+88>3I5^QY+Y L^?C>ZIO#F0;#E&O<2T[;F9+TZ89/Q#.6:--+1UL
M<KHQ%*<0Y;\OU^M<!8$'O<ZD=+ #8@7&O0[X2O"IX87&/C3(N-KCE2PXD0AJ
MSQ(\,^>;!6*QE"UVR'0F,:X#XO<49GFJBRD,/4MTWD+U9LQXOEH8;C,76\SM
M>AWZ^2,J3ECA&(/S"\P][?52/F01?7R.UAV&'NS/P <55\XL\B99K-OI+*&M
M.2E+Y6,V.\O9/CLEU7$!>%YSAUUP=HX;CZ>O0#8YG\KJK91?7).Z%!%29D;"
MO3W][BH=\8QC<<MK:VVZ7N/>OO>VEOML;8FGPAX-;<+E#X9<#.'\8G<8#AVD
MULF$8WX)L;SE2.1PS&Y)R$#"UPZE_N'O6U&=NU+B67A(V*+,(M)RN+/K)"^Y
M@;?+6WK\O3\L8DW:_J?F1TQ.W1@P:,&(X\8>+;QG#A-XF<,8REV%?R-EC N6
ML<T.=E922A(R&N%THD[7:Y*2$S#LI&6BF3&7D6CEU(QD>^?LT4CN&C1PNFFD
M<PJD @G8$$^@.-0+WPE,SQ5MR'+XVNE4I+:UW?B1C8!^&3<IO7,%A?,_AWHX
M.AZVK'.(YT@+M+C)<RN<+&R0<'%R"B-Z+,O[>5*%0,9<]P+ZD6Z#?F)O\K#Y
MXPD]X9?&)FEV64S(\PG#(OY%LFYJ3#+60L@QD3#MO#%SEP6N'*$M(8JJ!UI&
M>RKD*NW>59-(IFBWK:\TM[SF)N-;HS1A>91>P/EH!_/5AU/0'%S$>&AQJUG#
MTFZQ/>\6X.S]2ZOPFL<!IQF1K_;<>527QU@RZ\/G$ WLJX4F <N(2VUO(4Y>
MJRR9P#Q-W>XBJKR98X\,A+$,)<7UN1<DZ"^MCZ7N-?([=,)3+7A,<5<OE&YH
MXOLV,XS$+?AYR[PX4F1E\JW1&T6_'5O\/R=X<:#&Y5@7F*K3,2$S#Y[4CK[:
MWD;E=*@K1"C>[1>+WN4??TK)F ,+=;W!.G6_346%O*]^ML6UT\*+C<FK+Q12
M,5F:)*\RG@?+U QS;4\VS< R3&]</]&QA0,5VZDLL 2%F;4K%MWKTI;(*?B<
MPKL(I1K#6>"H;:R6.ZL7!@YEN+BX#7M:^G-<];:C0BVORM(NL^&7D.@\6.+\
MPP<1C:Q8GQ;QDY!R]2*C-Y*OP3="Q;E7A$P[BRSR4 $G5["@XMS?/]#M&37E
M36E$(VRGFDIMS:F$O,S2#<P<P(L;WY0";#4AB1?X$"^^FQPBLJ>&IQ/VKBCX
M@,KT-UB6DQV5LZ7G+43F-AEW)K'):F/IG@4C.&I+ =@QBPQ^2G! 6O+#*'OT
MS:4[G)+Q<95(Z1"%DK!%UA%B8 PL!KH+$6T^N6OOO;3;OCI">%UQ/L+5!9!0
MRO7:SD^+R5A$[+)$/D7(S^7K&)*KX9+/A5R9$PD6XAV46XD9OB2CXO)98@Y&
M36UPL%"V6P3+.Q1K&#:&#F7MT-M!];F)!/< :?9MALL+>%1Q;4:;93YT<'XO
M7\_@F;69I1LY9;O2MW<<-^,.,6FY7O<W+V;&%:>I3&5+EG:E7EM7A!^V77"Q
M2EBF5+0@L\G4ZW\A]E_SP%AKN;\W0=;6Z]+;^F$->_#]XA.%W#5!DW<>.8*B
MQA/#00SMA:H3?$SDN'SEE;!=)XA:CQ.3]_98OQ5E7**-%MMBO>'+HRL];Q9>
MWMA>8IK<?=*#"P$:BY:+A>8$G?4M8Z"U[6Z@ Z&_KIKKC<9X7E/R51. [AZK
M>7H6S5S(*$';)2<@KF:R#:HM"R9&N-E@6DZG<C&M[613KDO$>>PM8)6:.$08
M3S=M*MG;=(Q@UKFVV)\Z,)@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8
M,-AA:0)+8HH$B271GB/*U'+$F$++ W)&0*9/8'!+35X:O5Z< P!L,A$0D8R6
M$H^4T3V$!4[G2VNUB+? W(^>,5MRBVUO+\/UWUPY^DQEB)O'+AC(_$'PM91Q
M%B>>CX"\VH*6O'C,6&?J4)98FLY#J5MMN.IZTU9C*6&NU_*E/@9[&D]-1,9)
MNXV(MCUV6.?E2.T6,*#8_KYCS&XQIX@?"JXIV5?RQ&L76,,90>1:]QUDC,9X
MRS]D=C'55[Q(7O@_L^*ZY'WZ6PI)%495"OX/R+6)B6DL:R\,S9R\3"-*/,U"
M?FH6-,9<P(MJ=5U(!T'-?KYC2^MM3A0XX\*KB4DZ@2$S5;L8"ZKG"?Q@XEQ&
MC5[=<4(_'.6\VWY"5P_?9*$K%0HE&=RU)J+^TMY67I-*J$!5W4TK"T"B)L2C
M*K(;GK;0_/H?AK@YEM8#<@G0=.FY^_7KAL\D<&7'"^R+@^1R9B*AY;CL@9XH
M9[5AVO9]S*MB1A2<2^''E?$<J;,&6XK#4:\J4+<LHQ,'-Q":E$DZ]-7*:K=3
MF';AQ(GEEU_7Z_7YX+K8VOH#8D"_U@1U]?\ "^.B?A"<5<51<AP<E8J!D'(=
M^Q+P+1EBRZEF>?@+-9[KPU0#VM9"K%GA\AX#S)4LATR92)7I&.4R3 2[:[I5
MM@E9XBN3SKZ00YTW^/XX.87VTNVENA[6(Z^>VFHTQ.JS\#V;[7ACPMXJ[,,.
MW[+7!9G3'5^RB'TNO$!5'=5BL49+QU+*X_G'];LDW-3U2FK/0;E&,)^(KL?;
M'-&<,R.*8SD6S!J80,!S6N PL/F#^!'E?KB!T)X.?%/C_!5&QCCN\T&"9L^'
M_@<K>:J##91ML?6<X98X?LB9EELRHR,C:L6WZ 9UVV4FXXW95N5G<=V".GAQ
M]&4BT4B*J31HY2,9%@238ZEM;:@&UNHU&M]1OOB>%UX#,K6'A7\/O&,O]&,J
MY)X2<^87RM;T\GY5GY)&5KU1;6V,L$##Y/CL5P[ZQ/:PQL\8C6'LKC2M!.1=
M4:M'R46[<BL<]<8\PNW0$$: 'MW/6VIOUQ%"(\,_C?GXRATG(UNQ<G2\?1."
ML<O7<'F_*LC+9-I6.O$ K_$=?;-+-1QM6U:I+V[!K>8I#& ;3M@7&:*C$/K2
MVA9 SZ-,+S"]]?YVX&A*V6VO0_( 6OBV8^$KQ.5"ESL-C^^4F(<V&B9%K=WK
MHYAR]&0>585AX@M=SQB'$D_/LZ\^F*G1U^#V(F>'"2GZ\P7?T5G9G]=AH*RU
M=5\X>F#F':^@W WY.4GSULWG;6QQ(OA6\.?+=%SQB?*><'=-5QOC6$XGI['>
M#ZUE+(]WKN [AE/-N)KKABITU_/P%40O%=QA1*QD5HG-3<5"-:W.7,\#4*G]
M'&K!^R,(6T.]R1KH+@ WO\QH-+;ZX26;O#VXM,@9(XS)>FV'&L+.9XCLMGQ1
MQ2N\Y9S@LMT:IWC#M&HM4X=S8MJ]=)2(FC5VVUF>D5+FK8+FG#1EA-<*I0&F
M3%GDFD86ZV6]]+7%A8ZFYOOM;<=KW &&&D?"2XIIS%A*N6R42,=+8CXQZ/%5
M*UY<>7>(QZOGS*?!K<:/6*E,5/AWQ/#1]&:,^'S(-@G(B+HC-&NVBWH-84)R
M.D7"\*84..W4'UL&&MR==1\N^\U?$"X LK\664'MUI]E@XEA%8 JU(H0O\A7
M^G2-7RW%<2M!R1(WB/+3X]9.->DQ5#6^KQ-K:.#V%F\G5H=LBRC)60D"&,0;
M:':]^G8CKZCUZXA]>_">XMG-UI:=%RG&0V)*7F7B$G<;4VMYKG:,ZP15LB<2
M=7RWCF[T1>P8(R^W7LE;Q_&3-.<U2%2IKB#4,TKD'>W-,M%P1T87F'4=!J1>
MY V.HN+]3>W8Z6[V'P@L_P JVMU@:7&F)9)FJKQ/2<99!RWEEN5MF2X<>#7.
MO#7=S WA11;+8LX>'%BHC9^W8'6J,U.RD#7V$E#RS^?4/U^6#F&EQM;H-@O+
M]IU/??& N/A.<8,Q*\3A:-.8CQ8MEBP>(38V>1ZIG#+B=HRM'\5V<B9#PO2L
M@U9OCF.B,?M\.1X2-F5GJW-V]9G:Y$$*VQ(K-6R;>&%YA==]"EQ8?S18]=2>
MEQMOMAQLX^%_Q-3'$S(W+ 3S%&,\*U^F7G'V.F\=E2]PUB-0+IP:90P\C4[=
M!O,:V^97<Q'$+<H_(?GP.686B&K;*/L;C'$[E=LO94S"!@ 0;F]N@TL0=#Z"
MUL(;(_A(\51ZDXJF.KY5C41>S</]RLN)%,SVZOQN1K;5>%&WX<RK:IBU6[$.
M8HUG.N<R2U6RHU<RE#L:EQ7@1M+U>KY"BJW)M#"<VNNP! T\[ZZCII;;I:U\
M;(+OA+B"RYP%<4O!=-M6(78>%QUPPXRS#?+_ "ME_#+9+/PJUF"F<F7V:2Q[
M7Y%B5+*EDL,%-S,96I0\ZE!.;.E&QTF_=U*', (#*W2X) Z6.WR'EB LWX9W
M' WRMQ5W^!R;49]QE.EYA@Z,]LV:K9#URS5[(T-C6&J&'[_1JU@]"W1D!BR.
MK%D8T^Q-LUS\)!NR04O'4$[2XY&KZAA>86 MM:]K:VOKK?OM87MK?3#%7CP?
M.->S8)MF)WTCAC($=/T'C1H..Z1>\_9"A:K@"4X@;-2[5C3*%94Q[P_5RL6>
M;JT+%W#'$U4(W&6/JW&L)T/HX?Z+V&U0IS"AE!OJ+%3H!K:_,-P=3YF]M>EI
M%YE\*[B3RP]SFK(WBE.FEFIWB+N,/-U\G9+BTZKE?B#JW"^TX5[7((1->22:
M)XMMF(+M/R"R/O;Z%OWL!,5:-G9-=P,680,!:X.ZW\P.:X\[@@6.FGD,(3"N
M'N)"%\5:E+6;'^1+%'U7B%S[DO(O$5)QG$:QC;%BNU\(SZCXVH,I-6G',7P[
MV"G8]R%+H0.-DZ5EZ[W!RH\E)A[CO';QO<W$L?K]=/A@TY>FPTTWOJ>]_(CT
MN,>DO1C#!HP8\Z==XT?$>@KCG!.[T+*EBJ./>(/!#MY9:QPR7US6X; ,AQD1
MM$R_"U6KR.$*3DF8LK/AP?N[,ZCZFMQ)"2*@G>3:]E1M&R\)#KF,[+W T.EQ
M>_+<:W[V!VML0-<-E<?$$\0\\ZW@:TTR5$9&<X]SED_&.%U>#JW2UBRI*P'B
M#94PW@ZC9,;JU!*P85H-WX>8>KNI6]65"F D5-K=AMT:H+UI83"\J[]- ;$:
M74$D:ZD&^FO:V'.S[Q)^)W1,.7RZ51;+DCD&V\2W&=5,24^N<*"DS$4W&W#[
M;\TQ6#(JQ/H+%&5;A))Y^BXZB2%9LDC04H&]1T9'H1^2\6-9B1ODL8 %) N
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g209588g01n02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g01n02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1944&AO=&]S:&]P(#,N,  X0DE-! 0
M    %CB^5H@X0DE-! 0       \< 5H  QLE1QP"   "(   .$))300E
M   0MV9>?53;01#W5P=W'7#,93A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  -M   &_0         !                          $
M!OT   -M                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   -M     %)G:'1L;VYG   &_0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #;0    !29VAT
M;&]N9P  !OT    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     "_\    !    H    $X   '@  "20   "^,
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MI!R%)M.'*PQVC?ZH_*X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+D"X%[G;[OV=L-$"UN6\>4_E.#"A$D^6GEUCW\IPH2L=""-]#OT^%NMM>_3
MJ$Q8D\^6^^H,Z$P-M\+46)&D&^]_.9B]MA@J75   DFX&H&U_P!G<X$IN= (
M)\X^C;;82,$%J&A&4 FU_?XSL<'2_L-4B^A-K:B^I\[[:_##93T/O.L6$3;Z
M.#SI)N-=;\K:=(U]DX617DJD,:[O-@ZZD%8Z;D']:C# 04R-Q'2#[L ;H7"K
ME*@0? VGKKUWMBW./;@/'#BX!TXCYQ!N3_Q].V'D=[@GH1;3%_C2?Y7XG/\
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M5@_94/2X._<:]L+!2#H0<;A>U_+47'SMOZ8:)\?$Q[) PL7'6'>3A9PD(/\
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M?UX8I!Z>&AN??&_[L+Z^N9]GOL=+U]SIVV(.^Q/Z[X;*9D'I??2-(UZWTMA
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MO>YV&VNG[,-EG6( , :C2_7ZUP]B=OA&O7SN=;:8.ETG2^GE]W6WG_3@""#
M, :3:><1K?Y=,(;\_&+;_N\<%2]>VM@+:Z:CXDX($WFX!,VL )]NQYQSDP\$
M#8S'7X:$2!?G:Q.#I=!.BCIW.FG3?#D@R)CGM:-;^5Q.VV$%'F3&TF_C?0>_
M3P,EXWN3<>1O^>&*01Y\@#O:PY],&E9WC3Q-[:7]U^=C<Z7@=3:X_G$=O,]]
MOT< 4$?1.I/(;;_G&"!!T^OKW[8(%H))O;MRD =1IK@8(U$8*)C0SMJ;<QC<
M$@7N#Y$DGY86 *0>GA ^6-N>VX(/I;\3VP\ZZ7Z?"!'YQXX$H,V(CKK\,2K+
M2@??-1_P;<C_ -7Q=HTD]Y!%LG/_ "[:?"V,7BJ">XVCO=9O_-Z6Q] ./KK'
MYNXS"PL9A86,PL+&86%C,+"QF%A8S"PL0SB/_B\SY_H9FC_4<[#*T/@?AA8^
M0#CPNW%S.2;[2Z987U/]P:3O\?GKCQKM*D'C=>>:F/ ?Q9GKCZ^_1L?^!/ 1
M.K-9 Y?RE62?K>\&^*G2\+BU[#O?\+=B#^WK@J;(Y3R$1R._,'ZT[D&8^MNL
M<QSVYV,ET'X;V[_T^IP,$1-O8#^._P!1A\%2YRZA7WV_,'I\L"0#J-?;XCWQ
MAPHC0GPDP?'V#!T2%IW/,+==>HUW[7P!;Y'VD<CTY_D;B3"SO[M?KV8.B0E5
M^;36P WV'GWVP)01I?:U^?R]^F""TGIX\OJ=[X.E8(!!M?X'?]7'3K@/KZC!
M"XD?7U^6N")61<ZW/6YT_/\ #"PL%#Q3U)OZ]#IN?CUPT==?PVY86#I=Z'4C
MH.G0=?N.A%],-)&O6(!/GT'3V&,+!4N"][ZD=.@TM<7OWO\ U6<&1>^UOK3Y
M0;#18*%6%K]2=-P-CVT%NNYZ[##%(/*^\7\9G]_/!!1',^)M^_!/$( "2=!\
M/AKO@2C<>SV[_#QP07>]A^?X?6V#!P @$WWU&I_'\NF ((U'U\,&"#I?ZZX(
M' 20%$6W&V_Z_71L/A9%=*9#&HL'FNO^6D:ZVO\ #?"3]X'J+VTF8^O*]\"L
MRE?^:KX$_/:WGBX/:"='[^_&-)TMQ+SJ//3,50'4CMI^8&-+C/\ 6W$O]>JO
M]\OZ^AC"[*?W,=G_ /H;AW+_ !1KKK]:VQ4:5@BX('Q']?W8S<;^"AQ8M91(
M&W;^G"P^8VOI]>?G@Z))!'-?3K<GIU'KV^[#0.0]FV_MP87:#R-_RCROYX4H
M?21?IMN!<7U%KW'YX;+K!DVB=B+3IK'RP4I.XYCG(D3?EU&V"I7U&F_4 ^O6
MVW2VWEAB/[4;1&8].G.TDG6-8P\>WK?:.8GSG4X.EU0.AZ'0J/E8;?KRP,6F
M\3RTYFQZ7^!M"S*'WB5 $:B1XF\QSG!4OV!YMSVN>W6]AOO]^UQR[B^VD'>T
M:[?1!P06#K( F !'/8ZS?WB-<*4N@VUN2-;V.]KG?3UP.6.?,;?#;VC!R2)!
M21:-S^9(MK?;!4KMHE5B;;&VU^Q].GKINQ$W(!@'23K'PO;;;#I44S$@$[B
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M(11F8>79;=4$UF2Y(6AUS,U+A&-[@EYN=):@CGG^\Q(LB:%U<E(!'K$J"DE
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M+2V<E15,%IR L>C5#C&946&;)GA*E@ B%J20HM@61:QO8Z?"_P _Z,5L@F1
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M998DQFJK57XD=ER7,;8F3 "2EDR)T^<ME<^H3I4AW*A;J2%9!*N\60A"5.+
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MEHH%*BL-,RZ*K*3K%.D,TQIJ"Q*H]%53"S3E1T+%*=*4^\Q7G!HTU;6+2K/
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M8#$:,VAF,RVW=#06X4EUU3CRUN*A??<J%]XZ49@AML!#;;24H;0$(2E#24(
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M<\L$2^>IL=Q<DZ>5@!VTZ7TTW'!^=^GSL8'6,* [MS:V(OOI;6VE[WTWOKV
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M7SZ8 I($W&MXTZD8E"TDQ(GY[CRP4+VTT\NO<]M?T<#??V1N/$_7/!8*EPZ
M&^UQMI;7IK^CYX4#E[=>E^8\?/#R?A[A ZZ?CK@Z7K'7:WZV& *3XGGRD[D7
M,7N1$<C8K7\_'H+G62=O+!@\%>G4]?POK^-SWP)VO:VVA'.PYGG.'.UP9UY[
M3-O???6^"I61]9)MVTOH=[7O]^&C4^7QCX'EX80D200/H\_#>_S,ET@?6NKS
M^/IYC?3SOIAH.L6YX,+L)DZS[?S'(=9M@J74[\P%]+;Z>=QA8+,GF+_7EYXG
MF3'"/I'7?W,C3_OH]O/%^A />S?[FY_R\9'%;^CGGWO_ ,/'U'X^H<?G?C,+
M"QF%A8S"PL9A86,PL+%;<6J^O+>2)]1:J=3H\ERHT"EPI])G9:IDIJ;6:]3J
M5%#E2S=2ZUE^!!6]+0FHRYU,EEB 9"XK9EA@A86*E]GO,\;.%9S;7W:S7JY4
MZAEK(\J++K>8,DUM]K*;]0SJN@Q)T;)&4LK0:%7VIOTX_5J4\NO!IB53%1ZR
M^%.L1UA8O#B/_B\SY_H9FC_4<[#*T/@?AA?7/'R9>T=P_GYTJN=G9+.7\L4:
MGRH50;K%/H=1S+G*O3X5$@-PGU-TUEIV"RAQ1I+E/CP,T5*H4Q)$5RFOJ9;:
MYWBE.BK#K*X*B0I$V"7 A,$$$3J02"!!O(!!]5[)U[_#::AJD2EO(M+P1ZRG
M6/2'"H$%"@""!%E&!*8-\>:KB)L)YR'/ARJ=.C*+<J!.CN19<9:DA82]'?0A
MYL+0I#J M(*VW$*M8C'!NL%IQ3:QD4V2E0F;C>8,CD0+@B\8]UIJI%53M5#"
MLS3J<Z" )*5;&38C<&#.H!$#9+H)L3ZF^@%R.P(]=-1\#"4$3H8O>WUIO:,6
M@LV!UFY,  >[Z]F#I<).BN:WK;2WF?U]XFP&GN//IX6GEY'(-I!,3T^=NE[=
M,%2^03?MOK;IKJ;=_D</8QMKTN(G1/+QUYR"C!D;$&^WM\_C@Z7P=3^R_77Z
MUS\\+*?<#N=?+IOA>!M;K[Y^NN"I=ZA1!W%R-0?CIM]_3#1>-?"?WX>;Q!\=
ML&2Z=R;]O,:[W-O/<[BV&CZ^OAAY^OK>PO[<>K/]C4]G3AWQ6J.9,_\ $>A0
M\W1J!6(N7LOY<JR&Y-"34%PVJA4*I5Z<LJ9JA:C2XC$"+4$.4X%<Q]R/)DMQ
MG(>CPZF:=62XA*[A*4* *9@F5)B"-AFD7-M".:[3U]51T1-,\I@Y5J6M'\YD
M LE!G,@DZJ0 H$)@BX/0+C1/R'/XM\1)/"VF+I/#Y_.%;.3J8MMUI46B>_.H
MA--L/2Y[S32D#FCLKE.K;96V@ALI\)&=4ML%]Y5.,K?>*[L$D0DJ( C,HCP*
MB=K8V^&^F(H*-/$%]Y6BF:])6 F%/! +A!2AI)]:9AM(M(ZZYEX/\6,E4"-F
MK-W#?.V6,N3'XT6/6J]ENJTNG.2)K3CT2/[S,BLH0])::6XPVYR*=2A10%#>
M%=.^V,Q;<RP %%*PF3?4QK!W]V+#=92NN%EJI8<= *BVVZVM82#!)2E2B #"
M5'8D"Q(Q7B7"-_GII\+?/^C$.:\$09O(F/,FT7Z#%@C\KD? B?=XWP9+]A8$
M;]>YZ]#IIY6O\'!&Q%XL,HOS@WD1O/G@@HBVHBP@V.LS>;['7!PZ-!>_Y[C:
MWS\KFUL.1/([3\9B/"W,B(F4%S 6(.A4=/<1[=!)&YDP<V /II_1A]QL!Y=
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M[3BD0LC0$'RWM_1T_IQ1N--/;O\ "-AX",;\I-@4FTP/6CGSML+#D"+8(';
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MFH=99@0HRDP[(5G1!:1]FI),Y8@!945*4!HDD@H%HR@#!UM,AA;"*9_,BKJ
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MGL+VOUOT_/\ +"\4B2+$"PY[QI!G:?:05TCP'A:)%K<]\7MFYP_O"\$2#?\
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M_P 7I>S_  ;B7'*U#ZZ3A5&]6U2:9"''RPPDK<+:''&D$I2"HYW6T)2%*4H
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M"GRCD2^6PVA2PIM)*@/J7.N-7@;3C/'N#!Y"V2GBE X>\2M!"$532RJ("B
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M5X;R%QI0IRW6&A!*S,CRJI',F6U*<8=:CL1@RXM!?;:&<SFRG*8)G[TR$F1
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M6F8-P1!2I)ZF0H'SU'/'ME+5.,J144SH&9(*5H(4AQM0!$Q*'&U""-4FRA<
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M60D %1"4I388H.<2X Z5%?$*]142I2CPQ$E1,D_UA-^HCV8MM=FNWK+;;37
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M:7_>R]BS_P!.;F4^OLXU$?AQ/QF_K;LW_P"D^(\OZE7[?Z9^6.@_@S^D3_\
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M\*IUI5YTIJ$[-0PPII+]0DNAV2[99>=8HT,IS.H*E+[U<H;F1.52X4N"" %
M2J83&F)Q=ACBW'*BK#:*8Y&V12MY"^0$V4ZU3A3;:EI4"KN\R<@2%+U.'/AE
MEOC',DTF-ENF3,HT.G5!FH0JS2JF<M5Z9-@6<AR55V9,I-5Y6G"5Q#2W8D(/
MK0ZN3*>BID1\*LX[P>@4 [5I54JE*T=TNH""HD*&5A#R40;+[R%) RP@&#VW
M!.PW;'C"&U4/"G*;AZ2EUJH-2QP]Q\( 6VOOJU^D=<3<*;%. TI9"LSA0%(]
MAN$CN:VLAT-'&#B5'S/G[PY'TO5JUFQ.9:FICWR2NFPI-8FU20I[W""MF.AF
M,Z8,8 M1>=(+KG&<2XM35-4XML%3<)2B%LI   $I2IP%()Z F"5 &0/<.SO8
M+BE+PNF;XCQ&F36G.NH!#M2L*4M2DI=?%G7$HRA102A)E*%+ SJM-+V7%$7S
M;1!W FP+_ ^_?'3^G&8:]K9/_P"%8_\ F[W.OPQOCL4[%^*4Y/+T9^?P^'7!
M0_EU0_ZK*);SG4\7&O:>=[?H6);T]KE_^%8_^;&_B>L8?^!+I']9L=)IGXZ:
M3C1^;EN.VIY>;*$4MCF4$3X;BS;HEMN6I:SV2E"B3H!<8?TYLB<JCKHMHFW(
M)<43OH)^0'L6\"!^M*228&9FH0.5U+ 2F^Y,#7?#WDS.>4TJJB6\QTYP#W*Y
M*G$$?X7T+:CT/7%VAKF%AP_:C[G]Y<,_>W"<8'&>R5:RJG":SAK@(=,^E(00
M1W=BD@\[&;X]T_WN<[?\GY7_ +[$_P#M./H#OVO^53[^?+W?O,_&^=//W'\,
M9^]SG;_D_*_]]B?_ &G#^D,P/M$ZC?VDV'7XZZ+.GG[C^&(-Q$X!9RS_ );%
M#\"M9=F1*YEC,U'KE,%$E2J97,HYAIF9J/(5#J@F0)T150I3#%1A2&/XU3WI
M++#\.2MF9';OVIGO$:$7!W\SKJ#MN, YE<3ESE-TJ"DB2%(4E:3!!!&9(D'4
M2)!,CK)4O[&M3*E0ZA3)'[JGJS6:M*JU=S9/IG#BJUNJ/5?+5<R[F#F:J66I
M-)A.RY.9Z_FNB.T^FQ4Y3S7-1,H;+%+1(HTPO26K?:HM875%C(/,Z $$WYSK
M6-)3J205+*E**E.$(4I69"DJ(ELI225K<20/4692,LI*N9_8W:%/D9AD/4[,
MD1ZL5'-$VFU"B,Y/H=?RLWG//LKB#F5- S' IB*O&J%2GU&H4-RNKDKK!RN[
M%I#TM[W%F05Z2U8=XGJ23%@ )3-])Y3>^F'-+3G-)4"HK(*0E*D=XZ75Y%!N
M4E2E*253/=D)_9!PW4+^QKMY:BT<46K<0(%2H RO*I4UN9094>-6<F9YS7Q"
MH%3%/JS530II&8LTN.U*E>\"GSV824I:BNS)KSJ-2T?VT1>;G0@ CG<3I$>S
M#)I64)2 XX"G*0J9A2'%NI5!2?VU^LF8(&@DX59=_L:]!H,Z#6G8>9ZYF:!4
M:?5FLU5B+D5S,)J%+C\%6($I-0B4.(J*[$/!6$[#]Q1%;@N9TSL(+<9JJ1FX
M;^DL_P#*)CE>WWO_ /+W#"124Z"%2I2PI*LZ@@K]44X'K!L$0:<$1H7'( !$
M=T/WN<[?\GY7_OL3_P"TX#OVO[:-SJ9)O<2+'QD#;3%S.GG[C^&$%5R!G"+2
MZG*D4.2TQ&ITY]]U3L4I;99BNN.+(3()(2A*E$ $FV@)TPZ76E+0$K25%:0
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M<<>)7,AUG,=+0A=0%(?AWJ+B#7KTE0A;=-4D9G%!1]&?2"&JI* D%7=YBAT
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M*W@IN.T/ SU'$J0^=G<;?VK_ +0 &O![B<+'KD#-=M=-Q2CVV.!SO?XI4_\
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M&)4\4X N,O:;L\KUOV>*49O_ -MY6\SB243V;>/<0H+_  BXFM $7+F0,VH
M&Y)*J2!;O<[ 8RJUFJ='JT-68N?L5R=K"/"X.^^.GX1QK@#2P5=I^SZ8()!X
MK1CI8EX=.8MO&+6I? WB]&7S/<-L^H^LE?ULFYC1:VI%E4X&US8W]->G,/\
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MC]I]>.$Z_9\XR  'AKG]%_YV1LUB_P#\D["^N^XTPY<>$?Q*L_[%6I)CZO\
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M#-$.=2JGF;*D*K\/:6QQ&D9FI]=,3+M1H]4;K,62BK+ NTZD@=T$J*T$D)$
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MC;]&U2>G4J"ZPD/N%3;]4W*0TS4R&%PC7EN0'\XS%OTJ0(T((08C3C3[ST6
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M9U)2NG1'':1(G4=R6Z\F14($:+1T7J:LIF?14JI"KN:A+SCXS%Q3:3*6T P
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MN0$$BQ ((V-AK>VVUL9.59OWQ/D#\_WZF]\::5L-F/00F9E68CF.>HO B>F
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MP+@1;<JDR_Q@*RN+S6=I(*E))L+Q)@:<\9'!*:A=[6=K0MBA6!2]F<@4PT$
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M7UUAZC+J<&CJJ$A=-ANRI%-D%"T2@BI'=D(@Y4E22M)4$J0EU2LP1ES1F@J
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M.Q&OCXWP"S4ZM1K;+ ,==/?Y6..7VZ04E+?AZ]2FUQU Y@-?AL=[X=::8)M
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M(!Y@@>[7V1BR ANZG$IV@D G30$R;VF8G#:^:FT5*\"0VBVB4M%=B.OV03Z
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MK\H8S!:Z\]@9FW0&>47B-8.%C,(ZB?>!S,"VI'($S!$7)PL9A]^>NMR2 1!
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M+94B-RJ>1T\.HVP18IFKR=.@OL-2.DQS&%+$:IMDJ2ZA%S>Q .IU.Q.W6_\
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MX=+$=,3(<6!_-2( F+:D:?*1KYBLXPVI1/?E-])@]/9M?0S8:BD36U EUDM
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MX:K&8;60#>(@F\7U$3H;3SDWU6,]?A^OUVPW.-@-.>@VF>>LDP3S6,P0._4
MGGH+C4'D(^-UC,-[=B=9M.VQM!,W&DG"P@JO^Y=3_P#!T[_R5W%FC_IE&(UJ
MJ>;@7[Y!N=+V,"-.5L4.*_U7Q/\ Z.KO_"NX\V<\'FS76 X6UMI=C -J':!#
M/UB";G70$=>YQY9^D '^&/&C,?:4>X!_JZC'UTUQ]"_H73/Z+NR).4I]&XD<
MI(!G]>\4&I!'A-O9>+*J-,9'(N*V% '3D3W/\NP&]QT(TMCCPE9TF]]2>6PF
M/KS]+4MA/[%]-ATWW@:\S.D8:W5P9S@\!M/U2"$@ ?6&NJR0 0#I:YUZ:VD
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M]>Y[6.USB9#R%1*E;_L_@/?I[,1N,*-@A)Y2KW^'X:X)(FMN)LEYU>UKIO\
M+3SWOYVWPZEI@P5](21M:9&_C/+00+;"DFZ$@=#^9_/?; ([<LGF861KI]8
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MUC2UDJ(ZWTL+D;^A&FNH!+DR1.]Q^)/AL<3*8:RPDA/7-SD=#N8ZX=F:FE!
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MB)YE3*\BE(48F4*S#4IY @RDB"!ST()NT-<U7L]^TAY",Q1E>1W2P2A#B5
MK24E#B2DH4I,YDV6E0%J)^TGU'XX*E_I5+_K-/\ [Y&(>,1^I^+<_P!6<0GI
M_%'?";_NM./.GCCE&?4^*.:)[#DF,T[)IO\ &&UDHLFB4QM0\,J*0+HL24C4
M$Z=?%?TB-%7;3C:@2/M:2?\ [GT>GEY&\X^C?T&L+<_1+V+4DJ'\5XI<+'_I
M_BX/J$Z3%^=^>(O X>U-UM)%:D@<H(NXT;7MUY"=-+C<WZVOCDDH4-%$R+W'
MO!^N6/6/17  "Y?4V!U\1M:PL;WYI*MD&I-M**ZU(41M=;=M+$V"0#OT!!UW
MPQ0=)(D<P>8\/W7O?$:J9PI)[R=_[)BVGJV.^VI'C6RJ(J!+0S*DO2 I?* N
M0HH4;[$<]@" ;)MKKTN#"4J2K77>8MM$0)F)DR.>*P1!@J5K N3!F?,&\ $^
M$8LRCTF%RI_@&!U)YQ<D]?LZF_<F]M;$F\PB! '7W1)!^IU.+C305<C3J =_
M/8@ SI>"1A]>HT(ILI+"$VN5<X5M;0  7U&GQ&F'(MX]?CR]V)2PD028$7,D
M[6YZD1< Z[W"./E%A;A>@/*+E[<Z3_!V!5:P7I;?4:]]] R)F1()V'B-O(>[
M"]'MF2L&\ Q8Q-IF^^B2",2>'2JW  *W&G6Q8E*"A"B -0.;F%S;3:W3>^#@
M[[=(\9'F-3B9LN)$**5"9@6@]"0 )M-@-];X>D5"FI01-@2%6.I<:+B;C6X(
M"Q8'M;4Z#H'!0/O GPG]P\YP2B2)2L@ Q)0K7IMO8@GD+VQNEYMP>)3(3@!M
M;Q+):-KC[#B@H6)O=*2>IOIAB1(*4F;V))(T.TCD;D>5\'F,#.K,(.V4^)D2
M+B\@VT!V>XRY[R E2(;"A]H6)5??4*"!M:^U]0"!B9)<4(A"3U !\=>A,SXS
M?$*@VGUCWA,Z!1($:&WND;^>&BKT63);(<EQT"Q-DM DGJ22X?307WQ"XVH2
M247V$  >6VAWOK@TNA2<J H3$E0)GP$)$WD09]IFO$Y?C,R5-N%)6K_?D+Y0
M3TVV.ER+7TW.I%3(F9B\S,D? C3;]\FAE D&;W$'UIFV^H@G>V]CB0,9=:;L
MM$\W&NJBM/>QNL6];=>V\@1;[POS49_*?J-I 2G9=H^\9GD+1:Q]OCC9QF2R
ML--U%"0;D*O:VNH(YR2;'H =N@MAB(,3KI!]XVBWAL=2,3!2CKX^LD&>A.\>
M6V"Q&'D2XZI$LS4^\,V;Y^4WYTF]DWOK;R(OJ1:S)%Q<GU@8WVTY_401@')#
M;LV'=K&@2+I(FT&1I<F>9!Q>?'*5%3QMXM(7!D+4.(^<ASAAPI/+7Y]U!0!
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MS@B0,=-.*;\Y.>LQH$@,1O&@\B@R%G6DP";JUM]8GH38?#'C?Z0B3VQXV"9
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MD:CQO$1\A,8!NA;;-ZE(_P!HDZ] )D?")YQ>0Y)<6HO,/1D7.C8)%KWW02+
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MNY49.MLU]Q][G$^[<832,L26EI?"F"$ZEI3KKB; CE%UI2!8@;(/KUP[E.L
M7$@G72"=MS.DV'EB9FJ:*@(7L"-9\!) OYZ6TB:9-,YM-03[FU8>Z6-P0?\
M"=1=%_N&EL7J!3J0Z TF/4T5K&>\ 6G&9QSN%FF/?*/\]828GN;;?F9ZX[A8
M]_Q\6R;;^=YF=H-^=_&=,PL+3>#["#(M;32;VY7QF%A:;ZQ?\IU%XWWY8S"P
MQ-SRO'F9WY^6,PL/RC?EU ! '/6Y-\9A8?6 =<T@\^>P(!VB;XS"PTWF;ZSK
M>^QWVD1&,PL*_ON>8O).OM$@>)QRG<>H_'$]+_2J7_6:?_?(QG<8/\D<5W'Z
MKKP=_P#!'C&@Y3K>]]<=%>,;LX\0\QM1I * _3[1P+%)52*<?K+22H!9U%TG
M?0GIXK^D-9';3CB29AVD$&2+\.I#X;[1R@8^GOT"M.*_0_V**%99I.*B+7/\
M(.+P2H>L ;VOO UQ F8]32@?Q*.K0:^(DDZ7OJFWR^&A&./"YVVDZV]V/6NZ
M=2 .[:DVLJ-)(U2#&E@=8B).&>>NHLJ($1M!)2/JN:F]@- !?U*O4G6XEQ0
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MPG!;>6?W3<5Q8K-]!P^-S=0T-_AK:^N-JM*OX/\  P4+,5O')O< #A>MQ/G
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M":F\;I'U?JCKU"KA.AMI=76]B0;" M0,*((U.@WTC7S,";7$XL*AH?:*4L@
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,%Q'^:I?&H^+6/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g209588g01n04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g01n04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2ER4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *5:^$%@CA"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   @   #
MA"24T$)0      $,==%^5TM6[UV[XYE,#I>5PX0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M   0 ! 2P    !  $X0DE-!"8       X             /X   #A"24T#\@
M      "@  ________   X0DE-! T       0    >.$))3009       $
M  'CA"24T#\P      "0           0 X0DE-)Q        H  0
M !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M     ! #(    ! %H    &       ! #4    ! "T    &       !.$))30
M/X      !P  #_____________________________ ^@     __________
M___________________P/H     /____________________________\#Z
M    #_____________________________ ^@  #A"24T$"       $
M$   )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M             #10   [T          0                         !
M            .]   #10                     !
M       !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M    !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M   $)T;VUL;VYG   #10    !29VAT;&]N9P   [T    &<VQI8V5S5FQ,<P
M    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M     '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W
M)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'
MEP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M  5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   T
M4     4F=H=&QO;F<   .]     W5R;%1%6%0    !        ;G5L;%1%6%
M0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M    YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M    EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6
MQT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F
M%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M   $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F
M<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&
M]N9P      .$))300H       ,     C_P        .$))3001       ! 0
M X0DE-!!0       0    &.$))300,     ![%     0   *    ",   !X
M !!H   !ZI !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]
ML A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,#
MP,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!
M$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P
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M)=;OMKNQZ/LWILJS/YM=O@Y1'3L>S-NK-_V=EM[VO:YIAK3=<U[!6Q]6[_
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M\ 1V>_]8ZF_+Q,9U3<BZNEU[Q52+'!I>\_1JJWD>I0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%! &AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! ?_  !$( 0P!,@,!$0 "$0$#$0'_Q  >  $  @(" P$
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M7[=?BB 2&*3%L[=+,1+A>M,=BJ3=M;;DNME+BAK=:K].)2Q*(C[#)\L6 5J
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M4O6P']&*SN^D/:U-DRECJX8:8V:;!T)U%;!/6-4.''C-8>S$P_G"TL9B^NO
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M0VYVK Z.OP6C7,")##3@D@: &I=WKT204# R%0#DVQ%0;2_9BQS)&WQ8=?K
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ME(=2EB,S%>J=CR00^UE;JI"78V&5(PWEMSU^M.//)90J(*Z3@@]1:<0])]P
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M\W'C1F79$A]Y:6FF664*<===<7E*&VVVTJ6M:U)0A*<J5G"<9SB0"2  220
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MM^5/J_7=<:7[+[KT/+I/6?5MUK.V=_\ :JOVFB58"5$-%[B;&VFP;C)%V*Q
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M?4BZ:]LVQZW=.HNGFNOX2SP2P%N=M[330>,-8H.[8R*V@=;1$ C$8M090V&
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MG2U.KGV.UW^VT4;4]!JAM;4="EX4EUT$5J"D+K6GL["R))TE]IM^>R6)95(
M]NO!!.^6%.Y;A!E0,*BR8&K*L19<8D56J3L-Y?L1.$\E*XMSN3:$/3D.)Q)
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M&WA#-PCK^LJ3A[Z9*]SR8\I&/)67,9Q2]-'XA%T&PUORO*D'-YYY(.KE>D=
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MUY:PRS2JCWCXBX="%]KG+A(5,:H?/X9)6B5N&(X$GU7D"@,20 OD^KN;-O'
MAFZ /I>ZDR1Q1M&BA[G/E2-"DO1R&"S$))(JH9.X ':"YZ)GN..,9U_/%*A:
M,@=I]9/R]F[RJ?8;:&K]-ZQK2=2:6 [; ZFFB^Y&MK1UO[#;)G6$@#AU:L5_
M?;K],F5])9YW9\.Q2J^T.<?&--S8/P'/?W_#\_\ /W')'X?C[_L[?/VY?WPL
M8M-B]%-(YH^Q;-M,5/5L@T6MMPHC6K+%]\']L7DWL:N$M7QI$N'KA=,OT^R5
M!JD0)4D=7& C0T=(?@LQWESD9L&XQCC&5,[X_P!3#M!_<EL'_#\SD'T/W'&6
MSY.,\94G'[YQC_;G&/\ UXQG 0[76B%A-5*$<&2K+7((8F=!L3&7"0D?85$D
MA)<Z*E>78[)3(@G\-;B4X>Q#>4GS3C&<]AAE6))FBD6&5Y$BE92(Y'B"&548
M]F,8DCZ^/X>L YS,<BQI*R,(Y&=4<@]+M'T]84^A*]:\_>/MSWV&P"*M7SMI
M.S$P05;#DSQJ=EMUY,(4'A/D2,M34=#K[N(T..\]EMEMQY>$>EMM:\I3GKSA
MFI<3XSVA9VK+/NPIH3MI6-6"-90-S5B\&M855ZM;'UA+OE8H4VR50\#V(9"C
MIH.3:X%C,5&\$*A<FZG%*%X0&<N Y$RQF=WKQ=.JE"N/;^C$(VR2YSI@%H!C
M8& %?K\Z'>5[#-5.L#!&J9+ULB8LI@3:[Q5JP?C%D5UF$;+QHL>1-2KW>/C]
MGSVQG%GO%STS1[=L6H;4Z^]P-1R-7:AO6\[66V#I\$/$,ZTHDQ8AVQ1%";^9
M)O0[38?8K5+DO#(\(Z;DIC8EQ6(A*3!CGOQ\GY^WC&?N3XNVA(E1^I.ZD[*K
MV@C;=FTS(ZYQ->5J?O"/:*9J>-O2UD/I$.^OTR36P.IYL*XSRL&\2EHC3(PU
M$19ASZ>F?ZXS8KJ7:5)W?J_7VXM;%\'J!M"G5Z]TXQ[#T1<^NV<7&+BGWX<E
M#<F%*S$E-IEP93;<J%*2]%DMMOLN(PQDA<8QQC'&,<8QQC'&,<8QQC'&,X@^
M;'5H$9L)>2B&*!"YY<C*<SC"(\$=%=F2GE9SG&/)MAE:O+S_ #Y>7,:[;KZ^
MI:O6I!%6IUYK5B1CP$A@C:61C_[J(QX]_&9="C9V=ZGK:4;37+]NO2JPK_%+
M8M3)!#&/M>1U7\<J;UZ*AH5SLRS1VOL7N^U*H6VSAD&QSQ-BV'+=MDM.K*HR
M)*I#L^F!7P];>BI;R_#@"(?OMH3Z<Y\U\$SUX=SL3;MTTW&YU&HVFPJ^U0-8
MCV5W:>*+4VO*+(S-+JJC5=>R@=205(>I0.#GKO[1*MR?0:KV*AL7\/\ A_=[
MS3ZN\U"S%5ET]#3>#*57:B1HA&E?>WH[NU24MY<UF]/T,S%@+D\]3SQ?*L]I
M7W[4#I6@1CDE!+L#:T5 X]"<6V^+U4"C*M&W2CKC>4KC1I]0'NT./-2M"HM@
MO=?RG.7'&T+W.F ADL[1PI34P>TQJWI)>E80:^, ]F9++BVR$$-!4G^&;+6\
M1237F *T8C,@/HUIR(JJ_:5E;SR..Z0/Z>HM"PPS%89C1FFV(\=IMAAAE"6V
MF66D8;:::;1A*&VVT)2A"$XPE*<82G&,8QCFFY)))))))))Y))[DD_$G-<22
M22223R2>Y)/J2?>3E:MN]@54NQ1=5UVLE)VU+K&=BZY9E3*FH*1E/8BQU'9T
M5BTN6>*  .RWIY5R57H[LF$#-K@(D1X,B6SO-=IQ:@;83V(TU]5@;Y1+7G1+
M]<B%7-;V<SS]"QQ=,[*KS0B0J7 RF;[Q4VNN)HZE&>7=[%"FH#R4#5F=@BM;
MEC6\;R4Z9=I+#/31GCK66A#QQ/*LR:ZH\#75/#U.!)D$,P&WI!,Q-SA1*P'R
M4ETE8+&4<Q^'29\S*G%I[F/)'R9;B6TH:2A"=9<M/<LRV'54ZRH2).?+@AC1
M8X((P22(X(D2*,>O0@YY/)-AU.MBU.OKT8G>7RE9IK$O!FMVIG::W<G8?Q3V
M[,DMB4^G7(P "@ 1MLC=JPM@_3'5P!.S-R2HK,I59C3LP:W1QLO"OCV;:EH9
M8G-TX&M"5NC8&(DZTVA32X]:!ST-S)D#43W D@K5D%BVPY\L-Q'"I])+,@#>
M4G'=5X,DG!$:-P2.JYL_+F]AHQ"[LF7J]G#]$-5#_#/?G"L*T)[F-.EK%C@B
MO%(%=D]FM-(IKAYS9>QSZ]F[GGPW(4FZ3H7P!%5%R,^IZJZQK&9,R)2*O^$)
ME_'?EV*R.--3+8>-R&8GQ)KTQ&YL3R&Q:((\TCI6)3W,=>/DB&/O];@EY.QE
M=R!Q-+5B&8WKDOMVS=2C6G3H2"-CR:]"#J=:E?W,%9IIR UF:9E4K/?,W-KC
MC&.,8XQG$(KX%J;]2;"B6R&7G)'SD#HB9GONY5EU[Y*6</>ZYE:LK<]?K5E2
MO5G/GGG'H3JZNE>KUYX'/)]3]_?USK$40;K$48?DMU!%#=1]3U<<\GWGGD^_
M.7YRSLQQC.JEXA-HD=YMWV2S]7^J/?N\M=9K<YHW9G9KJ_MC6^JA5M,:2V>.
MV0_2*Y2M@"K/^L*]0[8#1[+5C(B(#(P;Q#>P.>F0UCI;K\/Y?W^>?OR1]X_$
M?X/R/NS>CX<2M O]*-"3^L3]TF::,5LN;!3MERGIVS)UB,VVPDMC3-DSGG'?
ME[!?V1)MJ[H]'=<'9L?U%(E61286,,CY^>,G'LKM>1H?KIOS>,06V;E:;TMM
M+:D8,\I:&2TC7M'.6U@8ZMO*7$-3G1"8KBVU)6E#JE)5A6,9XQG5MI7BF=N-
M;=3^P.Z;YO[9MJW(>Z/ZV[&:MUMNWK)JVA5.&<VCMJEZND;>Z]W6@$_*W:9H
MI#8 T.S4-L5C[DL$N"&N:'55\Q.@RH^WGD<<_)]/>/7X??D_E\_CENY787>]
M5HGBQ]->Q6T[GV9GZ$UWJ+-%W WJP*/LSL+L7I(O:28R\#-35@;6P]3J=B#3
ME1KD3'1(HH4299/FE-(@^T/<-W]Q]?=V^3_C''()[#@<]SP3W [<^IY/H.3P
M"2. 3G9"Y.1D3;&T;JW;4P80V!6,GY8>+(AC7<&[$)^-&E.H??;] 0N-;>];
MK:%>M]#JT^7DA24YSC.;4V-RBLBU91&)2K.#%#)R4#!3^]C?C@,W\/'//?G@
M9E5[EFJ&$$GEAR"WU(WY(YX_C5N/7W<<^_T&:^=?>%;3Z?ORT[C/;0(W&L6Q
MXVW-U6_7C(87#$RG%N5H; L\+8+YSUU!+<*- FSDSG)D)N:Q(:;<(KD,VVYX
MWGLZ>KK(J$=::J(BMY9(I6>0<>T.T#U!$!9)9F5"O2Y1@2(PIWUCQ/--0BII
M52&6+H(M!T>1F _>,R-!T 2GDLJ\ 'IX/U1FP43J&OT77ELHNI<(U^Y8(1YP
M:5=3*N#8:RE@R1<2P.#;7.),E6Q[D>!)6%EO8&3DQ,QWVL(DOJ73K5NQ<D$M
MF022! @81QQ\("S =,2(IX+,>2"QYX)( XKUBS-:<23OUNJA >E%X4%F X15
M'JQ//'/?UX S0MI?P?-X,V#:\79(?J_HNC;*ZJ;CZ^[1 =6K#M%%/[,7K9 :
M(& ;>N6F3E9J>K=*R*=(C/VD>,UB*FRV#Y&3#B360B6HK>-Q_7]?7.C.+HG@
ME[C'">C):[['UV8V)2=N76]=^BD<I8Y8[?=9,[ZUYV#JP"N.2:A#>**K]IU!
M0!.&BT*I,MBFIR(KZ(Z<PIL=_LY^/'N^'KVYR>?7MV/IW/8_U^SME\]G]$=U
M;1JGB?O/;)J]4VMW.0%U]IF[0))X@W1-$4;6M>KM4H%B<0+&$Z^R>M<[:T^U
M-51TLF&W?91\=*FF?.(U.1E%:9X4';;5Z*QMS4\?J_K_ &#1M[;DO>N^K$/8
M&VBO777]$WEUA@=>+NR$V<3U^_>W+-,L R)M:0+^PHX%^6Y."1YT-<QZ:XQF
M[[I]H+'5CJWH+KIDZFSOZ;U94*&0L;<9R$P=+!!3#!@M%A.N/.PX1 K\R5"A
MNO.N18CC+#CBUMY5EC+(<8QQC'&,<8QQC'&,<8QQC'&,@O=.,65ZB:H0VIYO
M85F:D61*%8Q[- IN6;#:5/X\LYS#,RV@%*E8QC\HMV,>>/+E1\5#Z0.H\.*"
MXW=]7OA2.4TFJZ;VQ+@\\Q6Y5I:B0<'D;3W<<B]>"C]%KOO%K,$;PYJWCU;'
MCZ_B+>"36:A8R?2>C"^QWT)!Y!TI/!]#,;8@2T_B4V,'HE86ISY2(49,GW%^
M?N.9?2UASW'/4KUK]7J5ZE>K.?//+.M6LLGFK7@67DL91%&)"QYY8N%ZBQY/
M)YY/)Y/<Y36MVFB\EK-AH>E5\III#%TKQTKY9;IZ5X'2..!P./09R/._,?*J
M:MQ^IF_-N;A<P\L!KY"^O&MU.>>8SS@.=&.[FL8_SQ^Q:])#4&;Z<YPF5J->
M<?YU7-U=XIZNAKQ_OK3?3%P>]?-C:#6P-_\ #J&6XO/?C9?9FSL_[/2J5!VD
MG'MUGMP>'Y2G&WO^K!U3K\5M#X9:AQQ#2%NNK2VVVE2W'%JPE"$)QE2EK4K.
M,)2G&,Y4K.<8QC&<YSC&.:7OZ $D]@!W)^X>_P"X=_AFK) !)(  Y))X 'Q)
M/8#-6>*%4]M]E1W9Z00UO#KPV<.C5((?VG-K)ZP1J\N+&![(EAFP)97QB+.)
MA.K T$0\$^#^URA!+*)A%).X2[Z#3Z:;PU)<Z+3=3W"(:T@KO84M+KU+VHF#
M)^Z2>5HG>*9K,<8;IB9/&$TE?Q!XPK^-NG6BI%+"E""QN)Z5BVE0QQU=P\"4
MK/4DJB2:C66:M%=JBA/-T"6<3V7E[)O78"4]7]!$%U7634AV'9.Q3T*--27P
MPYAN6(T6))L/#[3)5G"XTG9I%B51Q#GK37XMT(LRFA7GIGFNDQTSY5<$J]\@
M'J(]5IH05E/N-AOW*=^A9F!"^D/<M[9C#J7]GH@E9MR45Q)QQU1:J)P4L,>X
M-^0-4B(/DK;<,(YXUOK"EZHK^*Y2A.8$9Z4\3+DIDJ46L5F.2_3DA8[78R;T
MHU9;"14E*IQ@Q-ES7DH:8PZB,PPRUF05XJT?EQ+TCDLS$EWD<_Q22R,2\DC<
M#EW)8\ <\  ;6E1K:^'R*T952Q>1W9I9YY6_CFL3R%I9YG_XI979SP!SP !(
M'.[,O'&,<8QQC'&,<8QQC'&,T?4GPU_$ TP_L,-U\\4^/JC6EUW#MK;X^AN=
M*-/WIRODMMWTY?#$%=JN%L(G2^8\TVY'Q*D.L-.)9PJ-!@LJ1%:9/X#]?[YL
M.Z-=8YO3GJ[K7KJ2O_ZI$:$]>I<^^XK#5,Q8IMYV/;MARI&*S','V!.(S]K<
M@899*R6G?B?);3&0]B(Q ''Z_KWR#W_3]!QEE+75J_>:M9*5;144[5;@ ,5>
MRA)J5*AF*^?'R!1D7+2A2%JC$!TN3$?PA:%Y:=5A*TJ\LXG&:J*-X+G56M5/
M8E'NEOWKNJLW'0;G5NI#]K7^"75IC0";/#NP[7NK9 6N 7!S0:VB@1D2:L'W
M$8AYK8 >W)P,A/0Y< <?/I]@^?Z9//W>O/I[_GW>GV9\UWZ34+J)TQ[WFQ%]
MVIN'9FY]5FBVS-O;IL(NR7^SL4;7;M0HH-^8$!5L5'"U*N1_@C&&!29;KDF9
M)GS);CK28X^A^XY'P^SY^?N&;?\ DXS!S1F]Q+A6!02E"S%,(L$7+3;Y5P0*
M(5E^/'=6.8A5;(&<NPI(2$LL//)-"<04.J>RB3[?MJ[U2N:\\CV&2PG1Y%<0
M%TF!;AR]CS5$/0O+ >5)U\<<KR#G<JPF*5WF995*>5$(BXD!/UR9.M?+Z!W
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MF]1;3V%+Q<J=9ML@I>P[O6I.HIE9"S$[+UH.O9.R1RTB/778>04V#_;\O?\
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M0<D"V"M<%SV0-6,#\K.DCT=_[_X_SCXGO[OG]/A_G;;TF[0;_P!K[N[*:,[
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M$UK84*4$VHCV5.#KZZT4#14(:5:U''"[*9(H6AFKL$0HSQ21KST\9V4(D2+
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M,[X_U,.T']R6P?\ #\SD-Z'[C_+&6SY.,P.X5"P661">#;/NU!:BLNM/Q:I
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MJG91T8N L(0@UEB<*+C)C;L6= ELJ4U(C2&UM.HSE*TYQGC&:P7/!.Z )/\
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MIEE?3+8AAC:620!% )(^L220%557EF9F(5%4%F8A5!) S$LWJE."2S/,BQ1
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M22]:"L"?JC/:[PBK^1KJZQI6UD*U8UA $/FKP;#1@ *(_-YBBX 'L\4*\ *
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M0P*5^A4Z%7^(ARZ]-)T]/7Q[/56J!:.29 FQHF-I9(9?8+,TLUJ<O,B?OXZ
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M" 2YD+,"%X/!(R\FD^K%UJ&F=7TFT]A-RPR56H55 $@M+L% BU,3/$AH<*3
MK!)C5P^QR@<-YE<<8^8(RB#T-#2YKSLA3CBMU4UTL5.O!+>M!HX8D98I(5C5
MD0*5C85UDZ >0.IB2 .3SEHU>BM5=;0JS[?8J]>G6@>*K+46M&\4*QLE>04(
M[#0H01&TKM(5 +L6[Y(JNL :3C."6Y.RA'.<8QE2=[7D'G\8QCSPFJ3Z^A.<
M^7GG"$IQYYSY8Q^/+N^CD)Y:WL&[>GMDR ?;^[9 #\../NS-.DB;_>;'=/\
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M;G5V:WAE+/5-L+KK9C@M2:^I8C\MJ5 1P5D'2J EF22S98=))-ZQ;!=F)'<
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M*:8U BL?;GOY^I96FM(LF9N/3]Q8'XQ QQ]GE\L1F[9#>9U^8!5$A4#CRO\
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M(H5$5%'/"J H')Y/8=NY[GXGOGHL<<4*+'#''%&H/1'&JHBCGD]** H'))/
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..C&.,8XQCC&.,8XQG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g209588g01n05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g01n05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'W"^@$@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   +M9  X
M0DE-!"4      !#625@]H96QR($PF\9D.]J+.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             #8@  !"(
M 0                         !              0B   #8@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #8@    !29VAT
M;&]N9P  !"(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M2>CL*E?3U5V=591D5LPV@^I462XF/'^M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0'_P  1" #0 /X# 1$  A$! Q$!_\0 '@ !  ,  @,! 0
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M Q0;%OMF2^.BU]-+3;<[.'TXV9C.@0&PI=5P#(&%-1W6XD=,V7"$@$#SGW'
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M!N$DCDL;IY'EBRD+I+"L$A$DD=RH[1G6E^-1VJ7+Q@VE[;C4]GQU:%V;I*9
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MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0#V;T9
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MW2SDX[$^]6D@"U_3F(ZYIZ5ZS$RH.ZX]RP&0!M(R"V><>XX&<$<>3XKMM0K
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M2L]/+#^3C[?_ '/&?WT=R>U_A5K_ %F#_=3/^%7G3'\I>GORYI/Z_;U?-5>
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MG&,DG )('/@$DDX^))/Q)/-<,[,T\S.H5VED9U5F=58N2RJ[O(S '(#-)(S
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M<>A582D0_K%Z2JL;2/V$Y9;3/8EONO+F=XR%"+LQ%L8$!]S;V);+$[25*DE
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M2)4J2^MMF/'8:0MUYYU:&VFTJ6M24ISG"E5TSM"[[<SF%H6%%'5%WU;E;XN
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M%];KI0=FU:E[$!UH#9CE4V+V7C4PU&U#\!I/7NEJ\2B'6Z]71=;KM'UIIC6
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M[F>);QO+T(8C@M'=-NM!AZ]Z:DQMLW&G4NF!1PX'N&BV6U5=9R2U"0W*V#3
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M@'W RQP/J)8DYSSXQR*Z)+@R00PE%^\J560@;PIEGE*J0%]#-.2P<N=RJ4*
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MF$B29MS;:"<UKEJL?8[JU1^RKNM7[7)=#S-<D]HO130@</59WP.V^O>X.O\
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MD1*=5&HTN6#(V$_@E2?2NWV\DG   !\#CD\ <D\   :S21.1VH3$H_'E:5R
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%E.*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g209588g01q72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g01q72.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1,.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $O*^2% X0DE-! 0      "L< @   @  ' )0  M*=6QI92!&961E<AP"
M!0 /1FEG=7)E(%!A9V4@,3 W #A"24T$)0      $'=DWZ\SVBSAR0=U9.-V
M+Q\X0DE-!#H      /\    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     X 00!0
M $X (  M "  40!4 $$ (  M "  ,0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!U ZX0        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  (#O_XU  (  CA"24T$)@      #@             _@   .$))30/R
M       *  #_______\  #A"24T$#0      !    %HX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M              %]   &V@    8 9P P #$ <0 W #(    !
M              $             !MH   %]                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   %]     %)G:'1L;VYG   &V@
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !?0    !29VAT;&]N9P  !MH    #=7)L5$585     $
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MY?-!LT:!=TPS?LTYF'0)HS=G,!)*$>3%< %!!.;@U033.MV<%#"_BCF$D@V
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MP++RD'%DN,=Y9&NC(!1,G18A8"V :D:"[6$%V?RR6U -9&,ZP'H6#Z#"B$B
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MD^O*HY=O(\AG8=VV23].>P5S(Z/<2DBPBF@$,[DGK1@U YP(F+AXNFW1 YQ
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MV(Y#%3S/?5V9UW^BTCM_ZXMMWXTO;^T1RQPIQC/</Z!Z,^0?2=6Q5V;G>K6
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MKD2D71H2)K3L^,8;$6)$F.(5)6Q<T)6^$1 E3H=E)$D==8Y;(;,:(B5I&;S
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M*'%.2:(B\;.I@T%%R3Z"!^25)$.9P#Q<?-OXU.*5D?W.V>BL;0;JJ_Z?5<S
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MME8^V+6@:='N.U9WW;.5RP&7=)E,>\5QQ69&M$<E:&.FBU8.EE&LH*2BH+]
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M[O:LQ[#?SYX-):1O%LO=DM5KNI+Q2)S@LDLKK%4[#*W*8 ]/<THD5$(H03F
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MAMMIZ^[7;<1]:E- '377T:CXZCR'PY;\]]0T#"E<^1DY&7<E>2CUP_=$:1K
MKARJ954K&(CFL1&-0.<PB"#",8M&+9/7HI-FR*10Z) #'<_(?DN!V0ZMYP-,
M,A;BBI0:C,MQH[8)WX&8[33+:>2&VTI&  *IXL2-":+$1AJ.RI^5)+;2 A!?
MFR7IDMXI&W62)3[TAU7-;KJUG=1JW\O4.^P!IJ(CON/JTYA^3IJHIRYZ!IST
MVUT[NX!UU#78-] TW#1Z^OK\U*[?^!7@8&:\C9UYT0_1A@[/)T.BR*.\P/[4
MY86BQMCC]2.2L1"N4]941(_D$_)?9T)39;HDZ)/"O!M5:IC?8WO)%GM#Z?\
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M[-RR[,CPHZ64/1X0$=GP=^5X2$F:EPNL-(6&$H><1(9[RP        #0 #8
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L"E,*4PI3"E,*4PI3"E,*4PI3"E,*4PI3"E,*4PI3"E,*4PI3"E,*4PI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g209588g01z01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g01z01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X<3K:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<P,7HP,3PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S Q>C Q+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,C8W.#DT)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" P-2U!=6<M,C R,2 Q,SHS-#HS,28C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" P-2U!=6<M,C R,2 P-#HP-#HS,28C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"U"
M;VQD)B-X03L@(" @(" @(" @07)I86PM0F]L9$U4)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C
M>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,2TP."TP-50Q,SHS-#HT-RLP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C$M,#@M,#54,3,Z
M,S0Z-#<K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R
M96%T941A=&4^,C R,2TP."TP-50Q,SHS-#HT-RLP-3HS,#PO>&UP.D-R96%T
M941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG
M.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^.#0\
M+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF
M;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%<T%!1"\W
M44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"3$%!04%!
M14$F(WA!.T%117-!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)
M44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"
M04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X
M9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9B\X04%%46=!5D%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!
M445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"
M9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I
M4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH
M9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/
M5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF
M,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP
M2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$
M0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z
M2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD
M1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2
M;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.
M:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV
M+V%!07=$05%!0T5135)!1#A!05E53WA6,DMU>%8R2W!P-6(P46$F(WA!.S-Q
M839E3&QB85=25V%&<$(X2EI0:4MK:W)X*T%-9F]P,WA6:VPY*U=S9'9A3F12
M86LX,%AP<DI'<'1G:G-R=W)-<W9(,5=(;T1N=V$F(WA!.U-U>F=I:'A64S!F
M.'1R;E9T171D4G1R*TI:8G%O5S-K4F=!9E=%24A.95)06&LS=R]#3W5+<6-F
M-6$V<3%X0D@Y9'1'9W5%=#5L=4DF(WA!.S)K665N9%-'3D<T;$9B8FI5.'%$
M;TLQ24=+="\X<7<Q;C%O-&AE,E%A9$EN9S5Y4TIY.5I:5U9D-"]H64QB=5=$
M52LO1E=)145%9SDF(WA!.U)S92M+=%EQ-T9867$W1E=C+VLQ+W=!<'9$+WAG
M;2\T:FER=GIL+S5496(O04EW42]W1$5C5EE.:7)S5EI,-54X;6YZ0F(S17=V
M570F(WA!.T)B=4593T%A9W=Y>3%&5U5N*S5P44%N979167%N9#,K5E5.=6=,
M87EI>5-/>7=1>5%R2$I*=U9'6E9J379Q96]1-31P>#-P=5)Y1TLF(WA!.W!7
M=FM69C!L<65M>5AJ4EAD:W1U655A2D-(3GDX8U-R2U5M8C!Y<GI,>30X*R]H
M47%Q<R\U6&$Y1$Q.16)Q>F0T1VA364LX;$9A9&\F(WA!.S%51FI'1D@Y.' S
M3S1R4W9&<4MR+W=$;%9E=4=+3U9,=3!:4S-P>F9V3C%C4WEX:TMO0EHO=T,U
M<4M#<')103!/2W)B1#AU<$Y13W(F(WA!.U%79#A'=G1,=FA9<D,X6$9*43!P
M:CE8;4A:;$%#<S=$9V%!9&9"5EEV-5DV*S!%131U3%1J8U)25$M0565O5UI3
M>6-V9R]Y1W)46F$F(WA!.T5T4F0X5F%S9GDK;75(,3)+4R]J5UA1=W9R3D5P
M94YM2WE-45=K34Q#:E)C3FQB8RM'*TMP;D(K5&UQ=G$W,E5M;U<V,GES-FDT
M44TF(WA!.S<Q5E$V9WA(:E-Q=714>31I=$MK,$)64VQV>30Q;V%B3'%+,T9S
M.$5-0G5*07)31G="8FDU-&M#3V=0<$U.-CAA:T1L6$972UEQ-T8F(WA!.UA9
M<3EC+S551B\R=F8K;E0O<CEJ85AF.'%#+S=8=CA!,#9F.69S8E8S+TMG=BLQ
M-R]W0D]N+U@W1S%D+WEO3"]!3%AV+U1P+S$K>'0F(WA!.UAF.$%+9W8K,3<O
M,#9F.$%8-T<Q9"]Y;TPO=&4O=T14<"\Q*WAT6&8X<4,O-UAV+T%%-F8Y9G-B
M5C,O2V=V.$%T92\Y3VXO6#=',60F(WA!.R]W07%#+S=8=B]4<"]W0F9S8E8S
M+TMG=BLQ-R]!3D]N+U@W1S%D+WEO3"]T92\X051P+S$K>'189CAQ0R]W0S$W
M+S V9CEF<V)6,R\F(WA!.T%#;TPO=&4O.4]N+T%&*WAT6&8X<4,O-UAV.$$P
M-F8Y9G-B5C,O2V=V*S$W+W="3VXO6#=',50S>5HK5E K1W1B5%90,' Y8C12
M=D@F(WA!.S90;V5N.7-5<GDY4BMN>7A6,VY0.'%F.%,V,BMQ9G!4-G!Z:E-0
M,&91.50W07!8;#9I9&9L:7%29CAQ0R]W0S$W+S V9CEF<V)6,R\F(WA!.T%#
M;TPO=&4O.4]N+T%&*WAT6&8X<4,O-UAV.$$P-F8Y9G-B5C,O2V=V*S$W+W="
M3VXO6#=',60O>6],+T%,6'8O5' O,2MX=%5:1"LF(WA!.U1/;W<V9$YP,%AM
M37):,T(U4WAI>E=P3E9*2$PQ95%"36$Q04Y$458V1$<Q468X07EO3"]!3%AV
M+U1P+S$K>'189CA!2V=V*S$W+S F(WA!.S9F.$%8-T<Q9"]Y;TPO=&4O=T14
M<"\Q*WAT6&8X<4,O-UAV+T%%-F8Y9G-B5C,O2V=V.$%T92\Y3VXO6#=',5)L
M;BM43V\R5G1C,C$F(WA!.W0U:CE/1S=8:D]V,4Y34TM&9&E:4U9Q<FQ4>'!5
M1VU.<6<O*U9"9CER,R]P,"\V+UDR<G8K5D)F.7(S+T%+9% K=C).<3<O;%%8
M+V$F(WA!.SDO-F10*W8R3G$Y8W=+-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T8F(WA!.UA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EAN6&UZ5CE4="]-3C-$1&0F(WA!.WI24DPV9D=.2DA6
M4E=*4V%!1VY83&]G530R4U)T2U)R*W-%8E@Y=V9F,5@O04LU27AR;W=%>65Q
M,71E,6XO;'9U9CA!:V,O.6-E14HF(WA!.S1J,W%B83ER9B]6=W5F.$%K9$HO
M6$AH0SA2-S!03C5J,75.1V,V:F156'=M:S=M;C@R4VAJ0DY-6EI#0F%X4$UE
M=75G8V%J9$%(+VDF(WA!.S94+VUR1U5!1%-X>45I,B\X46$Y+W="6$LV+S5(
M>68X,5I'9WDT:C-R1SAX-BM(5F8P:F1N;%@T:$Y*454X9FEW:4%Q,DIM8G)D
M,RLF(WA!.TED9B]!3W)N9"\X04DK5"]!2G%W8TE4>$AV5U-E669-9D$K;G%D
M,$@W17IY9C@Q6DM):F4V2E-L5WA5-"]-6&U50E9L,4\V3&UP<4HF(WA!.W!+
M9G)Y531X3S19=VY,:U,Y<3!H,VLP;7ED,DQU.$5437I'<$I+06MK;DU1.#-/
M2$I&-$5U>%8R2W5X5E13-G1P2%I%;%(S4G5$<7(F(WA!.T%L5TLX=4I!-DAJ
M=CAS2D)10T9406PR2W5X5C)+=7A6,DMU>%8R2W5X5C)+<5)U-U534$=::T5K
M86AP135#<7%X24)95C)"2VMF4F@F(WA!.V]O-&=Q<7ES;UI30W!&45)U0T1G
M4S=&6%EQ-T98:F8U;3,W5W9M5S1#:SA:3TA-:G-216Q">39!+U0P>DMW:U4T
M;5E',D\V8G)%6FLF(WA!.SE+4G=&3DM--6]E4C9D9DA*-4I":$-*5&)N6'@K
M-&I)14IT5%DP0C9N<64S,UEN9$A*5W,Y3W9,-3)3,FDU;%8U4%5H44(W;&E"
M9THF(WA!.W)D248W3VTP;E5)47=K9TME;5-#=3%D='%H46$X9F-B661Z=6=K
M1&%W9W%G,7 R=U5M,7(X<69$4W9V:$9D54AY86,X5DQE04HK-T<F(WA!.TES
M<511471T9$=C=6I,46IO5G(P*V585'AI271Q:&M-:E-)23)Y:'5E-F%*+W=!
M8V%W+S5H;W8K241-8S@S36IY4FU"3'-69&ER>C<F(WA!.WHO-7@K<39L2'!D
M<F1.15E6-5AI=U-M2UIM:T%#24=%56Y20U=/-CET=V%6>6--0E9L>&,R43-1
M641P6&XT,BMQ45%24GAH5&-X.#<F(WA!.VPY+W-U1DQB141O3FIL<VAB44)4
M,R]-1C),<U9D:7)S5F1I<G-69&ER<U9D:7)Z+T%035!Z;&17:W-U:V%E-&AK
M4D)*8S-3:T\V9$<F(WA!.T-'26HW1%98:S-G93E+2$IW-'@Y4F-84&M0,&@U
M=3)P,U8S-FLQ,C!K=&YC>4U94WES<UE92U9:;WA',&-B4TMZ1419,5!B=&U6
M1%HF(WA!.WAP-S<Q*U!X-2]P6E8U43@K5#)&>$)(9E-3>E)44GA2:3$U96]2
M5E8O9F,V8G0K>58R,TY/;V]+8S)-2&-C+W1B.$]88T$X:C%V870F(WA!.R]W
M069R979::$]9-T9867$X1R].,C1T9CA486Q&3V%K3F)H2S%(12MI:#).1'-6
M3%IK4U W<V9J=F-722]E;CAD>D)X9$I"8GE2.%0F(WA!.T=X44MO<E5"<$18
M;#-Q3T90<'I%3GDS8W-!0D51-C-Q3FQ(1$-L>4=127!!6E9)06(U,$EP=&MX
M27-$049L6&Q+2%8Y5',U=%1U<G$F(WA!.TE7:T1!<D=94S1*3E%!94IJ;T-W
M<#%05#EK8C5F:F=:8C-1+U9Z8V9,2TUD<4I0;#-N:U!I;D5(;5<Q=4PT,CEX
M1$IF6%%L940T-5@F(WA!.VAI.5%K+T-#1TMG9D139V%N=FUX231D>#9E435F
M:CE0,W5T<FDR4'%'-3-*+T@S9&9)2G1:,T]O5VQU26Q%5C%P.$(Y2FDS<DE9
M54LF(WA!.W,Q6%E6-FHY<6UZ9F9K8VMD*U934$QL=BMZ.&0V-'!8,75)-2]6
M=&8V9FXY>3=63DMN,4HQ9')D27128TLS3T-R2DE*3G@V;%94:G@F(WA!.W%+
M34LK0C9B63)41TEI=V1H*W1Y8U=5>DY%8FXY6%@X2#5S4G(X4E=H2$AU8VA7
M>F)E-VHQ=TI5*U-I=%%%,S)R458Y.$TU5E9L65$F(WA!.TIU9W9#.&=#<$1!
M*T=116=76GAY2$U08W1&+S0T,6@O>D1X9CA11U5N;35-95--=TID:7)S5F9/
M6&UM.&M4>F1R6'(X6&MI=EHS:4@F(WA!.T)68VID449K0W)7:3=53&50:6-Z
M64A:=TUG,UED86%*<F1X359G:58U0R]$:7-S6$ET4W1/2F5U5&]O-#1V8B]!
M0W@K6C)S3VQU;70F(WA!.U<Y<$5S9RM"3&8Q07EX<CA*-4=2,U=O;U1U,U0W
M.')/;4Y7>D=R04E$,#5M0VEP>D1C-$),<GI8-T\P0DUI4T=N.&]5+W)96E9,
M2T$F(WA!.S5'4%-3;GEP26\O>DDP:S9Y;'!-<E<Y;$MO5F)M5VDX2G%N-V1'
M66-#2V9&,E!88F-9=C4K26Y2,DAE-T$Y:EI00S1H=DED0C-E6&XF(WA!.S5D
M9F9Z3E!.,VUE1'DW<%@Q># Y86%2=E1T-&$P-4]15'5E>6=$9DQD6G%H:&AF
M33E(1C=/,$HQ3U1H0F]$8VQH=FPS.#(W=38Q4T<F(WA!.S$Q5S)H:F=U2$5A
M>E%C;$M&:E)3=UIN<4LY96UA>E0Y<E-L34-91DAU9#-R4%HV34U:;&I*<V1$
M,65K>E1P179*9U-"-%IV0V%E6&HF(WA!.T<P;78O3T]M5U9F5FEN86XX<6]F
M,7--;VYQ67@U,C5U3',W2FLU169J-$EJ>34U:W-.9'-V6'1J>&UJ;W1Z8D4Q
M94YJ-"M+;6YW=#,F(WA!.RMD441G,45C;W-C*W)$5V%+96YL5752-4AV.$%X
M,41X6'HY9DUF3D]Q=&132U=G6F]W6D579VHU,5AI>'%66E)X03=N9GAP;7IX
M9E,F(WA!.S9B3F1N:W@V3U-74F91,T134G!%>G14-TU40VA#:&PK3&I'=E5D
M+TAF3&]G3D5I4EI:3'!C86E61&-W;#1)54%-2DLK<35U,$-!<7,F(WA!.VTU
M+UDT9TDS2#,R>69"62]4,V9J.6I(:F\W+TQV*UA0-&4X=F-D36]M;#)G-4TY
M24EX>F-562]!3C)"2C-0>GI6>4\W=%EX;U5P6&4F(WA!.W,R='%#6D9C,"]L
M02]I4FQ5<V=$:S0Y3DM82VU/,V8U;&%:8C,Y=D<P36DR8F-L=7!756-K2G!W
M6E%R3GE58CAH4W9H-$A%;G(T>&LF(WA!.T\W<3=,2#),:VQ!;7AX9%!0=CA!
M,E!,+T%-,3='4R\X,S--<T0O5UE,:C!'='A&4F=+,CA:3%9!*TE&44-$=C%Z
M3#AB:4Y$:S9F=RLF(WA!.T5M>'5W;S)&,4A/='9):U5H4FAX.5%S2$-.<V=B
M9U)11VQ2.4AY=VEE,7!6;R]Q<G5P:FA!4S)"16Y%35I#1T)7:'%3=7AP,#AC
M:$DF(WA!.S=+07E#,W5.04=M3VLQ<4I:16EJ:F9J23AF-S1X:'<T25!)<S%2
M=CEJ=T9D>G1D3E9#:B]!1W5R,5A&6DI(;#A%5F(K66(S541.650F(WA!.RMP
M67!C>&HQ8G%9=4%H57)X8W%3=C=3<71)*S-A;5AY;D5X,VEE;C0R*S(O:30X
M8U5H23%)9&5D5CEV,E8X17DP*S@K<$MK9#=E=U@F(WA!.S!.-&E',$@W>F=4
M1T%Z8W!#5F)A5%E+<$]X<6%65W0Q*W)C.'9X.%A(<C K:V,O>#A/86)A8F-3
M>%)3:7AV;WI*1$US,V]W+T5%:DTF(WA!.TMC,&1Q9F%8+U=P<V$W.4M"1WAC
M:'A8>C(V.2]U*S)Q8C5Y;S%%;49B:F,X=3<S+T%'6&5Z1'1D.'DR:U=U6&5N
M9E9P3%=12#1!44$F(WA!.TML875%.6QE;T)'>$<T,GI7-6-L5T)V-74R=UEU
M2W!(<C!5<F4V=3575&]"5&]+:6]'+V,U:F-28R]W-#EZ8W-J37I.46A#5%%(
M<TLF(WA!.SE-:5-Y04%5=E=K469A255'=$(P<F=T3E!O;E%'3&%&<')(<6)7
M12]F1W5:035/1DEB;R]#:#)+=7A6-40K8EAK:34O4T-A-7!T=3@F(WA!.S!C
M-4IV4D=G2W=S9T),<W-91&Q*1C5C;5 R5'989DUJ1FLR<'AS,E!Q=T]Y:6QK
M=65-:V],4U)I2DQ9;C1/3$MF9U!,:W%L<3E8<'4F(WA!.S%F2&IM03=U1DEB
M0C9B*UAN;&DW;F$P,5HW9U)W,GI3255I04UC>6M)>6AD9W5Z8DUW-CA1;S96
M>7)0;$%&3G5N=VMN:3905$=534LF(WA!.TA-0C)12UA8;6=79#)#2DAK1F8U
M4V\O5W!Y<5=)1GE-97)L1&Q34E(O;'9P43%L3'5:;75,2TI1>3(P=$<U>E90
M,C9+;S1!52M(=64F(WA!.W4R>'AV>45E3WIU3S=Z9&=E,F-N:&-),FME;S=V
M3'HX*VYV-4QF;4@U675T93!:17,V1SAT6E!6:6I*;TA"1D=7<#)".$LU2'1(
M4VXF(WA!.TQ$,"]51TA9*W5J<#AT>2MM47(S34DP:GEB-74Q6%=R3U16<F,R
M,71:;$1*339O:$M)45%Q:&0R2G!3=F).6&@P5V)*36-9;T(S,F\F(WA!.S=3
M,#)(1DE9>GA3;&4R+U8V-4Y!:W$X5TI!4&AN4FM7.&)'5DI.9BM4=$UV82MR
M3$]T9C57469R53524%12;'IT>F-884]42'E!+T@F(WA!.WA22&QZ>3-9849:
M96AB1&Q.2E)R;35);SAJ1'@X1D9F:%AT.#9K;D)P-#1H434Y5T=S,7,Y4DLU
M8VAY2&0K3W!E82]M>#50=6\W>3@F(WA!.S%Y,VAE97IU,%0Q>$5F:6EN5#16
M4$0T9FAF.$%M<60K,U1-+T10;S9V3D%N9&=556-S5%)E=DXV5&-U86Q/9%AO
M2VEN2&PK=G5V>GHF(WA!.TIG959/2DUC>5=E*U103'0Q<4XQ9%%545=Q4U%4
M5$]5-&QG-41T43!5;C%5<5%'56IP6&EA635-=T$X,'=W4TUH63)E=FM!:6UA
M-3(F(WA!.U-!=3E'=&)O15---'(O2U(O14A+-5EW6$EX-FU5959-9'4O>3$P
M>31V-V52<'!'<S$U3F1237<U3U)49W%L5EAI<#,U1W1F1'A'2E F(WA!.U%2
M;$ED,U8R5U!T<DI'0D9$:39E6&8X07-E52]M=6MU:&5D<G4Y=#)%8V,X8U,R
M,7-O-&]S85<P8UAW.%11531N-&%$=%1-9V=C:'0F(WA!.U1Q=4EY3FYC=D])
M=%-D6FYL:S5/,&=A<'%+5EE53E-A,38U6F%M2TEL,4M!5UA#,FE).5965S1D
M:#%:5W%#<$)(<T]M5F=B-W-Q5E<F(WA!.S%0;$9P-VE+='A:>6]9=VQ2.%-&
M2V-V,2]A1UHK3UA%3BMM>F<U66-*,C8W+VHX8DDW.5 S3C955EIV4FQT:'EA
M-FM!-55A;%4T<E0F(WA!.VM3638Y4#$U;&Y)4U%:8E4T07A215-)*V]3<F)Z
M+TA*35EB-C%J,4LR3V\K:F145&]S,6Q-4%919U-/>6M#:F9T3W8W64Y0=G=!
M040F(WA!.VA/-#(K5F4W.&0O9$LU4U!(1S1Y,THU6&1N>G)U+U9T=6-A9$YA
M5$Q04'!L-F)C>G)#<T5!4W-D86=Y4G-E2F)H5E1X4%AX>3)-<4$F(WA!.TXO
M:F9U84IX<VU01#EP.'9W96YD<W@O5E8P0S8Q*U-D-W1F,'-Z;FMO3DDK6EAJ
M.%1&934V04@K;6,X8W-P16UT<F5I>#1X14%D>4HF(WA!.U@V>D=12E4T<U=+
M9U9",T9+:EDK*T9V0E169&-V-U@P<F1M84Y99T$V+T-3451Y,G)88C)X=$A#
M0V]85C%.8VA&:UER1D9665$Q3FPF(WA!.T\O8D5L:T$K:%!,-#0V1'!O<E=L
M<D%++S@X,7I)2$IW<&-Y:CA,1C)+;UA65S%*9$QV1S!T63,Q2EE*1%EP3E5X
M1V-)9E-%;$=1.&4F(WA!.V1++T5.=2M+<T(P>GIN*V-I2F)P<3,U94-74G!A
M6%4Y;G%L:W%R0UA/-E)3>45S-DHK>5I!1T\O2F$P0W%1-E U-#%U2'I#3%<V
M.&\F(WA!.S9(2%I7=G!F<%<X9S%(4S1*<D(W9&PK=EA%<U%M;EEX=VQG-$AW
M<T)4;'5D<&-263A!-VLW<U!/6#5V6%=K3$QB*U8Y3C%+8W%'+U,F(WA!.TYN
M<6-0,59M335J94I):7IS6&=485-S;UAK1S1K,$%-5U1)+THR=65E=%%L;&HX
M>F57;#!246I34E1P95%82VMM6C%32&I'5V%Q=V@F(WA!.T=,-T%K;EE9<7EJ
M1E5Q.#!E63=,>35O9'AR1C='.'1V8D=.6%-)>$MX37-I>$PX57IW>$M/5&EP
M9'=!3599=$HK978U87A78C-K=6\F(WA!.WEX44IU5$IA6%-%<7)X23=H5VI$
M55)R:%%D<3EA03!X5F,O-3,O;#4V=6]W5SDY2F183VU1,T4X<T5C36E&+W%I
M3DI/:4Y+26LU27$F(WA!.S$K2FQ"<4M(<E)653!B.#9V>38Q6F1+5TA5;6AV
M3EEE3T<P<UIO2FQN13!V,EDU045:5BM+<3@K6$%K2&EX<&ER3TU69&ER>79Z
M3BLF(WA!.UE(;64S,6Y52#!F6"],5G!P1G0V<TU51W5#.'0W;')I,T%J;$5D
M4%0Y94U49D1Z:35#=G<W=&ER1V(R.'58:$XQ63,S:T='.&DO9E(F(WA!.WE1
M,SEX-E12=U!,250Y5FA53CA58UE$2T=0>%)S9"M616YX>3<R4$)(=51F5R]Z
M43AX-EEL:DAB878U8CE79$-)2319=%-V3&5::$TF(WA!.V94:6=A,&AK3$TQ
M<DY!9FA9:TU';VI+87)&:WEZ.'-03S)R*UIR9E5H<38R>5A6<DQ',7%B3T\T
M4T=A>FQJ2' S36)81S=X>512>6@F(WA!.T=!1E951VQ#0U%R3CA69&ER-3(O
M3V-A8D@U>3%+4U=7-5-A5#9T1SEV.$M2=5!25FQK4C(U5E%%55E#;GAD.3AX
M6GE015$S=T<Q=DTF(WA!.V)K>$)M:VIL54(O:4U816]D>65L3V%$86@V+V91
M-4E34$IS<$AX86IA,BML<UEI5&-Y=%)/5S56;%5(8V1#=2]W.2MV6&9).'EW
M25@F(WA!.V958D@Y1')D.#%3854P46\U;V]1:F0Q-&YD=EDO<4Y$2$Q)4S)9
M>6=*1&1"24QO,UE61V]1<%=.43-";4HS6F1Y03,S-6UW,4%036PF(WA!.W<U
M-$0P07$P5&)8-G@S5$AJ-FHQ5EEL<E4Q3D]32W1$='5E,UAF3$1Q9TYX>2LQ
M<B]+.%<P=68R26)Z3RMP=U=55%)24U<Y=4I*2&LF(WA!.TDK1E1*2G-Y9&9S
M,#9,-&94;4Q,3THW1&PK3V)L-#A00V)/-2MZ-$1O:V-%-TTX56LT*T5N:U0Q
M<4\Y2SEC<F-N;WI44S=B>E%S<78F(WA!.W Q=3!&9U-&159W=TEP6#=42W@U
M9E!I0C=:1U5G>FA#45IP2&%1:&]:2FQ8,5%O.5)L0D$U53-!<G942S=B85@V
M9S%H3SE)14-R,&(F(WA!.V=O569R>$I50C=T;TEP;V5N1'=T65)V+T%-67AM
M6$AK-BMF36\W0WAD:7)S5F1I<D0O.$%L56YK5G)U.'9*<D=35S<Q1#9Y=#=0
M.$$F(WA!.U=*-'I.1F1Y4U-347E,0SAA4$=05DMQ<DMD9T\T<FER271&,&%Z
M,&5Y3FQ:9VE!>C-&=W%K2T%P=5IN;EI60T)11E9P3TMI;E-N53<F(WA!.S1Q
M:G-69&ER<U95<E,P=&)/,FIT8E-'3S-T;U8T>%%22T521DA:5E5!069,1E98
M1E5.9#98<&PU4&)81C-A43-%.6LU;',U6EDP9#0F(WA!.UA);UAI6F=3:E4W
M<FEQ2GA6,DMS93%8.'9026UQ>#-386@U9C K8S-V<6976FIB4DQ->E15.5(O
M5U96:T1S441Z1&-Q9T=T4FEQ:$@F(WA!.RM6,S5D>#9P3G%A*UAR13-C.%)G
M8W1#<G@K;2],;49H87-38R]58FU6549Q;FQ7=4MO=B]!04HU3#E&;T<P3WAE
M,5E+4'%R,CAB44PF(WA!.WA89T]%3$%X<#A/>#1Q2SDX5E)M;2M89$,P=35U
M3&Y48D='>6QU;%9B:C9U9VI6*T1Y4T%L1F]N271--4Q5<6$W,6]-5E1(1EA9
M<2LF(WA!.UDO>G1G,&EF.'=T5F%786%'-VA3,T))5D-R07=2,%915U@K87!:
M:CE(:FIZ<U,R1&M9>G-W1S,Q3#9V2DA(3$%S:T53;$AI*T5Y13 F(WA!.TI0
M>$UV.#=%+UHY:EA#1V)C;71W<F)T16QQ;DHR53!K5TYG5E%M;$-+1F$Q1E%0
M=DYC3G!P44]Q>79$=TQL1E5K:4I65VDX=&E&-S F(WA!.V]A9&-I66IM:F=6
M8DLX3FYD=&5015=A5D-R3T%".6\Q6G%6-#%09F)%>%EM0VI-.3@Y-TAC2DEV
M0TYJ-E5A<4EL04HV1E9.1#<Q-CDF(WA!.SAE2%IE0DXU2F].5'-285AL<45N
M:6QL:VUO<#5G.%!T04HV9$9Q=$="<E19*T]68FIK53A+375F3&UO,E=N,F]I
M<W59:6M784EN,"\F(WA!.S-K:C U:W%8:UE"3TMP.$E!3W@S<4U!;4-B=$E/
M-T\U3%IR94=+4D-(:6Q9:$@R;V%5,V]D*W9I0FM)>G1Y4DLQ.&0Q8TEP0T5%
M054F(WA!.V]653!"<6%B9VUL5&QL<5EH1D,W;FHT3SAV1V]&5D%7;C-!57=C
M4EAG1#)V4GI84TQ%*TYV168K14=:<V54<EHO5558:%EU>%8R2W4F(WA!.WA6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C5&*UE(
M+T%%3#<O:74W+W=!668X9"MK6#%Q=C93<%0P;#DF(WA!.T]N;V9U=C=V:CEN
M.61C9V5&=&IX5G-K4R]W1%%Q=$YQ93,O2%AR.4AF0C976')8:B]O5G5V=SAQ
M+W=#5"MM2R]H:C95971T+RMH5W$F(WA!.VEV6'14.4PO04U-9E-N,7%Q9CA!
M47-F1#1A.% K,W94.&-/>5!7='10*VA99E98-G1Y.51M3U!(.4PQ-6-T<694
M9U!$4RMT1DHO,$PF(WA!.UHV4G!4:'=(3&PK;$LX2T1J,3-P,' Y1T0P<C8P
M,50O04I5<CE::C0O6%!5-$PO,65/2$-R8V95<CA&2SAV="LK5FYW<395:C%-
M9VXF(WA!.R]W0U9B+U8R.5=V,6%H-68W,6-/4$QV5&%N3' K1U%J-%!4.4Q)
M94HP+U%G52\U5D9Y2$=L86)F-S)5<&QV-W1S+V4O:6QZ+T%02W F(WA!.W51
M-55R,B\S<W@O9'(K*R]&339S=G$S,4]$-G(O=DXV865H,2]U*TDT.60K;FIL
M=S5/3$LW,U9S2TA9<2]W1"\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E
M240^>&UP+FEI9#HW0T0P-S!!0T,S1C5%0C$Q0D4U-#A&035#-C-%03(R,SPO
M>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^
M>&UP+F1I9#HW0T0P-S!!0T,S1C5%0C$Q0D4U-#A&035#-C-%03(R,SPO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD
M:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @
M(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^=75I9#HR9C5C
M9C)D9BTP93$Y+30R8F(M.61E-RUB-&9E9&1F-3,V,C@\+W-T4F5F.FEN<W1A
M;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z
M-T%$,#<P04-#,T8U14(Q,4)%-30X1D$U0S8S14$R,C,\+W-T4F5F.F1O8W5M
M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET
M:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW.40P-S!!
M0T,S1C5%0C$Q0D4U-#A&035#-C-%03(R,SPO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP."TP-50Q,SHS
M-#HR,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-T-$,#<P04-#,T8U14(Q,4)%-30X
M1D$U0S8S14$R,C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C$M,#@M,#54,3,Z,S0Z-#<K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A
M=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @
M(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z
M2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V
M97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E
M;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @
M(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @
M(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=$1I;3IW/C(Q,"XP,#$V-3(\+W-T1&EM.G<^
M"B @(" @(" @(" @(#QS=$1I;3IH/C(Y-BXY.3DY-3D\+W-T1&EM.F@^"B @
M(" @(" @(" @(#QS=$1I;3IU;FET/DUI;&QI;65T97)S/"]S=$1I;3IU;FET
M/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM
M<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86PM0F]L9$U4/"]S=$9N
M=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI
M;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z
M9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R
M:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M
M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE
M/F%R:6%L8F0N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D%R:6%L350M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L($U4/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^
M0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# S/"]S=$9N=#IV
M97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S
M:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86)?7RY01D([(&%R:6%B7U\N4$9-
M/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E=H:71E/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0FQA8VL\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@4F5D
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@665L;&]W/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#35E+($=R965N/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D--64L@0WEA;CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!";'5E
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@36%G96YT83PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ
M,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STQ-2!-/3$P,"!9/3DP($L],3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$T+CDY.3DY.#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P
M,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3DP(%D].#4@2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^.#4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TX,"!9/3DU($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XX,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T]-3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],S4@63TX-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,S4N,# P,# T/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXX-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M-2!-/3 @63TY,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C4N,# P,# Q/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STR,"!-/3 @
M63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ
M.2XY.3DY.3@\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3 @63TQ
M,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3 @63TQ,# @
M2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX-2!-/3$P(%D],3 P($L]
M,3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C$P+C P,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C$P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].3 @33TS,"!9/3DU($L]
M,S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/CDP+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C,P+C P,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,S N,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3 @63TW-2!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXW-2XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,].# @33TQ,"!9/30U($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.# N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3 N,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXT-2XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,]-S @33TQ-2!9/3 @2STP/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ
M-"XY.3DY.3@\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3@U($T]-3 @63TP($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STQ,# @33TY-2!9/34@2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.34N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXU+C P,# P,3PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STQ,# @33TQ,# @63TR-2!+/3(U/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,C4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STW-2!-/3$P,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STU,"!-/3$P,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STS-2!-/3$P,"!9/3,U($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C,U+C P,# P-#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C,U+C P,# P-#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],3 @33TQ,# @63TU,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C$P+C P,# P,CPO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C4P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T].34@63TR,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.34N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXQ.2XY.3DY.3@\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,C4@33TR-2!9/30P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,C4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,C4N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXS
M.2XY.3DY.38\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @
M33TT-2!9/34P($L]-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,SDN.3DY.3DV/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^-#4N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXU,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXU+C P,# P,3PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @33TU
M,"!9/38P($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-C N,# P
M,# T/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU-2!-/38P
M(%D]-C4@2STT,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M-34N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^-C N,# P,# T/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV-2XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXS.2XY.3DY.38\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(U($T]-# @
M63TV-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C(U
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C,Y+CDY.3DY-CPO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-C4N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,P($T]-3 @63TW
M-2!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS,"XP
M,# P,#(\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C<U+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],S4@33TV,"!9/3@P
M($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,U+C P
M,# P-#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C8P+C P,# P-#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.# N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-/38U(%D].3 @
M2STS-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,SDN.3DY
M.3DV/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-C4N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXS-2XP,# P,#0\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-S @63TQ,# @
M2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,SDN.3DY
M.3DV/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-S N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^-3 N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3<P(%D].# @
M2STW,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^-S N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXW,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO<F%N=',^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!.86UE/D=R87ES/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+
M/3$P,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STY,#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXX.2XY
M.3DT,#4\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3@P/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C<Y+CDY.#<Y-3PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-S \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-CDN.3DY-S R/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T],"!9/3 @2STV,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXU.2XY.3DQ,#0\+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3 @33TP(%D],"!+/34P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C4P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L]-# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,SDN.3DY-# Q/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STS
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR
M.2XY.3@X,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3(P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$Y+CDY.3<P
M,3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^.2XY.3DQ,#,\+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3 @33TP(%D],"!+/34\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^-"XY.3@X,#,\+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#
M;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D)R:6=H=',\+WAM<$<Z9W)O
M=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,3PO
M>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R
M86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],"!-/3$P,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T]-S4@63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C<U+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STP($T],3 @63TY-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# R/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY
M-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@
M33TQ,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C@U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,CPO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,# @
M33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STV,"!-/3DP
M(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C8P
M+C P,# P-#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,#,P.3D\
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,S Y.3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@
M;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ P@)=
M P$1  (1 0,1 ?_$ !\  0 !! ,! 0$            '!08("0,$"@(!"__$
M %@0  $$ @$# 00'! 0%$08%!00! @,%!@< "!$2$Q05(3$)&2)!6)?7%C)1
M<2-A@;$8)$*1\!<E)C,W4E9R=7:6H;*VP=7A-D-&=[71.$55@O%FA97"Q?_$
M !T! 0 !!0$! 0             % 0(#! 8'" G_Q !,$0 " 0,"! ,%!04#
M"08' 0$! @, !!$%(1(3,4$&46$4(G&AX14R@9&Q!R/!T?!"4Y,()#-#4G*#
MTO$6)6)CHK(T-41S@I+"5+3_V@ , P$  A$#$0 _ (GYL5KTXI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*5[_-%?[B.G/\ Y5Z]_P"Z-1S W4_$_K6=>@^
M_2M,OT\G^YGT^_\ /K,?^[]9R^/O^'\:LD[?C_"O,[S)6.G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*V)]
M.&C:;JEZ<LKUOAV,T\.^-=;NUG>AY*)71?M!?ZEVG8#:ZO@#Y8&LG.J, R<B
MKRPTHI_C5UAI"I(P9'K':3@Y/0@_F-_GO50,[#KGY'8Y^&WYFLD<\R/1>#X'
MU9;1U;H'1.4T^N>HO5VD]?0YW@8F2U#\5J<.R*HOKV/V4NJ+G.S&\QB3))[/
MVQLQ'O%%D:KFQK'3?W02=\YQL?/Y=*NVP^PVP!^F?KYU4LNTMI/6E7N'JAI=
M/X=;GU?2QTJ;HQK0^30VE[KK",XZC+\O'<L,,QXBQ;8VM%A\5.^VJZ*Y,GK1
M9,F&82/&,/7H$R3MOU8$[=A\/ZQ5",;X[ X^./E\>_8BM:?4+DXF=3Z]SD;I
M[K-"29)AJ/-EQ,"VI=>;,,K[8\&7-\(QRP A H U2-E/9@T%I;U+K*NE(8\0
MJ8B!;@,9WS\>VP_Z_C5#\,?GO^=;-K+7NF<RTK?X+K#5NE?VWQ?IKBR')]0;
M+P;-M0]6&)YK38B!D-[M&DV1;5U@%M !R.GRX'%F/I**[QDT,,?V.-GH$VC.
M<Y."< Y!!W\NWEGSJIP1L #UQ@YZ9V.3MUZX_.K"V;T?=+AN8V'[.YCLC7V!
MZQZ/M9;[S22+"JB]O,A7(),18V2M',S^:-V3Y6-DA1E@(38A4..WBA5=:290
MQ*5#7)\AU(Z_'T[8]<_&A SUV !Z>>/7U_/;IO4$UO1;B=_D>K@J38.0^X=G
M]-^V.H( VPQNOBLZZ#7\N?.IZ H2"WF&<ZW%Q )UB6PE?8"+&>,>,I@\;YJY
M._Q _/'\ZIC]"?RS_*J#F/33H[6&.8A7["VSL8;:MWK#6>Z;6DQO5PM]A<>'
M[!-JR)<6J\B9E4!Z9C4XO9+:MM;NMJ<)+MXHZ"2[#>3&<UDGH-LD=?+\.F=O
M/TI@#OY'IY_QQ^'K4K]8/2=J'#\HZPLAU+89!CM#TX7V@L7AP@^KBF FL]GP
M70=G&#?3Y%;VQM=6B45;9Q6MI'%96EO;VPY(0T 8I9M 3MG&X/XXQCY&A WQ
MV./U]?2NOLGH6U;J0;?9V9;9S::#5&V\3TWB8=#A%*2?F>59QJ_]N*!;)Y^4
MUXF.U\%HY1;4M)+%T-2(1,./,=-# T&)Q@=<]_(X\JJ5 SD],=O,9\ZMGJEZ
M'<8Z>L)R*SK]K-OLUUWDV+8MFN.77["UL.2R9)6S3&7NM@J7/,@S"6JQ>YAC
MIK@/,L7QRQE@.%N1VL%;) H-GMMOOO\ /;'S-",9WW'4;?+?)_+^-:Y^75;3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7O\T5_N(Z<_\ E7KW_NC4<P-U/Q/Z
MUG7H/@/TK3+]/)_N9]/O_/K,?^[]9R^/O^'\:LD[?C_"O,[S)6.G%*<4IQ2G
M%*<4IQ2M^)?2OT[Q]3&4R,R#3;HQ^E8G)(.G9F(Y2EX#D#.G0*Y;ER2NQ5N!
MM,][J[,FDQ9&XY)"$E6-+'U(&V DJ,YW(WV_VOCGTZ5>0 QQC8';?_9^&/7K
M5FZHUYIG/-0ZWU=A&KM*%;7R#1-E9Y+J#=^#YMK;?>PLO)IK^[@VCIG?)%=:
MU5E1V HD=SAF/!##4D]74EAV!D,)3R*L<@Y).,]1TQY$?QW_ #H,$8QOCIOG
M.,Y!]?+\NN]WX9A_3-A^K>EVPW)CO2+2:JS'IP=E&VYLLKK:#J:R.[*?F0(M
MSK)^-Q>W%E3&@T8PQDKDD]H&N&MD2:,;M3))..+.2!_L_CG;^A08P,XQ@_[W
M4@8_K&V]0WB6,Z_U-5=(V XWI_IHS>;?NJ(-NY_L?J8?+"/?G7&3756_5V(Y
M<^6</ ;6BK*T6I'GHZHJQ(OK$$PF&61LPY]22<[ML< #^(\OB=Z  8Z'(W)Z
M? 'L?PR#WK O/(I^F_J:V!7$ZSUT?)@V9995-UEF3BMHX#60&M-'%IIC3HL=
M.RB''ACX4J[<R $N4P$4\F%TS7M?=U W.X&XV-6G8GT)]?X?PK8CU ZPU[L[
MJ"LM&56I,0UA@>#:FP/<UGD>B]4XV%G)9M[KS&; ^GR/+<HS3$\(Q?"I;C+B
M"5N,IL@*T&<&H"?*481#)RP' !R23M@GUQL,$U<WWB.@VZ >7X=SW-0UG70K
MJ75+NH.^V!N/,EPK3<NCGT,F)X9C%]D.61;TP^RR*E#F]+-OV8%GHC818;"U
MJK^YJ+*I'.LJE\TLX ;[LG; ZY[XZ''E_"J8 SOTQV\QGSQ\ZX,LZ#M?T(^X
M\,KMK9?9;JT3J_7.;YG1$X+5 :^M[O99&$+74V,9:F5$V;@:.#,Q(+ ^UH W
M64_@771L&B+AA!B<;;'/??;/;;KCS-.'KON/3;KCK^/E\,U*R?1X:=U_N'56
M*YCM&SRL<7?^M=1;/Q"5F"UAV9?MD]1VVF "8[L\[,@L2&RF,7%,KER2MQS*
M:BGM5R:H%+)&BJYJ<1() QL3W_ECITZTX1G&<[@'IW_$]/AUJAB= FILYL\\
MRT?:5QKW"<BWMLK5FKUMZS7E768M^Q'H>];O8#LCVC5%IB@F1'ICE4-AR9+D
M2THD&0V8@LA7NR.O$<#;)P#W[Y\@?+TH5WZ]R/3;\=M_QQOZ5VNFGI(TUB^9
MZ:&VW?&YIL3:FD]U;6J=>LPJFR#5<>.T^([)I\?999;/D3#GY) =C<^8UY@F
M.%U@I%6)6.<PDD2S<)STZ9 SGU';'3?SWH /Q()QC;OWSZ>58Q_1^7&.$]1>
MOM79=J[5FR<9VSF^*8Y=NV+B,>3V5$!#)9I,[$B9BX(:8FQ0]$L99!C6E>PU
M_>-GLWVS#8G)& >A_6J+U'0Y(ZC-2!GNHJ;>E?3;3&J<%U2PCJ]H>C^##=58
M&/CF/)364%OD4>?G1K<DNL,KC0QM61'Z8PYH0(">I H_BYGAR-S@%LD_*G4^
M62!L-AFI Q;Z//5]CE=;A>2;ES6LN\PZEM]=-F#K4:_IK0!]KJ(AD==EN3$E
MY?62@5=C'XML*RM&LC$)+'8).P> DEHL0,XVP#U\\^G\JKP[XSW(Z>6/6K.K
M^A?7&4"ZRS?$=P96[4E_K[J+V#G][D&OZX3,:.IZ8S*L/,Y\9Q:MRZQ"N'92
M^ZK'8P 7?"D@02RD6LLLD#PT<748W! \QOT[53 SUVWSV.VY\_PKDQ[H=U/D
MZ ;% W!FH>@[WIOVEU"5-U8Z_J&[,"9IO/*3",WPNSQ0?+I:(@]TUC/-0W >
M1QUMF0HT#VC#1SFN<6-L#.0.OGN.U5P// QGUZX\_/IO5M]!^&ZGRGJ'VX+8
MUV-93K[%]*[QRW$#MT8NRTI@68N%&;BV6YOC%*^X>CJT5D5C>UU#-9%11*>'
M53ERK"^0V<#MD@''\#1<9/? )&?XBLS6Z.U7M++NC[)<*QOISO(\NR#J#PW8
M>=ZGUY>1:0L;?&=:6>7XABEMJO+KJ@OY\LK*L4ZW6XD&H!/,FM+8^W6OAB9;
MG 8>]M@C)WZ[X.^WY_.AZ [=3OC;\B.O7MTQCIMB+CO1-K2\PG#99=L9@-M#
M872SF/4GC>/QX+4S8:%%@RY5-8X[=Y([*X;7RNQ\:G@JR <?E]@EB(*.6=L@
MH<EV3OTQD#\\=OQ\ZH /,YP3T\L]\^GE4FZ_Z5M*Z]QS<5/EEY9YYN2#Z/\
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M$MJ\4%!D@;DV,^QJ/[-ZJS+,5ZOGX>E'X^:U5N'.V<U1EXL;XQ6LCZ@TW\5
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M'^/_ "-Q]F6?]T?\23_FJGVWJ/\ ?+_@Q?\ +7&[KTZG$7M^W%;_ -#L2_\
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MVSVN_P"AF'?^2<?9EG_=M_B/_.J?;FH_WJ?X4?I_X<_UWKX_P_NJ7_A[7?\
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M#DF2M1\8L3B'QJ](_41JHB,1ZH[Q[N<WN[LO9.Z]E7MS<L;0WMS' &*!C[Q
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M>>_J?ZSWKYXJU^WX_P *<5C\_P"MO^N*ZRIV7OW^7WIV_O[=_P#K3E<MT#,
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M<G\=A^GR],[[7L-]@/3IN?U[]<C&,]MYJZ8__P 1.D/_ )HX3_\ 7P>8[O\
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MS$"I#D-MC89!&14)KVJG2;);E(GF:2?D1XCDDB$BJKLDQBDB= $(9B) Z@Y
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MSML7>1V.,222AEU(TERN*UUG/!&6%B(LUK+C:'T<QQHT%A564 'A!!9C#3W
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M&K;BM&H[$"<QY!A=Q73^@QBS-]"!"?5\G.5&JJK-Z:(B-5415[_>N^!A0O8
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M.P=?MRJLJ1KZ;4[N5KG*BH]$[^+417*OP\5[*G-6;Q!I\:,(IT=R" 0"0O\
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M+KW<QDFD:1AQL3AP201G;<[G;&#@$ Y-;.D6H@4 QO&G "%<KD.2I(VRN?,
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MT;\?_>:]NT/[B?[@_P#<:]!'T:.P]VYYI6>/:%7.1BN/%P4^MLXM")6W635
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MES.P!)(#2RN0"2<'K7:*JH"T5'OE;W_WBM_S_::OW\S/"C]<CX'^8-8H;N6
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M1V+$Y-?'_B3Q'K/BW6K_ ,0:_>RZAJFHS&:XN)3L  %B@A0>[!;6\86&W@C
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M4U-;!5QP,E8'AL#87D++#J.JP7#(RSZ?>:D\>IV<L_#*!-:M*TT=R@7,4@&
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M5]9SWS^(-$2#2]'N;B[TZZNK>*\N66WM"QFTJ2(2W*RM%<R01\N-+DLKQJO
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ME.*4XI7CS^F:,ZJ,%ZNLZR/#LWL[+4.6P8>'389!;B)!4Y %J[%0;8&&@$M
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MA8F]SI>M:A-)?PPVLB:5-9S6#0"1HY7N9(YHY-2T^YCEE>.-HY@\:.L,T5Q
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M]4UKPRRT='ZQ)X;\/V,5MKBV%YK,>F*1</''/=ZA&((X+J9K>V1IHH[N4 7
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MCM[F*W5;I; 6MDK0W$[$O(QO(YY%*!5$/*1@QCXJ[32)(7TZ*(JKE'DXU?)
M<RR,I7!&,(PZGJ3ZXU&P9!D%;:@7.696'2Y57*#*,4:F2V]A4I6-&;4PESB8
M];ACD!#BAM4=Y$4PS61QG^D2V:)M!! L#VW*7DRM*TL?O%9&E<O(Q]XG+L2Q
M ;&/NJ,8J2 1V4@9*CA&1D# QL//;IOVVW(J3=+BZ]O[W)J?,<Q7U2:D%N*9
M)!E]?B^,CY"=>4M;.^X;E.)6)=I4@#6Q=R= (1C;V@TAKHSH1IV$AYXHT"A
M2JHJJF<\*@8 7.#LH(P,YQCIFJ2\Q #& <'#J%))7ASL>)0"=@-CO@XJ0VZX
MU:5[!5V&W<*?DBUUE86[ HL:CIX3 3A0VU-5F3\XJ:\J_M6'QSU$5A[MHC8A
MBR"KX2O!0PG*(D.W-'%W&,@;],[9.XP.OG6%IY1D\A^ 8.<@D C.Z 9'#G!.
M>I.V.E/%U1J?]M+G'BMWXO[IK_<S!\DKL="(%M;&PQK(<F*93E39K4E/J:9E
M,%0DGFQ1&IEN0 4T@ \3O>7!A]X@.N.'.>$MDXSV.P[8.^35.?)P@B!N(DC!
MD&  <;C!*YSL,[8P?2^Q]+:?:(78G;^PYI$5%1J,!66^,@E2F7U@77G#OL+#
M)SB2J(4,>21@DU21D2QD#ORO#L1#D'G+M$"G 8HRYS@X)R>XXONE3[RMUSG.
M>E8S,V-H) 1D8]UCT!SD!0=SC&_0X)Z51+/1^E);X=V'[ZQ2JQA^9932MJ;H
MC&#\M+KL7ANGCY&TEMQCF)U@F534\;\+K9#$ "DMV-L,EB?)1"V63V2(@LLQ
M!)*Y+X8A6/"3@@X(QE<!3W!K4<SM@&!N+"MQ#(7+ ' !.Q7.^Y&5.P&PXL W
M!AVNY,PPRN<+/C-GE!$$A-Y2V.2T\-15V4XPUP$*+DDH>0ED!CA%P0% @"S!
MM)J[$FP!(\I.>U73KFX)>,NTL&9+>2)XHGYB\,21@F$M&LB22M*RDKF.&0+S
M(T9;X[1F7WB@$@S(C9SNQ+>\I!XM_<(X>^0=JBZZW%2E'F*-C-28Z2.JCI+6
MQQIK9JZ>$P$X<"R'.L#W7$4?L9E--8@V=8;.%;E&V#WP%R5M7KV^FW*^SF6Y
ME1?:)WN8A<L[R1LTL8E5Q;0HAS-'<QP,K*C0\( "9;#+%-$& 0D  *???90!
MNQ))Z#OD]3O5M;8)QS*;7W?@.=/FGQNH?7VU3@5:X_%Q0@6D%&G5L+"JVQFB
M4MA",G=!823$3BCI82#)&>1N6;2VL2/>V@+3O$T!FE6-FED1%*,#A5DX6,60
M58@DC!R!A4]1G&55B#&<J <??RNV1@@YWJL:6Q.O,N"[[:MKK?-L*HZ/)FTN
M/SV^7!Y3;60\IM33SUV&V$%5=Y,&V_+$?D%CDM99246*U)!1LGL>-)2S8M5N
M)UA6'3X;ZUO+J:WYUTL44D4*.C3.SW(XH8N;$A6/V?A+S-&8XW>8AJ*59N)O
M>1 6495,GH N0>PQCH!L3WK)785CK'!\O+LKC-XJ"NGKJF6&KM*'$Q\A?'7U
ME;<@$76(9Q+K@X[&X)JB"IJ\6Q$A13F"@N:343*_'$CQ)>7<4$,=M[4\-I;0
M/>+=7'*$\2)ITD,%[;I?)&X<7$IDN7YG!(Q,,@_>MK@*O[SB_=F2601A C L
M>8O$AP6)4C"CA4D=-B:Q+W9E>'GT.,1Z]R+ +8US#'DV00A&*)=#J>\FOCJ\
M2K0QHJFRCB4 (L%/>@G>-/93R2E-'22TNWO5EE-^MW#'&5"6TC17/)*CE$M.
M79IH&4!HU"1LO1D4^]61V4X *GH0>'ASMG?&.'&<'(/$.E3EI3)*N:JKK>]M
MKC$8*-)HD'Q#(!+>"W"@HVJD&4C'U%'[:,1.P*%HLY,<C6%.6>5D,@8?(G5[
M24M#$J17@,K%3<QM#(C+,-[699.*"5(Y)0DJG/#&4C,?OYR1R>\0'(4!00FX
M+;C<] 0>A\SWVK+O$ [&:_RJ\K]D$W-H%C64'U>/9 @%O9S6KQ$@I0W8Q[!B
MQ5G/"=? 329,F4O ;C0A Q(D7H/E(@C<Q*([<:<J0S#V>:\MY1;<AV5TEE2Z
M,EPPCXK5Q%"4+\R>%(V5I2),A#LR,"9#'*ID5HR>:$.P5>(>\7=6+;J(U<8X
M@"-<'4!KS:%GL7+9K2RPV(ZV-.LBA+."I$*C;96(!ASXZFUDMAP(ZR"S $J\
M>KK&WAQ\*"S$KHV6?M,LW4Z7>6*:;:E4N@(.5!F-YRYEC3EJ>;&G,D#\+22W
M$L<!;;C$@96;92$AF;+<9;BV)(PQXF&"3GAR01GW0._:/M&:;M]A9*+-K/+A
MJ;/XH+9CJ2VBF!J;()HK!8U%NJY;;W9-9.*E!.I;4:. 8*&8^6\B%,A&%W]1
MU!+41Q7=K)<6KNA:5!')P C*M*&:#*C!594?CX5XR#C)V<$ #<8Z-G?)QD>1
MZ_B0?6I[ZF\#PV!^.6#:R'"LC?B>,OL2:NB6*HN[>NHJNMN*^Q'$+IJC$;4*
MT2>NJT3$J,"\%KTL; JM-)4=NCIEU(IFBMY%O+99I%B4S$O$DDC3+)&S!WN(
MU)X9'69G&.%8O=XFRPABJEPPXU8CC(#  ^YMC&Z@, ,9SU/2LL.C?$:VCU#:
MNB40K([+,#6D$#P5LYD48E-03!5TED"18M=,,.;"6;70GR/J#3"0R(V%L(\[
M;ZX6>4."0HB7W#QI_K'42&)PKJK\L\#,BAE (R6R>JTA8UM'*\/&9L,< /CA
MP!Q8!P!O@YZ[5GV 9* /6A6391NS&.5DXT;5D<OC\WL3U45JJC48Y_=?FYRJ
MJ*[2(&V/,D@_]//?(/QWW,T#MC<9'7)[==M^P.^-LC;H35WOBFLV22SG_91%
M%]EA;#&_X=D;(V9KN[$5%7Q1[?)J?!J(BIR\].$'\CD]>^Q .3T],9.V,97W
MLC).V>N.HR"1Z#IG'QP35VT=YAKP[\3-Y;RNN8^RXS:UL$Y#$;%CV3.0>P#B
MF2*6(J]7&TAE6?SAFAC;-Z=5-:2Q;5NMIRI!.SHW,!4@%O[ SQ+L,YR,@8'W
MBIWK1NVOA+&;41</ XE1^$%F#QA""V2/=:0%5P2B =0,UYK=%'>HK3LK/],9
MTKIAK08*93&@NE:'&6=AK)B(F6$+@G'2U5:XB(Z U*X)M?)&9>RV66P\[* .
M !EV)(]T#@Z 9 (P&Z#&V<0;47!+PV2,&3J)&/"SD,RJ)!@A<-P G@QNQ&]<
MQU7HJ!1'U]W=92UHQK[)MA$2.1 ?'1Y)$#$)"\ (?Q?;KCSE:0IJ0LD,:^P(
M&=*V*XBTC 5))7!#%MB,GA/+P00!A\,>-2!Y$=,:'4G+M)'!$5>(( XD!4RV
MXF9L\1/[IYEV*@\ S@Y!J'H:0' -('I;4@F4;)(*RK$7(HY&O==C-H+2P).;
M75@<C:68CQKPAC@V.KUE.EL2;&(6OS%K,*78MD=54D$@-P[>\ "5'%]WJ<[U
M@":D6"@H#S$?C"J$"F-^*/@P6($BH>+B!4,>H&3D%T_TVL!=WZIEQ!O<YNSL
M"(!:%7WS!$B?FA,9PYAN0#F$2F05#:8N26 VK#0IY@@PA*Q+/-?:BW]MM3'+
MQ-[3!PH/NX,J@Y)R6<*,ELJ/($X-8;[VU=+U!)8<Q^Q7IDD9DXU(M 5*\*J"
MA<R*%]YL $MUSZ0.=[7D=.*4XI3BE.*4XI3BE.*4XI3BE.*4XI4>81JC7NNJ
MBNHL0Q>OJZNFR/.,KHQY?7LGT%UL;)+_ "O+Y<?)M932J,*RN,GN_0J:J82J
MJ:HQN/TX0%"(%6CJ?U_7];]Z[@&L];U5A-;5FO\ "*VT)+B/(L@,4H0[ @Z
MMMA ;,8.!&1*7">QIL1,DCIHRVM)8])D1Z*KD^9JGBZHPH3;=WN]M?//L6\U
M]CFKI;@HT@B"NPG&<AR3*AJBEKGO]BJEL[[*##\A,$B8;?NKL<AM)R!\;I(0
ME4SMC\?Z_K;?'4U(_%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KQM_2T]0>!8
MAU\[7Q.RI*S*;S&G:S(M*?:.$8KF6,1U5QJ?7QKI=;7,-KCN88-:P#RI)/--
M8$5Q5V:9;1%U$M8-)+P&J:7J=WJVJRB[]@@ M)-/ETN\GM[^>2*Q,<R:C%):
M7-K.D;R2-:HD<CXX,CBV3K=-$D=E:/'&91(TW-]Y?W7#+(JR!6X<DX 8!L\(
M! )SC4KLS&-.8=4X%DV1:VE&;>E6>2,GP*LEN<&O&'&CEV&.Q9_:;'RRI'-Q
M.KL*HB<*CK3((22(^UA%(6VP%AM-N+W4+C4[:&\EQ UM:HEW*_VK!9PF&3VZ
M>U2SA:"[U)>>Y:X:9@J1\4*1N\8EUR!&TF%?!+\!(1B3L. KN@ 4J P.YWV!
MK"6W.L#,>@H4PG$0JROL3K4>_H<?6/*KN<A_91[K('GR6KZL85L<456-,/5C
MOB?-&$IA!9R]4ULB7!N.;<,S1*G+YF($X<#*0C XC@LQ))9B<8&%!&X?=#Y!
MZANI)'0=1MT&X) W[5]T&8#8IL^BSIN' C"XGE>.7L>'>VV)^.%08Z57G%TQ
M%C9SW)S8;1XJ*^0HBPA@C*F\5G%B@BA6ZRP)&LT[74J@\<LD*0EP6SP&. <'
MN#$:ML7"\;@,365P&C=!E692H93TR1N"#GH/Y5D:'UP%T5?0CU^NZZKNL>E]
M6C&K,G+H<>!MR-4GZM?>P4-%7@'F3=RQ\A0FSRLZ4649X]$E9(?;6$^X;@@Y
M6(>F-_[/4@#^).<G<5JBPR2>>V&W)8X8C)/WMP"<[CA.1WVJR\KZG\?RVC2O
MRK61;[.'#K+&ASB\A2.CQ\^0##JZ"]U_C:48U)B5=!:8K8W1]/50>O9ORNT%
MFM73#AFH,X9?>3WB" P) !QM[A VV_+<["KUM)8F!68,BL#@IECN3@L&;)(/
M7IMTZUCDZP"CG1CY9UD8U)7PLBDDFCC<]K4(].!K_P#$T5>[ID;XHU%7S18U
M5+!Q'WN( ^1SD#N<8QCIOWZ^M; 8Y]Y1C_:(R2<=!Y>57]468TPC9B@I%<J>
MFDBQ(^170O1',2-5B57-C2.61K$]3O\ %4:G@UN0=!GRK W5@!U8X\^O3U&.
MW7-=XZYQECG,G!2)TO=J/B6:*8B6)LCG.1DG>!RHCU[M9W5C%:DB]U<WE).4
M1AL >H&>IW&YS_ [[$U<I=CE>(XSG&,;CR.WH<YVQ\*HLDU DS3098T+C[+[
M:%ZXYS49$V1&QO@=$U'QN2*29L3F^#/.14^RC'XW52I'%QIE3PDY4E2",C)4
M[@;$$' R*+$''O1C?.25&#^7\NOK5UZYV;BV#7=<3>8^W)<8B?616&-E&NI(
M+,,92)BHV2T30C([=I,J2 WBN,.#EADF?#-*C/9XV\L.?#,MM.UG<2 XN519
MI <J0N921R.)5)MRK0GA7W#PC%K6$)W")D!AC "X;J#@9 SC!V(.".U7WGF7
MZIV]1K#9:_L16@S7ET!!5Y8R*%EM8#@ $'E(9CYS1R?8:+'0)2:YE?(=78Z/
M7VD$\CTM0<$-IJ5O*UQ%>V\KS-&&D>S$<K01JP6 -#,L81));B5 T<A5[AP&
M"@*-:/3[>,*@3_1C&<DGB  !RP9CA=B20?3O6+%MK.C;:3R8T YM7Y>8\I;(
M#;'Q=,Y\(Y$L"LAE?$Q8H7O]D8PF6"8F/T(YF"PRJW-V8^&=4,F<-RP0AV(;
M&2&P3NJ[</3B;&:S"S@;;A7!&!Q*,>?0#KG.#UWJZ*-+C&I)W2./+1K9$CD@
MLK4<D4IPT@D)#)F&11L>C)(X9DDB*6<5%%:L#7H]NK+&)N$2HHX6RI:%)2H)
M)(0L,J>(ALC&6WP<;Y%@ACR$C09&#A0,@?GUWZ8SUK-;ITZB;N?-:7$LGJ:M
MM(DQ]+B+/0(M&!$9(A%7&+*;EUV4D X<%O8O%&$RC'82?6G#CB20Q$DYO4=)
MM;:UU&ZA=A)<0CVN7A$)=8461KAEMK9\R2&"(S2F-I0HRKDQQA<<D#2M&0RK
MRSD  G?.=CD>9P,=<#?-6K3:0;;7V>TL5!G -[@(EB5D<U5K^FNK>XD/R4."
M$JL!+<0-8#P8Y*^Y*'(S\1S0 R+>F:7&.?(]+JT#165WSX'M]1,368]KGL+>
M!+>U9I !Q1.9)KL+%'(]D,32"*<Q]#:L?".$.QX>,-G!;=V9"1@!?<(R 2.F
MYZU?&! ZGPG'[C9N".CV'GH@[:1D>$D-Q?(@ALLG-BL[(O$E%CS0LU QFUS8
M*BN;3!1V[HP\O*B$6S6V634;F9-.N!):)<GFJ9DFN!*++@=^5>Q\R <QFY/.
M+PSNO,>2U3"*V*<A CO(0H<*!Q(JMDD+Q<3*1C)^Z"<$[8&:J&18=<W>L@LQ
MPW76R3ZK*"9ZLBWHL7;;U5DP5 ":DBO?4XY F)5(,-A:XC##7V%]3Y39BV9-
M9,.%(:"1;;2Q+J#V%_=VB74%J;LK-,&G1'RDX;BEYLZ%&@E=GA#11D'F1@*M
M9H75N)B>)!A5=2. E<J ",\6,$'!QVR<;S5T"U.3W<>: YE17005955&05%H
M4!-3PV-:PP^K@D<R2K:,=[MD&=4#7(22&-%4:M*DEK::(6&S794MIHC8-#<.
M\\B3P<Q97@D$:R2?O5=S%$XD@G, *([%I48LS!I[39Q&)% !XRK;DEFQ[I"@
M Y&% .<8&-SD5L#OJJ/'Z-ILY;3);6V+CKIGPK(\08.")#H3B7%,0(N(J>*,
M0?V252!XW'(7%!(&A&E8W[7%RUK(BP20PPO.O,#/^^]^)HT"Y*O'U3B=HW5E
M?!X2\Y%/S6(0[<.&#'#*2V/=7)+8'NG;(QG&!DV%6SV!I'M#_4.!:BL<L*3>
M$+D<]?.:1BJJHQ5:B-;Y-17/\D5R-59AB"I*$+L<+T.V<'&#GRV/7'E6=<DC
M?HP!'J1U&/P\B._I=<\,C"(%%&=#)&WUD]<=97JS][O\?GXJCO%SGM\NWBB*
MJ_9M7<9/4D @YS\.O0[#IZXVJKCOL>A[GSW&_EVSG((&U<?O%192/::R$B58
MU<I,<3&.63NBL8K45)(5\51RL<Y[^S7.5OBO=+T7B..+'?8]3D;G<C.-]O+J
M*LZ$YZXVVSY[# S@=#DC\,U7<,0N4XUQH48B,D:L$4?99'0K]I"99E=ZCGM\
M72(QK)W-9&]OIM;W7B<JNPW&,Y&/7;)/?;&0!L,[U=$I+#( !['KDYWR<_EG
M/7;KB_S**R+>\J$R.0;R19DE[L1O95D:D:,1R/<O^]<SQ<G=>Z-7LFNLR'L3
MYXVQG/7??RV_G6P8L YX3N#Y>@[#&^#D8_G/'3>6L&\])"Q'I-WV9AT$X\+(
MXF,;[Z%?W>U'^4CFO=XN7Q^PWNJIV<CF[NF@'4;,X(_SF(]\?Z1<=<_';IMO
MM4;K1_[FU-3C_P"7W73I_H7/QSD=S^&=Z],//3J\)IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OY\GT[.:
M14?TG?40"*$(6]@>F"+ @JJ$8\>9-%:YD>+"8=[4,:U O=Q+)U05T4I,H2BR
MK%$8L!=2/[7<(\:A0Z"-A(K&1!! Q=D S&PE9T"ODE8Q(#A@%ZW2[8/90R&:
M<!N;^[6:18QB60;(K #IGRXB2=SFM0@^[<K;9#%U@E*&D#  O=J4-$W&K!*A
M6* ^[Q9@+J2^=&K4F(2UJ;*2UF<I9S#)IY9)8EX(Y%F21IWYIFQ(;B=;B$3,
MI=(+I'2Z@3W0H2&:-0H"</" *F^0G"H9B<$,I)WR!L26.6.^Y.YSD] *J=QL
M;WQ"+[%C(N,68P ,)\M3(7/36Q RF>VW2A6D\Y %E8OF!9'7U$[*6)(YF"@P
M^HYB76XNHS()KE;F.269U,D4<,L,;!3% #;K''*D9#8DEC,SY)ED=@":&!0!
MCC]T?>!QDY.&<8._3)R,XJC29!;M9ZY<"D#PQO=*DL$4J1P.22-[F>IW@C1S
M^WDV3T7-3U$A<US/),Y<@_=/0;C(Z^>QZ[YWVZ;UEY0& K>\ ,L&X<@C? .<
M8Z?')]*YX[ =44BM<P21\T<DT?>18"$A[HV"9Y3Y)H_!SI%2.-6P]D<K8U\?
M4=57R2 <=R,YSZ'^L8SMWJC1D8X@S;^HW[G8$'X[?E75D*#GF?'8.*KNSU:U
MXS6$P2I'Y.D1B>"M1CD;V:B,9XM5C?:%?\>489_M8[8&3G'<#IGSQG&-S69&
MRH7@![;G&?+J/P[U51ZZO/5Z V[27RHR#P(:HI[W2QO1SHHTD*:K63(K^Z$B
M.54C?_B[7L=R@3.2'.Y_Z]=]R<]>W3%795>L94CRPRX] -_Q(ZYSO75G&*&5
M'O(*'9#(K&2(YZ>+&>$BR/C]61T;516.3T.Z(Y6^D]KD\69=P/O';ON!^O0]
M_P ]CT<(QE41^(9/$,8SY >>^<Y\NN]=*=S3TBA-)84D7EW>BI-]E.RM5JQ2
M-G7R1565KE[+"J^*2M1S.6DAOO,&(^'3T .?/H!V.YS5H7AW"\(SG ! SV.#
MGT_ZFI#QPNJ%2(<T 9T+XT<]JBQRQ(C?3<USFS3+ZDK(WL>HZPK\G)]KQ56Y
MHVQ[NV,@XP -AD]=R2>O\JPR*N"<X/GD_#ID#\N^^^]7'94V'6,OMSAQI3(8
MV(Q8XR8)'1KV>OM$8BME=+ QC'1PR)- WQE<]4[/1-PK%,>*2)5]T $2#W@.
MA*A1@XSN<YSY[UJ,95)X"S#)Z[# .Q!!)(Z]0-B?,U&EG:RXU-)'Z*EUT<\;
M&Q2(-ZT44LJM=$,K".WJ-=/%.Z1T,KY(&S20OF]">2+4X@DG"H C4C ZD#T.
MV?/)&3YYZ;/+XU#Y]\@D^K?#.W;X;9];HK\TK3I&QPA$L&G[M5[Q5$ECD9%"
MC73LE;*CFH]7012>$42._=ED=W5MW.CXN''X\/IOV\_QS^581%*HZ[(%'7KT
M&1OU].G8G-7I5&XOZ%@<6=5VQ=<12DE8B7&=+':4S[!%/F==5$P\F.O'=&$,
M2>9.-$@=I._VUI+(XI=&^=^*...1K995E O5>'AMIF0) C6TI(N3(78JHCDX
M>7N%# FY>)0QX6;=?=49)R<'!.!MW.V1D[U=UQJBPJ;W%0XO=D=GE-(R[KP*
M_*<2,!HHELK 88%V8UF46^/^NY102QEMK"I)+;8AP0"ES%Q>U1EOK$$L%Y-<
MATAM)(;<3RVEP&N@]K;3<X69M4;_ $LKJ\$,4BIRF)X2'"U9BK*", ]SD8P2
M.XQVVW'48SFI)!S?+,=K)(KE,CDV@"VXJ+)'U5YCF>F8=$#)E$.25FQL;GCM
MB+#'8&7$UFS)T+JW8^^".1+RH%C"JH\Z=I]PRRVYB&F/,LL12>.>R66!EAE@
M?3YP\*"1X2B-;JK1W49G80W2(Z5)7)!QQL I!W/=E9MPP]W&^^ 1@$8K/GIX
M$UEE]QAEIM^LT]EN?G8SCUOANQ=C4Y(-MD-X---:V.,WIAU3DN$Y#:X[2ROK
M;\":QI)X@:>&.UH_;K9^65$%/;WPNY;;23J5MH*O<)>64=M96T%NPN0AGM7M
M9Q>7+NT27=K&\B0MQN)LQ"6VGBKD-#')([!9RZ+"#-+/">(!(R\<R*B*S%D!
M$4H#8"D$@FE[=ZO]<[QJ4UC5V='K:LQ_,\K";K7)Z3:0]U+!"E=4XX[%3\$H
M\H"QJQJ*<'+:NR"K,5KP(0<A=73XQ<4D9U6=E;0I=.U:^OT-SJ*W.CZ=;0ZB
M\MO*5FLWE,+WUO=W-NB\-NMJ.=;SQ&X91(SH2JBD,-Q';1#')<3E^6)'<<NX
M/&ZP,5<C=MD*@!B<;@UDMI330<\8&6ZTS\[),,R*$LYMA3V637E.^XLID-R&
M'+QR;J&*C)J<@=?#,)'U_574(EP^<UH1-CD!*<N=3U%YX[>ZL88=0NKEK5([
MIK>*>YEMG>.*>U<Q,\D+V,,DG+EU(++RK?@'[F-5F;6]%O*Q(R%PC@!BRHR@
MX&!_I6)RI.%))XN'!K-.WL<39@=5BV2RLL*$FOKJLBPIQ FQ1%H#ZHOM$\P#
MB?=SQ)HF2&,%(#A,=)D##*A[*R</"Z3VEZ4TY@UXEU<WEY/<SR\5RT3F5[:'
ME.7M4LR+>01<R/GIS$7BC0NTA;EVN3<JKHRDE$8DNH.<%7R%+E?O; *>AK&S
M,,-J<$8R; 67M]C)Z,ECDFL*Y'CP^K%)/_BD811J.CB\PV%N<\*6>)A+45DS
M!8^FLKN[<11:A-91WQCC)CMXWD1C(LK12 L(_<+1A6C8(_4DX(J8LKT7&<XB
MD5G!B93OPD#KDJ2?CY>51[8^O($.=V:"DWBY\;9WE$2L8B,CB1%;&C(U3N^2
M1C98IEDCA<V)\:JR;4$(JDYP!DD8!/<]=LL"0NY )&3@&MLNSL_$<8QL!N01
MN>W7/7';?O53'M!;@=L8-8T2"-O=J"QOGG;/]KQ8CN\DCVS+Y>4CF]TC<YO9
M$5JK5< ]2<^>V-\G?/?&V_?L-JR(0>J@$#';&V.V1Y>8'Q[R!4L.HH(Y&BCQ
M(0.UKT<])B7,1G?S>SM(OJ/\W,\?L)$UD:-B1$[-M<<1QG;';IGYY\]SG?KG
M.,P.V>A]>OI_#OGMDG-6Q875M+[2YY"#J][F,8LJ]W)\6IV8K%;Y>']&KD7R
M<B=V]N_BE511@DCOT'J>_4;=>@QTQ1P2<9."1L#@?=R<#8#)!Q\<FI;Z4O;_
M /"(THYR$.:[:N$^L]7.6)\;KP#LJ>$?IM\%;V6)SN[%558Y$\UY(:?CVZSZ
M9]I@^/WQMV.PVW';?>HO60?L?4MSCV"[/7KF%\;XSC!WR!^6X]6?/1Z\,IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2OYUOT[36N^E7ZH6N:US72:)1R.1%14_P<=7+V5%3LOQ8U?C][6K\
MT3MS]]_\5+_PO_:M=KI/_P NM_C)_P#]$@_2M1MDYS0#T:Y6IYS_ +JJG^UD
ME^G\O]YX-\/][XM\>W9.VFO;UZ_^NI%O[/\ O#^-549K8Y)F1M2-B,548Q$8
MU%65[E5&M[)W5S6N5>WQ5J*OQ1.9*L<D2( 2 >HR<'XCI54B))1)7(1.CE:[
MN[U9/)>T$RIW7R[KV5C53X_!6M[?).UJ_P!K_>-9_P"R?Q_5:Y"885(B58HU
M56.[]V-7OXQ2.;W[I\?%WVD_@[XI\>7$ '8 ;#MZ"LBDXZ],8]/=%4JM_IB[
MN&;^EBC!\XXI/MQQO_QI/-C'=VL=VCC^TU$7[#/C]EO:T=1_^7R88JV3J#WW
MW[]J^J=$F7PE1)6>F.OC(GFWNY\;7+XN[IW<URHY>W=4547X*O ^\WIPX]-N
MU6$GKDYXAOW^ZW>NXV:5"61)+(D3AU\HT>Y(W=WHB^3._BO=$1%[I\D1/ES'
M(3Q 9..$G';.1OCSK9C^Z?\ =!_'!WK]9'&EE)&D;$C2.14C1C48BM2)6JC.
MWBG9?BGP^"_%.6(!S>G;^ HA)BR22<]2<GJ!^E?3'.2O21'*DGL\C_-%5'^<
M=B2V-WDGVO*-L;&L=W[M:QB-5$:G;,VW%C;9?U-:[_>/]=A78KYIFCOE;-*V
M1?%5D;(]'JKB26.57HJ.^TQK6.^/Q:UK5^"(G-A.@_W$/XX.]6U^91%%-6&.
MECCE<M*7(KI&->Y7Q0$OB>JN155\;T1\;E7NQR(YJHJ(O+7ZCX?SJJ]1\1^M
M6@*YS#C8F.<R+TZR3TFJK8_-\;D>_P $[-\WI\'N[=W)\%54YB?[I_#]165_
MNG\/U%7;4V]M4R-+J[.QK2R5*JB"J\TD,B>K)7T":V:8>6.24 B%[X9PWN</
M+$]T<D;F.5%PSQ1RI%S8TDY<MO-'S$5^"5)H@DJ<0/#(H9@KKAEXC@C)JO\
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HD*T-:_\ DVJ#M[#=;?\  D_D*],W/3J\)IQ2G%*<4IQ2G%*<4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g209588g02b95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g02b95.jpg
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M P # 0$            &" 4'"0$#! (*_\0 4A   00" @  "@4'!P<, 04
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M\G(X+G1,=9J(#BTB69[(MP;\NHJVC;E/8HT8.7_T99H</](5@!H) SH+_O5
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MP5POAQLSP(T]&K--]MFSIENLW=)+)+KZJ,+8B!$S&4IB,S-;+WR?L5>DT*S
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M;D;_ *$8_P"JM_O*W.+_ *CZ?@+LSZ1Z_DK.<RM)PB<(M$=A+:,U'$(VZBH
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M0-Y7]T. VNT<4,86."G:;X)Z;,&TH>09-&\52$@-G@-VPB9DF_<0>=N:#BN
M I\N'*^$R)KD1E"N!:?7*JKGHYWUYL,._,5RY"QD0BFV,D@LB%.(4[$E(=)
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MS?BR( N34Q=U^JHDS %!)H+=%,O9U#?L?^T"OX[B!SZG=23RZ#9/9U#?L?\
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M&3O""1J.J8'5^4TO3SV6=I+M72786<=@J[JR7-9#*^LEF)U1:XU-5EYX3*%
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M-+V)9>)B]ELM#/:XBB,/UPTLND_\LK>&-3K^ LX>' M'R0Z3+B2,0(FD"8(
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MF+A=JY2V_DJ(J[Z9_)MQAXG@^YJ -!D.J*BA7V,/"^]313%D+%L#HX8-:-F
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M!U10R5YAK0J#468M%-"[A_L^32[<($ WB3$B/0 DF!S/+*3EUP3$Q6L^NE=
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M:19L^2/;*'="2F_7A_0V)%,YOG?GZ+!!!K'I'Z56>;476M;_ +%QK_ML[?\
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M86Q&9)$3B)=(.0%-AJ/FKWP<5ZF*JIVJYW1,6KEC'[EZD$>R!@1VGL><NNS
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M55G<P"YA(4/#C[>KM80FYD\>EEB$)''!DF'3@I+CL %Q. RD>X1<1=,-8CF
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M6?:W61'9./C5"K0R<.9HQ)Q%I#V-)1&-[T?'*]%S&1AX$4H62 #T4D9V/C6
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M1B@I)>M-=@>MH*/(8K@BXG#(V%IRT:J#R<.F!9J#I<NP,F,B>>(B9J8!BAS
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M-#7 B#'$,R"06N #9'?SIRM!V2[_ -H=:.UG8"$M@SFS@SD5T!KZF:^78'\
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D$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g209588g02x80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g02x80.jpg
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M 0          !0<$!@@) P$* O_$ %80  $#! $  PH+! <$!P<%  4#! 8
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M3???OVWX"FY!Q&[KVQT/:"QO>1N0;!/Z]U [+3(]R4V*W/Q;>@C16U8]/CX
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M('XQ\$=7%MH])-C(CV$4D, $*R$7")$/-Z?/RS$B[Q:+M-N.XFN&G\?9KXY
M-<S<.@T;B9,E.&&1+KO94W^T#JV]8.T7+ F:'=, ;38X^(/W,U60?DA4(.=F
MX\!';IDW&GR40E8+$I9FQRQ(O0@*/;/!S8 /<,5Y[VW7N2S&$/"$C*7$BZ@N
MK^>\^S;E:<D'\T <9UN+A.#DG)36Y]@R/9DGS,P$BS"0,ANIO:&Q]R!FY!QG
MC%;:>-/B3MEK\JE) S^&,@0U7-X?6?)DNOZNVG52E>H^U:.WCG/XTXA("8R
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M2O@9H.:OD2,E'F#"]R10@12+8Q<X.,IR*8;FF\K8O Y^+%1#).3E][S]N_*
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MVZG>O6UK=O*6O:[#/*_?6)O+97Z>VX_)EETY6MT?U;7MCTY='?7II78=@WC
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MOQ' YIV9_P"4?4T?Q42_$<#FG9G_ )1]31_%1+\1P.:=F?\ E'U-'\5$OQ'
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M1,P+B/)=$L,;916R&#'%.2$!^!R/IEJE6;J] W__ %5V$;Z<3=53&TX1W6_
M)ND3%Y7*3"8O:8_7^BSFO9)Q\%RP]J1^7W'LM7>4S&;!; !) B ;2C1O'DG
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MF+\MA!% B"9EI<<G5XQJ$&*>ZVW6JSLU5Y>_&W<O?*&N_L0E[RKW'S"6 _\
M*F_O(_N5CIZ2VDW_ ,Z1^Z6?WZ?&W<O?*&N_L0E[RIYA+ ?^5-_>1_<IZ2VD
MW_SI'[I9_?KT@[F]S/W7R?G6QX_M)S&%QT8B8PP+L! 8!UL7KHQBR5NNKBZ<
M762ZB][8IWQQ[W/^MTW_ '5X_IAT<V;L3*Y/%R-B-9?1L>^AWYBHHQ#)=L0Y
M>LZC)88U6M;::FHN7N^@C2K:S2#-I]!VB>2]MS+I=#1,,(."$*T'KV)+IO7:
M#QO79U!<*"AOJO7BO %DRE$4>3_ADOI 3_FK*J-OL:[BH=GM9[PI"HJE$2B)
M1$HB411XS^&5^D"W^:O:IV^QGN"@V>UKO*D*BJ41*(E$2B*/5^=67T>3^\B:
MNX]8[FE-XZCWLJ0J*I1$HB41*(H\M\U$_H][]V5HBD*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B*OYU_9?\ CO\ 1T1;@)^:AGT>R^[)56MI
MZSWJ,[!U#N4A452B)1$HB411ZGSJT^CR/WD713>.H][*X/D^K.";[DXK.Y9$
M0J6\66PX(05?NS,O:Q,[N00"APR%RHQKYD?PUZ?V5"0TTU(#";4E4+7)1\A.
M=71*/3.TF="@K$OJII2N-V W]0-Y(]IW+XP7BOW/L<:>Z)B$"B)$M&A\1=.H
M*2DDZE6#4+I8U)GL5$IWD\@+,GH'61'?AH7:)MW3H3&!DZ#Q4B(:!$HT)9$J
M<?[S3M-!P4M%=5\:>.VSH3%=7:7V+(IK (RNKB>$2"7;%<ZEU]O0O$(#@N<)
M[*V,\D#V*G/V! 10N/Q1K,7,(BNJ5KCP,8C;?"Y$A).T]F%3N'3VK5I,EW/(
MZ04 GPD4E[4H?G/* G9(;,I=&',LVKJD/K"4R,RDQL3&/R>Q]+<@L6;>&.&K
MQF4A$@-2!L 1;B7!)H2I%=VP'=OJ.T=B@]8P3N9^F3C&:Z]>0]O)M>2;(N/F
MQ+86RMBGAA/"";)U7?%M+9=)I61+Q6&:YC^U@=A.!(C"M7Q<),"]F488#2))
M$A)WY>VGYK:ISK/N>NV-I%-MS5M"S>P #V/R>3N+R^;!(_*'>F'+HC#YM-8$
M*.BH%MI/7I"-.VL-G,IC,O;!BL85!1TRF0CUQ[$E3L^O9A7?3:HG:L<X)FB<
M7Y3E&!Y\<7EVF..PF7:AGNV]?W)YR39R3S7S R!U]-8, E4)"EMN$]G.SID:
M:%*Z],&9<R6-1Y=M@[)4TINO-#3;OV[#<N33NB.Y<S3"\MC3.3PP5J;9FY-@
MRR.P"6["CA3D')(=JCD1K*3R3.2"9BUD)XS+&TDW$Y"S]K*(_-]Y.==&VCT[
M,H3%7V#8K^(?QW;,>H= J-A741;6?<T2 9EKE1I"HRP=[/1/AAT5E>Q-;%1\
MW8ZRUAQXP(QTY$#D9.QV'E=42?5&JULPI0;K26Q271H(O8PUE2>)(I4_E^=#
M7;???OV* D<,[F$[D$GG)DL/;RS80MP,>EANR]Y"I,%$7+1[:*J,!; 94T+Z
M@9R\M'HC.$5=;MH7ALM:T7,ME)+B9#K/ROXAN[!@1?=TFM?:K/UIQ1[GZ9=%
M(SK#6T*>+PB*,XH18ABLQZII$I#KF9Z);]4X6,XMC3$O"$]@0-U(V:Y%1V:'
MRO!\5SF0@HX:%*G;7;^1W]73NINHN%=?A>"''_E.1Y/QW;LN-.QR^ZXD+U-&
M&<%>QG3^%]G:4X\;,D\C&195,PT%XXQ 9.VD@+MT9+)=: )[/YJ2G!>,!\1A
M6I(IU5-XKM(K6[>3T[MBZ?GLRX03$_N*/2_6,WSQE\J3Y![7FX4B;CY3PRXU
M+$M7P_:,>5ANQ!FXVRPI+C>"C\-F6HX[D >NLX6"?ET)5,51+LH*W< #T[J'
M<:UONVK$"Z;X=0I$)#!'"G:@B21^Y"56UNR;)E9#&(O#]1G-,J3W%RPV\4C4
MC#6UCR"E>O@@:&2:6S.2/SDM% (@5ET&.VC!6IK6HZ[L;O945_OOM:'<&N"\
M\8F9*%T8.S'KJS'5;X2_/SC &Q?:Z)M=*2Q\'BEI<XC *5$&^HQ$6-;% #F$
MWF,: CF4AD1)@JJVS*5/Y[,?[Z]H710CC-I('NPGR)'PU7]KQ069#9R=_*9D
M79"V,DQC>,F\%X@6D+Z%0YY)[0^,^$Q.)QT*3D-PS.YEX^OCG?,E32F[^_,J
M]Z*)1$HB41*(O!#NV?\ $\=__ V7_P"I"JRB^S7_ "[8_P"S(>^<+#S[6?\
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9/3WF/[^GHZ/DZ.F_2U&<.TYIKM8]@R7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g209588g03w03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g03w03.jpg
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M 0$! 0$! 0$! ?_  !$( 6H"4P,!$0 "$0$#$0'_Q  >    !@,! 0
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MA8^NW-MKGRF0,%2?;^O^WH\%("IC@V'<$C@7F.?G88*)X'/HB8!/; V-A&J
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MPY'H8$P-OJ!?>)M%[V\B(C ]# O ^&XG8SQ<QL>\@VG ]#!'ROL"(\E1-A'
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MT1>!$#UYQ'-K?7BD98(U$2MV(3(OGC[  #_N3X_IQL6<FIV+C4H1'O!.]^
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MG-<FZHB"^ 713]B'!/:P!\#CCZ\_0^E)<#=RG4"-)$QO_5L=H$P+]YW&@K@
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M/(B?*\<D@8S#<^>20?\ O_G_ +CT4#L/*VWZ8.8WD&9[Q$#?M!W];S@P$$@
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M]?!^G\OU]*2M3=T_(#S&V#$SO$WF?7?_ #@];12"2 I&\<JL&0H#^\"#^]R
MWGZ\#]./J/3[5=4-$+UJ(G\IFU_G!].1AAZ@9>)6H)4I9)587/?ML .=MP<:
M0JXE8/:&/A=V\R22(">>21V@< <<#D_4\D'D>K!6?5"D:/#(!$3)W\[7 W^6
M( R.G*PN$C3P +_,7%^WKCU>R*$5X5,<0;N")RJ\_J>WR1Q] 3P/'T'JM<K'
MUG45J()_(2?H.\^7<CDXLV:-EN$A*4P)U1Z<QN=XX_0EF)/'T _IS]?KXY\_
MQ],$E=U7-OL]^<2@ BR8B/47]9_?SYQAZ&!@>A]_?W\L#!3_ %'\O]SZ&$$>
M\-MB()]=QN1_8XP]# V%A,^D';XWO!@"^T8'H8(R!%MC_200!R3\!^P-L%R?
M;^O^WH8-,2-]OH=,6'[\;DB(+]#"\#T,$?G@>A@\#T,-+-X[ #]Q]#'SP/0P
MC[^]_P#&!Z&#]/@-^VWG\L#T,%CP@$>?I_/CT,#[^_O],$MQR>/I_P#7H8/[
M$^O)M\\>>A@NWU^_3 ]&00)(L<&).WW:YOWYOS\,#D<\??T0OM?TO@PA9V2>
MV,&\C@>3R#]?M^O_ ''HX/8_+!P4D%0(CT-^+2/7!1''@^BPH$7O,QL #<[<
M7-R=NXC ]# F"9$^?GQW/GW'8[D>A@'M>_S,G:1L#N=IB)W@>A@N+;@"X(-N
MQYO&PF-IC ]# ,6B"1QN>+Q&]KS$;;Q@>A@XY@[S(\]X )N=KG3SY$>DZD]_
MUP (XV)@1;R,][;GTP2RMR3P>.?J00/)\>?IZ;())(@R3S)CBW^)'.#':"+=
MK3S> /V[8Q/]_P!_Z_['T DSL?T^NWI^^%08_? _O^_[\^@4J2)(L=I\Y_V/
MG@I!,3<=O+[O@?WY_O\ W]&C\XGR'P&WR@7P(!@;7_69WMR9_:V-&_8^3K33
MCR47NY('C@'ZDCC[>/'CC[>?5QEE$FH?38D&WG$B]^;7,B^\X@9K5IIZ<PL"
MW,@QM>(F)!VV^L0V-PR7S<ACL=D8<B-2@;PQX4\ #GZ\G@\<<GCC@#>-972I
M:4%-)) (-@+B9G<6\Y'GP.;5&9U?XC4'EZ2KW8*@-,G3%S;CSG$IX3(/DJ$<
M\A['X'YO!#<!1].!P2>YOU\_;CUD,SHVFG%>&@0$W@"9U*G:\Q$]AMW&ZR5]
MZHIO$=45+#JD21)@(;4+B>5'M/TPL?<G]?L.?OQR?KQ]?T'_ ']9A2U%9200
M!)O$6-A 'K VW\XT)_(-XD<^L^=C/GYS8%L(NX]W'=XY\D?;Q]#^GI2=<6VX
MV[^A.&S'8GT!^G'GY<7P1($!'81Q]^"3^GUY)]+3,7W^'[8*0"3/ X)^!-XF
MWUYO@OTK []O*(_+S!)@C:TBU]L#T, 1:UKG:.-R)-C>";1:-C@>A@Y&\DSR
M!/;>.;VMVD&!@>A@A_[P/@/[XFOW#_#_ +_^?1:O(\3Y3W\OKW PGCB(,?#X
M[R3Y;Q8W4:V2J8BO8R=J&6<5HGD5(P. \:%UY!')\@>0?M^OHVR"ZA+@E&H0
M/C'UY$&>!AXMRRIQ$A>DZB!<6B"9 X'F,0#9S%G><K8O9>6Y7QPL-#7BC9OR
M]K$+RBGCM"@_<'GQSYX];E"*84[/X=&E:IUJ%IC24R1<P2HVB+^F,<D*-34F
MNJ5);&CP0E5IES7%[D#1-YN?0LC>$QE&U2&-NRWH:TR/+%+R#^^.V.3O [>Q
MOJI/)*G@DD>F7&ZIH>,7"6TD2F20=1"+ @[%0-^PWFRT.9.'4I1K<=A8&KW@
M3X:@3O!(WMV^:O'O]"BIFC/LSM'%&*<#%8"J\#\R\E&60GA@>2>.?'/B2Z ^
MP@VD3M?@SZVY[=]L5K;SU%6J<J IRF41H;NH  @ !-K=YW[VPD9>_<S%_%Y:
M/",$CDC[Y*X1D9?/ER?WN/'T\<_?U#D'8C]?7[XG&FJE)5_VT^$(,%4)^<[?
MZPY+>ZXY; HW4^5 155NPH'8\+[?@D=Q^_''W//W]2 XVAL:4GQ0"28YXOOM
M'T],5?@5:W"5.?R2?= 48( A7$02""1R#??"+;FPV2R]>"G*F.1@?F6#J"1^
M3\[>>XD\,00>5Y)\<^H2WGGE);=65)43H!-AM) \K2;7YOB<VPW3I4Z" 1$E
M)BQF(GYV/RB\D8Z]8TEH+.'S;9&C+VFQ7)#>..YE#$D@E&;M)!/?QR3YY;?9
M*4FG, + )XD A0D<&UA\AM$JD<34+#@5JTZAO,6([DFT#S)O-QB7ZNR87/P1
M6L1(&E]GNM0_7LE''<"0!^8=W:QY(Y'( X\T=0@,D!)L?*()\Q )^?%]L6!
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M !Y^G/G@>I=48IE<&(O -OT\C]<5](%&I00#^9.P^>WI^T3$3-([JJ(R\,0
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M*"J+21^4@<<%(X,[[? D)SRGUI1*?>$FZ0(,B\&#MP3CUZ-F)F#I("&(/>I
MX /</_Y@> ?M]?5.[3.M$A>HB8$]^^PD  QR=K[XLTU+3R06PD;$D&VVT@D;
MD7VCX8UR."0/M^OIF"E5IL0/GQVF#A8,B?O]!C7G@2W!-!+P(Y$[2>/'T/ \
M<\_?DCZ>?I]38Y?6JIWQ!(B#>!S&^_)YC;S&(N942*BG(,'?UMM/E.V_'J&$
M>G]9IS(9@$Y#*H(( YY !*GQ^G/)X^Y'UUJ.H4!"P=Q()MN#YF2=R;C]#C$.
M=..*<24F$DB+FP.UBD1 ^O;#SH4(*$*UH>>U!QSXXY_7P!P?H/(/T_4^LO6Y
MI^(<)2#ITZ3/>23S/(/%[]L:W+Z)5"V&57U*+D[Q.E-I'_HDR/TQO\DLWD<?
M0#Q]3P>?U_7[^JHQ 7%]1,\[GO.]OCBW,% ',D7]#Q.WI'.,&B5F+$GSQ]./
ML./T_E_W_H040 (^?G<<W^G'Q1$DWMM$_/TX^O)QB84'U8_YC_<?;[^CU*[3
MV(DC[/&T<\X3 D$F#<'8'X[;6[@\"]]=@ 2!] 2!_('TX-A]_K@Y$S8".2-]
M_K-_WD8\]#!':1,[;3(X!WFVY!Y[V ]#!SWBQO!//?:TQ&XCRO@>AA(GL3YA
M6F>]K?YWQ-8#+S^0^>  5/!)(X^WI)%^1,7[^1O,>4 >=\)!\Q8&W,;VV$SY
MGZ81MBVM,9B[T4D%<UXH7$K@+W%BC*0.#W! 1^8^?OX/ YNZ"FHZEMM*@#4)
M)DF)D+)3W).DIC8WMAI=2Y2T]<M0_E*28[?]I(58P!L1)F/F,5&N=3[ONS5L
M92EBJ]\I$J5R\?=RW=^?L*@\$$$M^OGCQZO%^,TAMMLD!$D@& /RP3O<1%Q%
MO3%!3-T=0VTZ:<5!*W0JP5ID(ON(U7CTOC3Q%:YGTFRF8N+!C>]A*695?O+%
M._M('D%@/IS].WC@<,:*E[^7!]\0?S'\L*WN=D][=K$F87LOIJEM2Z,,I0%R
MY$:9;6!?@DF#YF8OA3RFNZW'%3LX_)LL,#+)8,SL7=.?MW'\H)^AXX//CT F
MI8L08F"+S;D^GWYUZJIEZH)I3J3P9V[7$[["#-HWMA4GVJ66G#%1NP5*=4@(
M_$?#D*2JL..""W''U/CP>.?4UES+0;QMY#D_[_M;$>L9S:I3%05Q(W"A/S$Q
M>^\QMN<)6?EJ;$V.$]VO6L1=A>2,JAE)\$@*2.>[D>1QR #_ !BOO-KJ'$M
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M;#>Y%F*&<>U/"LB_4?I_$#G^OCP//(/U]3&*VHIR))M!F]HCZ;[^6(KU)3U
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M$A0%S!_;[_S@P;@S<$;@[[<]YVM!@CN<I'KTJTMV](D$$*,>68=W(('"\^/
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M/T)X]: H!0%>.O5(C^8JX%N3?SOOY8H4.N,/!330::,B&TZ$;V,)"0#<^9V
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M;H$_\EQYB) \Q(O&_.)/Q-B6W5CEE![N "6!\@?[@>!XX_R]8+.&T-5#J6P
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M0[B^!Z&"BY@&Q'(O>?>-^1](-\&PQ^[*B^/W@?/WX^H_J.1YY!^G'HTI*EH
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M3P/MXYX'^OIT  0,%<G]IY';]8(L0)MC'T>",B_;:\"-CV,D\$DR/F:LCJH
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MIVB?6V*K[1L56>W-)CZRQ(9'(D/'<Z\D@A0.T$CZ@<#D \>.1JF*=Q"4 Z)
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MQ^9:;3VW'?;%'6Y#F#ZI:73@2/S.+28)DFS2KQZWMMB)LS\84XG:/%XLA5'
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M(HIZ[O\ ,SA8KYE9K*=3C"2@F0$O (6-_>(!4 F0(]Z21($),9Y:442T&JU
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M<#T, [G[^?GWP/0P!?[V'G@>A@?<8\('!\#Z<_Y#T,#!'H8&!Z&#_P!???\
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ME,HC)162KSO*?:7U-T?G]!T]7_\ A[,\]<<JZ:LJ:8:VRM>N$)6DK\-95I!
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M+"2=A/''V=Q?_&/.1^H_S_O]/1 @VY[7'Z^N#\-?_$XP8MYX_=(_@?''GTH
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M/RDG@_?G[_\ 5S_V]*3[TZK[$;<SV_3!$P1> )XMP!VM?BV""222?)/U].8
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M?(QOO,_Y'\O13,7,?./3 B)L)^4^N!Z'E'EVC[\\#SGS[S]^6//L?Z_;G_\
M/H#R!.UQWGTMV];@Q@'^]HG_ '_:T3C3=V8 ,!X\CP?]SY']\^G@ -OO[^78
M82/.?+>0.=C)XDQ(M<B^#$C1E!+$$\\CD#[D?<'TDJ4"8$CT. #:ZH-[2+7\
MQ]\ "V(=Z-]01AJ&YZ\]*"YA]AP<\-^.>.)Q'+7*S4;?[8$]\ $G[)'02%AP
M"W;ZZ(_F%(FH34,#WD'8QZ]^(V/SO?G-#EF:5+]535!'OMJFUP"".!!!O8<
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M&>+\1=XS=IW7^6G@B 3OZ[D5!_\ IUO-&5MNKHV'J6MUJA;86E*Y0$C0 DH
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M>[]#X'\/M_&%F58REA3:TF5B=^)/]C\\2:&C?75-N(-@0F?,22(CL?0[^DU
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M9)9 DR=\4TQ)55=EX#<@,Y'D&=9ZXA>>9J7::0ERA624K1(_,D$)4D<H*"%
M $D'$C/,ZR7I=+W_ (9Z;51U@;7X>;)4V%-E4@AM2E*>"ECW0J4P3.XC',S<
MMIU&X+>=D%6::*62_<G]X4:@G<S32#W(IR_9*4>20@F&-G55X0^.\.I3DV4O
M+;A+5)1NJ::;"2=#+9<"$PE(2)2$@;&!,G?S32OU>>=0L(J@7%UM<PV\X]*H
M+SR6EK)4521K*IFTD QA6UKKOF]+S.'S?3[("2M'Q^*5TL5\M!(HGC_*T1B:
MHU6S")(W216*>YRCA_S^O,/L$]J55[>J#JFFZAZ:K,G:RVK>%!4U"&T%4:-
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M/KIP%B6VJJI6XE56XJ^AM#H! !!"3$[&O.5U[&9G%,N-@@@CC"J+?N3S1R3
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ML(TFCG=>U)'[ 22/ \L>#X)\<GQZB',GP0LJ41-@5'UVF!MQBW.5-:$M!I"
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M@ !>X#MX''T\YIS)E//*62(4H&+R" .T=OC/$V>\0 09GN;">!,1;R-^PWQ
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M X*GR1VGT,2&"\-E$&TV!L/(B]K>@N(,BM%Z#Y2T55ED"L>!P>_C\P_,$X(
M(( /!)''UX]#$HN*5N9'D /7CG"E3]UV0/PZ< D1'NX#'N!Y#$?<%2IX(\\^
M?++[GAH)%E >LW\_A/D-Q.#2E-E1<^9.TQY6 WC%A].Z1X?<*4EFU?GI.*[L
MD\: =LB)W]K@<@CCQR1R>>>0.?5&[F#Z%I2'(!F92DC>.Q,=C_L/M@*!/8@=
MB1)N.\D7(XMZ13D==JX/*2P16)9HX)3&9V4\.P;C[^/ X)(''V^WJU9>4\D
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MZ9/J1'M=VQ4_"L=AZ>)QL<$.)]G$+[=1I8TD^9<%$C(, K)PB_DDX/K(Y7[
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M,"2>/3M.(HZ(JI$.)C>Z0=K3(-@;7C<7QM',5UXY;ZG@ \?['_Z^QXY'I?\
MXEI__P!7'GJGZ0(^,>F\-N]%582"'DSJX"NQXU'Z"9QBV;K*0&/!;CM^_(/W
MYY('\C]Q^GH?^)*<V"+_ !]-[C?G#!Z+K5 @.P=A(V)BX\AY'TF+Z]O/P5U[
M@&;ZGQVD_;QX!!YY_AQYY^WJ.[U( "$I((YMY7X[\^=ABQHNA:A1_G.I5WNH
M$GG\I$1/8;<X;K[I'^8!)$(8A1P#W'Z \@-P?O\ 4'[_ $]5C_4U3! <(2;
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M "JHJC@ NIY/GD_H3^O@?0_U5A/V<)1N43]%52OU B4\D<_1AQX\<_R\_;P
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M\^>W/.'-K7P1YW.14?Q_K-T8T.QG>M>[] -4H;/>WV6[MG4/1K.J8_(18N#
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M\^T?3;$);S3FP&=?'7O^9BD<6A8CCY$D4@\$$\ #GD_T^A/J]RQTK:"TD%P
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MAE^Z7TNHU:"E:%"U]AO83QB4-"WW#Y26I2KW1C8X[[7+<(MS)2F"M6CK2"C
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MGR,0?&V++AA<A[HI#F/[X)36_OQ.]A\+S/ZX8V0^*'9LME-"S$F P"6.GGQ
M]1?B%QL*'("&]L?4C,=.<QD<'=#V7<87'S=-L;!1:%DN^SD<@9;!E%62 8 :
M$'WM[6O8"!\8WP</BWWRI?\ B&R=+$87'9'XA.HNL=3<I=JM?:74\[JF[YO>
M\6FN^Y89'K1Y;.2QDY!;$RUZ=0!Q()GE(F-]OO[YWP"B""28&T <]Q_GMB7;
MGQ9WMYCZGY'5>CFG:1O_ %RQ%W =7^HN#R&Q7[><QF:R-/*;)5US6<ID)L#I
MG^*KE*%MB?&PV9;E=YZE)L;5L-$(S[J$@RJ(XB9V/$F_>W:]QA:69"??WD_E
M,[VF#ZR3N;X>^S;;<Z^]1=@ZB[-K.+Q][(8/1=;EQ-".P:?RFC:+K?3^G/#+
M<FFLI8LXO5Z=RU^W,:VYIA"L<01!F:RM47&O#7HNJ0!,QHC>.QM?Z'$AED)2
MO4J9(@E!'_(S=5A)CGRPH]7NNO2#J#6B@W3I!C+W5?7-(P_3S&=2;FQ[;B)Q
MB-:QJX;7,E:P&,R]7"Y?8<'C8:M?%Y*:*.LQJ4Y,C0R*1F%K1FJ<6T$A1*H!
M!Y(W)[2 -_+GF.I*4KDJM'O6&^_>8N9'KMA^R?%GE>L53(#;-:@;<,IA\9@=
M@VV/?]^I8W)X[&8RIC9<E#T[@SYU*+-9*M2A7)2PUEP]IY;4AP223=XBUSK[
MJ F2@IN3^:8,DZ?=BU[G]L&  8!W/E8>O:;7[]]]'K9\8#;S@>J&I18*IC(=
M\@Z-T<C:B:__ ,C%T6Q60PV!6@9K,BL<I7R!ERDLJN?>KQM5%93PK#"?Q!B?
M$U #A).D'3%SQ<W/QC"RV 0)-KP!'YC&\\?#UQS$O6C9S'=*Z6(5D+*K#L+.
MQY//!([F8\D\?F)[_J3ZO:=KP6?#TA"4@@7!W).T2+R>^XPK1R3 N=MP/J.#
MWFV+3]*M+JVX!L&9QLT]-(VCCCKH[1$J0W>RCR?"\?0]OU//@'+9@XR%*2%Z
MC>;1'83)W.YM8"+VPXVV+G8F.#/QO'^SA*Z@Y+$9.W=HI?CJ6(X6CKK<A]J5
M%53VQAI.&8'MX4\ ^0 /3V5+<0DJ*(1I5?4;F+"(YVF_>X$8<+:;DKC2E1VL
M0 ;;WF.=K85OA<UW)9?J5J5.''2YK$ILM*WL.-C?MBL8+%2+DLK-8<LO;5KX
MVK>GG9N%]I3$%=I45[^D;35K2I%(EVH0XA0;*S_2K453IN 021%Q(FX&(#]0
MRBDJ'W7"RV&W$I<TZ@I900E)-@-2B!;_ )3I//U/=4?C&UCH]TXU7*U<<V2W
M?;L'6N8K"2V8J6-P.*:!$K,T*03QE%3@4A*L*3B)R/;XX]=LZ6Z3>ZB?9\=2
M*&D:*2X&&B5O+)*EH!+J W;=0*B),)DF//?5_6 Z4RURJ;;579G4)TH#KH;8
MHP0$)5X0:<+NB9TDMZB(U"V/G2^*_J!O76#8+&?R%V[D\MDXT2I#"DDJ":Q)
M^:I1KP#N/,THACACB4/(1&JS?E9^[5&7Y=E=&U3LQ04E(DH!4 Z7W" HZU2C
M21(A1!,1VOPB@SFNS?.%9C4+36US]/X)+:33MMH4X5!QMJ70 F="D!1U%*EE
M8*PD6I_X:/\ PP>H&9Z@4/B ^)K2HL#T_P!:K+?TK2M]A1+.S;!(T1J;+E]=
MOPS1QX/!U'MVL?!E(8+-_)O3=(UI12BWQSJSJ*A6RFAI5K?=(4'DL#5X*DJT
MH1*?S^*5 E0(+8$PJ01W?I3IBL9I&7*E2$MLO)+!J4>$FH;="EN+ 6I03X2H
M ;,AW4?>3$*[9]6_B=UNIF:VFZ?!":&NQU<=?R= 1T7K5XY8X8ZM*.!$6.KW
MJJK%%(D8$*(L9"KZ=Z7Z K':1.99DH-&KUO4M,5>,7&PA)2MP$IT*))24E"A
MW5?%#UI[3J1G,ZC)<K2HNY0NF8K:DM^$-2W#J:;< CPTZ JQ 5(L -19.V=!
MUZP8K&9C,Y;)7,!.[/%>QN0K4LC'5M$?,4[(MQS*\;$,%0Q":,^8O//KG_M(
MZ&Z.]H#-+E/4+-53OY4_^(IT4BEL!QY);4DE:-TDMHF4D$@\QCI_LB]I/7GL
MR_BN;]-N4-?1=1,LL/.5@;<52):+\%+:Y*E ON:4A:+ 2%#'/GXO_@^Z0:DN
M2EU+:)Y]E^7J95Z,%ML5DM;265XUN3SU[H_$(,B9)8(*QK5T,<#GMGD8N-)U
M'E^6>T6@R>GZGR5MUW)767LOJQ4*!2JG<"VUEL(3LH*)EPZCM"1&*SI#.\U]
MF><9]G72^>/-5F?M/HS>60EM\5+80ZVI.HI@MP 4!(TB=(40<1!I6MZ#T@PF
M BR%BSE-JR2U\J9*\JRTZ%&(^W^T[IHFEL6H_P \;<\<L>Y1P">G=$N."JJ:
M!M0;;;2EI$S^1+0" #$ ")^8D8X_[3"Q4TR,W>IDNU-6M3[I22@*<4["E!,6
M!B+#>\;#%T>EN]Z1E]@QS7,HDF+I)'(!>A@11/7#2K')$\QC6%)2I4#EI'52
M)   =-GU#7)RY]+"4^*XHH46UJ) 40$J"@D'40-]DR8!WQRWI>JHGLYI_P 4
MVX&60'4:TI*24))*-$P4A1M!"E1-AA@?$9MV"ZJ[)''C+5>>A3[J7N365]N6
M5"SL"T<C?*PORT*D)(H?ECW?N^BZ5R%5!0Q5)"W'(4 D20D2F)_J5>2#!YYQ
M/ZLZI7F%54_A%N4S##S394M()<40K9,I*4\ @J'IBN$>JZYAL8,CB,K.E\\J
M:45J.6F&#$2K(_',JQ #]PF1@.#$O/ V;*%-K4DH :2-05>; 7W(@B9L.8)C
M&!JZI=:$@)4M1/O$& 9L9&F9)Y*C![;XMM\.?5#-[[;RG20PS+CMGQMRL,9%
M4[*%6Y6QSI4RT$\D[BC:BR$-6;O5)$FDY<(@<*O.>KV,MIC39V@*74T3Z'A5
MD$EUO\0E3K*@$ *;*-24A1!2 +DI)/5^A49@^Q4Y"'PB@S"G<IOX5I #;JF%
M(;>;=+LI<"]*U%*!J.M(@''(GXILSNFI;5MF%Z@9VS@I<#=L0V<0_=-D;DC3
M (:5)E@[XG5^1.)*\ 0(RDJ2!856>,9O1,+RQ(4RMN22(]V(U*L?>]TD R#!
MWL199-TNG):E::\%I3:]*025#5,W]Z!<Q)OL(!N*NX/K-JF(6D;F'V+(U)2&
M%G*5L>T<:OP1[:">=V1""23.&4']S@>J%5-3OA09>)<2@J=4EN?#<%P@IU"0
MH7D$6@@8U[U0JF6@U#84VM02TT51XC:CI*I"5$001$&('$Q/5#;8L7BERFG=
M/:6979ZLF2Q^<O9&YDL=BV61EDFBPHC%1K1D_(D=BS[2MX['Y\1LN34UI=I?
M&< 2ZEIJ692MPCW$W6 @&3*B5;6L<0\V51,*IG*"C:55.J27BM\M^#37+S@E
MI>M25!!T )"IW!W8MS<K==(I-_L4:L.723V6A[*\LBG\DJPT(0C&.-E*L8X>
MQ&#*K'M[C!K\OHE5U1T]F:VA6/,5#;U&PX'EN,*04/)4H:/#*D*(F#IF0#BX
MR'-:Y.6T'4-.U4,TBJXM-5;C)\)E^G"GF7$J/NNDK9$)]S<G4=BKXW9,WC\G
MK^*Q62M9O76IQOAN;/?2^49XDLB,!4'S'='*DQY>4!55E8*/5#T+[.L@Z&8S
M&BZ)HG,F&:5KE75*4\NKU%[1+82OPS'N@:M6_P#3C2>U/VF=1^TMO(ZKKNJ:
MSJCZ:HF:3+%MMHH5-BGUK0XXMM+I<*5*'NJB0(UVQU"^'W;='Z!;WENOVTOD
MMDZH=2,/B==T37Y\?47$:5KN*CFJ6YS(+CO>OY!856C5D6HL$$$TBQM+::2)
M]?0E6[U'FP>SMQ%-F]4:@TH8*/PZCI*64N"H.M M*X1_Q*(!&(==[3Z-/1N2
M*ROI^G1F&6T"&G\Q<J2^C,'/>!J?PAIFOPQ(%F4OOR;ERT8M?N_4/;-EG79G
MLRK9R1C:L4D"*B-^TB6!X7!K]IC:.2)T8I*T:]Y5BR])RGIW*LM9=HFF&UI3
M)?\ $2K4M82$%2M1.Z2"A2#! 58$7\VYQU-FV=5R:^MJ76775@,J86D!M%U(
M0TE*1ITK2I+@5L2()!.E>U#K5MNK7J]O,;!-*:]N;Y>KF+_XE1"0JK+!;IGY
MN&3VY!:2.Y&(G/M)^SC/YQ65_1655S3@IJ7PG'4 %; 6TL:R05-J4I!!*0DE
MLF+D2=L766=?9MDM2AY[,WZIBD*G%(KW34L0T0 EY@)6@A))TN#2I)$P-Q<#
M"[_I?6C!U=HDV2/2=QPL066G/=__ &#*4ZQ$5EVKSE:\D#P]X=3)/+Y,+QR
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M)N5)U6[55S5+U6V_3UFIH?B64:]8D-H74,(,SKTA:V5%4'64.;IA_+_\&#J
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MC3MI*WU3  #C+4^6^.;LH5GC#>346JK<6-#M$V%BIIM< BH6M*6$D$S[E0X
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M3QZ^>)+;2R0?=\C)];[[]S<_/$%FRC6D*M,\2L JM]''/^7C^)X']?3>)@!
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MFQ5H[UVS;AQSTY;!IU*?SLE<UC:;YIZL2//!$TS &/7O9AK2#5AE"K!,!>F
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M2M1.[;I'YCI]X)C\O%B?69,D\1N8L?.9\K 3?ZXA72^J&1U_\2&7]Y5LPO\
M(3U8@6K3R=H0\HQ8*!W$\CM\D<\@>M15T*74L+;0%)TJU$$3!TD"Y!O ^-XG
M %OE^FVX$3SM!^)QY6V7:[=E9FM-DHYG]XNS_MX5[PK*53@_EY^@/')YX/U]
M0GFF0TH!4+2-0&E0NBZ8,1VO/>"+X00%D))(08"CS!WMS((X\QSCI+\&*Z7J
M.?V;:M\M3RW;&M0U<##V-+##%D+#3Y:>9'4OW XS'5U122T-BUS&_!1M)[/Z
MAIJO>JTI!K0VMMN4^\)2X)"BG0+\D^>V,QU>V_44K-"V^31MK0\H PF6UH6$
ME)]]4Z8L-AYD88?Q =;>FFL[AN%G_&NPYV;.S26[^,1C!BTM6% C%6G#52%'
M [F,9L")>.&3Z ].H_9OT!4]493U[6-+=ZC8I@:A\//)2BH33N-)"DAS0Y"E
M)22$J&Y!_J&*J_:C[34=&9[[,LOK&6^E<WK#4("J9A3E.TJH;J? :6MGQTQ7
MM#,%%"QJ;_E$[MA+^&K9-$Z@],>N;9/WJ63:YI6#TJ8I%!<M1VFSN5RL:S-*
M&BJQ"OCOFE@'=9E:.M*%@:0^M[XQSS,*"C#B5NH2X$M Z0E'C*T^_ 1!3$0H
MF29O;',%T[V1Y?7UM4WX9<\(+>)U%:T-)25Z$:E@*TS!2-]K60M(^&[><ENN
M.O:N:"&38,:G;D9V'S$%N:#W9#"(9"Z>VZ?M#*O;PB)(ZJW;A/:%[2.BNDL[
MHNA\V%4]G&=AYZF_#L5:FV%T!0TXAQU#"FC)=!!#@24I)D2,=)]FOLMZXZUR
M#,>M\I_#L9+D)8;JB^]3:WT5J5K;=0V7@X @- %);U2L0FQ)N)UMUC#ZEG,+
M<DFUZ_F,+BUK-'V5[%ZA\NS.8>\QDU9//NA8@\Q(+(I8\^MQTQD&7YA1L9AF
M&44%0EGPW:9YPC\8  EQL!1("1,%049N1&.?]7]2YQE=15Y/EF>9G0!]#K%4
MFF4 P52IM:2G4%G7)2E24P!>0).*P[=UJ,U6Q#3L@W*K.8(9$MJTYDC5I'K^
MW$#^=%57?W ?R ..1V^NIU/55.Q3H_#$&H0-'@!M8THT[ZE(#1@V'O3(MCA5
M#T'EE8'&\SI\VJRZXETO"K92"K43*DBJ!&K<C:#?%#.M.V9WJ'*U[:WB@,<D
MDK7W^:?(%R%0FQ)8E]Z>0HBA>68$   J /6$KLXJ*MLEJG"TZ8$!*$@ 18*"
M3 ]/+'8\HZ?RBB.LH(DZE?S2I2B;DV<4HD<S),;VQ"&N[K@].R<#8RO:R/#_
M +=L@PCIVH&[?F():ZB0/!)PZO[C?L^ ZA6 /K+*=<K4+:%4VY44]<E7X!)2
M'&6BVWJU+&EL_P!2H"BJ#^4';;-BDRVFI<S%$\RTNM>816NH=+*VG&6$)*92
MHZ2XI:/RB"+P(.+-4$S,=6IF-/S,N-U'9P+D-.81!89EGD-C&S3DAO:J7(WC
M+?F2> 1K^923ZQ+WL[Z4=ZZ=ZZ7EZW\VI%A+,*6-1<;'BJ@K";*D&4S_ ,01
MCH:?:?UG3]!.>S3\6W39 ZZ^ZI(_#N)"%OJ>8/\ *2I8UMJ2J-0*;!12H:0\
MYZL<=>;/[!#A\EL-6*2'#P588Y*\]EEY22PLG,")'W-S^8^2O)!;ST?,<R9S
M%:4.L:*1;7A/TRDS8@)"B0FX !B)](MCDF4Y+_#5+=:KGVZA#I<9JJ<Z%ZC*
M@@ K20%*/,#W1(.$;I1IN:V++6*-_-7,-/[B+#1I2BHD%9B.Z2&"-DKRQ(/R
MJ84!4?KR3ZO>E<NZ?:95E-'3,TN7J!<+@2I*5.)V3! 6"23=4) $J-HQE.L<
MYZC%2C-:^KS>NJ@H-H:6\RL^$?S$E+J@H0E(@ K@V%XQ?>?_ (17Q =7\Y@^
MHG0CK1I]C!9>/'OG<?M^<O8;+ZCD4K1B_6M5*U+-U\CC9T3YFI)8@J32*Q@E
MJN%,Z8.JZYZ6&9YQ1Y.X*U_(LP=RW,4L!U88K&"DNLDN-H2M2-8]]DNM$GW'
M5$''1,NZ3ZI=RS)ZS-*-W(F,\R]O,<M_&)2%O43Q6&J@H2HE"%Z20'-#J2"'
M&TD0.N71GX=OAQ^'+7\3)L6[CJ7U-UZO3LY>;$16J&IU=N2!6*X^-TD:3'Q7
M8RT%6:V>U@LK5XBX42T=49]F+_\  F':/)Q6(*U4S]92*KZBE5_+6Z*=+JJA
MI!!TRI"2;P><4E=T]T[E5)4=1U+%;U JD<0TJN8R^L:RUBM6''&&S5+913O7
M:6N6UK0FQ6$VEA;)E=N6]G]HRF9GGBR4LLM 2O)\L(YV015VBD4M'%&6XJH7
M[%12P4(KD=:R6DRUFFIJ6F8;<= ;-2ZTH*\5U"-"EMJ2I0$1I(3Z*E1&/.N>
M5-?7553F3U<\AAY3A90\A:0RAU25(;4E: 52D@A6D@D$63,//X>_B&Q.A;-*
MV;>O;@LK*;\TEE*UAH@X[XZ;NPCDE0$,M9O,W:4CC9N%%?UUT<_GU"S^&"VG
M67$J9;2DK1J"5:2Z M)"9(&HZ@F050)(L_9SUU3]'YH^Y6J144E0A7XAU:RR
MXE$I)#!6-*E:02&@H%4%* 5@ V!ZV?"3\,>Y0KURQO3#8-IEV1X[UZ/6,H:=
M&Q)9 E:U/CX^]X9'/*698H1&'#/( Y9CQW)^H\]HJM61YEF3= :<EELU%*Y4
M *0-*4D,)6H@^Z4J,V,GB?0/5&1]-U67L=7Y1E>:9PW5I2\H9=5I;!;>!6I1
M0\H$)$D*"1"2(VQ57'?%OT9Z$8S:NFW0[I]CM3V2A'.++Y&RUB]<R2@@5[67
M6M/9M^V\)BAC1EK *&9T4]S5?M7ZLR?H#+^G^H/:%F]1F65YI5IHJ,T+#RZ2
MF=0[X?AN4U,TY5("5*!*U4A!!,*WQI_8GT9GOM3=Z@R;V=9&C**[*J9=97"O
M6V<QJ6M&HK;??<:IU)4$D)*'])L5""">7_4OX@-UZGY)]CR,F3RDSV&-N EZ
MWMA9 'BCMO'+&\,8#&%8A'PHX:0>>>^Y(6DT%(]DM,V4KIVU+\%)0@ IE)3X
MH;)&YG2#,F!CSIU-3K:S2KH<\JW@XFI=0W^*"_&6I*@%%:4:BA0,)AP@@:8D
M##PZ,;;F<CL!Q,D%:]6G@:Q#)84&]6D[/<7MBF[8T"2]R/'&Z!T'NUN\NO.@
MHZ]U\J:="A<E9!(TJ,#28!U3,R/=VD;XPF8Y8TP%N4Y$LH*HVA"945S<&QL!
M[W N;=(,@FI[!H]#'[3BJ<=F0PU!;B@21J]B"!_<,?>4!5S&_>&?D$=SK)RI
M/&?:I[2LG]DM$.HLY>J5TBJRE8\!MBH6O17/>$EW4TP[I2V2"4B5&8 $'':?
M9![/.IO:Z\YDO3#5 FK9IZEQ=97.M?AD*HVM9:+!UN+<<NE"TLE"%76M().*
MZYCIE2QL_,#,V,F1)*]A'6(&N\D]=T'N0M$>)U0^Y%(/;DX1U(C<CKW3G4^4
M]0Y)E&:T)AK-Z&EK&$DZB\Q5TC=8V= "74!5.X%D+;0I(@*"5$)'&^K.GNJ^
MG>H<^R/.*FD75]/UM=25B*1*:8,U&79@K+7VY=2TAXHK4> GP5+"SJ6C6T%+
M38+X5K&SZ3U<QB8C6[V7P62U38\M9RD9,T&.CQE*]%-#==7-6E9CM5JJ112)
M\U*EF.0 (3V^6?:ZY[0:CVP]-TU*ZI'L[5EB6ZQ254P;;JRXVG26G%BL6=)U
MH6VVM!)TE8-L>U/8E2>S9KV%=0YE5I:'M2;S-QZC94BK4Z]1!#I04OM(70(2
M8+:TK=2H&%:#$F1-R^+K.ZKU1JZYJ-R23(Y/&XG(YRCD$2\V.R^6GL<U5>S!
M/+%W0"MD# LI]FO<K*G"30!NJ99T[TT[D]2YG3K5&Q0NK9:JW7S1LE&F4-O/
M ^$700I!DD'23,&<<2S3J;JVGS^C9Z=8S:MJ\Q;9>K:9G*DYEH=?2I072AUQ
M#RF%J0M84T%)0 E)TRE.,^HGQG]6Z7L4,7G6',:1Y#Y;$0XV3YE&[9H89NZU
M.RNO'9: IOV_F6$'CNNL@]FW2]4P,R##-<Q4 /T3C->JI9<IE %MQ)2E+2R2
M%&/$4DVDWQGNH/:SUO2UM9E3N8U>5U&7N.T-:P[D=-35#58PM:'FEI=JEN)"
M2 DK2VD*N4DITK+MZ??%SN>'UNKG]KV5LABI\G%6L5;>+7(25&DG6&2N+4';
M:E9%<$262.20 A) ]<U]L3?0OL^Z??ZFS:BK*.BI7J:G\6E<*E^.\'"VZJG;
MD:-3:M8:*E#8(,XZ1["ZSVH^TOJ%'2V35]'FN85**JL#&9,LT[8HZ930?2*H
M+<4'0'4%OQ820HDJ3!)>G4S;=,AV_2=GP^7J4;&T4,9G[<,3&!8X+XK6()6A
ME["B689&#+^9"LCAE_,W,CH7,*CJGI)BKI4-OY=F&7_B\H-2VHNO,.4WXEI6
MO0%)*6RA1"PA:2D((E&D1O:3DZ.ENMRTXX*7-LNS%%+GK=(M1:8JTUB:9Q($
M:5!3H6DZ)2I*E+C2J33/!_#ML-?J9U T+0]FN-A+.-V/,8REE<I/=FAAVVS>
MR>"LU+'$4F3PAK73%6IEA8Q%NM-6>!X!7FD9Z:Z6Z;Z45F75ZE9X_FN:57X>
MO;J:I3N6,.-E"GVJ9@K(8<20D!0;"5!1TE)) V_5/M"ZEZSRW)^@WZ;(6\IR
M9'BT-3E-(FES=UI06ME54\IEHU!+:SJ"7G"%#2J2%'#9Z]?!]UDZ\;%L&4Q^
MKAJVM:W@<7AJ%N!L3D\O)A<=&U_\/%BM'!/*EMK5FN[W(I[7:L<,*-V+)LLN
MSOHNDR9RAS.C=J?Q]4L5:*IU#[26ENK+3O\ )==(040%(T)6"2;QCFN==/=>
M.YG2YCTRH4=9EU0LT#Z-#-2_^';\-X+6\4-*<2HA6M3H;< )0J2!BAWQ/;#/
MT5^!?J'@=LSL^O9SJ:,#J>A:TXA.:S=?';-2R6?N6JMC_GHZD->K:CFL-WH@
M=(YO;]^LKYKVAYODE/EB,ER"FI6LMIT!5$W2H<0V6W6QK60\A*@K6IU)!O !
MD3.-O[.,EZAS/J"JZKZHS"HKLUS%_375%2MI;B7*0IIRS++BTE+;C 5(!!))
M&H7/SG+)?F7F2.4>XP[2ZN"0"?(!X\@$?8 \CUPOQVB4 *$!)!$&)]WNF/B#
MWQZ,TJ25A6Q@I49N!,1SMP8 FV/$282J."S*PY+$CM/(/U/GQ]#QR?X$>G5*
MU-K4D[(41$38&_F!<_E ['!:$&08 (@F#L=_.V^TVMYW)Z'X3%YDUY,J34AJ
M@/[L;CMF"<MRP7GGNX(X<>>.2/'G(YDMXI,*42+ 7,#FT ?.0-YP:4-I_*01
MOS![;[[_ $V(VMMDMHP%>+Y/"UXN:\21FP3RQXXX8_EX)<(2>/J?)_3U!IF'
MG-.K4$D @D\>@]=CZ1BWI_>TDFY"50.Q [DQ;87V@7PS*UL7+;.Y4J>>?KV\
M_4#CR?M]>//'\?5PEKP1!_J]XGZ? 6](Y@8M 1I"08.PB2=_*/D.,+BQ*A50
M%''@#QR/U//GZ^//^7U]+,<?<'Y;$?'ZJ!23;<WY_?\ 3;"G5CDLV$ D/9&R
MD#D^ & X(X^_'!)^@/)]),#][>IO]?LX(@V,F2 (')/^>W&V'[%"B*G:A<\#
MD  \]OGSS^GGC@^?KY\>DZA(O;T-C8?WV ^ID%"H-KS' F#V&UXWW]0(U_FI
M_GF@KP#F11YD(_+]22 #_3['Z @$>FS!DSS8?'[_ ,\2DZ0D%1V %AN18[<>
M<CRG"E[-:MW?/H_+#CN4<EF/D #SP/T^W^I+!@R)!, QY3\?+[OAUZUJ.K9Z
M[!3OPY:/YB=4[X(BBH&('+AV4\_7]WGZ^/U#S*057!(TF"9W! L>;6Q'><]V
M$&5 @D1?2 =B1'(VFWI(=>Z])\%K;O!BDG8FLLPELSN"P92Q)4<H/L."3]!S
M]>?3ZVTZ50!(!B^QO$3OL-AB*EQ;AA)V(*A($;@V(!YXV/GB V>[BYQ#)-+[
M9=@J ,4" ^>22>X$'@<A?^_J%Q\]S'IQW[?3?$YH=Q$\@'MWB^VWPF^'/3CQ
ME]H^U@[KSW@*?KV^.001]1QY'(\\\<$^AA[;8]XN-OU!L/7RC"\^-Q_LMRHB
M<#A1QR3]."3Y^OD<<_;Z??T<6GX;[][1Z?9P7;R\_3TCB_U[)<>)G(#P3O!P
M02 K %1]ASQY\C]? \CT6 ?.Y\YD?Y^?ZXRN0115S+*LL[IW<._(\KR3SY (
M'''W''GZ>A@"\#Y??;?YX:YV4(QA[/:$;*%;R H;GSQQVL/R_0L./IYY]*TG
M[O\ #UY'!%YC"RFV\Q/$7BX[R0)'I/,X4US,UM54=DP!(/**/R@?E);NY!\
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M ,$Z1N/VL2,1U)AP@7 C8S%IL-]B0#\QB%NH?3^YL@N9X5=6UZRF8A?-TK-
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MPP^JF%NPGNCX42#M9BOU7DJ?/'CQS_#CZ^B5L=MHWY/$1O\ 4GUG"PH:D_\
MN!L(-C<F\&;@_/RP\:=>6)53P0%4,Y\@<\_8CS^H ^GW]-0>Q^1P\2/>G:9
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MG<&P.XGU'E-K^F!(V!!].=[_ 'Z8V6KI$P[;+1H_"I'Y8 D^ ?KY^WT!Y_S
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MST%D-/0Y,W4O7&ERUY U'4DQN""3O>8Q\ZV:W3I]%F9,C!JMM+\UYI["QY.
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M/TY]5B_S']>_G_N<7#7Y!]\#[\\2O@*"PF*63]E)R6(^H/!'/)Y! _F#Y/\
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M%6PL=2M<O+26[C:MZAD^VG!'6CN120-+=?ML5:4;JWK:4>=N.LI2\V$!( 1
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M :$:4A,(  @2"2529)C2"!CR@YT_GE9F;;-:^RU!,K2OWUE2RKWB29(U0(@
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M8RQEIY'+XVK"R1G)U:02I4,O?)6%V>=2LC0$<ZZVS"KI:5UJ@2M#Z6G@TIN
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M:;W%DB_,1[<G>L9)0<(24C;D'O13X]3&BE: 1?N>Y_3X?,8F))4),':#-MN
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MYYUMR121F"QB+,M78YH$%:.[\@RE'D=8[%#2U=#4NL-HJ765ATMJ8?DNMU"
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MQ%&E#0;4#IU"+C7(F#-P-X)WL+[1A6Z29:]TFVK*Z;H.;@V:A;7&8G,79JN
MUG:*M[,U+#+D\-9V^6U)EL7CXIJ%3YB.LBVQ82O,Q5*ZW61UK%*FI;JTM%#[
M;S:RE)U!+B5)44DDPK2LE.X[@W& JD<?T+"E!*%)5&H@^ZH'@;F(,?'N7W^'
M[-B.E:U=[U3*UKE?+RSY9-6^3L7\)DZ51[-O.Y"+"VI>Q;=R4K3NBK6LU4_:
M9">U&?E[3X<I0[%&D%L;%P$JVG<0)FQV^,XLF&4]U#?^H23.UP=_/YR!BO$\
M>,V&*7-X[J#F+SY"<4<I6VB#,U=BIQU7@D-]9\3-DZLN+:54G5K+)(BPQ$0K
M*@=9":E3B]"](0@D)T@B0+ R2J1':#:QB,3PF/=@6B+;Q:]HD;F/@.,1=DXH
M4OS02Y5,L.P*;@>W*_Y6*J"]R"*5@X ="58D-P3W!E6^I74: E)L#![S$S:/
M4R/KAYO\IM<FXV!,R0(M$R(^<3&$%HWQKLU>9F23@A!RQ"'R?"@%?IR/M_ ^
M?4XA)2()FW/EN#_?#EB/I$=N +_28^&%!,J)(E",GAUY+<F7O'Z $'Z\GC@^
M>>3SZ04"#O\ ,8-/YA\)!CG[[Q\</+'I1DB!YEDG'DH3Y8LO*E1QSVA@>?MQ
MQ]/KZ;C:XN+SQS\+1\9'?#F@<D\G>!V$F/.XOW[8\AQZV+O;8=HHU'>47EF[
M2.2JGR!]@/)/CP3X]"+3OWCSD#]/+?!!,C8D_(>42.U[]Q:]MFPL9G^2QBR]
MS$+&BE>[@?5F);E6Y^@/:>..>/LJ0.8)[7 [;>NYDR-C-PD1%YX)F1/:W>>8
MOM %]DTK]$=L\B.3P93'(7<#D<CM!)'/CGQ^GU^GIM9E,6F8L(FRA/$  \^O
M?"TD$GML!\XXV/;UVPL+D*@I^Q7BELV'XY=T<A#^[P"0 ""?N>/N?KZ9%C,W
M!G>\B_WWV&" .J9 Y'K_ &DR0"1QA.H"E6G%B^LGOEVX15# *?#<@%CR>1]2
M/I]_/I>M1_XV]!^XG 6"OT[R1OQMY7FY'.^)SU7,U;#THX89XZU5E5&L3BO&
MY;PPBC/#.W)*EFX!!)7DD</M.J,)VMV["UR2!;SX["<5SM/IU*@S))$CS-[<
M^OUQ*F<S-.WBY:PR<N.%2O[9EK$L7+,P$8F 8H57CO9^>/J?L!*B#P2;GLF]
MR)[_ *CD6Q&"E(5"0.\;][6(,0!,[CMOBMN2BA65X:5=) S\-D+-WWW8-R68
ML'4<<@$#M^W(]1:B-( _Y R2"2"#>!M?O?OBR:6X0 N  +:01>1;?L=I^6V$
MF2,QR0CYTV67P0[%4[BW(\MP"%_=_3Q]>#ZB Q?L;?Y_Q'[X>!$&1&PD;P>3
M\AQ?M?#\P=U8&C>5U:SROMQ#M6 'GD=S?]/T4^&\^>>#Z<#BA.U_ESO,^7UP
MVI"%R3(OL"!:Y^AV'P['%H-1RUJ3%29&_P#EM5Q%!'+ Y:.."7RB1,K-(72)
M'[ @X8<!0RGS8)<5H1M)2DDD6 ([S8>1X[7&*FH0$.0)W[B=_0?/C]$3?,OD
M9>WC.TO9FC66%IXD,YBD#,(I06$L;E>%D#H.#R?'/IMPRHF. +Q!N=X!%B9L
M=HMB2T-(2!LKWC-S,08V_P"/G<WDXK5:L23V)5L/7K.K\))#.I#_ '':%)X\
MDGZ_KZCJ5%U0+QSZ#>\XFI0 D*$F1<]AZ><;SY8R=;+H6,BS\(0I ++SQ]6(
M'<//U(//@_S]%J%K[Q_C"HMW/;L/O@;;R(PW8KL;RRT[E6PL_/*R1&)XW!YX
M/!Y;@$J."/)^OT]*($"\_MO8_MZ;8,B!J!MOZ7B/N-CC<JTJ/:PE,T9+N&"@
MJX//'/:P[00?)^@'G@>?3)603M )_MZ^>!)@3>-NWH?I^\@X-?'$KQ6$\Z1G
MN82K&'"\#@@D*6YX(\>0?'CT8&NY)D6X _SOZX(WO]-A^OR^/E*%?[W"UY8+
M$:<\\A0P(4\'@#D\@\?P\\<'[JT#N>+3]=H^O)MAQ  ,J/NG:#S((W],))X!
M(C:#M'Y1[H[9!QX(8$<@@@CSZ&A(X^O]C&%2G@@#>Y[W\L2O!\)&][C\5>T:
MAU.U_*8[.WMYO[[?W&'(PYJ.ETRARDVP[!<GV3!"RK9B+!VW7\+V2MEL1*!-
MBXI<77B#PS^EJRFK,H%6PMU]1L0*=ZF2+$F%UZ*1,6,G4!W..75#R&GD^.TG
M3ZGB(N08 %YVVWB<-3XA.I'5_JIU'VC>9^D^3QV@YFSAM,TW6<EH/4+2<OH>
MKZO6@QNNTM:VI\;:Z?0;)B\89I8<S>R>5%6SWO42E3^3KUI-9G65Y=?,*E-"
M!=2*E;/B/A1!":,LO/,U! (0D!U)\5)0J%).'S2(K8=I@4M&-,09T  ZO50,
M]M[_ )C4+=^GW5':;LV>>'J1N&O:W4K8.3(9.[2CW+%X[&'W*FOVIUNY'&9C
M)T*EEYZ52K-D\FN*E%^?'UJ[#V"<S7+5TZ:MJNI@PXH)9:>=#=4#_47V!J#:
M2"GPCK7J/B2!IDO4Y+*RR^R8.G2I/O$\&1:  !>=S'&*L+F=FQ>0O1(FP8VQ
M,7@N&S)EH'M1L85*VPO LR^W[X_:!D4F17X9B!*0M#IIOP]13+6^DE(-0V@"
M$*684XI"-DVU$23 ]X@&P4ED*2@)<]X'\S>D623$Q'';MZ'1^;AE?OA$<:.A
M]X2KWA7;]X*(EY0\@GN90I)X[B0WI:R]JT):*"G\SCSU(VTKDE#AJ5!?E$3L
M-XPYX3<7$><#[,^@B_8XT)I\5(BPY"K[;2.H2<!S'.J@A59HY.?<!(3]DW>P
M8DH #Z>\)]]*GJ(TSE.FY=??#5N^F#Y<\X;6M.L(8/BWB\#RO^:.1P/W+BK3
M(0V-R+7%4-$M25FOJDD@)=9895BO5E;N[5>&4Q)_'@DI94AY,(=;6L3*D+"V
M#$CW71^8 V) D*!2;[AQ*F@-0A1 *DDFQ)!WWX%XG@WC&Q'D[D14WJ K20%E
MDEK.)D$+< 2*DJ]_MNPX?W%D"]O *D'N;U+"E)6[1)(@)'XD:C>]B. !($\W
MM@RGW4JF)GSL/CVD#FPF+XV/\0BM$T:0<Q2,S@+6L%3W#_\ MO7A [I?/=RO
M: S!>WGD+4M+2-;TA,@2VDKDJ("0-A*E$#>).$:4R=1M?<3?81N(^,W,;XW8
M-KQ=W\N2I6*M8"%7:)9W=1&PCD]R/VYV54=CVF:-ASR0H/<?2W'&FD!QUC,&
M6U :'7J9*6E$[:5!U1(/?3 W[X!: W$)@P>2?N]YCRWQAD4UVRG?B]DE01%O
M9CN3F3VB$9517>#\JB,! L:KV#GM[5Y'IHN$[6^_N^$-TZ4$09XF(OS8F?\
M7)%DIH<FRB&#*O-"O<O-1J]Q0&9>\B%PTB%U7MDX(!7G@H?HXC24@E(43S/:
MW;G#U@1: ([ G:Y(W W@'??R<6F[-6U^_;@SEZ*QC+M"Y4EJ_@R6)7?M5JZ5
M_G\IBODBEA8WGM5;!<*"OM3(_M/!KFBLM>$V$QKD@\G3$VG@^5[SA"B0(2!?
M5>=HL.23OV$[;8GS4.INM0I2S.R6Z='*8)X+5+,:KC<)5S>4#H?DJ-*N.G[X
MX7<?.H6Q9R65@C)E6Q'.]N&(M3U%#4O-J;4I6E13*8F-*M0@ZOK&&DI]\'8
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MB8'?"Y8W:D<LD0S>-L20320BKD)VKVB&/:T4D<[*3(/*]KDE0.PD%0?5\WU
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MWQ5Y%,=H&Q]5-"W6I?RE"C6NWM/QM";%UI*[1_+TSC=5Q>1GFG2S&CM?I;'
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M,A5EHUHX<C?>$R+-"^4RT5VVD<K&6*JU2"0#V0HSM-2Y9FCK]'U%1-9FBHS
M9@T@@%JFJID^%K*%:"H)5=,RF0)QK<R?SG)6#5=-YH[ED9<<N<?HU*FHI2@I
M J"0GWH4H$@G<Q-P;K3=>*6J8/%?-R69H(U61:TOS/>%F5FD9$$OYV59#PG)
M! [>[M/)[J[UA2,LMK?&ETI'B!O06PN+A!*TD@1:0D^5L>8*/H:N=<=99?%0
M$SX;KJG"XM.P6Z$MD JM,%6\F<3EJ6[9/K#)A*^L">*SD4J5JUAC)7B[95@6
M.1%X>3WNU8V6/D\R=R(& 4FDS3KYBDH'7:%#SCRUE"%:6BTDJ2 -?\V9&J3"
M50"#Y8O\A]E^:UN9I;K@VFE0=:RE;LA*5$G\S(!,)!@F#8!0$G$D]9^M.<Z4
MT)>C]-)\MGL*(8<]DKA=*D>4N4TEL"BD445B3Y>-T$MEIPSRJRQ$!>[UA*C*
MLWZD*:[,*BF+9&L(0IW4 F% :2SIV_\ 7&TF^.KL9UT_THA669:ES\='AJUA
MM0N-)45>*%E(($G1;L1C=Z%]<MXPNH9S,7Y)KNVW8)8-/PD<+*3;82"QDQ!R
M9C0H0_\ ,2S/[GOV L0$K>\$.FH*1I8:2I*$-J3XI<) \-))<*=(4?R@V@><
M8B5&:URD..5+:E_B4K33JIQJ"7'4D(4LK*(2A1224ZC"50"J!@_HKLNY7=\7
M,6<E/5.%L+D,C<1U2TLSR_,$=TZFJJR.2LBE4#1DJK$\#U.ZCZI_"94*:B0I
MUL(\%:]*2T6(5[H*U@S<6*1$\R<5'2?0B,SSOQZY527/$\="FH]U^4A*O>BP
MN2=QM &,^I?4Z?XA=DZK[#ENI >#3\1F]>UK':E;UR:QJ<E/%3Y89 96;(W\
M:NU9Z/$#Y"XTF+KXV"59NZE:AGO0^,.L<^<S/-*JA;06\GIPTFF84$AP5C+@
M2MU02I3?AJ1XB4*2LK)(]Q(./873V4MY-3T+REJ<S%'C-UKJH4ERF4B&VT&
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M+58*&TPH_P#+BW(GSYB;8AFO8QE$NC0AY6D8!N]) 6! ^JA0!^7R ">?/)!
M]1%_F':+VON?3ZXG-H6$PI0-YD2;6Y/F.V%"O!/*[3>Y%#R?W>XA0/!\'M/+
M?7CS] 2"?3:CI )\OW\_NX@1AY!@FQ)C@;_&YB2;S,SO?!%R*41N'EA8>2S&
M3GQP2?''/T^@(\<^/2 L3S<[ "^PY-K;^@B)(PX3J!\YW''.V\;>FX.-!+].
M%!',"Q"%01P5^O)'[W/GQ]1SX/\ 'T[].W/]OGAL(),B"(XD;2=B /EMY#!:
M(]ANZNG;$Z@<N0H4< ^"23QS^GU/VY\>CUJV!^@V[=O[<\8<2A/(,<P1OY1Y
MW,W^N,UP=JPQ$%>:TR'N"P([J"3^\S*/RCCCRQ[? _0^BF3>Y_OM]<)4F(C;
MSCS_ &';#CJZ]# H:]7M&QP66%6#\GD>.&[1QSSY)'G^/'HM]AM]R=]\$)29
MMMV)N8(V&Y$D[]L/"CC9H:[3B.I3C  "6I>'\_3F-2W//'<064L.."/L8VFW
MH=Q \C\.Q/PP)@[V[@#CMV\HVFWGJ3U'R0(:=I"@+-'7]T0MV<]G"R$QL#__
M )<<#['T1O)\YW/]Y^=N_$B=/ /K!(-K'FT$<<G&$5G(441%@D]KM!* 0JJ2
M$ $A8E)(8_Q7@>2H X]"3O'P '?GC?X? 8,Q)DQ<<*DCSGD#R/KOC-=@E,RQ
M7)FKJ>"%,<G/;] 2W9V@-]/K]A]B3Z2=1N#%H@F8WXN/KAU" 4R.^_?:PM)B
M">-K"]I)Q][7H*PFFR<]0JZA)89ZQ,LA/<_9"?>?W2 Q0K$_8.'[3QP5IE(G
M4#W[W\O+Y<7@RA:4Z1J!B> (@CCM??<R8MAR1YC2F16>C?G=N2TSW,M,\I))
M]QY(4HQ,S?5@E6(*Q*\.09'="G(%Q\2?VMALI;FX(]#;ZP?IOB1=J_XB6'T?
M=LSK)T_J%?U+(V5T[6ZN8TZCK>%R^K5ZPQJ6\KDI,I6QF1GM.)XL@;4.(MV+
M-R1J-:*:&&&+/]=]%UW40H,PZ?K%Y!F3+[;C[#*'*=.@&5 K;0&U72+!=QY;
M<WH*MBFIE4SS:,V94DA3BEH2L"#)AXI,P2(@\SN0:%]6^MOPX;]LNN:EDNE^
M7UO3LS6Q\MG;M7W9<OBJ^7R>;R,=/-O!D<6<IJE9*V1ABO8?.5+JUVA>U)6F
M@Y+[7(J7,<ORU3.99@Y5UE-3Z7'UI>67%^'J29*)]T*2@&?Z>VU<]3-PY494
MR&6&25.4Y4A(:L%+TW"5ZKK_ )95)5!]Z1B>=R^!CX5=QT3J33Z5]9<OTUZF
M=']>@V')5>HF;&<U3J#$F,M7:$N!$N,PMEVS!$219S63DL76D"U#C8YYXYX.
M=4&;]=T6>UAS"A\3**H(_ U"JAI0 96KQPI'CE3/N/,F7$)UP=))00-%35-"
M]24JDW<6I:50TI*@4I0;RF\3&\WL;0.*.1AOXFS6&;Q]W!S6(DM&+*8.Q0GG
MJSES7L?\Y&DS0SA7$%WM>O9=)!'))VNHZ=2U=-F6D-55&7T ^(W^(82$J E0
M*BYID#>XN !>)=6A:#.D%,R+B\CD29[Q!,1Z8UIKGNQ\R006XXP8FLS5$17+
MC@K'[@1G4'E#)%7[4*DH?S-Z=<1X5E+;41?^4XVY/D?#4H&W^(X6EQY(]QJ!
M'<"-ID$S:8V/(&$?)8[%0U(V_#X4M?O!JDZ)#&BAO=E,Z=O?VCP3.\HC+!%A
MC9EX2;6YO&YV_7TP@ JVGD]C$VY%K^IL2>,:=9XXG6"&[/)$RQ2QE?VB)"Q7
MN"23.P[P28Q"_ *N7C'#< IC<[;]A/V+\_.%:% FQW$W!OO?>.QG80+1AQ?.
MWZ<,)MRO9KEI/VD4512BLS(J,SD&N>UB)60?6,*WYE ]'/W\8_6!ZF\8(H4#
M8=N;#>+3?R Y['"K$TEY$DB>>LLJF9UK_(7J\YC95 D7V'D5U4JGN>XI9N64
MO]")'UC"2@B]K6%^VQ$D[$&-QQ.,_P (LM S"..:$'B9.VK(>\@#L:,-[ZL/
M;4RNL9C9^XJ?OZ/!Z3^]S%O*(GRWW)]=*?%X=9!"]6.*1WDX$<'L!V"QM^S<
MH0X+\J%60L2WTY!]#"?>WY&U_G,0.+SR#W&-(X:>.4"B]B-VCXC[I0\+%I"S
MJ!*TA"B,'EXF0,05++P#Z'W]_P"<'('>^^_.Q^D ;["V,*&#J7K5'\=J7<;5
MM6(:DN7Q=>2::@LDP46WK1RK[W81W?+&2)['B%'5Y%)0ZHMLK>N/#Y'$SVF;
M#_1(P ))BYDP01S';M'(.TF)&'U4U1=%M5K&R9/&[)C,Y@;4MRK2LT+YQPF>
M:DM38<=9I2Y3 W\7>JS/DJE:37<PM9Q'BLQBY[,&1KTK]:JLI'6Z9\IJ=2$H
M,*2;+3JN (E.J+QM(WE:$*U"T6)(.X^4;$#UN>!BPN?3H7AKN N8#7J>8UCJ
M%[8NU\!M567+5M438J=J\NN:SL>+VC+=,]MQ^1Q"X^"UE.H&]R5*UM5O8G(:
MYFXZ[5>7L9TFH>345*Y2VMU*5+D*2CWHU!4 &()@6O-L&I:$&"=))"1 )W/8
M$\]__;%IPW<YT%WC3MIR%[HWL$NV1Q[5J^L5]?R>.BU+>:^7SM:UD,-CMJT?
M862A;JJ^/GKQYV"S<U.[)!7RM::-<E%%%)HL]I<SI"K,J!ZE1IDU#=.MZE'9
M1J60XPE,\E8@D 7P%J2VO0HD*V@ D$#C4) @6WW .]\)=G Z[C=QJXW=M%H]
M(^M&,S&.L6.FG5*IEM;Z,;UCC9B:L9[L]W&YS2H<HM=I;:V=@?6\VTMB;#YS
M#4GKXTK8?0*9X98\BMHEG^3^#=34N1!#@<:86XMLAT+$.(2J$R."65K!60)D
M 1:UP+"T&QCF_88C[KWJVR8?:\?LF:Q.TUM<VG&X&UKMG,WLSGL4QK8?'5K>
M#P6ZW,?2I[)5UQ(HL>D6,^?JT*:QUHKV1I5XLI:L\GJT/4ZTI\1:J<I2\E+3
MI4TI05"7!IE!)28"@-C; F3<R)W)@SPKN;1L1W,3B+*V?LU90WS7"%DA,0'<
MZ<AA(5B '$43LJNY 2*4K[C*Q ]6WBI"0HR 5)0)2J=2B !! ,21>(',8"HB
M(CT'?;< S:^PW$R!C:BV[(S]HJM7L $QH9#^T_,0G<&:18V:4R1A>&[57R#Y
M!]2G:=UK2%^&"I.I(#K2B1$R0E9(MP1/E-L))3>9 MV$D6^'/??#>R&:MV&8
MO 6>8 %HE@ADY(*E"RR#W49EX*,W>X'('T]1"M(DE4^0&]MR1-KSO:1Z%/W\
M\*>EYE(=MPM7,R24,#D[=/'9^;Y1A#!CIK<:RV3'S(IEHD_-(\7[8%6$8+D@
MK_B+V7LE5.52\L$I$I, $0=B(@[GZ&,+9H*#,7TLURM!"-+1*-4@DDF=*@(-
MKQZ$ 8G3J]E(-KW.ML<DUJSKTSF*A\R[I-1J4IVKOCK4+CA;--%]F3N ,D@$
MB\JP8]EZ<SRGS+(B@DBJI@TE:/#4DE2TR=T@*@H,Z9 D228QY\ZRZ:>R?J0!
MR0Q4K?<8(4EQ!;0N+E!6&_S)]U925 0!8X;76G/27;6(Q&MH,7J]'%U!C5IJ
M(UN220$V;^1:,]]BY)(61S(1[:JI5>?J%LY?7M+I<SIU5+"UB65)MJ!A)]\$
M0DR1J^<VQ%37YQE%0R_ESHIU^ZAMYM7B*U+,!M*6BI8"C U:82?S$ XL7\#]
MC6=;T?J5E[<%#\:AV&H);C!9+,M9<6DM:)^Y3(($F^9>)6(4S,Y4^YP/4493
M14"OX=EJ6Z1APR4%3:! L)"8$WB8.\;B<6QS;-<\9J,RS12JI[+TI\52BH*0
M7"HC2'2%*U%!G1,1%MSM8V_A-NR.T96V\<EXB29)"JJ2G:Y<IR"W"*O:3].
M /IZTZ@*1%*W3K0M+2D^)*DI/YI.Y$\[>7<#&++[E<U55#S*D..)64$-J)U1
M V!B3M)',;8KYLD-26R[QA LC$QL0.&0\J."1]@../!_@/'K0EUNH2*@$$.
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M]R.ODX#+#?>\E=UCKUQ!4T3!::0R\ZE;L%24*4->DDH T$ZH*@>"9^.)VM$
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MPQ8)C0._S@>L<1QN#SP];>3FM8\(MN)R8%C6"!A*(ZAF+F7N$LJ-*7A]UPB
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M08Q1J(O;8JD96%5K=S_D9@'Y#'\PY ]9OJ;(0NF4ZCQ5FG6FH:;0M7O.-@E
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MV/R$3)<I72PANEK\Z95 "BBD"0 2)E5TH')6DA21*DD;8DDMJW0F!M87L=[
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MI TKL%[#3*C5JS4U5X?<:&K+P[3&D8*PH.LU"'-9\4+IGD5"87(.DJ;&I/\
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M#\L$BE9!F"#>1)^-Y'<Q([VMASS5:KR26K<L=VU-)//('C,4!:9B\I/;)(I
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MRD..FB[[<N'%NI>G#,MB3+T)-AJWJDCSI6B"V(($BNU:1ES*6"''W8#H5_\
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M/J>OQ0"K0AU+Q*I)D#4)]VY( V$SOY8D(2$W!M G;B !V '$WL<3UIO6,9'
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MA::"*=)9[5?[/>K*_K7IQNNSK*:?+JE!20JE8;;4#%B%:E%7SCW9DC&32"T
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M?5'/17ZT^U9JWA[6QVMGHXW(78\S+5RMBJU-YJD^0"6U=\8E?&SSQ/7>U%!
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M2R%44(*VN1Y:Y%?=*EFO#(7]M]>5N)F7F?=LJ"NQ,"_NW%N"2;3&&%Y]3#P
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M1KN5E9K=81H*Z1$3!8I%KJ@$14:MG+497EC+%)3H8:U)"H2AB$C>4D)MO:)
M/<XYI1YBU6R4.%0%Y*%C?GW@D_#Y[V83XF#,Q+'\O4AMSUW[;$5LTY88EC=I
M*2I8GBKT':,LL ELNKR,$6'VNVNLAU*&X4%(\,I24J2I)%D@$6)(A4CY^>+
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M3"BNEGTA#!KF7354+++R8++B5LJ5%^4$E)$#<C>U]6F-X3D$:5<WL?*('![
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ML.^08_-[,_Q9=6NIN]-=JY;*X*"#.;3!0BE7,->O9P9:ID\797$4L54QF2Q
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M-RMF;4'Y;,2NL061D54[R_)+QGAB>.Q1^<J022">6X.;&QL;<P=N>9)-QZ3
MP90Y ]+GF_U[=CWQN='NH>:Z*]4]9ZDP8BEGK6MR91TQMB:>E'9.5Q&0P[FQ
M8K5[,L1@7(M+&8X720QKY#-W"51/II@5$@*)44V)$D]TR/,R1(GG$.NIDU=
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M"G!J%DB=0GWD<@'@JM=)"=(D J O+:_ ET@RG4/7^A^'ZD]4*G5G;_ALP_Q
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M96NB;;0AE*5E(;J% : KQ$KT:]#JDJ2 R G7B8W3D-.AQ0:4IS4E*B I0BY
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M&HY73L1D+4\$EJ>Y>L4KL5G,D52O&K#FR#SHHZK7:W]+9(Y)[@3L!A>H2(4
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M!63B$L8N80VZ]6:0*BLI<ZIZ M.#*'VA4KK=)32FH_F#0I4: X/#; Y&L;D
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M.0R67W[?-[WF>25Y;E_)9_+S4L.EGY:&:=JILG'0RY&>4AG2FDUMV]EI6C(
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M@B_I]_ZG#FQ^3B,%FS(MK$VXWAHO9A$=/AI%#>U-VSS.]E4 :%+ ]MPS.Q
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MN5X,[@)9[F'DRN(#8O,1Q4;$C2V(^6NZ%A]#[X2LJI@XX&C,2UK_ )9%Y_(
M02(&W.'203( @W$3SQ?M^^&?TYVZ?I9M6-V)(,=G<34R(CS6)RN+QN8PN7H6
M%E^<AOX[-4\AB;/S/S-HUO?Q[?)V9?FH2DM:.5"S6C_$TZ_P]JQ,I0H#W@D@
M$0J4@0K5:8%^! =9LK4!<1S<Q<CG<=^9CMCZ$NCN&U?;3)MN"K;'0D7"W;&
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M !<S]#:XX!VY.UCQR<#&S,UN)JD6:QU*MCIZL4-2U&QKPUR8YEAM06':,5+
MD]QA&B659GD0*6=647D@[$'L.\=YG<VV&U\'///W\YYPC7\5'':JY2I+)"U>
ME\ZM=4<O>628FP\C!IB/E'K %90&2NI)[1(H  ._) ]/EY>1O]</),I ^O\
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M'MY3A1-^;#T@6D^>_![6M(U<E1>E,J+.)97'<*Y $$"%?;+E6\( 2..?W_\
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MQ;?XWC8 #N;&9D[X;$NP?(I7@G9E6RQ]MV8-''(C*&6:7E0LCF)4CC[>YSP
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M ?).EF-6EC:X)H>',@"0+7DD]HMW0_G[3Z0HD"!(((D@P8$B!$CL2.3;MA2
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M_?WMQQA7HY+"UA7_ !DRI:1WB!K2UK,9E@Y6P9(#*DJ&:VB(SQ7(B!W220D
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M[T:9LK7ATF5NK>H*5;BD..EALO+;(*%+*05*3Q!X(,'@ 1,9QU86H C\Q $
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M9IZ^E*O&K7=3S=0M,I>=+"SX:5.K&L!( A1$P;)I%OMM-,K*2III#:CH1)T
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L^N!P?4?H<+=O\MF=5_*HD8!5\  'P !X _@/1I (!(!-[D>9P)/<_,X__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g209588g04a00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g04a00.jpg
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M 0$! 0$!_\  $0@ I )3 P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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M>3Y_=E<=*^L-U>OT+I</9$D9K/96UZ7!6R4JX,99;K5J(9;<7HFF5><O,=7
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MGZR].]']21[\G4$38V9+9\U"SMZL5NM]@NEDL9E;@V:Y7LR4Q/FEDDKBX9C
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M&H$6J>;,D"'BQ(6LUF(:^U8KG;)5>1X*I5H#&?(=,S!?LTRA./$*.@F1-6P
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MDH$2:ES:@(!7)LH*2?DUB1I8L^Y+M9AGR&TOM3:99UUQ(["#1\1[ @>9)>L
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M793@Z[7&&SJB9;<""Z5DCN2698VF@F=(I/2].5(R&<R<<#(!//M;6JBLVM7
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M\7O]H/47^\Q_]'']'?UB_P!R6_\ NJ_SX_JSZ _U3U'_ &+_ /4Q_7E\7O\
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MO,?_ $<?T=_6+_<EO_NJ_P ^/ZL^@/\ 5/4?]B__ %,?UY?%[_:#U%_O,?\
MT<?T=_6+_<EO_NJ_SX_JSZ _U3U'_8O_ -3']>7Q>_V@]1?[S'_T<Q./ZJPF
MC^P.C+9I6L%1T$07=8?9I IC+3":\?4I',5]YEXAIPYK%F'ALM,#M%.,O_ K
M+:&FG7F\$=#Z_2=2=,;3I;25==!%8VM;?R4W2 -KK.HM&MZT<LX>R!M8: 1(
M4E>-F,K*L2/(FT;XJ;GJGHGKK0]>]3WMU:L5.G[G2,.QCDMM'N:74-'Y[Y::
M&J8Z3/H;&T,LMB6".5$$".\TD<4FQ#G1\XKCC&.,8XQGAV8XJ,KD](@9%P>%
M#R1('W7? &H]H1Y82"7OBK+;#A6&D.+PE64H5G*4JS[8S>KQF:>&)5+&21%[
M1Y)!8 _A]N3[C\SEFQ*L$$TK,$6.-V[C[ A3Q^/DG@ <'DD  GQGQ@[P?NW8
MCL3;H^M9JA%PL]E>CLQC+HXC0"(Z-<>-)=R>QAE0@(@)TG*2$?D]Q_#!LDEX
MU3GE=Z_1L)6KJLT<D CB4-W<,/U8[??W 5>T+[#@!0!QP>.6X&FF:56697G[
MNY>5Y5R6///N6;GW'<6Y/NWG +KKB]TZ2K^1-G5K8$'9%J=GR2<RH.1RQALB
ML13<7)A_8C,!$(8P+(E%1[3C2UK\##+9(>,IJTZRQR"$Q*X#B93WJT7NP !)
M;DA1]N/L?.66N5)*TD2N&D >,0L.QTD^S.3^P!Y Y_:'CGSGNSUT,K5.O;TD
M 1&QL3"QT?"FCM-X2_(RPCT7ET;+#F6<#)E,,D^=.?&VV_C/V275*5A;,1<$
M$ESQW$@AN/;S]OV?M[_;[<Y@U$D,J1 *0 "55@5+ _4>>.2#Y^_OSP//&:Z#
M99.6#6FO_9L*.;PA]E2<NMO(\CKR''<XRXO#^'/B1_83A7OC"4*QE&;!4 CL
MD8!2.0!P">0?(Y/V!Y^Y_ CG)(CF-RYC5F9?9OPXX!'N/'@#[?8#DY^#RJ4?
MPK7AU25M80_CV7\$Y]\Y1[_PY]LY]L8SGY8QGWPG&,YY[[P&//;S]N#Y_+@\
M<_E_#\SGANYR>%*J?# <]O)XY)_#[<C\./L,RN*L989[4B*4IE0I8Y0J6\(1
M@93"D.--(PG]5J0\UY?DM*U8<_O]O;ED*$[P[%U+%CS[ ?9>!P?I\\'C[GW'
MC+K@2H$[ A2*11V\\NS <$\\^X\_C^\^_P!X?4+81NR-/P$Z84HS#D5 .CNY
M6VXVRV3"!K=":<;;;PM(I+;R<9SC*O9>/?/ZXQCFV^@CAM*T:!/55V8#W+!S
MRQ'V)Y_@!DEZ+N6;-*W#8=W^3LK#"6  6'TE[(U( Y5.#P3R?/O^%IN:/)EC
MC&.,8XQCC&.,8XQCC&.,9KV[^677D?1V ;%%YL,\F,G,#" 2^(XN'96,S/@.
MRQ#+Z'(R/DY>J"/".O)95)/PKP ;Z5*>4C>Z)*\YV4%F5(Z\E+T+DA<(\%6V
M7ADF$@97A/IB41N#P)0C$'L\:/>R7:HU%NG \LZ;,3T$,;2PVKVN$,\=;TBC
MI8*R35S-%P2L,I5NT2CGY<D1][N%^CUP-0D[W=IXM^6P-*C9-:,-=(*?(/D5
MR"_QSL8&E+4E)R$N0W$",I>=EG< LD97U"C:=OGX9:_H4*4E>M0M-.L_S]9J
ME=S((D17'98,L*\J2P14]D SF6PI00#7V([HFO["O/:VE45Y8#K+B7K</RS.
MY(E!A2.?N![AZK,_EQG4VF[L.J..1&PJ:2/,0\:DIFTQ64R,1*9-)RZ6"!*"
MNGQ<T*(R:\0S)Q1)003K#R&%Y!.CDLZ_94ZUNG<HS1S/1G0?,P=TM;CLD25"
M'3A@Y=5)4#M;@ACR!QL=+?M:[8T]MK9H8[<+2)4G=:]DE7C>*0/&[%0.QBJ,
M2&0GE>>#F1:B CJ76JGO9F!9G9LR8DTQ479B%YK\%B,R$_'RJ(D(L0J;F&\'
M FMN/NIC(IQ\9D@(LA_V%NP7Z8V.MUMJ66*QLXK@H1QF:19XJ,<<]H3R*.R'
MMCD4HLSHTW)6+N;CC$NZW9'3[C8T889J&DEUL6QFE^722NVQ=J=(5H'999P#
M7[)# KK!'&GJ%4"C)=.V?*;^)CHO88N9M-<3]FC+CGD0SM8PX@.*+'A7BD%L
MD)EQG<,%QY31+9C^4%86.8VR8F^D.IUF[C::W?FN=0[<C7UY$>>G5EJZJ65X
M(3%"(J%9XZ;S<S'M-DMW2]\L2FRLG4&ZZ?G2KK=1#0Z3T<?Z9N0-%3N7*UW;
MI%#;M?,VGEV%U9;L=8_+@M%51&])8H9&%>U5&:I]RMT9.-LDRQ4\+.4LIWPD
MGKC%H5+B/L./8<^J4,"Z&\RE?UI 8990:,8\"V<+6MCNPS5=U72SJ[9GCL0N
M7[)%DX5%9HY$D[7([6 D3P >\$'/5+>RZR>G>Z>N?*[?7B-XI4$9D@D0%C(B
M21R0LZ$\H2KGO!)4_>S41(R"Z6$8%/24E,QTF+,FQ)A!WN,,ALA@:;%94^Z*
M4G+[BVTY^7W17$+>2E;&'7D;C;0:F^M/IJY9L4+=U(;M/]%7%HWIZVFLU'D]
M,K%(Z5?4GIU[:,\BR03A6$@8C(QH[.^UTU_K+7TJFVH:J2Q0V7Z;HG8ZVM:Z
M@U^YKPR3*9(4>ZWZ^Y3?@F&>EZJI$\<9;Q]U1U;8V15I^-#^$A;:]4S;719,
M9;\+6VL-L J4S&-J7C+<HT FP1T6X..V$%(!*''0VL<EVWL8K\,6Q6K&=K;@
MD=J5"*9(7EE;@Q"2RY$2^GSQ(W*EE4QA 6"YG::UK)FUIV$ZZ3721J;6YDJM
M9B@AC3B66.C&1+8!"ETAX8.Q!+-P3EYM*3#/7R,AKY Q%8DY,=AF^1U3EW"V
M,S=8CR)Z+G!1%8:*9C9>KXCRI6$4TH14DXVV^X@A0;(CF%L*MO8'8:B2A=J0
M0Q5$L;5&CEK--:+#Y:.=&22V\:QI#9$D7;%%;@0,1)XS*%RE2AUN\79:Z_8:
MSL16T2K-';KPT?2;YN:&P9(ZB3R2S-3F2RS6)Z%IR$,8#;_M6;!C]J4"M7^+
M%=# L@2C!QWEX=4A+9#PRLI=PAO#K2UL*6VY\$9RA6,+0A>%)QQJ_4:C<L5'
M)+02%"67L)\ @E23QR"#[^WG.T4+:7Z5:ZG9VV8EE 1Q(%))#(7'@LC JW'@
M,#QR/.2!S$S,QQC'&,<8QQC'&,<8S01ZE%EKE1L=I50):U1=[D95N"M1,0M+
M<6B+MU?C"9O))#(V3%/R @( #"F7F4L#!2H:R7T$?58G/3L*15:]P-(#3:]L
MEK0LI:_*D<L*PB.3Z&9>&DC8'E9@K<#L^J#[^S+)>N49$B9;\6MTQN7(Y&74
M5I+-:X]R)U'? @2%TF*]OJUGEBY=9AQI>USBYN25B-H5"L5L>B@VC[)90QY0
MAFO5<9]9DFLIP5.8\=$K])GXLR8IA!WTU !,.*)?;7.OF!=H5)I%FJFY6@MK
M6L )8B66/N6.6.,LJRP*Q1^#RO#$\'V@[4SK;]VI'8KVXZMF>JEFGR8++5Y6
MC$T)<*QBF4%D[B X;VX\9%T_9XR:E(L<&/E(<BUR#3 L84P[YPC7I%R+REAY
MW+;JHKS>0YI2_CGZ[:6WU+\*'W=9*&%VK?\ 7MO)7KRT(ZZV'%66)YTL^M)
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M*2AIIH9*F$CN_%E(+A?G4VZIC^N6.A3C6'9]1Y;U:[0MV:"ZJU/L+2UX+.J
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M,H9:,9<R^O[ P*EQSF#/!D4H=;DJ[Z[4;B]C&LU1G5JL4DK=X4J8R%3AI(P
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M9ZVP/U=&MV2%EGL#6.YV$,*%D*Z<V@49I+T#-Q/YB;&0U@1C$K&./ M-#/\
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M1>6<VG#[8B GG6\YS@=+F$\\QW9X56+UY5C:,J_8R<>  BGU$<<<%AP"OO\
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M4K8?@BBQQ#0/**AZ&E6XR3'9*:6P#D?#V6&5_G[_ -_/O^/.958ZXDUX2<B
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MV9W/+,Q8DGY4EE::669Q&K2R/*RQ11P1*TC%B(H(4CAAC!)"11(D<:\)&BJ
M!S\]Y;S1[ZRD-;@JK6+\#AM%4BJ[(0Q3Z 6"58G2[!%.M"R&7&UY<8?!6HJ.
M4O.$@NQT@ZUC+I65HE73KU?2M1S6WH.61FN+/!"88>4[64V4EA8^LJ(>^*0
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MBU_^RE[K3$0R]LC2'M5&X#"_U#0Z@ZEM=<;W?R:P;357-?K=@4LT89I[DO\
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M*V*M?DP9&)D*@(EJ@@V@* 7#P\+F6ARRY=F29&"4^7F2D5R9"'UMLK_;_/\
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MU/#&R#3:UY=^_AB8$4Y[J996AEW+:+UG4["[!L*=N2DNMV5010FK7>OLE>>
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M+21#H;!YC#H0BV&&8=(QCD>EY9R52"AA7G&F&5C_ "RI;6[O]9R3I5AJQ0I
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MA&/?.<^R4XQ[YSG^_FO/DDGR68LQ/NS,268GW+,222?)))/G,\     !555
M\!54!54 > JJ % \   >!G-QE<<8QQC'&,<8QQC'&,<8QQC'&,\^6B8N>BY"
M$G(X&7AY8,B/E(J3%9-CY$ MI3)09H9*'!RA2&5K:>8>;6VZVI2%IRG.<<\.
MB2HT<BJZ.I5T8!E93X((/@@Y<AFEKRQSP2/#-$ZR12Q,R21NIY5T=2&5E(Y!
M!!!RC/9[T_M3=@Z]%#P38&K[7 3(\Q%SL) AFQ1*$+Q]J)F:[ET,4J.*;_\
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M'D #D\C['\1^/MSD=WKUD^I53H^W;G$ ;BMJ=7:KWAM6,'$U3;H:)V?%=?\
M:L3I+8 FN;5-1PL%8&HS95CK4._/"D.U]D&85)?D'?P\Z+&L=AY'M[@<\@\<
MCD??\ ?X9F$/ZK_57,MFJW@^ZZ_M\-3[/+7T2:HUKS6:1L#7>CW>PVU=+'V]
MZ' "*V9K?6($W.6.&2(,@9Z!F( AT6W1LA6Q&.TGV'/M^_R2!^[R./X?;/$F
M/6$Z@UX"#E9Z/["Q,=/5#6NQQR"^N6V/,%K3<&R!M1ZTV#)QC%=>F JW>-@$
MI@*>E4<J;N"FG3ZE#3D9XC'6 I)X\<^?N/L.3]__ &^^=N<]8'I56J\S/SUB
MV1%NB26W1KI6W]3W1=JU;"Z(V C6&V+ILR%'CGG*M4*?<G6XHF3<=))DG&Y'
M$(!).P%B:B&.UN>..>>./SY'(_B.?X9B&Y/5TTS2MBT_7VNH"S7(,O8N_*_>
M]H6"I7NKZ;BJ+U4U!M'9'9"UTC8Z*O)0FP#]4V*APVO)V+AE+:>G[&0F&*F%
MPAS&&.T\<^/8'CD<^2 !Q]N0>?W9GE?]4+2<2]KNC[>C[I6-O6[12]PFQM9U
MKLX_7LH=":%<[%7*J:WMMKJ52E+F_#:[#E9 ,]=>BPRCX]^IGO1=\8-J8C':
M?/MX/'N.?P\_A_'^[,<T1ZO/6S< NAXVQ0NQ]7[ WD'JQS]CIVG6"4"UK+[[
M=E'M"U?8MO#B1H6'L.W84*-G*H*.DL7,=9:M('&"PMHK$O-L%3YX\\<_V@>Y
MX]^/[/L?P/&UCC/..,8XQCC&4,[']Y:OU7WG7J5M^,!@-.S?5CL1V$<V?^1>
M<E6I_KO8-5,S^OP*W]5+4H;-U79B):#P/(XDY"9CF8,*.*>D$.,L]!21X]^0
M./W\^>?P\>>? Y'G/#Z3=Q-J]D[5O:I[<TS#:5EM%0&@UVF.%MIED*A[]N76
MQ.Y+!KJ??+A8<,69U;0;'J\.SDB.$#O6N<L8C26 (D(@Y@C@#SSSS]O' /'(
M/WY\_NRG70+U?K+W<W9KFA0^O]&S5(VC3-Q7MV0TQNBS[$V3H&!US8PHBF*[
M+U$O6$)5:$=MH60%75(D"_2<V@U>6R(I0[13HK*LG:#R3R./<<<\_AYY_N_'
M\,F1[U=--4NQ]@8W:]7N<=&ZMVYV;I5%QK2HVS:,U;]>=.:;J>4[#;5M T##
MXCZ+ 4RX[$EJLEZ8D&X\M55*0S(NRQ#47EE.T\ @@^!S]N">>!^9('/CV^_@
M<Y[)?JZ=>8S;&U=<2=3VMB,HAVD:G1[)%4:P2YVZ=E[FUK*[I10Z'5FHP<U@
MBJZ?;KNPI66GSHT3\#,GE'-PX\2$3/,=I_QY_( \<G^WQGN27J\]+0X21L\7
M8=F6VJP.DJ#V"M-IJ.G[_-5ZFZYVA'6@RA.7"51#,BUNUV<^JD5J'HDJL>X2
M%GDXJ(#A7W52*XYCM/W\'DC@^_CCGQ^'GW]O!SECO5RZ:/3LU"6.:VGKE%8+
MWM&6J=V7I?8]+KE9F>N-0;V#M2 EY>6@FVD6"%HCXUH3""(+D_K'1L08,%:)
M2-@2V.T_EYXX\CD\^WCWSD%]6GJ(9$))'>W$_;,6F7K16IP]);#D]NQXE>UQ
M!;?L%T.H,5#'2[-"@M96: MDK9TI<%%Q+ UE3>;L^BLY8*D?\^1^/'\0>?X$
M^WG(AT-ZM$)L?7R=J7S7!\)6!]*Z0VE,5K7$-LG8^P(>0[)W7;"M,@R0@]$C
M:9%UB;T]KV)OLQ:Y:Z ,5Z3G_P 7.BQ !-7D[.QVGGC[\D>?'D<<_P"/C\?M
MY\9E#GK'=7<W&*%#C-CG:HENM&INQ0>WV*/:% 2;W82]"4+0.K*_4D0B[%,7
MW:$NS918T%2 E!R==(!RP6*Q/RE<8[3_ &\D<>/]$<M_8/QR_O7[L!KCLQK8
M3:6KS)9^ONV&X4^3C[#"G5RR5NXZ_M$K3+I5K%!R+:"HZ8K]EA9&.)3C+X9:
M&FI"+,/BS C2&4(X/'^'GW\Y-?&4QQC'&,<8S5%WO]0*_P#6B2WE!ZII%+MD
MGH;K?JK<]J>NS\ZV ]9=_P#8V/TAJ6NMJ@BQ'F(YN*J6XK+:',X(.4Z%2V8_
MZ[!$EDAGH+SQ]N21[<^PY/X?B,_O7WJ&VB@;QNW63N;4:75-E5R_]=*E ;&T
M>=89[3\Y']I8;:CNKS+,F[LQ%DU^7BWZ=LU!D?MKL$<38)ZCX",0U//8 8(\
M CG@\^_Y<<\?Q_N/X9^1/K+]+):U:>J^9B]Q*=S16JYN'L,]78>&@*M$[XMT
M]3M&2-Q4;9VY@8':YL%B7KQE?AK&+!5><K5CO[U-BIL0C+!4CG\B1]_)'OQX
M^WW_ +N<]#9?>+96T-XP?7_T]W^L>Y9MK0-@[&VS:-\V3*3FJG:^#?W=8UK7
M51D=29FLFW&Q6R-L&)R</E&HBB1L.R\;$SQLL. P_G^?[\<<#D\^_'Y^W/)_
MCX'CG\?&1]L'O)W,/M78. TSHG0<89TMT7JG:?9:M;:V;;BI.S;"V)K.5VW*
MZ<TW9:17,P8PM8JD.H-O:]O (B9R?F(X9JG @!2I[#' X')/D^"!]A[DC_A_
M?]L_>S'JTU'7O5W2W8'KI U;?MWV-9NLAMGZY1%SA#-T5G7?8&L(O;0[]2A9
M9V5AM@NU1QM%3CYX)H"9F7AQF63$D,H6RH7R0?' /G[<C\_PYR+8/UJ*=*7Z
M@R?XV!E^N%_[9;:T9#[.HE8VAL:S'ZZJ72K579VB7.,I5!A;39CYVP6O9**K
M80!:T2/ P(JC9 :,?!E"F&4*_G]N3[>_/'']G^.3MTU]1VP=E)GKRJS4VO0%
M3[-"]W1=>R40-:(V6#L?4+L01KH&-GHBU9'DP_WA:G*8N>1#(R,DJY8ZG:(N
M1'PW)QHD8RK+V\^>2.W\O##GQ^[V/\?QS;/QGC*"=C.\-4TY;]1#TZR:JV+4
MO])O7'7;M0/#76-EKIU]_?>Q9*EJ>TV6-A98A-38*W$'5JC,BW,$13L=.&%
MJ9=B2W6V5 ]_?VY'CWX\G^SCDY!O4'U$-B=F.P%$HLCKRGU_4VYM/=L=^:@L
M\>7-N6J8U9I'LOK?16IY^68*)<BD_O3K5KE-C/8#:\0\:;5V07%-J,=(95E
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MZ8W& Y=]?5[!J2F=<6XP21DRH$9.'',Q@<B[#3(+<0M*7G&"*@7GV6X20?\
M/'35P?#_ .*UWH&O85^E^IH6VNFI^J)%TFQDBGGDIQCN/H1S-6LQ"L0&*/K9
M/VFD>;[#ZUUK?%SX!ZSXLVZ;Q]<=$V%T/4FR,!B?JC3P35:L6PE/8OS4U9+U
M&PUQ28UECW<(Y588JVVOGT3GQSCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9$L-OG3$\5.!1
MFSZ4X77-E':<EQRIX"-=8VG&L"$G4,=$FZ'F1LK#1PWO&QOVWG'%.L-86\.0
MVTRO!_NY_LST=G.:EF:\=K#;YE$*K>V86Q4DRD7N0A&@-@P4M%.QUHK2869(
M:Q8@S(:0>&EXYA@I*@2U)(;PT[CW93S]LK>O0?0*3J0.K7:1UVDJG-;+K,C&
MU-XNIG-2VW*#KBKT&N. LNR#QA][@=3Q56J6&&''9I5#^G$&M/0<BXP4RO)_
M$_A_'S_B>?W^??,D$T3TIUY QRAZ#H:HUFO)US.1BW6JK%0D0QI(.3@=820S
MA+[0(H>MP2):(K+V%)$@AU& CY:0AQM+'G\__?\ YY@D1J/T^=#RFL8:IZWT
M349J]7ZC6G5L74H2!(E#K(/ VNI:^M%9#B_L%B52NURWV^OU>0CVV:95XVUR
M\?$XCFIPALEE26/N3]_?\O?_ -?QS^U:G]/'JD+.V1FB]>-/.:D)_P!(.8Q%
M1-<C;!2%Q-6LVO0+Z-!1:';#'@1=4O%KI589C([$: #:Y6O5L%E4RZ(0RG+'
M[D_;^)YX/]H^_P"'Y98FX=A]%4*.G)2V[;H$0)62:<)8\*L\687 N[!G(BMT
MM<Q'QY!<A&BV.9GH@6-.,%9"<0:V8LA *'B6V4 Y]LD6)ME6GI*>AH.RU^:F
M*J6P!9XF)F8Z1DJX<4TH@8.>!#)>*ARR&$J>8'D&AWGFDJ<;0I&,JXQGO\8Q
MQC'&,\.SC&F5R=%C2Y<&0?B)!H(N :KSTVP4H5W#"XEFW#&59R1RY\4B(L0S
MT*I_*,22?J9=SBU.KM#*J-(CF-PC0B$RJQ4\&,6%: OS^R)E,7/'>.WG-AJ9
M:\&TU\UJ&E8K1W:SV(=D^SCU\D(F0R+=?2RP;=*O;R9VUDJ7Q&&-4^MV _+5
M4;#":*N^RJKLF#%C9-JVV812VAZLJ-S(C&I=EX<<NDQ,30ERD 2>U$62-I@0
M\' 3:"8@0<9 S;6/F:I:@Z>V>UK[6H.]K5D*P2MZ??ZA=T1ZT45)I(S(D=A*
MB+#!/W0A5[>,_73=ZO8?$/0]*[CI;8S6Z<FEU4P5I-P+?RLU=DHWI8=]<N]2
M+4V,5=[VKM[ZQ+L-E0,-V:65I&?+E>F;7IBQ[^V3LZ# DH>I9AX^--=!%UN@
MA\:4&<F8#%A'M4$[LL2G6=KR&UV8UQ*B1$],P#K$]@L:(:<$E_PTK33[G:;.
M**2"H\<<9[4I*660-/#ZJV(#>%.96[J\U"989I8664,(@R\._I6;*EJOAMTK
MTEL+-2]N1>LVJZV)NJ6BCEIRK1V?Z,DTVP3I6;>:B3LK[2CU33GNZZALDDUI
MAENNLV^?G;\_.S'&,UC=F^V^Q>OVT;DBM/@;)BU5*(JT#K<^)?K8=.W+L787
M7/6&DR+98$UU<TK75JLVX9LFQ;'CIN?@C4AE4:N5:(MNL;G)SS*@<_\ M]@"
M3_A[?W^^2M4-G]B-9]A-8Z.[!6;46SXS>=%V58Z3==4:SMNHRZA<M49IQUAJ
M5BJUHVUN)%AK=C@+<1)UNTA3T&?!&UDB#G(J:78(Z7"8X''(Y\>X)'M^/V^_
M^(R\?&4QQC*4[_U5UHE]YZ#N&U:-,3VP)^PEU*GO1,"?*UN5D8X!4S'*V7](
M5T-,7!>!Y^%*FG605%/* +P<-ED-'/NI.CNCMKU)T]N]WJVM;6*5ZU-DB9ZM
MEXU]:#]*QJA2:.HRL]4SD1AW,<@EC[8QW;X<]6?%.IT!\1M-TAU!1U_3>LUD
M&ZW:7=E6I[2G6LV5H61TK\Q,D[6]@9$COPT(Y+ A06837E#SM=;^7\N=!SA.
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQFJ[9WIXVJ\6'=YT9L77(<1NZ/[#TXQJPZL/GI:G
MU'LE&ZC_ &GL=:+:ND<*C9%7F=9$/Q$FX*W%3HI]<<E1@RJCC\VST#[?EQ_<
M3^7X'C.7NGUZW%LG:L 9K"C!7&(O=;T31;G8;;!T6PPVOHG4_8@3:3]@A)*P
M;;H]JITX5%R<K(S9U<H.TEV<BL4E; 41-4^-$LC /@C]_'[R./P/]GM^_.$G
MTX"1*= 4FM7;7\>#(ZD9U#L.6D-7++G0VD;0*V>9LO4I8-IC44[9LL<:XQ)3
M,NW/^>?@=<71;KA.O6H.PLIS_=[?SQ^[^3G:@O3YMV;IK^4NVS*'9:9JFQU\
MFG5MG6<BS(2,!6MUV;<4=FUG2MUF(PJPI7/1\*@J,A0013J_BR#CX7+-P\(R
MI;G]YXY//OP.,X]>>G?/ZZM=!,C[_KR5JU7VEKW:Y_Y;5YCUXC#M;1UTKD-3
M->V-JX- 5.E/U^UM99"<AI!<))*N^ VRQ-@K16&.[W\>X(]_Q//]O')_N_#.
M[OST_++N/9F]+G#;*J=-A]T4:XP4E'/4NQVMXV>L.BX;3<,?/1=@OA=6!*@2
MJ[ V(NXZSA]<6^SUR$A-;V$@Z,C7IZ290'V\>W'[_?GW_P"?.1_.>FSLNR7^
MS;#F-P:Z=DR\[-+KT2QK.PAUALV\=I]"=H((64JD??P:@(!7']'"Z]GI6!K@
M=VV1F:,V5=+7(65Q<3AE>?''G[??\!Q^'YG^SP,G[JKTC=ZW[+M-Y*N0EL;+
MA[]7H M1.T%V,V-V'M4G:LH7;6+-M&S4-,J+(N,"NOU.D0*I69>L=J;>A6K2
M;5Q64)Y_+[\>./\ #]_]WX9L!XRF.,8XQCC&0)N#25!N\;+6DS7\':;S!0\,
M=4_OM+2IR3H%Q$VI58-#C2DK$B9>_0L0_9A@_!^T0;38,LHH9EAMK2[;4T[<
M,UEJ$%NY!#')461>>Z6E878U81_]L<EV&(SJG;ZR@+(6"J!T#I'X@=4].M#J
MJ/45[5Z6]8V<6SC@<%#%U%H+'2&TNNK B:W4Z>OW(=5-,7.KED>Q1$$TDCO7
MKTU]Z0^_^M0-GC:-5=;E5>X6RCR-'J/W\1-96">FP#QHC,H\0='AK%L;)@L5
MAQ(,8V3]*.8'$';8:C?PWZ@CZDZ;2XM*KKI*URU1FHU._P!*LT3B9(U64EXU
M,=A76+GLC#=B!54*)+\==!LNGNO+,.QW6RZB?9Z_6[9=SM#$;>R+UEH/9G>!
M$BL6.=>(I[;!K%MXS/9DEFD>1M@')]G&L<8RK'<BWZ KFB+C#=D$D2&O+J Y
M7'ZW$O2#%JGS5*;,"342H@Z*E8>QQ!PX<S#6@"7A2*K+A1TV+-Q1XH12(QU9
MU?H^B]6VVWEAXH2_I5X((_6MW)R.1#6A[E#-QY9Y'CAC!!EE0$$SGX?_  [Z
MH^)>]30=+4XY["IZ]NW:D^7UVMJA@ILWK'9(53N\)%#%/9G(98*\I5@()9ZX
M5^8UY);QJEIV#W5V)-ZJ_9'3SG8&]5P* BZ+9Y^JV":JK -&JFL:_P#B9\ZK
M5HO:.+5'&W?9$93QM?W6VO13Y0J=UKMA3VU"ILM?.MBE>@CLUIDY >*50R\J
MP#(Z\E9(W"O&ZM&ZJZLHC6YU&RZ?VVPTFXJR4=GJ[<U*]5DX+16('*. REDD
M1N \,T;/%+$R30L\;JS6]T%33M?:=H5.E!I,*2A(=;!X4J_#.O!&$'F&DAA,
M5THVOQ$$*\2MBM5N"*?AZM76XNMQJ_IQ3.,9N:O^_,UOEJ8HM&N=W)&<,&IU
M3L5J(#:5\72F*]#F2[HS:L)7\7'VPU-(5\%^RE8S\5>WMG'MSBK5LVBI85J\
MTY4>["&-I"H]_)"\>V;GIW3R=0]0:+00RK!+O-SK-/%,X[DADV=V"DDK+RO*
MQM.'8=R\@$<CWS6#UKZ>ZP[/Z.H78OM,S8=Q;DWG6 -EF6 ^]7F%CM?1=Q9_
M-UJGZKAJY9(H"BP]6AC !6'8EM,N3)H,.,DGO,TP/!M)TY1WFKJ;G?";9;+:
MP)>:9[5J)*<=D>K!6H1P31I4CKQ,B@Q@2,X9G<\A5^MOBK\<.KOA)\0>H_A?
M\()-9T/T-\/=O9Z3@UM;I[IZ_:ZFMZ.3]'[7>=87MKJKECJ*]N+\%B:5+K&C
M%4:"M!401O)+.'1NVW8,_LAUSO5OG-B%=8]P,TRH7RSE9D;5.:SMU3AKM1@;
M=,*QA<]::X%)E0LG..I;(D6!@'264DI=<>VG2UBTK[K36[$MQM'L16K6YV[Y
MY:-BO%:JI8D__JSPI(T3RD N%0D=W)//_P"D'I=!/6^%GQ0Z=TFOZ8B^+71$
MF]WG3FHA^5T^OZLTFZO]/]0V-+1!*Z[3[6Q4AOU->A>.K)+82)S$41+\\EN?
M.&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,9P%8)R*3@)3*3,L/8$43A:ATDY;5X%/I;SAQ3.'?
MAEW#><+RCY83G"O;C&:-J.-L*J5/1<U0ZUVIJ79VIZXV(=WGNTIJ;<EUQ9YL
M7KY?QI18 %PCF]6=A+N3VN<U?-:=B-6G383>O0[-&T:2J6K9$X9]GL^>>>..
M?I\@<<D?V@<<\^/?R?.2K6NP/>5!VC:M>JHB V?OB<NL!;:N93X^(IVB[1I'
M8;-^N476[*]B0=O^N-H=>'Y>I4?;;YT]$KO<-69U\6LR]HDJ!"LH0//'V_/W
MY_XC[CCV_#W,"1?;7N=/CBP]1GMD6O+]3ZEW';D[+:$F*-9]0%;>I/;N6V()
MK6-KG6?=$A;]<YV3JC3=/JUT1IS=T2S6[#*)3?)?[C^T8!E>!]^![_?WX[?'
MN//DGCP?R^V6ST9L'NY/WW5\]MENP@04]MREZSO5!C=1NPE BZ3)>G5"[TL^
MUA)VP4^.V5&>#MHV=JL*2G9X.L0Q)Y^K)FOD7P<,F,90\?;\/Q^_<1^[VX_A
MS[9P=@-&6>K[+'V;,!2\[H786X*2CL/1-'U*]%V:>UW5Z3V1-K4];ZY0%2E_
MN<>_MW8NH0=E0E48GEV"$J'YZ?#9UL_8J1!L _;\.>.3]SQ_8/N1_P \S3K9
ML0S6I,_5"*+N,34.U.Q4W%=6@[D 7%V*I:S;UKK'\L!*4K:4_#;HB*J[MX3>
M%JJ4,JHR>:5J88"0*!J5 "K@C#*']XYX\_?D^?PY'MQ_;FQ;C*8XQCC&.,8X
MQCC&:TI+KOM+JSO2Z;_ZN03-]UIMTUN5WQUNQ) 04LN?0Z0^[L73LG+/B0+=
M@PLLTN1J,R;%ARWV#009#W*A&:US23IW:=*[V[U!TM M_6;B03;[IOU8X)?F
M 68[+322LE<6.7D:6G,\23=S1QR'N@6MVV#K+0]>=*ZOI'KNV^IW?3L9K]*=
M:F":W7%1@BKINI(*ZR6S3 CBCAV-:*>2N$BEEA_5VFNW2H^[]>WIIEH:1D*M
M8%)3@JD;#A937]YCWOTPXR_5[6-%R133;GNTB4BFY&$-SC#T9*&C.-/N32CO
M-=>"A99*M@\=]'8PRZ^]&WW5JMM8I6 /@2Q"2"3]J*61"&/,]ITON-4S%X8;
M]0']7L]-9@V^KF7W5DO:]YX$9EX8P3M#:BY[9H(G#(.>V[MU52D.IG+K#.2*
M,9PU7()URT6XYS'\F8VHUMN5LLB]E7LGQA1;V4J4GYY1A6,\Q]CU3T_JPPM[
M2L9P#VTJK&_L92/';!KJ2V+T[$^.V*NY!(YXS-T_0?5^]9#0T-Y:K?M[/8(N
MITU=?<O:W6T:GJJJ <GNGMQ@@'MY(XRF%HU3L[NK?ZE*;6J<OJGK%KZ9;L<+
MKBT>(?8>VI]A"FAI.X0@[S^*? ,LN$A(B9![$[@ F1:\#;LR@Z$YA?Z?WOQ0
MW&NL=0:ZQT_T)IK0NU=+?[4W/45Q 5CGV55&<:VDJ,\8K3-\WZ3S+V!K(EJ]
MQU/5W2GP+Z=W-3I#<4^K_BMU'1;67NI]27EZ:Z.UTC!Y:NDOR)&=WL7=(K#7
M*R'7FQ%5?U&2@U>_LA0A#:$-MH2VVVE*$(0G"4(0G&$I0A*<82E*4XQA*<8Q
MC&,8QC&,8YVT         #@ #P  /  '@ >V?,+,S,68EF8EF9B2S,3R22?)
M)/DD^2?)S^N5RF=.1CPI:/.BI(5DV.DPRH^0"(1AP<L(UA8Q8KZ,_HMDAAQQ
MIU&?T4A:DY_GSRZ)(CQNH9)%9'4^0R,"K*1]P02#^1R_6LV*5FO<JRO7M5)X
MK-:>)NV2&Q!(LL,L;#RKQR(KHP]F4'-<&N=6=W>KM51I'3 &AMTZBKSIP.GK
M1M:]7>A7G7M7*+(,BZM?8V I-N!O<;4TE)BXF5@9.ORDA$B,-%! N):PB%TJ
M'5&BK_HO6)J=GKH2Z:V>_:M5+5.!F9HX+:0U;"6TK]WIQR0O#(\:@,J'CCZE
MZHZP^ 'Q=W#=?]>6?B-T'UMLTKV>N-1T=T[T_P!1]/=3;>&&."YM^G+6RZ@T
MEGIVUN3$;EVEL:FSIU;L\CPSV$+]V,6K1\?UMZV7BV;J[,7>GVO8.Z!]T]A]
MD:A8,K%NVC/S"&XB-TAJ?\<6JW5F*-^M6JQ4F:V=^T[K48^M+T8),RC0=BQJ
MTTNDM6-GN[5:Q;V:[/<W=<K5[%Z60"--7K^QOF8(VXA@KB%_7(0GE%DD"[;3
M?$"S\5/BKT]IN@OA1T_O-/TUT')T%\,>E>MI(-OI.D=;19KUKX@=9_-0#2;:
MY7]7;;?=2;2O^B$>W&K);FHU'GECJU5NVP^B*)C8%]<B;&0FRR#</M!A%UV/
M"UB4N%@DJ+"WNTMN-9F;=#T<NNQM@*>2HM,H*4P:Z^8T^\YL-#7ZB&IJ?-V_
M3F83.([P^:NQ026)GJQ6[ (]6Q%5:&.9C]7J*P<E@287\7]S\%I?B)U$>FNG
MDN:N(ZJL][I*0Z#I:_MZ>CUM7J+8=.Z=U;Y#27NH8=I;UD*$0FG-#)72.!XX
MUOUR6Y\XXXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&8^NIU5RTL7ERLU]=V%@2:J+<%PT<JT
MC5@V0%EC*XQ8%#9EF8$N4!"DB8=LM,>_(""F.CK)':<0QGC476&M-7!R4=K/
M7E&UU'S,BN8F :+4H"HARLNXRT.N4DA:_'Q[!TBL=EEA9Q2'25,M--9=RAM"
M<,9G/&,<8S"IG7-&L-MK5\FJQ%2-RIPLB#5[*0QG,O" RY,<9*A %H4EQH.1
M+B(HDX7.5,%/Q@#KS:UACJ;8S->,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQD2[BT1J'L#78^I;GH4'L2M14RU88^%L""7@!IL<(Z.8DT,CD#X44R#)'C
M-..97XVBWTIQCR*SS7[+4Z[;PI7V=2*Y!'()DBF[BBRA60. K+]01W4$\\!C
MQ[Y-.A_B)UM\-=I9W70G4>PZ8VMRB^LLW]8T4=B;7R6*]J2HSR12<0O8J5IG
M50.YX(R2>T9C-2ZK=>*)7X^J5#4U4@*[%?;_ !T0 .2@03[QI,D7XDK*6K'G
M.,))<]U9]W7EYQ[8SC&+%?0Z>I"E>MKZ\,,?=V1HI[5[W9VXY8GR[,Q\^Y.;
M7=?&#XF]1[.SN=YUGN=EM+GH_-7;,L33S_+UXJL'>5B4'TZ\$,*\ ?1&H\GS
#G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g209588g04d78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g04d78.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5:[:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P-" W.2XQ
M-C0U-S L(#(P,C O,3$O,3@M,34Z-3$Z-#8@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I
M;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO
M;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @
M(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL
M;'5S=')A=&]R+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @
M(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@,C4N
M,B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-
M;V1I9GE$871E/C(P,C$M,#@M,#54,3,Z,C8Z,#,K,#4Z,S \+WAM<#I-;V1I
M9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP."TP-50Q
M,SHR-CHP,RLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C$M,#@M,#54,3,Z,C8Z,#,K,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @
M(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FAE:6=H=#XQ,3(\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M
M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%1
M4VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311
M:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$
M:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W
M9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"
M451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O
M9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!8T%%04%W15(F(WA!
M.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'
M05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&
M0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A1
M5D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1
M>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q
M4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S
M8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L
M<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)
M1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!
M.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%
M9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K
M=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV
M9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&
M6%EQ-T98:$YP<E U<G0F(WA!.W%/<EAT-7!U<WAA6F1A;%DV=EEX2VMJ4TIP
M.7)Q0W@S3G)(16I--FU3,3E.>D-Y;WHO2#A*1T9887!D+VY.3C5*<VQT-T15
M3&5C-FXF(WA!.V-Z45AA5'EV9E12>G1D>5=A,U9V=U=3,VAJ:V%"5U9M231B
M349515EQ;CAL<"M9:697*U8O<55V<&5C<DEN:D=Y*W1P8F95=5E4:5 F(WA!
M.VAT57)*>C1F0V9I-4@W5E%Q6&5:<"]Z1W0O4#)V>BM8;W18;G5O<$,Y:$1+
M3&AT2&4P6%)A.%5%:$9S6E1Q2$-G43AQ.'$W5GA63&\F(WA!.R].;C4V<'%L
M=VQP83,K;V%E3%<W3VQY6&5N4C)K:W),8GE01DYC:C!65DA%-$-,1E=-;F(T
M6#5&9U941%<S+TYB5G9*;FQD>D)E>38F(WA!.W4Y>F9T9GA7,#DQ<&)Y47A7
M.7=B6#9X3$1&8E!%>F-5;T=J4E=F:4-&-6)"5T]W96)0.$%N24]'>F1&:'8U
M,'0O4E533G!Z:31L4E(F(WA!.U--<7-L;W=6<#%(2UAK.'9":E$K;'562W!H
M2C4T+TYQ.#%R56MS2DY23VIW86IQ3G!D,T9T<&M.=SEQ3&$T;6IT23=9:4IH
M4'I+26LF(WA!.WIF2'='+W<Y8U919#<U;R\U>4EJ<V)E-&1,,DLT=51E1S9T
M-&1-4U57-70W:U)X4GA.2&)81#!L4B]H6C!F:V]Q2T-R-'%Z9CAR.68F(WA!
M.R].4%5V33)O>&5B3$]7,# Q64,X354X4' K;DIZ45%Q:VE14GAU5VE,3DI3
M85-J9GEF6G=+.5%X5C)+=7A6,DMU>%9H;&PU6G5.648F(WA!.S%F>F$Y<3%U
M-S-T-T=)3&$U16-32D)D4W=O<4IW3E!G:D="2U,K66LP4%)!,&-V;7)7<')O
M02\V3VPX0U%E=UEI33AD+W!Y8UE%=58F(WA!.V@P:W W;C!J=E)':6554$U6
M.44X,3-R97$R,%153G-6=B]53'%D*UAW<5(P<#-W14%)>E)X4DY22E R27AV
M2TYZ8GE..60Q,U<T-UDF(WA!.T-V,7!,.$UG+W="8T=-1F9N=5!%-$MA>$%3
M*VYN,TE,>FPU875D3#AL835R5F@U;3%P<FEX,#(V=DQ2>F5",$QW=TY):$DT
M8FEQ:D$F(WA!.S%%5G-76BM6-VUE-CAT851C,T1M4V5E>70U2EI'-G,W>$MZ
M369M5&A1;65+=7A6,DMU>%8R2W5X5C)+;V(V-&8U9GAW,&DS9EA$+TPF(WA!
M.RM/3DQB=G)H+VPO2$=L=#,Q=R]Y+VIJ4S(W-C1F-69X>'!B9#EC4#AV-#0P
M='4K=4@K6#AC85<S9EA$+T%#+VIJ4S(W-C1F-69X>' F(WA!.V)D.6-0.'8T
M-#!T=2MU2"M8.&-A5S%',2MQ,FE/;')B4C(V4U-03DES4VA!,'-R1C5(255#
M<D\W1FU056YF1VQT5RMU2"M8.&-A5S,F(WA!.V981"]!0R]J:E,R-S8T9C5F
M>'AP8F0Y8U X=C0T,'1U*W5(*U@X8V%7,3A6=UI(-#AA63!T<3)"3$99<$QM
M4'EH<6(R,6961C-Q9$,F(WA!.W1A9T<O;D1%53A&<FE/8FLV45)/5TEL>70T
M4$QA,U=O6#5S-&96;FML9&A#;3102FI4:U)4+V=T<S(T;U)T,TTU2&-L-VYB
M-C<U6C F(WA!.V5Z=$Y.4S9,3%I22F)&,59P5DAO<45O>F]P5W1"=FUQ,TQR
M;S903%!E=C!-9V=U3$LO=$9L9VU3-'1P:TE"56@P64-Q<T\T4&=C:30F(WA!
M.V-O>6=A26]H9S-M1%592"]!0WDX-S9617)N.4AA6G%I2DMD,6%.;UII;$<Y
M:'1I6$LQ*TM135IN*TU$-VU9*U0O=T1L161%+S=:.7(F(WA!.R]W06U6>&-"
M3CA69&ER<U9D:7)S5F1I<G-64S-*355O,3-Z3%HV3DI#='I$3DM*635:;65)
M25)(1D%516IV>5I$465Q4'-G;C)X5D0F(WA!.W U.3AO=4I33E)10T=-5%-L
M;&M7:4TV;W)F16\K,%A7;FE$6'!V:7%F9V=I;S-"-DA&579H,3=36G)A839I
M;C5W5SEF5F-+*WA$36PF(WA!.T%+5DQC;#9$9G T:DMH;6E14T1S1V]:-$5%
M9S="=SAX849W-79F=U$P241*339X3W)'=G=U:VY&;%!W;EEI=5!J=S=W:CAX
M:G)E44@F(WA!.W8R*SEW.'<V0U@T<G%&=3-W.'EY>4M607%O2$IG94EQ6%=L
M5'8R>#AE2&5&+TU9+S5W*V)3*UED1V4P3C-&9$Q.0W!J5G921%-U1VPF(WA!
M.TE%86U.07HQ66Y957@X94970W8U:4A$64YJ>3,U*S5D2#5G,$XT,&M&+T%Q
M>4)#;V5256(Y-'9.0599:&=3<')1:75%6F]D-%5A:D<F(WA!.U)F148S-F0P
M4V](-E%T<71X0R]V;SDO5495<'8K,$]N:FHT,$\X9DY0:C0O-7<K8F$V>'!,
M>'9*2&51>4I(15HS36-I=E-*4U%8;W F(WA!.U!W,4)&8U!I>#=W:UIO15=#
M3U8O0E)T+TUM:%A#<3!D.492,#E20S=E;E9A<T-2>C0Y4%1A=FA49DEX>G=0
M5FI(55EZ>4DO2#EI+SDF(WA!.U V1EAJ*VMR5V]8;5(V,&1E3D]83#=85&IV
M:#AA2&50;78U:D@O3TAZ0S8S,7)3<FU54E<Y,&MS:&-X8T5.4TA536%.5#=.
M46I%5C8F(WA!.V=B67AY>$]W3$M/84).06\S3$=X,DMU>%97=&8W,S9$9TM1
M:DU#56XX<F=(4S5W4E5'+S%+;R\V4#4X0W-6.#%F;&QP,7AE>#,Q;&0F(WA!
M.TYP4T4P;#E+3G!+3WHX=5%O-CA"53<P,D=:3U!/44M/-W-C3W-K4E)(15<T
M9DIF;5!4;T9T8DTR,3%B;T%S8VI/,&)L4C U3'=C9C@F(WA!.TYL4$4U=CA!
M2T='6G581D4O4#A!4W(V0C59,74S82MT6DQP12MT=7)85%$X;45)02MZ1U=6
M4GID97!(.4MJ>F$Y5G)C8VI'46HY23(F(WA!.W9R-R]!0T--+TU$5#=3=R]+
M>GI68C)S66II5%)D46]",4I.<DI5:SEY8T1Q8W57535C56I:5CE',&LV:C52
M.'15;3E),G1R8E1Q0V\F(WA!.VM6;BMP;4Y/4VLP4$(S5U%6-W%0;FHQ=&AE
M>$-T9CA!;&$K;C V-'1R8E8W;3!U6EA2;V)T6DHS35-O-E!X0659,35C0T16
M='<Q3VTF(WA!.S)694=B2G1M2FIB6D(S6&M15"]U,FUI:U0Q8FTT17,P8E-S
M:VLP84I'06I/5FLT<V=D:DE45VQ+8CAH84YO9V12,2M*4#973BMQ*VXF(WA!
M.V0X=C%*6EDO;&YR.71D4&1.-7)U<$I:4T1-5E=64%5)-&ER,'5$>2]D<G=&
M96QD<55'0VIT-69R2B]3>4UX4D9C+S%":T$X<WIY95@F(WA!.S4Y2VUU:7)Z
M=UAT<S!I;5-21#EB9&E*5U=2=51/06$W=#%*,S<T9T<W=CA!2#=%8U$W=35+
M8DAY2')#,V$S3C-R36I.2&1W4VA685HF(WA!.VA,8E<P<VMQ4E-"<$%Q,4UI
M-T%%3'@W.&IK8TU403=M.7%:-6-G:TM!<%=0-69T0G!L<EDV6&9,64<S15EA
M45%T3%52>7!/2V,U964F(WA!.S V339C,V)J>EED.'-.1TY.55I%4W1-8E1Y
M=D]K1FY&96%H3&5#049B=U-.355U5F%-<695:F574E%F55!0668U24%'3515
M85),958F(WA!.VA'-%=+6#9R;T=K-G$X3#,X2FU-06152$]21DMY1E,V=7%-
M;V17-$Q65W%.<U93.&514$M!5U)F,&%H17%E:R]*-4<K04UR04-R1VPF(WA!
M.T-I,' P07 P,GA6:T-Q1D%64E%$64%D04U64V8O0RMN0V$W;5(U564X03E1
M2WEH5F1:4%574E8T,$1+854K6'IR4BM8:EI0930O-6$F(WA!.TYK-S<O:3%"
M=DIM;GE84S-5,7IC>E1#6F)G;#)J,VM79TI.14=Z8T8R-D-N=S!'4D]K:51:
M2C4R=R]*>'5Y4V0W+T<S-#9*9F(O;'@F(WA!.W!W=#)I;G5R:6]-:5)'2C%8
M:D,P<&16<G='-4(K2W9I9F)+;S9'3F)K+W-A63EN4G%I5#$K5C,S22MZ.&LV
M5&)7.#EU6DHU-$QH;U<F(WA!.V5+6FQ:471U-61554)2.$I*,WDR3VMI05)V
M4G(W1S9':6=!4G51834K4T-U=GDV,# R<WE7,7AC0UIK06@Y4C%+<5529V]R
M=TQ+<DTF(WA!.S%8-#EC<FQO63!A2F%P9&YX;S!49C0X=FUI;W9),FQO1%=A
M8VPQ8U X4U4U4WAE;$DR>41D:'8T5D<Q36M.2$AV4#1&3F<P564X+V<F(WA!
M.U5E:E58:V5Y=&)A-E<P=4IZ3&-7:S%O=G)/1$=05S,U8U969D)2=#)(5$5A
M4TE";VYC14E':6I%1VED-&MB*V%K9GDV,$YP1FPY4S0F(WA!.VEB,&QI9$DU
M1D--1E5,56IH=6%G3C=N9D(K4F@U;R]K+TAD-SAU.5AN.&IA6$]Z4$QC6$1/
M-35Y351%950K;5EW>$AP,'%!>D551DLF(WA!.VXU56MD2$4Y5"M09WEL;V]N
M;50Y;F188W9S9DM6=G Y-TAC5VLP:DE:+UAN5U9G9'A&3$=/4$96,TIN,TQ(
M;TU-3DU);7@S,SEH+U<F(WA!.VU';$5*5T0Q=C=$*W10.$%-;'DS67$W1E9A
M,2]V9F]/07!#37=*661O.7 U>&5#-V94.58P*S)S:F8V:#953GAP.# X:3!V
M<'582U8F(WA!.TQY0E=Q,50Y9U5',W9I<4UA,#@K.$%Z83EP2$$W:&IP5GA3
M;B]C4GA44EDY<3DS-6TP;3-7-517.4YN:3E263-7,3 K-3129S$S2W(F(WA!
M.W%F141B<&MO9VQZ<T=N>5I4=VY9,3%(4#=%-7-X-7=M:E)B5'I(;VIO4BLW
M5U!42FE+1'=P<5!B26QX2C0U9VYI0E,O>G1P2&YQ-3@F(WA!.VPV+V(S3W0V
M63%T3G!T,TA-23E,;E)Y:G=/1S1S8CEW<&]D:590>7AT<EI.-4\O-5)(4E K
M,F9A+W=$2FQC5E1F1EA9<3=&6%EQ-T8F(WA!.UA9<3=&56QV-W%Z=&)/4S1V
M1T,R,%E":TI"8G5!049!2DI*;T%!2S%Y5$9!3')0;%%X>'E.9#)C66Q66&I7
M5F\T,DMU0U900BM,0W0F(WA!.T0Q1TMQ23AY95146FTX1C=A1T5)6D-!5DPX
M47!C+W4V97!8:4LP-#%X5D]0<6QP+W9M4"]!245F,'A60W!C-D)*24EK;'18
M:TQ&46DF(WA!.W1'5S5+47!&0C-$141)1$I(=D1!6EEK,5E26#%3,"\S>D@O
M=TDO<&LR8G9Q;' O=FU0.$$T168P>%8S,5,P+S-Z2"]W22]P:7)V<6PF(WA!
M.W O=FU0+V=2+U1&6&963%0O9DUF+T%J*VU+=2MQ5VXK*UDO*T)(.4U69#E5
M=% X069-9B]!04DO<&ER=G%L<"]V;5 O04E%9C!X5C,F(WA!.S%3,"\S>D@O
M04U#4#99<3<V<&%F-S5J+T%/0D@Y359D.55T4#DX>"\X0U V67$W-G!A9C<U
M:B\T168P>%9&,G8Y-SE"=T9)4FU"3$4F(WA!.V)B55AI,&AT4'1L-3,R;U@K
M<'A7-% R5D@Q*V)M-SDV2W!**VI#0357;7=I4DUP9E)(8W!Q;6PR9&YA4E=.
M1&5/14-!6$)-:6A"='DF(WA!.TMF6D9064-V-#1H17,P<%--:#9F9'-Q3%IA
M63%)<%5384Q98UI+4$=+0VYW<#EH82]W0U-":F)'-41C6&)X>GIJ<44K:V5:
M-W=75"\F(WA!.T%+4$5-=C=M1T5#3E8K2%IX5&8T;&%V,#=:;#1S66M.,V4T
M2D=736-8<3DK-F176#5K='%0:S-63%A62E4K<U-7;#-!:CE#>"MR:W$F(WA!
M.U(T+S52.7AL3UA#461N0S%E:$@Q44AW*SEN3VE8=#-B950O3%,R<T14>EA&
M=EEX16A'6D5J.4I7;&1Y=C)A4G$S12]Z.%(S>6=N>60F(WA!.U13+U=D8SAW
M,C)Q5W1R66%D.5IT-2]8-7I-:W9&46M+3D9Y9%%66&Q+>D$Q2%%B0W53:TM&
M:G4O6"MR-U52,RMZ.4@T*T-T8S,S;4XF(WA!.V\W.4QE1TM'94,V0U=B3D<X
M>5-7,W!X37I536QT>68Y-#-2<69#4G9404-/<6MD>6AB*V,W5S8Q8E1T4&=T
M-6MA.35V-FMY:%9-85<F(WA!.WE82'=%36%T*R]194=Z94%Q27EU26PS<S51
M24I(9"MU:T9Q,VYB5F)"96-M:EA59C%M,6E.;$59:$E6=DI434)&33AC:%-N
M-W!0:%,F(WA!.W)F1CE'46Q/:&1F:EIN:GAI4C4Y9G-6-V98+TUT.61*2$1P
M-S)-3F)M3U=7-G1P2%!/2EE5:65G;&HK0G!:6%E52C5)=F)C:DEN14$F(WA!
M.S=&>'=D=DY8,&9Z4F98;7!4,F1Z<$XU8G%/3'=81%<W<$9X.4M,;6IU.4MU
M2EAC07%/2E562&E9;4\U-VU2*VM&371-=G(K-W5,:' F(WA!.V)34S)S,4-I
M,SE:5E-2;E8U1FQQ03<O1#A+;%115D(W-$-+2V<R14AQ96Y186I9>5=C-5I5
M8W%W9$-!-G9'=V1'56M%5E9L0C-'1FDF(WA!.W@R+R]!0S$P3RMN13EZ8UAJ
M>3A#:D\P<7-Z1C1203=S5U)I5UI&6#)Q3F=.-G%R2E!Y=CAV4U=N,5HU<F]R
M46]8-7AH:6YP>%)Q:% F(WA!.W Y1BMR;U(S<C%Q0U)I<DPX5EES=FMF:$QB
M>G@S=G S3G1+6DDU,6EO,T1G:U-O9FHS*T)$53EY83!P54A$1VIQ:41U2$(O
M2F)G,W4F(WA!.T0S9D0W=G@P6E1M635Z<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-65G)8*SDK9S1#:TEZ06QG1G5J,E8O839Y-%HW4TLX,6%+53 F(WA!
M.U!&1RMU,TE1:VIP>EHK3E1S34DW;EIA56EE1V5-9E531#<K5B]+<E903D=Q
M6$]J,FM)3D1D-FUX1'5A.%97;GA#;T\Y3UA3=F9$93<F(WA!.VLV2%1X>E-0
M.#)#565P95!':S=A:$U*1D$T;$I'441T.6Q#<2]H:W%C,V=G1%A#169O1G<O
M;4<Q=F\Y6G-O.5%H<U)W=$QX;W=(9#4F(WA!.T-1638W2V5O-E5P,SAC:$=2
M171N13$R;FIG351!.$IL>DAC;%4O-5EA4F%E6&19,4-1=3,Q83)V2F)A0W1%
M1"MH,6]3>F9!-FM$9F4F(WA!.V=/5WEZ13=/2G%.8DEX15(S8B]J,U!19DHO
M.$%Y:4]I9CES*S$O-4UR;$QR53-X5C)+=7A6,DMU>%8R2W5X5DQC:WAD:7)S
M5F1I<G,F(WA!.U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U96<E@K
M.2MG-$-K27I!;$IF3'--52MJ6%5-<6@T-4PW53!D5#-6<BMC15E'55HF(WA!
M.T5'>'I#:&-E53=6-U578E9U3$=O2F=K3D-!2VXW655S859O3V@O>7-K5&9.
M>30V,E%L>&IA6&50>"MZ>5-V.$%W6&]92E)T3W575' F(WA!.S9F<4YW2'E)
M;D(O2$=V3GEX,FYM-3A58CDS+TA745<R;457>5=H0W<R8V%H2315-CA/3D]*
M<#EN=S9N-3%W8VY85'DS3&DU>5!64S@F(WA!.S1M1T1Y6')H2E=/1TQ48F]K
M;6EQ<7)!,S!!05ET3C)V.&YF.&]J;VXO8E!T9BM42S1O5&9&6%EQ-T9867$W
M1EA9<3=&571Y5$9!83DF(WA!.UI8=#=O.7IA,DTW5S$S2V]%57EU66EP0D(R
M9%$U5V\R<4%C5F5F.$%M0W<X+W=!570T.71C,V-L=F)R2&)O='4Y>'EL;&$P
M:"]E248F(WA!.W%1:7I)5'E"4'A%:'%!<V-5=E1)031H:D5M.&=50BLK.4XX
M54U0:3 S>FI$8S(Y>4AN;$-4=#E9='!,9T=.-"M-9%=(>#=!>6-M560F(WA!
M.VPR<"MY8T%9.&])3R]0=CEZ<FAJ>D%G-S@K5BLW.4\O=2M433AZ,UEU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A65W1F-S,V1&<F(WA!.TM1:DU#56DP
M1S9H=$Y$=DQM9'5-34XW<6-K:F5#<F94:S0Q8DM%1$EG1&U5;SAT-C=C*V-6
M=6)U,74S<V)+,VQA,CE'3F8S<D-G9FTF(WA!.U=C55=O8F%G>7I*1&<R3&TU
M67=W*VUU2UAE5U-(4F)"65=J<$I2=G1(,7!A;C5N;%4U6&)J94Y+-R]116IV
M.$%Y-V97-DED3'9*>$HF(WA!.T1+='A&8G9)94PK;41726)I9V)K4V$O839'
M;EA!4F)M-'181U(O95)&159D8W(V<$@U;#@P;E9V>3,X-5=L>D0V1B]B-DQQ
M0FM503@F(WA!.U=(,6%24U)89%-'+UI0,S1S3F1O9D)Q551C2F-V>"ML:S-L
M+U5R97<X;BM81$U'6G)M,G-B84=.0E9M95-*4C!*1WER5C(O>5%C17 F(WA!
M.T%C,T)%4V532S%$>E195T]P,C)N4WA44%!D4$I(155#1F5556-C;$-3=U!X
M97-Q:F)R,6]..&Y)54PO2%@Y4EEJ92],.6XV,3EZ-6@F(WA!.W0T24Y1;&%#
M5FAP:G-L=V]-4VMQ:U-43DEP95)6-&A:4C%)4'1K94E-:$5L0C(O;C-Y,TXY
M5E@Q<$DU<GAK5T=&;UI'87-O:4U:67@F(WA!.W$V2T=&,45A;'1U5SE#0T)+
M35-29$U:8D=K86YM:E%P3%<T=6MU,&%#,6EJ;G5'05!W4E1)2D5D:%-T0VAR
M:UI(:#4Y.4II3#5D578F(WA!.W,O4"MG6#$O95=&:TQM-'4W2T=E95=*64I&
M67)B;$9D559W:%II-SA&2&E$-U9S;$%G5U=):W5U4%!7:E%7<U8T>51T8514
M5%%X>E(F(WA!.V]S9TET,C134T%)>DU50G(P1E14661+>&A%>6M9:FXO04=F
M<EI(65@K3C!X:#$K=VYL:&II17!A859O0C9K5'<P9%5:>G1-27EA0D0F(WA!
M.SEK2$(Q<G%I=')A>51&,DMU>%8R2W!"+VHW>6@O=T)82E X06=:4"MA8WAV
M>FU,=F-0.$%0-&8U=V0O:C=Y:"\Q8VLO-$=4+T%*<'@F(WA!.R]/674Y9GHK
M2"MC2&8T*SAO9CA!5GE4+T%)1U0O;6Y(.#5I-S$O4#1F-7=48E0Y4G-T4G16
M=3=+5517-VMH6D%#05-P;V5O0C8U9D,F(WA!.UEK3$A*>6-E4TUX8U194D]3
M6G5X5C)+=7A6,DMU>%8R2W5X5C)+<3%R+V4O46-"4T5:9U,X.#AX3F-0-49V
M-U,S1EI,;3DQ3612,%<F(WA!.R]M66IF>#9:6FDK<3-0-U!H95,K-&9F<VTS
M:W)1;U!+6&Q:>F-/1V-Q,35E4TQ5<41W0DE8<E5+1G P,SA-8S)4:4YT5U=2
M>EI!0C$F(WA!.TY"0VYZ>&4S:4-3>'0T;S1J5FM--TUZ1F8Y5D]012]38VIW
M3W<O:S)-4'%*=GDO2#9K=S S>E!*93-G<V)U1#!*1U!'1UI'-6]Z<7 F(WA!
M.V-R=4%68FER161E:#,X45)4:C5T14E2-&]M>#ET35@X-5=%>F%$*UE'<$%,
M.5A':6%H8D9L,C53+U5W>FUN*W@S.3A3;E5:44Y00T@F(WA!.UAN.$XV6G U
M571R96)Y<&]$>7A*23!6:&)'2FY5359,5S9Q4W!04W%S4CAS1')#;51A8G!Z
M4W=3=&%W=$QA.'9Q,&AJ571(>DA&=4(F(WA!.W!695%&1%1&5GHR3FTU679#
M:$Q/2E@K169%-FA1<DXO35)W5VQF065!>$=Y;$Q8.&TK5C-U5G54<'-0<G!.
M2&-P24%62WEW:$%H5V@F(WA!.TA%1#!L*T5F0U-+:U9W>$Y#:'E5-VUZ>E1'
M6%0W2U=X87AE1F9Q8G@K:UE62$9E1D]016-A56]/;$]M4FM,-7!"<FMH=$\X
M=6%&<' F(WA!.TQ75FA"0DE1-G1-<4%Y1EI(.5)L85$Q8V=S83!*>6-P13@R
M249#;"\V0S!4:S=F;RLR-5-2=$1),V]X,6%.-CAK3S(V=%4Q1U)'>'0F(WA!
M.VM467!&5SET8C(X46ET-&MH:5A:630Q0W%+8F)!8EEO44]367-2.#5A;#5N
M='(K1TQ2=EA-6F=,>D-/,&%:4'0P2E=1230Y54Q6;%4F(WA!.S=B9G1&;'A6
M2DY5+TU(>E9P-U-W=EEX8W)71D1C>E!&2U979')32S0Y36Q7549I>E-#9S9,
M.%(R0G%P96I13UI)635'1D,V:&E08VDF(WA!.W5+2'IJ;DQV0W!P-5IT=$]U
M3F)T;W120T=Y4$EZ0U-:8F-50VLO,VI&4418<'5+;G9L=4E!>48X;DDP<UEY
M>4%4*VXS,'E3-S!Z>4<F(WA!.RMN5VM.:$MI-FTX0TY,3E!/4D-*6&I91EAO
M86=O5DQB0VQE22]A>2M58U9#=G%P>C4T9$U99U))-'$V;F$V+T@R9#=-4'DP
M+S520S$F(WA!.R]W0F58+VLT8S)/:"]U=S=0<W8K-$AX*SEL3UIB<TA9<3=&
M6%EQ-T9867$W1EA9<3=&5F$Q+W9F;T]!<$--=TI9+V]E;C)L-W!-<5@F(WA!
M.TU98TQQ1W!C5#!)<F9Z9SE-8G!S>#5:44YX2W1B854Q9W)13DI,3EEL94-2
M;CDV3T$R0T]J0FI3;3-W9%(Q-UE38F)P-65-,W-*9DHF(WA!.TDS.&]A4F)U
M6# O5C)S5%AE3&MR;VQ246A!>$1R.4Q(15<U.&4P36MH531C9FXK3FM2<%!L
M2WEG=69R46ML=F)V8U)Z>DQX:6I$0V@F(WA!.UI11E1L5E0W*T92,7A,5G%.
M9$]1-%-"1U!C3UHY+S1#-SAW-U-+,"]+-WI:1DA7;C9(,4IM63E76G)A4FU9
M*S5*=T]U;DUY3FQ.9DHF(WA!.S,O2TDV2B\R>C=8+T%*37)I=U1F1EA9<3=&
M6%EQ-T9867$W1E5T>51&,DMO86943DYU1FM7-'1)6FQL9%I*5FMJ5F=Z;T%Q
M<S%186PF(WA!.U%O04]+;VY&5T-F.'%I,%@O;'1U9BM39B].3V$O=T1K-E!E
M6%5F>4YJ-S5F6BMP,R]+;W1&+S5B8FXO:VXO>E1J+THP93AR+T%#3FHF(WA!
M.S<U9EHK<#,O04-Q3%)F.$%L='5F*U-F+T%$5&HO2C!E.'(O23)0=FPY;C9M
M5C9";W-':39:2' X16IY4E)L;41V5&PX5$9U=TAJ;5@F(WA!.VAX1$A(:$1S
M9%!G1TM!:4]365IA,T]X5C)+=7A6,DMU>%8R2W5X5C)+<3%R+V4O46-"4T5:
M9U-K5V<S54YP;V0Q8U1':V-6.7%4368F(WA!.UE8."M,3T5$26=$;55&62M:
M=%8Q-'EJ4EE&:'19-5)'9%)M*TIA2V%V>&I01&ME3D]H;U!(2FU)2$YZ375M
M:&ER:6QC=31F<E1#4TPF(WA!.WI)2$Q6=%A!2F]6:DIA;&1T;61E,RM6:TQ$
M5'A9*S98>B]9;#DO-6XQ;E,W>FAE5VE4,E%7<EA%46%.9U)3<$MK>54S,DAJ
M,D]*.&XF(WA!.TMX851&;&HV2E90=5 T0R]Z3G%U:S9N-4<Q8W!,2$I(9#9D
M9&])6$DU3E<S:S5)5E!E:6UO.7-!3&A:3E!/0DE)-4DS>7!01$0U4# F(WA!
M.TXU<$9J43).;6=:>49(2C0P4D9Q93=-=T$X5&AA57=U9%<P=3%K5TLU=DE)
M2D<U;%5K:U)'4'!Q2&5G66HW2T5-9D%B-#!O6'@S.6HF(WA!.THV;G S150K
M;$PV179&,5!'6&(Y,C%$<R]W05$K13<W-&ID5'-Q47IW5'A,3D1)<W-4:7%3
M25%Y<T0S0D=X=T$R:V=J;75$2V5H0G<F(WA!.V]5=G)L<#9X9SEE4#%W1UEX
M8VAY05%+5U!'=&%+2D5R+W)$>$=':6DQ:F%N<'%S:71D46AP2D1$1T1);TQ3
M2S-%;TXY,D1B538Q>4DF(WA!.TYS:4-R4%!$1SAA4$EQ4$ME35-S44-Z049Q
M2T0Q3D%4:%%G36MX63DU<#@U,FYL*U-#0U,R;&YU3&]59TEO:U!-='A66DI$
M57)8,E4F(WA!.SE$:7%";B]-+U%906=L9W5F5F%&8FHP,%9$.$IG:G532W,V
M.4DU=2]G9F%Q<DQ9,U=33EI&*WDT1$-V9U)81EAZ<#EA=68X069R+S@F(WA!
M.T5C-6EY.%(T:W4X=2MT6% K+U@O04]#3TYL9D5L,VPS,7$U+S,V+R]!05)X
M<W(T:W4X=2MT6% K+U@O-$DT,E8X4UAE6&97<FXO9G(F(WA!.R]W1$)(1WEV
M:5,W>3<V,6,O=T,O6"\T230R5CA36&589E=R;B]F<B]!4$)(1WEV:5,W>3<V
M,6,O-SEF+T%)230R5CA36&589E=R;B\F(WA!.T%(-B\O0DA'>79I4S=Y-S8Q
M8R\W.68X031)-#)6.%-895AF5W)N+V9R+SA!0DA'>79I4S=Y>69Y>C51,4A8
M8E=#-%,O34-Z,V(R;$<F(WA!.T1T5&A!6G5D86='=DAJ5$UN1&=-=T1F5W9S
M='HY3'!*-5EG.%982W9S=%0Q1%),;E-.5',K1CAB-C-E-%)6=5EG,V]K5E5J
M-#9K8VDF(WA!.V58=RM!<C!/4FQJ35I$93DQ;F=L:6Y(,6-12DAU9317=CDW
M.4)Z9FPV:TEZ06PU9C5G,415671,5WIH0E=Z;79D54UZ9VHT:BMK2FPF(WA!
M.S1K9&%#;T]%3S@W1WA12DUJ.5$U2G!P4&UA>#!(>5IP<6ME=&-+:&=T-V1F
M:&%2-#9!-S<P1S1*3T=:=5AV851O2EI-,&\X9T]:.'4F(WA!.VEM;FUV>E9*
M5C198E=#3V=O:DQ*2S-497)C,$@T64]">68U4'=$66U24'=(-D5X.'8K8FAQ
M9'ED2C%3,T56-GE-56115$A,>$I*;TXF(WA!.WEP0S V;G)K4TM,:6%R<S@T
M>'AW3GAV-&AG6&Y$5$E,92LQ1T]Z25989W57845';D%)<C%8<C-62R]45$18
M5C)S8S5N;S5'9F-2-R\F(WA!.T%-9F]E:F%&;SET<5AL5'EY,#AK<6EZ=&)3
M-&E73G5)37$R-%9'8F(T=5!+;UAP6'%$9TU1964W>31K4F1):"]*.6I,<4YL
M<59Z9%@F(WA!.TYX95=2:UE33S9"6D,T04)D15)%0E5)=$-I<E=G-6-S:U-3
M2R](6#E:44YR."]X*V=);3@X=C(Y>6PR;G%-9W9P4DQC17!(3%1J2$<F(WA!
M.VQ%5U98:D@Y=V@K2E<W,'!S4D1H0V5*:F<O2S9"3E-T-W5,5DIH1F$S34TP
M1G,X54QQ25E&9T-X8W5)879+,&DK3W1E27!U4U=.:UHF(WA!.T52<$5T>F%F
M2'EL;S8V4F-A9$)#<U@Q<3-J=%HW:FE05FM31TU24BMO-#1S+T925'(X<5I$
M24]++TTR>6A,:')Y4VY19GDQ<TY+=4HF(WA!.S<U<C9A9E5B>3-M=#<R65(R
M-E)/8F@O561X0UDS569&,$)*2%DQ1U=3;5I#;4%&270O24]K4&)F5DAN=4AS
M,%<T149U-U)U26UU=#,F(WA!.VM6;6I,<S-+<D0Q1UE64%1P45)K4DQI2$Y*
M,T9(:VTQ;&]T;F%*145,;&]N855.>3E/<G-P5FEY4D-.1T<O47)3=E%D36A8
M<4HW,38F(WA!.U5S>6)&1#-7;39D945'-W198F=H5U%'5TY8;W(O85@T9V1M
M-VI&56PQ5'E(;T=P1S=A6D=35SEE3G!:67A'2$-2>$Q%26Q*4G8S9$4F(WA!
M.T)P+TYU2T5#:7))55)54E55559104(W1$98:U O2W%F32\X04YB9CAJ1R\U
M<'I3+VM-;FLX,2]*1UAV:BM09S<O;%90;68X06UT=BLF(WA!.U)J9C@P-"]K
M36YK=CAK6F4K4#0K1'8X06Q64&UF*V$R+W=#4FIF.$%.3U U1$HU3"]*1UAV
M:BM09S<O;%90;68K83(O-4=.+WI4:BLF(WA!.U%Y95,O=T%K6F4K4#0K1'8K
M5E4K6B\U<F(O:UDS+TY/4#5$2C5,+TI'6'9J*U!G-R]L5E!M9CA!;71V*U)J
M9C@P-"]K36YK=CAK6F4F(WA!.RM0-"M$=CA!;%90;68K83(O=T-2:F8X04Y/
M4#5$2C5,+TI'6'9J*U!G-R]L5E!M9BMA,B\U1TXO>E1J*U%Y95,O=T%K6F4K
M4#0K1'8F(WA!.RM652M:+S5R8B]K63,O3D]0-41*-4PO2D=8=FHK4&<W+VQ6
M4&UF.$%M='8K4FIF.# T+VM-;FMV.&M:92M0-"M$=CA!;%90;68K83(F(WA!
M.R]W0U)J9CA!3D]0-41*-4PO2D=8=FHK4&=R=R]L>#4Q:&I%8TXQ2$A'<BMO
M<4I026]$;&5024%,,30W5CA-23!7561F=%IX-TTQ03(F(WA!.T5H.'EQ5R\U
M9"MC1FUG.64U:64S:6QJ;$U:;61H*S=!545+5G!5279%93(R16%,3%ET;$1S
M,T]#3$EO14AM6')6<B]E+U%C,C5E:$,F(WA!.TUW2EDU<&UL5S)P*U@W<3%N
M1WHS,G!"6&]#>6LS."LT<FE#,C1C,'-C:$M,2#1F23989&Q*6D5P86%N87E.
M-F-R0FU,<4A$3$MG<70F(WA!.T$O,E<R4%%9;#--=3!41UEN.55*1&-E9F0X
M3V%U9DQ8;7DS47AO=')/;S)75#%*1DI!-VQE1%4K.#1E3D@U-T),8SA14'5(
M-C!/=FLF(WA!.S8O=#5L,4<W=7E,>C R5S%T8EE5;$5R9T%H5TYE,S=11W<S
M=V)K<E!T05I)*TA'3E)V8VYU4FPY-59G,"]W07$V-V8S245U<%171C0F(WA!
M.S=U5'E#8S1N2D-S,5<W,$I*=VMU1'%T8V-G14DW44@V3SEK4&LW+VQ%9$4O
M-UHY<B]W06U6=T]!;2M+=7A6,DMU>%8R2W5X5C)+;V(F(WA!.S9M9C5V=W<R
M:6YF57HO3BM'3G)4=G%:+VTO1$<Q<#,Q32]Z9FAJ83 W-FUF-79W>'1A9#E4
M4#A!3BM'3G)4=G%:+VTO1$<Q<#,Q32\F(WA!.WIF:&IA,#<V;68U=G=X=&%D
M.510.#,T63)T3RMP;BMB.$UB5VYF57HO3BM'3G)4=G%:+VTO1$<Q<#,Q32]W
M03,T63)T3RMP;BMB.$TF(WA!.V)7;F95>B].*T=.<E1V<5HO;2]$1S%P9D9B
M;4XK6$MU3G)3=&=3>&E,5%!/.6LP.$]N6%=M1WIE-'5,:458149W,&]&>$TX
M-59I:W$F(WA!.W%A1U%J65EQ=&YS4% P+T@Q<'1&8W!U:D<R=6%Q9D94-C%1
M9FQI>6I-:FMO+V]B>CE3;C$S5'%F.79$.68Q;75,6C1X.'8X05-J.5,F(WA!
M.W)"<'9N,D)I.&,R:BMO449A5F],=&Y)2%1K-U1L:CE*>%E3;51Z5V%P<&8U
M:#9J<&PS<#AL-7!#4C-K36QU-W)B,U!)3$MH46M6;38F(WA!.S<T<T=1-DQP
M-V%D;SEH<#=/2D=S-V5+,TUG1D%X:5%*>7!V4W1-5E)M2W5X5C)+=7A6,DMU
M>%8R2W8X02\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP
M.E1H=6UB;F%I;',^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$
M:7-T:6QL97(@,C$N," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @
M(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@
M4&]W97)0;VEN=" M(%,Q1&5C2S T,C$@=7!D871E9"YP<'1X/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*
M(" @(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B
M/D9I;&4@3F%M93H@(" @(" @(" @(" @("!35%\P,#0N86DF(WA!.U5S97)N
M86UE.B @(" @(" @(" @(" @<G(S-S<P,3,F(WA!.TQO8V%L(%1I;64Z(" @
M(" @(" @(" @(# U+4%U9RTR,#(Q(#$S.C(U.C4V)B-X03M%4U0@5&EM93H@
M(" @(" @(" @(" @(# U+4%U9RTR,#(Q(# S.C4U.C4V)B-X03M38W)I<'0@
M5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ
M(" @(#(U+C(N,R8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K
M)B-X03LF(WA!.^* HB Q(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I
M;VX@8F5L;W<@,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!<FEA
M;$YA<G)O=TU4+4)O;&0F(WA!.R @(" @(" @("!!<FEA;$YA<G)O=TU4)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @
M($--64LF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!I=&5M<R!H879E(&)E96X@
M9FQA9V=E9"!F;W(@0U,Z)B-X03LF(WA!.T5M8F5D9&5D(&EM86=E(&ES(&QO
M=R!R97,F(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @(" @/&1C
M.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/G)R,S<W,#$S/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R
M;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @
M(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM.G<^
M"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^"B @
M(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @
M(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z
M3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54
M<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @
M(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q.87)R;W=-
M5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D%R:6%L($YA<G)O=R!-5#PO<W1&;G0Z9F]N=$9A;6EL>3X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T
M1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y
M<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R<VEO;E-T
M<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS
M93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9I;&5.86UE/F%N7U]?7U\N4$9".R!A;E]?7U]?+G!F;3PO<W1&;G0Z
M9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$YA<G)O=TU4
M+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A;6EL>3Y!<FEA;$YA<G)O=TU4/"]S=$9N=#IF;VYT1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R
M:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E
M/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1FEL94YA;64^86YB7U]?7RY01D([(&%N8E]?7U\N<&9M/"]S=$9N=#IF
M;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @
M(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G
M.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@
M1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @/&EL;'5S=')A=&]R.D-R
M96%T;W)3=6)4;V]L/D%D;V)E($EL;'5S=')A=&]R/"]I;&QU<W1R871O<CI#
M<F5A=&]R4W5B5&]O;#X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HT,38Q,# W82UB864Q+6,P-# M8F$W-BTY9#8T
M9#@U860R838\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z-#$V,3 P-V$M8F%E,2UC,#0P+6)A-S8M
M.60V-&0X-6%D,F$V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,#5E9#!F9F0M8F4Q
M,BTV830W+6$X8V4M,C1C9C<Q9CAA96(Y/"]S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A
M=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I
M9#HS9C@X,&0V9"TS96%C+38W-#DM.&-C,"TU.60X.30Q8S0S8S@\+WAM<$U-
M.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI
M:60Z,V8X.#!D-F0M,V5A8RTV-S0Y+3AC8S M-3ED.#DT,6,T,V,X/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z,#5E9#!F9F0M8F4Q,BTV830W+6$X8V4M,C1C9C<Q9CAA
M96(Y/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP
M-65D,&9F9"UB93$R+39A-#<M83AC92TR-&-F-S%F.&%E8CD\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,#@M,#54,3,Z,C4Z-# K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R
M(#(U+C(@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS9C@X,&0V9"TS
M96%C+38W-#DM.&-C,"TU.60X.30Q8S0S8S@\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#@M,#54,3,Z
M,C8Z,#,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C(@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#
M;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( -L" 0,!$0 "$0$#$0'_Q  >  $  @(" P$             !@<("00%
M 0,* O_$ &40   & @$! P0&%04,!P4)  $" P0%!@ '"!$2$R$)%!4Q&$%1
M5Y+5"A87&2(U.5)55F%T=925E[.XT=+6(S*1L;<D)S9'5'%Y@9:AM? E*3A8
M=L'Q*#-(29,W0F=WAZ6GML?_Q  = 0$  04! 0$              @$#! 4&
M!P@)_\0 6!$  @$# P(#! (-" 4+ P(' 0(#  01!1(A!C$305$'%")Q89$5
M%A<C,E6!DJ'!T=/P&$)6DY2QU-4()%*5X3,T-4-38G26L^/Q<G6T)2948W.B
MH]+B_]H # ,!  (1 Q$ /P#[^,4IBE,4IBE,4IBE,4IBE?/]Y;#RDW(WA98^
M/E+XH1,59;:WB+]R=Y'1+R$C)Q=EQ7TT[K<;9VPEDTU A26^1L3]LVL$?W,E
M'GJ[H&[ML"AN]5-%#9S\E_\ J/8?H/F/TBLI-S<RKXSY]^2:U/J6U0[SCYS3
MH'+>]W8!A(U^ZML-KK1E2V1J>3AIQR@I)0C<CN>&1<%C%T E&RZ;=[WJ)"E!
M5 /A8^8*CZ\YS]52;ASR;VYN/F[Y4+2-ZF(U_K[B_LOCQ6M01S.#C8U[#1.P
M]/+7"T(R<HS03>SJCJ=(5PW7DU5U6:/]S-S$1'LXH0 J'S(.?R$C]5:W>?WE
M+^:FI.07-:P\>)+5+#COY+:O\19SD-K:WTU>=N7(=YR<D&LQ,Q%;NA7[<*&C
M2J ^;NHY=BW[XTZ@N>0/+M7J,?'JDJ@@9SE\[<$<8]?F<C\E9%[R\HYR":^4
M_P"%7%'6>IK52>-.P[[::WLC>%ZKD0E#[VEU..JFY(>K:6,^,XE#UFC-96OK
M7&\,4VPNK>J[I:0M$Z_)&FU4"C8S9Y&, ?,#)_4/R]JY]P\H3R.?>6 XO<-X
M+45KU=Q?M2?*" L>Q-@UV';NN1-XT_J%G='CK5P.#NIJ-UQKJ5F:NV3N#0S)
M*\STK/PY2^;U5VDHIM&PMG)XX'D"2.?I..WEY]ZG7E;N0G*K3:G![6_$G9E4
MU+?N4G+>NZ"D[I<:##[&B(J(L=2LC]%VI 2Q! X-)2/9.5#,EFSI5),Z!5RD
M4, J( =VX$@+G@X\P/UU6W%_G3R&T!O_ )7\2_*?;+TS-27'OCS7^855Y+:_
MK+ZA5VS: >S#JJ7!2W4T/.21\]4[:DUBXUM7VBSJ:.X<,6[>2=^C5GZA4$ H
M#R2NT\G(P>#Z$'S['/<5D3I3RQG _>-1W3<H?8]IHK#0>LC;MV!%[;UK=]=6
M4VECIF.PVM4Z[.PY)2ZTR74[AG&.JPWDY%:0D82.5C$'L_!H2*J%&&.,Y.."
M#SZ9&1G'./3FNZU3Y6;AOM"F;UN[^P;(TXQXXT&(VOM2'W[J*_ZDM,9JZQH/
MEZOL"$KMFA4I&UUVTFCEVE>&MIR<G)R"L:P1C?.YJ&2D%"C @<<G P0>?0D'
M /Y?.K9X>\^N._.!I>OF+R-VCK+K1>M?+SK[:.O[1K#85>B[M&KS-%LKJJVQ
M@R>N*M=HAJZD:Q/,3.F$DW;+AWJ2R1D050J1WQ@YP000<?2*TA;UYH<^[!S-
M\HYKO6/E ^)?%#6/#B0U@:D4?D'KF@.W=[;6_23'84FV:6F6D(V=,U:3;1ZW
MD'B+::=,R3C%-NC_ "*#=95P!-JY5B2">#Z$CMCY5F1IWRUNG8+A1PTWSRSC
M;77=S\F-6V._/=7:8UA>=C2[>N:YDY"'OFWQJU?;3DM5]3E;Q[>VHRDT]<>;
MPTN5&/<SH1,F[05$H=S!>0#C)('R&20,_P 8K(;=GE@N$6CQI2TC:]C;)B;C
MIFN\C'-BTCI_8FV:[0] VU==O7=O[+E:E!/4*33911H^[I65[,NB5DL9W$M^
MVU\X50(QSQC!(Y('(Y(P>2?HKC\@_+&\&^-=O>T6]7#8,_:&.KJ5NU2.UGJ6
M^;&*;3]X;/W[+9GGE9AWC)M3(6+CSREHG'[AFT@VKR*3<&.^EXUFZ4",0" ,
M$X!) Y].3W^CN?*NZY#^5RX/<;8?4$Q:]B62\%WEK5#=FOXS3>O;AM.:<Z05
M:)/C[CFXNKQ;EQ6]>(-E1.>8FP9.%S-9-)BQ=K0LP1@H%)SVX..2!SZ DXS]
M%?G<'E<N$6FVVJG$E>[??3[UTPZWSIECJ#6=XV=)[+U^S>,VSI>M1U7AG;P9
M=H@Y<2TG$2J48Y@X:&L$E/>BV\')"W4",21C&#@Y(')S@<^N.*ZFY>6&X4U?
M5^B-KP4]M/;41R,HUJV=K:MZ5TSL+9E['75!>I16PKK:JG7H9:0I]>H<VH:#
MLSVPBQ\VE6LBW9D?%C)%5JIL;)!&,<') 'UGCZ?I':N9N/RO_!K2U/TG>)B_
M7*Z0N_-9N-W4AOJO5FP-B3T?I*/2;*3>W;Q7*_!+S=&HM>.Z!I-/K(Q82+5^
MTEF"<8N[@YI%@H$8Y[#'!R0.?(#U)\L?K%;%J7<JML6GU78%&G8ZT4J\5R$M
M]1LL0N#J*L%9LD:VF(*:C7)0 %V$I%O&KUHJ !WB"Z9N@=>@*CV[U)<4IBE,
M4IBE,4IBE,4IBE,4IBE:1N3_ #*\I.'.R\<0^"VE>*>P([7''_6&Z;5.;^M&
MP*O*E/L6T7BMI,8Q>KS",>[;H*U),Y4C1Z3A/OE3J.52F3(G0G S_']XS2HQ
M\U;Y(M_[K?DS?SM[E^-,CO'H?T?MJN!ZC]/[*?-6^2+?^ZWY,W\[>Y?C3&\>
MA_1^VF!ZC]/[*_)MM?)%) .93B[Y,TI2$[0F';>Y    !$>O65    *81$1
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MP[:TT72K=K.%9D0=R"P4F4ND'#5/8,-8X<S:1AW"[IG'N'C*/>-U2#[0@!X
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MF)E"EVW4-W@W\-,R<Q'SSV;K!E'I4E*^=X=O87\?Q_'RJ192S8(P=N P.TX
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M+"S$$W#5V]EB'2*W2<"';!)%NHY;E.?L.C.%5%"ZU[Q-,%U9+:9F9G265@6
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M8_\ \N;L#*$ C!I6WPQ>G3IU^[U_U?MRRPP2/X[4KU+-DUDC$,0IP4()#E,
M=E0I_$P'#IT'KU'Q$/;'UY=4GX6'!X!/GA>P_1C^!5.1R"5()*E200V<[AMY
M!S@Y'(/(YK$U"N434UTEX&6HD$6M7R37E8R?;P#0[=JK(HHLY"LS#\R)!(47
MA%GD:FY,9-TA*G9H#VFO=FS_ 'B>9$"W$GWI0H0R$CNS;U![')YQYJ6QGMZ
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MREB>MZQ(%EZV@ZF3LAD%T8&5(22ATU7!BQK\A7;0$5P ^6U4(&"?"'E\=P,
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M^Z$]Y#4/YM:9\2XI3V/NA/>0U#^;6F?$N*4]C[H3WD-0_FUIGQ+BE>0X^Z%
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MIH?6_5/2,YO-"U&6Q=G9Y8FBBN([EL!4:<7*RLQ&T?SANQSP<'5ARRUIKCA
MV1M=6G[*_&YN3HM:LG99UA.1)VYR"M)MGL.]2;.&"Z"IVXA,Q+M$JK5$HE<%
M!=(=K;/>:TT<,$$7CHRAG*D[XP?B 7X6RN,%MS*1CMY^^=#]=:O[0KRY36DL
M[:"QB7WR\32]/GL[V2;9%&98+V"Y"S1-()I&M7@?8&QMP&K#?6O/N_:PL2TW
M$SLNXA)5R=S(-EDUEDDP<+$$AY2#<,O1KLQC+%!R_BR,7AP*=1-)),P$S>W?
M29,;28 =4),8S(9=O#,I!P@[D(02.06.#7?ZETWT3U7:0:?KFCVMG-$J0Q:M
M;));2*Y 0R"-96D"R$;A&[R! =K%@ :WN<=^=&MMSQ<6@X<(QEA= 0BJ+57S
MIBJ82^#A(>A5DB',)0.W.51=!8PI'[78$V<3/820Y)381D^&>7"Y(W8[D'AL
MX')YY&*^<O:![%=<Z.\34+&9-8T)W8PWL(YB0\K',5!7>!CGX>"IP2><A-ZR
M+&3X\[K=L'"3I!73^RS$61.!B&#Y2YKJ "'B @(?1%'H8H@(& # (!KV0J=I
M!SC.,8/U5XN\<D3%)8VB<=T<%6'..0<'ZQ^BM97R.[]1LX6?@/</ZQ.W<O5&
MMSYWK-)PBT4=MDW;A)==NU.ND1PN@U%$KE9%$QP452;BX0!=0A3$1%=$%!**
MA.T_VCY* 6/^R"2 6] 2" 3P2#Z4P>#C@G ^DXS@?3CG'?%?E)^Q7!N*#UHL
M#MN9TU%)RBH#EJ7NNTY;]@YN^;E[]#M+)]I,.^2ZF_E"=ID9QGG&['GM.,''
MIR.>W(]:?M(_*.X^8P<CRQ7J1EXIPN^:MY./7<Q9BEDVZ+ULJO'&.3O"%?(D
M5,HT,=/^4*#@J8F)]$'4OCE,@KN!!4%@6S\.5_"&>V5_G#.1YTP=P7'Q$!@O
M\XJWX) [D-Y'&#Y5R2NFIA0 KE PNB"HV JR8BX(4H',=  -_*D*0Q3B9/M
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MS@X506.#@<4/"22'A(D,LKGA(HU(#22-V1%) +L0H)&3R*D0"!@ Q1 2B "
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M/</ZQ.W<YZOG*I!O:>V6/-N!W/%Z\NLMK/0UDUMH5Y=(V2K:4#&-=WL9)GN
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ME#H(CVN@ !NO3L],,H.,9)! (SV!. ?0#S QY]AQ5U8B?#!R'D)VQE3O.#C
M7OD]P."1SVYJOU;W3V:@^?7&J(*E4.;S-Q8X5%4! PAXD,]*(")NI1Z^ &^A
M$>O4,NA", CG /T\CRSC/]];^+2-1FAS;Z3J3QE,^/'87;H0.Y9EA((!YR,Y
M^53%E9HR3;E<(+).6ZH=DB[5=N[:K= ZCV%VYU$3 '3_ .Z<>GB/@ &'*-&0
M.6/)(\SZ]_+R'?\ */(:F6QEAD\,G$@[HZ/%(I'."CJ&)QG@ G@BH5*=MA*$
MEXQ(A3F*?OF8=2(O$1'M]VJ & .\'LE%)7UI. [0CW:BP#- Q78>RD\D_%GU
M/S]#Y>=;58%N;/PIF.Z/9X<CG)4J. &[A00"!C)  QVK6IS^H<(1U3=JUX$D
M4+,9Q#3A6Y0(5Z[:M#.4G#HI  $W)6:;IF\!02J =NFF( <@@6<9D174295F
M <''))QM/' QR3@<>7K]1_Z-'4=Q-#KO2=WXDAT](+[36=\B&!Y/!>.)'_!0
M74D4H" $LQY/-4AS]2=(^00Y-D?*"JX]C]81 QE!5$6HWQJ9B(F$1'J5J9$!
M#KT*/T(> #F.RNDK!F)&<+] '\TCR')QZ9Y/''@?M@D@E]I75CVZA$-_$K #
M&7%G;>(?RR%CQQG..,5:GR.[]1LX6?@/</ZQ.W<G7FM9L7K@WIW8&P;#M^=:
MKJ[=D]B:UOM<V6#://::*AJY2M'@*A6G:J!R(59WZ&FR2[%5-11\2[VLIE2"
M_*8D( ;=HR@7 NKFYN,@'WM;V#W&ZMY^Q,4FF8T_ (VPJ'4>)G,IV]X1T<#;
M[DEI"/*W:&62[@NHAP/>(;^3WQ'.?OL<8.51<*?PKHD2@P@;U-2&U:!5*,^U
MCK>@7")@0A*509&:J<\O"+KQK)L]M3M-[1JFDTF)U59XU90J") ,JN[<.*JJ
MF+$J)+<8M$]Y8??!'91S1PJJ@A%9_&+W+@9FDCB9?#5"K5DD=I9'0^%'))<S
M- O*F6Z</(3(VZ0QK\8BC+8197#;R$*]SKSB;#:_N%OLJ5WL4Q&2\+LVM4NK
M/&4(UC-<P&W[PGL6]QT0Z9,4I"9*]M+>/5C%9M=P:(BXUI%MP,EWJBD)8A-8
MW%E(=[7%K;6)N6 \5+*Q@N[:Q@4#"?ZO#>2(TC O/X<!D.Z,EY1RF&XAFB54
M2&;WKP!D1O<O[L9I2?PL2M;"0)G$;RS;3B0!;+@-)Q%?/I%1"6DES:.H[^C0
M??%: 698/Z]7:ZH\E0(B @[*VKK=P4&@H(]^X6 Q#$[L"7Y7,VI76I,,275K
M?VC1C\!4OM3TW4F9><[DDTR*-<D_!+)G<P7%C!]UAM1PD-Y:WH8_A-);6&HV
M"*V#C:8]3F8\9+QQX(&16.^P>)MZO]SMRK#;,GK^F/-Q0.\(^*CH.NVV(M]@
M;:\K-0" N]?LC,Y'$75++36-_@4D7/F;B>?1CATDL:!21+:@7P5M2I.;.74Q
M#&P5U U"]&IB[#$ K<PW5WJ-O$,E88725 9A&\=Z5]ZS*!DW<%FD\H++(!:)
M/:M:KEF7W:XM4L#,4"/(89(7!ADF6:KMN\!+;//ZQ8J)MZ?2GJWNB"V)4TY&
M)J:4=K<ULW/1]N[PL<0W4BU1LKVS3]2-*QL!.*J,8Y%_(0C Z+=TFLA?M']W
MGBD' 2/4;<3$"26.QGT_6TM[%00%:,7.I00M,5\7W>VM6)+P,98S.T\%Q')M
M;QSI4SQA1&DU[IKZ; MVQ7+(_N=K<2>&I\-[BYG8C$B".-0'"S;^KMI:S9Z^
MGI:<U=2;!#[6M\G8;!3VH;/V'6J#?ZPS7E(5E6&TU V*4?6&MLG(Q3T*>:$@
M6<JH+>79GC'UF,N@4J$06%O=1:;$Y:0&6;IJTZ=BD:4,KJ!';M-.CAE5FF:'
M<UVPMIR%)?$\5Y&>^>(7DR)&"D8ZHEZBE7PS\+*AN)EMI(V$S2&*&;9;VZM-
MG-K?0L)6]&:OT_<2)6<M$;4>4>NB+O6B+ZZTZ;CKBA.(F;KMW((IW-@G+-VR
MIQ1523(V>(KMS*HJ7IO"$\+6_B&*R6*&R:;'BK#:VHLH'DQE?&:W4>)R5#LQ
M7L#5@-)(MTTP57OY+N:ZCC):/??7$ES/$CL%8QJ\A5&VJQ502%)('2[]XP57
M?<[4;%8925;K4V&DHAK#M#LTHV:;R&Q-2[(6;RJRS-TZ227D=11,2HHT[)TX
MV8E%2D.[39J(Z^XM4F\5BBRE[>XA,3G:D@GL[ZT9'8 LH*WSG< 2I53@XP<N
M&X>)1&K&,&:*7QD4-+$T3JZN@8A25*Y"MP3@97O6&^B^"NPWJMSL&]K9/1SV
M0HC?4U0A$Y:I6"0AJ8CJ>:U6Y.]EH& C(R0.@UG%WL*]4:IRDHJU+*6-JS<R
M"T.QR;N);M-2DEE:2ZUB'6+>\F,4<1\/57Z8E:4HC.BW*S=-(YCB9[9%NV1"
MVT%8Q7#6\EE'$H]UTJZTZZM$WLRM)IS=0[54LJ2^!)'KQ5GF_P!8+6R$A ,O
MEY2>,1==ZMM^L*?LVZ0+>>N![O7['&A&-)ZIS*TC#S[Q)!9!NDA,Q$K88MR[
MEXF625:R4/,2-:<@>*.4F9%S/)<R++A8Y%N[NZX&Z-A>:E=ZB\$B.6#QJ;R6
M!<X9D".S"50PQH46(G<H=39V=HRCX3BSTNVTI9U89*3/':Q7&X#$=QDH AVU
M53G@+6W3ULX^:G?6*$RYBYW9[>'0@(MQL&ZUW:]XWA6K@E)-V'GM,DH;9VPI
M^?21JYVR*S9&'BEA%O&D.K;#,NY4)6)8Y3;19S[I=3:=)I;WD;G+/,;9XY"&
MQ&;JV@G"+AT>\)6&QL(THD;QI'0'Q[4RVTHLI%&!X*>["$$?&;>:>,L2ZLG.
M;\$JW(5?8D-?-H7V^V#9<3,LYRZR:5>CIM":D8_6$/'VMBWC8M.-"<AXW3.N
M>PH[:NVTB_AG;Y^W5&7>(#3<R2130!8)XKO3M022-5V+?Z;JD^L0S+ WWM(7
MO)HQ);(!&8+.UB[QEVDLQ$9@*EX&M[VRDC=V8S6=]IQTN2*23.]I5M9KP)<$
MB027MRX +#$T8\4 <6EE>KMM2WWFY).]3O9"9?Q55ATI!;45IVK:(%!.,@HA
MDS8L')MK244NW2 ZR<?#Q8@Z4>&>NG(8"E%0*IFOK@G<69I=0T(Z#.22  %@
M/C1A0 LF%.4!!M[V*2(<%7ABA4<@1I#J%MJ"[.<Y:2V5'+%LK)*0 2H2^]3:
M[CM1ZQH&KHA^]E(O7U1@:A'R,B" /WS. CD(YNZ> V31;@Y63;E45!!)-(#F
M$"$*7H 3DD,C;B #MC7C/:-%C!YSR0H)^DFH <R,3DR2S3'_ .J:5Y6'R!<@
M9R< 9).2;"R%5JA\R*QZ8I3%*8I3%*8I3%*8I6O*4\IWQ>B).1B7CN^ [BWS
MN.= G43'3!RR<*-EP3/Z1#MD!5(W8/T#M%Z#T#KTSSB7VJ=*PRR0N^H;XI'C
M?%GD;D8JV#XHR,@X..17A]Q_I">SNVN)[:676?%MYI8)-NEDKXD3M&^T^/R-
MRG!\QS7!^>E\5O\ ++__ +'&^,LM_=8Z3_V]1_L7_NU9_E%>SC_M=:_W4?W]
M/GI?%;_++_\ ['&^,L?=8Z3_ -O4?[%_[M/Y17LX_P"UUK_=1_?T^>E\5O\
M++__ +'&^,L?=8Z3_P!O4?[%_P"[3^45[./^UUK_ '4?W]/GI?%;_++_ /['
M&^,L?=8Z3_V]1_L7_NT_E%>SC_M=:_W4?W]/GI?%;_++_P#['&^,L?=8Z3_V
M]1_L7_NT_E%>SC_M=:_W4?W]9":!Y8ZDY)O;*PUHM8E7%3:QKR6"<A1B2%1E
ME7B+3S<PNG'?&$[%?O"]"]@ (/4>UX='T]U?H_4\EU'I9N2UFD3S>\0>"-LQ
M=4VG>VXYC;/;''K7;]%^TKIGKV74(>GWOF?38[>6Y]\M#; )<M*D6PF1]YS"
M^X<8&.^:R7SJ*[^F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*59-,^ESG[]/^@0RT_<?+]9JZG8_/\ 4*E^0J=,4K3YJWZN)R^\?_E_<4_N
M=/[[>[?;_P!_7(/V'S_4:5C3Y0?7\YM)W9?-SE<N86WO"0SMRLW%B[:N$%DV
M"(.DA%)F@F#D6YEQ*<Z)$4P<E(L=42=ITY?)IEQ#+(3X3(\<OPDD+(!GX20>
M2J#DGC)..#7V-[-XH_M+ATVV42WEQH\>H):D>%*UU:-.TB9?"L2LN].5+J"%
MR0#6Q[@]QBI7&O6#>/KJ1)B>L#Q>7L5I4[OSB1?*&%$!0+]&+>/$A2E;-$U1
M(T; @R$RI6Q55--K^KW&J7A=\+$J8C3<<  \ #)\CG/T^M?-W5VM7VN:G+)=
MM) BJ$2W=60IM=BRLA_!(<@ 'R /&>;^WMM*&TOJVUWN;9OY)O'-._4:1OT+
ME9XN9)BTZ+&$$FK<JXH)JN1Z@D!@$A%5![)M$\B01&XE&(XR7<^:J#D_4/[O
M+ -6N@^F;SK7K#1>F-/N+>WNM1GV12W0^]A(MTLQVD'>PC1R(^[G@'G TL2F
MZKQR6=(O;)8W<)6R'6".I==DW4=%QK8A@)W<J9JJV<3,@*!0,NY>&$I5%#@T
M;H$ "YO[>VA$(F)W^.%D7(!4*V, '&/3&<X/KY?;.G]"Z![-8I8[#2K?5M0D
M.;S6M4M8;FXFD*G:;..9919VZ%B/!CP#M5C(<D5V<7IVA.6;YZU9L),Y'; K
M4Y4$70NSKM&[5!(RRQ5.R0R[HJBAQ-V1/WIU! 3=1R#$NX;HHU)4@@H"0 S%
MB>"0-J\8]>"3G.-<=:ZQ!+!;AI(%$4YD9,6Z1JA9R8T0(I947:JA3@8X/D?5
M.QZNG6DEJ>V6.KS91%1*.BWZRT&N012 R+^"4<*QCQ-9044R-SM0,8QS&3,0
M2B<++6T4JL.(VXVLH!(8@_1C/&22 ._*Y%(]3T7JVQ>+J[0M-U&Q*.DM[-;Q
M0WL1&=LT5P8HI$>,!F,JR;U"CDAF%;).,>]'>W8^;JM\8(5G;5 <)-+9652+
M-E'C,Z*7F=CC6[D"G)'R0F'O6Q3JF9N0$@F%-5NHIH1*IDE@#*TMN0)-HY/H
MR_0V,]\\]\5\T>U'H>'HNZL]4T.>35.CNH8KB;1=5B=)H_O4CFXLIFA8J+NU
M?"AF6,R0@,%VD"J/YBL'MSN&O]*U-(5Y.S/7UP<,VP$ B;L\=(0B"I%1,5H@
M#T%%5W *&33%9NFX4,"BZAQRXD&P$MX8+$[CSD* <XXSCL,<^GE7>>Q"XMNG
M-,ZKZ\U &.STVTM=)\5P5)E>]M;IU2-0TLN=BA3&K ,S*3P<5_Y7&FDH/D6>
M7-0)X_*[QV-&JCT)U%P2:@#N3"8@B4PF<J*'[11$# ;PZ^O,5CND9@<J68@]
MB<]\\^OIQV\\FOG3J/5CKNO:MK!&/LC?3W*CG*QNY\)3D _#&%7D Y'K7$^1
MW?J-G"S\![A_6)V[E:TM;J,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE4/F16/3%*X<A(,(E@^E95ZTC(N,9N9"2D9!RBS81[!DB=R\>O7;@Z;=JT:
M-TU%W+E=1-%!%,ZJIRD*8P*52Y>3O'<U&+LP-U:U^4 ]@+4RVTUMARPGRS&3
M[\($SPSH"$E?-/[O%D?LKEC.LF8@1X"YRN#Z'ZJ5=Z"Z+E%%RV62<-W"2:[=
MP@H15%=%4@*)+(JIB9-5)4ABG34(8Q#D,!BB(" Y2E>W%*8I3%*^+N^_X=73
M_P 66/\ XP\SXBO_ /GU[_XNY_\ 6>ORAUG_ *8U7_[E??\ Y4M1/,2M;3%*
ML_6.E]I[G?2L;JZD3=T>0;)%_+)Q*20D8MW*_FK,J[ARLW;@ZD'/5O&L"JF?
M22Y3HL6SA1,Y2['3M(U/5WECTVRFO'A022B)00BLVU=S,57<[?#''G?(P(C5
MB"!OM!Z8U_J>6XAT#2KK5)+2)9KA;95(B1WV1AG=D3Q)GRD$(8RSL&6)'*D#
MLF_'[=3NFL]@M]9VQ6GR%F1IS.:+&* FO9'$N->1C"-3"#\#*V$!KY')FA60
MSQ30OG/I,HM0N+H>L-:)?KIUT;1[D6B3>$VUKAI? $87\/F?[P&*[/'!AW>*
M-E7TZ.ZHDTR+64T/4&TV:^738KH0'#WKW/N20",D3 M>9LPYC$1NP;;?XX,=
M=3;=/;)HJMF2M=87B/E/-5R3ZZC^)<LVQKJT<R%4\S?LG[EE,!.L&3YZP-#.
M) JC1@_<F$B+%V=&U=:5J%D;A;FW:+W4VPG8O$R+[XC26VR1'9)?'C1WC,+2
M HCM^"C$8VH]-:WI+7PU"P>V&FFP%XYFMY(D.J1O-I_AS13217/O<,4LL1M7
MF!CBE<X6*0KM.\CS_A3O3\ 4;_B-DSUSV,?\[U__ ,/8?^I=5]'_ .BY_P!(
M]8?^"T?_ ->_K>OGOE?8M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4JR:9]+G/WZ?] AEI^X^7ZS5U.Q^?ZA4OR%3IBE:>]7!U\N'R_#Q#
MKY/WBH'4/7X[;W:'4/\ GUY!^P^?[:#@@^E7KM7C3/2SZP^C"KR4/+NE'+,.
MRW4<-CNT.]=$<H@1 4VZ;TQ^P+5(5 1(B8#G.42YMH;Z-HU#D*RJ%8?$ =I
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MNZYC=JOHBES\#6:_"OGNN+B37,<HPL)I^4M<91JY4*+'+UMC*)V<UKW_ &1
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M)/RB4H="9644@5^Y4,Y=)/>]3(Y2.D[[U%3SR,673[Y,5.V&5:QKLDDD)E+
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M6(&[5JP4ZU1B$S6K3#25?GXET*@-Y*'EV:S"19*F1.DLF5PU752[U!5)=(3
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MSW(7 \\=LD5H==ZDU7J&6)[^Y+06R"*SLH46WLK.% %CC@MX\(H5 %W,&=@
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MKYT'M=0]D5R4#_\ UW_=E !@' SN89QY \4 &<>6YAY^0X^JOR7R:7#GH/\
M>_OG@)?5R)Y)AZQZ>UMWQ_UXP/0?511D'/JH_(3S7Z#R:/#CH ?,^OG\XW_Q
M$\DP]WV_FN]0]0>K_P QQ@?QV^JFT8/'8L!\@"17X'R:/#CM]/F?7SH(A_\
M$5R4]OIU_P ;N!V'R%0KP/DT>' ?XOKY_.,'_:*Y*>H.G3_&[E:5ZE/)F\-%
MDU$5M=WE5)4ATU4E.0_)(Z:B9RB4Z:A#;<$IR'*(E.0P"4Q1$! 0$0Q2OI_\
MG;J77VB^&NE=4ZKK_P JU!J3"X(U^!]*S<WZ/3E=B6^=?E]*6.2EYIWW\K*/
MG75[(N3)=_W"(IMDD44U*S4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
%F*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g209588g05c00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g05c00.jpg
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M5%5R=9*4HK7_Q  = 0 !! ,! 0               04&!P(#! @)_\0 5A$
M 0,"! 0#!@0$ P,) PD) 0(#$00A  42,08305$B89$'%#)Q@:&QP>'P%2-"
MT0@D4A8S\24T-4-B<G."LQ<F8T1%5'22E+32TQA39(2%DZ*RQ/_:  P# 0 "
M$0,1 #\ ]/X0^O\ ^W+6'^9F:_??&^!V'H,:)/<^IP?A#Z__ +<M8?YF9K]]
M\$#L/08)/<^IP?A#Z_\ [<M8?YF9K]]\$#L/08)/<^IP?A#Z_P#[<M8?YF9K
M]]\$#L/08)/<^IP?A#Z__MRUA_F9FOWWP0.P]!@D]SZG!^$/K_\ MRUA_F9F
MOWWP0.P]!@D]SZG!^$/K_P#MRUA_F9FOWWP0.P]!@D]SZG!^$/K_ /MRUA_F
M9FOWWP0.P]!@D]SZG!^$/K_^W+6'^9F:_??! [#T&"3W/J<'X0^O_P"W+6'^
M9F:_??! [#T&"3W/J<'X0^O_ .W+6'^9F:_??! [#T&"3W/J<'X0^O\ ^W+6
M'^9F:_??! [#T&"3W/J<'X0^O_[<M8?YF9K]]\$#L/08)/<^IP?A#Z__ +<M
M8?YF9K]]\$#L/08)/<^IP?A#Z_\ [<M8?YF9K]]\$#L/08)/<^IP?A#Z_P#[
M<M8?YF9K]]\$#L/08)/<^IP?A#Z__MRUA_F9FOWWP0.P]!@D]SZG!^$/K_\
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MXHS2BD#L/3!)[_OKZ]>_TQJ=MJ=J/>P[NONL[RZV@9*QB47(8=CD-I,C7D;
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M5@G45^V0NHQW0&FC&-TFKJ] A_TU7QNO$;;S7.GGFV45=0%*(!DI  /6=/S
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MZ\MNGIJ926Q_,<0A>ANY)49(D =8))!$2,">THY]G "+'YHM5W)+B(V+QW;
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MRVP1'[ZP>KI+G;D#WFIG:4!<0#853;=;ZU!=^HGB02!"(2)15P9IJ((D+'-
M,(,)$]021(^D?/?&XL9RM<IH5<DF.<CF+"3>QU*/;K,"+GK&O6C+)UOCKD>+
M%:!7&B=DR'>@C,$15\*)N&I].ZJAN;?,=D5-N'[*&J9+S)(2D%0TE&YC:#<Z
M=5CMY>3'7IJFE.@K4LIL==DIU%(!@J %MSN1().%/3YHS'9$'XOJV$3I%%-
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M^\7AKC=2RE10=0,6!/AC<JLHS!,2;&<>V-R[Y)AE#]*H3#DV1D@^_+,4!"*
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MJ=:E+<6@*2E13,6 $R).Q(@$><&,-+O"]4TV@,M.!I>DK*I 4H'PI.D22!!
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M[G/X#\M\23AYUUH5Y:<+<BEU1U@U,3\I/0Q^,:[; *;(4E/N2&ZF.TXX[((
M;?!WJ4E<>C@*"G6O2JFG6@]2"8[?6P,Y*TXG4 D(%S_JT]1!N#%_GUQVU7$5
M31+0RV"^O22J0H&;D7\05Z?+K" RK%H$4'V,7N!M'7GX\)IBPC+$9;ER9+<1
MB0$A'U1OI=>'KD"@^G:)QU5=1I1XPJLJI4-*+))7XHD A(@G83U $C;;I ZJ
M3.JRK+1?:<;;"TJ4E ,K&H)*">@(421!B!8XJYQ?G*F8AD6;X[J;)I+;&Z/)
M;RKHY=?'L4R8FX=F_&Z$<;C% L:Q!; HY3GXMBPT9 <F87;1JOV\^_A=4MO,
M74J8#RDH"Q!0;0JY.J8V@1'Q7M==5P&UFN79?5Y6VMNH>80XX%K"DJ)))3H.
MF-_BDD@[6O+_ !O632K-<7+(H<R"] ><]#%F0GGW'7Y8[(]#174!AJP;(V.]
M$5!D11<5U^.C:HZ$B3GE'4MI<:6RXVHJ'A(!M<'8]Y(O!!,Q.(:[PIF- ^IE
M:*A#LC2'5%"22H)A(((TWD=Q%[X7]WS%TV"09LVLO*_&#,7X+%Z[8Q&) E)%
M&E/OQ9!LHC:(J$;;KP=OX2Z?S YTY]1(6&E53;))A"5Z[JO8%"3,VO:UT]1A
MR>X"S13;3S^7//I(2XLI0@);1906M:EB0I(D1MI,]\5ZV_/BN(3;YO&LMN[J
M]>>?;5JJ65*@6[QEL^Y9/SS<KY<%YAV4T4A(MJ+A/&H,=IWU)]:ZFI6WJ;"5
M+6"IL+44-+'])"RB2F!<!/3L!A',MX?IU-^] -I; 3I9TJ>!&\E)*0H&;R>E
M]P(ZVW.1S Y4"T\]C&7L 5UU]=/9\.LMJ>82]'2],C75;9H$P2:;[+U2=*W7
MFANU$:M-^0KK"NDJ0ZI537TX0ZDJ53H2I3>X/Q*2E,@V!&PF !,N]-49"$H9
MR_+LP<J%D /*<3S%*L"0$!1^D@3UVPGW=;HOK9"0:9K#97>,WZO'PDY)1MR7
M'B5'&>JUC9#2LH2J3K9OY"2$O>8,&R!CAH>?>HUGW>I9"=2B$I*4)*?$=$E5
MCM>3OU()Q<_#7#V7YVPAJLH:]IQM 25O%)5K 2=80ILE2?%\4Q(,"=WMB_,M
M/AO0X5[-S%R(RQ'EI/II!WD=H /H$78LIY^?$5HD(@;.,U*%EX%<:94NA-*\
M[*T(2MY*"%2!SAIGJF#H$=)!.PTC#Y_[) 5/.L--:%)5\2PVXH*)A4@$I41!
M/A^8P\;3GATZJ:Q'%L3L$% :=:F448RZC1147HYP@1'1V0E5UM'%'J4.HNE%
M[:?/,R0"E(][2M$!I)N)_KU$:4_.;C?;$,K?9.RU4(54U2<N6IR MQ])038A
M(GEZRJ8*8$6(N-.*UM?M;@U8R.WS#%)600Z;&PI!C1;FU8L3A3Y"DV,^KBK'
M:%I1D 3,+H9:2NC-M-DB&\@MZT'F5+#5>AYYNM*PIEQ:@EUE! 6RJ)"D"]@H
ME4 ;!4.E?P@IC**C+LOS!A"3H56NL!+SX)!Y:FCJ26RI,085!)WL<>*#H_FN
M<Q+#,7K2/F%C53"BY#C.3/2V7V%B/CZF6W9./V(NDVZI!+E*2[%)7:/&BH\#
M#]3*RQAM=)1)8IDN ^-#:$%9CQ!(!3I3(C2%$?ZBHZB8C_L]_"VD.*96EUF"
MAT)44:A.DNK!)<<(_K*0)LD)! PRX6-8BYB]WBEG5.43$1H7WVECPWWJ6Z$'
M6H-J%B+:2)E:Z4@XZ(;LEIQF0K3"LR$:Z8[64E2E2@DKTJ5K20[K38D;0#&X
M4-1,&Q[<2.(GG*H%Q6MYJ&RHRDN)$0>7"@KL%:NX@1:4_+<->&#E1QVH*6T-
MZ7%;54Z3GK%).QV%-LFR62STR&@:-25M$<%%W1.(C[JEI^K+[B>8HNN 2"O7
M%DR9)F+3%H!Z'#MF25OIIZP-++-0A"5PB$MEP D"_2>P%O.,2)Q*X;R*_*-?
MO.1K&"Z9MOJZ#33H(S%5H7FT 1)PUC+WG!145X>YU(XI<5)Q'6A[-&VZI:V&
MFGE /H40$Z#*0H 2$Q%@M)F9! C#[EV7!JF14(9YHTG2/AU2D$F;R8%AVF\X
MES =IK+'AC641N?&]0J// VT+K@.2#!N4T#Z"VX!@!.!W%!-^G9>K=$GF0\3
M,FB3I""AHJ2A1^-P!1 .UIC8V(/U,-K<O=9JGGD*#2EJE#1OJ*C.DGK?K'3R
M(Q:K[+7#L-Q"EUD'"HR18-YDU)<3VU@,U[IV?NPZYQZ0RPJMFZ[&KXIJ]LA.
M"H[[HB$OJ'V0UC%=PW6/TZ7$H.<OI4'=]8HJ J(L)!!%^IQ0'M/?JW\]H??%
MA:V\H;0@A6H!L5M:0)@1"BJ!T&+8>+5Q7&#@P8.#!A;9A8>ES;22'[V"#[SR
M7)6$KERFDI"NEC8#E$STP4-E6S+3,O1HPM@59CTZHFU21OI#.DR:BKG0)*]_
ME^8_=\(=Q]>H[>I^GS.&3PF%P<&#!P8,(+FFB+/Y=M8H*%T+-P:XB(6^W2LE
MH64+?ZMNO??^'')7B:"N!V-%5CM_\G<ZXZJ$E-=1*&Z:RE(^8?;..1##^63)
M(S;IQX[91>Z/1-)>E735$4E7KV5&PZ=D+8@+<MME%./*O\T^%M*4@$ZE$W*1
M:#ZWBUNN/3E1F;+J4\PJ+D$% ((@#9.TQ$&"#T!-\-MW!QP]I&L@KH_J!;!8
MI@K;X'NWU(0"B(G<0>DC514FE( )4<Z@38V>05./)"C'@$DA1BQB\Q]!\]\-
M3G^;3HIGE#4?&=*PJ0;ID@0 ($QZDXU-^-CE4S89!>/1H341MQQON$VBO*VB
M$9=8[J*B(=(FFPM&BHBJJ;GN0KW@A3H@'3H0D$ DQ%H*B8!%C$3;LKK*Z5MM
MEHCFJGFK)Z1;5U"K])$;PK$1^8K4W(<LP6R^A>.-5&--1T;+(;45D.O=3B"*
M5E?&Z6G2[HJ(.N/O-$J*:MJ(EN^&II:%M*GFUNP .6"$D;74HP1:1 $WV%SA
MMR/(:K.,W2PW5(;7K6"I"5N'09"U0D$0FYMT!WVQ4M19R_I--L',:K)D+)I(
M _(M[684OU:O&X+L$JAV&C$: VR;4B"ZW/?-'HL8"81$-1=G,T5G+#)>J>2P
M#R>33--H#*4(E+_/6XM;KI6"AQ"F4I"23KD0J;M>R\<.Y@ZM;-/7EUD5C3KE
M4^X*M2WBA=*66V:?DI2W*^875*+HT%L"2,+>ZMZ@Y4_W;RUG6 &JH3+DR4VP
MH*76H(++R* ;HBH@HB"J?+PB<-CF79<B5>]O.+!N2A)-C,#5"9WGIMVQ9V4T
M^8T[*&J/A?+J;P@)>(<>7N""0M12D=M[WCKC8X6>NI5QFZC (+UZ+;K<^YM+
M"RM(?4G7V78E>JQUC.-,H/5ZJ=,:,AZNT(?".M"<JIUE3JW7(@I02E)(M8JN
M5= (2  >F.+,>&.,*]9#E6BFIS=+3#;3:R5$J"? K4X"3 "9(M:+X464V%U>
M226ZL'99;[)#C--0X#*^4Z&H,1MB.2B/A3)E3547K,E3=95EF94@TBFID4PL
M-:B-9[%3BI(WN 1/](O>!9[P+6T*5KKG7WG(7_+4EPF4#3"6TF2"=E+$#=4
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M04R9TE+9;(E*R8E)453$[#%5&H5))U5U.R2^JJ]&*1V>,*H;8%I([53"!N-
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M!B.O-PY9-<LNN+M-%9G6[>G.1N54*0:-1YED$,B@Q7W5=91MF1*1IETU>:0
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MP(&*^]JOM0S)[+_?LKK,LIJVL6EQMM:FZFK:IN4I);;6\Y4*IUE?*&E;* E
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M"O#B,)U/E IP67/<:!%0G"8C";R@.Y* %TB2H@KIJ:!W,:6HIF4<QPHY@2"
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MCM9F.99XZW4U:7-:&>8M31YQ4K^6D*24;C0E"DHTQJ!-L,3(M,^8;DR;AYS
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MK'PBTQ\CP\->UZGRRJ<?H*8,+J ><A2G%L*U'43H6509DV5MOL#B*]IIJQ]
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M8,'!@P<&#!P8,4D^TZAU[^L>DS]LRLVL;PFYB3JQQMIV'.C3;@.ZW+;>16S
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MV:-IW*9>[%AE$9MP4WZ6GHY=6Z[;=3CK>Q;JFZ(/U>/KXUJJ@I)"6US;^E4
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M>06*R6YVXP'9TN5!C)/F.-M/HUZX02Q?5.ZK-F?O[><M5+M4T L H0X# E<
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M38-\8[L8&F)$=M6B!MLE-TP<>D"_T-APNT:*EQM*@EH!84"G5J22"-2C*8!
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M(GTML2)[?^,L6]@X,&#@P8.#!A;Z/(XFEV!]U)"._1JLZTE_01)'5V$W[O\
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M]:5F4QH=996=$60XQ-KV8]YC(O>F&=%=?;D!+JK)MMU^DR&":(]668-O,MO
MD>PB3:]Z5%=Y:=]M"E)40E4@:Q!*1UD=4J!A8(F(B#&-]31N.- H$V-C:\3.
M]NF_>#(G##TRQ"+#M:BW:D>^L1MI3C=-:F*#*A2(P-'+Q_)83:"=+E52+[2S
MZU].U,CNLVM6_-K9+3R85"%R"5 A2I5_I,F(2;RF-C\Q8@QNH76PA:-BD%/B
M@$0D77-TJU&.@-H) Q8C89=6TU+"K:)@PFR'&8X]@%<<Z%%$=-!$/K;%=E3Z
MUW5?J5GKW$MH"4^%1.UK ['KO87\_(8*.F+KJE.$J28F#YGPB+@)$=]ST@XU
M>YO[:5"EUL8)$R38FZZ$9UU9#T4B$17\U"6.RA#UHV73T$I*OG?=K;JEI44E
M5U").Q@S-HN (B"+'J9PZ*H4!.I*82(O\B1)F2;]>O:(B+]_RZ!DQ2[/((\R
MPMF5=EQ(<,NE!>%"<$")5VZRV0$,E$1W0E3QXZDYJ64+;0HI<6 ";F;@Q CI
M8P"=R3M/50M,I>9+R$J2%3I*HC>+@7)-[1TPR^2.GR; =8,="VJ0E4EKDN,8
MQ>8=DS,A:RVJ9N35,V*XA$3?5<XO?U]1F&,6<<E*JR2DJIC2FV+S;W3E&9+&
M:42$Z07:EAM222"07TA1A74A1MU$B.F'+BK*Z9>2U3J5$K0R\\B% E,-J7TF
M (C:XD>>/T4JO^[:[_88G_+M\7-CS^G8?(?ACW<&%P<&#!P8,'!@P<&#!P8,
M41>UHF^DU+TJ%$)2=PRWZ>E=OS+D-T^2_-"7_P"?E5/M-=#9R,1.O^)]8B/X
M?Y'>?+$GX::#JJX$Q":8@^?^9M]NXVQ5:W9B0B:KT*I(*HO5\.RHOU;*JELJ
M[^=OG\EXK(+G3;XAW_O$]OG,3&']/B*AL!/4$$";1'6+];^6,LW9 ]L31*A(
M0DGQ=2"HJJKMN.Z[I^A?&_GPJ)QGA8ZQ>X\R/03T'Y[XRH2CDH ]Q5-$3I54
MWV543==CV1%)%VW3YJNVR<*E B=KQZ#Y^0^E^^$DSV!D38WMOVO(WN<?VIDV
M2=);F*INJ;BH[+NJ(J*@KX4M]E5?FGCQQBXRVM"@M&H'<$V5?L9 ](ZX4%0,
MH64JN0H;I(V(B"+S<]HD$X=E!J!(]RO4&0"%K1RF#8-E\>HA;< A)M?"H39=
M2@2(GR5%W7Y\-E12PRXTA(6V\A;:D%-PF($+FUB?Z;B -K]E%G%12U3?/6MY
M )#JE+*1I,!((&K:#,&_>+8BSJ?AF.763R\^L<"QO-LD&&]69#B=S#-^'K+0
M1S(HE_52Q8,*?52JA]MB[AN@\SDZQ??<**Z[,LHK=;4F;9CP-F(8Y;ARBH45
M!Y:U!%*^O?78_P LS*2 -!*C\) Q-:=IFN:54T]6AQE9!#: "JFA4*2;W)(*
MX*4@ B)'Q9K#>3+E'YF*)K-\/QS*L>RA7>S>0J/)I4.YI[!M!:D1YT$A"+T@
MB"C#CU2:FJ%OTB"CQ9E)74&>4Q6VE+A( <02'7$&"4F825)(NE8$*&D@D'$E
MIN)LYX><;99<YU&N#S%H2ZAT1L4HTP3&Y48 (@[C-S_9B2*NN.3I]KKGU'$4
MSW9OH$"R<$VW3!>R]"BTJF2(B*/0\KJ?G;INO#=5Y73TX"T)>9&D24A023?^
ME*T?4;^9Q,F/::P^66Z[*6' F(<TF D3"0 V!94D&;3'0X7&4\C^K%'AU)B=
M7JVMJJ6-GD-V[%J),5^>3X,PJ:*V3<XG6X]=71'9+3+DDU.1;2S(P11%&&JK
M<O9:2PNL?#A)U-Z5D^4**^MS!D3)V P]T'%=%65ZZMN@IFF2C0EM\ Q$ +3X
M!X3<)3 (!C4J)Q_6$Z(YWB[% 4K)K>Y@8WZR584;"]#&8Y9(>! A2GC-'XV.
MU49B%&E1V"$9RPI8@^AVCBL[J*OR=*6GS45#K*5*2XE4Q)C3=6J ".GT(.'6
MKK6:Q+JU4]%3.5 0E#B"0IH().I"D<LC4/"0>@ ((PK,Y@:D8GD5-07.4YZ^
MSF66ED60U8M0W6Y$6L6-:"]!CI7OM0HL2R;K8Q-1C5EMHFFQCGNIH]TN>TF4
M\ZI;K,P2"24M!*5M $ I"1RRH "),F]Q&^.A5-29TFCIG*;)^8EP4ZG42I1!
M A95S!*B("A-U ]HQM63P_7Y!AN99=<9/?>Z+%AA8N0W"=YB//>B-$[VDA"<
M.,$EN(4@72<;><91.@7$ D;J'.&*]3]*\\\M;C:G&&US"7TA16J2/$7?ABVG
M<:C;'34M-9;3*-#3T;:50AUUE@P0N94EPN$)4F9'A)GL+8D+*U;@8M%1D4&*
MPB," *,BPCF,=T)+92&7D=41;<89!M[J1MD0;7I5Q%+CF&9HHPNF=J0T027&
MCNF1:3(Z7N 8(,;1#1E2:BJ9J$A3I;6I27%W6O4DR%*ZQ-KV%KBXVUW)*#):
M2.E0^CKTJ.Y,8><Z2[Z2/RK/4J"B@C+9=#*R=S$NMOJ'K4.,7'$O4X?0K4D_
M 1)"DJ$I5T^+?8GY]6Q]QVCJ%L.A82V3"BF =$P=S:.LD6ZXTM,;?;07')/I
M>V3LHU4'V2%1=4S<1"==;>ZU^," ]NDA 1VW+C@<0"C451U (!!MU)@CO%^@
MQ',VS/FE6A<&-! ).KM$"Q&\7ZSY:O=3IEDP]&:1QQ72$8Q-BK;+I(.[G2\B
M"#9>"_)JBD*]2J!JA(D>K<SIZ=2&5!1))N ;'H-M[@S(BQ^4?30ZU!TE 4J#
M<P8B;1.P'U[1?%P'L=*R95XCKHU,:1DW\ZII#8HJ+NT6/1&T)=A$>I3:/?IW
M1?FJ[JJ)Z9]@2EJX4S=2S,\25)28CP_PS*HCOU^LB\2:E]HH2G.*!"2"$90V
MDP(O[[6'MV(_=S<]Q>6(#@X,&#@P86^8,$[FNDKR0WWQC9+DAG);K<+F,P4<
MP'*&D=D3<BEL9/4B^1I&;DX!&G7$EQT:^[:9Q65<R6CO?]?WYX3J-_M]^OI]
M<,C@PN#@P8.#!A3:ZHA:29PB_):IM%_P6?$1?^[CAS,QEF9'ME]:?2F=QTT0
MFMHAWJZ4>K[>.?+7;EQQ;4F(_+LJ\'G%:41=, /= %5'N;*BHB=2[&FRILB?
M%X1?(3;O,G40%;E,'28%B)F>@,R+3Y8]49;F=30*0EIQ03JZ$]#,'H1;96UP
M"+G$ *SV>N(V=I+>AB]6SD,DC/PC>%QESK)0<:V54;/J(!0A\HHJJ(J[<=;(
M2LW<#9&P)4D F\IA0&_8"(V G$J>XIK6&4D\IY"A*DN-!06#\14"H%76 HV$
M"8W3^J&D?,GR]BZ\U&B:QXBR^RV-)D,=V3;%&)=E9C6(DLYX^@>@ D>M#K7<
M89B)(CG1U3]"^@*<6IHD:E"5^"2=28(U6BTA1Z!1,X9,UR[A'BBB<=73G+*X
M@ .L%#;2W2(U%M*?#($W$38+BQWO"-3^7?46IAXGJGB5GI!D$ICH9JLAJT;I
M/5& @3K%U!@M1Q<91Q ;<N(M?VNZO22*:[R:CX@I7"JG=<<3J,I40M 6!:UI
M!D@03YF+'%2\0>S?/*%+5?E*J7,VTPJ6%H54-@__ +QHG8 V4V22)! WPG;+
M4VXY:.<#0+,<-MSR^EQ:XJG<><L)263+S#\E8KU<LD)!$465'D.BVVVX"-MF
MB,*V BHO>6K96^^ZAQ'\A**IH:2I(+#O-3)^%0(!21)W)BPPP5[-6UDB _3!
MBH<K Q4*D K4_3I:4=((6" 09*2D$7.PQ;-79I=ZB6-_:.PX+34S(\E.=UB_
M,;>?=N+,G'"9>,^RRY)-7-@0.I&U1E[M)L5?OUO,JWE+"D<U]YSX5%$N..*-
ME;?%MO;H#&+>RK)0SD](XNH"W44K*= >;#B%);2-)+:E$0!(M(F\FV-D>:EL
M0XM4QB 6EHBDE8N.-RW'W9#J[=IR X2JO=0B0G6YA]**I*UNOG-RK+92AI 4
MN2K^4"38B!I3J)(V^+N<8TG#::@O5-96*13I\+[58M"62-.H.!Y83I C1($&
MP*KB-&MN6NLU.K"SC4N=(K:^++1J?A=!&>@L6%'C5A'FOUN07$R(6139DW*G
MH-6++$N(RK<62';D-LJZVWU=8Z\4.Z4I<2502+P $E2B;RHDI2+$E)&J=W++
MLJ;RZH704)<>;K.4 M:TEM+E6OF,\ML$E+;; 4X]&HPI ,:A/SQG2+##R&?D
M\+!,/6_LI2.%:Y!)K>Z#+"-QJ^.,)N+-)MJ!#88B0V'!%&&&@$&VMDXP9!6@
M2 I8F%*> $D204PHFQ.X,;"(@/%2'*1ING>?S ,,I,HRW+W5*.N2L%]8;2 K
M>.DV)G$R<3QB0##;4R^JZU544=:J:\G579$39'WB8:)!\B'^;(@HB"B#X1'%
ME"BE"5.MM)/1 "E '?Q:QTMM<;B(Q5F<NTR7G%-T%6^H%6E=<L-DS)EQ !(5
MW&H7D>>&,E'IW $79[]I=2>E54Y#XM,[CX5.AKI 1W3?I157;;;947AR;I\K
M2)=<?J%"X"EZ4!4W$ &8OUOM\HL_79RH::>FIZ1H>&*=D$W(W5!),=;3$]AC
M&29>%MN;0*"N$O*"9=!F*(B;)U.&9*JK\]Q3_=NF^U511H1#;*82;:O%8GI)
MD8;C29FXKF///*F9)041YBU]R-P>YQKE@_6RFW8\BHB/,G^8B-(@-JNR)\+8
MHA;%Y1%7_'QQSFJ1XDH:0DJ@ [0"8!GMTZ1-\;?=7&QS.:O6D7 *M2K$D2#(
M-H@&Y/2XPO[34VIT]A*S&DMUR@A$*(8M[[*BJ(-IU+\*^$1$\H7E41>'S+@E
MAL*-2F)DI"I,V,#Q:K;3 F1B/UK3U:LI31KD0 ZXVL2.GB/4[QN)B-\0EUYY
MI<@RB*C#$ER3Z-IUMB3)3M VBD@JK8(B(2JB(O6JHJKMYW7AR&8J4OP#41 E
M8!D#: 0#U,@R;==\8M</D2:E:4))^!)DF+GH8Z>$[W[8@;B%]97F7R)D^0[-
M=[S:*Y)+N(*&HJH@))T@B+MX1/ELGE//$QR$J4.8I143)W587%I-NGUOB!<9
M--TY;IFT)2D)282 F!))-I)@F-_ZOIB=VA4KTVMNE<=YA-Y&:4(-/=OI5"64
M.WCI39215_1LFVZIOMQ/*=(" 4J$3$;SN9WD3^/>\5CEBE*X@H H :*I GZ*
MV W^?G>]\=<G"XNC!P8,'!@P<&#"WT>8*+I=@<<X;]>36-5H%"DUN%T[\949
M3\DY5Z=2Y^#0"3?_ ,FQ>9(IVD5!BND.^P?G/G_QP@^OUB?M;#(X,+@X,&#@
MP82FKG=6PP1&&N\\MK<BT"^$1PJ5]!,E^H05>I57PFWGAEX@*QE3V@2>;3BP
M),%RY$=?MWQNIT!;Z$DD>%9D;V'F#CS.C(C0&4C@V[* &2=;143O$G3WA$O"
M(JHI="JB)OLOR55X@JRH-B!) $F"3TF?3M&\X<4BY!)C8*)'38FW4G_A$8\$
MXT>CNJ0D!]OXFNI.I"'YILGSV7_HKY3RB\8MN<Q0@'4F3(!TR(D?I.WEC,P
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M@?D?MC>?:U5%LH/&?$9:.Z#F.>E!\RC7!O;:?IC7YO/O[&=XVVYF"29ADXC
M(>F6:S>DB7I055&74 ?&RD2B">$54\<9+_PYYZ\5..\ <-N*/B4MUOA=2C%Y
M)6Z23]9PB/:K4-I!1Q?Q"VD[:*_/$[WF$KL#'6/PQ[Y//S['C'!APBPNP@B\
M*-Q8D'3O-B$6UW)!1B$)(PW\:K\8@"*2[[*J\9M_X>^(5(*6^!L@#: !I_\
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MK656Y+;3HF,8S:XV]8.R9=A(-];=]BQJ@6X:JT!%A2'ZZ2REF[5V],KAL^J
MO"'^)KVB9;GG%O#O ;6?_P +R&A*JWB>N;J%ML-/.EH-M519(YB*.G6U4O,I
M"E\NI!20=8'J_P!@W E764689DUEC5=G%93U8RVF<;#KONM,V"7:8J20A1?Y
MI6LH4%);2D)399^>$<S7,3E&CV9X;K3DV1YUCZ9S3R--SR.9;.QQSBKL'G<F
M>HZNWF2WZ9ERE7)ZF;(CLL!:JX34A778>S3/[ \MR^F]M5'2<*<2U.9Y#3Y#
M6N9DI@.-4=8IS*UBG6M *4%Q#]0ET%:2K^4VN 2DCL]L5&]1<(.HSC*V,OS?
MFTB.6Y3I;J&RBMI%.W3<"0II)!(42>DSC,?M9-[!>.\KQH+&+(+M;JCO6@*A
MB4';XU(]T%$!5ZE\*BKNB?0U25((*05 RDI)!V) 4HBT$7@P0-QCR01<@&03
M<PH&2D$[CH938D2)!@P&-',;V#!:;>LH\A'VQ;8>8=:>LG%) :9!E [[AN'T
MB+0 1N$J((KNG'!55#&7-OU54[3L4S3:G'JAUU"&:=M(U+6M:RE#:$@$E:E
M 7)[YL,NU*TL,MN//.$-MM-MJ45+)@ $3*CV">QGICUY;1:J8A91(^;:;9[B
M-;/:8]QV=WB&18]63A= G&U23<UL!EQ70 W&E!PN\"*8=3:(7#1E'%?".>.*
M8R7B7)<SJ0G6MBDS&FJ7M!OJ0EEQ6L"9EO5';#C6Y!G67M)>KLKKJ5 D!QRG
M<0T"@7"O"-)$7"B+?;#0&8+%B),,)-M9*BLAILD$(BFF_?= E$43ZU(=B)41
M?/SX?UE9;,D(:3L2#*HZ Q-HB-KQAIN -,DD@ &PF"((%A^1F3CZ6-UCE%-,
MK#N6-L?2'K(;"OC&$BVZ76T0MD!"$3(4\;;^$VW1#3SJ/Y<-M]$*,:NQ'6\6
M$[],(0?$% 7N5)F-4==Y&U[SOOMZF7@; K1R:Q6U;@HJF^XC:27#0>E&0<5%
M1#3_ %=O"HJBN_ H3X-!<<3L )TC8R1:1]-X@]< ")OHD0L^9@0D 7!@>70V
M(.,7>2'^EH:*K9@T8H3EA,8!LW)*J)&;H@ J1F1$JJA(B^%5$\[IFT+GFK*W
MHA*3(T^4[ =)N//<8W    $#N+VFY];GKCJ<_L\LVLG:(:ZO5)DY$35&N!'#
M3I<-Q,3IR<5P5V4212V021%Z4%43I457R?[?PL<593S("CP\R8&P'\2S*(\N
MO7??%I<"C_DVJ.H*!KG"([>[TOXF>@^N^.ASBBL3?!P8,'!@PMLP@K)S7267
M[K6:E=DN2.^O3',:MTI_48#E$5)!7-Q8Q+S%$E]WT"6.(PK6RL2D)16<>-06
M=G-CKW^7YC]WPAW'S[>1]/V.N&3PF%P<&#!P8,1EYS]OP3^83?Y?Y*,PW_P]
MU/\ ')7WH*X?_P %5_\ X=S&UC_?L?\ CL_^JC'Y=6I3+CUU7>-T&"6VR(OQ
M+*>ZO/U)U)OO\OEMXXI_A,ANBJ=7AYCAT]B.4$B2) (,[]Q>XQ.\T<2%$;>&
M-H@S>;7OM?R&^,%#@*2?$*I\MU^?C??;QM\_X_5_W/6M.T]^D[]M^PN,-:%)
M"$B8A(%_(?OZ866LM2^YC@FR*F+;A;JFR(B=!+Y55^:;+_C_  ^:O&2NA%3<
M@),7/4]HMY?.2!CFJE!QM24&57, &X\B>A((WZ=MYD>P5SY[ O:/:9UAOE'9
MU!QG.L!D]+_94EG497T1 )445/U^/14053R)'Y'RJ,WM>RO^*\&5@3.JDJ:>
MK01 NE+E.H&2+::A1N1<#?PXV\-.%K-$)VYC;B"#L8A<1UG3 OUQWGY!IKC6
M6W$27D54S;E$@S&F%>0T%MMV0!IL($"*9+Y4T7=/D75T[KX3S/+\NS>AIJ5]
M"77J1\ZPM"H "@2)4(5>18F;SBV,IS/,,KJ*M+1+8<1N%@D @Q8'K.\=9 [>
M/#-,:'')EE64$%FL:L9Y6KZ-HXHJ\301R^,R7\UD!'IZNE-MT%#W+C&ARN@R
M\ -GE0"(2F !8?T@S(G:.L;XZ:S-JBI$OR[/>YG>X,_7[[7A!S^458W*TIK9
MS!RH3=O?ST5OSTS(< 78AJ1?4$@VB(5W14W0MT0N)7ESC<:94948(!)-K'O)
M\QUVZB.UR%REV E)2#90)$WB)FP[7_#$#<PI+?4W#+73F[NY#6#7(.OR\?6#
M4VE1(EN1 KTE%7WE-<1V;%RO%(BVC -6 L=+8R1001'^@174&84^94KX:<;<
MU:#K2I&FR5I4A223OLKR(D6X4UXNU(+93I@@0>I$%).FY[?,1.(5Z;\I&)Z:
M9U4SZW$\9L8F*SFYF+V#V-U[EG1E&DNR&W&KQT)%HDE)DEZ8CKDQQX")U6!C
M   $PX@X[SIU@-(JWE"H;4A\(<<:0ZH)2#K0"E*A&D$$18?/&BGI6"ZMSE-I
M2 GE'2E13\1,&Y!N(V(V%X..J;"-)-*,ST]Q7*,AP7$\@?LL.QR4<BUQZ@LY
MSC@4M=&1P'I\5_OBRT/I413[P@C;6Z  @E6NYKFC:5.JS"J0V%(EIMY:$DJ=
M0F9"@FQ4-C)@ ':>I54II<)"2D&/$"009 !,'3T,FVPB9..=GGWY?M6-%7>8
MJOT?Q6'9W=[D\?433Z%708C4<L=>R +ZPB4M*D$H$UF+'DV%1[OB.QGU2"AQ
MW>X*-F_<.'*JGC;)5\3./-T:6'6R\%NE*UNLK:;6ZZT5+2$.<LJ4LA*3,I*;
M8D;M:\KAYYJE0%52@%)1 4!XDE2>B)TDRF0HD])G%)T3F/&= QR^U P?4BFU
M)K2M*]FJI67&,4R*QG#)9$95-+G-%':C@ZV:PI<5U]IYMQ6YC[1"+%_JX.IZ
M=%4QDV<98]EBPA;M345++M92-(4%%2'D)U@*(*5K;*4+3&I(Q#Z>O=4RW[S2
M5(=&I"4I;6E#BB-E()@D"]Y((-S&)G:;3K?2C!\CU9L],8NG[>4X_!B9G(O,
MA!FYMLN?A6\"LETM(Z Q(SDMN0"N1'3C^BB11=<9:/I??KS,*MC,,ZR_A^CS
M)_,TY8\I-*MFF<6RFG<4EYXN54@DH A.D.A9296%*TX<6Z'D,BM?8#*'QJ.M
M0#A4DJ2!RKE$J$ *TJV@$7-<&'X3<R<2R&5D.:X]AKMYG4J_CLS<P:B5Q-^Z
MGYK;1Q83=E"9EK+A'#C*^VV;RNQA-UQAM *Y:[.FTUM+145)4URFJ-2'@W3D
ME*PM*2LK66Y2I*@24D@&! )U"/HHV]#JWG$)4IW4T"HB$Z1: %"0H$1U!M:V
M-_L*C2/';/3'):Z\@W>0XYF.!2)$V%F+-M*COA:UA3I@I'1HC!N6IOD*-,M-
M@VIN%TJFW.]5YI446942J%RF14Y=7C4M(4VH"G<(0H%2DH*@-*8,I) !.-*&
MFFJEAP$*#;K:C"AJ^),?" 2 3,1$2"-Y_2/T'ORR?233W(!<1T;3$J281H@B
M*F]!9,MD15141=]E$B$D1%0E14X\^<%NJ10N4Q,.H>45)F8TNE9(5L;$>9V@
M8PSU ->\L?"I4@]2%@ &#<3OM:.U\,7)WE*@L!5=]_2(GC]$Z-NB_+ZO*+_^
M?%P\)OZN(,J23<U:1!GJ%?NY['RQ'*F0PX%7\,B3<7'[CZXE%QZ#PUX.#!@X
M,&#@P86VCT%:W2[ X"U:TOI<:K6O=)8YC6(E Z64VCKC&&V-MBU&H(OFNH;*
M;6Q]^B/(,?/"G<_/][X0;#Y=H^W3#)X3"X.#!@X,&$AK$JI+P?9-U]YW/_\
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ME-^/+_$?^++AQ+RJ/@?AW-^+>6XZTO,JA3>4Y/K02D+34N\ZJ=!(U! IFRI
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MJ(M6;4.YDQJN=-=K' ]%Z*/)?BLM!'.)%=V(6WFW&@5.TG<<-&Y/EF8TSS+
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M"BV%.^,#P72RTDD :G#K!Q(*K.%LAO+Z*A36NH!22ZD!((C5I$)M)\2RH)F
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MC\J#7MMMRJ$'!?68<. 11Q<$VVX[:2 &3YC5M/TS=50.JJ&VVDNNHU<S6")
M1MK,#X8D$@=</-(PIAY++[8:=*M.H1H F$FP$VWOY6Q7KJAI/ENF%JS5Y?'$
MH$A>_3Y'5.C*JK.,J_D;"KL6G2%V.X BX""8O-[(2BA=**RT694F9,ERG(Y@
M4L.4KJ=+H(F4.,JA03T)(@BQZC#Z0_3$)6825#20"0H2 "F+P1$@$&-H,'$@
MN7?7O"ZV\LL=Y@,=O=3ZZPH&<?QV3$RF9C5E+))#+=5!M<E8AS;+T,:*+RM
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MWT)+J&'&FPHN%E3K2%EQ+Q+?,UCJ,.&</4;E<X[3/-O-J"FTN(G25-K4E7Q
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M+RM:P2&H0ZAXKI17Z"9&4+NN/07,&L'Y,&<;#/6<!RV8L9I$]VU8(HQKL)&
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MFX%@FT1>?+$N-"=?K*UT(HH5I:.NV=12NU#<UZ8H+U1"?C*HNFXB^IZOC[C
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M4S1 >5L2\:ZC-<]RGB.D]P?13TE:RIBI+50XU5O)2M<M):9*5K3!$""))DB
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MK6RJS(ZF0]"2O<J[&%-B2G2[;P=BJ3,LL:IZNI6PEJM?=99IE%(=0$)</B:
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M'3J5L'3$&RXHGVK9)2YT:[+%#4I^E= 2@'0@K;44MG>%@)0H@6 44P( Q:7
MU<[24U)5K"@A+P2K5!<5< KG90*]0V$Z0J\G$LLQR&5CE/'U!QA%FXUED-MV
M8L8MFV;!4ZW(LGH54%5< E'\U1/ZT^2?,Y_(7:3.7,FS)!8?HW7%-!6K0MDK
M4!I4H J*;$@@&]@0<>FVJ]%11(>8)7J;A9 $),#>#>;1%IN+XP%/JU%RW'K"
MBF(,>3,CNC$>1>GNO]IQ#8=7;J!T53I'K79Q!^%=DXT9AD!I*RGKFP"TTZDJ
M2DDJ F)TQ"AXIDGU)QM;JT/L+:"QJTP#9(*@-@>BKFP!Z806B=I(P[58>\&X
M2)-OC\QONJVB-SU8F,DI#X5>ZU\&^Z?/?S\Y-Q&P,QR(:4R4I8J4A0@CE@R(
M@D&+D1N,<64K335X"R=UMD S\02H2+;&1T%[X>>65\>QS=3(5(WJ^WBH1JID
MXKBM/M=*=* A  GL9;J72O7Y1-FCALZJ1U@A1)<3( !'PGK()-B.^V'>O6IA
MU#P4#/29(!5>Q C8")ZD?.;.-3X+^DL24DH%%FI],+++[;9N$V'^C< E05-
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MZ*:O:#+780%.E,*X.-4M9NBFYW''5&Q=EO*@)%?-[T8;#$1.A41%K0!+BR6
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MNO53:G$5+@G2'"@!2=1!F2J)!(.QJS.>)<T#=12Y:^^VA2B00Z"X23XE<Q0
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M3*!;=J4I403+9@!H$2%(N;SN#X1%E"+J/'=*A !$D&%$$B"3L 00.OECJO\
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MXJD4IHF0)6?5"V:.(9'MONWU[='4 JJ>5V+SPM<UF69TZ6J1TME"Y(2OEE<
M  GK8R9,&]QUG_LZSCA?(LW=?XFH154BF2A"E-J=#1DDGEH,^&!< F# F^$S
MD.61&+B:&.N'!@6"QO6(TBQQ-63ZP-$5$5$;=7N(/PHJCU$(D([2K+J!\4+#
M>8%+[[,D*5"S)2I)$Q/PJ(ZDSOOB'\6YSDSV?U]1PZRNCRQ]SPMIUB$A0,I"
MX4#J&H!21<"181BNY,NI-=7M$VZ,F;&KV["8[V8<8I#H-LG*FN"3+,9ONHXZ
M\X72TTA&2](>.MMMMDJ5(0H@J+8C48!DA .JY$;03MMB./OJJ$H#25K2" 5E
M*I$FTDI@;B.O;;'9!RC8A;<O=KCW*[77N#Y-BN/<L>FFH\^]PB\AY15Y#J+G
M6H6>MYA;4EV#L9NXH#KJVM@4UHW616WFH.ZRC<-H%\;>U(T6:T&9Y\X*LUSN
M>U^74VIAQ#18I6*$4J='+/+>)6\EP%RP2DE N5V9PRI]#:6( 2FG:6 50HK4
MMT+)DB$^%,'3N29-L;K*GSJ#-JEV(PI$QFD,9,<A<=)R+(DQ^L&U$#,7FC,D
M5P=B^ML]U1$H]E6EML.MZ5I9&J=,A:473) B2"#U':+XF*3< &?$ ;P.D^A^
MFU\23U,Y'\"UPJ=/=6*;*M+=+;ARFL+;5K(=0\SR.*Q>SG[ :ZN?BU\FT?KX
MP ZR8N.PHL"*;O;9)7G5[*3'(EG,Z)= SFE!EZDI*RAZII&G4DKF0VM*GB%I
M\4DP "H7-\Z#BBBX4S-=7696]F)) 2D)_E)06DFZBI")U2+JU28C2"<:Y-]G
M_FV(6\''\<FZ.9Z25?O.9/H<JQFH:A./6+\)F%(:RB?4S'77'([[@G&BO-M-
MM]*N=TB:%JS'@CB*M6LY7G%)FP40%&CS5"PR  D%Q) Y97$ *(U"2?@)%FY=
M[8>$7P:BNR0T(*@A#8I/>%*(2%*5II><0@ZH2I13J4%)B1=C)R?:TPH*[Z=8
M=8]8(@^ERK )(D")X<12OB0DW%"(A$E52V55^20&L]E/'S3P=4MU#>J?#FM.
M3*CJ,)0ZB+'2)(2(@7.)0GVP>S)]DT[S"V N ITY17!"(4"-2O=K20!O,F3:
M90[G*EK9C&5%G$316/97D)XS@P'EQJ\KW)(=(,R'J>LR:$DAYQD4BL CR *$
M+R ,H^Z,H;X=XNHZ%FBJ6W%TBDI2\H56I8002I.L!]6A*Y<,)4292-20E..>
MMXK]E^8-:VLQI4N:2I/\I:!,$B4J"4E6P.KR,WLM.9WE5U-+5DLXS.QT-F4W
MT.@0V],X-GGMK2U.2/\ I/79 VW/C=4*R9B',BK6Q'_=#@O(CD*2^PU->FG#
MU3D?#&3-TE'15KE2Z\%KS$(4'RV4JAA:V@%N@.)0X7'4ZDE!#:M*RDT?F&8)
MS*L46 E+#:5IY3H0A1TJ_P!["A !1( 2;I4-0"L0SSS%^9?,-+L>T^HM1J6!
M>88>/0V*IAJ]Q_"'HD'U4D+AMREK*R3[^5J3!:1STDN*RZ3YN.MFJ@LIRC->
M'Z//ZRMS'+ZYZAJV7"A2T(>K$*6R$(9*'2L!M"B5)4HH4H+U*,!($>=4^XDI
MIWV0M*DB2HI;\)\6D)*% F8.XD&!&-0YBM-M0**'G&NH3L?LY%)I-B\:\&SO
M+658'<XY!=H9L>G!VJG,N0+.(U2OPFWBCB%M(G-/JP!,OR'#A*NRG-497PT3
M7Y>1F-05!-"X&5MON\QA2WTE".9=:5E*]*6PT@$A  ;ZQUZE4[5IY:S[OIL[
MJA41I$:H20$P/]>L[JG%.V.ZVS\Q;/NPI+,E9#Y-PW5&6W)D'T@AL.@ =)R7
M7&FE5SP"HADX ;DGH*MX6_AZ6&VZQ?(#<Z@M25(N8&D:C "56$R>^V(S1YL*
MBF?:=9 <==2L*T:I#8DG5 B2K?H+3 M,3V;.N*6W-]I?4>ZI4)P+U3%>MI6#
M1J.225=,$1P21ONJ+8..M&B$I%U(G$(]JW#E6WP>\\G,>:EIQA1"M6J-8.D3
MX5!0\,E*3>T3AVX?S=MRK+":<H)04ZB@:>D['<>*PD6M-@/T6YSHGC;CBKY?
M8K3%/*KYE15^?U(OC_%?\/->>RI\JS_AM*B=9KD2(M<.Q?Y?VQ%,X;"!7>1=
M OM"B(_=NN)D\>S\1'!P8,'!@P<&#"TT;82-I7@3"1O1HUC-8"14H,PQ=(Z"
MRB=E,>U E3LUJ$#\U(633)-LTB?YRZ9*B\*=S\_WMA!L(V^OYWPR^$PN#@P8
M.#!A4:BMH[=X("_7.R#]/_\  9">=OJ\^>,TB0H=X_/&M9@I/:>WEWMC3CHS
M<<4R5$V+QNJ_4OS'QOM]2)\]TV_1QI*02=YF#T^HD>O7?Y'+4#$$7CKW^6Y^
MOG\\/;PNRVK2(I+X^?G?=/)>4\)OOX\[+O\ 7QK7*1WN -]SM,VM'X#&:51<
M0>F/;AE>HR2<,51!^)%^KJ1?"?+Y[;^?DB_Q3?C8R),JM WGJ(MO^XMC%Q1T
MQ $_C>_?;SOUG;#0GRFVHRBB[ELJ;*OR1?.VR?\ =_CMO^CH4J ((DQZ?K]_
MPT@28_7MV'X^N%8^X2R#)$W5%5=OJ^+?ZTXT B3WZQMY7\MN]ML;\?0A0QV\
MIOLO_P _5P6DD6/<S'3S /[/;!B/FNFMF-Z,8V_/FR67[N0PZM76*X**1B*H
MDF0JDBMQP+95W^-Q?A!%7Y-N8U]/ES1=<4-1G2FT6B9]1;K/E=XR7):K.ZH4
M].( @NN1(0FY( _J40#I'E)M?%!6?:HY=K1F=C<VLTI%=ZHGG@%TU#I9Z%2,
MVVC9"C(-D:&!.B0&C;0@I$JI5RZM[.:UQY:E%I+BU7!"2E(A('^D"X\)N8ZC
M%[-973\.4#--3(0FJ>;2D*(&K43XU*-C>9!,=.D1J6> $K'9-;(/LLV#339@
M++)&[%!YM\&T5U3#TROD2OQ5;<<>90V>GN&R;74BJ#;A"A(.E(2 ?AB#!!_N
M-IL9QOIJ,K""E(*0"HJ4H ZR94J/,W!$2 "+8J^U.TVT_BV\FTK[V8#[[*N/
M.PV[%N=96+76<AAEKTT.,#1HJ,D\XZTZCJ.D+Q-.M]YT8Y%25$N%D!*M .ZU
M[A,@>&9'B,#?SQC5!RE"AR=2W"$E0A20D&20H_$HB? +1'4X0,AG)&P=@8OZ
ML7RB2779,NQ:G ,1SN0G&'8$1'19;0_4#+>;G2=A<[<-AUHCF-]8RY#;:@5B
M5ZE%2U"Z5 @IB2=-HM)\M\<+F?N<Z$-D0A+6D(,A4D:Q;>XO) CJ 3CZP<3R
MVX)T7F'7Y!NE%>=G$V#IJXZVIR&(449;1C-%YP@<]YU[C4=H&(K;3D8UD-]5
M2Y:T%DN-K*!!D0>_A($3> +>77&3&:9L^M(2TML*FQ-C)A*B#-@9((B! &'C
MA/+I5P;AK*G&5GW\)D6H2'NW"JA5A&S5EM>XHO?&[N1/F0=US8D0D3B'5V:A
MLK:R]1;&RE"Q!^$E,;P(B?(D6M-LJR92PFJS$\U8.II,^$"01J&Y'Q&]IVZR
MW5@-U/?:D1D5Y 1L'6U16!5$V\_6B;[_ "\(NR+XX875%H SK4K=<B2K<GUG
M>X$P#8F5H;YL I@I)*8$"]@FP L" /S)C"TR&0U*%(\EH-FU510%(MR5?"I\
MD3=-U_@GS\)QSE95?3/<]X'R]/[G'8EA#:"I8@I$VZ$VL>N\=?([X^>E*G$U
MPTC1N4+@NZE8&';^9@A955#TJGG]*^?'GY[</&1T[CN9Y:[J@"OHU1)_HJ&S
M'3>($>NQ,6XGJVTY!G2/]>59BD$&]Z1Y($;03]COC]&2K_NVN_V&)_R[?'HO
M'C-.P^0_#'NX,+@X,&#@P8.#!@X,&#@P8Y7/[0VC*:E\MYML'+M5PG4%JLC&
M^+4)5.WQLY,B>)&"JS&!H#%ULA=:)?R9B1KOZ6_P\E4<6B0EO5D)6J"56&<0
ME)%I),009['%<<?P#E))@?YT:N@O2'[P1L>OR/-9<65!2$$RQ<G9,)N.&XRS
M'COC5*XXBJW&>5%?F0Q4#:-N4+P."BIT@6S@^F$I=4#IAD"/%*B5P")*0!I5
M<&4"9O<8KP)4H !1 ))&K3I$GK$"#O*B/]-XQ_EOA-?G$(K/&ICE94N1QCRV
M72*'3.0W%5]IQJ)*#O..HZX8N13;<6,XA&R\(*AI@E[D_P FH2'%*!BVI9F
MI*X&F"+!5I&XF00+5K0H*TD*!"D1X=)E)2=Q>3$W,&)  B?J=H>4NI?3'HK5
MNX^:QI%JV"!.C]M55$<8<;%\!Z51$=0G&WA1%Z]T3A@S[(&,RHG&J6F:;K'B
ME*GU*'-#0D#2XHB2)2#<*.E,R1B49/GSM-4ZJUYU%,AM12T =!62))2G5%@5
M W&HD )%L0QS#%[K3*3[E+JDG9QFG9*=HD<%6B4^WLFY#T*7QIXWZ454\;+1
M7%_#57P[[NPTVY7.O(2X5,J*EE!*M:I590$$&2-A%H.+)R/.V<R9<?0A:6T.
M+:*7-P4@$* 2(&K5,&\6(!,8,/RN=%MX+E9-.I?KT.;ZIN0Y%?62RB= MDAH
M2.;HB"@KOOY3;;;B&A2RDM!A3B)(4EU,:5$E,E"Q_23T$=)MB1(>:))0O2LI
MC4F0H6\MHB1.T7 C%F?+M[6SGQY>^S68'K5?N8\<L0.@R5P,BJ&V60 4(8EL
M$@ +HZ )6Q0E'PBJFW3#\ZX+X9S%:EOT2Z!YX%#KF7H;:6ZLV"W2D@$;DZKG
MIAZ:K'N6VFJ88KD)00VJH5_-"8$0XD%8$7C:;QWV/4+VENJ&N>:6&1ZR8M@N
M57TLVD=<"F&,LEL=A5T&V#%H#\*2MBTB"JJ@H@KQ#%^Q;AMT(0S6527%$Z5.
M+()).Z@E5R-MIMCI:XD>I$J13TZVD C4D.*<3U@C7I"1$P.HGK;'\QN8?2YY
MP7+G0C#Y'9W*48DVV3)%Y1M45DE R145455V_CMQRCV /+<6JESUQ*204@("
MH '52B"K:W;TQE_MVIL!M:7=8[%)%S)@P;7WD=9W Q[ YN=%84X7<=Y=<'=D
MUIBC[4XA=5TT3J0.A61ZT5/A\+U+OLNWCC7_ .P-UM);J,^><!B8:1JM!%RO
MN+WB+7. \<!:P$H?2#,J!(((!M/V^L=\+GF6YRX>J%/68?0Z4:<:9L2XX=R?
M25)I+).E40%>1=D=5/BZE!2ZD7\U%W5WRKV)Y1E[P>J<QJJE0$(;2E* %29)
M\?CFP Z7WN,:SQ?5+)T%Q8$$I=45 1<%,[$_2W4C$==-=>HV@MSW@:CY5)=%
MHI4$F'D8=0MC1LRW; D7K3?923=%%17;R9W[$LDS9QH$OK>"I3K1X4),1$Q>
M9,SOM,8<:3VA9HRPXR'.2TH%/\I6E2E$08"3,;=+[XUS5O4+)^9')F;*%50,
M98,HL&/40XY-LJZ9BUW'53J5Y2$E)5^7S113X=KHX!]EK.2T-/1980BH+S4K
M<;&D*UI!L(!  4HJDZ1<I.('GO%*E(>>JB0D(<<6Y.IQ20E1*25$F5;!,^(D
M7OB1^F?*_3P)S./]U<GO4B,S[9D*\D@UJ-H"RS=G2A;CKV4,B1@R;)U [;4H
M7.G?TGE7#.5Y-3:ZA":M:M(+E2A)2IV(46F@%* 4HF"HK4  8 ! IG,^)J^N
M<AA2J1L*4$I96H.+2HRDK6" 3"?$ $IF0/Z<.A=+,%H@(L@5_*7O4S/35->[
MVZMM^*BFC2&;WJHZD" J-O245M$4 5P$13D2Q[T@-<I :!2O^< O23L4)(@!
M-P GP@62 +88T550ES6VHM.:5(6I T*<!BY(,*G<ZKDF25*OC9J#([5(]A0U
M^/4E7C4]N.7J:R2^Q)JFHZF@!,:0GGIKW4"$R\ZR+[+[0FU(;'XBS<80DMN*
M=<4XB0$K2"%ZHD))A* 00(!@I)!3.V@B21 4J38$@@2>AO?K/4&USCU,=MIP
MY&,8_ @,R$[MCE\YGO.6S[!-C*:?!EQMIALE!45&F4?[B*XXG6JJJ:=^:XI1
MU$I81"0B1X3)!4I0  $VBPMC(G4 DZIB$@W.Y40(,  DJB-Y-R;]:W]GWC+'
MT6UR_P _.Q!W4NM=:>62S,8!KZ*5+8LPY+*J+L1M05&5+9P$56S$5'I3R/[?
M%:N*LJ\.B.'V01I*23_$<R)*DFX4>NX['%H\"S_#JJ1'^=7VO_(IKR-_K\L=
M!?%&XF^#@P8.#!A:9BVAYOI&:M$:M9-DI":5>;3194M/\I!3.PQQ]K%Z;J0E
M:&1J$U)II:N+ HVV\KD4KS9^_P!]\)U']OW'['6S+X,+@X,&#@P8B]SL)ORC
M<QB+\ETBS5%W^7FGD?/C4_\ [A__ ,![_P!-6,D&'&SV<;/HM./R]FXP@AD0
MH0^%0A7<?AWZD11V153?94^:+X\<58%)/PF0=S'_ ![=.V)@%ZOA/E)!&\#^
MJ3VF/GC"3$28[T FX;](ELJ;=)>?'A?X;EX5/DORXVI/+@J_JV O._8'\/GA
M%#3N1UZCH2/W^F(WZMOQ(0Q@62T3VR];"."CPET[EU-[]8*I*J>41//\.)7D
M[3A2I6B$%1 4H1) !V,=Q\]NAQQ53S24SS"'((  5MT,@0+S8GH/JD<:K(5_
M>P($JPBUR6,^'"&3.=1B+'*7)99%^6\8J#45I3[K[QD  V*J9BFY(_5#CC-.
MMQILNN-H4M+:2"IQ0!(0DDI2"KI*@+C#93-M//H#R]"5* DS'B4-S!L!?Z1:
MV+?=7M2^3J+#QK13$[%JNP?3HBQ@7ZC&2%C*+AGT<&YS_(+9Z9(<L)F1V#3E
MD]*1YYJ!6-MQ*P&X_:BQZ'H<F]HE5G>8YX^PBG.8$<A+M>AP4E.E)#33;0)0
MG0=2E"Q4M8!@)"C9YS#A?+Z--*A0<4EHH4D,DA3D %2ED7))!F;08%Q#_P"3
M_P!H9RW5FMU5:ZA9!::,87B?*_@&B5?;SZ&RS%FZL]/\ZRF\CG%@8XGJX5?.
MJ;^"C SB0V)4&2+QF!M"FGCKV<<39GPY04&5+17Y@OB%W-J\EUA@!NI9;#OB
M?<:0HI6V 0VI1(,I3%RR4/$E(W6E:B6*=+#;"?"5"&UN*!&A*E00L]-4FY&+
M Z/GYY(I&2VMK)YG,%D,,6D672!.Q3.Z1^8UT]B8_+D.X_-:CJAM)*C-FXP;
M(R&VW5DFV3PT[5^QGCQ2E%.2%9*URKW[+R%RI6E2$IJ I(*8,$&\F>@DS7%F
M3I6HFLM(N6G=K"3*-]R.VQC"&YX.='EYU,J^7K%M$M?:UZ\JY64U=]*PW+<I
MQ**7OA(C<$YL^$U4G%;<4#!'9\EEDS,D56P=<ZI/PC[.>,>'Z?,W:W)F4D-)
M4P'*7*ZUQ)0LEPI+BGEN!:3&@!12!8&T=B^)\@JET[515)>9+I"FM#R"H$ 0
M7 D%(U"09$7O>,*>UTLL&XK=GE$*\SH8\&*\[=WMQ<Y=/KHP1VG^GU]S-LI]
M?"Z7&W@&+(&M,2%^.O22[0]_BG,TU;M":K^$5*'G$"F9IJ?+@\5*TI@4C+*'
M[)&DJEQ,D$"=1N[AZ@]GF84324Y:A#R0%%Q?,?+I7L)45EH)*2;D))43:XPD
M[;/,7Q@D@4^+-6;L<R(T9>D*HINJ=E29<0U5=M^TA]PA\I\.Y"]TU+G>8:G:
MK.JFG0L64M=O^]XIWVD@I!/<P7VJRKA>B;Y;&1TE2X4RVAQDJIU1XB'5@*0G
MP@E$D%2PD"2;:V7-765PO5/^2VJEV@MK(C2XES>5SL?H=$ ?)6K#U+9-/ )(
MOJ.L7!!QKIZ07A[8X#S9]+57_M75-4Q6$J#C-,]J41J*4J#8!*T$Q*(@F8D'
M$+JN(>'6'UT@X1R53P23_+0XE( (&I1T6 6-P9,>'?$.<.S3534[4ZTHK?6K
M4+"HA39KZ-.97DU[.AQ@FJ)Q*BNF9)7%828H=WI K!HG%;1LE(C4DN_,J+)L
MHR9BJI^&Z/,R.6D)IZ*D2DE28"U*33+"$[22D@$SYGST7'ZK-JIGWE=$"IPD
M.OK24IF-(U.IU$ $;V'<R,>S5G(M4=+<UKL4Q;F<RK.H%A$@3&KRNR/,:'T3
MT\C:*NNJZTG$5?:Q14&YHQ9=A%'K(&YQ@*H&S):;)<\H/?:KABFH705A3%52
MTBECEF)2L-B4G2"@P/#! .^..K:<9<;8:S /$F"MI\A$J5,*.I21N)\2A8@D
M*$#:\NR[4;!(V'.9AKWENHN,7I5KV8X;=6&4,QP9&>XZ;<<+"TG5]Y'AE";E
M,2XQ1U)X!3TOA5<XJ!.6YJY6L460-Y>NC*TT]6TW2^)Q*8(!9 <;)"B/$+ZC
M!M Z7$KIF4!RM2\A6GFMJ4H1*K0"HI<TQ)T6CIC0\SP;%:/+;(Z]NW>CFC4J
M(E?73Y<'T<A4)F2P$(G&^AU0'H7IV510D1/DF[+LTJZFA*7ETX4TXID+>>:9
M<44*4"%\X(4%!)%I,Z@1<V5NE83S7)YBC 0$**T@* F$))L+28 !L=M6)!<G
M"5.+Z]:<7=#59#'GMY31Q9LM_'YL"LAU[MA%;DR%EOBRVR3C)0H9 0D;HSG3
M%=W"/B+>T-3E7PM7H?JJ924L..I;14MN+<=2E9;3I225 >-P $ *0),)TJZ,
MD9"*M*DMJ U&5:5!(2"#<F$@S ^1) )((_2)@RDF8+5R47J[U94'O\]^I^(O
MS^O_ //BG?9,L+XFX?0DRIO,&]7E*73OUW^^&;B%.E5=-IUV^>F+=)G]Q:<O
M'MS$)P<&#!P8,'!@PM-&VT9TLP)H6B9$,9K!1DZO-J0FT1E-@6IU(?E9W Z?
MDD?*I#UR"(GJW")47@_??"#;](^QVPR^#"X.#!@X,&%;J J#?X"I+LGK[]//
M\:*0G&Q'7Z?GC0^"0F+W./2+31@*;HJ]*?+;?=$3_?M_\_QXRL2;S/2Q'3;]
MQOC%-@-]NOX?E\L8B?5"^FWCQNJD@IU*GS1%WW39%W^7UK]7&IP= "3:QV^\
MR/E>1 \LTJCY?G:_?;'P@1TKA)&T\DJJI*B_HVV3S_CM\_X<8:8N01;L0)!!
M$#OY"9^M\U0K^H?+>_E>YZ=?7'@>=D3'E:%";!"53)47Y?-5+ZMM_DGU>=^,
M9),7&T[R)O$W];1>W3&0 &WU_?Y8Q3S:-NF*+U;+^=MMNOU_4GU[[>.$DIL(
M/>WZ_C^$87&C9_F,7!L:FWLAIV6^'3'K:Z,VX]+L[%]5")"B,M";KSSSNPHV
MV!FJ;[)NB(NMUXM-%9!49 2E-UK4=D@"23Y $QTC'124ZJJH;9"@VE1EQU1
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7\(B(GA$1/DG"87'^\&#!P8,'!@Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g209588g06q74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g06q74.jpg
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MD2,R@:&QP=$D0E+A&25UUR8H*3,T-S@Y6&)XE9:W\?_$ !<! 0$! 0
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M[01=-'"+IJY236;N6ZI%D%T52@=)5%9,QDU$E""!R*$,)3%$# (@(#R%/MY
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M I@LW*LF9=$5DQ52!5$IA43%1(IE$P.4!.F G+Y*'G@2M3T (#]A\\ YX X
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MY!0""W](8Q0G"R[U]]CIAEIMN9MRY9;^,S/YDT. . . . . . . . . . .
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MP!P!P!P!P!P!P!P!P!P!P#"J>]8_$-S+Q[IDZA:^!O'D?08^NY )1/[>"_,
M@^C^(1-\L_L'I]]?Q_Z?LOHS_-<J7WZ=^AFKS)H\$I%1LW'/HB88,I6*DFRS
M*0C9!JB\8O6CA,R2[9VU<$40<(+)F,FJDJ0R9R")3%$!'R!^=+XE,)\1?K X
MS[/_ (566ZO?*3/62$T&]5Q (20HF<-:O8F4D2DY[,S<['3<-&7PS9ZA:ZD
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M-7*IBMYAK2/)ZF2O(4< < < < < < < < < < < < < < < < < < < < <
M< < < < Z* <4S@F)04])OEB<!$H*>!] F HE,)0-X$P (#X ? A]P _/G<(
M7M$7LLFP46G%.Y"HOI2CVJ,=*AG*&6!*E(N<J)FIHQGAZ)_H65EK<M]19AL9
MT%#.'5C/%S ]EP\.U9G6)[\NECB^+BW;I&U+:<\C>Y0;E WFLQ\W 6:MVQ(
M4CI*6JC]&0AAG8M0["<;-E$UW!T :2K=VV,U<*"Y;"G\E?\ TA3"/)J'9K2;
MP=4Y5T]8M)>?(4< < ^2R**Y#)KHI+)F_P!9-9,JA#>WC^(IRF*/M[>X#[<
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M'AQ)2U2F:SZ_C,+$FX3]&3YY'SX\>WC[^?U_;Q_A[^?Y\R:.> /(?N' ' '
M' ' ' *?*O&\?&OGSLYDVK-HY<N%"IJ+&(BBB=10P)(D454$"%$?0DF=0_\
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M3K.A.-3,6E7]8-E1# <I3A]C% P?OX$ $/\ </.9T.W ' ' ' ' ' ' ' '
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MSDW'UR(D9R6461C8IHL^?+(-73U5)LW(*BRA&K)%PZ7$A"B84T$5%!* B!1
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MXJ78,Y2,?MU&KZ.D&R+QD\;+%$BK=TU<$40<(JD$2J)*D,0X#X, AP#5CI>
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MQK#,9.Q6R4F(*37D:LZ.X>RCR2;M5I@B[)H0(ENBXO\ Y%HZ56]&JUM5VU'
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MSM(WP8$RV,+MBC;%]V]R3B5U.Z^OGQURH=RJGJYI)OB&=:CJ,C6A;)7F,-7
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MW6P_^4;U<?(__9!QP/'MX_\ K8UOW^WGS_MYK^'_ %\&%^_%R^C.3F38X X
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M]?U^G^_@#S_C_D/_ !\>/^7 .> . . . . . . . . . 4N;8NY.'DXYB_\
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M\+F:V=X_OHFB<6;AM-1DXK[=:ZHWGA]@\_L'.1V.> . . . . . . . . .
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-R%' ' ' ' ' ' /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g209588g08n95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g08n95.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6A#:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<P.&XY-3PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S X;CDU+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(')R,CDS-S0Y)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" S,"U*=6PM,C R,2 Q,3HU.#HT-"8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" S,"U*=6PM,C R,2 P,CHR.#HT-"8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"U"
M;VQD)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@
M(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @
M(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C$M,#@M,#54,30Z,C0Z-30K,#4Z,S \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 X+3 U5#$T.C(T.C4T
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C$M,#@M,#54,30Z,C0Z-30K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM
M<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T
M:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$P-#PO>&UP
M1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA
M=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14),045S04%$+S=107-5
M1VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04),04%!04%%028C
M>$$[05%%<T%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G
M445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!
M=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%
M2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M+SA!04519T%A045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"
M05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!
M04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"
M04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C
M>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I8
M5T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP
M-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53
M355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$
M9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X
M<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD
M;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C
M>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!
M=T1!44%#15%-4D%$.$$Y531Q-T953G%'<%=';E=R,V0O8R8C>$$[4C(Q=$=#
M6&QL64MO;T-4,3EH6$)+44%S<V]X36I1-79)=DYF+T]3=FPS5#5N=#E$=&TQ
M2U--,$UZ+T)%,4-1=T(K,71114=L1&U.3"8C>$$[54AO2$]X-D0K8V%90DXO
M>FMN-3AK;5IO:&)24D5K<D=)46%$<TMS5%A);DY*=CA!>65,>E0W468K8VUT
M5E)K5%=D3VIM:G%E8S!&528C>$$[96Q0:"M%:W)8;#%.9F]X1V540U=H:652
M3#)B>78U-C!(>DA:=UA.;$DP6G5"5T]+66-72D9144]O2D)5-69$3D=49S5C
M16](9&M/5R8C>$$[=$QS5F1I<G-69&ER<U91.2]Q1FIP.7$Y,694<&)7.%E,
M4$Q)=U911E5S978K4W!/0U5G3V%9>$I.0C5R-6@O-7E).&HV6$]98E0Q3B8C
M>$$[5%I'6EI'9RM&4E1O5DQB37 X4FQ",4$V0S-.:&]*;C9V4WAQ4"]N2U,Q
M831O*VA%5SEF=$QC1794+U9-649F<'E0-6<Y>EHK44@X-R8C>$$[-T=9959V
M>C(X;38W8TIA>4=3=W5P6#124GEG<T<V52M*4E%C=6='4T=O:C$R87!A1$HO
M1#9V8SE%:&YH;6I%:TQR2D<S4FQ)22]$3"8C>$$[=U%D=S1K;VU*;VEI=G=S
M6%EQ-T9867$W1E5N.'HK8DY#.',V8V(O5C=L64EA.%97;S5S844P5F4K=TIY
M13AG:GIB8U='57I1948K6B8C>$$[9BMC;G12;&M-9FPK=U<R:E5G:5<T<$EX
M1E!I0E5B9&5H0GI';&UK95=Z<TEA2T5F<4XK-6A$+VY4*UI%<W!K3W-4<GE.
M94ML5E5B.28C>$$[04%O>4IN3'9B:&=X9GIF=%I&;U O3U$O;F%Y2TQF:5!5
M259"<GI!5GI8<%9L2&(U62M.24AM=VQO.&-H=',Y,3AO+VU.<$AM1WAT-R8C
M>$$[9W%B3G)K9G4Q:U!W;'5257)Y3DXK47 K<758-#@T;'1Y3'(X,FUL03DW
M3$UV8V0R2W5X5C)+=7A60S9N<75N-EA:=F58.#97.75L2R8C>$$[=35P56LP
M5E9(5FU9:T)61S5/=S-W13!,5$=*2F]C,WEF*V0O-6<V=C5H.'IY,D-Y=D1P
M1FUQ3&(R;V(T5S5Q<VYQ3T(Q63AH,TY+8B8C>$$[6F=E2G@K<#,P9% T2' O
M:39L-75I,7A61U%X5GE%<$YS24DV1S%*-D0V37)-=S5%8TI:5C5B.'HS*VM*
M85%T4$]L=&%Z=DE5:FI7628C>$$[4U)Y8U-9>4=E2F]Y:DM84C!*,T\T>4EM
M,34Y1UIB:#E%9FQR*UE.=#5O=$I95S5,9#(R>$UN14TV+WIC5DIZ631-,T=+
M-G5I,5=L;"8C>$$[:4E*1WA:=&U1-&IS5F1I<G-6465R87):-EA9>5AL,C-'
M3TUB06)S>F1L561Y9CA!4&))6DUG:$=Y,C1-37-S>$-0379J9CA!34PX>B8C
M>$$[9DU(;E!5-5I,;55X85EK<DY:5TLW3$=N4F562SAM-#E46'%44VQC=S5%
M>4YL,T=/16-9<5!Z-S)+=WAS-T)60EIJ<T%/<'E*3DTT>"8C>$$[36I1-7-J
M,'IY<F-3,&4U+V1P+TM0=$@K;5EM5%8O>EAD-F)S66YF2G-/-W%Y:7HP=3-T
M17!!9U%J9FPS<FU(2U)L=5AE-'-535EQ228C>$$[;U!4=DQ0-6=R87HX,VYI
M:35+<&MT;41,56=!4%5T5F9T5C0X5# V.3AY.$=P-$AN=&0R4GAJ:U0U+V0K
M,WIE=39F<49P<49N1F57:R8C>$$[9VQG;55-:G%14G8X<S-C2FE1<U!'6F-5
M<V-J1UA-26I*3F)S5F1I<5,K62].,F@V0D17+W5O,'574FYG=%,Q2DI/2VQT
M:'919D-F:28C>$$[3S)1>51%4F)B:'A(2DE22%8X92]M4C5O,69Z1C5V,4<V
M,4-6;3E+6F])65%4-F-A4DAG0D=P2C1G.&$O33EZ=FU#2D=7-35U.&QJ1R8C
M>$$[3S1X-40X5WAT1G)H66A'=W<Q>755;39%161&86MJ658Y<W(T.3DS2D=,
M8EE-=#AR*V(W>E),23)$,G8Q>3!A55-),U!I.%-S9C-I:"8C>$$[5RM%:74T
M1S(Y83EC4E!H<T5.5UA394I2:5AU,S589FU,8F591F946DA96$U)<D%*='!7
M441F;U=$53AA-6YA9DYX8DAM-EA784]73"8C>$$[,59S9G9E:%IL3T$W1EA9
M<6AT4S%#,C W5#=I+W5M-#(Y=$<P<V@R<E)25V=Q4G5E9SDX5F51*V%R,CDQ
M5S1G,4<Y64LV96\Y=&%S428C>$$[631Q9TM%,D<U;S-X3C-),C(R>D@Q1SAA
M-WE"*U!G-3)G,GEC5S-P0FQV-6-V=$EE8V9M=#5.,'1,1S(Q;E$T4W-6<D9(
M8C9H.%1%1B8C>$$[5D%J:FPK37,Q82]#9FE/,5!C-5A/1F-M+T)Q1$DQ23=V
M3DE)83!*>6]U64%M5G9#4$1+6D9Y.%5746%0;W0W9G-Y,G-$4T)+8VXR0R8C
M>$$[:FPP<7A.0E=H-C51451Y8W<U25EX8VI43F1-+TQ7>74P4T\T,557,3!X
M<5EH1'E&9#DT,TUI8W9H,W!16FM1,'9&>FQV-VY86F4R0B8C>$$[03=12DAV
M<CE"6DYO6#5D82]W0U9D8G1.6C!A-&HQ93)J25<V4D8Y0V%H0D5H16)S,C%!
M2U5F:V9#;5A2,#@X8V=194E/3FTW47A:."8C>$$[8V]Y2$),;4]O=CA!1S-+
M=DXW5W)";$1#=$-+:6])3R]S8S)$;U<X5F1I<5=E661D='1%,#%R>5I$2S=-
M<U9V07!!36MR+UI3<#)(4R8C>$$[<$HV1$5Q2&MM;W!Q1W,K66A,<3DX.4AD
M441'-&E30TI713=P17)C;&]W4E8S0EIJ;4IN:GA3169E6%HV3$EC54I:04XW
M15%F=% V2"8C>$$[:W9M1#AS8FI49&-L9VEL6395-34R9'<T1$\X6B]:*TAB
M:VY1;F)X-#!/665F3G=';F0Y;F%%-FE0151W:C=5=S W43=#=U%#3D)Z-R8C
M>$$[=3(W2#9C,3@X:W!C,W!T4' X94E6069(<6E:8C(P9S):=T-/,U4O8TXX
M:4EK=&LX:UDO56%8,E V43%*>6UN,GIZ539U9FA58D4O128C>$$[>&]"5VYC
M-4M/33(T<SEB04UK:B]!0VXX,%@X84UT+UE+<G%#5CE356)K9EHR:EE6<C<U
M;E$P6D\T22](=V1,;C=B2$M1;#A"*S-K>B8C>$$[:CAO<F9Z1F]%<R]L+U=R
M4U,S4V(Y+V%/>%8P3$%F1W%U:%I#,4)5:FQ8,GI-,&]L06U-9S9(=$]74$I7
M4T)V;V4O.$%(-FYQ1UIR<28C>$$[6%EQ;&9M8E=X;W5J>EAO5EI:-G)(87=-
M=U@Q2G!#1E)A:VIU86XR=T91.&0Q94-'5R]A9E5::F0S3GEV1SAL:T%9<W-P
M06-"1#A)5B8C>$$[555C54<Q36]Z>'9H2&XY>FYA3UA#2GDR,FI8*VTW=FAB
M0F9Z:#AR,EAQ>"M99$ET1G0W4U1J2&5X4DIX54]D:VQO=G=!2#=*<%1E;B8C
M>$$[57-C<FY#;2]4-7I,66YD-7I"0TYJ;%)C>4E42S)I*U=54TQM-#1S;#!0
M>3EF86E634UF1TPT9S%W-$EI1$EO2EAK06%N8T-G.&9$9B8C>$$[2V5%>35/
M4E!01$505CAU<DU.4"]!0S-S3'-I2UA65&)Z3E-Q3D%+:VMB.$-:4EAP-UIK
M=S!O:U!Q*W@Q,E1T:FA*.4<S.6(Y;7I*.28C>$$[1R]+,U=.03%/,#%J43E3
M:C%!=TXK+V=D1&)-=T9!44MM5E152&\Q3S)7>#!K;T5'2G5N2'DY<5DX,$I2
M;$AH=FPQ,RMZ,U!:;S,U>"8C>$$[<3E#=DE!,%!55C,S>EE/:5A9<3=&5U K
M9D-2-5EU2V(Q;71"5#4S55%W1DEE5C8Y8G=36'1T25,S<5%X5E9F,F9I6G=4
M,38Y=6U3-B8C>$$[9D9J1#8O:"ML549L8EAD:TQ3-$I-3G=$0DMG2D99-6=6
M:S-(5&)B2W!D5S1':4,K9G)D9&AM1$HS,$%M,6Y':&11-VE.0U)Y:V%P0R8C
M>$$[:G54>$1.465W>6E7-VY13D,S;T@U8C9P0F1A6DYA+T%T,4A-5SE,;V94
M6E9!871D.7AU9FPW6EE"5').5U-:8U):8DIW8VM-4E9D=R8C>$$[0C$Y<69D
M:VY%2UIA4C5K=3=#4E9M:UHT44M#8C=4<#=.,35$36Y(;3<S1WE93V]:=$PU
M:W5&<T9U<E9O1'=P-G-C>DU&2TU1039/:28C>$$[=61I96Q0-V(X:RM%5S0X
M23)A5%!23EHO4U-Y,5=/<U%7<GA/5U5L<3=F17%-2V-F1$DT<V]N>5101UDX
M,'IY,6=X1'IZ85,S5V]A528C>$$[9R]U;S!U6D-35%%/1$5I;6=/+W=U,E9Z
M;4$U1T1!6C-824U-,414-T<Q,4HU6DI433=T.$E*2C0X6%E!539:4F-P1C(X
M231C5U Q028C>$$[.#<S,S-R=35F66LO-6A8>7(U675,>4Y/571M2359<3 R
M-7ER058R-D$X*U(X841+32MM-&AU,S9,=%51;C929&@T-BMS-FQD2#0U3R8C
M>$$[2VXY;%!H2#,Y9GAY9UE)>&,V6&%/8DHQ;V58-'1&85IA=$Y,=CEL4GEK
M,T%01V]',65P,WEV3$MG,S9416-K9TAT,FHO5FAP5G Y5B8C>$$[:E=/,SE&
M4VMA1W%R6&1H6')8:U18=EAR:D4R2$5Z=TU::TAV4C!-='AB4#9S1&-'86YW
M,'%P*UEY8UIM4$IO;$=->%5M5&%,-6EJ;B8C>$$[2W=Y+T1);$0V6C-P43%$
M2C1G2$YH:#%!;',V;E9A17@S2$PX8S R:SAX4$1D3$4Y;WIW3T]59#!S:TM+
M,VEV1U(Q8FMV9DQ:-6]X3R8C>$$[-V=$15-M.79-<SA%8S9!:%I65C%$0VA!
M659&4C0U6419=&=25$=0>D1:;'-D37 S=F%(+T%+4EHX4V]E6#9V8C(S-F)L
M;4,O=E)(1R8C>$$[:%DP-D9&86=P:WIY1$A&.55V9W,X>5%X4V573E%6;S%K
M55=D>5)Y04\V46QL86@W;U%'2'9M4%!K6$IX9E=093A/=#$V6FA39#5!2B8C
M>$$[<F%28VU",S1Q0WHX4GEB:6]Q>$%*6&]"-#559#EN34(T4F(P4#AU=&).
M+W!:=$I:12MT5VIN:D5&5E-)2TQ19V)6*TQL6#,S3S5Q8B8C>$$[04MD6'%1
M94QI-S)54T)72#=Y:$IR4E1S9C@K;5-O:F1X9'536C9.-6=V3D]M:E=D:3A(
M4EI45FU8,F8K6E1M4FIZ9$,T*U1$,41/9B8C>$$[,#8W,DIU8F5:54U1.5-2
M0VAL5F\O155+;6YC:V1";"M39$-W-#A),F%24&QV5W)N530U:F-F5G<P6$=G
M=&YK9C=69G1E;VMF:#)Y1R8C>$$[3$U*,GEY67I&3V-U83!(<D]M2G%M;%A6
M9S=M4#9X1U9356)L2#9P24M%8F]W1$1F=&ER>%!8-3)T:%150C9&>&%65SEI
M07%5.4EK<R8C>$$[4E1K94I$;&PX4E$U5FQY.$E(=B]!149Y9$YP+T5L26IM
M22]P1$@O>D8X>3)U;#9"2%E7,T=E-C%+3C!5:V=H25A12S=M;E5K1VDK*R8C
M>$$[+V%M5E1Y8DXR;G=%>7,Y2&Q6:G=E4D9D=4-K9TTS5V<X8WAY-U=/>6,R
M=C=U5UI96FM)155W17 R5F=9;4)P>49A<TYL,G)82W=0528C>$$[,WE0;S5,
M+TLR<TQO*W91,V)L=G%Z5E-D5DI5.$A&2VM$<GA/.5!%6DUG:EIP;$54:G-J
M+T%$87)A5F54-C9T+V-.<59Z4CE)35-'5R8C>$$[1T]+4V%136MS:W=007%I
M-U)Q=3%70F]".%8P84ED5DU%4UIX-5,X>%-E661*83EE,$YT.&)2<6A,4TMY
M<49(2E-544AE;S)R4VY82R8C>$$[<$-M44YP.6]D-65Z>%,R.71"2DUL>DA-
M1G1/4$M26D92=G-#;T9A:BM0:FQW2BMN;3!3:5!Q-4TV+TQJ5'(K>F=V5W9)
M<%E7;$U81R8C>$$[3V%.:UEC959E=G=N<BMY5&QM;F=9,V)6;6Q%,51-<WE'
M;&I0;C(R=7IP8V0O8D4Q<UA,,TMI=%1B34M354%",U5H6"M3;DEY:41U,B8C
M>$$[47E3:4-!870U9%!):VUR:4YP;%@Q,TQ*43$U<WA-;FHY;W%X-F1H:TI:
M04I6-69R8F-E2UAH;5A-1U(K-&9R65(K8DAM4S-$<F]&;R8C>$$[>D=65$A,
M9DUP25-G5W%X158K2W!)8S$R1D(S-E5:2C-S-6UL>%8V;44V9$%:,DMQ-DE1
M2R]',T5';G5D<WAY-T="<&LS;#).;G1B;R8C>$$[:$%50FI$4V-25E-1.4)Y
M-FET1'0S<#=::#5W4TAF9&U6>$4Y9GAF-D=B955.5&-7='IP-6Q#4VQE9'!Y
M<%1M9'%$:V0Y-D5$2SA5="8C>$$[<5HY<&%C8U5C;&)F>&4W.&17-TQ88GI4
M8FPW6%5M83126&11*S=Y5D(K2&1I3FTW8F9Q3U1"23)+375K:&QJ>%DO5'DX
M:"M0>#--<28C>$$[:FU6-#0U-&E56FQ$>&M%16EO<4XQ2D@S2$Q!96]D4$M.
M17A+;')E<3-%.&1P1S-.6FLU.&U#3WE.>4,W:V]P0R]:-S!Z2S1J36-U5"8C
M>$$[<716:&IJ24E/>&5Q-D='1VDV94=)3&96;V520G%+*VU+-S5S368P:C-/
M;VYZ2T8X,39.3'$K:E,R,$1I3SA1<DYA4T=T0DQ'86=':"8C>$$[1WIR5D0W
M2$I&065,-G9E,C!D=W1Z8VQO62M32DU'1DAJ3$@P:7(K0E8Q04DW8C54;'IC
M2FE09BMH>3E.<'5+135!8FIH+U0K>&IF-28C>$$[<&5:-&)',$=H,E5L8G$U
M46972F\R,E=%:S%3<6MF12\R4T-0<S%(9DLX:RMJ8G!S3R]%6&Y&9TDU2E52
M,T5A<U%'8VEO544Y5%1W>B8C>$$[2$QS-#=*:4E865-24D0Q4W145D%45E4S
M6FA4<T%#9FQK04XS2FMF46E03$]S<F\R='A8:VEU,7515G5):TY#55E5-F1'
M-&XT<4AR5"8C>$$[2GEJ5&IY:GAX<CA"-T99>F%09#)C=#%,2W=)56DS.4UJ
M:TI#07<U.'9S9V)C;#8K,EIE3U%L1VDV9DQ#55I,635$2D9Y-#!(26=6<"8C
M>$$[=E%N<C@K=E1-85E!3WIB16UT,5139%(Q071C-F)&0E!0-FE/:T530W)F
M17 S:3,K2F%(-'-U:DDQ6&4T.#1I-S=M8F9L<%HV;F)(528C>$$[:&4R9'AA
M.'91.4TS0T)/5E!5<GAO>F1.<3500FI-8G1R>E-"<6UB-6M.3'-666PU,SAJ
M,D=T;V)X66HY9%93<VY!;&955&E13U%(,B8C>$$[:71F=2MJ2W,R3&IJ5&LV
M6%5(1$U31#5:+TUU>79B4'I42DAC:SA416AH:DIQ23!&5C1J8VEH2VQT=&I7
M=6$W1EE&2&U(;W1256E*>"8C>$$[,VI*27)#,G5R;6193%=&-34R<59I:55U
M-4-G<V%+=%1S0EA*:TY!24A.3D1$<49H2U!R5G4X16M5<E)&2C1Y2U-W:V,T
M,E9X5&MN228C>$$[8VQ)-S<U0U%B-%-"2$\P5W%W,C,W>4)L93EP4EIL;WEX
M5D<O2"M:+T)V,F5O*TMH5U%N=%)18V1M+W=F>"M.=61A9G)/=&%B1$YB>"8C
M>$$[.%HW3UAE-'1*5D5S8C$R4'=T=CA1-C V.3A*,F$U-&A0;GI(-"M8-#<R
M45=(-6Y3>&HP<BMZ04E92&Q!4W!!,C(T3U0W;G(T63)(2"8C>$$[;G!33U0R
M6#AQ8D\W:VM85W(O5#)S-&(Y0S)K;5)G5UIE24Q336=(=V5O:"M$9F11>#9%
M5GDX34]P9%AQ5%(T4CA8<'5:1&EU>%8R2R8C>$$[=DI03V8U95<K;C-*=C=0
M,4=T56(Q-$QE9TMX=4$Q44=(>&)!,3,W9C9P<F<V>D=A-&@P9'HR5'%):5AH
M5"MM6#,O=&9.1W!.971Q;"8C>$$[,3EE679E0U9X8U T=4=)3DM5,G)L66Q9
M='DU62M%.%!C=G0S2S5%<S1L4$Y',4YB5S56<% W='AW63EX56<Q1D0R<&Q'
M5TYJ6C)':R8C>$$[>F-%-U!*;$1O2$%K:4E.9'A4;U%E-'I#3R]K6'!)5$)(
M:VUT=C5P:VI2579R3DQL;$A(,50X1'-"545/84YY,EDU35I33V)H>C=00B8C
M>$$[3G=K62M8369$=51U,3@U-F9D3DA!<U5O=4I+26M#25I'95)I0494:G5X
M2DY"=&QS8VPW3W-Y.6Y3>#)34EAF>65X959.2V5W,'%->B8C>$$[4BMN9#-!
M16QW:&]746MF0VA+-V9#3W4U,W)1-75D4&DT23<X>3AF<G,O:5I.=G!(3#EA
M8S5E-&)S5EE*-30X9S9F97E387)B=R]V>28C>$$[0SEX14121V1A37)S=%%.
M>6\U2#9F2$UF531U3T\S3GIT0G%V0GE!;C94<V8Q+T(X=65E8F$W="].9#AT
M,$A$<S191U%B9V-13U!Y4R8C>$$[;D@V37=S6G5,=DY204-7,TDW:$QB3TMA
M5V%/1T9':VQK64I(1V=,37I-84)603-*2GE286=A5&EA,#%,4W)Q3TQ5<D=7
M,VQ"-4<R=28C>$$[:VMI3$M'2VM%2# S<%93<&]C:$E%1G5H35-'>%1'-G-V
M,&,T049B;W)66F5V;W-E=D-O0C5Q3VI%1"M:4CEL<TEM47A%4E!F=2](>28C
M>$$[2T%T3')78D-2,W,W;#!:=FEK544P:W!7:$MM;V%L92M34&5/6#0U;TU!
M9'!$9CA!2$PX9F]4<3,X-RMB16E#3VM&=S%E6$]24E=H.28C>$$[;S)29G=W
M8U%A:F]W950R6#AP9$(X>E@Q;S)V83!S5FMS:6<V3W-3<TI.>E5Z3T=**T)L
M2$926#1L3&1I<$]89V@Q9%1R1$5(:$A4;28C>$$[.5)T2G!:67HV,%IJ;5$X
M2D9O94I99#!0-U-K1V]0,$=H0D%Y6$-6<U9D:7)S5EE&*UI0-55A5C5V9V%C
M3C9'<'AX<W-%=C=*8FM'1B8C>$$[9F)R.3EE=54U34EL=C%C<E0V<5=08FY&
M-&YB+T%*8V5C=DIV;7$P=E1/.6A"8D]Z2%=O8F,S46AJ,VIA5#!#<#4W3G5"
M6&)F<'9M4"8C>$$[=U-I6%E(530X:U-0<T\S,G-M,7)Z:'%6;#5B:&PP,WIP
M8S-(;45$,35R0G1)5T9*6EHU4WIE:DDP0V5L=T5S:%II>F,K,TAP:$TY="8C
M>$$[:G5W:&A";'9!8U Y8CEQ4E=V;7HX-F9-6'$V87)Z,V-C-FE+-&EA,&<T
M1E=.9FDO9%4W,2M8=&ME2V-M>F=W43,U165:6FXU62])1B8C>$$[-VU#3S0X
M>#-,5W(X1G!A,E9!.6%!,6536#%"52]T2T8V.4US>#9F63,Q87-V85IS8TDU
M9%0K3U@T-7 W<2\U5V%*-5HX<F%H9F588B8C>$$[;3)S3F9H4EAS.64Q=#0S
M9W1U37%0>6)N1S!+8U%P-'8V6$E%.6-U:FAI1&9-=4IL,75367$V:C-$.&99
M:U9V-3<O35A63'<R3VDV="8C>$$[-5DX>#9R<#@V<75N,FI427I2:V]29&5T
M2DQ"2$U5:$PK;TE0:%5T46AQ,$9R:4UY=F\O>C!(1#9H4#598V-Y<VYR=S9G
M=C=S57!)=B8C>$$[0U9V:6)F.$%D+W,O>G1I<65E5B\X92MP9"\T<2]24FHK
M2#9I9$PK<T$O8FLU*W%*-B]S96Y4:C,U93)+<"]I<3)72T]A3F\U1C5),R8C
M>$$[54@W.%9E169M5"M1;#-D6',R<F58+U1*;6-V3&)5-&)S5BM+9S)R57-4
M5&(U6FE4=T5F4S=41'(W,GEB*V)X6%5.0S%B4S541F97<B8C>$$[=T]+06AX
M459+:&=+*TY#37AY2%E1:TI#=V)553E24EAG440S<&=)8D%75BM5=% X,C9P
M2DA:-EA:=F125G)U=G=Q1TEQ9698.6YP6"8C>$$[>#)Y0G=C9E)T:C)K8TA8
M8G4U=EET3R]*5RMN9U-7*W9X6E-0479A<6=N2U8O6DUO84Y34C1H8W-J,F8S
M;%0W560P4'0O4E(K.6TO;"8C>$$[<CAV4$LO;#956$9L8F5R96EV1SAN;SAQ
M:'%G:%-!<7)S4U!H04Y->7-/;&AJ,TA.,'5T-U=Z-FM623%(=4A*:W5:3')(
M67$W1EA9<28C>$$[.'<O33,X;4Q$>D]8,4-W8C9V<6YW0W!Q5DM+84U+9C9P
M<4(W9E)L1U1$930U=5IP.5EC97@S:3A*;#AJ96)03%=U5V-L,6%Z44=#-28C
M>$$[:%IB<4I$2G=98UIA9V-8<59'*S8Y=6AZ1DU31'4W35IO5$=X6FAR+T%*
M,4ES8FAB2'HS9%AA5VYR4C9D<#@R;CAP<$9L36M$0V$U9"8C>$$[25$S2TQI
M-TUW<E9U;DIC;DM7,TYP>#1T.31$-7-9=614."\K8V)U,F%E3UA56C1K:T9V
M=W0T,4A",G$Y4%125E!X2&%V9G!L6G58;28C>$$[-4U4:GA$63$X6'!N;&8X
M04E3-'4T>$XU;&TK<')X06IT-TIV,VY*4E1M>E-I441L,6]".4%'6%DY3E<U
M*U1I6G4P*VM2.%0K4'@Q6B8C>$$[,6]F-4]E4DY+:U=9,E1A:&-)>DUK=#@S
M<3!$3'A+;4U"25-/*S9D9"]$3%DV94DX,T=Y.6]:6F1E2#-F:3%(.#1:9&5H
M,$-X;3!38B8C>$$[5C1B=4LY4U(R,$\P1CE-63%J8VQ:241.8D%O5%1Q5T9A
M1&EA-64T3'HW5#=J.'E.6#$K,#4V,S5Z,"M783515U9X9&%&6G<R8U9S=R8C
M>$$[;59H9'AX4T=*;7 O=7E336-4>&)H.6UI<F1T-7$O3D14=DUU:U!E1'I2
M<FUJ,F)8175Q47)O8V1N-G));'=G;UDU2$UV<5-56D4U2R8C>$$[:7)W,EIJ
M54MV9$Y1,4A4.4YS-4PS54QQ2WIS-%%$3F,S1')&16=*04):,TE58FUM-7A6
M9%I8=&QF5VM6-5I8160Q851Q2&AU25A74R8C>$$[3C%04FQD4U999DQ&5W!R
M-GAH=5E,5V$T:6IU<G)L.5=G9#%74U@P=T,O<'%45G5)3E14<&EQ-C=U-U-Z
M=%IB<3AM:G0W5T)':VYN;28C>$$[64I':4M+<WIS>$-Q;TA5;D953D%.1&YM
M;'1O0F%Y>G="1VYH:CE.;E%39W-H9%)U=DU#<3$V-#!T;WE/3T].06MA0D5(
M4E9!02LT628C>$$[<75X5E%V<D-X=C=35WIV<F5+-W1*,31Z5S V3$I'-BM$
M27=+<U!N:7%685 U5#AK861D=%!O,FIA6EHS;'-Z4E!,6C(Q=D9*1WIO<B8C
M>$$[36AA3E%Y;&M+:VIU2UEQ;FU+=7A6,DMU>%8R2W!.8EA8:R]Z4$)/8E-F
M5#EA9VI94C-$479$9$MR:F-+>%%V>%ED=2M!:3!G,',O=R8C>$$[<C514V5/
M1G)#,CEA44TX8T0P2F15;T=)4FEE45AK2S=D.&HT8V4U;#1K=3E/24QA,W0P
M16-%4U)2:6=#26]554=W,D=464YW>G=42R8C>$$[>E%Y3$MQ<S!B1D=$04]H
M2W-P<#-6:%%J1E8K2W5X5C)+;T15=DU'9S983F)W86YQ5G)9>EA2<&%X6$TX
M8TQ3:TUQ,&I6,E5T.%1Q3B8C>$$[=35'2V]Y865#0U Q2C5&:6IQ<3@S64M/
M5'-&55909&U)03DX5E%A-B]O5#9U*VI,<4YQ,G-2<C9K;6UI84TS2W!13GE-
M4$PQ04M-1"8C>$$[5VU+;VTW87I72&QD;4Y995-I<W9%3'E:9W%$-'1Q;&E!
M4&9&55!*;U=I4WEI8514-UHU:#!K84=-=#DU1F-&0DYR<&)V4CE04S1E5R8C
M>$$[83-S,'0T=G)&,GIS:U%J:$A,.3=)4U)X5#1'*TDW8DA#:%9H=C='9657
M,V=U27!:-$%J5'=O-G,V0U5%>&PQ0G%O8T-Q,38T<7(T<28C>$$[-T9867%S
M:FYG;&%2235&9&]7.4]:5DE*4BM)9FEW2%$X5T)O97A'2W!4-7<X=E-E669,
M,7AP358Q.51L;65#4T\U<$DS0G)E9$IX+R8C>$$[9%-7.&TU:G!62D999%%1
M8U9E8UAF-4$S9'=T,$0U:%%F5V):-V5J5U1Y8U=E+VIV=5IE4S9A855+,%9!
M<W-J5DI,3E5L=5-Q278X028C>$$[.&@S=F1B=3E3;#AW3S!D>E!Q:WDR<C)I
M37%J5EE*25-R15-,-FYP*W(Y<&AU<7%M=U59<6DT9GE6159X<DY.86(V:'%U
M;5AM;'@R228C>$$[=&M63&1,=5EY3'=:6$1'3T909U-,641C:6QA67%L2"]!
M14QX3W5O5SDX=FUM67IX:4I,:5(W5EAK;%,R;%9O2U-'6&MJ<&)W>'=C,28C
M>$$[*TEQ1W%A3W=X5D8V6BM2;"]P-G=V1#5H:4YZ8C(V=U%Y+V\X2VY*3E8O
M4VEK>$IC2W%O2VU0,#0K2%AL6%E,:7%%=% K8V-R83-44B8C>$$[241R4WE7
M;6U#25@Q=6)'34,Y359X4$U423-Q8VQ%:5A(0GA69S-"0S%E2S!68FPO-7@R
M:B]D>#)U=6DR=&A!,$US07-);D1-.7!(8B8C>$$[4T]J32]+37EM3&Q,>"LR
M1'AB<%A#<D]V>2\X04EL=C5.=$Y7=$QA84]7,C%(57)J56]9-#1"04E6;D-G
M46=+>D)G;D-I:T%B8E5W2R8C>$$[>6Y&6%EQ-T9867$W1EAN9FU4.&])9&%T
M2EEV,&MS335E*VQT-VAR5T]F,&YV=%)I=GHX36I56E%S2FA:9C(Q63$R,GA6
M2F)4+VY(-B8C>$$[3F13:W5T43%M3%4T6DIL;$U&,5E2=650,6E+-&LU3UI4
M>F54,$92;EE(-&1Q531H4W%W+S@T.%%N53=/9'1C539D8FUZ32MM9E59+R8C
M>$$[5&PK<7@X2D9R-FYW3&-->E!+;T9'66=S1TMG-$9:,2M84&MM4'E8-5IJ
M,$M/-5<W4T]A5UE806E%3$U:;DQN:T%Z,4E*;T18-TY",B8C>$$[>%9K*TMU
M>%8R2W-C.'EE4V]D9C%/,G5R:2MN9W19<E=E>G5B3T%2:C9X2&-3=WE&6&MD
M6%I6+S!E:#1563$K,$\V<D-99GE(0S-%128C>$$[>C9V07EW*VU$0W1G0D<O
M;W1B3VY*5VYF-V)7665A;3=U4V1U;4<Q4G9N2'DS;T@V571',3=Z1$LQ>6QV
M2$E(;70P:VUB-FI(9D]S-28C>$$[83-33TI(43-8<4I336)X8E904E8U9$IO
M4&M$4VYS6F13.#8Q=#=0:7)X4RM8<FE/,EIO2E)C*VEW4E932E$W25I9;$EQ
M,C=F1E1I<28C>$$[<C9Z-6(O3$=(5')/1T1Z94Y'1E!317%A3$]O=4,Y<$AB
M2T]*5E%Z9V\X.%HS6E=K1')3<7-Y<60V9&](-6-A1G!V;4QL<G)*8F599"8C
M>$$[1W,W3U=5-E1D>&Q5;'1M-%1X:T-R=%!X:V0P2'AC:%$P66)Q<%9P9FMZ
M>5IQ5CE"<4=N965,<6531T)P8G4T9E,W:VQO3DQM0BM+6B8C>$$[*U!O>5%W
M45)W13%%:DQ8=$I1<6]#,3!,.'5,4V532S,X+U%3,VM-33ET2DI$;SEX2D5F
M,&=:9T<O8U!W16%X5'1W151+;&%/86EG>"8C>$$[5FUE;"]L=C5:.#58=#%Q
M1VTV>$ET;7,P<U=Q-F1.<')7>E1S,F]Y,VA,*W0V8VA2,68P;4Y+3G=5='5N
M14MP:$HO>FHY0SDQ<&A/="8C>$$[:CE(5TQX4&-A86)+4#!:=VMC2U-,.75S
M66YE2FYL03)9<T]12E=P5EIV-40X;'@K571.;G-)-VA,:$IN:&M$2D0V0D)H
M<S1,53AG2"8C>$$[9FM73G1Z<G0Q<#)Q47)T3B]-<GE(<5)J1G!R9'-437-4
M42MQ>&@U;6575T-.1CE52E8R;'0U1C1$-'1U;31Q<6IR9GIH-5-U8F1R;28C
M>$$[,C%U=VYT:VIE9#5O-W%&,$554E534T9L66=+:&1E4C9#;SAC5E5,:GHO
M-4AG:45R-CE91E,X15DY3S1I:U!+-G%99FA2;5!X<4-W4"8C>$$[.&],9EI"
M3TMQ=6\K8R]+5VTR679,,U=,3T<S6EHR:F-Z>&MY0S%Q3&HP,4),3UEI<$1H
M45-$=&EQ>B](;FMF-&8K9&DP>C1L3$PO<"8C>$$[;'9U<6MQ4U!J-D%I:'A6
M5G5F3U!L1S!U26)E-C%Z5#1,:31H1GIB=WDS54M02D%W3$-61EIG5U%H4V51
M,C)X5D1**UE8:U)J3U X028C>$$[14=N<#E806%5>5A-55DT36E/2D9,<V]A
M37)+=GAR5F0V5G)I<2LT."LK4F)A;W50365L=SA72TXV;#=B<E)G2VQ45GAU
M35925FPU;R8C>$$[.',S,3,Y4W-D6'-R<3AQ-B]6;V)I2U-7<U%5>41G<D9V
M9T1R>3(R<4U65%!&6%EQ:S)U96-03&5H6%5&<G%T.'1R8UA-3GAC=U)L6"8C
M>$$[671&84M(;EEC1F(W2VUT3W S<%=H>%9:8V5D+TLY=$Q"1E!E:4YR:6$T
M=#0R36-V05-7:VYO>F@S-&-50WEK24=99TU307!.8U974B8C>$$[*V9V2T5L
M:F-8>39L1TQ3,',T9%-U6FU6,4-7='='355H-4M0=&A$4F9T93(T>%9T=E S
M:U)E2$QZ2'!9.55%>#%V8F8T9T<T;FHX928C>$$[.4<R*V5+=7,O4'9K:3DQ
M3F1,<SEE<TQJ54A#=$AB4C--5$\O27-+4C!B-'E$1V%H86MD*V]X5G$V+TU(
M>4QA<U9M,2]4>$E*4D%9;"8C>$$[=5EN:T5H8U(X94-->F)-9FDR*TAQ84%(
M1E<W-WHY-4QS8GEX=$QR5V)72V95;6M3>B]E06\W4E V5&HQ0E9&<$HX2'A%
M9D8X4%AB1B8C>$$[53 P-U9D3#%/0G Y3G9)3#)"6$UB4S(P:5-O2%=H2VQK
M3$-O<4YS5E)72W5X5D%A=')U:S92.51/;S-!='AQ1C%&65=:25DX-VUE;R8C
M>$$[:FHK14=H86Y5-UEQ:U-F;7@K5S<R:T8R=FU'>DU&=R]P;S-/:%4O1CA5
M:6MC;VLK06M/-$,P,W)41E905714+T%#;#%Y84]853<O4B8C>$$[3E1:47-3
M3&-81G)/;C<S:TDO9V1M47,S>&A$4W1#=TA6<U956EIV>5IV,G5Z35!,.3!S
M84QD,W,X:5=J>$)8;4U+>5-3<T-L9E=1<B8C>$$[=3%E6#!9<6QL,#,U0E=E
M=7$Y>BMG>&8S<696:7I#2C=D4G V<79">CA6=$$X875Q:FQX86Q&,S)'2W W
M<4TS-552>'@R1W!0;TM2,B8C>$$[9C%94E=L>6)-3$124V)4:D<O,DM*2693
M,C9(-&5U2W1,2BM5,FY44GIQ*V<R8S$Y8451>6<R8U14,F-Z+T5&8EEV0S=N
M96YW:S1Q;"8C>$$[1W!$.&@Y575V5G9*9$-A83-U24QU4S=75T-&5VY74U%1
M<DI01WE,2V5A4%=*,F(O04-L-EEQ;DLK85!Y,#!31SDQ1TQ6=$YT;S5J2"8C
M>$$[3F1V1&-235=-:49O=4M)>D5M44)M5E5(>$=P04I*>%9-<EAZ;C54=7)M
M93!H,64P3C-B6$)T2C=:<&M36DIX3#90<'1'>%8V=$E1<28C>$$[-V9&555R
M55EQ;D]+=FY/>#$W.&AB4S5T;&XX<5@K;C9N4S$Q85I)6EI:1FAE,U%01$M8
M4S5"25-&:DXY:F1A,4A/<3164DYN-6DO2B8C>$$[<4A49%<Q0V92<BM,4E=A
M2'EX3F\P<TI%<V)34U188WIL>F-U6$1/9S5&1T1,=T=X1DM+;S O.$%+;4Y'
M.'=8*V=A5C52=G!D4G-,<28C>$$[,5=664A$5R]R=W-)8F%4:DYE>$MW1#-1
M53%!-6-I5S=K2W!D-5(Q<CAP3E,O45=K5T=G>C,P46<Q93)V3EEQ.7!02S!D
M:$A*9%1.0B8C>$$[8G4W>D<U:FPT;S!J.#%),C-&8U93,E0O04I5,&14:2MR
M85!Q36UI:4]35V91-$IK;CE793%2<%=U6&Y856U8-$DU87)55EEH=41%*R8C
M>$$[;W5+<W!V4$U8-4PS>5)75C4U9'5Z1W1J6399<U1Y>$IX<S-H:74T25-"
M94)U4T(P*T@K.&M)8F@V9U8V2W!(62M:4"MC9C1T5C K5R8C>$$[>CAP86]U
M<$IB3F57:V1706I3>41S4E)R=U)&;%,Q3#=6-55(5G1S5E1+-FXO2W%Z,%11
M+U,X;UA5,3<U:71B93)S=$U.-4IW:6IL=28C>$$[*U-W3DDP-4UA<$UR3R]P
M;V5"*S-X3#!+<C%44E!Y,3AL84AQ>F%T<&5N1S,Q0FYN;&%B,3=H-G9D0D)-
M94UK:DHX6'!,,C(W57=+>28C>$$[8D9867$X>"]->2\O04,V9SAW=U%E6F9,
M,3%Q;#=D43(Q<TPK2&AX:&IU2DQH231W-U1W>5(X-E1E<#9A+T5T03%A2TU6
M66999FU:*R8C>$$[55559'0U:E1Y,V1X5SER8UAQ,C$K.'%I-VQK='I&9'ET
M8VUA9$9N<DYC33!9:VUK4$U$:4]:;T95>5 U<69L4VQL9F%3,FAA;6EJ4B8C
M>$$[8F5#-W-V,UEK+U)Z<VEW46AX9&9B-&%G2DMQ+TE+5%9U4SAC5E-86&)8
M.'-D4#A!3&=H<V1/=3E#13 Y-6-8<&=L83=L;&@P,E,W<R8C>$$[-4DQ-5AK
M5',X9S5L=E0U<71F,V\T;F-Q:5!Y>G8O>6,Q4'I8<&EA6#56=61,,4=+-759
M.41U1&-Z3D=)-V%%6$IL;6IA6E%J<W,U2"8C>$$[2&<O:'EP:7%%+WAX*U--
M*VPV;'%E;BM73#)2<E=7,W5"2F13<DA!8C(P:FUE>6E,4&5%0D9J4BM#9V-/
M3D57<D9%2W%E-FYE+VQH-28C>$$[9'1D3CAV83EP5CEF>C9$850R.&0V:$5C
M57!U<E9,:2M+,759*U1S<S8W4%9Y>E5J-4Y81E52-64X+SA!:WIY5EEA4EIA
M6#5A=4Y/,"8C>$$[,UA28C-S-GA4<&-01$ID0V%!,5(U1VMF,'9Q84MW5&]'
M-D)V:%I6-DHU1C@W-E(U,#!"3F(P<4\T:'18:V5(,#=P0DA)1VI.1'-R3R8C
M>$$[=$XK;V)!<DE-5EE0*V)S*VI295A,8V%V;W Q>3)E-&-F5E9N83,Y4&A:
M,T5K:S-.4T=Q<TM/04)V56EM.41I<GE4;"M33W(R<W-W."8C>$$[<#-L:G%6
M-F]T6'9)-VAB:4,S=4QY3FYJ0TM,,E!N47AS=VI603%6-&-69'5*2V\O>5 X
M03AQ9S@Q9F]R47(S4TPR+W9B>31V2C1D428C>$$[;FUK:D5S>5%X>GIY>F-,
M>59H5VEQ9TQY9EI"3&-Q;D95,# S>E(K53DU;V5Q6&5J95@W*VEA6"MK6EEZ
M8T=!=D9P36MA=S!K:G5N828C>$$[3F]Y:7-K;S(R64)I-&1C5E-%,T@U13-$
M5U9T92M2.5)J,516-4=K:G,W959I<GDS56-%,W=Z3&1X4CA*4DQ(>$1C869T
M2VYD5DYD4B8C>$$[.'EF:VYC85,S;FE8>3EE,T56,V-(47)T-5I*235U2#%(
M,'=&:F4T15)5=W-%*S!P1E-F=&1653(Q,E X;D)E86@U37503&QZ95-E6"8C
M>$$[24Q,:F%135%J<DQ*-F-%8TUH=5DO:58Y55!,,4-V,G1Y44)G5FAI87 K
M5'$V8RMM-G U83%057)J5#='>'9B=3=U2G!)*U1L4DAA*R8C>$$[<7-D,TIW
M5FAC4D)&:35H43E'0VA$47%N36YM3#AL8FI5>DID*U<Y5VDQ1%5P<D-Z93AN
M=4=$>F98251(8G1*370V-RMM640K.#5B;"8C>$$[5#A12G%-5F5H85HU2CAV
M83-&;V9M94,R3FLY,5!B-CED5S=Y5%A"858T-5HT-#%A4BM%87!09'1+47%5
M3$-T061W1EHS:7)Y-E17+R8C>$$[*V-G-#5%5F9,*VMZ>'9,8F,S5GA%631P
M14Q81WI88VY*;VU)54XS<%AI461L5D133F0O-7E)1VU79S%$>3=P-79%85=/
M.$IE17,P828C>$$[=WAE;$MV<#-I>&U2<%1,>50T5DY!2V]$>7A66'5T9"\U
M>4-32S5L='9,,FU4165I;'!B<U92,DQO5$Q*23,Q-6M527DP2T-V,G1M8B8C
M>$$[:CA3<4TQ-UAF>G)H*W).;W9L,GAU5V4S9V4T:6QK:D-P33!82V105BMT
M4FUQ4R]!04EY3U!X8WHY;D951C5F,4PX+TE.3'55,5A3<B8C>$$[3S=V64Q3
M4V4Q:VQE0E=N=6AE9D1B17=4<$=O83 K>3-!04Y1<U1U0W%G,%@X.7)F5V)7
M-W1.2W-B84<X:6MV9&1T-#-H:V=K=FQ$4B8C>$$[>'A6;&U%>6QO25E%-4EE
M26(T:4M!9W%P>EDV<BMD:V9L5RML=3E(<UHO34M242]O>3)"4E9A6#9Z2DA-
M2C)&>45B+U(Q4U=Q;$M&:28C>$$[04-25$979#963&9Z85I:>39J0W1T<45K
M16(S;'5P1$Q(37E!>4E'0EE%2S%25W5+;W)&6%EQ-T970RMD.5$O3FUY,7!7
M.&]A8F)A;B8C>$$[<'HR,%%A2S9-4TMS+W%3*W%W:TYX0DE$=SE0-&5,2S-I
M<$AX2W-$.#8V-RMA=S S4S5V3E=G,D-7,&HX,71O-4-&1C@O<7)$8DU)-R8C
M>$$[-DXU5#959GA-2#1-2D-V<'-Y9T5Q>G@Y52]..61%<S56,&I4-4Y93CE'
M=#=">3129E58:%8S6D0Y66)J26MR1T]V2G$X95%3:$="528C>$$[=6@Q,S@Y
M>%E15%A(;'I45&1',V1R;3)I;%AK2C)A4DE5571D0D]+8T5K:U!,9%AO=GA+
M87%P:G R=&9M=F-E55I(=71&=$Q4>F=S<R8C>$$[6E<S96I74F=K;DMK.&MU
M6'$V>$M764-486\V.4U663EP1W-F.#5'4T\P*W!A2%E1<U=M2G-W64=H16%2
M4G1%<V)R9&U4;DQ)<G!6="8C>$$[:S5C:GE&0495-'-T8R]/;5128E=A-SAV
M5U5'<71D>7!C,C902$EO=&=Q1T9V.38Q0V-I>F@R1'56-&EK8D$W2V]B>E!F
M9FYO9$UT628C>$$[=$9S8DE8<VQL8E,S<SAA=V=P9'9+9G)%35@Q:39:5CE.
M3TY+<3198VE'0F]P5E)':S9T*V0P=FU30WDQ3%)T3F<P2EI1='AQ>45--R8C
M>$$[>%(O861)0F1C:TTQ2TM$>3161F585$98;VU+<$@U=W5F3CEV<&E0-59T
M<F4W,4@Q1TQX6&8Y,EDQ:&MC2TM3455A4U95:D164$AL>28C>$$[24E'2W-&
M=#ED+S5Y1$UP=6)N>3=99TI$36=S23-G0TY+=U514V5Q,3)Z-U Y=&%+1E-T
M3V)%8U97;3%8+VY)4F(P6$,V4EI3=U!:028C>$$[=&%&8F5/3T\W-7-#;R\P
M,35*0G-V>"MO;S1(;'<U:C!Y<6Y,,S,U>5!P3F]W,"MW:3%:<GE*8FA606$S
M4S!L=%9-<DUP=4]B;4,T6B8C>$$[:#A%:6PK26]!1'5Q<#9R<D@U>4-D5W-.
M1'1J0VQP0DYW1'=U>EAB,G-X;6=9=F-X5E),:C!H56-D="M2>%93=&1C+U!"
M=$PQ2C=J>28C>$$[.5E*9G=Y4DQP641P4V%-:5@Q1VMJ1C(V<G5S5E(V,W=H
M;7 V:%=J2W)/9C4S=TIP1'%,83=L5WI38E9O<$DW8TDQ,D5U;FQT=S9Z4B8C
M>$$[36],3F)X;WEG:F)K5#EP5U92;&QQ+S5Y5&%0<')85VEA9F%A=$YD=$AQ
M2T)X3D1$83@P0U,P1G=H+W4R8VYI>FUQ9V-F:4I25DMM,28C>$$[-R]N25IV
M6$LK5SE*:55C6DQC1U53<U%9;F1O5R]W0DMI2$E0=VHU,7 Q86A(4E9K4&M#
M9CAY6C=Z5EIV3TYV2&%14U(R1&%B8E)'028C>$$[<$A+8F(O5&M5>%!++T58
M2#)F56,W9$1I<DUS5F555T@U3"MA8E-7,6I4>C=Q365L,B]P;S)N469766MA
M3D%!>7$O,70S:C5G9G-%0B8C>$$[5#EG2U!H>%9"850K5FXU:'AE64PV,W50
M3E=O4C95:&MU3&951FQL450S13AA:U5G4SA+<7-5,THR0FI53V1M3&AV:$MS
M:#AZ+VQJ-28C>$$[;S%J5V)Q*W,O3RMP859A6%9X0D]B0S--;U))-%EZ1SA5
M8D-D3T%K<GE014%6,TE*;V-#;U=4.'%V3S=3,DQ$.'=D44-7,#8S3GE#:R8C
M>$$[,TMD>55-<45R9$EQ=W0V9G=2.%-%-4XQ<4M+=E1C5F1I<G-69&ER<U9D
M:7)S5EEB-7HX:BM93F4Q2T<W,#=Z4&,V3D)'<U%E,6@K<R8C>$$[8U@Y2G!'
M6E<Y0S5T=FAL-7%(24AQ9D-/3')V:7%187@K55AN0RM95%<O;G4X<W)X3&TV
M;6=U-#1P5VM3,W5F4EI,5W!U<6Q),V=R=B8C>$$[<S%F<VIR:7%R-6<O2TQZ
M1'%Q5T5C4&Y454Q32WAS8F$R2VQR<50Q8GDS;D5Z6'IN-C)N2U)Q54%.94\R
M-6]!1E=T4R]+4'I*9G)C5R8C>$$[.'9N3SAB5'!,831T24Q.:F5N9W-Z>5!&
M2DI)3#%8;FMI.5%)5$I65U)A1F$O1496,&XU5F5B-4I%;%!N-U5K;&EM=#)I
M369R0F91="8C>$$[,4MT1DI',7EY3S Q15HS22LP1'12>4U66FXU43!454Y$
M.'4R96PV:G%C=7,S;'8V;G$V;%!Z16MV3U)N1F95:VYB-%993'4U-F92:28C
M>$$[<6-9<3=&6%EQ-T973V5E=DMD-35L,'5#,'-T5VPP5S=T<&UN:'8T1C53
M2WI7.'-(=S!A36=J,2M6464S,&A6:%50-4TK8VMC>5,O;28C>$$[2G%6>$U)
M9E)J;&M754UV2D56:4=3-5%J-&]W-#1K5DE(4&U/45I63G(W.'103E5V;&MA
M4EIE9'(K,7929'<S6C%:>$Q.35)&86E'4R8C>$$[2VI802]D>7I,-GA3=D%6
M2VAE*TMP6C5C+TI,5F1#+U(Y<F%E8TPK3%(W1E56.4QG.6%#3U=L,$QM46QL
M=4-536=R2#A.4&@X9#9Q;R8C>$$[;E9V>6HX>'HO6'IP6&YF561*93DQ2V95
M85(K<3!A4GHX;49S<4-D04974U(R-4QX-58S*WEV1E9$,E@U32M:<F1K:VLX
M.39L2F-!=28C>$$[.# V=&-X=$Y,-D-1=W1+<3-80GA&-E-T47(X5S1A;T]Y
M<38Q+THW>E-)9VUO*V4Y4C%):65#64Q.-C1J2U%0-G!J6D9U45!J:U)'-28C
M>$$[0VI,46AA0FII<C%,1EA9<3=&6%EQ+R]:/"]X;7!'26UG.FEM86=E/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT
M/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#HR-3DV,S8V1$,V1C5%0C$Q0D4U-#A&035#-C-%
M03(R,SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^>&UP+F1I9#HR-3DV,S8V1$,V1C5%0C$Q0D4U-#A&035#-C-%03(R
M,SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P
M.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S
M<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^=75I
M9#HY-#8Q9#=F,RTW.#-F+30R,F8M83-B,"TT93-F-S(Y,38T9#8\+W-T4F5F
M.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM
M<"YD:60Z,40Y-C,V-D1#-D8U14(Q,4)%-30X1D$U0S8S14$R,C,\+W-T4F5F
M.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^
M"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I"
M,3<S.4)&1$4W1C!%0C$Q0D5"-D(W0D4Y035%-T5"03PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-RTS
M,%0Q,3HP,#HQ."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,C4Y-C,V-D1#-D8U14(Q
M,4)%-30X1D$U0S8S14$R,C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#@M,#54,30Z,C0Z-30K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I
M;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B
M"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A
M;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3X*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*
M(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T
M1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM
M.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI
M=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX
M;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O
M;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!
M<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF
M;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I
M;F<^5F5R<VEO;B W+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP
M;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^
M87)I86PN='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.
M86UE/D%R:6%L350M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L($U4/"]S=$9N=#IF;VYT
M1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L
M9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# S/"]S=$9N=#IV97)S
M:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E
M/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1FEL94YA;64^87)I86)?7RY01D([(&%R:6%B7U\N4$9-/"]S
M=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S
M/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \
M>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3
M=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @
M(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O
M,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A
M<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .$".P,!$0 "
M$0$#$0'_Q  ?   !! ,! 0$!            !@<("00%"@," 0O_Q !-$
M!@$# @0% @,%!@,"#P$! @,$!08'  @1$B$)$Q0Q%2)!46$6<2.!D1<D,J'!
M"AA"4K'P,]'A0V(9)30U-SA3<G-V=Z*SM;;Q_\0 '0$!  $% 0$!
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M2!M>D',!+D'=[1"JO#IES@;[7V%DKCU%]'/T4U2'15(KT"H0#@4QDQ$H@)3
M9,X#TJ$$I@XY$ ZHTZAY 6VH*2H @@@C.>1@CJ",$9%<N<;4VLH6"%))!!$&
M08((/!!P1R#BE5KTJRC2E&E*-*4:4HTI1I2C2E&E*-*4:4KQ772;)BJJ<"%
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M%/H4MPC D$S@(2E(,Y@ "9$=ZY3=> =7LEI9;4PIF20ZX'6X())4M*6W@D
MY"U#D*(-7I>&/XAU9NUC<XZ.A8H.!=%;+1T7:_AI74>9RJHB"3%2,D9-JNV%
M0@*H$37$S958L:H4II&,20GO@WQ,R\LZ4[<!Q;0/E%6\*+8/^F2L DMB2@Y)
M2%(,!"2>3_:5]F^L>'&;;7';1M-E?JVJ>ME^8RE_:%*"O92II2IRE2$A2AO;
M*AO">B%-0BI"*I'*HFH0JB:A# 8AR' #$.0P"(&*8H@8I@$0$! 0'C73JXO7
MWI2C2E&E*-*4:4HTI1I2C2E&E*_!$  1$0   1$1'@  .XB(CV  #N(C[:$P
M"3P,FE07WN[O8+;'BVR3;==)S<$Z_*2L4P /.^#QS%FX<.[7+MRE.;TC%-%0
M\>T.3^_NRD P>210R<(\7^*$Z):MM6VUW4K]8MM.MS!!=6H(^\O)D$,-*4DA
M)RZYL1[*5*4GK?V3_9L[X\UEUZ^+EKX7T-I5_P"(+],I4JW90MXZ=9J(A5[=
MMM+&[BW8#CY"E);;=_F79HS1>LZ9#MF1[[/RD]/VR=DYIVO)/579TA?O%G";
M1(5#"4B#5-4$4DR% ."B<P"<YS&AS5N&U%:U%Y\I2''UF7'5Q[;BC_4XO<L]
M))/N[N_>0R+:U:19606I;%C;C9;V[9 2TRA(Y2PR&V6BHJ*6VTID@8:DO_O?
M7]^W;[=OY_7Z!WXXR*U"I)]HY)GKCN([\3\.9K)('(\?]/KP(?;[_8/8>/MJ
MA,"?KZ_;-4Y.03 $ >D?KGCCFMPW2[AP'<?Z_P _V#N/M]O8->*E0#'K'NG.
M#P)@]( ^)]T)D@ 8_0']SVCTZ33A5*DS]K=)MH:.7<F.8"F4*F;RB (@'(J=
M/'8/?CD?SQ[:;4]9L=,;+EV^AN!.S<"M4XPD<\=8G,3UG'A/P)XB\6W*+;1M
M.>N-Z@%7!0I-NV)R5.D1C_MF(,QR9P8YVPMFGD/[2H#E< *?T:?_ (9!]^#^
M_/YY$1 .X]Q[<LUCQO=7>YFP2;=DD_Q%"5J'< G!B1G&< C%?8?@?_#YHNAI
M:OO$[J=1OA"_NJ8\AI4 Q/!(((GVNTCBI?P53C(9!-O'LD&R9   *FF "(!_
MS#P(CW .?I[#V'OJ%_>G_-+RG5.+((6IPA:5I(]I*TJE!2H#*2(Q!!@5WMA%
MCIK";:PMF+5A A*&4)0!$@9 !,#B3D32P18 4O)2\=N1 >_2(?TY*''^(>Y?
M8P?\0W*0AY)<MLE()=MY)6@"5+4TI7M.M $DY+C202X%)3YI\7+HDP5?[B?U
M[#B?PG,5\O&JZ7D.V?F)NV*Q7")DQ,54!((&ZTC$X$#E,4IP$@@8!*/2'5P&
ML7>H*2H0"DS@=N/?$#UB1US6W>:67&']JF;AM32]P!0=P(A85(A0)29$9R=L
MU,UCEMOE.1KMYB+=!4+)E<8%C)>)L,I\,B; H8&R2DDT<*':,'31<$U%G$;)
M*+N4%SBDD15-)N\)-+75&+Q+3JG&V+EA"@4*.U+ZE) *RK>TE1"00D.;ML;0
M!^-/"[CP6YX0M=4\/7NB:AXC\*:I<&[LKW3+3[W>::D%U:;9UI >N6GFRI*&
M[JU2VTXV M2DJ6XPJQNHWF2J;Z&L</-,TY%J@W44>-ERECWQ01!=<BJ@*]"C
M-< \X *?E(H%724342*<LKT[57]+NF[RT="% I*DA9#;B!"MBB5'$92K<2B
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MKNW!FZHQ3Q%-L*B)G!VPJ%6:M10DWS<B(K(R3Y=&;>#/%#)N#H[KBR42&/-
M0K\1EH223&2@8*2%((]I KEOVH?9;JGA^QMO$:0Q<6=TKRGW;7>0A[8%)4\@
MIA'F *A25J2XEM2R$*20KI=;N$7;=!TV4*LW<I)KH*D'DBB2I0.F<H_4#%,
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M[_8.1#37#Q$_0$=3Z=AUYYJ4V=L%D=AP._P_YD=Z7T?&@ % "ASV^G[=_IP
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MQ]UU'WI:F[=2H6"2I2$J&TN)$C+>XJ2B(4/9)@S7/_$OVA:9:MO&Q;%U>!!
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MUUO[&_"K?B_QYI6GN!/W/3@=<O6U)*DO6>FW-J"PH@B$W5R^Q;K43(;<<5R
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M,H=8A>Q%O[PW6<D#Y4'CIRS*(@S'CZ1\,ZNC6-+M[I)!*D#>!T6("QZ9(4!
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MD4O8INU<' J"J9E! !%$!X7X[ '*(\*%[B CRF'/L'?@=:>Z*@ <\D _RG/
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M&>H>J9?=P/PQ]/2L],/HEB5F0Q$T(^)5+#MEW!A;^2"+@(M-P=(RJ2Z0FZS
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MQ/M8@<9D01/ P:^@?">L_P"<:0RXXK=<VW_37!,;EE(&QU4')<;@*)_$XES
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MJUM])9/"\OW4'$[U0E)C!VCF3P<:EFUD[$^:H&5DY!\[72;MFK9P^,JX<KJ
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M;]RRLK8;W%(&$E*G4RH@PH""#2]@X\KB013YZ.X& 1#@.2]^!'O].>._OQW
M.^M.L[$$P>(CGD=8Y^HYKH=R=Q;3D [E'.24P ([<G'6)]7X!/U$3*MQ ! K
M=N\3 ?;S6KE(IC?7@2MEW( /;_$(=^>-:V8<3)/XB,'@$$P/B$_$"O%?X>>(
M/OB!V['TBJR?%&Q\UM&UV$O9$R#+8HR=&)$7.'\4E;R#'.HJ2:)'[#TGGHJO
M.@)ST@8BQQ !.(ZCGB9H?].] *E I41V21SGGVT@GM XS70_LVO%-ZG=61)\
MNYMBL)G'FL$*28SPV708$YZUS^LDQZ"A]^/?[!]P_P Q$0[\_P @ARR8/R]P
M^OUFNZ,I$\=9QWZGTZ<'\XI7,B=P[!] _P N/^G/;Z#_ ):]XY^/Z?I&!W.>
MDS(+)'&"($GID]<_MQ/J*7#%$!$O\@[#]^>?Z<\?7Z_;6IN%9,=9^'6#S//2
MI7IZ>,>I,Y'O'S]?EE=1A%.HH%1,/<.!,8"E$0'GGD.H?8 $/E#]N=:A]#,%
M3ERD2)*&VG'%C'X3N#2),08<([$S4FLR]N 1;J,'"ENMH0H$"% I+JX]"VDC
MKTEUV^4DL47VEU1H0!<1%EK4[DMPDJHBJO)Q4NPFF5$*X3Z'2+&NG;(FL* $
M:F<7(RK9VV=%J4(_/(K#3F;.W*D*6M]X(6XMQL-N-H$+^[[$K=C;A;L+]IQ*
M4J2?*3,(U_5KC7'WK17EM6'D7VGV:4.%U#C]PR[;C4BI3;0)626K8A)"+52W
M&W!][<2.BYU)MG+5O)MUVRD'(-6CU%RTZ5TIA%=JBJ11%5,4SK-7+4Y3G,54
M2* 83B8?_$#.&=L".OITZCIT_0R:^='D%MQQ#@V*0I25I4#N"Q@I(Z$$$$1(
MST%>Y9111L94J!$#+E 0$Q1(BB')#"1-$"@4HEZQ#K$?FZC$-U%$3")R1,9Z
M<0<3'J/F.]6\I"HZ=>F8[SUGT,1C%:L%W3Y+TQ13.HL4KLX& !)Y8FZ4A.)B
M@HH/5T F0.DIA\H0X(41"L08S$Q/4GKZQ[IP1(.*LG=C!)&[.1').>N/0FM/
M.U6-.D1$QA*HX$5#D5*)R*NS&*8ZI"]@; F81,3TZA!*8"#U@)^H/1MYQI:5
MMJ4A2(*5()2I,'!"ADYP?]HKS=MVG&U(6$K2H%*T*&Y"P>XXC.< <XP95&.<
MWVW%#QE'6%PM-U-T;RDU3K"[>1P!W,0BO F?MB$ 3%$P Y*F4#&*L4#JEFNE
M>(DN0Q?D)7A*+B-H,\><GA)C!<'L'^8"-U075_#BF]S]BDJ294;>05#JHM*G
MVQU""=P_DD0*LQQME #-F]AID@WDHE^5-P]AS+=3-V0Q0$RB(DZO2/.C_ X3
M*(CP4JR:J8= 3-E\MP4G<DP0 <$',@\9QG@\Y',,=:"I2H0H2)(@@B<$'(CJ
M,$&1@U,6KW!A:8U5W!2#EDX$GDNTB'!*3BW(AU%!9(#=)NA0H'2./F-712B7
ME1,54];*4W#<),&,1@I/0]>.W'0R*P84PX"H2F<G)!';Z$]1FHV3.\3)F-)F
M2ALB8HNXLHMZY:A:V=+EY>L231!4Q4)5K.UYN>/1:OFP$=I$>G0=))J]#END
ML11,L<7JS+-RY:.7%N+ADA*V5K2EP$C<DE)*5 +20I)@R"")!K;"UWMH=2%!
M#@E*NA&9Y&0""#!.1$TH:QXB^#)U0&SB8C6KHA_+72&330714 >#)J-'2*9T
MSE'D!(=8# ;Y1#GGC+3?H,>R#/5*@?RSZ\$_O7F;50ZGXC]P?7B)^%3VBY%M
M+QD=+,C@HSE&#21:' 0$#MGK=-R@<!*(E$#)*D'DHB \\@(AWUG@R >X!^=8
MQ$$CL2/E6=JM4HTI1I2J>?%FDSR2>V?&BIA-$7')KAU.M^1 %VL>>#8I%  ,
M7J'R9>1  'GCD!'MSK"O3AE'1QY"59C!4)^8D?&LZQ1N6ZH3+;#JTQSN2VHI
M/P4$F.IBFPK-5F))T\GED5(]D1)_)@HMW<&(DFLZY13Z4S&$"%X*JH5),W'4
M4!#Y=8E[JUK;(4E)#KB 5*0@C8-HDA2QC!S"9,C,5,/#W@/6-66R[<I_RRTN
M'66D/725!]SSG$MI4S;8<(]L$+<+:2DR@KB#$]#;;!UV[1%P>1KM:3&/,HF]
ME55G"A2MTB$ZVB"B9&K--PJ<JAO3% RI> 454#@ Y]X@UK5M3N-.8N'7&;%"
M"^FS:4IMA:D%(0I:,>:96E4N*7MVI*0D37US]G?@C[/_  -I^I.:'IUOJ/B*
MX<%M=>(]02S>:H$/E0=88=_!9-;-R%-VK3)5N4EY;Q$T\];BVC)^11NV00 %
M0$XID(01[AU&'@ [<<B(<?O[:M<<=6$[UK6  !)40)B!F9]3Z]*D]TU86;#I
M99MK4N)6I10EMH$J!Z^S&>Q CCG+I2,NP;Q2*R[]% &+WH 3." !?6)"H40#
MJ^42G9G$#  "(G[^Q=6IMGGE (:<4H_TH)D#G,="?A-0I>L:18O/KN]1L66W
M61O6MYK"FED!)@E1W)</LF<(QP:IC\3O(]7QA8Z!DU%!U)!DF)D89Z$8ARBK
M9:2+)LNX=.U.A))9["2<.(%$#'5%DN<H"!3B'-/%O@;4KK647%NVW;-W#"3<
M*?4$@.)( 4$("E*ELI [%!GG/=/L>^WWP1X=\+ZKH=Y=W>KO:5J2WM(MM.:+
MDV.H)+[EN7GBTTTW;WPN%)4I9.VX3M20G-+EBW0W6>$Z,(W:0#4_)2J!R[?"
M7OW%17I2(8 ]NA/CD?Y:67@'3[<)7?/O7CDB4)/DLS&<"5J'3*ACH*R/$'^)
M;Q+J)<8\-Z79Z#;JE*+A[_KK^"#!"EA%NVOK[+2]IB%&)+5+SLY/K"O,2KZ0
M5,;D1<N%%"AR/T((]!>_(\%+]?ZR!JPLK%.RTMF6$@<MMI"C',JY4<#)/.3V
MKDU[XDU_Q"\JXUK5[[47%*)BX?6I )R-C22&D@0("4"!Z5NV*/)B@ >P  ?@
M/;GV[?</I[>WTQ+A7)YS_8'M&2?UK.L4&!/2 >DF!/QC'K'>:7<6"("7E1(/
M;CDQ 'GCVXY^O[?^NI?MKQ<[;6X5(GV67%8Y)3">(Z@Q YJ2V5Q:I*=UQ;I@
MB=SS0A74&58/<&"3ZU;/LBJ$%1\G4M>Q,&#JZ6)H]51^)H&6-2F3V%=.X8D<
M3GRT+9+IE0<N79R+'AXUVVC$1:RSF619ZEJ\3:ZFBQA(NCN3<J6/XEL5H5M8
M1CV;A0CS5&5-!:63M<+H$TUCPC>:A]G.K>+%KN46#)M'-(M[=:4IU-I%^PU=
MZA=[@5.:<A*EILVDJ0+A32[Y7FVQLU+N0(W:HJB!1.7RSG.J[$OF 0A0$ !,
MI.PJ& !+U&,)2CR(B!0Y#;A* 9]H03*^8 G*0 058.28!F)@D<.6Z\X@$P=R
M4I0P"4;E$C*BJ#L23N@)W$0 "216:+A)! I2&'Y3]8% >3";I*!5%!   ! A
M2B %$H@/5\P" %U>5!*1!X,XY)$#<0!V ,8ZF9P,?RENN%2@(4G:2H0 F22E
M,S(*E&201 &"#N&G?(HO 2Z4S N)C&$4P)RH(I@ $, ]0B3@P]8*"8O8O!>2
M@8?%82HI"02HS)QF> >OODB!!Z&MA;..VQ<E8+8 3#A60@!945)XE6!MV '*
MC,*(&5!V.TT)R#B+<B9HF("ZCCG,=@H(F$3^G$1,=H8 [CQUH% >_2'4H&WT
MW7+[2EA(5YUN,*:69"0.0TLR1P?942D#\,"37EJ>DZ)XH:+5ZUMN%@AF[2E*
M+M(@;?-  2\#QG:X8@20$U+W'F6HFW%2,U='B9]H("=$1!)V@IQP)1 >061/
MW[AUI*%Y#YBCSKJ.D:[;:@@/6SNQY$2)"7$*Q*5)/<=#((,C<DS7 _%G@6_T
M!2P\R+W2GYV. %QEU,X,\MNIY@[%H.?954IZW=D7YTHZ7%-K)'$"(."_*S?_
M $+T&$>E%P;ZI&$"*&'^"(&$$BSNQU1+Q#+\(=P L?@</2#T4?Z>^!R!7$M9
M\-+M4KO-/WO6@E3C1R_:CKN'*VD__P @DI'XQ WJ=)_D,M1@W4K,-SNHN)2,
MXD')% *X9QR8?QG1@. D529E 5%^LZ7E-@46,H":!@',N!Y:?,2DJ3_, 1('
M]0F) Z]>OOC["MYV*,'^4D&">Q[$YCUQ[O""S]BNP$(=G9VI/, !*"W!^>>/
M^-H9TF'OV$QP#]M8:;IE0G<1WD''OB?F8K)+#@S /:")/P,'TXIQX^T5R5,0
MD=.1;M100!-)%ZW%8XF'@I2HB<%1,(]@+T<B/;C7JEQM7X5I)[2)^7/4584*
M'*5"/0Q\^*WVKZMHTI1I2N<[.TB>1\0C/CE3K!:-I,%#H*<_*FW]/5&BB9/^
M7J0;J>: >Y'' ]CCK#2/^L4<_P"D ,\2H'CL0" >W:LH_P#I4C_[D^_GKW$C
MW2>XC19107>8XDH=L[19*S\U"PH.7"J2""(J*+21%EEECII(HHK1B2RRISE(
MFB0YCF  $0VVGH#E^P@D@%20<3@GG$G'8 DYQQ6BUU]5OHEZZE.XH;60)"9A
M,Q)P)/4XJ#\'C!C0)JVH(NF#]RYD42K/&$DUEDS&,W0<*E,\:/'R"ASJ+ 94
MR:XEZPX$ .50 :PX'=:?(6MP(0EL%:2DP$A8,&(!+BN@)D$BLS[/65,>$&BI
MI+2W[ZY=(2K?QL:2"H<P&AC,$J@YIY:6Q*"YW(#P*0= @/<1ZP'CCL'T 1]_
ML'L/.M9<J]C;'.9]Q^OGT K?*]IY9/\ (=@&3@Y)Y$F2>><<1ES)A$%HZ*7Z
M>HR"KUB8> Y!,HH.T $??N=RZ$._RB \\<@&L5DPI8F![*I]<I( XX2.9ZD5
M:[$CTD? <'XDGXSTBJ'O%RQ\C%9:Q+E)HF1,<G8W-&S!B\"=W8L=2AX1=\L/
M8146@9"N-Q$>YO1"81XY ('KC0:U!TI!A9W#_P!R0L@C.!NB.-HCUKMOV<W9
M?TEZV62K[I<>S(.&WDR$\_UH<.)RKN157;,G $ 0^@F_<1_;MSR'/]/;GC6B
M</$GN3_?]:Z?;I$^F![O=^8GZ*RCDN?+_?[^_P!N?WY#G^H:UCIRHC_B?7TG
MWSBI):)P.YYQ,1';CU/]Z6C%'DP=O80YX ._ _3]NX?7M].^M1<*Y^//3G'R
M&9(]XZRJR3@=2,<<Q\_[^O$.! L7KYVU8LF*[IX]<(-&C=( ,HX=.%"HH()$
M)YBAU555")IE(01,<P%[B.M<\PR2E/WI#A40D(89?6X5*,)2$O(MTDDF,.1G
M!XK?VK[B$J6JV4VAI!6MRY>MVV4H;!4M:UMN/J2D)!5);P 21@P\&/\ -L71
M,\8WK[5VR-1:;<HTUDE43>J96&RB*L5.VD%40 SZ+@63Z2CZ8')DPCT5IINV
M:/K/+MCR:UL&;*W\IE16YN#CSI2$J<7M*8A)< 0TDE*$A:A)4X#+BA7-?$-[
M>^(4Z@7DEM-W8/6VG6P43]V2A2+E@;EI;/G7SC#:KK<A!RS;JE%LVJNAB6?+
M-')7)OXB8J^='LT@3.D<PCU)N5  0$@>:9-4I5"?)P42]1=9:2<<#GK,3$P.
M9].#.!7 E^RHS)).!')!)GY_GQ-?CU\Z*@"9RBB=?@XE$@BLJ)^>  @B(@4W
M6 @F0H !#%Y$>2G"@GCJ)Y^8$'Z)-54<?(#&<<".OZ^HK#326D0*BHL<6S;J
M15Y*0./,3 BY2"8"II%$$@3.J)NL.L@$]A,%?:Z^A$Q Z>D02,>Z>*I!5CID
M&!SCX^OR/:DK/UZ,55*2.5]&LV.FLR,FJ8OI1*) 3]$X0$5DE>D3B!T3F2'@
MG43R?, <BWN;BV<2\RM:'$S"T<GN%?RJ28RDB%#F1%8MS:6]PVIEU"5I6,H6
M) ,P%(,A25 DD*!!28@@9IX\4;BI:I21*9D5P$A'&\I-M.'* &(DN;H1^)%[
M%*!C )"NB 5(Q@X4*@8Z1#S[2M>:O0EJYVLW"O909AMU70)G\*R,;"8)_ 2?
M8'/]7T!VSWO6^YVW0"5 B7&1R2J,+1UWC*?YQ'M59GC[)JD(V:]*YYNI+E(9
M,B1@7>1)%!ZO,9&$PBX:!U<G9&'Y #J;F(;J36E;%R4':O*#\"GU';U'Z5$W
MF O(]E8^1]#^Q^?-2JC)9M)LDY"&D14:O$1\A\P7$A@ >W40X<&(JD</F25*
M D4+T+)\@8FM@I*7D8."#!'(/PX(/U!K"2I32S(SP01_?_;WBHM6;>!D+%%@
MDX/(&-[FO%1SQ5!M<VU*EI*K2C$I@,UD$9V#;_#FWJ4#$.9N\63<MU?-063\
MU$X!&W-31;W*[1U]CSVB-S:U)2X0H2A6V02%)@@@$9R:W*+=+K:74 A*Y@@D
MY&",@Y!.?GQ6_JWB*8.L!BHJ3,8BMR!5"EE$TE$S>PE,W<) 8IP'MTF6 0'L
M/WUDIOTD24B)Y2L'GCIQZ_  U8;50X)]Q']CV]*G%5K)&7"NP]GA5@<14XQ1
MD&"P&(<%&RX"*9P,F8Z9@$ ]R',4?H.LY"@M*5#A0!$^M8R@4DI/(,&M_JZJ
M4:4HTI1I2JG_ !@:\[=[;JM<&*8G7H>5*S*J& G4"+9X@^;"J;N %#UI&*(&
M'Y0.L01$. '6+> ^5N&2A25#X&?UBLBV/\2/ZDJ2?<H02?<":B)%.4GQ4'#0
MP*)/$A5:B' @HBY1\QN8..>04343$!^H#R'WUD?B"3[E?#G,^E>200HI]%I_
M(C]:K<C%EOC<.X4)(D03+8(\RC@#^B3=D=(F;-&G40>I)5F@+HJJ:@$ 2')Y
M12@4P[37"%6.FJB"%E,]3(*A/L@P-A&5&3!  ,5&_!!#/BG7DET[GK!2@WM,
M H=8$!1402=P482"((),$EU8)V9%ZV$@@)CJ)D 1^@'^4> X^I0$/?Z@(=^X
MZ=P!2(,?AF,9B#']H[?*>W*84TK$$J20>ZLSZ\?I3Y$4*C#2ZYA HJIM&"(_
M4RB[DCDX 'OQZ9FL!A#Z&X'@#<#K4Y<0.TJ/N V_JH1/:O)9]DSU@#WS/Z U
M6AXGM];5O:Y$TCY?B65,I12:)#\AU06/HU6;EG"7RB!C(3$Q64#@0P"4KP>H
M?\(&COB5X?\ 3,R2=JE$>]0Z3G*0,]..9KH7V:V:G=4NKR#LM;8ID3_J/J"4
MCME <.9$@ ^M #(G D  XX#GC[=OY\=@X_<=0YPX'OQSQGOVF*[PP)C\OR$]
MOT]U*Y@7DQ _/O\ < Y#[#]Q^OO]_IKG3DF.F8S'QGF  .A'$5(K,&# G@'(
MQ([D\2/='PI>QI $0]OJ ?Y>_P!P[<<]^_\ /6GN.O\ QV[XCZQ4KLA@8' [
M_/';KSP.]/9CU)JWE#S;Y!!TPJL9+VUTW=)D.R>J5Z.7D8V+?%/R46<Y,I1L
M&L \B8)("E 3F* X=DP+F_8;4 6T++KB3P4,I4YL,]'"D-Y!,K'NK/UJ]78Z
M+>/-**+AQ"+5A23"T.W:T6X=;Q^-A+AN /\ [1)P#$39-=^M)/'[]VX>23E^
MX?NW[I0ZKIR\67,Y5>.%CB915=RJ<7"BAS"<YU!4$1$=2I!A1"I49()/)DR#
M.9D?K)Z5!E)0[;-J:2E(2VD!"?9""@ ;0!&T((VB ,#%=#^R3-#;-.)8*J/%
MTV=HQM%1\.Z0.Y,JI+U\B/I8>92*<@&*+$P?!Y!$%%RI+MVSD5$B2";8EH.U
M:TQZQU(/J!U'NR?2N9^+='<MWV]3;)5:ZFMUPP(#-W,OL$S !42XW(3N05)@
M^65&;,H0'/HVC<G2U:J@4RCDRQ53%*@4YAZ%% X; 911< )TE.(B3GA3@]X.
M8@X@3F1QTF!F2.Q,Y@ 0Y0)CM@G,3$B<#/,&29 C@FHOX[WM[8[Q/SU<A,@L
MHVUQMI+2&\=<DT:R[L$H*OIFWZ:92*J:LDV=NR&8MR&1(_\ 4 1NJV;]34CK
M)79W#2 HME0VJ5*?:VIZE<$@0.^.3)@UY)N&5%0"H((3[0@&9XGU$=.W44_"
MSE)XHV;HHBX!$#"<2"=51TL83)%$P=14B@<3 *:8)EY%,#=0 / 8\0/Z2>,Q
MV/7/I'NF>:O*MQ B0,^\\=X ^ ^45]R$>B_0 K]J0P@J!FB7E)G% ZW3Y?2;
MJ(!%$^5.5C]1BID^4" 7DQ)CCKR22 1ZXP.@SSS-%(W#VAP?9D20<=,B1.?0
M>M:^@WRSXAGG 1HN7T,"X*/8E0AD4'J"@BHH[B#'^0'2'S$<H$X2<&*"Y?+.
MH8RDFTG75VNQFXERU,)!F5V^<0,RB.43(&4\;5176-!1=E;UN W<IDD$;6WQ
MT)/\J^A6.3&\00I-F^,\IL+2U96ZERB:$D1,"+H_18H"45X^2:#P8Q>HO0HD
MH4JJ*A0.04UDRF+/[>X!"'F5A;:A(4DRE0/_ !Z'!!A0('/GV%(4IE]LH4DP
MI*@0I*A[^")]T0<@R=QG/-TE"M:G;X-TXB'2BCBO6:*\PP%;OTB>NB7*!^ !
MRWD$ DR)J@4#@1@FDJ4#% 3<[^T'2V[A^RU1I)2MYM5M<%)@E;4+942""2I"
MG$S,I2TD=*F'A&]2TS=:?<!+S2%)?9"T!8VKE#B1(, $))'=PJB33#2.X>)N
M*2:%[J=*O"1  H)VZLP5B+P7CI "S3!X0 * B  !0  ]NP]^=H&I6YAB\NFA
MF-CK@$2)C('P SQD1$N-KHC\[[1A)5G^&/+G_P#YJ1GKUXD=9N_HYVJE*IZC
M%HU8,CU:OG9L62"39FR:FB6AF[1HV1*1%NU;I"1%!!(A$DDB$33*4I0 /HO3
MRI5A8J6HJ6JSMBM2C*E*+*"I2B<DDR2>IKC]VE";JY2V(0FX>2@<P@.*"1.>
M$@4J-9E8]&E*-*57'OLJ$9*7+;E:I)H@N6 NCQHBX7)YA6*K]U! 58I3#Y9#
MB!3"542B=/H$2F+W'4 \<7=U:N:&EIU;=N_>^7<!)(2J%LA 64YV^V<3! ,@
MQ7T%]A=CI%XSXY<NM/MKO5K+0C<:4\^CS%VQ\J\+ZK="I;2\?+; <"/-1CRU
MIDRBYARSCH"=4!1-($X&:$5!$I2D*6-<]1C"/8"%#D1Y[ '?VUJU!;C:PG<H
MJ;< $3E25"!&9)Q/7M-3>V"W+ZQ6\0EM%]9*6M:MJ$I%PTHJ4M1"4A(DDD@
M DP "(77W.\1*OH:/5F$)$B$  L6L:*3I!)NHZ]&10'#<QF_'4B"1Q45!<@H
ME25 3)E+KT?T75;BXM7'F5--"T3M+H#>V E1 ;)WGV2B/9S@2,"M]:>+? 6A
M)U!%IJS&HZ@YJ*/.1IJE7F];BG&QON$C[JA*'TN[P'R$D**$$J(,>(VX2LC+
MJG</%DRK&.1)!$PIID#D1 ORCW "E .>0X$?80U-TZ9:6["4H:2I0"2M:LDF
M )/8DY' KYO\1^-=?UO47W+B^>;:65;&&5J0TA <,(&V"=J0!D^\":6KE4YH
M)\LJ<RGG/H]J3J,)OFZ';DQ_FY[E*ET_00\W\ZJT$I<2  (2I6 !P4@8'OY]
M.#41?<<<E3CBW%2,K4I1,SG)G(&#!JJ;Q;)*,0P+@B"742-.3&5;G/1R AU+
M$A8.KQD7)J^W)4E)*8CB<<@54R(\<BF/3$?$CB3>-MC.QA)5TRI;A3^4?I76
M?LRLUH8O[XR$O*0PCLK8259]#@8.<](-%K(G<H  CP4/M]?E[<!WX /Z?747
M<.!Z FNPVX,CZY,C]/SI:1J?=/\ '<??ZB C]?Z>W[:UCI_%\!^@_.I)9C"
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MGE$@J'.8J94  54_G!4ZA3&!8_0*9R!T 4X%"J24F<8C'2.I Z'Y9/<@51:
MH1$D).8 DQ !G/(D_(\TH\29DL.*G2,9.E<.:P)RINV:AQ<N8 3<<G;G 3>J
MBN! Q2DZE6Q1Z1Y)U)HS/2/$&46MZO<@P&KE4R#T2\>W3S.F-XCVTPG6?#X.
MZYLD;5"5.VR8(QE2F1CI[11P9E$&0JSO'F2P9IH6.INT96$D 37D8E-<#(.R
M& .7+0P"(-GQ2?X%2%$JO!4UBG(!0+.&'RWD'<A72?9,CF?B#.:@[K(7(5A2
M9$P9!'3H<'H?7O6^W"Y.=0=2J62Z;*JDCUI0]<EDRF\M9!PY;*OV*3Q !ZFZ
MS51F^24$Q3%4%PB8AQ3.B=3G_P!HFE-W2;'561#@*K1Y2<*((+K.XC)VP\.3
M^-*<B*EG@^^2S]ZTZY0AQL[;AI+@"D@B&W0)! "@6OBDDB28BD^W!0MK*!+O
M4*3<PZ!(/ZJK,'.F%,0* EZI9BYX#@ X .![!P')=<R3_F5O_H7ETT!F$NN
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M":8*B@IZ50XE7*=4G40BI#@0$SD4#RU .8OEG*)3"4P\#D*U!A30*23*?Q
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M)O40Z9J.2X'Y"/$?*D4TR"4A3(/E>ZBQQ-//#=Z5!5LM7XTE;22<>8!#J)'
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ML<$$#= ]"8&-T@!@*403_P /D)F*<Z*70@993R@4/H[H(4XLID))P#G'2,#
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MWI-W:ZK;E"+E2UH(4@%MS>TI"G"E40H)(28$*W3_ "TKU=OV\^(())/!F,+
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M<B**<]?>6^LK7W 2D8 !@1T!D\]/0# Y-IFEL:7:-VS4J,;G7" DK6<DP.$
MGV$DDQDDDDTS")1*( '_ /SV_G[\:Q5'H".O![F3TB)X]V:V 3!P<"<>I_:(
MI3,%.D2\#W 0Y^_T#]^P<_C7@YF!Z''OBLED$&3P3\)YY]X'6<4X$2_.B(%
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M"CS]&HV]ZV+764./("0AF_; -[:C( 7)B[93CV'#O2" VL0$G[,;<4PL.,D
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MP#[#P'<.P^X?7]_Y>WVUXN08'Q_L9Z'GBO5$H)(Q!]/S'!$$2"(/!%*=F=0
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MV%A<ZPU0@W%0D)B,24>RYV$Z6+QU>'%[0I=RE(AQ3A#*RV$I9O'AY#A4D/.
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MVC)DS;$2;M6C5!--%NW033112(1-,A2% H=# "0$I 2E( 2D    0  ,  8
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MGVQKFLJ:E%J6&,L9"< XD+#'M"RE,JSB8B3/E*H(61RR*Z2*+AC#\O7:?*2
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M(N+5,C()S#0OL_O'W$OZNK[K:@R+=M0-R^G$20(MTJZ[MSN2/+;)W5P[QO\
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M4R+9J(5A*O96=B(1E5YU"RNZJD^31&#D63X?-8+HII]<'\Z;3V]..)_2:;/
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MXGPA=J*9ND;4X \E1 !S !N#M@]$D#/7(K.'VQW" X4:7;)6ZK<XL..!2E0
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MS[N:M%P-X"U#KCAG*9+?H/UD!3.=NMTO53"4 #H5*HYE6CE,0#LJR3K#U,1
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MDC@Q7BE%QB)NI&.8)&_YDF;=,W]2I@.D#L/D*K)B),=NE9P        >P '
M!^P!JM4K]TI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4H
MTI1I2OP0 ?< ']PYTI0!2A[% /V  TI7[I2C2E&E*-*4:4HTI1I2C2E&E*-*
M4:4HTI1I2C2E&E*0.5<GT;">,[_F')TY^F<<XNIUCO\ >K$,;+S 052J<2ZG
M+!+#$P#"5G)+X?%LG+KT,1&/Y)UY7DLV;AP=-(RJ@$D <DP/>:8;#6^3;=GB
M\-\:46RWV+OTA6Y*WP=3RS@?/F 9FU5F&7C&TU,TMKG?&..!NS.$5F8GXT>I
MC,GB$I)DXD2-F[E)4RJE)',? @_.":EOI5M&E*;Z]Y3H>,WN/(^[SP0CS*V0
M8[%E!1&,F)'X_?)6 LEG80(*1,>^2C!7@ZC87WQ.9/'PZ01XMEI!-VZ9-W*J
M@$S'03\*VM%NU?R/48"\U5255KMF8)R<0I.5NR5"6.T5.<A#/ZS;XF"LT,N)
MDS=3*9B(]Z0.DQVY2F*(JI2LTI3&[C=R6%=I6)9_.FX.ZEQ]BNKOJY&SMJ/
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M"B)DS'3,4Y0. "8ABF !*(#I2OQ)9%<HG0626(!U$A.DH10H*)',DJF)B"(
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M?+^?$4;4^+ V&"7D\JP,2WB!A7LHH[G(=N[:ND$B*&CUT:#@3S%%$#(B=V,
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M98Q_&RM9L>\#*$)N!DL86)LA7GR4:-,E$86_W*FK(),@BU$).434@B&;4/\
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MYJ>?(S$-<6W/;^;-,54<@T/"MVNM@K<_B8]6G\<7S-&&\E8>R98Z8@\GD_\
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M@&V!L?[IF-HFK_,UVJ6-6E5A^.2(./@KJSA;&6KRXM))] OCMV41)JH"(@]
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M2<Z4Z!I]%L;>+<1M3!C7L 6NQSF1[H23K;-_+P<.2%,T0GYN'K2  "3R8]V
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MMK8JM79V,L];EHB6AY:&CY"*=,G3<BH*2<9X$#W=O=FF;JFSG8]?JR]94*G
MNQJ63,L,)>TT?*&7*S=DLE/5H6AYSBIW)M<O$/D"=<6F2Q["1668F6L\E$W>
M?JZ#^XM9J;:'>Z4D_IT^(QZ3CL#C%24QYA&DXMLL_.TANX@(J7HF*L<1E&C3
ME9T6H57#S.SQU29U*N(D*S@SA'6A6+?^A!%JO%PE;9D:(C%&6<J3/YGY]Z3-
M@VJ8#LU"88UDJ"1M5H?)-MS%7AK]EN%2LU3RG>[9<;O;K_3+Y5;!#7NF6F=L
MF0KRZ=R]5LD0Z*RM<Y"('1@I!>-.I)F9Z1\(B/E2/D=BFT^4KU;JCO#T2$!5
MJ'E;&4?'M)^Y1Q9"CYR5%WEV#MKB.L;5W>RY F#'L]CD+NXL,J\N9SW8'R=M
M.>:%23WY@_+CW1TBG,7V[85=)';NL?0SENIEQWGA5NX5D5D%LM/VKID]N:R*
MKXR2SUTT>NFZS%4IX<Z2YRC'<"'"DG\H^%(?$FS+;;@RTP-VQECQQ!VFITB6
MQC49B2O.1;>O4,8S+ZMR3K&513NEML+:K8W:OZC7'<)08!".J-;6BTCUZ'BQ
M5<^<H23\YX SGM[S6TG=I.WFRY4+F>:QRU>7X;%5[F^7"P6UK5)V\T=HR84C
M(%JQNSGV^-[=D.E,HN(:T^_6>IR]PJZ$+")P4VP+"Q8-%)/UZ\B>8,G'%.Q1
ML=4G&M2;42CUYE 5%HZL#U""0,X<LR.;5.RMFL*AO7KNUE E)V;E9!PFJJ=(
M%'JJ:1$T 32(JGU\JCM";"MI-?@+M58[#L:>MWZ@/\3R\)*V:\3\="8LDW2;
M]WC/'#:=L\DGB+'PR+=E)H4O%(4RMLI2,AY-E&-W\-%.&:JR?WZ<]SW^-.1&
M[9\'Q4*: ;45!:.5R90\RNOB<Y9YJ0?Y2QE'T>+I%YDYF8FW\S*3\*RQO22"
M[D7[H)-:!1=S!)!VZD%W:J3_ &^OG3<(["]I2(WHG]CT>XCLAT[)V/IRO/[1
M>I*HQ-+S2"H9:KN/*9(6AS5,2Q^1A64/<28KAJ:I/*B59^HLJ1,Y55DX,Y!F
M>LCCWQTGBI<HI)H))((E B2*9$DB!R($33*!"% 1$1$"E  #D1'MW$1TJE>F
ME*-*4:4IA'C# E@SK=*K)Q,-,YIG,"5QA>(N4B)=^A,X$D;A?HZ"B97US56F
MR,,[M;B^-UXCK6EU2.G7Q1J,4Y8BHJN8])Q[\?'M3?PFP[:C U>W4]IBDKZ%
MNL33H"6/9+MD:WSL=7\<S1K+CBOTNUVRWS5JQS 8WLQOU+CJ$Q]-5B+H=C31
MGJDTAY9!%XFI)^@.O/OGUI+Q>S+9W(I6'&$7C*S,GE/R2WS),V!.TYYKUM<9
M-O=":TR4N;+.2EFC;9<9FWT6%0K^2#0]_G$IY'SFF14'4E*N0>(_O]?7&*2?
M3B.!Q/:E(_V#[19"(I5>-A>&85R@U9.A0E;@IZY5NMR./4+ [M37'%WK]>L<
M9#Y,QNRL<A(S+#'N1V5KIC!](R*S.#0%^\!923W_ '^/O]>:5!MG6VA6<N%@
M>8E@95W?9'),K;F$V]GIVLS#S,< UK.5A4ITQ+/JBU;9$AF:+>X,&,(U83S@
M[J2D&R\F^>O'"DGN>GY<?+IVIDK/BW8_M=?8YA+%39\UERQE;'YJ0X<$SKG>
M^25MPLA*VZB/).SJNLAV^MXOPI'FG)]JM9Y>(P]C&-?2CA<L*VEW!7BJRHR>
MP,\ 9P>P)./4QUBI/8WJ^&+'C^9LV-8^(E,?;C2*Y8EY6,7D5([(:64*M#D4
MM?6Z7!PDE9JLC#])6Q6)"M2HF3;MUC*"*J9'P_*M(PVK[?HRLS5-88SAFU9L
M4GB&9FH@CR;%"0D\",Z)'XA=JJ'E#."'H[/&5$0C2I+)IN25QH,F1\99X9RI
M)^O7FD[=,0;:-X+&-MDXS&\DI4MEK%;2VTJ]7^@3#-6(N3C'V:L92%DQU9:A
M.2]67NV.CUZ^4:6?2%1G96HM@E8J0&-9JIJ21\>X_O[\'GM6CMNPK:=<Y6)G
M)/$Y(F7@9E*P04A1KMD;&;F$ED,8U#"[=S#J8YM]5&,3;8JH=4HC5HQ\ADVK
MT69D@W3"0E#/5)/_ " >L]?6DWD7:=LMB'- D\FU4I%GTE0,1P8V3)657R64
M'K:SR,]C:AY/8KW-RWSJVB+-(RTK5XC,+:\L(%1S).62;%H+HP*2?WX&./3'
M2I#Y=P5B[.D=7X_)5>=R:M2FSV.H3\!:+=0;K3YU6,?PCJ4J-^Q_/5>[U9W(
M0DI)0DHI 6"/^*PT@]B9('4>Z7;'4!(^N??WKRQ_@##6*G==?8YQ[ T]S5,?
M)XLKYH5-RV3CJ&2=4M!X(C?U)VR_JK&NXG9"3=)+S,G*N73Z0D73ETX4452M
M(OMGP07)TKFYQ16I,AR5RK&396Q&G;,FS5OE(QK.XAK]W4KP39:LC9(_%MAD
MZ0YFTH9-])UPD4QEUWQ*_ C&*K)^OG^M-2VVM[.=P- I%[K]0:3M+NS>\Y:I
M=YH-XR-1I&SP.Z"63RKD1T2V4FU5BT2=%S'*RS2U6FCR4BK3+ <8WXA7#I1S
M!!JCZ_/_ )[TR)!]QGTQ^5/O<<$8AON,([#-EH<(MC.#;U5O6JK$E=5AM3_T
M(O'NJ,[I#ZL.8>6I$I2G43%N:C,U.0AI:LN8]FO"/6*K9(Y5),SU_OS\^O>D
M.3:!ML_LXC,3O,40<U1HO)<)F4L=9GL]:I65RQ7[*RM\;D:T6RRRTK;KC<33
MT>S<2<_;)V:D9QFD,/.+R,,JK'J*2>_2/AVK[N^T;;OD7(Z65[CCE"6N8O:;
M)RRB=DN,56;?*XY?IRF/9;(E AK#'T#)<O0Y!%L\I<KD&LV60JR[-@>"<L!8
M,_(4DCZ^H^%>=@VA[>[)7:I6'5%=Q,?1KSD#)%.?TR\Y#Q]::U<<K3EHL>2Y
M.&N]$ME<N;%K?)>Z6=>UP:,^6 FV\LK'/XM:-0:-&ZDGZ]! QQ6O@ME&UFL0
MD%6Z_AJM0\!6?@P5Z(8N9U"/A4J]G)MN4@FT:V++>6T91&;F32^QS%(I6;1Z
MV0BD4"5],D2"DGO_ '[<\\5*32J4:4HTI1I2N;ZH;9]P,>S<0^W3"N5L";J6
MV5?$KLV1,_VU0(6C7/'.76.[8VW*'0M?ZA?,;BQ>9BONW/(=,J#>.(YQ@G0K
M58I%A7QD!6O"KR1U((A(CMQ)]^#)]?DG*/M2SU+XYL=7A*!F&J5JP2WAZP64
M*6SQ7,[>DY^<JN^7"%LS79W<DIN'R?:LAY#I^%XC(JN3\[U5Q&15^K<FU,G=
M[W(PS1*!561,S_5R9Y28Z1$Q DQD$4ZF6-N&X;&2VY*#P$T?8(QM5,I;Q;%@
M2V.K*C3<3X@JUV\*[%$;6[JTE'\HG$47'T;NP<Y-E3/3IMH6KV].R3I6;5LF
M=915)!VSG !CDG>>O?;&?A3/FQ9%Y,R]>L3[>]NV:<,4IU1/"CGLCXV?V<L,
M]?UU;Q G,MF:[E+3<BV#RSR6(:;;D[MDYI+L97*S"JS4^RD+.R;,[#**J(C,
M?S08_P"W X[E/J,<$8MYVNX<L&'8?>QCR(J$A2\;'W$621VZ55N=1*O,,<V#
M;7@-V_2Q]'^I51A*NXS6ME=5&)9$8L6EB5GC,V;=%4HG58>G>,_,\_"*JK<[
M+]S-!VZ8JA\!T:^TO)MY\,ZA0FYEPUGY12R7[.-7RCM-F;Q6[6\D+[659O,D
MYB4VY:E5B26N=8? A*NJRSN]9B6\4YBU7 B221&[$^Y70 GF)@>O-.!1<+[D
M,6XZO>>\'XVOLQ-X6SMCW)&&-O".*1VQUG(]>D<<R6)]PE:H^(+%EO(,G4HB
MQUN[DM1&5E<4V)L.7\31EOA8),9AS;YQ20<<2()Y/,B<"2/C@Q/;RS/@_<M@
MO$^Y_$=9H6<,[W'/7A8TK"5/O>-R%E8R2W;QT]O0L^<K189)]8(LF/7-FL.X
M2K7>$DG8-"3S5HXJ]96?V""AX%S3I\.F/E202.![1)'0#'7X1GWGK3L4K$&7
M:MXCYLA16*;K8HJQ9JR!(7:YY%HTQ$2=)QA*8>GHZ$LE(W/4C*T?3LGXC=3Z
M-<KE9VI9,Q3;+%1[!,!:FAZRZH<=;!K5)$1\>^9[1@QV/$5=QI5M&E*-*4:4
MHTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4JJ'>OC-[:,ZH6')^!LK[C<)K[:
MK%4L55;%Z2TPI0]R*]N?/7EC=1;:P0:E-M]MJJU0C,=9N<BWCL8+U6T@ZN%'
M"PD<3BKAQS!GYC]_4=1WC#"X9PGF>KY!KA]V6$LNY^W1DLNRQ[C3<'4K2^CJ
M50Z92L'X K6>TG&4F$RBTH\1%YLK>XK(.3<;.X\JFXR&N\1 IQUK9V,&=554
MD9VD 0J1'J8P9S!$'D1Z28]RN*=UV0-MV(,(+8%SPSM&"_"YW-;<<ER-L9M$
M("[[A):T;,(ZLQ=1D#6)Z:__ !2,Q3D&PP5X20/ OHB3,C'32LN:R1<6ICTR
MM)'H/:GICICT[0:=26Q3N*F-\E5R='X*L54D:_O<LZ]KN,-CFWR$^^VX.J?>
MZ17K-8=T%JS9)1-RQG>&3RHRK7;OC3%D9#8F=N@2LD>T>U12PR:DB")Z=3@Y
M!P(Y&<DYZ=JEGMEVQS6*?"CAL5(4G)E9SUD'9G$#F%C4KDA#9YEMP-@V]Q%:
MMZT/?KG*NXN"RDSGVP0U5EIB41K=9EHR((*K*&C^I)5"05G(C<8ZB)[=O05
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:4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g209588g10b55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g10b55.jpg
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M,ZBD(2XQ8G;I";NSR%H+B"W;U/"4OC;"G$!+1*VTJ<2"A*E"P-Q;EFZN)Z]
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M) +>6%D)="%$"KZYPM=DJ/=I;*KVHZ07O5E1/D0!F84:.-$QTS#!DJ4FL#1
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M8GKC#6'%(7AI^6XTR]E"_"6ONJ[.*DZ5U/"DPH<O3U[C2[D<6^,_:YK3\Y0
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M>6.%;CKJEO.D\;BU*5Q'\=[_ 'Z^:FNDB]ZBN,VZW.>HNNS9SBG''$\:@$M
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M')D0Y".7(BOO1GVR<E#S#BFG4$C8\*T*&1X5^M4&;&N,*'<(;@>B3XL>;%=
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MG,=['BY5A3F5<U7;M'LTJ?V@R@N7/8O=_P!&72R1)33G*>C6"<7YK+P<*TQ
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M&59PG&<Y]F,YSC&.WVYQCD@ D G ) )W.!WG W..NV]020"0.(@$@ @$D#8
MG &>F20/&M>U3USU$'KSL2W;9US6YARXU2ZU*L6=G9D:8/UK5R(.?@-5JQ36
MP&$9=+%TPF+)9'C&)\U+N92D,QV9$27[E<[]H2%9;%:],7^X-0[5<K1<[C;E
MZ><:?U!<6)C/Q=RN-U,TJX8L4O+M\!,3D,\(;!6XI#K?RW9=)]JESU%JN^:W
MTG:9%RO]DU#8[/>&]7LOQM)6>5;90M]EL]A1; DJFSOAV[M=G)XDR LOJ#;2
M'6'_ )F^E2ZO5S6=>B, *R^,Z4;]IVUEH,EA.8]UM8L,S'><Q"93)*CEDVBL
MJ=,:[ZU8??<2G+TK.<[5=I5H1/U#.<<FW!$GM+LFJK;%>;6>9:+;(EK<0"\H
MMQGQ'7&;9:5@#EH2<(; K4GL5U Y:M(6QAJV6=V'V*:FT'>YT=UL%K4-ZA0&
MVG%B.V'9L54Q,UZ3(1E1#KJT_P"H]DW9I;4>T1&VZ!=[;KVF4,-3-!O:BD-U
MVQQ#4TN6@&*_*C%W&H@H<W&%SF(4UP=$4[-EP,8=Q.D8=E(;1QFK=4:<E:7O
MEGME]NUZEW;6J-3MF? =B,Q8KT:<VY%2IR2^5R&5O-)?="66GCP\E!2V5*YO
ML^T-K*#KC3.HKYI:P::@:?[,W-#.IM5V8N$B?-BSK8\S.4AB%$2U#DML2%Q6
M%+D/1@%B0X%NI0+:V_T_V6R[[M^PY>A:5NZKG:E4 P9BR[&32GP1 (B=@G(;
M92#-+DXF8DL-?5I8PE,?"DJ7W\X3?TMKBWV_1-JL36M;OI"XPKG=9<M=NL)N
MR)C$PL_#H4LS(B6^5RUJV*R2O! QOQ&N^S"[W?M,ONJ7^S33_:)9[C8[%;X#
M=WU6-/.6Z5;TR?C'4-IM\]3P?#K2/O!L)#605<1 ^/<73YM#:!/5)X'KG7E/
M9TQ4*\\-J!,_D_#NA*#8*_-^A63*Q8T!&:,!%@_'@$B0]?F3SR<(&LQ7'YV-
MVE=<Z<TY'U+"EWZ^756K+I.0_=&(/P3MICO09S/]R1XSBWC]L39,SEO1X[Z>
M"$DYD+<"&JT:\[+M9:REZ+N5OTGI:Q(T!8K6Y$L4RY_:;&H)<>YVR1_9DR:R
MU&!TY;85NYD>7,C*YUR<'#$;96[(J/;C1+YM/:G6=2ZOKNI$I]Z3HD&2L=D/
MPX<S7+J]= R#DS#2!9%PW'AY0\\UZDFL24%8,5Y+,MAU#L;G;7>K+IS3?9-=
MKE?KI'8LQUE-CP($%UYJ_I3?IC"6BHR6$Q''04(7\8TM!C/N(*VUI4E?5K]I
MK4FL]9]O^G[/I2R3).I!V;VV5=;M<X\=_2BSI6W2E/\  (<I5P:8PXXC[.?;
M=$R,RL-OMK2IJ^;AT_[S/;*@D78 8B KV\-7;!&&X!RM5V&3J5/6%:FJ+@8E
M819+#L3NQ9KLLW9+0_ S#[D(2E"6X[*N'M6N=&PK \PE^6Q-G:/U'9)$-Z'<
M)SL>Z742ULB+-=N)@0;$"ZTEJ) MR7P]Q/22>):QV.^=F':/<=71Y2XT&5:[
M7VB:.U1#N,:XV>UL3+)8E6Y$@SK8Q:$7:Z:JPS(6_<;M>%QE, 1X02$M-FY!
MO3;=(,*GNH#5]DT+ZTR^[C$]J9$3*<U]-FV=33OG$M8>D3EQ)PAM8GO]_&&D
MH5V^7QV<?)[0+0\]=DF7.7$D]DD71\5E3+I:3?&6K<%)Y15PH9#C,HIDXQE9
M(_'7+0^R74$:/8EBWVM%PA_U!3NT.=)1(8#Z]+R'[NI#G/" X[(+,F"E4$JX
MAP '_P!H5;]1Z>-QUS9+TD4-B5ZD-R=K2)X\A<Q=UJC[%T@&4CL:T&%JPW=J
M&3*%"$279_&L+8]>&IJ4NSHS_DG;MTUUI2?8$MR7W9UX4UIIMA]BTR;1<T+M
M+T0R#J"1%N*K/>H\:,PZS;^""I\<3)*67$<Y/&6/LLU[:M6K=A1&+5IU#VM7
M9,65?X>H;(XUJ"-<!$&D8<VT)U#IJ9,F2F'[QS+HB,K@D *DLN?#+^01T\;=
MI$"@DH]!HVSYK73=&T>=J]CLL4='J)MHI/(N'Q\R6))P2@.>U/S#,PX:(Q5_
M$5M3#SC2O"QME:[TO>'KW'7>[QIUE6OW-8P[C MSDA=TAKCLL)A2&FI49Z/,
M84P'8KKI<C(YA"TA0XJT0NRS76G8^F)C.F=.:PD([)6>SFY6>[7=B*U8[BB9
M(EKN<9]^%+CS;;)1)Y$^/'2U,<#*2VXI"@@583THW,/"/"YZ0-I<3T8-Z-"&
M9DAI2E7OS=FDN1XJ)S.9,$*Q@D-CP2+B6EIB1F,+::6RIM-65VEVF6]!DLF;
M;4GM:5K&9$:;6 ++RK<VEQQ3*N6]+7\/(<>825 NN+(4H*"C>A=BFH(,>Y0I
M*;;>E)_I_'9S;Y\AQM15J4R+P^IIE,ELNQK>T)<1J/+6$$,,MA2$J;*1FQJX
M"2JNL]=U@REM)>MT6H@2J67L2&4D@X >/G):?3]2^WB5'=PA['L<3C"\>Q7/
M(=1S8]RU#?KC$*C%GWFZ38Q6@H48\J<^^R5(.Z%%MQ.4'=)R#TKZ%T=;)=ET
MCI6SSPA,ZTZ;L=LFAM8=;$N!;(L62$.#9Q >:6$K&RTX4.M7USAJ[)3BE.*4
MXI4.W_J T[JT\.K-]O(ZNFR<5B>S#?B%I:8H^5,]7QB1F6-'S(5?&OS<*C,D
M3LD="<=0XE#^?#<RGM=DT1JK4<)^XV6SOSH<=Q;*G4.QFBZ^VUSW(\1J0^T]
M.D-LX<6Q";?=2DI*D#B3GH6I^T_0>C;E$L^IM1Q+5<9C+<EN.XS-?#$5Y_X5
MF7/?B19$>UQ'9 ++<JY.Q(ZUI4$N'@5B84J2M*5H4E:%)PI*DYPI*DJQVI4E
M6.W&4YQG&<9QG.,XSVX]G.JD$$@@@@D$$8((V((.X(/45WP$* 4D@I(!!!!!
M!&001L01N"-B*\\BIKU,L,QT>&PRTPWWE*[C+:&D=Y6>U2NZC"4]Y6?:K/9V
MYS[<YYDM:W#Q.+4M6 .):BHX&P&5$G &P'0=U8-MMM)X6FT-IR3PMI2A.2<D
MX2 ,D[DXR3UKV\QK.G%*<4IQ2G%*<4IQ2G%*<4KQG.,>W.<8QVXQVYSV>W.<
M8QCV_LYSG&,8_9SG&,>W/%*L:+LRB3;L=US$LL"1<JR!C66PAFL2%9#!I;W@
M,2")##'JN*^I64.J'NS4D6HCT>:[$1#D,/N<RYIZ\LVB%?G;>\BU7&:Y;X$I
M7 /BY;2.-:([''\0Z@#*0^EHL*=2ME+BG6UH3UMG5^FW]17'2C-VC.7^T6QJ
M\72 D.GX"WON<MMV5*Y?P;+A)2LQ5R!*0PMJ0ME+#K;BK2H'4-IG:-@EU>AW
ML<?.Q(<@AY)N$8@)GCXDKR4D@$EE1L&#8($>3V-/3 4DC&;SG"E.X1G"N<I>
M]"ZLTY!:N-ZLS\*&XZA@O%Z(^6'W&^:VQ,:C2'GH+ZV_OI9F-L.*&P3G:N#T
MQVIZ UE<W[-IK4D6YW)AAV5\.F//C"3%9>Y#TJWOS8D:/<XS3Q"''[<[*:2<
M$K"2"9GYU*O0*<4KQG.,>W.<8Q[,=N<]GMSGLQC_ (YSC&/V\^SBE>>*4XI7
MCLQC.<XQC&<_#GL]N>SV8[?V^S')R3@$D@=!GIZ>%1@#)  )ZG'7U\:\\BII
MQ2G%*<4IQ2L*-G^C_P"G/:!R59) 0W3#!!]<HF_0RD8/%(RG596[)>$D!AD/
M'?>5G*WW!T"$J0ZI;\CQ7W''5>O:=[;]>Z<AM6]N9#NT5A ;CHO49R4XPVD8
M2VB2Q(B2G$( "4)??>"$@(1PH 2/GO6/],793K&Y/79VWW&P3I3BGICFFIC,
M!F4\LE2W7(4J'/@M..*)4ZJ+&CEU94XYQN*4LR3I/I2TKH)UTA1*TXY8Y#"H
MK]LL,M1FQ9BKQC#D:-)6VQ#&,O8QV26Q$$?B7C"4R_'2VWA'7]7]I>KM;I2Q
M>K@E,!M8<1;(+0B0 X-TN.-A2W9"T?\ Y:I3SY:W+? 5*)[9V>=BG9]V9+7*
MTW:5KNKC:F7+W='S/NI97CC:9>4AMB&VX!AU,&-%#X #W,"4A.1W.@UZQ3BE
M.*4XI3BE.*4XI3BE.*5+0+ZT0?O/\]?%*JW%*L:Y_".^Y+_/&XI6.^[-BYU)
MJ>^['1!03?J5>F$H0]U2T,3".<HBC6)*V\X<1$<GR(V):VLX=1&\53?U>$\[
M'I"PC4^IK)8"\8Z+G/:CNOI *VF-W)"VPK[I=#*'.4%?=+G"%;$UTSM#U6=#
MZ(U-JQ,=,MVR6M^7'C+*DMORR4L0VWE(PM+"I3K(?4@\:6>,I^\!474*%U%U
M^?7K;L3:%%N%")UB>;OHMRIHJ,RC2DBVR<+W&3Q&"*K$-8?4[#(YL[T1](^,
MJ>P\Y*>1#;['>WM!SF)]LL.G;S:[W'N+$2RR1<S=&KPT9*H[WVLS)Y @2%H"
M'6!;TNH+[@96D-H+JNG:9C]JMKDVJ^:JUCIN^Z9EV>3<=30U61-D?TZ\(29D
M<Z?E01*-UB-.E;$HW=QAP16C*:<4\XEA%"@=6(FR0XZ(U*O-,:O=/N]BT[;;
M1!!>I;Q[D04LP^Y'BP3)(B(?7!8]<#8=A'P?6@MM3S><+6U'=NO]F<JWNN*<
MN]FNR[+=;1!U5:[<]-^+L_VG,:BH2XZ]%CL2D!Y?PLAV"^]\/(5P*V2I:>-C
M=ML&[,-I9T]J.P-ZDL.HKKH.^7F/;?L_47V%;7Y[JFF(T^7*@N*CM_'Q&+I%
MC_&0TEQ.%*0TNBZ;ZL&RM4I2=KUZRUDD5TQ.VHY>",2O-URTCJE!AOW0B,'
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MM],>;+8>4RM;3J$.X1E"E-N)2K.4*QCRZ+:+K.;+T*V7"8R%ELNQ84F0V%I
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M]&;5ZHR6MM1U/>EDJD_JZMU5T;6[-#AJZ7]#;CHFLC9HUKJ/H()-L]QV3L;
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MR&T/$J_Z0&U*)/=UKZ_O\F7#L-[EP$E<Z+:+E)A(">(KEL0WG8R0D@\14\E
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MG%*D*G_K*5^%?T+?%*N[BE6]:/K0]]]8_28XI48<4K5!K(/H0[K1C;N\K3.
M;YSN NS9;0*/E<;,KMTB;%FB0%.#AX*2Q%D3@*T+AJK\0%(AM!)$N6AF,AC$
MN)],ZAE:UA:@7I?1MM9FZ+_M6*JWVZ3"C?V_/M+EA:E3;K*E/&,PJ5\6N2Z)
MKLU#JI:&FRIPKY3GQ-I"!V9W+2*-<]HUYDVSM*.NYS=WO,.Y3?[OM6H&-52(
M5LL4"!&3-EM0A;T0V#;&+:ZPBWNOO);92V'F))NO4AM,3/VS=QE@I<*OZDW,
M%U4QI::"\Q<+Z.ED:X.DG8Q[)E@A#)F<'91*KL0 T@?F$(D8EM3<LR7,]?M&
M@=-RF-,V>1!N[T[4^DYFI5ZM9F\%JLK[3$^0U#<A"(MAZ/$^#;CW);TM#X>D
MH+9:XD)KMNH>UG6D&5K;44.Z:?CVO0^O[?HIKL^D6WFWW4T5^5:HCUR9N1GM
MRX\R<+D]+L[<:WN1#'@.\Y,@-O+/R'-Y;]6?,2P5LID$*SU?*Z:100E1W"*F
MQIJ)&5$LQ$FP?'R)3X)<V,Y$&Q6X/GW&I/K">XR\RPQLAZ.T2F%$;F6R[/RU
M]EH[0),R/>$QP9$1QP.V]B.N$^VVB8&G$N2'%/<@*;Y# 4A:G-5Q[1NTU5SG
MO6V]V"/ ;[=/_22%;I>G52BF)<6&2Q=Y<QJYQ77G+8J0TMB(PB-\2M#OQ4E;
M:VVVS/4!N=7N:IKMQID$^[U1;&T&4O)2J-MP9H:M@DSQ1S-?;,Q8L8XY)EM-
M18+!)N'*F-0HKZG4//J>*T/I+_ZC=46J[/0D=G-AUK&LT>YJ+S,N?-+$F)\:
M8CCCD0-M*6XZN.IUMI3KB.$H0$PCM.[0#]D6!=^L$:Z+[8]5=F<S4<RRH3'D
M6^U6T285Q^S$SFF6KBIY]"&8[<I$=Y]$=EPJ2XZ5VHSMRV6?8&D"]JR/M1S4
M^Y>JBD8,UN'D7!O\>C:AGS81> /1(GL0GRB)*1[S$21*B(GQGLQU*1G#:>37
MI>V6ZQZPBVT/VV'J;279O=S#GN_$/V5=XU3'9>BO/*0RMU$=39?0MU#;I9<2
M%@$9/"-ZZO5WU1V=SKT8UZN.B->]M&GOM"TQ_@XVIVM.:%DR8TZ-&2Y):8=F
M)>3%<;8=>83*9<+1*2$BFC>H7?%[UA?9<XU &LVKISV#LL46'"ZP!)TPD"BJ
MEXAU)D5L0M:#8.8-S/!ILY06,+URR,PY[F/%0H;FR_H715FU%96F8KTA=MU[
M9-/28K\FXS8]VCS70T7;FN38HUNAS&9')F&W1Y,B+/@*=9!X5!\5(G:EVE:D
MT?J5Z1<(T1%Z[*M3ZNASHL*T6R78)5M9+PCV-$+5,V\7&W/Q/BK<+Q,APYUI
MNS;$E0YB3$KV.]0&[*I7M?4VKGA1*16>FZK;2E6"77*RN#:Y)*1*BCP]AG63
M8-=CU^K@H,&*!.VD5*)&'C.9!.5$B86F%S!.A](W.=?+M<84F.BXZ^N6G&H+
M<^XA^V-1VVW'Y<)F!8IRYUQFO/.385NDMQHB8O!';==P7JS<[3^T*RVS2]AL
M]SA2W+/V36;63]T>M%H5&O;\MUYF+ NDFZZHM;=LLUNCQF;9<KS"?E3UW#FR
MWF6>(1QXZBMP;#OU'ZDP[UAJ5"K-!UWK),BCDAT4L:M\O95>&6">_'LC1J/Y
M3(N5.P( NAXQ. 3EQ,YE84AW.<3H/2MBLEX[/Y28%TO5QO5]U 47F,^Y&AVM
MO3\^1!80Y;U1'.9\0VS\3-3*<CO1VGARR%)%1VJZ[U3J;3O:W!<NMDTS9],Z
M6T>'-.2XK,ZX7U_5UKAW.4XU=T3V>3\$]($&VN0&9<:6\R2\DI76T*N?YO O
M]S"_XDQSYSG_ /WTW_\ 5R?_ .Y=?8UI_P#PJV?_ +?#_P#\S5:3_2>FY9K>
M>J-?&#/J"FQ*B-++)2(\N7"&2+3:RX@X??@PDKDSD#1H""O,>,V[+4B/(9C)
M[\GNK^O?Z=(3431VI+Y%BB9=7KJ_%#"%MM//MVZVQ9,2$EYTA#)?D37AQK*6
M@5H4LX;R/SU_K$N4B?VBZ,TQ-G&W6*/8HLXR76WGH\5Z\WF="N%R<88"G9"8
ML2V1B6VTK>*6W4-)XG<*AD?T+GZ[;BYG:UN#U_IPJXH=;YV]0K[4\!=JF54M
M8*%KI./'68M]D\/,)D*EJ2Z&DKP]*:FMOAVC?>'^UJ'-ML:+IZW29FM[A(>M
MK.DY2%,S+5<8X EO7H_<$:VP<\U4DE"92 4-J:*)*HOE\;L!N5MO,R=JZ\0K
M=V96F)&O4CM @NHD6Z^V>62JWL:: +BIEZN?#\.W!X'50G5!QU,A#D)$_P"_
MI<V%6V^N*LS]-52;0]=6J<0J42H/EIYF6Y6/<RZUF4:G394MYZ?+)B8MNGL(
MDNPX!).8L1QR'&;6OC^TNQS5]D%R:U1<&KO>[:U'N:[DF.S&;3<!<$$-Q6FF
MVTI:1'DN6UI90EQYE0<< =60.7[%=3VUK^H:RR-$6A_3VFKU(EV1NR+F29SR
M[0JTN)+L^0^\\XN0[,A,7J0VEU;$>4CE,J4PTDJZ(.?!]?JG3BE.*4XI7,)U
MW]<W5=JCJRW%K[7VXC5:IU<*5Y@(#BA:G*8@,S*76R<E#;Y&OS)KF'9TV5(S
ME^2[G"GLI3E+:4(3;0A!0DE()(JJMQ86H!6 #ML/VK$?WRGK@^/^P_)ZC?-;
MF7+1\HK'FN?-^B?VI[Y3UP?'_8?D]1OFMQRT?**<USYOT3^U/?*>N#X_[#\G
MJ-\UN.6CY13FN?-^B?VI[Y3UP?'_ &'Y/4;YK<<M'RBG-<^;]$_M3WRGK@^/
M^P_)ZC?-;CEH^44YKGS?HG]J>^4]<'Q_V'Y/4;YK<<M'RBG-<^;]$_M3WRGK
M@^/^P_)ZC?-;CEH^44YKGS?HG]JZF^C:[VK9/2]I2]7<P\?MEGI<0F=,R&8D
M=\C.<E2VUR'&(,>+$;4I#:$Y2Q':;^I[<(QG.<YJ+ "U ; &K2"2E).Y(WK]
M=8UWM.M^E_==ZI)=X!;*Q2)Q0$9CLQ)#PZ>T_&0W);8G1Y41Q24K7C"9$=UO
M/;[49SV=DH *T@[@FBR0A1&Q R*Y8O?*>N#X_P"P_)ZC?-;EKEH^455YKGS?
MHG]J>^4]<'Q_V'Y/4;YK<<M'RBG-<^;]$_M3WRGK@^/^P_)ZC?-;CEH^44YK
MGS?HG]J>^4]<'Q_V'Y/4;YK<<M'RBG-<^;]$_M3WRGK@^/\ L/R>HWS6XY:/
ME%.:Y\WZ)_:GOE/7!\?]A^3U&^:W'+1\HIS7/F_1/[4]\IZX/C_L/R>HWS6X
MY:/E%.:Y\WZ)_:LM.A;KHZK]J=6&G-?[ W&:LE/LADW&-A)(6I1F)[$6HV$B
MPVX^/K\.8WAN;#C/XRQ):5E36$JSE&5)5BM" A1"0"!62'%E:059!.^P_:NG
M_E2K5:'O2O\ 5?U": V]K6NZ?V63I 4WK=9HI @C*[.;F%,6<U!Q+6X9#DGT
M+\I%89[C3K;7=;PKP^_E2L[V4I4#D X-:'5J21PG&1OL#W^8-:K??*>N#X_[
M#\GJ-\UN;N6CY16KFN?-^B?VI[Y3UP?'_8?D]1OFMQRT?**<USYOT3^U/?*>
MN#X_[#\GJ-\UN.6CY13FN?-^B?VI[Y3UP?'_ &'Y/4;YK<<M'RBG-<^;]$_M
M3WRGK@^/^P_)ZC?-;CEH^44YKGS?HG]J>^4]<'Q_V'Y/4;YK<<M'RBG-<^;]
M$_M3WRGK@^/^P_)ZC?-;CEH^44YKGS?HG]JZ O14[OVIOSIXN%QV];YEULH[
M<MBK4(K.ABH+S .'2M>E(P]+0> .C*;:GF"4C#BV%OY5*6E3JFT-(17>2$J
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M#2[6[#F,LH<5]GR%"&W(:6ZZI2>4Y<>I.H0QM+<-_HBZ,6J%9J]3K]A 2;5
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M$NV2I;TA;[*HZ6$,*0^@-+1)=6I04%MH !.'6R>D?<%@ZO/HP4MF@ :4>O\
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M.!":Z"N68SA0Y(6H*2"0<XS@#)XNFV<[>0QXFL>!/"H@'OQUP.'KW8W\"<^
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M> ]A57)\3[FGT7-K?&=L+Y:63^\N,#P'L*9/B?<T^BYM;XSMA?+2R?WEQ@>
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M0WI<PVC+[T_AJ36#%+N,Q5NN)!P78IMD07#O@UUNSX)0C;442FE-#R,(8AN
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MF:_U^LYF$*(191$WZZJ;Q22D+(A1"4%YY]+\F0.?'Q9$%>76'HS"F5-H\@T
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M1OP=BO6KG-4Z>2J]:Z=[3'>TZ9$UEI:5]M'1T'L^$Z>AZ3'@O1TZ>8MC%E1
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MZR9H%(31=6PA[S.&BI-YHV:SE/8YB>0RTI,=SMQVX5!B(BP5)[<I\2.XM/\
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M@A0O65X=#'VJS3R<(M=WW6*XQ+)V W+<M7CWYZG?KY#?)Z;[=_BYB>F#TZX
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M &WCF(^84Y:_E-/I .LW[7;8OXNB_P!MXYB/F%.6OY33Z0#K-^UVV+^+HO\
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M2B5*4I1RI2E')*B222222<G>N\H0AI"6VTI;;0E*$(0D)0A"0$I0E  2E*0
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M$YCGJ/SVO!"JL0B5R9,<("XC":_'3,2Q(YAP( 2=\'A'7KDY&?SK/B62H;9
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(XI3BE.*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g209588g10d10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g10d10.jpg
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M 0$! 0$! ?_  !$( -8!20,!$0 "$0$#$0'_Q  >  $  @(" P$
M    !P@&"00% @,* ?_$ $<0  $$ @(! @,$!@0+!P4   4" P0& 0< "!$)
M$A,4(146%S%!45AQF-<B,F&Q&#,T0E1RE*'!T=4C)%*!@I&R&29#4W/_Q  =
M 0$  00# 0               0(&!P@#! 4)_\0 11$  0,# @0$ P4%!0<$
M P$  0 " P01(04Q!A)!40<387$B@9$4H;'!\ @R0M'A%2-2<O$6,S138H*2
M)"5#<Y2BLL+_V@ , P$  A$#$0 _ /N YV%UTX1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%I7]1@-W
MDNN]M<VCJ_KFU&J;T^J(??KS<6_S]?P=T;1*WT?((:N#A45\M&VZN-H[7NQZ
M-*JCQ&L#H5BW]5C*K#]J &86*#<D6&!GMG\\8QM?*YH^0 AS@.8VVO86-B<@
MC)N2.@MU6*]>->]GDW7NF>L]3W&*"7C4/;?&K6;0BP0G'S=M[L]Q;?KF #@3
MI.5CSDC5]HUQ-"1F$,2H=<FUV-'RS$9BLM+&YQNUWWDD#LCRVS "W!9>UNC&
M@D_,%0'5-$>H'T^ZRURYZP.[#(;7W?3=( 2FM=65BTVN'J2R4+2&UK"4MNPQ
M^[8_:&1]_ML;),4BB;(G4[7='IOS-: QBU@US!FS[X$BS@,=;8 /8[X.3B^/
MFJN9CG6('*WF-SB]R  +<N ,C<GJ#98^T:]52NEKI?P58WA;MCRBVX[1EBZ4
M*(BNZ]JVQL="'FAVHG7J2?B2Y5;I7^$)BHTI\%L9Z#:-=HAS:99;,^:"VI\6
M^;_/8\NV#MG'2V;]7]V0 2T"PV.;CGWR,$VOGKDX"L-6+IZL%KC!YAPK?JQ'
M9D=< "!HO3] 87:*YM;<W8FF;1NUF(6O5X ^'NFL=-A](7XL@97]<A@EMGN$
M3>OQ (Q)HL&1S=R-MP.I([#86/\ 14D1#M_$;W)M8-L  2"";]2;?5>GH/??
M48#['ZIZYW2/W]:]2/\ 7^C@]F3MI:\&5 K2+R#TD[*MYJ]VPKJ)PGL"6WN4
M1)HH<Y^.%=O)@?, FRFI+X'E%-T&32ZXO>UAN+6-L]._J?<J9 PAY'+?FN+&
M][G8 &PP;D6(%K!W10E6Z3VZUKLGN1>Z/3-F-[M)[\[0D=)%"G6#<=G0BHVK
M?I"34#,#<MBWD4T:=JDC5TJ6[7JDUH4=+8'OCX$*P,S8*9\A8YMU)S87WZ7/
MSR$NTM:"6VLWF^)H.V<6YM_7I?96%-6GU8(!7=0VO'M@&Q>H:SNQ_7!0GIK3
MJ2V\I$'<SU8H<X@\W4JZ!(60/IPQ-O%8K]*C4>!?;-3JK&(IP,*6,<>7=<X)
MM>V-\^W;M:]E \O%P,VO\1P;9ZDVO@[V"@6Y"O49V-L6DW=BI[MMPRJ7?7T+
M65CNU4;U.?O>O:KWBZUW <<WG0Z=%J5?IYR3416RF+"QBITYV9J@'@X3K8E)
M:?%7&;WL3@6N+7^('.UONQG"F\8!'PC&;&X!+2#RDW-LCOGJ=UX3]H>K9>.O
MQ(+L(!NH-BWUO:0$V3U_I6M$]OL;.G==QLBL:R=$$=2Z_@AM*%=QD+*$SM"M
MU:3/KR( P/%["G(.6]H3EW6Z]>F=L8MM=2!$#<%IM8Y) M<W.YN;6QU_PC96
MSW_>O4@TU7^J2>NNOCFR*SC15&L.ZZN]6P96P@#.@@;-QV'0/M I%<,N7GLV
M&)0]35;+LJ4JO6*LRC0O[/*R)*RLDN%MSC(W-P-K^O\ HJ&B,\W,;'FQDYO@
M'>UF[GW[!:^]^ZW]4(ZO9"3D[L%,,VW5>RA1:+J"F0XM&NFX#O0WJ*L9)F1Z
MX'P_"#"-QQ-W5*G62+/#Y%G*DFOL&(Y.PEF[#!Y_7Y=N5M[V];X^BK!C &V_
M4W-@YWKUP;=<'H"-F&U ?<FT]5^P5&L;^TMB%J9V[I8IB;78-?UKN+=G2X'L
M#35NVJ,I<K7[&O@KEEL6NYVTZ0(F5EJL$K' &+!19*[+,^?F59L0>_S+;@G:
MVXN,*@%@<#@ M/=P:X@VW[8.;V.;*J!K6^YFKGK4SUJZ^]G]<Z9B/&8@ZF[8
M)VTZN-")>H+Z99TH=ATNS6$T9UK7W]85'L#::G2;'\@6KU=K][LD82*&&EQ'
M8MC /H#[M]=L%5@M+2'.83<7(L,<CQOB^>4$C?&^5Q9]H]7-^HZI*2ZO:]I;
M(;UYIG=0\=<-84FEA*7O@UH'OR&NFL2+]0$U".U6!EZK76;)MJUS9Q$47V#[
M$G1@8] 'B7Q6'4X.W4@X/H,?>@\K.0,N:;$F[;M(-B=[%P%NW=9U:=\^HU#@
MZ:CZO"=L;<WF]1YUHM&V>MVJJ!+MM>;N>AX=LJ=JJ-/U?:9T($%K1S<DFMG9
M:>K9DJP >?#G]D2 M?5?A+L6O\Q:^1].N]L??3RLS?D^3B=[V(-][@7'Q"QS
M;<>D[JO9J>OOIG"]Z:@[&;(K5(M&YW>QE'H,78A:_M,%=:[2'T!ZT1J:<$V=
MQIJZ$*G(@R7BC;4%_$28XZTS'RM*WPBXO:]QUMGU]L70'+[%H-A8FUL6OO<;
M74 M%O5?T?JB>+JU'WK+VA.U)J9FNVED%7-H%VS57H'8@W6->[(.FZ#N[%G-
M8EOZCIM],L1 K$RQ,S$'=XT?)=JRD8^+ '47)]<[W'L#\A<*O^[<[);:YOGE
M&2+D6(MFY&^.APNY1W=[\WO=EBU!KV^EY6T'+#O%BR:ZJ^MM*6ZJ:NK.O.V_
M5;7=3(5*=!A&[M.+0-!;)OAO< K9TUV76;V\3$(A@)]7^R!B[B; ]^@P+V'K
M]V%')&!<C #<DFYNT^MOWAC&UK[YL#^*7JHA;N*JSXW9UAC5W8Y.K:[,8TGK
M217-\@A7=39E'LIKLA9AX.OP=1!QW3\5KC8M#L.OVM8#;G83I8A!58ID>/1'
MI^*_7>PP,YW/;'M?\:;1D7P,9',;CX01RBYO\5P>WUM#8+8GJO6<$,GV>F[.
ME[ U]9-JD FR"&GP+4%N<6ZG[B;@1@VKLZXU1)BQ:WM1BI#(<"=,W?7B)6Q#
M!=4V_NC#4N+F!S;YQ>V+=#TMWM89^=B55:(7VL0#;FS?F&+W-\$_X=L@*XHK
M;'>Z=TLU]9#E=VY6MIN;_P U/;-O!Z\JM[W7!Z],VBPL/;6UOJLQI/5L4P;F
M,-5<;"#V?K<%LL&L2S-CD:Q)SH,1^?5<VZ[YQFWH,>@R/6RHLP/.Q'+@$D-Y
ML8)!..]G$7ZJ)NO.L._5Q?[H[HV9.N]8[&WKI10]=]>D6894ZS4:[L2;6MLN
MBYPN*-A/L52RIL@S6UTV6#C'90H%<;:7&2VW( 2N0P< ./,3N1C]=/;'LCBP
M<@%BT/)=:]R+C%^VX&+D94>4[3&Q3*^O(GKUJGN[UB?';NT)*WIL?9!PG8U/
M6 5U][2BMCVP50]LF]E B\X=9S=''WC:Q$ 3U]LFQG:0]$9MK]4Q,;6/2XR+
M_?<]?2YR#Z]:N8?%S%CL.L!U',#8D$6VP-Q9<!.^O6(ET5LLN@[$'[A7HD<4
MBT"-HND+U5(ROHX2MY_81.XS!T@\.[#0.Z335!#Z32237Y5=0.BYUR5"%)EU
M%0"^VQO;:WIN#U-^GZ#EBOFP'-OS7-N:UA8F[>7-R <;K,=OV3U0ADO8NMAK
MFU-JJDT N,!-NZ2UE UK>->V?JK<+-;+L<O]4 !"=;WA4NR<R'JJA:O$$AZ"
MU/$UJ23J%MDV _L,?)YO4XZ@9%LWMF]^@[=5 $>#=HL<Y-[AU@ +FX+<D][B
M^RB*X6[U*X-_K%O<IG9249U9$W/6(%2I>JJI'UQ3Z/9QNDJSJ>Z52RYHMVF[
M)MTZL/7JYWX:?KVZ"50L%>+!:YK.*5C"JC=QYA:U^HVQ; !L-^_X"RGX,Y;8
MD7R;DB][YP+X&6W]1D31J(=WHV-JCN]9MV5;:<;:-S]/1W6U#^,$D5:;8MI5
M';_J+ *ZNMA@X:GBHNPS>N2FACQ6?7:I4U%%6.K$V H:/('#(#)!ON6V][<W
M3?LH/(.4 C$E^_P\K/<VO?!/=4?USKGU7-.7!B_!:AN$A.U'I"]]2:C(*RB=
ME21TS1NR_4JS5S=,("5 ;!&&-O&M);-W;$!2R-!V)89Y'4!Q,>HWW[(A5$U'
MQ>N!;ID8-QN+D8Z[=<+D)B(L2W+@[%AGE>+7%K-N&XN +[B]U.5FO?JL5F#>
M[^ I&Z/Q6V1J/1,$=8JI0A9$*FQ48-W0*B!YRGV?35XAA#%ND2]'1-FM#=4:
MPA8/F(H\W;='BI,-\9-W=C>PV'N>Q[B]NO4*D"/ NVP)-B;8);>Q!W&>7)]0
M5-QO:7JS0AQ6WB!=Y*9M,W?HU^CXTMK_  G5E-J6V.O[%%O%#BR 8VPVC8LS
M4=JWJ5IU8O-BL(*]E:;6Q/W;=*Q"<@_%WX/>^+;#%NV=]]\*D"*]L?PYYCDD
M&X] #;U&][+U#KUZKMH,16X)W;58HD&TZ?#5&Q&=!ZC'WK8&NKUW*L.L+CL'
M:M;)T21&I5VIG6:9#V>0K((/2(PYP#6;0>J@B&1L],(3\7<VN+8%R"=_0@>G
MR2T7IL;V<<$,! &<@N%OGN,6R+3FZ?4TF[^ZSU78U.VLFB,F7*MO0L:U=3QE
M,ME44UV$A1ME2I-=U.EVMV=!*N:4S/P,VU28++QYY^#I$C4BZK6* NN+_/&.
MO47ZV[>W5"V/E<06@VN ";WQ@7<<9/0G&XZ[SN5KA3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1='"K%:&F"MA'5X&/L!
MU,=!LY"$P(I@RB(G"(J"I-B.W-()C(QA$=,M][#*<82WA./IPESM?'9=YPB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(JT=L^SU1ZBZ@D;@NH0J=#HM=.IK3$ K5
M*T-A%+N>BU\65MMTOA^KTBBT\?+EMO'K;:CXX4,C^QM*I,^5"@RH)L/P]_R5
M36EQL#;!/4[>@!)/8+":AWPZ_&JII\[<["]JP_NH>W,J=)M68)TGEV39B5.$
MM.V/74VZT.1$M]C%28&NRT*UR!NQ<O0DU!\K+E)AHCF&+XN+Y[*2QUR +V[>
MU_?;?MUV49Z5]47JOM^A +O-M+^N)=M$6>U5BD6]K+UQ(4X$[<_LDU,@@4E8
M <C=86O;I,IE5($F[!9\5DY'KL,NZ+F?"!P/Z[>U[==][*3&X&V_<]+XO]+C
MIU4PZ7[R]:=[U'6MKI>P&HK^U/PZB5JH6,=.$75L_M+7A7:=2K,\'\&3C[5E
M4BO68T[*&RR5?Q$J]ADQCDJ&+D2<2"#_ *'M?\%26.!((VO?Y8/XCURH33ZF
M.I&NPFW=$%*V]7V='6"V!-AW@]M31 QZ##I.HQ^Y[+:0FGY&SD[]ME5%U(BA
M4@S5]7EXR'X!QSSF( ,2(2XO;\QVOWO]RJ\L\K3>Y<+@6/4D6+K6!QU*L!:N
MZ_5:E//LV3==2@IB6*'59TMC[5*#1IB;6*1<T8*%A(V<,%BXM7V7KXR5/D)<
M8 $BW.MX,$X+Q>&TZYAW_6/YC*I#'FWPG.WW_P C]"NCI/>3K]:QERG&+6W0
MI=&OFR*.:#VSV-D4HU[V5LO5-NT-X%*)1OL"X;9K:Q=94M]!!;1,?DE!'O9D
M-,.8?2_W&WXJ2PBULW (^;>:WR&ZZ*V^HEU.J9X75OQ%=L=D);@H>DU!:Q73
MI"; M6Q#MPK=?+/XDP8+,ZD_;.O[L.E7 $\8"_:-8+BH4B:5BJ@Y<P_T]21^
M101O(O;%B<^EOOR,>H[KM*+WUZR7%.M!T_9E9J5SVF"&GZ]22QH83(,,')5B
MB5R$3.UJ2:J$$I:7*G8<5(8_8&YUK6((L5V.3D0I+33F&UQ>U_R]MT+'"]@2
M!UM[7QOB^>W52EI#LYH7LE%-3=';-K^Q8U>AU<D76$P0:5%%788^8J!A+1*%
M!=E!;(/B3G0QB&B0,GNC2D1B6N8+(1XP$'8_HJDM+=Q;<?,;CY*=^2H3A$X1
M.$3A$X1.$3A$X1.$6C7O#KK:1_OY1[9]W=BE=+C^NNN8&)(7K]V4WS57[W!W
M1L@E81L%&A-^Z0'T2W9JDH$Y)LESBWT>H<^+PNNK8B*;E4F]^MK?]1S<]B%R
ML(Y",7YB?WFMQ86W:XD7Z"WX*FEKZH=U!YS8^P6R?8Z_&D1?5BO8*NF@0UT0
M9OD_L?K;776__NP4 +G/O7?23QNYZX8C3&5"P &2*H605$DF:]/IL<G-_BZ
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MF;7Q/PW @54$67S?&UK=;WOV[BW2^RJ\X]A:][>E@ .I(! .3N%:ZP^F#0[
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M608DB85>L.+<*MV+EG5KL*?\X1.6D>^"P!B/Q$+ARL$'TJ<:Q5<<MNM[^_\
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M;2.@YF.";'8^^+6&_6^/]$#"6\P<W<"US>YO8;6N;&V;=R%(@'N9U,LY$,)
M=C]+E2-AK1BY XL78E84LI5 "+*\7L,-2R*&WA,.'3+@35-2OX+H:JV,TPIT
M2$)3(RX[CZA06/%R6D6P<'%[;]MP/<VW6!__ %#^F3I^A 8'8+7!5.PX>U"
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M8JMB 356NN5Z3+F/P83T&5!%[7V!O[X(_.ZJ:XMN0!<BUR+VOO@X6KV%ULZ
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MZZN82A6]DG"4"D!),2R@PLEQB%#=M8.QQRC>YV^>UATN,??[*?,(%K"X)_\
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M_P _0CKWM?U0O>T@.:W%BW<BX)L06NL2">Y&!CO,^U/3#Z\;8U\YK=^_[#K
MIG>6X=T,%ZV]J:9;*[<MNORB-I'5"RVG65E+4-ZMLR,YJ)^I2 M_ 1X[*IUI
M*L_,)?GE&?4D].ON/ZJ!(X$FP. .MK#&;'-\^EUUGJ":"Z0;330+/VFVY8=>
M3=-Z9['F*[,K=N:9LDC7C^OP,/8&P)T%5=MM@LQ#3#[E(VC2C,>))>K&R(=7
ML"XQ=R5]F3S@#OT!_J?DI8YXORC<BX(P#<VMD6Z@^EP<+OA_IA:!@/4@C1KW
MM.J-T*;KIL'BOE:!/AY#ZRZU7/J0Y5Y+9K7YEMR':=67:Q,6Z;C*+&W:EH-
M"]=D,9CY<@]=K?*UNW91YCLW -QUOU=S7W[[?)63Z]=4M>]:Y)>31S5Q++,Z
MST)JJ2FU3PDQMJO]=Z-)U_2YD=(BO@\H,% \IR39WW%.PI9)*'1(\-%PJ&J0
M+?KT _)4N<7;VW<<=W&Y_HK.<E4IPB<(G")PB<(M=Y/T_JC=>UFW>R&RCIRQ
M0+,=Z]7'6NOX%WV(&I 6]:#"R<5RV[$H .QA*=L0B!MZ!%HI^+!$)MAY8UMY
M&&)"6UIBV2<[@VOC%OKLJP^S0T?]0)Q>SL$ ]+C!6O36_HY;6J\NFV&VVCKK
M9K'6MYZSVY)BQJ(V%K:IP30^Z]+[%LX$97:)7!X.Z'K!?=>[B!2,!YA)RU:U
MKD&XW*R'*^/V%-I#2+;&Q'X$&WO@^^Y-KGD\T; ._=(WSES76ZW  +=]CBVR
M];?HT;J0/OXUW?U4F2;;U#=T +L[HTA&/"S#_3ZB=945.9,AU]JS$M."K;4Y
M^Y1 >5=7Q4.QE&)$/7$&X-%+V9<I]-K?_K;M^NV4\T7!L?WPX]K!W-WM<C!-
MA[D8$JW;TB5SK?9"M'QHT35B-C[=XI];(5JSBDZVIW9SKCIS5J&*=,IKX0L#
M,"MB:[N=I,HKAJNIGP=I60K&+H/R"3!9R]K6SCW 'OTZ$?DH$HZ\W\.<9+23
M<@W&0;==E?GH5ULNG5+0J=276Q5,\_&O-QL8"+3*]7 0BKUFQ369L"LKD56B
MZP#V4A#EX(3YEF:UY4Y,]9-,:; FRH+IHI4T$"Q5#W!SKB^UL^GS/XG/HKH\
ME4)PB<(G")PB<(J]=I .K;_HW9FGMKWNKT %N.AW'7[!JQV$37W8<HZ"E0&3
M(-\K/'_$,UN5+B'![L-],F%.APY3;C+B&W,0;6L2!=5-)#@0";$':ZU1Z7])
M$L-?^_UI[&@=UR+1L_K7NYHI(K6)]9=-A-OT_?W;9X ILR0B2@79K9M0$V,=
M$^(Z-K3<>-$=;)PD-LM4\IWO?((]MSZ9_+U7(91L 18.;[#(8.F6@FYW)7*T
MYZ/*=6HU:7*6G3:+'I='2^#3[16M9+!S1(3JUV>W+O#89&!-?(.2@!S?5,V7
M!K%U?'2D1GB\,U+,.FA4]$;$\OMBUL6V))Z]?T$,MP1FQYSD_P")K6@>PM]Z
MG_<?IUW_ &IV=*]N8W8ZP5C9=6VAH"QZ3IL.LTZ9K0#KG2L$E *TN[2255G;
M1ES[_%VGV/@EY5 V)1068.SQ#1H#9559K,L6W-[]K8VM^NEE D :&\N"'!QN
M;DGM8@6!#;7!..QLH2UOZ6LT1%UNXBQ=5[I,TKV3UALJ-<XNEI.;UM-_5!_=
MK%L,[VMWWP,I.[HE9VMAS!6,-96%NE-?G$Y<MLXP.JCE[V/RWWWSN;[]^ZDR
M_O#XA=I SM>U@!T;CUQ:VV?17?1WE#JU5Z4[V ?$"!'43.ICD&JUUZ*K/9R!
MIB_]<:+VK%)>-H?C%*UIO8MFK,<$^ZE^1.K5()P38^97EO.1R^O0 ^X%K_*_
MHGFB^U_B!S_AN"6_,C[U).L.@HFM=']L]72&Z-9 C%]W0$M8*T:\"H;U]K_:
M] .:J(TNN-4:=9H@R<O-\U&&*W:C ON*V?DF[ ,6/9LA$O;CDAHL1?<_?8&W
M3M?ICZJ"^[P[E<<9!.2#<'('8X-C^ 6*JZ9$;%=*+NSN#V>TSL;7Y'L]7NPH
MG55D,W:T:$:CC-!;]UZP)U=C?.V]AP8*K';=P@=D-AJU&#TBNC=? P];KV41
M8I1E;JXXO>QVV/<GW^2<U@0UI!Y2V]A?):<\H'0$9R;F_6\7,^C1;I- N@@/
MORCU"X2JU3P.N]L:YUQ.$V6U%!^PKT?LV^=Z29%K(L["WA<-6[/O6L/O/#7&
M;BQK38C2ILZ$;CU\)')C?('MF][FWT57F@;M)WN"<# P!C (O8WR!ZWY+OHJ
M.#ZDV'%;'H%ALK #M9K$3<+]0)9HW4M-[;ZZUOK-H"KU<I@JX2BS]%:XU[2H
M<EQ<E$:R3R-V,-*@$##BY;D]>A&W2UA]%'FYV('PX!L"0XN<2 +&Y)MVP/;9
MAU'ZGC.J3F\1U9?K$.F[2V'1[U6Z?4*XU5@=/77NOFF=0V5M R(O Y<ZV6O6
M1F]D9T.-%7+DV92B/S9-,N=)J M_I;H!^5U0]_,&[W%P2>MW$CZ V^2N+R50
MG")PBP2S;2UE2R<<+<=BT2IF)<5F=$$V:W5\"3E0I$A^*Q,CP"A"+*>BORHL
MJ,S(;:4TY(C/LH6IQEQ*8N!N0/FIL>Q^BSODJ%JBV5Z=M\O':8CW&;[)GJYM
M -N_2MIU?38E;I:M9"=0:OK4^A$=:V.9/JLS:\HU=*QM'L9\Q+J^R:[3FSVU
M1L^=1S3U99=F4EN;WS<?0?*^1?TS\URB0!O)RXL;FYO<Y-LVL+#<7Q>_1092
M/26.TD5HO!4UU=(DNOVWZ+>$7=K19 1<]K5^IZLWEKBQ;!W!:I=O++,;Q.R]
MKUW9;-F8B,CQNP-:C3D^:87.&KJT<N.GICT(N?7-_<*KS1G!%P1:][7+38;8
M%K9S;YKC#/1]R6UV'K KL2W$J4GHY6M/B_ND 4^"5V?1UQK/5N7VQ$NL'F?G
M1Y[K_785$158\R/(F@RYN1FT?&)-/QW+>V>EL=R +CT(_HH\P W+;GGOD_PW
MY@WW!S^%E/E/Z#.!.G=OZG.[2H%7V+(VY4^Q59ETZMONTC7=MK>XJGM'6#2M
M9S;&-Q-HQ2]:O818Q(9NAAK1,FW!(& %,NOD>2&D"U^M]L#(-K8Q]%'.>8/L
M2+%MSN;@\V;;V)]A;HL4IOIZWW9VQ*;N+L-O6G;RK,7L-8=^PM81_P 1]CZG
MJJ2&C]CZR%0=6/[GV5M+[)5 V%<QNTAT8=%$TZHSZL$$4ZL#, Q4UB.6Y!)!
MWQN!@@VN3U_71"\ $-:1\(%S8$Y!S8#<8ONJX5#T@GK%J&UU>K]B]5"[ /":
MBU4%V#HZE/"D')FM(^W:#N7<6YLM74ZNP]G=UZ8WUL37]RL\>?#DAYKXXI,E
M&T88A# ;C<'87'I<$GI<@E5&6Q%VG<D@D=;<H;@6:TM!V]K973Q/1ZK^P-7X
M&Z^WYIC9MI:H'<+0UCVP1J\6Z&0];VUIW6&@M'#PQ\(?F3AUET-J+3=#I1F+
M/(?%.0['L":PH5*L<G$]RW'0X(-QZ  >EK>OWIYMC<M(!Y2!TN"2<$9N7$K;
MYUOZ^5;J4+[ -P2%-K&M]@[S-[DK0 (*@TJHZSKA;7.L:C+KJ8R76 L-MRPT
MDY:ILR&T/A/R[,\\\QF<J7*DU 6O[W[67$YW-R[DAH&=R;D_/=6SY*I3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X14D]0/KG)[-=<3.OP%(J5TNS=W
MT\<K2+5$ JP,@5[=.N+/>'1Y,ZRMH8Y+I  ['E-QW67#$?R(5A_$M+"X(OVW
M&_N+JN-W*\$D@9O]"/S5!-Z]3N^[,'8D[1%^V"$&$NS-K^Z^M*AN C6 U>ZU
M0=(OA].PM95L1M73U7HL6L[K)2;):0;-K"S2XJ$-2>!;"JH&+K,]20[OU(%C
M86MC:VQ_15;7,QS 8:,D?Q7S?!)Q8;8Z=U%?83J5ZEVZ2'8&K'2EH,42XZ2M
M5-;AA]ZRZ_5=BV\-#Z^&]=F  !W:;0.A$#1ZD;9A6"*%U9J>)!5;' MGM>SZ
MP>>+5^"'7/49Z^F.O?T'S"J:Z(<IV(/;(&=R!FV.I]+6SG,[K[ZIDBR=CIT/
M86P8M7/R<OT6M-;C1#)6#6;N]],V8-KNDW"7MJSMZUW#7>MM?VOJ8CL812M6
M125_MB[8;O6QY\@+L&GS9USOG;([C[[7Z?,J.:*S<"_?EZ\I%R+9'-8V^+;I
MLI:JO7CMKK[H];-:TVL6D5M&Z=O-K;,FB&MXS7-D"M,[+[%6C8J79&TJSM'6
M!2TWEJF%1C%D;C[KI!(U(<,K>NA"5A4$ZL>4#-[YSFUR=\7^1"@N87@FUN0#
M]W%P+8%G#?T*]?3K0W=+14O?.U=JU^P[,WO=^G?74.(G'=TCCE5N&_--T&XU
MHU4B\&79T0@\H]8UUXLJ\($,"Y,0W82TDP@^7/Q9 !POC) M[@=<J'N8[E#;
M!H<[9MB&DBW3IG%U7K1/IU]R]%LA-;'B&N]G4BP]B>H?;"X7"K$)E76-W'KZ
MVQ(79,T8"W"SFR1P]LT&(J^P)16N)%!"%F'6)N)7ADPJPU(@-(M[M/IC!M<_
M/I^2J=(QUS8@\KF@;X(^$;=-O93,_P!1-UUGK=Z3E2-]>JQOTMU$K$01O/3I
M*TZU2(F2G>IUTTYA$2=?9>*;8& UZL(R=E;:I><Q8*R$!MYUICS5;#<7M:^W
M8C[KISM+I3S<H>1RNL;BS@;XSL/3=81J3J-ZANGG>N-)$6PM%K5$&:#0(72=
MV8#Z5TO6A>[=@77LAJN^ZPGQ8DS=;)K2I^IZ<TU8D5@XQ6I%9&D1K>M61;I,
MY #AR^W?;.<=<8';T0OC(=<"YYK_  _$38!I!R!D$D8WZJ.(_7#U>8^GI]2S
M?+_)DPMLBS$N?+W86=W-=0K^GM@@YLZ/8HW9J !&5FO[>E:\M342K["TI7K;
M"C$R,_K6'#!W]57N+/M\^^=N]]AT^\)S17O8;'9N!D="T[BXR'6W#KV(N]U>
MU/WOHW;V[6/=EN/7O2IS7TR++.V2^O/A4W-D?JUD'G6]"![&F5(; E3AE_DE
M8CV@]5&:UB5EI[9FWD&D+%U $'<D6Z]\;"_Y"RI<6%@ _>!Z#IG<D ^V3?TM
MG:URI<2<(G"*B7:7JU W?O\ Z3;)<UEK^XB]/[CNIS:I:T!JO.)(UW.ZY;ZJ
M%:&>TU$>FGQT7:=YJQ&*!8^99'$'G+&B,TY!>EMP1<@VV/Y'\U6UW*UXN1<"
MPSO<?@J U[JYZFE9E]/UM;IV>4Q #5,UV!E'-S%+FZ VRC:5.G[ FGV2FUZN
M$M&L3.FP<FG JE"JVW0XPL]8R0NCUNXV]S:0RFSL;]+Y[$7ZC<"_7K[JLNC(
M=@>@ M@#'0V-SG(QUQ8QV$ZF>I';[_6+GMG%Z='T[LSU^W#6:OCL81-BZK/%
MANV53VV>#*,[EL2R]/'OWC0!O-8CHUZ(M5*"V46 TY42L\]4RZSKW/<=3;K?
MJ=KCM<84\S!>ULM(/P^K2.GHX==]SNN75.LGJH.:?%5W;%SVA>OF;:RSL6C5
M_L U2;?9"K_7VY52=?0&T96U;E,QJ*3O8G5+H7UC@]0@Y$$'FO"M"@!#SVJR
M:SK=?:^=N]^_KGL-D+H^:XL.QY;@9&.4BU[7%\YSS7RK!;:ZN]]&>HW235/6
MG9LO4>RZ%U\HVAMYJ'W5N&-JWV'1=6'G+R"2T^X)L%E W/3;NJ8$T?[Y*J=N
M.XS&'71R'UM20ZP P;6/W=O:WS5+7,YGEPN"26XWR<7Z7!OL<@*(373'N_=+
M;J'9FU%V.WG1U@Z:;=V&!J^[6P4H/=P/8ON'L_<^O:P558P3<^H:<IV\-85:
MG0WR#((O7Z5%9K+4LL-0T_%C<'?(/WDFWM?KTV57.P7 M;(%VG:S0">MS8_.
M][*RW0/K!V,ZT!GJGL1ZT']=2.K=#&RM?%-J)N >%OT;L7=TBXB:+ )&9 RB
MA2NN#&KQ2\5S(2HD)D5)":A^PL&RLB6@@?(=>N;_ )>GJ=U2]S7&XP>:][?P
MV&_>QOZ]-K 1?U_Z9[WE=-^]&KS&J:SU%W7V;J%GJE0$T2QTM[45%@8U&[JK
M5M>I;&LY1$I %5"NC0T"Y7D^WF]7(X0-66/#'P& %:"0 ;.N "?IM;U4E[0^
M,@\P:03>]SFY)N.][ # L%'FXP79#2.GIFQ^OO56C=.=V3=G:!UGJ_5.K3[%
MLSV&+%:9>M0&X6V86H:_.HT+7>L8>PT;+UX=L6$EXC.JW3-P73VVA\) W P+
M;6 R3@WO;MN+]LHTM<;.<7"SB20/AZ_#<BQ-K&V+G%UW&V^H7=NR5CL[IV01
MVGN$9:]4DZ#JK9EL[-1(>N#=+BZBU%6JQ6K-I(VV4=F[DD[0KFPK=:]FS<5A
M^6Q87B4S8MI9FQZ(*6.1DXL"3OCMWO\ B;GO(<R[2+#-R.7.YV(Z6MCW]UUY
M[KIZI9!_M%F;M;8RF;'=Y1"C(I>QVQ\>RUQ78Z3;*@G7\>3V!IY&F0:YH'$2
MAW&I5.P=0)5D?=7$7>+.='.;$L"SLY.^W?/OVZ?"A=%\-@.E[C8\MC?!O\6?
MXO8=-P7609MH+U]T\(WNW#;W +H-?'[!3!L!*UL_>*'"1'E+=L9@@8)F)SB&
MVG"<R:<L+SA%4K&;'84I2:GU"]A??ZKB=8N/+M?&+?=8?@ISY*I3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1=$<M%9K+*9%DL0*OL+\
M^Q\X7'B65^/IGVN3Y$="O&?IGPK/CG2K-2T[3FA^H5]%0L=>SZRJ@I6FV]G3
MR,!MUL5Z>FZ+K&LR&+2-)U/596V#H]-H*JND:3L"REBE<+]+A=:#V#0K._B-
M6[O4+#)SY\1P=E#%G\^/S\-0)LAS/C]/]'Z?IYUZ/7=$U%_E:?K&E5TG_+H]
M0I*E_?\ <@F>[;.R[>I<*\4:-$9M7X;U[2H1:\NI:/J%#$+[7DJJ>)N>F<K+
M^>JO!3A$X1.$3A$X1.$3A$X1.$3A$X1=&2LH 0K*"):#&=3_ %F%/)7(QC]&
M<QFOB/XQG]&<M^,_HYYU7J^F4)+:JNIX7C>,R!TH]XF<T@]^5>SI_#VN:HT/
MH-+K*B([3-A<R GL)Y.2$D=0'W'5=,WL2F.K]B3C6,YSX\N19[*/S\?XQZ(A
MO&/[<J\>/K^7//9Q5H#W<HU&,'N^&IC;_P"3X6M'S*]:3@+BV-O.[1I2!FT=
M312N_P#"*I>\^P;=95#(02+7QH$R+-9^GER*^T^C&<^?&%*:4K"5?3.,I5X5
MC.,XSC&<9Y[4%33U3/,IIX:B/'QPR,D:+]"6$@'T-B.H5M5=#64$GDUM)4TD
MN?[NIAD@>0.H;(UI<,CXA<&X(-B%R^<ZZJ<(G")PB<(G")PB<(G")PB<(N#/
M*#A37QR4Z+":SY]JY+R&O?G'YI;2I6%.*^N/Z#>%*^OY<ZU564E$SS*NHAIV
M9LZ:1K.8C<,!(+W?]+03Z+NT.FU^I2^3I]'4UD@M=M/"^7E!V+RT%L;<'XGE
MK?58<]LZFM*RE)%U_P 9\94S!F93YQ^?A3C+>%8_M3[L9_/&<X\<\&3C#0&.
M+15ODM@F.FJ"WZNC;?W%P>A*NR+PYXLE:''3XH;BX;+6T@=\VLF>0?1UB.H"
MY\"_5(BM+;)F.TXKQC")B'H/US^2<.2VVF5*S^6,)<5YS],><_3G9IN)M#JW
M!D>H1,>; -J!)39.P#IV1L).P#7$WQNNC7<$<4:>UTDVDSR1M!)?2.BK  -R
M64SY9&@#)+F  9*R_&<*QA2<X4E6,92K&<9QG&<><9QG'TSC./KC./IG'/=!
M! ((((!!!N"#D$$8((V*M4@M):X$.!((((((-B"#D$'!!R"OWDJ$X1.$3A$X
M1.$3A$X1<2?/@BH,TH3F1AXT=%D3B$^:^W&APH41I;\J7*D/*0TQ'CL-K>>>
M=6EMIM"EK5A*<YQQ3SPTL,U34RQP4]/$^:>>9[8XH88FE\DLLCR&,CC8TN>]
MQ#6M!)( 7/2TM375-/14=/-55=7/%34M+3QOFJ*BHG>V*&""*,.?+++(YL<<
M;&ESWN#6@D@+1QV>]1VUV4B2IVA)CU5J<=QZ'(O>&<(L]B]BLMK?"8D(SFMB
MG,^Y460EK!]]&&9/S A2G87--?$;Q_U/4*BHTG@B5VFZ9&YT3];Y+:C7VNUS
MZ,2-/]GTSC<QR!OVY[0R3GI270KZ0^#?[)6AZ/24FO\ B=3QZWKDK8ZB+AHR
M<VBZ3S /;%J/E.MJ]:S FC,ATN-QDA\JO 94K5V7,F+ 0D%CQ4D;*RUY<E$R
M\Z42(25Y\YRN1,F.O27EYSG.<J<<5GZY^O-;JJLJZZ>2JKJJHK*F4\TM153R
MU$\CCNZ2:9SY'GU<XE;FT.GT&ETL5#IE%2:=10-#(*.AIH:2EA8-FQ4].R.*
M-HZ-8QH]%UZ%K;6AQM:FW&U)6VXA64+0M&<*2M"DYPI*DJQC*58SC.,XQG&<
M9QS@:YS7!S26N:0YKFDAS7 W!!&00<@C(.0NTYK7M<Q[0YK@6N:X!S7-<+%K
M@;@@@D$$$$&Q5WM =\=RZ:GP1U@+SMDT)*VVIE=LTYV65@Q,9PE2ZY897QR$
M!UA&,88@2W)H?*$Y91"C..8ELYCX&\;.+>$IX8*^JGXAT0.:V6@U&9TM5!%<
M NH*^3GGA>QH^""5TU(0"T0QN=YK=<_%']F?P_\ $"EJ:O3*"FX1XG+'/I]6
MT>FCIZ*IGM<-U;2H!%2U4<CK^;4P-I]0YB)'5,K6F"3Z!=6[2IFXZ4)OM$*)
M)@BJ%)RE:4LSQD]G"<3!!>)A:U0B<%:DHD1U+6A:%-2HKTF%(C27MY^&^)-(
MXLTBEUO1:D5-%5 C(#9J>9@'FTM5%<F&IA) DC)((+9(W2121R/^6_&O!?$'
M '$5=PQQ+1FCU*B<""TE]+6TLA=]GKZ&?E:*BCJ6M+HI0UKFN#X9HX:B*:&.
M0^>ZK43A$X1.$3A%@NP-B5W68D>>M3[D,+,.C@4@@E'O:&N$\/I8G3$XS[\0
MFG64IE.-X6MEI:G_ &+2VI.?#U_B#3^&Z2GK]4>Z&CFKJ:ADJ +LIG57.(YY
MAN(&/:!*YMRQCC)8AI!N;A7A/5N,:ZKTS1(V3ZC3Z95ZG%2N=ROK&T9B\RF@
M)^'[2]DA,+7EK9'M$7,TO!&;,O-2&FGV'6WV'VT/,O,K2XT\TXG"VW6G$94A
MQMQ"L+0M"LI6G.%)SG&<9Y[3'LD8V2-S7L>UKV/8X.8]C@'-<US20YK@06N!
M((((-BK<DC?%(^*5CXY8WNCDCD:621O82U['L< YKVN!:YK@"T@@@$+V<J5"
M\''&V6UNNK2VTTA3CCBU82AMM"<J6M:E9PE*4IQE2E9SC&,8SG.?&.4O>V-K
MGO<&,8USWN<0&M:T$N<XG #0"23@ 7*KCC?*]D43'222/;''&QI<][WD-8QC
M0"7.<XAK6@$DD "ZKG<MES2;KP\"\[!&)RIM<MO.6Y<[&,^,J2OZ.18ZO\Q"
M,I><3]75)PO+"<4:_P 7U-8^2ETR1]-1M):9V7945-L$AV'0Q'^%K>61S<R.
M <8VY]X3\/*/3HHJ[6XHZS47!LC:60"2EH[V(:YANRHG;_&]X=$QV(VN+1*Z
M)\YSG.<YSG.<YSG.<Y\YSG/USG.<_7.<Y^N<Y_/ED$DDDFY.23N3W*R>
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M.?$]CW:\<9<':_P%Q%7\,<249H]3T]XY@T^93U5/(.:GK:*>P;44E3'9\,H
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MR/J9I9XG4<\'V:9YDIO)< 1F!WLCN.QKN#A2SCLNWZ+\K;7AU*H81XOE<4Q
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MJP00S4O+<^-VR7&,8QC&,8QC&,8QC&/&,8Q],8QC'TQC&/IC&/RYL&  + 6
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*(G")PB<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g209588g10p11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g10p11.jpg
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M>90"T4]73Q2*& 924DD5@&!!!(W!!&V*5+D.>5T"U-#DV;5E,Y8)44N75E1
MY1BKA9887C8JP*L Q*L"#8@C&6/F&)2ZV9<Q,HQV53U[VCGVL>[K#5L$CN[Y
M1S)PY3HL9[N^%RL,5CE[T>R?+;O%,RRZ2"2ICKZ)Z:$A9JA*J!H(F-K"259#
M&A.I;!F!.H>(Q))DN<PU4-#-E.9Q5M2I:GHY*"JCJIU&J[0T[1"651H>Y1&
MT-<^J;)X-1=/I1PQHV=X;(DR"C!'C@R>D,<YS/08@A$.<XA2E(YK!C8USWO<
MC6HKE1.*2YSD[LJ)FV6N[L%1%KJ5F9F("JJB4EF8D   DD@ 7Q<2<,\211O+
M+P_G<442-))))E5>D<<:*6=W=J<*B(H+,S$*J@DD 8V[/-\+I)A*^YR[&*B>
M)HWE@V=_50)@V%8A!.)&E2Q&8T@W->-SF(CV.1S55JHO%2?-,LI9##4YC0T\
MR@%HIZNGBD4, RDI)(K ,"""1N""-L4J7(<\KH5J:')LVK*=RP2HI<NK*B%B
MC%7"RPPO&Q5@58!B58$&Q&,L?,,2F5LRYB91CLJGKWM'/M8]W6'K8)'=WRLF
M3A2G18SW=Z+E:8K'+W@]D^6W>*9EETD$E3'7T3TT)"S5"54#01,;6$DJR&-"
M=2V#,"=0\1B27)<XAJH:&;*<SBK:E2U/1RT%5'53J-5VAIWB$LJC0]RB,!H;
M?U39/!J-I[),&-&SO#9$B048  !E%(4QS%>@Q!"(<YSR%(]S6#&QKGO>Y&M1
M55$XI+G.3NRHF;9:[NP5$6NI69F8@*JJ)269B0  "22 !?%Q)PSQ)$CRR\/Y
MW'%&C2222937HD:("SN[M3A515!9F8@* 22 ,;=GFV&4DQ]?<Y=C%1/$T;R0
M;._JH$P;"L0@GOC2I8C,:1BH\;G,1'L5'-545%XJ3YIEE+(8:G,:&GF4 M%/
M5T\4BA@&4E))%8!@002-P01MBC29#GE?"M30Y-FM93N659Z3+JRHA9D)5PLL
M,+H2K JP#$J00;$8RQLPQ*96S+F)E&.RJBO>@Y]K&NZP];!>[N^5DR<*4Z+&
M>[O1;-,5BKW@]D^6W>*9EETD$E3'7T3TT)"S5"54#01,;6$DJR&-"=2V#,"=
M0\1B67)<X@JH:*;*<SAK:D%J>DEH*J.JJ%&J[0T[Q"64#0]S&C :6^E-DK[)
MFF_X0<(^M=#_ "_BA[N9+]F,K^^%)^NQ=_.KQ/\ Z.9]]Y\P_9\/?C*8P.#A
MA@X88.&&#AA@X88866_[\B_\F7_YK^&*3\Q[/RG%,.U-H=H/JSAJV>M4^#B
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MP23?'AK)^RSYGNLSQ*.I[>VJ*8S"/T<\.561:D!LJ?/%FHFR=!I 43F#NNH
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M[;>&^'*?(.!/39\ARV>J$:T?"E-G*P5%7.]=41R59RVJDUM)4&41R2W1'4*
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MRV8,ITH[2E0^(%XT_'0<'##$F:*_UX])O^DS _\ M35<9WA?_.;AW^O<H_\
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M3R]_S]/?[N!^,;;_ !;;_'L;^WK;$ZD[; ].?*_3??:W2]Q[,94*OM^C;?\
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M!T;ON=SMGIU>I^:+X^GI3!%!P]1S%=/IM/E]4]0IM;6J5>85-'JZG52NE^2
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M$ _F1&O79R^+F]>5VR?VR)X;^._LZ8F6/0Y4&XWWV'6UMSTV_)C=*>H2>))
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M,JR7*'$N7%CAI</P6HK@U)LUDU#74"U25E4:H2S]Y SSSU$JH5LVMY5C5 Q
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M;/A+]$='=--$,OTLP^[T\U4EYS<S-5;?+:BJEU4C$KB@9&K#8CAF:RRV"2[
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M<HDOEU-88$11-&L88 I"5RM*@SD)R\W)\A%8Q%:]K7;]'HB<54E8'<D@"UO
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M*8V:-N:L0!MOSN?'H+XVI#D<$K%Z\S'M1'==^9%3JB_/OUVZ(O3KP(!V/(D
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M6-R!90>8\<=:]2_UO@_YTC_]6F<=/SW_ ")?^WC_ /+)CCG"G\Y2_P"YR_\
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M<I-]G(K7(O=JUR*CF(G,NR(J;ILL5E8R%1&R$6"DH%8,#T) /R;D<KVQ+9'
M.L%" 2 VH'K;:X.JY!&W/?;'%'MM=FXF,6-AJ?IY">N-3BK)R"C B*ZAF2'?
MJDB*$2*BUAS*U^S%1D<KU8UO=%&C=DRRND<&&?2&4C0X:ZD&S6WW!"['4 +[
M+?;&GYYEXIV%5"'-/*-;JP [E@X%B%)!4MRW)L;FUCBK_9J[6.;Z"Y(C8YRV
M^)S9+/76,2C+Z*82N:U\FO5=VPI[&I\DK6]V54Y##>U4<W-20I,FP ;:QW^/
M?D?"_L'+E+D'$<^4RVU--!(WOL!8Z+7)NHO96',6L-K>8^EG0#6G%]8L;K\A
MPV7%GT[!^ESWR2CBR,1<)1NFEO&KNL=D%"-79_,\KG"# ]+=)B!=C>ZD1V4@
M  >L7/JJG5KBY)\KENH!'/K"YM03T(KHI!,K,D:Q1%7F>HD(5::.,GUYR2!H
M +*MV?2H9A8)3'ASCQ7N];T5Q"'-"9HWD@R!LEA.*?6RFJ$S!3P,6,5B,'(:
MUOH\ED>7$>$,"=+68B1;75EN RWV8$V-F%OA -8FX!NN*L1AK(XYT#PRQB2*
M6*0:98)M+"2"=!=5E1R&%O5=2DL9>&5'>F?:^TNQG4"AE3<%D"%/KJ^3))CU
MO8#&>>E? E3+1M;->( "DC1H4ES(4B0LDSFB !\DQQ"=?P:7W38D %"=[@6O
M<@;7OMOMUZXU;,C)3*5K%#>N0LT:@: [>H&3<D@;%@3U)MR'R1:_UJU>5SZH
M4)[# .5%:YKN^ U'*CF$[SJG,J\VVRILB*JIT7C((-SOT\O\=AX^S&ERJ"[:
M/@W/._0[7ZWY_%X8K&?FB'5"C(0:IOMR*B,\T=WC7(NW,NZINJ[>6R<5-[>'
MGL;_ +_$+^7.WPH0[!4(PC4=W+G*XC6/55V:G7HOBW;JJ(B.\T3?QD(O>][]
M/9^+<^.XZ[#$ZN00=B+C\&W3V<O+$QX?9%DRX"-7G Y[5$YKWL*U43HW=5]O
M3E>FRJ[JJ>"T76QU&]UMM?P/Q^.+Z*H.DH&V)/('D0.1YC;?KOTO?'T ]@K7
MV_P5]-BM]:E9CLPC"41YIB>D4%@KD1$$0O,UU5*>Y&2P<RC%SJ=S!-60DC%5
M=,LPMRN-QMM;K<VL/9^3&ZY+7:4:DJ2TD,P46<DZ;[7ZD'P\OBQ]%]#?@RFG
MBV4=$8=/U.5'1V_<24:G>-3?KW3UV(%55%43F[[.YFMUJ6/NW*].G[^7[\\3
MSP-0U+Q-M$P8QMS#)8Z;$7Y7 Z$D7Y86[(?I5<:/NB.02J)5151I![.&]?#?
ME>UKO=MY\4[ BQY;D>WIT_-U^.T@<I,KJ;'4+GXQTY;VM;\N/>+6J2((DW1'
MC1&O8OW3-E^4UWCLYKN9J_-T\.)X22IU6V.D6Z6\=M_$V^7$,S@"3=X!LXO;
MS)O87.P/E?E<\\.]3=XU$3HNVZ]5Z[_/Y=4Z?/TXN+ ;G8&UCSVY[6Z^T?)>
MV,5R_#^_7\WQ8AG+X*QY[BJFPRJKF^_=555W3KTZIU_C\;"I1U8LH(7J;BVW
MM]O0#V>&U9;.)*<(+!E-K;;_ "VWVO[;6\<;6EO.FING2]?U]8EOUWZ+?UZ+
MY\7&5.#F>7<Q_'J2WW1'X<L6W$I__1WB"S7ODN:[6/(T-1^+_#';KCMF/'V*
MI]LW^L?9_P!\&/?]<=Q?Y;_E0_V'_$,:KQE_,DG^\4__ )SCCWQL..0X<U?C
M9[2MKI$)ZDGVF3!QN)#=R#&\\D$<@'N.]Z(Q7FD-$O,B,8WY;G[;HDC.%8@_
M!5"Y/6P.^WLQ<QTS2Q1LAO)+4BF5#8 LRJ5.HG:Y:QN+#G?#NA:19':1XDRJ
ML**RA3AF+$E@DV !&9'M 5)?U.?5PY(7--ZUE-9( )Y:[&\@GB:^/"$^32-2
MBDA@ZD6N" 2+J6'P6(.VD;$[N@YG:[3*:B55>*2"1'#%'5I%#!95B;:2)'!!
M[U[,JDQ4U1( 50:O&.X#!NL3E9 :R( P29>B,$:K<C1XO24UJ(C:L\P%Y8CG
MR+=D22:LA'93QFNLYR)$!([N+RLL@0*""(^>KF[LI&H HM@MQJ(U'U1O;$M/
M0I-2O4&0J5-7L#$;"E@AE![HNL\@D:4(S1(PA7WV3U UE8FC%PPMZQMG6%;5
M5]M8,?')*D""E/=4L"9&LI#8+ I,97VI9S*ZL6QM2EC-BMKT-)CL)+Z2OJ>J
MPU%1O87U*Q! O>UUMJ8*HN26V.*YR:8&<"2(]S'+)=2[*O<S01NLC! NL1S&
M01Q=Y,2ND1W9047"--Y69'HAB/*&.ULY<>4^)!)/+!KXDBE@MF-CA<A)!)=C
M=ABM8G=LA!CGGRW)":0H9I9A&&)MZH%KD"[$,Q%SRLJWY;D@#>P-"BRYZPP
M%@)975BJ&0I&C0)K"@W;5).$ML$"M(Y" L% 6G-5R #*O)42Q-"B"'%D0AA;
M*O[2EQ^[KJZ(]3/51L!=2 2UD- Y2UPU&]BV0QQ(=\W,("NKF#R0.Z,Q\[J"
M+?3?ZMS4&71>JK3LDC1H C1Z=51+#3SQQJ=1V"SE7+:3JC!%N] 1K7>(%IXU
MO(<\W+5V5?$$I6#:VPA3_7$=+ 7(]RQU!84<J+(@F5TN,8JQ)3 RH$QG%19-
M146^$I.W0C2;'QN&!!&Q N-B,6L](T*S,2?>I(T%[>^))WR]X+$Z=,D#(T9N
MZ,VAPKQN,,OBIBSP<,,7$[-W:JT#T$QO(,=U:SX>)7-S>,NJV$_&\PNEDUGH
M$>#Z4A\=Q^WBB3TJ)(%W)SB/^I\_==VYCW83-!>6/E_)]2!_2/CCJ' O\WUG
M^^?_ +"+&[K!VW>S;VBL4U!TLTESJ5D>8X1.PV]M81\5RNDC2:2S>)XK.MG7
M=-7QI 029*5\F,=\:P9*"4@X18*@FFI9<"*E3T*/U!Z?X8O>,B/<64=144__
M )B<4NXV#'(L9!!-((@@"(8KMU:,0W$(Y&HJJJ,8CG+LB*J[)T1%5>B<,1 +
M&R@L3R !)/7D-^6^),QG+(]%5CI;.AL+516K)RU[W@!&.,ME1%.(G] .GJR1
MZG'#/7R33:B<4D0I( I,+FE4'CUL7#*+KION2"%<#K8VU7!V86(N0=LE35:P
M1"&6"26TPD,9TJK R0%E/O?>680A&C9GA<E"8PR7;;+EM8%&QA8($D"LHXT%
M&3H$)DE+P46%&BW]A)!6C.YQTCE*6N.9\<SY;W.>8K>_?*(FW/>^LSD[,;:"
M22@!-N9L#;I;RQ,U7$OJBA4QQ0+& Z(&%0JHJU$C+$&-PI)B9M+%VN2?6*]+
MU+IXAI"-P)*D$Z+<QC1X[8]:LB/:QEC-&K2UYV/;!$]8K'/&8)!"&YL6.-_H
M8H+"^WONHC2;FYL5-[VOUY\P;WW//%P^90HS6H.Z5TG0JNF,LLRA0/6B8$1C
MU!<,I4 Z5'J#57.*JP4TFOT[C&@0AMD7!8U3 ,T2LDX^Z)/,5U;-] : 5/8M
M8"3(-#*^T,&4DJ-Z0.0[DC9IC<[*"Q&UGNO,7N66Y !  M8[XE].ADU-'ERF
M-!JF98HR%.JGT2$F-^["K#( K,R,96#ZEU!FY=Y?22JZKJV8E&#-J;D4JQF2
M@0XLVU9%EVQ94>>VOB0AQW3VSXT25&!''W ZF-WIYQ5&^+.D;AF8R$AEL "2
MJW"VM<F]M)(-]]1L%ZVTU7 T<47HBAXI@\KL$624*\I97[M$"]X)%1E51I$*
M7:0V*)N59577<"! K::/7+&F3I<Z?Z)4!G6BG0"06'=6UT)D<=8))$40(_)&
M.)PI!0I)1[N)DC*L6+$W  %S9;7O:Y-]6Q)-S>X&VV*=551SQQQQP+'H>1WD
MT0J\NK2(PW=11A1$-2 +ZK"S%=5SAB\5<6.#AAB]-)K[G&EY^PCIEC8* N.:
MT6>;U.7%M($J59ABU&25K(JTLD%A%#",K;B7WSY,6<UZM#RL9R.Y^&\?<7YK
MD/'7 F1424;47%&85]/F33PR23I'2C+N[]%D6:-(F/I,FLO'*#9;!;&_MKL1
M[.\AXL['>TSBK-),Q3,^!\GH*S)DI*B&*E>:LESQIA7124TSSI>BAT+'+ 5!
M>['4--WNT#;S*#2S)[ZO03I])66]O!:<:E"LRMH;>9&0PFN8X@E,%B$&U[%>
MS=J.:J[IM>= -2QJ>35,0/L(<8U'A<E:^=AS%#,1[1+ <<*:OM_ZNZ:TQY&J
MVG9+ZRGXYI?>T]+E]I@.D-XJ93IWGF=7MU"NZ/(]0<!N,0R8N,P<7TDCR;6D
MR:QRR@U5KLQ2ABXM6R;# &CC=K1OI +@E0\@]5U0 @A'#*23(;%0IC*W+'&W
M+72QK[[&68I&RJQCB8ZHY'8AE9XRC:0L6ZL664/ITK>=;;X0+'L>?FS\@QG$
M*X..5.JLFH@)JQ$=E$K)-.KG(JBGT\R^@EX? #AFH6>IC-I846+1;;*[!L"+
M+.(=@V&=4I"C8Z;,QN4!/=^K9P"70AR71=0!8A1?J,5S7*NO4J@*LQ'OHU%H
MBP$;J4 2232=*AG.QV-L(60=OG-<;JZR]LM"\4C4ESBNG.2Q+>=KB:JK*INJ
M-EK*W%QY?9V>DD6KQJ VFT4N6V-J^=/1F:97@N&5D.U9<S<@J8BD0W E8D%Q
M81 D]WW8;2!*23>46%AZJNQM:QE:N=0"84L4C8,9[*.],VG6QB 46A8$W/KN
MB '46"C]OM<,;BDBSTCQK#ZO4&1FL?%;_/M90XWCN/+IW9T59E!M8<@B:>7E
M-I[$D3,BK*;$YM%.U"B9%E4R#0%-4LL8%F=Z&/6M(S%=.H+%<G6"1W8+@O8
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M.E6(UD3-H$CG>ADYP#YFBYFL;&<-J-<BHBN*J+S%?OA:Z&J:57CCD8+>RA2
MQVY[6MRWZVMY8L9:VG+/&]3"$ ONR@W!-[=3N-]R!R Y##CN+>[="+*##&KX
MP2I%AFGP(SED/:K!<XI$D+V.YNCU<F[&JY55.)*?*9ZB>.(KHUL-3,1LO-F
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M"6V(D1'N-]:JWPE!&B.WL QH48,D@4K;(UM7F"]X94.?(9"8:1'DB<PHR/\
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MT$&?9[3O.M/PO!!+G8AJ:I8J.>)UJ143E1-/2@>C-9FN=-_=2_UO@_YTC_\
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M *P-P0MDW.U[6W'Q\\?/YK/V8(>3Y]/O(^I> 59[")#*M7D-TROFQY)AQ'&
M!E:EXU!13SVP#+;/H[!LF#9R7U@J.."XF98+ZBDLI.]S?GRVZB^]N>.95,KB
MIE!I9G75ZNDC9;  V(!L;$\CB& =C:9(E%>;5_1Z*-E]ZJ,Q^3VA)I8Z64V
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M+XOQ725/%8YR[O1$1554VZ(GL\O=MOUV]_&*4@HI'6XM["0/E'Y\:E7)W4[
M !0;$"_7<<[6\.>&I8E=%R^JY51&S(AVD]CGQ2 [K?ILO2279%ZKU\DXC<W3
MP+:?B//\?Q\L5(=+4TMQ=K:@?+J!SW-QTYV\L2(B^"IT\%3;R]FV_%?_ !_?
MVXQA4V!&]Q?8<L9G&<X;V+T16JG3KNNWGOUZ^'GOOMY\+ \[&W+R]N^_^&)0
MMF! LU]CYW\_/\V(ZT_<B:PX S?_ -86(HB>&V^1P/#I\W3\>W%&A&G-Z *
M *^C%O+OXN6_M_-C+YXQ/"V=ZB;G)<V&_/:AEVY[]/D)OCM_QV?'DC$$=H[
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M_'^_E?UIWA!8V.[NPOTNQ(&XY@&QMX6]FXR0J;(U_CT5-U^?Q]OLXHV'@/C
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M1+C5I.V_(@_+MTY^?7$*^>TL<*,+",R,%]4A5:P4\@;@ KT%^>V]F>RK/C2
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M2-.\;3J5-B=3!B!8>"*S;GP4V&YV!Q([:%OI+;@66U]_:0-N9PT_C_%Y6O\
M5,U6.#WC2)-I580BM1S1 3UGWI@N3O">LFB]4,C1I4HL\8!-<6Y]#_ZZ/S]6
M78;;FZ;'>VGX=R %.]J/I!^I/Y"Z$FYM;X7X>7/?Q]?'V,G=JZHL&M<]XRN2
M72E016/<ST=C06AGSYBO1D=8M4V>\<PPHQ%8O>$'#T,_5H]P+;2];W))C 51
MSNU@5N? %Z2?J,GRI^1S<^ %_BQX^/\ 'Y'.6GFL4;FH57V6.H$ W#:7OCRV
MW+HK=A.63Z,(QI[H3%DMAN5XA$>A]>^CMN!ZLMR;V  ,8._B;*#L3UQ 5)/*
M&3V:H_T^7LN?+'[\?A+SHE#:JY$:X8UEX^(CV.(4:/.T]R)*Y7/'W+!VKH)G
MRN\C(-'@,K(^A\_?XK#F=,Q%[ V'O?K>>C4+6-]P,1])/U%_+UHQU(ZL+6MU
MMX>>/UN>QW+\BHGO8YKW!>R73;2$8T3GD"-UFR0V(QI$*Z?(#'A^CN!(:9PY
M(5=#T/>W?1^)]6387MOZEK_ZO.]Q:XQ#TD[^\R>6Z;^>[<O/PW%\?K<\CN[O
M^DUCLYRC>K9=(56G1"KZ*!@;4A)YVN$X1'5S)<49ARF.E;1#N:]#._OT?E=9
M1?:^]XQIZD:K$BVVX&(^D_\ 5/\ *GX/6W_X]=L?B9['5R-]3SM^?E(J3J%[
M M5XVL<I&6SA'(1A&F;%AODS6"-#[Z,$LT(E>A^$\9WM\&6_R=W<;V%S8?"L
M3I.'I!ZPR >)*?I6_#X>.WXN? _5$2EL.=G,O=OFT(G-$U'[FDO+;L#";SL(
M- 2RAG.?&G.9$<*(XCWH?/W^.PM<Z9>>VPM&2Q\U!7==QJV>D&]NYDOX73Y3
MZVPY<]_+;'I<]CH_D2GL7*[E0+?2:=A3JJL1[D"6R&2, ;7C<LFP;"CE65 '
M&(<LQK&1]#_ZZ/;GZLOB0-PA!)MR4DBS7L%)Q#TD_49/E3R_UN6_,VZ>./'Q
M_C*C')43W->-'-<V73.1Y5:Y6A B67/)8[D(Y9X&/JQ!BS9!YP@QN<D/0_\
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M8>+S=J?2/?SLL@W\?O.R)/'KX?S3BZRK?,*:U_5,C>VZ:>=ARY_OOKO%[_\
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MMZJW='4Y0:E]938C?QZ7Y8A=SX"FE?TUG]X]G,4'I3',[KO(BOFO:R0WTRP
M0,=XYH11@@8U2O)W< S9^6]].D=Q$-N>BUCI'JWMZJD$C2;G>W](:<9:+?\
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M:FSGHB[*J[*GL7=>J[;=$3IP)-MO,\O9\9OT/+%JD+R,)IB"U[*.=AL;#?<
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MFM@IRS?5<Z5+LKQ\F+A])J-+M19)7REW]:TTI]4VN'#LW=@F]F*@*_J[L1L
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M=;<K>WQ_??&T*?R^+DW\O)?/QW7\7%)HR]OA"W+U=^GB+CE^XQ=+(%O8C?\
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MB5UI3N?)C-8W]5DQ"M;Z?#:G57$<T8Y<9J(JOEQ0A389S<^-K(1)$;*"R,&
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MAQL*..WO%17N861$ J*BJ-W?2@-Y'N0;B2%" MW17$XLG>'2_J;[[>0)VY[
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M.$7NR%M0N***J,0@89#<RCC@6W4GK9Q')'&YH'-@))K'#.,4FW#"':.;&[W
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M('R/'L_A0Z@,BO#F6+P"#J$@GQF733I'$KDLKD FXLH(U!P(]VV7>_K68%;
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M4B#7+-I"JH*- PV)(N6:,?)JVZ"V^O1Y)G%([- ^7ZSWLQNE="3+ZH,FH&K
M;X)"Z8UMR4F]K#TW;1P"ZBOGW,/)"U<NMN,4LI5Z\>GN=Q19#'C5]O,QT]%?
MV<2EJYL6+4M)72"@6<Z@LI%3$JIDXSI.,:H$$S+!WDD+>^#4H"AVMLI&P'(6
MZ"]S??&P]]'44\+9G+%%F,>J%YJ21WD558 B1@L$FHW))C*WV)%@++M5VO,)
MKY]+2QLQU.QBF*4<I]_.O+-M?9,I(U#7!]<PX^3EGYY+OJJN:>;-N;6WK*BM
MC0<7J,7&(9K-LZUC!+A6U%@S;@[,X[P'2+ :?6N0647W(&UNRY:9>_2I0LB,
MR)Z.$,CQ1674Y+/))+;NAK9@5*V :Y+OU"UBPG6KUG<U.<8;(?9&8&DPR!JM
MA5A9UN/+31ZUT.-@!,C)F<6\AQHT:1:MCTA!PV!G'G-'&B.*+K?9%P;E/'_'
M.1<,YZ]0<IS6/-6J?<ZN@AG5:3)J^MA,3/'*P8U%-&)"(6!34/5-V'F3YH[M
M.XF['>R+B[M X1IX/=_()^'5HI<[R6KJ<O>3,^*,HRRI,S1RTZ2Q^AU\P@!J
M8K3!'&LV5VGAVC&#V,&LF9GJ6;#2S2'*^(.C#>JR(.SM "7OHMF%P&R*V"&0
M*86,6.LDIXFRR(9@\<>XHRNDR3B7/<IC-0L&79QF5%3]YZ[^C4U;/!!WA !D
MD,4:DR!5#DDJO0>H.!>):SB;@3@[B.67+GKL[X8R/-*[0TL,"YAF&5TE55)&
M@63NHQ/-*$B:1BB*%+FVHM:TP#&PD[_%<^;E5.^1.C!LP8[)C(U\.9" UQ6A
ML9@1@("6<SS.DM*TE?) D1RDCN)@T@6=V5&>ZZ;CNFN UCZQ%P-MU\^8Y$[;
M+F)IXD=DBEU%E!CG"H2B$OH:1%+W8$* M[$;GF6+;B+5S707&#,2(KP-G0DD
M^AS$"<XTDQ'R8\60^,=$[T#SQP%43F*0(W\S&RRT\R$ QR%5NNL(X4[[68KX
M'?;XMQBXI:E)U#BP+L6TWNR^H+J;$\N1MM<7Q(>-Z6ZG92$$G'\,O+*,< #A
MD"CL;'(&0%) #(<Y@B:TH%0HW/>U'(YNRJKVHM$T[R"R@WOR.UMCL1S!]OR8
MKR5$4?PF/C8*S,1<+L!OLQ%R1L ;CEC3'C-W$N(]+>-'B\B0QSTDY!WT."-&
M/<%ZR)(PR&@8,['A.][>2*891R7"49$;(M(\CA=U O=R&"*=)(N0!8;$&Y\L
M'KEIU1EM-(VE%@B(,TC%@I,<1;6=)N6%B1:QWMC0N)\*CV!,MJ@@P'.U9\>>
M)U>9O=QWM+'DE[E7CY5Z\S6N8Y',<QKF.1*<E')<* \A2^IHQ=2QMNI O8#;
MF=^9Y8NX9VE42-')$65?>YHVAD0V]=#&YO<-RY;'VDR;B.&Q,FJZV_+J%@M/
M1V<5)T>=,MY$OOH;!S#37Q6U\.1'D2*T4(CIL9987A>YHWO8K)#@4TI&)8.^
M@K8D:&8V-^86]K;6WN2>FXQ5EKEA52R#UMEU.D8OT'KFY!W-PI  -KW ,#:K
M=H3"-!218[+.EU +DT2W@A!3QB6 6-KC@BRIC'SHH70_U8^U;-112'N%(>P3
M>Z7:ZI<NDNYU1B,AD9Y$UZ2PL"!96! N0Q(W%@+XH3UE)/$DHEJ"8W]6&GOK
MELPUAGVA,=U *W+;FRN+'%=&=K?/LDA[Z=Z27M\])1VHD6MM;<R<H0JBJVH$
M79%=NB(K$;NFWDN]P<JRQ$ FJY&LP+A2D:DBUUNRWL0+$WVO;I?$/=.N>9C#
M1C1W=QK[X. 2P5K+&59;GGJ6Y',8F;#.V@S3W%8I=4M+ZFSS<$Z<.73#B+'-
MZL':!.+OJO+;3&71;Z'7V $E1I)HQ%B16S(D.8)Q7-@F54LDQ]%6)H"+QO)=
MV-A<FX.FW(?!L/$#&OYKQ=)ER+%41/Z2#[\D3,B@F1$&DD\RA8E&)W74"1L4
M/,=0M8.TSE ]/]-;/"=-[X&1(19:>EXS#+63*1LB/#,*FK+@KFR9;+"6.1(;
M)<U P(@QP#R5'*N>[ILM5JB6&.4!;W""ZL7T !2K+;UM_5)TWW!Y6^6<0U&=
MU340E:G'>CNU$[ N@A+;D.L@Y7-F4NVWP25,AUWP8/:*R%H9>:=H"!'$8:..
M:CK,MNE:CTV<QK[$>(C=U5VRJY&JNW39>EF<_P!(+Q4OJ;A2H$1 .Q-]"6_I
M'9@+\]K#&R+04Y=TGJ[R"P,<DHDU>W5+*21M?4#X=!B[M'IW;]G#'=*]/X>5
M2LM3&\+*A[V5#6N/8%LLWS*X)WD-)UCW7H[I_HJ-=,.YS ->KFJ[D9T'),T,
ME'2EP0LL)?UV+$D2LI&JYN0!N;DWZVQYOXZRX'B7.VBM>.IIK$=0,IRP#DJ^
MJ!N!8 =;XL[C>J<*QLTK[9KH:LBUK1'(U>ZYWUT0I$<1R;(BE>1_BB(YW+T7
M;?-/)$[EHY58@$,H=25N=P0#<%38$'EU WQJ,,4J(JRQNH!DLQ1E#>MZI!(L
M0PNRVY@;'$DY!DE945DNRDS(\>!#C%F2)A2L''CQQ-5[SE,YR,8%C4W5RJB+
MT1%W5N]G)8 L2%&HG4>6W7S&_LZ],96"%OA%2>5@-N?*]]QL?._EBJEZ^ORK
M$FYU3",^(C)-@-W</$\U0TI'N(D=6-(U! 1906.3OFA10*-"<K&ZTVF.>4(P
M[MI&(O;EMNI%N=SS!Y6Y[C<,NJ&IPH>_=-\)?I2.J&X%C<EK@W %M.]XY!)%
M($PP2,(,C&$$4;FO&0;TYFO8]KE:YKFJCFJB[*BHJ*J*FU7>]K$'P-M_B%SX
M8V9&210Z$,M_A(18B^^X)Y#ITZ7&(NSZM!J;KGI)HU-178EH[#'K]JR1[4?%
M=:A&OV/\;D[\S6RS%G.G3(Q6JV14.,K%51D1,Y3**6C[]P#H1K>.Y)<BXZ7N
M#TZC;;7ZZ<5E92T:W[I&-956O8Q:=$2MO8!@FL7&Y.QYC$D765%M;N7<*KA[
MF<R(SP:&,$KT"WEZ-1R(BN>J)LXSB$1$YN-3GD>HE<_3-ZFQN%Z7W/4W\#<?
M')/4(SL0X]3U%#$;*H%@NWP;>'4'GRQ9$V?MK](+7)!D>V8Z*M1"=S+NZ<9G
M<N()%7[H2/5V[>FV_14W3B_@A"V%@"UM146L;?COS!ZFW/%&*TKEB250:B!;
M3J# J#MN>?YS;"3V=L%:*$_*+,2*>7S.&K_NFC1SN9R*[KN5Z[*JKNK$WZ;;
MK5E<<A:RCU3\7+G;Y/BVQ?O(8(FD+#O96LJD\E(L6(^%;GI-^0%^M[8*1CU7
MY2;(FS6M79$:G@G*J]$1$1$]R<8QY)&DN+&UP%!N-QN;7O\ &+#\&+"YT@_3
M$[DBYN;[[]#U_/NFV AR8L@2[JCF.V1=MMT3=/F5=D\O/B(9RRAE %_#VCZ8
M_+;G\N*BEA8V%AORW-OCZ^S?ERWQ"<A.X.4;ODHUZM1?!OCX?P+[MMNO&14*
MP'.]@3[;;\QROMX_%OBZ#:KWM?GMY[\O#<?'?&)KT7[EV_MV7^?^SB!4CH3N
M>F(XD_1=ZIK!I1X=-2L%]NZ_[J*OSZI^/;;R\.+O+[BOH20?\LICOMRF3&)S
M_P#F+.OZIS'^YS8^BKCJF/+N&_DM6>XK'0XXX1B*<1>ZL'';%>@^94[QH$=W
MBM<K7C:1CQM(UI41IAB(RM!(L4@=BX #"Z :KD6ZD>=]_+D3BE,AD0J A-P;
M/?3M[ WXL1\N 6GZHB1L;ZC1C'?T4URB1 ,6"O)#:D>O<-KD?%AH 1/18PR#
M<*59-DWPK(OJE5Y[)SML?Y3<W W-SN=[JA%KZ,_U.G\ ;L38[$?R=AL3RV)Y
MC<X$P"U1R*V/C@]AKW;AK*8Z$3E._E@(V'R14*1W=&EA:RP<.5)/Z2LJ/!("
M'ID5MWJ3OOLFXOU]?>P-P#ZMP!;26P]&<<HZ<;;$%KAK6V]0 "_,C>WL%OU,
M LT[M/0\88-KNHV#.X0W*X*>E#CDA. ::-HVE$>8R0K'@"!G)#)) 6/ID>_O
ME3>]P;+?V$B2X!/, ];_  @#B'HLFP[NGMU%VM[;=W8GY+<N1.,:X!;JU>:%
MBA%<[F,,JSWCF.1C^5TTKHJR)BH][^DEY&HIS2&HR8T,@;TR*_\ *55K;&R7
M'L'>6'Q=!8W!(P%-)8>]T]_]I_BO[WOO<^TWZ6QZ7 +=7$7NL=<YST1YW>E-
MDRQ(]NS)3QQ&(T7*,;U@QT'7/40HA(SZ]OHO 5D6WKU/LLE@;WV]\O\ &3J%
MR;WWP]&DZ)!Y;MR\/Y/ERY;<Q:UL?BX!<*CM@8XQW=(P+QNFB?%11HCHL1PH
MS'0HK><T89(:@FK'>X[Y*SBG.5Z9%MZ]3S-[A#<<KGWW<G8F^U]K%0 'HLG2
M.G'A8OL?+U-O;\=KDG'M, M.9JI&QIC457,Y1$_H4G>N<IXH5@K&;(*K 2RG
M()Y?2]QL>V+'B#"]-C^J5/.Y^#N.=B>]Y"Y  VL;\R;O1I.7=T]O"[V'F!HZ
M]?.WQ>4T_M%:U'Q,8<BNW*)_IA1%?W8V^E&4T9Y9LMW,>.I9[Y'+'&-S?Z(E
MV!3O3(M_7J1X$! ;;[?RFPM8[==M@%M'T9_J<!.VH$M8[\R>[-[#;<7Z@[D8
M]+@%HO.J@Q\CG$W*\KY:DF#5Y7M],*D1"/2.J"+'AL<RO$0Q6-C)'B5HHCTV
M*_PZD"VU@@L3SM[X>=R">9 'BUX>C2;^]TY]I?<>!.CQ L-QSY6&/Q=/[3Y6
MT;'%V8UK%_HEBH%&A8Z WDAM]%KW,[UK@PD!WJ  A4<LJS68%;%M=ZGY$Y[V
M:_>"[#;<WM<^"D/1I.B4^VPW:X'A_)[#<WL+?*</+%*"51I-;(97B9)2,H@U
MO>,CB<)92E1H%" 35(I6E<?D?).0A&',\0(K!VE1,LNC2TC:2US(%U>MIMZP
M9B1MR) ',"[-BX@B:/5=8TU:;",D@6U7O=5%]^8'MY#!FM02[IVP65[[1BRV
M$/"9*!#[X+ 245KBG4:;*1PT8@S >A5&1[R1QFCF4D@BE+F3NO4(#:6;<D;6
M4$[B^Y!VO:QL1&HC[R/3HU^L#8$#D#O<E;;[;&^_*U\1L[ [)22'KC_,8J#"
M8[;&&Q)D=CQHT;!NF$: #&#:JL*PLU0JX3;%)3BS#9'TU=AZ586)%HGN"=[7
MT;F]]Q9;_P!&U@+,TO\ ]L?#:1-QRO;4.F^^XZ&^^//Q"GHJ;8V[<4-(D=S;
M6(C@P'C&CZT7/.>U"M5^SI<ELY'ECG*)0M/7#K7IJ_77,DGWI[:M[-_)WML-
M@1L0""0VJ'HI^MB;6M[XFXO<_P!+:USX\K;BUOUN!V UC.!C31+%0I(?],H:
MM@F?Z0I7M1TPBF+):YXVO,IX@5D0_P"EZ!B3!37IJD;U7,V:\;G4O(7][%K7
MOM8[-ZQ)4K#T4_6Y&VWOB<^=OA[\K;DC?PO?&S )C4 -N+-:(9D.-CK2,]H)
M7./^BS\MDPQN5S4/W<:1'$X;3B?')(.V2UZ:+D^E"_*_=/N/#>,CG?F+BX%P
M 1B/HO\ ]L>O_P!1.>_^ORY;?@'3\7 9SF$:_%5>V053RV/N(//)E*)6K(,\
M<H;-GH11(R&RN1"L4JHL=8\:,]-%]JNP L+12;#P'J7(%K^M?;:][W>BG;^+
M$^/OB7]H]<<[_%;PMC(3!+(BR7%QM#.E<@YJMLX(UFA$\SXPF)Z1W8(\9R)L
M+NVR'LD1AEF2/1K!]D]-46M5;"]AW;^J3S/P+DFYZVY["ZZ7HNQ_BS$W^J1C
M:Y(/P_(7&Q((%S8X_4P2R:]SVXZB$:'T5"MLXG6 [T<9804?+>X:$:UKWEDN
MER^4$IH9\>1,BGA1]-4VO5#8W_DY/A#<$VCWW'(6&XNI (+T7_[8[&W\I&;B
M_FYMMYD_'O@;@5@Q0J/&T$^+'Y(#FVD-?0AJ,N\<2/E/:IT:8@/2)+)L1I58
M8<)D8;(K(>FKN#57#'UO>WWMMJ_DQMR-@0UAN2=R-+X4Q/.WOB >._K_ !<C
M;H;8&8#,8H&CQI&,CD(>)O9QW,B2"%>XYR-6Q4IWR7M0[6J=P!B,..Z,KF32
M3GIJ[WJN=@WO3W(MM:R #3<CD#?>_+2]%MRIB;"X)D3GX$:S<&PY["Y//GY3
M )SF-$_&]Q$D-DD82TC.5)[&@:RQ.X,^.XR#:KFH"&ZO:Y02'*'GE07UCTT<
M_2A<;"T;CU2;E1>,VY#G>]P"39M3T7E_%VL=S[XFQ&WTXVWZ'QN";'%..U+2
MVZ]J3X/9S:R<1E7EV;>LR  LL%>CI.#*U9<F&%(H&.1CU8YW(U6L<B.>K'.7
MSSVG1RS]I?9'-%')+%'FV<-++''(T<88Y19G8@]V&TM8N1>Q\#;UKV(U%/3]
MBWS0T$\\$$TV09"D,,LT223,L7$ *Q*64RL"RW$8)!87YB]K=:-,LKS;(JRQ
MH8T0T6+2CA&=(FAC/20V=..K48145S>[.->9.FZJGBB\;EQ1D.8YK703T:1M
M''2K"Q>58R'$TSD6;F-+KOXW'3',N!.+,GR#+*NES&2=)IJ]ZA!% \JF,T]/
M&"678'5&PMSL >N(>^P!J1^P*W]UHOY>-:^<[//J,'W1'C=_HD\+_5ZO[CEP
M?8 U(_8%;^ZT7\O#YSL\^HP?=$>'T2>%_J]7]QRX/L :D?L"M_=:+^7A\YV>
M?48/NB/#Z)/"_P!7J_N.7!]@#4C]@5O[K1?R\/G.SSZC!]T1X?1)X7^KU?W'
M+@^P!J1^P*W]UHOY>'SG9Y]1@^Z(\/HD\+_5ZO[CEP?8 U(_8%;^ZT7\O#YS
ML\^HP?=$>'T2>%_J]7]QRX/L :D?L"M_=:+^7A\YV>?48/NB/#Z)/"_U>K^X
MY<'V -2/V!6_NM%_+P^<[//J,'W1'A]$GA?ZO5_<<N#[ &I'[ K?W6B_EX?.
M=GGU&#[HCP^B3PO]7J_N.7"M0:&:@U][2SY,*O;&@VU;,D.;:1GN:"-,"8JM
M8B[N<@V.5&IU<O1.J\7%'PEG,-72S210!(JF"1R*A"0B2JS$ ;D@ [#<XLLR
M[0N&JK+J^FBGJC+4455!&&I)%4R3021H"QV U,+GH-\-7X0*S[+5;CFF[^U!
MCV;Y!5%N[]N)"PH\D,B-8-@5ZV9)ZQKRD5P21EBM"CR2$1[7[,9U<ZR[89^
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M))*K&"0-_8#L6U:3'(7N N5SRG&-K5Z[.(B)LB(NZ*BN^5T5-_)>,:B7505
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M3N-R58,.8Z>)M@+F2G W+UV6*H\3Z?"2.?@+_%U..QN51]/\P=#?:Y)<1"0
MS 1B8[EV6XJ_DG$A$.LAV-V55Z6YKX %COE]^Z*BG;'4394E"Z4HE065%Y_T
MEC8_;'?PVY;7YDXWF6B6;27#W0W4++(ES?J$9;FVUB#?\3;E8?IA+:HR9AG2
M#>,(C#'JKJ6T9V C.B,[UOQC7F>X+G(<G0D@J^DF<^2C"MJ:Y[? B_LXOP>K
MMUZ^SSM_<T:MN_TD$'^,SVWV.W>CY;<][[80M<LCPN)H]<UYC+D$&$&AB^@E
MERY,Z4P%G6QHII$Z65),HX#=Q)D23R'G.X;WE<1[W<V^]E63\6YWQQEV6<$Y
M[#POQ35T6>QY3GLT8EBRZ=<IFFFD>(0U.H24B3P#WB0!I0;"Q9>,_-$9UP'P
MEV3YOG_:APE4\<\ 99FG"[\0\+4]1W-3F],V?4%-30I.U51E6@KZBCJF+541
M80,NIKZ33ZCR;'I0XJ19<.,- B:R*XP><;6B1&B56.55<SHQ?NG;HNZJJ\>2
M>+8,PH^+N)Z3-JQ:_,Z7B+/*;,ZY%TI6YC!F53%65BH%32*FI228+H2PD%T6
MUA]$>SULMS+LVX"S+AW*ILHX?S'@OA:NR#)Y'+RY3DM5D=!/E66NS23!VH:!
MX*9G$TH8Q%ED<'49(J9D"5(C)%>-S_2 -[SOW,ZH9FZHCW(YWM39%1>JHGAM
MB$=2R<P6) )) ^ UAZQ^,;7&^_/&7JX:B&.03 A!%(=/=@D@HUKD*0#XW-]N
M73!&-! UZN"V:1%1'$5ID1JKNFZ/YN141.JK]SLG54\>+<,(EU<R6TWL2"I)
M((-['E<6(%K_ !)$GD*@.8%(NJ@H;CS4 L"? VY\CAR*R))AMVCMCHNRH\!H
MS'*FVZ;HK]U7;?IX^?MXJ.3(!8-:P)T.+G_NW)4CQ4CS'08P--%4&\C2D;%7
M21@"-C_1L /'EOCU&@E6$8 D.K6& O.PK7;]#JBJUY$:BHB+UV7Q]W6:-I-#
M:&< /&"+L;6$EKD<SMM<&V_*]L2R5"]^DC=V"R2;%2"/6C!L0I/A<W._3P_(
ML!L=WI,E[U>W[A&\A'MV3QY6JKE=X;<O5-MNNW$@N 6<ZC< $@$B_0*"NWF/
M+D;8FEJ#(HCB50#\(G4H;P]9A:W2Y/MM?'XRRNN_<ZIL;2(C53Y0YQH;T^;D
M,Q^R;]%1=TZ[+YK!:B<'WN26$$[%'DC+6/)K-<WY;FQ!%]A@::@[L"LIJ2?5
M<6:GCF4CVE&4D@#;;?G:PPT]8K?*Y^G%S!GWMA8@*M7SP3SY,UQN[N:TK'-"
M5SU51.8TBN;ORHS=>B;KZ?\ F1LS$';]P+)75XAI$AXK[R2KJT2%&/"&>*H=
MY9-*@N5"!F +L !JVQX9_P#WA>1TU7\R1VJQ9+D339B]1P'W$>79<9*E@O:-
MPHTHCBI8S(X$(D9]*'2@=F 4$C@5KFR1!U/M\;F/]86!IHQ5<LCZR">K!8W,
M:Y&*#7/FG#4=W$@111K2IJ3%*\VQ 0C/%'!3XBK(*CB3BJK2HA,1XGXC9Y(V
MO&P3.*U0QEN5*!+-<-HMZRV7&1X-RFMH>#. ,ODIZCT@<"<%!$EC99HWGX;R
MF41- P!1HV=H6N@-D]87O>Y78"SK.<,U?DY3 KV38DO'I5)93+6I8[EM)[BV
M1 VBEN"V\1K7U+RPYT<=<,S21XMB,31062.?<39A'1T$9ADA-1-*DL7>7=)8
M=T=XF1XU*C7 1>1;_"6ZZP>N\%\-G.\PJH*Z.MCH4A[J>>E[N%XZEU:I@5UD
MC<D.L4Z@F)E7U48J608Z.]KK7S4.\T2S'&FDJJUN14PHKC50DD'>%LALH\-D
M69<Q2''-%'6)(CBG*\L0T@?=*BJ]FK97GM5)F-'%-%2/ ="LP[Q"6#M8%AZ0
M%N3;UMK<R =MWS'L^R;+LGS&MH:NM6NIEE-.)XHI9';0 RQQJ:596&Y&A)'
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M %6,?7W]DV7+G'K@P1T,>1&K*H\=99>_@6L*9X92C+'NS1RJJLK,A4H^Q<[
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MWLT\^\_,_P 5'^=>'T7,E^QF:?)2?M&'\'WB7[-9'\M?^QX4:CMMX#<6U74
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ML[B7WRF#*; A69#UY$1"Q]BB^XQLL/;MP1*4=6S6GE(%FDAIZDD7^E].4$W
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M:Y&]@3C,\/4T\&=Y;-/35<44=4C2224LJHB"X+,S  6ORVOXXY8M6#LG]/\
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MD,:QK[-F2&J[6_L<D-3-RF[;21[>WD7\VVDP:ETQT"(^SM<GN+B604=#K9'
M81A"@P@QY/29(RA31J"!-11-1"Z MV !.E451<VL#MN3B$F44DP=).^,;S-4
M=T*B;NEED,SRLD98HO>23RR,0+ZR"" J@*4/1'3Z%9UMO7Q[ZJM*M(PXT^JR
M6[KY:PH\JPF$K"R(LX1"5T\]I(6P KD=):R.Q2,:%B)+Z5(05;2P:]P44BY
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g209588g10p12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g10p12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1\44&AO=&]S:&]P(#,N,  X0DE-! 0
M    'OB^>2@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             \L   1M          $                          0
M           $;0   \L                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   \L     4F=H=&QO;F<   1M    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   /+
M     %)G:'1L;VYG   $;0    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !CA"24T$#      4=     $   "@    B0   >
M 0#@   46  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ B0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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ML?6#'J7NC[-1.O\ -;OM#F?Z3[(K3*+,EC7Y@@. /V4?1:>=MI_P[F_]L_\
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MDD^9E+_I+3.1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ Z0$0 P$1  (1 0,1 ?_$ !X  0 " @(# 0
M       ("08' P4!! H"_\0 1A    <  @$# P(# P<'#0   0(#! 4&!P (
M$0D2$Q05(18Q(B,R%QA!)"<W45)XN#,T0E=QE]@*)28H1%-A<W21D\+$_\0
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M*QS$/;65OU=G0$[TRB+2G)KYO69:N5ZYM'%AO56=*K_O[A5_#XU\^$+2+Z<
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M+2$*]3XY].2#EG"(JKB8"JI,<(G")PB<(G")PB<(G")PB<(G")PBU#MN@2=
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M9=VUS*ZWWI+LQ5^L6'&!QLV50686>Q]M.PYNLU?SW2;3>=)NFMUFRMZA]OJ
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M%NOE%HG7?,.LNDKTBA0TA@-&ZIZ*XU#$V)Z]%-$H339J-LJ_TUML%G3:.+/
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M-L3 (V-:-B<]UF)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(HY;?\
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MC=+3!U&+*,"O9(Y_[L9OIUF:2\@HG'B54SLS!),'2'UH';E'J\<GH;X'#N:
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M6AI5I29_!JT9!TUL5I-5U<BC:^.7"TQ9$9=XJFY![;Z7[OC7E_GE/976O/\
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L+_\ IX1>]PB<(O18_P#MG_USC_\ 3A%[W")PB<(G")PB<(G")PB<(G"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g209588g10p13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g10p13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[28V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )AJ^EU0X0DE-! 0      !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @   #A"24T$)0      $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q >0            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ .__C4  @ " [_^-0 "  (X0DE-!"8       X             /X
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      S4    &              /*   $
M;          !                          $             !&P   /*
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   /*
M     %)G:'1L;VYG   $;     9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #R@    !29VAT;&]N9P
M!&P    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
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M0[;^95^E_P"#1\)E3,2EE.XU-8 S<"T[1]&6N#4X$W6E?BBX&.@/%?4_HO\
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M)))*:'6[;:NF7>@7?:'@,H;60'.L<0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"KM.1ZT":M$P\[8YSA!4R).<C/([<@^WH>#D<X()^78?C)8D!>,#_94'U/+
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M0W0B4F1-B6PFR7N[XKG<F#UK[(ZUK^J0?7+N#UEWOUPUWOG-=V=!M]<BZT[
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M;MG8+&@-75Y;B;SI.U]INVVI]'WZPW$\:M:]*T6V[FLNFB F62'E$W*FIJE
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M)F20SKL/XIZ9*BS6NCC'8Y]\\=^.,>W?GYY &*Y\IM VMNP<G>-I.000NS(
M7((WDEB&! &UIIL7C&[<UU1^M57VE4]5TC?.SNP=6@W]_886Y:.!M=.BO9H3
MHL7O\)I_:MGA[1IEBV>-(3[!4:9<BD]VJUJH; O]H<<!UR&++,>W)X 7/)).
M,# QS\\=\#)!%;^BC*"C9=EC5( 3)(\K$!@O30C'(<(VQAOZ(:22.0ULSZS=
MD]V;8[3=TM*;7UW4-=5_0'Y%R]900AUZSVDQ7-HP]H2%G[R:8<; -SS<:E"#
M0NN H.<5B"34+*&C9-+ZX;CC]M:6V84+N+8RY)&TD\@*NT$;1PQ+-N.2,#&:
M.6GO#XAHTMVCIFNM:Z'["7'5Y+4U=KT[0^O]J6FF:KV1L#>;=7L6GKN9LFR:
M>QO"WZ]T*_&VE=R54EZ9@TRR/,52VPPJ"$62U)4C!(.U@2A. 2!QG'/ /J.#
MR!R"1OEMVB"2LD@@F61[=I#'#)(JD('$>Z0E!(P&5!$H20(R[7:.9Q/B 6\E
MUOZ7;/"V#6%UNN[>W&K>NFZ6VZ%:M?,U"-:-A[$HE['Q];F-D6FR4*YU(M12
M->]=AM]Q!R# $X2'Y,!9,%QF" /F,=QZG'.#@=F[C'H1G/-:Y$5&!PS1L@VN
MK>5GZ:EBK-&,JLC>9-H91]F6#>>OKH'Q,B>SFPXU[1.R]B2G %<VIL&\ZNA4
MB)1-0ZJ[ V#9%HZO8L8^X;#$WBR$"^E*S7+#>C=/KAH4&?)MDY30_$]048X/
M;CY'.>,9/;')R1_XSCM5N0RIQRK%B<JJ;FSMV^<EF5<Y&TKWV;\8UYXRVNM@
M%-?17.L'9&I@=A(ZG%6+<>?T>Z( TWNR?>I?7RX&(@#<9BP_$MMTBSA,H0+#
MS[" &0W#YP:.9<8B.,#)&1QZ\X/?MQZXQSCN,X&2("J2PZB#;NP2),/A6(VX
M0D;BH1=P7#.I;:H=DL9X>>E=G:;IFW_S3U]^51B_;=(W$30!FRW=G5.NUU->
M UT0V%/SRYNPECY2(":/;*N%JG8L%]V,6LMG?AC8$L<.BRQW')QG)S@8!R2<
M@   <X    ':MD\IF(=F0N6EW[$$:DM*TN]45(T1&,C!(T10@4^5054;!^8U
MHIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*XLB?"BJPB5,BQUY3E>$OOM-*RC&<X
M]6$K4G.<>>,X\\8S^OZ<UO+%&0))(T)Y =U4D=L@,1D9XR/7CO6Q(I9 3''(
MX!P2B,P!QG!*@X..?PKE8SC.,9Q^N,X\\9_QQGFP'(R.QY%:Z<4IQ2L$KFT=
M97 O+ 5+8M%M)V U(>GA:[;0!LM"9BNLL2G9@T80E3(S<9^3'8?6^RA++S[+
M3F4K=0E6^2UN84626WGBC?&R22*1$;()&UV4*V0"1@G(!([5T2VEU H>:VN(
M48@*\L,D:DD$@!G4 D@$@ \@$CL:SOFBN>G%*<4KK_J1?VF#GUH_[O _(G!C
MX<;[3 O,G$S(W!#V_EX'YEI3*S#][XV9.,/Y;]W&%<9.,9X[X],^]3N;;LW'
M;G=MR=N[&-V.V<<9QG'%=!%U[08(0S685'J$.MV*1-EV"OQ:T%CA#LLEA&",
MHR)9A(@%)!##;>)KTV.^Y*PA&'U.82GR5%17L86,"W3JF(##X(D4-V_8(0T6
M,B1X \?"C];M\-1XD*%%;:C18K#:4-LL,--M-(2E"$)3C&.;8_N3_P!TO^/#
M5G8?T76O^&1?\YTFIIGV2OBB(P.3.!QY@VF<H*)FDH<0D82,83)(Y%07WFY1
M#$".M#\W,1I[$5E:77_;0K"L\$U]96\]M:W%W;075YUC:6TL\4<]U\.@DG^&
MA=A)/T(R'EZ2MTT(9\ @UH@T^_N;:[O;:QO+BSL.A\==P6TTMM9?%2&*V^+G
MC1HK;XB56C@ZSIUI 4CW,"*ABD]CZ'=B%?CLMS @RZX)?E_83)*J?579T3*@
MQ)HX4@58R9,>=2HC"D-5VPCPYQR*_G.8")44A$A>5TCQUHVKS62()+6WU83G
M0[ZZN---MK#6TD,<T-J+:_N+B&['7BD6QOH+2\:)B>@)(IXXO::[]&^OZ#!J
M+R]*\N]#-J/$>G65IJ_Q>@B\CN);>XO&N],M+6XL&^&GB;4]-N;[3UG3'Q+0
MS6L]Q 7B"[SZF:0T;2-P]JZV7ONK:[NJ@3JPNI07;"L+L*-@\[7[=)BPK "8
MDA*W%B'99I4F20@M0FY&9(F?A'MI]C%+%,@DAECEC?[LD;"1&YVG:R;@<'.2
M#Q@COQ7AVAE@EDAN%-M*H"O'<Q2*Z;BG=#$SHP5NIG:K; =A+,JMK>3M_P (
MW1FR++J+6/6/9-EN_53=?4;45>":H#ESC4_:TV=OBW: A:\<,[7%Q;2Y3[4>
MW7&.S3'QT/V@[-B$\61+4-V#LSQGC\ .?08[?F.<#DY!)SB6)7.Z')#941 ,
M,[$QD1!02JAU(;"X<Y61R'M/M;MAX=6]-<Z8ON\M:RS1:]]L*%UKJ- OVN&Q
MNZJIV$H>YA ^%6;4.018G"0&MMA+%F;BY^(2-+S#(QA\EH_(LT2OF&" 6!X4
M DCG&?W$'\\@XJ5CD4-(A4A$1RZX8)U,!5S@E)0QP/NLK*64X 8V:ZZ;FZH;
M?[*=P&=#MO%]O45S350[%7R(P736[).$Q-CB:(! DIA%P67>HN15V"G)M>%P
MH#)1YP>\3+SH4A T?3_+GGD9XYSW'?BL'4JJ!L XW;=A5PK ,K,2B[@ZD,A#
M.-I!X!&:)]4=3^%1OX[N;3^E=,[*#HG9QLQV9;+IO80&V4- [NL@M.^=&6 A
MM0I-'/B]WZ],X;V%6\TJ\H+-1R#:UA3\:409//S[]OG_ )_D>1R!02R#?AO]
M9G>"JD-D,"<$$ C>Q4@ JV&7#*I'PU14/"!N\74FWPVJ!.K*Z.Z\YV\&O=^N
M!;6=*I-'BWNVZIJUBV@_,VBS77]LE;1;]E/4/85IC6*YMR46XO%O X^F'B5)
MY/<-C@<<$8]B!D  ###MZ8S6QRS,2)(I3&PV[(B-RA<E@&A0&*,(%*2!=H/D
M0IO(L;:]:^$Y,NFK;K:[AUJB6BM:]UU$URE_L(-!"C>O];@#9?4IJ74XFQA]
M8V+#HE>4?.Z[M]E"V2768+,XY6R\),+,QAYLYQWSZ=\@YP,8[9/';N,8J(Q<
M!B\<;DNLB^6'<K*\;[P%V%,=/>PPOD"[UV[ 16&?7^I[?<WJ7HK1,[K=:M77
M[5&@C;M6@GCY,EG5'3M6UK;UGLU#VJUN?(NXFJAM9BIYU_1ZI2K3-*505MNS
M;3.R1$:H88'=@''!W9X'8XYQC@9. >V2-N-IK)ED$8E,6"3-N.R/:$81#/2$
M8,8#3 )*<+N=%@V-&36^+F-<U.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7HXXVR
MVMUYQ#332%....*2AMM",94I:UJSA*4I3C.5*5G&,8QG.<^7(9E569B%5069
MB0 J@9))/   R2> *E59V5$4LS$*JJ"S,S' 50,DDD@  $DG K\\'BA]P!E;
MV3K! "9;88>%6"=BJ9N#E<$1:B4<XZ/2="N1TN2WQ+;T5^!!.S8ZX<UMJ=*"
MQI0J6W.+?#/&G@OQS]*6J>']3\#M-#H6FWWP2:D;ZSLUO;UA)=RW^FVUQ=VK
MWUO!:V\B6]Q/)#:7C=06LHMI3<S_ *W^B*_\,_1YHNN:=XOTF+5M?\1S?!_5
M4-O%=36 CT^6ZBT/5YYW6+3KN[A2YO;J" 22V2V\4.H,NI+#80;*XO:380V%
M$<:H-QV)AQAI6?:ZR=K]4OIQEM.<^E1#66QX4Q>,9_E<0Z/C2%8]2,QFEXRC
MZX-.\<VJ@&3P;K)'!/UK_)Y\#Y"Z\31N^.XW0J6S]Q>WPXZ-X)O'(^+UCP[R
M0-VK>%/%D9(SP2E[X2EA3/&=ERX7L)&',DU+M'*L'O,E.O?8VNOQVUK7)EZO
M,?4R<H;RYA(]Z=@68>4O./:;3* PEJ<RG&$^G/JYIFU;4;$J-3\.ZE$F0'N=
M,N=)UVW7YK!I>H3ZNX'_  E21]T,2!7)-X+L6&[3O&_A&[W$A+:[O+O2KL<X
M'5:[L_JE,C!\FKRJ.S,".<8G=Z-;#"+H@CKW=@@HVZEE,&R46+37Y*UY\D8A
M8NA^NIF^K_-^*IW.?+/EC/ESHB\0^&Y&1)_$.EZ;+)C9!K;7>@W#$XPJV^LV
MEC,7.>%"$GG (%;#]&7BLQ&XMK>SU.W +-<Z%?0^(;=%'):2?03J440'KU60
MC'(JF?0#NAN+>W8[95+N^N(-3K-N"6/:3)5#ZUS<%ZUC6^MAHIQC#>4QTR:T
M,@E'4NNI4J2Y(PPEUMM3B>FUU[PCJESJ>G:'XRM=>U'0;Q;&;3K=81LM'B%Q
M->),D$2WB0:I-=6#36LDL"!8!*%DEB>7U/TA?1M=^$O"_A[6KBPNK:.\%O:I
M-,KA'>X;4[WIE7F=X7,73D2.:*.5QO=<*&CCW0\[:^+4XI3BE.*4XI5?=O/R
MT[4ZJQFX"W8+VW[H]*)8D1T-PI$?KKNQ$.(N*M>)+ZR")$QQMYA"F8V![B9"
MD+DQL+VQ_<G_ +M?\:+G]0![\CTSBSL<BTUG SG3X5(SC"G5M,8O[$!E1-N=
MWV@8<*V)^6TTXI*EMH4M.%80M24Y4C"L>2O2K.,Y3YX_?RSCSYI*@D$@$C."
M1G&>#C/;/KBJSWY(!QD D X[9 [_ )U&E3T_1J448*@H11#T"#,%@XA"PG2X
MFLBR$J/,FC:N(*$)8ZOP7WXD/'L"XT?#46'"'1\M#8<6&S0Z=X9TC2KA+FSA
MG5X(9;:SCGO;VZM]/MIY$EEM].MKF>6"QA=XHALMHXPL44,";8(8HD]-JWB_
M7=;MI+6_N+9DN+B&[OI;?3M.LKO5+RWBEAAN]6O+.U@NM2N(TGG/5O)9F>:>
MXNI-]U/-,\!=W.H8SN9K2BZM,V"+7JW7MQ4W8MGCR0RC#=GK(&!8A1ZHH93.
M@(ANGQUBD1TD7LRV8OI5[L"4ES*,7_R''X>G[/X_8?-9'.<DXX.>QR.3D'(Q
MD8R.2#G P=46MO 68K .H5[8&_(^SH*+UUKONV9)2GG!A?:1?36T^T^RKXN8
M8@7=!,4]L/\ B19!C9;$QV76(=0;5[Q+,YE,&>,]CV]_^WOG]?E61,>3A7Q@
MXS(I(.!@D],9 ;<2  2"%!!!9K/]A/!NTMLF7JLEHW85^ZPJU01U:P!JFN/P
MP_0& -.["!>P%Q+Q1!RM%+#'VA=K$''3)5Y5:76)E@JFOBUM VN'4VA4QD\9
MYQC&?;CC/?;QC (]Q@UF)W)CZF)A%LV+)YAMC^[$6_UG1QD&)75>21ACFKV:
MRZ\/:[[,]G>P'XEBSX782NZ !PZHP(5"=JBM* [X(DR'B?SGF2B;$NYHDLM-
M0(&1WP7$.+F9DX6U%:CC P#GG))!!]L# (P.^2V>_':M=FJO#&[(=?2B[5H_
MMK2Z[9]=5V#JG1,>PZ+78:W+T,YN[86\++KW>\=Z_)+VDP=+7L?76[CK$IJT
MF-&44+.8:7).'X[LG;Z C\3D8P,8P!C!R>YX('H2V;M$<%(V4Y.0TF]<%$ "
M@(C#;()&!9WRK1HP)C=Y>)6/"'/4;4U,JM?WF"-;$U 8ZF'-6V&[ZWDEZ%,5
MU@E;+M*ZUL*C#[>,GE:A=-A;PVQ8VQP>TCB%:<F5"8T3*DZUE^:\OS['U'!R
M<<XY&,9X7)SV%9$P@DH)L,CC:70%'+,$!<(1*@387\D)9BP&T*&;DP?"-(3;
M3&N5VV9J@P;=V)T1V"5AU/K\!U]4FE]1]G;-V3;ZW6:@$/.B:\ V6O8;86$P
MWB2^-0%^WLSUM*$YCO''MZ =_;_I\JQ+*Q!*M_JU7E\^95"ALE2=HP,)Z#RA
M@, ;$>F_7-WJIH&O:2D62%;EU^Y[DL[!N"%4 B_#VCN;8&U( E@6N<2S'37H
M5U8K^7$2O:EK&*FLQX;4A$-B*P)R2><>F3D@#@ G S@8'8#V [5:+BHIQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2N"3*#@HZ<7+SH@P6-BOSB!&?(:BPH4.*TM^3*E
M27U(98CL,H6Z\\ZM+;;:%+6K"4YSC3<7$%K!+<W,T5O;P1O-//-(D4,,4:EY
M)99'*HD<: N[L0JJ"2<"M]M;7%Y<06EI!-=75U-';VUM;QO-/<3S.(XH88HP
MTDLLCLJ)&BLSL0J@D@543:6SJD[3B.S-UGF]:=<0R??8%'/D0;!ME]M+DF&@
MH&PW]Q^&IV(ZG0U#B17#UT:;R]88D<%EX"2\>RS^*2DEY'<6OAIG5;736CD6
M_P#$TC,!$;RV"_$1:7*P'P^E"/XK5%(-^D=H6L;GV-Q?6/T?H$M)HK_QI*ZV
MS7MH/CH/#MS-Y$T_P^MOU?K3Q1(Q,3:A;+-%IDFZ/2.OJ"IJ5EK0['=7=U=F
MMD4+=]\>7KZ#**#/RYUQ&Z['-TS-;:F!0C!.LYV,PW'F59VPGCSKLRUZZ<%3
MTL+L\$:9D&1E3AQ1]YJ,VJO%IEO83W&C0V%S\6D=G#-<3&Z$;1)=32VLG07I
M0XMK>UCWHD;RR&20S2*GQ[Q%>^)KUM%CL;[4- BL=2?4R+.VNM1O9+]H9HSJ
MFH7-G*;4NB@6=OIT3W"I#<SW$L\QN)DCVOLWC<VK&VF-ETU.SZ;';;0UL;3H
M2;BR#XJ$I2ARW::<DDC;N6VL(P[/UJ2MLB;)4ZZBCUZ"C"&^KK7=L/MXC<Q@
M<3VRGJ #UEM<LY('=H&E+'_V4%6!NM2L3B^M_C[<9)O=.B<SJ/>YTTM)*W'>
M2QDN6D;)%I"G:::3L"E;("IL%%LX:T",R'H;TH1-:DYA$(JO1,%DXR58E"BT
M%WS9("23$4C ?2IB9%8>0IO'7#/#.F^&1)%R02ISAAW5AW5E/#*P#*>" :L;
M6[M;V+K6D\5Q'N*%HG#;'7AHY /-'(AX>-PKHV59001642HL6:RN/,CL2H[F
M,X<8D-(?:7C/[X6TXE:%X_\ <I.<9_PYD\:2J4D19$889'4,I'L58$'\Q76D
MCQ.LD;O'(ARKQLR.I'8JRD$$>X-49ZU]>_RMV_LNZ*I(P!'LWV# .1$+V*8D
M6)E/ ISXH;")!8$-J%.*M3I3KS\MR9&3$ACH$? YE<R=\\\)^!/"GAK7=;UC
M1M-U:TOM1>2)6O0!90V4HM;FXALE#DQ"2^5L1R]1Q# G2:./*O\ 8?I ^DOQ
M#XO\*^%]!U/6;6_MM)2*2>.&&!+JXOX1?6MO<WTJ.S220Z<\4>8DCB>6>66?
M?<,!%>[GT:OC=.*4XI3BE.*5!.V?\HO5_P#WT6?_ *<M\\VQ_<G_ +I?\>&K
M.P_HNM?\,B_YSI-3MS5593BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE1V8OB:Q)//VML&#K=?'0RDLVL],D2%QB<PG"&LLB?P^SE\C+
MD#L,('19TF0]*F18<#$^2ZAI=)=:P+"2\;45L[2QLH(KF6[:\E=S'<2W$-NB
M6WP2%YY9+<HL$<KNTLD<4(GD=5/H+30GU./3X])-]?ZEJ-S/:0V*V4,:"2T@
MM;BZD:Z.H.$MH8KH2-<S0Q11PQ2SW)MXD9UK#<+^7N%J&"I-2G6RUK3%.Z_Z
M^(EMPF143$C.1&UNQAK#4X=3@S$N/F97:Y.CD9S#T5QX'7[E>8+0ZLT'3NM>
MN8;K5;61;2*1+C2O#4I53NC8&WU;Q(1O19%D ELM,;J)9,J3R)=:DD2:?OU7
MQ%8>#XYO#_A26/6?%-W;O!J^O6KE8+6"8-%<6&C710M8:4ZEX-1UQD^.UI!-
M8Z3#]6&X&JQ_4M//[UWA^*=E'6]DBM,',)/GL0U0Z02VO >CS6-9:LKKLB:P
M)UYJJ4U"*WHP_()62^;+BU\-8; ]&UX7J\?Z#;VATZ 75RPFU:]A98FP52PL
M)05<P1DGI/>+F-&8F4VN]W++<6YC\]9:<='A&IWTOQ7B'4;=TMY=ICBT?3)U
MV2_ 0$L;5]04&-92[7<MIOEFE:.XM!#LBYHK33BE0W=M&4BXF57"%DO0=C8C
MM1F-EZ\G)K5P4S'_ %B133[<>0(N@F*K.5,UV]B+/74KSESZGW?2XGEEM(I6
MZJ[H9\8$\#=.3 [!^"DJCN$F21 >=N:KKG2[6YE^(7JVEY@ 7MF_0N2%SM64
MA6BNHUR=L-Y%<0 G(BSS6'_BW>.K<X;V!5T;FIS/DG\?:L%*A7P9&3C.52;9
MJ1V5(R<2RC&/D$=9%BQ4C(RK,'6H]C'DG5U;RW.)H_BHO_GMEQ,HYYEMLDOC
MC+6[,S$^6!17/\1J=CQ=P#4K<9_G=A'MND4?UKC3F9C+@<%["2661SY+"->W
M"T#NUW<EEV?&'[!U[; NO3X\ L?6:79*U8V%F:O6['!F'_OKJ9=%R(<R?8ZN
M1!20$(@T7KLSY3@V5&F"&HL[OXJ2X59X)4@<(5CBD212R(XZF^5]I!+HR%%8
M,A!VD%:PTG5#J4]^J75I/%9SI#MAMYH9OM;:WN%>7JW,AC97DGMWA:%9!+ ^
MXQLK1BT/+"KRG%*<4J+-YW:1K726XMC1#5:KDJ@:LV#=8UAN:2"Z>!D56I%S
MK)FUH$,22JJV+=@)G'4C(T@@H6Q*Q"8=DY:;5(QD9[9Y_#]M9)MWKO&4W#<
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M0)G%AC!B$VI[#*$2X[[*W8ZI$5Q^.V5&E13RT$14Z.QHBGAEDFCC96>W94F
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M;(:5)'X)Q6F8Q!,1UGYD=I#+^5-XQC',\,3O'(\:-)%NZ3LH9H]XPVTGE=P
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MW/G17$(<S<*JJH50%4=@!@#G/Y<\UZJ*.*).FBK$B*=B1H H.?NA1M"@Y))
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M28+]!Z #V&I:=<:;!X<\'D ZE9VT=[K:@G:_BWQ2;?4-3B.?,&TJU;2/#)!
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M(G%VF!&,A9P>?"99-R, @^Q![ _L/'Y$8/K6:$*RN3RKHP!17! )))5\HP!
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MHE&"@"Q@*H;!4_9LIW$$(6ZT>IW0_3SLCK.Y]"]:[,Z:&S%0Z[U[3M^VCO\
MUQ8^N$ZWW7=5*799FL*#8;18]M5>W@-*=:P]X4**Q*'4S<C8-@'+$!X[=$BM
MOVH"2<$Y ! )SZY/&#GDYX( W,<X&34]1F(5YBP59@K.92%W[V8(5)<]5B2
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MFL3%*S[:FC=X#$+C+Q_,A$+6BA\U&&#S'N5MW*C3)"[*D%LGQUX[,%1(XB3
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MP2D HV3"IQ[D \\'(QQD>F,GL,$\\'!K:82I"LR(VQG*L2"H$?54$[=NZ12
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MLMK===<6E#;;3:<K<<<6O*4(0A"<J4M6<)2G&<JSC&,YX)P"3V')J"0 22
M,DG@ #N2?0"JTZF:=VY<)?84JVI59^#.K&@QSZ%82S19+S*CFSLLKQY(([5E
M0HDD%(_5QC7 RLN,X@RK'8H;E?;?SJ4WS#[/!CLE/I"3Y[C'8-<D H>2(%C/
ME:21:I=/!U"Y;6) >AL:WTE">/A&8&6_QVWZBRHT)Y*V,=N1L>>X2H:[=Z@1
MV5L=1H8RPR0#>N9,:=;#6(N2@N)*V"4KX0$#R*Q+@(FV',!N<?\ =S.;R#$8
MCHDQG$VT>^S\D^E#PFOTA7NF:+!?RV"Z!+'<:C>+'\1;QRZU/9VEI9&WZL"R
MWQ@2:]#]8&SMA&LD974X77]0?0WXX?Z*['6/$-SI<&IMXG@EM='L7E%I=2Q^
M'K:_OK[4!>=&Y:#35N7M]/,8MR-0O#*T,RMHMQ&TH;N#MO5;3'72%+?(HV-;
M:M63[Q!W$B;+UAK2"F[; DELY0K+\:SC*O"H)1_V_)4R_1$Y4TJ0AQ/W'0K8
M:99H%DDE72=-CMX9IFWRRSB%+&UDD<\M.&;XMF[L8'; P<?'([U[O4M9\0O%
M#;N'O;](;=.G;PWVISNEM%;)G[-+:2X>X@CR0L=IM.0,&U_-->=IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*KYMZ"EW:G50CF3-0J'M^Z14Q&Y3K8^1
MB?UUW8XIZ7"3GV9,F-F E$&0YC+D1N3-0UG"9;OGMC^Y/_=J?_[1#].>W;.#
MZ"K.QYM-9&< :?"_&,DC5M,0*3C.S[0L5! +K&QR47%@^:JK*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4JLVWI$C:EL@]=PKSJ0LX;$M&]2D5Q;?UVMI,J
M3&&4%$EI25LF-MSAQ$/(2TK#\*B"KC+]R 1FUN1(K[HFYD%BGW&427C<^6 M
MA(0>/-=%70\\0I*3M8H32:B3?W"Z-$3TFC6XU:13C98LS+'9@CM)J3QR1-CE
M+.*Z;*2/ QEN]6IC7]50\,&-SRTAV#6:568V4Q4F+&0Q\,"&9]IM28<!#B</
MDYB&5,!04,B6?0F&.?4G1K.IKI%@98H?B+N:2*RTRQ5MC7NH7!,=I;!@"8XR
MP,EQ/M9;6TBN+J0"*!R/;>'=%&M:@EH\PL=.M8);[5K_ &!X],TBS4/>7?3R
M@ED2/$-E:AE:]OIK2QA/6N8P>FJVJQPJL0A9R>2*G)!)RT6@W *F 2[!<9DR
M,3FF'FQ1"*OX\:9$BQP<%]R0T&#P!PF+G$:+C"N73_#\-M816]W--<WDD[:A
MJ-Y%/<6C7NJ32I/-=,MO-&>FDL<<=G"[.MI:0P6T9$<0![=5\47%YJDUW8P6
M]G8Q6RZ7I6GS6MG?KIVC0136UO9H]W;2@RR03S2W]Q&D;7U]<7-[*.M,6$>T
MQM-U[';&L_J5)!Z1J032=;<?<=?=:N-NCA-G;2D8D/..JF(?KKNDQR9:LJ>:
M)";!$=>6]\EMOU[J+;3;6 9W73M=N69F8P6^^TM [,2Q<2?',Q8DNKQN3G!-
M?<L8=+MHR%674KF;4I@B*B]"%I+2R4(@54 F^L6"* FQXBJ@8JS/.&J>G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OA)DQH4:1,F2&(D2(P[)E2I+K;$:-&8;
M4Z_(D/NJ0TRPRTA3CKKBDMMMI4M:DIQG. !)P!DG@ =R?:I569@J@LS$*JJ"
M69B<  #DDG@ <D\"JR5KNYT[N6O-@;;JG:#0]CUCJF0U%V5?0VTJ<0JE'D27
M,,P&[*:C%G((K[5Y260JY3J$&WE(:$*FN+2G,@$]@3W[<]AD_H.3[#D\5DL;
MN<(CL<.V%4L=L2&21N >(XP7<]D0%FP 37H;V!1MJE.G^P]9W"M7ZB6O;-D*
MUJX5 T/L-<.CU]==^M8EBRXN1)@S&DO-/1W<LO+RQ)9>CO8;?:<;3LC^Y/\
MW2G\C-"0?S'-6-BK+:ZT&!4_5<#8((.UM7TAE.#Z,I#*>Q4@C@BK2\U55TXI
M7C.<8QG.<XQC'ZYSG/EC&/\ '.<_MQ2O/%*<4IQ2G%*<4IQ2G%*<4IQ2G%*K
MAM#LK6M:3R%<>JEZ-7!2(L6JA85<G-0;>>,S&@]:$"S[K>1J$FC\F*+5/<5F
M,,2J41(>R.@3)#-?<Z@MNS1]&9Y.%C54\LKN0L:*W^VY52<83)9L*K$4U_K4
M%BSPF"ZEN2%%O"D#A;F:1EC@BCE(V#J3.L9<^1/,[D(CD9KIW7LS7U7E.V6?
M&-["N)21<MFV:,VMM@U<"<>,S);@)=_IF:[7!T,=5*E#>RIZ%5@0B/)6_,3*
MDO[[6$P1DR,'GE8RW$G8-*P .WVC156.('E8T4'+9)Z=-LVM(&Z[B:\N9&N;
MZ=00LMS(JJPC!Y6""-([:V0Y9+>&)6+.&9NGIN/S*NDC:$C'NU*M_95S5;:L
MY4R04MQ<&V[!0C.,)5]R]'57JM*3A2<UB).*P)#L&XN(3YO2Q]>ZH_B!_-IM
MC\18^'4[I,2S0:EK8!&"+MD-EIL@S_H^*>YAD:#52!](UG'AO18_"\>%U;4O
MA=3\5N/OVVU1/I'APD'*FQ21=2U>%L$:M-;6=Q$ESH0)E&VV@/2:M9+C8928
M0&I@2]E-2U?M%$@X$@F1D9Q^^<,Q(SSGEC]<^GRQ^N>>PBC>:6.&,;I)9$CC
M7^T[L%4?F2!7C((9+B:&WB7=+/+'#&O;=)*X1%SZ99@*BOK;6"];T_69-GC.
M1+I=G3&SKU&?_FD0KALLQ.NIL,XYE#:W6JR^:35A^5H3ED4$@14H;:8;;1TW
M\B274@B(,,.RVA([-%;(L"28]#*(^JV.[NQ[G-=FK31RWTPA.;>W$=G;$=FM
M[.-;:*3'H9ECZS^\DC$Y))J=><=5U.*4XI3BE.*4XI3BE.*4XI750#H4I.-"
MQI8=/)5R9&'V"!$FQY$P).F#H9B)$*QFG%/0)$H40@D8[4E#:WH4N/);PIIU
M"LXJZ,7565F0A7 ()1B P##NI*L& .,@@C@BM:2Q.\L:2([PLJ3(KJS1.R+*
MJR*"2C-&Z2*& )1U8#:P)[7F5;*<4IQ2HXW'*!0M1[1EVBAE]IUJ/KNZ.V'6
M("MYN)S8P1-<)9*T0/4L(<Q9B=N@^^ A %HRV6DD&X+ODV^O.)'<>G/\=\?O
M%9("70!MI+* V0NTDCS;F957'?+,H'<L!S7Y3:UJW<6XJ59.R!WI;V-UGLNK
M=J?#^V/?>M,+KG8Z-1*_TUZK['--UC3.D!!*+ )=@;[5 !"3<;YZ  Y\K+0,
M"58!$$C1<:6(5@"!@_ULGN1YL@8  ]  3D\ UT,(Y50QJD3A9.JTDR_:NJ&0
MLL95!&& *H@+[I3M5LE5&SWH!J/9^NJ/H [?!5VU:*V1WJ[F;8I6A[;7PU>(
MTC7^V0'9JXZ_9L@1\4JRU*QQP#RIZZDV7A01+=D?BF N#,?&8>V,_9SC STU
M.[G)'5B&WOMQDALXW9 &[&0>NQ8&QUE BAA8PR&4;S(R#5=,0P$%S$(F9UE+
M"(3;XD"RB(R1R;O.::JJ<4JG?>DC?\=?3]/UHD[%L^SR0[73EC!5&\7)RGUR
MP)E+MMDEC=?5^R6)AABMPR0Z-.BC_7'*$Q_QW4S%1DKJM9:?X&2*VWK+<,L'
M42*:4PQR?ZV4K DDF!&&4,JY#LN#G /G/%+W?U/-;V0E$]\Z61FBMKNZ-M#-
MN^(G:.RAGG 6!9$5U3RR.F#N*@P5UUK_ &XM>MJ?)L6W=L#)0L5:*_9)AD=K
MRJ%'S]2,&0];DA*7LWJGBSSJS<0<&O&V++8[>R99R9E()"W)P^2T[Q:>FJ2V
M\)ENKI659(Y&=8(G+Q.RH4AN=-$ICE18WZDD@?#G*D@U6:-#X@N+&U:?4=0C
M9$N(9S)'96TAEMY98H&BM;[P[\0T%U"D,PGGN5E42D/&SHV9E#UOM.TY4&2.
MQ-B-NG_N?Q')G5SKK815%5 >?2,P5=%0:24-H.,MLNQUUD407#R^EH@Q%RAU
M:>Q8]2^R!GG!<L9"4L9%AV]@2%B++)C@HC%<\@5910:X#;J][>YF,O6=X-%F
MBM-A/3$IB6SEE68 %3;PR,I($@7!->\(KVB6Q7WGSY(&\?/R *Q]KZ]5BR2J
M^AE;#;)VQ2=<=CEBX@*:I_*F9L6?,>0W&?7*A0T^WZP;42%.]D+R%,2V,;F,
M9&'D,%^5V'/!5CV.54#-$?7=L):5HC+*8BEQI$$[0X( FF:QULQK"P)(978@
M [E4X!I??^UO;^M]DZM5!;, MJZM'ZWJ[8MR_ASV  "Q;AN0HY!ILV71)FUR
MMLL<(7(J['TMEKIX.-?1;'H3D,F^8J[1:HGU/58]2CB50UK&\=K/,;"9$6:[
M8")C$;II'5#$-LB.BXFP0Y,8;S5WKWB*#6X+=-DEA!-!I][=?4MW#$MUJ<I2
MU=K5]1DN)U1K<"*>">*,BZ"LDC2VPEN03V3V+&1[5(^ZJ<]-/+0PQ)J!U [)
MR9).5->D,MR*FS%V+*S<A#68ZUS#M7R6#PVE,/29C34F,X];O/?*)"'C;IL%
M8#2[_EF) Z8$[-*@QDO'E1D;F (KTCWFL(+AC<6S"VD6)POAK6V:1F) -N%O
MV-S&,'=+;B6-1@LV"">61O?9L;(MD;,ZB3ET^*,ES%C^M&])$<T@I\7VF:E*
M;V4Y&M,N+\MO[**$=FO#?:E?-PQF)(2W!FU)3(,VY,0!.+&\(;=C CQ,1*1D
M;@C';SNQ@U+W6N(UPO4M'^&6-F*:'JI$HDQ@6[#4&%PRY'46(MLYW;=I K7V
M>[ ]T:+60U9UT#J]BV)L!P>S54@-1W*MR([/TA&W&,LD;KL2>(R8$! DN.6#
M.C9,V$_+;CY0W,4RI-?J5]J\$2);I$\\^WIA;:6,C"-,_FFG*;U1#N3!8' P
M&JGUS5O$EI!%!9103WUYL%L(M/N(2/LGN9</=7C1=2.&%P\11G5F P&Y$V:T
MVQV=V=3J%;(4[7XIB]4%B[)^-U^N=A@ )68<AZ74"Q5?9"OH1:(TZ(^,3#Q
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MOCZYU2STZ>U33K&.XF2PD$IBZCZ;I#06=F\,98[A;Q:<(!&S&*3: >^#7_Q
MIX_7KIC7>HH<^7;)_P!_F)8-C 6"@9B3$^,*+#']*7Y=*AJ:R^VJPKL$Q4]#
MV9$=$',;/JMUU7PZZP,MKXIC^/+6\$<^B!I+.:,A6GO6CO8EA@D)W0O,D<94
M,26 )%1<:%X;AEU9(]8CF2RM(98V2YTZ59'E1F/P+_6-H=0G0C[2UBAW1, C
M%BV!IVE:8[$7SM$^ V)3?:U=:NSK96YVD%J/7TG*7"FS6[,6J,#<#VNJQN&3
M.7"6X]EMQ@+F37%+A/ X]5>7)QRK]*=O%$DMMIK?5R:]_(2&&6XUU=?&I#3?
M)K$FA&WETE-+$Q"X:[9A;DZB+OXM1II^T?4&@VGA<M;:PC^(H/ 9\26\,FHI
M]5&Q2!K9(C&-7FM?BMJX!2.4+J.VU"F4?%5^@63&O@,)<1M0LMV&1!5F%BZ:
M*C:>J:AM3K<#,MA "I#&,UM@Y5FHC42&R6FS%2(,6+%Q&=5A]:N:9==@'6E?
M1=5N6M+CX:=(XITEOI9"1\7 \\@66$%2[R1GIMO!P01GX)'IUO//IYN;K1%-
MY92W<\TNM2G,A"-B_>-+J2TOF9F/PY3+OO# ;>>\L!+=:).T55F2Z]B(Q6,4
M"+*UB&)QV)+KL))Y;$F1NFG?C-E;&)CBV)\F@J#K<PIB4<S&3!EXOJJ1?$*-
M UN[-@8RYMKC38OK43XVC3C=7"(AM@P-P;LP@JC=,.Y7.FTTW2IET8W.JZ9;
M?&M>?'&2[U16L5@WF WRV^@7QM_B"%6 V2ZH9,@S);*2ZT>[>&=A!]C58K?+
M)?J[16]4RV@**(_L2E#3.QV' A(U'++UUV?HS,N0MKY>($(U.;D"QC).('E6
M;&';)#H]=\7WND21V5M#IN@QR65]JC:QXF3P_>6^H3VJV:VWAS3/C]2L+6WO
MW%Y<7%V][>6J7$=B_P "SQ+/<6_TSZ/O#&DZMI=]+ B:[J2Z[864NG61G>[L
M-*N!J"G6K@3>"]:N6L5:"")#I]I<%9[N!]0CM',%A=6>TB[V &:XTZ-G8F%!
M\;08=T^1M-9^\MT[8Z1,C,7)>SV3>(2Q/37%)&K)""])E?82525S=DCGICN!
M-O9:]+J=I:7UQX9U.TN-2T^#5Y5M[G28K*QEGA$TNB"VGGBO1>+(6CAE,"64
M:M$LTB,DJKXOQ)I/AZVUCQ##:ZWITBVOBJ\TVS$3Z@JSZ5%="(:I%'8^'[K3
M39E2[!H=3^) C;X?2KA!$T\C5XAO5V;JY-APRB/(AV9S9.&=< AC3DEM<_-=
M9;?9W_:G:<XEI,+"D#6=H,EG5>N1,K6'W8X_>NI]1[>/^3VM6WQJNZR7%YHT
MJ:08=Q,6I?#7;FXDNMN+9M/$T<?43KLNV3%-=:?H\<6L/;ZOI]PUG):)IZQS
MZN9+])=@GDLTN?#=D)DA+.9?K Z1(@1NA%=>0R]:%G;I4.U[DZ4/8GRK<2Q;
M<M:PJ<!,BNHD0L0X).-'VC8T5N+EE4M+9H21L4^2G*G'!<5;#3<F%U=)! W\
MGM9M_C6>!8YYM/=]-9-H^+O6M[MT-O(6W(L!F<!6#JI*@[KG3-*CDU58-4T>
M9+2SBFM6CO=6(NYG#EXK$SZ':M/<1G:)([N.RA!(Z<T@+M'JAT]2-C"-P:U]
MG7M3 E1?9K:D]>U0U%UQ,V.^#C MBBBM8)MC+=B\'03D@\I1@Q::T)P%>8@J
M^U(.(!Q55%M])ES?W*Q3P"6PU/4]2\+P>';=[YM9TV71F9UU^ZS/+9363'3N
ME=P16UDUA)>0+U;Q2SS?9->\,Z/%H6JM%JUY)-:^#/#VLR/=7MPGAR[DU6XT
MQHK*S$FFQQ6FHQI+OLA!J%^NHQ6]RWP]EF8P[7CI[:\0=L-\=:I,:3&ML&-5
M%R^OMIM#8D-F3+1*B-BZ_?!4^]17V4LI;LD.6$:@>G#\B#(3*:;:M7UNPB66
M272M<:.SF%K<?#VMU++=RN2JW%BL-C.[VJE27DCBE3!4LZ!LGXU;:/;SS:9&
M9=*/Q=C+<R[O$VFV2HR*K!+JXNXQ!IMSYO+:3[WE(*HQVDGGV"W[)@S=JX''
MAJ(P*'6E4^._UTVY8%#9<QR"V55*G@;LTG;#,K*Y>4Q:+!KTFJ8=;>,NDF!\
MGY,R:YI=N;E9M/UUCIO3:]>WT[4YUNUN&581I:P:/.UVT1=?B19?6!B =IE@
M56*Q;:&MPFBD/IV[5'O%(E\6^'+(J+;>0+U;R6,:#N"?8OK#QI?':MJ"\D:G
M7GVJLFX,[@N*HKFS#(B%UEI),&C79_M5JX-5[\HG?I):SEJ]JXTD?)C3VW(R
MI*+I(@XCQP@^OOV:%+K]B5+Y+SQY!I37%E8:+'>2:1IK^*=<?58C:2-H<I$=
MO9Z4UWX?OOB]686EZ?A&>P5)$<,6<70T_P"C^#_!^FWVC:9<WVIZ;I\FJ^,[
MOPY9!XO"FN/<S1P:>V+J>^U&UEM+*)IX56ZL([XR?%-=):-'<:>+N\FN[+LU
M=8U8P;M[BGG="B2UF:QHO9Q4E-N2:ZXITXJ\2K&^(B2VI+;+KE!*"Y]M.2F7
M76R",&83;':WB#1[AUDM[/6=E[;OJ]HXTO5! FG,&E6WF*:3T8=0,:D)8O<0
MWI+(B6;LT?4^?W^A=&?5=JZ9BT\0RZ4@_E5X>0C;<"/;%9&X6ZN+(A@#K4 ^
MJH4W,\H$,I&1@9]JF2]3/3]C[.DYD1[4X<A,Z456 UP<P[-3!S=/NZ9/+:ZP
M'2E"0L1!RMR; IF.^XLDS)]#T1Z]I]Q\.L.FZG']:+(]J]SI>MQ-8K:YZJWG
M6M8$L7G*MTAJ4<33!E-NK!D:M%UI#01ZV>GH/^CI+-&,?B?2[V91/L_])%IJ
M936U.X&ZELH[Y+,;UEZ+(Q7KQT*5-#T9$Z_=CSTE%D++Q-.5$36)A92E1,-0
MM@C*SK6G08M3B9QE(Y7U@C$UAZ;\R<0]O"F(C\16\JP2QZ/?Q)J$C6R1MI&K
M))9M$P#3S)>9EM$?<"D]Q]DX#&/RJQK.?2Y(9]33?X63X2SAE;X;6[2]A=75
MCC2YQJ-VMY><$S0Q2SR1,%4I&6"M3;IW7KN.3U/!&2XX@$I=$N[D=F63NQ6W
MX=A46G4MY3D:TE248#58DKU0V!H3XX,,53D/"BMNNN+71Z)](5SXGNS)/I]K
M:6_B>.^U"QM8D>WU#2HM-NHG,6I1,H2^,JWZQ3ZA$EH(-0B:S:*Z#K<K]%^D
M#PSIFD0^*7M9KR6]T_5-)L[VX,>GC1[YM0EU&Y1[":R1'6Y_FC3QV]T;BXNM
M.D6^>:'IF!MLG/5U\1IQ2G%*<4K5+XP1F6+ZWZB@%3I*L:<MW<SJA2^S1Z"<
M(U6% ZYV3:@R%L5NSVP5*'3:Q3BBOIPUI+H*#&4!B,J)+FMQ);[;K!/89[G\
M@,D_D.3\JR56<D(K,0K,0H+$*BEW8@ G:B*SL>RJI8D $U6KP]Y?9:W]=M(E
M=2 Z;M34FL.X_;J-J2W;2V];A$MWKR!([_UKIU^"9;H6PREIIT<4>B@JV=1,
M($EP8E?CM#WJ_P#).C-BMA9 <9:-5QSZ/&PQ@<G"^N 1DY)P#VP3]*'4$DVJ
M]S8PVZJRLI(2]T^X38$0J7,=N6)DZ:L@9^H\K(C[5OO^Y'^J;K-_S"[3_P"V
M+FNN"N/(L?=!O,?X^GNLLC#DA#;^<]B]HL_'CJ2O*Y&,*ZP+][*%)0G#"?2I
M?K\\+QA.?.>.<GTXX[GV^7XUDH4[MS$87*X7.YLCRGD;1C)W<\@#'.1UEC>[
M:6 (1%&-$=4K/ DQUY<!&M^;(EC"3K/]-'CRF9W5N3$]*I#;64NO,.I87A+V
M$94C'.:ZM+2^@>TOK:"[M9MHFM[F&.X@D56##?#*K1N%90P# C< 1@@&NJPO
M;O3KN"\L;V[TZZA?,=[8S2P74 8%'>&6&2*56,;,I"R)O4E"P#&D4AW KX>
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M9LNO#[H0NH)9ZR8*SZZ19F>:'&6GIL=EU"8;PC SD'N..>WN.&]01Q@]NX8
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@_73/_P RN*5V'%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g209588g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g11i11.jpg
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MTB(Q,W*R(R0F-W>V-#A1"D%"<24H,C5#87FQN,?P_\0 '@$! 0 " P$! 0$
M          $" P0%!@<("0K_Q !3$0 ! @,#!@8/!P,!!0@# 0 !  (#!!$%
M(3$&!Q)!49$3%%)A<=(5%Q@B4U97@9*3H='3X? RE**QP=35""-"\3-B<G.R
M%B0T-C=V=[8E@K5#_]H # ,!  (1 Q$ /P#?7W@/<?X\RW\+'?R7G]*^TUFQ
M\4+.];/?NU_#3NF<^WE(MOU-E_QZ>\![C_'F6_A8[^2\=IK-CXH6=ZV>_=IW
M3.?;RD6WZFR_X]/> ]Q_CS+?PL=_)>.TUFQ\4+.];/?NT[IG/MY2+;]39?\
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M0<A%$">R]REDHSH<.,V#-R4A+13"BMTH440XUFL>8<1O?0W@:+VWM)%ZQ_O
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M<*).RX1+*+.4.4U=_+#97SYOJ9"ULILI\X.:BUW6K+R3;5R.?;$>09(/C2K
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MYF9M"7M":F8C(<2,Z&R7;! 8JUM[L3.;EM ):\A0#,)!'F<<;"V@IJJF*16
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MD3XR>PIU"^ %?_+W/]7QVV\Y/CC;/KF?#3N=,Q_DSR8^Z1/C)["G4+X 5_\
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M\F/ND3XR>PIU"^ %?_+W/]7QVV\Y/CC;/KF?#3N=,Q_DSR8^Z1/C)["G4+X
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M2=I2%-9YZI*D8^-+MV2Y]DI@@8XDC1-PJ;C7FNY_GJ5Q5OVZCDOGG:X++O\
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M/7B#)/0.Q*1[S8K=VUW>I;K+U*FNE=6H/-<M"83X+_5L9&[?I2,]G;:>3E2
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M<27K+41>QX]/XO,E(ZY9EA-H&B<BG64A)LJ($ECAL_"*UE)'UB"L1TA&.)K
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MV+B\IN_Y)QX'%A^O.IE[TN]_V;ZH_CM+?[(\=BXO*;O^2<>'(/L]Z>]+O?\
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M'8N+RF[_ ))QX<@^SWI[TN]_V;ZH_CM+?[(\=BXO*;O^2<>'(/L]Z>]+O?\
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M'8N+RF[_ ))QX<@^SWI[TN]_V;ZH_CM+?[(\=BXO*;O^2<>'(/L]Z>]+O?\
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M'8N+RF[_ ))QX<@^SWI[TN]_V;ZH_CM+?[(\=BXO*;O^2<>'(/L]Z>]+O?\
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M=?Y-W&$=L;(LHZ*Z8)< (K(0;B2'0S7O@131) P-:+&%-"$V7&B7&$^*YU2
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M,ZZ<2B\J'O=U$]VM=/WQJ_YG*_T?QV4@>#B[F==.)1>5#WNZB>[6NG[XU?\
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MJ8Z%H_78H17S=B=WC,F('2\4'CD7#TE!B305H#3'S<PI7I&*LB-=JG3R4=8
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MY.GFSJ:9=DG:<=%9']D!SZ?/+7@<M>,GQR(FRHELYC:3-9LY&/F3UJ4+8:1
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M&E+N:XA2FG>]79(5XA8JKK?OXA.ZPF_:&V:&@X>J<]7K KE^U"L9!M$8C.H
M'"P+M724]A: K4A8$\,.YS"GIQ-1HB*:1EPBY;0..E]JHK3F-],,-R%C>#)#
M0"&AQKI!PPUGO2#J% =U5LOXH_:CM5U<M"K0M+293(CMG6IWK=2P?,0BQAI
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MX=1V*D-*L;.&8PP2="9+AO(Q84&:D!0*S BWA-(@:3AKPOQ/-M4R<=SZ,0O
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MIZP'OMLO\R>_SN-!G);Z(]R5.T[RGK >^VR_S)[_ #N-!G);Z(]R5.T[RGK
M>^VR_P R>_SN-!G);Z(]R5.T[RGK >^VR_S)[_.XT&<EOHCW)4[3O*>L![[;
M+_,GO\[C09R6^B/<E3M.\IZP'OMLO\R>_P [C09R6^B/<E3M.\IZP'OMLO\
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M'U(LFWTC[IXF@JGOJ_%[-4'#<BW41?9>Z9?JN%'NZCC<)> &.8(3 Q]-)H%
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MUS>_B&%)Q>/7@;(K'D]B^&%3/;V32^3OV^7RO;6RIT-/NNA@N1L$&R>QS1:
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M)PB<(G")PB<(G"+I5HZO&_6#LSXI<>Z@4;&2<EBG7;IY(JSJ$<6&0\=/K-?
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M3K9;1^_!S12*R.="8M"Y HS@D1"K"#$&KN: 9$_D\]L^.Q\JG.@]AAY+7$9
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M!\EAL'B<?CFFGJZ+:"DBM3^B@[#IIUP&M6;)I7[K5D**A"@)HM.[&=MHPA'
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M^O\ 59:$=*58K&^UD<)3,'(VG9>+6+&,M2D5+>B ;>?6EV<L11,VR%3$*6D
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<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g209588g11q01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g11q01.jpg
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M@;6W)"5AD28S-/_$ !T! 0$  @,! 0$            ! @,$!@<%" G_Q !
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M]%@)!K'#DC+OAL.+@@8D<\VU=[>?E-7+@;OHNV15<J:,]L"_#B TG'/&/$9
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M_P!/;#^HJ96U,=Y=2WV&3]>T4CQ36Y\E?1N=-%)4/<(W$TY,; 88D?3*Q)<
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MXT>R^-RN+A3(<*W*'EV7T,)(OFQ.$^F_, >N<*0NX]_S'K304WM6OZ;E5Y3
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M%_\ O#C;H?4?";]1Z'Y3S&:>\<=^Z+_]X<;=#ZCX3?J/0_*>8S3WCCOW1?\
M[PXVZ'U'PF_4>A^4\QFGO''?NB__ 'AQMT/J/A-^H]#\IYC-/>.._=%_^\.-
MNA]1\)OU'H?E/,9I[QQW[HO_ -X<;=#ZCX3?J/0_*>8S3WCCOW1?_O#C;H?4
M?";]1Z'Y3S&:>\<=^Z+_ />'&W0^H^$WZCT/RGF,T]XX[]T7_P"\.-NA]1\)
MOU'H?E/,9I[QQW[HO_WAQMT/J/A-^H]#\IYC-/>.._=%_P#O#C;H?4?";]1Z
M'Y3S&:>\<=^Z+_\ >'&W0^H^$WZCT/RGF,T]XX[]T7_[PXVZ'U'PF_4>A^4\
MQFGO''?NB_\ WAQMT/J/A-^H]#\IYC-/>.._=%_^\.-NA]1\)OU'H?E/,9I[
MQQW[HO\ ]X<;=#ZCX3?J/0_*>8S3WCCOW1?_ +PXVZ'U'PF_4>A^4\QFGO''
M?NB__>'&W0^H^$WZCT/RGF,T]XX[]T7_ .\.-NA]1\)OU'H?E/,9I[QQW[HO
M_P!X<;=#ZCX3?J/0_*>8S3WCCOW1?_O#C;H?4?";]1Z'Y3S&:>\<=^Z+_P#>
M'&W0^H^$WZCT/RGF,T]XX[]T7_[PXVZ'U'PF_4>A^4\QFGO''?NB_P#WAQMT
M/J/A-^H]#\IYC-/>.._=%_\ O#C;H?4?";]1Z'Y3S&:>\<=^Z+_]X<;=#ZCX
M3?J/0_*>8S3WCCOW1?\ [PXVZ'U'PF_4>A^4\QFGO''?NB__ 'AQMT/J/A-^
MH]#\IYC-/>.._=%_^\.-NA]1\)OU'H?E/,9I[QQW[HO_ -X<;=#ZCX3?J/0_
M*>8S3WCCOW1?_O#C;H?4?";]1Z'Y3S&:>\<=^Z+_ />'&W0^H^$WZCT/RGF,
MT]XX[]T7_P"\.-NA]1\)OU'H?E=QDUDR:NVQ T&=HY3SC5-I'G;%357Y6F==
M]EE9&_UVTQIC?7*>$=<YVVUVPIC&F==VW@#ZY_L$W\2/3']RHB4531TRHJIH
MEICR8SNIOKIIC.<^3&,[;9QC'ES_  QY<_QS_#'.2UKGGA8USW'DUH+CMSV
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M*-N3PE4L[9579]E-CH-XWA\?!QV?;'D0< <A2!661N-+E\S:/OBPX/@L0 2
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M^'T3VS.PYE,T:RA$@94ZQ587):69Z9K<C7]5J:S'.Q4E'I)'C6LEDTCUBU=
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M,X\E,"W6"BEV[IJK 6VZ#V^QO9]TG].2?7"MZB"8LP.GV=M3>-M7+8D%&.L
M]-M8PILUPFL$415634*9/MC[+59KTMZVS]&1X/0$@T*2>WU+]>2V(V#9E?V
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M"P#).B?I<A+H3<=NV&4).6&P?0*G&G 6?!F@]TB>7)JDVI)%P':M$6KUX3;
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MJZ28-FI:J-CPRHII6ME@E:^.0!S"!D^<9<U/+CRXQY<>7/\ +']^?)_/R?\
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MPB44TS)'P/(_^W41A\$HY.CD<T[$KI^M]*T&N-'ZFT?<P/T6I+)<;/,\M#S
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MM;9=6%2&:8>*0*PB$.DMA]A0L4TO]>\144-M;2+UVX?ACY?$H*0#79X^6_\
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MW:@)0ZSW,Z^X=GPS1H3--F8PLYPJ^9,T#!5-HW73;ZD7N$O.5"Q;S/\ Q?\
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M8_">NFL_>7\F/_I7' [I[CY3C;U]C\+,!+*A,B=J,@QKSQTDWW=*)?1Q9O\
I)0T421V4^6Z8()Y\BBZ6OR==\[Y^5Y<:YUUVSB%I',?A.-O7V/PO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g209588g12k55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g12k55.jpg
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MLK.TT]37)"4S-SA"6')SAIBQTE-A<9&3H='_Q  < 0$  04! 0
M     0(#! 4&!PC_Q !=$0 " 00! @0!!@D##@@-!0$! @, ! 41(1(Q!A-!
M46$4(G&!D? '%2,R,Z&QP=%"4N$6)%-456)RDI.4LM+3\30U<W2"E;/5"!<8
M)4-$5V-UH[2UU%:$EJ+"I?_:  P# 0 "$0,1 #\ ^_CBE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE:%]M^Q.Z:)M[K%UGZZ1>KV]O=F%[EG!+SND
M*US>N:'1]$UFN3EM+*JE)FZK8K;99R0NE5AZ_$C6VMB#L.S,R<<\U%I!*5(
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MLNM.XNO?;[9E,0;;("XW+8F=*[QTSJJJ6JRQPM;BY'5<D+B9NA#]*&G;5'F
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MV*G4[X%TBM!-M-V!JJ4&K>O._P!:UZ^T';#8B,GG)@\TV["R;$_6015G0E7
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M)ZQZ]H<[3*C8HW6\Y:[(6;*[.HF^V@+CJS9"I"[ZAK(\4J"56 ='6^0=D:X
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M>%G2VS.)N9$,B6^3L)WC!Z3(D5U%(R!M'I+!2H.CHG>JL3+UPRH#HM%(H)Y
MVC $C8WHG?<5#M!:2I_5'>U;UO3P(F)B-J]= ES98S'LLVG9VD+(&/,SK37K
MI9Q*V6(VJ9,2@[8RR2T0ZCUN9R(<ZYN\IE+OQ#B[Z_O'DEN;3._*1N2240VF
M8MFC,(\SK9+6S?%6=O;#J"QB<1D?.CU8BB2WE1$ 56@Z= :VT+ AN- L_FNS
M$[9M;WP:V_W%-DU_5UZD0%>2657)",@O#.4Y78YQOY'7&<*Q_6Y?G)&/8PKZ
ML)RYC.<XQC.<<!EYF@QE[(GZ0V\D4/QGG'DP#ZYI$'UUUWA"RCR'B?!VTZ]5
MH,A!<WW8ZQUBWRW(N0>XCL;>X<CDD*= G@PW84*'2H?2DI'?I,;K'85#@F14
M)SC#T/<0"M)L,93CS9PV"Y>X^65CSX2C$5A2LKPCRJQ;V!+2+#R1GICQM[9P
M!0" T-U&V(5>D;X1KR.71.@(M\Z .X\/WDV:N_&=M<?/N?$OA_.WS2L1M+O#
MSQ>-)'V= M.N#N+0?-V3=: 7>Q??-W7"5"K7^K6N?QU*_D#>>*5->*4XI6F&
MR.DVO;AMBG[OI\_;]:;/A]LTG8EOM,'==F&*N5=J;C;LKKQNM+V&%0H2&O+0
M,97[8^]3YP4JH.V*+%AA9J:$LT(J0=;^(U]_H[CX_8:^^)99;I6^O;4C4*XB
M9D8_:^CSHC#;YI<B=+M;#%)2''5Z,C3#9-0+L?&DGXR4 A,09(R#9&50SHY/
M6^"(H)_$=I#=2+%;RVV2CFD:1(@L;XZZ5CYDA"*3O2]1T6(4;) .+>%EMW9
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MK@W/5;E>M/;7I&NKF_KG8-QUK>JK1=A#(==)H=RL-7E8BL7,=MA;;[C]7FS
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M['&XPR\^A#?M73%9QD5OS9=I+'"UQ)+(D2"QO07D940%K:15VS$ ;8@#9Y)
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MFRY!45)Y2H.G6:!F@Y(:*CHUN1Q,1@<,+@ZPJ*2TD44J<P\V\U"MJ]=^2AW
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M7%96XZZXL)2W''%JRM:UYRI2LY4K.<YSGF6+^^4!5O;M54 *HN9@  -  !]
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M4V?<_;4XXJ*<4IQ2M6NT$]51-:;(!\P:;:#6*_+D*5'N(*^1IN<*V.E<JH=
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M8BD(A$5[Y+#X#^CV0EQF5IG;CDST70L*:<7B14;@G'JKR@OU\*2AW+OF??\
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MIC",B.2:%^#SH.%X=;&SZZ_!K"E)WGAH;SV*'O=QCZCO?ZJL3'4,I_\ =O\
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MFQ8)H$;:&)DK/K>'O1BM1*<89<;=\R9DYSU$+8QZFL%H;&X\.J)F;R+:XQ+
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MR/I$3']W]![5 Z3KV*T,+#]<*@"_%Q%VTCK.HTPT7P)(*E8>QW4?<$H0E"/
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M573+V_L=[$W!UHCU!KJ\AUP>&/#EL^Q\HOO$&8C!;8:"Y;%XA7"@Z \_!72
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M>IG?,@N-&7YO+CRR$EIV(\Z5YSCR^H.UG"L^G]MX84JQ%U%%,P5)-?.6(F1
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MC1FU\T,ZY61D4G0+"-R!R%;L7/L/M/\ "KJY@5-.*4XI5([_ (PN6UK: \V
M&O1[L6PI)A-<.LKS4T#.0TK$NHC09.+=/:<S'OA?+T%@+(),&SB1&PCS<R+6
MX:UG2=%5GC#](;?3MXV0$Z() ZMZ!!.M;&]BI/+ZU\U6>+J7S$1Q&[Q['6J2
M%)!&S+L*YCD"$ABC@=)I_;^EMN;2CJ[/S6U*-7':'+-W:O8$U18FQAO^*Y"/
ML,/=8[[*!LG9H&;J\E)U^;KL;+U]LELQTE3Q!(@"6L*W$X>XCOYENL==VYMK
MO'P1&S6YA,L<ZB6X,EU-N*>""5%C\N-VC,=Q'<6\DD#;^+,6&.2.;#8R2VRL
M3%XLKD+Y<C+:.8VC\RPM8K+'VL$W3(_3/<QWL]N_ESV4EK=0QW MR%7O&<BQ
M90.\:B6R2E>$+^Q7=D-.J8>='><9]3;R7?;N.M*4,MUI#BV<I6XTVK.48V >
MPT/ZWN_3?]=P_7_ZEQ\-]OC7._.]Q\?FG_6_C4.JX^Z3[C>"HG8.KWF\*B0)
MIG.H+PU$-6*(1(1Q:QBB=O#OKE<B,1XLHPVR2%B-"@BQ3<N%/M8QXXK".XN+
MA8KW5RL/7$;N#I$L*NGFJ?D6^J2,Q(X.QTPIK1ZM[&XR#W.-Q]A)%'UXZ2\\
MFZ'5YCVMVT4PM'0DKY=O="YN(64ANJ]N%<,/+*9]Z6W6/9@JFJYZK(ECA5R'
MI!ZDO;K8$;Y3_1DY(ES;;0C(+I "H[S,OODID2@F,B^B_DE&3UV']KWG^=P_
M_A5KOG>X_P 4_P"M4C16=N2<A#8M%PUP3!QTS&S!8L!KZS14L6J+>P6P./(R
M.RYL,/"RFV<.N.Q9F5#X<0A#;BTN-T.UH4(CAN5?CI9[B)T'/.T6UC)XWK3K
MH\\]J#?J1]0(_>?A]^UP\QJFG%*@\7K'6T'.JM$+KVCP]E6Z8^NQ1=3@8^=6
M](8=2>\J7$CV9!3IR7WL&.9(RLG#SN'LKPXOQ4JM=XTF]V(.,FZOLV*I M2L
M50N*T3M&(N,:(W4BY<R;=2%#SM;EY%<]'G, /A$2#PXC<>V5&-B2+F2TSYDR
M)*+>18I9(GB61HQ*%$@Z7W&2H8,G4A'4I 8E65@",JSDM8KA'O+4WMN!('MU
MN&M6<O&Z1NDZI(4>&1DF3<;HSQA)4>-F0UOFO]H;16F+:UV,JM6AB0')K( _
M7%Z$E6HX<,AU&'TS&T[H<,DM3;1CB6AG3LB+2@=++ZO2SJ6LLC(PZ\O)''QM
M+6SM8F.AV$EPMV5!_E<$_P TI70Q9GPY;1GRO"%O=3@$+)E<SE+F($L"7:#'
M/B [*NUC!D$8WU2)*0-0:D]<MFUYAJ[: W)7]5O6MY,A=H2<U1:;E4MB2H*F
MXS-SD(*R;@;DHF=G1(YHA-F@S8"3G8A^.78@"'Q0F([I<?=VUKCH<5=60OK:
MU\TVDS7#Q7]NT\LD]QN\Z)6N(Y[B62X>*Y294G=Y(/)\V82<_E+ZZRU_-D;A
MT2>81H8H88H;2*&"-(;:WMK6)8XK:"V@CC@ACA"JL2*K!B PELO3>Q6S [?0
M9#>>IT/1!4*Y\ZC.M%X#^3SH&8V>A9"/.DNP.0LV*!L(0T\$T/\ - F!VX=P
MM3^2"!L6;M,+>V\EO+C[]5<HR/'E(EDAEBD66&:-CC& DAE2.6,LK+UH.I64
ME3=Q&4N\+D(,A:^1(\2SPRP3QNUO=VEW;RV=]97*)+&[6U[9SSVMPL<D<ABF
M?RY(WZ77)+%[7PDU7JS+;[TO*2$T*8@=<?U<O&2E*"6PGYM(+:[%HB!(]+&7
M%R></"N-&/BL@"/,NJ4UD+-B0JAK"^8@ %CDX06(&BQ"XP*"3R0  -\ "L*5
ME>21TC6%&=V2)6=EB5F)6-6D9G94!Z079G( +,6V3P7W/:JK#"I8W!J6PGR"
MW_8UZ)ZP7LJ3DVQ7!\DJ'(%[%$,"X :?;*(40TO+[:5-LH1GQ<0,^*T>G'W@
M/H3DXV'U@8Y2>/B/?X516Y?-;2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2L=+1$7/1Y$3-1X<K&%X;P4 >.V4(1AEYLAGU6'4J;7Z3[+3S>5)SE#
MK:%I\%)QG"E?M49'KCTQ2PA5QJ6&Q4@*9;4+@=G"4M,X8RG+?IMX0C"$^7P3
MY4^'UXQQ2JRKVO[/%QD77IFVP4[5PV!P#*\F@Q,5'%Q \86"F)&8$.6Q'B8)
M6 :C&63,H2#D/&/1)4IM4D[)_C_'O5F,1<<+&M0PX0S44P&B/:CTLH]H@)#6
M&$BX9SC*,LX9QAOR9QG&4_5GQ\<\5%?@.'BH^)&@0HX,6%# :BA8ID=ML!B-
M882*R"T,E.&DBMCI2REG"?)AO&$^'AQ2N6-C0(< .*B@QX^. ';%""%:2R.,
M.RG"6VFFT8PE*$IQ]6,8\<Y\<YSG.<YRI7=XI3BE.*4XI3BE1%=*B5R9$KDV
MS^Y)-%D'&OIA:,@H?$-$/:;' 5+*#$"60&RDB-%99CRA5/@$C.@/O#+4J7<4
MIQ2G%*<4IQ2OYG&%8RE6,*2K&<*3G&,XSC./#.,XS]6<9Q]6<9^K..*5UPP@
MX\=L0 08$1K*\M"AL-##MY=<6ZYEMEE"&T9<=<6ZO*4X\[BUK5XJ5G.5*QLG
M#*)'D<Q)GT>EY%EEI<]'Q\80?CVV7E"^LF0#*8+;'40_EIHEMQ+?KO>EEM3J
MU94K@CX)UIUHF:D$6(T1WUXPLV*BAWHEQ8S@A*X]P49#K"BV'5H?7EU2\I<=
M:0I [F64J5F#00I(0@"1#%D 2VEL%!&CM%"$L.8REQD@9]#C+S2TYRE;;B%(
M5C.<*QG&>*5V<8QC&,8QC&,8QC&,8\,8QCZL8QC'U8QC'U8QC[G%*_O%*<4I
MQ2NF?'@2HCP$H"') $X2D@(\9DP1]*%I<2EX8A#C+N$N(0M.%H5C"TI5CP4G
M&<*5W,XQG&<9QXXS]6<9^YG']C/%*A,O4CR5QV*W:I*F" $-O+BX2,KKD6=A
M1CI9J"ASHDA]"CLONI><$*&SAQ7N/*I[+BG%*D,/&9BP1F""URDB@01B1FR1
M0!9"9(%92SD^01&"A!>Y?SA3JT#"CC-K<6D=AEKRMI4KL+C8YP]J57'A+E&!
MU"LR2Q6%'LBK4I:QFC,MY(;'6I:E*90YAM2E*5E.<YSG*E=WBE.*4XI3BE.*
M4XI4(LE"B[-)"2Q,O;XPT)MEICZ/W"PP82D,*.SC)$5'R#,46XXF1);=>*">
M>7C B_4P]'1SHJE2J-!:C(X"-9>,(9CPA06GY PF1/?:$8;';>.D#77C#C'$
M-X6286\Z24\I;[[KCJUKRI7=XI3BE.*4XI3BE.*4XI7&ZTEYIUE>7$H=;6TI
M33KC#N$N)RE66WF5(>9<QC.<H=:6AQM7@M"DJQC.%*A$#00Z_*BRK%CO$DL*
M'<A1P)VW3$Q%^V>8@67B2 #7W&C95;E>&*1+G>YDAGSYS A(X\U(COJ??[_?
M53OBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5CY65CX2/*E90
ME(D>$C#I1*T.+0RWE:6\+4EI#CF4^=:<9RE&?+C/F5X)QG.%*CL?L.C2H@IP
M-JA'1S1\EC*6>R,ZZ+@TV.P3@8E3)*6%G1L@*VZMI*'7@R4MJ5Z2_!2N]],:
MG^V6#_A0/_7<4I],:G^V6#_A0/\ UW%*?3&I_ME@_P"% _\ 7<4I],:G^V6#
M_A0/_7<4KN@6""E7U"QLQ&'DH:4^H<,X8AY+"5H;4]EIIQ2\-)<<;0ISR^1*
MW$)SG&5IQE2M>;1V8IL-L^H4T"RT@BNN;4(T5LF9/F) 4ZH[GGZ-#WC5VNP4
MMQSL.9.W("4;:=:,DQ&A#SH&!;=<LLY'0Y*IU_'ZN=GZM5L[Q45%;5>*?1V8
MPBX62'K;$U*BP42[,&LA(D9D[.<"1@>7E)]<TG*5>B.WXN+\JLXQX8SG"E16
M&W-1K"&[(0F+K*!,2DY"O$B:LVBZTU+UJ:D*Y/QSBL4W[0N(G8J2B3V%8PL<
MX(AA>,+;5C%3*R$!U9255@&!4E74.C $ ]+HRNI[,K!@2"#3ZP>XX(/(X(V/
M8\'V/%97[)5=_!U__BHVE_0WE-*?9*KOX.O_ /%1M+^AO%*?9*KOX.O_ /%1
MM+^AO%*?9*KOX.O_ /%1M+^AO%*FD><+* !28+BG@I$08X-U33S"G12V4$#N
M*8(;:(94MIQ"LM/M-O-YSE#K:%X4G"E=OBE.*5&;3;X*FA#R$^[(,B%&,@,K
MCH*>GW,E$>/I)<&@(V3)8:SY<Y42^RV,WC&<N/(QCQXI72(V!4Q22!'9$A3X
MC[HQ&&(>;*;;(87EMYKUA8YYA2VG,*0YA#BO(M*DJ\%8SC"E<7V1JC_;YWY/
MV+^:>*4^R-4?[?._)^Q?S3Q2GV1JC_;YWY/V+^:>*4^R-4?[?._)^Q?S3Q2I
M+$3$=.@HD8HGW0;CI#"7?2?85AX1]P4EIQ@EIE]IQE]IQM:'6D*QE/CC&4YQ
MG*E9/BE.*57<KLZO0#TNF?"M$,%#R-?B%S!M5G50\E)6F<#KD$)"G!A%)EG3
MIF1 "\0T.('68PHI3*,J4F0&8Z523HG@;X )/ YX ))UH $FGV?;]^_I[UGO
MI9&_VE9OR.MG\R\BE/I9&_VE9OR.MG\R\4I]+(W^TK-^1UL_F7BE/I9&_P!I
M6;\CK9_,O%*YQK+'%$,BH'G&7'UY;;6;6K%'C>?"%+PEPLZ+'%:RK",X1ZKR
M/.O*6T>9Q:4Y4K/\4IQ2G%*J>Z;QU9KXJ3C[3:VAI6'&BS9.$BXF>LT^(#,R
MT1!1Q[D!6(N8F<@/2T]#!.'(!6(*Y(C++>8:7ES%2JSL$169F("JH+,Q/
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M]Q(KH4+*P)O>';1,UE\+9*0T>2R%C;LVSTK%<7$<<KNR_FI%&SM*W C5'9B
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M]O@=?KT>_P!%=3J#JW:.H]>[!@MI_164M\QN?9MM'M$$ +"'7^,FSQ51MON
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M:M#NS4)N^:+MM-(=@'*M;++I.NK#)'/;D'"I?>VLPG\%GME+&3&.BO$MN(8
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M.OE/;FUE'/Q*?K]OC4A2W8$Z!8Z&] =R>#H#U/&O>L)V]F8#2\QUXW=DH:-
MU??&8:PP\>SDB4+UK8XDJKV22C*['MOS$^Q0H>3-G'(^%CSR@(]R0-:'0TV\
MOF1C+ZQAEN<=>W<%K^.K*6QM!/*L?FW\4D-[8QKU$?I+JUB@>0ZCACG:29DA
M#L,VSPN6RPFEQF/N;U,>GRF]EAC/D6EOIT:2YN&Z8(%(+"(2R(9I0L,(>5D0
MWGJX-S8TRQOJ7)/<"EHV4!U% DLL#!P.NIMV(>:LRQO02>JQ;#:@XZQNKDG4
M%P=?-CJYB/C36Y[,ARUK9W,E]/D,A'/;SQ-<V=G87$?DO8VPE1)'FA91*EY=
M/;B602],EO$RVQCC=9^OI\YD+/&8J+PEAWL[B)C89'Q%F+29KD9;,Q07+Q6E
MO<)(ULV*PBY":QA-HK09"]CN,D+FY@>Q\C,[94S!3&J;\MG&&ZWL..KTP6TA
M/NTU[9@A=!2+E[PPI,8FZS5&FY5M:TCI8@D&NXRL%E2*LEJ&7'7I4:@O8X)7
M&@P@OU:RZ>KOY?RN6SFD!/3J$.>4!%OPH'OK3Q3@0YZLEX?N,A9Q,3Y1R'AJ
M6+/&7HWHW)PMGG+*T95,ADOV@72SN#<_-K7'5K'W(_Z-^QO_ "A_+RK\54GY
MP^O]AK9SBJ:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*HNVZUL:IT
MR_0FU-@0,JU47ZZ=&UZ#I,V/+ B3TG8HLE$-/5N12].1*9,N*CW!76O<@O.M
M/#$F/(>3EVUQ#"CK-8VUX69&5YWNT9 H8,B_)KF %9.H%NH,P*+T,HZ@T:Y'
M)T-\#6CL?$'G>N?AK7-02"U!:H&'FK^]N/<<U<IFN9<+EYFKZSEKN+#L)?E1
M:S!P#-"C82'6VZ[E:H**@@73I3#*97,A(#,$(Q;Z:]O4\B.\;'V:N\L5G86]
MJ(HY9!TF0R7<%W<7$BH B27<T[(FU3I5F!W5KD<9;F-I/#F,O)$"!WN[O-@3
M=.M^8MKE;15#D;=8/)4D[T-#60SI6$M%7Q.R#]G'L$M#2#1\E,1T5-WD^OS0
M3XDG6Y=%D$D5, S\6[C)M.RED"#->PT R)(@,&MXME:0X^YCO;<,+Z-E=;Z5
MVFNPZ,'4K/*7=$5UZEBCZ85/YD:C8-62\0Y7*6PL)[@08M3U1XBPBCL,4C=A
M(;&U6*":XZ0%:[N5FO)0JF:XD8;K*52E[)%I<:4YN;:KF68YTI@*S5/5Y]N5
M'-M.JC!)!+5(CG53*Q$#+?8D,/RB"G%ARAA4@A\Q>]DR%I(2[8:P5FY;RI<C
M&A;7SF6(7Q1.IMMT1A8DWTQQH@51H C  >:YUO\ ."$_#9Z 3KMLG9[DD[)Z
M]9HUZ]A,W5&S=DP1=E2J7D:V54-9K/??BF'8R/E,Q6::A\*>FX&/ADEQ;I.5
MC>V!CGTI-%*)(QHY<?%+<31XBU5KEHWF7Y3D>@RQQK%YH7Y8"'>)(HW/4598
MHR &#,V?<W]U=V>/LIY%=,8EQ!:3%!YZVMQ</=_)&?\ ,:WANIKJXA7RPZ2W
MESU2-&T:1SO7D'975"6VT6:U2A;T7(1P,/9(>JPSP01D@$0@XD2!@HLL4\YF
M+#(7'&D/YC,$.ANX<(:R_F+B>"55$-E#:D'9:*6YD+#6M$3S2J!OG:@'?KKB
ML( C>V+>VP!KO[ ;_H^FK8YBU53BE<!(HQC*QC!V"AUY1E;!++;[*\MN)=;R
MMIU*T*RVZA#B,Y3G*'$)6GP4G&<*5KT+UPULY99G,IJK2ZJ+@0O$!"C:^A79
M=V5L4@]-VJ3F3B@/38P1+$G*$"CO,.^V>X\1AAX=M#F++8V,[F2:SM9I&T&D
MEMX9'8 !0"SH6.@ !L\  #@5N[7Q-XCL8([:R\09NSMXAJ.WM<M?V\$8'($<
M44Z(@!YTJ@5G871E"A;%..@Z\UC%5.2$&5\IBJC&ME2DM[$6,<-ETK"P&,U'
M1@:H\!B-2EH]B2)7(M8?"&<>OQ1I JI"B0HGYBQ*(U31V.E4 "Z// '-:NYN
MKF]FDN;RXGN[B4[DGN9I)YI#K6Y)96>1SK0VS'@:JKB-6:.K=YC0*EI*HUS,
M&G,18I)G1TT7&FUVWR34D[&5DF&@\U\UPN>BQE3<DZ@E%7$<=.??!8?<;,V3
M97)N>I\E?LW ZFO+ACH< ;,A/ X'M6)Y,0'Z*/7H B?LUQ^^K'MG7[64@&2]
M7-5:D$L)<O"2CDE(TN,:;P3$R3!S$HYB*#'?-D '&DDC#E+R'(N-8 D\K ?>
MQRVM_?KU%;V[4L2S%;F8=3'NS:<;)]2=FKKDR*BN2ZQH(XU<EEC0=D0'81!Z
M*NA\*_MNT11Y"J'Q=;UUJ9N=-3Z&3IVD1BHY.)$AY,W(9%CA$/*,]O)2IP(W
MJ8&=D'6V"'&1W%OM5?C+(_V_>_YU/_M*H"(/Y"_4H'[JN6%BQX.&B841+:!8
M>, BQD,M>@R@>/%:$92TSA;GHMI;93A#7G7Z:<81YU>'CG#)))))))V2>22>
MY)]2:JK)\BE>"7?7IAV#WEVI.V/2.MNC[I#UZ$U7.T7:=CUAU6M]FD+!6CR*
M^WKNPRVY(Z5V''5UZ;N)%]VI-5]B+/A-/:MC(;1D[]EJW34/(JK5@!HDZ/<;
M;7OV'!]AOC9.^*]WY,-R1CS 63S8MTIAQEN1CE#I."4O'A@@510Y0^'F_NHR
M\.\WX_US:N*HK7RGZE%7<KO:L_9 K:3+P7:0 YJ2JQL8399*&BH^4LT17L1,
ML($AH( .*C#3BR#D+;E2!1XY9A!$ABRVD,UTEW+UO)&$,:-(YACD2%8!,L)/
ME^=Y**@D*DJ Q3H:25GW8\09),4N(B:WAMOD[VDDT-K!'?3V37MQD?D4]Z$^
M4-:_++F:9H5=5FW"EQYT=M:I#GIF")L$G.TRW$7"4IZ(L HZ>M,9J]NHD^X2
M6AT:'=9KKLB]),N*8:.^9 1204+01$R!+OJI;RU9D8,K%64AE920RL"""I&B
M""-@@[!Y!K2:V/??&JKU.G3*5 #0VKMJ[V7"2Y"6 XJ#GM96>&A!R$+2TMF1
MV#3+0?7J]AW#F&VJ\I\,1&%LCQB&&T8;V,F2:X):\M+.\D/>:6.6&5P1H^:U
ME/:^>QX)DG$LI/\ +T2#0L?E_HW>/6B K;Z2#P5Z@W1KT"Z [ZW4F@-'V.@P
M*HRO;^WR7& ,*Q'PY#.D)MX9I"<X:"BW9S4/JLBL^;.!0%'MAC,H:$$0.,RT
MQC$MGLK6/RH<59B)>(XVN,LZQ+LD)%UY,LD8WI(P>B-0J(%154;')Y*[R]P;
MN]>-[M^;BZCM[>"6[DZ55I[KR8D2:YDZ>N>X9/.N)GDGG>6>1Y&D$+1=@R42
M"=)[IVW"'%L^N[%N1FAR7P4N.94PR2XC2OI8+P-AOW;32G6AR7'F&GR$--D+
MR?EEO_<G'_Y3*?\ >5:[H;^R/]D?^SJRJG7GZQ$8C"K'-VHE1L@>1-V%JO,2
MA3TB8Z8XEUJKP-:AD-LJ=RTPD:(85AI*?66\[YG58<KK(Y=(8X%.OR<1F*#0
MUL&>6:39USN0C?8 <54!H:))^)UL_8 /L J2\MU-.*53NY*8#<J^F*DZY-W4
M"2.@0R*L*;&M0"G8FQ1ENC9BPAR9 S1$:',5Z/&D<C^]+7'%D#-1A:'G?)8N
M+:"[A>WN8DF@DZ1)%(H:.1597Z75@0R$J RD$,-@C1K.QN2OL1>PY'&W4UE?
M6WF&VN[>1X;BW>2)X3+!+&RO%*J2,8Y$971@&4@@4ONI("YQ4,Y,%7)4A3)#
M%IJ[E6LY,%-Q<^'%R$>W\CDQ7(]32B8^1/AEBE/HBY  UT.58>$>=3S86EW-
M9.S0= 5XC!+%)%'+!+"Q4F*6&16C= R(Z KN.2..6,K)&CK@2#S22Y9F+=9<
ML>OK))+=>^KJ.SL[VP)!V"08&]0HB: B(V];7OU>GU2+4W&0I6PX .=%Q'S!
MCE?D&\M13!39I( ./F* 5+$6IV7BLN%@X?PY-U<07D7E38W'@!ED22*.>&:*
M5#M)8I8[A7C=3L;4Z92T;AHW=6S<=?W>+N&N+24;D@FMIXIHHKBWN+:XC,<U
MO<6\R/%-$P(90ZEHY4BN(FCGBBD26PM!FC2Y5!5ZVN-&"/-,1AI=HA5D2^5(
M6M\X=,?$N,?*LMK$]BX[A@Q;_O4D#H;;84O5?)7_ +<N_P#&A_V%9OXXC_N-
MAA_^WNOWWAKB<HD^BTBP[-OW ]#KB5G'6(BT5]$2TZEUYAN-%0S&XEW)M;N!
MR'$.@(B<1JWG$FX,;0*X^2O_ &Y=_P"-#_L*G\;QZ_XFPO?^U[K?_P!9K7ZZ
MF$3KQR+E!))Z^["F4!N8=3&3,V 3&/.):<;PHEAB'%==\,N>KA/N$H2ZVVI*
M<83E*JDMV1@QN;EP/Y#M$5;C7/3"I^/##D59GR:3Q/$,7BX"XUYL$-PLJ<@[
M1GNI%!XURAX)XWHBQN9-:NG%*<4JL-IZ@U[N&NG5Z_U8.R@E1SL:IEXP^))>
MCW)6$GGXC,Q$NL28L7)2U:@2)09AW+!GRT7W(Y"6$(Y! 8%3V8%2.1L$:(V.
M>0?2KUO<36D\-U;2-#<6\L<\$J'3Q30N)(I$/HR.H93Z$ U6>M^ME!K@#TR;
M3VZO;YG!^91=3OFQD%,@&23DD-#2-G5:L2=B?!<4C!$NXD!DPC"WQ8F-87@1
M.+;6%E9LSVUK!#(XZ7E2-1*Z]1;3RZ,CCJ);3,>3OO6RR/B#-Y>.*#)96^O;
M:!_,@M9[B1K2!PGE!H+3J%M 1&!&/*B32 (/F@"HD9U'T#("JV#M/7HN;?!0
MCC1=Q1>MCR5LCZ[ "N9'^87Q%B&L]@,'$8<-?E',#%$.K3GV:2&L+7NK7*9&
MR1XK6]N(89"6D@21OD\C$=):2!B87;IXVR$ZXWQ6D:-'(+(C,. Q4%A\ =;'
M/L>_TFJTI.A.K&X)&7BGH9-GJRW0[/2HV3W#N^=GY,4,*'61;U1UGLL:7 Q;
M69^)$C@V1Y =Q9*Y8>8>;E<"CILE=W*A+@V\Z*P=4FLK*50XWI@KV[ ,-G3:
MV-\&LVRO;W&RF?'WEW8S-$T+RV=Q-;.\,GY\3O"Z,\3](ZXV)5M ,IZ14] Z
M0:,KEP">JFMWHJN' $/6.01M[<6"LG!^LU&Q\7746]L 1XQ4@LPVQ).6ZH>,
M^4OQ3N2A9 *F*_N+<DP"VA)(),5C91[(X!(6W&^"1_OJ]=9;)WRA;W(WMXJC
MI475S-.%7>]#S7?0V!P-#M[5,:YUBH--VC6;=5*Y/1[%9:+E&)R4W'M^TI)D
M)"'GZX7"9I,_="JVVEL.5&DAYR1&G4J4DP5F+C)!L"815/D[VXB:&:97C;74
MHA@0GI8,/G)$K#1 /!&^QXV*P-]^W/L /W5M+S J*<4IQ2J,W5J*J;$!A9R<
MBKK-'T2P W>'A:/;CZG+3,Y"1%@B8=EL\:<@$,. XLL@:*XW+12\E(:2^4\-
MZ@C]J>%+B&2"0R!)0H8Q2R02#HD212DT+I+&P=%/5&ZGC1/22#L,9D[K$7B7
MUF;?STCGB NK.TO[=H[F"2VG26TOH;BUF1X977IEA<*2'4!U5AT8[2D#$UV8
MD00YR*MD]5' )I84O&WF>6XJ*4AR&C['LV+EG#V<EN%+98F%#PQIQCY$F$EA
M]:&\:VQME9NTD$.IF55:>626XG*KO2F>X>67IY.UZ]$DL=L2:SLIXES>9ABM
M;^]ZK.%VDBLK:VM,=8)(_2&E%CC8+6T\SI54$AA+K&JQJP1540VB]>->4*DF
M'A'['T[$G!EV"4KP.X[5%UZE)>2\822F-9GETNMFL#J2986(1C-9%ED&^R=-
MCT(,)Z5LW?2I&MQ\DNVB01K-=V%C<W)11THDEU-;O<2K&H"QB65_+4!4TH '
M.B) 3T]0V=D*\@7?P4,%79Y/2!L\G9)K\PFJJY>W;K5Y*X;0ME")4^(Q+'[O
MDI8:TLGA9'L=="CZ[*8PFMU_)@@3Y,LH>P9F'R!7<N ,"%&X\N0>>*2&:SQ4
MD4J,DD;XG',KHX(92#;=B#K59-I/<6%U;WUE<W%K=VDT5S;7$,TB2P3PN)(I
M8VZMAE90P/(]QKBNVO1I$!9*W$05M[ S%<.CI(24+E=[VKY+5A1$!>S+:(?D
M2KA+V9]S](BA2GRH1X14L1,FLE#Q;1"/(RQ(L:6^/*HH5>O'64K: T-R20/(
MQ_OF9F^-53W$ES-)/+Y0DE=I'\JWMX(R[';=,4$4<4:DDGIC15'HHJ$;]ZSR
M%XIDA0ZW9=XS+ET+$P\:9OB9A*Y4QX*3'L*52!DE'W.16B36(W%@(8I]J=R2
MT-[EV&3EV7Q4^2F=2I@QR@ZY3&6",-$'AEMPP[:.B-C8[$U:!((.P-?WJDG]
M7[Q^ZMX>:ZJ:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2H*#
MK*@1<B)+1M3A@9$ AHL0H0;V[C); 94>V6G#2DH42D TH/)"T*>6,\IE:U-X
M2G"E3KBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE8B2K\%,YSF7A8J4SEI3.<R$>(9G+*O'S,YR0TYG+2O,K"F\Y
M\BL*5C.,XSGQ4K)LLLCLM#CM-L,,-H98890EMIEEI.$-M--HPE#;;:$I0A",
M82A.,)3C&,8QQ2N3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE=8
MP(.1$( D!!CP3&7!RPC&&BA"AW4Y0ZP0.^A;+[+B,Y2XTZA2%ISE*DYQGPXI
M6,!K%;BS<R497H..D5-%,*/!B0!#5,'/"D&LY*'';?RT80"$^4WESR$/!BNO
M)6L=E2%*SG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K%39DC
M'Q)QL1$.3\D,QET.&:-%CG9%W"DX]NV:<I 8ZU)RK*7"%H:\4X2I:,9\V%*P
MH-CF"1Q<OT^6&D<QT83*1Z9&O/IBCS@FBB(I1>99EHUV/=6L5XL5*A'UM9=&
M<<:6E7%*[OSB6_:G,?OZN?SWQ2GSB6_:G,?OZN?SWQ2OYF9E<8SG-4E\8QC.
M<YR=6\8QC'UYSG.9OPQC&/NYX[=Z $G0&R> !W)]JX [(9(""G@5R0-!.'8+
M"-$E*P2(6(2TEX<H8AF=6R^.0RM#K+S2UMNMK2M"E)5C.:4=)$62-E='571T
M8,CHP#*RLI(96!!5@2"""#HU=FAFMII;>XBE@N()9(9X)HVBFAFB<I+%+$X5
MXY8W5DDC=59'4JP!!%=^-F'#C38\B*.BR0A0#%),=CGD/,2+LBPSEE<><;C"
MD.1A&'4NX:\,*:RC+GF7Y*OO]_LJU]_O]M4+=.RE,K&RJA1Q+'028]6U8G3>
MU9*3N T4?KO8-\H:K=J&F8CUCNL25OV.6;60(FO/&@G9$M$&6RA]^8AQ)!4Z
M[_1OZNQ^_P!/M6RO%14<L5F'K:8U1$39)3$I)#1C7T=@)*?4(\4ZVRV1)HC&
M'UQT:A3GG)DRTM !M(<=+(9;3YLJ57=&V1;]AUY%H@*/"!QCTS:85L6P78H*
M:'*J5IF:E)-2(L539V,9(1)P9F,I F903R^53!Q+>4NJN21M$P5P 3'%(-'?
MS9HDF0_24=21Z'8/(IL'L=\D?6#H_K!J7?,=D?M0IG\8$S_NXY;I3YCLC]J%
M,_C F?\ =QQ2GS'9'[4*9_&!,_[N.*4^8[(_:A3/XP)G_=QQ2I1$FNR$<(80
M.V*0\UXD#-$**:8(0I3;[3)*F!5D-(=0O#3ZQ1ENMX2M3#*E9;2I61XI6EFV
M>_W6W2.PI[6VQK!:8.8KI=4@SIK-&L[M(=N]V "FZSK46\8CTUAS8LQ69 :T
MQE4<DF3Y:#P6[$>_-C9,$-4A2>W[1_&MIYYZ\MR]<16(^JEP+I:\6TF=EI8&
M6"!PZ+Z:Z\&!#R DD4ME1N5MR)L8TVZV-A+CJ7G<LJBL!2;S+7NOMV2(@HAH
M!Z5LD2V@NQFH(]:LV27K)BG$-5=U"<.&0Y#B$I<7A+:DXRM6<9SF]/!);R>5
M*O2_EPRZ!!^9/#'/$=C8^=%(C:[C>CH@U"L&&QR-LOUJQ4_8014J479D)RM<
M37D)3CQ4I5FD$IQC^SG.:IC&,?\ YSRP2 -D@ =R> /KJH L0%!)/  !))]@
M!R:_7N;3^!X#\I9'^BG)J*>YM/X'@/RED?Z*<4I[FT_@> _*61_HIQ2LE'DN
MEB-OOLMCO96^T\RT\HAI#H[[H[F&WUL#+=;RIK*D+4.RK*<X\S:<^..*5T;+
M9JW3*_,6RX6"$JE6KL<5+V"RV66 @J_!1(+2GS928F90@6.C(X-E"GBC326!
MAVDJ<==0A.<X4KH5>]TB[LY(I=RJMO'Q&PDSE^KV&(GV<1%F"S)5N5R[$F%H
MQ&V".2H^$.RKVLJ$G)0#I#&,N<4T?:H7<]AV*AC2TU.U>-77&[)0ZS F!V%Q
M9LD9?+O!48-Z0$5#_P#%C()UA *)PVL_*AD$8;5E:$)7<BBDF?RXUZGZ9'UL
M#YL4;RN=L0/FQHQUW.M#9(%02%&R=#8'UD@#M\2*G?O+7^ 83\IC/Z,\MU-/
M>6O\ PGY3&?T9XI3WEK_  #"?E,9_1GBE/>6O\ PGY3&?T9XI7[9/GDD#I/A
MXP<5Y[#*WQ9P@QYM2TJ]/*1G(,)#F,N82E?B2WE"597C"\IPA2E2#BE.*4XI
M4;N5JB:+4+5=YY;S<'3JW.6J96.UZQ"(FO1A4O(K89\R?5>2&&]EIKS)]1>$
MH\V/'QQ7&C2ND:#J>1U1%V!U,Y"J-D@#9(&R0/<U!( )/  ))^ [UE?<F_@Y
M?[Z&_P#ERBII[DW\'+_?0W_RXI3W)OX.7^^AO_EQ2GN3?P<O]]#?_+BE8N;L
M&:_"R\](1Q/L(2+D)<[V[PKI'LXT1XTGT&E.MI<>]%E?I-J<;PM?E3E:<9\V
M%*D?%*<4IQ2H!;=E5JFY2U*(FB"W9FIU\<6.@I,A#\M=YH:O5L7,JZ./ "H/
MERQ@EEGRX@0C[X[)A##Y0C3]Z""6Y=HX4ZW6&XG9=JNHK6"2ZG?;%1^3@ADD
M(!ZF"]*!F(4PS!1MCH$JOUNP51Q[L0/KYXK(_229_N?V[]^T/^FW+-33Z23/
M]S^W?OVA_P!-N*4^DDS_ '/[=^_:'_3;BE/I),_W/[=^_:'_ $VXI1JTE_,8
MF/.J%EB4S!CX(YQK]3>#:(8BY&6\"$Q=ID3DI<'C"&FU,A/8]=;*7/3:4MUM
M2I=Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*JS<^TV-+Z[L>RCJE8;A#
MU2,DYJ=#KDWK2N$1L-$1$C+FRY\WMO8.LJ1&1C"8](;Y\M;0!0GSA2Y!T.&8
MDY2.5(&SK>OM_<":A&B>P0W8S6$[L"CTZ3JLE$V.TTQ-8NUPU%9EM6FK9:',
M%D+-H'9F[:+@=F1>^7R#$?;CIJ(-%/CYB)CI$1P7"A&CK>_B-_O /ZJN*MN2
MSN3%S@P DOD:$5),QA)!8#<@N(&6>V&04(&\\*R:HAD5U;7J.C-M/.I9=<6.
MRJ*Z^P[.Y2:!>;FT,@QVHTZS6=H-U2D-E.0$*;*H&<6C[=*'U"8:6I'VR4KS
ME/UXQS+Q]L+V_LK,L4%W=VUL6 !*B>9(BP!X)7KV >"15$C%(Y' V41F ]RJ
MDZ^O6JB.B;]/[*U?7[/;HR)A+J@JQ5J\P<$4^;#PMVI=EEZA;(N,,)_X04 '
M/09S013OVQ0N&2<>*'4YSD9FTM;+(W$%C-+<6)$,]E/.BI-+:7,$=S;O*B_-
M60Q2J)$7A'#+W4U3 [R1*TBJLGSED526571BKA20"5# ])(&QHZ&]5(-JKRC
M66PL(<<:=>I=F%'<95E#J2C(<P47TEI^V0[DEYK#:T_6A><*Q]>.<WESK%Y'
M1TS6-TB<])ZWA=$ 8?FDNR@$=B=UU'@]0WBSPUU*KHF>Q4LBN R&*&^@FFZU
M/#*(D<LIX(!'K74U"(S&:ZKD",A+8U41)TH9E"<);'&I,S(U(<9K&/J]$9F&
M0PUG]EMM.?V>4X=%BQUM;H-):>=8HH&@J6,\MFB@:'"K %''( -7O&LTEWXG
MRF1E8M+F6M<]*[';22Y^QM<S)*Y_GRO?-(_]\Q%2@;]=<U^+U8_.5NYLO4_0
M/VM7+^@^D_L6O#+<MCUT-W0N%0-E;D#:Y7NYU'DL]01]LR\4'V)$:@]#$?HO
MXK7S6KI2:+AM*6 "J3TW'5780&HYB/Z[V^0V@7%VM<G&YG[_ '^_PJH;UZ:T
MW/&QWX[^OV\\;KWNXJBL+.6".KHXA,DF34T=)!1(^(N#FY][!D@YEH?) T#'
M21 86%8SDF3+:8C 4>#AQ8[><+RI6OG4^P!2.FX\ITEL=R4VYV+C@62V7HLH
MTN/WYMM3P[49(>F>P8@6+-+?C7T9.#9%*]RVG(K^4;'(PNLZZ5F"8[$S.0I(
M1)<;8D,Y'"KU2H@8Z!9E7NP!H0[!_P .0?3J1QQ[\#?ZZV=YKJKIQ2G%*<4K
M#5_]21O^^7_IA'%*S/%*\8^YO6KLW=^TVN92F7BLO:1W9?M:5>W1:*0_*25!
M,U; 3>S*M.[/C8ZJG0>P]8Q9-!V0!4V=EV8& 3MG=]9A'8IYZ+JTB&JH$:.^
M_I]?&OK]?AVT>:]@9D:PD+A\P$K%Q:&)D0B<3)PI$PJ3@4-OX-C(U8\S#XB)
M(AU0ZQY=]$L.*AIUM<02I]+C"J:T?H^^X+2NE=2OSL8=*.[/[2;%TY%M 9::
MP =/;TVVHJ=-R\XM+<5!P\!)RAN$NJ5Z0^&VU*4I.,]?+@[K,9"_%J\2?BSP
MUC\M.9F8=4-OB,6OE1=".6GFDGCCA4A5+-\YU )K#-PD*(7#'S;N2! HW\YI
MI>6V1I55&9C[*= D@5LUNR""NM5 UI)+,3%[,GPZE-(CWB!3'ZZD.0L%C&9/
M&RE^-]Y!P1X2CVG&GV,$^ C[)K@SJ?-\Y E]:1XR4OY64N8[.<1EE=K;HDN;
ME!(OSH@\%O)&9 0RA](0Y4CT/P%D)\#F+CQ5:B WGA3&SYJP:YCCF@CR?GVV
M-Q<LEO*#'=>1D,C;7 MG5XY#%^61X%E4RC6)[\EKNE%&%Y-D,5F'$EB59SEQ
MR:CPF@)I+V%8PI)#4J,8R2A6,+;(;<;7C"DYQS*Q<AEQUD[/YDGR:%97YV9X
MT$<^P>0PF5U8'D,"#S6H\66T=KXFST,,/D6WXUO9K.(:Z5L+F=[BP*:X,3V<
ML#Q,/FO&RLO!%3GF?7/TXI6-B?O//[LD_P Y%\4K5#OU&E3'43<\9'1T#*2Q
ML3768,>QSK=<!'L&;K6E0$L'(/7[5;)-C@IE(,W4(![95#:M5LCX6KNVR";F
M%2(ZI'<?O_W']E:B?"U5 G73N?,UF$T.)%D;1I<;(6CK;L9=SU#?;<! 31UI
MN%.J3UXMQ&FHRQ%S(]A,U:X+$M0UFF[&>'*;""DQ]DVM4MV YXWH'N!QKT&^
MQY]?AVK<[M'BXIIBG'"*UBEXV7UI]HP@.4S:/G'Z)'5?NE$%J.3$_+,C^'H(
M:"]WAWQ\ZUI\,9V6(&[U1[VU_P#_ $%S]_XU8F_1_P#3B_[5*VNYK:NUK?I:
MP7]^Z;9AKK(JEX*1M<Y;-8&^F*WB,J+5EFZ:=47<M*420]#R=:9L+1I6?(Y'
M7,"/&\N8M]IKFL)<Y!KW+07LAE@DN[BZQ;Z0>5:)=W%E+:,02[-#+;+<!V^;
MY5[%$NC"ZKZCX[QOAN/ ^#;[ VHLLA;8>PPWBV -,WRO-/BL?G+?-)UJ(HDO
MK3*OC'MXOG+=8&YN901>1N^R'.EKRZG%*Z)WW!/W<+_EYXI7>XI3BE>-4K0:
M:!\3BAW2*[FW6RU)DC97V0=)3':Z>DX/5W82<BJ 'JG3,5JP';\>-&!;3JDM
MLC9$1K2;UA8EM,:RL$B-+1U8S$0H"JO3M]>AR/IUZ'0[UOEV]5=/T/N_DQ&*
MRU5OT/&Z%S)ASLHJQM'HHLUD9J)#8]I&+&>#P6ETTR7$=#*R,ZD<EE+J<YF/
M_P"'V/\ SRV_[9*M2?HY/\!O]$U>N;Q7L7M.N%&83:G*EF[,@JRVGUZ^B8Q!
MO%L>+GJ.^VD%LM$X0WE#&"1<K7C+[:<X=5UG)F9B*[$R4]/RD?"0D.$3)2TO
M*F, 1L;'AM*?*-.-*<:&%%'90MUY]]Q#;:$Y4M6,8SGEN::*WBDGGECAAB1I
M)9975(XT4;9W=B%55 V22 !639V=WD;NVL;"UN+V]O)H[>TM+6&2XN;FXF8)
M%#!!$K22RR.0J1HK,S$  FOS!SD/9H6(L=>D@IF!GHT&9A9>.(;*CY2*DQFC
M(^0"):4IH@0P5YH@=YM64.-.)6G.<9QQ#-%<0Q3P2)+#/&DL,J,&22*10\;H
MPX974AE(X((-3>V5WC;R[QV0MIK.^L+F>SO+2XC:*XMKJVD:&XMYHW :.6&5
M'CD1@"K*0>164Y<K%J![3_YL-C_B';_Y/2/%*GG%*<4KRIVKJ;M-^C(ITW%]
MF+OG5%SV[5K+2Z358Z=CZYJ2*JM;UA,;2H>V_9W#$#>JWMZG:KV%"ZV:GX##
M53N>V9RPQD2J6AAYQ2JMCC@< @\]][T?I&QV[Z]JV_[$V*OO0E9KV"L$ST?O
M?J\0\ .R4\]')D-^:^4*8:IGR,BB$C,&LM$$J6.M]2!L)]TZQY=S@O\ AT__
M ,&\1?J\/90_NK&N.(U/_O[4?;<PC]_\>*V7YIJOTXI3BE.*5&)_]5:3^,Y?
M\C+=Q2I/Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*\^_B9MWA?5R8=I>
MN++M%@*UP$C>:O4K_L/7$V1K^.'E3;$RW8=9[9TM/C@SBF JE,'R%WQ5*E$V
M,W8-LK]H@:>;!&JE>X^SG6N??8(_55>_"?KTG5.G*]=1)508C]=[!O6OJ+-U
M.=O%OIA$-6FHD <RO0U^W+N&Q5ZH1<UB6AJ=7DWX:+EJ7$5^YQ4+ !6YL1*I
M<[8GGX[UO?QZ0!OWXWOO7I% -',.&M298Y\DVQ#MR!HHB@!RS6XMA!1+ *RC
M5",D$)=>:&R4_D=MQ+.7W\MY><535==ALK>U#:8A*LH:MA-6H)F4J\CGRS8=
MQK]&E4LK\R?(0N,L):!E^/VCZFU>57AY<[C  #+6LIWNT6YOTUO]+CK2>^B+
M:YZ!+;H7'JG4..]6;C9B91_+Z8SOVD=8VU\>ECKXZX/:HGUQP\$5V#@'L^&(
M/L?L)T9O[N$"6Z-J]^2M&?*G*DNE6LQ:O'&?*]EYI.<H;3GE.3(>##2CEGQ0
M5S_?07]_;*#[$0PQ#CTT>YJ8N&F'H)>/^E'&QU_TF/U[]*LK;B'GJ4L-E2TY
MDK5KN(=]/&,J4),;$JT6<C.,_5EMP(LA#N/N^DI?A]?.5S(9K$HF]R7>-A.M
M;Z)LE:12=_3H=MCU&P.:Z_P8R1YY9Y I%KA_$]ZG5V$]EX9S%W;L#_.6>&-D
M_OPM?O5JU9K\XTK&<*'V1MEO.,^/CY7MF6LQO/U_<QEHIO*?V/+E/A]7AQB"
M?DUPI!!3*9@?.[D-E+N13]'2ZZ^&JCQ<H&2L'!!$OA;P:PUVVGA3#0,/I#PL
M#_?;J3C?KKFOQ>K'YRMW-GZGZ!^UJY?T'TG]BUY@;.Z3[VO7;1>Z&^U!,91H
MS<>J-B4?72+3M2+,J<;"E:-<V- K@8C8 E&G?GU>TS8*%4H<FM"5AN$[(;EL
M%LAK'8\BN3S[^WV^_P"SX4V-=O<']>C^O]0K4CXB--*N7=*@2T-HGLW8BM6&
MZHV9=9&'NV]HG1FW]?TRX4]P2L:[C:QKZS4ESL8/;[4%"U^ B+51F)RM@VR3
MV=8H<2+I\N!-5#@;V/;6AOL>_(.OJ/.N-G5>_%AM$%51P2I^03'L2<L#!@K4
MP41[B5DEK0"&E C#ZTK(6A24+6E+2<X\%N)\<>*J*^<"+N&ZXZY =C=>A6RT
M4CJ'?]SS3NM&&3X<.]2&^>[?:BC7J+(AY3 185RAZ#BND1;$DVV?7'Y 4B2C
M26'"@G/;;./#+AHL1D'A@N/&D.'LOE\I7JQ<>(\-X*ZQUT-@M\GN<I.\-TH_
M3K'T(R/%U5I9#.9S-&&9+'S7\M>T[37$\<JGD#JCA0-&Q.E+;.P2!]&],N=8
MV%6(BY4R:!L-9G6'"(N7C7T$!EMLD/!D8:>1G*%*',&(%>QC.?(^PZWG/BG/
M/&[RSN;"YEL[R&2WN8&"RPR*5="RJZ[4\@,C*Z^ZL#ZUN$=9%#HP93V93L'1
MUP1\01]-5!O'M'I[KM(TZ+VE.'PY-['LQ%>]C#GS"'DU-F+(E<&?+FGW(YO#
M4L.MHTQMF-0EHI99HK;&5YYK,>(L7@GM4R,SQ->+<-!T1-+OY,(S(&Z-E-B5
M>EF 3ABSJ%W7H7@G\&/B_P#"#;YBZ\,6,%Y%@GQJ9$SWD%F4.5>ZCM?*^4,B
MW#%[216@A9[EBT8BAE+Z%VUR?CK57H&T0[BWHFR0T7/1;KB/3<=CI@%B0"<6
MWG.<MK6,0TI:,YSE"LY3G.?#FVMYX[JW@N823%<0Q3Q$C1,<R+(A(YT2K D;
MKB\C87&+R%]C+Q52[QUY=6%TBMU*MQ9SO;SJK:'4JRQL VAL#>N:S/+U8=8:
MO_J2-_WR_P#3".*5F>*5X5]KJVS([J[33P=I8&U#&;-Z*K[-R1^B8JZ;4IEC
M@I6K2NOG.O\ M KL%17ZM#4.*DJO>YYP[3UZ,HT_LBV6C4R+W<YFUU.M*K&M
M :Y.]<G1V-<C1Y)X!!'QT.:]MIR(/EEPJ@;'+UY,7-B2IK<2U$.HGPAFR$.U
M^5S*QDDMJ*-6\V\0[%+C93#@K"6)%IE1#+ZJ*\GE8FIW3)047#HE&]2UKO/N
MG$P2H-W$=L&,W[L&&UFRR'E#:B"Y4,79;^7F!VAATQ?H.9;]\RTOTF(K:WT4
MOG]#Y&3P;B# %?\ +6,N&Q]QDF9D("K&PL$Z>79IPR#\FU:PDNCCIV(SD)NK
M8.I%N95B&NYZAYA&N!TZ/<5Z9-OHL.RH4EEU> ZS0')E0RDIRAXK8,HV+#&X
M5XY\KT>!2[$+GR>.,MS"\94G&<87Y+*C-F50G0L+*4NG!#2WUP(HG]]Q)87*
M\=Q,=Z]>YB86G@^Y;H!?.YZ"WCE!(>.W\/V+7-Y 0!HI<SY_%R\D?/L1H'1*
M]C6Z/9AVR'\F6OE&PKIC#>4X1Y&Y^8=N+'E3C&/!"F+*TMO[OBVI&<9\N<8Q
M&, C2[@ Z?)R-[QH  7,QOAH#T*W0(WSKX:-3XI;SY\-?=77\M\-8(E]ENI\
M;9)@Y-DD[828IU?M\]6V.K9JQ>;*N8IQ2L;$_>>?W9)_G(OBE:^=PZK'7;K3
MMFL2K,L^%*0(>%I@-:7[<$XT\).Q)X9</KC5M@JNP[+)@F"CF M5"QP\S'$L
M-S QK7R]7BJ1W'] _;Q6D'P?8TY.BYN8L =AC;:RQKW6DW V#1V]=.IH@ND:
MBC5T1J^%-WIL;9$G<XS7S5?*B#RJY(1@4;;7;.[8@2+I,V*3.5+=_P!^P=_8
M!^O]U;)=]Y2PTSKKL;8 ]@=5&UF5TU-Q]>;B(]>1I6#WCK:53))D5X442M7L
M_3;!>3@7&75J<RO'I^ET'A6V6\S^.LV_-NI);9N2/FSVTT1Y'(X;N.1W%8=X
MYCMI)!W3H8<;_-D4]O6I]H_?=@V+UQ:VQ<J'.T&\0\#**M= GV%CS4=/QL<B
M1 %=:<'%RE=BBS(27$:]NUAI,TR-Y59:RI6'XPL8/#=YDXK2[CR5G:Q23V=Y
M 5:.\C5&T(RK.&*W*26I._G21,= '0VOANT?.Y'$6#@VKY"^M+28R#FU6>9$
MDED'&EBA8SO[("03WK.T4BI-"]?;)4+1%7.KV6B2-2K=M@),>?A+@Q.5Z)OP
M%ICIT!P@*4#E@:++2(TDPZH4]$GDAM[.7&4.<?';K87&%0L6;Y-<XLL229)G
MABOC*Q(V2WXNN&)/3LR'?/2*[&ZR<OB&Q\<SB)8E;+8WQ5Y0"QK:VD5]=X-;
M6.,'I5(V\28^)40L42V0 % S+L/S>5P=.*5T3ON"?NX7_+SQ2N]Q2G%*^:VF
MMU.I?&5C:K0S=IP%WE+=N\Z=+[#5WKCKFM25,G;$7M*_PW6KW^FK3V&VC$V*
MTWO"(NV#VS7D7(Q($K&1]\FH:L.P1"J]_-YUV';9.^PWSH=OV;%>TW<>S3,3
MUX[!1@-+L$N$7UUW4<5:PS*P- 0;@M%F6L"2:)*R1L\LIUAYX]C,;$EB*8"?
M:>/%*6,T]FXT;R-@/>]M1_\ /2K,OZ*3_ ?_ $3Z^GUD5HUMG<]P8[,2^U->
MU^.M\%UEH4'8=MF1A#\?*HU&'"SH]NJ<?*%LN04C8B+59YRW24*87%-CQ&ET
MN-+)F'HUAWHL5X>L[^W>6]OGM)K[+KA,*D4:3++D/R<DTE\C.DL5C&L]K#YT
M(E<3W*ED\N-R<::Y>-^E(PXCA,\YV1J/9"B(Z*M(2KMTL5'2O?;"O1#L"[6+
M'7:9JV<?C2V=RW^IUAN%-4ET>SUZ&/;OMVB%#>/E. DJ-59X&1'SG++H)KJ7
M<+:4I"O-<\()H;7%SE-Y2_M;4P2#]/##*+R]A*<=2O:6T\<@/'2YW['TG\'X
MR-C?Y?Q5CUG0^$?#^5RORZWV&QM]>V[8+!WJRC]#-;YO*V$]M(-,L\*%2& (
MZO6W$[$0.Q->S,:'%!:KVW<*52A EI4RWK5UF(M^O1TI2XYZ3<95;5'0@[.<
MI4T-%,MK3A:5<M^'A-#!?V$L:QIC,I=V=FJ=ACRL5W8KK9T([:Z2%1Z+$ >0
M35W\(OR*[OO#WB"SN)KJ?Q1X3Q&9S4TP/6_B17N\3X@D+%5ZVN<IB[B]D?1#
M2W3L"016Q?-_7GM0/:?_ #8;'_$.W_R>D>*5/.*4XI7@9V)K-OI7<0OZ40!\
M?UEV;W:Z=;4L-R'J?72S[*1OJ-E-$:OU(BF78GM#";AJ>LI"V0E.IMSB7>LU
MQO4?4)_98M9L4=0+%ZT:^_W^Y]JK!X^(!XV>W.^-=_4?.UQSOM7J9VHN]+@*
M)&JFY^*'(K.Y.MEAE1<N-%&Q$:-O>@R3DD>.SZI$4(J+C99YD\I [)"17QF7
M7''/27OO#4,EQE&MX4+S3XKQ!#$@[O))@,FB*/BS, /B:P[LA80Q.E$]J23V
M %U"2?J'>M;_ (679'9/8C1UD*VY-!SETJUP5[(P>)?B"5T:T1[$S5VCTO9Q
MB0*ASDV.J.22&65/.5MP<I19PI4@7O\ \(6*PV-S"' H5Q\D1@<B99HFR%GT
MI=M"RC0CE22WN H9U_+]2%498TLX^6>6$_*2#+U=0 4H1&^R@8;[J0Z$\;Z=
M<D$GTM.-#C C)*0)8" CQ2#3C"G4,C"!B-+?))(><RE#3##+:W775JPAMM"E
M*SC&,YYP#ND:/)(RI'&K.[L0%1%!9F8G@*H!))X !-;2"&:YFAM[>)YI[B6.
M&"&)2\DLTKB.**-%!9WD=E5% )9B !LUJOU@MFU+(?MEW;2P!Y&PV*N;0H<"
M IYS%6U/?JT*#3*](NOQL4M4['$4^<;GTX%RA,MDI>'W\O9<5S/AR[R-R^3.
M3*+)<36V3LX$)/R;&W]N$M(')CB/FQFTE68='$H=NIBQ8^H?A,Q7A?'0>%5\
M*">2WQ^/R/AG.WTX13D_%6!R4L^9R%NJ7%THL;B/+V+6#>;LV@B4I'T!1MES
MJ*\JJ,3_ .JM)_&<O^1ENXI4GXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE:9=\[3#U_K[)0URK/SS5.R[36-4[NFW,6A0>N],WPMV(V#?C,4V,EI]I47
M#J7%14B@3$-!6";A[#;"!ZC$SKJ52._L?3Z?2JM^''6:P#USV-$ZJ!E:=1)'
M=NWV=6W$/$J_%V.BMO@0E N]!AKU5H98->B*S'P]4#8-@I&'L,W39:VLREL!
MLN)^74/?GOZ_3Z^I_P!_H*WYKPA0+APILD1+ECL0S!,F4P*.0>^/$CL/FOL@
ML#!M/&/-N%/-BL-#-N/*;8::92VTA45"]S,,'UFNQ#CBTORNT]/8"::\OJD.
M0>SZI:S$(PK&?,AF(KTD81X8SG @I"L>'E\V-KAV:.YN)@ 5BQ>7ZR>RB?&7
M5HA/Q::XB1?[]U'K5J;72H]3+#H>Y65'/V!2Q^ -0FB)>K78C=< XMKV.P(Z
MH[+BV,)SA]$A"P$%0[0ZM7GRE8S[(=2P/C#;:FWVSO,IW#B,-)>F;#VLH!\R
MRO)K20_R?(NT^56H'LPEBR!;D@ADT 02P?-F8>CHK#_"0]+?#\TQZ]>#W]+)
MOR_<2>MX3SYPF8OX;[Z$YSXY'K$!8+>VM>,8S^E(DX&,1G.<>7U764YRG*TY
MYS&0/5+C8.=3Y!"VB1\VUM[B]!.O3S;:)3O@E@/6NM\.+Y=IXIO^GFR\.3QQ
ML0.)<MDL;A&4$D?.:TR-VVAR420Z(!%-?8] W9,?A?F3'[(D\XQG'AEOYU7Z
MS9UHSCQSX>+DZM>,_P#62O"_#'FXQVU?)Q'M%DI=;([3V]K=]AVYN3H'G7/J
M*>)3YEOX6NBNC<^%[0$^C?(,GEL0K ZY^;C@I]BI7?%28;]=<U^+U8_.5NYL
M?4_0/VM7,>@^D_L6O!S8=>I%]^)%L*B5_KSHG8?:ZJ=DNK&\X7:HFLNC-D+U
MQU@J-=TD+L,G;5CM#[G;.#V6 V5:9BES41!%6.&L9/6Q^F6:%H!\P$[/W^_Z
MZGG0.R!HCUY//U:]#]![FO5F_P#3C46SMR?9KN$MN$B>Q6X"OHJL%O3;E,UT
MV16I4N3C+*BF4NX5Z-Q8EH-7%RKV<YC)R,8":F8HXD(8IM4;XUQWWOU_W5LC
M.V.!K HYUBEX^%#+D0(@4F1);%9?E)0A(D: TXZI*5EG$K0.*RG.5O/+2VC&
M5*QC*HKSAZ;:(8LG7[LG$7$UB4KN^>S79>UUPF-D2UO!5$S:T\/7E>=0<<5&
MR(%BBY27]JE9.6B'D.X-<];+;71Y[+09#\1?)/-0XW!8ZQF+J$/RVU5EEDC*
MN_5&56'H<]#'IT4!&S0+22T>5)2I,K)=+K?Z*[ABN8@=@<A9>0-CUV=U.- 2
M-+ZQTN0HS94=5=15_71]\K\!(2CF6Z/<*W;#ZGNRB1<S+%+6;!-7\Z ,KXYK
MKTFB?M\L(V24 ;!@1]KQ+F?QEC7\4Y:9!?P3FTRUVQB@CN5^3J^,GD "1I=2
M)#<V9Z>E)DMK8*@F\UI<SP_A+S*Y>Q\/XFWFN+C(3)%9V\$4MQ*I9S\H81QA
MW,%O'_7,K:U%$LTCL(T)2T-,ZX(V%$N;EWS05@;.V$..H_75L*"M$-K*#@W[
MA#UNN5X5UI\((DVL60DJWE#YS\^F9,I]]D=ID0,3SW%6!OHCE,S9=.0O@I>Q
MN62XAQ\,)NHH+>!2&12]O.S7+*=332,Q"A45?3/&/B*/P_=KX/\  F>$_AGP
M_(XM_$.*CGQEYXEOKV/#WF2R.0E1HYIXH<GC8X\1%(/ZQL[6)(V=I)I9;.T:
MXX!1DT<IO+$CJR8D]:D#J5A;B8NMK:S2CG5I4I&5SNO3*C8\X2KQ:^;^@XAI
MYIUEO.PNX[(63#4F,EDQS+QL16Y'R)SKC\M8/:3Z';S>DZ((',^-E6?-G-Q,
M'M_%%I;>(XY%!"FZR(89J%5(! L?$$.6QW/YWR3S%9T=7:XN;:N0K#5_]21O
M^^7_ *81Q2LSQ2OF\^(C,0+_ ,1SKZW9)KIFW'0%[T:"\/5)7KP+W\';)D3)
M.*#F&>Q93#;]7;N$I7)'6S&G6R-J""25I+J>&+(=$J>56O8]QL'GG7MZ?7O?
M%?17+PP<QF*R83)C_*I<27%Q&S,G$8(,$2\ED>03&EB8E8Y>'5Y(B)'!4:4M
M+3A KBV&5(517GYTOC&[Q6-_9>RKY.U<=J:46RI2%X=+CMT[XO,T>S_7YPV0
M%N*(BG,.N*5[J#(QE"<8\[O;>)G:R.  ;\JUCC,NNMCI23$8:RA4G@]8DQ,T
M@T>$E0C1)K L_G_*=C@3W$1[<]-S<N2#[%9@O/9E/%7UU+FG[SJJ$V9(#FBR
M%DAX:K)#D&VT%1T?K-HJG/!J4WG*7V2;<)<;"._G"5+8GT-^'D:1SB+B$?C?
M,7XT8\A=^;8LNBK8D@SXUT8 =4=Q'<R7R-R.F["JS*H8]GG)!:66$\/(.EL-
M9R2Y-=,'_J@R9BERJ3(VS%<6$-OC\)<1;^;-B79@KNZBV*ID@6^[4CW_ .L+
MD:E:!,92I/\ P62J8-;SG&59SA:<F4PS&%IQA.%)4CP\Z%YSK;0LF0RT3=GE
ML[M/\"6SCM=]^1YEC(-@ ;!'<&KN8\J;P[X0N8_SH;7,XF<[!_+6N9N,J!H?
MFD09V ])V=$-OI90+)YLZY:G%*QL3]YY_=DG^<B^*5K?W3V1-ZCZO;?V)6YZ
M<JLY6X&/=CK5 $TF/(J[\A8H:(S9968V-2MC4>N5& ;D'):]6JR42V1U4I0=
M@LBH,YV+::RJ1R1^_?[N?LYK7WX>=HC2S.S5!KN[GNP]5H>X692)VM%/]>9"
ME6.5VQ!M[5NA !_734>IJT)>R[I:9V9V/7IMBW3(9LO"6/-G=9MV(X!4L=ZX
MUQK7/IQZD_1WXUK7O=?<;79=\T[8(0>4,(S:KAHNM(KTB0.FLJ49OO6&%$NL
MI"46@EQM#C"G<DK;\C[F,L^/IJ;W& NUL<M:WC%PML+F8E "XZ+6<@KR/G @
M$<BL6ZC,L#QC6W,8Y]O,4D?6-USG%K9V1LC6Q0CZ'KOMG3%UBW\.)4*372:<
M"]),J3E2?##B^N]X#,&QGQRV>._E*T/^1>J\1=,^*\-(NR+BX_%C$:&YL?D[
MC.W"'>BRG'RQJ2"3I^D?FZKK/"*M#=>(,GL!</X>RMX=\L&REM#X8LGC(!Z9
M(<EF+:=&(X,7=20PMFR5ZM4NN:Y$K<#$5V H5PHL35H"OQ8$1"P$?,DHUF+'
M0T2"T*!%QP41;GPQQ 61V! O%H=GR(2PK5Y(*HLIR-FVR-F4[;#7;G&DC9&O
MR=\X.COI+  DZ,^&C)+)F[!&TF1\-YKSP20'CP]M_5,BMK>_ZXP<#*"""ZKO
MI_/6V>;&N:IQ2NB=]P3]W"_Y>>*5WN*4XI7A_$[+V#;NZD;U^L^P*Q'R]%[A
MWG=\1/[/VI9J;9;?JO-2FH"'U#JGK3LC5M>:OD?6HDF$BXZYZSLUBH@9D;(;
MRB[LNZ6"2JQ*JO0GX <>AX.SK?&_?GTUQ7HOW,M=?BNM78:MR)A#<Q8.NN\7
M(H 2,EY DQ@77TR,:\SB+"*RE(:CQG"5*4A0XRG#'/(*.^^UG8O_ (RQW_/K
M3_ZB.K,WZ*7_ )-_]$U3G2W3UAE.L-W,VD5&$R?:=Z?OLB.# (CG(BG; H<#
M6(.'E!C6&E2TFF! ^;G$R0 CKY$RZ(: RMEU&=]XIN(+?*6UEC@\#8*'Y'+,
MDXD\W*QWMS=WUW!(G"*+N<Q0]#, EO&R-TE=8]HK/$\DI#?*6\P*4 Z83&B1
MQL#^=\U>INH#ER"!5<]%9ZP;!N4]1KP4$<_TB'.TK -244&F>D)FP(#'=M;3
MS:'V1P*I7ZR5K&$F8Z0>*L>$VMZ:'C2D*8,YO.VLF4S&/\5"&)<;>6-X(G1X
MY?,\1+>O9^(9%'Z6U\E[:,I$= C(S*GY%(RW?_*H?#_@R;PXCW29WQ!D,;D\
MN@>2&&W\,6MB+WPW9R!)#%>G*RY(Y659$'R9<;BW^=-+((=[X!Q<5O#8L0I&
M6A+/2J#<PO#RY07+1Y=FJ5E>^USYDNC1D?167/41C"FW6/3=<\BVQ]! 3%FL
MA$00ES96%XG?32QO=6ER3SH,L<=D.W((^<=:6W?J+KP5X>NP0TN,S.=P\W?J
MBM;B+&Y;&IR.DI)<W&<=>EMAEDZD7J5I+CYMZY"H'M/_ )L-C_B';_Y/2/%*
MGG%*<4KYEMQ/[. ^,["/4_7FQ)ZND[CTBS9;B]\.W6->JE8B"ZO0@9QZN]UH
MCJIV1VIM%A<:Z0S89">GNOD52QGI*K(WG38VN_2"!5<W\S7'8[^<=]^/F]0
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M1\HL-X$UDQHAH,Q&!UDM9:5D-]?VX1*T&,_IS*/%2DI75EP*XL ](DHW'MA
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M#VT*6(\<#D7R+927A#SB64H6G&%98RVO"%)NPS36TBRV\TMO*@(62&1XI%#
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MH%CU_L+%)%@XAYZ$K<U+;%I9$WFW158=F <2KSWNS&WSXHM0'7^[M]'OQ]^
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'.*4XI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g209588g18c00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g18c00.jpg
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M E Z<J:WWGNSR*]U7_L=]$8TOBZFM^\:O(;+*\[;-%R:_4VM,RHL%TV?#2X
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MU5+%N%0$DC)A2(K#33'5EC:#&C1YEN!+KZE%LLO6I>9PS4:X4WAC [#4*"O
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M94=Q3,B-(8=2AUA]AU"VGF7$)<;<2I"TI4GO.$3[*IUJA585=YE?+1J@<)D
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M#GX]).V^SE4DZY,==&OV%IJ'"L4.?%E]>F+99=Z6-H:-)L0.A)UQV78./?\
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M2 !CZ6;9!8YG5U/<6BUB'<:;;Z+B^<P[3M_X>^G6@M2Z_6RBP9ZYA"!<:R*
M5F*6Z\TQ<V(\8:?"CEJ?+1V&FXKD:7UZ4\5PP'JV2X:*./=C,J#YG@5(O?CJ
M+A<Q2LT.^&,ZU,\;/:-DUD.U N:"S[%)>-BMUIUR6K'':BU 0*8J%T@CE1IP
M_P"VSPY-R2W)(%&C\0[EPSTF"*: UUJ?B#Z+FCT1'HB/1%V]^(?_ -Z.T?\
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MKI^Q3RQJ?+LBV2Q5]U@@:G%#*5*89AR'FV^]<D2"I?:$"!C)TJRH[M%U&MU
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MPY@B*0$(1;#/,4RST5HD(Y/*-A;*@5?2M:*1&B$KBEO$6&7W8SZ?<HS#:#O
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MT1C@]"C^ !YD_P"S]>O^$*_ZGZ(QP>A1_  \R?\ 9^O7_"%?]3]$8X/0H_@
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M^B,<'H4?P /,G_9^O7_"%?\ 4_1&.#T*/X 'F3_L_7K_ (0K_J?HC'!Z%'\
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MJHXP58UT?E2,\L'!;PSSS0PK4-#%YQ52-S^NM$V_#<]M9K.+S7LXU,EEDV1
MT*!FF@&04.KV^36GH1%_X1Q#K=A$"C%AJ+EAKP<H5B$8_>G'R"X,KWT/S)PS
M+]-_2JUE+:@W!F9H-MUA$9]=3V?YR2V:Q+J63CM'OP@)+J].F7RQ);&BFBI%
MO[>F8+)6-00.9$$)Q&)]ZUX>6*ZF]%$>B(]$4)LO\]9_JJ/[Y[T7+;J.'R4Z
MVVJUZ]U2S4BVBXIRJ7*O&JK9@DU'7(1BO6$;)$&A<M'.\ZN*0&S),20CG>=4
MT\OG.\]_?T75?$T=X9^5=C\9/+(#JP.-9]MCX/6_"?QO6Y;:M*DW_$\:<E3!
M.PE2JRS >JW#R$L9UP]=PYJ6-F1(]%I;15B"]%;AQRTX<<7,,V@JX'VEU/\
M @B4\G8$G1?%FES<AK_F?Y4[L5L5@B8R;HU]KFO92S'S ZFH,6$E9RQ2JVYR
M6,DP+G21TNOV-#%A!(F06V#[)-XLSXZ3^J6Z+E*K_AN>6:*A:Z8R"TH#LL''
MO*ZHV;=2EP\3:'F6WV/7&2;<6.Q;<<HQ+RUOPS7S,R';34K;B%)(92;A,'$$
M+J7!C8!8KO#(_C8DC=@5($"(,Z.6Z.-^+^PO7V=N6,^&4_ :!3+=X.6!OQ7"
MG_'.M7'4#V Z;I9G2KS7!- U";A @L*SJ\5>I5&?9]'K)Z^Q*8Z'/= B:_17
M)Y";':=WF;D&X!DC%WJX59Z]X=^1>E##][.^+=\5;+-L?F5;:Q5()[PPV",#
MJV[1\4Y5JUL^2;I8^9@8#7*'07HMJN^0;.#U;+3 .57:M/L](O1NP-O///E5
MQ$B!L_V#L31KC6/9?3G:,?V70<;\, JZQ6WM S3??$G1==%5,RW&J=<A9S.'
MSM+EU:7;";),L !243. XCDDA928UN-Q,>=.4[Q18# G#%LR&"^>B?PW;K Q
M_,QXGQ\H,72R%!_$9K6UD65YF@W:U;M$O1'&Q5RL:R?Q72$4LK>>3!K,P@7@
MTV2'!/3N 6:^SV"6AM9))!V6T;I01QZK:W>%^^UA,(75_'*O6#.G[AXFS#02
ML"_'ZVV6M0<P\4]!H]ELF;YIKN@TW"RM@!Z^:#"Y\G35&1\(67,7NF52R686
M%,"2@(:3,YNPDB:/3A=573_PSMF-81I]4T_Q]KYNTPO#W\13-L1&74IA!N36
M-+W#RIV#4,%B $4YP/G5(L",^L]1Y L--KU'J.?N]F  C=.%L<$M%K>#B3NO
MLG:J*  TYY.I*Z-LOX=Q5W8X VOX!0HWCY.N/X=]LM54A\SV#4#9;$8'E-!V
MHW8*;]P938",6+:\<@')1$5.EWJ#R##8588H(FW *#:B:^KNWR#PYJ%=_#YU
M7-:I L&'^.&3#=6@[=^*V8ZP\2JE0%G<HW$?Y/1?%>E6BQTH\&L[.:'4&,&&
M-4^M&(4_/1L02IZ'4)E6>E!WGE4.T"35B-E]2!LOSJQ/RJ5;\!=YEPM=+J\4
M"Y*ISQWX:=C#9+9@'@CG<ZW'/%'S*EZGL54JM QRYHRL4J3AA8K5:86U;3C9
M2T1R!FGV*_C:X^/'I*N(<@GUN?4?R$$OJ;#62KQC^'NL5RQ6ZR:QX:Q_*NE7
M!_\ $$"TO)7K+@TU>7%]\\Z-NVZI7LA&TS0:_5!0'8\DNE @6:QT<L?TFB_E
M"$&E5!Y<J<Q ?OSFH2#0L6V1>6V0#0&A$<5K7?PYMB%Y_?B=[H=3T_R6&7[\
M+292]VED*E+NAUOQCK7B4)WB\5FY'YL:SU7CA3/M:G2H\]\ ?N,54AAN 7X9
M@1YA#M"T#U18.[>.67WW]%A'HB/1$>B(]$1Z(CT1'HB/1$>B(]$1Z(CT1'HB
M/1$>B(]$1Z(CT1'HB/1$U!?Y@W_XLG_ZAST6=C\1S]RG7T6D>B+F_P L+SMV
M>XI8#_CIC,C<]?61 "JG4&YE3BPQ*RA>+%(WLLQ<;MG0TV/H@M4RR\JT2Y5T
MI;9\"#6H9^N)*/60.5#/)8=^'[MK1<($O'>T7_\ #<\TLY@X?L;?D=KV9>44
MA<OR.7@S6I['Y#:CX]EJ!!T05*RW3]"S.BBC,$L+R.F#6K15V*52:Y'J+D*%
M5H$8L6+0(&ULEPP(H\ %V, G-^L+L7R8H.M;?FUD\?,X+2,H=LU5J4H[L%BK
M$6YT$O6U6=N)?\9^S5;7<YTZ$<N-2'3 QJQ!WP4<15K2]*JUO8M[3*@X^>.%
MD->=/ :>75??A[8WNV(9WL-6W'F;1GR_DKNEQHH[,Z-+H@-JF6G0#1864BB7
M]/TUJ$#/L2&"E5KWU@TE40+L6OFDDR,1T@X5VB"S/0.^>@7??HLH]$2,C_,)
MO]5?_NE>BFU0\#[+:#_,H?\ 58_]RCT39H. ]DJ]%4>B+X?[9XM[W#\G_(Z\
MYI3]N(77=MN\8-6P?::3M3=5QG$XE&HN(Y/LP_6,[=T^MN&?J:SD)4H>&KS'
M186H5:UA:4.5'(P"O!I:<$!R(!%',DF.N0RE^3^)?F#CWG#1=OMMWR;9:=*R
M/S5(:O>*QC9RD:#9;5K&@^*!FBYX]*LGDI8AZSO*]C]>K&:FX=:A4:EYIC9&
MF6$9TU<J[:P9'#-+Q>(=^'#712?SB!>0WD31V,ZJWC-K@ZQ3Q6/:?@EV@ZW0
M8>?T;98IZ'8B=>\Q,VYI,:K6RK8^;#@#Q:LQ0F_4R\0TD.4&1R\#PSW"!@7)
MRXF1H6N*.S&L+Z=@L]H57/V6UUJDU*O6BY=B=M]D!UP.*/6KH^65GP>V,O!A
ML$#?84XZ;F1.DI$GL>48*2&?@=GRENEE2_T1'HB:C/\ ,T_UF+_?)]%G;_$\
MO<)U]%I'HB/1$SV&:3& #A(*(</F1X<G-$@69,:&Z;)Q(3[\ 0U+F.,Q(KA*
M4VU#1)E/-1F%/<=?<;:2I7"+DKQ1H5T\>?&C#JQ;:58K?K]XFC+7Y$D:_*J*
MY,+:]AD3;[MVB6::9M(MDA6 U_,&("&:W-M!N& ; B*T'*"QC*8KBJ2YTH.
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M:>R]"MD\EF9UC;#YIG4P?&U.J":Q(EW:9'?)Y%,9;5<+<293 5R#:@[_ %Q
MFO(4XP10E*G)+7>^GIB30O%#;B#'OHDS%PW"]_CJMN63R5^LXCN:YWR%^OCM
M>4_RZS/G<\=.0TN-:+QKZ'V[H"YW5,+IOO\ 2)9YQWDWO>^W'IR?QQ_)Z<&O
M[HYQ?MGB_EU@+9/)5^=5FSN:9W!@2]*MXNW2(5VF2GQ&60F'E4JTBF50$)(V
M8U(2RV8!.*;8&-K6MJ0[U/MZ$;-B:!HO?@ .*2](<]+&OQT2>M6;R>E+S+EI
MS#-Q395[44ZLH9>9L]548$M/]R5=8XL>WP^NVNICHM*7_I^5]+CBF/J>HYSH
M[LL39M<].2#>N!?]?YW%%X [1Y32(%/</Y9F8\C-S^[$;M'@WN=+CA-(@//I
MH=;#/+'HZ4KQYA,=9PRXEIX2MQQ+3+W$<[T1LRQ)D-#.+WJ/-(#M1 I,W[^'
M2<,VCRG5#:6_EF9HG=P<C87F$7R<IE'D.U*Z@9G:'>C_ '50I,/X7I-P[SDM
MA[O6TPN\Y[^C;.3^34_CGBC[34#M37V;GU625H\IFH!MP7EF9RB+&1U@R!CR
M;W.8CS]GEO-)ME+G/<'J[$J ECKS@NRI2N206A"'(K?%=[QZ8<FLQ06-:^<;
M,L!2)J?/)AOO-G\H8PO155O+\U)2A@G,9&8-$+S.A-6BQ$Y,/FFCK(M$!?08
M^L(7+57)C/'UG.M-<>0Q\SOL],2;O'1JUNIM4+B(XUGSNGZQV3R6BSK^W5\T
MSHH/'6Z@P\XD$KM,@/V.F$66%:*9L+*(#G I>N/J?;KXUGK[9E#:%O.,=7WG
M#;,2;O%#;B\/A69C#:YN*<EM,LGDHB>0;@YKG;X]O:J^"&R'KK,:D2<(DLMJ
ML=\D,\@]XS=QK_7$#ZIQ78LQ"4J7,1WOMZGIR:&W\I8<*2DXOVSY_NL2R>2R
MY\)N9FF=,CW-N.@9\AF[3')$?!([/55^_,,]@\X[>2#_ !*)]3ZKD6&COQ(F
M+[SV]7TY/XBW\KCA64G%STEC[+->LGDK)G4-NRYIG8R 0N5[A:'('7:9-?KM
M''M/]SPX 97 ;X8-6)Y,=!X6\IAH.AQ:FG7OAYZ>F6)H&B]\T2>YZ6->O&B1
M5BS^4<J)FR[7EN:"9A0/I3^I,"[W.(,U8V+>E)RR#677![73T.U,(B.6:4^F
M.H"MUU+")'&^=Z.[+$V;Y= \.+3QC7BM1MH\IG8(%PIEF9Q2$C)K08L,>-?)
MS[ [9(CKW*E38#RAZ>S*B792PLK9%I1('K<6EN*YQ'.]AW98FL1:9K6D)ZHI
M2>..'5#EH\IN0EK;RS,U3N8-#L+;"KY.2RKR(7,^";G:G?M_>\H+$+^79N/M
M]6Z]_)=A<Y^WE;9R?R:G\<\=$G2G?K3QU@U:/*AB!;7 65YE/(0\[I9*FQYM
M\G18YG3)ST9-[K)=Y(Y:AM<!,*E+"&VTNO%5M-)=89XYWJ0&S#DU+Q:Q''"%
MY88;Y?AX4IL]F\G8OZF_E3,,W+?:NYA^E'W2\S1_YKX5Y'[K';1\N Y]@[4U
M*D\J_(_U/Y@XVWU_Z;X^\Y/3#DW?XQ6\IZM+?O%$CLMC\DF39EL+FV>31\+2
MZJ-I<B9=)D9\UF<V(SV[V8PRF"I(RQA'5/I#!&U.LE$MH4Z^U\?>>J!LW)H;
M7L-1T6=IX=OR#:UKYRRY+LGDMR:MMO-,Z5 YO46O(?5=IG'^^.RXO5R]$4U]
M![<O[,SV9:IWQ?2.-=ZYV;SO[/3TY/X__;'!:G2O:'YU615D\E7IU?;+YIG<
M2!)U:TB+)(B769(?&X_$9<54;@/95!3R;;"[_&D%:XM2(X]"U*;DN=3[>GIF
M30-%X<5I7RJ;@5/26^/U;SK-E\FI4K-46O,LX%0RA;2V=3>%W>;/>JH87'DJ
MRN966W(#?#TNU24Q6[/&?5'2!;=<6PJ1U'.=>EC)>&BO]GPUDF(R^F.O@22O
MVCRFDP:,Y9,LS,:0(4J]SM CC[W.FL5^]CWI*<]! GECT=+A+"RF*L\5=2RZ
M'6ZZEIE_X.>\],R:AHJ)<F>"!X<6GC'[^UB+:/*=<&(Y+RS,F9Z\..'YD=J^
M3G&&=^CO.IK] :=Z/YURBD&.,N3K;WG)41Q:T(AKXGG>UMG)_)A'\<\:0DQ%
MIXX]T3K1Y3MPB+D#+,R?GM8O7S@R._?)S3$K=9+[*;)1)+O!_>L4H:QU]P=:
MD\[*FN(0A<1'%=[QZ<FI>/XPQM-4+RPM'&=>"S8[1Y318.@.5C+,S*$!U3S^
M9F\<E?)T%BR7$B]&3HX:PO('N="B:VRJ4NO$F4ON&EM-)>:8^9WO &S#DU+Q
M00S:F>"3/".,_I+;-9/)>+-T=NJ9GG16",L.=1LP?*7:; ?M%:)L1U::2LC3
M<!S@,C6)"I+=<A,J?0<;;;6\N/U?><@W8<FA>+RPK>'\9,P*AOE_.2V)63R5
M:FF6Q>:YW*@,:_6PH-^3=9C#\[%93+:K3=9K28*N1;B+?ZXV,K*5*C3D)2I<
MMOJO;U6V<G\2:?REAPI*3BXZ7*6 B6EDIMQ_4JLUVM=@7FQC:#^73;QO[_FD
M5]G\JV8Y\YAC[38BO%SON@1KYS,#K#/RWW/F]]H6AL3Q7/;KRCOYP5XS)D0?
M$E3Y\F/"@P8[\R;,EO-QXL2)&:4](DR9#JD-,1V&4+=>>=6EMIM"EK4E*>]Y
M%U7S.\>?Q(JM?LL\@-<WFN(Q"K8^&K6Y@WN\.V"98O#O7 <NR85MT\-$$K.P
MR=IA@KF%LE9@C9ZPMBII:,P[(:6U[%HBC7C@06(^>!"D]J_$CR(84SX#5Z;L
M!ZQ6OR&SO!;35;#C.S4"Y4%.DU"RW>M7DG3K/G$>Q3:^;"5N0H$]R#!@SW$F
MFGBD.=4K&-A$W2*M0F"#0M4%JZ_#SA[\0WQ6BC[P=(7*UBZE1Z1KVC=O17*-
M3&T.\5#!(<\AKQ/*+E,IS->U5=+A#"$YV!0IYX@?&0IAJIQ3X2'*(LE-TXDD
M!H=S2$R0/Q L6<,6Z:5)64151M'P<[4JJ3QC> VY6H_N.F;_ )S48P?+C6=0
M3EF&7Z7BS\K-V*G!+'I0L?:;9:!P*F=KITD1OFX:&^_854BC^?\ XV326;UX
M<6THI<]1M%]I@'/A6&[,3T(+9LJ+445I@R_4N#17[!G7Y&3I%0.&YUV@@QBZ
MF6CVT7-)5UU@D\1C\U'&)FEDIV'=M<[NX'QD\=ZOGI#1%96_MN@7?6RECC4>
MAT23:WJ13A\*O5&(X?N-NO=C&6E,*)]XJX>OA:>:*D2TV;(#A") (<F[-?73
M]M"I4OYZW?'+_DF=>3N&6&DV&YY#Y-7VS0L9#7KR-D+E^/NG8W3QMJIL#+:H
M:L*<OO=)T@IHG)UXKM7LE8[%#4TP-Y9Y\2(6(U6,15A5\X;FKO+^>7C8)G59
M'+'<S-=M4;(9;.C5K)M3L>5 F-\>"L8\JW:6'I\NFU=5Y79*ZY$;,%XK@6%8
M 92TI BBXZ;)(Q]\/%8K_AP5$)'XDOBZBT2*:.E[-9+!VWZMG8*+4_&W?[-%
MN^AX=:"=1UFC9^5#9Q+%7:Q44F&*RCK-=FSX,<**,G$SG!@$])&$8_-10R#6
M.>1E5^-_%"P9S2K2.)2SSF*,89XU[O4]EKF;:K8ZW"I>_P [3(2;)K9,73Y8
MO(*P(73@7^<+\[77X*"%EFG8X\73K-.#$8\W((X-^UT:WYFX"YIS^5)L%H^[
MLW@MEO+:K-M%1D\G5@(:8?,Y="UY=73FTV^#AHXBW( 1K,X_]\'$:BTMRX#Y
MP".1BS\[4RU4T5CS'SO6?%S1O*/$8EML=*JV=6R^4\C>LYT7+AN@PPF>HOP8
MQ5TWZLUHG8Z2<C28<6)< $2<$EOH(QX$Z1('OI01B"Q@NUBW2^E57]:_$9P!
MV+2!5UGV\+<BH/Q\=T)8/*=8L><9?9?)&OU GF8NYZ@+ILRD5H?:R]R$ @A,
MV?BQTRY'^=G1[46<_&(QTH344#O?14%DOXF)BWZQ;&-"I<#/\*%&_-:+$L!2
MF:X'O8>O^&-KI=0-FBPX_78;=KGV^39"!'\N4D),*U65"9I<U!2UIE1FRIV6
M[=P^8YUJNGY'XA/C<.'F'S\G6JN="77/L_E9_9?'_;A&GRK/K(ZPD\OBA\YD
M4+\WG(M^:JECAUTD($S1[QD*3 S),,U EP&2C'WN+53(%_$N\2S44G/_ #-H
MX,6'KFR'21>W83ME0$1R/CR-,%]QH;92QT(;"G:9F ^NV!ZT4 <_+LC+H [#
MA0ILX(5C0R,?"#6E^Z\8WXF7BC()/#'2NP#78+^>O&91OQO\@ 8NM576BK0'
M+M'M18MFT,=5\TT XMX55[L>DCPT^2+L3G7VH=6LTH03=/Q45%JUFBF9[SMP
M@'93-0^'3YAB%*UL#7"#>+:XW2]#OF(5:XW#1<XSN^JI*JK=+L$#9_=W&PU<
M(DWC$BI6:!7OO!("3A1B,?:XO3SAD*H\E_$AS&[T.L:5=FIE(B7/ _$O4P>6
M0*1KEGV-5R\H2NS!@5,$5J/GT.1?X9DCDY-F@S:6-FDBH0#9[_8Q==H4FM'B
M14[)'4AX:&UU&F"589#\1+QD@QZJW'):J>LUO1KW!^<U; =PLVI#)N"$:*,V
M 3;,Y"4";;:85I#FDTR7+B6H6(Z8%'1Q:LJ-CY\"1+*;ITM<"KW)T/"ZZWH=
MYJ>GT:F:503<2S470ZI7;Q2[) 2^F#8*G;!$,]73<-,IF/)3%*B)\.='3(88
M?2T^CCS+3G%(24I52ST1'HB/1$>B(]$1Z(CT1'HB/1$>B(]$1Z(CT1'HB:@O
M\P;_ /%D_P#U#GHL['XCG[E.OHM(]$56[+:]"I>?E#N6T$7H]U1/ #QH&P74
M;GM6'PRQX:,.7&WVTA$*/#*E1 <LC<;$V#!V&S$1820+K@$D8F1&.D&L+Y?6
M/\526+R3*K<-KGC\NTZ1Y$;%A\*TV#?+(/\ '"P5O$ZC<;)9M?S?5JSCETM5
MYK)(F!!4Z -%9J]V';"I^#(,R@U2D6,DX3YX%K=DR8 ,!RY8,SBYJ_)X'T6$
MW[4KOX^5K1\M&X->M)ME5J]C 1!^Q665@1YHU(&R9LZO[,!RH]8C%9579$PG
M6CL;*^]/2FQ\61!$PYSQ.$4AY<5M/1QSF-56_ACO^M^1U*O=WTK-<[H8(/IE
MIH><G\TTNS:56M3#4B8NNV6^A)MJR_*RT2KKNT&P5RLS7PCC=JA@'[6)6[5R
MU=*%TW]W^ A#='Z];+L7T41Z(D9'^83?ZJ__ '2O13:H>!]EM!_F4/\ JL?^
MY1Z)LT' >R5>BJ/1%SCY*ZQHF0U,58Z-6,ODB4SR,C0])V_7!^.9!D%.%!"!
M-RT7*PJ$60]-47+L"ZL(@!J^[$C2B[AD\8%0!B(Y0J ^=&#DG"^>5E_%9)=5
MX\PJ_4O'G-3&S^-E'\BK#'\I_(BTXZ)J8_2+3+J%,#@S%;PK1W["*,% EADL
M7.Q":&'2*;KS\UF 1LD44S.'U'G!7=K6K0');FOI'Y$7K5,USPA>LP"XL48J
MD<M9+^0W/4[=DU/K-" @R1@Y9$V&G9-KTR0^,1";?E1)H09!;%\G3E%4NQ6H
MDJS;W;X*@Y\@_P A(O%34=/VO LYUC7\P&8Y<K^'79_T]%V@K;4AJV4F29%-
MDD"1RH44O#,FZJL0=+5XG61Q*L3B3U?)HZ1&R^)(0 6!<9\\*Z%]%$>B)J,_
MS-/]9B_WR?19V_Q/+W"=?1:1Z(CT11&^2;Y#J)R3F 6HV*^LQ6U5L+?+.9IE
M1(3.R6$NM'+/7JC?#(B*F'V2ZW(@5$VZN2VQ'5&;:><DL$7+_AUY [/Y!Q-B
M*:?F&8TBN9]J!C+*1<,LU.U:=6-1+49Z2$U$N&D6[)LG)1 %-OL4AG3!+HN4
MT>L]7N*X'. QP8Q8(-?.P5( :7</PQ<\>!"=<<\G36K^2WD?@Q#(+=G(G#*7
MC%MKEMND@=$):G!U&Y^0U)G6 +5H4B;.!4V$7P6>U5R-B>'G;7%F/'45\?77
MZ\4.U&@'+\F_U=<^BB/1$>B)JG?SX3_X[_\ <=]%G:_C_P!#Y3KZ+2/1$>B+
M@+;O(KRCS#R Q[*:MBV!WJK;=HT>LT]]6]:(&U:)0:Z%AV'7M2L=%1X\$Z:)
M 9L,4^E:?U0D-'31>AUB-,C6*[#QK*>7'X;Y5 !!))## DO =Q[4!@LH%XW_
M (A,_>?(V;A[U(SX>AWOD)Q\)4]3E6[:<8[@6G"\WCI\F\P=I(1C*E:VDEVQ
M4'X+*7^8VRV,A_F.)(<L41YT5.RP=\6@N'@W;DE.L>?,ZF>8BO%FM\\:!D8,
M.Q#\R6';]_LV86DE:-G.W&/#IV?U$#C.A"#AF-7Z^ E DVJY4ANX6>Y"JF#Z
M[+8E2D///.:-#S>UA=W%S@WPOICZ+*/1$>B*$V7^>L_U5']\]Z+EMU'#Y*@O
MDID)3?\ "=.Q(7>)6<\U2LOT8Y;H EPP3@TRQ2(PZ^P \=HR =@F[#27K!7
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M 5AA%,M"ZTHGC)RD^$%-\->7;[ERI>*M>\9?U&_+?T7W#[#D</+/SM^4/O\
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MB8[K=F23X^W$3*=Z,XSWB?8XCTB'?5Z=+(QR;=C\TADJ/XYH1>;=90_R#T$
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M.YL@;&?&WS;\9?'1FP47R$GTX74*U?*UXSRU"I/BURMEZ%OH'1+;O"N:G=]
M*B-!JE%MH+]"(TFR4A4IV8^_BAY\EMH&2"6:K$R]1 X1-5)O$KSC7Y'_ (@Y
M'VUHHQGNA^.%OF9+X]/03XAJIPZ7J =@1<;J*(#(G.:W?ZRBP7(NS.4RJDTZ
M?6<Z<BQ[,!M$T]5"(B6J8J6B+#.5<?EB/N!#>@]6QO;=J.>4%I-XU8,US*DW
MBS5G&_'7%JW;QO-5T[?J<!+L9[<ZC?X,"["1W-= 6.W78YT?1,;A#)%=/6@"
M04M>K.3IPBE*X"^K/HLH]$1Z(H39?YZS_54?WSWHN6W4</DJC#6W>*.[Y]!I
M1^V5'0,Y\AL[U),6O%!Q:2%T7.*K%GA-48D1) UGK@B!#^X0"\:;R,[)9ZZB
M*U(2KG>Z.SM!W!AGYTZKH-H00:2#POR;VR$K-;[XLZ-3IE:LEMI=RHF@8A;]
M-)UX^#F&*[:\*'LRA%S,E@Y(.]#(UGZ;LL>4%3XRWYD=3K/1TAI?>*;NU@UW
M>9H$W@\&:B>X.C<E2U,B_AX97$@D:@.S8#^7*C7O,J(<Z,L1(W%J+]5,YI5=
M>>/E8Q [,CP:9:C=-K\67.DR@=>,3!0X3!@NJ;Y-TXON\Q97>BL-P@_?<ZI1
M<$?AXMI,G;H&R=UO)ZW>]-/R2E9(RV %3\TR+\W2BI2/]M>9*@M\*FUSKF#D
ML$H1^<]&F&!:7X41V,&SM%F!EP(Q)";S7Q?I\,FX)4?PY,'E:&@-6<NI9++;
M%X^3-)F\#'9A<)9>O'2GCC+/&)48@2+3QG+L;;H\A4PEVOCBG!*5CQL2'#BA
MLDLPJ_05Z:H=JKG+SF2.>%89(YX3!)LR"59SB/+S[?CL"9$EU^;);!>07D4)
MMD"R\<8<&OQGK'IP;1;C#-2N)D#I\.T%F)KS:)3B>-TXMO<A4H]9T,\(/:."
M@5,IOX=% :E5VFU/*0:)WD1G&,.1(X N\\WO>*62'H^39Q!DS(DA\:SEUH@1
MK100 ]^+1:B1X[( L052I27FZ<6WN6>J;SWN1S:>)(KFZ]G:G^'?>].":*_6
M<N/Z7=MVY%KYIX*95((^1>*+#3>V ;!<C-B!VGU%FJ!8KM\9APCDP2*CA73\
M\3\4%QNFK4 / &A5&T6@P?W'O%B]U.@=P\++EF="Q0)(H)C*]=YHXZA4!H,4
M37+8G*RLBS:1&AP'A[2&TUDNQ(+$.3>Q4O2T*<A=E*[SG1V2'<49^=.JCT8U
MI7P)KO%K\%_(>/3RU^<SG2&;?BVYKJ$XV$*R7#.&'A'Y7WL>R\X.8?53S8H4
MS!M@.;U#93HH?)1!?E#X,AF[NU,4(!XF@1VH3D,]K_1UBJF-QVGQ-T[.[)0K
MM::A;<UO?CG9-5L]:+C2\H'8O&^3'>KMGL)&&L:GY]9?C2'QLV KG"3K+JTI
M@J1WXO4W3B^[SPCL8,B?VZYT 9M^&)F4F=;*_6<XK4FL9]G.^D"<9-V5]OSU
MF[5:]YO>7VG'7VWH#-YJ]3L(R-UEZ6T4$0'9,!*&E)ZW3B^[SPF\3>SR;$&9
MT=='Z3M?BC)02,Z;:JC+1XZD<VUN=-,C2TKN<%= A3J]FEQ8ZV-<4W..0+20
M&C7X*9+[#!>2B6W&2XOJ6Z8BKMRKT4<3-I:2T6$X6FJZEXR&GS$2]W6OPK+@
MM\KL)DV^)=(%\DU76Z+:*#32XA)$$6$_F,U3-#LP<>Z\/,">C[!/AEXZHTE]
MA3=):*NVK5Z(X#RV>?\ B^?OC]XO>(&'WRV6?2=#P^[GV;3D/B?%!4'Q^1B=
M5&Z75M$#[)0A]CKPP_=HIC3'[[6J=9!,RM2:7E-0=K4./2*!4&99%N4W=K%C
MM<L\KK6^+%I(,O4-CB',EZE=V,VGPUGFT+9=H;YTQY831R7/LY/ZF9Y<5&K1
M*O,>ZXJ!Q/;P(J0N&'^[J4F!]NAM,-37/AY[MTS%MX\+$J/KI7M^E55'SS\-
ME4]@?1J/D'U.\E[YE0L?"K1/D2P2J0?9N^AT"M094+@^I 8-G$Q+2=KP!FOU
MLL=&0BJXT^?#BO-MTR2# #Z TZIO.WJ?$OQXUY#13$B:\$=I?J=B))SNY3ML
M*NZA4#;P<TV3MIKQ>20@*MX\AR#$G0267QTE1S$M3H^3V _/'Q^3H4V0P^W3
M,49]'IU4&T+&O<3UHJJ!9?\ A:R(#<H)0<9?&WO$M8N,#G*X:>B2/'XPR0$Z
MU$!1I413=<S<@ET@V9HP5D2&>DJ7,B5_LKB)'+N[6#!8Z'"N]?>.7!Q?4CJ(
MT4EM)_QZN7DKF7DK<]OIY4-A7C#<]MR&GMT&=&)52D["H/6+KO1"^NO3B)04
M4K(6/4 -3&@Z\\-9,62<<;LS\H!VL3=VL7W?_EA-X4>H<\!Y7I=["W.[>$>N
MU R%WB;0KE5\XKM)W&7VQ"3+TFC![9Q8^CZ,!+0H#1NN$R3)60/@%JU-B'V(
M1*;"?4Q$F2VG+N[6#)('$5" M0V>MOKLFX$2\#<&AS!]<A9CGD7QAG!2DY(F
MN$(KN=F/)B.E$ W)DQACLDB=UIN9QPP<<>*EB[\AR38)G)+CCO8-DEF%7;E7
MHA+U/A5?7S)_PR2;A\'?\]QR8U1Y]9\=K:#)5LJZ)3*O9,W:J9F]J#L1.B;5
M%<.W&PV2JLFXIF#5CM@*F0T@,4FR9*S'!H3R%3R94;1%"S'H2U,$Q2L*W.6'
MPMCKF">JH27)/EI5JM.C+$%5KD>7H$8!_*;4A:X*NO7L:+J%>^A,K<5 ::"P
M>+(?&USW;IQ;>Y94WJ3_ .1WCRVBX7\??%_Q/I>Q,7ZZ:IB>L3;9"W?PW!5T
M!XW@LM9T@[>S]5L^S@]MBBIANGZ'<G^4EIF5'J5-R')$.6;0B<;/7BEQD28M
MW=K% #R-"J=MV#M,3BP?#M4F 'A='U/-?PU3U9J&?U2I9G/%;1=[$7I76(5I
M[9;)>\ "$QA4B$NLOB;B&*Y=6G380+)8L I(*OSRX.M+;%E9T*5-TAXHSZ/3
MJIO.:U?GG37C-5>F2[3XDU2BYC4,=LM*KU .TJ[VW,059$$A@B=3J%/GO7XX
M/C<%L]Y]N*\)SCDHAQ!0L3>FDG>D)DM^0]=W:F#! /$T"A(J3^V]U,(_E-X_
MRH<4A'TP*[#FX\8WZ*^F*9^!['@#JV#%Z3SHSBN"X+K:T.L*3PFKJ>_+@KYW
MG>CL[0J+[O.K(XR/\OPU6)7E/X_PH<XA*TT(S#&9($W><^J*9ZB-DED<:9!W
M=?$C.JZ,(N/-(980E1%/5\^;";YSO>3=.+[O/".,BC\HZ5"#_E/X_P!7B7:>
M?TT(-B9Q6:1<;N^]%,+37JSH[T:/2"\SC(QU3D>PO3(R(B(J9#[?74]EM1T\
M5WEW=J(J2!Q%0CB9I5++!Y+X75I5]A6#1@XR5F!JA5V^LOQBRE5HUI[,>10A
M\WK(YU+CME9E1W(2HBI+37'4\F.1N\[SD&R2S"KD<!4\D<>:VXZ+,_R6PL9-
M+#I^C!XTT'J-?Q4M'7&+=7"U&U-)?K].=Z@<I'2)-I:5L/-J6/1SOL],:[^S
MTW3BV]R%2CCNW-#7DKACTMJ"UHH=<M_9Y_CPTQR,6^)>T"V.2I]!YWH[B?NL
M9CO'5R.JX+ZG_P!B>KO[/3=.+;W+*..[<T!O);"[#-J@X-HP>?-O%UMV<U2.
MU&+)6:NU#:<?M]?C=='-I1+!M-.+E.2%,Q5\3WZ:0_WVYUND.X, $\#15)Z_
MY0X':6\]=K^E!B;>K1]$E9ZIF*81RT1\F5(1HKL+YPUKK2:LJ)(3/Y-Y%4[U
MI7T7)7NGW'9(=Q1GYTZJ./\ )IP7F+\IO'\W"KI 7IH29"MF?6G5:Z^W&,<0
M4SZE.O,6FSL<<&H6B"&=CO(D-/I:F+ZVKZ>,]SV[V[NT+4+'0FR..S\M,\OE
M-0?RF\?T"425:8$XQS&YGD1USL8Q\/,6;*NCEW__ /#??[2F;SL?L?V^Z?'^
MWD#X/WO3=VL2^ZUW-F\"FS '/L93J3\IO'\/"/D2>FA(D*KYU6-:/R'(QCJ1
MN=7-UIBL6I_C8U:U02[K[2([3*7)J.KY]1%9Y[]XW=HT%VYBRK@7U6]@\HL"
MJK.@OV#2PHQG*H6>D=!6_%,+Y6(6KKC-YY(F\9&N]=1:%RXR8/(7)2FNNI^M
M3%]E>S=VHBKMRKT1QFS\O.JA6TZ)XF:#6- R_:3M6/URL7G.J9> )>,>2JO:
M+8" VS9>W%(#(K!$1:FC$018*I9*]/CD:Z9A0"T$L,(PV)#0;.T685!(X"O1
M5QG2N;<U!0#'@I208*@".5*(.I7E:&KL&-.<N!DPOR[(_43Q,BQ60RLC8;?H
M\WZE<A=IM9<W]1UN+]877V%"XQ-TXMO<LIO:Z1[13V5HC]E\:)U_AW ?= S]
M[L-O*>+T(@A5D^.=<J9/G6(KG3<);'!2"(F=-FS7B/8C:7>.=926?80TRANF
MK6!Y&A4<97CE.M^+P$;1Z3E%HK8\9IU^VGE'"BHYQ+-DO\"T6/0]J[#[-AJ4
MU/:M)NR6$RJ6[&BN2YLG@WJVOE,I;I#N# !/ T5=[NI#7_*;Q_M42BSZ_IH0
MG$TNO7FUT5]F*80FQU[-7I+%Y*0^/#6E-L5UZ')1,3+3'><ZTKL1J1SJ>];I
MF*,#H30*.(FM%B)Y3^/T^&-(1--"/PR^4'MQ&OIC&.(EY16''6CUT;XH:E7!
MHUQEU#S"TH(JZCOR83G/;O:=G:%1=N9LCCW[5\^TF*>4>!-AR,Q>EA4QFL3@
M>0#CW8ICX48Z>7R*(O??8;U7VN<^XAMJ/SG2?.J]W(*$\[WC=VL?RW?_ )80
MD,9L3RR@AY2X!61%EFG=,"#HM H]'OMQ>>C&%I!5"_\ 8D:G')7&1KBG(IU^
M5';BMQN/R6^NI[)883SO>-W:B*D@:D50&!H![)RL/DWA%3>T)BQ:.&%O93-S
MP=H2'XQ=?:Q-U=B/)SR/-^2.=XZNT,2X[D'L+LI+7'4\FJB]XKG)NDM%7;5J
M]%5Z$O);"P\P\/):*'B3:QH]:R(]'<CENK&Z/<&D/UJJ/=;'+2J>6:<0N.\R
MIR"CBN?/E-=]^<;IB*@D:@5*CB=/&XZ56>>2N&=E<A<T4/V4K:W/'/C/TQ;X
MN[6U%3-<S_W^W?#]V1%4E[LCW^U?!WGL0ZK]GING%M[EE'&15N>.*J@'9?#<
MI1E8O7BE9_).OZQLU.551BK5 1:]<-V^Q:;M _Z]A,8FP<(7&PV.S&YO"$2.
MY.(R>P)?RNMLI'9(J* $\#15Y=Y!;F!3D%(X>Q^*^AW/$;W#ME9L%T.P]N!8
M>>Y&.HG2X=99%KV^"%^9"88:;'LU45TSTFTUUW@IK@Q;W?CXX.R0[BC/SIU4
MW@U:_ ZT*DX?RF\?[!"JQ$/IH2="NU(M^CU60U%,)09I%"=>8M]AC<=&MK1#
M!NQWD2FY"693G6^]C1W^>W>T[.T*@P0.9IU1QD9]_I8:\I_'Y^*W-:TT(N*[
MC$_R';>Y%,\2O%QDGL.??N<Z,XK[5&DIZTN/WG"G5<]T0%)]N^F[M8-=WGA'
M&11^2S/\IO'\7"+D9^FA(T(#F%=V<O(7%,=3!R^V.ML5VX.\0-4M0XHZ\VAA
MEM*YZ.KY\^&USW[QN[1M4D#4BR.,CS_4W73RAP.MC+Y*.:4%'L9@.SJQ7UQZ
M,84FMA=-DQ$4,A,XR-<ZZS9%2X_(:8?)+K?S4_5MQN<5WC=VHBKMJU>BFU((
M%8TP;T^XJGT_Y+875YEW'G]%#C)F<6>E4R[L/QBREUZSZ*TR_2A$OK(YQ+DB
MP-/LKB+B*D1V^+Y]4]'[[\X&SM%HJ[:M7HJXIP[T\^PLR_)3#8,V:/EZ('9F
MC=<"81.CJC%NKCZY8VD/A*0OJ1ZD=)D&G$+9?2I0Y/%<X[-;5[\]3=.+;W+*
M.,W;GA8B^2V%S9L0=%T4.]-GZ^9P.)'3&+<4_K]>:Z^9HR.J')1PI :YU;KZ
ME)&JYSV:G.=_9Z;IQ;>Y91QW;F@'Y+8999E+'@M%#D9FB6NYT>EL,QRR5'[7
MGC;SUS"Q.NCFT-R0#;#RY:Y2H\=SB._2O2.^W.CLD5% ">!HJ_TN?=#D>!?E
M;S)3%_?J.D?G2LZTG,YBG;H(5<J#4I43]:*J3Z'4%59\[5+K(]5USVZ)GT^T
M/!(#DZO%U0HJD-TS%&?1Z(-J(-9IAYFC/!UU5Y#/*/Q[G#P4H5I(%T<<R^P[
M !7'AEVV9>74Y;L>P6N,W]L1\H8'5'<:=CK0U-[QOVCPW$^WNW3@U;F;*.,B
MC\L\%Z+\IO']N*N<O30B8C>+1?(A;W8ICX4XM-E?11;_ -YP;U7VEZ5_(IC\
MY]TXK]JH'$_O>FZ<7W>>$<>>_#5:E_*CQ]!0K.1+Z<$@PJ;1:EIEGD.Q3"D"
M*)>W8[%2L<CC8Q:UPS;LJ.B,VPEZ6WUU/U,=CGOWEW=K!DD#B*A' O2NCI18
M?)[!:I^H?YATD,+_ $H[G?-#^?&+J_*_=92RK.^3ODC7?F]M*9#/8/T7U7RO
MF<^M^E]N^T&R2S"KMRKT1QG'>G5([%Y)X<%-$QY31!$.92]"KF9VAAR.54L/
M>[O%:=JM<D=;'K2N8:;?95&=CJ>B(XOGU$EGO.\XW=HV,@D:@74VB(D1M!YI
M6J<E^2V%MRU0%Z*'3,1M,;QV4QV,6^/FTRXW9<:@=[P=\/W9V-SKJ9'%?:^)
MY[*G\5^STW3BV]RRJX[MS0-\E<,+S < ;HH>7,LFE6/'P;"(Q9*R.E5%EQ^Q
MU)GK@Y"4D!333BWW75-P5\3WC$MWOMSMW=J8, $\#0HX-#I\K2O>36$6N3G\
M.O:.&*2=4)Z"&S]EB,60JSD\J8?DZ#$A=>'-):<K#$5]R=V9V,V[QOO(:Y/>
MIYV;I#Q1GT>G5'$36BYUD\_#_P!3T?/MZD?DNQWNX Y>K4VQ)5<HHVY0\$=D
MLL:&;JC/8=3M5BR5Z.[RHV>Y5\C:JBJ)&74)D+Z2&IINF0U" =":*C:A@8+_
M $=6IHI\6U+P]N925>BEGK!0Q8_%RXVF18>-V:--F^+G2?U5P*(?C1HSD>O<
M*0^/R.,I8L")#"5PVT^R>^FZ<7W>>$=KTGI?S1[*@K#F7X9\JXF-=,-"8EO:
MQW+MJ/6<?==F"NR,<KP<14<NN!6($L,&"1$P!$ 8+'1Y4*214CCKI"$X_+FO
M/MTXON\\(\-SD4ZB.U-%V ?\IO'^KP[N0/::$&PLWK-(N-WD/1C"T5ZLZ0['
M8I!>9QD:ZIR/8794=$1$5,A]OKJ>RVH_.=[QNF(JX&I%0HXZ>=-:5P4KL/DQ
MA54EWV!8=&#BY>8'*)6KZP_&+*56SFFLLOT,=-ZR.=0Z]9&9#+D-4-4EII+B
M?K'(W??G&Z2S R"1P%4<9$5T6T_R5PP7,+0)^BAXTP'J0#%2S"XQ92H6I6EE
M#X"G.=0.4E1$FRXA;+S:EP$<5SCTQKOOSTW3@TWN0OP1QW;FMA>ET72IMJ_(
MUCAV+\@W ]FEP^C;EM_8KU57FN6&N2OJX\?YDP7V=$X^Y&^?$5\Y/R9#OLKX
M1!%;A^2Y[=>7R5(-.MF<XGE]]UR[0X8BAX[GUXT&SS1X),^2&IM3KY*TVYX8
M,'QG)<E?1(V=(6-'M*>).IXPEIUUU*>PFK\2NH%&X!2P;&JY" +FPAPGD4D%
M0V-0H?$86L)/81+5!;CK92M$-UE]+DB#Q'&OW^_-:]^]]$88I31+/M%?<ZZQ
MP6'6IL>R)>9^BA*Z@5S]^.-=;^5WJ1_/A^-F&OG(W[/B0W^SW]$88TY86JQ5
M=?2IMP:%>22C,QE(7#@N)GQ(/$KCQU)4VKDJ-$XE*V6N\<:C\XE2$HYSG?1%
MNX* 2'IK+HT0_(F<A/D6G(<)UZ5R'[H'/34*;4M_D7Y?4PG'^*XQ\'4L=3\/
MMPBQT: ?3)D*@!WD*F<FRWNQ83B5$(/NA,N2YUOO.S(?P=1R0ZKY\?X>IXM'
MP]YPC#'@HFJP+KU=KQNT/5YPK&!1B=T=A5NMN6(^2FC8#TYR2!""(DHH=L\U
MECL<7'&1Y!@I+<8A0TO/OM-J(EH^* DQQ<Q@1#A.2>=-P8LP4R.)Q9,YEMV5
M(<@OL-2X1/X'T-D?C;;EM.*ZS*[Q?NGT1ACPU4#*7[,:SJ^;8O,CQ8=_OM,U
M70*(.C@.]A_EO-"><!]%F)*,1?HA$A$W6*8WV(X\Q(,MD);C*)"($SK9_.#?
MI&CG[O\ 27W.VY;F@ZO$;=( @!QFWU7*ZZ[P3V4E^UZ398-2KE5BLC(,IR-T
M]8BT2!(XMM@='^>Y++/183,F2T1L8/3P*9+&5QEMSY@\(TU'&]%O?'$@-ML!
MW5=5T<Y\3?$MC7%I4KL17PQ5JYWO6^]YWU7.35^>>*C# HW+'!;NB*_Q/$/#
M _P2HK GB784+X9,)KG5QAG.+:]GHK?$=6Q#]E-(XCJFV^?#[\BK#%:ZH>$
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M+T?-3T0+ZGH5P3U/V^)[=%M-J4T-[SY/MT>VKG.MP_YNCO/=+?.^CG.O/*A
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M0JD>*5\Q+!Z2X:P4E)\9M@A^1?DH=''FY$V^5ZHYHS?\PN/CQ^6=5QU4I[/
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M9<K?IT KO=@1(RC.JM=3]^*-$"U@?!]LM66!S:%?R4B[ Z6 @ ^L"Z4/I(B
M5VB(R Q:D&.M2;]5]#?191Z(D9'^83?ZJ_\ W2O13:H>!]EM!_F4/^JQ_P"Y
M1Z)LT' >R5>BJ/1%R_Y16&SB*P$$#\JUR_TVWR3=<OEKP&V)K^S95#?"290.
MSU ;&D!["6CER\5%7+$*A8X-CK'W: 62,)!/O<\&5%;<Z+XRK\7=LJN&5,&0
M\;_)J!Y+CO#J%D7C9J>$^0#=)&T"ZUO3=K+8U6=]JV<7JD9N#NE"!VO,+=JF
MGFF=1S/1RDS1PL0<M K@702TX>H9W+CJ1!(?#XY?5[R.E;W<_&;6\QSFOW4;
ML9*3F6%JT$8P#!1I4+6).95O5-YRZ0@Y(?8"935= NUE9?,0PIJ'9LY-1!H(
MDQ%$2C)9#/I)G1RU+LW-=:TFEU;.*;5,^HX2!6:71JX$J-2KHMGC T%6ZX-C
M" @B"SSO?EQ!XZ)&B,)[U7>-M)^)2E>_>E*J3^B(]$349_F:?ZS%_OD^BSM_
MB>7N$Z^BTCT1'HB/1%\O?*NK:Q5-SU/2J;BMWV\-M_A)/\<ZZ/HOY9>56]5K
MMQT(]7AMRY9+"!;K]/T6'JG6YET_RH" _(4E-G?'JF $$2HM+,7UEI'!N,P(
M*[NPNADLLQ+'<Q,D6RY?.<KSVAE2S*G5,E"50J0BOSB+2GDH>4W-E#G9*%.H
M0[U+O.N)2KO><(:ELJU/11'HB/1$U3OY\)_\=_\ N.^BSM?Q_P"A\IU]%I'H
MB/1%\:-JQ?1'_)B]6?',9\DJ/O%R\EO&B[A=] ;S8I?C18\9J(S%JWKQ*_9X
MB[@:0#YS*Z;H&9%\I.YI;+7;K"FIW&K6-WI:$8S\M Q+$,88.#+,:UF#1WP6
MSQ]RW;Z?.\.*#9,0T<8WX$C?)<K?KMQ%3<!Z^X1J5NSG-1.23$VI,BW%==&6
MOFDNM$F042J3 : 5ZF ;+)A0G"$B3$@!L,VE(\E;[ME>VVHQYA9S7\3T0DSY
MTV;Q:NM$T#B*HW6LE@ :?DV=Z<+U.>NT=EU0YDD#,INB1(0^(:8ML^RQ M&E
MG#[96/!(&AV(V7#9J1:9+7UA?:?T64>B(]$4)LO\]9_JJ/[Y[T7+;J.'R54-
M:?\ +U4#/.W =X[-DUUC0U:LFN3]&<A,7%#TK]*FJ"HE%2^_6Y$?Z/M^<L'&
MR3#W9/ "'$<:]:.[+;UF<#F\]&YKI.C\;VLB _Y?=A"NDQWCJDCW'+&Z;3!G
MZ,J&G?TOO<J<07U^*EY61N1_I^V"5*XFWMO=>X/96CX.^GI_]5%A2]ZXLDZ=
M3KIP[HD/^7WT4CL0?XZ](?H6(>BID3]'Y#[Y*]D-_?H3_6XO7N8FB+\WHF8W
MSMW7(^7]7'2W\7IZ?_538?C:]<BFJ3H\?O\ 2P>D>7R8-V[61WCJLFBCT5><
MI-S]&1!>TA;L;]2F;GV#&4^S2V6>S.TEX+QPV\YR/][;;3UST],/O5+P*6:1
M.4G ZGZXSV2NS/\ EBF1IG*= \?G(K<_,>8]VQSM";?DC'&6/UC5HW!L9:(\
MZ-(^IYF_*W\UB0SQC\R]:7USV@W8=[NS<F^4+V;F?UV[KU+O^57)UDX!@8(L
M<G4*FW45%9U_3-<QA3#7YXDV%,2-UEO2VI/SN5>..ZNLNL_+Z5=0OXO5]/\
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M*.$J'^=&I7+#O"GRYVC.B$<5H&2^-&XZ32"DL?#*Q1UMI&:V6R5V=)%D69$
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MT$:$:BA0X$F3(B;-8I%5M0\.5.R0VL4(J[," 2(L/AV?OXP64<ID\_RJU11
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MOC[=O); YRS%$+&=;SRC#ZJ?F"9X$<>7)SG0#E1NM=N5<J]C>D190)TG&*'
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MDCG1[<%UWZ*(]$1Z(D9'^83?ZJ__ '2O13:H>!]EM!_F4/\ JL?^Y1Z)LT'
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ME5.OW8U. %KR O:!\Z8+-E,AM>7W0]77F ):;)!BPT$:;[^/?NF\22[&3R?
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M=^RV)<2Y7D;!L]<&2P$2MUC@Q71 6+WG-WFM971;-PJ4E$1V/:*[(:(0)I6
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M*U,YR1SXQ@)V,PN"TGJ5MJ:1U2U^WIO;428+B;Y1A,5JO<]XXX;9_P ]_?\
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M?B.?N4Z^BTCT1'HBXJ\_*Y8S^!AI]?KA^Y1<^\B/$S7[I4:L%(V6QV#-\?\
M)O)]*T)H+5Q$::6M1$/4JP5L\6JB8,\O9G0200@?/)D(D)]YE45JT$=01WIC
M,)F\-&Y]BT#S5V6#7[56\UVSR+JUES!JXU&RT(O:1=.\9\$RNT7]%/N D%91
M(P_=**=#"91<./?L0^K1[1";DA#0DC->>?M#;A[DGV/*AE=W>BB/1$>B)&1_
MF$W^JO\ ]TKT4VJ'@?9;0?YE#_JL?^Y1Z)LT' >R5>BJ/1%P%YW[@]A<#)35
M1QDWH>PV2QV:K9SID3!M?W&L>/,(E7>HNVF72#B%&O&@M#%BOHPHNF5]D+.T
MX],'5J58ZK6FK+<ZN5 =YXR ^@?P57,%B\8LJ5X]>!E@RRDW[3[!E'DYX]RP
M>B:)D]XJ.K"A)WR6#V[=;^4SRWU&JG\K:LY]L[9+4]RFU:! K"V8T93-):'H
MZ6@9VGCTEIT8#5AXZZE\M1>U;L,AY9B-)IMTI=7U"$*\FZ?L%LTW!!VD5"'2
MPE[!T"DWEC"=2$WN@VPM8ZS%U6?71Q6M&0 >YXT0*)*D;G!KQ9#"N(9BW<-3
MC+X2W\,4+I%9_#T\,:MK%&YG%XJGC9CE6)T]V<:EEA,>O4("(&ILT*P5.F%J
MU;GQ\2._:J;*$2.T\\Y/KB#E@0-29FDVFWBQ<.97=7HHCT1-1G^9I_K,7^^3
MZ+.W^)Y>X3KZ+2/1$>B(]$7R7\PG)="WS8KG:<TTG1J=L_X?MAP7-HF?Y?=M
M21.U.!=-!*6#,B+%+K]@15)NL"[Y1$""%K^QU<RW2"OUYIANO.J9+0 +2Q<7
M C34+Z&X#5+/1,)Q2CW:3];<Z;DF<52W3/J>3?J[/7J<&$'Y/UG%+Y+^>5AR
MW?J>+5Q_X_F\4KB_?I9,DJV_1$>B(]$35._GPG_QW_[COHL[7\?^A\IU]%I'
MHB/1%\:-JT&F:7Y7R_&XCE>KY-D #?L)V+6-"K?B7Y$V61Y7;]1)F8VK*H8O
M4*'CQO-*OF&?&:#E$;2]AN%U09-MT%C-A[-;H84O;YA:#@/!@@.1 +V=WK#7
M!"O_ #[*:QB'GCY<:E7<R)UJEW7Q3P*]7*VUNEV(PO0M.A[-YD6&^.)F"1I0
MM>[_  *\1J37*T,Z8L(ZO2J37@XF,'56!G)<\!\_I"20)H2!H(;@*]UR7Y8Y
MSY>W_P GO'_>@^*9WI^:5SR$P#^#^]*U+4JC;LPSLE7WSNGV'1,K?\:3ZJ78
M[I:5MQ+E<2=O?[5ZC3,]J**T%)S[Q,-54$,9+L7#!GH)>>#9,EE]S/181Z(C
MT10FR_SUG^JH_OGO1<MNHX?)50UFZ^3DZ!GCMHQ&E@YYBL:%.T>)"TV,4:IM
MI#O24YR"#R$#&^6.#<6$172Y1M,=%<4^M#C4GK7>]T1LRQ-FBHOTME=)T>>
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MO(;CC>(TM<WF#0[8W&[IL9+2O(!R9\N9DO7OMO>)JL:%_E+=_P#;Z=YS^1Y
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MQ08TE2.)0J0Q%(M-/*0GB5.(5U/.<[SGHLF"1A3WT1'HB/1$U3OY\)_\=_\
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M1*.[:!GE0CGX9^4%Z QE%[W/8+[F-.\>M"\>L-K)4GG(U_$LKT,,"K,XH"L
M.C#R]UME6K-7KM4IMQTA^UI%@!BVBT,Z9-60V9*[Q=V$D$UDCF[&I#UY,_2_
M WA-_1[19/*_6;1H^G.Y62N=GL->PB;4#8/+J_HM6"U2PY%^F+6;V'.C(O22
M4\H#.AIKR;>(K]R"&A)P:T_Z*;V@&*P2U)J]%;]0\.\+J'B.]X8$7I]CR!59
MLH$STB1$UTTE-XLQBXS"H=RE0*L(H3PZTG7R= B4<36Q% 3! 0*5 $00(IB.
M1W+^U&9N<=;NJR*^&14FKMDU/R6U7R0M.8TO0@>&!-29QZJU^C7*_P">G\\7
M>CC679S056S2YU2L1FH1K5:7) \4"LED6"K@PD<*$I14%K 2'9W@O<E4-4/P
MQ!]RP',Z;Y&[SHETTBF87AF. 7B+./DP.5HSRX9'KU@HK(-C/6:UK(.YZ/CE
M!$7QC4QULY>:'2@@9UN)/DG#YHKO,2P#.<AW! A[ EF9G*M6J_ASTZBE"%WH
M_D%HU<V&5M$S6QFD#Z_B4=@)82V&T[Q]M.>CLZ'9L/SQ.<EJ!0JIUJJ_E_AX
M0=KP<['LRR,>8^0+.]:*,TV+O7)[I_[^'_1E2QQ^-O\ M9#0HURP*ZQ=(M%B
MIEVMQ2W^/2=#88G%E6*I3193\XC]0N$&SB(XR$) Q'Q<2BCJ@-"#8#!7>AF#
M3W+YM9+O#KQWDYKK/ECY"6X!$HUC\D]/CS:?GR+F*N3%'S6GP'YI%4.>)0D1
M"):?LUJV#:K5!#29S;3U[$13$Q144]%@//.Z$N (@5R3]  <N:[\20@*XGJ9
ML17%L+DHZF2SWBXS?>\<D)[Q?LIAOO.\6[SW;3WG?B5SV]%E'W"![>_UL3V^
MFY-]_J6?;Z/O?;DOW^/^;=[^SC__ +KO?V<7[^B(5/@HXM2YL1*6FFWW.JDL
MIXVP[WV:>7WJ^<0T[WO.-N*]D+[W]U7?1$+GP6_G?,FQ$?3_ "?J/CD,I^1]
M3_-_G?$OGROG^_/D_'\/S??]SXO1%E4Z$CKG%S(J.M.ML.\5(93UM]WGNTRY
MSJ^=0ZYSO.MMJ]EKY_[/.^B(^NA>_M]9%]_J>0O;ZAGW^L[SWY$]OC]_J>\_
M;QC_ -[WG[?@]$0F="5U'$S(JNK?7&1Q,AKO5R6_VN1T<XOW4^WSG>K:Y[N)
M]OWD\]$0B="<ZSQN9%7V0IY+'$2&5=?5'YWKZ6>)7WYBF.<[U[B/BZWSG?CX
MGV]$6$3X#G&^HFQ%\>;==9ZB2RKCK3/>\>=;[Q?>+;:[SO'5I]TM]YWXN\]O
M1$<GP.\YWDV)WG8ZIG.\DL]YV(COLN5SO%^W8Z._L4_S^23W_M5ST1'2$#G.
MJ[-B<2F.B6KO9+/.<B+[[(D][U?MR.OO><0]W^35WO[%=]$0N? ;X[UR;$1Q
MA#3KW5R64\9;?[SC+CO5+YQM#W>\XTM?LESO>?!WOOZ(LKG0F^N\<F14=CJ:
M0_Q<AE/65O\ MUA#O%+Y\M3W.\ZTE?P]<]^?!SOOZ(CLZ$GJN*F14]0^B*OG
M9#/.IDN<]VXZN=7[I?7S]J&>^SBN?^RGOHB/KH7>^W)D7W[)["YSZAGW[,3S
MW5$]OC]_J4\_;UC_ -[SG_:CT1"9T)?6THF15J==<8:XF0TKKCS//=UEOG%]
MZMUKG.]<;3[K1SG[W.>B+")\%SY/P38B_J./=C_!(95\_D;W^HZS[+[\WC'M
MWYW4?%\KV[\?P^WHB$SX"N(4F;$5QQER0WU,EGO'&&O?YKZ.\7WBF6_;OS'$
M^Z$>W?B5ST1-0:? ^WH[];$]OER9OO\ 4L^WT?U+B?J_?X_YM\7[/G_^Z]_V
M?'[^BSL?B.?N4ZJ(0$\6I4V(E+;+<ASJI+/.(CN]YQI]?>KYQ++G>\XV[WV0
MOO>?"KOHM(7/@M\>ZY-B(Y'XRI_JY+*>,)D>W(_7OB7SY?'^]Y\GJ_AX[[\^
M#XO?T195.A(ZYQ<R*CK+C;+O%2&D]:>>YSK+3G.KYU#CO.\ZVVKV4OG>?#SO
MOZ(J7HN15JBZOO&N,6225LNZG,\:)M$%C^,U<?G%$@4^NTP(MI*7W('"/;/<
M>Q9JW9"3MS.]92F.MM/"I, 8?N4PW#%&-(HF,5*_Z>4LUARG3<CTB7=TCJL'
M)WR[9$:A'^=+A L&%7Q/+(1AJ<+C:\/@M0$2%MC&(K:&TI("SM=QP==#(G0G
M.M<;F15]?6ZVQQ$AE77EL<[U]#7$K[UQ;/.=ZZE'OUOG._'SGMZ*+")\!SC7
M6YL1SCZ'7&.HDLJX\VQWO'UM=2OO'$,]YWCJD>Z6^\[\?>>WHB.3X'>)5R;$
M[Q4=<M/>26>\5%;_ /;DI[Q?MV.CV[\;W/Y-/_S5ST1(R,^#]OF]^MB>WVQZ
M9[_4L^WTBFU<3*]_C_FRN_L2_P#^Z[W]G%=]%-JAX'V6T2? 1!C]7-B(XS!A
MO/=7)93QIIYIOC3KG>KY\#;O>\XVM7LE?>\^'O??T04' )6N?!;Z]QR9$;['
MZRE_BY#*>L*D<YV.E[XE\^5U_G>=9XOX>N\[SJ/B]_15"IT)/5I5,BI4V\B,
MOBI#7.HD.\]VV%\ZOG4O.<_:AKOLM?/_ &4]]$5:;30 &UX[K.,F3K@<3K>>
MWS)2I88["<)BF;Y52M7G/CVI7S(SA>#$*NRXL62VM*GVF^/-*:ZKG2""#A<H
M[[^'3XG>1XN%R\4\&N\=GXI'F:1#^7RV'1V%72JVT56""D2VX<N&5@UN55R3
M?8RI8\-8"K@Y<69\E]LJ-HBA-^ZN.^XY=;6S"=I7DI<\W)@-#@7/+FZ\-JDR
MK!*Z+S5&>&LJMU37'C1M<H)&3*L%[=;MDYRRUVZSPI0!8A+50!1V"/H*-W=]
M#\<U)O'?'*OX^9LS0@UN)W*86MVEZC;;G9'PC9FZ7_5[_8]-T>UOP0$(2 %1
M"5PM1B1"#@1D(0"&=ABX[:DQ.OO$)<X_4*[^3X'>>_)L3O/INS??DEGV^C3W
MV5+]_C]OID]_9U__ -USO[.K]%$*GP$\5U4V(GB&$2E]5)9YQ,9SOLW(5WJ_
M9+"^]YQ#O?9M7>_NJ[Z(FHW/@HAN=7-B(XP_ 6_U4EE/&4/O(^0MWO5\^6E[
MWY\I2_AXY[\^#O??GHL[?XGE[A.RYT)OKJ5S(J.L+::>XN0RGK+C_P#[EMWG
M5\ZVM[WY\I"_93GO^YSOHM([.A<[WG9D7G4R$Q%<[(:YU,M?[41N\ZOWY(7S
M]J6>_P HK_Y)[Z(CDZ%WO$\F1>J[(5#YSDAKO>RT<]UQ><XOW[(1S]JF.?RJ
M>?\ :GGHB$3H3G6THF15J><=:9XB0TKKKK/.]>;;YQ?>N.-<YWKJ$^ZF^<[\
M?.>B+C;R#\5HFX6R1>*CMUHQNP73'+-X_P"B$*<.II]R]9 9*/%W(8[MH'$T
M5RYTV<0LSE-N8U,M@%^;[)PQ7CZG!2A!4%K/=B[>'Z75-3#U2EU:LTZK)@#*
MS5*T* UL:Q+0XQ K5<'QQ(UAA;CKCCD2! B,1OGK6OV2USKCG5>_>E$__7P/
M;W^MB>W(W)O>_4L^W(?>^W)?O\?M]-WO[./_ /NN]_9Q?HB%$("..*7-B)2T
MTV^[U4EE/&V'N\XT\YWJ^<0T[WO.-N*]D+[WGP][[^B(7/@M_.^9-B-_3_)^
M?\<EE/R/J/;Z?YWQ+Y\KY_OSY/Q_#\WWY\'Q>_HB:R$Z$B>-2N9%3UJ8MAWB
MI#2>MONL?R3+G.KYU#KOOSY;:O9:_?GP\[Z+.U_'_H=G=.OUT+G?A[,B\5]3
MR%[?4,^_UG>>_(GM\?O]3WG[>,?^][S]O$>WHM(3.A*ZCB9D575OKC(XF0UW
MJY+?[7(Z.<7[J?;YSO5M<]W$^W[R>>B(1.@N=9XW,BK[(4\F/Q$AE77U1_?K
MZ6>)7WYJF.<[U[B/BZW[=^/B?;T1<#N^(EO[Y5V;RH#^5=@8)VUNMAX=0+9O
ME%MA5/*:SP2LUEF=68^*F6&F5"W%!LNQ76579,,F=LI!)8Q-F+!5ID.5>&M6
M\G)EHH/V5T#)Q\5S8].W('?)H.Y:/@- QN.MA@"0@5<;F=JV:W KR,BDF)+!
M$@@MLI/ZN,6;E W6@(QIV.I+\Y+R[\.S_:CQH'/M]+GC4OPZ_%?7K53=)NM;
M!2=4!:-G.QWC1H<>$+,ZH>H5=AUB/.M\0>_%$,Q#8\8&8DR1<*)V+&#C!XYU
MF%%:9X5&T1>S7CAA=^KGP&^.]<FQ$<80TZ]U<EE/&6W^\XRX[U2^<;0]WO.-
M+7[)<[WGP=[[^BBRN=";Z[QR9%1UA;3;_%R&4]96_P YUA#O%+YUM;W.\ZTE
M?P]<YWG4<[[^B([.A)ZKBID5/4/HBKYV0SSJ9+G/=N.KG5^Z7U\_:AGOLXKG
M_LI[Z(H=8'V'YJ?DO-/?):^0[\IQ#GRGVWG?F,N?!WOP.H]^?&VKV6GWY\7.
M>_/1<MNHX?)5(2_'OQ1Q2D!+.7J]3SW/_'[/]2CCK)8;48%5O.,YN<>>:U:4
M6-&K F'$!S(BB)$R7/2GN"(J7WXTR PS\2-':VB[DRS\J=%U L!HW&W/"H_$
MB?X8^WFH^=^/FE^/.MV.JX1:LM;J.8;4/O)T1@API#B6L5(%@+F3(MUZ07/C
MXDP_*;5/B3"L*,T6CN28Z%-_:,O4C:XD4*'883LD NS@BN#SLND)'B;X\RH;
M\!_-1SD.3B8GQS?9Z7LO..8L#?;E"J+U2325\@PWVFW$$DJX=<ZGB7BCB>]3
MUO;57OO<S4J,,6;DHEK&%^(-1H6HW#90E)I^;E\]I=/U>UW6Y%*O5VL[SB3#
M_)L*P'I]B'P0HT#*:A(:(IEP),ASY3<^9*^9U*F]M!F)@DCB:IN@V<F*/AAV
M$*!Y]'_#R\MY&Q/Y+=\+WV7=9F5E-H1E^OP+O*>E9DUR-E,NR1:=<)CU>0';
M&J:$*;9%,%^PW_J^$EM/]Y!M$,QHXAKU?CJJ=EC((NQ!PU#HK9M>%^,/+&S!
MM]=JT2T;#K@72!P\I9RH\I>]>S:N3SXHJ#@*.QW21BM5:O%#3X@0SV"D.(($
MB YV-$DO(;QR:$<C4*,,:G[/F-$N*^.OCE7HI*V&Z<"#0 >Q$?*HN=)GS<$<
M*UJ&,<X4T\A,E&VX</Z,4PZY+C2%-UJ-&:<?<&HXA3G&\<VW>3NW5&'=^?G5
M5[<ZAX1X#5:CKFA$,QRVF5S32^GTN\W+0'Z_7TZCJD9[D\L')&[&U",&KA%6
M^J #;[/9E-\<6(%I^7U26\:/8#D*!4!Z!ZF.Y_?'*>,8R'P_M]2R#1,(A4*Z
M4>AKU";CURH5WFV^M#G-4=FC-26'-#K&4'%7#<KI >69GOSUAYK4F)%;&2HZ
MVVQVB7<U9Z6HC-9F^?/'4L#>)GCS7X52'!\T'0H5$HERS.IL(+V5Q(:C:"[(
M>N-?94^:=<?8-N2I"GI4Q<@A'^9WD*7&3Q/.7>VIFI!/$4*C#R%EKQ.\>F(;
M0]K-1R(;.($/'!ICA>R]2C%"LKZTA0^*Z:ZOL&3)_E5$^JZ>1W]ULJA'[OJ;
MQS?>YY1A@4;EC@L3_$WQY)PC Z?F@Z1"/Y17,/+L*+V5*9N5U%UEZNU!:FS2
M%MQ1CL=E;4]E31AWJ.<DD7^=[SK>(::%QQRC#SVX:<<E;63Q/\>[=#T*!8\V
M'%(>K \]K>@,.EK(RFR!,J>BR,_@2%1C3"XC=;>AQG([HU4)^7UKG"3LU*E\
M5=[:@O1R(!K6"&E&&-,'K5+3_B_@]HFWH@>SR 1F:9::+=;R^X5L+2K!:,T:
M89HY:0F.791&= -QF$L,0$Q(DKY?.D(\M75=Z&UM!IH[:/7JC# _Q8F>+V#D
M)I C,SR _-*;$#W^>^HK84JDZ_6F4L [JI*#"6T3(#24H;'MI0%=YSWD#'5?
MM]-[:S0$<C4(PQ7X6T;QAPF'-AD8V>P&IL#9C7D+$?X4L*E,['8651S-W2E9
M=3:ILYE:D.#EH4#;YWW8&-*]N^IO'-MWD*!&&+OSRM0'B_@]7G4@D!SP>.FY
MQ;KQ?*2^V4L+O0-MTAIUB[&6$2"[S<EX\T^ZA^/.1*A1N+[V!&B*XGO*=K:+
M@DR #J!3HC -%//"DE=\4/'RI1L[AU[-APR-DPK10>>M-E[(]RM"M9=E/:'#
MC=DFGU2T65V;*7)<)*FO1.N]X-<A<2CB6\9FK/ EJ./-488SW?[*T&^)OCR'
MAA!XW-1T6'6\NLN+!&$E[*M,#,+@\_(LE3;4Z:6MR*4>D/+=G/J=+,]<[R*0
M83Q/.-[:F:D$TJ*%&&,Z5JLN>)OCR[$7!<S4<J*YAT3QM6STO9><5B4&7R=$
MH7Q<-<7]"S*3QY)/BN'E=Y\*RJD>Z?3>VL_RWO\ Y91ABS<L(,>)WCT?@VD:
M8S4=-A77/ZAEEH867LK:2U!H3S#]1KKJF#33C$<*]&96S+B+CD9'6^<FS)*>
MJYUO;430DBE34HPQ9N6."];%XJ>/]L_4?MAS@>2_5S]-/U%^86LC/YG_ $>2
MRC-OJ?IC+'T?Y62PSR-]L^A^L^#G2GUW>J[V#:(9C1VYUZJI29\8,'L$VU$#
M&>#YTR[:!4=3M#ZREA;46OU$9:CU*QNI8+M(8D!F6&D,Q(B8XZ1Q'O,AR5=5
MWK>(O0$<C4<U&'7SKK6F$+\8,'<EKG+SV J6O<XODHM[I2P^_=OA15P8M^^'
MA?B.3F8JUL\&<3P KG?B6)4OG%<N]M9_CN__ !PC#%WYY0-\8,'$301$=GD"
M--K.H6;: 3Z2EA6H?IUQ:<9LMK;2Z7<;=E%&G7$NPI"'1+/Q>\6 PKG.\F\:
M/8#D*!&&*?*TK?BW@E1D9W*KF=CQDC)RFBFL]<;*V)[M:*:S'DQ=#EQN2C#Z
M9:[*Q,DMR4$N36HG'>]&MPE<3U-WMJ9_)GU:G1&$12G-(P'B9X\U>%21X'-!
MPZ'G-0O%#I3#9>RNI!5+2'I,B[!F%2#3RY+)YZ9)6_(GJE3(W7>\@28B4IXE
MO;4S4@GB*%&$12GLLQO$[QZB0HHZ-FHYJ%!Q<UX\16.%[*I+.-6%Y;YFC\4L
MTIQ4*<\XM:R*UJ.-]5[,%&D\YSC>VLFN]SRC# HW)8E>)OCS-A3QTK-1ST(I
MCH+ )['2]E2F1D%9<:>!4I2D&DK1#'N,M*;(-J0:=ZCVD$WN=5SK>VLW.U:I
MJ488%NU/99L/B;X\VN'>X%@S4<2AZ95Z)2[RPX7LK*;!6,S>BR*,)?5&-,KB
MM5]Z%&6P\/5$ERNM<X0D2TJ7Q0;6T&8T+CB;Z\T84:OQ1+;%XO8-;)>@SK#G
M@\E*U0YGUDO[SA6PL]L9O*F8\?/Y\A,8PRB(Y7&8D=$=H<F''E\:YTDU-5U7
M50;1#,:.!P-1S1AY[\=4$/%_!RLXN2(9X/DS3VKUS<2[ZBEA0J;JM293'KMO
M6ELNAMN6,90E#<%E#8A[G/>4/?5WO>MXYMN\C4(P[OS66O&#!V)C,]K/8");
M&WD/)!I_A2P]4C;"L?D4A?.)Z7ZCLZ3'YQM0U2>@4<_:V*0K]OIO'-MWEA&'
M=^?GSDK 3Q>P:N3JB2"YX/@3J'>;EI52D-E+"XH->-!9<8N)]E+Y=UN0^;9>
M<0]&FHDP(_%>\&)%[SG>#M$U-0 > HJWVD]=\5/'^J-YPU7LX'C6\CC:5$SI
M+9:R/?EF/KZI*](:C=DF7NS.6A4N3V2HGV<J'\WOVM4'B4_".T2[FK/RIT1A
MA>0GQ-\>@<&MCA6:CH<*H9S;,DKC""]E<2,SN\O//VNLMK>-../1C#TAY;LN
M4M\G'ZYWD.;&3Q/.7>VIDR03Q%"B:Q'B?X]+$)BJS4=UCN*3/&[K?W:R<YW$
MG"KI)="]^&N*^A5.[V1]S]_OW%?N\*\;_<]-[:S+[SW<7?P+&R PX$<G3H4\
M3O'HU!L(TIFHZ7"M>:U7'[ PLO94))9O27F7ZM5W%,FFW&HPAZ.RMJ9&6R4?
MZCG)<Z0GJN=;VT*&[\S=:887I8O%/Q^MC.C1[#FXXFSK<'.!NB(=+61KEF@Y
M&Y&=SJ/)[&,LJAIK#D.,J,L9V$Y,ZUSA-<[BE\4&UM!IH[?_ "KU1ACP8QR2
MH[XP8/9IMR(',\@$)F@76F:+<'W"EA:Z;NF>LLQZ:=>3'+M-QWP;,=E#,:$B
M-!D\1SLZ+*[U7>P;1#,:.!P-1S1AA19O&/%$M7Y^G,#:,0J/=;YY2$+W&NLM
M^J-ZG2V94=W3Y%A8L:@C#=>9@S4$&E2D5F'R'*[/'I5'>ZAO'-MWEA&&+O&>
M55[)P[Q:K@&%IJ@M-$U2N7^P^4$2]2KA/8JHRYV<6J98=4</RK#P(D:0#K5-
M=D29*JLQ 5]9'C,,^SOIO'-MWD*!5II+]],?:;\?R7Q%M8/,M'PUC/;O5Z%9
M=(L^877/+X]=ZR.LNB]EC=)GB3H:RF Q9\NX[,AD8\F208&O_-:AL07F_9+>
M)>7<!]0*<D9H9FLU%):[XG>/53AT&!7LU'#(>7UR_5&AL-E[*\FO5W4'I4B^
M#(ZI)I]<MJPO39*Y#I%4R3%Z[W@Y^&E*.)IVMHO-2">(IX%& M2GGOFZQ#\3
M?'D?"&#H>:#F(0;(K!@XQA)>RJ3%R6U..O'Z:E2S2G%PR+C[JG"#JW#+75]Y
M&),\YSG!VMHU-WYBZ  4\OY^DG*>*/CZZ&(PG,W'*BO88.\=W&>EK)SBL9KZ
M^2@]&ZKAGB^0H4AM#B"/%<..=Y[/E'4]ZGK>VLWWN>>*$  EJ CEA!+Q.\>K
M2'M$$]FHXC%T.AT//KFRX6LC7#E/SM4233 CZHQIE<9D&_$CN,R(*HLV3UKB
M9TJ4GJD];VU$T)(T)J@$#4#V3E9/%K [<]HTBQYT/)O:W.S<EHBW2MB9[9IV
M1,1HV<R)/(IAA,-588B1FXR1G(3<SC7.DT3E=5U4WB&FC@:.[]7-483KY\+T
M*>+^#FIM@(D\\@2YMITRK[&??45L*%$=*IC2&*Q:7$M%VVVI(EIM"&H49#(I
M[B?>7 ?5WO>MXYH&&@-1S1AW?FO&3XT^/T!3YN911,-,+;)7D_)(RC1V/'B[
M.F!]-,T:0\Z91'9?;'L]2]!=ZFN-,H4XH6GO%+]-XYMN\L(PP*OSSQ5+9"W^
M'KH=KKX;#-!\?]&NE&N5TW($"S;; =[L .U6[K(RZWOH6OW8Q-[%G.%8T.<N
M;$=!07Y\5IB/$>?8XJG:VB[FH -*"G17=:Q$X->.<YNK/$>//B_0SV/UT;5J
MK7[-14;"3QD"_:BJ#<9G0F6$;+-KHF?8%SK!'G,&XGW]YZ.49 I*0U1^B_JH
MW5P[1+N:L_*G10 "@$)S"^)WCU7H-3&ALU'085%HERS*J1T%[*XD/1M!>??N
M%?94^:=<?8-NR7UO2IBY!"/USO(4N,GB><IVMHU)D@\Q3HC# OWK[H:\3?'E
MB(W :S4<B(SB!#QO;9X7LO>(Q,I*5,GT/BE&NK[!DR5==42ZKIY'>^S95"><
M3QO;6;C:YBA1ABS<G=!#Q.\>BL$P-(9J.DPK!E5;Q$PPHO94)FY94'FI%<J*
MU-FD.-Q!;S+2VIS"VB[W4<Y*(/I[WG6]M"]"2-";HPQI_N:73==O%/Q^LPO0
M(IW-QQ"/JHS-JU?VW"UC:Y8P>628BZ# D=CF651$5Q<.-V.Z-5#D2_E<X1>F
M<4KBF]M1-':D/7JIM0"15P>A"?K#XOX/:YM[(V#/(!*;IEJHUVO+[I6PM=L%
MHS5IEBCEWT1B[+<5T U'90PP/1$B2N(YTA'E]ZKO0VMH--';1Z]56'FF<K:7
MXPX1.FSR,O/8#TTGL8+R G/]*6%*I&P5II# .ZJ2@NEM,P>TVA#8YM" CO$^
M\@8ZKO>]F\<VW>1MYKE&&+OSSQ6L7Q?P>%.ADHN>0&IH_9C?D)#?X5L*E,;'
M8V>L&KNE*RZFU39S2NH6.6A01KG?=@8TK]OIO'-MWEA&'=^:R!\7\'K$VCD0
M.>#QTW-[==[Y27VREA=Z!MNCM/,W4RPF07>;DO'FY#R'X\]$J%&XOO8$:)WB
M>\':)J:@ \!15O./GOE5:<S'PA\>&,6'7&3E&0,UGN@T'#8U[TU-3Z])UQYQ
MZ_U>I<MEMB.6@K:'B:E/0$]+DXRI;?!B8?%M<]-XS-6?5J( ] 2V [?J.VBL
M0=XF^/(J$$'C\U'1H=<RRRXH%827LJTP,ON#KSUDJ:%.&EK=BE'9#RW9SZG2
MS/5]Y%(,<XGG*=K:-3=^8NHPQ9N6."'/$[QZ=B+@.9J.5$<P^)XW+9Z7LO.*
MQ*#+^NB4+XN&N+Y!9E_RR2?%</*[^ZLJI'[OIO;6?Y;UGWLO7X1AV;1N%%J8
M\2_'BP0;2-,9H.FPKM0*=EUH867LK:2U"H#T>14*ZZI@TTXQ'"O1(ZV941<<
MC(ZUSDV9)3U7.M[:R8)(XFI1AC]MG*4V3Q6P"W_J1^8\Y'D_U=[FW=&^86L;
M/YG[D*6$YQV3]*98^C_*Z8S'(WVSZ'ZSY?/N?UWNKW@VB&8T=N=>J,!;':G1
M(['XQ84<-E2)7/H$R;>-&K.HVI]92PMJ+WVB1&FJG8G4LEVVV) 9MAE+,6&B
M..?^#G9D.1WO>]N]M9, @<#4+.T!$"=H/K6J<E^+^#N3%$%YY 5,7N,;R24_
M]UL/%=VZ'&[#C7WJ>%^(^N:C=ZUP9Q/V'O._$H4I?[WJ;QS;=Y86F'=^?G:*
M+(SQ@P<--!$!F>0(LRLZA9MG!/I*6%Q0_3;BRY'LMK;2\7<0[**,NN(=A2$N
MBF?B^*+ 85SG>7>VIDR #P% C#"\ZWXM8)496=3*[G0\9)R8IHQK/'6RMB>5
M6BFM,2(NB2X_)1A],Q=F8E2&Y*":9K43CG>C&X2N)4F;Q+S5GU:G1&$12G-5
M/&SOP3SR\YAAJ26/U?3Z]0[M4,IR4EJC,31%4'2%$9=TA5ZE%+A^:3HX_P!0
M4>>(_;B+\=#$KL"9%1&7\MO&9J03J117=B! A\/9[*:0/&_Q8:*.T(?4JKT]
M7_'][&)-29M1=X^)\>[Z2-QN IHC\PK*Q:U9BP:Q1!UDE,)GS)H<O$&FNNC9
M;3#>.;[W/*C#%FY8\TT7G:/'7Q3$Q8@RX5>HA8UYSNJ^+0N*=MQ4/VT4<3\T
MA4LI#?5V**Z2(I2*D2A[ Q3EJGM0)+G94EIA_P"%O'-][GE&'DI^L/B=X]6J
M%>QU@S4<1A:;5Z)2[TPX7LK*;!6,S=COT82^J,:97%:K[L2.MA\>J)+E?*YP
MA(EIZKBF\8FCD:$U*K5U2RR>+N"VZ9H,^QYW )S-4/9_9[^\X5L3*K&=RQEB
M/02$A,4PPB(Y768S"([0U,./+XWSI%F8KJN]#:(9C1P.!J.:C# FNJV(>,&#
ME9A<@0SV!)F'M8KVY%GU%+"A4W5:HRW'K]P6EHNA#<L:RTVAN"REL0]\/%21
MSRN][UO'-MWEA&'=^:]P^7T/,)MM_(E=CU[]0KI8-0N7T\HA*^^7RVO,]L5B
M?^X3)?T\@GV!$Z[%@_2CV?D\^FAL?$OXA)-;!N2Y[8GB']U2WXEX0S9/PZO.
MVO5T03/GSGB#Y&" @,+ E%3!@J1R2VQ!XP4,@M/S2!"=*=:C0X41AZ3*D.ML
ML-+<6E/8N^Q^6S_T/<+E&H:!I&YY_LF8Y?YNWG0=EGX\9,Y F5XL7#QWB5/1
MZI*$&JF6)W.95Z]#,@)=@BBZ[:JE(*-IL%5+FXBVW(RI/4$HS[) %9,\.[+D
M^U;UY.;G0\:\G5%-)S/QJ\F-ET$L5J\V[[OF*,ISC.\L$T7%P%KN?CX&)ZIG
ME?U'3:]K&K%+,#76(%C+',HIEK/-#7XE?,E68M!+,[ B2\#:9RQ ZM0%=0:]
M"W30/P;[-"M,RS779#E*@H%$C5#N";67%L[9 5GA2Q4DQ J=Z*%6:!'K4ZQK
M,BZI9+&ZQ/-%8-=GD9+$(I&\&@.+]9GY3AY'8UO655W4_+W5=;F;!KXS(JWX
MYTZ#XJ98;\8F*EF^F[YEI70;78SD^T>8&C-P@B1$$Y;[]7(14YEV6"M".YO4
M6+I/X:00$49@[EYH"P_CK#R67$]6TSRQ;@:0&JMBW*54P.T;^]G$Z%8_(_1X
MBJ9,_"UOULKO*IJF]B(6O:-2H_DA 5-I-FL?'1LC06V8]&7P/VLQO14LX=J!
MZ"=YK%GW:]3,J^"-5V 3*1X[3+=Y :#5?,#QE\2*U?'-9M=YT"-&O>GZ;<PO
ME06 $K2[-AYN1D>. ^[%RE J':U2Q4\)7W!-3 .RW)$IG7SS_5 S/0@V80T5
MK+:G5=H?B"M5T;WQRN1D[M63RL^TZQG:EY'8]GPS616(68AFEJJ+?-6S8A2=
M$;)9QHE=L=BI<JP\J\9JK&I09WMPITDC#).$V;P"XH;R*:X^:+@"CW^[$YM1
M=VZ=H>=^)ECV'RH)W#R)\;,WW_Q3D^2ND,U#QPGXEJM]!4HG(V+,0EKEF/)"
MKSR4"Q"*-KVAY#3#T93]>OE7K18JP#M6(+%A+Z$B. )>A(8PKGGY;,\W;2%V
MKR@3L6._AZX_9\"ILE^T5./;="O>@><M:F72\93 %P@%]\@XV'U;&;*2SZQ5
MHFH+IC]>64HB3RPT)@J=V*3M%VX;,![.3-6NE6?D_(6[.Q:?4=BW&=BEE\B?
M$*N$C-*O7E79#HB+86-F5O@P=O&^URN:K'%6"NQ,T:O5;"2>",:/=9DU@Q3K
M.==%UTH6&'FHV6H"(#CG=VLH_HEH\HJ?8A&<VR^[6&\:Z1I?FU6*]?;5IGE3
M7K04-UC1L\>P8';]IQ.N7/:[DL5035^[E$.[%9M;U-8R; M<V^'@%:$RBL,3
M&\0+!A!=@2!A\6K$E%Z1Y4@-O\9B>E7+=-'NY<+X4"['FPA>_>/UD9<M<&JB
M==NP;*X%,NWC!M%(DRBI^V^10S5A&8Z1B[ FZ!ZW?*:^$H*E%F)$#\L6D2[O
MAG!BI=7I^'3>]AD>0=IIE\L>RZG%(Y9=+);-"M%HW@<&KUV":76!XRK:_P"/
MVW5*=5?'W9"PNPG.5:N^-^M3<LL%9J-R(/Y]!'0J/87Y\\?VR;5(9GBG8BHB
MI#TROMGZJRCT1'HB/1$>B(]$1Z(CT1'HB/1$>B(]$1Z(CT1'HB/1$>B(]$1Z
M(CT1'HB/1$U!?Y@W_P"+)_\ J'/19V/Q'/W*=?1:1Z(H=H-"K>H4RP4"XLE9
M-6M,+@P]##6.QU.=/&*?9>DCOOU3*A#\6$10SV"4CPB<9!,7(F"IW'Q\V7&>
M("TKX"V#,]Z)_A=8;BV>X7*L^&0,>WR?M-0#6NOY[8GHU/G6=62YGRN6!,&1
M.SHB4D+M5R#A>*FV,71@F<OC9]4O5CCK+0,DDG>=P6=B[DG7'6K+Z#5;3LT@
M>$V2USR,RBQ%7*Y@?CU>=&QN)596ED@E1'6:H@15Y+0@\?[8:#4TP"8T.V!Q
M[Q"PA*U7BTEVN$Y$%(Z<0R2UR6U_U^\IO_#BDDYI;S/,\LS&LU>Z>3D6_5[R
M&$U)ZA579)1C"\>KIKE3J[;L@ ^)S?\ )XS/G[E3Y,JO7,J&($9TJ7=V+E,D
M$VK6BF)/"M9SAF^FOHLH]$2,C_,)O]5?_NE>BFU0\#[+:#_,H?\ 58_]RCT3
M9H. ]DJ]%4>B+5:$.(4VXE*T+2I"T+3Q2%H5SJ5)4E7.\4E7.]XI/>=YWG>\
M[SV[Z(OFMXWQJ:*M/EEYNZ.#C4R)W1M"PG/7>525&<H_CQXW78IF\Y0D**%.
ME7?U5V6MZ#J10N.'KD6ZM3\RC.\GBJ;6WVRN -*&I/T[-8OJG/1L>K0K\2CQ
M>V<37"\FUVK'/*"NW"W3"5E.0QH<*/P=FK5H6R3(3P5'#/R.%BO0=:B H-@L
M#Y>P$8Q$V_,GJ)_$\1_^R^C'HHCT1'HB:C/\S3_68O\ ?)]%G;_$\O<)U]%I
M'HB/1$>B+X\>;92F4C?=F.[8"F&*'JOX<]TQC(8RJJ5M<>UZ/)N]VFZ7D%:B
M#1A/ZF_ZD(.X[]AIS"$FKXU47^B(9)%3(='EH,PR-H/PR;0;ZS9?2S  URKF
M$8I7M%>>DZ"!R3-PU[D29')DA^Y"Z:&@V=Y^7Q;G)3SIMB<MV1QQSCZU*=XM
M7Q?%TH6<M1XX*V_11'HB/1$U3OY\)_\ '?\ [COHL[7\?^A\IU]%I'HB/1%\
M1]RTWQ[T;R[)>+\/H'(QX[R3\<=Q\@]/-5ZS/7G;]WS*1EUDQ;,\@?:$3F(D
M,9RB9>(TK4Y)0:&"5V*1RZE#"%CL%VL]"+5 "X+@@"K N"^-.O'HS-LXI&'?
MB#^9&BCPQ@* N7B5XZ:?H=R*2[=:W3EJ8V;S0G61W[N9E'2+[=:K#  8$IH1
MW[;4*E$KE;JX$4#CB!R9<X8?+_"A,#B?;97)?F%&\C+SY2>-6P_H*3T3(:5Y
M*^/J/&<Q7]%K$ 0S7[35YYO1]&M%0+_2V 1=[5/G(I\,D>'I@TFAT[Z<5,@S
M=0ND.55K99C+'=+O1]"[F+-7@%]X/181Z(CT10FR_P ]9_JJ/[Y[T7+;J.'R
M54-:T?R/)0,\?LGC8.K4ZP5C0R>@P&]GJQI.>66OO2D9_6(\J*(9;MS6A,M1
MGI!L8F+$J/976R;,I3"^]T1LRVT]&AG>MX;OE='.,WICKHHK9RNY:519=.NW
MC0[$%W'"K49M8X!Y%LUHL-U*.\ZV#QL9<*9^7['#19([;+W=3KQ87"!=?ZTX
MRI2%]Z;9_M<#\32YK;%V1]H-&M1!L/;1**R;VK/:. I=#\3ZZ!K=)\:Z?.IM
M/$:]4AH@/IPJ-#"M^.0U*1'6((*J!HS34'2>([7);$1N-'&MJZGO &S_ &8.
MWXVL:]K90DS#\Q)OXTJ0G=(\D(,"[O@O&H>=G!:/13=*@N;/512;M=CCL9-X
MI#TJ0(=;K+%%;=D.LV>>F1 M'8OP#XT;KZ.\-LQZC4NVS06-0[XMV1S@4B>W
M[X:I79M#\AAK^F-UKQU@69BM3\R8S9]S8*P%[ID&RLL+TN?):EBG54I69/./
MLQHI54QR[?(XX*5#2ZGG( (<M5X=L7OV29B\2T=Z%>I?0/(&).LC GQZ@%X0
M[4*G6*Y.7KE:'JL>8E6&UVK4'8KPMQP-)JCZG&&J/*4\7/<;X[#F,)7SG*VS
M_:Q-+V%;YLDXOFV?UHL)T'R![-XRKQZ@)A_KVY0^S/U<K/5<PA,3YK>]_3<%
M_'V<Y*_R7]*OBY8T)Y]1TE\'[OJ,,V>E\5[]DG%\VS;HLB- \@9<^KL%O'J
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M8K!R-Z=B?K/5G$M;I'E*:'X/R0D3Q"X1&+Q,I6I\3RO0^J^0X-6OG5>C;/\
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MWB;]EC[(J4O0T2%3K')4;Z;5,D?3+/=)N N+YROK%\0WQ([1+N:L\"6IY>Z
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MG"H<FGC67(5ECNBGACT..IXH)7!+%.-]06G3D+<2IO;430DT%36T\T ! >X
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M3MH9J$_,8U&D1]$IPQ.H1+@RPY>R ]N;[KK2,M===8(L&_Y6S=CJ6#_=6CU
M!'J:KP8P(J_)DY>W667L7U+9(,ZR1QWCF<,11.HU.FA)[6@U"(BS4(VPTY8=
M5CL2/Y4<.J+JUL2:O-_SX5ZUUP?WX5<]&']K/0UQSS3*/H:M^^'%8YJ>R]F\
MC]\<CG(O=[<S/LW]0:AU',C1$X^CR"^3SGS>A7)'^2<H?_Q6E?/FJ[\OT89L
M]#5Z=)>EDY7\*R(U+9)T^KQB7CF<#1#.EV^H'I[N@U"6BJ48$TZNN:A)8C_R
MI0?<7$-M1:U!_P ]B.N\60_=2KT8?VL#0UN.6:%5>-9U;:3"\R2=\;#U63<'
M]/;O2Y&B4TGS+FJ<W(71'R/(/[;*G4UM,M#D!/WJSV1Q1S]UM?H0)EZ-!G/!
MNZDQ'&:??D)*$US<",&G22GC%8 4L]0+M9[+ >TFE35TNX5YV2BK9Y+?C>S1
MB;>6VF'8A\=_FD)R2E!/]YM?JL/[7:AD9Y8+%7EYCQUEG7-O<A-2'/&,^S*7
M@Y+2G(/=(I:UM:U$E_(A8#UY//E+,DX_^5MWI/\ HK&3_)/?RGJ,/[7:AI_;
M]54Y6TZ>0L$-<W"+!-28?C%8",L?D-9O0R WI-*CK-Z,8=90=QQE][^2ADZN
MVXZ](MTG_1XGQA28//B6CT8?VNU#3/ZJDX\QX6I.-K/K>W!X6CR 7C(?M,JI
M@<X)TF#'TBEC%Z67MC\5NZU^ ]._DJX]FC3TA^?/,_Y)8TQ%(#?ONM^C"/5E
MX,-3#OVPCG'MX_:*I=8M2V05.O\ &#>.1RR1:Q;: #I\YC0:>/1H==L[3"[?
M;X+$S^4 1L]<=>:FB2_?N!_L=2A/LEQ'HPCU5>QAJ/QT=KHYQW&O#3KHL3=3
MV2/.(QHOCD<G18FU ,^A3T:#4&4$LP)LI<+[>VP[_*QQ-><ZIE^EO?Z2S^I^
M.)WX>\]5A_:Q-#7'/-$<XO\ )GV^'OM%U+8WIT.-(\=#D2)(V\YG4F>K0*BZ
MB%E@YA;@K=5L(YQUX0>=2EAFDM?Z3P>KXN5WX>=]1A_:ST-<<LTPCG%].O#O
MHM:[J>R%9]#C&?'([7(EEN5\ 6T@_H-/((H%:K3+SE2NLV/#_E3L2_N-MLPP
MXK_.0'KW%E?=*%>J0)]0,"&,DU%+:ULCG'<:<=>FJ1UK6MN+Q<U>.>,I^L/V
MX1I4Z[Q9&CTLDK,2-1=EHI <@Y"Y\NR.Z<VQ'='RPO\ D];Y,2@U^\TYZ,)]
M5&:"YSH&U*.<=PPK^K76@O7-PF0@,B?XQ6 5*)Y/:;L6@N:32I2P&A!GWVP.
M1/OL?R4XE:VFVGXUKB?Y@%\?2B=SXT+]&V9]5P*&1GEU1SC-QRZ]LY'-<W!$
M1;Z/&(^Y)3@L/2TP^:32DK7K;\SC$GQ_X\KGR^&H<;O9B[YW_11U//DM\^9[
M>C#^P_)J&G]J4TKHCG%M.G'MJLFM<V\? MDD7XQV Y+"9U3+77A[.D4N$NWW
M2P/,-V?-HLB3_)"I]):<=?EV(A_F<SQA2!O/B6CT;9CU7(H8&>?5'.+9[<:Z
M:S'M9=8VL1^IOV/QI/6?E/\ TN_(O8^C4P;^J/YR2RJ^_;^3?_AK]*5..H(_
M>_\ XHZQWH+]BT^HPCU,[O!AJ<7[7RDX[^4X4UA*3>I;(.FVV.+\<SIV*#T6
MG52NSF=!I\)%OI9]EERRZ3%8E?RHF!2W7'&)==(?YY,*9ZL;^ZOGL87VF@V-
MJ#GTRCG'GU^]'%ZELB9BV$^.9Q<9.^1,R3,YH-0XE>1/Q%OR/(/Y/>?,2%AR
M$IAKH??]+'5K^<W_ ":>^JP_M_%Z&O\ 7]T1SB[5%,_JJ!FI;),G5^-.\<S@
MN(4U>TTDQ/<T&H245W/@S3BP&MOL,?RL\;:W$H:C52)_G\7USBYW[J>^HP_M
M9Z&N.6:83D>WVO.L:KLYB3FK1WQO.U9FW%M*@W>3(T.GDTYB/J,>4[1RY!N%
MSB[(UISS+$8?$"_Y16U2DN&_W&G/8PGU49H,O7@VM;(YB.-(^TCKNN;@5@T6
M09\8K!6Y5DIE\/VR"_I-*(KH-FK3\INI4J8_#_DCLN_M,L/PC(K_ #:"3*2@
MK^\TYZK"?5<-!G)Y=2CG'M'[[:K,76]O>@Q)+_C&?BRG\/.:+)@*TFEN+AZH
M.><;%82I]'/E/&#K24/LW=O_ $7A<<XB5^\GOHP_M=H!I_:6Z51S@TTZ5*Q+
MUS<&()&3'\8C\R7%Q6OZ#"@(TFE-+):>4=:08P]M]SGRHY:NMK<=?NCW^C)#
MC74Q/WEI]1A_:[4-,_JJ.<&FFD?ZU$637-O$PK_(">,5@LTJL5.@&Z?!CZ12
MQR]#L-G?BMW"HPGIO/E )6>-/2'YI4O_ ) ?3$4@3^\ZWZH A]IG,P2VNK]4
M<X[B?\2^RZGLHB9H[ /QQ.V>-4S^<#*5,CZ%3QJ=*$6QB,Y=;! :F^[E<8S5
MUY]B? ,_Y78NQ5.!OW'4>H (]35>#&!J_35.7GUWT01U/98D\S&A>.)PE$'Z
M]6J*,(-Z%3XR#><%V4N'-C:8>_E88NL.]4Q(J,G_ $B)=3U<+]WO/1A_:Q-#
M6PYYH$?0U;]\%EK4MD7-9CN>.9QF*YO!+-79O=!J"T,Y+$C\=A;_ -93SYJP
MQ-[WC-T1/^E497/F/=^#OHPS9Z&N/W1'TNW[_P X+ +4]E)3Z;&+>.1T!$/W
MZ[5FS$'M!I\Y%*J->9=<JV@RH\3^6,PKRXAMF(!'>Q8(IWBR?[B>]]"!_9X%
MC)N.7=7EYGS_ !-6]9VLNWF2C?C0>K*[?&U!Z]-R-&II+N7/TY4I-#BD%0N?
M#9E:HEEA8YT)[(K')2>'/VM+]"!,NS-!EZ\&[V3E[?:\@^N;?/@UB22\8CX:
M68S.X6\[ =TBE3%U:\@GGVZWE\A^/SY1,A<FFVGXME@_YD$<?2@C^\A?JL)]
M0J!0R+FEM91-8C6]O2'2ZGQC/K>YA<S2^1N:32N*[K:2[L9'C_\ ,[^Y]Z<B
M>Q#E[_\ A1*._3]_EN>C;/\ :X#L6:YS&&=9V:#G[ENO&.:="VN;?!@622.\
M8SY>6)R^HW((/:TFE1%V6^''F6[%E4=^1SY0XC3VG'7Y-GF_YB+<8Z@?[*6G
MU&']FDBAI8\\55?0GI]KTLNL[8(9TQP)XSG[.[4(&92:,Q'T:F#5:A+N#D5-
MZ'CUS>?#6EY<AZ0X1D&_Y*R\B*2$_>=1ZH A]IJO!+-3B_:Z.<>W[HE=@U+9
M!<Z[1P_CD<L,6O7JD5NKSF-!J$!%XJEB89<M5]B,2_Y4+#HKKCK$P&3_ ,Z&
MU,=6+_=6GU&$>H""\&&H(%^R<CV^T/ZGLC4V3':\<CLB*UNHK-V9R=!J"$2<
MGFL?,(;VEA?\JV&$._R#M&7_ *52^_OQ_P!WT89L]#7'[HDXOFV?TL#]3V65
M/$QIGCD<'Q)NQV.A$)Z]"J$A C-!3*G NTNL-<^;+%61WB6&*='_ -(QW5<7
M,_=YWT8?VL]#7'+-,)R/;[6:UJ6R%IN>1S?CD<K$6TV31!%RG2-!IY)&<!*J
MQ)<IEFG,POY6PQ](=988@#0_^6UY4E*S'NEM?H0)]3T:#.1HW35'I'6H\\T0
M5K7-O+PL\D'/&,_6)5IK.A&+E!D:32B2\X.U9^6W3:M.>A<^589&C-,1WX),
M/_D-?Y+2@Q^\TYZI&RY;:< ABQ#O4M9NZ DM!#]O;V6(6N;A(@BI,KQBL$&7
M-QJQWXA 7I-*?6)TL2Z\@+BKC[7\E**V5MMMV/<6/]&QW'N)F?O(5ZC#^UVH
M:9_54G'FM?G[3E-:VU(4B^CQF/N2$8&,T9N)S1Z8E;NJD'.-%,'XZKGRTF ;
M*ER7;NK_ $7FI1\N+^^KGJL'_+^34-/[6Z54-#'\3_B"FM[>*#6U\-XQG[))
MKF?Y_8:K#8TBECU7NTV-4-JU4:&],_DPDNB-//R)ALI_FPXF*I O]]Q'HPCU
M7+P8P>>E%1018>>=4YV?5=G#OZ8V"\;CMI:J$_,HU&?CZ'3AB=0AW"/%=O1
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M !_M.+9_0;UM7DUM5%K!,X8CE!5CD5[1_(0F*+5$$ECY:<L1 &!'B76+,-+
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M=/17ZWP6]&TMMP04^9#9^ZF!ZF"!E/S$$7Y"7%\Z&T0U()(@7J.&BF]LR)D
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M7;:#=;-]%*7 :^]YLRRQ6?M#,326FP@_Y;#?W<8,3'A&E?$LDS(4M7>MXQ2
M0(%ZOG1Z)O;,P9(-K4NMIGGQ^'[.GSR,@'Y+_4DMJ ;[)^7)4TU^H-:90P,^
M2RC24ML5CY;:?JZBTE-?FJ]U28+G5=[V;QTH=F@H7[S6J;VS@U?GU6L3SV_#
M\A3X1%@'Y+_4P-N.^04?YDI;C7ZAV)GK!+YK*])ZV]5_E][R+4'$JKT-7[T:
M WWG.^KO'3\1LTL/F*IO;.M7M7R>*S7O/;\/VL3J&0%@_)?ZC.+E>[W6_K)2
MYS7W[1FGV;)]V9E:2XV:&_!(<^TBB29$ *KX5#68ZD)[P=HEW:0!06^<\2F]
MLBQJ307?[2*L><_X>M1AYK!#@_)SY&4!]*!5+ZZ>\1<^@U=Z4_;?O;LS2W5G
MY/S)CWV246[*?KZ?EH$KBI;1SD.T2^K/RHF]LQ!A\7YU_:U&^<GX>8J""'Q
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M9$.>5D-I*DB9!<@B>&*3/A54&=]I5R+>60+/MQSW&M9N:,-<#;,/L5SKU=O
M_/(2HEYAP= 2!8M$<M*7V(],E,C&.WB7&DN1DS8DE<CI1_R8@$M+\7MI76M
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M%2968?\ R>Q>"N$Q@LQJ%#YSD;\PS;#+G!GY?6?JG5-HA+?['CLH;* ^H.8
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M@,PD0)UR7<R+H6IO!N(:@]W<_#W8/<[WA]JXS\-KQZ\2P1G/26PX+4/"-#9
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M/1$U!_YJY_6Y7]ZKT6=C\1S]RG7T6D>B(]$1Z(CT1'HB/1$>B+PE?S:1_P"
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MM99S+;D367W?(\D]%1O!+1G8/<PIB$O8Y*C<:@^/W9"5_-0/&/\ O)1HZ?\
M2Z4KORGT?!ST<8LU37/ZHDYOBV/VL LQVX=/ILDQY($C\(%?KM9+2/<S"ECD
MW:F'V7&ZGGC\F(OKP*-175H?8L@SG3%@ZUQLKSB%*]4D2VRT!I,9//\ Q)SV
MXQYA)JWEF["F\R2>\FB=G<J4;3VK^Z[E=(%=U*1;E2NY]*E(@N=34NY4EZ.B
M(T"^)%NY%YT_\/7G.^A(EMEG9I,-7B_*:80/$O5XKC@R\@^4[U!@5B,3\GRA
MF8(S2X5.P$%Y11H*K5?CCS[E8U%Z-&7UH1*IC3C+#-3@=Z".<C\<)*2IQ?H^
MS/IN#4P,<^J3$VF*G*2Q<?WF+!5%3Y1%%/JPN1GOU?Z347BN;(\1[+3Y _)^
M:IOI%J'W@[].??\ *"T\^JZKCW?;U''];NSFF,\W= " SV-KF_Z2HME.]38%
MCC#?)\H(F%<OJ-0!$$911IJJSH01YARRZLU&DN<9*R[BTVZP]4)W>  G'^N#
ME=4VGWKC^KR]33'+-4(.6C%[E>EERO=RS&EM@?)LG5WK9 S*-07VLJHY;N73
M*DY%5?R$5N<YQ%M5J:&9+<J,=^%FI<E]4!^)3#?N<1Z<O)EZ<&[W1CG';/'
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MR:T4LQ/7D]&BJ/Z27=?77M@<CL.?)'3*HVXRRS2H?^CICC'%D%<4XKVK[/\
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MLQC <I.>SS0ZL3FCZA.M5P78'"-2K=,LY7@+MA(01YJU"QKHMX?XE]"*S?I
MF0:X:;Y.I-260A!XS85K3KK5J)<F*#(LT]V'4H4P6'T$1#*.S[#$+#K'#* R
MU>&=CM3)!7=(+$@5-[<M(2-7XC;0P]:F;%BUI@UJKGH58+E!Q2 9=K)&NV'6
MZIKAJVOCD2!X.DTP]E4]@;=RSPFFO#Y4<K<;)28\R,WPHW-^MCUD0'5M;IYP
M5' K1:PMISZ[&0U2AQVYAZL.U\I+GV4CE6EZ^'KHNK=+,GWT3:UE%EA/FI$:
M*.AFYH)KG9(I5E+U@@#]6OI?F/&>+@_/5JS&X=5#83I#5FD)K@I^#:)0BD1H
METM>C;1GX2O/?FU0@[%'R&\"T*UK.%:Z+=0([6 Z SET/*JX\C:CP MW397_
M ,12MW(U# T_%=2+2[&>E56CD97*_ J5E/A+<%H=J8;T!LE/H,T:"LQUCC1B
MD6:^1#8(>5-B^/(^R1#A&N_SPYF8ZLHK7?Q,*^2="SBF3VQBN7.]Y6&J\D3*
MAFS8>D:S1O%<Y7K3>PPGI+H.0W9O* ((EJ[(154101"''M,JU2:[7[,1K:'L
M_P!?"4M?B=4A:@+/<6UN7+/TJ!K,6)7(8N[/1\BGU:A7)-K)?DJ4?0%,Q@FF
MT]$JNGU"(*"3Q5MNS.BHPDR=)NEGL[7^O&S"L+RD\UW<)':U!J^>3;18Z#2K
M(^-+DR8B'6E:1'P_3=TK0$D&X7AVPA6GJIF!9PX>#QT-LSYD 3 6\B/:R]0(
M _;6[>/]/)]3\P!N$&'J_I-3G3T5#-<TNVEW8$6IH"OB)VERM4"!(PT':KDV
M0;'.'\?LWW8@1,_9JF&("RY2Q31(ZSE@A&>FL7C[H,E<Y$_Q.1XHC8"!S*K7
M5*7G88]/T5PB'(3+K&,U=<PJ3KH6H&W:*8;3*I[#!6"6+P&):2SW1/:W)C*C
ME7RH -#)M2SU[=#%%8S7XA$20T3:3@^H#B5;(TL+;8]D3 JJ 1;3+K7L]SU+
M$&T<"6<N/-6>XUC[A/:K<- H0L\02B:\)@0CA1O9QRK[%2O!?--S98\P3)R6
MU!+S Q03J\(*U(BJ&WR9^4*,?LH'.C!'Z$9960YK0:[672 HD50!)S8\*_HI
M9 B!AFR$>1\$JA+-^*E2#5.NEEQ.EG+7)H[6FR'_ ,RQ8(T">8JOCYM6WT63
M$+1[&W,&!=!A8[8)HLZR(L;J( *:(F Q\H\/."2HV98Z/D2V/'!726.>72;8
MWM/ZL5).91<>E;;8)=H44'$*T1S+)]XV[(WS[J8A">3%DAL#(%ECC4UEMB<@
MDV0&MQ$N2 HHH0S-+MU8'Y9<M5CSN\@]$'YY6 68M4;8B9[0&](IEAQFYFC-
M: P:G0=$H2QE(T/7O&XRY'57-(@5.TW*0>DAB&@TRYQZD'EB&>/CBK"IRT&+
MO8XB*$+J<=YF5YH=Y(OV*DV\;)\:*);KT:^>.CB7-&#T#EPAVDC0(DXC('$(
M/WBE3HD:0*LUF#B72PH#:+"&N<2QUD&4:@RW?O>O1U5%J_$.C@C%AK,G([E4
M2M.O&:52TG[A$3^0(2RNO>/-%U :S=&9(VK.DJW7-YC3J^4;L#XE\M7B\L\T
M,KR:Y,N!4!^8,7NW<3RRHRG\38>Y/C.)P_0&1<=9ZM&Q3T(JY=4:!,LGA<&S
M48(K3 11HG7[!%\S:?)/%H@:5*CJ%SWZ9 NPSH:=8R;OG_\ )_:%;>:>;"]@
MTG-:K4LSL-<K-BM!VEW,K?E0 ]C"6\/A@[:G:X/JC93[UQ,4?9JO&?L,T>X-
MDOI.P/IX#C0:<7*-!X.,,X'@99Q7S;_4LY2JQ8LQ*5LI:;R7S6>3'GP9,.%N
MO*_JF@5T6B$]+B6(J+G9SETTD4L<$4J$/L16&%CQID8?:R57(QKH_*/M5U,\
M_"R-5TZDL5&)"JXK5\=I&36TY6[T(&WFOH\G<O\ &7RC**/E(@RIE9.86G1&
MGJU*J)DM!5$7%(6-AMF+*B2"K0,L2>A(Z@*SK#Y9&XH_0Q0</'1;1_D=4\,H
MYU^BZ"<S9@7:=7RG(I5EMEK%\@U.0?K)^_FG'J*F^50V?EU[@:+]I^9++12C
M> A[VJ/#HE.9^1NQ7\UGPEFAYNXB]^/>KZ"#F?F^RBF+)I657[.J)*8ZI-6L
M'*CEMB<O#)P <C]T*PRQ$ME]8UGHMKEF)&M>@^3T[QE_S$55O'3 ]BM='DG;
M-J^'QMFL->J)(0&$@Q-?Q^+K6D/C25S,0&'^#("WX56"2""R)>2]%40F#0L*
MP6,.1I;5G6+)YD,BL?<V_E+D5ZDCMWNF83%VXL B3BE-S6S7*I6^\15N'Q@6
MK)FEJ*?< LW(T.1"%,Q2=J0$Y)D11Y&D!ZA[X=J>SZ.JID?B>YZ$CFIUQR/6
MJP-I2+DG1",NO3VH]6G5>M/VH>(ZV9' 94<U:8"(T&N![K'H9.SG9B ]%B7.
M5"*_0$:DARW?_;/?"O3#O+EO;[_.SN%D&B4TK7 SIBZS+I&:KL4 F1R,X!8A
M"SC0FUF_OK$Z*XS+16X,*,MHBEU];4:&^2(T/GP\E2^5_B)0+#4<=<TC+S];
MO.K4W&" EFO$:Z:J)V[[D(J<_/:D$)QCY!T:0M39&\GFQ9IY<BKU'-[":/SU
M0WPLPL1I.A:<3/ER,JP-<\[:GD&B7C.#.::,4)5=RD"*]/$!9D^#?K7>['C=
M7&@ZQ]N@D'BGVPAN-3=L$4&@[< D$:;G$*4S&)YTYH!&AX\<_"B,W\2'/H@E
MMW]*->3:9$.E3X]'?K:^V9$#1+3D><TXK-#C?NIU@49U#59M'AN10L\H2F99
MJ<D '-JKT*&6(W"_9_KN'JHE9?Q&",FNP;%0<6M#*%Z?1<I7 T-0P!*)6^VY
MC6-1-!?D,GDEJORG5ZY!ER#10(3BGBK$H*.@1XC_ "R0B,W0LVA/UY1=$"/,
M6GG,ZU'01U1M'6LEL 7.+0#E."(Y/FUD#D2LE\B@(1.?67LM;L!JK"G_ +&R
M6<LT^R#Q-#A6NP+9"R"-Y-,\%2;7XEE(Z(8L,C(=+8!)8LPXI-<>K,.5!N]9
MKF_6.34^!S98,699=;\;[[">/6"'7(PF04J#AN(.CR[2[4"-6?F' L^1 >_.
MTP'E?8NYT%L=ES+KM\M7D)N&% *, M-:9@-3,=G;.5E2RMP,F&@K*7*+BMAG
M]F=5'[*L#XX=,%5IF404#(WP>K??TJRD_B7YK('!W:OENN6@\9(5\>BJ#ZVN
M2=%NW>FZ/J^>_>AP7[Z2B+NN+Y;8=+A)B#R" 8TI4H5L= J./3!I&/G%GX/A
M+6?Q%ZA(1GY-&2:,U6=%T95$#%7E!7RD&$C7Z5AB[98JR)EE2E6#\T&]#H*7
MK3]D@*8%F8_"G+$]5Z]:"-+.#!IHI]XJ>4=IW#'R.G7.I"17!=6K5DE=K$I2
M(BEE<1RC4YXMD>6)S"BGN3KX7BP9BE\@MCQ\!B4\J<MUY\A#'K[D?"KAO\1Z
MHI<ID*;DUZC%[/;\\K14=#)UNQIJD#6&/'^10[ 7G56<;AQQ\Y/DC0XY:80<
M%@1I$7:1D*PF)KE$:OA&^;&U:MYVB68_B51;)%S2%;<ENSMJT"#F9HP/H-<)
M6$#GX2^9IXMVAZ<1L,6242:BQ#_DR"=Y.G0:8W& CBXUZ/)L0ZN)T(J0U\U.
M"?KJV8<.?B.ORY=)?'8)=%"[3FK&IK']+A2]M=J]Q"9X2RIX("JKQZ48*6.;
M=Y<$]5Q$<O;1_P!F2U6 5P,E!H624:NA;G/T5;E^\\<SS?-<DU*RUNU)KFLA
M9Y6+V"H*\_79=<-5)F] S*91.%\!>B4HGHFI68?SB"(VCXEI[LN#&.!F0L@C
M&1CSSB%1 [\0N^VZ_5ZNY[C2#@:S$L[0/9L)&'4[,TWH8L09A I;+U@)#F)H
MT,68,E+"\XRF-\,T&S4II"#%DF2K9+08X/';7V>_[;YJB M9\=+16<JO%RC>
M1] K.BUR%'*4T'-K@BY7;Q[SJN#S_3!]J(LS+M?DI0VY;(R3-'01 NVDEDW'
MQX@<>*;M9$%KX)QHJW7^)!4OLHXY'Q_0)<<I?*MC4.*R9HR2#NW6:A5G2D4C
MZ9ZQ-\; Q*M:(WQW^0ZR$<-Q) E<>/\ 4BY9 A#8OV+><"I*-\Z8UHH?DU9*
MYDEY%FO'_.]9N0MBZ#B 6L7PEDI?1:<=$#+(H>B(MI%WS<G#Y+&**-+ D!D]
MQV(=;/UFOD:CG'(%C\J)BO/TL+BO0+[C1AJUF[?L(#-Q]2+P#4:[LY)L#F;6
M&+$%#7SEV=*5^!.#E"306JG"!EF!;3HRO0:V$7,]$:/B8[-W5MX)YGUGR N
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M+]JLM.C#=)\O:RQ6ZFS8\YLEMNARL#^#Z].KA&/#K1QVG5N-'M0QNXLFFZ\
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M[.*#OIITOL.+V0^YV.S\!5SD^/\ 9ZE./Z69C\%,:_3FA_+SA?7,\;_*%?\
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ME:!G@:V& I.^LBB'0)_)J+7 \HS ?@LF!+T2%\3]IL2#Q'-.5,RW/NO1W O
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+'HB/1$>B(]$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g209588g19p20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g19p20.jpg
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M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^*
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 30!80,!$0 "$0$#$0'_Q  ?  $
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M!2G=P<8MB^4W?#6+0AFDTS=9,T.D+F$/5IK)D2UU"VM*)HB:(FB+MKZ3C_\
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MF[#E@U;2UAQV]WT&D,NKF4@96XA3":UW'!L9CLQCJ329-#XPHJQ%M]CC?O\
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MT;-U5W"6&0EIE0 DL!/V?\37OC$SA<L*S\.-&%&;FM9(E%9*XD,*/1@6J35
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M$8#AQY@0 1:<U1"R^C(Y8L(3R%K *P(7J/.\Q*#OQ>X+"M,%-+9Y><=88"D
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M]NB9IRBF",ND*;_?>2B83$T"<C#.LEG3"LW++=SED(<8Y9[A#(.&E%BIZ/\
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MBX=C>9S-UKS3HK:.1KM6OB-N<I)(H..T@?KJ;R:Z7)F94TOQS*KF*>:U7DY
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MT&RNVW02:MT&R.V6*+=%)!+'+/-3+%)'#%-/;)13+-13+;'';;?-3++/+?\
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M7H.D[.[F3%:7>]Y\O*3M2PUIO)%8=5D\%R2)UQ(DAU822%P=;:(4:<3LN!@
MPLI=LB/5<!%<L)7+ %DAG<<G4Q:4U7$.:N'DWC[!8@:69<4?6N0<D!Q3G7M-
MK>P(C:$.&3.#EW9N//')L1B\(B#$>,(&8F>)Q&4AC\>D(L(?CTDCLI!&8_)
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MV>[TRIBI*0)BP39.:-A$FS+L $F<[&8XW$OV[9=%A%OCO^51XD8I$TP:"H
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M####'?+///+?;;'''';;??+++??;;'';;?????;;;;KU]!>=?34E*V]Q-GU
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M[29I%JD?E3#>O1[U$%K).4\?"%AV<QRD]8QX1=02RJ<L&J"R<[+#@3][/(D
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M8N[D!M9XF+?-$@C,<V8=QY9ZQ$8B(W-(P*F1<T>@6@ ]/Z7O(U>4S\94L@7
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MJ#'&3D@ZW4PRQZ0$Q0B(L'>0L\E"&+;O?YSYJM&M*)HB:(KK='+_ .>/C/\
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M  $D,XKH[#D  KV:JPFB)HB:(FB)HB:(FB)HB:(MTA?^MO?^7P_[FL1T'/\
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M6MQ<E;UX'3#TMRW[@KKX-US71/ Z8>EN6_<%=?!NB)X'3#TMRW[@KKX-T1/
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M\DT^:JET=Y$0(X-28R3F)UB,I&3$397RX02 2(/#9R9.2#G;*@JRE7DV9O\
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M@$-98<3T458Q]&N6L?M6;1]I&>.?(CC'83.-P>EHH-M6O>21/&33#-R!B5<
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GFI8!W+!1VWPSQWS:]66&:V&.6.__ (;^S?;??;?_ /W1%W)Z(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g209588g22i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g22i22.jpg
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M<X&V,C-"9'1U=X2T)S8Y0V-F=GBW-T9ED4=46&*EM41%25)59X.AL;+$_\0
M& $! 0$! 0                $" P3_Q  S$0 ! P($!00" P$! 0 # 0$!
M !$A,5$"$D%A<8&1H? BL<'1,N%"4O&"8G*2HM*R$__:  P# 0 "$0,1 #\
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M(E$!Z(K><MG#-PLT=MUFKILJ=%PV<I*(.$%DS"11%9%4I5$E4S )3IG*4Y3
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M"4P?</1,%3P^0O0+C5_^S2_[">7_ /\ ]/1-,/#'[%?GQZ+"WM^'/_C)(?\
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M,'(PDI#S4>S(Y5CC2$6VDF?F1Z=P<@$8@1(EX\IN>#UT8Z+"=$3HBWM^'/\
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M"H0=WNUGA)Q]9XVQ-&#Y>1LV49R[HL&]8UK0LZL\W>OJ>&\Z\Q*  M!.9P]
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MZS@GP>J05Z*KB]SFG3*-YJW/FB?UHN.$'M@NEYNUX>T)PGZ@D^GFZ]V=QI)
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M;>6)*>62Y/24P>#UF;NMF4/E=09#<LXD!.,5D2Q4'Q@A&D&!B@2XL/4G'_@
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M4Q.-N<G"N)[D'?;/';#!W';[M18&T6:&J\Z?*6 FK%,J4O+,@DY47)FY:#-
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MG8-DD%\9H%^Y%0=RK.OI5*FDEFOTY;+U!:/H<8C"*R3A*KM;W:DJ'#5@)AR
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M87.C:E9/-:U(#>Z/"9Q;#JI.#!/T2O%2""K;T2.0 \9'%11]L5/P4 "%\E3
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M,]#IVK9G.7@M0L[./LM;O65QI5 GYIW!3#)W&3%9;%04]Z5ZV51'TA$R)A*
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M%GOD;W)U/(>YS<S7=%5I0*(P"(!C2JDR"OOWTK @TK<,V"$E)/R&2DH@$61
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M71*KE%ZN'-*Z-92O0M7G,UMZ$%B]*@XJJ5ALC"GGK'+)+;^1=3"'8FA+$ /
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M_)X+Y7Y68^4CE59&X'!AR,2XS*]Z'8#F+JP]RIJI![(1/52@'8+LGW@R!_\
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MS4^J"=W27S=2']P6&#S]^*7IF[3*2V[M(TKY7LCL\&&TJ]E]77E?D]!-N!;
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M)B0W3*2T5) D:<_>NB/7:WG#J$G>5V3UT]^3D0NGEFV<UG4K+[6D6%V'TM;
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M!;Z^Z)?(1C8*LP-,1A):6C7\22;3.UC =F=KJH1AQ=.TD$U3-4TUCJB4B1S
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M<9145;A<YN*HT:SE;M8@9G>1<6P@:LTE(8DD^DY=D9Q(SL'"Q"$G-2["/7(
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MKB"RU)60<I&(,3.PJ")+U#;>W-6%??A84NU\@=!V"*?8"A!Z[K5(V6^_:#Q
MS#8-VAK'58^EQ4Y Y#O-VFEFM#IM\9T6-4F8JRY;HTG79&;M\G0YNK/9F/5@
MB9H:8!$%A-QQ.SZJUZU\*%>$VBD:Z[V6A.9K/>0VD;U&:*QXWPJ7)^Z_:-&:
MU#)TS7>1MATBU/;I#T"*UEVPSYO#46FUJ+;U:K)S-1GT8MN@D3-#-H!)+0U
M&:DUK#*TT_@U5ZP0VKQ^A:3E1GFB4>@UPQL=XM5;'ZE<[QF6NT;:JGMG)++C
MZ!>,UWK3CVS.X.+LCAI6,RK,_39[0ZL:NLX^XIA!E<TO/,O!!# U$'VLLJ5+
MX9;NF1[>UU&]<?LOW*K[72-MS2=P?AM2\9PVJRM*S;1<C5KUCQZN:&ZT#18:
MY438=2C[4XLO('YJR?VAO(4)[2"Q7M7Y3-Q8ABY=Y>K1(&FBW$XM8#:,!KVG
MM[OIR&LW+6]IN>VV>S,:0GGL2SF+K'UUDYKL#62V>X+,Z]"%KZ;:!!_89663
MB1:-9:3F))LZFI(H2[;!@K$R+A57,GY3[5R6;W23G&ND)2ZF?9DZAVS2#Q:3
MTI>FS7(61K4L1\X<2IMRNV;T2\SR2[".-$S\9+F1<2"$X*; CP!N[WL_"6XK
M3&X?"'7M69X[DB^W4%]7<JRFC9E$W>T<9X*8W;-)"GS4Q)OM)XM;5":55+7@
MEXM3650:RAY\NQ0+)]!PTO$PK0P2[&9+6:26J22'+%]"->H6<7/ &_*:2B^9
M\BHUCAS#F4VYMQV8DQHB]\4T=U+'G;+3IK6E=,^5/\Z?SCV8FH-E'Y9#6J$D
M7C%*0M=BAXLT3(%EPU)9H,5J1J>:UWJ'P< K\I6).4VK.7TK5*IR$IKK0X/C
M)'0>Y[ SWO)KYE[BU\C]FDM:LUDUG0JH-O9SK.:8MJ36I11E.,G%-:*3D-(T
M\J<3BG> =AH&TG:BWRUGAU [+@^%<<+I9D)7*<TLN+26HUB2JC:4B]VJF)LF
MTA"T"Q1[J7]G$5N?O\!2K79&KE*S-9.(KKRGNF*[.>7DFA1R"3J7Y/7LXYNM
M>KO\*C'RW6?MO'5_6>+3&PUG(7CZG9EE==;U%QN'&_<X+=>/>UR$#&2=<B9-
M_3I-O;:5<Z^Y8>XT*A6X(4;/65J]%/>BN:\\3H0Q'/LKUGN'_)2?MF?;4]Y:
MU-UR$SZ]7F<A9.2X\R3[ H:A:%G%?SJPYQ5,82WAE=X5/O68Z]-[/)[Q8I)2
M].YMP^:NZN_9U6*(")#01>;U;K'VL0H_"F]#)9#.!Y"RSV;<<?KGBS2[R6;1
M:KCY]9N33ODW'Z#+P+"UQK"1^76)9M!2U5CW$$VFF*3IXQF*Z=TBT8D.($T@
MD%@=!##[[+M1G&+3+]SXOF\K-[!2@S7CI7*BQN,[4HR)RS3N9CFK7FB,.1V<
M9\G=+-9?EE"QNYSE EBSUC0^91%LAZ>QF95Y3)>7 CPVC\VU#\0&YEIGTFQG
M,H?%<AR['J^LLZA,MSVG9[%/'("#M^RI]?CX!"0>B)U3G?2!& /'JJBJJJSM
M=955550YE#%DR2;K3?*OAZUG*V_+5LQT65F4>1\'<Z%1$']=:IM< R:WSVKW
M_P"S6J()RYQG(:*U'<=+M+98RD *L"YI]*,V3CJ/#OC%K-(-FYD-/-@L1SGP
MO'4_H&+6B0UW/W,?C+WCH_K=P-QQA(_D_5&N 1=$9O*%EO)6N:' 2=1R/6GE
M&4=Z#1[I1]3?*,KQ?H**M#.,EH1.M$S5;5W#EB[R1J0\&* M5[IIWP^M,Q9\
MUM''GDM#T2^RM)T;,[_/7C#ATB$GZ9;.06P\A*5(5BML=8H:]3T++;!N-]B8
M2Q2D]<JG/LI0R]CSUX9%D@R(2]1T+2P%C5O)?XBOA>TBJX#R$X[4K3)N'INU
M\?\ "./L(^E:ZVG9JCP6$YF.:QD_(."342C<9BQM0+,RI2HUA!%^9=-#R25*
M*1'H6U)ZMTINMD^6G'.[<@FF#R6;ZM"Y!?< WJ-W6K6*R9JMJ]?DW[/*]9RI
MQ7Y>IMK]FSD[5U%ZQ(2*;]O9TE&SN*;)BT73<',DMM]$?*@-=PUM0=[+%;_B
MQR?=76D[BWY2Y:CR+JM.T')Y2V+<79E;)K5D5ZFJ7:FD)(9.CR/:V-C=Z7:Z
M827K=VC=<0C%VLY-1$_2Y=LJS69$<48MQUO3X6MFC?"'8W*AYUEL=LM44JM*
MH$154KMHG'JL73D10KI]7VB[7G:>-.[U>YYG.81IFBSMMD)"8,^A=,J$-)1\
M$\KE5C$&DI'S97-4M))-8D ,07<#K<T6:X_X>KTO+ZO<I9G2\]7=U/2+SH,;
M,53CY"Y[R,M4-<:W;*['8MKW(2J7MI&:IB%(3MGKUBL3F/-K68M3HY9N\2KZ
M$D9.>>>>?MFAII>*@N :$M,WTA>F/193HB=$3HB=$41.?X/4_P!:A_3$Z*&G
M/#[A2_15.B)T1.B+7JH80-=Y*[7R.E+.6?DM1SK&<MK<"I#"T-G]/R9[I,^Z
MCVDN:5>!)A;[9ILS/21D8R&%/V44T<_,_8-7"!5X T!)XDW^/VK9W7C_ ';D
M-Q0W+CG?-+@&]DV6GZM14M$KV?.X^*K=?NTE8$:;YTAW>9%Q,25/J+^#A9QV
M%OC$;?-1,A86K2JMIA*!BB L0;,MJ^BB=$3HB=$42/\ APO_ %6;_P 5T6?Y
M_P#/RI;HM)T1.B+ ')K#C<B<L;9J2SEJ!F^M\=M1^<FAAG@.7!>0N7;L>#^7
MA*0XE&U%S<U7+)>]$(0TP$T+&6"/&*>E06Z$=0RU1TCB)RFL_+EYR;K?(OCZ
M[AH**AX#$\ZVCBSI&H'P6*4A4H_0I'/YFK<NLFK)+WI;U63//:+(YZYMS6M+
M1M&82*=69/F$N5<,S'=C7C!HMB=(S;D]/*1\[G?(6F4ZQUC49NR5^$F,=D)_
M.+-E4Q41KZ.8ZG",]/A+1/ST).+N;C":/4+?1@;RK:)8OZ7*12$DUEBD6TOK
M<1R8NIKB]@BG'?-9&IR=M"^W*Y:5J6R:5<T($E3C+%I&Q7N<T"X.J_4B2L\%
M6K#.3G#1%9@59V>?L8*.8%F)^?FCR,T_(2YM '0,MBNBB=$3HBB87]I?]X<_
MTINBQ@H>/P%+=%M.B)T1:_ZQAIM/U?BYII;.6$#C=J-XT@\(,,,B-R+<L#UO
M$0ABR(2K$*^,<;42V89 6,T#LL(,/[)L,D$HQ*@L"+ANX/PL2;#QPVG0+MF&
MP5O8<YB=8PS1]2G,J&SXW-V#._LQU.GHTZ2HMVKD=K,#/REUBFB)'L7JM:M=
M5,13W48K2E(66EV#P@(EP[[L?8Q<>RREQ:P4_'#(T,[>6M.[3\G?-9U.XV9G
M7TZ?!R-ZVO4;=KEV^E*8C*SJ5/I[6SW249U:M?/)QS%PB#)*2G)R5%]+O2$O
MV'(!AV6Q/11.B)T11$W^T1_U[?\ I2]%#3GA]PI?HJG1$Z(M:^6V1Z]NN&VC
M+,4VU#C[;[6ZA6C[2#U"<N+M"HH2C9U:ZW&MJSHN5V2#>7"'1<5E6V5N[0EG
MKD;)OY&K2,39$XF<BRH(!D/75IT-#2K:ZPK3POCYI.=<?;#@5XM>!F@@JTK2
M,Z;<?, MF'5"D5B4@748H@^J=LWS;W=CE?F;UU,.95&RP!Y%1=89!NXD7#F6
M7(\@R[N7+OV58KBMWXZY+Q.NEGA;MA-=XWI\=]HKJU<LU;L&N1K'/ZG08R3@
MK;5]$BY3,X]1G$V5:?AV@6:0E4+$Q9LK)##"+NIHCR3J[B:=I[*SN.' ;..,
MG(/:=SH]OU"51U:A9E0HVHWK8MXTY*K,:(I/N)5T[D]7UR_(VES-N9&("ON9
M"':R.?L(Z:B*O(H1=RLC5X5.)P PA] *\ M\.BRG1$Z(K'LG[?3_ .BI_P!*
MMT7+'4</DK$%(XR15')B)&^P;]8_L.6T9=@:W:6K-FT8=(]S[I/7!-$M_K=*
MI^Y'Z$(I\O\ IST6_@+KTOOT<3OZ<(=J!F9J6=IYKH,(#5A^]TIO&2*IB>,)
MH;!O\^&*R5_DF)K3I:LR?03:"+@7+35C&B4/K-A5_<"%*;*>P" !) "F<^F'
M=FKZ<,MI1K6?6ZF607,$GK71*GQDBJD3(R([#O\ .?9#8+Q861K+I:LL>]*W
MD5Q<1>FF&)0^K82N>N(5"/.#(L&":(%4<>F'=FKZ<,MI1K6?6ZK4K!)Z_P"P
MJ5CC'%5<F7$2V#?YD,LMUQM[0UATM63/<U[D*PKP6B&&)1^J*S >L(5:(/[,
ML.":7BLOX!TS5].&0!2C:BQ.J-23!)XO=*[QCBJZ3.4TM@W^5#-[Y:;\U-.:
M6K(GMKBU"H*U9O9AB4OJ.FPOJB%<@3 U+% 1,"N5O$.F:OIPR *4;4;W*,(V
M>367?W2#XQQ4$2B)I[#O\E]!:78M-;FF-+5?'LKJQB<5:?<C#$I_/:!%>H(0
M=:,#<D<!2 5VKXATS5].&0!2C:C>Y1A%2Q>9F?OJD1QCBH@E/3)L&_O@IVLS
M6MH&D]+5=GGGDV)A4HUH,,23YQFD=Y=HFIF] C("E 'JGB'3-7TX9 %*-J+$
MZE  +U)K?SBJQO&2*C4ZTF38-_=A6=GD]J2,_P!+5<GEWTF)A/GL^88DOS+*
M&?EVCZ8())M0 H _/V#IFKZ<,@"EM1N=2F7<U)K?SWNC/C)%,B0I"[!O[CY)
MNKS>$S.M+56/(R#P1$V:2QAB2^]QU#OV:T40331#[@D1Z9ML/XY:=Z_EOV1O
M=]/K?CNJ(<8XI C!,-@W]7Y?R$4Y#E,MI:ISNI)40$<K>F^4A[C$2=NR>?"!
M4BA]WS,0[=F;;#^.6G?_ .MT;W)ZO]H'&.*!,J?VP;^($Y&#R0 PZ6J)QE!_
M^Y,8WRGN.%?Y SG_ (KM_P#K3IFVP_CEILS_ /UJ]T9M35_U2B*<8XI5-VF.
MP;^3W?(<G(LQT]+5*="3((B&4MC?*1]'#C=_Q\\ !2,'8/F?3-MA_$X:<9_^
MIKP4RC?\LW/Z577&2*=$EB&V#?T?F^]-M^.9OI:J1V,BU-Y%S&,,$2/M,96_
M(XH0 =-4/N&2#IFVP_CEIW_^MU6K)D@]%1_QCBI EB(;8-_;!8MLCMO5,RTM
M5N>*?QQ@,7.H,P1)OEV2.^W9]20]5-P41 9 O<>F:GIPP&D5K)WW0A]34'I_
MBK*<9(J5);"'V#?V06W7H?8%C1VEJM3P;V&,4Q*'6C!$G^4Y@_$O:4J!?6(\
M 3 +XG<>F:GIPP&I7<S7=#A!O5^!V5)KC'%39+N138=_COKG4(#4G!HG3%61
MZX[KXD,E3*B8(E3Y'GDIX $U6"@X)( 8P"\3[],U/3A@$4J^IWL4RAB)DO[?
M23_&.*L!-#34V#?XO[1-!K&AN30NEJL#U1S5S)F2JU',$2K]/4F9], L->*#
MHDF4Z@"Y1\QZ9J>G# (I5]3N-"IEW-0:V^/H)9>,<59B:<178-_APU"YU&Z.
MS0&EJQIZ<O4#)&1K^?&")5^F:K.^B 6>&)[LLN!U0,NCYCT&)F].$L")%7U.
MXT*K<:@\QY3HRK:N,D5:R:P1;8-_A/M;LM*LSPU<TM6*/1U:09 S>(S4P1*W
MTG 6+T "VQI >EFRJ+ 95OYCV#$S1A+ B15]3<C2W5#A!>LD'IM14M_&.*N)
M-C(OL&_P(;-+T*7?&J^EJQ!Z >@F0,W8Y88L2O\ 1T99_;@%S9D]^$\"JX&.
MV]01 ,3-&$L]0[N];L\< A#O66/1J=%6Z<9(JZEVTJ^P;_7OMP<YVY?C5-+5
MA39T.="V%LCD@EB7'T2WM?M@"\II_,/J(%G &%KZHB 8F:,, B15WK<AXLP1
MJR0]C[+ZNO&:*NQMP,OK^^UW[<R9P20"IZ4K"AG'V;>T]J;(0+%+_0Y[=[0O
MUX9/YA]2>NY\_:^K^*S?CZ</I>HJ_P#:[:(<(+UENUE6Y<9XJZ&V<R^O;Y7_
M +:F.>,'P572588,]+G7M/;.<H L4O\ 1;RU^T+]<+I^_&P^NY\BM?5_%#$S
M1A+/4.[WNVED:M9#?XEMXSQ5N/KYUM>WR"'882AP;TM9TE6()0TZ$5H5O(Y@
M4L2M](2]F]H4;D^)[X9T5W(F3;>K^*&)FC##U%7_ +3+:40AWW#=/]2T<9XN
MTGU0ZVO;Y#?:M5J557A:]I*L62E(TDK8J$UG)2Q2WTK8[#[8!MDJ3WAIH5G
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M\?O9ML/Y9J=J_CMW1MS ;]\4C>,\5&'K!R:]OCSZ7QR7QI$LAI*KDDRQEP5
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M4Z9ML/XY:;5_^M7NC;FK]=."C6'&>*=L'I1U[?$/>\B!Y"&%MI*J1F\DW4,
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M?NU/E_EX%ZKCTOA=G>2,PTX-<(098M1H$?ZJW+&M:L1MH& Y)W"FAH[#/&M
M+'52NO@QAS40:!:7]=]XJ'SY70_06&63E_ D7[I3V F\"] 0&?"[.\U!IP:_
MTC&9LVS<YY]U2VXUK<^?7S0?).X5(N@PE#C**1A5*Z]#(9"K%:!99N %TJ S
MCF]B@L,FWE?!&-]T?V(F\"]P(#/A=G>:@T&S7"$&^G0W_2K:,:UN;/JAH?DG
M<*P6]5:EP=,(RJE==AEDS6RM@L%I@Q<J@,P^N@HK&D6<GX-F N3@S$W@7N!P
MAGP@L[R9!IP:XV1C,M1MF[ETL6-:U+GTHT5R3N-=+<J14JS4B-*I7709M8H
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M6:M&3EI.E#:K+2HS5W-L<P[8D&9-\FC80:KHODX_]3(**.DB"6L64'$!AH2
M7L5LPQ^)[G5WR?Z_8YMOV,US2,+VK5,%U+2J#G$K!7];'J#,7:UL*Y3Z]LCZ
MQ*6: A(B6M,/7-%1S.$T>"K<R_IMND8)/YV!1FF"U0])H>.SMK*P7</B7;7#
MSMRC8G%;9(U^A\D.#&50\Y'UR@NY_6ZWR/J%&LMFC(:MMMGE58.[V0UN3<U
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MLC/X0=HYJ-5JNGML7QGM>IL5U($RM3);8E"3.Q45KWOR&6C2G:HF58_,2"J
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M)E-?Q,=NGK=.,:VA;J%:;\]&(RR&IT BXME.2?S]J+;I!-C%QB]7<%H@ FK
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MPKL9(,N2$MOSH25X;L, 04CEI]I9G[4:K15>CO193HB=$3HBB)O]HC_KV_\
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M "OPV2=J]OO5 JG*?TR ;5\Y%0.1HV@Y@I"WB;C)_DRX"^?W:!_[Y_\ %?\
MXG1\-C^+?]7X).U>@^3\E44JG*@4W8):OG)5#\B"69F8U(6,5#C2 CZF8JAY
M_IE^,'8"W+_B@_\ W.CX;'\6_P"K\$G:O;[5754Y3G)+@TU?.D5%M[:V.&,K
M2%E 9<>"#^J\Y=@!_P!47A4.X)6T/TH@_>).CX;'\6K_ "OPV29I6*TWW9']
M4Y3J$L01VKYRV4=;9'3]:,O1UE2QF$)&*,G07X I^K+DZ*!@0M =DT1$!\/S
M'PZ@_BU?Y7X)-]>VNFFG?5)2J<IUB6T(G5LY9J/=>AIJG&<TA9P$+BZ!B?.Z
M3* "GZX6M\4#@TL1>R;83 (E^[[GIL3$S_*9&U$+Z$;/1M_-!NDU5.4ZY+P$
M%J^<L#R&H5^7H1GE'6=!7\G;&3^HZC- "@?-++)%!0&$Z7L1F)@$2CV^X,L.
M#0O.LL1'"/"F:/I6F_=)^J<IW)-#"NZOG,:I)Z%6)/-C/J.L\+6<W:&2&UUJ
M? % ^<3TL4%0C9@GB1B)RB(?B] <,.#0O-3IP"3M7MWGLEEJG*=T33@J^KYU
M%*2USJ#[*32-(6?%J='9&1&YP5D IP^>2\V4JX14D3Q+'"<GD ^/1\,0:%YJ
M=#PV]TG:O;[2U53E.\)K 5'5\YASS-EI+O'C2=(6?A3:LP,@-[BK2!3A]02,
M^4K@(9ZGXA%BH03=_#H#AAP=7FITC;6929D:=->=M(2X53E.])L84O5\ZA%)
MR7H2V)&EJ0M(EHT-'"W'0V5M IP^I'=C KD(-PGXA$BHF)@'P'H#AAP=<TUL
MW!)F@M\O\)=*IRG?EVX*-JV<P)Y]SG9\'&8I"TF%!:Q@MOM+2N0%.'U.I9P*
MZ" .F!?DPJI^?EX#W X8<'5][-PU29EJ-%+]5]76J\I7X[C]":KG<"6P$S<,
M#"8I*TF.?J1?M/M/-<Q*</JDMI\'GT\"?C\E]9+S\O3'H#A]+@ZYIK9K),LV
MC5YO\*MRJO*1\;:!I&JYW!%G6&=IX:$O25I(:)(1@-/M*<7 2G#ZF0LPD>?(
M$D_$8;UDO/OZ?0'##@FN9C6S<-4F:;?O9+;5>4CT^OC3=5SN%3FX.AM\6+*T
ME:1&D3T<5H&@O[6)3A]1LK$8CL81JGXC$@LEY>7I] <,.#KFWLR3--OVJVBJ
M\HW9]4&IZKG<2G,56EL\B+)TE9\:GVY@5L%ZF+.)3A\_C)XQ70P[ GB,9ZJ8
M&\O >@.&'!AW8ULT1OXPO+$;1[[?>TTL=5Y1NCZ4-9U7.XM.5H]2C\N+(4E9
MZ-5OK(K?ZRL%B$% ^=PTT8KD8J+)XFCP53 PCX#W>F(-2\Z: ?*%]&I#W^DG
M:KRD<'OXU_5<ZCDY+.:S%YT5[25G9JWIK0J'U5:)T04#YO7Y8Q7 QT,3L=B"
MB?D(^ ]P.&'PFI>:C3G])-](X_7>3LDQ5>4BY[H,+JN=L4W^5P,/1BNZ2LY-
M!:ZV*B%AN$P(*?KG6)$Q5Q8P!>QV@*$ 3?B#W/AB#4O.F@$>>R9I2..^RK)U
M7E&J>TC%ZKG;0CS'(B#J17%)67&(VU J7SF\20@?]7U)Z8%1:5L.RC8#E 3#
MX]/3$&LS_&W'FD[4A[[_ *'14>U7E(H>>%CJN=H$<X='U^O%6I*RHQV^)E3"
M2T!Z8#_JNEN3 H+>K!^F) 8H"?\ %Z/AL?R>O\;:SNA?1J=W]FYHXJO*0QY,
M6VJYVFFK@#:MQ15*2L<S3D60" YTER('_3Z*J('%.HAV5)Y 'G]W1\-C^3_\
MVXI.U.^^W[V0U5Y2"=P)-5SL"&XXA5VY1I*PBGR;\2^6HJ#Y_CY\)@,(4O\
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M55Y2,CY -RU7.YI.$@[VWV@L525HXUVGY$'7V?2%4$QQ^G&5=$[09MJIY#+
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M/<,OI<'7--;-9/5--&^0=NZ6&J\HW)]&&MZKG<824H=4CLR*_I*SP:OH3,J
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MZU[%J5PUJW24FJP:LVZZI[)=)-%L<$ .2/09H*&.9'S$H9[=@RS7W#\X??\
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MG1$Z(INMUN?N,]$U>K1#^?L4Z]1C8:%BFRCN1DW[@WB@T9M4@,HNNJ;\4B9
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M'*5!8@BH(/1>*=&TNZ<J"Y30M+!I.VSX<^&[)>^5#:48DD86P\Q*HRU+BQE
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MOG4@G5H!B%(7:UUE?9*<?OY-A6T4X^5?2KYW+%,X>.5#P83#""[<!7HKF/\
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M*^7S0T."+8GRP9+S/[\67H"\\C>X]3R'N<W,UW1&E2JC (D&-9KS((!1ZM!
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M9IXE] 4_$.T<W15=U*JR'SCW]9K[WZA%@:?]W"QKGYX:*\?E@S'K-C_,QCO
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M9K"[IAYMI$HUX[EVNFVE():4(WG3[75<\V.-"->@[2UT-Q.0EH.9.KN:M2=
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M<@K])<KRIJJE%E?A&[?1[2YK NPM3B*6EFD=#.YJOS\;%%&/O7:O"FJR9?\
MEYQ_S"WW&C7:Z/XFP9]3VUZN9&]*O<U&UZOR#=RYB3OYJ"K4E$EDYT&BK6O0
M:3Q28GY51G!P[%[-R,?'.B,?/--;:JV67._BH]KTK:?M5;LH>":F>SJLI5KK
M&.H=N@?60D5)!@]KB+U$D(WPO696P* @=*#K]+?V:44:UUW%2D@3*;>1]A6^
M3X@?&V5+'-:G:)V>FW\RA#+Q2V:;#&EKBWSN@Q#OZW>IYO)%HJZA=,I*M?;V
MQ"("SN+17F\8O[:2/(-",?/-E>N)<PL:W. S>2K[ZPP-ATQM *P]%M51M4':
MV:MCS62U=@>09OH5!$D">HP\J=*[)+J4=[.,3UB/L3NQKM(IP0@C_?.E5%K\
MYN-Z%B;57ZFNCB:DI\:[ H,,:V61:6IV1]=XYQ(5&58T%Q%6FN,G&;WE5_:(
M)Z_KK&,KKB<=2:4$]B9*0(QVO4=YBJYH[G%QGD8N8F O4Q',X3-IK8WB<]FV
MGUZ06R>#K*]Q7T:+B9RG,)29J$E76<@]KLS$LWK>S.8J:AX 9&;A)>.9$8QO
M1<<GSLXJU]]*L;;JK>BA%V>ZTU*3T&KW6AP%AL6<7&<H%^84JQ6ZN0T)>B5"
MXUV4@Y][3W\VPCW 1ZZKD&4S#.GY&-ND[K&]E2X1Z_\ ;"TE[2'>+O+GDWH,
MT>4N]6CS3F-4>M8K8=)JD[)(,*_:JI1JM2H2H6F2HSB?JM<G2H/'ZL;<WC"0
M$D^PT.K@==#*Q<PR#X>]/'-X**=7ZR1-@I60Z3F=9@9CD%JE9:UR SNAXUEF
MH,H^OIVJ/@G[W-<NK-+;V^9.R?340TLBKMRX>6.W/I0CF]^[O[^,%L:/"C)(
M+#MUP_,U)ZAPVVY+8,>.[//V.SM*-6I&IVNK5UI5(*3GDFT<PJ"%QE%XYJP=
M1TB\;E81;V:,QB((D21RX,."]!5WFZE%N%?']\QNB$Q 6.PR&B%AU+E9[!?+
MC,6R>E*S8:M:*G8'5C>S2LC]05&5HM)-6I-)9-:)8U"OQB ?+H\C8Q'/OH-0
MQ[+%6D\..&L<G0D=686B6;F3O%,HL98-"T^P*.[#9:)K=AN3ZMLV<R\D8ZVN
M:++ZI+$7K/RM)DW:-'44R;R%/HYH$C\--!IX'_U91C>,G'.C+PL"Y(_&;N%@
MHJD3]27VPOYVU6/&=)E>256(R(]EA%8]<M[&3M"T3$MVT4E7V'R$\>G66:$8
MF1S[]PQ[+H4WC#QLXVSU-TUA]013ZIUJGX)0I*X7^Z6UG7(2XR6=9A4Z; (V
M"6E19HS\E!YU6VC,G=@$HF,R"+:;L%IF9@CD^_O]E6/5_AT8-&T:IUFW.;Q=
M;75(.J0371E[Y=H>R,HVJ0EZ@64-61;69U](U0S/3M",A68MR9E'+V0KN.5;
MOJS3G==(3)-R]]5F17B5BO: ^71MK@%*_(7QXT<UO0[S!/GL=IT_6K/H%:EY
M".GT'TK5[5.TZIOY2)=N%$S#!,VZ"J#1=^W>$<^W:BM.L<$>-=1A5J["U2>)
M!&K<S28^)<WRYO6$'2YFESV?*U2!:N)Q1&,C&52LDU%,5D2#+)E<(KN))RXC
M8Q5D1R[Z^=>:M5SP?XCSFA+@>-DGESK$G5=6>5D-'M+DL265V2?V&GRCNOJS
M2I&U4E]IJMWM2$,9).M6B9;V6-F6$Q$QS>+C2.?.#,_#18CQ_P"'SB3Q"X-K
MQH,UK%IJ<K%YF,Q5;#J]%<9_6Z]GE;A5LN9NYG6=!M35E)5]W"RLLG'7!G'(
M.BUJ9KD;7[1"_/G)5SLW =:,^CM\K<6TX/CVHWT+M-1\^O8*L[SV#FFC.P6^
MO5ZP.,EL9]8RI"QP39['PEM1SNWVAS<*L[]N\:M)N1>MW3AV#=Q'MBCD>>-R
M6#[OQ[XY6VW8IC;^\O(Z#RK%M X]L<3@[A8F#ZUT>ZP.2R"E9NDQ$3S>7D(-
M+/LD%M)UVP"[+:(R?"95=(/8UBX=$<UU=WZCW/53#3X>O%]C(2\FRJUH:OIB
M86F'"S?1+LB#=1V_T%^^9M44YLJ";24#5M&CY<RJ2SZ8BK6\CI1Z[;Q\&6*(
M_GG:VBPU1ZS\.R)C[[JU5M*L;5,Q;5_9K XD+/J$13H>'^OXW5HK5:M"31F+
M"XU6]Z)FB=@B[O5VEHK=QFHVQQ]3DG'U%:F$P21QZFS;6;]+DMV$\#7T\OB$
MB;0)1708O/;!-4>G2FZVFF34#:PLE4J$U:7500FJ9$,;<TCY./1L,Q)13E!I
M5F<U&RD0I#A+@1R)[^<96RNF<;.,W(#19.?OE?C;;H-3@*)3[ 5I9YED]C:_
M":+ ;;3X"P1L-+-$ :O;176<@LSD&XFGJM*3M:DBO:G:IF,DB.1P?O\ <^VR
ML"/P'A^U,>[L5%P8SE\M.8>K]:7%2'<Z6_G-GQ>TPZ4>I(F01L:TWJ&F4=TY
M2123!<D<"2H?((=TV(YC:1T'P LOW'BE@&BM5V5^SF%NK-3)PQ)HVL_N)M*$
MSXR<@B^CZY[]9<U<EI=-ZDG-V6%,QL,H$-70>22@U^)%J4=O?HK:B^'.60L;
M9X.-LVVM8"VR]QL,M7B;GJ 086&^W1_HEJFFD7]2^U;NYBZRLI//T 3-'/CR
M<E&R#%W"R+Z-<%27_P '#P*XV/%'"&.?4W+ I"3JAT6'OT%"UU]*2SEBK%ZC
M"6&OW]I*$,]#YBWLL9:[ BY;+]VK/YD<(I!@D@T3;E'E^:QF\^'[QKD8R)CY
M."N4JO!2#Z4B)B6T>[2LLQ>OI'+Y(ZB:LC,NFATT5<;S\$6R[)5M[B*?3*Z*
MUCL%@F9,JYG>O?[*ZA/AW<76\4QAH^LW*+91C&,BF"D=J6BMY-I&,*1#YNZ9
MH3GU(><2&?I%9J,)8'R<B65D%Z94;&#]"V5Z-GD".?B@N].*S5G_ !PRW,;E
M.7BHL;"UE)MG:8XL;(7&T3-8@HZ[7)?0K8PJ]8E95W"5UK.75V]GW:<6S0,F
MHY+&-3-X*/B8J/(Y]NP8=E:65\.<-QN4JDG2(JUHEHZ+$U4AYO0+K9*]"3,?
MG$=CS>V-(*<FWT;]7AED2RHA["JW4?GA#2A_4"4L=FD9@CF=_M^4V70D>#O&
M.2CV3,^;-V#YJA<$G%J@IJ>KM[F'%[L+&YV65G[W R4=;9N==7V(@]"9SLC,
M+RT/?*_ VR(>,9F)9.DB.?;0:4BBN%KQ)PDM4MU5FZDO<U+XYLS^W7.\3LW:
M-+EI2WU.&H<W+H:-)/E+?7Y,]+K=:K$:ZJ\M"&@X:N0+*$"/3B67HD<_"NJM
M8#FU6:TA!DPF'[RA:-:=<B)R<LDW,S[[1KI6;U4+-:;#+/GJKF>=2%?T>U1J
M+*0,K$Q+1S&M(6/CF<!!-HXH]=_]7;E<,S::I][HK^&>&KVC6E[=[*FVG9QA
M)!;GDG&SB5CA)IA(-I>N3$5.0T3-P+Z">L'$'+1S.0BSM7*":@%7,;0.2Z66
M\?\ -,>E;/8*9'2Y;'=HV+CKE8IVR3MDFK0,5;])O;>1F'DT^>"M)GLVM7AX
MHY1*@5-E(Q\$T2:P%?@(N-(Y/G ? 6 H'X<_%RJJ>K6*Y=:\JE6V%69*P^H:
M Q48Q4? 4"M$(!T; 4TD+J(R^CL9!&=&69/H^)>PSAH>!LMJBIPCGN]!7PE=
MJ,^'?Q5A&;B+AJ/.1,*^JSVJRL%&WV[,8>:1D**^S1U,3#!K.I)2$Z>BR"U>
M*\7[H)(-81ZFT+*5BL/H<CDUGCYYS*S5JO'7,=FL58LM[:6-V]J\+.UA-E$W
M*TUZ#GZK9IZF6>?JUP@H258Q5K@)::SZI.'L?-M79%VD<[ACF&#G;#&RI'T\
MU'R? %:>9<7:I1,TU//Y*1</G6V:7I.K:3/TM2Q9PH_M6C3PR3A6O$CK9,3M
M:;Q$2T@H%JBA:'A72$.95UW0D73#HC]J/*MZA\%.-N:V"MV6FT^6AW];*[.+
M5"W6<(2PR#V6O$XO*VJOEDRPLZ[-*Z1<G7MG+$L08LC&-%(P[&H4IK7"$DU^
M//#<KKQ/ GC)7TZ,A7Z9-03>@P$96(Q&+O=W:FF(6#N-GT.%:6QX6>-(6<T=
M>KK;[0+F6>+NI20L\ZWG5I6+E'D>J1SYP;E'Q8*EUX2Y-,UR=94UF2J6B2S*
MP9.QFYM>UW"O$J%DRZN8](P]DIJ=RK2-KBCTRH58/8NIEBH:=KT7.F>"\(\]
MZ1RX)G_7]U<=RX;X7H.593CENA)R3IV-1+2%I8-[5/0TPBR0HDAFSP[Z9A7L
M>^=/Y>I2\HR?2X*)2Z3M\M+Q;^.EP2?)D<SO7J_NN)3A?@0Q53BVE?L$6I0U
MKN\I4U$W6V1]AK$KH6D4?6K-,Q4RA+%=IR3N]9W5I$BBYUVY(YM(UH[=6LSL
MW$2! 2*>>64I,<2<8F<]HV9J,;BPKN>0M@K-;>PVD7V)M@5>X1ZD5<JY+W5E
M84K5/1=M8*%)/%F)9X[<OVL9/H.VUCAH>78%%#3W"3CA/+V5\-%5A9:S7*I7
MU>9KL_/0S^'LM(H,KF-=7K -I &5=CFM+L5MC'$%%LV\&_=W2XSKV/7G[)*2
MC@J_LW^WY[6"MZY_#_XP7NK(4R?I]B/ (-+?&BBUT.^(2"\5?*34L]MD>XG!
ML*DXI\YJU%JK%Q*_,2SY#1KE5"72&=L02Y 2*;:#0OJLKTSCGGV<VUW;Z&>Q
M5E]-V>P6RWLVEBEG<;<I"QS&FV=VUG6,BZ=MC1J%NUFV6EFT9I-1:RI8<C=5
M*-BTF!R/YT'L%@]I\/K$GY9)W?G5ROE@5UC7-3K<R^N%L8HT);6=JN&S24!2
M8/Z@?0\"P*_L["+FE&;8A;&XJ\!/G:QDA$0*4(1SMIH- P4@U^'IQ:90C>NM
MJ;82P["NTZN1#1;0;R]^2IY_$89"5"8C%G\\Z<)V*'8\:L/#YRNJX=22] 8N
M9<9!:4L!Y<CDZ^3]GJKF7X1<='M5D:;)U.:EX.8(Z+,DE;Q<WS^6/(4/1LVD
MEGDHM.C(>H^J>L7MBH5NX00;JS"3B/19J1,/[ CD\E>^?<:LNS;0I[581"T2
MM_L==&J25FM]SLMODC0"TFVFWT:FXGY%\I[5]--$)(&ZQED(HQ!CZ\E#0QC1
M@E'T^![U6*JQ\/?B73HQY#5W,#1\9(Q=3AWS0MLN*Q'+.FR%[DHDQSKSJBI'
MKAQHMC+.R2"B4A8FR5>:S;I\A5:XG&%7-?@7?W#_ .E99S?C9E&5/:U*5.*F
M EJI&V^+BY:9L\_.R"J-[2S]&UN))Q*/W/S-]+AF-.45>/"JKHK,'*S<R)Y*
M0%P1S3R'^RK/DN%?'*9KS>J2]%<25=;TBLYR,4YM%I!!Q3:C5];IL+#N54)A
M%TJ5*N;CI4>Y>>N5^[^>(N7#H[J)B5V9'/=^97 IPIP!ZSN2,W V:RR>@H(A
M<K19+[<IBV3L@PD:!)P<^XL#F:%\WL-8=95F_P!,R[ [1S")4R$38BF5%;UR
M.>S<E/37$[&K#F-7R28C;.^J=0G;59(A12[VPL\,Q>H*_P!7N:SR?3EB23IE
M8ZWJ5]@7,*=8(./AK :+@HV)8Q<(A&$<]FY!OH*T;OP4XW:%;5KO9*G.*6)U
M(%DWKV/NUNB@>.$Z]D%91(=-A,(%;MR1N#Y<"J#'VB<@:NKH2H/V$]864J1R
M-?)^RLT9QB6<Y.N1S1H5Q%+)YUGN4D,M+2LD 4C+I*]RU+B_&1=N2BM&/M)M
MZJTB(#(2)9%).0<N4V#$K<A)/4GF:KH27'[*)FD_9Q,U@DM1U-.DM?>UF3?/
MWT5+7B5U63VUV\F6SERJ26BQTZ47M"5??@O!I.&[!H1@$>Q;-$R.>S<F;V6+
MD.$N&0]LD[E2$M RZ5EU'YGC3*M.N^>5[T91\WEY%BUK58F8^"81KV>2=V-Q
M'L6#=HI89JP3!DO?3<BLX(YI'0'X4AKG#' =PO2^BZ)6IJ3LSNN5ZK/5V%PM
M$&T>Q%4=VQW7T73&'E&:"H1Q[U;0!$2@S>'ER.Y%J[D8:OO8D@)%..E;JYH'
MC!C]8U539(*&F(VZ+E8K/!;VNR$@I"6C:#%Y8SGY*OA)_*I"81SR$B*J51XW
M69>UC&,B++YZV2EBE'5KO.&V,.7RLDW4TN'?(VZ=N];7@-=TF&"ASUL5OBUP
M5H+=A946E4;6P^G7PLVTC4")'1G6[9B#%M6:>C7BK\.@43!\$N-E:G(6:@JE
M/QC>KFKAZC6&]]N_T5435BZ8KH+ :U45)X\'%^XMO'K)I63])F/OS5MPV6[M
M;!8D94CGP#<>Q/#1=2=X$<;9]T\?KUNTQ[]Y++S@OH70;K$NFDN_>:6YEY".
M69S29F#F9;ZW=8Z1.U]/NU<0:[0&LK4JK)0Y'(_P'W63,^XS9-E]X&_4R/LD
M?*HQ-\A8J)=W>WS%3KS+4;56;SHQZ]59>9>PL2]NMSJ,-:+!(MV@/GDR5\Z!
MPG\S?D<%'^.U%PYIQ:Q7(AJ1J'6'D2-'!,M;]>PS\G[($\NHF-D]3YE(NO=]
ML_S:H1'ZK];NO'*R@_KF_?.G!5S.Y<\9^U:ZW"GCJ]C;;"RM,>SD+>';%Q9(
MB;M-GDX]\VCKUJ^C,H8&[F5."$$C9]LT=4(E$2-#1LVC#'(:,BHIJS(Y\W#>
M=:JZ:GQ@R6GT5;.H]C99&N.=!HNG+_4-TM5@DU+=FD_1[)271924E7#MNQA9
M/.:@J>*:J(1\PK'OGT\WE)6P6.0EB.?<=7?W*UMW;X<V<:C#VQCG]A?9),Z,
MUU:%T*ULG6ARL_+5C:I6]6/08F#=U[4Z I#C*VC09R?+'RY[3157B,(67HDN
M6M5DT,5&)JRVD:-L=!QW6:[3PMX^W!&*"6JLH1[ 3V@VFN3#"TV)G+5^QZAI
MS_7KI,13HDB)4G$O=)6554072<, @922J@LS5E\ZBE2CGLW)F4"OP,XY.9F/
ML"\)=G$Q!UNI5>L23[4M%E)&J,J3-YG98!U7I25LCZ48R"-CQ[/+$[6.]71D
M+#"OYYXW6F+9<GUA)F/<FE^VI\ :YM=X;8)NMO)==3K<W:I9O%/(V-0<72W-
M(N"</8&3K*DY6F+"9:DK4\G#2[U)%] GCB%D_964S<]HB8F:8D<T^!I*Z:G"
M;CB^80L=8*2\MB4)3MAHB:MGM=JEEY"O;PDNUTQO*F4F")O%I2-?S4) K^DD
M-#KUDLM=H1:S!SLE'KD<^W8,%V('AIA, V703AK-*KNSL5'LC/7JW3#]T:,M
MM$NT> JNY<R+5)I.YI3%BMX]!FV63BEP=(KK3$XO)%'T\U^UULKXD43)M:::
M;7U@%M5<1A\!S6$63FW<G5,_:7&7N\A&3%HF[/-JVI%&4>QT;3"!$P:U.KC!
MW#"YG"2IUVI4E^KGS3>^NBQ]E_!.ITG8);6+5:%KH6.EI%]E-/;IW>(K.<,Y
M=_LBLHT&)G],O$%)&?1.TV.&495N"HE/1031.SIS9-K!-8 CEF\:/9OA2<K\
M//C1-5QQ6)")T15FYIYLS5D"[%J"=A^R3Z5FJ4AD)+&2U!-%S9I7+#,-F];!
M[X!(/W=@5<+6)V[EER.7?=Z"KOYM%%UX_P"'OQXE$IT=>KBFXNI/2]HT6&3T
M.1GY6"I/VS;!>-;EH.DUEY.OXJLH).;@A$3#V)3:*6<*]$OGK=HBUCXN-(YN
MT 1%%AM?@3I\K(6Z$<;/$4K-KJ+Z,NE?S2*M[%I>HF7UNFZ9*SY\ZN%OMN-9
MK=96&JDUGUR4SVAM:YI;/3;M9+9#@HSJM>AB.+=Z&G$BC T;KTX#@/J=!T*-
ML=6UME;*W6HQ]6JDUM=FV'/;#'5=SJ=NUIE&3Q\)NN>5.VMH*7ODY5X*$E:N
M2K15.B*[%,81L094CHCWV?E%2['=9!S+A9=<WI7+ZJ1%\H4.IR*@;+'U!6-S
MEK*L:E:;"GIQG]YM)K*XD;1?"RKB]PHNJ7>;9=6L6%6?)QEE-#6DU>@2.(L+
MGYX#0#LM>HWX4SCZ;O[*6NM +,S9D7= "-SR.)&4!)U?<]OEPJ#%))O&Q3>L
M:6UJ-AH.C#6ZO6XZSUB]651Q4DV4H_K"Y7-1O>* "U&B7W6>K%P5G)_C3D6$
M(WV"@WV;7/7[>I),(.6<0I$-2SSD32V5:A&+F:*NRCJ>?<V)&1FHQ<,I%U,6
M->JE,AWD57:^4)<OP]E@"9^%=9IB,M\:VTC-ZV$Y9;[*03J(S(SN1KA]"RK9
M\]L]G;69_*#H$E*6!YHU3=R$!;[O<GC.'I\K$L-"%*R,"U<KFXGGN"S4AB(O
M045V5KX:\Y!/L_?*S^2/DJYI.37U&,DJ++RB.2)Y9R.A]Y?(8*X"7C&%0F=3
M9QHU#2I**@*G$3*[* L)JXJ+"4B)PF86-#K<,-) T<NT.KIWSX?-IV'8-DTB
M#T2H4N/U:$J#.6:DI03DY:$JA)8E(ITRVS,^XEW\?3+$CCSFN6Z.IDA"TFTU
M.W"QL>4S%DA9&WV\@Q0!5G\\#C0S&&H;X;6IMI^PQ#&=RFGHQV>0K*C;*E1E
M;+;ZW8'DCRADWU%ID=)6LPL<TBAV:K05J@W;.M5NT5"&DJS7*O"P<]&Q.:$S
M:]0YL #[MJ"Q>%/USX74Q#1MX=+VO)5[#+MKH% :+Y'5I6NYP&@-,"CKC'0$
M7(0):?'&MD)E-[@IR7B,YC8EP&HRDBXHCU@65J\T1Z5:'F8=FX.X"MUO\*"P
MLH5@R+>LPD5&KE@]DXI?.TVD)9F$3L7,G1(6ASB;@DXP7I,+$\KX L8T4KKI
MFQMN#T>9C(&-:.H]G429MKZFK 7!TOKKKE//N"ESSS8,=2"POK%1(L8^S;19
MB)-V,+H!LDJF+M<&J\BA.7ZSZ0XM=0V'.WVLPTF]2G88L!,6R$L=P?STDU^:
MD<%[Z<R2;"A:BR#=N J%VVV][-*66L.Y.;T.@Z#11DZC\PF,\D:?9>-\T^7@
MIA=\96/E)>/PJ4B!E(DD>X3;6PJ2HK-6SQ!^4?SK]F-5%;Y\.Z!W76-8T":-
MF:T?I%3=-6Z<[GK::GX^[#A]QQF"L,@_77]"2+3BS<39*J[ J$K%.0EVC%9F
M<S-\!48F&O5M0>M1P5Z<=N&5@Q'>--V"4T%A:37M+4P-(A$O6MREE-/TB'T*
M/1M+\S\8Z5:92TBS4.BGGF]M?HU91JW@7E$C"3E>LI0EP U/#UV;=UBRK\ -
M.;MXRJ36VQM/S-M/Y5)3=+R&)M#.!EUL=DIZ[UFQTJFZE:-,SW#5WVF-LUF7
MV=9K5DL\3@*I.PSQI.*ST([J!4XMG+$.:S&E6$3QV7/EG!'4LBTRHV>*U&+M
M]7I=*RS*X!":M&UTJ;:9QB^EZ].9W'SD-F=^K.=:!+Q>9Z'6:5(K7:IR41,2
MM0>2JD4UB;*Z@6I0EPVY.FK:L^EUP<K/AYV/D%:=AE:]:\LKD5LQJLYL![%E
ML19;&66KV/W/)(Z4=3$@V?+NBU-&=C9ZN%A5JK95@<6"OMKI6&#H[J0("V[;
M[OW;]*U3_#,M3]Q-*_:C3Z/)25CU2>=WO.*5)Q&C6]YJF]0>U-9Z_6!Q/B,Y
M;<?0@W%7RR84!4(]O:K N1&)3,LVE"N;9Z:[,>OPMJ.&_&2T\7*M+U%Q-41[
M!V">=6&0C:E 3$$T8R+.GYS3HA:'9*28P;,LJ6J6*<L*+*!C3 I+U^.4<3DK
M#3MQMQ0ER_E2?E;J=%$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z
M(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z
M(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(O+;6,#7IEYQNBTBJ<B+Y&O\
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0G1$Z(G1$Z(G1$Z(G1%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g209588g22s22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g22s22.jpg
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MLDN1DXB=@+FQ(VJ28BY4>5KW$#"#!8JCL,A$5'1A&^S$XW"/EGA=YT&NNBM
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M'QS/L:KI=3<6M1HUR/XLUJ"-_P D9PQ/P )^&>=I-_MH-]FK 1M)=@+N+5R
M!9HV,"F& 1WI-LIT' QTC'!!R;;Z BLX?BWC6$=5E+KB%+1A35^'M9T UEUB
MC)1:VLCP)*\+2,L10/S1QR.\14NGW951COV!V.TT=4H:F)31LK96$H)&19 H
M+ABNS.BJX(5NZ%@-NY!RX=8V7\:8R)3WTQK^&1]Z]IC)(%]#$_AF/ND:8SD_
MA@NUOM-BX@(JPSDI/0U4W:L\76'9&UT2U-Q(B[9;TD5Z.)J<</,M@1K0H#K#
M5QD#)6'0;BEH% <IYKA[&0MO8KB7;AGXO.[SKDE^GL+<V.LF=SK^G U3&BA8
M4VMS%><KCZYRM2RE2EH5M+'V:K4F,L#L2&),.PT:6Q+L9?6PU$W*V]VG!JFX
M%T3;;R.[-/=_R,S9KR..LPAUP!#\S9WHNSSXK3F>W.C&D1ZPT%+@(TEF-CP"
M=>)!(8W$3(DI1A&\B-+&DA4\C/&LD32(K;%D66)G4%1(A/,.D)B66)ITDD@$
MB&:.&58)9(@P,B13/#82&1TW5)7@G6-B':&0 HTE@(S<#,/!J1;ZTD;,=#*P
MSFCFJ>P,FLML$L]H\-4HZYVPY;E&",CY0/"I7 N#E'+Q9&Z0BU7<;W=/*\R$
M@:99!*BJ4D ;VL0&>]M81BI$=4&FRRS$7AIF?0.5@NFZN&Y90I.N4BH<WQ)
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M*--"A:%X]"^U)5A:NS1RTI@K+6C:)%,K6[9DYD=C.)8RMJ3EFL]6:..1?::
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MJEY1\EG RNVE:6YW;3:#'U:G7)^9C.8OZ ^'-'T3:+;6*SC]BH.FQ, O&?\
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M*7,6:HT2IE)AY6.CA)V&&  V_AXN)4Y*2AX50=)I_;W0.K)1Z5N5E8!258,
MRAE.QWV92"&4[=U((([$;9!',"-R-P1N"01N-MP1W!]".X/<9=_Z#83_ (^;
MU?ZY=P?CFMKV]/\ ZNT/^A=/_P#!S/\ 9L7_ #G4?Z1N?^-E V[@5J-MW,>W
M+<W'OL=*.3E!FVE,O1Y\P*308JKQT<6U99<<^3?G$NT^/?C9^0[:="L6'<(
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M(V6V\VRJ^-RF&)ZL5,FOVN;@MR+Y5)>9*9J$-$BR)MI77+23:Y.6M46_83;
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BY63Z=WW],9'Y4HE1",J(?5GJ4XYY><SGEUCGB\:M,9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g209588g23s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g23s23.jpg
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M)6T(89#+-5?/T%?D:>$3PB>$3PB>$3PB>$3PB>$7ZCO1T?\ R:Z=_P#N%_\
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M'GO;9'SG^6G,3PO_  _TA^FA^:GNRW^S!]LI_F/'.GP>>]MD?.?Y:<Q/"_\
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M:]-FZEKIRX:'6)NPVW]4\&5ZZU$ME3 9H3CP=IKEQM$D2!]A)T1ARA+:H%@
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MP_'H^-FW>$Y4S(_G8GZS6U_9O:_\Q$S\/QZ/C9MWA.5,R/YV)^LUM?V;VO\
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M8/GS%T@=8#-Z:6Z7-$;Y*W))9M2Y\O1\;-N__*&:8;R#^=BL;]9K:_LWM?\
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MAEEQR]'QLV[PG*F9'\[%T,^_BG). LY]/\L[*I9N7%>QFR:VRG6[A'/*0A:
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M5IZ/C9MWA.5,R.7=3+)71^LUM?V;VO\ S$3/P_'H^-FW>$Y4S(_G8MX]6[V
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M(H7*8C712Z%ZK&,=JAP+O6<14D U!%YH/5#3BG)X9;#U8M2]\1NL00TZK0:
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MW0A8A0S#31R+T>%G*6$3'8PBFCUQ,/V<'F)B?ZR*$TK3#9@-@6>-?[1_H$/
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M-2;JU+AC<78TOZL:X#IKT)/1T]=YMA6ME38O,QVWL[<VT9J<C)6Y"\D=[+5
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M7 &F0$&%!7;#U",VS,P$3 Z;7TY(##5A!Q\'"2^9(51=KDV;(:W687DEY&J
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M*L@90'.3"#P6"Q.*H)-';G/SNQ5G(7". D3!3QR9G&<836]QU=5H'K-+2"0
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M5MVW;8<+R#.J>)4=L==3]>2HB2X44AVHV6O=UBGKU@$?,BU2X9FMVV[L_F_
M7J*+W?\ V5OC:G9=6ZW7-6MBT"ZVP/?6,<++A&-]V(S#'UT3&C8-H9DQ#Z.8
M(MD%BO:P3K,]#!B7*2VY%V&B-V/2H "4I2M<:'N_S7;4$;%;6A>WK&5V0'UO
MO5K!I!(-,Y(?%(^%K!FC9CP?VG3BT[*8I#^; S7QT=I YI4@[BI,AH8WN7L<
M)UH%B#-:;;2\BA H:7WCHIU5Q^]W2ISVL[&[<UTPO"EHU6K-S9J_JKL[L65
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M3!YX,M ;%&2,>- M4<<34N<1UIX,K:PSX05>&1:OY6@)[FD/S*C[>8^EE!"
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MX+I4IP:4HD(@MJKC'B#7Q0E7HN80WF'$@<S,QBC@4KFL:E><80TV7='9??\
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M5$EG7JD)S]8I45K2[+LI^'9C>I-;ZS;,*:<M)9@Z"+EX-[(6T Z80W)N&\!
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#(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g209588g24f55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g24f55.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M/73,+VR'V>%R52P=0^1E,2A2K:=IJF,!H25@\62AK61I3B4$(\4$#F@C.27
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M?LNHON@._!<WOQ#JKY]UOF#3_P"453^5')Y]$MM],-7_ *@GS6/D<_9=1?=
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M<Q[26302MYLU/41.?#4021SPO?%(Q[JKY[5JDX1.$3A$X187O.5WNNOQ[=3
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M[-?+VN/KQ<^RG^D->/\ :Q/_ /J@GRF\G?\ 4'1?\+V+_#:9=<Y:/[7N4_\
MC[5O^.5RSX= .L(>6]3>JTPO?IS C]>6GVAC<8IVT&-1&R!J<G(Q/)WL?.7[
M=6?;&LX#8DR>P'JU75&+EV(B=/0Q^3-XPT,"GLBEMR7+'N(<X!Q&V^^P! X
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M2 T<W!QMN<G?CG8JW4EX=*GBU6VP<D ?M$1G%==>IM9<T4'&8.#C_7&P:_\
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M2J,IB#K#]-!>.-&.Y/<XH"-,7(Q4)@JQ@G'4>K@.WW^Q2&1;X.?+^.W4L?\
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M%&V6$OU)<[E# _34D<T<UMN-)\=.>VCM=:X;UG>8YYC@]T/-NIED]?@U/JA
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M ?6[$F@TDM&35/;(2E24L2>ZD>2+$2M...Y SC89&1G?PX/A\&ZAJ6^.SL5
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M?N6%2*-'0LJ@T(@R0E4Z_,1YT-P8:K:X.A\M45F2>BR!!!_NJD,PJ]3>_O\
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MJN@5V)["6C=P8+.(\SLJ0)R5418]AC+3E[0FY%CTC?Q\V"U_5@9^Q<&4'[H
M+$0"-"XK'EA43'LE681%XY+-H+6@'&W8,#"H.HZIG%X63#:HK@(\D,TG)UB
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MMT^3\N;][.L?N_*OR;CI^4/O7HSS[?/9Q.CY&._W*?Z(:4]MUE<\3/T=R,=
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M&.WHE!N_T9O6CK9JHKJW=-ULZ*Z%(W(':0L&IWR?=\Q<$LANK"^NZ%I1,OU
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M2;F=2F[8OAAE@\(#CZB/K&%$W9'JI(KOLVJK%B]C,:Z>0)4.@5=I!I@0-E1
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6<(G")PB<(G")PB<(G")PB<(G"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g209588g24s24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g24s24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X54S:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/C,\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \
M9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @
M(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE
M.B @(" @(" @(" @(" @(&<R-',R-"YA:28C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!R<C(S,#<R."8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,#<M3V-T+3(P,C$@,#<Z,#<Z-3(F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,#8M3V-T+3(P,C$@,C$Z,S<Z-3(F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[
M*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N
M<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N
M*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($-A;&EB<FDF(WA!.R @
M(" @(" @("!#86QI8G)I+4)O;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q
M+3$P+3 W5# W.C X*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @
M(" \>&UP.DUO9&EF>41A=&4^,C R,2TQ,"TP-U0P-SHP."LP-3HS,#PO>&UP
M.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3$P
M+3 W5# W.C W.C4X*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @
M/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O
M=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL
M<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ-#0\+WAM<$=);6<Z:&5I9VAT
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP
M1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E
M/B\Y:B\T04%14VM:2E)G04)!9T5"24%%9T%!1"\W44%S54=H=F1'.7IA1SEW
M241-=4U!0311:VQ.02LP04%!04%!0D%"24%!04%!14$F(WA!.T%116=!04%!
M05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"
M9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%
M03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"
M05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!:T%%
M04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!
M04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!
M.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU2
M0D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II
M.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#
M:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY
M5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.
M:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V
M;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:
M>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,
M0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!
M.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R
M4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU
M:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!
M1#A!.4HV2')D,7%-;#=(9#9B3G!K;'(F(WA!.V-347=P8TY'5VYI4VQ*,$--
M,W=.6$95,GA6-3EQ=6<O;5A/3EAI<TPQ3%I,=3EA97=M83AC;4=%3'=245!1
M2E5&,CE6;$15;W9$97 F(WA!.UEL52\X;V%:-7%S9$YU-'1B=FMU<GE3-6%3
M,FQ*85E,1G=24T154E4U4TLW:%)S;UE#=3)"561:*UDY1VUT24IN,4,Q1'E2
M<3=!5$DF(WA!.T)6;$).2W-C:GA$=EHK2$QU2W-.9#!1-T153&%V+T=A4"MU
M4$5/.69$;#-&2%I*9S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@F(WA!
M.UEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98;&UJ2D8O=T)$
M0C8Y<W=M1VY2>68W<F]684\S56YB-'1I9S8O<7!H5C8F(WA!.VYG5C)+=7A6
M-49P9B](3710*TU-9B]%0FY.-69Q4'9E;W@O4U!C:50P3TA".6-F945:=F]0
M=4PQ5$]J95ED:7)S5F1I<G-69&ER<U8F(WA!.V1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<GI(>3%,978K8W5U1V5E
M,E5.0DI7>71B<39L8CDF(WA!.S)T<VE3>E%V1VM!<6Q&1$QU2$1R>6%M>%8V
M9&=69S)U95%.8S%34%9,5F17:'0W5%5,.612:2]C4WE3=W5I46]Q9W10=UIF
M,TQ-5DLF(WA!.SA35#)',D95,SAO*U9R<E%D3G4W4UA56'5P3&TU831764QX
M2T%O:55P25IA<R]P.#-09&U/,D)70V%8+T%-8WDP+S1W>"\X045";DXF(WA!
M.S5F<5!V96]X+U-08VE4,$](0CEC9F5%6G9O4'5,,51/:F599&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F0F(WA!.VER<U9D:7)S
M5F1I<G-69&ER<U9D:7)Z1'E.3SDU*UI'=5A:<TQ3,5)7=DQA23(Y;WE04S-U
M1FAD<$QO,D53>4Y*2D=Z:T,X8G)4:%8F(WA!.U-1<3E0>%9$>39J<#A+4U-3
M,TU58V-4:4M6,V160WE.5&EJ16Y::GE&0C<T<79T-W$Q=59:-V%:2FQ2;6ID
M;S)$9T]H;WEK9VYC2'$F(WA!.TU6950V6"]X>DQ4+T%)=W@O=T1%0FY.-69Q
M4'9E;W@O4U!C:50P3TA".6-F945:=F]0=4PQ5$]J95ED:7)S5F1I<G-69&ER
M<U9D:7(F(WA!.W-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<GHW4C<O6&TO3TQ83$4S,'-M:4IA<$E,16A7:&IM358F(WA!
M.W1U<C=U<FYK>$M50S!)87!,14)6-D1I<D1D6"]!0WIS9%9';WA81W!84S)M
M<#-46',Q<D=T<W%,2SA#5WI&5#9*8BLU47)U97)C=G0F(WA!.V(T<6UV;&YY
M9G S;#=4-VUX=$I:<$ER<68Q,UHR0W-#23!I4E9-46HR5T]&4EAQ97!/*TMV
M4#A!4R\X06IM5VXO1T=0+VE!>FTX=C$F(WA!.T@S=E59+W!(=5)*-DA$9RMU
M4'9#33,P2#-&-G!N4G9-3WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C(F(WA!.TMU>%8R2W5X5C)+=7A6,DMU>%8U6C5A*W$S
M9C4T83=Q9&YE5W,P3%=J,C P0F$P1C!K,7,P345G0T(S=D]!844Q-6]I9$-/
M5E%C5F4F(WA!.W T<6MK,VYB>71#;'DP;6])0EHS2S)D=T%(67)/-VU.531Q
M<$IQ-G-T4G1516118U92,FLV,W!7<G=3>C9B8W)D4E%Y1T=2,')14TLF(WA!
M.T$Q3G=0,E=$03E#0T-.<U9E6#98+W=!8WDP+S1W>"\X44=C,VPK;RLY-FI(
M.4DY>79+>%=*,DA65DI(,$1$:4Y42'9#-4)C4U!*:U F(WA!.RM.3E8O=T(Y
M468X04%V.$$X,35N+W=!<&8P9G0O638W*U1"+T\K>#,K3TY447%Z=U%S;DI1
M>6=/<$E*04Y#5V%N,UI+2&%&;F--6F0F(WA!.VTP3G!)=CA!>'EF*U=(+VMR
M+WI::R\U4F@S2#AF1F@O2G,K.$MT<#5Y*W-88TU"<RM(<D]S9DPQ2S U1VQA
M8U(T-5II,6M*>3110S$F(WA!.S5D1$M%5$EK8DUL>DQC1C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMS2S!$
M6&13:S@F(WA!.RLV<&\V-DA,639.0VMK='9Q0C K4T=/859N4G!73C(P9U)I
M.')Y3GA%6'A$-'572V]B>69R+VU/.3@V879P5C5F;35T9$UQ:VQB55(F(WA!
M.U)S*W<O9$]O;TM%.41+-7 Q05!1<6TY-2M7=FQ'.&$X33ET2WE8.&I3,VM)
M=4IX2$EZ4T=5,5%0>' V:D]W039&,G!4:V-#<&IP;FPF(WA!.U1Y+W!T:&-7
M1G1A2V)/-FPY831H;4Q4<7I55E9Q2E,O=W%S87%O-D%!64I!155754IM2G5*
M;W9-=$YS<DYT3G1/545B5FA7=%55+V(F(WA!.U%"=3,W5DXX-79+0GA(,VPV
M<D9L:TEI:6515G W3S Y1U)V46HU0E=)4$9A,30X83E0-61S8UE(15!E<SAS
M=44W;FMV1FQ:9V=I0TTF(WA!.T9E2E5H1C(T0VE5,B]:0F]01$E5>CA76&5F
M-U9/5WES;%)E3G9'3TQ2:&%)=7=6=U%"=#)Y8TEI+V=F=5EY>7HW>C@Q5#9L
M6E5P.5@F(WA!.VIP47(Y:&5H8FM2,"]M,RME46]-=D9N,VQ6=$QB5$DW,D-7
M-&=I.4@Q;$UX35EA<74T-3%&1%AL,SAC>4Y+22M)3#5B+V,T*W!Y6E F(WA!
M.T1.13-T6#9'86Y5=DIH8W59-$,U3$5T.5A.4UA89S5R=R]A5#14-&IB3G9X
M668V4#)/;')55EAR*S-P=CDV<EHS4&Q/-'5)-$QA2T$F(WA!.WI-5DUA:41J
M=D1'5E-H2T%F0DA65CA"=&MO*T5D:'=N-4U:>7IG6$EY<C-N<G5F;60P=VHP
M9E-)*U!P,DYU;D5O5C1X24M'23%J<%$F(WA!.V9S2&1F1$IJ1D%D03%(535$
M>FQ,-6YR>BMB6#9',&8P+U0K;S(O<#AE2$0P:S0X969Q57!4<'HK3#4W-"M&
M1'5(>5@X>FQU*TM6*S@F(WA!.SDQ9F1T-VTR,&931T1+,6IB:U!Z1$%X25%F
M54E:-C=F=$5!;GAX.$M(8U!K;S%/5"MD3#5N<'DK5'8P4G!2-40V;$(X6F-T
M*S948WDF(WA!.W)W:THR+V)556)X1TAW;SEW6#AX:R]N4S9D5# U9DQO-#92
M<$I)2G-O0U%622]D2C%64%15.4]Y9D-08F)"-%5/-$PK67EF>G!F32LF(WA!
M.R]W0R]D>392<%,X94YL079!>&Q+4DE+1T=V<&MB8F-+;FHT9'-)>%(W9W Q
M1U$O>%,V.50Q-2]0<3!.1C!92W%I=W1W<4M%465K;$$F(WA!.W%T>D-J8F](
M*TMN:G9G.$=(8U!K;C@Q;"]N4RM:.3,S8D]F4G1(8T5063(W0F=W64Y%:'%(
M8FUW3E(K,#-X2#-X3TM(8U!K;S%/56,F(WA!.W!3*UHY>34Y2S!T>5=E>F=:
M;3E1<U1':$I-=S1Y,3(O8D%O,VHS=RM(2'5(.7%"<4UG-5-05'%E;DPU9$\U
M<CE%851Z-2]5;T]D83@F(WA!.W934W1E4$1R5"M4-&9L=&<X2TAC1B]-6DMR
M:6PX>C<O04PR,3!N4VQ:5U=Y9U9K35I2:$5G24U+;%EI3G1U0VMH9D%D35!H
M4C=H+UDF(WA!.W Q1U$O=T%5=795.65F>C8Y-U,V4'!#9T)B1S-52T9644EK
M1D%J8VM!,B]:8F-E0G=E1D1U2'E5-FY)9C1P9DTY5W8P3F\Y0U!Q3G8F(WA!
M.U)L2TU04U1D4R]Q14AB;U@K3#4W-"M&1'5(>50K6GDO>G!F32LW-W1M,C!F
M4T=,;')',UEY8WDU35-%<UIF-WEU,B]/;GAE3U!H43<F(WA!.V=G86Y)4#1P
M9$]P-F-V;#!C3DDP:T5K5U5!2DQ%+W5K-G-N<'-E;F10:%!T=&HT54\T3"M9
M>69Z<&9-*R]W0R]D>392<%,P-#)50S F(WA!.TM%56E154UA96UH-F9S;V5+
M*T$R=RM&2'5#;E5:1"]&3#5N<G5F;60S3&\K:TM&5F)',T%49T9!:5%!96U3
M>54R+UI*2DAH9SA+2&,F(WA!.U!K<#%/5"MD3#5N<GHK8E@V1S!F,"]4*V\R
M+W X94A$,&LT.&5F<55P5'!Z*TPU-S0K1D1U2'E8.'IL=2M+5BLX.3%F9'0W
M;3(P9E,F(WA!.T=$2S%J8FM0>D1!>$E19E5)6C8W9G1%06YX>#A+2&-0:V\Q
M3U0K9$PU;G!Y*U1M,&I3;7)Y<V]'<5A*<D5H<5I%.4YZ,"]A46-7.%(F(WA!
M.W1H.$M08T9';WE$*TM8>E!48V9)-W9/=DQS;&QC9FYH<CDS0F1P3'ES>$-)
M16UG96AG.4=.,F%-5"MU:%9W>4941'@R<GEQ9#=';%$F(WA!.R],*SAS<&9Z
M5#AZ6$M#3&QF02MG.&%)2E=20W8Y.7=K36EF6C(Y5T90;3-D5FQD,RM:=FQM
M,&@Q0U=8-GA45$HR=#=G0TEK:V]:;&4F(WA!.U)..3!5,FLQ5#$K03!(4V]6
M3DY!.#$V4G)L;E!E5V)S:T9V3C9%:&Y(<"]%>4I):D-P*WDV4V]Y+U!X,GA/
M>4-A96(V6DQ%3DUT2W4F(WA!.V]P0VQD>#)55GIM.'8Q2#-V5%%Y=S12=4]3
M=E!,2#9%=GAR.6QH,4A95D]/4#9H-S!Z>5)O-VIQ=CE73"MD9G9(:%@Y5U%:
M94Q(=D,F(WA!.WEA5TUO2T]P<7E5,TAD:%1*=S4O02]C>&QK:EA-9$8O<E)5
M<GI7;E=T4C-.36=N>%ED-%4U-6]U02M.9G1+96\W3TLU3TA0-$@W;4TF(WA!
M.SAS2S5J-2MA;UI9:#%D4C$W:G0Q*S=)37IL:4]O5F)057I9,S%V8WA&1V5.
M;4%$2&)E3FAV46IS8WE.3FPX3U)L5C=/4'%22$I(:#0F(WA!.V=.+S)P-2]J
M<2M.045T.395*S$S,T@W6&9->BM5:"].*S,Y:FAF:TEF>G@O8CA65WDX*TPY
M64,S<4E)5U%S<&@K,7EQ05!T3E-H<6,F(WA!.W1X839-<C1H=R]B*VAP>6%1
M0W5'46PX=C%O+R]!0GIO;FA,-#E%-E9P+TXT-6(K8WAF>G9S4#9M<CAT4'DK
M62]7:3E0.#!A5&93=D8F(WA!.TA)63)J575X;#1Q2TM11S,U2'!83$E:-%0U
M1G%Y-'I$-G$K651$-C=:8W50,6E0:TMG:FUT9FA(2G4O6F1Z;&Y%1W)J2&4T
M6'1K854F(WA!.W5)>EAI0E(Q-G5V2F4O9&1X-UDX45AJ2&4U8C9Y86Y'-&EA
M=D=L2%4Q-6UI.2\R=3)0148T>#-T9E@W1&IY*W-X8V%C<3@Q<%1L=W(F(WA!
M.S$V8W1V;F<T:#-R>&IV8V(V>4%*3GA%04]65'I88FEA3C,W13<T94E,>&IV
M8BMU,E<O.$%P169W.&=F:EA9;T]49"\R4G5C94E,>&HF(WA!.W9D.61S=CA!
M;&]J-T0W83DQ-41V,UAF-5DX45AI2&4T6'1K855U27IY2VAA3W4U9C=&3B\R
M<6)E3U!%1C1X,W1F<$-W24)&>D929T<F(WA!.U4X,3-"4$5%8B]Z8EE/260V
M.%DW,TYF,DMG;')I24%62DID4G-P-&YV,D\R4$5/.65-9#=B6'1K:$EA-&I5
M9W-$5C%'-F)T,R]:<G8F(WA!.V@T9W9'3SDS,39Y-6-F<D5F3'!4;71A,#5E
M4&AV:GA"94ED-VAE,EI)06YJ2F)I1D%D9'DT<6Q.+W=";T-O.&-E24QX1'9A
M1CE:1VPF(WA!.TQI23%!26\V-VAJ4E0Q-VY963A16&I(93<V+UDW+S921G-#
M5#AA-T%.>$HV+W=!,C-Z=V-1-S$T>#-T;2MS9U="=4EG5C5C9UA88F@F(WA!
M.SEQ=2\W4&9$>$)E360W>EA13DDP97DO4$A7-6)/1F]*<')%3DI';'1"1D1Y
M65%U-W)+:BMO,W%-,5=R1U!I<G5D<VMY96]91E-I9GDF(WA!.V0U5&YM;&UN
M,&5Z;&QN8WE43SA%6DQU>DMZ33%2=5-Y2U0T-'%I-U129$ET3&%3,71B2T-#
M,FUK33!S36-A<6IY35%3-TM"46Y98C0F(WA!.W%G=$XX=F%!9$]T4V1-=$-4
M1$A5;4-0*U5F-4]+2U)0*TAF3"]W1#%B3%0O04I%4B]W1$Y/2S W+T1V;"]W
M1#9T;' O>4EJ+T%/86,F(WA!.U9P,RM(9DPO05 Q8DQ4+VM22"]Z5&ET3R]W
M04\K6"\K<EIA9CAI22\K86-6<#,K2&9,+R]!1F),5"]K4D@O>E1I=$\O=S<U
M9B]W0W(F(WA!.UIA9CAI22\K86-6<#,K2&9,+SA!,6),5"]K4D@O=T$P-')4
M=CA/*U@O=T1Q,E=N+T%#26HO=T-A8U9P,RM(9DPO=T0Q8DQ4+T%*15(F(WA!
M.R]W1$Y/2S W+T1V;"]W1#9T;' O>4EJ+T%/86-6<&1(;U=I4FMM4%0W6D-D
M:59H:D9F=4=+,'%F;VY3=BM73T0O:U5N.4UA5V<W.44F(WA!.S96+WEX=V8X
M:6LW9E)J4S!(9F]N4V@P<V]0.$%K56YB-DU&3%%11CDU3CAS6#!Y>EA7;E)0
M27$X1DLQ46-14V5I1E(Q631$04AM>FHF(WA!.TUX-4EF+VQ8=FLS+T%+=&MF
M+T)39C@Q6DAW;W,O1VPK045Q=E!Y,G-F<E5J5TYV87@R>E5+>'E!<U%1;T(S
M269U2SEC;WDV6&E.:5(F(WA!.VHK4&4U1TQ6:4EQ55))+VIY568K5F(O.%97
M9B]!04@O041:;%@U1U@X."]J-'1V-39(.'=F:C1+2R]L=&-R54-#=UE666=M
M;TY#4V8F(WA!.SDY2$=E:FU4=$I-9&)J<F5(,TXO.'$U=78K5V)4+W@O-G!:
M1#AL4"MC>2]/-'8U;C-,52],93=554YV<#5.4V4O8VLO-S9Y571(32\F(WA!
M.WA)1W-X9GI0=5AF.'$U=78K5V)4+W=!9BMQ5T0X;&LO;DHO3S1V-6XS3%DO
M>3-U,6I65&(V95-!051V,B]W0V571U=J;5-4>$EJ<DTF(WA!.U%(,"]C<W4O
M>3EU23=385$R,6A223)9,')79T)/,S=R1T=J;4-057 Q;4EJ-F9U4VHY1V%B
M+WEY42\X04ET9C9:<E!%;#-L,F9G=S<F(WA!.V@X;'-M;39C15EI,6A"04Y$
M-F$K2'EY94Q*3&E'-35S36U+2$-D:'DW;G)H9V=.87AR=E=V=VIF;#$K+T]G
M;U!.54AM=FQN47)I2#@F(WA!.S1T8C%3-C%/,W5R=#1*564Q:6IC4$A%-U%T
M8G$W0T9)*U-10TU'<VI(=E1C-4I,,'E34T]/3G!*1T-2;T-Z=7AO04)U4U-E
M,D)7278F(WA!.RMA9FQ-859Q3W%X4U-Z,D]M>5)X>7IX2W))-E-Z3D%S,%0X
M=41297!'-#4Q06]P4%-H2W%B*UAF3FUJ-B]P8F%N6D\P9'%J:$=--BLF(WA!
M.VM2>5)*14\U<%(T-55:9EDK3S)+;R]3+RM/8F%F.%E9+W=$:4%X5D4T<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%DF(WA!.W$W1EA9<3=&
M6%EQ-T9867$W1EA9<6AT52]W0T]B9"\X65I0*TE(0T]A=DY--60V=&)*+V1V
M.&HK<DHT=G)(=D1$2CE*.7HQ8D]K95@F(WA!.V5884A!=CA!>79Z>D1/<SA"
M4#%&165!:3,Y669U8E=J2U-F<D)(5V\T:$)T.%)9;%%Q.5)X5DIP=DIN;$=D
M<%=L,&%Y9' R6G!I,$4F(WA!.UHU32]%<U<R,S5C0EAX>%9-3D\P=E1D370O
M<3)N5W-6;F(X;68P64573D]41W!01E%":7)T32\T-71P+WAH:B]!3TEJ1E54
M:7)S5F0F(WA!.VER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7%',50O04DU=#,O>&AK+S1G8TDU<3@P>FPF(WA!
M.S-Q,7-N.3(O>5 V<VYI*W-E.$U-;C!N,U!6<S92-60U9&]7;V%0<% U>6%V
M;W-.<F$R83-A.#1P;&YN33!T>DY&2&-3;UE7:V%.2V<F(WA!.V-T;W=0.')K
M85E696]33TDT,F1Q;%9"66A15TY"=G-Q9VMN,D="5T,V:"MB=6<R;6PV:F5Q
M;D]3>'56=#!T2DI5:&UK4F]9<'966DHF(WA!.T],>&=#8TQX6F%H-DMA13='
M;%1R>6(U>71V33)H='$P9'1*8E)R2C9::5 W,70P4U%5.4U'<$%K06-5*T9G
M>3EQ-$94:E,O*T]B868F(WA!.SA962\K241&551I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%L9'=M
M93%M:$(F(WA!.V]:63)113E!5T)'259H+RM#.58O,S="+W=4+S@P6G$O-4XO
M<&9:*S$R+SA!2UDO;2]A,#-K;E9757(V<T%Q2U8U4#A!.#!:2TA:.44F(WA!
M.TAI*WHY<D=885%)23178EIS;E903CE0=4EP+WIT,5,Q=4Q/0C)T<E):<D\W
M.4-&6E5):&=6=C-P=&A->'!-=W%,:FE!,TAJ:7(P:D8F(WA!.U9N;U$Q2CE.
M871U>&].*VY8-VAI<3565E)244%+:S!',C5.5"M/2V]F5% K3V)A9CA962\K
M26I&551I<G-69&ER<U9D:7)S5F1I<G,F(WA!.U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)Z>GET-5<X>5=F-6EA
M;G)6.4A),$9Y3'1:3#(F(WA!.V1R2C%K:F%74#9K;'0V56$S2TQ(0DA34EI$
M>#5B:7981EAO56I&63):5DQS;TI#3%-R161H>4E&5#=N1E=!-FPK65=V=S92
M<7,Q=&\F(WA!.V1X*VQB4S528D]W:W1B;'I*8FQ)1VM,4$5$15I637IO07-N
M17-U>D5B-%94,WE:-6<Q=E=.1&$K,5A42'-B>%I39W11<E)S4GA2:C@F(WA!
M.TTO02]!-TY'5#!*56MB15E&5'EX:65+>70T;D9(:FI25TA88TM!8U96<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7(F(WA!.W-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F5B*V4O3V9M1S1V
M-V)1+TIH95,Y.60P=G)U,VI%>G=344TF(WA!.V\Y2V%+4F5+4G,P:3%K3$%(
M8T%J9&Q+=E$W33-2=$E$9'%I,UIJ53-#>&ML0DIX2$U)5'9X-61+-$9E938O
M-3,X>&%H-6=S-TQY9$,F(WA!.SDW8G=L6DI,;4I18F%75DHR:G5,5S=K:U$O
M5C%72D-Y<W1767-H030Y4W(P6D-X549W03%">4%.440S;V%#=C-91F5E=#4P
M,6Y7=DXF(WA!.S)L=V58>5@P86]N5V5)>'E1,V-)8U$S6')K:C%)1V<U,6I8
M.7!V=$56545Q>BLU=5EB83)L=5HR-%%123!K<C!*;VE$:WAO2VY91$$F(WA!
M.W)Z-U0O3B]M<E<O3VM+-E%I1%%O,41/1SE/5T=A,&0O.39236IH,&M)*WI'
M>2\U4%AM67ER4'(V*W1B0WEN=F)U5#!R5S)J85=E46<F(WA!.VYI:41K>&]!
M4V1H,$="5T-A0C5R.#0V+S5Z<EIW=S(O;#8R:"]W0DQJ;&1*:VQ34U=4,$QI
M,FUG1&9(2D=&67$U-# V03AG=TMS,S$F(WA!.UA6=$\P;7=L,4156C%T<DM(
M:C9S-S$T<GI9271A5B]A65E&65HU3#AX*V1D8SAX,V0Q4&%T82M8=C-K5%%8
M15E!4U=&>D=R5VLT0TXF(WA!.TUS;$-8-7)1169#44]037%Z2%9T63 S4V)5
M6%=O6$-7,$132D5S<VA)5&Y)94MH;4%0158V<V1G3GIT9U9I4#5D83DU-#%Q
M-W4W,U<F(WA!.TQ.<E!3<&=Z4E<Q>$-9<%E::#995T]&-G%:;V503W).1T1Y
M2%4Q;W!6:R]M5'I$86%&<'!U-75,5%-T-DYJ8G,T:D4Y>7ES,%50<4XF(WA!
M.SA+1GET3U1B64936#AV9%0X>#9L2'%.-7%P8S)S,#EB4EI6:E)O;E9N:6UG
M45)&;&%+37AQ5EES4U-X-6)G9T95,#@Q95I93D-S0DDF(WA!.T938E5,:FMM
M;E=B=C91;FQ#.'5(<45%3'0Y-3)&5TE'0E5Q+TQR5E!.1V\R;#-C-G-J4%EY
M5$8Y3G5:+U)J=4-0<WEX=$9">FHY3T\F(WA!.U9816(K;V5354\O57%O-WIH
M-71J,$<S:&IH:5<V,4\V<6)7>$UI4DTX8V),-C=Q,&A#5FI2=5A%;F5N9T=)
M5E%N-6%8=FTK.3AU2F0F(WA!.V5:4D@V<S-&-TYW<%-6-%=24T=M4W!#=5=*
M-F9Q<&EQ;BM96&Y76%),0V%Y,&Q$9&59<&\Q3G1:>&=V37%4<UE5=45I-&M3
M.$IA9D(F(WA!.U5F-5)58C1Q;69K:RM:5#5E='HU:4E/;T5K9VUN<65K9G-E
M='A72F95<#%O:2\V;TY11E5M+TU$>G1*<&M5=6TV6'IK,45)2'9'='HF(WA!
M.T5B:3)I8TAH2D9&3CA-<DUW<%%6<%5B1FEQ<U9:2#5:8GI!9$5T=CA13$5U
M<F=-='E93FMA:FM),4MU1EIK-&QG1TE"<E$P=TMX6#@F(WA!.W<O4$=P5V=/
M:65726IE83@X<5$S0WA",VMT=6%#6D=A3E59;$I),5E&=V9H1E-+=%)C2W-V
M,$TV=61*=%1R26E'<&Q".6%%1F5!8C(F(WA!.S-B96Y7:'!8<'1G5F=F;F)Z
M=#5K=716=&1&.&M$,3=Q3S196#$P:UAR26HR,&=35S%N5F=O:5$X,5!Q8W0Y
M9TM+5V13<C!A,2MS+U8F(WA!.V]V<EA!6%A"9EA%5E1(-FQ0:31C="M.96QC
M0W%M2W5X5C)+=7A6-6XK64AN3%9R<E4W;GEF;T5%-C9H>%):6C!!17!D+U-K
M:DU!3$$F(WA!.TY'07@Y67EC1DMC*TQ%<7=W<7DW>3$U6&DP>4LS=3<U>&9A
M*TE$8C-/<4]785)K959P;5)3>$Y%-78R04(R,D=W059G2&TS>F0U<#@F(WA!
M.WEE8FHU4#A!3&%4-F9(851X+U<Y4D%!;%9O8FA05VQ(0UI3<V-A34=#4TI3
M545D:79)<3E(,$QY,UEA4U!85E).<7,P34U6+W%4.&HF(WA!.TQC1T9A0FU,
M<S=!5DI02&PS=TLX-#AX*UIV35!N3%AJ;TAL;5,X,' Y3W52>74T>45D6DE:
M2D5D-W!+:V96,CE-:%9*16Y+;DM-<38F(WA!.VM&6'!E:2M8.4XP:$I'=&]6
M1C-C:4PV-V1B;5-D;TEL:%)N6FDW1VEP=%9V2'538T-V3$QV>D(U;S@O95I%
M<V1#;G5D2W-,3G!#2EDF(WA!.WA*1S!.0C9F<3-B>%1+3U1U2%=/3&-J:7=D
M451Y:DMV5DQ,5$Y*,$]Y=6US3%@P;S-E4S=U5FE$4$I,2S-X3WAR5FYD<54O
M1$%R>FHF(WA!.U-D8C$S>C=R:U8S64YD869P5G5W4V8P<%%)1&)&;W!:3&4T
M0T9Q,T5I1497:&M.1EE62SA75GER,$U185 U63!/.&UT3%%W,E9Q<SDF(WA!
M.S=.0F))6&MD=FEL:TMR,60R3F-#=D]F2S)P96-04%!M239U=V94=$-T-6I#
M,$AQ=C94,CAC>D]I9U<X-U)Y>E-C23)-;TE(16M52S F(WA!.SE1<7HK+W5.
M1SAM954U2G)A>CE04SE+:$%J<S=92TM,>4$V=5958G16,V1T=#)9.51G5F=0
M:WDQ.'IE8V1B=4YB,6$U;5121TAO>C(F(WA!.U-M94<P;DAP36AH:50Q=FE%
M36HP9'EM-W%A1F=A4FQ7938S<6UL*U1V3$EU27)*=G%&:4ER94-Z=%%I0E$W
M3$5G<3=2>&]O3$-R37<F(WA!.T="5T9E4W1,,6IZ8F0S;70V-4Q02F]/<%%'
M3CE.:VML1FY-,&M):D0R<UI-8G!&-E1U1T1Q4&E0-U)14&A6;#-N6'I,1#50
M.'-.95<F(WA!.S%I6GI(>'1B0WIH0U)X:5%Q4D5R1FUJ4D4K14PQ.$988V=9
M1EEJ-4,P2%AV371T8S9N-7),6$]I-G!'2D4P*S1E86MR>4530U990DLF(WA!
M.S!554EJ-'AR2#AD849G84=R1E=4+VU"-7=4>7!O.$QX4FA*8G!J0F(S1$IY
M=#=C2VAD<$I61'AS=U)&2D5A2&LQ3FAG5DEV24AL2%8F(WA!.V11,#DW+WII
M2G)O6%5K9'IA-EIF=$LU9VU75G!89F<P<VE!1BM(1F%!55=V1F526$-Q4"]!
M1%,X*UAF;'%Z='),5')E4CE5,5)H2&(F(WA!.UA(0DAJ:55Z4GA/,T9P641)
M-#EA<7%P.3)O=4)895)F2U8X9$QS-W9Z4VAU<C9'4DQV5#1B=5=A-6UT5T%K
M2V@S;&1L85-0-G<V9V@F(WA!.U)10F$W9V-3<3<X=V9056UJ6%9T;W1P8GE3
M6'0O1U@Y4E-52FI9;5 P-V1L-5 X05=(8VA525)L5FEV3V=967%J9DQ(;&59
M>%<R;RLF(WA!.UE18C-68F52<$Y/:W536&YT;VUJ16%*25$W46U925 S:GAQ
M;TQ%.60R259*+W=!>"]03GA:6%DX<F%F8EA$-FAF=VYL3D8X36AJ;6HF(WA!
M.VQ53&%54$EZ9W@X9U-"2'1X3'%Z1$-Q8V54=DM-,6IA5V0Y-6=D9%(X>'=E
M<WDS,&=Q,%,S2$%.1V=Q>4Q226M5.$M$<E1Q4U%R1E F(WA!.U S;3=83E8X
M=TAY8F]+5'=3>'E)3'E334]K.&]!4U=S56MC,$QX4DM845-/,T5S<D5O5'A/
M1E=C95=F2SA/;%%16%8T5G9034)T:W0F(WA!.W(W5FU"36MO1'1+=T)9;6EM
M4U)J455(5%E!04%+;G5+=7A6,DMU>%8R2W%F,64S*W-#-#E*4')!47AI8FE/
M9D%M<%AL,7!55G!I<7 F(WA!.VEQ;71V8G)/.#9X24HU049E54M!-TMV449U
M<$%R:7%P:7%M;'1B>'I35$I%:5148V97:U911V9I2TQY66)M9S96>%95>%94
M:70W94HF(WA!.W!(:6E33C5M-7ES<6=&,G!4:WA(53!(9D965$963T<S=#1&
M6EE):VE6,DQU155+0S='<DUA9'EE<'A657A65&=T-V4S:456=D5K35,F(WA!
M.VMK4GAQ1E5&:5=/=V].>6$T<79:5EI3<D%-<D-H0C-"0GA646UE,S W5#5*
M231$-D9P17IR8C(V5F)J1W!00T].97 R;T%-5EER3BLF(WA!.V%8:W@W4TPQ
M<$AC6$IA3V4Q169R3D=N0E=C>4-0,45:47-I.&=P63<Y3FUO8598<V9Z2#AL
M=DUD4&AU949X0S=W4E=C54UK:$EI;$TF(WA!.T,K;7-+=4-#5G%&1R](96=W
M2V@Y4B]-=GEV.$%5-U0Q<E<U=3=857)5,V%O655P.5A62EI(85)*5U1:570S
M8EE';RMZ5V]W<7I'2FLF(WA!.V%.1VHO=7E!56]+0VA',C)"5G,Y=F(S169P
M>GA*3DA52&A);UIA<6%G,%!G4EA&5E1&5D]A,G0U*TAR4DI,-E1I4U!M;V)I
M-B]:6F$F(WA!.SE'2%DT<7%9<7!Y5SEV2SAC:VM33SA*-5)/>6=L1TEP5E-E
M:' T67%Q67%P=F)7.&LP8WIX23@P4$PP6D=51FLU0VIC5T\T<4]T358F(WA!
M.U9-5E4O<3%V.5DK<RMK;C%J:#9F<F-2>C16-6-E6%AJ6&5M2W%M2W5X5C)+
M=D]R>5@X-&1/=G!9;U!2,65Y5E%%=E!2:&EC=3%Y2D0F(WA!.U-%4TIY5DQ5
M96XY;U9C,7=Q<&%J<68U,5<K=6%K=&QP;')D-E9"27@P*U-2:U@Q62ME,TE+
M968Y,V1$<%%K=T@K9F161G=A,RMA.'0F(WA!.SDO<%=I=U=L;E<V:4IT,U=D
M;$A&9G$P=$I':C5%<T0P3DM.=4MR=7%P-DYQ+W=#84-7=6]V96%D3$YC45(R
M<3)I,T,R,T=2;6Y+,T4F(WA!.S!F;TY#5W!B<TI04V)I95%+.&@Q2W%)=F1:
M+TY32%1,0SAI,&$S:W8U0D],-U156E=326E71EEQ>6U51FE517)";#(S2$ID
M<31Q:%DF(WA!.W9-9C5U3$-:;CAV>%-3>5A&<VDR,45616=:<%9N9C%0<D)9
M;C1%6F%R,$\T,S)652]W1$9(-7AK<48X<S)T0D5795(S6E(V;F]G:$8F(WA!
M.U9:2%DO=F585VYW9T0W5&9#<7)X*UDO>F-K.4IX-6-T,%@V>C9C-E--<70V
M2'!.24A5:31B9FMO:D]X,V%O<49Q>7$S.5!F;D1,85<F(WA!.V-H,$LP='!(
M83-.-&E(,6U25&0X6G=O96%)5E,R5W10,FED;7A646TQ8C@U-6]8<TET36AT
M>3-Q4G)Q-3E)>D-G57$V=VPS:7%#4W8F(WA!.WAB3CEQ9W!X2W%-=$YF.$%Z
M869565DU=DPY<6QG8G%'1V%:-4M/24<U971)3T5K;CDS4V=B:#A85V=",E91
M36PY*V-O86(P<EEU>2LF(WA!.W0Y54QP84-/46=Z8GEQ2%9O9V]%26A53654
M8W5B1F%(1E=F-D<Q-#)L5S=8:&UA-4MN,41C<$9(361Z5&UK2DU93E U8T-O
M-T9867$F(WA!.W1M:&EM:65'6D)*1DEP4U-.:%975FA19V<Y45)I<550-4LX
M;T]!2#!7>5E"46TX168R5C-!-EEQ,4(U3#AQ=SAY=6U13S=U,')Y4TDF(WA!
M.TI(3%!+6GE3>C%B*SA9:V9D:7%P3#53.')Y>'=2>39485!(8E4K<F\P2T5)
M05=90E)4659D:E0S>%9.<U9D:7)S5F1I<G-69&ER<U8F(WA!.V1I<G-69&ER
M<U9D:7)S5F8O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#HY,$)!0SDR1C!#,C=%0S$Q04(P13@Y0T$T1CDT1#!"-SPO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HY
M,$)!0SDR1C!#,C=%0S$Q04(P13@Y0T$T1CDT1#!"-SPO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S
M<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM
M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HX1D)!0SDR1C!#
M,C=%0S$Q04(P13@Y0T$T1CDT1#!"-SPO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HX1D)!0SDR1C!#
M,C=%0S$Q04(P13@Y0T$T1CDT1#!"-SPO<W12968Z9&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X
M.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD
M969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C@Y0D%#.3)&,$,R-T5#,3%!
M0C!%.#E#031&.31$,$(W/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3$P+3 W5# W.C P.C R*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HY,$)!0SDR1C!#,C=%0S$Q04(P13@Y0T$T1CDT1#!"
M-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,2TQ,"TP-U0P-SHP."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL
M=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N
M<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU
M<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A
M<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z
M<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @
M(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G
M.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA
M>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T1&EM.G<^-3DU+C(X,#(W,SPO<W1$:6TZ=SX*(" @(" @(" @(" @
M/'-T1&EM.F@^.#0Q+C@X.38T.#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @
M(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$YA;64^0V%L:6)R:3PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O;G1&
M86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U
M;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXR,SPO
M<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FDN='1F/"]S=$9N
M=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D-A;&EB<FDM0F]L
M9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP
M93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXR,SPO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/F-A;&EB<FEB+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G
M/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE
M;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!4
M4&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R
M;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \
M+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'
M<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C
M97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E
M;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_P  1" $Q B$# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M          @)!@<#! 4* @'_Q !-$   !@,  0," P,&!PX& P$" P0%!@<
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MG=ST^EJ52=8W%'-Z?28!J@JN[]B/0$DG\IQYY4SL*J81,(F$3")A%3SZ@/\
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MY][Y.J/W5'_&-N_M2UG,G^"7#^+;A_9D_?(Y?_GIAO\ UE9_Z/'R=4?NJ/\
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MK(#<FQ=9U'N^[B(M:[J%N/O=KFG.>Q"^4_P_UI'HR+Q#?INYMT3-7FUQ:E,
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MB[S4X;1WNI>7AD-#)N/5D<8W@ AN=I]%B9'7'-*JIUMZ)[FA)U0MSX"-+K!
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M!(P'8P2,<E?L;<WF"2B,0HQB0^W2(0TI A(] ]GLTEV(&]I_;\9?M^'V>WV
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M2&FJ PG ?T9-A.2,!VW!.01W[@^BYD.M]%U&I*K1L&K]+SZOH:1M?6Z4AO\
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MM)!G:$44+1HB=CT(LO>A>0!\6/A/8S()CKW6IF VB4VRDZ@;S[H?]D.X#D\
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M &,XP!Z+RF+5:Q<'786V@%U=%T'7,4=.+@Z !K1"ZL$?M)BVM:.F9"S#6C&
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MW+&2,G P#Y=_HSW(5B6%"Z;BL"W-ZYP&0K5 0(U*P25 F-6KU(4I(SQ$(D9
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MWT=,HN3.HR5=7++H[3MT*L.P$DU9MQ";0YP925R=AEL00!*X:"!P00"3D_?
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M$FN'GGHRWE#S>%W\W5-^SBNIY8;7#B#4[TZ"0'R>VE+)'8G'TA5ER,U"5X4
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M&R#I>L)2Q(DU\ 3!QGZ\?7^CNI-X4)A$PB81,(F$3"+&9I&AS*)22*%R.31
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D$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g209588g25s25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g25s25.jpg
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M 0$! 0$! 0'_P  1" #, 44# 1$  A$! Q$!_\0 'P !  (# 0$! 0$!
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M\6JX'0H+G39N_P!!C'!(@P2).R;)74?]95-/A4]>F]%9+WY."2MIT0J?6_\
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MD;P*<N.B>(3U%Y#W@!O<C[\;QS%_I&\"G+CHGB$]1>0]X ;W(^_&\<Q?Z1O
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ML88<-U#^<AT0EH:*4J"6DU-"!3)2@!U_PP]/H-'MH))8]";"@T7G$9G<K5<
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M GJ.](G\/58_#J'VN,;^D[O'Q2@W#@$]1WI$_AZK'X=0^UQC?TG=X^*4&X<
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MY=?'2E!L KPJK5IQ.RH2>K,UPY9U(K4Y$#K5Z2ZANLB:5?*(7.U+0FIP_61
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M>]A]/#R-0UXE69&,S)0%/*LE_D!"P))2;>?HN(E'Z[3DT^D:\.#%</CZ@*_
MC?M)-!5>I7"Q5'SR(1:>#3T3FL>#RJ,%W/BE !Y@V*"2&K,DD0:ZO&+M-5NO
MAN^:-G:.%$]NS<-TE=?!NGKG&\ %H!TH%H)(<2-:E>,=<P_K>INEJ2I6JZ_D
M\#+JYH4E/94  4H0'A0*_2AJ!N38Z3DFY?<W8_K(BFQ@B^=B) 4?Z^2N?.CN
M*NEVBN Q#( [#LW9Z[:[%M)ADDDY#%37,XORZ;*;<NU6FZ;=?L;/,6Q2;7?*
M:]>2RS&DD-Q*)]+CRS ,:C4^ZA0-.NH>/?P(/&WN9[%&="&IVN<$'%D%G^[]
MBVA0E:7IBJ2[KIGL%=2!NKL)^2GY#L:--2ZFC2:YDY?F ^9 6#AW\I %<UK+
M)(0G9\F_F[1&QZGA *@FD!:!!J5/X>I@9R_B9^:#!3Y5W;[OL"R!K:4#&&HY
MM8=62!E$-Y;*O%-3GF,CNW#+[RWO],UI0;B:U_W:Y@'9V9:K!CM:=:\?LJ*W
M8+BK#=6.-P->F82:GS[*D@TN488L"[)LQB[=!:,HQT'U'6K'")%ZY/M92UK7
MIJ7$0X0X3E#;4N =D?5GD<ZU)&X$U[-FU"64()Z\AEED!7>6C9J3F<E\4XQU
MFR::TH9?DNHIRR3;B@DYVL()TTM1@$UM:W2 ?EYQ".PP%YJ6:!1(B[E81)'P
MT@4;O(Z8P >.X\3BKV33\V6NM*G/<3ZJC(UT]:M64/Z=]!45R?0"N^K00/7G
MIL8N7^4Z<VC7[N<)N0T(='JQ#%H_&8[4A<2MI$Y>.@M]G)B^<X2-#8Q/P$=+
M7+4SP-*@Y@)'9[H$>!C\RC@ZOW5&.HUIEN.FN?7_ (4(AT.8)H3M&HJT =1-
M#KF-@*Z0ZMH+)I3*JX+.:Y>6]5@B#7$),0?2.CK!!BK=D+FLU*BL>7U.2G->
MZV+'HL)"V:#PV'2),N +3$:3:(L45'4NB.3NRHH=,\SU9?>Y8M-*YT)(STRS
MJ :&E<M=@(ST/*@(9\H='X.JH^=6U&41PI.*0NN:];4/-20!\ Z<*D7KO8B>
MMI6R9&: R2ZR-K!;3D,IMV;%6!4'$$FDF9PG623$KC^8#:.H;,A2E:FE=1VK
M,X"=A.I)K0_F(-: #2A! 'K)"UEIC_E19:*M6%=N3% '\=N,*PD%=XJP:?52
MA0.83&NRD%,$6VQ#0M=+FUJ^J)RB58#E([KTY2P\R<Q4E.DI"8'&<CUZ=6=<
MO=U]:#D]<JY:URJ:4]5*DC//:%UUTA1'J!@[TZ(M$[-S<)+ 2<F LIPWK[#N
M)2LO=ER/7((8\B 02:7:NZ^>U\1<MI,^D.K);LDQ3T=MN2'8K0X:UI0UKOKQ
MTSW+!Y::4 V9BHRH-1I6M1LT7<W,U@G"*=1S_-^?]H5_W4^:7_J/J^ 6YGZ1
MZ_B5R#OT-Q-_)NH@S);DNJ81WJ@'RP+:<"D.*6V$+1Z2 2$:$1F/3<33 F[
M,:K@22=Z5J#;VLH.C#]P],9;OC!<V_)XK/%ID,M#GXTSVY*]Z=I<=4",W=9F
M4ULB7V3+&\SG=@6%O$<2B1F!\1B\##IJLX%$8'#10T+$8;'Q#$='XF(;**-7
M9@AH^/F#)5^0FOJR'Q^>WX*Y>%$X1<G#>D.(!)X<G82P[2%;KO+AD,%BS=Y
MEXI4%@7RME_9UF5XU(U\]+KR\Z<='9 @A81J>Q$24E<JT&15J,-.!N"M>H;/
M=E3L4)DGR?U.S1S*V<QE-GR6!R=]<Y]O5KTS$V,/BLVZ@ )Z/VK/8R5!0H38
MZ<E/H2Z:/V*)N?&XU&2\N*OXO'@^[*.: R5[-F?9H/<%OT^CI%LTD#P?U&]2
M NPIC+GDLG%KC3=3M)1-?*J[ 5<C'Y%$=*?S2RP,3$HK'4P.S"J1YX&8'N)"
M,.-C1V2O31*]0TIM[=ZZ:KZ"QFKX%"*SA3#85#:[B$:@L2%[.7+S8;&8B&9
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M#)":]78JXFW1'")=1M3T"/LZVX1#ZGD8:5HO8ZI59TG89L)YU>I+VP)LRJK
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M3= 4W&:+:+:;[.U546"#ETCB^(QC,9-6F@;A_,7%QH T"M2=E%DUCG.+0*$
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ME, KI8'H%WRY5$KAHSMEP\:C]T]KS5V('$RE(-:,PYPG8L@,@'#*E=0$YRW
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M!F]W$>">HCOWDZ_#.?SKCGT3H,_Y>*<@S>[B/!/41W[R=?AG/YUQSZ)T&?\
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M.+O%.:LZ3O=X)[.E7O53^$MOS_C\1B>C9Q=XIS5G2=[O!/9TJ]ZJ?PEM^?\
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M_ 1S[KCDCZ2%[0)B_J[@GSI-/H39_P !'/NN.2/I(7M F+^KN"?.DT^A-G_
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MOOTZU:-R=;5,43O/]Y\G+F8NM"PP'*Y$D('-HVW,$:^4M3<4Q,FS0=F3*,(
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M0"4A\L"F1LP3\;1JY)AUSTKKN!IUZG+U+N/ISOYMU#!+%D+"+KQH5"[9E%>
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=QX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g209588g26a95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g26a95.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( )\"7@,!$0 "$0$#$0'_Q  >  $
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M<RSNRE+5=6)G$5P)PFBHI6Z_S7\R5I?==I_<?<IK! @T7!AHU'!;$)'HZ*'
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M@P'13F4G<BJ<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(HNK<;@>4M=3
ME(7ZSM%^2\ZE!6T+]<94A\+:Y+*/FY(AM/E5<M/0]YTY3&.7GH6(_L-T2C:+
MIW3FX--<YXN#I4&?AT4T<?"I1Y%5I_SD+CIPB<(G")PB<(G"+S#[6]\Y3UC[
M("ZW*1&/N:=)]?GDU)V(Z1)Y=02U#DGE$8K).7*HF4&6E;RN01X?"G2Z8YH\
M82F4@5G,A9L%\HY)WZ.CSK\KKPF,).2:C:KET/RE9UIQ.@'Q5Z$M;K$%CS*1
MW; 8-,=-1M?S'L6POCU6.7F:3=N*S7!.3E&[?52-L92B\%/BJM]+^(TX\$\X
MX*BO%6O,L:V[N]B'J-@Q5S6=;UQ:6_=JLNJ->BY&\+3L)#@]@5!$;<VE-E*Q
M:1A$9A(&08B;T5#0PY' R!-P+"-SQ= :XD1N5OIP<]>A+^COWT;ZW<ZGW22[
M#]=ZMN,T%8QX[,@+A20!Q:SAP)9R$(8)1H]ZG5>>-WL&<%PSUT(P[V5=:#5V
MNCE9=;7=;>HMAN$3A$X1.$3A$X1-Z6K"[T=H]:D29S ,)43,CV+UV49IMB>N
MJK'5WHH*?,%MM\-7CE'R%%=TO)5SMY'EXUVU[N16HGUE8I[&V?F+V6Q40X,*
M^>NG;AXT\<%X[>EV1$.GS(&N.V&JLLAJK(%:$@^+VKL-92WD##RVULG<SJ"@
MXIF.AH=^^BW#+J*#EZX#X-0D1#MEH.7SUBC333%&R<FH!%/^3[Z=_,>!_;DQ
M_B/GE.W'JE^5<9ZK+>I+P/\ @YZBOD'+_7YW^)KQJ\)U1M4T=.JP%53#F4.'
MG8D8(%FS)X5>:O'C8QHV07WV*OWZFFR:&<IXU2W3TSC/CVUSM^?GTWJ#6LM#
M:N4S^(M#,WLS?0DQA7,.V]=P[LNG3R&:;;8 AW+D$-- &K0:.@@+XE_2IL%9
M&P5H+*0ED9*XDL-'R>-B8QTX?QC\/W[J-#IV\:,9$1#3)9=G) 8:99(O()O7
MMUTG_FGT+_9X'_\ NMSY6U4OZP[7_MJ*_P#*ON[4*_J@U/?^K<%[VUM'SP%>
MV$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%%5VM$GU8R5JL/:E$U=@GE,7
ML,E%A-E_(D0A37SD0ACT=)2WFMM,+:9&O$<#U$]"KWS@]B[2WHQ_.G.H</R)
MSZ!BI5Y%4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1<5/\C?]'^1M^G3
M93'Z,_ITUSC;?'_\-<XVV_1C/CSPBB^D&J;&GZS9I,&PI-M"8ZCH-9PZ3U\T
M8ZIC6^N&C>$31Z2EL620\7F] LB?O"['&OF7SA5?7;?-.)Z:^ZBC. ^-W?O2
MY2ER*IPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBBNM&B;8K;FZ;!JQR\
MM1^[54;0R41'8BIM#(2CE^Z=21Z\;35UMJAHUVF<5T8Q=ZDT1#-F6I4$8<.:
M<W!IKG/>B@NKP\=P4J<BJT_YR%QTX1.$3A$X1.$3A%!MD=;:5MU_,R5CP=K*
MG-@U.M2,MU?DC6C4I6RQMW(_4>K%J2;LV#QN=>K%6,B&H-)*/>ZMEV)=ONS:
M91(LNBE35M"0D3C\<A@%HP@X&-1F,+.6"10L-#Q 2P!QM#UZ4P\-.UQ0L8P:
MH/WK]P_VPV345<J*XRIDBCB7]4:-F[*PFAN+%$E[-LF+W#)30.:3:-29M:$+
MC\9BT6F\4DT?D(T[!S@4%#P#!JO#WX1+=)LZRY17W*E=GLIGS_OZ2BEFO*^A
MU40>*UM7P-M&H5"@C&/1H&U5=.$APH<CA%NCL[?+NG[YQMC&5G9 @[=D"#M1
M=Z_=.7:ZRZE3!9EPB<(G")PB<(G"*4:L_P#5"?\ N&G_ ,A/FMYF\_P6QWG\
MWQ4W\UK8OGZ\,C_G+IG_ (&/_P#/T^?8OZ,O\QVH_:L%_NC:_.C]-C^E-B/V
M!,/\Q97K%TG_ )I]"_V>!_\ [K<^>-5+^L.U_P"VHK_RKZ_U"OZH-3W_ *MP
M7O;6T?/ 5[83A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4=6R,7,5^>&MFZ
M;M9QL(\ANKF:XT4\R<&.-O'FN]TYC_(T2V4QZHWQCRM<>L?&)].QF@TY_=O\
MZC0J#\:_"]2+R*IPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBX[X\>FV/
M]NNV/];'Z<9_TZ?RL?\ ^?Y7^S\_BX11[48Q<-5\ $NFZ;1P.B8-FLU1]M,(
MME$&"*>Z"6+&WWGF$TLZYTTQ+]]I#C7&,%,^EX4Y3B>$][KN)08#\_C>I$Y%
M4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1176GF/6MN>9\QY7RJ/O2/,
MXG&-\+^QD(\?I/MEG++*_FO-?G@?B@_F/,^B8]H/:/QTYN#>W]'QOYEB*?6I
M^L=.-VGX7*5.19+3_G(7'3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%*
M-6?^J$_]PT_^0GS6\S>?X+8[S^;XJ;^:UL7S]>&1_P Y=,_\#'_^?I\^Q?T9
M?YCM1^U8+_=&U^='Z;']*;$?L"8?YBRO6+I/_-/H7^SP/_\ =;GSQJI?UAVO
M_;45_P"5?7^H5_5!J>_]6X+WMK:/G@*]L)PB<(G")PB<(G"*U'3@B,!#$DD!
M%H' QX40.&RS];5NQ%B!+19^2(O5]_%HBT8LFZSERMMG&J:*6^^WYM<\(OG%
MHKPP-PSO7&UG)#*P3E7;#K9*X8\GU536J&+#HUV2G!F$C19)]9XJ.,I%)X 6
M% 14JM^-+NX.^)61$6P9\LJKMKDLRS3_ +P.&(%<Q-QW]];#F/"66%IUBMZ:
M@6Y%_,5.S=JU[6%X,Z?E1[K;'*.;^$/>=2HU/3-HC$D:O*'X/6NZE@[AR$Q:
M+R5J!TD3QKM'GZJVTOY^:O1W"F3?FP!I6\_5K33?AO>97ZD.Y_;NR3/1G"C>
MDRL4O83W%BYLKKK(01*TK$Z]$+:!P*4M]F8^1B:ZJZ:"H-"YUN6CJD]*%LS<
MFD,#C L9&:3"I07XX CSTQW[][!21!>]5H07P=+_ +97='X1/;-C=_V/3DB#
M1DUFJZ_<+M._DHZE1UZT/GV4H5CD:C@? 4P])&VQ!X[9"'2Y-PBZ>+O$2N35
MJ@_5!TG[&4="B)MX9-!]-Z>K9C2<0?S6P+4(4O,!XR[9*7$Q:8[]A[2ZSQ62
MPN5C: <Q6P:JE,^JD\^:2DX:K*7*1Y$JN%KJ0%HT=#M"9.)K=0&M!HJ:WU!&
M&>NFBU\KGPV=CCZ:KJR;.JB(2Z;VG676 ^/C<*F)T-50&0VO479VXY:LYF(N
MKK$F@1RI':"V%(Q(E'94C')L0]FRLO;1B/R>R,%2Q0D5P)T5N( Q(%]>*^_
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M/.)>Q0D\C=RX/' P*#2(A,WSF,U0,@F@.G?PW[A?FP]U>!3PT:!/<$/ 4H+
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M(BXR\UDBPQU(\.]EM=O2-3[@*'<&\+9WP47$C%G_ )_=@UV2;&S'[A&^JO\
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MF ARY_D[^7S?4]L^90S#2V!;:F$[M5(IC+(J$;9B(V%LI:EN>"60#IU%1T)
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M@\*6],RM#XNKDA@[A_E6/B5/3L2C+;:2X>>6TSZ3B1;,F>QW"WEX+9:-LO\
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M<,;J5.!4UPRU/"RRP\WCA<98$01/V/48*TY"^HRNV#.DW4@O.7QVQ@E /WK
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M-Z,#3G=EL"58Z,8^/7<4YN#373Q<"@S\)S4_?PJ3N15?(MV/_G#WS_;/:/\
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M/I[A:0;O7*EI2"2!P,89)CXT6R@?60AY]VL]=-\Q\:DFT5>$<X6V3TR+RA(
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M4X1;^>#0_G71?_A>:_\ (E^:GWV#PA9,?:'G]Q7TJ<XBW+PK\,__ /5]<_\
M=[9__)6_/K/]&#_5VV_QV=_V9XO@+]-__7ZFG_16O_V[,KTBZ*_S1Z)_X+T_
MYH2YZ/U6/ZQK7?M5O_P7*^G-0#^INP'[$_\ 61:R=(I)GP"=3X[;CZ$1F*R&
MRTWVK>/0U40"C, D)X8J1<O"X(B0WU1$A-B)%=9RICSN7&R*:2.$T=/&(AJ
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M<B6J5>M $1EQJ P9-G (V'DL8K.S?:D<"3)]N&A>2-1VZ$NEBLE?-(2]>RO
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M_A8ZNK!K))9);[-C(T>(MH0W@%QM5I7"TI5VBKXDT(V\"VL.VI;:X)Q0Y0W
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MW1K%SHDX'E$"K=*?)LW88TRU+X$:M'7ICK) 6%+O6HMRR:L&BI0:_P"37*W
M7U9&(-032[\U:85S@\PKT:.*A,-TQUT7N$.W*)SH'%%"DZUKH$T+##+[)&2.
M(N1E+/SZXMNXT'B]V@QRB[>JZ*J-E,I92:.\J>;US:;R3A6[*QS5I\5 *\8'
M'7H5U(=7GR0]N;#SH,; DF%0E Y#0268+/F5MRJ30]DHJP>:ZKLE I:*$MG:
M2F5,NFBC59'9-17=!)EWTH:_6K>/[(!YZA2G?OP'B4E/^KD#$PN0/#DI(CY)
M#*RN*2OW#-!9V,/R*O;Z6J=@IHWRV558B%6FS/3=KJHFZ4?/FS[=QHT:/T5,
M-<)(H,2S0'060T173?WQ65*5KF!/GRJ<7?>5*?Z?:N9.4%B)F!C;HC.)= H/
M%'R4@.+&#\0@D7FSANK(DA;9LR9/VLAU:)OR#9#9N_\ 1TLMEFBB[QG0\NO!
M- &B;L"=&\-'[Y2[A)%."G33O=WN^G7M"BU,QJ3B8J$6AE1Y9^TSA9?4I/)I
M4 6PS2#HAKA!M'P6KI_A%(@Z](U;*DF+;5LJW0>.VP/*4J"2:DTS -%GSX<*
M$?#'217OPA0K377TC<H&6EA,H&,B,9W321B[=B[/2<GE0:1(:OD@ K?<VJ&U
M48Z#5'P48>=I/W:.%1FC;51SK6G@9I=4$5K6F)[G@KH0"OY=^_G4_@.LJ)*+
MYVALS(Q.=3 9UFB; (W*%=@1UK?D,4D9W$F((#VR^H]XJ-6(*!],.AXY$*\9
M;IF5W8=77$O+[[P"V?1-!3S9SC7>!2GO9YQ56P7UDFA%VM40^\AZL+?#FUB,
M8NT>$?/&3VYM:&NE<UHH6;[+R$4B-T?N56^2!=2,+B78IH_6=;#V[7!]K)^M
M0BM<U*XTI0UIP[R4W[OWBM/-PT(-,RUWLFMFL0A5<R-#1TV(&"5DPJ5,W:;Y
M#.LLKB2-D'CUNS)MF9(:@[!22.HJC7[5%TU)LB6RR3;9;T)KFRU4D9J,M#@:
M&!I==WK2J?F.+GS]\T*\S46_G@T/YUT7_P"%YK_R)?FI]]@\(63'VAY_<5]*
MG.(MR<(G"+4Z2R\Y7W63LG/HRNBUDD(:=J9?'W+AND\;MSD:-6(:$KKM%]=D
M'2*+]DW45;K:[)+Z:[)*:YTVVQGM)M_*(;]ERC_+85='9Z^$C!IGUH?\\CUX
MEG.W/A9RG71S,JD@]P6 ?.L0TQK*;ONN06*O9!(U.M0.>'ZU+09E7LY=.:J<
M7.16C%>3E*/1)E,QC<D(6[#"?0P<RE?5KR#ZE;\*T..%:5XJ8$\&<93*)%X3
MJ#2:W9)7<<NNRY6$G?>Q>,/)_#C&@&,5[*KYZ,YJE.N$D ) #,$QM!.[QEE:
MA\Q&P7NDIAQB)C8\0?-ST/+EB,FZMPNP.)H=-*7T&]6N^IDB5H>%<.DJJ(G&
MIT*$;-.I"4L&L*4%[ZS(=:O=&]JLN4](WLKA$4DD8DE;]31]0V]+18^)01$!
M*EDC+V(QR.D"<*5=^A7ZM,+ZM9\* $;Q!-1OA8-T^LWPG$8G72BOK3$7I/*^
M*0)H#OU]8M9;Q^2B9QZ]NQ.;RF:SDI5Q42?#1I<77C2..\7#49XH%W$EXQ#+
MV:2MP7"$(9OH<*4T'@P-=-0=\A2#V'O+PI4=LWLVPIF R\NC&@%_;U9&-*2#
M&*R1AD=H 7(>OMBPNT-E-B%C7).;_46A4JJ-T0>HL(VX*JJ0V/(1X?*9.[]^
M_P $ 9NJ<2*TX;\UU!SUQ"E"X-^]A'I/W-C:<IM=6ZX!>F0E)6-7L " +2GU
M)C#5/RMZ:B\9C(K469=J""]D1)FK&P^A,R/ X8HIOI!EP[?%B*5%U1G!) T8
MBG#S*'Y3V%\)V0/R&$P>O;,'K@Y1>X_,Z,]?F6H5Y&'W>'JK&^O!L(Y?#&H>
M0/FW3B9W=*9.S8^3H@0"E5Y%AI)(BZ:C2RHS2M0?LF@/]TD@^< >>Y61&U?"
MRQ=@Y0DV+&DD<*$U&4KFX/KI"B=B5?!XCW"LRIG4SK:# P:3&Q9W.>NH*O;6
M>QQ_'):W3Q)B$LA,)R&;M(BN4NK=3"MY-*T%U=XUSBN>BVZZ5RWOM8MD>LNT
M.I6OX'&NO54%645VK*+QU.R;*F=@=A11TQ)"_C+E(M+0%9PJD97*ZWCI9NPB
M<IL-^)>8PU1;,$R&@%UYJ;]Z@S<)-]3@M&AUQ^$S,$2"MI5E>)9C678@W(AT
MMKBJ$V1=.%*]8.]:&PF"5T7@M?LI(2CTY$4"R##I(=[$U0;E$WBB*%V2LB2>
M#(>5HS0W@&G'>S2N.:IS&Z\#/W51V \+F5-=4FTABTQ?C)><'.[A=37KX5@?
MJI^7N6,-Y95TOU'4]MZ("K?K\1</X];^%Z-CDTLO62%6!*5,(XPJLN0AFIIF
MPOQNQQTZ*TNWRO>6L+$!6U7\3LF,-S+6/3,.W.!T9 ,6#&,#W>=_1]W@U?;=
M1MLMIKA9'^6HFLW42<(J*(JZ;[%A@L[X1.$45T5_F1IS^RNO?^D1'.UGO\^3
MG]JS'_>WRZ&RO]&+.?L&3_Y?#KON-^H,KF0ODBJX7=#8-Y)-M*X["%FWG3XI
M'/D2>6,B( 9Y_"F6^V'[-;+[178<T\V^=ME4^K&.G&ZE<V]W&*[TX'IIGTJ3
M>15.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7'?/BTWSX_)\6NV?*\>N
MOB\6,_G\>V,ZX\7Z?'MC.N/TYQG'"*-J:?*$ZGKH@J37-*O(<!<*%G,JC\Y<
M$-U!Z&VSI:8Q-D.C4G56SGRMS@)BT%D=LY<LT$T5-=<4XGAT4YLR@P'2#SC%
M27R*IPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBC*NGZCXG:FBA1<E@?9
MKY@FFM*X[)]12:<1AJ^!:#0 R9N(@@ELYV=8BDDW?2)NH\4-+O=QAP4@WIS<
M&BF<\?#T*#/PZ:YAQ<'2I-Y%5\BW8_\ G#WS_;/:/_7!WG.8^PS_ (6?<%H:
MQ/"?>H8YDHL[CMG3^)8B^(U*2@7V+D!.51?+!1-'8,?--!H\L1;;^:SOLH18
MB!S-VBOLJV7;-L(;HY346U4Q++)K45J*'&\#!6I%-Z]8IDL3R5R=U?.4S&2&
M2V"2"NS=XF3])],P^170RGNBYU=?]X351SILFKC&Z>=<ZX\65+J9L%%+JO8Z
M[UI,SEZMB&MS[ 4_"-G.4QWHF!A5[J3*-EA&&. [KUF431*D5G3!9P^*MVQ-
MTJJ_;-W">.0S2F2*?E3''"Y*GO=WP6+QRRC@4E/2)'921*63&)-')=L3=K;.
MBBDA<H&4C"[W;"RJI$=+!P>3:J*XWR\=CO,+[:Z.5%-19!R<V2010:,W!1*X
M[^/?A67+=EKR<$!Q5>PRRS\6Z(O6JZK0.IY;TR#WC1EX_2V&Y1*NC()3(XNX
M*)O%BB.J>S_=PJBDIHR&='OTU'%FT*U/OY\?.=.*P:-69.X>BR;QF2O@Z(Z2
M:2]BFTU;8U;25,8Z#:%T\*(*>)SJ+>NF6-<^-'S2VW_9>5C7;%++)Q&:GFT7
M*5I[^)7X#>=M1C1NF"FY8>FTCPF+-4T]&*J;8(!+O3X-LW3<-%M$7 8R2?D1
M1)/74F/<NU]VCQ'SFV.0L,G$9R?.;CS7)4Z>^/OO7'%X6MYU\KM-"2FQ(/+8
M^_U70'+HNPTZD*LLEC!=!9DH@HD8DBNQM;;*?G6Y'"3AFHVW11RFR&=&%-(P
M%!S7>]6I^'Q]]ZS=3M+;GL:K%VTB=M")"52Z4'98CLW]=F%)=&8S%'+7*FS3
M.!>[,3'=FS<D)W9D<MBQ!IE?5!9356:VS6M+J 4T4[X<!S)6ZG#STZ/>L0&W
MW<(=)X@-GIIJD^$@PBVNN&>_FF$9C^8J!RPV5:J;"WXN.;;A6I<9EH6U'[J-
M]GVVF^^-KD,Z!GYS7WW\-ZG?B5EAELV+7C%^.ADK( 61%TF_61;:-%O,$T6K
MABB7&*.VSA4,:29.G#5,R'48E-&ZNR.KO">-=<"RRU>16E1GP.(-,?.J"1AW
MZ/,KBQN^V!B"S9A.##1)9G V/C0RUT600K!/1& ;LG&&WI#!W%D=,(BW[%5N
M_P!$ME$E7*J:JNN[(9T#/SX^8Z,$J=.CFPXE=<=BKHP;7D'MT_V(.!C(0JGN
M/"*"O0!I-<T/22 *#-@*"K$TZ=&&CM :F\;EG;HDDXT>N5UU&0Q^J,:Y\>_>
M]2I[\-??>L9FED&IL%AX0GY>R453DSM=XX=K/G\@DLQD3N0224%7+C'E[DB6
M5!@Y3&,YU]$"LMU-U7*CE=4&0*TST\P H!YDK\>,J.^9(M_/!H?SKHO_ ,+S
M7_D2_-3[[!X0LF/M#S^XKZ5.<1;DX1.$6I$N*F@75WLT;C>ZB4A#CNUQ4"JD
MT1?JIFAY>Q78O=)@Y0=-WJFCY%#;1HX;.47.V,(JH+)[[)[=I-OY1#?LN4?Y
M;"KH[/?R2,KAL]:&O+D>O)V/>%)[-Q$.7CR5!"++.UW1,O+XJP6'GHZ[=U*R
MZFQ&Z -\3#8<&6B>E.W'/R3JK(T%B,9P:;G70]("2DAMN>AX#JUWU!7&@)\W
MVJ8DC 4/!HQ68R3PJEM@Y3UOB452HVY];1M.+0R43NNX9:X. R*(S'L+ Z1V
ME]=/[%E<8>J9KUC+B<FFFD"1[#AL;1[&A<Y!P!'>2#2H9K6M10$\%&216[.;
MLWGOI"E1^$J[9#8C#3MC%H&7-R6M>NHRR+6E\4D82AJ"D\XOCOG&9W+K)A\4
M2&G&#Z-LJ-K6KCK3691\<E*Y="5RN\=9ID')@H1HKGN..;IKP+9*IO"6=E9I
M,*D*3VB8A6E4R604'%K&8E1MD9G@/:Y^N%HW03FP@B^1&,!\3AQ>MV;;0<?B
M6YTN!F3)L4]E9 &V1,DH+_/3?I2@%UY.%Q_.8O"%>$/D?5>$T7-J4CL9M!E;
M@.36 /P4&$7(Z506,-Z_(Y:1DYB7PED,.'@D[T-B]&R<]EZ@@05,AZIDP #,
M3$4(!6M;J4'!73=T<(6O\G\)IVHBKB=.B=/U<SBJTDNX)#)4Y#V;ZNJ^-4OX
M1F'=*#5J77A$CON<AS6N)FI?A5I$_9K=J!AAE38T@!**F8N3)&FIH#YRS44X
M#0'?4A5MW:O:N_!WA>W<_ .;R6C_ &=["C+>;QB,2%.2KT&U[<WA5D//5/%D
M&;,T[0AH).KWXML;%D";ZK1!AZ0U>2#?0EF#?TGWW(1]:F&&.F@X?C?<M?;"
M\)5W!Z^L9:5L2J(V]D#?L'%(=/HSHD\D*$43WZ2]/K<D$#I &0EM9.IANXLN
MT[$",&XR56-9Y<L$(.8%4=C+O",;AU5H+J'$$CC: K2M] - WQB<O4\))V)@
MMAJ0'%<#Y U7[#W9'8^RGC*:KSR\Q"'A"[.ZW,JRH-Q' HL"*D-/5( "VX<W
ME;"2(Y@IB-)O=F09"06"Q#I]_P 5*"E=[B^J"">$W#]U=N>CO<"^^PD\*QRX
MZZA,2#%Z3!7-"G</83-@\$:NKKN6H"4/EBTI>/6A<LLTK,+-6CL2B#P.:R94
M,X'E$V;20$"A%.:HSWBN&C-PKTWX43A$X1.$45T5_F1IS^RNO?\ I$1SM9[_
M #Y.?VK,?][?+H;*_P!&+.?L&3_Y?#JIN#9YK74AV8;$]'>-@_FM@ZL"1)8_
M\>%X4]'4L_7>#Z^-+R\+>N]<YV;Y5U%_^,Y'YYU8QZ:_"]=Z</W?&Y27R*IP
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBX[^/R-_%X_'Y.WB\GR/*\?BS
M_D^<_D>/_9Y?\CQ_Y7YO'PBCBG<N]JIKO9_L2W>YAP#+K8NK!%B>R_JY#SF7
MJU8:ZUVJXSMX_+WA>N(YM^;(O'HN4^4XGAW_ (W\=Z@P'Y?"[B4D\BJ<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(HTKW+S).T?2]B>VF++>X9^L58$II
MJSQ$8=Y&HS$(UU>I#,+>?\RE8/E3W"^7.[[;,?WC?BIS<&_I.GX7<Z@S\.]H
M&CXWJ2^15>'EK^##N>>VE94Y%SBL&@R9S^8RP<U?OI7H^;,9%(B)AHW>Z-XH
MX;ZNT6[Q--SJ@X71U6UWPDLKIC7?;D,O@ !DFX 8C,%K+!))NO)T]"P#\DQ>
MWS@5+^T)C_!_+KX_5/&%,@Z1S]"?DF+V^<"I?VA,?X/XU\?JGC"9!TCGZ$_)
M,7M\X%2_M"8_P?QKX_5/&$R#I'/T)^28O;YP*E_:$Q_@_C7Q^J>,)D'2.?H3
M\DQ>WS@5+^T)C_!_&OC]4\83(.D<_0GY)B]OG J7]H3'^#^-?'ZIXPF0=(Y^
MA/R3%[?.!4O[0F/\'\:^/U3QA,@Z1S]"?DF+V^<"I?VA,?X/XU\?JGC"9!TC
MGZ$_),7M\X%2_M"8_P '\:^/U3QA,@Z1S]"?DF+V^<"I?VA,?X/XU\?JGC"9
M!TCGZ$_),7M\X%2_M"8_P?QKX_5/&$R#I'/T)^28O;YP*E_:$Q_@_C7Q^J>,
M)D'2.?H3\DQ>WS@5+^T)C_!_&OC]4\83(.D<_0GY)B]OG J7]H3'^#^-?'ZI
MXPF0=(Y^A/R3%[?.!4O[0F/\'\:^/U3QA,@Z1S]"?DF+V^<"I?VA,?X/XU\?
MJGC"9!TCGZ%LSU'Z!6GU_NH/94JEL +AQP>0#E64?=R)8ENL6'*,T-T]"4=&
MM<IIJ;XV6SLZUVQIC/D:;[?FY@V]#;-*$7@JLL$$&[N.!>M/-*V)PB<(H0!C
M+:B'KX8'BU='A3V83*2,"1.R9+'R&[:52<I(TV[P2UJ>1-FJ[+UGEGOE$R]3
M7\QAQKLEYWS"7=OGDHB]8>OHN8N'K$'!PSQVZEL-$.PU"PSJ'+3#YN;0S33+
M>MY8RG+!9RLFAIE'QB%<6@EWA3B'@)/%.'LQF4:Z?/IS&PCXL1\<_C P\AW<
M@C&';;K7];.3$O0UD98+.5DLWSUO=OS?59]<4M_ SFG69)XQFO(T)^.KE>$6
MF\42+VBF'9=/6]V_-]5GUQ2W\#.-9DGC&:\C0GXZGA%IO%$B]HIAV73UO=OS
M?59]<4M_ SC69)XQFO(T)^.IX1:;Q1(O:*8=EU3O'=PD&CI@_K2HWS!\V79O
M63RVY0Y:/&CE+9%RU=-EJ)W1<-G".^Z2Z"NFZ2J6^R:FNVFV<9:S)/&,UY&A
M/QU/"+3>*)%[13#LNOQDZN$:S:#AU9U&P'L&R#)BQ96U*&K-DS:I:(-FC1LA
M1*:#=LW03T1001TT212TT33TUTUQC#69)XQFO(T)^.IX1:;Q1(O:*8=EU4^M
M[M^;ZK/KBEOX&<:S)/&,UY&A/QU/"+3>*)%[13#LNGK>[?F^JSZXI;^!G&LR
M3QC->1H3\=3PBTWBB1>T4P[+IZWNWYOJL^N*6_@9QK,D\8S7D:$_'4\(M-XH
MD7M%,.RZ>M[M^;ZK/KBEOX&<:S)/&,UY&A/QU/"+3>*)%[13#LNGK>[?F^JS
MZXI;^!G&LR3QC->1H3\=3PBTWBB1>T4P[+IZWNWYOJL^N*6_@9QK,D\8S7D:
M$_'4\(M-XHD7M%,.RZ>M[M^;ZK/KBEOX&<:S)/&,UY&A/QU/"+3>*)%[13#L
MNGK>[?F^JSZXI;^!G&LR3QC->1H3\=3PBTWBB1>T4P[+IZWNWYOJL^N*6_@9
MQK,D\8S7D:$_'4\(M-XHD7M%,.RZO];QQ[#J[@41)+-7!&*PN+1Q^NQW549+
MO08-B,=+,U'"+9?=JHNU4W;[K-T%=DMM-E$4M\[::\>91+$9,8^,=!MEW%1L
M5$NV7@ ;98?OWCU@-AEIID-AEH!H,M- &M&B+URI+!/9;)Y3+GS3MM] 2R @
MGK;HM%TT]A85TX>-.RVRPV7;3;LE@M,,-%D@M,LFH%ANE+"]:2-+9FJ0QML$
M\;1&/Q.4J+>3(1.V/) S@@+B[[S><>=VR3?(9::Z9>L?.DFS-%3ABXC\Q[KU
MV36!_(\QN4I<BJ<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(N*F/'IOCQ
M>/QZ;8\7BUSX_P V?S>+;.-<^/\ V;9QKG]&<^+Q\(HRI1/"-15LGJT58ZZ0
MN/XU9K1^*Q15MKZM0SA)2-0=^4AX+?7&<8R*C1%Z&99_[!@Y6;Z:;YIQ/"=]
M08#@X/<I/Y%4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X11;6R6$BML^)
MHJTRK:3Y7.RD>B@+#S.T.A6,.TG$8(/G4D2WQKA+$AER8Z5J[H[BW(_0.*".
975.;@W])TX>:Y09^$Y@-&C'AQ4I<BJ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g209588g30a00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g30a00.jpg
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M 0$! 0$!_\  $0@!60)= P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
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M# ;H[(*87RJFUW226W3AJ%) );$6$&3I'FJ 2[9!SR]E72G.N-KWLWDI* B
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MSR\PO,WG=83A$X1.$3A$X1.$3A$X1>FAC_TDXK_QH./^FLCYP'_DU?\ %_\
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MGQAJ7*J+3-5P(+,$3"<?=.Q<%-1JH>FK$/B$UU%\)#EB,K680- 0#20U3&D
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ML8+R"1D-5F8 (.8*KD5VRZ>JB6VNF%,5UBA@QJJJ)%-(9RTFY$ 7*U32[EP
M+DY/RDDY!25H=:C,-+0EM6TUB?8<-8P$Y(HD4IW0Z;,;LHPHMI(V\B@[P2SF
M<6?!TVZSYRF6#IM=QJ2SQ%XIJR):,5-8+N#0Q .)A>S%V+VYPAI9F(J<.&<]
MQ .6BI*?7N_%=Y0FE1]OJ[PC*>LTT3K29[[Q'94:W,I:RC74+G(#*@AVU*IX
M*X:9W&N6[[7Q:K)J[7'1''3-N(3RF5,-1=J26O!CFKKU_P"JEM]AI&!&1F.&
MPT4/?=R*5GF8Q)MZZ9D8A#I!,G8EW)QXIT-T)O&L>7'M&>J^R^7[EMHKIHGG
M??65_$IH!<@D-P@C$Q(#M=G*HI)9LW8EV@$F>Q:CVK*R=(3I9>]?3C2N5'7L
M4Y_M$SVL)W>^XRS]GI*LL, MG7N\9:^WU?Y6]QC*'D]7'EYK%2^'$,7VN'Z7
M48L[%M6CJMO4[UCE-S0DI-PDACXEB*MJHJA69E<$<NU#-P%W0<*43RT:.$?C
M!:[7=4IC935UE+;7VB"^_CKC-58I+,2<-5793YE!22"0T$#_ .3MX2M1VC B
M%5V78=8EGK,D5KJ<2N"DB(["^![]_$CK\"\>,<.4T7.&;EPP46;8<(I+>COI
MZJ>F_FUQJDXJ15;$ >PAPA#$@Y$CHJ+RJ+TS^JE_KTJK_AFJ3][)^<?@?37_
M ,E?BM5?E_:/->9G.RRN^FO0P@W0!QN9]@:,KJ[)1#VTX!TI,S,A%G$1! -O
M(!(^52_(#>!PV3& ^J;T>!.GT%O([9:O%V>R^^$>/SA<45U4NQJ <.[0'<C4
MMR!6\%GJI%1_*7>;.68$N(/JN1VM26J_C>\R'UI/B$/3VTUVEH^'R!]%_%0W
MF,I9UD+4>L'WU6D>,@$=]'FVBQG_ +,3VV>YPCSKBI!8U '1P^MN4K+%G8MJ
MT:>*S3U)7/%3L=B\GJ*SXY)I?MY(G'3T!E8<[)]\[I)XTCH@@);D#6V5%D=/
M*-;N<^=5+7P\RFF,P5T$$BJD@7(J! YEX1B&<&;09Y:K9DWZEW)!8Q298E%)
M$XEMX/K(&@:K;1.4ZV4(?UH;8AB;,O%7 A(GEV2P_3)#FS)NX6R/TV7<:)8S
MKXY'Q*2:PX:C"]3C"<0<,7[.:II(:)+Q+P68C7R6@Y'%)/#CSV+3".G8E)1J
MR;<G'Y,(( 38U95--5-,@**-VK]FINBJFMKHX;I[;)*:*:XSKMKG.P00X((-
MB"X/:%E=XG?IRV6!F12%N)Y!5WPKLE5W6=5VCJ?]JK*;4B;.7"9 GC<5JM\
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M68)UCM.83:25^:"$*TDT9K";6N[&V."D49>N8Y!P#R0O-&H]V)^0V<$VS%=
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MO(BZ 9L_F#\6->Z@1[9PMNJZ5>ZI[ZHMW&4TU-T\Z<M55-(<D6) < F'C50
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M5#66(/\ M:I(:JDNU32)((M$.)E=R,NX_6&!6=UV*1(DS(E:FAW8)K.+IA%
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M8N!&:@9%W2ILGUB81L*08B)NGU+"=:"E=/Z^L$R^>%QJJ#5[)F$B2M434PT
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M83,-U:,/MY/.Y%_MKJ@UTY4_"JX ::0**:@2#]9(80 "SR7S[]U5CB8DXB"
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M;IJ6"OY&T<M26Z"R,A>DG*;!0=A@_?7Y9J/Q'I% JII 9BQIS+-(R(R;DF,
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ME5Q&'8!HW.S,(-(+8W0(R]8:VU5V1<YUM7PS56#:FK"?B!\Z)'-X!-V#P@J
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M577ZL78RQ0JI>H*6&IDJYZVU[<UC1C6EKMO 78-@2XA9S-[7<3LRNC\3 TC
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M7':2$3E\ND,U2(3^)305U3A?8JMJG,0;6.Y13@=:=;2L4ATGL5A.%6ISLO\
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M,+8BX@ZWRX=1#\D%=HN".R\L5M_K+8D6ZS=:(^&B]4=P)D(*=J[4B*J-C0L
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M("6&WQHQAJF]PY)K(MO5T\_GP-+/-)8@0;OIJ!FF(1>7;L50:]QV[JOXS/\
M'7SL8CI);O1I/6++U]II+ ZBR3I7%CFA7RN<,ZS3]MY%9)A=3;7=9#'M,^?\
MS#+8J;.[QR=K[*8H=C=K3[RYJ?/]J$ *G8K3-(7L4_D\)Q'=783"-'6ML_=N
M%\ZZU!G)+3[LW ^AX2#&WL?8952\/5\WYF'Z>*GBWM^[1,0F#%_??R4ZS[&(
MO)_$(%^$=QM]Y=2+>Z]90XB.J<4 IN/>?_RXD!3W^<L+,2]GGU8YA%777W#?
M_*\^I^8:;S3!:\G<:C=4%VO(?WNM>->W+>20>CY'BA>P8?%[S(I#4A!F!:,S
M-8[!I#L&S(;49X**8C$<(90^0'$=5'F7 U5)QZ6F=O)AAFH8J3A#P;\M6S6:
MB]+Y'U_HK)-=P&\?A-T2[- ]ARNM*6*C6Z@ 1 -'<AL??8ND&^[ZT89*:8D<
M,USO\AL8V5:9P.TW<>W_ #>3@4N1Q4R'DV_=H500*7T \!ZJ]E^QB(B=69!\
MU'<3_:M:><6]O)1\1U7B\P3;LT'?V#"R7O\ 7)BPU<+^@B RBWUW<)J)^ZQY
M?',: 7$EF>1N1D%7O!COY*'CW:)&0$NO(W%*7D*SV"$R8JD\+PK1HRJG$:99
M>Y8VXM@CO]J/S.,>V"H:ZOO>.<X3SLGX^/*:?JXJ>%L[O]NK9IB#@3(<+3T\
MOBOK)@,,L:<=7^Q!_P##7M:%C\-B:D,(LY6)GT:'$T =S:A!LB9(DJV'(&B&
MK<L64?#<O%$G:@;=XS9.&[#+8J;.[QR?79';62W>W8/>:N$NN&(L;$[#21Y1
MW8<O(^O]8CHRN3",I+F-6M%YULPE#T/4@!M*FT9E<H%OF;9L1/[!F,H#;Z+B
MF!M(>Y=-UF'Z>*GB>YLWW:/DCWVD]'A9U16)!H&/ZZ]:JXHFX8% 'G6N*&8(
MLI'7N(M4T-CL53%QRKI?(R1DB5&6$$#BF@S8>_7*OU'FJ*CPHZ=*JN-YA@EQ
M!9GD[C4;H3Q-+F7R7*8,/UID44Z;3;3J7V<!HIS:"4M#(DZ;S400A[&M+(&2
MRO9?V-CK2;:,9;%(=9(-C:H653_$M)-9-N^E>VRI$T9V?W#-0Q4\(=W@P[4Q
M)\TQV9^+89>%S;)=<2'MRWC\;OZ1YH7L$5Q0LR#0]4.(@6CLS:.QD\@!Q(*I
M9Y)Z8E$='Y7^3(D-E&66XI)5UZ6^=/)D*7(XJ9#R;?NT*F(3!CW"MSKL8BUL
M*45_^$=QK;QBCW%V[2M"(Z[Q$TFWW8Z?AN$+>_QE[9JOOL;(QO*">N^K9SGW
M>/3_ #QH=Q=F>>;:;JO+;.M-S[O:V@5;T]8VW6/M/*-+?8RM\G$8I6*928P#
M$5?BV.S:PQ&3*. #HWDIAR"2U7=>^:LGRF=D_0\-M"AR1BH#9FI@>1:5#4
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M*ODSC;D8Z7MNI5^7]P\U+MYK#7;@ S:2V,N7<K:KOHNU;GA2SB2,6R&SER\
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M.VJJF"\K@42,2V/2(OI%)H'>#3L$U\9<'4CD@CHJ3KDP2N%&;UDU#+N/DD7
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MI90DMZZ]D"<0[*A83V$CE<R:R# 7% S6*5-!AARBHFB<;O)&#W<I1W;[N>&
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M1@B8U:$U8_'5AHUPBVU9JM=D/YOAZ6/"Q)<28&F_.Z2XF&GGK[95<95G<AO
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MT>@79-E,*0*2"]Q!J(1*N% 5VQE*OHVQ7MFQM@R[5.<CBK<8F\A[30SN@4R
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MELU$+6L1KYU*R!& L 8\LD-V7ZL_6.R0'7JCPHG"*%U_K_?^[<?O]>%G\_\
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MX5IL.0\%]>%4X1.$3A$X1.$3A$X1.$6N+=MNOJ(K68V_:I_:+UY 1"AV5G]
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M$E[6V&@V1I=S9O[YK7C;J$-C<'I"-IWEV#+:4-,BDS:%C,_;O#-DJF9#L:V
M6H\U")8E$<8;+Y8#AR20[9N.32;Y7WSKY\L4U'#2,0:!;EH^:S4.&YC7.<UD
MFNG8R0PFZ(?O>W8@6E=UBHV4Z.B+!;M)#7J^I=(S]IUF0R#5UC<,SLG[#8,H
M@_WR.VW;^Z\<^I@*F(X:8#2+_NU*H#TB3(%LH%O>JO9?K@Q+SJS)UM:UQ,5;
M+IYS3R\<'R]%O%XDV<-$&F9U"QF1>^P:PTL(872D&[AVGHX444]CGS>7$> &
M$%W:3L3F%6O)GNY*(CW5D?'B77HEI<EYE-NO0F3"630O-T';*T-9,RV9*/;<
M1P(2S+'XC&WN BZ6XS#)SC"NVBV/T>4U?5PT\396;[='S1I$F U[\]U6MNFH
MS:O%*\_'KL9A!2\,WA]T8L-OB7:N\HX1_#O0M\'Y,5CC&/4Q&O;94]3.=OD/
M_P <8I?#39F:.;:YOJC<[O[VRY*SR#JV/D!;L*6WN.\1FW80+&PKUD)FR#5A
M5^D<':#M"%1H9$*9B9(MKI[HPY5W)X>/,[+832QGR\8OIX:>%[B[_=JV2->3
M/=RT4H$ZWL0DYJN<Z6O<A!:JZA:U"WCI.8(N8O,VS5@NPQ.9T,P+3V.6"MA?
M+E<_HX9I[NDTE<,L8U\N6*"&IDN[2-@=-D:7<\LNBI #IP, 0VE(;I?'8DFE
M2EG:V<U/%K";NY'8"^IG<S]H641P#3UDD*SOO[#(5-!AO\=KJW]WXX]3+%-1
MPT\09F@0STS!\T:TF-[\]=.2R9#U"&R&-W[&][R[!B]+]F0:8O"PB?MVAFM%
M0QY ]H!JAYD*KB*QU_NA@:2'JI$MG(I15KA=/._J8"IB.&F TB_[M2C7DSO;
MEHK>ZZX,75A2BPLVM<:*THH]Q2"D70F".D1#M'&['?-AA!/Q>=V5FI>QQJC)
M=G*J>FKAUCX_/JX\L>&87=VGD^FR-+]V7/FM-S[H8(GU;T]7"W9+M1&D*>8R
MMBVE<4M%J*F,ZUE;X6^4<V&8WCKG20.@N1>K8$JFU8X8M7CY+;5;*^-M-"MB
M3AH+Y&EP.0>%,, .8?.[ZKO/F%I.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%"F_Z)C_ 'DV
M_P *W"S5^7]P\U-<+2<(G"+1UB=G>M=0G](I;'86CJOE*@]L63C5B6S H4?W
M%/%'"+0GH&DI\81V'NEFCI)L]PVRV74;.-$E-MD5,:E6)L">Q6N;7#4=:Q(?
M/K&M*N8!!2RPYN*FDVF\9BL2)N"[19^)0'R,Z38!WJQ1BW7>CDFSQ3=ZT06<
MMM544]]]2C&S3HJ0EVNZMKPU*QD.R=!+U\O+-8$C.T;BKQ6&K3G<9J:TAB4G
M3D6P125[!M]"^([J^R7^+VU(>S]IG"W"K'0]%N-K)(\]/%XJS.AW<G #0A@[
M'FQ)FN;#"9*L9;QTF5%I+;/1[ ZO'3Z(=V[020)*A"VC-1;8>ZPD44UPB<(H
M77^O]_[MQ^_UX6?S_P"/FIKA:3A$X1.$3A$X1.$3A$X10P/_ $5?^VN/^>G"
MQ18\_(*9X6TX1.$7,G;.ZI11]6B"T & "MD6);--T=7*4M3(KQ$=+KHLJ-U\
MSD\K:!WPPN2CD*8FR,R+!!1022D+4!N 8& [HFD49E0'.P<GD/![.H7K'<5D
MS>2]AJ?N;:#D;/ZYV7'8>3E]:QT]#H5/HK.ZOA-J0Z5#H9)IA8)J'D46LN(1
M(\ =3B5)9+15P<8%L#S;4:.(18BQW>1?3G;/.ZZUX43A$X111O\ JMU_L2_?
MI<+-?TGL\0I!#^@1_P!TG_@UX5IL.0\%]>%4X1:JLZ]Z/I/ 3-S7+5-1XDN2
M6(YFSK#B,"Q(,AO8?+X"9E1@3\KD5\J,^2]A[CV/R+#W7I>\;^H58FP)6>WN
M&HW5<;7$UM.N7-1:CW);:TV\WC*U<:BF;Q4<\)[3A,GM&<#VI!!=BY>Y*8;(
M/$56JJFBZ>^F"BH@/MEU7DX*6RF,]E^O\BC,!9,"4ZD0&Y*Z, X6.*.MF Q_
M+"PZ1N6$=9DGVF[)@Y+KLT7CO79LVW56QG3A5CH>BV>&L:OI'M$=(].8>>VL
M",/IO!,!9*&*XFL,&9C^"4NB>6#U?$BC+#,LBV'AX1EX+;9D@'"SK3)<?[@H
MQTM!V.BN7")PB<(O.OZM6[A/Z<7;;9JCNY7S6&Z:;71S[/+S*LA!I99Y=?YF
M^CO7?+917;QUTT5VSOC.OCC):H^H=O@5Y_3"K[GZ?B+P[ET[UHJ;H[$*5ZD7
M8D8K:-6AK98F\K&(F*]D-?R:90&+!(Y  HNHAD2FOM95N8<30IF>O FN@^/M
MWJCJ9^Y/]-[95W8$NY$M:X@F=-EU#V?[BW?"[PN>G:KEE6QK[7-?3"B<<D<T
MCBTE9Q4OW+["W?5]C/)(P9R:/J&5VT2AL+)P\#DF!WV(N<>J1]J;27;7W[]P
MH &!+R:__6D$=Y()7,/8CL+:[PK/Z*LAW!K(.4[9G;2IF-T"HDM%R1(,0^E5
M->Q0QPU%CI ]$1BRHRZF6T$EZPO9<44CJ;(DV#@"1Q=J-(V8AZ7A_N;Q#_Z5
MQK3MSV"@<SHT#)# X+UL9N^F-*"Y7'*]C-NP=R5N"I*6'N(7>4RB=M9N.B+Z
M-V=9HIE -9'4J54J1$[61DV6)XFA%\&*D78:Q8L"9$,:8EI<&POZ,V-?<HAG
M:L14>7D>80)STXOF^7[HFWU2?(RJL+&IN-CW62BKM%!$ R"3PPJ8;;H>'J[L
M'*CMOHEY%BRT=H'5_1>6&>^G<^1]=K)[$ 9O4D=:=?/IH=.>\4GAKRIGI[-K
MSRWJIL^R;&A2IO$[%;PB%O4*V6'!MQ+ I(!SXVT>ZE<,PCH9(8"X&X!6FI=B
M#-1%[",FDA]5MUSWF[9E.P$]<QJO]]*5KONW$>I+L(8#TG'X80C!"7P&!R65
MEK;F/9"+V.RMU\[FBTZK.%!::?"I<$UAD"%AI$<FJ$T8U&#3?"3G=B1DS6%X
M+DG2 :=V>U^T7ZYW<M/JC5B?9M;N*X2I+%<+MY35Z=%T9V#L* @F,JQ,UWTB
M)Q\[5X('=RI@&GE67K9'1YM$!SE05N3"&J#%Z68\ZJ19LW)$];K85A]_[$B0
M.N'69;7(!S./IX0+L+N1?0633ST;GM.W*-J>":BX5"RZ$ED8Z3GK-(@X?#V;
MP<E(90H)8NI2(&H$B;4H X>7?E#.9[.Q:&&]D;SLZ[:WJ&Y-9 @1I/ZA/5G
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MY=+JYR)/MKF4WOF++4MB';P4=CKEJ8Q)OG$K%^$;X*;6E[9++7,7S(/<Y9X
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M[C]+&=\H^T\V/-G#AXOJ_3;_ -OZ3BBV_P#7>N>;3ZUWI;@Y:>3VI>E\]O\
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MA=?Z_P!_[MQ^_P!>%G\_^/FIKA:3A$X1.$3A$X1.$3A$X10P/_15_P"VN/\
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MH^2R;CT,52=*;W&_5^#UQO$4=D$T]V^&R6^=G*?^7X\/#-PAR,0^EWR)TYJ
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M,UZDID@(W2$\&R,(P1]<*^9M63O?5XHZ;LR,6?WEXO"VC KUJ*S"*4?AUA1
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M$.R(\I\8CH7RJ[V'$!!=@]T1UVW;OA1-FKKJX'NTT2,="JECNAU36?QMDQ[
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M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+F7MQ_J@%?_OYU*_\
M^KJ6X5%^RKP*Z:X451G_ /X'E_\ [;,__'N.$5NX1.$3A$X1.$7 '>+_ ,=]
M /\ CGA'_1Z[.%1:KEYA=_\ "B<(G")PB<(G")PB<(G")PB<(G"+F:?_ /FI
MZW__ +;=D/\ _9I'A7(\QX5+IGA1.$3A$X1>$SW_ -=H5_\ L]C_ *1G.%H?
M2>WQH7NSPLIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
GPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g209588g30s33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g30s33.jpg
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MK#I*1()VB(G<S:1/KPL_K'?I_P#?JR_MQ?\ M.G/0Z/^&3_(W^>&_3*W]_\
M _G@^L=_^=67]N+_ -IT>B4?\,G^1O\ /!Z96_O_ ('\\'UCO_SJR_MQ?^TZ
M/1*/^&3_ "-_G@],K?W_ ,#^>#ZQW_YU9?VXO_:='HE'_#)_D;_/!Z96_O\
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M39D+IWR4(4A1"M<*U* 3"4B;BY)DC:X'></-/T^E:FU)2$:-7@02H:W% ?6
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MHDL:.K,S?&/&V62BKD\3F$K<;3U>4SM5G\YG[/.C1*'GZ4N]:12NI6A:RJ4
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MAKO_ ,^K\<9;-_\ &>MBWGMMAM.K?%000)(('<V&#]_71$B=IOZL$$B0"1Y
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M:CBP:F^EQZT\Q9>/D'7:BBFP=6]4! -P=HT7_N]4JW_:E)F!;<G"O1J-#A2
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MGLH#I)>/:@\Z"LD\.5I@="ER]]?(9=AC<B-HVQ#EPF2+GH#!@ADKRRP2:_\
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M'>:5Z-A:KF^1'RL61S6>9R77#N4OY[GF69/2J"7\PJD4T\M:^4AS=\Z)(;:
M4IPD0$B9&,;Q]Q90<#<(<0\5YFI)I<FRNHJ13J6A"JJH"%)I:5DK4D%ZI>*6
MD)!U&?")&&0W7*!!YUPV[O[+$3ACR4M%4@V+[4Q87)6' 7)4 3+  : RR@C/
MM(_BJDR">F>,A[IH&P1_H5PAPQDG"62Y939.:<NMH<?75U5.H55145:(<54K
M2!/B)4EM/@;_ &$B!C\)_E#X[XG^4SBG,<]XB%33N/NAMK+Z"IT4>6TK3I*:
M:E2M2PE9;TMU52 'JN"75DJG"4I-':SSUK)<M/E;L%P^A;<FDW,=O;$,GF<4
M)',))/>VAMC/$1?'P6,]J9+)&.6TJC$L90S]9HJ'*56AUQ;+CI17!X-.,N-J
M0H(;2E]*EI974!EL:"(*DW !Q@*6H%/4-+?73FJH6W49944Z"FM;4M22XM;S
M*DI6INE+ZB5B#I,2H XZM^"/Q>6\.S#XCV7TW*-=EV(M,;8MT)X]7I0["=/H
MVIO+B4ET^>MJOX,X,2=SC:LF5'E/C$)3T_(_E!X5:8I*G.Z-AO+G*$4Q<I&W
MF$!=%*VWU0$PJI14NHC22V6M9(U))/MOR6\951JZ'AO,:QZNI\R<JJ:GJW6W
MW5LUBVR_2MA2U@IIELM.!04 L/%(3(5&.YV?T?F8U'/5>Z=T553V]_9%3Y??
M\_V]OEUY515(2DJ*M13<P9238*@B 1.Q O'F<>T5V7. 26[0F?"9F/VI!(.P
M@[=>APZE?9K(C%[HJHB^;LO=5[^W\WR_>G5^T\%IE)!G<=/(CKU_UQD:ND4%
M$P1!,&/=/GL#'QG"I@(8]J>_V>WS7W7NJ]^RHG?V^?O\NW;WZD@R >\_?BJ4
MDI)2=QOC*Z[CF#HP8C9XR2/A/"-XIBO+YOAO#ASD2J)\U2'C'3O5J+]W?\?Q
M[=)4L-I*R)"05'U)!5MUVPXTDK=;0F-2G$)$[2I0 GRDX^25_C9R0:RN-HC?
MB/.YK8!R(IE=V1O95>BHQG?LOLJN[+\_=%ZK'.)*:!*%W5L(\STF^_\ I;'J
M+?R=YB\1RG4!!0RLJ7M#J2HW Z1:VUR,(BW\<-J5YV9K,!"_K)$^Q(D?*Q.R
M^5ZCQ,1BN3V[(V1R(J*OF5$[=1%\2%9BG824?_:*5(49D )L0 01UN3(QI*'
MY-V&5)],J5J41)4V&R!.R28W$*)F=P9F1AJR_&!RR\E'R6@PK?.J>E#7M\B=
MU^7^6<]51%]D[=E[?/NO58KB&O"R0I(&HD)$P!-@!O D#?;?&G8X"R 0V&'%
MJ78J4XJ23N=((2),F  !,;"<*FD\6O*1KG"27-&K'-3SD$CH.Z!KW(Q9$\DJ
M)*D7F]22&)OJOB8_TT5R>5>JS^K=')=*"R]]$ZF5 :7 6RK<24I6L 3'B,]#
MB2> \FI"FJ9:=;>:<0IHH<5!6F7$*)))\*VTJ$S<$$=NFO//+&V(UU.)C@(Y
MN/N,;&(#&5J(9#7S4M=*D$2L+0A#7DVT2SDEGD(XZ4V>69TDDJOAE]E9X0RI
MK@[+*')>'V:I.2)8SO(J?PEQ&>992/FE=8=6904JJ5H45FX$WU&?G^@X@JCQ
M=G>8YUQ*]0U?% =R7/JI1\+N39I5,>F-OLB$J2H4R%("$C2"0" !'IX>B^/+
M_2VFJT?%!>FRE5206)U3K")S:2FNK<>W?5!GH P&$M[3Z@P-H5A\1%9!C%I+
M7N3LX:O5G7%^<9GP2PS0N4649^QF3_%2EI0W79-64E*P\Q2)4V-.IQ]Y#3KD
M%&@P#XCBUSG*<BRK*.,UT^?T59GF2/Y8SPZAE"Q39[0U#[1J*QO6"=##*G'D
M-@A22WJ)$0>D_)W-15Z[ $Y@IE10_5BO.BHZ,9)*_P")EG*$M1EA\C1D:UPS
M@9!I62P1LC6*14:Q>^ZX?R>D;3F(=3Z0^FK=0E]Y1YB&TCZ&"#)@$D*D&;@=
MO!>(JFI"J)*TEM+C/I#B4^%MUQ92I1%MM4R.H(F^&_VO.P8U<,^IH),O#ER5
MLY1:2S.^ MYI:6QIB$LZ<TF88EC&6,EE!&$./+\4! /W=\0U\<+-^"7,Q?RN
MN>S%]U>5YB,Q8'T:"H(9=:53NJ;2"XRI#JCH650I*2F"#-_PIQ/Z(<RH&Z&G
M;&;Y0<L4ZI!=4P34-/MU5,MP*+3R5MI05HTRVI842"(9O=\FXKD<&"]H;D>>
MDM ZQED!6-,KD"T0(HZ7(1#)ZVO(=&61W-8D@\:SCG,:OVFN\A7\+9)QAD;_
M  ]Q53*K<L-:Q5"F+[S'I IG2ZPAQ3+J%J:2H@+;*M"M(M88G4F;Y[P-Q QG
M_#[@I\U50U-"*XTS-2&VZM(2ZI"'FUH2[X I#H 6@W2;G&@9M;766 U:#703
MD-&5@L9D\(T$0(T#GN<KI4])@P\#'32-8C61L1>Z.<CD=K"]390PL*;6*9+8
MT);38I3X&FDB#*FT) 3^U$&Q,XR?S#4UU4RZW7+5653I*_I"AXNN'6\Z7$E/
M*YJE0N-,@:3:,-'M=Y0- L*T#<9PB\L52J%8$#8?1:CS.1+" BR*"AK'C3K$
MT1DKRF"2-=(GK)W;WQ]+Q3DG&E-F]!0*JWJ?+*HY7FBRR\PXV^X5,/TP74)8
M+CK"BM#SU,7@%(EO5(QZJWP+G/ 53D]=7LT].]G%,,RHZ=+U'4)=IFPEYMQ0
MI:JH6VW4)TJ9;>0RX4* 6E!*@)%9$!*CC>@UM[,26-<SV(0=2:]D)C"05&?9
M>:<?RP/![V,3JTN%4=-!)&][8Y6IYG/D^R#+>%,E9X.R/THT61./*;J:UU=1
M4N>EU+M2I3BW"K4HN%2 -DH  D8Q?RH9G7\3\0U'$M:EINOSEAI!8I6PRPA-
M,RBG2A&F%JAM*5:UDJ*K3 NF:W%U]L6^Q#[5HIAKR3$F1LDC948JO[-CD<U(
MYE7U&KYT5'K(BM_55=>W39=DBJZIIJ&@HFZQ;U=F-0TVU3!U]1!<K*MTA/,(
M2DA:UDD"YZXR[^>YSF5-EE!5U>99O5T;364Y;3%Q3[C;3G]U2TZ"5\MM),C0
M 9%Y)NX&:^"S-\!)2Q 75@0=$'%61L;.^PCDD:YT),/?M'"_R-0AS_L1-1'N
M?Y6>;KM4XS54'I2WDM499YR*YMQM30:44Z'6%@E*TN(4=*DFY( D$#%71HS1
M>8/4>AUNMYJ6%T3S#J=+R$J*V74D!8<2XE"2(F">HQMLQSIQS9<YWA/'G'F=
MGU7H%9BMVTL)A=I7SBQD5GKPARRM#%&HW>A$*3)6Q'OK0HFR3J/)%$F:9RQ=
M1E:S65S@#"S4/4P*$M.HYFMJ5B%J+K4J6$J*=3EAUQZ#F2:^C72-@<JCJ4%E
M2DDDA?*2E12)A/+=*PD*$D)$W!B^T T=6.2;>$/$MK<^RJC17$$#RK)$Z)SV
M$#.8C2H2)IV.15CG"D=_Q=4;(R6)NI0]2NI#;80IIBF9J$+TI<0G4E0*DZIT
M\O29@!?7S/E!HR<P6VA"G2MUU"DZUZE:%!.D)!CZ0%),V"C;"2R/-_)7'Y5I
MEMA8O,BEB@<$%82.*93-1[2@2$@*=)!!_P"3))PBQ4C9!/7GRADQR,<[KS?@
MSAK/$9+4_P!L\VH<WKZ?/L]JF,WID>CE_AYRH<J*%JJ* D*73()2G2 I"&T0
M9&H^S<<5O#51F["N#,FK\JI7\BR*G>RA]7.6G/V&$4M2FFU*44(>4 I:BH:U
ME9*0"$B)/*-R5;<A:2CXQJ:497"4%Q2BUU2-9/\ I<EM(?>0@..6:.<2"1;H
M"KIXHO@QW1QUL(AI$$<Q%KD.?9?QEE;N99#G S:@8>?I4US1'+7Z(LMJ24K2
ME25-:>6O6/$1K.]IV9<.9CP4[1T?$^5JRVNJ:9FJ4P[&N*@$MFQ(@I$1< B-
MAA([_C3>)=6NTW-SJ=??4@S[!*"6KMZ6OIL^D\Y4T-:0<%Y%;7BQPDW,+( 3
M"9&EFOG(EA:][U'S$.AQ@LM@N!LNNO-I6\LJ@)"20H-+,2L)TI2J9'7M56T#
MS35(&E+2L3##:[*;'TC;KQ"FD+<,I;! -]CAC_%#R@;'PE8#: %1;KE#345G
MGV>E.J" XWXAAA03O-)Y8D'L$K(I#'/F*&EF1LLBM^WYU\I>;EMOAS*J>G#[
M%6BNJ,PK2L*%$$!0I64E$)<=?)4O690$(6/K$8].^1_ABF<K<_SMVJ#-1E+%
M"UE]$RI*_3E5CU2W6E]M:.8VW2IIFTC2H$NN"04F1RI21LDBK.*I$S^\C&*K
MFN55_6[HJ=^RK[]^R]NZ_=[)X\TZOE(UI!)2)N?M$1O,  'I!)Z2#[NZTC6I
M*"2EN4(V$@7!((B9)!Z& =\;\"<(-6OMYX88$E5L5=# 1,Y$6*1R3+(R5D+D
M2:.!L\<K7^IW8]T<D<,D$LI%29 4 $V!@["#>YGI_7O4UU.ZM20PVVJ0;K"H
MVFY2;BU[;Q,G'0CP>ZVIL.<^)ZVO'LBRH^3L)&=>&&.A:]\NSSI2#RP1@0--
MF(<-*K(IIG.&C";/"Q[%FD'TG#CZ3F]*E-Y4=7<04D6]<S?8;8\<^4#+JFGR
M+,G:DH',*-"424I*=6K>XLI/W3W^J)4[*J?A_#KV-7UC^M[X^:$?5'M^\XIT
MG"L'1@P=&#$7/%+XF ?#1E@-')1!ZLR<#3Z C-NL=97W$^6Q009^GM*=V:X\
MW=>CJYME5C/,V)N)RL)]I6B'ZD*8T9LL>H?#" H@&5!(!\P?R\IN)Q+I:</J
M(U$0)!$1,P 9/6Y@7(!@6Q$<3Q>\_P#'NMY3T/(^;PFIXUHV^-[2"@5FXL$U
M%96>&'EWCOBW*TF9JJ[A.K;"'8+K8I]5)?Z+961;3;'75I^>'R[,#IX2:U]L
MJ!2G22HP"39) !!-B3?8=/7$WT%E00#)5]&F2 !XTZC,*M'38#:]B91<5>([
MD#D?D',80_AF#'2DYW9ZK76=YL[X)]92YW1Q9FF*R&>O.,*+0Z-VE.L:PML.
MIKN/I*H>"^25AZ@TDNFDMU"G"D!(05 G5V ,2)W(/0QMTPRY2(:2M>LKTE("
M;0J03!()@".A,&.]HUV'CIU/'"[M-+42[JT%W^VR.8!FE,J:9D4'B6\=^.SH
M<@O'7%6_WTQPF%\,-%FTD H-)"=835-G9@T<;-AK2HZJQQKF3])!,3U\:TS(
MWB#>\>?1]-&A[EZ06]0!44[CZ)A>Y@"[AL2+"W;!IO&;S_B\KXDKZRXXP3C\
MP-R&1QR+=;DR:/':_ ^"OC'Q'VN&TE;1\=UTN@R=68;N7Q:Z#2C:&[M7A47T
M104D@VBJ.>F5(2ZM*$P@ IN2 2 H@V-K@'IM8S@]#IRMI*E**EF%6Z:U(D7L
MJ0(!!ZP9 &).>(3Q03^'X'C5=!E:"YT&O9\9I<[2:3;V+J>EK=+Q_E=-<Y:W
MJ^(;*MNZRDM^1*0>*PWTO$H%B273@1D0%V\T=1+J*M+"&5:$GFC4=(N!:Z0.
MFTDG;MB'3T)J%O@.J'*( U :53-E;&2 8B;CZIC#<'>*7F:^DX;-X\XYX=6D
MY6YAWF"#$V',>G TZY_(\<>(/0#$785-P]>0832%WW#/Q$P"LW48O<G(31PV
M<A]Y1-)JG5!*DA"05P!JD@:9\0(LOII'F#M=\43(+B5EPE"022D!))4 =)!&
MI,'ZW6)@#=(8WQ]/.Q6/BM\4C-T?QEQ?R(<FBT-O(/8YGD_'<%_4;6>7CKB3
M16IUER'RUS-)Q;09_+X%4M-9A]RZHAA"J4$B[\X:4P6B5 "21,@_5/A&QD#V
M'>#CBLJE94FHTH*E )$2-)(4/%]D#49Z$3<C&AH_&]ROM+NNLP^/L=1<9D0>
M#TLN4+=7)')5<7SAXE.2N"]8*'077$<U5IJ!UQ@/@8A)YN/]+7YPB6^C-&TU
M]!0XU K5J)(0A A)E,ZKJ*8 /^6?6!W *T4#39\:U.D%P +"0GPH2L'4%6L?
M5)(W!.%[F_&OM-=/QY1Y_A[(&:GERFXQV&('?S*6N;$QW+'%'B$Y7HOKQ? <
M4V1]#LZJL\/-]6WF8IL]IZM9]%2EU6JL!HSO1Z<R*3"FM9(U B/JWL2(@V/2
MTWBX'',M2XK4AT,I3*%) ,E04D2 HR;+ &WU=KC$U.-MJ)R5QQQYR0 &16@\
MB83'[P&M+DBF+KPMCG:W1B!%2P_Y&0D2"R8,0^+_ "3YH9'1_P"35J]3D+YB
M$. 0'$A0':;Q[/NC%:XV6EJ;)DH44DWOI,$WZ$@_TPM.E81B^/\ 7;^_HPI'
MUA[?N.)>]8?&NPH.H^+#&*2SSM\OE5?95\R?=\_;O]W[?V+^"KUQ0D>J_K\L
M+0HI4"/+K'4;X;#3!)(R14;W1J+YOM=^Z_N[>R^RHJ+W_;W[>U'7M3LWN2(T
MDSTL#W$>SUXT^6510M(3,E2;BVHDCMO,]Y/0XBWN*5KF3(C4^TUWW=U3OYO?
MO_J5?N_!.LA7LJ3J*6E)OT01)'O!]GX8];R"N4GEGQ6@@GH9 ]IL8\L0BY"S
M_P#Y]JM^2N_6_P"=V7O\OW_C^*I\^L974RG 2I2DDV\1@BVT&-^GJZW&/?N%
M\S4E2"5&!'[5^FVPMY=K1>(([ZC4$R0AD7E3SHUW9/N545$]ODJ*[\/9OS5?
MGU@JMA33A ;(223(20#%MXZ[7ZP.HQ]&<.5Z:A@(*@5$ SJ!O:03WTB?, G#
M;]0\:F1W&#HP8.C!A$[\EXV=G2.V=3J0?0CJ4RMBMGR>;05DS XPII8(Y''O
M'0-ZK(G:*=_F[0K,O7L'R'G3QTRX7PR495F)05+2@!6NDYB@29D,<W41LWS#
MMJQ\F?\ +."3\C;P4TZ^G^T_#QTH0764*YE:&U53+8+CS2GBTEMN"GTGD$#7
M!$"8]2.7$*D(81.WGOD<%I9*UH,,FB#M3[.(I]\4]X;1 A7BA'^:-$046T5K
M4-)@:OW%45 =:0IFJ<<4J$4KK#A<H5)(AHO.HEJ_AUDJ,@DQ>,?C]2T_^UJ2
M:3ETY;<74T3B5G,$K2DJ?*?3PFH#B2%13M#F!4)B<;QMC #;4D&GNZ0RO8-.
M710TYEC3QEV[I@PK,8_XRCCD\GD)J'N:+&U$,F+)6]%B)'^+Y5/(;J*1W- I
MO2E*.4B0V\1X@M2?"E;8*00H@@*(),WPQ24;AH*]O*66E.FI4ZI=2E8>8:*'
M K04:E(<E4*"]*"C7UV>?@&PLV\A8&*JDCT6>)Y4S'PES%9GRW-41"9$1\<K
M_AVI,-'93BSE6XA<HC9@HFQPMK[R8<J!Q!]'E->VH4R\J;RK,ZUMI00E.HMA
M24I>("80I)4A&KZ-2BN"52;7AIA^JS_(GE.5;>;G/\LHW74 *"0TZ&RM3%.2
M=02I;2EK3S"E&A9&D#'U3Y36ME2)S9?LJB>7N_NO[$[IW[_@JI]_NGW]?(M%
M7!2$F+* 41J"K&"+CZPZS>?+'W]G&3%HE)$P"% )C5'<=#UZQM;$@<]HT>C4
M5_S5.W9?9$]E[_AV1%1>_LWM^'6GIZW2&X$20#'4':; &#WCKZQY[F&7)E8"
M((D*!$$&XN.]R9\IOAV:RU8_LB*WLJ)_SD5%_P U/;NJ(J*J?_'J^;=UI!2H
M3!.D*VO[Q-CMUQC*NAY9)TR.\0?7YB+6/J-L*6*PA5K'.FC^VO9J.E:U7*K5
M5&HB_K+V:Y41$[]FN]OLKU)"DD2%)(@&001!V,SL>AVQ3*24D@C8Q[2=('K*
MO#'>V&/T7B6XEI[H_,U^C-VNHJU?%9Y?BW-Z?E30U1+',_R%W7<>T^BEH).S
MV]VWZ5D:-D9*Z1L+DD6 O-:$.*9;>54/(6$.HHFW*U;*BDJ2E]NE0ZIDJ E/
M-T!0! D[;2@^3SBVLI6LR>R]G),K?07*?-.*,QRSA;+ZQ 44K705/$%7EZ<S
M#92H+1EB*UU*@$E&HI2J,?B]YITMUX2_$R%#X?\ G(:LM?#OS4"1IK4+CRDJ
M:80WC?2CSW5Q7W/(U?JX*VNB>XXZ(',GV[1HI&BU11?IBR1W*]Q3+I1EN9+3
MRW(6MJF:*AH,D-/UK3J3$PE3:%'L+XGL<$T#533IJ/E#X$;4'VM2*>HXAKB"
M'$^$.4G#+S"S-@4NEM1_;*?%CX>X6ARN=(I/IS*]Z(QR1D1=U<[W5RJU6HGE
M]W-7O[^RI[IU@5Y@KFKFCS1M*4J42J@2\FQ$RBGJ:I8WD+* +05)*@E7U'3\
M'+*0FAXPX*K1HI#I>SI_)SI#2Q(7G674M"E1)"4I>=;!)(D02!K'N:Z1SXGQ
M-D2)DT,3G(LG=%5O=J.1.[>W9/,OS]OOZ99SRAJ'O0FZAI52H%7+<2FGJ8F(
M%.K2Z4@I^MHC5(FQ&)^8\"\5Y7DSF>U.1U"LI;JO1W\UI'VZO+4:DM:'!5Y>
M]4Y:XEPNA*'FGD)<5X- (!5LHY8XD8D?IR(O9?4(;*V)47W<G=8G(G?O_P U
MR]T]T^Y.II!!@W(,'UC>?;BB0$H*(("TG3T"I B;7D'L 9WV)PLLY-# :WUJ
M\(EB-\[I('M<V'[2-59(IH2&M17.:UKWPM1LCD56K[(J5$P-,@SJ*XUA 2E1
M!Y5RX2L( @2D:C82<-U3BE!*7'%Z52$H4X6]2B4B>=(#82V7"23<Z1O$?1OX
M8J&H\5U"'R#>VTM'5 Z"YSM3QQ'$T"?9[*N#"U:I=78OPLE9CJYMN%*8X7L:
M<.Y:\4VIC&64WVC@OB7/Z_AEM-8RPP\PRTUG!IX4TTXHFG"J+3 0JI:"? B?
M&HI(44D'Y5^5#(\AR#C!]O*ENUB7V7JG)JFK!(2TD<Z*E:M0U4JU*3S'%B$@
M+U#;&]FON/:ZRT/$'&F"@R)5J53D61@9FA/EUBU,ER:%.<+<6EN.(I5AI9SJ
MUHT8\K$):)+.1W@:W4(S1.3<99+DU>Q7NTM?D&8UZ,W+#:\ORJL35T[*<JJJ
MAI(0BJ<ITAUI+SFM]+4-@B8RR<LS7B;@/,N*J7,J)U[*LUR[+/F66V,PKF':
M-2JG,FV]0>0PA8%,X$MD,J7I6H$1C-985^*XS*:^*U6_!Y$N!QP"61K('3)4
M >H;#$L4,XU;8W:ENA<LTPLTD$[V)')*]Q4KAC/<TS/-^)!F&0.\/T-'F-3E
M>5+>+B4YZS2J1RLVITK2A*FZL._0<O4E<*T+5!B'Q-P[0G*^'44>>,Y[65.2
MT^85YITMJ7DM15E7-RE]QM2SS:(,IYP<T*;UC6E.H8BYJM1%JDE*F9/8.B=Z
M#ZD=)H R22'JVO:63&D?9A4J/5[HI$8C(WPQ_:>JIJ:;.J+-UU;&55U-5(HZ
ME5#5N4-2U4)I:M*4\VEJ%,.+#-0V%?2,NE+J;%28-T,\-/\ #GH:LTHGVE55
M(W5TGI=,MI=11ND@55-STH+C"H.AYLEI1!A9C#(U$_)V&Y!JZF^I&09;8V,"
M$5 @,<%7,-ZT;>P\@X[2AS!$/@D@GDF<0U38)4EF@+>JPZQI=,207%%M',0H
M$I2H(4 O4N0 V 5$DF H $@P<:-AS*LSI%-M.(4FG5]*>:A99.A4!Q:"I.\2
MT5 J%R#I.):E\>\J(7>1L^J^1!G!FKQQ![&>[TSZ(MA,<E;;1,BEK:,FQ"6"
M0U8+ NVAAF< 2-7D3&0PY^A9XQ=X@K:RMSS+G^"4 /TE _E(8JV%MMI+SIS!
M82*BF;$G5);,%848!Q&S//?D[8X?RW+Z'(,U/';]2:2HJZ?-"<L>UN:65M4"
M%%*GW"=)"$E1(2@ [8:36<)W;C,D&,;FJZGGH/4=?/+C?60&?21S[;SL B)*
M,+B,)AB044:61(E@25(T8]Z7N6Y]D.:4.89CD]=19CE[;E2M[,*!^F?R]"VM
M:W''JAA:Z=KE@*6X7'1RTI45$ &$5=)F>5UE-E^:TM?29L6:<-9?5L5#&9.!
MTI;813TKZ$U*N>X0TP&VB'5J2A$D@8?FVL<I!QWQUQ;D+P68G#0VL3I+8V.M
MM--;6AOTI<&9^M>9-(>&QSV#P5P;C3PHXQHI5>\B&5[&2UE)X\S9S1FKILR;
M:J&:[+'$5^7/TZ@0T45-.7:=95"E!Q+A"AJTP!B!FM!6O/+:S#**NC?R]:F%
MT=:R[05M*[ )2\R^EMYI129T*2DW!((OC6ACZLFH.JPY!G&*UL<]6AU?]8((
MIFL]$MU*22EC#"]SF=WR0"R^5R*J^16JLKB1K)N)\CSGAS,*BI:HLZRNHRYZ
MM92ZPI+=2A25<M8T@%()!@W-C<F*O)*2HR'/<HXGHZ2G=JLIS-BN;HJPH>:<
MY"@H\TM!=0H+TBRA !M88];L&XX7R]AJM$PTBO=F;>NM" &2V5R\FXJ3H/@*
MA@ROFA(B8]9I[)CF0!_#JJD2N1L$V;&4Y10<&4'!],[F%30Y;E3.1T#R7'A5
MNM4JVVVJEUT*U!U95J0LJG0@P8&-:UF>;9CQI5\3N-972UF8YPK.ZUAP,M43
M3E4E2G*9K7".6A*=)3$<Q: KQ$80WA\Y<[$7&HI(*ZTM&A"D&&D5046C;,PN
M!Z27,$@H]H4D4<3X7$%O,$F;YY(#"8HE\NP;:R]Y#.7NLU%&/1J5LJJ'5?2A
MMA+"@\5GPJ44:@5>)8)( .,MQ!09Y_M*U.LO(14O5!73J#B"'GW'T\I2"H*2
MTEPHD$A(A'8!<%:O47^JAMKXZ>6:.PDMO5)?ZD*/<2\M49&LBL<LI,DCWQ^S
M(WO?Y6>957J[3ES26%TZ EAL-<D%GP*6C2 D+4()3>P,6CU8P[CU'3K15--E
M=2HRXO2"@*"O%H5WU"57LJ9N%#"IWP.8U.PETL)Q!).B0)G8=))H%+^"%B<,
MV%OG=$0.UC8'1L>^-4C5[$5KTD6/1#T.B73J2F6$N-&2-4*U J(((*2"J]H!
MN,/OKJ:UPU33:UE"VW2HA13X%MJUA5X4DB0;P95(&&TY:DR^?Y0R1=;705]0
M%Q]F*N,8!H\,;RF2$&GG3# JV:)Y!5C-+.PML4Y!$$TONQ?5?E>"J4Y;49[2
MHH*.AR/YP7\VFCIFV0^7F&G'RX&FTA974%T*49*I*C))QZ)QL\]G649*\]F.
M89CQ&_2N/YF]75-14%L,5+K-*PRX\M:@E%$AI3;:%!*6R-( ()?/CFRVEALZ
M[3CZ8NWP-=G" M+5:(M$JX:2P"^')K[$0PEZSULDTK((4A@:2TAHKVS-1S6L
MH>)."<O5Q,>+7*K-$U#N3NY#2Y#3//,Y74+6^MQ%6EA*DLBO+"5-\WEE82%)
M"BE) YPOQG4?V93P924>7+?1G#&>O9ZZR\_FS2F&VWRQS-"J==*S4*2C07"Y
M*D(T\Q0!X0^/755])XB-9ALHTZ?'9B.IFSK%+?8MC@T^>I+KT1B"'S20@BB2
M@5HL"JGIQ@OED:KYY)'^&<2-JR^M&2H-2&,I2JF8Y[RZEQM+A]+<IW'%J6I/
M)74!A+2E2A+'+%D0/K#@0JSC)T<2U');K<^"7WA24Z::D4BB*Z)#K:&T)0I;
MRFG*E:TCQ*J5+,ES4J$RVWT@G=1/5E:US6^8LA9&^7OYED8U6LC1%3L[LQ43
MLOOW3MU1-S%[P2)]U@+F/AL;]->ZR&S=,C?5'AGK)CI(,S?VXP/A99?++)-7
MPM<[LC4F>]4[KV555S^_V4]^SFHBJGNBIV7I<P)-AYXKU(<*5: ;S 0DF;CM
M<GU=O=++P07!$7BO\/\ 3-LHY12N6L;+***V...9XMBQ873QL1OG0=%>L+E5
MR-<YZ]D<Y571\)*2<^HDDB#KE-C)&F.L2)G[L>:?*C3J1P5G3JV2E2&V2APM
M$%!54- PK3"2H>&01(D7N,?9<OW?CV]_]*_]W;KVX3UF9._:;?"(\L?'R@ M
M8 @!:P!V&LQ'E&V*=&.8.C!@Z,&$WI,9C]E$%!L,GF-9!6%N/K8=-05-]%7'
M.'F#<:!':B%L#,<&00(XD9(YW"D3CN>L,TC')6A"P M*5@'4 H @$=1/7"T.
M+;)*%J02()22)$@Q;S ]PQYG8C%6<HT]ECLI83!D7Y8<QN<IBI1"]7$1!JBA
M9)PI'CDZ:$LN'1$0N9+=Q%$QV;RF3RH_A;;,$H08D"4@V.XVQT/.C9Q8V_:/
M3:;WCI_3%V<Q6,QPHP60R&6R@00TX08>9SU/0"AA$EO/(#$'J0Q(1A)SWO.F
M&A8R"4QSBGQNG59.NI;0F E"1&P"0/N&.*><4#J<60=Y42#L+R?(#_7" Y+X
M!XPY6 K@=+GT#EJ-"[4@6>:D^KUHR[F#V8!1!A%:R)EM"8-R+O'D"6\)XJ6>
MKN+^"*#0SLM8FW*9ET:5Z409V )WM,C8F8,@$S$QAUJH?:N@+7(@6*@ 8]<3
M";B\)C:V%5F^+>.\CEJ+$Y[%T >7SE*%GJFKGKHK)(:JORP>'@@*+M4./LYY
M,=7A9HT^S+,/L:4=E>>20+_DNE!MI"0@:%"(N$F1T!WF!:\VC#:W75KUJ*DK
MG4!<%))DD6$2?%Z\91O&_'MB+FZ^PP&*.!QL;(\>";DJ D7)PQ#1AQQY@:>O
M?#01QAP1",94L$8T6*,=J)"QK$Z0VO39"M,Z;),2#,>L$SY8YS'$ZO&I.NZO
M$1JB][W[XL_1KQPA)Q?Z/<*A=GI =E9D_5#/(38[&KEDFK-:?-]'>J9J*V:6
M66OT!#I+<*61\@QD3W*O20TS)AMN2050E-R-B8&^%<]^ .:Y !"05& .H%]N
MX'MQD%X'"'UQ-0=B,@;4FY^LR9M69F*0JN+RM++/-39DH*<&08C.U$Q94M72
M31/K*^0HAX8L+IY5>LI1$%*0"-B +#\!\,)YKA,\Q<@[ZC,FV\S)C%D''F $
M) ,%P>,%+J@A:RJ+@RM%"365P-W#I@J^NGC ;*""'I!X-$*(*^* >^@AN(HV
M6,3"6I#342&T1W"4]/,#"B\_LIQSU%1!OU]O?'I3X+"YYTKJ#$X^B=/=FZ:=
MU-F*.K=-I;((JMLM%*X$&!9+ZPK3CJ\ZX>KK$P$PL,@F0<B:-Z@V@;(2-]DC
MKOTPDNN*^LM9L!=1-@9 WZ&^%&&&)7!B5]>(,!7@##A @!#Q"!!!BQ,'%$#%
M'9' ,*-!'' ./!''#!#&R*)C6,:U%=(Z#8=!A)))))DFY)QD=&.8OC_7;^_H
MPI'UA[?N.)>]8?&NPH.H^+#%')W14_%%3_2G1@PD[@5)(WL1$]D7S=D3LYW9
M??NJ*O=>R_Z>RHO?J"^V5F00-))O-X.WZ'>^TVU"_H*1<'P@$[#S]4>4[XCW
MKZKS,E[M^?=$7LOMV553OV^:?=]_S]^WW9RN862I,IFYW/\ \OZ^_P!'R6N"
M"@%5Q<P0;$^<7BTQ'WXB#O:'SLE7R)[J]%[>_=/?O[JB?M_:B]T[=D5$Q&84
MR_%XDF3(N=_*08MUW]M\>T\.YC!1).^TP9@1U]1[;3<F(.\BYM)6$(]B*J=U
M;\D]T^?9.R(B^5OX_-.W?K$9I2+*%D*2%"X/E(%[>L3:;&V/H/A7.-(;(408
MOM>TS<]HWO'0C$22QGAD2#O145CE[*J]^[>Z^5%[^_?MV5?;M[^RKUER()%K
M'I/XB8]?YX]FI74NLH<'[8$W&^T;F\SY]\8W7,2<'1@QJ;RH'OJJPJ"TC4>P
M%E&?ZHXY;6.>B^G+\,7',-*Z&3R3,;)&J+)&Q45CFM<EID>;U>0YO1YK2+TN
M4CK3VD?\Z67 X&%]"R^);?&^C9*I(QEN-.%J+C3A;/N&*XA#&=Y94T!>+:7%
M4SKJ%!BK:U Z7J5TAUI:84E0U)((&.<^[S.JQE@[,WD [LL+=1$ GU2G5"D5
M,LQ%U*^F&%B''AG -8P2P;$9)/ZQTLSG*]_QA/WEPI\H66<5Y;355.:6D#J'
MTO4#SK+-2U54[6MT--!:DE*U@IIPA6M8TRE)) _$[Y4/D8XE^2S/G,JSEBNS
M%%*XXYE^=L4E8]E=715:2FF?55*8;4HM*4FGJ0^AL"HE,EKZ3"$#V@4$[=%4
M G: .2O$C;(5\*>R XBT0!PE97V4(\$PI2D )8DQRMD&F":K"7JSS"Z^J4$Z
M'6RVI%0SRPJN>:2&S*5PV.8HI@)5]8A,#>8QY>TT6XIJH(HWU.* 51TY2E])
M:6E+;BVEN%3BE$:6@DE5R(B_0_P@<86V;U0>XTA=C5"BC&%4.0(("2 2SOIU
MEF-<P&".=OP-,\:I^&L&QROE@>]8((XXH4\!^4SY4<K-(KAW)*\5#[ZD469+
M;T\IH-J4'&&E:PHZ@H!U24A!24PM1"@/MCY"?^3IG@K\NX_XMRAS+\OI169M
MDE-4K**FLJ:P_P"Q5%53:5:*=IEQYTH<4'4O!M0:4@Z\=K\5M558FI+^M[JG
M=5^2_P"COV]E^2?ZNO%J.I \*% )22E-Y( ,"Q BT=1>UA./HK/^'@-2BC:;
M@'J1!]OKVO,C$I\MJ6O;%_E>_P NWNJ]E7Y+[?=W[>Z_M]N_SU-/5+5HA0WO
MZ[21N>\QVF]Y\?S;*=#BRE&Q,S/BCI;KO\#?#HV_*^=P6>+T>D+EA "46".
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MS4'1\9!)+'(CO,U$56K8<+<4Y[GO$%-25M6@4Q8=?=::;2V%#D.*: 4+A27
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M6R3&4T\Q$[!&J<*22/"8P*-POQ?3Y[S::H6&:YDJEM12$K"2 I3<**BF2 )
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MX7+4AQL@LE&6.)SHAK!Y9TI"CQCP*TB&&E](L?X%#K&5LRSD%SBB2_1S//\
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MDB&E)BAAE<UJME],@20C2GA/.4Y6G-Q3S3*%TJ'TC:50$N+;)!""5"%;"03
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MYGX%JZFKILB[856N(?;703CYZX4(NB,F!C=6R##O>EDX::9I\I+/3G$G&A=
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M2K2%)):0K>W5) VWV]LX\^S#B[,Z,JS&MS/-77C]=QZMJ)69*M2$)<"$-F?
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MS(2@B$:K7L?\D[20OAE;'*S.4CJU%M4F+I$0("2;R "9[D[1[=6'>6X%0$L
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M4U3.3KXH%(71F&C+?FQ=*BN4\MLC2CYO4*DH)@$<Q*"HI$:BG'T[_P FMO\
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MS/@T+63B3J^Z&;.8K@C$L(.]G!\/:O\ *8V*9R/.5)/0ACF22**.-L5;3*@
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MPZFJIRY35#+R #L7"VHH5) @H4 J=[#K./,Z7-T9974[E VGFM5#12L&Z1K
M4E(._,3X  18F(N,(G%-W]W58;+\)Q3.Y!SFKN33W"QC3P?1+1V!G*3#.R."
M0,D=K89E-\B1J:]\$PTK63-Q;69*J6Z&CIZA-.ZRXJA?5;5HIU%M+RT7*4$
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M)-%$4D94CDL,KS2LRE_GTQ9,A16VMA"F]1&@.,)5/H[B&QRPMLZ@!JN1C/\
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MLY9GAB3!126=A9Q0^9B.80+(4*9 76HK&W6*JEIGF*D-BM"F@?20S"F"K4%
M*;=2AQ"D@%*T!:2%)20'A)5"MES*<QJV:NA#QR;4[RF<K%56-5E>*<M!"R*D
M-J:5S%+"FE*:4%(6L*4%SHK_ $)/Q=[>VUS.D\I+)K,\HQ\4Q"Q+/-'\5*](
MWRI! DJHC?.T>%KN[8F(V"90AMN26VQH9&I>I*!I$.+4M1>4!'C4 3![G&O9
M:2U+J6F6JI1)=6A#92 KQ:&X0G2V'%O.!(F"X8V&%9>F9^N(,/NWI /;LA!-
ML)Q99(LK*)0V=\21,]T2L\HK*D(-YD+U:5\5&T99VFN'5QEGGA:&R"^ "A!(
M&H%208F\B22/L@D6G$',\UI\M2T_6)6EAQY33SZ4RBGTM+=YKA ("%: @&1*
MU!/<%*XYM5?3:BNFBG=8BTE]$'$6/;59E;?T48ET3 56E1A&,*?2C&P0B60?
MI/\ I&&98%?Z$O33S3E,ZAIY-W4*6TI!U-J2FY.H$B8!'6\S&%T.94N:-O/4
MA=TL.BG>0\VMIQ#Y0' @MN)"DRTH* 6@2% Q!!.QSQWQ,EP#:&IZ)>3M0AY"
MS$B9%+5#I;U C)"'.1&/+KH@QA8_*DDA#88FHK^W20I0D C8S/>T6]D"9\L3
M%-A5E*6($_1.*;GH 8^L#?>Q))@'"68$=+ XF,(N09B*KRF03*.QC4[>9\R1
M>FU$1%1RJ]&HJ>7OWZ=4'"A*D-N. I!6LB$I$2I7J O[A;$5;K"2II+K;9,R
MRL)#BW"#XD@OR03<+T7FR9,8\_//Z2CI))Z"R),L/G=Z*S(U6)*L??R+(C'*
MQ']O.C55J+V54Z9O[#\8PUI5M![^7Y8\O*O=4[?+Y^Z??T8-)DB-M[CK@[*J
M^_MW17?ZE7_?O[I]_4A#I)2F!&V^%A2I ( GU]O7B7W@"5$\9_AM]N_;E7-*
MG\Q#O[^M5PD?_K%EWFIP?!)_#'FGRQ("_D\SZ\0BFV\ZEO'W!*O?_0B?Z$[=
M>[G?V)^X8^%UB%K'^^O_ +1.*=<PG!T8,'1@Q<WOW]E5%[>RI\^Z=E_;^'_Q
M^2D F%04P=8(D*3I((4.U_A@O!  )MIE100H*"DJ21^TD@&.HGU8Y2<^9:QX
M:WLT\,<S<?JRB;3/&-8GH"32/6>QS[W>9S&35DLJ/%C57>>JG$?&LCXRT@\
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M6M<V'XR<=DLG9RJD<:OD5C7N1JL8Y4U60*<14N-H4E.I$I0M02DJ2-1,*B2
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MJC@8=9.VAI<YIN(7#2!#^5U:&WW>>24TR@=*TL=$J,V OOM.,$:WAZHX8_\
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M?N[W[?<J(J+]RHO?[E3NB_/V]NW;HP\%7)(Z188T^_(N=)=2:B-I2FV1T3=
M/0E#51<U..)9>@+4RD$ Q!_#G3A*C6G".2LA+#AE5)?2DL*!]E)6P\&-1^DI
MR])2EQ92APJ 2;%I$)("H58@ 3C+\09?65-31U67&N*N8TQF;675#5-65&6M
M&H<0BG>>(;0ZW5.H<@E/,1K05" %;8'2WEL)"RU88';CTM12Z,GXASH]#8PA
M VMF?(^$8$8F(BUG=,L< [PH2(D9#)(^%Z1M5=/3MO.J9 Y>MQ381]4("UA
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MI*U%]3LU/=%[+V[_ 'HJ]O9.WO\ [KV]\S6-( $S!,6,2/:#Y]/=MC:9:^
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ME)0F:8B20J97RO(GE5\CR7.]5")'N;W=)Z_:9SO=5>G?MV3MUL7TEUAQL)2
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M];7)&5,)=:N5FE45]?$4Q"8%KQ:"?+?&)XG<#E-2/*(&G,F(N  G422228
M^M( &\WCYU_I.N1RJZP![KW[]BH%]T[=_E(OM^WY+\T7LOO4O4M4MTS2NJ@*
MV!'47V/3[\>I4V89?!U5M&V S2B55;<2&C*=KGSFT7WQ[,M:WY)8@^Z_>5!^
M'_\ -3^[IDTM6DP*1WOU-_Y>V)B<QRT"V99?$W)JV[?=Y8]ULZQ$176->U%^
M]3!T7M[>Z(Z5.Z>_;NB*GS[=)53U!20:>K$B\4RR/88$CL9OWQ/:S3*Y0D9G
M1%4 1SZ9(F(/C54B!O<I&TE(VQ?]+5+6M5+.O7O_ /AHR?M^^5/GU'72/@ ^
MCUE[7I5]!:+_ (XMF,URU$ZZ^AC2 (KZ,S_^<<#;:H5W=;2O;[?><+V^?R_\
M]\^DABH @4]4+S)IE_U^[$I.=96+"OH>]Z^C_P"^&+OI:I^ZUK5_8AHZK_H2
M157_ $=)-*^JWHU9?M3+GOWQ(&;Y6"",PH/;F%%_WXQ<EG5_/Z3K_=.__P!&
M#]_?Y>RRHO\ H1?V]ND&C='_ #%9ZO17"?5T@CK.'T9OE2@9S"@M'_\ 4:(?
M>Z<4=9U2(J+9UZ=T7MW,%3[OP69%3Y_>G0*-X_\ ,5?J]$<'QF,+&;92"#\X
M4%O_ +RH?^]QX.LZM&]TLZ]7=_DAHJ^W]:O]W;^?H]#> !-/5]B!3.'V];8<
M&<96?JYEER#&Z\PHCVM ?%SZSZNWDEK6_/X\!5_%3!5__P!^CT1>YI:LG[1I
M7)CMOM-_7@5FF5K$+S3*5CSKJ8>R4U23[CB_Z6K%^=D!_;!_;O\ /_[ITHTU
M21 IJN(@'T1V8V%^MOZ82,UR= A.89</J@Z<PHH5H@)^L^HP($22>YF2:I:5
M:K_],@$_^O!O^^5.D>AU'6FJ_;2N#XD1A+F=96D IS#+S>#.841^Y\8K])U?
MYF!_;!?]MUWT1_\ AJO_ -W7^6&OG[+?X_+_ /W^C_\ W&+4M:M5_P#ID!_;
M!O\ OE3^_H325 (5Z-5F.]*Z![S;#R\YRL()&8T 5;;,:&1<?_;],7?2E5^9
M@)_]>#+_ .,O;^=43_7TI5+4*WIJNW:F6/? Q'3GF7#?,:%9[JS"B)ZVL\!U
M[8M=:5B?*S _M8R_W3?W]<%&]_#5G>U.L^_:,*.>Y:1'I^7W_P#\^B_%_'G]
M(UGYD!_;!5_NF5>CT-[^'K/_ '97YX1\]99_'T'_ %A1?]_CU2TJ_OLZ]/W%
MC_W>MW_T)T&C?!CT:L]M.L'[CA8SW+0(]/R_VU]%M_[?'FZRK%55^D@/V?\
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MDP!(2!$#RO:T0+;3.$M+.^:1TT[_ #+]IRN=[HU.RJO;NJ]D^:^W;Y]<;,K
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M\O\ 81>CYZ7_  K'N_X<'S(Q]M?\ROSP?H:IO^OR+^\ -?[TZ/GI?\*Q[O\
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M.#^<F?V:#_%T?/[_ .Y;_F/Y8/F1C[:_YE?G@_1.#^<F?V:#_%T?/[_[EO\
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M2/HKQAT=8^FM&64TR00@+7F*7-*JJB1Q0-A=)+(O95\K&KV1%5RHB*J5:94
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M^/\ 3!Z%1_PZ/U[,'UKT_P">G_TV_P"'HY;7V/C_ $P>A4?\.C]>S!]:]/\
MGI_]-O\ AZ.6U]CX_P!,'H5'_#H_7LP?6O3_ )Z?_3;_ (>CEM?8^/\ 3!Z%
M1_PZ/U[,'UKT_P">G_TV_P"'HY;7V/C_ $P>A4?\.C]>S!]:]/\ GI_]-O\
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MBRQK^/W+[)V553OV7O\ /[^WMV]NZ?)51><M5MQ!FR@)O-[W'KWZWPGZ.22
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MMA]<<OILODBLF+QQO#M)9W.V=MHLDRAI@Z"<ZW#O9N.]A&+9#P_ 00U"61Y
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MJHN3=B877VUQ4VJ9KCK<ZN.G?1[#/X$\JSEH*$Y(A6Z_69ND#6)LI%F1;1D
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MV<]R)W:Q'*K6M5RM1/,YR-;\U7MT%P""")!D:CI&Q%R8'7OAW22E82DJ44&
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MGI +4D46 \&(]3K>$.F^&$*>>7'7PFRQ764TV;LJ&<T="\::@)=>K"M*:=(
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M%&D\S4^(DI<IK$YGE>7UBDJ6:RA8J5(J:=5*XI2D@+#E,X2IM?,!)9!<* 0
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M4J/,4W3)9+3KLW4_#[^R>RK[]E1%1>WWHJ*B]T]E[_/HD=QUZ[1O[O/'K:'
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MK,H$%Z2(\)NH8S.'?#APIP%!:0\38&MR\MT0TFQ.0BRMK*=&+-Z0K+.\,L;
M:O@2>7T@!B81$=))*^)\K_.G:_.,SS+0JOJ5/!D:4(^HI6HR5%M,"02+D7 G
MUKRO)<KRAIYK+:9+"G5ZPM"%)2V8 /*6L<Q),$*ZDDC;=\>R?@G^CJLD]S[\
M7.*]<P8.C!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&$!R?GK'6<=;O,UA;@;"[S-J#
M7D^661$*F$E9#$]D+7O= 0YR0$MC:Z58))$B9([["SJ1UIFHHW5)2H-/LN+2
M0#J"'$K((-C(21>QGSPT^"6'@!)+3@ &Y)0H #UXXPA>(1U'F0#JTMX9+9D'
MM1Y&+!-!*Z%\?:5J^58D]=',D8Y4<DWD8]$<YO?UMFB9?TK4E*FWD\U  &@&
M19.PD@FPV!,6F,Q1H2JH4VLA"N62 J 3"D"+WZ^KKTQ"SFOFB*XDF*C+]0R>
M9SVOC>U4]5KVO:YZM7NC$5$\_P#S49YN_MW[W#; 81I*0E,ZM@(!  V[QUVC
MVXL*EM++6@P0257\Q$]^F]X]F.M?\DZ%IV>'O7WM[6V-?3:WEN^OL9/82L2&
MWHV4>9HR;*K&[>K&"MU2V0K27KY2R!YW1M[1K)+Y/Q8IHYL\6U(.AI"7- D@
MD$@*(N)D&"+ "\ 0_EL-TC95X"ZZHI)$%:84HP=R(!)!MT%[8E7XB^59,E4I
MD<^<X;370SY3S!I/(514BN=%)-&]KD</8V:I(.!(SO/ /$<;$HY#:Z2;SW.*
M\4U,MIM8#[@@)2LAQ(W"O"0H ]^NPQ.<6#ITJM,'28/E?:-\05H\TZ4AD[A_
M1;Z",9YE3S.1')V<JJB*KE:O9O?W:U.W?LJIUB5&3J4K45:22HDJ48V)-Y&T
M$SVPWRRHDD:I/UB),#M;V3M VB,+]N3[JU[HE>V/U'M557RHKFHBK^JJ*J(B
MHGMW^TO;Y^YJ*?"5$$]"HR?>;^6)/+[MD38^$ 6/KW'E[ML,!RKOJ/$3R57H
MSF6D36*0*$D3OA4>SS-83+.L<$4GD<UZ0L:3,Q'L66%C7-7J6PP705*D"T%0
ML1?;]=<2&LO>>"E)TM)3%UPG5()D3<P9!ZWWVQ$HC?Y#3V[(G3S5-ZDL<L(]
MRH[1#7M?Y(X&6,9#XH)'*Y6P_'1"#>?R^0A'^1'20P6P82=(! 4$C20!<VF8
MZQZMB<1ZK+:M@A:.4[<%6D)44@&Y)@$$"\QM!Z8\*W0VV'Y(Q][E2C:?65FH
MJ%J8$2<4A3"+" 5097,3T)@CVS/".C2608D$B: ACX99(UD4CJTOLE+BDIU
M*TJ(!21)! (L2.H,^[$<J(*4ZCJ!%I@Q:;3M,6-Y]F/IDACT7TW>R&%4S\Z^
M*K3/!ABF0W0Q,4<[;MUL7(2\(F*8AP_T?&&/&H\<<J$/D>Z-[MDC^\"E3RX%
MS=!N1/:#;L<2U%)2% C3'B(V"MXM:8(D;CM<8W37(J)[HJ^R+[IW[_A^_I2K
M&]@H^'I(Z1W$=L)D$ @R#$$=9N/AB[KF.X$_69_G)_<O1@Q+CJOQC\1JV?\
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M!VQK/&-ATO,\E!6L. I ,:1"AJDD&+P0!U]<>>4CM52\74GS4R:E]-<2VA)
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M)[>ZOB2Y(V+]%!5U]1THT#63^I&383D>DR%K)(0RWRR#07KW&I4V%4S"TO\
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MC[$R$G6,5P<0_+4;YS;8?$S\;#VA<C@5<38C\>DD8> V?U"HLC/-FV2MI99
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MP.&/OYDD']-4E'+;)_EVG12--0GN1\1ZR^?J[+#'*Y"D!:%0"8$H$&XF">Q
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M?_SOJ^MFR*@Q<*M^P@>(HLV&V-/)Z"HZ59&*C-JVH2*="Z:BH1,4E$P:=JX
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M!*=,FPB9$")D=_.,-Q@.)]?R801'35)D>= @E*U.O*!,3,96E@B6:PM;RS9
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M=+R-2X+ VVHY+EJPB76%[RI1VLFO!KL1<W=%=9Z'C>&R)JJ^LN*X@V[/RS]
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M(K+$:>-@-*)7C.@ <2*01^7E[L)4PT?^;186@ >O8?&\X=X;+YD*QL[@/.4
M=M='PVMS:!TU<+86UH-#(./8V9D T9)YXX\TL$!94LI$,,LD4<C6/<U3]>[;
M"PVV)(0@3O"1>-NF-#K>,\)N@LS5ZS-5MS3Y&[CT%)3$PI]#P6$5#>YEC2:I
MGEKK"O\ H;26X;ZJP&*K7L*\[A5FA@DB,!;0H!*D@I!V-Q?RV_4XWYV:SEG6
MV--99^DL:>XBB@MZDZI +K+6""$<>"&R ('D%.BA@$$ACC*BE8R(8>-K49#&
MUI@+;9$%"2.T"/=TV&V,-,1BT2R1,AED2XIQL[;HF?J42USX0[A J*R["?\
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(#,GN?><?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g209588g34w34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g34w34.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4M::'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C8M8S V-R W.2XQ
M-3<W-#<L(#(P,34O,#,O,S M,C,Z-# Z-#(@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I
M;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO
M;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @
M(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(Q+3$P+3 U5# W.C(T.C0R*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#0R R
M,#$U("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP
M.DUO9&EF>41A=&4^,C R,2TQ,"TP-50P-SHR-#HT,BLP-3HS,#PO>&UP.DUO
M9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,3 M
M,#54,#<Z,C0Z-#(K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z
M=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ,#@\
M+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF
M;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W
M44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!
M14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)
M44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"
M04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X
M9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9B\X04%%46=!8D%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!
M445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"
M9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I
M4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH
M9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/
M5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF
M,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP
M2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$
M0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z
M2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD
M1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2
M;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.
M:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV
M+V%!07=$05%!0T5135)!1#A!2CAK=V1I<G-69&EQ8V%2-6-B570F(WA!.U!V
M3#%B*S)T;'-11VUH;3EF,4],37%+>6E/2U)4>61W;S-R6#(S>%-O2C5C.'=Y
M1G=M;#-B1T]V<4)92E1X-',V3E=I-U5A2G=F9%0F(WA!.S1(1E9..40Q<$9U
M1V94-VQ6=$=#6%)-36=%5$XP5U-O*T5M=F9&56)A954Y5FQK=6QV94]K<%II
M33--;6]#4T5)6FI32F5)4FYQ.4,F(WA!.U(X4%%%.4U6<%%B>3%R>&Q626)#
M93574U-32T-A,VIE84M:;VE69C!:14)7441I9#%/2W)%.'9A*S=+<39B9$9M
M24-J,%I.>54Y5'<F(WA!.R]K2$PU8CE-5G!&-C$U3CAW-DYB4C-..6%/:TQL
M,6525EIK:EI*6&@T=3E/04Q'3W$P2G%P0D=+,&MM2TA9<3=&6%EQ*VTO>3 O
M-5$F(WA!.U12+RM-2"]'-UI%<S(O>DM:;#AI-G=Y:V=I2%EJ62]B6$5+*V%0
M<DYZ+W8Q+W=$9VIK;4QV<DYZ+W8Q+RM#3TMU*W,S4"LO6"]W0T,F(WA!.T]+
M=2MS,U K+U@O-$DT<3<V>F,O-SEF+T%)231Q;6YL,U(Y5S$V.64P=$QG4G1&
M13 X:GE.25%%56=(-%DQ:V1T,D@R5E!J,')I<6LF(WA!.RMK*UE28W1B>%$S
M1G=Y<U%R=T(U56-#6#!/56),54UP;"M!1614=#%X5E5J,%1Z1V)I4T-E0S9T
M6&A6;FQ-,&,T-#A9;FQ!64MR34,F(WA!.WEX3GAQ3S%444%K2W%2,')Z2T5L
M8S)D-$5G.50Q,CE/5VEE:U%*3UIP.%!!;C1Q.4\K2W).5G1D4C!Y."MQ6$4O
M2U52=WEK;S=%56XF(WA!.VE76E)V5&-,24LK*TMO5#9Z8R\W.68X031)-'$W
M-GIC+W=#+U@O-$DT<3<V>F,O-SEF.$$T231Q-S9Z8R]W0R]8+S1)-'$W-GIC
M+S<F(WA!.SEF.$$T231Q<%EO9&ER<U9D:7%/,"]6-W5W=#=Y0T%*>'95:E-6
M;4)*6#!P:VY5<G93=DM-9&$W67!:1$PK6G5U=E!&2W1T85)M3S0F(WA!.VIU
M*T-*2GAA5T]A86-L=55J2#0U3&QY,5!A;$UA5S!/9GI#,7-W4$8V5G9Y6D)'
M:W9&*U5A+U8T-UHK4'@X9C-K8T,X=5%/+S)A63 F(WA!.W1Q1G U,3%7,S%7
M*S%(,&]:5S%#-$8S4$$O<6E-5$LW4U)S:%(P:U@P>34T+T@P.&-6=%AF.'=D
M8FQV4').>$9B>FAO<&]*;U=6,6HF(WA!.VM3-'5$9$YY-$]J06E1:6A6:# W
M-S%A5S%E-R]!1%(X,#-7;GDR37I1;$II-U!+14EF:SAV<6QG43%+,"]D.5!S
M8F4K3DQA13%F>GHF(WA!.W$R<5)8354P3G9(2&1X3D9+26QK1D]D,SED6FAY
M9'9I378P53=9,'1S8WA1-T9867$W1E@P,RM7;B]+0V%0.$$X65 K3C)Y2EIU
M+TTF(WA!.W8O;$).62\T=V8X04<V-&A8>DIK;41S5F1I<G-69&EQ66%*<E4R
M:UA:=5EO26)G<VA1<$U';TYW=UI7:F%/4D="6'%R03EU;4M5+V<F(WA!.R]-
M-UAO<%!73G9A4UA(<4=4,3)344Y1,V8Q,'!26D94:C9V*U17:#8T,'1O0T1Z
M=G)C3FQ:5UDY2C1R0F)L26UD5TQ-3'%.-&HV:$0F(WA!.T1L-EEM9C O0W9C
M63!T;S%0>DPQ.&5O6&ET<%=K=$9S:7IO.5%O5C%A44986#DU2C9R1GED:64R
M=WAP8EDY<75Q6$=P,VXQ=31#<DLF(WA!.UDT66E%0D%P0D5S2VYC;F-R1TLK
M*TMO4$9$<U9D:7)S5F1I<C9H+S56.35*+W=#<DQA9CAI>&M78G8X06Q8,VMN
M+W%Y,FXO27-9<3<F(WA!.R]L6#-K;B]Q>3)N+T%#3$=+=2\U5CDU2B]W0W),
M868X:7AI<G8K5F9E4V8K<DQA9CAI>&ER=CA!;%@S:VXO<7DR;B])<UEQ-R]L
M6#,F(WA!.VMN+W%Y,FXO04-,1TMU+S56.35*+W=#<DQA9CAI>&ER=BM69F53
M9BMR3&%F.&EX:7)V.$%L6#-K;B]Q>3)N+TES67$W+VQ8,VMN+W$F(WA!.WDR
M;B]!0TQ'2W4O-58Y-4HO=T-R3&%F.&EX:7)V*U9F95-F*W),868X:7AI<G8X
M06Q8,VMN+W%Y,FXO27-9<3<O;%@S:VXO<7DR;B\F(WA!.T%#3$=+<#%:,E9P
M6E=S9')A4DQ"8E)$:D9%9V]Q:G)11$96=6\V9%IA;%I45TXW14IR5V1E37-2
M2D%95G(Q56<T<7AV+VQ66&M$+W$F(WA!.S!*+WE.;2\U<G<R<G8K5E9E45 K
M<E%N+T%#3FTO=T-A.&)6,R]+<79)2"]6;U0O:V).+WI8:F%U+W=#5E9E45 K
M<E%N+TDR8B]M=D<F(WA!.S%D+WEQ<GE"+W="5VA0.$%K8DXO>EAJ874O-596
M-4$O-G1#9CAJ6G8K83AB5C,O2W%V24@O5F]4+VMB3B]W03$T,G)V*U9695%0
M.$$F(WA!.W$P2B]Y3FTO-7)X=%AF.$%+<79)2"]6;U0O:V).+WI8:F%U+S56
M5C5!+S9T0V8X04DR8B]!2G)X=%AF.'%Q.&=F.5=H4"M2<S,O3F4F(WA!.TYQ
M-R]!2E96-4$O-G1#9CAJ6G8K83AB5C,O2W%V24@O049A12]W0U)S,R].94YQ
M-R]L5EAK1"]Q,$HO>4YM+S5R>'189CAQ<3AG9CDF(WA!.U=H4"M2<S,O0418
M:F%S<W=+-T9736$U<2]N=3%K;4]L84)$<4UA3S9W9S-347,V05%'3G%V4VY)
M=DU'1DYU3F0Y9WEQ8F%&<58U9E<F(WA!.V1B-C K<%@X4'!P95=O:T5Q>'I0
M0DA--D-284)U4'$X82LR2W!J:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)'4% R;BLF(WA!.V8W,U0T13AL-FYB85IE<DE48U!D24=$4C R0W-9
M<F=!9R\U1R]I35915VAX+VUR8C9F8C)7<%A7;%@R<'=X.#=Y-V-39T\P:S!V
M1&DF(WA!.TEO-$9O<V%Q4'-$-F-/>DE6,5)K<R\U:5%M4&U.24EK8U)I;C%N
M<3-Z=V=!<$IJ-7%Q4RMF5$TX5$13=5-+<E9(,6EL1TQ$+T%),7DF(WA!.TMF
M4C5Q=CA!>G9N+T%'<2\K;FI&9E(U=71:+T]%.%!-:E1W43=X:V9V*W-B;$0O
M>$A$:FQ!:3DK=C)&1U-(0V$Y,S)I,6(O;F-0.$$F(WA!.W18+SAL.&XV4$YG
M-R]N8U K,68O04UL.&92-7$W+VYC4"LQ9B]W06PX9E(U<3<O;F-0.$%T6"\X
M;#AF4C5Q-R]!2C-$+W18+T%02F8F(WA!.T@P96%P<D0V,V]X*W9X.6)I4%8T
M5C0X<69&>')V4W942WEQ+T9867$W1EA9<3=&5TTV+V,O;4A',7@K9W)45#4Q
M5U-L<TQP<$9,258F(WA!.W0V1G5,1#EP<'=F64M10U)X9%96.'9(5EI,82]B
M55-T='%H;6AA.%<P+V52:6(V:F(X,51M<D5R>39F<GA#;$%E6CE1=DE.33 U
M8F8F(WA!.WI)*VLS=#)*1$A*3EE#-F590T%S,T<S44EY<VUZ3"]L9D-1,5%-
M36A2<$%.<$)A-GHU:75Z<&US,F9M<39M,&$T2W!C5WIA9G T;S0F(WA!.VU:
M1S5K>5)Z4CAX.%-+07I54VTX:DMP1$HV5F$S2UA-4'%X<39R>F1"-FEL0V94
M8W!Y06%N=W1X<7 W:6A'>'A1<31Q-T9867$W1E@F(WA!.UEQ-T979W=,1F4T
M;U0Y3TMT-'$W1EA9<6AT4C%05&1-<S-V9%-U-&)'>FHT:5,U=5I&:6E5=7=6
M951U5E5666=$9G)I<4<P<E5D4#$F(WA!.TME4RLP-C=I=F)+84=,,&)I,V1*
M66TT>5-Q,T8P2D)O>6M(9G)I<4UU<EE80TMV3F]Y:D(Q9$].458O,6=W+T1*
M4FQ30TQ1=6QY>5,F(WA!.W-8:V)M-6AJ1$U10512-5)864%96FEI:4HR5$1)
M36M"1$)Q8T%D27I#>4=34U)3,T]T2DI'96AP-&-S;VI'8V1H6$TO85A*;%!(
M2VDF(WA!.V(U1'4V0VQ3,W5,=C8R8F4T168Y,S9I=$AY+VUP43%W=VY,:6\Q
M>5EZ:$AH-&\S>E)E6$Y$<U9D:7)S5F1I<G-69&ER<U9C96YH-S0F(WA!.W%K
M2&LK5%5:<E<K:W8W9UA%:V0Y9#)T=30W5SET8U!(14A)9&\S:V]0:61653E&
M66-K2GA60659=%,O37$S1C%(;U=L5VPU24I83G F(WA!.U!--%-0,&5%2'!H
M,#E:6$PK<$Q,>4]W-'@Y2VQ15EAA6&8V:D1P5C%C-C(P=&IQ5%1W2%5&,'E"
M-W-*3V109TUQ<6]J=6HV66%U.5 F(WA!.T%C=D5(1UIB03$X=C!S-%-%5'5"
M3#,S*V=H0S8U<7-.,6\Q<6M0;5<O=T)+3C5*27-&>3EG>3-5,4EE6$)),F=I
M8FIW6716535C<54F(WA!.V)A;4EX;4=X3B],.4-Z:TI'=T)(,U@K:VQ,.4=V
M,%,S:&TO5"MP,S%V<55L:71T9%11=$5%3FAC3$9,1V956D%$94=.:'A#.#)&
M4E(F(WA!.S,V;&EZ3SDX>5=.<$4W;4<W;4M+5T-15VQX2U=P34E/2VQ5-#AU
M8F9:<EAJ.%@R451I:$-4*V5F3#!-;')(-FMS<EAG57AE;$1*24$F(WA!.U=U
M63=1<7I+0V]:2G!1<G)7<6YR=E-Q<DE-5F1I<G-69&ER6$I14712>4\T2&9B
M1E9O+W9M+S%6+U<R2&]H9F=3-T961SA&,&)38U<F(WA!.VIP1F1E;3-O4U-O
M6D56-F9#5U%015=!4%5C,7(T:D9712M61U0X>E!Y=71M.#0R34UK97)&>F0R
M9',P<TU43&(S5&5I5DUC>G50-VPF(WA!.U<R:S,K5S)+<V@X=&58=$4X=DLK
M:S9.8FDR<V]);WES460U1T)E4UIZ>652;F-K;'8R:BM'2W S:7%59E=.4# W
M5G)L5T,R.&-S14PF(WA!.T%):$-S,T]B:V9H1DLW:757,%I22#0W;4=W2V%W
M>E)Z47!.17=E2U)1-DU/:%9H54@W<W))<&U#=7=+:$QI,W4O<EEU3&-X+S-F
M<',F(WA!.W-N3"MA=%)42UIW;'A72S5..$IX-&5'5C@S9C=L=CA!;#,O-&9(
M.34O4BLQ9C-8.4PW2&8W;'8K6&8X031F2#DU+U(K,68S6#E,-T@F(WA!.V8W
M;'8K6&8O04EF2#DU+U(K,68S6#E,-TAF-VQV*UAF+V@X9C-N.4@W5B]D9C!V
M<U)38RM#.#9C-D1L5'!8=E-U5VDV,V%45C=.-%4F(WA!.T]X5C)+=7A6-' U
M>'1%,69Y:'%Y4U)8>39D8659-5DU65I8=#19-59T;6QE965'46952U)Z4W5Y
M=65B,$MK+V$U67!E:V%U4%!5544F(WA!.S!79WAA64=35&I:3&1,2W-19T-2
M8U$O<'9534@Y469#=$].1'-2>%I1:69+-3%%<&8O<$U1:E5V5V@K=6DR-65J
M-B\Q1S(Y5#!U9G@F(WA!.V-/5F503&5M2W Q:7)S5F1I<G-69&ER<U9D:7)7
M+TQR=%1P:7%"=DHT-$Y1=#5*2SA21$MO0V=S4U=K:%9105!%;DQ):31N,R]R
M65,F(WA!.TY(.&53:D1B<6UP971);RMU4W5P;&-+44%V<%-"55)Y4&E#:&0O
M97!O2S!W4VQ9039"35)U4VUU45I/>%94=5EO<')E5TM61FMJ:U(F(WA!.VQE
M3G='5F=246AG,GA(>GA6-3$U53AW,V5I+VMZ86%T<$]K3G)6-6%Q>4QP=6YW
M,C%U2C549&U+5F]5,#<V>D(V65ES+TM,;'E58W4F(WA!.W!/2W-M.&QA-W%/
M=3)),5!59$IM,%,W;6E54' Y>'DY4D]%,#9!+T=K5"]%1G(X4TPY26]3<7E0
M1EA9<6PR:%1%-F)A=TY'>5!&8E$F(WA!.T5L=4Y#0W1!4E%N*UAV:SAN,4@S
M<UEC9VU/45I/>%9B3$MS83AM1$5%,"M&5V,O8V]*>%9J9FUJ.'<O3&YL:65Y
M5%=(;'0T3#%,;54F(WA!.UA*44)),'1%1'E&:UER335)66-6:6IC.7E!;TIX
M5DIR8C@Y9GDR=34P=#=,54IB<31L=EET3VAJ4S)U1C5Z>6M!56%215%"86MN
M:U(F(WA!.SEK,')T5E9N*TMU>%8R2W5X5C)+=7A6-5HU>#%,4CE2+TPO>E).
M*VI42F)A3G),4BMM.71&2T1,2&-X9E=*-%DS3'$Q5VQK-4XX2DHF(WA!.S5D
M355S,#@R5"MD631O=CA,45=K,#56=E4K=3%%66)N1W$W<39.,%IM,D)Q065H
M-#%53"]!0W$R<$Y&971Q:7A*<5IL9TXX<T9F4D4F(WA!.S5S8F(Q4DAY2E!$
M;EAJ53E-5E1Z1EA9<3=&6%EQ-T9867%H3'E36DQQ>$-31E5K;5I*56]P1$0P
M6DA&86=K55I",$]4:4)2.3,V5TTF(WA!.VIU1G!L,4-7.31W0TY,3E4K2UIW
M5UIN-3!:5E5-=7=59F%09GAX;T%B.#%S,G!M,4$Q83!A5C)N9$EB:&\S:T,Q
M56QO:'-&0VIO4TLF(WA!.S!R5$IC6'!.8F-V,'-A.5$K3&QU4DYQ2SA'-7A+
M67I'=U)G<#52>6LP8VYI+W=$<V5M5C-S>G!-8T-867%P,TUB4U<P<V%S>4TV
M36\F(WA!.V1!<%I34E-O1&@Q<5!D4U!B1E="9FM(1D9&*U9':'!(-G1!3&IL
M-C%U='$O33--:%EE:VI/2T)Q9TY8-&AU44-A0E9M.%A,.4HS1E,F(WA!.TME
M:D148B]+;'A61EEQ-T95;W1&=3=/-U<S85-/5TY)<F5)14E68FI74E(K,C(O
M=S5:3VIV,VMS23).:S-Y=&TW1E5097HK:D5'*W,F(WA!.U)7,5=P>FY&5D]X
M,DAX4C<O5&=--'@S;'DK5$M-2E,R:4Q0>EE4-3@Q<3=G;#!33S(X-U%E6'!,
M*V%3,VE74%0P=FAD>6PT:7%J:WHF(WA!.RMN=U5-<$YA9DA8<TU);$=7.&53
M2E%L2&%1;W-#,'1O=%8Q4%,U-V(X,G)M-3%'>FYT;TER9&)A.&AT<FQH2W-N
M1S5T:&-)2DAK93<F(WA!.VE4;'E#.$)W2VUH2W%(=&UH-F1D861P<5=L,693
M86I-<VMZ;3=M,F1L;&UE4D9/-2MW<D)".'5G-EEQ:CA69&ER<U9D:7)S5F54
M-FDF(WA!.W9M5%=F2G9M:3 X=E=K1V\S>6598G%%5W9',6AH9$EP5F1H34I)
M-&A,4B]T,4MU>"]W0C)(<7EL;E!M=3$X-#-.:$<O;&4X9W-B.$$F(WA!.VAO
M<GA684DQ2W16:7%43GE89U4K2&%J3C-#:TM&,VQ.3E130SA45EAJ:S%26EE"
M9GE15D546$%S3%E3=$A52V5*971.:'1I<64T<3<F(WA!.T9867$W1EA9<6]T
M8T)B=4LR-#=Y4GE38W9$,#)28694-FU3-&1R4F4Y2F9Q4'$S3CEP9VEK2U=V
M<G8V:G)11GE92DM"5%-T2T$Q23@F(WA!.V1V15=1,D5U*W8P:')L=5(K3VE*
M*W14;2M&<F(R,S=I3F8S='<Y55)4=%)9>'A033<W.4%01W112VTQ0E-71GI,
M<DYU="]/='I#,78F(WA!.V-6=#%J-%)5-5),4FQ,3U=R>3-$16HR1TXW56ET
M-U)L-TLP16]U2E5*9VHK265K2&QK8FA&2WI!4F]P66YW0S%*=TI25G)C2F,R
M,%8F(WA!.W=I=6E427-I<$MJ4GE!34MG4$<T5FMB9F171E(S>%95>%9#-G)E
M+U5D3'4W,S!*<FXV=$1*3#E7=&]Z3$Y*=U5T=VIJ1S=U,4M+3S4F(WA!.WA6
M-3DU1#!8>DQQ9C5-5U=L0FXX;C8Q37-I;#1B961*3&5L,'I-9E)U1U-53DMG
M3E1Y+V%Q;$)41E=595-T0S%(47)%85IQ3W)483,F(WA!.V1W>$M8,4,T-65O
M+T]A9'=0:F56+VA$52M*,BMG54%66DAI<G-644=O5VAA84M:2FYH9&YJ4G5(
M06=H4WA8-V%T,#5(2D-7,55X258F(WA!.W10958W66U6>DDV>5-P>DE!2D-3
M<V]R>$%(465'1UDS5U!*135":VAR+SA!4UAO:CE(*VHV,TEC=G)(3&IX;V$P
M-&(Q<E1$1W5Q<T\F(WA!.S@W*UAF3VUS5SEN.5(P-WDQ93-54UA-8W-U<U%Z
M5$-*6B]45VQV4DAO2&I$:5%.<V9H-U9X3F1&63E&*UA8-6PR;6]#*W-B<E%9
M66@F(WA!.W%59# R:W<R545%5%<V<TI*83-)<S5*=E9L94M)13AA:F='1#%!
M1T)75&%J<"\U=69O5S1I,"]69$Q/<4Y4-G1.3D1):7%W=DAK2EHF(WA!.V=S
M<6Q483A)*U!P5C564$QB9%9+3%!29GHY2D@Q=E@Y2E%,8E-X;F=N<3@W9W)C
M96Q-83)S4$5+,&M&5C-Q15!I87%V4V]W-&I53V$F(WA!.W5!3U)(46UM*TMR
M<U9D:7)S5E-B>7AO.'5M>#9I6G)E2S)L=G(V5SAK145Z5$LW4VA16D1Y:6A+
M1FEV,E!I<"]-8U95+TY-4&Y34TLF(WA!.U O1$4Y:D)+1F(Q9G)W:TML=6-:
M4VYP:'1G;V9L-#%P=#EO2W)V2WDV:W-D.'5Q4$9*<5%M:$8V.75'14IM*V\R
M,W%'34XX6$AL5VPF(WA!.V-65'9&6%EQ-T9867%S:VQ%9D@T5V)M=U@T4E=L
M934X0C<T445%<%1/13%(5G)D0U0Y4DYT4%(P9F%C1F]A-W)V-F4T-D@T:B]K
M+V$F(WA!.W5(<&EE*W@X3V)79E9,>7(Y4W!R;'AC45A';4=+25,X<FMO0E9Q
M:#)G:U9+:%9B-$XV<S,W249D.')I44%76D<T4C%V03A(0TI11VDF(WA!.T-K
M=DM303=333-*;4M+<7(X4DI9:U4S-UI":W9A0TYR:$IZ6#%),&1&.$],;%-F
M*TE$1E9T>"]E,C,O1U$O.$%*=#A65G-69&ER<U8F(WA!.U-F>F@U<# O>7(U
M8W9.9C%"2DI,3WA65VQJ:$U1:TED,5%C4%=E1D-A=# U5E!15DY":7%$.&LK
M871-.#$R6#9E,#)+84<Q=31L0W F(WA!.V-)<5-6:6UM:4YE1$]H,U0Y;&HY
M*S)+<VMX5C)+<EI);W!6-%-)<G O2W="1S-S8U93=4,R,%9&9%IB845/2EIA
M,6E"4#DT,5 R9D0F(WA!.THK2DQV3$AH2&-S5S8P;7DQ2&MG5T-*-&%%<$=6
M0EE.,S1R:SDU4C<Y,D]W2TYI,6I4<&EW:FTU1F%C:'A9158V9%(W6E=9:V,R
M64DF(WA!.TMP.69T4#A!9FXT3B]427!D.69T4#DK9F<S.4U69#EF=% X069N
M-$XO5$969%=$2T=88T560CEJ:7)E2W5X5C)+=7A6,DMS6C@V,E F(WA!.VXV
M-VIG2&Q(56)85#-73U54;3953GEK3'A'26ES53)Y<7-G8F)F;#0P6E954C51
M:3%72S%U-'18;6IU3E934T)B*V5%56IE8U=&<THF(WA!.U=155@T4SE34&A(
M>4=+<#EI<G-6534W;3-T,#E3-&Q31D-1;V529V]Q96=Q85E216YK9VM$;6=B
M=E9:63E1<S=E1TIP16UL84MA<6,F(WA!.V1H1UA$27IT1T-"5&9I1RLK;&))
M-#=I4U=%<#=G26$W=CE.8W!$<60Y1C9O8S$P*S)C<UAQ3F\S4F%Y4R],:4$S
M9&-!;%@P<$UB-7$F(WA!.S X1W!83W%1>4M'<S=:3&5E37I";S)L16I3>$9A
M25));D5R1U-$=C=H5&M,,G!L5SEQ.&UJ,FHS='1E8U(V.7,W=7-R1&Y**SA6
M,4LF(WA!.T(R2EI5+V5%.%)T9U-J<U9D:7%J8V8S='0O>&M0+TIT.%96<U9D
M:7)S5F1I<49I2D]P,T%O4E-'1V@R,RM+6$955FER<U9D:7)S5F0F(WA!.VEQ
M1&M.>$1F>51,8G9-:VM584%X;4U52TY)5%AM>69Z:DQ"4D97>$YG<G9R;'@O
M>7=Z+SA&0B\Q5G=C23=X.78V;#1J,T\K=5A(+TPF(WA!.T10.$$X1D(O,59X
M-%(S:C=F,4QX2'5D.6-U4"M71V8O04E+1"]Q<FIW:G9(,B]Q6&E08VE567-I
M<U9+:V=%<6%62'-A16I)1FLS:7(F(WA!.W-69&ER<U9D:7%(,4I,-E14<G!.
M4&Q31R]E1U)B4V%696%*359):EHQ2#)L1%5*1TMP3EIA3C5P:'1A='$Q=70O
M8T-+4RMK5S%,;S F(WA!.S9W4E)/>4%Y<%)735912V0X16A9-6MF3#E367EO
M.&=F;BMT2CEF=5!-=6U83FQ"8V$K-"MV>GA7.$Q1,D5(2&Y,27-10EIP;$LX
M4S0F(WA!.TI0:'-+='1K4D%J;5-F>#55,DA)1'EI0C@O,&MT=C5D.#$S3%-1
M>659>D5)<FQ54UI"3$<P:UIJ1&9:13%+.'E5-&HK5W12.6Y*.%DF(WA!.T=W
M<C<O=G1H4C5N9C=0=7!D-5DX=F5A;TQA-&ML,5=(;DQC4W$X53ET.5DU4GA3
M<VMB=$E:63-B,4DQ1&EV5&Q496Q45T%F-7A)*T@F(WA!.S9M>54T+WI)9R](
M.6%",%17<E15+T].-V]D=D1:=S9V<$EK;&MU:G X2FED5F8P87!*1F53=7)"
M=&E'-'0Q0D%)27AK2C-S4CAV,F@F(WA!.UE3>&=E;T5N>6Q8*SE,34HW3%A:
M9E1R95=N-W1W-'):=3(V*T9B9S K67E01&PW-"]W0VQ0+T9-=4Q$+T%$6F8V
M668X471V5S%Y,'0F(WA!.UIR=5,Y=%!3=#0S;&M8-G-5<45(3#=5;#!I3'-/
M<DU"-&Y"=S5F-3!F.4MF*TM8:7<O>EIF-EEF.%%K4&MB>FQD961T2F)6.4IU
M;&<F(WA!.W196C-T<%ER;7E+=5A215DO675P0E-J:F-.:G<U92M0*VQ0+T%"
M4V5,1"].;"]P:"]W05%Y13(S;51N>4=O5V=&2V-485-%5G(Q+S,F(WA!.W!R
M*T]%1$HS>"\P<"]W0TM2>%EF-7-V.4U0.$%I56LX,F$W<E!L>E1',4\K,5,Q
M4T)E64-X-F1.2U=+4E!-4GA&-'4U5TIG=GA!5C(F(WA!.T]704<Y*U1!;49B
M03,W+S)+,VQG*UET56DP+UAP.59T-3E,=C1)8G5'>49I.79)<5-W:V]!+S%Q
M8TLS-S!&-FAU;$)4<FAO6%EV.$$F(WA!.TAW1$5Y0FE"6$QR,W-O=W-(67$W
M1EA'=$11,%!9;F-6>%9G;FM052]--S9H<4=G83EF4EAF;5!33&4Q9E5R=&)C
M:4-16%5L>$I$-E0F(WA!.W%B8TYX:E5"=C-3-S=F15%4:7)-9E0Q3V\O9G=5
M-R]U6')8+T%*1S1Q>&9Z+W=$;4)"-4IS8F4X,5)X3$AC3DE%5T-/4&Y31TUY
M=E(F(WA!.UIB;4IM*T930GAR.%9+,')I<DDW2V4Y=DQ/0S=I;FE%5GA':W-9
M849G,T8Q1$-O.5AR431Q=FM/;U%W3DQ,8U%H63%,>451=C!55DXF(WA!.U S
M=4MS5SAG9FU*8BMD;TQU6%1/8T%S+U%-=C%M,4M61C%%2C0K2E=D=U-%66-T
M.6HT:6A+<DLO5#%/<"]F=U4W9G58<E@O:V)I<D8F(WA!.SE7."]$4R].=&PU
M8759-41C6'I14G<S4U%+,%!/-D4W4C%0,6XQ05 Y16LU9D)T=#)/2W-O365P
M,#)N9W)T,6AF<#,O04XR-'%K;FXF(WA!.U!Z65!+3VA3-C%Q5$Y.85)/:4UT
M<F%T23E83D%45UI&558O85IG3595=GDS+TU(5%!03V=0<3)N>%1W<$1/,7)-
M='A'<U)-:6]J:W$F(WA!.W%Y5&9$4U%D5W(W9$U66E9I<G-69&ER<U9D:7)S
M5F1I<G-6471X1&5#5E1A96EQ4'EA8WEH:7AC0E%H2$5J<%1F0E=X<FUY0C,S
M-4DF(WA!.VE/3DDQ-&]!05-724AI>$Q-9G!*>$%P0DYO2S@Q>E1,2SA7,74U
M2&=:;WI.-C=X4VDS0T)U4'A82E@P1F%V-TQ06&-B8FI#:$%T-38F(WA!.SAO
M979:=U$V<D)D>3,X-S)L<71O5&1C<&]1<E-Q,V]#5&@V875'8W112T16<41&
M57DP+U8Y3#%%33)N,U5D,T=Q;S5M9UE34D535DLF(WA!.S!K5W%%,$9A03%!
M;V4T<7%I.%9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-664XU:6@O3BLR,695
M8B]Y.5!P=#=P9D%'>C!Q.35#5#0F(WA!.UE.>$=54T-K:E1R+T%,<VY+1E<O
M,UAX<5952&-Z9CA!3U%-;'I+3$=(>7A&86]K2V\Q-3EE16MK=F]X=$\T14QY
M9U(K<UA6051Y;TXF(WA!.R]%<6]I94@X.#!T;S)T2B],:W0P26\P;&IU5G92
M1UI&86(Q2E9E34LS>$PV2C0X979)5DA%1C%61T)0*V-G:U9X2R]L5U5L05EZ
M5%4F(WA!.T9P25I&3$MA1#=#>#AG=F5T2SDX5EI8-6%J.#)P0F1J>DY.6E18
M2G54.51B5#!L:FHK<D-/34QZ4U5U>75:03=%8S)!0D<U>%9/358F(WA!.V1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E4U+W$S<&XV>'<Y3VYX97!4
M:E-O-C$Y-EEQ;#!N*T9F571V5BMO*W!Y8C9N>3DF(WA!.T=V3&MN4#!Q.2M8
M0W9(=G@Y<U963DHO=S<V=#$K:5!Q9G$X:RMU+U904S5C=E1(<"MR-F4Y9E1P
M>#5F<RLR2W!J:7)S5F1I<G-69&DF(WA!.W)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9F+SEK/3PO>&UP1TEM9SII;6%G93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R
M/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\
M+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD
M969A=6QT(CYG,S)O,34\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT
M/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I
M;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @
M(" @(&<S,F\Q-2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$U
M,3$X,28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#4M075G+3(P,C$@
M,30Z-# Z,3$F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#4M075G+3(P
M,C$@,#4Z,3 Z,3$F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C
M>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC
M('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B(#$@<F%S=&5R
M(&EM86=E<R!H879E(&$@<F5S;VQU=&EO;B!B96QO=R R-C4N)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M
M96YT.B8C>$$[(" @(" @(" @($%R:6%L350M0F]L9"8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z
M)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B965N(&9L86=G960@9F]R
M($-3.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I<R!L;W<@<F5S)B-X03LM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR
M<C,U.3 Y,SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO
M>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A
M;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\
M+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G
M.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @
M(" @/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @
M/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM
M<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @
M(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$YA;64^07)I86Q-5"U";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P@350\+W-T
M1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/C P,2XP,#,\+W-T
M1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC
M;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA8E]?7RYP9F([(&%R:6%B
M7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM
M<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE
M/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z.#8Y-#AE,#4M-#,R,"TP,#1B
M+3@X-3<M-S1F86)C9&9F-#9D/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C@V.30X93 U+30S,C M,# T
M8BTX.#4W+3<T9F%B8V1F9C0V9#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C Y-C!$,T8P
M1D)&,$5",3%!,$-"1C(R,S)$-4)&1#DR/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT
M/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HP.3!E8S,U-BTW.#4P+65F-&8M
M.3(X-2TQ.#4Y.39D868P-F,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @
M(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,#DP96,S-38M-S@U,"UE
M9C1F+3DR.#4M,3@U.3DV9&%F,#9C/"]S=%)E9CID;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,#DV
M,$0S1C!&0D8P14(Q,4$P0T)&,C(S,D0U0D9$.3(\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,#DV,$0S1C!&0D8P14(Q
M,4$P0T)&,C(S,D0U0D9$.3(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#<M,S!4,3$Z-#DZ-34K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C@V.30X93 U+30S,C M,# T8BTX.#4W+3<T9F%B
M8V1F9C0V9#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,2TQ,"TP-50P-SHR-#HT,BLP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0T,@,C Q-2 H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N
M9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_  !$( /<"60,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0
M        !P@&"0,$!0H" 0O_Q !=$   !@(!  4&" 8,"P8$!P " P0%!@<
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M=D+C-><P>0T.AK0BC\89K*>PLS&VD 2MK2E6]RY;;VY(5H)*-O2FK#"4*(@
M$Z-*$I,G++)*+ 'V826-)U-N*\I!9[@.:J;F2P3")A$PB81,(F$3")A%O-Z!
M#]]#;/\ ((Z_VAU]GA/P;YS[%[P<7>8>U?6'FLME,(F$7SC_ .$&_P"2N*7^
MT+J_FU69[P<7>8>U>$_!OG/L7S3YLK63")A$PB81,(F$3")A$PB81,(F$6]4
M5GT@IX^<4ZLZ1:A[C@ HY 0*>.E\U#)6P\ISKUQ"S*$;Z<SHWHXA&M(;RHV-
M5LYFE#J8,E"ZD-K7IT-(,\;',YT;FFY&8'GKT]OT^1>X(RM#VN%OBD7UY>G4
MJ;]<8$ROGW9\=OF6G<I&%]X,2>X*QDEH,J,<E0M>GYO:8L%X0%(T!!,BCRM(
M_$I5I2!",Y&M*.VA;SCCD"7',0QN493O T@<.&O/3@IR@O=<YAD)!-K]%K]O
M2 M>E>517SAT7-D6TXPIB4V(@Y>1V&-4W4-Q8G]-%3HQ7RE6PI'$0>]"UF*W
M)<::G +L;.5*.O\ "$+,W$B2P)MD)MT7&;6RP:T9+D#XX -M;:7]'^*NSS#L
M'B5Q@YA1VAT_#VAPUJ5(ZPDUHRUSC!;F_@9)$V:02%#'DQP!I6=G;H^I;7PM
MO0]SY7(T"U<>+8W(T0<6!SF%V<W\:PZ/)Z>WBLG9&ORY1:X)/3;EYOKT+";S
MXB5=PVK7G59TWA4:DQ$RL)GJ3A^G?$9#DC:V^=M&IVNEL?V?LPM0IB,3?M-K
M6]%EC 6^P9T2[WO2L6PR'EY8 ;$:O]!M;AT\O+T(6A@>X@$7LV]CQU!TM];*
M176J>+L?Y=\3Z5F=301)!^3/!J!L"M>!D2%*F*XIJHEX&&PFQ1OJ-(ECFXMB
M.-D+"AZV-4[(3S ]I&485B"XL<ZYNUQZ>+1:X] N;\5D0W,QI \9O3K8\U6F
MSN+C!QNXY4I2LNJ=IG_+'D5R3=TP$8-D()>CK.$3!'"D,2C,A/)/W&062]I6
ME6T/VB3"C6N1NXS?*248BB<@\N<7 Y6M;TZC,;Z]'#EY.A8%H: TB[B[TV!\
MQXVUM>WMNG,*0I&85%S-A,MI+AC7<PHRA93/X=#J%6RF67=5TAB,96NA1%MV
MP8SLK!(U0WA$G3*&U'L2HXHQ2G=DZOJ-4AP#G!S2'/(<X"[A8'7H'F\G'ITN
M<RUMGW:T$-)LVY(TZ>CZW/'2@O2(_O:^C(_-A'_-X5GJSXTGY7[EY/\ BQ_D
M_O6IO/1>:81,(F$3")A$PB81,(F$3")A$PBRC-=;"Q?-A:Z81,(F$3")A$PB
M81,(F$6=5G9<XIV<Q^RJV?SHO-XLH4JF!^3I&Y<<W*%:!6V*3 )'9&O;SMFH
M5RI/L*E(<$(3MC $)@0##! (L=05()!N-"%FU?\ )&[ZLMIUO.O[!=(U:;\N
M?W%\E"-&SG>>5$I7B=7\MU9%K:JCK@A<G+85YS8K:#6TM62E/(2%&)$HB8+6
MD!I%P. Y:6]BD.<"7 ZF]SIK?CQ6;61S8Y26\SBC]CV\]2ID^';591#4M:HP
MG1()BR-Y;6U.+20@8T@&=$A1E]DE@:](X[WYJI:)J$M6*U!P,:.#0-+>@^U"
M]QXDVO>W1IPL.CT+S@\P.1X;9F=Z!LY?JUK"B@X1,9?YCBGE+U%C&QE9AM)K
M=YA\RI2Q-D=9DOE"!M2K=!0@,TIT<:H,-9&V L+ W \O-,[KWN;VM?R<E'OI
MLM'T1IZ)U+58:H23;5C)HB!"T@()FNF\QKT_ = -X7W1X4!IA 4_G3R$/:[S
M271V@F:FPOFL+VM?ILHS&UKFU[V\JGR1=(?S2EE:J*CD/("8.4&6M6V-P2&)
MHZ2_.C.,G:8]M=ILE92)NZI%:80TR\IQD2D+@F,-3KO*"33 #QW; ;AHOQZ?
MH' =BR,CR+7]/2?2H!>+HLY_JJ(4B[RI0MJV!O;M(XE$A(&@I,SO3X<N/=5Q
M3@0WE/*D:LUS7#$4N<5*<O:C>B22P@+T#+*+EUM3H3]?,%CF-@V^@U [?>5&
MZ):L;5B1Q;E:IO<&]4G6H%Z)0:E6(EB4T!Z56D5$#+/3*DQY8#DZ@D8#230
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MJ%;[8S2BXXY&GHER<E(:8/: M8>N"W%;"D0>3(BBDQ>!C:3?4$\;&UUF)'
M:$#A<76#M?/7DXV\C#N4ID\+=;75-IT?6'NK.W'QM5$SB0D;AXHT02E;D\<
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MH;VSJ4)-'DOBH]R/$> X"H\S8#P#(" D(,:UI:!H;WYFZ%[BX.)U'!3E)NE
MY*R=/8B0UKIAF3V]"GN$VMN-U+&V1=8R5^:],:I[ESVE#I^=9"E9QK&UK6#=
M (VY,X+0IF\ QE#)QW31;XWBFXUX&]]!PXK+>NU^+KQTYJK5K<A+&N6(4[")
MLH:#F*C(;N"0(MM:BV]40P;"W V6Z*0&#$Y*NRUI?_B3 EBZ]#WV?P]]68:
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ML=VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/
MAPO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/
M9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X
M_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA
M/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5R
MC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^
M-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VS
MJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]
M5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/
M=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-
MVSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ AP
MO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O
M&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K
M%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA/
MAPO]5RC/9O&/=^-X_K%-VSJA/ APO]5RC/9O&/=^-X_K%-VSJA<W@8X;>K#2
M'LZC7ZAD9W<_H'N4Y&\OI/O5J\Q6281,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(NB>Z-B90-(H<4"=66@.=#$IZM.4H V)A@*4.(R
M3# F!0$&& +.5B#I.4,8 #,"(6M;(O.2RN++A,H4,E8%@I*E/71P*5Y;E G]
M"E+ <I6,NB5(]NJ5,486:>H0Z/))+, ,P80B#O9%WFMX:'Q,):RNK:\(P*52
M(:MK7)7!,!8A/&E6I!'I#3B@J4:DHQ.J(V/1J<\L9)P & $'1%Z.$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A%%<KO2E((78)TWMVLH>34S-&9%:1THG4882JX89JH<D<.>9R8Z.:4$4;98
MK9W5+&UCX)"0^*6]80V#5&D&!"4@$\ 3?A9=1EY!T)))?%:^CMVU(_3R<P=)
M9T)A;+8T/=)7+ZW7E#/03^+Q]"\'NS_"UR<HT]%*&I(J9%1!)QR=:8648()+
M'D5+^%"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81:5>=71_6[=MD<JIU29_FMVOO@\731KR^V
M"X;)<YVQVY!Y&1 6YGD I&SPN(RNNHL[,3@%LCI4-4O4G>W>2-#DN?7]2N?7
MZ^=%1!JZ+#FBNFM5.88I6<"(:EC9JOYRV/E=QZ6\5H9$>1W+BT5K&J:*IBL:
MBSK.[HK&ZZRB-@NE,,J",2&2QQ^-E0S$*)M>'@BN5P(XT<@^&$';B9>G:Z70
MSN\N,\0-IF$.,$ET2?$D6XO4W15F3=W<"(PI-;7"R[,K>460WJHP[1^2.1;J
MB>["T=(G5W9T9%O/PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(M0]T='A,7:V>1UOTLDIUC7V;8G1Z7C'HJ
M\+WZ*(+!M/AWR$L>Z;"*MU^88-*%3218[=)XXQ1^;-[18#LSKVE.J71<39'6
MIM7%D#PX_P!+L(M[[J N-710WC2]KT(Z22P:W<*^@;A#;3G$BB4BF[19;=9#
M!Q7Y <:7&JJW0[B"1$74_;O/4S8YTKF<>DR 49&SZKPL]X+>FHI+@0>.N@X:
M"X-_/I:W(\=-;!U+P(8Y\QS.5&<K.><0$OOGDVEU'H'RTL>-19 6S<CK48RA
MM[.2<H"G/7%-H'!V4".-.<7A6X.2@8CUAF\Z2CVEEHZ:&F;@VS=0(69!-68)
M25-3)J3FFGD:7R/UMF<;V ' +P?$"XG/*+@&S9' <!P -AS4H?L:[!ZZ/21?
MIHV9FSX73?U!LE^KM#_"L=R/PDWSK_>G[&NP>NCTD7Z:-F8\+IOZ@V2_5VA_
MA3<C\)-\Z_WJ&*^X) DEHWY$7+FETBPFBNI+!6J.:(YDV:4I"DD-:QJ4N.EQ
M^C1>5&;=755LD?8+[I/W9/4+L=O=_B>/,I,'V:K8=G]E1/BE'B,U67;/T+FE
M]-B]91Q;MN09 (8&!PN;NN[ILJ>@GFJ,4QVDDD?N</J*&*GRO>'!M1AU/4R9
MW9CF.]D=E-A9MAK:Z]VY> 22#U58$P8N:/2,A>(W%G9W;=J^9EFJ$VEB),,T
MG9Y'> [TKMAUVP=L/:U\7:U^/*)NUTQ<T'9_9*Q('WNT/2;=56[H0 2))OG7
M^]20GZ-UA,((,%S.Z1_M&$EC%U<T+-UKM" $6^K7:^+77O\ %F'A;+_4&R?Z
MO47N4B*X!WDNH'_U"N7]C:C_ *YW2/\ Z:-F_P#W8\+9?Z@V3_5ZB]RG=#\)
M+\X4_8VH_P"N=TC_ .FC9O\ ]V/"V7^H-D_U>HO<FZ'X27YPJ/;;Z/Y%#*IL
MZ8,O,_I& O$4KV:25I$JYEV:H3!<V*-N3H@VH([P'?$:5)2MFE=L/>%]H':#
MVNO5+M+MY6X7LYC^)TN ;("JP[!<5KZ8R;.43XQ44=#/40YV:9V;R-N9MQF;
M<7%[KI=C,&I,<VPV4P2O?4FAQC:7 L+K!%.Z.4TF(8I2TE0(Y+'=R&&9X8^Q
MRNLZQM9>K771]-LFKZ"2-TYE](J)SD$-C#VXB(YEV<22)<ZLB%>K$25HT6BB
MMJ%!FRR]"WH .H/7OJZ\V<#V[K*_!<(KJC9[8XSUN%X?5SEFS5"UAFJ*2&:0
MM;8Y6YWNRMN;"PN5I[3X/385M+M#A=)+5BEPW',6H*825#WR"GHZ^HIX0]]A
MG>(XVYG6&9US87LLR_8WX]ZY/2-?IGV=_>9:>&$WR>V0_5RA_A5'WN/PU1\\
M]/V-^/>N3TC7Z9]G?WF/#";Y/;(?JY0_PIWN/PU1\\]/V-^/>N3TC7Z9]G?W
MF/#";Y/;(?JY0_PIWN/PU1\\]/V-^/>N3TC7Z9]G?WF/#";Y/;(?JY0_PIWN
M/PU1\\]/V-^/>N3TC7Z9]G?WF/#";Y/;(?JY0_PIWN/PU1\\]/V-^/>N3TC7
MZ9]G?WF/#";Y/;(?JY0_PIWN/PU1\\]/V-^/>N3TC7Z9]G?WF/#";Y/;(?JY
M0_PIWN/PU1\\]/V-^/>N3TC7Z9]G?WF/#";Y/;(?JY0_PIWN/PU1\\]/V-^/
M>N3TC7Z9]G?WF/#";Y/;(?JY0_PIWN/PU1\\]/V-^/>N3TC7Z9]G?WF/#";Y
M/;(?JY0_PIWN/PU1\\]/V-^/>N3TC7Z9]G?WF/#";Y/;(?JY0_PIWN/PU1\\
M]/V-^/>N3TC7Z9]G?WF/#";Y/;(?JY0_PIWN/PU1\\]=A)T<\?2*TRO7,/I$
ME&TJ@E1HA7S)LQ0D/V08$S1*E.,SL'IS=A[!Q(_P32Q" +XA;R';7S.:YO@_
MLB,S2V[=G:%KA<6NUP%VN'$$:@ZA!3@&^]J-.<S[>E;$LY%;"81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3"*NO(<"T7H.$E/2E)P<B*Q$XEGI#5!RI)LQW 4
M2B.+6I@(5 5XT:@Q2>0XE&(R%2(*0LY64O1$5BL(NKY:C\M\W>5IO.'DOEOD
M/?E>6>1][W'E?DW:[[R;O_VGO^QW7>_M?:[?Q81>3+)7&H)%I)-YF^-D8B$/
M87>42F2/2LE SQ^.L"!0ZO3TZKE @$(VYK;4JE:M5'""60F(,-&+00[WA%"E
M2\LJ NMD7OT(GNDJ5LE+3"UJ"P8U+JCD1<DD30BD,7;P12UF&&290&6L#BA>
MXBL3-)J&4M2DM>PJ7!/H9@2+*)+R&HF'*&=))K?KIH5OTW9JU:DRB6LHU"J>
MR AX5,L4$20K-,3/+BFC[XH3I%82!"):'$T6P@1GB 1<$UY&T57T'E=C2>U(
M61$(3")99$C<6IZ2R12D@\%TMU+I&E9HX-V>G9 P'-RY(X[:&Y<:2X)C6[N]
MK@[3X13,4: XHLXH7:+.+ :6+JWKM ,#H8!=6]:WKK#O6^K>M;UU_'K6\(N3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M5^XS_DYDGYP/+/\ YJ;EPI/'T-]@5@<*$PBK-4'Y>.6_\=ZI_L2A.=;CGWN;
M$_F[&?\ Y#B*YO"?N[M7_KF%?V-1K*N2OY ;>_B%(?YB9G*,^.W\IOM"Z)_Q
M3Z/:%,Z3]R)?_+D_\,.8J6\!YA[%V,*4PBA[D/\ D O+^1ZS/ZE/><QMM]YF
MUW^S&/\ ]E5:[;N:?^8_<_\ ]MME/[=H%[%-?D?JG^3:#?U7:\VME_O9V=_,
M6$?V?3K2VY^_;;#_ &IV@_M:K4DY>KEDPB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(M3?(3D[RAHOE3>*!CCRN[Z\8N%95IT
MEQ_J^MGIXFSK:!UN0ZMRW28/31J02R0)O.S\XK7E)#69.GC-:-BIV(CTDDB<
MXPPBU+UYTG?.QX7\8$PYB_/T\>8M%20U-(J&:X$MY821ZO;E9!;L>VQA=8RG
MFS(UT+ *NJB3IR8 ZM:6-[?C_2$?("W5-L)%<K@ORCOKDE6\5<;+F1-YQ]EY
M0<6@(;G"V0V(^1OTVXUU#:]J5L6SPF/LC"[BJB[IM.:S,3 2DR6'!: Q*<KW
M>61QW5G/K]?KYD6]69P2)6$U%,DS9$S\U$+2G$I$J,4EE@6D%'D%*-"2GIS.
MV E2>#6MCV'J-%UAWOJWHBK-X%Z!])?I(\V/W>>:O,^H7Y[W\"=)/)^[V+3;
MY-YUVHVJ_P#F>SMO6Q>7?'U:2ZTET12'8/&.IK H*WN-Q[,HCM<73!YM!)<1
M'%IZ9S+;YY&CXL[N+6M6B7^3.I#>< Q$:84>F+4IB!&I3B^\*,(J$7)T6<GY
M%Q5I:+XY>SFQWYM0S^'!>5]1U2B8V6L;*AL(ADF:X'$"&XQ'";/**@J221VY
MB7!UD47E#_*CV5L2L+N"/HR*#Y%T1W& #0KD:;D7'HX36<F)L"<RUR8ZY7HF
M]2Y6CR4O<+Q8CDN>$P$C@=#.6+FR,4G?7%.M0L###Y8G.4IS]HS"*/IGT8_!
M:<,<,C+#S,K&)Q"Q:?;:C@J.*J:-)=IG,(M0$VXJ&/M<2M([$.RV-KT%D/$F
MFU11DU:S/]N*"WYQ<25;H]('<B^A$UT96(4?9W%X;4*UY/VRQ](O7)$:Q^<4
M34L=3T#0E/. <Y+RFAJ<G8Y&B >>4W-ZY:,O25(>:6X(O:PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$5;N*32V,53NS.R
MMZ1J:6V^>5Z1O;D"<M*B1)2N4]RA*3IDQ(0%$DEA^(!980A#KXM:UK"D\?0W
MV!61PH3"*#)CQHH>P)(Y2^95A&I!)G?R/3F\KR5.UBWS>A3-B+OQE*2@B\F0
M(TJ0O?8UO11  [Z]ZZ]]%0[6[289214-!C%92TD&\W-/$]HCCWLCYI,H+"1G
MED>\Z_&<2J2LV;P.OJ9*NLPVGGJ9LF]F>'YW[MC8V9LKP#EC8UHTX *JL?86
M>+<8^8<:CZ EK8F*R[Q:VAL3=OR9O;TB1J+3)$^C!C&$DDO6@@#L8NK7^?+/
M;*IGK*S *NJE=-4U.S.#33S/MGEE?OB][B  7.)N395^R\$-+38Q34[!%!!M
M!B444;;Y8XV& -8VY)LT:"Y*V*I/W(E_\N3_ ,,.<4NJ;P'F'L78PI3"*/[9
MC+E-:KLN&LVTP7>6U_,HRU;6&B(2:<GZ..34AVJ. 6<,E-I4J*V>:$HT197:
M&$L>]:#NEVDH)\5V=Q["Z4QBIQ+!<4H*<RN+(A/64,]/"9'AKBV/>2-SN#7%
MK;D-)%CTFQN*TN!;7[*XY7"4T6#;28'BM8(&"28TN'8G2UE0(8W.8U\IBA?N
MV%[ Y]FES0;BND.=^8$1B,5B@:'IQ>&,1MCCP5V^0#XFVMTRMB5MTKVFU3)^
MD^U.DW?;(T>=HK8^[[TSL]O?#875=T_#<,P[#AL=LM,*"AI*(3';2KC,HI:>
M.#>&/P6?DS[O-DSORWMF=:Y^GXY1=Q+&L:Q?&#W1-N*<XMBF(8D:<=S?#Y1
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M+'F46%*(3 (=&$+S)$"J22V:2V/QY@9RE:Y8OV,LE,H*0+FPX_7DJJ5QTI]
MV5/JDAJ.(VK%V2W(?!'])9<V;81'X)#)78U"3;D[&*RFZ@<\4OS?)S:/KR4S
M99(&EB>JU3IR&M$3.U2MX1 $4Y3KJ#;HUU%P+C2QU(%KWYA6;XG/3-(ZC<WZ
M/.S8_,3O>W*QP:7IF7I71I=$"GE+<AJ9:W.*$T]&M2*"Q!,(4ICC230;T,L8
M@[UO"@\?0WV!64PH3")A%J_=[0K2/U%S-AS]8<'9)<XVQ=XF^+.TK86Z1+@K
M2VXI$)&R+%Y+DI"K,*-+3;)3#T>,L82MBV 6M?0\=P+&\19LU4T&#XK74XV7
MP5AJ*/#ZNI@#V-E+F&6&%\8>T.:7-S9A<7&H7%81B^%43L=@K,3P^DF\(<3?
MN:FMIH)<CG197[N65C\IL;.M8V-CH5LX1[UM(EWKX];3$;UO_3K90>K/GA!!
M((L1H0>(/(KM&\!YA[%V,*4PB81,(F$3"*JW"O\ >YQ+^-=Q?VTV%GSON5?>
M/AOYRVH_^5XVOK_=W_\ ,[&?S-L/_P# ]F5:G/HB^0)A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81:IN:-72*#R8_F%85[S!= :ALJG'FOJAC
M=+Q6Q5;.TODCKN R^ 19F"SJ95)IG=+NI<8@WO7PA9VYB!9);NXH%"BNHJXI
M7U^OT(KD<>I9 [A;7*Z&;C].:2EBQ4LA+CNX:F:ZRM=T:&S:!U+\H"4<O=%L
M2/5K0F-HE#D-*:X)%H@)2S2-F#(K(X14;G?,]?&[\MGCM$N/EJ3R;5G0!5X-
M"T"B,P^/6<H5R6.QLF)P5YEKFW(EB-I-DB93+9LL.2L+&8A>&A 6_OK.YMJ0
MG_14T8NFKK-<HKT]\I"<LT5>"FS5FS9OE45D4<@@YC<%[TA5KW#%*/:<=P0&
MRI?QYFKLP3=@ S)!05XADJ);UH7U2WM9%G]8<[X?RZ8ZX KAZVGIVS\C..QR
M>OI/*(^^NKY&;/J&$\AH*_LJQH&44N/.K.S8\=+&<A.8;$Y&E>V@:MT0(T3V
MY$6T29-\T<6LHB"R9BBKP%:4:<XR&*JI@B,0!*/"<D UI)-%#2E!APTYH%FW
M(P!0"3"MI#=GZ,)K<4AQ6>G:S!Z^CPZI$K7/GKL-DQ2%T(:\.C%/%B&&N;(Y
MY8X2F=P:UKFF)Q>',M<'GP6GJG/QW#:_%*,PN:RGP[%8<'G;.7L+)754V%XN
MQT;6"1KH13-<YSVN$S0PM?4?T<<W?3?Y]W>E>^C'X.[3Z3? %7YNTX^3:!W6
MX%\(PKO+-KNM3IYW8HNHG\'R?174V:^9? 7==\,#6>&.!^#G>&[$/P))N>^,
MH!;\$=_[_>[V\@J_AWXGB[L,^T+[#X2=POP!^#O ':8;7_"F][Z\(H=Z:3>$
MYOASX.-/N=Q:+O'P9'VSQ]_G'?"F2>J[^A-%6P[Q@J/W-=[;#Y8OJJ/,3"FK
MQJ?)@%A-!#F%RU(YF^H4R0V2:3C=GA4^)B2FLT[L(]FIM:5?3,+@Q:"G>S&,
M0H\1J3*YS)J+#9,+B;"6L#8S!+B.).<\/$CC+OVAP>UHC;D+G_'\8J,%J*IC
M\"PVOPJC$+6OI\1Q:'&)W3A[R^5M5#A>$,9&YAC:V$TSG-<Q[S,X/#&:'J^H
M?I4*'@#' 9]!K O8RLVCDW%8_)*FY$LDS=IN;RAIB.JXS)7E_N)THEQ6@J[D
M$QV H<#'1F0JJ[C-B0YNKU%)F:-.;D39<O)]?KY;*I4\VE0'21.,TX1-YY0W
M6)U%'ZMC0W^H+ID#6..3A@M#B6ZS6S^137)WZ%E6,VKZ;@_)2$I6QA262G7'
MS,*52SD*I5YT12BE1LXN\JF0-6Z#8E[2$,$Z3&16<]%/UHQT_4^XZOZTP_4L
MGIB0;><Y,K*$!VH_6C(:R1YJ+>#RRZ['IHC86$BW*81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A%$#Q^7NO?Y(KA_KE1V7D/WMXE^?<#_L_:)5$WW>P[\T
M8S^VX$I?RC5NF$3")A$PB81,(F$3"*"N1% 17DE7R6 RI^ED4\SS>!V1%Y;"
M#X\7)8K.:UE+;,8@_MZ28QN90MWVWO34F,.9YC$)/'5Y&S"US.>+1)A)2#;V
M=JJU4'1?<<:1L>I+$A+M:753C/& ,$)>9.QN<(>YY#ZLG5)L5PR='N*$OZJQ
M$E6V5,X@$IHD3)  HG1.J*@A3FRL2YL*<QUX:\?20;#R7"LQQFUH-<2,(=:"
M'7('EGK6M:UK6M>*FY?BUK7Q:U_W84'CZ&^P*P6%"81,(JJ<O8K&/#?>[M\'
M&'SKZ.I4K\Y^9V_SAY5Y :/RGRWR?RGRCM_A=]WG>=K\+M=?QYV6Q%95^%6S
MD'?53N?A6B9N=_+NLF]:,F[S9,MM,MK>1<OM92TO@]C<W>T&][PJ7[W<Q[S/
MD)S9\N;-?^E>_E5H$'[A1?\ E$W_  09R$G^<D_+=_[BNF9\1OY+?8%V\P62
M81,(F$3")A%K7XP<I^/=<TTS0R<6K&8U*666VP!U9'(:XM:A$MMN<N231X"T
M9@->4(%B547L(Q:$4>6+K^/JU\([G_=#V)P/9>FPK%]H\/H,1I,3VD%323NE
M;+"9MI<7J(@\")P&>&6.1MB?%>%^INZSW(NZ3M/MS78[@&R&*8KA%?@NQIHZ
M^E%.Z"<4^Q>S])/D+IVN^U5,$T+[M!#XW#HNK >-WBA\^,+^F</U#.S^RUW.
M/E?A/SDW\E?-_L"=V+Y 8YZM+_>4\;O%#Y\87],X?J&/LM=SCY7X3\Y-_)3[
M G=B^0&.>K2_WE/&[Q0^?&%_3.'ZAC[+7<X^5^$_.3?R4^P)W8OD!CGJTO\
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M$.S-@WZ #YS;V K3WXG.F*\=9E=>#NOO#D$HK83OA4__  ,V8*K"7D?5R5^
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MFD58S2\V&GOZ2OEED&@@H9ZHC8)7OS&-=K9%1[@9>=[<B>C2MR?W!-*UORR
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MG.)<YSG4&T9+G.-R7..8DDW)N3Q7M(T-QS#6L:&M9@V,-:UH #6MK,!   X
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MBTM"8:UI(;9&M*.=SDJ9V3HTN@#7?0\)P:##<"QRLV@ST[X9<-D;@K]TRKK
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MM9NIO?2QBJ S:_3KTO(LRH8"6_IXO30WAM#;J\QO1I#2;"VT'(W3=; ,7G+
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M^1[@UI(HZ"J@HL&CJ:EX9%$:@N-B7.<ZKF:R.-@NZ261Y:R*-@+Y'N:QH+B
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M\O?'.O**(;GI^:U(VZ8V2Z%&*Z\K90'K"I0C,3&%_#6>I=;T(N$M*HHEM-V
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M87%G>D>4M>WBZX-Q;FY\+Q9F*5N(X;B%# VO@HHI8JN@FJBTT0G#',?%74P
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M@/LACO(QUA-A%L;+R!I]<T):9E%JS82DAQ9@QY'(8HI:2"9#Y.@<M3>PU&G
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M+:^+_%>/Q?B_R^Z__P"ZO\V>&/\ W7K-;_\ A_V2GT]'^"]L%^YM/^54</\
M69E&7)EP?)8R H2#JPI999[*]'R%U[9^BHA6#2 L,J>EPD8P*239$8>FA#"
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MT<!=E:2&@F6HF<#'24K/ME3+XC+-#WLPQ#$&4+& ,=45=0XQT='&0):F4"Y
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M*'9'$$-?E=H[*;'*=#:QT6O2BV5[L9LAE5.DM=9M"J_=O2-:3@ZHVU*4L?\
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M _XF1?\ H-#AW$^<^U&\!YA[%F>0I3"*M'$'\@47_C/;']KT[SK-M_ODJ_\
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M= 2J-HDJ@1:AP1EG>T$,IV:Q&412&/X9P<[P,<66;18XUQSVR^*Y[&NUT+V
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M=+(Z60LBCJVL8'2/<\AK0,SB>)7=\)]7?PW<_M_NK[]9CX9XQ^+X#^K.S_\
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MPB81,(F$3")A$PBPBS9*[0RM[!F# S&2-]BD(EDE98\4$X9K\[,3"O=&YF+
MG")0,QT6)24( D!$<(1^M%!V/8=81:1.(G)[EAS H]U=D":$\A)96-R\=YFP
MV7'@Q. P [4NXQ4C?TQ@CN2CD0BUBNM9[:LFK<K<?\XO:=)'T*&:[329(Z+5
MOA/#6SM;%05F'4,SWB]5BE/6U5)%& 2XN@P\MJI'.L&QACF@/<"]P8#;=H)<
M+AG,F+TV*UE(V-_^38--0T]=)*;",,FQ$.I8V-)+I"]KG%@(8"X@&Z;G9'25
M;4JT+;0U+Z$G1H5>EI,A&I(-$N&M!M&E.=9XR$J%B'2+0EP-EEE$@6H1 ..V
M:8 GQ?A&+Y"';<8$UY UI-@,6J;.N <IK-N* $6N07,%Q;0%6K<5V.#KMV*V
MOE;<^+5[?X#1DBV@(I-@<2L;] >;<,QXK"#9WTI1BA&2KJ2'-Q3@L&DT>PE5
MJZ:;0 0K%OEBW;K=)02TP]H](BQZ >(2]8B($ !9IAY4C")AEWVVM=-8>.*3
M8G#:#,>;756U6+Y+<=8W@GD%#\;P'QA3; B(Z975^WU;B  %[A[*+8_!,V;3
MXLK+7/G7:>GKI!VAA>Y \[L'R9D9W)Y4-4#JKC=(Y M*:T1RTQ!'VQ1>9RQW
M=U@"!$-S<0F-4KEIA*5.6(TT -YLPRE:?MN/;73\1:*39.B:1?Q39VRE<]IM
MQ E(TMJ#IK38U&]MJ?9+9&F.AO--MG6NZ+B\>UN'L()'$Q V)X:+)T;-S%6$
M ,=9)R.,">669L#7&^'# : (PZ%L @FV4Y&DFZUO>AAV+0@#Z];UUZZLWFP8
M4P 9,<J+7N:O&:4%_G.&8+A9%AH"W+Y;JODKZU[BYE'LY27((%)A>*2!MA;Q
M1BNT&* W.I#PX>0<5CR-TL$^<$5?(W?F298#C'Y#+FR);L[BC&7IWA\7=8XQ
M/DM;$C%-P*=QY&\RIA;!+1F$"$L<"RP ZPC$'W+\)%]W@4 N"+RXSM3*[4G7
MQ<>B:#R+6-MK8"^FH9<4<;NQ-@%PX-BP+9E@! X7DP65Y;?B"X@V%[W)-5[&
MX]F2+E)&8T\"Y+(YI.HB_64U1E9+>.SM8CE#ZP%!(5*E*6?NE[&JR1!<YU&=
M)#=153Y*@&L1)_VI$,S5_2;7XEAV#5&"X8R'#Z>HJN^G.CSUA:\QO8]K!BKL
M1<UCW-I92!('-EIL['-=/,7551@=#78O3XQB<8Q&>GI'T8BD H(9(S*Z1CGL
MP7X+&:/>U$9#;-ECFR2!S8XP/RHXQL, LMO@L9:.2V[#E3$X3ENKF0R'BA.7
M5TB+-)HC$I'+3FQ59;)M2QL3S,V#SRI.4!ZBEAIB=,K&E-*#\]Q6CV@Q9YEG
MVZVL,A+2&S28'6T[ P96LBAK<#J'11@:98Y6Z=()<3]%PO'=EL.A;3GN8[%O
M8UA;O::;:W#JIQ.KI'S4FT[8Y9'$WSRP2:V-K *>FZB+QC1NU+)QYK1].T;H
MS0I9QWXQEKS ZWK?9->&'DTA,[W>NO?E $.M]KX]E[Z_BJO@K:R+_P /M72S
M 6L,2V<@G-A;0NP[$<)%W:W(: .@=(L3C?<]J 14["8K2.(MFP?;.2%C3KXS
M8\6P+&G&UQ8.F/ 7/&\E16><UF9*F7-'"2ODY!P B"C)E-;UJ[E!T+81!5(T
M5@3A,D,UV>L!8%ZL(@""+8R]_@YBX;=PDY3LEB(TMF;B^#D\--'8YEL;V-W<
M\HX(UO<NJ  ^3;W"20;EL>S^T :[6UKOV:+QPO<,-[Z6M?UK,Y%<H6NN+ .>
MN'!+>Y1^/1=T,*=)BWVC%W4N22-6SB;R&**-9"J3JFXMJ5*WEK;G+2EB2KF)
MV<P ;UP!"T<0QW;G#J&OJ? FAQ26EHJJHA@P;:AT\U1-#!))&QE/6X!0RR$O
M:"8(!-43 ;FF9).]@5Q@6RO<RQK&<,P\]T;%,*IJVOIZ:>?'=D(<.C@AED:U
MSWUM+M+BM'!H<HGJ3%31$B2=[(VOMZ/'7D%>$BK-F7N/$QY0'JI')&LE+"MQ
M:O(^A)1*W$\LPR-3F2H'UOT+249*IT.3 ;G9U/+.;]]TN) '3P':W;#$L&PV
MOK>YUBU)5U=*V::#X5P2 ->7N:',I\1K:.OIF3,:V=D%93LFC9(&E\S0R:3<
MVOV"V!P/:/%,*PONK8)64-'-&R"=^%8_7O<'P12/8^LP3"J_"ZE\,CWQ/DHZ
ME["YA#V0RB2%D]*;<N%,G4*-\7IZ?I.0:?LI-/JD/4&Z*+$9LI.0"9=LX\SL
M]@HH&NT88(( _'O+;PAVF^0.+#SXWLOVZ8N??Y%S?@OLA_I-P']7MM?W[/#W
M*I-H\P.4<1O*'U^Q<:'$N+OQ-?F+RG-L6R5Z[4CEKNS._DTSB$C/KYKT)N1)
M]) /:DL<<4A->)/V&)8A%G/XAMKMI2X]@.&P=S/&)Z+$68BZMK!BF%R" TT
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M%TBSLK<R&3HZ5[4G:W(QL.5/EWTZ>,\XM*E5"/;R#Y]&R75OV!64$MR;UQR
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M$L>1["OR3RYXI*"2E"?DUQ^/3GE@.(/)N6NC23B30Z&4:4:"1B 868 01@,
M+81AWH0=[UO6\)8\CV%<GBSXL>LK07MAKW[Q82QY'L*X3^7?%!* )JKDYQ\3
M%B.3)@F'W-7)(!*%B@I(D(",R1A#LY4K/)2IBM;V,]0<424$1A@ [)8\CV%<
MWBSXL>LK07MAKW[Q82QY'L*>+/BQZRM!>V&O?O%A+'D>PKA,Y=\4"3$Y)W)S
MCX4<K,&4D*,N:N2S%1I9)B@PI.6*1Z$<8!.2<>,!>A""248:+6@ $+1+'D>P
MKF\6?%CUE:"]L->_>+"6/(]A3Q9\6/65H+VPU[]XL)8\CV%<.N7G$\2DQ&'D
MYQ[$K)()4FI=7-7.U)2908>4G4&$:D?>@(/-2J2R31!T6:8G/  0A$F:"2QY
M'L*YO%GQ8]96@O;#7OWBPECR/84\6?%CUE:"]L->_>+"6/(]A7"5R[XH'C4E
M$\G./AQB,X*9665<U<F#2J!)R%82%( 2/8B#A)%254$HW01[3J2#M!V6<6(1
M+'D>PKF\6?%CUE:"]L->_>+"6/(]A3Q9\6/65H+VPU[]XL)8\CV%<*?EWQ06
M$%*DG)SCXJ3'!T,E0GN:N3R#0;_$,HTJ1B+,#OJWU" +>M]7X\)8\CV%<WBS
MXL>LK07MAKW[Q82QY'L*X5/+OB@C3GJU?)SCXE2)235*I4IN:N2$Z9.0 1IQ
MYYQLC"62226$1AII@@@+ $0QBT'6]Z)8\CV%<WBSXL>LK07MAKW[Q82QY'L*
M>+/BQZRM!>V&O?O%A+'D>PKA.Y=\4$VR=*.3G'PC:@X"9/HZYJY*V>H,T(1:
M<GMR,/>G#" >P% [1@M %L(=Z#OJ)8\CV%31&)5%YNQ()1#)(PRZ,NH5 FR1
M1EW;WYC<0I51Z%4) [-:A4@5Z3+4JE&HVG4&:)5)STYG9.*, $H7OX1,(F$3
M")A$PB81,(F$3")A$PB81,(F$3"+RF9B8XZC$W1]F:F)O&J6+A(69N2-B,2Y
MQ4F+'!8),B)((VJ7+#CE2Q1L&SE*DTP\\8S1B'LB]7")A%0GF2]W_&K.X0N5
M43UP8:[?.5,7@MV0ECA!+TXS*)R*)31P(5/,Q.4*C(I#V%4P!TZ)4;*4>\.;
MFS&'21M2MQC8]%!OT<Q[1^Z_F57^B9N?D_;3A?1?(*1V1)T[-'J0<W#5BPDN
M'^CWD/)%%NAY#4S#^[B45VKB-=%L=7::T>Q/H&PM]">6^+M.PAZ*5=%]C]7*
MN:T#M XR"?#^+4U8%)'J%!)7I%+7SB0UQ8L8:4/_ ,"):.,[8(Q-W Y2%8!N
M3+%AA&@C5*E.B:AV/80S$/@IU="W$3/'3BC)=WP99:9]7':, N,;Z>.203 ;
MF\;V&02-<P6C<%Q5]!\*-H:@X<(9)S6AG^3".*J91R7EOD#VU,D<>Y)$QSL>
MV,QN#US3&,UP9S+J>UG157!4LA=*V=4X/.2=+NRO.]NS:IWV#$L!@FLU88Q^
M:ZYL\A:82ZI_(!NQP"T9R5W=3R,I\;PFFK&X?/74\5<]]+&RD>^T\CZPSBF$
M<9%W[WO:<@MN&MB>YY:&DJ(<'Q2HHGXA!05,M#&VI?)5LB+J>-E'N.^3)+\5
MFZ[ZI@0X@N,S T.<0%^IC%:W3<QJWN-Y4UNBE,6HN=5,)6Y^;R[(,5VK9-7.
M,#0,PQHA."EA.%#I^G-+)< !1K'0?91C)<ER@F:G&L*HZH4557TT%6[O0,II
M)6-GD-?.^GI1'$3GDWTT3V#(UP;D)>6M%UC3X1BE53.K*:@JYZ1@JB^IBA>^
M&,44+*BJ,DC06,$,,L<C\Y&CVAMR;*WN6BKE%MXOY44I>VI,=+WJOBH_6TV>
M!SJ-QHJ92.':;HVY*OA/'H@<W.Y,J?6/96G)GCAK2ZEO;BF3-@VU>%3M*:1?
M,I".6W.=\3T"\16V[X?XS-; =7.JHN^U\@>IH\.CARFXF14B@.2LE152V-"U
M]8^,LSN>T7L;$>S-<62OCL!),9$936GT#Z?\/\?I1?5[U:U^+75A$PB_G5K?
MX]:W_P#MA%_<(G5K\?5\?^G"+0]TC%_\KJLY(M;=Q/FEQS"8;I:Z1N7']NJ\
MY[AH'!)QJNZ6U+.X\>LJX#-)6XVWXY'$DVE&K:6NT?E*"OZP;8,X$6*\Z+(K
MC=&18MI652ED.EC3"?61'F:^YM&Z5LFS8Z7')E/*C11J#+4KTZ$%QJ(^<BD$
M_<K!B[>[#848U3?'DQ0A*/)M*#"+8WU:U^+75A$_'^/")A$PBK%S%L*YZRX]
M3V2\>ZUD-IV^<2V1^',4:2,;DN8U4D=$C*MGY[/('N.M\@15VV+%LR.C.WA
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(3")A$PB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g209588g34y88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g34y88.jpg
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M P$! 0            <%!@@) 00* P(+_\0 8A   0,$ 0 %!0@(#PP(!@,
M!0,$!@ ! @<($1(3%!4)%A=7EQ@9(5B6U=;7-C=U=G>4E=$B(S$X05%25%56
MD;.TM;8D,C4Y89*WN-+3U-@E,S13<7.8L0J!H;+"XT-$=/_$ !T! 0 !! ,!
M               ! @0%!@,'"0C_Q !C$0  !@$! P4'#0D.! 4"!04  0(#
M! 41!A(A,0<305%A%%9QD:&QT146%Q@B,H&5EM35X? (-3=U=I2SP=8C-D)2
M55=T@I.RM+72\21BMN4S-$5SHB5R)D-C9H.2IL+$Q?_:  P# 0 "$0,1 #\
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M\$+(\9QPZNCS?#D%S1'[!V[S#\A*?X=\CE(+J[8NGBH[B,5GFMAD^DVF\HU
M82UD$AV#X^36<;+D$E!9QH$7&R%ZK8&;C91X@0?+%'"^4GQ3@]W1V</']0I1
M@D/DM/NB,MO9,B(RVCW%@L$6[J+/899&Z/BORQWUL;RL'E#^*<YF+(UIOCU
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MB\/AWGNS@J10% "@"&]I?99Q^_#(]_T*;DJ2X*\'ZR 3)4 % "@!0 H 4 *
M% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * +(V9KF'[?UU.]4[!$)'X)
MLF(2."S$(LHJC@4C4J$NPAICVZ&2;AMFX'O7":3ILHFY:JWP<-U4UTT\\1EG
M<8DC-)D9<2/)? //G;R#F^Q^KB'%2/>59WT)X.D'3QKGQ^6U+$W\H2AY NH7
M>PQ';5IBT62%/'"RRCMFVAC:,NEEW-W,26;NW#=2C8/&-H\9X8^WHSOP.?GT
MYVC:3MYR2B,R+/69;\G\/FWY6\H_)#L=H">"ON7.0Q[B++_)_BS,:TS+$-=
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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MQW[CQDO#CP#*JI% 4 * % $-Z)^PDY^&3D7_ *P>SZ )DH 4 * % "@!0 H
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M#32ULPV7Z:=$9<DNI2:&$/2GV8[2G%));SB&TY4HB&]53G#Q 2_ON2&H;_\
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MNW=C?P*M[<N6_P#S%4]K=HO^5]4?G=3]#![='E-[WM"?%VH/VE&]?BN_0,:
MUL>0&I"LY(*(2A^S2*20WCXS)SQ8^==Y%I>;DDE?K$3)%^1<."YPDZS<.E?T
M_L[)IX?*6LZ2+IS5-Y1PG'WHM9.<BL.RE-KD+0A*3)3JFFF6S69J/)H:07#W
M(^^^374T[6>@]+ZILV8D>?=U34Z4S!0\W#;=<6XE28Z)#\EY+9$DL$X^ZKCE
M9C(&M8&\!0 H 4 * % "@!0 H 4 :^.2E[^[C\G-C^Q<CRHO_P#.VH@]K?\
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M*I$A0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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M0 H U\\DK=/.7R<W_P#NY67_ )-0![V_^M5%[U7]7SB#XI\/ZC&P:J1(4 *
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MW"W]/<5ZF5WWO@_T.+^@0/""X^^UI^,9O^)=%#J\&."@"1H#KQ>;#MAG%2>
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M[7H6_P OD+("?J % "@#5,TWCJ/2?E!^4[W;.P(Y 6I_6&B6H5>1/>YIDG#
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M?9S=>:>?N&6'9,QV,PRAU#2ICS\]]#<*,P\1;2B2TNZF_*1D06#1H5K:8/\
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MZ*LK6:SNZB/518:XQ-4[UT_")R.2U$Y?0#K;#G%&HN<)44\-$>.:7[LLGN&
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M?U(T]K*UWYJ^3W_? ]O Y_-DCY8J_98/?+-I_N9-^6M9_4C3VLK7?FKY/?\
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MZY]G_B>I_JNIZMU_>GI[^VU-^T8>MBW[_P#6'YOHC]C ]'\D]<^S_P 3U/\
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M Y?)J089/18UTVQ>L'.&;=ZUNK9=JOADBNFFIC?&TGKC11<=8:6+PZ@J2_\
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M(S,N-&B:=TU2MQY:T+4ARDI(5;)6V3:UMH9D2H[TAM)&2MEW+B2<-1"/-?\
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M)(I9I.$%L,>V:)XK8IY*H742MUZE1&24Y[?.!<3/L+HQTF-I=4"0H 4 * %
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M''KZKR['NJ% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M)NM:ZO2DI;%@^KL^'J 1(WUY"@K51BRV!, XX4*L8NP;[(?M68D IFYS2?\
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M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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MCDI)*(SP6<[]^#QDN)9X9(4FA1%M'CP9W[^LA -5"D* % "@#WAZ)^TAIO\
M!5KS^R(>N!7$_"?G%P)5J "@!0 H 4 * *>6_P %$_N>]_HRM '\_>K@6X4
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MZYWJ-UF6:G2>NC.[1^EA&U0(6/%'CPF5<VL+<.($C.N]@"AH990Q'@,JD '
MZQPLX'EU667?,8)PC3G<1XS@S^#CC]6X0;9DK&_9SC/3P_7T" GG%C>:<'D.
MT1^OS;[6X!>2YYR-50*S?NPD3.WCIV3-8I<RO)7D<#%>JP.R 6/)QT(_LLT?
M&<,VZV6-1+29D6=YXW;SP9\"SPSQW<>D4FA1$9XW;]_872)+A7 'DW*I7JN.
ME($I"V.UI1'HN.D,B*!>ZQMQ) [B2CU9D('DWDABCAW&&3XZ)$2$4*+GV[6[
M<*S>NUD4<X-Q)$9D><%G&\LXZL[C[<<!)-J,R(RQD\9XXSO+..L4V:<,]G1>
M+YF1HXO(BX9_O128#FS2-(APT6T4YAZ4BDH8^UFA165=BVE[5^=%L0S9< S3
MP717-M_$EQ(ED9XX9QCPGG<98W'NW<<[^H2;9XW9,R,\XX8+I[?K(6M&.'?)
M.9.6S6/:N).U'<0A4Z0S=&HL(:WCNR+N;:_S4>F#K!D@9FMF;A2+Q9=PG*3B
M*=EQP9PBHFIG.VDNDN)EU\./#H+I/@76*20H_P""?0?CX?[<124.+&_EX(8V
M3?6Y-K$P2$J=DE21*/BCV#&"E%@DT)-8:3+M)D2%1,PV="Y&5& '@X*_9O6A
M!RW79N<$FTG.,[S[#Z=Y9W8+B7$-E6,XW;^DN@\'T[]_4,?JJ%(4 9B^3\_7
MG\=_P@L_Z 0J%<#\!^85(]\7P^8Q[4ZX!S!0 H 4 * % "@!0 H 4 * % "@
M!0 H 4 * % "@!0 H 4 >"[<..5MM[2M?'*U[;&F]KVO:]KVO:3$[7M>U[=-
MKVO\%[7_ %*N!PF1Y/<?$^@^L1ST7_:O_)>@C!]1^(PZ+_M7_DO0,'U'XC#H
MO^U?^2] P?4?B,90Z,Y" M<0?8NH=G:PQV]J#91&+R,I&6TO?0"1@YC#<B&
M*31B7,A$AP8+W8EB(PNQ? ";4FQ623MW7-#M%*5),S(R/!EGHSQ[,D*TF9$:
M5),TF>3QDCR7V\XEI#F-K=^GM*$2;C!&4]#[!>:N*"-5ZZFKW79.)%]1BWX2
M/%5)VC&#SB5$I$,*DTI\3.1_(G(WKS(JT>A7R6.=XV#W'M&:BSO,LYSV<=W1
MOW=I;A.T9Y(T82>-Q$9<"P7A%RDO**RB03"*S:1:U%.RT:YC)\L\D!DB<BQ[
MM-G#H%"1.MT$5@Q)=FV'AX"PQO*EG)!T[4<J9K!^T3R47CFRP9$9XV-GMW&9
MYZ,\>&[PAMJR1[![E&K=DN)$6.'9]0_$>Y^M@S*'R![I1H5W+J@%MR*Z>V-Y
M^DF02,1[;;^7/72<J@*<>5:S0M%L9Q(FT?((GHTU63<ME#0LDLR3SS<WQW[C
MV3,L%Q3PP?1G!&>2//60;1]*#R1&2>.-^<Y[=_D%KB.:[5+;PW8LBU2H:CGN
M6&G%:20YC.E [\O&<=68:P(R(7*<HF2P!$WR&%RZ+12/%T&2BBC3MW.5\7N+
MF_<FG/\ "VB/';G!EG?Y VCVMK9/WNSC?U8SP\GE&._'S</H"WKKK=+*-><F
M&O94C)&T8<%\AGB2:&#A-,>J:P&/[M[VP7M;)WB*7ZV6%[V;8]?HQK46TDTY
MXEC/U"E.4J)6R>X\XW^? _6A-Y'] [:$[3!!A4ALW0D(<_$SUE\PDJB<N$/X
M_*(T3S;9).4T"0<FZ11=H7LJR>8MGN":MV_8J%))18/PD?49<# C42MK9/?G
M)8/@?1P&6<0YW0C4#O7X[0O'/#74&CVYHQNR> S.UB\XDNQ#L-:OVL8CEY>^
MB0M*-Q,)@6(K,V24=+OU'JB3UV0<*8KX.*#0:L[2LG@R+!8(L].,GD]W7P\8
MK)6SC90>-K:/.=_'=PP1"5-/\OM0JA3X2X,5H6"0767*"2-(R2DLKV5*-J;F
MY!:[<01)A&'S:'L6D>!";("FHT4;7QQ'#;K.R\H-N^U=I0I*LD>]1Y26XB+!
M)/._?Q/KX=A"4JXY+9(MH^D\FHNC[?"+*/>4TF1(!"%QD$?#-BQDAHA\:.K[
M%+.M>'_0$1!%H_=OJU@""ILW$D?Q>/N))D:EDI9-UF"KF,#X^[>*.$W-%D]^
MX]K=C^-GISG=T8QP$;:L%A)D>[/'&[A@L=/3GIX"RQ7,G3\7VVALB%\6K1]B
M='[L8[0'K;B,EY1,T]WQLA'2S(-*W,-2%Q$+%L";MU&6-X<?(V4<.,2IE_DH
MDJWG8/'OLF6SL[L$1I[,GQQO\A 2L'DD&7'/'._CC=PXXSG]0[.O_* /->[,
MU)-6&I!AF*:TX]#./I77D@E2S\;-Q4<G$BV-%) 2(XQQ'%D] R]_&BF#2PM]
M9QE&5$\7K; TKW$:,D99WFK:R1<-Q$?3U9\&>P02E$9'LG@D[.-^-QY+.X=W
M57E&9E!8"]C,JBQZ82IK/MF[,B\U![*)Z^63EFU6J6<A5FK,/'R!64L&T@1P
MDPU,')H22Q>9.!STJ\$.E6E%-D9Y(\%@BQC.XN&,\/$? $K418-)F9&9D99+
MCQS^K'PBW)CSCPE?%I#C<IK(BXNE&H1&V9^7;%<SX##\H818OE9!K"/R:)N9
MA S,C08X"2;!OL\G#AP=P]'1^*B6:Z2#42,*VL])GPP9YZS(\'CB6X#4>SL[
M)\"+>62+'2721GNZ1K_Z+_M7_DO7(./!]1^(PZ+_ +5_Y+T#!]1^(PZ+_M7_
M )+T#!]1^(PZ+_M7_DO0,'U'XC'O#T5:^.D=.8Y6OCECJO7MLL;VO:]KVB(B
MU[7M?X;7M?X+VO\ #:]<"N)^$_..<2I4 % "@!0 H 4 4\M_@HG]SWO]&5H
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MCP&-8E<@X@H S%\GY^O/X[_A!9_T A4*X'X#\PJ1[XOA\QCVIUP#F"@!0 H
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MLB#2^:#EN_"&1[Q/+#*V6%E^R5QP5PSPQ"3_ %%Y"(7UZ96GJXW'[-CGYJ"
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M?82#_#)QT_U@]84$EQ^!7F,3)00% "@!0 H 4 * % "@!0 H 4 * % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M+X143AEC)9,B,LYW[)]&_/#H/HWD9'NQ')_R89\C%6;&/[>U["IRN8VD=?;
MB>G9S&Y1"SNQ6T%%#I+IN<Q7D+'=PQ8[%@>O@#)^C/-I[/BT]?L!)"2QA-@
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M@!0!#>]OL)!_ADXZ?ZP>L*"2X_ KS&)DH("@!0 H 4 * % "@!0 H 4 * %
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M8L42;C8Q=)DF](1YJU<KW&N\L&JJ_9)V5OAGB#[>,3U0 H 4 * % "@!0 H
M4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@
M!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
L % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g209588g37c50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g37c50.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6SU:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<S-V,U,#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @0F%R($-H87)T+F%I)B-X03M5<V5R;F%M
M93H@(" @(" @(" @(" @(')R,CDS-S0X)B-X03M,;V-A;"!4:6UE.B @(" @
M(" @(" @(" P-2U!=6<M,C R,2 P,#HR-#HP-28C>$$[15-4(%1I;64Z(" @
M(" @(" @(" @(" P-"U!=6<M,C R,2 Q-#HU-#HP-28C>$$[4V-R:7!T(%9E
M<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @
M(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T
M)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N
M(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E
M<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!<FEA
M;"U";VQD350F(WA!.R @(" @(" @("!!<FEA;$U4)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C
M>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,2TQ,"TP-U0P-SHT,SHR,"LP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C$M,3 M,#=4,#<Z
M-#,Z,C K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R
M96%T941A=&4^,C R,2TQ,"TP-U0P-SHT,SHQ.2LP-3HS,#PO>&UP.D-R96%T
M941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG
M.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,C(P
M/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O
M-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!
M045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!
M25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$
M0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX
M.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&8O.$%!15%G03-!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!
M2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"
M05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#
M0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1
M:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.
M:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ
M3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K
M9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ
M<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%
M1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%
M>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K
M9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q
M4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y
M3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K
M=B]A04%W1$%104-%44U2040X0394+WIK2"\P;U X06\W+S5K65%G)B-X03MV
M2#A+2%EQ-T9867$W1E=93"M8.%143'!F-E94+T5R=V970G!8;W9X,VDY65)E
M=EAJ-FYP-S T,#DX8E13568T3SAY*VYA4T=Y64QF)B-X03M34E$R.5=J0C4S
M2#DP2%AL5U!N*WE8;T1I:6M266539%1M:G5:8G8O04532T<R=G)I2B]G:SE2
M.4]!.5=+:7969FE91&MF;W)J86%7)B-X03M1*U)03F,V44Y&648O<DI14G%*
M275137%L-"MA."M59DY25F591F-B5VYA2#53=611.#!X95AR<5@V<$\T8WE0
M1T9U3U!#0G!G04DS)B-X03M!66M,4V=B8CA-54ER569)96]*37-/;'A8=#--
M27I,3D1D5VAS<%%N2E5$4GAV23=Y:7)F1GA(=SDX8E131V)Y2#5R155K;W-E
M85)')B-X03M65TM3=W53,75A4W%O5GE72V1W=%1J83!H1SAR-CAU:T171W,R
M1VYK0B]6-4I89U<T:'I(6#%/0F)B;'AP-S1O4D4S:VYZ4$-J=DI:)B-X03MC
M4DA$2F-3:C%):5531D)*2GI!97%S<4U$=V(T=F)&86%T=DIF;5<U4EI)8E%'
M3G)E3S=$=$Y#9SE#6C)22$I:>%-R25)V=C0T<E-()B-X03LQ1'DQ<FUN,E56
M-V57<E)7,'9(:2]*5TE-:3AK1'%P3$E76&-"=TMJ1F%25VXK4V9-5C=$83-%
M9'-&=&)P-#!36C5)>'A%>CA%9# U)B-X03MC,5%T,%EI:#=9<'!.9&4O3%!5
M.4YJ;&MT2C%V,5,Y5W=J4D)'<W)Y1E%A:$9K:R]A64QX<GDW<T9X=&%3=&9)
M;FUP<'!9:%I#<TUA)B-X03MY>4]:;T)(-F)S559H25@T16-L24Y$<V5U3G)3
M<C5F.'!187!9,C$U4&8X03%33S0Q2TQ44#=R,4],5%)--GE%.# R-4M&<#<Q
M<C)X)B-X03M615=(:VDR.497,6Y52# R86$O9E1B849,9C$R95-)<7-J2#DU
M1GA65V-,:71*6#5I,%=Z,'I76F1,<TQU5%5*64I'=#5M34AO;C%K)B-X03MC
M;U5643AV259'>'A1<G0U13@R3&57,6UD4%DS1C):1F=14$=15VE1>4]H64YX
M5C%55C1S469B1F%B,$QY:&0V;G)S*VMZ4W)B>E<P)B-X03M4>E1#34,U9&A'
M05-K2WAT4U)Z>3)!8GAX5%-++W=!17=,93,T;C%)46%8<'-5570S95!B>4Q+
M:&Y)5T]),C5O,W%L=3-+;G9I=$I()B-X03MR1FAA5TXV66)3.6HQ0S):1FMI
M=5EW5G%(1F%/:#-2>#-8=&EH0EEQ-T9867$W1E5W.'9F.&0O5% K675$+VLT
M=4MV55 K8V<O=T1P)B-X03M19CA!4C,O>DEW0DIE4#153WA6,DMU>%8R2W-X
M5#AW;S%N6%9F,%5H.'I*0CE86%9V5V9J=$8V26Q-1DME<#9E,6564&)':S)H
M-W9Z)B-X03MT1%!D,F5P<G!C838Q8GDR<S Y-C!R<W-H<S%654-X555*>4-$
M;'5F86U+,FI,=CAX<F%31F]B9E-F<3AB46%L0E$S0F,X=%0T;&YQ)B-X03M9
M>#EG<C W:G<V;'!B4FUM9FUV1G V>')&;W=614YU>&AJ;D5C464S57)73D)%
M95!-1W)62DYE+V)"4S)X5'ER<F\P3%AB9E979TYY)B-X03M)0DMP:$0K:U<Y
M5THT=G0X6'!4;EAP:%%N5F@U-3!Z4SE15%5T3#!Q6F11:5)O-%IB=3E.>6DX
M>79).%!3:E R3U,O83<Q-UDP;3!E)B-X03LS;G)18E!4=$QN,#9X4#91=$IT
M46QT-UHU6$LR:'53;U%S9E166FQP5V<R<%%6.7A3,FQ%;FYC=F]X=$)9<4Y2
M87A44S5,+S%'24YP)B-X03M'-%E+26%51"]#0GDU9$\Q8TLR;6(O;6E*66\T
M2CE+17-":&UT<FMV3WI41TME3#!M:FAM9$=K4E R<4]83F4K3DQA03%0>C%&
M9#94)B-X03M0<'-/;F96;W!B0S$P*TTK<U@T<F%83%1H>E9">35C=4I&9F8R
M>'!B6&5:4'I$;3%R4S5,33)%5G1,9$Y%.3E01TEX-FI1:6EK0EDP)B-X03MC
M9C=*,CEQ1$=L=%9S+WI%:71D0U13;SE,5D%&=$),2DA,=U8S=$QH6GA*=SE-
M+T9*>&]X3$AX2&AJ4S(Q8F9M33EV4$YC2G V;5IT)B-X03M8:S%M,EIP4U)'
M,"]W>5)-3U!X:FAS1S)P,7AP8F$Q:CAW+S!H<$XU<&-E;DQB5W1X0D9"049A
M3F93.4\T1G<U-'A1=V\S26EL06]P)B-X03LQ,WAP8E-/3%AM:CAT=&]Y4D5/
M8C5,.6)O4%%G>'A.1T4T,"]Y<3$U9E)I:$Y035AN=30Q<E=.33%'4S!70DY/
M-% X059K8C1:2F95)B-X03LY5V%3=D5C5$LS6&(W.&%4854S5W5Z4V5:<'1E
M9VI%37HS<E@P55)034EX;$UQ<512959$-UEO6D9$*UDX5G1E4GI796Q#0T4S
M1GAE)B-X03LS8U!R<WAK=6)I,V5$:W)S;G=+;VQ*0S!0>GAP3G-C,$A68F)4
M8G0U8FUY4RMH:VIA3F\R67AU<$Y#2DEP5D)-8G%2<V-52CEC9FU')B-X03LQ
M,V180S-U;FDT,&TV=%E,3V%Y95HO5EIB6FDX56AU2V-J2W)-9FE+.4YQ63!M
M,E!A,W%6='%&-S8Q=%I2869B26E243(P5SE&455")B-X03MD-D%U-2]A63EC
M54E$1EA9<3=&6%EQ;4AL-R]J=C9:+WI&=V8X;D9X5C9H+WIK2"]!3DM$+V\W
M+T%/6D=!2DQX+T-H,DMU>%8R2W5X)B-X03M6,DMU>%8R2W5X5C)+<VXO04,W
M,%=0579-06QU26MN<SE/:64W=4EP4VEX>6-"4T].;6MO;$AK2VHT='%6>$M1
M>4A89DEE;DQQ;7$V)B-X03MK67!H<'AH=#=U>G-.4$UB=GEU,TUB2W)+2&HT
M47E+=TE8+TIP5')G=&%44'I$-4,X<7DK6FMH8C9X85!Q8VPV<TUD;TE59V@K
M<%%R)B-X03M*55(X0CEO9&=2=C-X=$Y*9EHK4W1#97E#=W1+8EA61&]S:V)3
M:49R:4I,,C5M:&Q66D]'>"]D+W,P.7=A66]7-DXU4#AU;E5R864P)B-X03M-
M.'-59#=Q1VY8160R<TUQ=3%T6G9+:VEQ531J='-A-S=G:D9A53E).&@V23%R
M;V0O2C8Y>#8X.6HK:TE(26E!4S=K0T%'2C!2*T)9)B-X03MG2S9-,TU6*WHQ
M>%=N6"]K<GDU2F57:5%1,S983W$S,35$1&)O,$%73T\P:U5U84]S93-!;FIV
M=#$S<%%Q,'$V:#5-.'0V6&]U='EP)B-X03M(4&1U,FU79#E:3U=6;FA-.#=)
M9FDY3D]11%)G<V5!*T-O,C8T<E-R9BM1=$=U=DUE;W)*.5E%5#9L1G!L=$99
M>'A+25=K:%8O6&U2)B-X03M50VE09F]O6'9V:F$P;&QZ-4<P0TM"<F1B:35F
M55)O.&UR3$UP:DYU5$-Z:&MP>#5%4#9:<'9T-S0R=$U$=V]D:7)S5F1I<G-6
M9&ER)B-X03MS5F1I<G-69&EQ6658=CA!:G8V6B]W07AC2"]*>&-697EF;E(U
M63$W6% P4"MI8DXW=C9V.5HY8F=62$AN-EA'=DEJ<GA/04I,>E O)B-X03M!
M2E9J-3@O-G,X=B]!055F+TY71S%P,R]!0W)(>C4O,5HU9BM#:B\U<7AT860O
M>7)(>C4O,5HU9BM#:B]!3V%S8E=N9CAQ>#@K9CA!)B-X03M6;FPO-$M0+T%*
M<7AT860O>7)(>C4O,5HU9CA!9V\O*V%S8E=N9CA!2W-F4&XO5FYL+S1+4"]M
M<D<Q<#,O2W-F4&XO5FYL+S1+4#A!)B-X03LU<7AT860O>7)(>C4O=T)795@O
M9V\O.$%M<D<Q<#,O2W-F4&XO5FYL+W=#0VHO-7%X=&%D+W=!<7@X*V8Y5V58
M+V=O+RMA<V)7;%=,)B-X03LX=E!Z2&EG;6=I,#(U:F=U06]U26QK54I)15!*
M96%H-DYX3S1R:F$P<G<K4W9Z56=33DE,82MI4T9(:FA62G=O4DI$5C%50U1:
M5T\W)B-X03M!9&-66% U4"].:#59-6YG=C)L:#5M1U$S1E=4,58T>6-4-FQ2
M>EA:<612:7)39510>E=255),82M627A%23%%.4%O9UEV1GA!:S(Y)B-X03M.
M;4I4=THR>%9Q3'E4*V%K6#DQ83-S9C=X-79H;D,O=EI6-%-0<R\R;E0T5U!5
M:F)&5F@X:2]M96)A2S%.;F5',6=B;D1"-G<Y3D@O)B-X03M!2FQ8;E)4-VI'
M,59*=DIV-7)Z>E)4>E<Y.4Q.03=345-V8V-M4C)P>5I'36Q62C1I<$=+='EE
M5'9Z66M:,FMG=C-A4TEW4TTQ>%5T)B-X03M%>$Q.1V%Y8F]3>$I8<&ER43AM
M+VUU2F)I65<Y.$IR<V-B=5%82'A3:6Q+4T@Q2W50;FEQ=V529GI11DM79#4X
M34)T5B]F1&$S3F%W)B-X03LO8B]U>E4O1#!X5D,O=T1+<V90;B]6;FPO=T-#
M:B\U<7AT860O=T%Q>#@K9CE795@O9V\O*V%S8E=N9CAQ>#@K9CE795@O9V\O
M=T1M)B-X03MR1S%P,R]+<V90;B]!1EHU9BM#:B]W0V%S8E=N9CAQ>#@K9CE7
M95@O04E+4"]M<D<Q<#,O04-R2'HU+S%:-68K0VHO-7%X=&%D+WER)B-X03M(
M>C4O,5HU9BM#:B]!3V%S8E=N9CAQ>#@K9CA!5FYL+S1+4"]!2G%X=&%D+WER
M2'HU+S%:-68X06=O+RMA<V)7;F8X04MS9E!N+U9N)B-X03ML+S1+4"]M<D<Q
M<$=A2BM7+VYE1%=B0V584UI5:6EU66YK8W1(44MR9VLO83A-8E=N,%IK575X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X03LR2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMV4&9Z43AU
M87AR5W(K5R\P8G!5)B-X03LQ=TQ3-3EA-#%I1V5&2'-L4U-/4F94:6QM:'$P
M:GAQ2&163$--37$O8DEX5F=':F9L6"M93G8X06]F;EDO5B]Q,3%#>2]W0VMW
M=CA!)B-X03M62C1V,%@Y6C%$6GIZ*W1F57)V6F%T*SDK241K,49884XK5F8U
M9S(O-D@U,E Q9C9T9%%S=BMK=W8Y56YI+U)F,6Y53FY04#8Q.5-U)B-X03LY
M;'$S-S,T9T]4559E9S(Y-S4U,&XX=V1%,&96=&)T.58P,U=,9E5*:$9&67)A
M3D5B4#!3;%@Y5UEV6#$O8G Y>7(P1$9867$W1EA9)B-X03MQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T95;SAW-C=.<%,R87=76G9B:3EM.4-+
M15-,1CA8170Y<&A4=&U.<6118V15)B-X03M/27E.9'IM85!3:DYX6$QH15)D
M,6%%+U1V;3,O04ML:"]W1'!.='8V-5@T*V(O52\Y:T<O.')P=CE7+S)%;F9P
M,WIB+T%.4W<O=T0P)B-X03MM,C,Y8V9(>F8V;B]!3$E,*U8P,RMR9C=#5'8P
M-S5T+S9L:"\K:S(R+W)J-"MB+U4O=T1:0F9Y=6TO,6(O65-D*VYF3G8O57-0
M+S!M)B-X03LR,SEC9DAZ9C9N+W-G=C585&8V="]S2D\O5'9M,R]Q5T@O-E1B
M8BMU4&HU=CE4+S)16#AR<'8X059V.$%94V0K;F9.=B]5<U O=T)*)B-X03MT
M="]82'@X,RMP+S=)3"M6,#,K<F8W0U1V,#<U="\V;&@O.$%P3G1V-C0K4&TO
M,5 O6D)F>75M+S%B+UE39"MN9DYV+T%&3$0O=T13)B-X03MB8F8Q>#AF3B]Q
M9BMY0R]L9$XO<3,K=VMH=%(X,V599$]S<&(R.#AU4$9B46='4U0V,T$Q05-!
M3FQQ97 X36AK,657165+5U!99C!G)B-X03LR665Z.$]346A(3&-J+U)K>79.
M9S9H,DMU>%8R2W-*.'EF.$%K,2]*4"]-1G)8+T5B5$978EEQ-T9867$W1EA9
M<3=&6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ>'IZ6B]X,'9,
M=B]B44@O2G0X=V1:.650*W,W4',O=T1U.'8X07=V.$%31U(U;D]S9&ER<U9D
M:7)S)B-X03M69&ER<U9D:7)(9GI$+S51,U4O.5)0.$%K-G596&%0.7A,.&18
M6CEJ+W=#3E$O2%%S:7I.9%DW1EA9<3=&6&YU=6%T<#EZ*V1(;%A4)B-X03MO
M6F5D-5E73W).9'AC5TA!5'!A=$@X4D%5.&=P-D@U-'$Y0WA606593F%T3D,P
M4%5.87969')05&)E5S=U4D5V2B]3:%%U-59A:71&)B-X03M5-'$X=4@O3U58
M-69L030P-U=3:$A)3CE45VQ/=&8W,TLO1FDT=C4W1"]/1# S479-3FIR;FQY
M>C$K=T1M>78W6F)U,D5G-% V8G)Z)B-X03M8:T%7;V%:63541&1#+TYB54YD
M,#9W*V]A2D5U=%AQ=&-0<#@Y-'E24E=G=$EB=%HR;E,S:UEH;'9)16])<6-M
M27(X3S9R3%!*=758)B-X03LR=F579$\Q=3AS-')&=%-T-')U1S)H;F$U0W=Z
M>')*2'ED;W)F-#9..%%#,$AI8U94;D9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&)B-X03M73V5B4"M/;#5D+S=A02\U3G9M1')0<G@O=T):,F9:+SDS;"\T
M6"MK36IZ3V19-T9867$W1EA9<6M0;6IZ6$YO4'!&3D,Q4%8P:U8S)B-X03MK
M:S R3T-266=L4#=Z,7!O2U9R=%-U2V](>6(K65-E8791;'1D03%A>'-,<40V
M>F(V:F5X5S97-V]A8U%R4E1Y=%9G,5(X3TMS<WA6)B-X03MJ=C5H+W=$2T<V
M;B]!2VEF.&Y6>D,W4B]U2F9J<3=0<V8O1V]F:F]8:VQG+VQ45V9Z23!J43 P
M1G1+,6E/-G50,'AE4S9R83-';TUS)B-X03MD;D]W:CE70S9M=6<V>FA(4$4W
M54YD<35N3W-E*S1&9&ER<U995#5K+W=$2G(K4V8K64Q7=BM),FU+<S)X5D(V
M,7!.;G)/:C,K:UAY)B-X03ML<DQ58F57,'5L53A7354V1TYW1TA1.%=/*TMV
M3T(O>FI0.$%L345#9E4W,F=&4"M/:&5F.59A6DAH2&,P9FQS9C@R4'EE:#9(
M;T]N)B-X03MA2F]6;F]D:7),<#EH06QR8F\W1FU%4TQX549U<#)Y5&5H9$PX
M;2M79$MU5G5D4'-59VY3>&<P<%I!>FLO53=A;VAI4$IJ6&I8-U@R)B-X03MJ
M=%5M9WA6361.,#9Y,'I4<EA48D=0,&)+>6AJ=')71W!B:$9%;U)&<7A,1VEQ
M0G5C5E)/2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X03LR2W-C.#)F.&1,
M>3<O=T)T068X04IT.'=D6CEE4"MS-U!S+RLW>2\X3"]31U(U;D]S9&ER<U9D
M:7)S5E$R<"\X8S(W+T%/34UN+T54)B-X03MI<D=V>6DO.&QF-5<O=T,R6F)F
M.&UX:7),<U99-RM99B]+1S9N+W%*+W=!;E9Z0S=2+W5*9FIQ-U!S9B]!0G%(
M-#9&-3<U2&@Q3U X)B-X03MX<'!*-W!R93)U<C=53&U,5')I.#%7,&M:6B]6
M:U%,<',Q=$):>7-Q<T-X4C(V1BM434MN3V19.65U3'DP=#-G4S1N:FAE-6LY
M1S)7)B-X03M2,55Y4SA79F=G2DA*=4--,4)V444Y<T-Q9#-Q;6U78SET0F58
M:T9T4&5V-E9N1DY):5!.24)8:$5R148R<#)81E5.1#5P.'-496@V)B-X03M/
M<C)5;C%Q6G)7,318151E<E!(.75+3VIF138Y,4<T>%9J;FU4+WEA+VMN+T%*
M9W1A+S1J85EQ>F)&56HX.3-7<S)N:VY8-WI20S8V)B-X03MX8F%D9%0V9#9C
M66UC,T553%!%1FI934A*8T%5;V$T47(U95@X,'8K8VAZ0T,Q.7)9;#0Q2R\T
M96EP>7 P+S-K.&,R4&<V979Q3%1X)B-X03M4-V<K;5!)*V]E63<S.'9.2'8X
M0599>DHU:6XP-DM7-FAN6#9Q5W5M:7%Y=494.3%6.6I23G9$3F-E8F,X,#!4
M.'9D6'-L45AV;$=8)B-X03M59$)J2D0V2&-0<'8Q;659=T)%=6)G2F-#>6UA
M26AL.6,X6E<U1FU5;%9X5C=,;SA%,79P3FQ"4$=)6F]R94I*66QK96156E5!
M6E),)B-X03M*.&-G0C(U3G5E<'=+:3A69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5EDU-7,O-#98;#,O04QA02]W0U1B-6<V>C8X9CE:,F9:+SA!)B-X03MD
M-68K1B]P1$DX>FY73WA6,DMU>%8R2V]B52\K3V)D+SA96E K26Y&5TYF;$8O
M-4LO=T%R9CES>3(O-4YJ1E=867%X,SAW+RM53C%0)B-X03LO550O04I/<FU&
M,FHO8U,O2%8R9EDO.$%J55!X,$QX:51Y.35U,2]Z>G%C1VMR3F%+=7%A;#97
M=G9Q<W-42S9V2T58-F=T,%=624AP)B-X03LV6E=':VY%8V=%66M:>G)(<C-N
M5'EB3')U<2M83E1T6D5H=3E&=FUN85=2-5%"03EV3$=Y<$=N=VQZ2S!:<6%'
M9U!X9&E&96,V3BM1)B-X03MM<S9D.513,VMS8DLR1C!S;'AB47DS179O4G)0
M<#%W,'1T2DQ'2&%A5U141W%(;T9%;$%X0V)Q<6UM9FMB-6YT+W="2&5T95=+
M*VI*)B-X03MB4EA8;W1,*S=G<R\P6'=N=#9X:CDO3"MH+VI";T(V;C)J>"M*
M5E!8,$A5.4LO3G9Y;S$W<FPS<DEU3%!71$5L,G-#:4%+3&%O:CE')B-X03M/
M26YL>49E5F5G>%8V:&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<DA03FXO2%,X=2\X06)12"]!0V)F)B-X03M-2%=F6&HO<D]Z
M-U O=3AV+T,O,&AK95IZ<DA9<3=&6%EQ-T953G%F+TA.=2]W1&I$2B]X131Q
M>'(X;W8O2E@K5G8X071M5S,O2G-9)B-X03MQ>3=&5T\O;4@O>6AU<"\V:68X
M04HQ8W=U,&8W:5@T-G5Z-T@O=T%A:"M/:%E$<"MI95=L."].6E=(;7I2>#5H
M.5=9=4E.2S X83,V)B-X03MP5FUU2S-I:FHV:%1N>E!O,38Q>DYD63EG>%8R
M2W5X5FA0;50O=T%M=C5*+S5G=&$O=T-),FU+<S)X5C)+=7A6,DMU>%8R2W5X
M5C)+)B-X03MU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5FIN;7HO04DV6&PS+W1O
M1"]K,BM93W,K=D@O5V1N,F8X03-E6"]!25@K:TUJ>D]D63=&6%EQ)B-X03LW
M1EA9<6AT5"]W0T]B9"\X65I0*TEN1E=.9FQ&+W=#4W8X<F8Y<WDR+W=#5%EX
M5FPR2W-D+TU0+T%*43-5+SA!550O:S9U65AA4#A!)B-X03MC4R](5C)F62]W
M1&I54'@P3'HS>6IQ1C-B+VUZ93980F4S=W-*3"]56E@P8WIX15)/>&QL831U
M3%E755I3,VUK3EE71GE72DLX<3%/)B-X03M:>G)(<VU"6%EQ-T98;G5U86UK
M+S4P*U9R05<Y>$<Y;%DV<7I4>5)/:T5N<DIA:V5J2U)X:TLX9FHT+UHR<FER
M,$Q&6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&5T]E8E K3VPU9"\W84$O-4YV;41R4')X+S%N6CEN+S-E6"]H9C91>5!-
M-3%J)B-X03MS5F1I<G-657)U-W1R3S!M=3=Q45)7,79',',X<F9:5D5"6FU0
M<T%+-'%W1R]W1'HP+TM'4WAU63 X,F%E>G9%-G%05C9K<5%/,D=I)B-X03MQ
M4F9L<BMC=C5785@K6"]L-U1R+T%->C)&=F4R;&A"1&-W3DM#561%05I44V\R
M3TY&6'%7:#8W;RMV859"<3)J,V-D.7!T>GDY0S9H)B-X03M02D@T3UDR;V9:
M;$EW2VQF-6@O.&]B<68K;VXO04-D6$U,=$@K-&PK3W)S*W@O.$%';V9J;UAJ
M2#5B-G9E4F9M=F)A2F-A3W1T2F$S)B-X03MD.6)Y86Q(<75P6%5B*VY(9&]Q
M2D)E6$9'*TLR8V,R:E R4U%Q,4)'8S9X.44T1F1I<G-6650U:R]W1$IR*U-F
M*UE,5W8K23)M2W,R)B-X03MX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%9J;FUZ+VIP95AF*S)G4"M48C5G-GHV.&8X05=D;C)F
M+V0U)B-X03MF*T8O<$1).'IN5T]X5C)+=7A62790,R]!0V=V;5 X03=:9#<O
M=T)1-S19.#%F1BMJ+SA!2$IS=BM994PO:4%Z<TUF,&HS3W%N>DM,)B-X03MY
M5$8Y3"\X04]/2"]!2DIR468X05AV.$$O=6\S1V-J;BMS*SDR,&516E0K668O
M2T<V;B]Q2B]Y9%A.8C)J+V-3+TA6,FY9+RM.42]()B-X03M1=D]F23)T=F4O
M;4ET4')$*W1E-FUW:79T06$R=6)E1U%Y>6-0,&Q*3U-&<6E$:45Q9&Q+<BMZ
M;D]S97,V;G(K:C988S)&<F8S4U%8)B-X03M'<51',W-);7%7:VM61VM90V=.
M0491,5DW9$)7<$91<5-7=C5P95%R=C9N-D=Q<2\Q*V8V<F$O=7 Q-5-F=7%C
M=5-$9VIF5UEU3'12)B-X03M7-7)1;FM-5F1A+VUL-4-U+W%F;V%Q<B]!1BMF
M-G)A+W5P,3539G5Q8W531&=J9E=9=4QT4E<U<E%N:TU6469M5"]Y82]K;B]!
M2F=T)B-X03MA+S1J85EQ>F)&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1E=/96)0*T]L-60O=T,R9U X06LR*UE/<RMV)B-X03M(
M+U=D;C)F+T%(95@O:&8V47E0334Q:G-69&ER<U933'HY+WEG=FU0+W1L,W8O
M54\K1U!.6'AF;R]W1'AY8DPO04IH-'8K241/=W@O)B-X03M34&,V<69-;W9*
M35@P=CA!.#0T9BM383!(+UAV+W=$=6\S1V-J;BMS*SDR,&516E0K668O04-H
M=7 O-FEF.&Y6>E<Y;R]W0GA,.&18)B-X03MA9&HO04].42](479*=DI5-WAF
M;FQQ3F=B3W=90R]V-V=83&%A;C945EIZ9&MS.3):1VMJ:4)J0V\K-%I(46-6
M1%5'8S9X-GHU<CAL)B-X03M72&U/-S!A-FY+4E,V5&1M-$UO:D13>5).8GEW
M=D%*2W%Y2WAM1&YR.6YP,T%6:%9J*U$X9'8X055V5C%T<'9194-/-R]W0D=#
M971:)B-X03LR;C%$-G9#=$I$-F)R*VE)955M+TMR9D-+:6ER<D@X:#0W9C9L
M-G5T=$XV1'=2,V8K:D)05W,W5#9H.5AH5VMH.4XQ+U)%4$M49FQ6)B-X03MV
M:$924E989GEV0F]F-70K5DAI,4158C0S;&YR1$U.4G9*<G-2.$)B2#DP2E,S
M<&<X.2M05V<X359E;UEQ-T9867$W1EA9<3=&6%EQ)B-X03LW1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ>'IZ6B]X,'9,=B]!1S!"+W=!;3-Z0C%N,30O-GIS
M*WHO-W9,+W=V.4E:2&UC-G@R2W5X)B-X03M6,DMP1C4K+S516'I(+S)Y-S,O
M<4AF1$AM<C1V,&8X030U3FPO=T%W.%@O14)N65DO<$AU9%90;558:VU,-E@O
M04]C8U O2DYA1"]R)B-X03LS+SA!,U5B:D]2>B]!1FXS=3)J>41+9GI$+S51
M,U4O.5)0.$%K-G5A,W1(*S1L*T]R=$]X+W=$1V]F:F]71BM8=%DX=S-F-6QT
M6FDW)B-X03MV3')2<E,O,4MT-FM&*V)E47-R26)/4C)I1FUI,G)X2W%U<FLX
M;$E'-W183V19.5=W2S=&6%EQ=VYZ2B\U3F9Y5"]Z0F$Q+WA','A6)B-X03MM
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<V,X
M,F8X9$QY-R\R,$(O>6)F34A79EAJ+T%+>G,K>B\W)B-X03MV3"]W=CE)6DAM
M8S9X,DMU>%8R2W!&-2LO=T-51CAX+SES=3DO=T-O9#A-96%V:2]2+SA!:FLR
M6"]-4$8O=T%11V1H:BMK934Q52M:)B-X03M295-9=G!F+T%*>'<O=T1*3F%$
M+T%+.2\O=T(Q1S1Z:V,O,6XS=3)J>41+9GI$+S51,U4O.5)0*U1Q-7)E,&8W
M:5@T-G4P-T@O=T%A)B-X03MH*T]H96%E54=G8C@T6EIR84DX3'4W,4]655-A
M.4U!:6E-:V)88U5Z6&-L<&-'4U9U36M+469U:3-9<FUC-G@W8F=6,DMU>%8U
M-W)L)B-X03LS9E-F;E0U5W1P<D8T3%,S<V163G)F1U-.;'5$26QQ6D%Q2U,V
M96U106591F$W67$Y0WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6
M,DMU>%8R2W5X5C)+=7A6:FYM>B]J<&589CA!=&]$+T%*3G9M1')0<G@O,6Y:
M.6XO=T(S;"\T6"MK36IZ3V19-T9867$W1E5I."]F)B-X03LX;TPU:B\W6F0W
M+S%$=FAJ>E8X6#90.$$X8VUY+W=#665,+VE!>G--9C!J,T]Q;GI+3'E41CE,
M+T%03T](+VMM=$(O,3<O.$$W<4YX)B-X03MN234O<E!V9'1(:T=5+VU(+W=!
M;V)Q9BMO;B]*,6,Q=F%0.$%C4R](5C)N62]W1&I54'@P2U5E6%!Y,'5.23%$
M4VUM,6AR=E-F3"]Q)B-X03MJ47)$-G1(13A1;6IA12MT8TMX86%K8FMF6E=P
M,TY337I85TTU>%8R2W5X5FA0;50O=T%M=C5*+S5G=&$O=T-),FU+<S)X5C)+
M=7A6)B-X03LR2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMV3B]0178U:S94
M9C)-=&@U;'1%<W18,5=(5#=E,69403=7-EA*86I'5#9W4%4T8V8U)B-X03M6
M<C=9<7IB>2]:-CEA5T)I,795;SE6=F5B34QQ1S)&;W9!9U58,'A*3C S,S59
M<6U72W-C.#)F.&1,>3<O=T)T068X04IT.'=D6CEE)B-X03M0*W,W4',O*S=Y
M+SA,+U-'4C5N3W-D:7)S5F1I<5)E9G8K548X>"\Y<W4Y+S9H,W=X-7$K3#E(
M+T%/3U1:9CA!35!&+WA!6C)'4#92)B-X03LW;E94-6Q&-4II*VPO=T1N2$0O
M>5179R\V.2\O04XQ1S1Z:V,O=T):.3=T;SAG>6XX=R\K54XQ4"]55"]!2D]R
M;70W4B]U2F9J<3=4)B-X03MS9CA!>'%(-#9&9R\U8396-49I,6U#9E)F265O
M-F)C4GHS87!R5C5"6DMT=3,W>%I):3A6=SAG02M+2F9G2C96,C-Z3F19.6%X
M5FI:)B-X03LO369Y25I,2T](6$Q3-B]317AT<E8W4U%835IL0FI5<3AK2'%*
M2#A5.&$Q8V=69%(Q65EQ;S)V-7!E47)V-FXV1W%Q+S$K9C9R82]U)B-X03MP
M,3539G5Q8W531&=J9E=9=4QT4E<U<E%N:TU6469M5"]W06UV-4HO-6=T82]W
M0TDR;4MS,GA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A6,DMU>%8R
M2W-,+TTS+W!L4"]!:C O=T0U;5EQ>E1&6%EQ>'IZ6B]X,'9,=B]!1S!"+W=!
M;3-Z0C%N,30O-GIS*WHO-W9,+W=V)B-X03LY25I(;6,V>#)+=7A6,DMP1C4K
M+S516'I(+S)Y-S,O<4AF1$AM<C1V,&8X030U3FPO=T%W.%@O14)N65DO<$AU
M9%90;558:VU,-E@O)B-X03M!3V-C4"]*3F%$+W(S+SA!,U5B:D]2>B]!1FXS
M=3)J>41+9GI$+S51,U4O.5)0.$%K-G5A,W1(*S1L*T]R=$]X+W=$1V]F:F]8
M;68U)B-X03MC84@U5F<O378P.4DX>3)M<GE75G Y8RMT5U-W;5<V.68Q641&
M95A-9'A-8F@T*U!Q35!46&-Q,EIZ<DAT8SA1;6=K:4I+:5)3;DE5)B-X03M*
M2$E5<G95649E5C)0-4,R=',Y=7<Q4T].4D]R,S!&=%IR8G=Y=U)Y5U5Y>%)2
M<DMW:%EY-EI'-W5+.&EZ+T-+:6ER<D@X:#0W9C9L)B-X03LV=71T3C9$=U(S
M9BMJ0E!7<S=4-F@Y6&A7:V@Y3C$O4D502U1F;%9V:$924E9%4V554$QV;#<X
M,G9+8C9086965W9B4%='=50V:W-N)B-X03M);TQ5<B]E33E+8WHP>%8V9FER
M0G9Z13@T96102S%J9C9X6F%.63,R:#9F04HU6G!B>5-'-$Y0=$%23$1)=3-B
M-#A65#=Y>F0K8V)J)B-X03LV>B]I5%1R4%0K4$0V<CE3=6YU=61E6%!N>FEH
M-#!O=$]T831Q;F5+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8U,2MC=C5M-G0U
M17,Y)B-X03M(:S!Y=W0W*V963&U3,TLS36IX26=J:&%8;%9&8R]S,#9:9&=W
M;DI,:$A.:D]F0TQE4&$O*V4O;E17=C!D.5DP3%19+S!B9E$V:D8V)B-X03MD
M,U X56M(3&ER5F=0=VYL=E1--RM38VYF2#=F,4Y(-7%0;6Y6;"]Z:W0U,VPQ
M4%0W4S0P1%1%:79R>3)S>3AD,6-->2]76FQI1%5-)B-X03M3:F)N6$MS,UHX
M.&-E26M5>6AN16I19E)M641E>'IZ6B]W061,>3<O04YT068X;3-Z0C%N,30O
M-GIS*WHO=T,W>2\X04,O,&AK95IZ)B-X03MR2%EQ-T9867%K6&XW+VQ"9DUF
M+T%'>3<S+W%(9D1(;7(T=C!F+VIK,E@O35!&+WA!6C)'4#92-VY65#5L1C5*
M:2ML+RMC8U O2DYA)B-X03M$+W(S+W=$,U5B:D]2>B]79F4W85!)37 O35 O
M04I1,U4O.$%55"]K-G5A,W1(*S1L*T]R=$]X+SAA:"M/:&5795).9EAZ2"M:
M96Q*)B-X03MB6'-E<C)U;7!E,UEV<EA423E*:$)33#9Q-5!/965E64)R;%8T
M1D8S26%P-#5N3W-E-C1&9&ER<U995#5K+SA!2G(K4V8K64Q7=CA!)B-X03MI
M3G!I<7HX-W9-970K5R]Y>#%F5V1$=79Q5W%7-U=A,CEZ=VIL-&5T97=W=CA%
M<75H<6MJ1&-92D=G,35:8TU3934X,S8S*UE(-6\V)B-X03LU<$XQ<$]Q96%P
M8FI4-WA$1F-W9E5R0D]32'1Y4T)72#!(369X:39$*U=C;F-%4F0O;D(K8S!&
M<DY-4$XX:$U58D]!8D14<45Q0V8K)B-X03M79DAX:7EX.7)Z36=+1S5F5C-L
M83EU8C=Y>G!&-V10-FQZ9%=6=DY02E%,>6MK:59M3D9!07%4,D=:3#!+6C1Q
M-T9867$W1EA9<3=&)B-X03M867$W1EA9<3A,+S5Y;2\S;3AO9CET0S0O=T-O
M3U1--W,W*RM(>"LU<#%(,$8T:FY3=7585VXO2&0P1"]!3&)';2\X055:1FU(
M,F@O)B-X03MC;'4P+W="8C=G>FU(67-C.#)F.&1,>3<O=T)T068X04IT.'=D
M6CEE4"MS-U!S+RLW>2\X3"]31U(U;D]S9&ER<U9D:7%2969V*U5&)B-X03LX
M>"\Y<W4Y+S9H,W=X-7$K3#E(+T%/3U1:9CA!35!&+WA!6C)'4#92-VY65#5L
M1C5*:2ML+W=$;DA$+WE45V<O-CDO+T%.,4<T>FMC)B-X03LO=T):.3=T;SAG
M>6XX=R\K54XQ4"]55"]!2D]R;70W4B]U2F9J<3=4<V8X07AQ2#0V1D=0-50X
M=$YR<T]V+V\V0DYA9T1H3E%206MX)B-X03M%:6Q'5C)7;G%#:DA:-BM06$TQ
M,6EB67$W1EA9<3@Y,7585E<O3VYY=$AC45)2-F-L:G%V,4-D2D,P<VA:3%@Q
M:$I'5D%4:6%C84UA)B-X03LK,DMO8B]N2D0O>51E=2\X6F10+T%/-FQB6D=F
M2G Q2#DS3#-0;7)-2C1P0S9N+WAZ8G8O04EW>68X44]&<W<O5U!E2#)H-4HO
M=T-5)B-X03M-,$0O04Q:,7 O>5E4334W9$]S5F1I<G-69&ER<U9D:7)S5F1I
M<G-6948O.#549C=Z9550*S)H8V8Y46-M6C-:,SDX4&HY>E1Q4&],)B-X03MX
M2$]L9&-U=% K3S=O2"]B63 S+T%+:DES=RLP4#=K=#)N*W0Y=UIZ1'-73V5B
M4"M/;#5D+W=#,F=0.$%K,BM93W,K=D@O5V1N,F8O)B-X03M!2&58+VAF-E%Y
M4$TU,6I5:CA%6C9&=4E*-'%+:S X0C-/2W-$9CA!3UA1:W9)-T8Y13AW3&5Z
M23!S3G%D2G5X2SAC6D%D,5%R>4MQ)B-X03M71E-"=%59<7I85'(U8BMW=#=X
M25IO1G5%5U%1,TUB47I)1T9E36MB,%I'2&-(1E5Q."]F.&],-6HO-UID-R\Q
M1'9H:GI6.%@V4#A!)B-X03LX8VUY+W=#665,+VE!>G--9C!J,T]Q;GI+3'E4
M1CE,+T%03T](+VMM=$(O,3<O.$$W<4YX;DDU+W)0=F1T2&M'52]M2"]W06]B
M<68K)B-X03MO;B]*,6,Q=F%0.$%C4R](5C)N62]W1&I54'@P3$ES>EA73WA6
M,DMU>%9H4&U4+WEA+VMN+VU#,7(O:4YP:7%69C@U268K4V(Q,R]J)B-X03M,
M<"\O04A5<F))>C5.3V\O=35E-3@Q6FA01DE852\X06IM,V8O1T=4+VE"=W1M
M2#9X-W<K,%!*4"]+1V%"+S)Z<E0O:W=M6GHR-D$X)B-X03LP+VUF-48X<W)D
M>#9N<E9I=6\R84(U3DHK=5=K9#1E441+<7A4>7AB<W)!:FM2=&A!2W-%6"]N
M2VHX=6UM94E7.3-Y:D-L:6)J4U%P)B-X03LU5G!X8S,S1G5M.41T,W<X2E8V
M5&]0;FIY8C5G;4YV;VUU-F9Q5C!S9G)35W1P9'=817%2,4%,36M4=5%!>D%%
M.4LT0T-&5'9!<G-6)B-X03MD:7)W<GI:+WIK6#5B=7AD859:,B]M6%1,;7EU
M-4E*8BMW='108VQR9#)I:U%F5THS2$5S4#5A-4$U04,T=517-&](:&MA3$4O
M3'8U)B-X03LU5#)T*S%Z<D=O*V)B>4='-UHW83!7,3!N,#5B545C1FY)94YW
M-3,U8T14=T]$>%ES4#52=R]Z;G50-6-F;69O;FXV,78W:E,W3SES)B-X03MV
M,&1-<T9X1F9P1D<O2C!%9TMI2U=9531N>'E93FAY8V57330X5654>G8X035Y
M;2\S;3AO9CET0S0O-F<U37HK>G8W-&9(-VU/;RMG)B-X03MV16,V5C%Y-C O
M-#=U9V8Y=&I49BMO>4Q-4'1$*S5,9' O<F9C1V-W-T9J;FUZ+VIP95AF*S)G
M4"M48C5G-GHV.&8X05=D;C)F+V0U)B-X03MF*T8O<$1).'IN5U!N>B]N241Z
M8C5X,')Z-W Y:&]U=EAM;%=C=6Q#95-#,4U15G!28T]N32MP2$IU5C(K9UI6
M:VU9.&Y8.6]A=5=')B-X03M)36$S-S-M36YM;GHS2G%-3W!0-7$Q2G(K,VIE
M1T<U2G1U85)Y;%,V02MJ,%EO=&9L;&9J1C%8.'-:9390,B]R6FHK5DAN:GHU
M9&9M)B-X03ML-6,P,U5F36PY<4]N,W)8:3-.<F-M26\S<#)5,'%F66I1-T]O
M4%A,3651>4QN.6XV-F5A4D5G3F@P9E%F;C<O04I16'I(+S)Y-S,O)B-X03M!
M2V@S>3903C)Z-'8P9CA!-#5.;"]W07<X6"]%0FY962]P2'5D5E!M55AK;4PV
M6"]!3V-C4"]*3F%$+W(S+SA!,U5B:D]2>B]!1FXS)B-X03MU,FIY1$MF>D0O
M-5$S52\Y4E X06LV=6$S=$@K-&PK3W)T3W@O=T1';V9J;U=26FUU<V1I<G-6
M63DU<#@Y84@U6G9D2W1.4SE8,4Y7)B-X03ML.4M&-#%$2D=056EH36MP3$Q2
M0DQC>')T52]&,&]#47%X>GI(<G5I2#@P+TIS;S%#,DUC3FYR2WEU2F\K2T9H
M86-1>')T5VAP6$95)B-X03MQ+S5Y23%Z4DQN.&].8FAT.5%T<'!M:S O:DA(
M3D=Z1VUO,C5.04-4<T)827HU3D]O+W4U934X-6988E O9CA!2"]W82]W0F-W
M-F5-)B-X03LT2F1Y1S%+.'1$<#$P0E!'4UE:04%'6"M5*RM.3FU'175-8F11
M*WAF2FYM2'DO2#50,$M/5%4W4DA45#=65U9P-'=14D%G24E,6FY0)B-X03MA
M=FU(.#-B;E(W;C@T9DYK+W$R.#AB=%EE;DQY4C%)1FA#1'AB9G5-,W9:9D1W
M1RLY>$Y49&EM3"]W0S18+VPR+W=#4V5B3#!E5&IE)B-X03MR>F5K+W=$3T]&
M.6]T;BM:;7%Y=F-7,71%9$9#:'DX84M73C!P<%5K0W1";6XW57%X5&PV839.
M=G!B+T5V;'HO04MU=&XO,&M29CA!)B-X03M.5V%H>5AF-&PX=68Y6%=Z+W=#
M:VE,+VUR1EAF-&PX=68Y6%=Z+S93278X06UR1EAX6F0S;&XK;3ED4')X,&)6
M.5):5'I88T<W:TE))B-X03LS-DA-6$PY5'EV855#8SAT=3<W;'8Q,GHO=T(O
M>"\X04)R+UA+-F-$9VPS4%HO.$%N1U!73DIT8F)Z6CE:=F)E1#%,*S--9G%3
M;VY))B-X03M#,&I"235%5GI+>&93.58R64MW4BM0,VQR+VY*-U=.275B6'EN
M.5=V<F5F,#E1=41*-F-Q4'A"=$I!0V5*3DTR6%IX<DU0:CEZ:S4O)B-X03MO
M3'AB-CE:9CAT15@O0G(O049Z;RM-9#=R*T5R<D\K<W8P-6]2*W-2,%A6.4]:
M:GI864,X:DI*,S=$35!8>4)X1G5W03A4-U<O=T%3)B-X03LK6% K<G):+SE*
M15@O3E=C,#="25!-,G5A3$YQ1V=T1'%&=$ES3CA(;%I*;S)#3#9B1&LQ1'-0
M;FU$<D(V.&8Y6C)F6C4O9#5F*T8O)B-X03MP0V8O04]*9DQN+U8Q<R\K:VE,
M+T%*<7I/9%DK8U X06Y);E9.3750>D@P>5<S=31:;WAO+T5V2$EJ2T<K=$]A
M5D)/*U5:=6IP=3)!)B-X03M40TYD-WIN-C=:+S<O:B\T3F8V-5)4>B]!05,W
M;5,O;%)Q1FA&*V(S;%-A5S5I:FAJ92LU>4TV:%9R<#@T1E-4459*<&QU2&TW
M9G-E)B-X03M*17IF8RML4%!8;4A12E!*2&U'3U!5-U(S9E1,>%526C1Y4U1B
M=4%!03):435V4E!J:E-B,GI';%=133A926=I0D)D9C5"-S4Q,$IJ)B-X03MH
M1S=Q-5).;$8O6'),+VQO:2\T3F8V-4QJ2&5X-%,K:V8K8V0Y9#!3,R]*+U%O
M8FI53&%'5EAV:3!C:S!A<TLV:&-%5D))3S1.8S50)B-X03M0.5HY-W19.&=Y
M>GIV<6UM6'9K-U926C-C3GE54TUU25I%:S0Q;%=L94I.33%V85 Y>$PX9%A:
M.6HO-#%$.&1#>7I-,3%R<U9D:7)()B-X03MV3E!K6%$O33$W<%8S<5AQ*W!P
M379Q=W!'=U9*0C9K57AJ;$)6<6]:8F%.='%(-&5T0U%65G(O;'(K6$QU>G8U
M5C!D;EEK<WAS3%5K)B-X03MK-VMK;5!&5G O3$@X=%-+2'EN;WA(:"MJ-U@O
M04MP-'%G3EHX:F9L0F\R;7DV;'%8;&)28F5Y9S1E=$XK:DQD=W9.=V=*0U)-
M,4]4)B-X03M#<'!19%1T:71)2T1Y.2M2,#$S3F%P-6,P55!"8W1:4WE0<$U5
M8TEU5F5+3#!23SA#>$Y)6'5%5E9$5EDQ07)X86ET2VUU9FLU-4QV)B-X03MD
M4S!3-7,Y0S!M,'0Y4'4R;G8T1G-91D9Z15E*27A%=U9!1T%D,65J8F)9<6UZ
M9FQD*U=B1W)E561&2CA4<#%O9BM:94<Q82\U5EHK)B-X03M74#A!,4M':68Y
M=S8P+S9P-#)66$PK5B\U6G(Y;GEL;V]R-&%D86HO04IL-$Q6=B]!2E9L*U<S
M+T%&2V5J9CA!8U!T9BMQ94MU+S56)B-X03ML*U<S+U5P-DXO,T0W6"]Q;FER
M=BM66F9L="\Q2V5J9CEW*S$O=T-Q94MR5"M6,S5:13%0;$A24V8K,F1A9CA!
M5E!&56<Q1%-0>4@P)B-X03LW5U)O.34U9C!33%5$>#5**VEO;5)3-FPP5C56
M9TU33S9Q4W%S=UIU=WA24TUF.$%,:CAS=&4X<E!0;W9L,U(T-#E7<U1*<'0X
M=6Y1)B-X03M2;%)C=S%H;4$Y3EA5:FU'-T59<%)';"]L4BM8=&YO=&YB6#-L
M;E(W=31T8F5/3S1U1' Y=3=34U)O1F0Y-'EZ1FE#9DA&5D-0>6(K)B-X03M4
M5#-7;3)N*T9T2%,V,6$S:W4W0T-44UE9,V5+15)M47-R=W%9,E@Q,'%J,&)F
M<'-A1WEQ6D0X<F9Y>4)Q4$M/:6=J;V8P9&%F.54X)B-X03MB5F0O>7),.'1V
M.$%Q53E'+W=#-&9A+SE5.$-P3#5G.&DK4V)+.3!72WHX=F%B8E)8;#1)8G5/
M1WIT-#%M:4UB2&A)1E%",7(R3S)9)B-X03M/<E!R>"\Q;EHV1#9-=CA!=W8X
M05-%-B\U5FPK5S,O57 V3B\S1#=8+W%N;6,V>'!V>78O04,P8C=8;$Q25#@Y
M4'1F*W%E2W%6>"M7)B-X03MN-5AW45-4=C51,&-P16I/=VHP=3-K8VA253A5
M4TIN62M#<4-4,GA7:W0X<RM79GE:.'@R:C-U:BM69$UK=&\S84EY>39+='%#
M-DU5)B-X03MC3#E9=#1U9D8Q2W1X<E%I:#-X5C)H+VLU-4MS=%,Q=31V9$,P
M;3=T.5%U,6YS24=S64=&=$5)231Z16]:0T9"9$=E:3=B-'%M=CA!)B-X03MY
M<7HX<V8X07%53D4O=T,T9&%F.54X3FQ89CA!2W)0>7@O-FQ$4E K-&1A9CE5
M.&)+<G@K5U U86=52&Q04F=",$@V4'1F.$%Q;F=6)B-X03M,=DY8;&)Y>&]N
M:R]71S!84TQ,5$=N:FI%-U=D=D9B;'=S<3A1-6I6959+;6QC=W4P9C=I6#0V
M=7HW2"]!36%H.&9U3$YS>EA73WA6)B-X03LR2W5X5C)+=7A6038W;SER<E=I
M,RMK6%ER8F%H8GDR,#(Q4T9L46]34&-6<4U696)Y9FM08GE7=6AP3'%Y,TYZ
M;S9U.',Q,6%#6DQQ)B-X03LV;#%#2%5*6G!536].2D1%,&),>2MY,S)T<496
M1#(O+T%$:C-$82]O,6)4>D).6GA75VQY-F)C0S%T;V]N;&QL:6UI83175&M7
M:C5F)B-X03M73U1P=GI+<5-A<7!#<7!P,S5%,T9J<5-8:T]U>%)24&,R3GID
M5U5&:3!6=4)P,3,Y86IJ=$5&>5)B;W@U8V=E9GA%<TMD359:8BM7)B-X03MV
M:TDK4V1&=4Y,1B\Y96IM=5=U54EH.45*>5)5<%%V2WI-94A*;5IT>50P>%9L
M=4MU>%8R2W5X5C)+<U!V9DEE;U-E6613,4MX,7!R)B-X03M+>#%O>%-A<EEI
M0EI(;&MH="]Q>3A:;6(T23)J0SAL-$5K:EIL>%9H.%@O3U!-149N0EIW83!)
M-$E6:EAG3%-I>'E#,7192F)Q,T%M)B-X03M(;S-4>5=B4TQ.=G@Y4FA2=G19
M<6ER6#AH8E,P:C!'3S(Q8C!&,&4R:6=M84LR0U!,3$9),')4>$US9SE&<'DO
M0V9:+U510F%J<FEQ)B-X03M/.&TO:S1V;'9Z3EEA,RML4F5'># Y3$1G,71W
M;&-R83(Q=%5Z97$Y26@Y535P1G@K174S>$=U2W93359D:7)'+TYR2W5O*UAM
M66A6)B-X03M';T-P3W<O=3-Z03%H.5=0*W,W5',T6$1,+U4O4T4O*W0R;BLO
M;R\K0T@Y8WI016HS:#$S:'DW:3<V,V%F-RMJ+W=#0T@Y8V9%:C-H)B-X03MF
M1&PS1C,Q=3 O,SE(+W=1+W)J-&ME.$PT8W4T=DUB<CAO-%I)9$YI9SAX2D5T
M;DQC;30U44(O56AU3EEJ,6-,2%-:4%1D6DE&5&XX)B-X03M64G9X1TAX23DT
M6'<U9'A3,U0O>40P:7A.=6)B>D-,6C1R1#9J3$YB44I$2S=.6C-.<DQ-2$5P
M;UI$8U)U83$O=6Q"2C)+=FE2-W=V)B-X03MH>3=I;C-K4#AR9$DX<F59-W)8
M<$Y1=&)U-75,9$QE,V=H=&MT;TQ10C-:>&%O6EIJ16IH>%9!9G16879X540T
M:V4X3#1C=31V479R)B-X03MD<"]V-E X031)9C%W94I(=D,K2$QU3'9R9' O
M=C90+T%)268Q>#A34&5&.$]88U=09FU$8S(W*U1T4U9:55II:55!644O,VDU
M:#EO)B-X03M40G=Y,R]&=7DW26A)86U&:CA55U1:;G5Q9&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D)B-X03MI
M<50K6G8X0410,5=,+T5(<&96=E4O8RMT5VY/:#95.7$U:39R=W%(:6-N3C!0
M:CA2.$<K2W0V-VU/9CAG:2\U8R\X06@X=W8X0SAV)B-X03MT9&XO04LU9C O
M<V0O=T%G:2\U8R]W1&@X9CA!079,-U8O,7DO<"]9-R]K15@O3&XO=T%0:B]G
M6&PY<2\V-68P+W-D+WE#3"]!2F,O)B-X03LK2'@O=TQY*S%F.$%83"MN.6IV
M*U%29CAU9CA!=RM0*T)E6#)R+W)L+U0K>#,O24EV*UA0+V@X9CA#.'9T6"]8
M3"MN.6IV.$%K15@O)B-X03M!0S4O.%!J+T%)1C5F878K=5@Y4#=(9CAG:2\U
M8R\X06@X9CA#.'9T6"]83"MN.6IV*U%29CAU9B]$-"\T1C5F878X07)L+U0K
M>"\O)B-X03LR43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#I&049%0C4Y1C$Q,C=%0S$Q.#)$,D8R,3DR-S1#04%!-SPO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I&
M049%0C4Y1C$Q,C=%0S$Q.#)$,D8R,3DR-S1#04%!-SPO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S
M<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM
M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^=75I9#HY-SDR,S$U8BUF,&-B
M+31E.68M.69B92TU-3(P-C4U93@P-6,\+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z1C=&14(U.48Q
M,3(W14,Q,3@R1#)&,C$Y,C<T0T%!03<\+W-T4F5F.F1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P
M.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^
M9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP
M34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I%1#<S1C!%0S1#1C5%0C$Q
M0C!!13DV-48Y.#8Q1D0R,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TP."TP-50P,#HR,SHS-RLP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z1D%&14(U.48Q,3(W14,Q,3@R1#)&,C$Y,C<T0T%!
M03<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,3 M,#=4,#<Z-#,Z,C K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P
M.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \
M:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R
M.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P
M9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM
M;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L
M94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*
M(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E
M/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM
M<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%10
M9SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=$1I;3IW/C4Y-2XR.# R-S,\+W-T1&EM.G<^"B @(" @(" @
M(" @(#QS=$1I;3IH/C@T,2XX.#DV-#@\+W-T1&EM.F@^"B @(" @(" @(" @
M(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X
M;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @
M(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N
M=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E
M9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B W+C P
M/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86Q?,"YT=&8\+W-T
M1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5"U"
M;VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86UI;'D^07)I86P@350\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@
M,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/C P,2XP,#,\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT
M.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE
M3F%M93YA<FEA8E]?+E!&0CL@87)I86)?7RY01DT\+W-T1FYT.F9O;G1&:6QE
M3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y"
M;&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO
M>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P
M5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F
M.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!1 %] P$1  (1 0,1 ?_$ !\  0 "
M @,! 0$!           )"@<(!08+! ," ?_$ %,0   %! $  @P)"04&! <
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M+O1D(A853>A9'!S2\2+P*-C,P<L2%,=Z<;*Q3NU0FK):\5+6I&J;I5/=]O\
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M Q 1! A<,@Q0L\@Q,,K7ME@)AE?'/#*U_EMECE:]KVO\MKVO:JNTI;#^* 4
MH!0"@% * 4 H!0"@% * 4 H"RGV/K_PO:W^WPK_IY4KYK?;'H?C/IL-DNE>(
MD6Y</H]M@OX(N_&F.:IV?;QZ2I:=I+H*2U?:?$* 4 H!0"@% * 4 H!0"@%
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M+"GVWU[ITX^&Z74O2.(GOCUOT#P!^QGEEA3[;Z]TZ<?#=+J7I'$3WQZWZ!X
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M[>C:34VFJY+GI_DV5K.#@FG3-\U?\TB4^J94% * 4 H!0"@% * 4 H!0"@%
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M5OQCXR&I3[JLM7;K>NV:N>IBWV35R4-]'5%U0UETXL01T\VI'+@F9=%&L6)
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M!!M!V/)I)MEL-*>S$@R-M.VY!F!72UIVD8ZE!G-MK6.([?2VV2Q34TY&"RH
M@XIZ27SRP.*Y_.QD4T(&(&&+8+"G:6-E:TXVRL[35KJ\9",Z5I6FLG2M%6FV
MBW'QWW#<-Q+BOOCAN'8AQ"FK%WZY7:]NR5HXNT5F[Q9VG%J>I#7U*:VI'6KJ
MJF!!^Q7./(T"*6,S#NX8+CAY@CEQYK8HP(P0F-\1 A0A(<R#$#SQO?'/#/'+
M'+&][96O:_14BNMVBU*-WL(RBTXR5C9IIIU334:IIYIK-,^6QP#1^[VMG;W?
M ,#L+>QG&UL;:QPFX65K96D)*4+2SM(6$9V<X22E&<9*49)---%@>#(@:VOL
M*Q' [',+)MEPO&C'BII&G$;*GU\RVH_;28U4,=;/$2*62.*PJ:E%A%$T434\
ML.;R&% )%0LL0<*YZ[=6V]K;?6<&OZ]QNZW])4@.8@=73<MP@@Z]OANJ)@ 9
MJJL;H*U)2W@0NFXE,#6)U4%E9U$5<QFHB@&DZZ> "4+"%QAS05V=YU\7H.@(
M^G,5(^H[QTSP4WTH1G($>2S'CS<ZNX"JA)SC#F[!UB24\%5TC)'<9I\.)4>K
MA71U@1#R)8*QS$3%*[C"P)6"N=>CHRV&U!<' L  7#OE<,N"&#A?*]KY7P"P
MQ#QOE>UK6OEVN-NF]K6M>_3T6M_\J$#]J 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@(_P#D<\2\?>D%$OK%1K#_  U\F<&\,M'/+VQL9V,G+?27]&^F/F]T) *S
M :YB@% * 4 H!0"@% 0,\*GCAYG_ .]FV+_SIU"K:;+/W"\2)YJ%(4 H"M%R
MX_.E2?-(TO7SPK1GLC.7]W\'<.\[Q(ZD]AOW);WX8XQ]'X*<!S%P'J7'\]PR
MX#VOO&JU7EL_E+[GDO9C?]1DQ-8YEQQD0C4JB,TD%&[M;:AF\'6EN@^HEU=8
M.$FX536:83KB9K2FE%3>\QR[A*5&DY94HHYNF=7T)TZR77BY1&:WM+8R2F$?
MU)4VP75Y"R(G-'3KJ4-;1!!W^XQCEF4:>CA=+A$4 SF8P;NL<6C(>#KQ6,"N
M!<KB"7#$DJZSK6N7;;=G/]MA(/0E% * 4! UV1W]&P=](_6G\4$JA4LNV?N9
M>(GEH4Q0"@([9AY9^.77^2G7#TR;9QG'\F,<X63W8SUOX1]]4,Z<3B2N6+G.
MXT$T6[<9-4"1O#JC N/5& ^F]LNVQL)E";55%M,QIX<KB7_;DA[_ /;L]V:$
M>+G^2R2]@/QH2FQ69)D?+Q)TL.0FL@/9EN9-Z[O>X6HZ4HJMM];(]T! #]QJ
MB4=*'2W7 A"]2/AU@>&?3C82-4;3VK)FODR;<MJ(7TKQV2BF:Y@<C0C9&F&2
M2T/-EKKWQ:QBY%EZ(+<=;@+.9ZL]3<6:^I1P_P %(:<9IS]?AZS25,PFK>PJ
M9WP$4J\Z573-\_\ DL]KHN^=?>V\,?-A7=Q)JQI.,R(T8-]NNB97?$K(2EI#
MB)'=37)/M'#<R<XW2U'FZ'-FPU-*>QZ/XG:<CR(E-E905!4:93X0(82B%.^E
MNSV]7C=$;CD3I52)$U$B-B8)'RI<Z3,86RM@.5-!8#EQL;9XXYVQ%"$PSQME
MCCE:V5NVQM?IM0@?50"@% * 4 H!0"@% * 4 H!0"@% * 4!'_R.>)>/O2"B
M7UBHUA_AKY,X-X9:.>7MC8SL9.6^DOZ-],?-[H2 5F US% * 4 H!0"@% *
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ME4*EEVS]S+Q$\M"F* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M!1+ZQ4:P_P -?)G!O#+1SR]L;&=C)RWTE_1OICYO="0"LP&N8H!0"@% * 4
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M.>)>/O2"B7UBHUA_AKY,X-X9:.>7MC8SL9.6^DOZ-],?-[H2 5F US% * 4
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MQ]Z042^L5&L/\-?)G!O#+1SR]L;&=C)RWTE_1OICYO="0"LP&N8H!0"@% *
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M'?2/UI_%!*H5++MG[F7B)Y:%,4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4!'_R.>)>/O2"B7UBHUA_AKY,X-X9:.>7MC8SL9.6^DOZ-],?-[H2 5F
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ME% * 4! UV1W]&P=](_6G\4$JA4LNV?N9>(GEH4Q0"@% * 4 H!0"@% * 4
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M9,BNX)F9<3 -!6=P[**XW=Z*[U3!4LM%T-?RZTL.V02N!40D&")B=S&$- V
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MB9=W\;>]IT:L7<,_<VTCZ<'^G<,+GT-Y1X?T7OS*\GK%-']5&Q]7D7U:6K1
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M56DDW)'1"X:K:JE6E&\GS[.8['(&Y?&9*T6Y)TJ;):8R3"LAN@O'HJ=($D1
M\8Q>KK3B+5?038,D7&IJ+77SR.2768Z1R@X)K%%LIMY4-=R"&" N3[=02DGD
MI)K/).JYJ^,SKELQJ\VI;0M8KSG":#-II)(B-R"\9 9J;((B1WLL>2BZ2PL5
M,%9Q"$0P>^"60+)N(@R(7S/DB^:<!F/@(4=*T=-]'2O2?9AM%K8(CH#BQGV'
M+-]U-J27FVEW.2&B$C+K0ALV"0EITI:H(K8$3K>C(Z9+E'ZL@#YI[3,#!A+A
M@CGGC:X4>Y\RV<[V+X^8YJ&Y]A#8AM'7C \MQW,#73%<= 4UV.7<B.Y.2UTL
M7+'!D94,(ATYBG*F!$Z1/]P'>H-9$#Q(]@%D4-EAA1"C6U4,N4 H!0"@% *
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M$XML==T&*I04E!'CJ0UB7V(FL][*J0<$3EM/;2\<7 4]6-(!X$8FX028XN:
M8!%"6+$LPL[8B%'5JCJMJHZKI1WTKLSKJ>E=.@DC.<3'II5TSOVEQ02?[7-R
M$H(UVX7>&*N4:1=3$6QTP1J'"KC"/ADLBHR*9 4@A<R@N MPHZ5HZ;Z9=9G"
MA 4 H!0%:+EQ^=*D^:1I>OGA6C/9&<O[OX.X=YWB1U)[#?N2WOPQQCZ/P4LN
MUO,<MA0"@% * 4 H!0"@% 10[$\:.<Y<@&OVWA212S<C9E8,56GV'<4L;.\T
M/37U1?;JU@<HJ@%EW($/'#UD)255*Z@"+F=((B 0+]&1<(4F)U*D7'GSH]R?
M;==%WMO.89-<6TQ)<QIDL-24HN&RRV=Y"967$AR-YTYWO&N]#:9S?[V)!Q-,
MX7P?4?\ P1Q&"$. YH"GFI9B]8#8G8 X&LMW-'K3K]OM3%<E<+C_ %>'M0&0
MP)/CHLX8-TF<NE,LI:^/.#-CN0$)]I; #=DAD0X,D:,G<K'#RHS#MG$PG<LC
MMJ1D59+E%\\DJ*&GJ=/M]L_]R.OG)TVR4N:JI6BS365=QD-.XE)(;\DEVV@R
MU%^&LIS<6 -W58PH,5XGMDTF08!9D>-I(C!K/Y3>JLFVCI9.QFCBE7"N#*#T
M;#67W6U,15\93S<&8AK99K.C2>5,W5NE-N;SKM>5#'C<X>)WQ0&9&CXE[7MV
MQ1#\,;^PA&:2J1A(B@=<J%N@]D9[E5J62121&[@<$;PJ8$AJ",QUMK&RQ<C@
MLI#M%4U ,-#!RVT36<7MYXIK=O==AO[QU:A3-J0VI<2Y=F+*2 9 >;?7F8T0
MW1(TC$8N14%G)37,(Y"49D55N5G:563";@>)I;H4S9)EIA9.;R$.9+@F3IH0
MD]9I][/)*OQ++O\ 2WM)&Z$HH!0"@% * 4 H")^8=,MO$/8+969]+-A(BB3'
M<UK1>BS,:EB,'$_G9%SRBEGF8U0):@\5%=2(W5)=%8(J:4%9LB))YO!N-M)2
MY=0')G%)%$?;[?;_ %F362:JE78Z5YZ/THZ>_>,1[O*0YU?PTLMM25Y<VXXY
M]D 7 MMJP#ER3=(FY$Z(YDY>R;Y-+1\7$_S;#<2FCY(">G-]#%= @.">5+=<
M!0*5/U91^-US\1KN3X:IE%9Y&'UF;HCRBV%HIY V+KLOH<=N9,EMTK.]K1?K
M3-'MB%T=QG4153(\+/XZ;-8,Y/",O]=2T)S*F"0>2@R8XCK*M:;=6N=5EM:5
M*Y].53(TU<4DLN%,()4+R1!+=)OWCH:G'!-)22HM7G04;;$;XJL./*D)%D%P
MH015W#9.9:ODUG/@"@GCR0RU@VHAF4(0N9$%*E-N3<E1\[IMR[V_>?D)Q/RY
M'\S)\^0O,$<J#VCW8YJ2Y&2#-3:=3H::JS2FD#0TS<R;(^;=5497'?@19O#2
M V'.B"]S@*67>TV6"Q43!XF(ZZ:2:>QIM;<Y:W5O6_/FSD*X^M8'!IIJ/%VN
M#I=3?>RZP%"3SAYSM5",-AO*7P]EU^R25LEMXT:/"HQ<B3=Y=.NG]VFPBPI,
M0,N8&+V"$R$).KKWDM^Q)?Y&YM"44 H"/_D<\2\?>D%$OK%1K#_#7R9P;PRT
M<\O;&QG8R<M])?T;Z8^;W0D K,!KF* 4 H#7;;R%%39+579#7M$6R#:6)P@Z
M48G2G$JES!Q,0E!_LM9:Y-64"A2^)HR33QU,,T9 +96'%!"SP"O;/+&]",71
MI[FGU,T.V9X^YRDH[!JY#<JQ8V%UDZ63CI/(=Y':3K7TTVT9L;<:)QI^,H%M
M+J&9P<K=5HZ#%*)"Z8LEGR2KVPYH 8C< Z^WV_V9%26=>>2EU5_R9@]K</+Q
M12B<74Y-CU4$+S'Q/2.>$S:ZJ)W<A<=D8L)A/!O"V,=M<3.1#365SK8ZWMBB
M256L@54/,3,SV\*;7O\ 10CK9NJYI+;L<JY_/1[UU'R#<3,]L9TK\EP]+,#*
M#V=:IR"M)7;4T1RZW9'";$F\DV@2\"HMHBB+J2>39)8 9$LW%@$4(PW'ZAG3
MZ(9,HA+# <Q$:R>VO_13/\E4?7F]Z=.^;>:$<=P&D;XE1<Q>Q"0TMU0QIK#;
M06%%&S*O4DFZL0L<BE04%PX**:+@ANTT:R62"4E&LRJ05$S3LQ!L0@L[B$I:
MU.F3>ZLG7(DYH2B@% * K1<N/SI4GS2-+U\\*T9[(SE_=_!W#O.\2.I/8;]R
M6]^&.,?1^"EEVMYCEL* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4!&MRK'S:5K"GJB>/D6/ILLL4^2,8XX99%S9,%<,%A\<1
M,<P\L@A@\!+8YX987OC:V6.6/3:^#NR!MK6[Z!V-XL9NSMK#2+";:RFDFX6M
ME&]SLYI---QE%-)IK+--&T?8B7>QO?"K>KI>;-6MWO6AV/W>WLFY)6EC;6N'
M6=K9MQ<9)3A*46XM22=4T\R%/P@^X_EP7?Y"S/=NM7?PR<)?MKO?R3#/J)O/
M^+AP)^T+#_VAC?\ -!X0?<?RX+O\A9GNW3\,G"7[:[W\DPSZB/Q<.!/VA8?^
MT,;_ )H/"#[C^7!=_D+,]VZ?ADX2_;7>_DF&?41^+AP)^T+#_P!H8W_-!X0?
M<?RX+O\ (69[MT_#)PE^VN]_),,^HC\7#@3]H6'_ +0QO^:#P@^X_EP7?Y"S
M/=NGX9.$OVUWOY)AGU$?BX<"?M"P_P#:&-_S0>$'W'\N"[_(69[MT_#)PE^V
MN]_),,^HC\7#@3]H6'_M#&_YH/"#[C^7!=_D+,]VZ?ADX2_;7>_DF&?41^+A
MP)^T+#_VAC?\T'A!]Q_+@N_R%F>[=/PR<)?MKO?R3#/J(_%PX$_:%A_[0QO^
M:#P@^X_EP7?Y"S/=NGX9.$OVUWOY)AGU$?BX<"?M"P_]H8W_ #0>$'W'\N"[
M_(69[MT_#)PE^VN]_),,^HC\7#@3]H6'_M#&_P":#P@^X_EP7?Y"S/=NGX9.
M$OVUWOY)AGU$?BX<"?M"P_\ :&-_S0>$'W'\N"[_ "%F>[=/PR<)?MKO?R3#
M/J(_%PX$_:%A_P"T,;_F@\(/N/Y<%W^0LSW;I^&3A+]M=[^289]1'XN' G[0
ML/\ VAC?\T->Y1ER19I<@3OD]SFG:XP4LJBA*APJFDQ<$LD.:,E2E@DLD0+7
MP"&/&A+9W N+>XV5LQ,L<<+8V;C^D>-:47Z.)8]?[3$;]&[V=UC>+2SL+*2L
M+*=I.SL]6[V5C"D96MHTW#6>LTVTDEDC1/0W1K0;"Y8+HIA5C@^&3O=K?I72
BQM;S;0=[MX6-G:VSG>[>\6NM.%A91:5IJ)05(IMM_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g209588g47x49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g47x49.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &NZ^:)0X0DE-! 0      $P< 5H  QLE1QP"   "   < E  "')R,C8V
M.3$X' (% "M-:6-R;W-O9G0@4&]W97)0;VEN=" M($%U<F$@4S$@:6UA9V5S
M,2YP<'1X.$))300E       0Y751(L329RUQFSZUI 8!-#A"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!90?P         "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _@
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              28   #Q
M          $                          0              \0   28
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   28
M    4F=H=&QO;F<   #Q    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   $F     %)G:'1L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M2222G__2]522224I))0MMKIK=;:[;6P%SG'L DII]4X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MX:'(I-(F4M+%,:?I,V--0S!J;SSTQ<BI-0_AW15$NP_-FR/,0IM*-;-/%L6
ME)G30D&ISJ=0+AE)=F +4#L!&N_TK#,3V4O,; ) RDD.4J9W+:[EHUKM!Q5X
MT:;LAN$4VU=5NU'\1LBLR)"4+LR\Z8/BA3OC&W$I;I\IYCRPZA]"8RDK0RZA
MQIIP993*G2B0V8U-*@O\W@3KJ#:(C_86 "R4G6Q#V<!]+58[-'5/P=;^JWKV
M_E4NN2X<K<+;=R);E\NP)C$Z-,F)?JM.BU=$B*/A0NIO4&IEUAAQU#;L=;B%
M^4\T!I)TOLU'8DMT;3R<1M94P3$@@N0 _G_BL;>:BB2+ O7=3;G;IM#E[7E0
M;>6Y_P"E$FS4*J3_ .Z<>S'I4?SZE(3Y;2U=3,1Q/ 3GJ6@*10D"_OWO&.W_
M !-[7AA,JF*NVX(CK#4AB50[,N*4Q(9>"2VMA;\&*5A75@'I R%<X&3<$*58
M:/[]_<10*221F 8/4@>CWK2F\4#?B?L]UI3Z+*W;4T"H!7_ $\%73WZ$&2%J
M('. GJQZ:%"@]#334^'\M%AG2@0"L.:"AJ:4MU'K%3"\3>WTL9>I&X=-(6E"
MTU*Q*XRILKSTE:6F7SC@Y*>KIP>H#(S7LUMF*2!U9]-'?5O&D7=HC10-6H"?
ML/;':)>E>)38ZK5!NDM;B42GU1Q9;33Z^F=;DDJ3U$X%=B4]"D (4?-0XIKM
M\^2!JPTO3QI%0I)L0?XC,\*H0*DP)-.FQ)\8D 2(4EF4P24I6 '6%N-DE"T+
M "N4J2KLH$HNBKTA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-
M(0TA#2$<O_'+X*3NHQ+W)VRAB/=:6V7[THL>J2(#=U4RE.IFI,&FM1UQJA6G
MU-(8DQGI<$5"$VIF,7:DXRES+PN([)0"G(_3T?0UH'J^AZ/&)B,/VHIY@;#5
M(W^[,]A&FWAR\0M<MCQ"TJQ+&L]V%N)=MDUBGURWJ])39^SUUUZ@.TZ*S6:7
M=JV7(4JOQX+E/=N2GV[1*Q<4&H6R];<J#1:C<U2=3/B$B:.T%$BJBW7]+.X-
M:OEU)#1#AB99,LI95D@%QU*P:AC8A]F>-R]V-Z:'0I:X.^.^4NIOMI\V?M?L
MLV*#0(JC&,>5 KM;8FJN61"4X7%*1<-RTQ#BDI=;I+:<8Q9:<_=PTJ;BYSLF
M5(EKG+!!_6$.E#E@"H@;FXC;RL#C9TLS5?T^'D)^;$3IR94L)%2?[F4D@7"7
MTH:QI)6?'/MU:]1=8V>VJMR-/;ZXD6I-T^;N/=LQDA86'$0X[3#;:W"E8\RJ
MU)QI83UKRH'6QF\*Q\J2G$\2Q'"N 8==IO&.(8>1,4?F"$X9*U3<R@ZP,H+(
M4X!I$",1R\A:I0QO$>,X@&N&X)P^?.97RE\0I*990"<M%WRJ<98L&Y/''XCY
M:%%2A9D8H3T?C-2VRV^6TWU=2E(CUMY-29;&.E"5Y+:5%*\*.3HYO'.1L,3+
MQO/<HS4EBGAO#<1B$ G03U!*5-T!>HL(V<G!\1G#/@^0.(300R%\1XE*D3"-
MU24%;$U9(9M=HQX/&_O\E3?1N]::@E1R@[];6H6 2 0?+JB6@/E&3T@XX(/.
ML17-GPV ;_ZMXLM1H%(X/.T+$A@YW<;4VC+1PSFD!T\A8$)9V7Q9.:VCIH6Z
M$1>EM^-WQ)H<+T2MLW:A:PX$4N]-I+U</E9SY+++SLUSC "&1SPHDJ'-\KF/
MD":<F&Y^GRYI9T<0X-B424G3/. 4P!J:4;JT8\S"\;0H_P!;\/L6@.V; \03
M. LY  #@,X9QX/&2F_V@]S(:%.W0V\I<IE?RK:O7;VI45AUM0 +::W3OBX+B
M.ZP68SS1<)7Y722-;C"8<<14W!>8.6./K(?LL-Q.3A9Q&@3*Q1E%2S8)#DD,
MSQA3YW!9"6XAA.9."+%IN)X<N9A1IWYR"3E%7(&CUO&3;)\1?AKO!/GMTJZ-
MI:V^XE0N':RZ)SS,-]M^/)1+;9M]V%44)#L5E:FZA:DIM3;2$N><CJ2)L9A,
M?@4%7$>%8["(H/Z@R%S<,54<"=+"TJ;10.5@X-7B/#X*3C_[G"^,<+XA+2
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M,IUH-R8KT,!(^8)],XR23]_3ZXXU:2U3[]UBY*"XII44KTN7WBK;;&.E/?/
M[CT]\_\ 3OJTK#%B0=*>Q&0$ 5-/1@.KC2O2/5,=9Z0H?GVR,=^_?OV]/;OJ
M!4P $DNVSM]*:Z?>+\HT ?\ ?W3;:*I$9(5P">/?']]1">&J*]'_ &B\2R!8
M OH&IN:GWIO[I8/(2V 1ZJ';/&<GDC\^>??FTS0P=0#^ZM%_9%G+&M@07-*
M[^4>Z8ZO7/MQ@I&/8?S/.H#B0E3 U'RFK>NV^U8O[-12 0:"CEB*V_%NH$9
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MV(4IQ-4<I))) )J+MZC\1]"\.PLK!X:1AD(;)+ 4 &2%  TZ_7P$4+3*E<D
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M('C$TS"X22!GC"2.<' R>,=N_![<G5"P#W.^Y8#\::18HD!W:OF:^RT3+,,
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MZAB:-L+#4[5HSQ1,SU(2@A?2VH](&" "M(2$@?Q#_P#*6CG^%*$)X#6H%)-
M[LY /S:@Z D:5U?6)<R:UJ4E)J[!BX%2PH">HCEI^U?IB)FWVSU?^'+CU*W
MG4TRPD?\O%K-#EK4RI6"0V_(0@@%00%I1QG7*?BMAE3. "<)94J5- !9RD*<
M*HUBFCM^\=<^#F+[/F=<I4P!$_!S$E)/S$9&;0$@%M+1QNBMX 24Y'3Z\\\
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M(<:D5%ZUO'%V!$RKJ(Y/*<8 [C'''/(YQVP,8XU\P+)S*&Q#C1R'_$?6!42
M[V!#G2I&G7]P\73%BG(XR>^ ,8'O['&>>>/OSJR'RN]R& H6\>K>7C5KEC1>
MDCI3U*QP?8<?H/\ <#&C_P GW[Z[$I*C[->FI)?T^LRQ$((4KYL\8Z>.0.V<
M\_7/;TU2IZ#?7TZ^((VB8)">I]?4]+V(.]8FH\7.,IQQZ8SC_ _7VP-&W NX
M_?Q]]8B4HDD/3[M[\(F&(.3_  X /J#SD>A)Y[8[]NVK@";"+(EF803C",G&
M>1CDGL/S!^OUQJ0(8=X5>E1L#I^?WBTK2/XZ^_K$DW!4?0#@8R,<?ESGZ?\
M35P %A[]Z1&9@+-HY+AV(_-=G]:UK=.. 2,Y_P#J2._N<C''_;58H5*-BQ\3
MUV:ONMX]A32/0#[!'^1I%O>-R'\"?S'\--)!X!/V3_8Y_+2#K%CY5'HQ/VBF
M73E \<9[9RGZ=B/[]_TTB[,:.'\6+>K'^(CY$,)!ZL8P5$XSC"3DX^P^8'&<
MX[C M6@%!H ]B&ZN/P_2F\7JF,DDOW4*!?J*'6E[:.6N8VKV KE$L#<78:X;
MNFM4:@O[<4BG)K$\*;IC53=57%H9D2B W%*S4XRVUN%+0;65%0""1['X2X_
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M2& Y)::4GHZD+0&UI5RA:2,CU' >=N/8+B.#"^)8V9AUSY<M<M<W.BJ@*N:
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MGUS_ $QJ26;]&/OTB)2M!^*[-$RU'RH9P>,]..,8^OWXX]-21"NP\?P8DVV
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M"W>DRE) )+)3+$AB]B5R%J(% % 7<Q\_<V2A*XO/0/TJ6DVJ2HS7#7&6:D5
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MH."!_#G!YQS@=B>W?Z:F%K-IZ:4B S"FC MJ;@J?[BOI$NP@#/N3R?L../\
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M^6<]10'D**/X5YP1N\#\/>8\40F=.&'DT)! 7,J+!;^3N;^#:'&<Z<'PP_\
MSY,Q1IEE2U*<]*,69W9O&,[6CX,[_FK5/OFXK9VVH;"0M<F XF757EI>;2$F
MJ2I#ZXZ>CS%)0BHQ%DI & <'UV ^$V#ES$S>(8N?BPF\N9-= 4SAD@I/B^9]
M(\AC?B)AI><87"F;,-!,4"D6!!RD?I)%+M6S1?U)I?A3VBE3OP^,_O!?%,8%
M0GREJ%89C,MNAI,B0Z]BCM)+ZDM*+KM46VKY1Y9UT3AW >#\- 3A<+*20 "Z
M4AR'T8DD?6YZ^%XAS/QCB2FF3E292OT27ET?4AC4  D&X:+RMZ7XF_$Y1GU4
M2UI6RUC2JL*1'"TFE3I5NPWHT>7,;JCB8]4BI20^E$.D0H3LIA*EP:DD);=7
MM3.2V4)2$Y38"[G* UF#.Y,:/LRKO.<[AE$]YJ.2JYK^UHW$VF\*6WNW<2BR
M:O"B77<-)Z9;<R?%2Y3X]5=I4>F2Y[4207E3YRD(DH;JE47(FK;?2XL)E-(?
M3"N8I;:4 -7=BX][Q*A&0,[N7^@'XC:34<7PTA#2$-(0TA#2$-(0TA#2$-(0
MTA#2$-(0TA#2$-(0TA#2$>,B/'E,N1Y3#,F.ZGI=8D-(>9<3G/2XTXE2%IR
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&I"&D(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g209588g48m20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g48m20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1EF4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &4J^9'0X0DE-! 0      #,< 5H  QLE1QP"   "V%@< E  "TIU;&EE
M($9E9&5R' (%  ]&:6=U<F4@4&%G92 Q,#< .$))300E       0I*7&7ORA
MH3_C;Q(Y4ZN>YCA"24T$.@      Y0   !     !       +<')I;G1/=71P
M=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L
M<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @
M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!>]OG         "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$
M)@      #@             _@   .$))300-       $    >#A"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8              04   *P          $
M     0             "L    04                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $%     %)G:'1L;VYG   "L     -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    "SA"24T$#      .^     $   "@
M/0   >   ')@   .W  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ /0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M2/?69M9]I8UK6VW[ME#7V6_\7_A%:=]5.L/ :_(J>UI):'/L(!=J\C<S\_\
M.2$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X  0 " P # 0$            '" 4&"0,$"@$"_\0 7!
M  8" 0$"!PL&" D*!04  0(#! 4&  <($1(3"109(5>6UA46%S$U5%:2E]37
M(D%1<W2S(S(S.'&5LM4D879WD;&UML,*&#0V-T-2<K3!)4)U@?!3@J'"T__$
M !T! 0 !!0$! 0             ! @4&!P@#! G_Q !:$0 ! P,!! ,+" 8$
M"@@& P ! @,$  41!@<2(3$305$4&%5687&!E;'4U1<BD92AP='P"!4C,E*B
M0G+A\18D,S0V-W1UM+4U5W-VEI>RLV)C98*#DB5DPO_:  P# 0 "$0,1 #\
M[M<MN;G)O6_([:M%I6RE(2K5J<9LH>,)7*J\\505A8QZH473^%=.E1,NZ5,
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M"1P-=5*M)243X**[/8F1D(IZ3<3,B;V,>NH]XF16V5PBI4W3-5%PF50AC$4
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M1=2OYRA@UC<]Z\*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7T7^"/\
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M\Z^VM9CM.+05OM"0EQYIQH/K;K5=A<I]4Z]TU9./?$FKV&%JE]=NW.P;_>W
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M%@(1,%6:C=<YE0;IR#GCCB3QX^0<,>@CLQ0CZ.SB/M'ISVY\E2C9N>,W<O\
MG'A.45@@VW=JNIZ@J\;$R:C=AK>HTIVDM!-$?&&R[F=.FBET<KN5D%G#A5=8
M3E*<A"-WEQY'.>W\D<^H=N.+&,XQYNKR<AY23Y>NH\XL\D*5HF,W!6=AZG^%
MVG;AK,-69RO^^N4J()M(F44E.U[I0P)R8"LJ9( %H[:*$[L?RS%.(8W3U''+
MCCL&/S^<",]6?(3@=1[#V"IK;>$"BZ5;])ETOH:KZUT[IJX2M[)K'WPS=D=6
MRU3\2M 2<[,6V<5>RQ9-E#N%4H!<#+#'.NPX4[\J3=%"-T\>/,8[,#GRZ^S'
M#@2*8X@D#AGZ3]'Y^WS67EXQW!":XT[0*R35#V#WZ.XX39>S]N2,XFVG7: N
M'BENL<O&%%FS:N&Z+:)4:@BW:QS5DQ.W</%7#Q<01Q/(8!X#D./+/DX]N3@<
M!F,'&/[<>DCTC(YC&>5:WX2+?=8W9O)FRH,I"RU'U_748AM)5@BR=;F;G/N5
M;-L>>AA620.Z:R=MD7H%D.Y(1^+<72 G;J)*'('#/Y[/L'8>LC'"JOS^?SU5
MSVRNE,4IBE?4'X!__L,W;_G98?[G1&>2^8\WWFIZAYS[$UW5RBHIBE,4IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KX/N9_P#.YY,?Y[]C?[RO\]D?NCT^
MTU YJ\_W"JT954TQ2F*4Q2M@J=C=5"SUZU,6D<_=UV9CIENQF&:4C%/58YTF
MY*TDF*Y3(NV+GNQ0=-U $JB*AR^81 0@C/YY\,<:5T6G.>^LHZJ[4)ISBS6-
M2[)W149"G7JW1MXM<I7 C9],H6)2 H#MR%7AUWBH&4:&9Q[;Q0QQ/U4-V@4I
M"3UD\\\,<QUGR]N,Y/6:C''D,<O..S&/SC'6:P=WY_NK[0'+";U[(FVB\U7&
MZE6MB6QK.E1D8V+;>YB-L::T2.G%(W(\,!6"CLSH\:<X>-JQZJ_;.>=WCY,Y
M[#D^7L^WZ!3T\>WV\.WZ?36H2O+C7MQJE3<;*X^5^_[=HVJO@DKUSF;"[&H+
M0S,%4*]/3=#*R%!_9*XR751CW))-%H=P<73AJ=3NA08.<@YR<X\I\OM\F>?6
MQP X' (_#AR]GV\-FJ'.R(A@T_=K1IEA;=ZZ"HZ= UEL$UJ?QE?&%C&*L=5'
M%MIJ#-5O,2%4:.%DH]1F]C4G0=@7Y'!RD,G&Z>(X $\N?T?9PXXYCD*8]G/)
MZN7GZ_+U==?U'\^'B6P^*^PY6AJ2TIQRJ-HKLEWD^1 ]ZD+.$BHXF#')&B2(
M[#N157,U(FY*<@ D0Z8=#!.[S[,8 X\.7'T8]/6:#D.WK^_LYUZ=%YK4Z.KN
MO(39VD2[%<::VE9MDZID&]VD*R,2G:["O9Y"N6%!I'N"SD:WFG*DBT.F9DN+
M@J::JGBH*(JQNDYX@9 SPSG\.S@>/.G6/;G'/S<_3Y*U*E<P"U'F5;.69J,+
M\+/9[Q8QI99KQ<6@W-J[;F;!,>(J=YXB+H3@IXF7O>R =DOQC)22 /)C[1^%
M.WR\?L ^ZJOTB]OZ1L:G[%0;(3+RG7*'N#.+F3JO(]XM#S3>93CW95#&,9JY
M.W*@N).AA((F .T !DGCY#Y.HXQY*8X>G/VY[/IX<.JNAE[\(A6[56=A5V,T
M]8&"NQ-KT'<$G+SVT9*TNV<]3;3&SJL!&(R$21"-J:C%@HPB8QIV%8YP]6=+
M.'222+8M(3Q&3G'+J_/'J\N<\Q3CZ?.?O'W=@Y<HSA.;I8OE7M_D4YUWX[![
MFKMOJ5DHI; =J[:PEP@FT*^\0L!&!RD?( W\8074CSD 3B I]2@(@DCAG'(\
M.T=H//&>'$>:I/7]'/'6#S'$<A4*:)WXUT/LFT6*%IJ=DUU=:Y:]?VG7MAEU
M1<2^NK8BHS=0BUD8-6KE&6;LQ2[J99M6HG<I"IXNF102%DISUG/5Y#V_V$G&
M3BHY#AU?D?GC4_UKG+#:\L_'=KK/4QJUJ/CY<I_8#"E/[8O.6.W6^SMUVTM+
MSUK7CD"%,1$Z+5BV9Q:+=!J@!3$.H;MEC=)SD\\ =F!@\O)Q'.F#P\G'F3QX
M]9ZN/YQQ@'2G(#X(.2T-R%][7NW[D76P6\*Q[H^)]][MGE#@R&1\66[(-QD0
MZK>+?P@)#^03M>:<83@=A''RT(SC/40?34_77FAJQC2-DU?COQF@M+3FXVJD
M1L>YOKS:[_+R=<<O@D9&"BTK*\=(0[68<]22/B/<$4;&.D"77NCHP$\1DYQC
MR<N7YX==,'CR&<^7B>OB!]''T=<A63PCL)9H+9:+K3<HWL^U])L=/6&0)LJ5
M6JT$A%0D;#,I&ETM>-/&0"+KW.2>S+9,ZJKUPFD*:J(G<F6;IX=8WLGK/, 9
M[?+Z>?"F.)/+JR//D\,8Y^>O%R7WPPC^%N@^.2%UH=WV28&*VSK#K^7-84$=
M>4=>8/JJF3]A321:/9*,5GG:ZD:@"ON:E&L044!0QA5#YRE'J]&<\,GTX/$<
M>SM#L'+KQQY#T#R<#Y:Y:974TQ2F*4Q2F*5WP\"S_P!7^0G_ -:UQ_Z"XYXK
M_>/H]@I5Y.0/@P>/>YMPWG9UKG]GM;#;Y4DG)MX6>@FT6DOXFV;@5FW=5IXN
MDD":)/R5'*INUVA[700 *P#@85CAGD.OC4<^/G' D<B1U8J'/(Y\6?I-N/UE
MK?LCDX5_%_**8'E^D_C3R.?%GZ3;C]9:W[(XPK^+^44P/+])_&GD<^+/TFW'
MZRUOV1QA7\7\HI@>7Z3^-/(Y\6?I-N/UEK?LCC"OXOY13 \OTG\:>1SXL_2;
M<?K+6_9'&%?Q?RBF!Y?I/XT\CGQ9^DVX_66M^R.,*_B_E%,#R_2?QIY'/BS]
M)MQ^LM;]D<85_%_**8'E^D_C3R.?%GZ3;C]9:W[(XPK^+^44P/+])_&GD<^+
M/TFW'ZRUOV1QA7\7\HI@>7Z3^-/(Y\6?I-N/UEK?LCC"OXOY13 \OTG\:>1S
MXL_2;<?K+6_9'&%?Q?RBF!Y?I/XT\CGQ9^DVX_66M^R.,*_B_E%,#R_2?QIY
M'/BS])MQ^LM;]D<85_%_**8'E^D_C3R.?%GZ3;C]9:W[(XPK^+^44P/+])_&
MGD<^+/TFW'ZRUOV1QA7\7\HI@>7Z3^-/(Y\6?I-N/UEK7LCC"OXOY13 \OTG
M\:>1SXL_2;<?K+6O9'&%?Q?RBF!Y?I/XT\CGQ9^DVX_66M^R.,*_B_E%,#R_
M2?QIY'/BS])MQ^LM;]D<85_%_**8'E^D_C3R.?%GZ3;C]9:W[(XPK^+^44P/
M+])_&NC7"WBOKGBI3+?5];R%JD8ZT6=&?D5+7(,)!TF]1BFD<0C52/C(M--N
M*"!!,0Z2AQ4[1N\[(@4*%@@C)SGT4\G9QYYYY_"KFY14TQ2F*4Q2F*4Q2F*5
MXU5D4""HNJFBF @ J*J%3( B/0 $YQ*4!$?, "/G'S!E24J6=U"5+4>24@J/
M#GP )X52I24#*U)2.U1"1])(%8YO/0;M;Q=K,Q3EP(@ (-Y%FLL(CU  [I-8
MQ^HB @ =GJ/0?T9[+B2FT[[D:0A''YZV7$IX<_G*2!PZ^/"O)$J*XK<;DL.+
M_@0\VI7_ .J5$_965SYZ]Z8I3%*8I3%*8I3%*8I7%K;7@I^.&R-H[#V%/V+:
MR,Y=[C/VF61C;#7T(]&0FI!9\Z28HKU=PLDU(LL8J":JZRA4P*!U3FZF'U .
M!A6. X8%4C!SSYX/$CB/,:CWR.?%GZ3;C]9:W[(Y.%?Q?RBIP/+])_&GD<^+
M/TFW'ZRUOV1QA7\7\HI@>7Z3^-/(Y\6?I-N/UEK?LCC"OXOY13 \OTG\:>1S
MXL_2;<?K+6_9'&%?Q?RBF!Y?I/XT\CGQ9^DVX_66M^R.,*_B_E%,#R_2?QIY
M'/BS])MQ^LM;]D<85_%_**8'E^D_C3R.?%GZ3;C]9:W[(XPK^+^44P/+])_&
MGD<^+/TFW'ZRUOV1QA7\7\HI@>7Z3^-/(Y\6?I-N/UEK?LCC"OXOY13 \OTG
M\:>1SXL_2;<?K+6_9'&%?Q?RBF!Y?I/XT\CGQ9^DVX_66M^R.,*_B_E%,#R_
M2?QIY'/BS])MQ^LM;]D<85_%_**8'E^D_C3R.?%GZ3;C]9:W[(XPK^+^44P/
M+])_&GD<^+/TFW'ZRUOV1QA7\7\HI@>7Z3^-/(Y\6?I-N/UEK?LCC"OXOY13
M \OTG\:>1SXL_2;<?K+6_9'&%?Q?RBF!Y?I/XT\CGQ9^DVX_66M^R.,*_B_E
M%,#R_2?QIY'/BS])MQ^LM;]D<85_%_**8'E^D_C3R.?%GZ3;C]9:W[(XPK^+
M^44P/+])_&GD<^+/TFW'ZRUOV1QA7\7\HI@>7Z3^-/(Y<6?I-N/UEK7LCC"O
MXOY13 \OTG\:>1SXL_2;<?K+6_9'&%?Q?RBF!Y?I/XT\CGQ9^DVX_66M^R.,
M*_B_E%,#R_2?QIY'/BS])MQ^LM;]D<85_%_**8'E^D_C3R.?%GZ3;C]9:W[(
MXPK^+^44P/+])_&GD<^+/TFW'ZRUOV1QA7\7\HI@>7Z3^-7:XC<(=1\:F-Z:
M4"7O#Y*WO(!S*#996+?'24A4)5)H#,6,+' F4Y9)<5@4!43"5(2"3LF[="P1
MC)SG/'&.RIJT=G^7'_ZPG[I//1/(>8>RH'+TJ]IK Y-33%*8I3%*8I3%*8I3
M%*8I3%*8I7X @(F ! 1+V>T #U$O:ZB7M!\8=H $2]>G7H/3XLD@@ D$ YP2
M#@XYX/(XZ\<J@*224@@E.-X @D9Y9',9ZL\^JOW(J:8I3%*8I3%*8I3%*8I4
MH47Y/>?MG_ 2SS<ZO3]U1UGS#VJK>,\ZFF*4Q2F*4Q2M+V#L2E:LJDK=;_8H
MRL5J'0,N\DI-RF@03  ]VU:IF'O7CYR?HDU9-B*N7*IBII)F,/3+G9[-=+_<
M(]KL\)^?.DK"&F&$%:N?SEK(&ZVT@?.<=64H0D%2E 59-1:CL>D[1,ONHKG$
MM%J@M*=D3)CR&6T@ D-HWB"Z\X<(98;"G77"E#:%*4 >3:O,[D)RZO$GJ_B1
M%P&N8=DP.]DKU>7;<+,I#JJ BG+1T0=)<(\@F$O<H-VLH\ QTQ=K,"*%#.AA
MLQT=LXM;%^VC/S+W)=>#3%HM+:NX$R4I*E1GY04GIB ,*6MQAK@>C2Z4G/(_
MRV[1=LE[F:6V-0[9IJ%'C=T2M2:E>1^M3"=5T;<Z%;-QSH$D_P"31T4M\*W>
MG[F"AG>8_P &,^N!T93?W)G;NQY8Y15<LXN46B8I!T<PF,5HI)NII7Q4HB(D
M3(U:"0>A4Q(F4"C:7MNK5M"F-'Z%TW8XX^:AQ^.B3(6@#"2Z&6XJ>DY;Q*W
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M/5T)3%*_DRA"F(4QR%,H(E3*8P 8Y@*)A*0!$!,(% 3"!>H@4!$?, Y(!()
M) XD@$@#ED]G'MJ"0" 2 3P ) )// [>'97]9%33%*@N;^5Y+]L7_>#GNGD/
M,/95*?Z7]8_=6+R:JIBE,4IBE,4IBE,4IBE,4IBE?AC%(4YSF(FFF0ZBBBAB
MD3333*)SJ*',(%(0A0$QSF$"E* B(@ 9(!40E(*E*(2E*02I2B<!*0,DDD@
M $DG &:I6I*$J6M24(0E2UK60E*$)!4I2E$@)2E()4HD  $D@"N=VS>:[^8M
M\1K+CLPA9"0FKJTUVIN6[HOD]71%O? <4(>.5;HF]W'P DMV5#F39K*E(1N#
ME(XN$]^::V/,Q[8_J'7;LMAB-:W+VC2UH6RK4$FVM%._)D!:AW&T=Y&4@*=0
MDJ4X6U -JY$UO^DE+G7V-H_9/&MTF1+O[.EG=?:C:DC1\*^2 K<@PNA03<Y"
M0AP;REM1UO)0TT74J6\U+LIP?W-:*U-2NS.4NS;1<0B9)Y&5VD*1](J1IDK%
M=1BP(BW0*J#0[T$$.^ 6IQ1$>], ]HXVZ)M/TG;)T6-8=GFG[?:Q(9:>FW5+
MUTN0C%Y =?*UK(Z1+16K<)= 5@IZDU=IVP_:%>K5/EZMVR:PN]\[FD2(EML#
MD33]C,Y,9WN>,&FF0L,*?+:"XV8JE-C]KO*WE&D6B--;TL$]6*_";TV50;X]
M1>GG"/)3WS0L8\C4G;IV5S&O%ED':)1;)HF25670%100["OF(.UM8W_1L2'/
MES-(6&\VAHM)BEN.(,J0A]33;9;D-)2MI7[12@I"4+PG(4G]ZM ;-]+;2KA<
M[9;+?M%U7IO4,CNA4\/3!=84-<-+[KB5Q7W'&I"26FT%#JW62I>ZIM>=VITB
M^6U_TIL:U:GY*HPUTCZ.O"L9[=&LHM\:/KRM@ZC"_"!"IMDV\:JZ3*(NEH\"
MBW/^5XLL03"E@4_939=562!J/0"Y5J?NJ)3L32NH)+733A#_ ,Y_4LM3BG'D
MH5P:0^2%IX=(A6-[;EH_2 U1L_U-=M&[7T0-00K [;XURU_I&&^6+2NYX[@5
MJBW(9;:B%Y/^7=AA/1.?/+"FU*2QT3CY!A+,&4I%O6LC&R+9%ZP?LETW+1XT
M7(!T7#==(3$424*/4IBC^D!Z" @&@)$=^(^]&DLN1Y##BFGV'D%#K3B#NK0M
M"@"E22,$'SC((-=A1)<6X18\Z#(9EPY;*)$:3'<2ZP^RZD*;=:<22E2%)(((
M/D.""*]O/&OHIBE,4IBE,4IBE,4IBE,4IBE2!2OY*0_6-_[*N>;G5Z?NI6NV
M?Y<?_K"?ND\K3R'F'LJ!R]*O::P.34TQ2F*4Q2F*4Q2F*4Q2F*5B9^?A*K!R
MUELDFUAH""8.).7E'JI4FS)DU()U55#G$ $P] (DF7J=94Y$DRF.<H#]<"!,
MNDV+;K?'<ES9KR(\6.TDJ<=><.$I  .!S4I1X(0%+5A*2:MMXN]ML%KGWJ\3
M&;?:[9&=F3IDA80TQ'925+6HGF3P2A RIQQ26T K4D'C*[2D.=NR+=LF_P \
MKJ_C%J9G),HR8?*)-Q2*MV014!=X";$)>4,1K+SRAQ4)%LDXZ&(FLY7*L7K1
MHQ]C6G[7I^RP4ZAVAZE<8=D1&0IP+4C>WP4-$NB'&!=BPDI"52'B_*4I+:"D
M_GL\J=^DEK"_ZOU1=1HW8_H=B4Q'G27$-%AMP!3*>ED%$=-SGXCW&ZK62F#&
M3#MZ&G'7@\BN=8INM^/?)^(@=X.XK8-#@'K.2)+5Q9I+0KM&1;HOJS-ST80S
MKOXUNDJB^F(#M*',04U %TR$I'&=W"ZW[6^SR5-T@W)L=ZG,NQ^YIZ78TME;
M#BF;A$AR"&]R0LH6S$F[H3DJ3^S=R6]6VFQ:4V8[78-MVAR(6J-,VF2Q+5-L
MZV)MODLRF6Y%IN%RAI+Y7#;0ZW(N%L!4M20E:2ZP0EWO-JG5.IM:LYN4U- Q
MD1&;">M[0]=1+M9W'R17"(JQYHKO%546<,1%PHLP8L029H^-+'23 %!SBW4^
MIM3Z@>B1=3S)$F18VG+<TW):0T^PI"]Q_NG=0A;LM2FTH?>>WG5]$D*4<5^E
M^@]#:%TC'N%PT+;HL.%JIYB\//PI+TF)*;<:*XG</2.N-1[>A#SCL6-%"([?
M3N*;0-_A*V8O6?4Q2F*4Q2F*4Q2F*5)U&,4K!X!C%*/CGYQ /^Y3_2.>:^.,
M GGU>:HY$D\!@#VUNPJI!YQ53 /TB<H?ZQRC=5V'Z#3>3_$/I%4!YG;+LNK;
M+J6XU"0[E\P/8 <M>^-XE+,!-&F<QDBFF(@JU<%*'QE,9%4$UTNBB9>NW=FE
MCA7Z%J&VW%G>:>$/<<W1TL=T!_<?941E*T$]1 6G*%<%&M+;5]07#3<W3-TM
M;VZ\RY-2ZR5GH93![G+D=](R"VO"2#@J0L)6G"A5H=);IJF\::VM-;7(D[1[
MMK88)59-20@)42"*C1V0@]115[)U6+KL$3>-@!4@%,"B9,$U/IFX:6N2X$U!
M4VO+D.6E)#,R/G =;)X;R<A+J,DMKX'@4D[!TCJVV:PM3=RMRPEQ.&IT)2DE
M^#*QE3+R0?W3Q4RY@)>;PM/6!,.8Y64US%\(K9K!=/@AXGT=XHTL>]+<V]WW
M* F.+.F0ICK/?&44E$U3M%'14WSM,QTR.&44NU[0"Y Q=[;%X,.U_P"$FT*Z
MM!V%I*VK,-M> ';G*PAK<4I*DAQ*"6FB HH=D(<W3T>#R[^DC<;A?4Z+V0V-
M]3-SVAWMM%Q<02>@T_;@J1-4XA"T*6TIQ"'7D$I0['BOL%25.I4)MX:ZTW]I
MRK6+6.WY"G351J#QA':HFJT0&[]]7^[='=A+-"(( @*)_%>Z%T"CXZJCGOG#
MH *L;%=I=\T?J6X0K[IMBYQ;E<FW7]11IRM]EJ;O(#9C.%:]X*&_O;FZV$A&
MZVWDI&=;%],;0M%VBY:6UG+L=PM%ED,1-'3[4@LR9%H2TK?%PCAIM+3K:]P)
MWBZZM1<4X\[P6;FYK.MT4Q2N5?)C_M=G_P!GC?\ TA,WWHC_ $=A_P!=_P#]
MPUSIM _TFF?U&/\ V45 ?Z1'S 'G$1\P!_\ ?,M )X 9/8*PK[N)). !VDG@
M*\:AC FH*)DC*@F<4BG.'8%4"B*8'[(B;L"?H!Q !$"]1#*DI^<G>"MW(WL#
MCNYXXSPSCEGAFJ2H8.ZMK>W3N[RT[N]@[N]@D[N]C..K-5>I=TV?QXW=0=]W
M.18F;3MG"H7.,A.R5FTI[I5)%!)RJD!4W0 CWCY$%@,JBI'D%9P83#W>P+G:
M[!K/2UWTA:X[P7#@?K.UR)8/2NW-M*E.*;"N+9*@&E;IW5!T[J !\[1EON^L
M-FFO-.;2-2S(2V;M=QIV_1+9_FT2PON)1%4ZXD)#P1_G(6XA2FC'!<>4"0W]
M-J#ILY01<H+I*MW*2:Z"Q#E,FJBL0JB2A# /0Q%$S%.4P>82B AYLX74A:%*
M0M*DK0I2%I((*5).ZI)'40>!'4>%?IDA:%I2M"TK0M(6A22"E2%#>2I)' I(
M(((X$<:\@JI!\:B8?TG*'_OD8/8?H-5;R>T?2*IWS3L\O5-:UZQUF65C)N'O
M$.\8O6:P JDJ1J_ZE4(4W19NL3M).6Z@&271.=)0!*?-C[,H,:X7N7"G1TOQ
M9-KDMNM.))2H%QD9!Q\U:#\Y"AA2%@*3Q%:NVL7*7:]/1)]NDKC3(MWB.LNM
M*PI)"'LA0!PMM8)2XA64K0HI4"#6W\;.2%>WS754S&;Q=Z@4D4[-7A5*!C=H
M.P29BR&'O%HIXH4X ( )FBX&;+#U!,ZEOUMHN9I.:D@+?M4M2U09FZ2!@Y,9
M\@83(;!&<X#B2%H&-X)N.@->P-:05IRB->8(0FXP"L;P)X"5'!PIR*ZH* 4
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M YIE2D*+TY:=XQ(84T!TJE)/!6TS5%]_2%U\SLDT%.,71EI>,G4=^0@EF6N
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MN-2FU(2M#D;NAIQ SNAD9*F@H]."$*F4I"%*0A"E(0A0 I2E*  4I2AT "E
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MBE,4K0KQ_()?J%/[1\RS3?)S_MD_^E-8=J?_ "K/_8*_]PU4B[_]]_\ N_\
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M'W<9K\QMHS/17YQL6Z#;.@*XKL>WQ1;V420>F6AVVINMX3;9>XO>=@B6E;2
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MYU:G''7%DE2UK42I2E$Y))S7;4:-'AQV8L1AJ-&CMI:8880EMIII "4-MMH
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MW9LQ+H"F.G68S8^<II:P*P+6>E+_ *MD6^!'U9,TYI;H7QJ")8TN1-0WE:E
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MW%J8*5=,M:0HAL+"Y9+V2B4.R4J9>R4$TP A2IEZ !"%* %(4I0[)2@  4
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MO%/<DY;2&FG%I^>EM*>&0A+8( UN_H#](JV0)-BMVTW2^K[++@S;<M>K;(]
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MI3%*8I4@4K^2D/UC?^RKGFYU>G[J5KMG^7'_ .L)^Z3RM/(>8>RH'+TJ]IK
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ML_RX_P#UA/W2>5IY#S#V5 Y>E7M-8')J:8I3%*8I3%*8I7]BH<0Z"<X@(=!
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MJI2]5KLE=Y=_+2<"I<X>+=QL,HC!LH:"/',%7BI'DHZ.N"F\./#B<YX^3'4
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MP?;^-*>\6+^=/_KM_NV-\]@^W\:4]XL7\Z?_ %V_W;&^>P?;^-*>\6+^=/\
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24Q2F*4Q2F*4Q2F*4Q2F*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g209588g49v09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g49v09.jpg
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M P$! 0$!           '" 4&"0,*! (!_\0 4!    8#   !!@@*!P0'"0
M @,$!08'  $("1,4&5>7U1$2%1<8(5B8%B(W5G=XEM'6US,XE+:WN-@C)#&U
M)29!45ESDS(Y4U6!E;*SM/_$ !L! 0$! 0 # 0             " 0,%!@<$
M_\0 51$  @$! PD!"@@+! <)      $"$0,A,00%!A(305%AD7$'(E>!EJ&Q
MP='P%A<R0E9BE=44%5)357*3E-/6X3=VM?$C,X*2HM+4-D949G.CPL3R_]H
M# ,!  (1 Q$ /P"L^>0/'C & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+>+(E-RI<DE@E[W_ -2M.42, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MJ2UU12FJ[JF;::<5.QG!2E&"DYV;2<G1549-^8Z!9ZH?H& , 8 P!@# & ,
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M)5IL'2M.)OOS@^)1]E7C;[[]O_Z$\_+^"Z(?IO2'R:S?_-)5;?\ -V7[:?\
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MB#@!,*-+%KZA ,+$$8!:^K8=ZWK_ (X,/; *\W3^4GD7]8:2_P"5#I[ +#8
MP!@# & , @+FG\F*W]+?0G^/EE9KQ\4?0B8_._6?J)]S"A@# & , 8 P!@#
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M729.0GTH/-5'Z()+)\LI.WK9R@WR80^4/-WK6S3A_&,,WK6Q"WO6 >^ , 8
MP!@# & , XM]Z7%W;7G1;7!N=;;6:B<_I.1O#97E<\)*.D;"KY8U/,=CKA9J
M^6N_15.1,Y46YO(=1- X;<6I*>(Q'(J^DR41#V4*6K2KQ_6HNFJWVX>SLFSZ
M4Z:6O2T]2J6:;D6E:E8F(1+%"G28KRYZI&E_W5(I--^.8>F3?[ @T0BB?]F
M."3(X!6>\"G@5O<:G)ES:4QE7W-P.K<>U*E#JM7F\J=&[9U+>\EO*9(V(T)1
M3L!R0J6)V.=C%K<8E<&8+6I*=P+,8 P!@# & , I7(F>[.?(#*WR-S^MGB)-
M<PD\N(C[Q5TBV_C3V+9:^1KVPV3)+53H1&H5,L5$)5P8R  B4Q/E$6Q[&+=*
MDFDZX4QX+LY$.L4VJ8UP>]]OJ+J9)8P!@# & , 8 P!@'\"*+'OX1E@%O_A\
M(@!%OX/^[X=ZWO,<8O&*?:D_24ISBJ1E**QHI-*O&YG\^0(_^"5_Z8/W9FI#
M\F/^ZO8;M+3\Y/\ WI>TKI>'(G.'2\BA<AZ#J.&70"OF*:L42C%F,J"9P9J_
M#\V+CD+\&%/Q"Z-GRT)$1;&]DE:AN-?HXVJGQ$PKFXF0/&EE$IM8.A!$=\-'
MCZ#O<7D&XW+7%FB9$6T5!9O;-@2FJ'^1Q*DT_-D;FTUKB321="YG.D]')45:
MGR&2M3BJ>6A(C5NX'!^3$.P!NL^5_)5QKC2JOX'Z4G,W!U.3%7?Z4ROJR3VE
M$G2)Q\6K,(B%.F-T\@U;Q)^=:OA8I WUPR/\RKJHJN95K]#&M,M7QR&-8D9I
M9:UZ4.HRLJ4J^SQM]N+?C9)U?5QRW&9]2T<@TDBI]C\QT2^436D22V00\2B+
MU!+4=.K'-"[QG;VI<W,2U!3U7K$\A?$*A>4E2;4IEH2GQ:-6%71\&TWVWT]+
M+0"=VH+J4Q"<V\+X<WGNY+,):FTZFM292G1J7,INV;I88WIUBM*E/6@)VF*4
MJ4Y!AH33BPB&&0P#6$DVAB\#:8AEL86@>7YUBS.-(_-2D#K)V(#N8]QQM$2K
M'I<_,Y<??C'5H2[-<&\#([C5IR0MJS9('DKGT%;XX1,5\TB2*(JC4I":5*Y&
MSIHXI/6K0MR(DA\.6 ;#C5;@,*!*66J$-0M$%*5H9XM%[ R*J2QQ">[I5S^R
M(U4?94\D?DRIU0ISV2.JQNI:5^=R3CP&-K*I&Q/8$[HM"2A.&S.H2SQ;;E>B
M0,JG4)U:<A6D/)5)51)2A,I3F@.3J$YP F$GD'%B$6:2<6()A1I8A , ((P"
MV'>M[ ]L 8 P!@# & ?/CXU43F+W8'/SLQ<WPJZD+77MTEHWIYB+-,G9JE"Q
M.P-D::) <[W54GS?U6*:.L%7RZ7E@6-BU4-N:GR7P?R341+!<&EBVJM8?_F7
MOQK=W[9"E)+,T$K$B9O6%-B I4@1'C4HT2DM*4 ](D4F! 8H3)C=")(/,  9
MI0 &#"$0MZT(,G@%>;I_*3R+^L-)?\J'3V 6&P!@# & , 8! 74/Y"9[_P"0
MP_WJ8\J'REX_0R9_)?B]*)]R2A@# & , 8 P!@# *Q6[SS-[/E8)+'^NNG:1
M0!:D;;N%U&/GL,4&H2FJC#'D>K.Y]LV2?*JX*@LE9\62!;?)(TOFK:E,\X,4
M>:R#.V39%8.QM<P9ESE/:2G^$Y>L[;=*2BE9K\"SKD5CLXT;C_H=>LI:TY*B
M7.4)2=5:VD+J4CLZ=O?6<G7QD7_0TM/_ ,1KNW_U.-_]'>?M^$.0_1'1CII#
M_,!.RE^?MO\ VOX1H/B"41V+<Y5)H>5;#104,-<'QZF<B473;=22$][0O%=K
MXAL:&M"%$1G\:7L[18+9*HU/XX[MQJYWCQ34E;6];(7!+ZRW5MT2JVZ*M%7<
MJMNBP56WQ;.\6EC?NW8;WNOPI3BWR=+W'PY^T723U#))5<SY8Z:%V?45KR9@
ME/5W0IR/<TB=E]9$/[Y$RUI3D@8T*2G[9I%N%#FM&RQ29&5ZZQ]]:]?"%[>\
M*UE1JBO4E\E5OI2KY4;Y5NW4WM[\-3I*UZ[X7KBZ^BVU<Q4+$HRR6,?%837#
MO*HRH2<@R2D9L5%'RYZXMZ*VV.<6*[D.*B13VNXX],4=&L=&0262:2'IG#EX
MS%))MT3KA6OY2=71HU:'^&!;M=VT6Q5<T4S :N@O2=7773W2;I+'F==$Q. U
M+PU5_*C!4Q\&65DV)GLI\?8">OF#BXW4D9GF'NSN0>P*79RV K./._S4]1NL
MFKZU:HTKE?+6QJ^6[T%^:^Y4ET0[':^FW^01Z8/#KRBMI:T9P!.Y1]_F<\36
M! WV/.3;!]JGQ@B<021^-N^],S&^D(TC\YK%^FU6XOCR[GZ36ZG.O*GO_F8N
MM.8^@^?XOV6_POHN87M:%U/TKG=(LMX#@K/"(-,#:TC\9B07Y? *M9W,!1LE
M84OX3*&] M8]15O9P-,/*DNI&\R<&TZ74IPX>/WK6KX<]Z5\-+L'DXFKVV!R
M^C^@8S171L"ZBA;([KIS0BB4S!^Y0O#E/H%E=52TKH8UI>),KF,'Z %+MN*Y
MOG-E/MM 61B"@=&U2H>_O[LIR3K<U54XT2<6J884:Y*E[,I8GAG]9O7)'/-,
M;L"D+0/J%,[*G*B98V.48J[\)I_SCT72\H<R+7!&97)9>BA\TOAML.+D/U8,
MYB@F"Z"G):7I:W&-X:RJVUCPQN<7QX*EW$F>4>&.J=FGM&.&"CDF0]*\%\XT
M.!W?I9-2'.8]#T@7TJ4?.)_H.UQZ6'*_P_J/S5N2KWEM4M[$\,:^*;:4)*5X
M;^5WKKZC-;Y/",FURK3?XCJW6D=7Q"N*_B;H-,8YQ>$Q2.N)B,P9J0:]D8D#
M:L&E--*(--3"4)C!$&&$$C&5L(AE%BWL&A)NV , 8 P!@# .&OBF0T4DN:NF
MYTCO422"VCSI<-'6'-N;Z@K6\E#_  Z82>&.4@IUWC%G0.1%PIXDS0TKI%'+
M#A#V6](11]Q+>XPY@21IX9!47=NN::3=+^/.E%=SNWG;=D2ID+*T(D1*M.C1
MM:!*D3KQ'#7$)DZ0HH@E8-0,U0-644  % CS##A'!'LT8Q[$+8D^;#H7ECQ&
MYK?_ &9.YM6##/X3:E<4VS,A5:74[/:9ZH*K>U(?-';GJ,5]*Z[KYN:I9/.:
M6N?DV0QJ9DYMLMF4Q?-I90N:)8W1"'#HG&B6^KQ223U6DZWUHZ-7;NMVN5*K
MNBK*Z\/R.V.(^$M#?T?T@H8:8?6="LE,"A4KB'=,QI*-+Y2W29S0MH('2#Y
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MUR8EC,_/K=.2P#(86A8F)2.Y^DMU?2_BZ)-^-IOC??>=>L&# & , 8 P!@#
M& 0E*J94/TY<I^P6I8]>/#U&X[%WA-$ 0 ]N<4$67R1Q9S3BIA!)6I*5$'RM
MX",:14F).+-*T80(1(1YM;J43Z\N#7 RE]:M74W>M,QWS,SC[3-Y?V&C_P"3
M6*K@O/[11\7YO8/F9G'VF;R_L-'_ ,FL57!>?VBCXOS>P?,S./M,WE_8:/\
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M5CBG$G&><L;=-XBVPPI20606XN6CBE&SBA)P+,X P!@# & , 8 P!@# & ,
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MR9FQD*"3DQP2SR32P 6SP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MB\@2)(=)CR4L;EBE2TJR2(S(%2EN=TZ9D?C1@:W8\]I<R24"I08:W+0!$F-
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g209588g57a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g57a22.jpg
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M 0 " P$  P$            !" ('"08$!0H#_\0 41$  0$$!04)"@D*!P$
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MQ"(6VD[VE_/1+M[O=&O!245A52:,HDF57IGZM_T%LKQCI.>&T,F0JVI:"<%
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MI[S,_F. . . . . . ;M?)P=YOLS[*^ @?F',,XQM(9YMO94?)P=YOLS[*^
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MGX!*' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M;Q J?+(5J=*=%%&HT0U'A2'W!L]#3:E0Y&&P,7I?TJ[I_O\ 7OX4SP"7^ .
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g209588g60l12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g60l12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?84&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M   _@   .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          CA"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #-0    8
M W$   8>          $                          0             &
M'@   W$                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   W$     4F=H=&QO;F<   8>    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   &'@    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M^@#[3S('= K^LV;2=N0P. Y\?QE.]L]UA(>J#H=)^ 4]ZYZGZR8MMI+[!7N
M]CQ $?\ "MW?]);.+E5Y# 6D$]B""'>;7!&B-U$"K&J<V[7 .T!X=VE3=KHH
M&""UPD'0A1K.T["9'YI/AX)+:6>"T^13 HKQN81\PJX*:0OB;#__T-&4\H<I
MP57IT;2;E(.0@5(:ZHB))H"T2G&(N1H>*0.3@@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_(W&^_Y7Q(#N/74>4Z_>AMFN @@$$$3J/OA9ZE0+=M2=+G<7N-]=/UP2AXB
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M)4WRN. Z JN1HG6Y40 1;2^Y)O/WP:9 TS#6/$-M3KT,SJ:6+*5+C6IWIJ>
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MR&06*HQ(4NQ;8<*H;_,2 6TMRDL%Q6F@;#F@-B1;%)6&W^[SGNRX2"<Z8<3
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M;*"ZX>10!:=_?YK)0"0% *44+*2""2LG:(^<T!IQG7@!PM65=T94DG--")%
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MIA:J<OMI3K:F)$U]MDJ]I!)[*Y4EELKU2VE9YB@=JMP#2J,UX6@K7W;:2"E
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M 4I(6DE"UH*5*Q'$%"BD^6\@[_?2W./-NL.%IQ.5QLF8HE7!23 E"A4'<'Q
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M5JGM75K2NT9',.<A"BM1"&PJZE#3P6Z/WR\+*04M P\I9*@)_"E(H2M4R*B
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MGKG_ $KFHU_?5X';'5$$:[SO/6W.I!($5H.6HYV\E9%P/@>E];]X\ ;>6 *
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MS*9ZTCAQ0OZP92T>BW #H?Y4N1M_2S',&3LKYAB+;F.5&5*Y?LI[+<6DRVB
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MO9?V0N';GMCA_9S$[W>KC<KU=\1?=O-S4PE]OW*XOWM,*O+3S(0I30#A4@^
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M9TJ9F@UMG.%:U$EZ\S62+U>$S6M$N) KK U\K1CE6G-OE;$QV+8D);AK]1:
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M@ZTVRMHJZ*4LA">=(3H+\BDG>!]S,2J@DDF8@TK%12@]=+:^%7(W="&U!4H
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MC6-=SZGCOP%M"]HEE#I,DJ)YPJD:Z"$^<S:SL3E0%":]#^MLH+&]/C]+'2X
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MFI#/*25I6X4&["B,C$&XR* I!/\ Q'+7A^$$5&LQ),^L]D;\B\)O+:R.\EM
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M08F02H*)IE_LV_C_ .O RE @LB I+B%*5*5!1"TI6% JD!24)6A*258[1X'
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M9I;"F?=1= ' YWOALI60,T^K-%&8^$YEEQSMDJXDY9# :_T1;4*GSE9UYPH
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MAM_\8N4M//\ X3^NML,<3PH"?VKAL?\ ;6/_ #V+]E8[_P#=WM!_\(OM?_\
M%\XL1.3'!>V<.&WNXB92V_\ *APW[5PG_K;#?_?&?_-9?LK'/_N]CXZX1??H
MU8R<EO'7^=W#;P_XP\I@D]X_X4_3"_:F$_\ 6V&?^^L?^>R&$XZ?_L[C_GA-
M\_\ W<_"Q4Y*?W_G;PY/2W^4/*A_"J;_ *X7[5PD:XMA@_\ TUC_ ,WZV?\
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M_3&8 Z9I!Z4^AGL;VO(/_HKV@!&H_95Z B*@ M\:QSWLZ<I-/< (S?D$D?\
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M85<SC5WQ3%G<10AE*;XFZOWRY>Y&\/=V"XV0ESN4EU>02 E-LSV27'M"S_:
MQK$;TB_CLY>L#P9C"5NWE2\.5?KOA>+_ +0%UNO?*2R^G,U[PXEELN')*UY:
M<UD/@]1?I<BWP N?+Y8^<"@5B?R/2-.DGE;[O"YWVW$CUD?$]39P'Q?H1?4Z
MV/@=K>X>_? E)CX"A!W.A'YV-*M]#.Q!\Z;;?.EC!P;CV3YVM[_XC;:YP,$:
MB+'G)&Q'/]*6<(>6-B"--R!\[BX\P>["L>81K!Y@G>?/AKS %G2)8&BKI]WA
MN?E^)W.!*4G:.E+$%$; CK(KKP,].EG3<@=%=QO<;'XBX[_A? %'"O '6?OC
M'"SA58!KN9%!TU\Q9VA^_6_S/SZ'O%O(8CRJJ1,R=0"*'2=AYTZV/-IH=I!(
M5]"?ESL9#HWVU]]R>[J/CT&!@@U$C6D&NLZ3'6>%;$()D&ND*^7W/2;.$OD:
M W\+']-/<,-(FA/,)%.&X'R/E8I(.YX5 CH:&-JBQT22-%6TM>WB.XF^G@?E
MNXD4B8U(-=212>9IO\T"2)UV'*M:B9K-?ZATA_464#X!7Y7_ $PO"8  GA!'
MQ'ZV.AWCKIZCZBRI#I=B26N=">TCO(YG%<J$<[:D\RSKRH3>ZU658 FQQT'9
M&\>X]K>S%]%WO5[]S[0X)>Q=+BS[Q?;U[OB5V=]VN;.9'?7I[)W=W:S)+CJT
M(S"9MQGM&N'[4]GW;O"_?;AAPQ'L;VGP_P#:.*7CW7"[C[Y@E^N_OF(WO(Y[
MM<+L7._O;_=K[F[H<<R**8..U5?JV6J6P'&W>Q13F2ZRKM&7"B(I 6TNXYVU
MD7;78<R2#87(Q![5KV<3[8]LL1]SOV'^_P#:W'+[[AB=W-UQ&Y^\XE?7O=+_
M '4+7[O?&,W=7EGO%]TZE:,ZH!-G^SUA?[ ]FOLRP3]I85C(P?V;]E,+&+X%
M?/?\$Q/W# \*NIQ#"+_D9]\PV^=U[Q<KSW39O%V<:=[M(7 Q-$LV 418:7TO
MYV/AW>ZVV/+"FH%1,\QTI7KKYZV^@@L*WFD&DZFFX/'IL-+/&Y2=+*MTU.OY
M'I?3;NP)!' ]*QUX6,&"!(B#O,1PW^!Y4F'2)! O\_UU _'6^!(!H8,>H_*S
MS(I\*QU%#\.MG:)0TZ^'\/X# %L'0D>AUUD1!L86:=)(,5!UGGSLZ;DC^U8B
MQMH=K=YVO_@,1J;5_M#EKUBHGG377@8<%0=> X?GZ"SQ$DVW/70$#?37ZWMK
MB+)Y=:?$2/CRL8((!D5^?#KRL[1)&FH!O>U[?E^G@-C@<ITB=12M>'#K]BS\
M-CU^6EG;<O;4$>.FQZ>?776US?; Y1L.OQC2(-==8L^8\3]\>/2SQN4--2G0
M[:C6VWN[N\]^ *-3O2.'P$_ >>MI XH0)!UUH1//0>7S-G2)1(!OO<:;CXZF
M_?YWP&4UFD5K]#I-I0X)VXTWX[P3UTB8L\;DD#4C07\>G0W'O^>!RB#%)X3]
M^6EI<T[Z:R=OC3I3G9RB0"+ZW[_RT&O3#0K20>$S.E:C3EUUL07OH!SD4_WJ
M>HI0B#5XB21LJ_=N+> MI]#NP) .H*=])!\]9@37G(L8<,:D D52=_.:1P^-
MG*9-[<P []Q^OUW88IW%>D'ZSST_.TO>)5K'R,_<30C@>#E#J2;I58C4'3K\
MO=@2"!!D"HB?OULH2J@4*\=P-8(X:Z"/*SA+ZNME=QT'X"V&^''?ZZV M4D"
M.8J/G8R) [RGSV^.MO'887'E\OZ];1J:W@'X'[];.DOJ W!!%K]X/X_&V%3>
M::=;1%OA3D?O\[.4R$FP.]O$>'C<_P =\*P%)&VG"OWYVN7@^L*<XA$;_P P
M4 CP_G_D,>?7NQZ![.)_;=\X?LE[_P"=N'Z?&WCOMJ,=F,,/#M#=_P#_ ).,
MVR2I13(C**?O%.AO^'F.\@D@WQZ[>KLEU"I%>?&FE/,P>!M\XW1\I4!,;"M-
M)@_*OI632M:9>67X4M':M+"DJ2L'4*T.AZ:]X/0>&(ADW9P*28A6QB?$(T.M
M"?Z5Z87?WID3"I $1O&XV]9BDUMSK]([T8.&^9^(,_/3F7RN7 FO4ER?2YU0
MI<QMJF)72J:[+73GXR)R&X\=AV(],:?5'<0F&I3L0);?ZFYWYJ]]XV*.LJ4V
MI)-5(02E*Q2H4!7=)F9&4G"ON".W!NZOJ2%-WAI#@<25 (<<'>*;4!$*!-"?
MQ)_"1!C(O1ZS'4\@5_\ R=9EF*E0ZLTY+RW5GK(34S'2$+2NR4-MU'U9*$U"
M.V.42F52TI#509!KWU@@YP-:?.),:Q)/KL3;L>RN)G*;D\JH&9I2M5"132,P
M/QJ8%+97QOX>Q(]31F.*RI,>J.HYW6THY8L]*5J+942.5N8FY2G4=H%I/LE*
M3 PO,,IU'4R"#KH! D3.]:3;7Q6[%EQ+[8\#JCFX)7'+9<E0Y@TMA%)RS#J=
M(?<D)]7D--$-*<3S)2H*0A+EUBR!R$)-Q:RKE8(MB52I^FD_KN3YP+4FVY-(
M(@2)'"#)X;>8GG9W#O* 1!DK$5I;BVUJ86X$EMQ14+6" GG)',H 6(L;BY(5
M%FUVG4_ZP^@%-)'G-K99!@QPD 1X8DQSX\@-+6_ERC&(T/VO 4I"GTAA+: %
MDJ58E*0FX 0%  BQ(L-/:PP72HDSJ:[\/E46L)NP(E)I&DQ6H]2=R!QX"VY%
M:70,W4*C4M<9QN/3X$5AIQZ-"C.R RA)9 8C(79Y8+JI4AR4YVREI"6VRV"2
M=="@D$T BL#2- -Z5J2?.+5KE<%7=QUQ6675E< N*C-),K7 ($#*E*$%($9E
M  6JF3DND(,B0II,=M#K24E:>8&RP4!I/,5=H-+%-A:Z2+DC$,S.U8V@\A_2
MF@MJP0" -B9&M/IK78<ZD52CNI3.$=20B,PVS';!'[ZT@72-$JW5J3?J1KAQ
M.VOZVKJ3!!T!-9FH-?2GRZVJF#"F/U>5$<4IZ7(<C>KP8Z=&HK  *I%M$E;S
MI5>]U)24GK9&GW\^'/A8DQ,DB*S%9/+>A-*ZR2(MG53#3,QUAA*6XU+;]5NE
M/(')G(@2G=-"EI*6XZ%624+]:0!RZJ@41I0RHGCO\R 3PH-+:#2<LDZI2!&^
M8U48UBHGG)M0O +-+6=<[\<<Z1W0]3H%+IU!HCX-T*I,(U@]NRYH%QY\NGNU
M1E0T+4Q%]0#C.O9*G$)&Q Y<3Q]1PBV.MX.+>=2/"2 GAD30&HT)&81 KQFU
MW^@V9'^1^G-O%1#<J80%'916&E :DD7:OO;482A#CD5$IKU$\!; O:@+K=5?
MQ*0H<X2HQ/6L@08%=P=U%;'R/X85LT.& D1761N:4KI:D**\7>(M92#HA%/0
M;7W#!7Y:!?C]WNT"(\0Y%4#C0T@;F-*?*VH"#=%'D=>,F)\I J=P(K:^TWL%
M"Q! TOKK;W CY8.D930B:@4,2.I_.V9F!41OQVFR7)"&FENK(2E"2HDG2P%]
M\') _F-:CB.(Y4KZ\U6D0?KPBU(52N/YFKZ*=%),9ERRU"_*>4ZW((&VIN;[
M#38QDZ <33777C.M"!ZDTO--A".\.OE0\>DZ:ZF-[99F-3<&G,Q4D I;%[FV
MNWGW^?7KB-S\%21*AT@ ^7#IM::Y@J<4K:9G44'P&V\&U:LN&[F@W'0]ZO'%
M1"@)DZQQYVV5Z)\_IPIZ6Y#/*4'GE V)=<WU_?5;NW\;],=:17@8^?UH-1];
M<^E6@UH*CI.@GYV^)>*=5I\B+'7Q!-L"1,5IO37\O+C8Y"J3/J+7-Z.[P7Q^
MX' '_OO\-1J+7/\ /*B_/ZMOB:Z(2+W=E#47AD[;.)BNL;?6V;C7_,^+U/\
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MS.<61(;]?EL0ILYI21<SDHG/28Q Y1*Y'%I[%*[5BZELHS:K7D0(U)!4(UI
MDTU$':S8D\;O<U!!&=<(!F"<R@E2C0F@4HC7Q1)UM5?HG09</@SQ;JD&.MR7
M)A.P(#3:0%.RV*',]591L!]M4HX 38#G&U\4'*N@F($DS'&IBNI@'0&=-AC"
M>Y"4U*I$ U("9B/F*B+;,^B$_4LKY=DY0K\1R#(:F.R:>IP (?8?':.L\QL
M\V[SN!&ZFE>S_5KQ)*5*@$>*NVH$<34B(%!2O&V?>[L\&$9DQW16!2?"N"..
MAS ZSF$Z3;=B2\EN,ZYS 6;41<CN/G[L.D5@C\YKY\:"M.5L>(4*17KO6(&D
M<8^5M>L@2_VCGO,4H*NC]H%D+T-PPA3 UO:UD"VVX[\-4G2M2(I6ORJ/@#;6
M6,MUC0Y4TZ $\Z$]8\[;)ARPZBPZ&PT&_2WY8FRC@#KJ)U)/UMC[SYT];5EG
M[-+<.&J!$<0J5(LA*6U E)-DZ :D#<G;W;B3E&IWV.YFNE=M9K,6M79LN*$B
M0FL^4$"!MK/GMFLVR!0/V9"74YH';/!3A*]%:ZZZCNL--?P$"*F:S6)^AG?@
M8!.]K5Y=3(:0"9IRTGAY].5H;,U6,R8M*2>1*CMJ-+BPUZ:=QU-Q?%5Y0@B>
M0Y@Z]/B.!XZ5Q8R(!($P-?+4Z\>/#KCT=8]N^FJ;:=/:\]<5PDJF(IQM=7MY
M_2W(%YW[=[4'[5SP/WS];8[,IB8)2-=R-JT/Z\J6YQ)4$I%0" = :1]F+>2[
MK<D_D1W']??@<M*&1-=9]#KRZQ8@1$$>? G?;X;0+7/Z.JTGC_P-VO\ Y8>&
MEK;7.<Z*._?7Z.);J#[S=_\ \>SK3_.)^XWMFXT?^1\6@R/V9?IG7_U9T<!R
M'&MOT]J^\?/\-,=P#(!XB;?-UOF'LK>PK*T96XZ)=%J\5UA$EN32Y\=R,XRN
M2W(0]$=;6PN.W$J#CZ'4J+:F6X$U;J5%"8DE2@RM65N._I0Y,K%#A<4<SRA!
M9I%7'#RE4F&DMPJI&31GI_:)D41V%2:G%@6D)13Y\VD4],Y"%EAMQ#0>=Z#M
MIBEV?]E6!82A%Y%YN&*XQ>'EKN[J+JI%[O5P+88O*@&GEC(KO4(45-DC.!F%
ML'V48)?+K_: Q_'W%W-5RQ3 L$N=W;:O;#E^2]<<.Q8/&\W)*B_=VE=ZGN77
M4I2\ >[) -N<Z) M96FO7X[W\^_7S&/G8H3N!6M#QK7G]Z6^Y0H'?R.OWO9T
MB1U"NFQU\;_/? %' \P/I/T-?G8PHUK-(.M.1TKK9RB1;< _"UN_W>'YX$I(
MU$?&G&G4;>>UG"BFFA_J:[\(WI-=+.$.I.@4;G8=V][W!T\M\,1'W^@TWTKM
M:8.&@$'UGF3R'QTLX2\I-M?/4'\S\_=UPWW^5I X":>L_.#3XTFSA,H7U))T
MU/X'O&WCAH$DQ4T-I JE(^$@]1OYV<H?!TOK8G>WN[]]!@2@5IQ-*'I%1YCT
ML04>/#73J3(/&E19PEX=;>-]]?';KW;=+8 I( /&-:$3M]^EC"O77PF?E4>D
M<[&2X-P2">H-OGW?"^HZX$TM(%DZP1S'W\=+9/$SEFF%1'<N1:_5&:$^*HEV
ME-REB(IJM4^32ZO'Y"%%,6IP9<AJ=$0I,62ISUAUI<E*74V$7N\H:[E#SB6O
M'X H@#O$E*P-P%))"DSE))5&:MJ#N%89>+U[X]=&%7G]R>]4B5%5W6EQE9T2
M5-*0DH6H9T@9 H(\)R%OBKG\/%]6<*VMU0I@6Y(?;D+=31YS]5IZ7U/M/=NA
MFK2I-8<0]SHE5EYRKRP_45&5B48C?A'^4N?PS4$G(<R021)A?C,SF7*U J)-
MJW]V\#B/V;=\H[TC*( +R$M.%(!&4J:0EH%-4MI2VB$#+8+'$#.$:ES*3&S3
M5V*9/;K?[0AIDE4>?_.%UB367*BT4G]H.S),2-+4[+4^\S*CLR8JV'VT.)V^
MR.*8M<^T_9IRXH=O[[7:#"G;OAR'V[L;_>3B5V<1=2^Z"TTJ]/)0T'GLS;2E
MAQ0 !MR_M&[-]G,1["]MD8HN[X3=GNQ^/W>]8TY=7;XG![FW@E^85B N=W(?
M>;PV[K=?-UNQ0[>$(4PF2L"V,U+/F;:%ERELT7,]4IS4.91I,)VF.BG.,28%
M-9B19L5<=#;\628]/@=J\VXEZ2N%#=EK>?B,N(C]IF,8T]VQ[77J]L/X+?KQ
MVKQB\7K#!>FKRO#+VJ_WI3MS-\NP2T^NZN#N%7AF$/%H.)$92)O83V3[*,>S
M?V<W"XWBZ=J<)NGLZ[-7.X8\JXWBY-8]AS>#X>F[XF,.OJUWBY-8BTHWM%SO
M)6[=$WA3"B%!<X2OB5G>5*B37LV5M<J#.IE2@N&8I'J<JBJK!I*HC:$H:CLT
MQ.8*VQ!ALM)AQHE2E0VHZ8:@RGS9>*XFI:5KO;Q4AQ#B#F "%MESNR *)" \
MZE(_"$N*2!E@#W1OLQ@#3;K3>%71*'V7F'@6Y+K=X]W[]*U*45*4Z;K=UK<4
MKO%.,I<*N\E1?Q^)V>V:D[66\X5Y%7>I<VBN5$3EF:*74,PN9NDPV7K<\=O^
M=#IK\94<LN0:JEJ;!5&?886V(Q;$@ZI\7QX.J;4R7,WB#:WC>"A)()2._)=2
M4D*2N%)((!!*[,=GE71-S5A5T]U3>&KT&.Z_=&\,747%MU66,ZA<TB[*"\R7
M&<R' M*E!4W_ )9.**V$1U9]S(J.U'JT5#2JBLH#%=FL5"JI((()F38T>0IP
MW<;4TV&'&DI"1(,<Q?*$"_WC*$K0!F!\+B@M8TDRI((_ET3 )%H1V,[*E16,
M$N.=2V'%*#9!*KNA3;!HH0&T+4 D0E68E84JMER^+_$NIM26:CG?,,UJ6DI?
M1)G*>#A6N8X^OF4@J0],=GRW:@^V4/5%YXNSG)#B6UH%>-8LZ%AR_P!X4%B%
M#.:@YIKQ45$J4(*S!420(D9['=F+NMMQG!;DVMI69"DMD92,@323(0&T=VE6
M8-!,-! )!#1^).>*+ IM*I6;<P0:31GG95,I<>HO?LR#(?9K[$EUB M:HB52
M&,U9B:?!9(>169R7 H/&U=G$\28:::9OC[;3*E+;:"R$(4H/!12@DH\0O#X-
M #WJYJHVM7SLU@%^O%XO5[PFY/WF]I2B\7A;0[YUM)NJD)6XF')0JY70I.8%
M)8;*8(DMZGFNNYA<9>K=9GU=UDJ4TY/D*D+0I42GP%%!6=+PZ53HYM_HH3 _
M<N:E[O5\OA0;T^X^4$Y2Z20)2E)CJEM H8(2+7L-PO#L(#B</N;%U0YESAA,
M!65;KB<P)F$N/O*$Z*<5QLT1+Z*UN=_X&VGE[M=Z)3&H('D?EY;?E;62X#2:
MFM:^@IO% 3RL\1*%Q95R1J-^GC^%]#WX;*>O2OZ[;V,'36M:5&AT_B GE0TL
M[1)5?4@@6T \[[;WZ;VP!2#--=]_OY[V*>!D\OE32=!\9W<HE>.VMOH7M\/S
MP!:!T)%(Y<--/ATBQ!9C8C@*\HH-QK3GSL\1)[E'7QOKX_D+G$:FB-IYI^@T
M WD\^1M(%B*_"?UI^M.+M$GI?IXZ[:ZW_#WXCR#UTF)])$]0?*QB-C\9LZ1)
MVUM:W6PW\]=>^QT\- (U!\^<>E/SLX,?>D[\M/UL];E:[W%K:Z^0TZ^1/OP)
M3.M:;\>.H]! L060(TDR8@>40?4S9VB5;O!'RTTT(OKY=>ML!DZ[;:\:S ]3
M:0.$ "10^>O23QT K'(.TR=C>XZD>>Q[O/OWZ8&/TX^E?UU&]I X#0@@GI]:
M::F3SY.VY0)L#<:VUMT[MM/(ZX#*-J'4'6T@5,Z&NXK CSCTX6=(DC8$ F^E
M[#Q[^[?KY8:"#H%<X ]#/TL6:3%1$&8FLQJ --]?.L.T23I8WU!WWZ6WL3<=
M-.F!(3N8,4I.^M->%:\=K2)6H5F@X3'4T/E( UTBU[<$7>T?XB#0?\7R/#7_
M "A9 _+KMT\^_P#9P(QV];C]E/1H?_KMPBNDF/NMO'/;FO-V3PPQ_P#:2[Z;
M_P#).,ZCC(X\+6O&58V)[Q^8O[[_ )X]M%0)W@_6WRHDP$[&!SX#ZBG.QI45
ME^/-#R;H_9M4]H:*2I5.EI;6E6Z5!TH*"-0L C46Q7<0%(5FJD(<!K'\"O#.
MH.;0[F(BEKUW>4TXTI"H5WK%8G1U!,C>@,B*@FHMH;5H#M'J<RFOW+L-]3?.
M!8.MZ*9>2#;V'FE(=1I]U8\L<8ZV6G%MG5)B>(V(Y$5%O8KK>!>F&GT$%+J0
MJ#JDZ+1202A0*3S!MBV9(]0FT.H-4E[L:F&.V@+4$J0J3'4'FV'4. H6S*Y%
M17D. H+;RCHH)4"8>6PZEQM10H'7:#J"#0I.X(((VM'?F$7N[NW=:0H* 4 2
M!XDD$09H=8(((Z2+4EEW.DO]M?SRH4=<;-M.C(I^<\I..A!S)1X2NS;7%,A:
M.6K4I2N6E3'^3G2XN@5I:0[3*HSU;;S6(,RF$OH%42#,[@B928H3,3E5.IXV
MY7B\8'>I.9=T<5E4"F"(H%&!X7$B)2") Z ;:LOY5XM94:=9?$B/*27(DMGF
M:GTR<RI3:B$N!+\*?"?2Y'E1GFTNLN(>B2F>7MV54O$TJ-]P1'D?O@;>@#W?
M$;NE:5!25C,A:3,&!41H=,R:Z012TGDJN/9:>8RCF]AR:AOVH-4*;-SF@2DN
M(/-[*T I+S2N=3:B-%(4TM<\A8!2)Y#5.]>M8I\:',R.7=PMN$C4H7_ M,T(
MI/ *!J#K(J-EJ+4Z,ZTI^FA0=90GLF77$I838VMSKN!>]R+>U[1O?$9J/C72
MAFMKR%$ZQ%3.AXU!.FVGI868:I)=@ARIQ&E!2[ML(;2IM38*@%/.W#;:;V )
M7S%-P@7-P$1).D:  :5U&TTXS%ID_BA)(BM=?3[WZ6@&ZP\[3DLPF18K(2I#
M?JT5"0"I28R;W?L25=JK0D<Y40+DA0 01QDZ?G/*FNAI:)9J0I4U$BI)@UKT
M\Z6BXM(A5-X3IJFPBGH7(7+=>48L?]Y;J2JW.M) 2' V4E7(ELJ7R@)2LHY[
M6!M)<52B4U)(/,1-()- (DVCY\U4YYM+?:")%0IB"PJZ>S:)25O.-I*@)$E2
M4*< ![)M+,8%9:+CL),S,1J9T^/"U^4H3(\( H-@-R3I-*ZC0:BE>^D92VZ)
MP+S8'P!4Y[%/C200.9MR;5Z=';B WL?5&G%J=&H[<R;%:$MXP2\J\8B@A1[I
ML'*/X3 45+K65$@#@D)'&W-W][WB2D>$*0A!XI*AXHBLQ/$".!-I?T6\J#+?
M!FE^L,A+^89DJM/(6@ ]D\MJ-%NDV)"HD&,ZDD;.; 6Q9>B3.A4 )YU)X4V,
MG3R"NQ_?)(,!"9UT*I3Y>&:S'.I%K@J#D*F)7)"&FEI'." E)!&H-P!J+#46
M/=KBLF9I0[<1SX:?I;7HI)"Q((_B ((,\1KZG?>U&YTX_5*CM/1(SZ7/94D!
MQ*5GN!)%E6VL3<DVUUQ?;"BFIFD#28^H-=X]+<W>V&$K)2D#: 2#Y#\(ZP*T
M!B@H[)G'>K9<J$B0U&#YD/J=4I7/S<ROO&]R-[]"=R2<3Y4S-0=9J=_*=^6U
MJBW%+06P*&M)IL)XB(_K:]8?I"9IS$$Q(-.<0XY9(*>=8N1:PL$V-[&QOXZ
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MMQZLE;4S,OMX(2MAE82L?XBP?PS$H360H@D%7\(TA1,95^OA"BA&NA435(V
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MJI\M12>5,J""H*/*DJ1.*04#51-C91U1R$#[Y 1;\"H_F14&#4+U&E8-:FA
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MY]V]W%-Y8-R2GO;L+J<@#CBU)?S$H"<IMQWLU[,7"Z?VAL?4WV@9O&/WK L
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MU.:K6"HA)(3=5C8X=-RO*P2&'LO\2BA02($R24T  DD<*S:RI]IL@+6VDR
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MY;G46^?\RFE%"Q04!\]SO:^*A4HU0=@-M.)4N-2HZ' D@DJEO2:D@Z=>QG-
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MSDG.<*HB#+0J%%J#:RY(B?:.--L<Q8U/:'<'SVO[7W2_XQ=[_B=W[28RU?\
M$%W%RX)OM\:Q-]%YO7NUV1>&;L+P\E;@8;6MMK.&TDI2",GV*X@A/LV]FV+8
M/V5Q##,!OO87LO>\'P>[XS=,67A>&7GL_<W;AAYON(OX?>+][G=5ML*O;[33
MMY4WWSB0XLA5I\*<X\#,HY5@KDY\X(<5$'.[F8859H]3F5:C3ZE1*>F#$H<I
M68*30S%:@-SI4YZ'7J*]3)*I\=T-O*"5(\TO;;MP<0V#=[P2E*P6L[P"E**
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M \1TF*3UX?+6S +(M?33<>_N_7],'K-)KH=-M*:?6T@61._7C^7+;YD#F_M
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M1DRV9=)YI$A,^*EEQMN4ZTH(C32[#*EN,K5@74%K+XFW,PG]TO/$&"%0!!W
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MB^W D%V0CAE!+@L\ E'^5CA9S7"W%(3913;V02;VMK?N/9X"<9O@,R<*=B0
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M#:Q@@Q"HUX$GUD\^GP(%@[BU^M_K3Q_C@"@UBL?'[^]K."H'2-8,@_"SIAP
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MMH0%>)P$3EREPB9J ?'7$ JR7D )8#BRAT%#F<F%AYQS(X6VR"3WA4EH*&4
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MEOLL!#,%B-#IXI[3K,J1&4PRE,8^;]HVUW@7AQ=VO-W?8=2IH!#CC+EV4VE
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MNEW>5=[RTM+K#R6W%*:?9(<;6$N-D+ -O,/:QAG:#LI[+O:7V@:;PUR\X%V
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M '/7F\AQ2B52#(H)$_?#AZD\KWAQ.1)0RT.[802/"V)(*@D56LYEN'=1C\,
M;"4^>P\\RS["EE+B246M87-['8VN"1I:PMIBFI:01&8 A)!Y[TC\S6:6)+9
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M7 XE4>2A;83SI7$F-K2%0Y26B]QO%9;TJ" HCC_+!V-#N#P)C_OM@,P7G?\
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M+=L25>$N=QB.&7O(""+O>+O>,IFF;N5+RG6BHWI-;>D1J,6;*746K6%WU/\
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M>VL=DFUO$6VZ6TMM?K<8B=4%+RUI374Q2)XGE3UMS"9_&"),D4WF=9J#&_\
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M,F:@5^GWK;"3H.@^5A V-QA!9K-:=/E9[7SZ+CBCZ3'H[)))!XY\)1:P&O\
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MD/-.K;2XM S*00/&%F4DJC*5(@J2D9IU.'B=Y60REA\]PZRVXMMMP=VEQ,^
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M_P"6=_Z:L=6*A()!J?#OOS_+SI;"3H.@^5@X<DJD =9B9KSY;<+/:]O1;_\
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M7X\;M]:6]A65O85E8\EX/.)6E)0$QXC-BHJ)5'B,QUJN=;+6TI8%SRA7*+
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M2O7SLZ8-^;6_W;?/;#03H";"N*1%9/RMR%D?YP__ ,L[_P!-6.K2*3!&L&8
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M=/42=-8D196D&XW>.FFG\#?Y_J669DP*:4]=9]396?-Q@+::V\^[RT]]O#!
M :#SWLK-ZQ"7)HU6BL\G;2*9/8:YEI;1VCL5U""MQ9"6T\Z@5+40E(U)L--S
MLS>V+AVD[/WV\YO=[GCF$WI_(VIU99N]_N[SH0T@*6ZONT*RMH25+,)2"2!;
MENW-PO.*]B>V&%W,MB^8EV6[07"Z%YY%W9%YOF$WN[L%V\.J2TPWWKB,[SBD
MH:3*UJ"4DA65::_"RW0(4D(]8B4:EQG^R<0\WVS$)EISD>;*D.I"TGE6E10L
M64E12;XL]M+_ '?$^U_:C$KF'/=,0[0XQ?+L7FEL.^[WK$+P\UWC#B4NLN=V
ML9VW$H4VJ4J ((MG>R_"K[@/LV[ 8)B7='$,([&=FL,OQN]X:O;'OEQP>YW:
M\]S>V5K9O+9>;7W;[2UMO)AQ"U)4"<K:B^&W?IT_AO\ ,[8YF-S4CC^H \_C
M;N9)FGK0_ GY#SL_:B['EO;SZVZ_X]-=L/,;'SD_&OPD;<+*!0@>E-?@=M;/
MFX]@+B^^GT?'7>WAT:I-?3AY3OYQ&TT8J W\A6>%=N?W+Q#%@- -/E[M?R^6
M'@?TX<.G#2*<+1E9VI\?CKUXV<H:'07UWV%_(;_/#V&SIN.5;[=UB/,#QVM>
MWPW?3KY'U^SMH;,3'/Z<SRIK9ZW&M;N[AO;YVOUVUPN)CSV^&_W%G!/0Q6/E
M9ZW'L18>\7U]Y\^XX510TZ_<B?+::6:E9TYZ?>]GC<?;3Y?KJ1?O(PX'QCKQ
MVT)' *IKH;*>%?EZ_?RL];C>%O#ZT'G;WX5!I6=^72:SP)Z@#5B1%2#TTZ&I
MGC&\:&SU$<#?4WV O^OGU]QOA2HZ?T_+X4H28L!63I0??W^8L\1')Z<H\KGX
M;_/IA\NY/E4<*Z3OP\[#4_<>NTZ_&SQN..B3U&NI/Y"_T-<-(VK\!RH*R*BI
M/&;.8',SMI'"=;/6XXZC7;J3^734[>6V' 4J/AIMTX<@8DZ5LTG38[#R_363
M\9>(8)V Z;ZV]UNO=\M+8D2V*'4B"=3!FG([4U/"S6>MQO#QOUV\_P!/+$E!
MZ^8]"#Y'+_L\%9ZW& &H'Y'QM\.[S.&@G:/+IPH-N%-2:FS%0&I\OOZV=H9V
MTW\!^%];_IAX2G4R9T^D?G^<C*E1% =]=/3[Y6>-QR;&WEL-?+_&WGABK@ .
MFMG"0*FL5D_$_<VJGTCWT4KT:N/,IU"EI<R+38'*DB_-5.(61Z8VHG^PVY*2
MXL"W,A*D_O8,?X5Y).K!%3Q=: FLZ\K0J&>_8. 8_P"4<P)__!W*^K,;U"2-
M-8VM^?,.["X)\CY]^WQQG))E(FE=/,[B?OC-NQ!@[@;P;%#@Z$CQZ?(F^"$F
MIWT'#F#KSL0D@3"HVDS7[WL5+IZ&_EH?RZ^&%']#4=:U]#RXV8T$'-.VX\OT
M_2Q4O6L;^[7KOK;YX$@&1%=#40.-)^$">1LH5 H8//7F:V,'+VO>^ECOY?5C
M@2FE((%.$1.L\/L6<*BA C0T-=CY^G/:Q.8&YTO?H2%#Y'RUL=/ 81%0-.NG
MK%B!$@ GI2*#CY3209ZV,VLA0UND$7!/M#W_ %I@%4!\ZQ(.U-C9RJ*:&*'4
M?3Y?"SYMVY!&^MQY7M;4V(WON<!$#0F8(I/"0K37[J!8"JA%3I!-==0?B/Z6
MDV74D65[6_N_0;>.^AO@9@R-)W^NOD:^H-ADZ^?W--[9%EV<FCU>-5H[;?K+
M"[DVLE8N+A8!%[D:*/M#36P(PSC25C0B1-(YF(GG)VX5M8:O;C)29S $0E6F
MD&H@C:ID"!;>/(G&>B3FPQ4'#39*F2V>W4D,%5DJ]B1H@ J2 "Z&KD@)!.F(
M4,K;4?XDF0".M#QKI&E:$VK8@XB\L^ $*"DG*14Z@@30B53L>51:EJOQ%J3\
MR08RPEHN+Y%(N3RE:K$%1(-Q;=.G3PE3=FP2HU)J9X]=8^]A;/"3ET$;\)WI
MP^7E;$WZY,GK)D/.+).RU7T)%[#SZ#W;XG2D 4 $:@?TTUK\I$JE-?OSKYV2
MESK?>U]=_+?R!UT[L*"">'#<'[U_K96<!8.QU&H!^K?X8?6RLOG('B3N?P'U
M[L#E@TH(T''CK7SLK+#@M8Z?A]?5\(YMH(]#\X^]+*R^8Z6/EK^&%G&X(TFE
M/OA2SR>)];&2\K8V/B=/PPX(,P9BSR3$P>I_4 ?";&2\DGJD_P".UC?Y8>S@
M Z$B.,<^8VUZV7VFALJWNOOX$?'YX8U!_K9 P?Q2-_CI7?B#O6SF*ZL\]R#;
ME TZ>UY:8$!8G\/I\:#];.I41'U'R(^MN2LC_.'_ /EG?^FK'3),G@(,@::'
M4:6RAH.@L'""?%28K733GIYV>V9<.LYS.''$'(O$.GPXU1J&1,XY9SE!@35.
MIASIF6*U"K<:)+6PI#Z8TE^"AE]3*T.AI:RVI*[$.E10M)C\*I$TF#N=_N(M
M#>&4WB[OW=1*4OLNLE28E*74*02 :2 J1-)MUA/\LIQ./_>2X:D]_P"V<X?A
M^TOS]V+@OBJDI1&D@J-?32W'?W(NE9OMY/\ NM_'P'T^-O?^G)\3K?\ :3X:
MW_\ ;C-]OC^T_P L/[XK^5 !TDF?2EF_N1=/^F7G_A:)^*0/E;Y_Z<GQ._\
M62X:_P#EC.'_ -T\+WQ4U2B.I!TI&Q^_)?W(NE/\MO//PM4_[MO?^G*<3O\
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M_:Z;V\_&V'DZ^+_=2(^-?E8E$<3_ +IWWFNFD>=N4LC_ #A__EG?^FK'3A,
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MW^6% X#TLI/$^IM]##-A]BUL/]&C],*!P'H+*3Q/J;)6RR!HRT-?[M'CX84
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MF'V3?7]Q/<?#!'ZCYBS6*&62!=ILZ#=M)_+$*B9-=S\[/)XGU-OO8M?W3?\
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BF)@FNFMO,-M^W]FC]W]U/^MX8*!)H-!L.)M)F5Q/J;?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g209588g84p49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209588g84p49.jpg
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M='9W@X25U-8X6&1G:'6%AH>7HJ.DIK.VQM/B_\0 '0$  00# 0$
M     @ ! P0%!@<("?_$ '$1  $# @0#!08#! ,("@L$&P$" Q$$(0 %,4$&
M$E$387&!D0<4(J&Q\#+!T14CX?$60E((%R0S4V)RDC0U-D-$5(*3M+4E)B<W
M155C<Z+2U!A&5F1U=I2RMM/B.&9GA)6CI+/"Y$=E=(.%AJ6FP\3_V@ , P$
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MB.69AP^_FK]0MM_WY%2T[7H2AIU-2*=+!%*U*5TRW)4N'1*0G<3>UX8OH_\
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MA^@?J74L5+C327:IKL4M%]SFIU9>F60EQ;CC817E:E*',$T[A/(E14UK+/M
MSRBRVE579;3U=6[2Y74BM76(H:8M9BUQ"L"L6ZQ3T]-4+>R$,-H0KLRYF#"4
M=H\VEJJP=N4\-^!-Y^[7>6Y,K%7;Q!A'>E*H4+>)08+DW#M(PC2MW>/\0/8B
MQC3JE6:2FB8'F5C#U&;FUYR [4Z>]4Z?"2XB1);IE1QU!E--54M45+7VC-6I
M":EM',VAE--4.%QY*UH[.G4MM +A25(*@F9/*K8<]XJS+*<TRH(::--692E]
M>6U#J6ZIZM>S/+:9--1.-,O=OF"&*I\HIPZ&G4M.N$%*"ZUFJE?1Z8:FU+!U
M)E[R<6P:GB7"==GOTI6"%RY+&(:%4=V\5];52I4JI4(89DP-X!JD/$9J+V"%
MMTE")N\*G1*BNI4ZXGA=E2V4&J>2MUEQ11[N5$.MKI4F%)*V^R4FIYTNE98(
M0.:I0E?.C"N^TZK;9KGDY71NLTE93-![]H)0E5-4-9HM(+3R&JCWI+F6]BNE
M[(9@"^5(RUQ;09>UTWN>&O#^['=ON@QC%WEHJ]5WC'"Z:BU(H-0BX4AC$F&8
M>(:A)H>,F$2J!7(^ IDO]E<9HIU0J#\6MMJLB,IN3"C8FMRAJDI:%\586NK[
M$*!;4&4]JTEU2FWP"VX*92@R^$*44N=(*1M>2<6U.;9IG="O*E4[.5^]]DH5
M+2ZQPTE6NF:344*BBIIU9BV@UE 76FTKISJL%#B\YXT\,&Z3<S@K?A6\0S\2
M8OKU#W=5Y. J7BFFC"LEBLP=\&!-VM/WL4ZGX<QQQUK!F+H6+%UK=O*F2ZA2
M)D2!B";/I>)(E+IZJE?J,GHJ!C,''5.O.-TKONR'D=B0XFNIJ1-:E+50.T8>
M2]STI4I2%)2ZI2'4H2%X'+^,,[SVOX>8I6Z6AIJC-*?]I.T;IK$+8=R/,<U=
MR5UVJR^&*ZB<H@QFJ&T-/MK=ID-/4JWG.R><#^%S<?C#=QNV>DS\:8?K^\^#
MX?:93<:.LQ*A3(>,MXF)M^&',5HB0W*]2Z9*P]3)N$L-_704W)JU)BTZ&RPB
M+,KLY])4^39<_2TBBIYIVL&6(34D)6A%15/9@R] [5"5-(4RSV@/[Q 0 GE+
MBB(J_C/B*AS3-4I;H*FFRASB5YV@"G&77*#+*/A^KHRMQ-,\\BJ=;K:HL0I#
M#[CKBU<[=.VDX2WE>&?#6 J9N$EP=X\FN2-[LO"D6HJ5A>IT^D1X^),/8+KT
MBL82KTI"*-B>F4*7BN5AJJ>ZSG7(]6HUY:X4N5/HU"QM;DS-,G+BFI+BJY3*
M5'L5H0 \VPXIQEQ0"'4-%XLN?$2'&Y)2I2FVMCRCC"LS)[B1#F5IITY(BL6T
M/?&G7EJI*K,*9+-;3(*JBC=J44:*MGF:2%,OP@.-MMU%1EIKP9[K:C2IU;IF
M^7$K5,B;VT[LO>I.[N35/8JIV\/!V[NKIJ*\/3ZE2J=B2J#$%9QMA+#TFM-R
MZMANC08K#<V;5I4BCW?Z/T:T*<17O! KO=.8TJE?AJF*5PK#3BD)=6'7*AEI
M3@4IEM*0%*45-X<^T#.&GVZ=[(:13J\D.;\B,U0SS!W*J[-&.R]Z::>>I6O=
MJ?+ZVJ33E#%6^ZM10VPA#Y\0>!K"U!I.]*IS-[$FF+P4Q$D4N/.PI5I0@-/X
M$I^,8LC> 8<1%3P1!Q+49KF$\-/XNHV$YYGQ79E4I,4@T_87N'6FD5BU5RD&
MG"5("F5K"0:5-0E54$I*Z=+RU%EDOML*YDE:VT1RA4OM'K:E_)FF\D0\,P6M
M+RVZUELN*3F3M"M.6=HLM9B[2,MBMJTT%17-]FM+;+ZY#N)OA'P9;LH.-JOA
M2OC>/5I=,W@[G*'3Y.*:'2Z)A^JX3Q-O>KF <1X[7!PKCU>(G]W6(:?3*7,P
M_B!51PXX$UMEJF5&H,R*?B%VRUP_2)J%L."J4I%50-H4\TVVTMAZO=I7J@I8
MJNU52/)2A33G.R?W@"5*"D.FA6^T#-W,O8KJ8Y4PA[*\_J7$4=2]453%=29%
M3YG29:':S+!2IS:D>>>14TP:JDS3*+S32DNT@QI!\(6"DX/H6+JQO'Q'"I[^
M W<;S9C6&**NEXO91N!QAONJ<3=7,>Q.TO$2L"5'"S.[''BZHU3!3,7UJ R?
M=GU*IXH)R!@LM/KJW4I53&I4KL$<CX&6/YDL49[8=J*9;(HJDJY.2H=0/A,H
M&:7QYF'O]31,932N.IS).7MH-;4!ZB5_2B@X=:<SI":(^Z#,V:U6<9:&2\7:
M"F=5"TPZ=4]\6"Z?NTWDXEP91ZR_7J52E4J13*K)C,1)<JGUJATVO0T3(\65
M,CMS8K%31#F>[R7652H[JVRE"DH3@LPI&Z2K=IT++J$%)0L@)44N-H=3S!*E
M * 6$JA1!4"0;P-XR#-'<VRFDKWZ=-*^\'DO,H6IQM#M/4.TSA;6MM"RTXID
MN-A2$J#:@#*KXQPE\^?ZYW%^7ZUVI% _EY]\>%MNAQFN<=3Z^/0GOL;WTO@R
M'Q<7N!?GSO?OH!;/.UN=\@*#-KC;2?R^6)$N:7G<C>+:]_Y]<*DN@=KY:W&?
M33MI?3MM&1>]H(\;=?F-]=L2!8/R\;]W=W3@P=(YCXV-OU\-D1/SZ6TN#M'W
MI@I\.[[WP9+PY]M3IK?/GZ]A>YV#D[_E/A<::B?,Z8/G/=YR1U&YCRMZ8.E[
M3EKGI\^O7UO<[ 4D=_>-,$%3N09'?XP-8\"2-;#&]S;E_HVWE7!_]><T,^7_
M *C*^>5_/\=MH_\ >6?_ )91_P!6G',)(]LZ=9_O;J%M_P#MD&GW\L:/)=&6
M9'S&>>77+/(;:J1/\;CTQU,+G7<1&AL8OO\ ?E@Z7CU^!\^1\^>A)V8H![O#
MRV^^IP05H)(CKX?.-A%X M?"A+Y_#YY6!].>5]@*"-(/RP?-$3\KC2=B?XZB
MTXS_ +A-T\'>]5,4PY<S$JEX<H-/J\?#^":13:[C'$"JABB@X<D*I-,J]9H,
M!4+#T2M/XDKTI^H-M1*73'E27(,)<JKTW*Y1E:<R=J$+4_+#*'4LTK3;U2]S
MU#+)[)#CK*"AE+A?>45@);:/,4)YG6]4XMXD<X<IZ!UINB K:MZF769I4O4F
M6T?8T%76I%2_3TU6\':QRF314C:&5%RH?0$!UWLJ9_96)X6]WN'<+4;%%7Q@
M_BQW$&ZG%V*6:8NEU2BTA-:9W9/XRI[]"Q/3ICM$K;^#*R6,-8HID2L51L5Y
M)8>1[-,F&SFT\-T+%,U4.U1J5/9;5/I06EMMAT9>JJ;+-0@EIXTKL4]0VEUP
M=L2DBQ2-*<]H.<UE?4T%-ER<N31\0Y=0+?34,550:56>(RQY-70O-IJ:5.9T
MW-6T#[E.P?=#SI,E#BF'Q#>&_"& ,-8WWB8-KDXTJG;Y\=8+B8<?A2FZ71Z+
M3-X>/\,T2GTW$=7?(Q7*CTK"]*F.O4FI5RJ(;GR_K^G4A$%BIU>MGG#]-0T]
M774;JRVC-:NE33J0H-M--UM;3LH;?<435*#=.VLEM;JP%J[9MH(#KM_@SCK,
M<XKLJR7-*5KWA[AC*LR<KD.M%^IJG\FR>NJGWJ*G;_['MKJ*^H:2E]BE8)9;
M]S>J2\IBFD-9\)&"<+T5W$&(\<XTIM.IF$W\4R6'\*41B9BJ,W@7!^-%/8!,
MC$B&JK3($O$[N%*Q49193!K#$=7LG'U2J;%F>X8I&&C4/5=6A#=,:E0-,TE=
M2D4=-5$T7-4!+C;:Z@T[KBH"'4ID$E3::E+[1\UKJI-'0Y5ECSU1F"*!M2<P
MJEMY>M6;9EE@3G 10E5.^\W0IS"F9;YNUIUK^)*0V^Y)8'@FP=*Q)AS#K6]6
MM3I%<PE-K;7U?@2MN1ZB_&DX!88K%#JAC.TV9@^H(QC5%PJ\754-I_"KS%;Q
M%0V*H9E*F3PC2+?88&8NK4]3*>!11.E+BDJH0EQET)[-=*Z*MPH?GL4JIBEY
M]D.<[-5WVKYHW0UM:KA^E912YBU2J#^<4@6PAQ&<+735;!6*AO,F#EC"7:3E
M%4I&8H52T56NF[.IBZ_"E@NEX2POB>L[T*BL5+ ^(\:59BCX8]\A2$T'=S7,
M>RZ5A3$+\YC#%:FT.92&L'8A;C5R4N/7)[;B&VVV'HQJ'ABD;IJ:H=S!P]I1
MOU;J6J?F2KL:%ZL6U2O*4*=U;*VA2O@/*Y75@P DIQE$^TG-7\QS#+Z;(&$]
MAFM#E=,Y55_9NM^^9U29.W49A1H:77TK54W4JS2B*Z5L+I&"DE16E>&S>-N'
MP'@5S=/#HU0KN(58BWNU[!V):_4HS3%!<I;4C!4VA0'D4JJ!<"IHH>(E/38[
M-08D2UFH2(TMB/'AN(AS#(J*C.6(:6\^:C-'J2H><0$L%H*HULH4&W90L,U$
MK2%I*R7"E:0$'%K(N-,XS9/$;M2S24(HN&Z3-*"B8<*ZP5*F\U:JWDFHIPEZ
MG-91<K2UL+0TD,)<:<6MU);-[.XG!V#<)XAQ+1,6SY58I+]#JCM!^K8K=#:H
M^)\;;Q,)1:?3*@Y7JC6'I5+."8\U:YS3Q<B5-+3K[CS(ER8,TR.CI*9^H:J5
MJ>;4RZ6.R2EE+535U],EMMSMW'E+:]S2LE85*7(*B1S*O<,\:9IFN94.7U>7
M,HI:E-93IK.W<-8JJR_*<DS);U0PFC8I4-U'[5<: 94GE<IRH(2A?(C+V+?#
MIN@;PPM-#J&*L/UF11:YBO#=9K#4>7"K=.PUX9\,;XY;$O\ QNU&12*I6$UZ
MFPJG2:?+DMUF>_"*G(=%:AR,C5\.Y2*4]BNI8>4R]4T[SH"D/-T_#M/FRDKE
MT)#3CP?:0ZRVHAYPHNAD(5K65\>\4*S%*JQK+JZC354>75U+2J6V[2OU_'V8
M<+MN-?X*IPU5/2FB?=IZEYI"J9E#L!VK4ZB/5/PWX#P)X@MS&[JIXJE8VPUC
M3$@IV(E2J15,*(D4V)7%4KZ\HM1<?@LU'#&)V$+GT"KTJJ.1ELM/!NJR6 Q/
MD5G>'**AS[**!RI56TU74=G4!33E-S-I?+0>9<YFPNFJ4CG8=:=*8"H<4F%J
MR5-[0,ZSC@GBO/:?+D937Y50%^@Y*JGS(H?=I!4>Z5=.$/*9S#+UD,UM+4TZ
M7 M2)ID+YV4+T^$.C*H>+ZTYBO%='51,!?M=&I=;PQ :JE$J\3!E=QC,PGC>
M%"K$QR@U69#HK3E(=J(I$*3!JL1UB5-J;4BC)?\ HBR6*MXU52UV-#[VEI^F
M;#C#J*1^K72UJ$/+++JTL@M%P,H4AU!"UNI+.!_OJ5B:O*Z09;EM7[WG/[,=
MJ*3,'E4U73.9K1Y4UF64.NTK2:RG:>JE"I2Q[T\V[3.I6VS3J158DDSP685B
M5W$$%S>C5HU+IF%Z76Z?(?P95':R\U4:OBVF2,25/#++*<2TK"%%:PQ$E5BH
M5"C0XJ'*]$9I]7J,%N+5ZG,YP72)?J$',74--TS3[:C1NEXAQVK;-2Y3)3[P
MW1M)IDJ>6ME"07TAMU:$I>=I,^U[,W*.B>'#M,Y4U&8U%(^A&:TR:1!8I<KJ
M$4%/F"UF@J<TJU9@ZW2L,U3KI31.*?I6'E.4U/A+=AN.H&,]V=1WA5C%%9@-
MT^5C+WX4FDT^91</QL%T?#]:CP<55695H;U+K6\=59D8?W?1VX3K$^NT]3:G
M9*5S$4[!Y=D--69<Y7NU+S8;56<_8M-K9ITT;+#R453JW4*:>S'ME,9>D(*7
M'V^65 K[/<>(>-*[*>(&,CI,NI'R^WE78FIJGVJNN<S:JKJ1Q[+:9JF=14T>
M0"D;K<\67D+9HWPH);(:4_F6E[H-SN)-_&_O"L*A5F/AG=UO(P9AC#%#I$^H
M28OU SO;H6[_ !A4JO.FURI5IV&_!6_*D59FIH:BMU*34V(](2W3J?$R[>2Y
M/49[GM*BG>32Y?F-'34S#+CBD]@G-J>@K'7EN/N/%"D%2E.I= 0EU;J4M<K;
M:-6J>+.+,OX+X*S)VMI',QSW(,VS',:VJ88;=]]7PQ6YWE=/2LLT=/2)=0\$
M-(IETY4ZJG;IUN57,^^Z'_!9W?5BF8@Q31]Y%6@41K#,C$5+IC^%Y%5J=(+.
M)M\>'9,K$+5"F5MR%A6%+W4,(56G5A+#>+::F?+1,C16*]&>%,O>;J*MG,7F
MV!3*J&FE4JG7&>6ISBG4JH##CY12H7E(';*,)%6T%KYTI342_P!\S/:.HH<N
MJL@IGZQ>8HH*FI;S-%-357-E_"M>VW0JK&J-+V9O-<3+*:1"25JRNH++1:<<
M718^W3[B<';P*#@N94\9UNFU_%SF\B2Q1*90FJL78&[JF0I:J=3&XDB56JGB
M+$,JJ16Z? A422IF%#JDM"*A);C0'<;E604>8,42W*U]NHJSF2@PTP'26\N:
M;7V;00M3SE34+=0&T(87#:'E .*"6SL'$O'.;9'6YLS3Y31U%%E:>'VUUE16
MKI>1[/ZAUH/U*G6VZ.GH*%JF=4^^]6("GGJ9M2F&U./HRA%\'^%I;%'?A[TI
M+L:5O'K&"Y]6DX6F4F$(U-K^+J1#9I;%4<C?6V)*NSARGJC42D3JI5(=5K#E
M-J=)A1($>L5;))X-I7$M%.:*4A>9/43CJJ5;2 AI^K90&DN%';5+PIFRAAI;
MKJ77RVXTAMM#SV <]K69-+JT.\--H<:X?I,W8I49FU5/%RHHLJJG5U*Z9+GN
MN74J\P?#E;5,TM,]2TB:BFJG77UTE-XCPNX+I53BNU#%&,\04%&/*!AZMRJ5
MAF#16,'P9BMVKTZEX_D8IJ]"J.'<02OVZJE,I335(D/2Y6%Y,J'39;,B8W1(
MOZ)T+3R"Y55M13^_T].^IJF;811-K.6%;68JJGF'::H7[^\TR TI2U4JEH;6
ME;@8E_OFYQ44SJ6,MR>AKCDE=74;=5F+U8O-7FAQ$EFIR-O+:2M8S"@;_8E-
M4U2EU32&FLR;:=J&E(:56/0\+F$*Y4J="C56N8:2$J@3H+-&]^KU#:J6^??9
M@O\ ;G'\>L8G98I6$L#43=_1!C&H4QN"U$CU>BJ=B)ENRZM5)/Z)4=0ZVA+M
M12B"VXA+ <?IP[G>>4/[0S%+U4E+-'E[&7L>^K92@(2\Q* LK>=K?WSLUHJ9
M]YREH\Q,A]EY=86:*M53\(<'9O\ L7(5TN6*759KG=;GM8<IIZE3ZG7*6L"7
MNQ2S2TV#-YNZ'#6"<%4S$5'Q9.K54+F[5FMP)%.A1:>AW>-NKI^\EA5'F,5*
M1)E,T<OR:3+7,A1%NNJ9(;94TX'<!FN2TM!0M53%8X^].6)?;4TA#8.9Y2WF
M:2PM+BEK2SS*96I;;94J/A24D'>.&^+LQSK.:C+JS*V**E">(ET3Z*AYU\HX
M?XFJ.'EIK&ETS;;3E6$-U308>>"4A<J7S)Y=?PZ>HRZ\O4:]\SMK9&LS\_H>
MHUMOC?YM)!\KW[S^(;#6\=,'2[I<_'.W>^7W[ 4 [1X&/R(Z?>K\]M(OXZ^8
M[\*$NY#/EH>7K]V=OEL!01._Y^6""@8U]-//U].N#)<MU'S'P_GL."P5+IMK
M?R-OE\/CSRV6"YSW?._C!OI@P>'/YY?P_7Q6#"QO/G'Y?I^0Q]@^WN#'QZQ6
MRPL5LL+%;+"Q6RPL5LL+%;+"QS/\/#3@WI8#9;E8"9KT*-B88VQY1*_OKEU'
M?BIG#]3B5-^).QKNPPQ@7&(:Q0Y Q4XN@XMKGU)%ISR:1Q4U+I,BOP[G2!"1
MR^BB1T$@3B-,2(/6;F]O "V-5_IN5<.ZN,>?[+Y>?[=X5[C;7N)O]HZ[PI_^
ME,8Z-[*K<?\ #YO9>8Z1_P"*,PZ]-?UQ\GR7B.=OG<>>I\OPO;D10#M'A]Q\
ML>U >A!MX$F^WITW.%*7^O8WO\-//(VT'?("@CO^7U\O7#SY3>_IX>6N%*7A
MU^X'TME;\>>FP8?!TO=?UY'\_(;+"P9+HL#>WS'GEKZ_AL!3O<'_ #>O72?O
MSP049F>O0:[QN<&2[K^'\^^7GLW*K>#\SUW!UM-KVVP07K-CW=WC:>G7?!@\
M-;CMR/Z[C^06DZCNB8^8WM_'!A0O?Q!_,'QWTP4.]R,AW'+37XVV:-=#OWZ=
M/"QB8@S;!<Y\?S\Q>+^ \,&2];F+7Y'+3I_'[MF*3??J#/7K>/(?E!!=KS,B
MXCQC:+>.N#)>SU ^77D=?PV HZ3/C( ^1T[CTQ("+7_/UB0)PH2]WY\C;Y'7
M82DZ"^MQY;=TX<7^_P!,*$O^G/ID/D?CL.%@Z'^^7GUMROGK89<M>JPL&#W7
MYY?=U'ZZK"P=+@RLKTY:_#SMWSY[,1(C#@QI@Z7C8>F8S'/]97.S%()]9\>O
M\[;]9<*(&I[M_*^GE\[0=#PZ_H=M0--/PVC*#_.TZ;Z>4S@PL;]^GW^NNHOA
M0E[^61RN?A^M-F(C]=O+3SN>HP0(ZB?3[\-1O@Z7M.7KY\CRS/7UV;!29G7>
M]^GZ#!TO=["_SY9']'TV1'4>N'YOI$G:]S8 _.==9P=+P)%]?GT\K]+'+ELT
M6@6^_L=VV"YO,29&VU]) W-C.\R<'2Z+?F;?PMY?C8 4F!$ @1()'7Z]>O=<
M%-SJ8M8 ]-8TB^T6ZC! YG?3H=?Y\_RV4F(,>!M(\= ;BVHPX(.F"AP]CYC^
M7K\.NR^$:RF#UF8\CI]#WX<'I]S^1^>+PZ1V\L_D>??Y;* 9A0/6;7@W%K?P
MUMAY/WY?H/#"E#^8SY@:VZ#H+#0>I]0*)U'A,=+F3;ROI)TN25$3&NHGKXR/
MUZF!A0E^]SKI\N0'*^>H[[1EOH+@WW_/87[X/D:5F-QWQ8Q)[](VN#A0E[O?
M]=+Y9=Q?.^T9208U,=+6])[_ "W.) O2_4=9B?#3QN-\&2[S^[IY>8T_+-B-
MC\]<2<P.D^%IZ[GI>=._&^33I_U-9TW_ /:T6A?L=S"SI;EMLQ'_ &F$C?B0
M;D:9:=YW%OGCF,_]V1/?[.5?_1$.[2W\8QHVE\<[]=;6_,V[YY=#MJA1'>/F
M?" 8\\=2"M9O,:B?4DB/F/#!DO?=E<Y=C?6_/7[AL,'IZ?GT\XP7-I!C303K
MM!L (BT_,R</>O3X];CSN?CLV#"CW3W:B!TUUD=]K8.EWI<>?/SO:W2_?EGL
MOLX+GF)()VT!'@1O_ WP8.GKT_=-_0BYUT[#8"D=/3:POK)B-._3!A6EXC8F
MQUWBVMY%X&#)D$ 9ZWRUZ=N?++KGL)08D'UM]^<8.;FTW'3S]-]3?#]6<1U?
M$E1<J]>J,FJ5-YB!%=FS'/:2%QZ7 C4NG,J6?WD1*?"B0V!_<88;1_=V)YQU
M]PN/K4XX4H05KNHI;0EI FUDMH2D1L!BO24M+1,)IZ-ENG80MUP--@)0E;[K
ME0\J!8%QYUQQ1W6M1UG#>EZ_,?+[QS(U'?2VT'*!I/S(W(D=!MW[SBS,]_SP
M=+O.Y^_X&QV:^G+Y@QK?2?SOYX>?L@&==?OZ#!DO:=/.X^'<CKZ[-;<W[_A(
M/^EU (M>^'GRZQ>;;@V^D8,V^;VR%]=<N5^FN7W]DH6O)(WM!W(M>!<QX@'3
M#@D&U^X3)'6-)B-+_/"E#W3G_(7OZYZ=MA( ,3'6;B=XCRCYQ@TKZ^(ML)OW
MD7TD>-X.'1ZY6L?SN;Y$]>VPE.Y'G'2-_3NQ(E8O$:6$FW6TV\=0<&#O<>OY
M_P 3LT6@WZ2)_G]]Y)\UID>!$>AF/J?H#AW3._(@]^9_.YML)2#%HZQU.\3H
M-X]<%S ;P?3['?@Z7^N8R[^?Y\SEZ$.0[0? Z>.F'!Z;[C^&"AU)YVO^6??K
MRTV$CJ.[]?RP860+WZ=?I]?G@H6>1![?K/MLQ .OWK^N#"@=;?3R.AP9+N>?
M?7/+SU\A^>PE \/U\\%(.AG!DO6'7,]#]UL].G7ML!21M/A]S],+!T/<KWMW
M/3ID>?(@7\MACN_EAP3O?N-Q]R!]VP1+^?;K;IT(Y_$?=LOO[G!<YT^>_P Y
M^F"I<&M[>737/TMW/3JQ$C8^.WH-O7OP06([[V]>Z/OK@Z7E)L;BW<\_,&P/
MELW*.\"TB;>.Q[IL9U$3@@0=#]]>N^%")&@-S^/ZRRO^6P%)U$'33PZ=^MOS
MP4VV[CO\K??AA4EP$ WM^'KZGUV&#]_=_P M\*8[]@=#]WB\C82!@R7".?J#
M^5[\[ZZ["0#J)P0)$SXQ<$GQ'YS/SP4/7-K?A^?ZOL!;&Q];_I@@O6WU \";
M]VL#7!TN]^FOJ>OS\NVPE)'0ZZ>GR)_7! S]C3'V,;>WL?(#%;+"Q6RPL5LL
M+%;+"Q6RPL5LL+'-;<#4Z#7]\N$,%86F[SV\.[H*-6IU.H6]W&F&X-<I3,:B
MU+ ,&/3=V-'PL,0T]*(E6=$5_&%<H<SZG"IJ*/*4XTM,BA"23$DP(![E23H?
MG?6,1C4"]KPHCH1IMK]VQJ7]-^KAW3L'_P!M<7UM;]O,*?F+9'X[:]Q+_M)7
M>%/_ -*8QT7V5_[O<@_T\Q_ZIK\?)DEW+6WEF/QM^L]N2D$:C'L^=._3!DN<
M_F-=/U\>5LVP7,?'36^G=I^>#)=[@_(Y=-/UY;-'>8Z:CYW^?YX<*'>(\QZ$
MSJ=!XZZ'2^1STY'IZ>>F?,[#R [0>HTGI$_EYX(*/^D1$[>7?'46/U.B0?XC
MGKT'Z (Y[ 4]#)Z:$???&V""AYVL;>7\L*4O]QE;G]_+\+:ZY"1U!'3;#X.E
M[O\ 'J2>8Z'+D-FC[-^_[O;:,//=!M$'3ZX*ESO;*]QH?G\.NS%(.PT.EK_/
MRUWMIA2>OI;Z1/G.^#!P\\P?3+Y7Z^GKL,$7!F2>[K>_7??H=\$%G>_6P$>'
M7!@Z,A<'XW/Q_7383%YD'PMMM'36_0WG$@4-CX:B_P!FWC;!DNGF>6=_P_G?
M09[,4^8.D]+1TZ_(],$%$1MX6)\=OE]3)DND$<AYWZ?CTZ_$2)V'IU]+Z[C!
M\]MR?+SO]+?6QTO=#WRO;X'+I^AL!1TD=;R+=VI._C;OP8,@'2=--?OK&#I?
M[CESMRL-0>6P\I\?#]-?EA\'2\.9MIV\KZ@Y_#,VML,86%"7K<_PSSM?EY\A
MR[K"P9+W7KSR^X>6NGSV6%A0EWH?CS[W'Y\MF@=-/+#S\\&#QRO?OS_CU[Z:
M\AY1&@[CH=/0FPZ WTW?F.LGSN#?Y>7YX.E_D3?EY_<?A?MTV$I.NEM#L!&A
MOY3!^>""]M>A&]]P>OYX4)>'(GE\];CT\^>PD$:V^[[_ 'UP04#]_?RGQZF2
M]F+'E;OSY:=<NO/9L'/6_C^NOSPH2]WY];7].=_T-EA^:]_H/EH0(T@R#?!T
MO\K_ 'B^7P_EY'8>4=-_+T_3PTM@@=3I;N.XGOZDCOF9U,ET&UE7\\^E[=>E
MKZ^AV8IM$3^5]8ZQ/?M$6#@G4QW'R)@VD"#(M8:F9P0+Z]N67?KIWUMKG8")
ML 8C4&UX-KWOW'<&)$X,7_A@P</*QY9?=EEIVV7PGJDD;]X.YV\Q.%,8*EZW
M,^MS\+=/3\ER6V5,P0?K-OKN.A!!1'W&OA'\-HPH2\>O+F>]_P"1O<VTTV I
M!D6WZ;"!K'EO;3;!!?4C<[C06UZ_7TQONR[;Z-!U?_X:K0RU_P#8*N:7^[I\
M=MCY9X.*1MQ'/_\ ;//O^Q&.;\W_ '84JG_]7*O(?TCWN=OY8T72]EK<^GWW
M[B]S_'52DB.\GQ_/782<=/"[;^>W2Q@^IVL<'2Z,L^A_"]M;<NXMZ"1MIKY'
MPZSOL<&% ^?W]ZCOFV#I=(YW\K<K?S]>AV8B=I\9%M8VZ_S(P0/0]8_,C]<&
M2]IVSSR_,7.7P.6FP%'28]>O3PZ>$X,*U!O(/WUZ[] (P=+M^GKZF^1 \_T2
M)2==!UU$;:#\AA^8;$SK8ZD@"+ZW\>O@9+O0W'QT!OI>ULL\\_79L&%'<7'0
MQKIK!O?H;=XP9+HZVT/7XBWKGLL&%S8P8L-C(Z']/7!TNZ'F.8L>HO;3/]=-
MA*0>[P_E]DG#S<P8W$CNN)^Y@0<*$/#K<_"_W:=OY@4$:&?#77S\_LX,*ZB-
M>D"-B9ZZ:3;!@]?+\;:\@/EL!$:B/+6/K&'!!T(V_/\ 3QPI2YD.??F+?K6_
M/8>6]HTT/?;O M;0BT8($C3[],%2[W^/ISY^NS1!L".\7W)B#H-S&]KX4SK?
M^4:_P[P02<'2\1;4>9\SKK<Z>7D-F !G0^ @W &A%NLSKT$X?P,;P3(U^[$3
MXF).E\'6Y_F-;B_RT/ELQ3?:_<1>#;6-I[O" 2YE7G;72T_IXWTU!(.E[H;#
MSO\ *V6?XZ:;#'K<0;"W?I_'!A?C OX;W3X[@$7P9+H/?RU[WTZ^FFS%/4#Y
M'7^6#"P;7M&A@B]Y%M;P-!L,'#HRS_ETSL;Y=>>=\MFC3NG[[_LF2,&%>'Z]
MP%HF\23\Q@J7K 9_B ,_OOR\M-@*1WCKOY:Z](P05;<>O6QT%K3MA0EX\\QR
M.OKU^9V$I/CX8(&#^FL?3UP8. VY<QK\=/NSZVRV'Y8/GN//:/"Y)^^N"A9\
M[YW_ %RV:.M[ZD7WCTG^6""TG>/'[C%X<'EWZ?#X>IZ;"4"Y!CNC]/OQP6#I
M=_"^?2W(#UMJ.QRV I(VGO%_N(/2^NV%@R7=.1L-".][9ZZ7[=--APL'2X+Z
MY #GYZ G73RT'9B)^7WZ$^N#"SZ><G2^EOSO?"A+I&BLO7L/,6)\OG9BD'4>
M?KK]GY8,*!^?E'C!^77I@Z7U#7J,QT\OY\_+82FUH/\ I2#X#3>>FM\$#.A!
M^>N%"'PHVR_'.WW7MR[F]]A*8UM?Q'T\>_N&'GQ'AU$_>MK^&#AP&V=K7]#S
M%_USOLT':\=/OZX>>X38;SI&DP=+^./LIV]KX^0N*V6%BMEA8K986*V6%BME
MA8K986-(L.;W&][&^O=I3D0MTD&?A*I8QJDJ9A_>G0<?8CE4U.$L5X<>H\%B
M)A:GOPE_6TV+4IL=BK(?,&G/R51I$$+>!D0#^*^LB #([STC3 S)'X9[C)T-
MM._'/OZ<4\.Z)LWM;"Z/7_7]A,<R!EK]VV!XC$Y+6ST8_P"E,XZ#[+3''F0$
M?V\P_P"J:_'R0I>Z$'OUO<=1GZ;<G*>FN\&!Z1!'=:=SOCV6% ]XV.IUZ@R/
M*>X;8.'NOS'Y7^[8>4S'IH# ] 3^<&8N3Y@!]=2+]]R/YB"9@Z7>YMKG;[\_
MR]=ACP'CX3KI\]QM@I\3X>,::_+8[X.EW(9VR\QZ9']6&>S8?!@[W\['X97V
M4#I@@HVFX$[2;^/WXZ8,EW3/\#TR_7WC9HU[^MQ]_+!!0MM\QK>W?\MHB2=+
MY'/X_GI\;Z\]A*!W^41XP3IW8(*/<1W:^A/EA0E_//+RSTY?'6XZ[#R':_R/
MF#^OT(P_,.L>-C\_RG"A+X/,=#G:][]#;ETV CJ#Y_=\/@Z7=+GT[]S8_H9[
M,1YQL>O>3)^>%@Z7>_QTZ=3;/^.PE .DCZ>FOY8(*(TTZ'S^[1."I=_/+/RR
M^.P\JIC7K?KUGZP=.[!A<ZB.^8^O\?#!DN]_P.?3KSO^KB1UMT$>/4VTP04.
MO>-CTMZ=]_*2I=Y GU^&77L/ELW+(FVL=XM,]WC.""CK!^0G?:?.;ZX,EZUO
M++GEVOH---F*1T\9!F?'78_7K)A>D_/^$R>^!IWX.A[S'86^-KG]=CL')Y?/
MIW CO_28/F'7]/73!T/9_K.W;G\?F-@@BWWUWOIMUCS?"A+^F>>7/TTT)[<^
MEMFPL'2]]]LM3Z=#Z#986%"7;D7[Y<SWU_6>6RPL&2YR!]#^OE?9HZ6\/N,+
M!TO$==>M_GJ-A*)Z:>'G '7Y6C?!A6L[^?E<Z?9-H)DO#K:_+(Z=>?PV I(_
MB('J;?.^]X&""YVZ:7.\^,6F.\WPH2_TSMK\^N?+2_\ %B"-=]/EZX(*!-C<
M>1P=+W?II^1.6?Z.S8($@S]^NOSZ=,'2\>7P^'(W^.RPIZB?O2T?+OD&T'2^
M.HSL>8'7/4'8>4>?J"3KK.N]_P L2 D]3YIF/(I(_EI@X>!Z?EJ/O[]0;9;#
MRD7'?IT\[R>Z=?(D#MKWV/T_,"=L%2NYRN#EV)Z\]!:^O;752>D@38B_<=-Y
M TMO$X4CJ/6WKX^N-^6W#_J93IN?_LVFA?3_ -DFX3T/ZZ;;' '"1VCB('K!
M_9I )-Q$V_3'-I_[KZ;_ /ZNSU_^$0/\;?7&B =U%^0UM^KCG?7Y[:WRV$^'
MPW\SO]?$6&.F Q%_EUC6+G^$:'!TO]">^=[:ZVL?CIGZ1E W&IUC7PD:?7SP
M069\--B3M.PZ]V%"7[ZD'/E8V'7*WKUY=A+>L>0O]3X'S\,&%P== +FW@+Z=
M0)C?;"E+PL,[@=K:#UMY'/\ &,I5X:>=XC\K=QT-Y OJ?E$:^)B=#O'J5+H.
MA(N/X>?*U[#9H@Z0?3K^I]<2<PZ_?AK]^&#I=-]<K9 =^QZ["4^!.Y-I'EY1
MTPX,:?E/\/+!DO9'//X9#6_H<CR^-@4FXBTVOU)/2VWTP?-U$[[F+=YG47ZW
M\SI>'KRS/W\];<B=AY3>VDW\,/S1$&.M@1Z6(TDQUMWG2[U/QOU//\]FP04=
M1?PL>O7Y?H)*ET'0VT\LCE\QV^%]EB3GG6/+46@QZSXGPP=#Q %C>W7,6Y>7
MPO:_/+8"@'N/=I]^F#Y[F]H%B/4#RG7>(MA0A_.U^0R_#I\--@*#M]^,QA^:
MTG32>ITT$VPH0^.NN5OGF+\NH_F!$]Q[K$'>_P ONQ2.OWK]+X.'?+,:7SZG
MK\M.NS<IM\1L9V^]->N%@R7;\[^>1.6GZZ<QLPM.H$=21O\ IUO(T)PY,ZWZ
MV T[_P"&PP=+QL0?GG>V?;TO?TYJ!:.L2(%X@D#ZQ%KWC#[R#II,F!(@2)C6
M/EO@Z7NO6]_RZ>E[?'88F8BPOL1ZP#'?!-]+0044ZWZ7WD^/RTMN<'#V0L?N
M]<L\A<99ZZ9;-RGP/0_*^A)OZ8/M-@3\_P"=@/ 8,';_ #T.=^?X9_GL,1M'
MW];?+NP?,#UZ@@R1\]"->M_(Z71E;6X\[=.Y^-\^6S$2(^M_SU[\2!4]\G3H
M#Y7C>)ZS&"I>/,\^AR]<OG;IEL')XBY%]^FGZ?J2YHWC<]+1K/B-?3!P_P!<
M\SR'7SU_&^P\I\?#QB/OOZ'#@D:'OU_+?;TP9+J3H2/U\>7388C61XS][?=\
M&%G>#W_=CW:>N"A9R(-^GZUV:)U@V\^_\M,$% ]WC'ZX(EVUN77I^?+TV H&
MQVL._KX=>FNEL%@Z7M,_+IUR[Y6MR[7V$I(_A]_7"P=+U^MNF>8T[99?<,MA
MPX)'?XWTT],&2Z#8?SM^N=SZY[-%H%OR^_N-<&%]?X#Y3]?G8Z73R)O\^ITS
MMW/IGL/+.H$=UOEIW];1?!@@Z$??WZVQ]G^WM/'R(Q6RPL5LL+%;+"Q6RPL5
MLL+%;+"QJQNU\+T7=QB/#-<1O.QIB2%A14-REX?J],P/%I_M:7@"5NTH[DB;
M1<+4RM/&F84E*AMARI*3+?;;FU!,N7Q/*(J)FPOTGK/7K? !,&9L-H[H_GUQ
MS ^G+-MSR57L1A='/+/'^$LC\.O\<%Q%_M-6>#'_ $IC'0?9?;CK(?\ 3S#O
M_P#!5?MCY$DNG+IU&GPSOMRTI/0;:3%YV]--.G3V*#I%NX=;B8-ND^O@9#YR
MSOVY]3ES]+<\]=A(\-];&VT=?OK!I4>H^BNIMW=W3!TO#KTM;+[\CL)3KW]=
M-C]] >D#!!8,;:7B#X Z7G3?7<G"A+W15[9WSTU["U_Y;,1-CH9F#;6=#]1O
M,X+F&H@Z1(O$18@_7:+S@R7K'._ZZ$?EV&P%,&+'N%C&GAX];GP,*D3IWD6^
M4'[&^JA+W?R)Y&]NO\M>NS%)^D38F>GY]-\.%#ZS%XCK^77;!DNV&I^\9]/+
M7E?OL."GO^?7]<&2[^AR\P;]!_,;+!<QB#?;](CY]1;!DN\[\_+N;:'GY#I;
M9HM&W373QP05Y6(W.G=)T&Y%[WM@Z'R.?2]Q^OB1L)0#M'@;>,1\A@@3W$=Q
MO!TD'<^.^%"7Q:_S!_*_,; 4$:0?OOP4SU\QA0EX&V8^[YZ:@Y_=IL)'4>H^
M^["_+!TN_=S^7WY];<M2Q&N^EC<6]?X_/"P<.Y"QM?U'Z/;UV$H&T_4#3S\[
MVUVPX418'[\],&#ORUL;Y^7ZRRV&#!W,P8O_ !M:VVOA(%C<>GU_A@J7;]_D
M1?3L?(?'88O<0+_+Q_CX;8('<&/(@@FVNG=;!@[EDKXC\^GGILN4[7\/./SM
M^N#"H.YWU(G\MOUVP5+I&7Y=/Q(/;Y[ 4Z[^(]1/H ;D#3!!8W[MR;>AN-^N
M%"7S8"]_36W2X%^]CE\MA*/*]MQ^O6">E[G!R.O3RGK'C@Z7^_;] _AL)20)
MU$3(^YP^%"'M,S\1]VG?8<+!TO=]-<[7Z:Y>?GZ;+"P=+U\OX:Z]?+EVOLL+
M!@[W]#\-?R/X[- U%C$2.GT^6'DZ3@R7CEF=;WURY9Z_#8>4:[QM;S\>FVW?
MAPHC?\^MM=,*$OC^?GKR)V$I/Z2=?ROL"9^N#"QW_IU\A$R/2=3)>SM?G;73
MT.OF-A((V(^G\/,X(*!T.%"7N_.YL>>=LCUZ7S^&S8>8(^7?U'>.H[^_"A#W
MX9=]>9Z=-;'/9H_2^_C@BJ?6U]/2YB\=._&_C;M_HQWE:7\;K2?_ 'B*S;UZ
M7_+;8^7_ +42!;_MAM_][Q?U&.<2?[[R2"#_ -STSX?TA!.PBU]/7?1!+H-A
M^%CZ6RTY>O;;62E0-M.H)'R)_G&HQTN;3XCJ/6)[M/6V"I7Z$>7Z],]E)T_%
MU!UWE/B(L;=PTP4X*'".AYY9$CKEW[;-"2-2G:\D2/OKA8*EZW.UNN7PMGLW
M(3&A!Z7'SC[WP\GJ=9U^][FVVN%"'K6S/+73X_GEL'*+V'3I_+QM@PO:VT;?
M+2V]P.AP=+W?GK?EF!S-CW',9WV MD>GSZ#0?I]##D02;Q-]._Y[ S.HD64)
M>OH1ZZZ?CH;GOJ=HRDB===_H/OJ<2!9F]Q]Z:??G)TN=3IRSUMGIIKEZ[-WV
M'?X?P],2<PZ^/J-1KKY8,EZUL^77/M<'N?B>NK%,]-N[Y@=+7G33?! ^>O\
M'3Y^F#I>TS_,V MEIE_+(;"41]+SN;7$CY;WB1#\W43W6WU[QUMYSK@P>SUM
M>]Q;.WF,LA_'L!!&WGMTP:56UB!:^I\-=>G2!WG2[U)UMG:]L[6N3Z]QG8;-
M@DJ(Z1U3)$C4&/D#U,7P9+IYG.V=_P /.QZ=NS$2"-<&%I)D6O:+$==A($]/
M$]3)?[W_  Z9'SZ]NVPE .EOI]S^?=!A70G3<3N;VZ#K&Q)C"E+_ "U^/W&W
M+N1VV H.UQW??TG!3&H(^?SV\XP=#W>V?ZRUS/3KY[ 0#^N_C]]W3#S]^GZX
M.A\<C\/R/6U[CMLT0.OB8O<:CQTZDWDX4_?RP=+MLKW^(/77T^-NVS1:;IZB
M 1T)@6^EIMK@IZB>EXCSZ7^G3!DO$6SS%^1_#7S.?;/9H'E8F"(\[V\!(T@G
M"\#X3MYZ>!\[8.E[KEKGK^B#Y:6)V:.D*WM:!;Y1U-YD;DD%'?3J=-]_&.L7
MB-,*$N_Z7Q.1^?H;9W.5]=ACIZ&9\#:._P !-M,&'!N>Z]Y\-XL+P-L&2Z,O
ME]Q/EIUZ'2VS%/V-B9!\]===;X,+&W=Z&/,:6UM8@@#!@[T(^XY6[CH3IE]S
M$3_'T_/O\,&%>!G0:';KU,V-^DC!DN]>776P]?7/OGE?8"BTZ=Q/U.GY:=+F
M%7M_/J(\M"-K:8,'M!K?F?3/73X^>>PE)'0^'WW[8<&#O]^N"AP'7M\QKU&P
MX,+Z_P 9GTCOMIMN8+/6X\[Y^?X;,1,]"+]2=O3\\%S)M>)ZV_A@B72-;_>/
MU^K[ 4=)WZ>72/OS+!TO6]<[ @W_ %SM\M@*2)L;$W\/O[C"Q]+O^&R__P"+
M9KG_ -]J^O\ \K?\>U]O8?O?_D__ $__ *G'S-_H0G_QF?\ YC[I_P",_P .
M^,>_X;#_ /XMFO\ W;5G_P#QK9>]_P#D_P#T_P#ZG#?T)'_C(_\ S&!__P!6
M/#XVGA:^[=K/_P!NU?\ ];6R][_\G_Z?_P!3A?T)3_XS/_S'_P#I/Z8M_P -
MM[+_ -39KO\ Z[5Y?_RURS_+GLO>_P#R?_I__4X?^A";_P#9,]W^!ZZ__&=[
M?KMBO\-MW_Q;M'_\[5__ %M^FR][_P#)_P#I_P#U.%_0A/\ XS/_ ,Q__I.*
M_P -MW_Q;M?^[:OO_P"VWY?'9>]_^3_]/_ZG#?T)3_XS/_S'_P#I/W&IQ0\;
M;U[?T;-<A_NM7^.&AE\^VR][_P#)_P#I_P#U.'_H2G_QF?\ YC'?_P#&C?Y7
MUQ?_ (;+W_BW:_\ =M7\/]S>O;9>]_\ D_\ T_\ ZG#?T('_ (R/7_8>W7_9
M..2?TM^_.'O)W!8AQ!5<-2:-"PY0J;$?C4ZK-U*5+%0QYA4-K:=D4R$TP6WO
M9A04VZ%-J40I)M?!\3U+O]'LR<80WVJ/=>0/*46SS5E.#S%("A"28C>+@8W7
MV5\,T-/[5>#LOS*LK%T5:<X4^[0L,IJFPSDF9K;#*'G5M**G4H2LK(Y4%<#F
M Q\JO])F"0<J/BPC_2G48Y^7NW<ZD_/;C8S'-?[.7 ]/\*Z_<>F/>?\ 0W@@
M&U3QB>\,Y,.G^?XCTQ>-Y^"^5&Q6<O\ PVD9CTCZ;(YAFMQR9;?OJM-]O#>V
M''!O!7^7XR(C3L<F[[_C/?\ KB\;T,&#_N+BS_W-H_G_ .#'GKUV'W[-/[.6
MCI_LDR9) N/+OC#_ -#."C/[[C&][M9+^:_7?K@@WI8,&E#Q7GR]_HX^^*;9
M=1GUV$YAF1_JY</.H\K3ZQ;8#!_T+X*&E1Q@/!O)H]"HCTPKA[S<(RI,:*U1
M,4!R2^U'07)](2VE;RTMH*U"*2E 4H$J -@";=7]^S(D)C+K]347,@==]>ZT
MWPE<'<%H25E_C"$I*I[/)9@23HL"0-=,=I?"9]&0WXN]W6\/$6$]X8P;BK=[
M4J73%T66_ Q:]7Y%1@)GLJ%)7"P.UAZF3VW5,TZL2L4U4>_4RI0WJ<$!,QK.
M\+M5'$5-7NE+#+M"MM)9:7VCCQ<2%(^!WLD-H4%$)<54$!;:T<H'Q#EGMR.5
M>Q[/N&\L2]F694?$-+4U8KZVC%+24#5.^JG=2:NB<KJBLJF5(2X_3,Y2V>PJ
M:=U#JE$MJUC\8/@6WW^">LX9A[U&\/U2A8T%3.$L684J#U0I%1<H_N2Y\"6W
M*B0IE+J\1FHQ'7H4EA;+H<<73YL]EAY]-^ORNIRY38?".5X*Y'&EA:#R@<R5
M#92>82(@ZI)%QI'"_&>3<6M5*LL6Z':)30J:>I:[)U':\X0ZV9/:,N%M7*NR
M@  ZVVHA)TU2^?+Y>EQ^6V.*9TBUK:[:@DCYCOQMH5&LB;WTWW%[^! T C!T
MO7MF/U?GI^O.X$1_$0?N_P!=KX(&=O"+@^GYQ@R7NAZ#D0#^%ONY:;-!&HC#
MSH1?O^_RTP9+G/X$?Q_1V6""C<&X.LS\NF#)<[WZ9V.6O?S_ ([-'?:\@WGI
MX1@N;0@G>1KWG>P$=UKC?"R/[=]P,QVG7W% V::;6ZX0 22$MI4K("ZC;("]
M[7.TU+05=>\FFH:2IK*E84I+%&P[4O*"$\RREEE*W"$I!4>5)"4@DP,4\QS;
M+,FI%U^<9C0970MEM+E;F-93T-(VIU00VE=15.--(4XM24-I4N5J(2D%1 *A
MSVT=PM2&7H[@ );=;6TL Y@E"P%6/(D $9C9JS+Z[+WC3UU)4T=0$I66*MAV
MF>"%SR++3Z$+"50>5408,$P<-EF;Y3G=**W)LTR_-J,N+:%7EE;35]*76X[1
ML5%*XZT5HD<Z0LJ3(D"<7I>[W^61^5C8?<=1M3\<9'"A+PROZW_5ONOLT?2/
MO\^MNF'G[_6=?#!DN=#;/0\_U\>6P\@VD3(L?K;[[SJX5'\_U!^48.E2PD+X
M5!!M982>&Y*@!<Y9\"A:^90K7A-I#35(:%06'"PH@!XM+#1*U.) #A2$25,O
M)2 J2IIT 2A<0(S"C74JHA54RJQ(4I5(E]HU*0A+"W%*8Y^U2E"*NE4LE("4
MU-.HPEYLD@=O;3RT/Z\N?;+:  &9M )CPG0'IXS^5P*&H,'Y^'?],&#O?XV_
M7S^=]AC?6-_'YWCZ=V""HO\ PZWM;U!M;!DO'S&7?K<_AY<\AL)3.O@9%]]-
M(B3L=NF) L;_ *>70GTFPCH=+VF=_4] ="<_P!Z[ 4>(CS&D[7%YV^>I C[[
MS ZC6VM]=,'2]W^&OG8^G382DC8GIZ3!&Q_CKA\'2]Z>1S^%_3/OJ#LV%A0E
M_N1V'/+6Q/8_+U6%CUZ:S%CORI!4&(K+LA\H *PRPVIUU24J4E)4EM"S92DI
MN,U)2"K8'%]FVM<3R(4J-)Y03 [S$#%S+Z-685]%0(4$+K:NGI4K(Y@@U#R&
M@L@$2E'/S$2+ W&N&.7O0P?3VH3J\.5(HG16Y;:)N-J1"D-(< 4A#[(PTZ&G
MU-+9>4RAQ]#2'D#WAQ15:DA]YU;G(JB1V:@GE74.%>@/Q -) N2#,?$DQ(@G
MI53P%EU!3T2ZA_B2H-93>\)<ILFHTL#]XIOE25YDZHF$I<$*/[MUHDI45(0E
M&^;!@_[VW>F>\.E=<\_V5T/+L>QV,^\?Y2@'@\YTTCD^@Q4'"N3#^MQ2?_Y9
M0_\ MDXN&^G!HUPVX>?_ +$*F7\O]RV7Z.PR_'^,H1U_?.>-_@\/EUN0X5R7
MKQ1_]ZZ'Y?X:)Z]9^70QW>QA>/\ 12R\4?L]*>@M>.Q%+^KV<84]UYR6-Q#D
MSVK51^H4M+5[ >R33_<_:E1#WO/#_5[;&5O)X05*J0J'$,V<<*2G]G$P(2%=
MI(F(CEDS..4(X=RU?MU:R_FSU%.OV8E_F714J:M+IXH#8):]X[(4O*;NESG"
M[<A%QS5'B4P6--WF)0+Y@XOIUS8]1AQ-KCH.V9RVU3WA_K33_I.?3E_/':_Z
M"Y1(_P ,SRW_ ,4R\ZGK[W]=+&P&+_\ "9P8C,[N\2@ ?\K8!-P1_P"V^D?
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M%AIDU%0XDI0'GF@]R(2WS*Y4-J1S$E2BI1'*(OZ3]D-#3^T+V<M>T#-*;,*
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M:IJ*=3C92LL5#S1/9NK2IQ56ZJ]';C.U*H.QFVDLML.3)"V4LI0EM+26E+*
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M];0O<>77*U@,N=S?3+D<\K^DL?*C'HL.>8M>USH3>^G,F^9';,#986*YF_\
M,:'*YO86T N1VV6%BB -;F_G;,\KF][B^5R=<QHL+%7UN#>WE?+,W.MO-6EP
M-EA8\!%AUSRUN,LC<YDY>@(%MEA8K.^=\QK:Q-KDV&A!/(@96RY[+"QZ+:BP
M&8SSN"1KG?XZ7SV6%C2WQ*,ID;P-VK"CPH<IF( HYBP 2==>6M^=NVU//QS<
M)9X.IHO^FTQQ9X9<+7M"X5< YBE.9D#J?V;6#\_7$"CT6(@#AD%', .$',W_
M ,ZWGK;7RX<&TZ<VMC\[6F+: 6%[=/2CE<\9EH'Q2".^;2-?KUP\,1&&+?VA
M2DCE[90-M;Z@&^EB!Y9G8^4)O)C77QMMX[Z1UQ1<>6Y/[M*21L@1O;2;$^&)
M%%>I %EO*XKW(4X; $ 9@$99W&9N.F8V<*3K-IW,F.E_I$=V,8\BL-P@:'\*
M1J+ZD3/EJ)B<.871% @*0HBYL"59WO;/SL!G<6M8#8I;V)/F/L8J%-<DR0H;
M7! ]-/$^IP-4&"_Q%J,M1.8LVNVM[Z"^6E]>N6P%(,V [X_/Z_QP_O#[=E/0
M!U4/XQU,^/?A0Q1EH_R<-1!-TD@'4"PO<#+7.][YDC4.S5J$DSW=#;6)Z@QB
M-VM"@>9\"W?^0]2.^V)!#ISJ%6<C%*5"RK9V%M>5K>7GL!:4#)21-]#K>XOW
M^7F,8]^I2H2ET*(T$QY]\Z'H#O?&0YF"U;P<*IBQ)*4XIPFVN11ER$%;=1HD
MA/LZA0:@E2'2_39+:UQ7VRAQ2&9+2FT*5%92G8:-+E73)2TX16Y=#E,HS*Z<
MF%M*.I0E1C=24K!$=FDC5$YVUPYFZEU3/:9'GT4^8M)*(IZY-V*]@$I2A])
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M, P"HDQ&ID1'=-Q?H, MXJ!]W#:3W0#O.GE!F)%\;T'F>=KZ#,"W46-];\K
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MF/#OWQ'9TZGD*_M*L[VLX>=P/W3E8'XG6VT:BG8GODSOWF=9U\,9)BGJ=.R
MCJD0+QO:8'7J#KAHCR*.3_7?;4"3=VZL]"=2-0;W'6V6@@H.L&_F)(ZC2_\
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M2]T.7Q'/[M?P.RP049G72^A]1K/?.%"7],_Q_C]^S0.@P@=9) [K?2TZ#2/
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ME,TA@MIPWX.W6[P:Y(HM8;PEB&%A9\2JP]C"ITBMP,(Q:%A^+)K6(*S(Q$W
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M#T5_$M;0R7(U#I#CZ&G9#CA'LU37@5M4V&I0<ER!<A$9F6^PT1),@#6Q.I@
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ME?:#./\ <OG.]Z/_ *73XVGV8"?:_P ##2?VW_U'F>/D3?$5B2IJ-+$AE*4
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M[W5IL'$E<9FSIK3Q4'*BXQ50NLNJ4HK1[^W(4IMY2%@H4M.UAN@2XVEPNI0
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MY,8/IC5NESF07XCT>2@HDQF7;M/)4K@"%<2%+29<V<6SP)Q2XVHH6E66<J@
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MP?[Z;:&Y&F5STS-MG"A/Q)!(FY$Q>]O..[30XE6"1\"K:R"+]#X">Z]IZO\
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M6AMI R!6M21F-3:[H90I4<I43H -?2YFY(CO$8M-K>L$ J6JP2F22>@ N2?
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MI!,Z= -)^6HO. Y71I($;0([P;'>#M^:9[V*KY) SR%AJ=.6?Q^_8%<A$6\
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M1@W-3'"7&Y#\2$*FF"VZTY><]&<80J<W$2K/<+^Y?M1":\I2PH$2I7*FR5$
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M:D<N7,'O?0G:5+:"((N-B/E?8W^[XP+[SID\Q-SO/E$Z0/NTNXAQ[7 TY]+
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MXD8E13NIV]0>A&E^X> T.&*3(9NHE0SOJ=<LA;+G?OI:VU5Q:5:;GJ=;W]-
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M=T>@O^IDZZP,=G:#HUF-(,VO^NFM^E\,3SR&3Q->938F^>NFH(YCK:QS%11
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M%/"@'2][ZW_NC+,<R#GSTV$M\_=>1(/E&W3TF,7$N!K\4GK>!W:R/EBWW5U
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M<1ZZCG;3EK;^>R)Y1\23 CO$C4VBUY(OH>^!--SW0J9CN)TG6UAI>/'!36$
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M1N>IRGT>'&3,>:B35+;,JLTR*T Q[N'G2I;R1=I"@@$J78 G:/B%+B/9[Q9
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M];'O^]'3P]7 F66TQK+C5P/!9(%MX]<71=_6[A:[IQ,EN_*33JNT 3HDJ7
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MS"-X_KNI)BQW/C&!->(G=2C7$SJ2+9FB5P\^?#3S<:',#K:^R#P!$$_,$GK
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M_3&AJ*!3D@7B,*SSNW>]KV.G;E>^1.5MO.G8"!! MW6GP%]M/XX^C_N]+/\
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M_P#PNN7GY#+:TEM:?]Y!\DS>W321W;:P3B+F:5H\GUCS&ICT&$KS3"P4N16
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M&OU.EM+'# B0EA9^Q=-SRN-=+:^GW;8X5"&ED1\)O($B^OA^7C;&0+2G$ZW
M@B=AI>_>#MAYCU=O(!!)TL$D_(#K?EZ6TNMUK1@"YTT-OEKTB+V&*2Z)=SS
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MO-_2C_\ :L5_J=V]+_EI@#_SV(O_ $#LOZ+5G_&*7U=T_P";'WOA?WYLA_\
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M,?!35,4[[&J(&W3I@1H57(^Q,BI&62EO*\O]Y![YDG:,TM3/XTB/\Y4:?Z(
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M-0Q'>M8$'7_>[=T8D'M#X?&E%F,[_N:;_P"=%4"? Z=XUN3NVQ,3<S:,<O\
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MHFM)?]@ER(XW)"PPXEP["YP7FR75TZ5Y<Y5(23[FWF-.:HPCM  PM2%R4$+
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M>TS^//Y]\K6TSY;-$=8M](@;_<B^'P=+O?S'+ES]+9Z9["0;V\P8ZG2;D$S
MU-YVPX/RTF_EM;7KK83@Z'CU_$=[\Q>^?GLB!, 7 \.Z=I(CJ!$1AQ'A?O\
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M"%I:YB@@A0&'>F8)QC5F:W(I^&:T^QANFSJQ7'1 ?;:I=.I9IWUA)EK>0VE
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M%%)TF.8@7S:^%*=S+AER*M;;2,_K<]04,H"4+K:RMK#2);"@D--&M4@+$$A
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M!5G'=;EX9:K\G'.^+!&^63';K<BA4^-6L)U/&\F=2G(4&GNQY5,KM/Q[5XG
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M^)*E%.Z?>^9VH=3Q-5H-8CLNS>IJ9]%,H)6T1;OO%!BO=W3<&1_V:>E8=H6
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MSDU5&+,*84CX-PA-WK8XI5$E8>P1A-E##.(\!8AW784PO1:865U";BF'@UW
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M',WRSMY'2W(]\[; 01J"/'!8,'K6SRUY6OT]>74F^1V: -+??W]=;X6"!T9
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MI$O=5'B4..TZ,)4RJP&)4FI[S*@B2I=074Z:A9,4R4D'E$:$SY2 ;[P=OS(
M$$<UYTO8&#M;:<<]/IPCP[I6%7S&%QSS_P!WF%,_G]_F,!Q+?)*[P8WC_A3&
MYQT3V6&./<@_T\P_ZIK\?)6E[O?KG?\ B/AMR2#X>-OGIZQTUQ[.GS Z7ZZB
M)])ZZ8.'1R.G0WM?7+S^/RV4&W?<??=OTP@1>_<=O#7!@[Y'I8VME?\ 7KZ-
M@@2-_6]NGA][#!@[U.O7(]/(=?GLOO\ GO@N86U$=#KY'ZZX,E[OY7SOWO\
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M.0^0UV'EO/I%CWB#$=-21TN</S>O747TT$WUT .QQORVY_V,I[D/\-MKH?\
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M^S@AM^G36=L[6Y?3LTM,M%&XTYF+M15MMY4*A&84"Z1.9*I%U8K:3W9+OO+
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MW=?_ ,U/"_?\6,3^R\VWK\O/CD.2WT_^)_I?RP0;^MX?+$V.,[_]_%9YWO\
MW.GSY\]F+E&?^#*V_P"%/&.@CFTC2^"_9F;?\?R__P"\&3?^R=/GZXZ0N[V<
M<N?1"3,01\1XJCUE7T@2*(U4?VFGNU!F(KP^KF);,U:0\Y#$KA=,%12RIT>T
M*@=MC+C!X/7#2P/Z1A(!>>)#ARP_$#S<T<O]6>3^L1..,)H:U/\ =$--N5%(
MXX/9&75*_9.6I;4S_2X)+0IPQV"5DR?> V70/@YN6V.77],N^C4;S,: D?\
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MY)#B&FVT)4$("1>W->2ZAY#SJ76R@MO!Q:74%L)2@I<!XD% 2$H(5]D) %@
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M'BM[860V>FG[K?S ZX;7OH]?":DG@W.C7(*Q7C,D^@Q&+7Y:;1JIF1HT#TD
MS'KJ!I(C%I'MA]H*HYN+JKH>5+8'_P"2UDWQ?'^CW\)SHX7MS[!:'(8GQG<@
MW%BI.(P3KF.*QY@VVC##:22&P#TT&UXO&DB-)\<._P"V+V@]GV:>*ZPC<<K$
MVDW5V,P9-E$@VZ"-AMQGAHW.>'ZN2L1[G\,UW -6G0UT^?*P[CO'< S8#BT.
MJCR648E7$E-AUMMU"9$=]"'4MN!)6D':Y0UE1EE2*RB=>IWTCE6MEUQHN-D@
MJ0OLUCG02)Y5&$D B#?&A\7\:\1\8Y<G*.):^FSJ@;>%2S3YGEF65R*>I2A2
M$OL&IHUK8=Y5J0I;"FUJ05)*N548Q%](/X*F?$=0<$U^C8\K3-?P[AB70-VT
M[$L#"7U6]4'9GUB]@C&%:HF$J7B9#4J49#.'I\BJU&ETB;*6Y'HC2*M)6_O*
M\\4][D7EJ<HW6^R8?<".V8>*BI=-4*0A ("R0T0$I@I*4)+H!TGA*I4T[G:!
M1TK&8-U2:S-:*C55AI^C2T&D9IE[=565*9#:4+K$0%J0%%;RC3J"?EJQ-AW$
M."L15C">+:/.H.(Z!/?IM8I%285'FP)D=7"XR\TL YBSC3B>)IYE;;S+BVG$
M+5D 0H BX-QW^N.BH6E:4K0H*0H!25 R% W!Z$89TN)U!_'[O.WKL/(+Q_+N
MVU%L&#'\? ZB8OZ],&#I%O(<_G;3GD-A*"-!.GCWV[SXQ@@0-)V\;:F+B\G>
MT3@Z'SI?[ONTUZ'IL)3,B-#H8G8#NWU^DC!A1&]_&%7T$6!\C\\*$O"XSME\
M^_*W;/9BF#T/J#K'B+G0_3!<PT,=;VC30Z3;OW[\3"%#;I4!-5Q!194JGURF
M5)K#TEF8B,D5*.XVT);B6EJ<4W%<X@IEY"$NA06E#R1=/0,KR.FX=R=/$'&W
M">99ADW%N0YXQP56TN:-T*$YY1/,TZ,R=;9=6ZY3T#Q4E=-5M(14!P.-T]2V
M 1Q/B'BZOXXXH<X*]DGM(R')>*O9KQEPC6^UC*LQX>>S=USA#-*6JK7,@IWJ
MJG:I6:S.*9+:T5V6U#KU$IA3#M90/J*5L@D2IKZ>-4B7*>*&TDEQ^0XH)"$)
M!)4M9"0EM"1<V"4@  #;1G%9AFU8"XNLS*OJ5--(YU/UE94+2A+3+:0KM'G5
M!"$M--@J(2E+:+) QUUIO)>&\K6EEK*\AR:@145+@;11Y7E=$VMQRHJGW.3L
M*2F0IYUQ^H>4$!3BW'G#S+4HNU3^IVA3DTJ3-D.*I["ZJF:RAGW>J$K]YCQ^
M&Q4PW9/ I?$K.Y<424HS/$M)PM2IR,<-5^;UKSF24;O$;>;4C5+[EQ"I3@KZ
M.@[,)+M$R0@-+<"UFY+RRI2&M5X#S'VBY@YQ<KC[)N&<JI&.+<S8X%>X;S*H
MS$YMP2A+*LGS3."\5(I\UJ@IU50VR6FP1RBE92A#M2\SGZG^RN'TOU&EO4P2
MJH8%/86P:G#<+X]X7.0EI+R&WEJ]HQQ/.7;4DD(26 -BSQ[B)7LSX&9K<]X>
MJ^'6\SXD.2Y%1NTBN(LJJ%5857O9PTBF15(8JWBIZC+M2_++C2E)0VJD2G1N
M$*7@=OV^^UZJRKA#C?+>.:C(.!!Q5Q?FE-F*.!^(J)O+2G)J7A>I=KWLO>K,
MMIDHILU%/04G+5,U"&UNOHS%:S4ZHHJT.)0JS6&Z72:4S4I=/=33_>5JF/GV
MIC*5'2E\B0X566XM246X+?Y)*5D><M\493EG!/%W%;'#?"W#%)Q#FN1OC(AF
M#RLVK#[U^SW'*-+5:L5U07"AU]Y;;,=D ?\ !PT_%O"[_L]XDX@]K/LT]F]7
MQ[[0_:#F7!/#?%](OC$Y+2M\-95_V.&=,,YJM_*VE911(82[34=,T]4%7O14
MD"N541[B4CA"@H$I"DW!22@V(4+VN% @I4,B"""0=N;N-.-$)=;6V5(2XE+B
M%(*D.)"VW % $H6DA2% $*20I)(..[L5-/4A:Z=]IY*'76%EEQ#R$OLK+3S*
MU(4H(=9=2IMULPIM:2A82H$8*A\C4G]<^?S^.T10#I;%F?._@1X@WM;ZVL,*
M$OZ7R[@]_GUY#8.4[&?D;:V/WIA<P._=T/H<*4OCK\[99>G?7GL,=WW]CY8?
M!TO VN1;YY_+G^AGLT>?CY_?AA#N^^O\<&2[W/KF#]_ZYG8"@>'@)'2PU[SK
MYX(*(WZ=^GWL?GIU[\&7T?6']Y.#(F]3?@U5OJ:OMHDX.P?3YCE+,^DDH6SB
M"MSXQ]^1'J!"_JVG1'(;QB!NH/RE(DL,HPF85J972!"'DW2[VJ>9!,R4%!$*
MZR20-AC7:_B^OR7,&3D=4Y1YA2JYQ7,.*;?IW2-&%(4GE< /Q*)4!)1$\T;W
MUGZ/GPE5>89SFY+#7O:F8["GFJAB5E2T1F4,-K=]G7$EU\H;1[60L%U]7$ZZ
MXM9*ML$:9I0A#26T;-ME;;8Z\J4K $DR3>\^6:IO;=[361+O&.9O+W=?11/N
MG0 *=72J7 $)2)'* $B!,LK?T;WA=LM,7<Y08Z7%J<6&JSBY/&M6JE^SQ"CC
M)L!Q+*B  D"P&S^X!<2D&P2.8K5 !,  J) N3'GK.+!]O7'Z!"N*,PDJ*U<K
M=$V5+5^)2BFE!482!*M (%A 6-?1K^&0'[>Z*D+!-["NXR01E;4XC/;+5-[
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MVAY*1DHOR"XL+/VE-)9224H2!@\U=0_5K2W!89):9[PC\2[1/:*!,W)1R)M
MQ:X88=HLL:4XI7O=7%35J5^+F<'[MHD_A#37*GD@ ++A E2CB!JBTA9(4S<Z
M'[!O8W[<\SW[C:BE#)U&N@$3YSC9.UK!![2)WY@/S[_KALDT^B*! C?%L9Y\
MCP\B#;^)V2D-=#8:G;;PM>QMOIBRU45XLIV)Z*.NG7>VG\HO-@TI(4?=?LZ_
MY-7)-KY#/+EH=+$:1J2B;#QD:=VDXR[%15FW;&Y@?%WCJ?+]#?$5DTF-*N(T
M)9N=2CA!%\SG;ORY 6'.,H21^'J;V\)!OT(@'KIC+LUKS4%ZH!CHKF(/> ($
MSW]2<61\)D$%<<C6_P!@$ Z];ZF^>72YM=PR!L=IM'CT])W\\$YG-CRN3X&#
M!D7MZQ<= ,.0PU&;U:((T(:-^VA%]1?L,]2=CY$BY3Y$GT BQGRBW4BL<U=4
M#\0@ZCF_+;0_8Q86Q 5_5J X= M"LQF#F0" KMR)N-=C%@=K@WUVZ3H3(D6W
M&'2HU(^-)U@E*AW6B3/ZW%SC=PZ6Y&_+/499:9D#0YC;NF//^/18W%C;3IE<
MGME>XL,^O986,7.[[=T$6 *K5=X^#\/T]W&]?W:QI>*JW"PFU/QWABLSL/US
M"U+.)7:4:I58E7IDZ(ABFB4F;[NN1 7*C*0\L^S63 0HGE"X2.;X2 03RS @
M@WTWQ'VS427$I'.IL<Q"96DD%(YHD@@Z3,6Q$QXJ_#&MA<YKQ!;FI-+8;?<F
MUV)O)PE,PY2A&J=+HQ;K>)(M6>H5#??K%;I=*@1JQ484BIU*8W"IS4J2AQIM
M^Q=T[-<[#E5)L381)L"3 L!)M@?>:?7MVH$R0XDI$$)NH'E2>8@ $@DF!)Q*
M9._7<?"HF(,23-\FZJ)AS"=2A4?%5?D[P\(L47#-8J)0FG4JOU5VL(@T6I3E
M+0F%!J+\:3)*TAAI94 6#;A( 0LDB0 E1) U($20.HP7;,@*476^5! 4>T3"
M2= HS )V!@G#8[XD/#M'?G1']_>Y9B32U5!%3C.[TL#MOTY5*K:L-55,]E==
M2Y$53<1H70*@)"6S#K:5TJ3[.<%,;+LG;?NW+Q'P*O(D1:\BXZB^F&]X8N.W
M9D3/[Q%N57*9^*T*^$]%6-\)F_$QX=':@Q36=^6Z9Z3);@K9=9Q]AEZGK<J:
M*2[281JS=272D56L1J]1YM'I"YJ:K5Z?48U1IT.5"7[P'[)V)[-<?Z)FTS:)
M@003$ B"9PWO#$QVS6W]=,7B!,Q)D0)D@@@1C-Y%CD+7&>@Y@"U],_+//,BV
MT>)L:A;^RX-Z>ZWV027/JS$O"E9N%6CJ)!/_ #;D7SR Y[5<\_W*9WXT?_3*
M>?E@<GY/Z<<-<Y(1RYC,7/\ L&JCYQ\\1N3+F E!8;)-[A&9T'(VMEG?+,"Q
MRVXE"AHF9'4W!CIMJ8UZSCT(RPP84'%@3_7E('B8\HN?D<-+IDJ/'[LO+/1(
M!TMS.>>78#IE&KGZ&.AC7H>[J.DR8TO)[(".U3X22?IY^9PMBU41K!^*L!(L
M?LW&5CEP^>>67:P&RYXF01\^OAY8K/4?:F6G4R3)O>+S^*-3/7#ZQB2!D/9'
MB(TX.5NX'0:G6]]0=B#B1J ;[@_QMY?EB@YE=2)/.F=+*[['?;KW;##S&JT)
MTC,(R/*Q%N_KTZZ;&%)5%K;D1/B; _(STW&/=HWT"""H]_? O(^?K(C#]'G0
M#:[RNY*SYW(OH;],OGL04C0E4Z7)G\_ET(Q0=8J-D"TZI'KY=\3AU:?B+'V/
M:*SO]E1L;YC4\Q?//*VSDH/4]TG;?IIBFINH225<@.AM&_</X8>::5LRF)+"
MG&76'FW67$K/$AUM27&U@WU2H!0 Z6L+WV384VXEQ!4E2"%)4#!2I)E)$3<*
M$B#:U]L4ZH(=8=9<"7$.(4VX@ILIM:2%)-M"E4=),[6SICDG%6!9,Q:4>R?I
MRA(]E]IQAT!3$@D 9&*^ILMK!!4R\A1MPD[;A6O*KZ1%8  5LA*RD'F"T? X
M5#8MJ+<*MS-N(N2DQS;AQ(R7B)NF!5S-U([/G,)=1(<9 Z]NT%\P(A#C:@/Q
M#'R?_2!>%^1B.D5[Q X&H[KN(<*3%4_>_3J<RE29M)B%]B/O!]@FSI>@AF-
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MYV$[Z">X_,8Q%11K$R\!?8G[[AYWMB519#CEO9PD$FVMN76Y/*XTS^6Q0;$
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M\5! 9;-W2MU2^'U)P[EF:4-"#G.8O9AF#X2M[F4DLTUC## 2E 5RR2ZZ;N*
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MAN;#ES:'B2DU"K8D:IST53JQ2L2QFJ0B7[:9':XX=1IL5;"I/LHK\-HR4/(
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M-0XSJD/KA2':E2ELL^Z^Z1VE\2<U2<5,,H#+]91U;(3RI0MTJ>:G3LG4H4X
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MUZERYXI7[V14LO>YT%(EJ(2L5$.MM++H<4H%3KS*R$CLT(3S([/:'<9,W?\
M[$4FGTK".'\-,^UD);H=7$JKF=(:>'M*RJ)BZ97%F7+F-.%N0'7%H7#0B&Z(
M\*,B/KN>9E7>]U##=6IVE2@(*$0M@)<',M!2KM$P5'F*220%!*B3!.[<.9'1
MMT%)6^Y/4]6'0\AT33U:'6#R-.)?ITT[REMH2$)=M*4E:>4*(QF>#ANG4-V=
M(H%"I-"D5-Y<FHO42E0J4N<^XM3BW9:J?'CB0M2UK62[Q$%1(S.VLN.NK"0I
M:U<HY4@K)"$]$ F$I%H2D!(M;KM#2:5"EJ*4*4XLN.+6 I3KA))<=6H%3CA)
M)*UE2E%1*B223BF!N5P/0\6RL9T_#4=FNS'Y,IR2IZ8MAB3+#@ER8M/<D.0(
MTB1[5T./,1T.)2ZZAM3:770J=[,LQJ*5-"[4NJID  -GEND$0E2PD+6E, @%
M1!(!(/*,'39;DS%6O,F:1IJO7*B^DJ*N94I6M"2KD0M8)!4A(405 &%*!GJX
M+6O"P"1?*XL;:VM:]CVOGZX\LV'Q"P@W.@@]#U[HZ:8S::AP6YG3!OS#7[Z_
MKA/]6>T4.%#:Q<9@DB^FA5T'7TV LJ,!-_"-IWB?EYV&)O?.1)YE%)OJ4@CT
M$_GI&Q+M%H"E6M':N=?ZALWS%S<I)MW)\]D*16I4>_KX0(^5L47<Q G]ZOR6
MK;S'?(2+3AW107+7+#&?(LM#X@I'3RSTVD]V/4GRCIW&!?>(N)V%0Y@)LMW_
M )Q<'P@G;Y# G:06P>*.R<_^#1\K C.]K9],L]F-.>NVA!'7322+1&ORP2:W
MFB''1_\ Q"=;;F_4;GZ :9*;H46F[<@.'32PL>G(6^&9HIQ:2D&>@YK>0O\
MSP:W01,.*D:DDC?4DZBT@X<6827;#VB"3G8KL,[7MDF^7($:7Y[3"F0=5 =;
M7U[P!.WKKKBHM\IGX%>(3S?/O\/G@KM.]FBY6B^MDJUN->&ZCE;73X[.JF;%
M@9VT%M]K:]?+ MU/,?PF.\0/#;KWD8V/?C ^"QU!*5#_  DVU_:%Q_[#A:,M
M,\@?EJ-MT+:1[-5(V_ILDC0W_8A.FWWL<<P;=/\ ?V0J(/\ >M*;?_+4#K]^
M&-0'&4!7"$(-\L[  '6Y[6\P=+D;<_4A ,#P!OKOK;;PQVM+BB/QJ'J;V.AT
MN;W@C4XI%*2X>(.(1D,TE!Z?YR#8'/.XYCJ=G# ,24'6)-S]CH-1Y8=58M,@
MH4KQ"K^$*'=L;[C92FDM)&92H@:V1;D0?LI%[V.IRT MJ7NJ.J?&V^WRWOY8
M@-8I6Q2#M?OL>91^^NN+':8S;1L\\T(/:V:2"; _,>0*ID@ZCQD0!U,?ST\B
M34J-QS "UB1W[$ ]X^RV_5:2NZ&VS8VL0D)]!I8DWO;MM'V!O!MW 7&MMS>T
M VMIIBU[V0F"I0,:A4GUUUF0-[V.%[-/6@V#;:;'_@T)[YV!!MKKS[6V;W:9
MU!&P_4_>D8K+J ;\RCT!63;K>_=^6^'%$5T #@0KL$7R^&GXZWYD*:._N('K
M]^>V*ZGDDGXC:-%03:.NV^@MIT4!#B/]Z2.Z0I)&N=DD YWL?Y;/RJ1T/R,>
M)\/(S:TXB*D*U<-QHJ#Z@@F8[Q]<2S"^*L286J#53H%3F4R:T0 N.XL)=;"@
MLLR6;^RDQW"![2.^A;#MK.-J&UREK:JC>2_2ONL.I((6VHIG_-5%EIV*5<R2
M#$1C"9QE&5YO3+I<QI6*MA0)Y7$))2N(#C2XYVG4R2EULI6BQ200(SI)WR0,
M9TP4O>UNRP1O-AA2^%G$-$ILA+:%6R;:JM-K,9E8()2N(S%4FP M8*&WTW'N
M9M )JZ>GK@#(4H<BXTC\+B;;%*4"_6,<NK/9=0(<4YD>;U^3F!*4+4^GFV)4
MV_2N$$6(=6Y) ,03C$F(=P_@'Q\EU59W+XTW=5&2FRZMNRQ(J*B.LC)QFCU2
M=*PZA*%'1G#R0I-OZLFPVS+/'>4NP*O+:MDF)53N-+Y=+PM28\ FX!) QAG>
M#_:'0_[7<09-F+;9,,YM35"%+ .@=IVE.SWJJ+$QS$2<8;F?1R^%JMK4<*^*
M#&N&P2M2(N,MWT&JNH18E*7)D2H85BK6D6!4WFLC[+0X@-LBWQ-PV\917N,$
M?U7VE C<?$0E'684J28B<5EK]HU$![WPC25HD#M,NS1'*;P8:**EZ]B"H) U
M4=A%&?HSMV#512J=XOZ *$GB4XY'W6UMZLK"5 <#$.)B6H14\2+V=<EDA6D9
M:22)/V_P_JK-$) UY6'5E0'1+85KWGOB(B45_&12$HX$K5.D6'[5H6V4F\!3
ME0A@BT24MD">HC&=,*>"?P&X06T]B#%.]'>Q*:4%.-3%R\,T:24\A HM)I%4
M:9419258A4NQ59>A$+G%?#39/9NU=01,$,N(00.Y24*OO\5NN(C1>T^L'PY9
ME&3I6!^.J8JWFS_YP5#K14-1_@I'<+SMAA+%7AJW;+8:W>;JJ5@UJ*$);GX=
MP1AYFO.!L  /UZ?-%<D.$ 'WB;4Y3I62M84K6DOCB@"N5EBH:0(NAEH+(Z%2
MG$KGO+A\"3BFY[/.+:U"E5V94M8ZL&45>959IDDS)%.Q2&G2-92VP@18*&TB
MK'BD@1G%+H6$9E2<2%%$S%M9]NT5D* 4NDTIAA*@!PJ]FY5'DA0X5%:1<XVI
MXX,GW:C4X=G*M\J&_P#O3(2+=.U.XOKB[1>R2H=2$YCG;%(DQ+&34(:4$R+"
MMJW'2#-N9-*V8,B";:T;QM]&-\>$L5.K)A4A*N-&'Z,RFE45M02!Q&''5Q/J
MR!XYCLE:"2&U(0.$:OF&=YAF)(J:CE9DD4S [)@;"4#\9C0N%7<1..J<,<"9
M!P]#E)1J?K"D)5F5<M597K'-,=NZ(;3\5TL(:2K504;XP6_-XR>)8.NO#I]Q
M)^X99[8<*2;DSOW_ %$#?0>.V.@-L1'(")WOUB/+R'3KAFD2(A!X["^9LE!Y
M9Y* Y7&1Y^6Q0T9D$'KK8=T;]Y.F+[;=0+I/</QC0CI/3IB-3XE'F(4RZVR^
ME=P6W8:76U@G123=!!YW'>^60%MF0085UY1S:3JF\CI?&1;-1$.)241<*6"#
M:]E B0+:::][)#PK28@=:@T6EQF7KEQ$:FQHR'N*_$76VFTA=[F_$DDYF^HV
M I"U2I2G(_"5J4J+[23O.XCI?!I4PRDA*$-@W4$);2)Z_"D!6U];Z3BZE[O<
M,TB3(G4K"N&Z9-F?[,F4^BP(4J3F56DR(T5#KV9)_K%JS)5J2=K"EEQ"4.*<
M<2D?"E:E+2G_ $0I1 &U@,5^VIVE%324MK5!4I"&TJ5/]I2>4DCO.EM(P\M8
M4HK,M4[ZD@-SG$E*YK,1A,I2<AP+D*CATIR&2G+<N6Q )*>4I/*#(2;)F/[)
M!&YVCZX8U:B>8+3S;E24A1O_ &DF3J9VF\#&-\>>&S=#O/F,5+&&!H$ZJ,@-
M_6T*74J#57V0C@$:=4:#,ILJ?%0D6:CS'7VF;<3*4*NHY"DKZZC2I%*^IIL_
M[W"5M@DSS);<2M"52+J2 HVDG%%\TSR^T=0E3H'*5H!;64F!"E(4E:DP( 4I
M4 F  <,T?P@;@X\,4]G=3A!]I (#\Z([5*JD$6)%9J4F35TY<TS@0<P0<]I3
MF.<+5SFNJ9M\*'0V@Q<?NVREN)VY=P-!B)*,M$%5*E2K@*7S*6)V"U$KOIKJ
M ;8Q7-^C\W**?=<9AXHC15N+6BGM8F<5%82H\7L6'9<>540RW:S:5SG5H%Q[
M0[7TY]G*0#SLJ(CXE-ME1 $20%!-]SRC46C!I:RU:>1?;<N@ 65$ Z +*><Q
M-BI9(ZVO!*[]'ENP><0Y2*MC&B\"A[1LU2G55I;-[J2VF7!#S3O""$NKD/(3
MJJ.YG=QQ/FR0H+;IW=8A/(0>\I4 1W1I(!TQ.WEF5*(*7'^8B)4M9W,?B21W
MP1$W,Z&>8>\(&XG#<9N-+P*WB22D@KJ&))\NJRGECA%ULMNQJ>UI^['I["""
M?LV.U%W/\U<42JI6T+_ P$MH2.GPRHSU4I1/6TB^WE.61/8I>5,]H\2HJ/4I
ME+9C2R8V/3&5<-[G=S^$9B:C1-VN&:?-0DH;E(I;*WF4']X,.26GU1[Z$L%!
ML2/W21M"YF=0\GE???<3,D*<4 3W@P#K D$=V)Q1(3_BNR;BR>5L'E%S O\
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MCF!F+WMMOG.M7LR40!S'C8)%YD?L,[BW=IMCD [%'MX2"3R#V5&83_6_I2#
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M8S2);1']1[2V?$% DY<^*QR_6FQ)YK&#I?\ , VOX>6"56,+'^,B^G*0!W0
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M'R%_+'B(*5FZ6.+H5 ::7%P+WRTOEEGM HSHG6]]/,3/D!AE/D:K Z@;SMK
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MUS&MA<C9_B5W ^)[O#J"+$;BP.("IEHVYC\O#4D_*US%\6+H3RR"7/M#.]K
M>8MF.U^0ZVVC+!)DA4]P%_"\WUOK>>^1->A%@D 'K,VZ'^&^!FF2V+\*FU#H
M24'K:YN->I /IL@A:($R;0(B^H&^D;C7>+X?WIERQ"D[Z\P^D[=#Y;WM.RQD
M#;AO<<6ARYD?C?G;78Y,20D2#O>#??FF3M'72, I+)Z]-('<-3KIT^6"+D3!
MJ .=[@BUA<ZZ_>=3F-AYC!L-!<D=3M'>!O'08$(9M<@D=XTF!%_X=,>-.W5Q
M/?;-M% D"Y _=TO<Y'4Y]MCDV/778[G?I?6VD6)AUHBR;?GZ?EW3KAQ$UD9$
M)_ZJC;Y@]L^>MM20.D@&Q,WVCP%^MAY8K]BH[J]?T&WYX$Y-CJ!%AI8V3UOZ
MY9=^^PE7@+W$WCU)G6W7<#4TLN V/34Z>H]?0X:76TN$EME9!S!X3;4\S89:
M:W[YVV!4':]^@$7UF-KR=9OI&+3:BD"5@ :7'Y3<[1/2+89WXCFJ1PJ.?)5\
M\K@<SVM?:NZV1I;I<R!%Y(!^N+[50B())[S,VOO!@=-!KAL<9?3K8CHGMRM;
MEGVS(OH-JQ!&OZWQ:2M"M))Z3];6MXGPP-M"%9A)6H6Y'+U'(?B===F'0;VP
M148@F!Y#^>')EMP 7" >A4 =/(9WY ]NFUE*28L(\>^\[WZGK/?BLM:9U/30
MG?Y"/I>^-LV@M/@N<^R"?\)!LVO>X.[E8/K>XMVOKEMT,!1]FA$"?Z;@F#;_
M &C.^.-KY3[=4_$0#[+B)(N#_2D'TWGOQJLZ\NV:#;L#VUS.G4 ZY;:&>8'\
M)^DGH,=>0TG94SX3W>$]_2VV,.[W=\6%-SN'3B7%#MF2XMMAD/1XR%>R0%OR
M)4N4MMF)#C\3277S[5PNOQX\=B1(?:95=R^D>KG@PPCG<,6 *C)-DA(!*B8)
MZ0DJ/*F3C-9;E3F8%\FHIZ*EI&%U5;7UKR6*.DIT%*"\\ZH'5;B$(2D*6XM:
M4-H45#"'P_\ B-W=[_:9-DX7>:3)IJK3(J9+<M*4A3:7"T^&X[J5,*=9$AJ3
M#BNH$B.MM+K3R7=KV89=598M+56SV:E"4R(!U@WD&8,$%0,$3*5 5LTR<TM*
MSF>6YI0YWE=0\Y3)K\N<6MMNJ;2'%4M2VZAI^G?+9#B$.H3SM_&FP.-E?9P.
M'^YIUU%NHROI^=ML<2F\3,1H(\=OIZ8ULJ?)W'?XF?KN+^.$+K3!79G(Y %)
MS&9%\N_+/78% &^D7G0CTM;[C$R5N 2N_4$3WV_,^(!PY184SA!3("00,B"2
MD<A8D#GF4]#K8[,$+5I"MKQ(^>]B#K,=^*KSS,F6SJ)(-CW[F.DB]KWP[HA5
M$#_+DV_\F1>]N7M";_+GESD[)^++,&;<ZMNNP\\4U/,$_P"+]%#IN>4?./I@
M#T.: 0J0!_\ ._\ _O+X#7/7.)3;ER3/F3]^>#0\U_8\/B'UY;?/2,-+T)TD
MEQ\JSY"UKGG>XM<#7/*VT)!W)'6+?J1ZXMH?0(Y4 >)F\#2X,]=N_ 44Y%\G
M;G4D$JMI<V.NO:^F6P<HD:Z_UH@]WRC0]1(Q(JI4!=-ND1:3\O$]VV'%AI;&
MG M/4?96?0DCKJ0-/+8[QL#\NZ]N[YXJ+6E<3S"-K$?69UV.V'!$]#)LK[/_
M #AP\M <QRU!M?RVD0] _"#I8"]B!TG8> @QIB%3"E$D7'D?"TR--Q'EA3]<
ML6_? N.3GX 7';:7MQ_8-HM(CR-OL;8B%$N1*1>]T[=\B_I'AL)4\OBR#<'0
MZ#U-N^7(G2^>P%XDD 1-O&-(\IL.M^A,4_9F3M&GRWTG:VQN,)5,\9XN,I.E
MA;GYCTOEWL-HP)W \3&)4KY9^$'U!^1_EM;%BT.)'V7M+ZI!\M"GST]#;(@
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M*'$)(O)]--@?TU^C22IAU0(XK$GB '%?/*Q(/09'*ULMH^S4@G?U _._EBX
M%I%XG8V[]?I([^F%B)J$WXAPGN+@_@".YML8<Y8!'2-H\2._SDX@4P2;$F=?
M7QGNMX>.V")B3X+'' +C_"30V#8Z_P!&ZEWR'IR_/H25C^]F5@6/&R;3I_V#
M(UZ3Y1Y8XZIB/;L$$D1[+"O_ /RF.I\>I],:JNR>)) LG6YR)R/;KJ"2>IMS
MT4KYAI$Z]?X8[ AKD(U-A$ST\^L$".@O$:L^*?< WX@=VTG"L6>FG59I]$F#
M*=S;4I#T>3[%824@H5)A0W%(44H>2T62]'6M,J/E<CS4Y/F#=6&^U2)"DF8*
M5)4@Q>UEJ&Y$S$"#G*)^CJ*#-LAS5;[&79U3,-+JJ1M+E11OT=6S64M2&5J0
M'V@ZSROL=HA2VU$H4E24XQ=X,/"35O#P,15C$5:8G5BO--0Q$@ M1F8K*F%I
M6ZVF1*;#_&TJSB)+GMD._P!8ADQVTJR'$W$ SY=.&V2PW3@Q)"E$JF25\J"?
M0!(%I"B<1)9RG(<E=R+**RIS8U>8M9E6Y@_1^X-!5+3NTU+34E&I^H6 E#[R
MZA]Q25N+*$I24H&-^%)6D?9=([*-QR&9(!&ELSZ;:N4P)DSWDDV[@1IT\HQB
M$D$F4:WF/GL/*\]V!)F+95]OXBY&G,&^6=AH>HO8D>U*=-CU\A%CKT\-;8(L
MI<%A] ;V,6\)$'Q-QAVC5U:0 E5[6%K&]],[9^A.O,6V)-0 >^/ZMITO/IL,
M4W<N!YO#?NO\]?/#LC$$BP"0HWY JRN.VAMD<]!\)?>7"+%1[P)N.MHOM&EI
MQ35ES?\ 6@>?\XQZJLR%_P!PG,VN<SK;][TMVRUO8%.K-CS'P _+T]>MQ%&V
MG^L!O;;K<6\=+R=",)%RGI*N%9X0HF]LN_4ZZ#T[; #,S8_/QN/UQ+V2&Q(@
MD >'=KXR0-3,[X6L1TG1U0-].*WKERY97'6VQ8@6LS^$1M:QVMW_ #,VZ87^
M[C0.N>?%GD<],^9YY'ELN41MX1W>'@!^@.(>UWY ([AO?<=VVOEA%(BI )]H
MH999Y:W )/4?HC1B)UQ*AS3X1.XB_>8W^6F&)U"DJ)0HDC*P(*3UYV]=3R O
ML"D 73,2=?EIKTWO'CB^A0( 4  =[SKUM/R$8M$J4V!]D],B<QW!O\+_ '7V
M *6G0 QM,:[Q_$Q/?@NP94?Q>&EORMZ'OQZJI2.7'SY@G,YY_GGRO8[+M%)M
MR]QC] =-]!H!;9)I&CJ4[;:@7!( )F=IB_J%52D<TKRRSY^5B,MEVJO['3;N
M/W];VQ)[FWU3]_/Q&$+U3='[S;F1Z$Z"PSS^\Z\[; 7EQ$?POW ;_/SQ8;HV
M[0I))ZQO_&VVG3 TU-)-E%2?.X^\7MF!U\N1)=,7(Z;>O7S,C?P)5)$\H!\
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M>+C^7=U^>&*@=%1XV'C/RWOMOBE! O\ U2B>R?Q&7P\]GCNM;;T^EL,.:T+
M\_UCY^&$CC:E))#2E))(O86'.Q) '/38"VI5TH5J08'3%E*@+*<2#$W/YW],
M-+J/9DE313F<RG*V1%R-._<FU^4*T*2"2V8ZP-3]/Y],6DGF_"H$Q_5-_*\G
MTZ>=J([2S<I2.9M8=2+$]<\P.A[;.E()N #KUO\ =_+;4$75IM)\[VW]+:Q:
M1A>VPVFW"JVEK$'+70@Z?D3GM,$ >=OUT^_7$"EJO(YNO\@1N!X;6D84<(1G
M<$<SKVU^_7J+;''+%P?"^ !G8B^]L%:DQT$\7#<96.MQH=,[CRMTOM,A:=P!
M;0_EM]/+$2VG%7$D&=[7U$7C3?UPXMSH:;?9%P.J1D#U^=QT//:8.(ZCK^?C
MX_9Q553OG22-X@S(M83;ROBGJFPH6"[&Q!^T!D!;*Q"B;]_,DY[)3P']8G:!
M/S_77#-TC@U3)O\ 9DDC>T#0=,1R9,85>ZK\OM&Y^!Z#XY<[;5UN)5H9)TMX
MWWB-K[$]<95BG<$0-IF(^?6\]1TU.(\X''U'V&0!N1Q)N=<PDD7Z7VKA))E/
MD)C2?E:XUUF#C*I*6DCM#J->4D".L P3.EK# UI=:%W/:I%N2C_\*2.>MM;"
M]]"Y8)D&9W[HT,DP;6).""D+L@H\Q?RD?K\L-TA;*P05KOW4H@\[?:( OY7\
M]=D2-S'G'TN<3-A8N D"=0(^=C @:3IUPC86PVX"H!1R(_O>MS?J#LR5-\T3
M<Q,DS$]]]/J,3N)=6F 2-CJ/#0=Q^O3'53F.]@=+9 $#(B^1SOKR&0V])8\-
M[CO@'2+ $"Q$V-YUV%ABB+)-M,CKD>AS.76V9S&>62PB(28TL=;'H;FW6+FX
MO:U=+][ 'O?('4&U[DV[:;+"Z3WP >^; Z@Q,DQW:8JPL0;Z'R',=^>0.9YC
M+)84""#.A\!N._>P-SN+6\Y?W2//+YF]Q?L!GS.RPVW]4CQM\S,B>X"^YQZ.
M>8ORT&@Z9]!>]K9]-EAQO<3MH-!TOT$S$7Z8].1O\!EEE8YZ @Y=\A<\EAS8
MSZ"UK0;Z @V[["3MX;G49:CI?N0389WUY9$:;+#&3J+:CI/>03 O.NUB-,:,
M>/C$^(L&;C<;8FPDPJ5B2D87<DT:,A/M%/S36*6PAI*0%*)6'5)!0/:))XF_
MMI2=KM8RU4<&\1,OJY&7'\H2ZJ8Y4',J63>!87UOIBU[/6B[[>_9D!1C,7&Z
M'C.H9H5*6E-744G".>5-/3J+9#G([4,MH6E!"E J2+F_S([C]\F]O>7&J-<Q
M54)<G%,&73! J]*,N+4F*W,F*:=H' 'W'G'D*]FN$V2J1[-LEU4AN0TH\TXA
MR3*<N+ H?\2\'"IMQ27 IE*04O&$Q\4_'(Y>:0D)*2,>V>#.(LVXHX;SZJXG
MRG+*"NR55 ENJR[+1E;::VIJ%,5&3N,)/(^6F^5ZF5"JE+;1<><<0\%'Z$,,
MTV::32'JH]:JJIT%51 +9:$\Q6O?.%*!P\/M_:VX+"UK  [<W#0"E<A^#F5R
M F3R\Q";&Y, 7Z8QU35D%2.00)$P0>@G0#YW-K6Q/&%^[A(4$D"P!%B#V.=Q
MRU-N^0V,$HF0(B 0+_SU/F;XPSB>>2#$R+^?=]C0[X<A+:4.O:PL+7US.0_6
M5CL_.GK]^4XK%I8V^I^@PF<? ^T@V43R(L+YZ6Y6SL=?D*E#8_?F+^N)4-*-
ME"1H)!VBP,@BWE\\)S.>4>%!O:^=R!SRR/Y6\]8NT7-B"? >@$^I%O'$HIV[
M$\W@9&@OZ:SY:F,><;ZU!7$D6[>5[Y]///MH,+Z_(=?TOI@@E !$&_H/G^0\
MM<*6Y4II0X!Q6YC+/E8D$=3ESOD!D""UBP^*;6FWUC:#T\CB);+2A<P3UWZ_
MD-CN>]>BHSUI-DFR<L['H>0/2_QY7V*7#HD_ZW=WV@_(Z1(Q653TXB5">@DF
MVQB>N /2Y9S4@]3<_@KIG;*WER ]K_8O?4SY@^.OCON:&69$*%]M/Y'YX9Y$
MI\DC@^T3;-0/(?P%NF1M;*LOG-C!VM?KJ=#X]8C%YMIL?UK1T,D2?T/2\3.!
MLI4+*6V3?6V9'7(&Y!U&6>O+9D@C4?,>'D==],$LB82=--OJ!!'B--)PZ-/-
M(M?[)%K BQN?.U^5Q8]+[6$K2F-H[MQO]3M;0$#%1QM:M(/F-!IMW$V[SOA>
MB>V!:Z=?\T$Z: VROE;N;]RY=08O%MS.]_UW\=L5E4RR=^ZY(N?'ND_,[86,
M%F0075I2FW[MP+C3[7("VN=^6ECL8(-]O3%=P+;ND$D:&--M_EAV;AT]0%FT
M'KP_$'[)'3GGST&QA#1$WGH0G[-NF*RGJ@:J4(ZZ7MN#UC'CE/C6/"T;<CQ*
M'.^M].^N@L1L*FT["W4P#KY'"%0YNH?ZH_3\NN&E^*XP>)MSA&MLS:YL!G8Z
MVN;Y#(==HBC<&.Z)!]=-]SKY8MMN)7^)()ZZ:Z:6(UVUN>N&Y<^0R#=2LLOL
MF^1TUY>?PVA4HIU$[3/2VD=W?XXLHIF5B1;Q'Z3TQ2*G(.:2K/J=<\N]]?2W
M8E!2CM \=+0?R$;7&$JD0)FWAW:B8^43K.'!NK2D@9_+,Y=01J03ED3?EM)*
MQHI0$38D#[T^4:C%95&T;VZ;#?IY]?XVN5:78YDDW!^5K:YZ<N^R*E'4J.NY
M,C?7P_7#HHV^HBT?QM.OY@X1K<EOBY( .A)Y6MIRY\KZ&^S!#A%H38R";[>
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M\SRT&FI-M RFTFU^HOX[6MWSK&+"*A9_JSY3UTZ_+#.XRD*(R5W) YG+7EM
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M"8BKB]LOK"& ,P;7-N8URUV?/"!P!Q63H%95_P!8TN*O"R5*]MOLU2-2WQ(
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M'= J7[XEZ1'GJ]J'PIGV!!"D'C#@(*5=!#3P]F2D""K^FR52-"G]B$;:&;R
M1W X\^/\.\_]T<*!#B1_W&U54D@Z<8]G CDOO(-]M;:N4_?])'"FHX*KT9>5
MS#D4R<@'4F[LF LV)%CP $7-LMM$ J02(DB+3L(Z['PM8;XZ\[P55*_Q:VU#
M0\QY; ;GXM=XFYUU.)"G?E&<2>##>)!?3B8I"+W!R-ZP>'D">1!UT$H;K#<-
M_.(]!Y]<0_T)JY',Y3>;A)&]QR?=XPR5'??6 %&GX+E2+ V$VLQ(!)-]0Q'J
M-K\Q>^S*IZPW(_.('>!I://7%IO@IT#XJI@=R9/320@==;3,B-(O(W^XN92;
M[O&21?,8IXT\^0H85\=.EKVA4BI1,@1,';UVQ:'!"B3_ (1K_9;!GP':ZD3M
MAI_PDJZT>&;N^?023G&KJ',KC+A<I*+6T)]IK;*UR*ZE/29 @3O'<;>O?'I@
MCP61</+\5,;WU_?0!J)@_/!_\(UXHXOV"K17G<&="X=+FZ_9E6>=B4#3U#<R
MSM UCFUL (^"+6[[QAAP>^ (=-^C2H '_+GPM^N&F7XD:R$D1]WD@*SLJ17&
MPD<[*0W2E'T#E\K\KD2M<: ;B2>_I!(_,^&)4<)E)';/N!(%^1B\ "TJ>$2=
M"4D[Q$#$/G>(S>*>,P,,4"$#>WOB)\]8U.7!4(22=;V;UY;1E2YDP/ QJ.I_
M.=,7$\-Y7'[U>8K(_L=DT.EQV*SM_:&F$$;Q+;TF$A+M&PK(.0),"K,J/*Y]
MG6^&^1!X4  Z"QV0=7:#'B1W;G3N_AAG>&<F692<P;N;%;) GO53$QM^*3;#
MHGQ0;Q;!*L+X;XK<C54W-SD :@NWD2--I0XX1J/$D=!_G";V$>N*YX/H3)0N
MLM-R&%3IT: G[&\K&?$SO!4D%_!M$<US9DU&.-; W6M_M>]];VV<K7_:GS!P
M/]#J:)2[5"= 4-D=VR8'@!TP5?B/QLX+#!%*!SO>KR2#Z)C)42<]#EE<] *E
M[&3$=WC]W[\2IX392?\ 'U!&T-([X(),$V!F,-[_ (AMXEC[MA/#[1L<W452
M2<A?,HG10.5[Y<[$#(2MW;EWV_4BTC7Q&XQ83PQ0@2XYF*B)_P 7V"1L;@LN
M'\XWPTGQ%[U&CG0<,?\ 3IM5&5\LQ61<<AF?0C9<[AU %[Z_3FB.NY[[X=7#
M.6JD)_:'7_&-=XF#3[FY@>8OA:QXE]XX']=A3#3P&7]3]:QR=<P%U*0.5LKZ
M:9WV,%5OB ^^Z8\#8>6*Z^$Z8SR+K )D<Y95MH893ZC3?#@/$ECYQ-DX+H]\
M@")M0MV^S<D6SYC(YY#:0<_]H?D?EOOB,<*-C^L_&MT-R!O-OE![B#@;V_[>
MH^G^RX6PTQ?F^:L^!SS")\>]A:^8&IMEDX2HZK ]/Y_+"'"[2=5NF2) #28!
MVGD.]AKAE=WV[Z"L.?5.#^!/^])@U8A8Z%2JV5C,V'"0;\CLBU_G3_RAI8[C
MS\!X8/\ H^VFP#QMKVC4W$Z! &I'?T$"SA%\1F\"#PFIX'I4P"X6:?.F0N69
M ?14N$7OJ57'4@G9<BDD_$+7 ,>DS,_>D#%9S(>BG 9M*0K2->4HG:#;0QA_
M8\5SS5A*W>5-!&9$:LLR5 CF [38MQT!(%AF1>^SI4L&+;=8^A[IWU-\4'<@
M.[FTD%LI,1W*4.OUOAS1XMX@M_K"Q':QO_:8-@+ Y$V%]?/S.TJ7%@:B;" 9
MWU WGNCTC%8\.*5)"TGI\*HU,ZCNVT\#BGO%M"*2&\!U]2K#)V5 :!)_TDJ=
M-@>83EG<7OL1=4!,?PTOIJ>A]+C#CAI8OSVL3"50-?\ -$P(O-_+$=F>*6NS
M.---W</7-^%<JMA(OG:[;=)^T>?V7A?2]]@4ZM0&@%IM?RT^>F+;>1); EUQ
M1Z);)TZ'FWB;V_-,QOZQW* /]'L6Y S375H%[W/V7:6NP)%K%1(OD;G- .JO
MS"]_PC2UYG>=^G?BT,J=4/W:'(D@<S8@D?VB'9'H#'E+@C>SO%D(NS@:$W?-
M)<KZ3G>UN$4I%\A?]X7%CIL8;=/]9'>)$^(B2.FFMIFV"_8E;:$S/3D!UB\N
M'O\ *\ZPTS]X.]QW-O"V'T(%R4.S)+Q(Y@*:7&MH<['49$9;(TZ_[0\9$W.D
M'2W4>)&N#_8M44D*2J#/PI6R-NIF;G3PB,,3F]#>-$L96!:>\0<S'J;[.0M>
MR5-/J'6W$HB^IYAV"AJHCP .G?)D:23T[XQ"K(Z@$?XY)G=M"AUU0H>@B# G
M%G]..,61P_L'"0<O\I7W[=20@0D9>1N;GRV LITYE6F!R =USZVWMW'##**D
M;K.G^]JMO;XM3MZX$=_V.VTDC!%'MHFU7E$@=R6E D'.]@3;34[/V"/[:O\
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M]\E3C:'&TBFJR7$N4]/5(2@!@E;BV*JG6&DRZ2ZEOD[24!YP+XA=U^\/%\_
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M$3UP_P .C59X N3@G+,(:(()-K9N$9#R\CM9;9?7!%@2+DGQ!$WZZ>>F(%U
M1KR@F+0.\WC[,:;"21\.5%2<IKQN/\Q&7+3XVR]<MKJ*2H.KB@>@T/T.V*CF
M8-)-PGQ@#Y7O]WP[MX4FK0%F8^-/[C=LN5R.F>=M;#3:<4+I EY0F9'KXG?Y
M"<5%9O3I5R\C9(C0?I>Q^SA(]AF:T"4U%9UR6TE?S0I-N?(^>68+HW1H\3:"
M""?/X2-=_I?$S>9-KOV2?I?43(Z :';;9&FES HI6^24FP^R$WY9C/4^8'4'
M:$,OZ%9UN02.NFL:7VTUF,635,P"&TW'06,>$ZWG3UP55&<4%<2RJ_4JS OK
MF!Z\M>9V<TRR!\5QUO).H%]!WZ^0PPK438#;3S/CW_3?"3ZL>C$J;( .?#PF
MU\\Q]HD9<S<GTVB+#K9E)!B+&9.DWT\O"!.)$U*'!"A8VMKXZ_Q\=U#+T]*K
M-QEN6U4CA*<KVS44]+'*]MI6ZAX6#15 U2! O!U $Z3!P#B&#^)P)ULJYB-H
M,V[_ .;BEZI%/^PW1EG?A'RX_NUVL>\/G_>%>93\OBV'6?RQ6Y*37MD3U^+]
M,)'C,5?C84V<S<\0&GD1;/K?U.T*W7E1^[(UUM?7:UCXXF0&!HZ%"-KV\R#&
MQZ0,)VJ?+?7=2DA%QD.*YO?57"0+#6VN=[7S@2U4.*E1"1,1>#:\Q-KZ:^!L
M)5U++:82#.QL?.Y&IN>AMKJ],4Q: +L(4>H6FYMEJ2E5[W^[3:^VR4@? G34
M$7ZR2=;=.[&/<JPI1/.0=8*21Z"0+=Q\AA:&?9"P0^V0 /L_;%Q<6R)O;I?G
M?+:82GJF^NUA:+&=XOTOOB'M.<R2VJ]YL9ZR/Y;7UP-<Q]B_"^H?\Y"D'X@G
MX^AL+[(O*1_7N.LP/X=Y%ML$&&U_B;!UT(4)UWO]3XX;7Z\^D'B<"@!F0J_R
M-CR.HR[;5G,P" 9/-&X5-AXF8/<+_/%IK+VU&R(_Y('K (@^(Q'9N*FD$AQ9
M!TMGRS RZC6U_+:@YFZ1,:DZR!'J>O?<;XO-Y>A%R0!U@F=H!.IOT^F&!VLR
M9YX(T=Q256^TH<((TU44D]CIGF!GMC7J];MA/=&OT^=^L6Q=;9;;$B>\FUNX
MG7H;1.L:X-%I]078J;;020;J7G_^RA0/H;VU.6P--/+NE,2/ZUOF1X'3UMA.
M5+21!),3,1:.X'UM'2)P[)H51<'[S !S^RI5[_\ 4'YCF!EM<%#4*B"V/!1,
MWMH($[_%IOMBL:]A.R]( @?KZ:><7M_9:05A<AP%((-D @DWL!<J[].Y[.,N
M>!!4H6@0 ;]P.D=UNX;8 YBV9"4D:Q)M:(Z= "3K-\2&%AQJP!X[Z?O9\N1O
MIWT[[7V:%(B5*)L3!B/+SO>_08IO9DI.D #J#T\1WS'H8MT!B8>:<^CJ7#!7
M8^,%N4- ;C= MFU]+<-SE;IGSZ,FE0/9P6_BY?Z9!1.\G)N@GJ!]QCS<_FCB
M?[IY+\ _]Q%3/B/Z;)7.EC-B""+=<:3.X0*;Y+-B<^+SZ&_GSR&6VD&C00;V
MOK(D>?U[]<=Z3G8,7Y=)M G3IWG?K@;5*3$(2>$"]@2,K]21F#TN.1V-#(;,
M"!N9B_T]9,ZQK)JK>WO)-N[3I!_EZX=6G6V#]I/$!J4JN"!EYVUU'RVL)4 (
M.W2_?I]WQ3<0IVZ50>A$$:$'RL+';"OZRIEK%M 5:W[V8-M;::YV)V8NMQK
MMMH.\:QJ-/"<5_=*OF_&2/O;PWCRPTRIT*QL$BY-LQR[Z9B_0"^6@VC6ZT01
M;SCOZZ7OWWQ>9IZ@$<ZB=+=;>>MN_P ,1>4^V5<3(NH&X(!T-N>G<6TS[VHO
M/MH)4#<;"+CI8]1ZZ1.,NRVK19A)UF-N[6Y&VG63CUFK.-6NA8_Z)T SY=._
M>PML**] B9$$;:?+?OOX[LND2H&%).VNL].\FXUWPO3B()RXK$>A]1>X/(_E
MM/\ M%H:J%^MOTQ7.5\U^6>^1$:=_C8#UQ8YB-M0L5 WMS';4][Y;,<R9O\
M&+=+SX2,.C*U V21?N(OIT .UQ?;#0_5O;WL-=3RS[6 _6HOM67F#9T/7N\]
M_P _UO(HBV9/W\_SMAK4ZL+XFUV4;_9M>_P.N6>=M+V&M,U"^>4*!)U2!H1W
M:^<S\L6DH3RPI)@3?0[;]?*.[7#M%-07:R@D$Y9E1MY<LM;$GOM=9<JB!/(+
M3%YN.FEK:Z],4W?=DS:?2.AVD[===,/34*>X!_6D'G8#GIK?[QZVOM<2'R->
M^P!/F#/J/GBBM^G1_43:=;P!]S;QWP55$EN W=7GT&7RM_#9RPZ1=9[]+BUB
M(G;^& &8,)(A*1Z2?G.&N5AIQ:2%+7IR)%_47MKD>7:QVINT*EZK7YWMW#^$
M_E::S1%@D"\CX8!_41]B#ADDT5Z&D^[RW5*L.$*0/9CJ#GQF][ @#3:JY2.,
M@EMQ2R(.D =9,DG:(CJ1!Q=;K ] 6A(3<7,DZQ,6ZC\1!GNDH&9,Q*O9O+X5
MI.8R%SF18\P18 YWUR V@34O))250;:^DZ?Q,QMBP4-J$A B^A(!^>')+[IS
M+JNV8_+G^N6UM-0Z?]\^>PC2('TWL!B$H;FR .FL]V_GA4S"?E&RG%I03R-B
M1Z:#/7+M;:4-NNB[A"3, 6G^?GW#$+E0VT+)!/4C<7U,F>L>6D8?(]!)";.*
M^)-NO.^0] /+:VBF4!^(D :DWZ6-MOGK8XQ[N8@&X /</IUWL?"T6>(F'([O
M&EU\)( 4@E[A!N+6L5 %6A U.?(;6$TZ?ZZE'H02.NMP.GY[S1?S1Q!26VRH
M&01R$D7V@$QUG3?":;AZ&T% OJ6>C;BU=[<5PD7S-N++9ETS1'XEQO>]M--C
M)%[?G*QF3SO^]A(FQ4 "+:@&5:]P\<0J;3W8ZE*B.NH^T24O*"TWTL 1Q)ZG
M[92- ,P=L8\TIHRUS) [YT[K7[Y-M+8S3+Y<$.<JY[M)Z'QC0 7Q''J[/@K(
M>9"DBWVD*S\[&U^8!N1?3EM7%6ZC51)WZ?4>/V<3*#1B41WSIY&PG!&\>H;L
ME:7T'^]]A9%^9R'EH;^=MK"<R6G4@G;43W:?2/GB!5/3$P1ZC3TUOH/2^JYO
M'9=/"VF4L_Z*5=>I -NFG3ML?[4<Z"_4GY[#UQ'[G2S($G_1U V_%OWWTWPM
M:K\B5PE:'@DYYW.O(V%_3YZ[-[^Z221;N]+[0?+OQ+[LRD?"(-KQIX2=9BPG
MSC#O'EI< #B@,[C3Y: 'TYZG/:=#X<L5>.@M?TTZ]W=B%UHIDI%SN/+?6_3\
ML2")(C-<)"QGJ%'B3EK<&XS-]!?,>6UUMQ"8(4/";:WMW?RVQCGFG5R"DSU$
M@WO8B#^4>IZ&;>AL?.W%;+"Q6RPL5LL+%;+"Q6RPL5LL+%;+"QC??)_["S%?
M_P"1_G7J3?:MQ-_WON*O'+/^L:/ \!?_ %Q7LD_\SQ9_]#.<XT9@$E(N;Z:^
M8V\XL:>9^7+'U/J<?21__P#-2?.U_'$ECDVUY?E^9VOXQZ]?7ZD?2V+WOW?U
MU&RPD <PL/L8890!O< ^>?\ F]=J3MUJ!N)T-QBZSJ/$_3"#V;?_  :/^JG\
MMJ_(@K4"E)$:<HC;:,2J4J2.94=)/3QQZEEDJN6FR0E9!X$WOPDWTUOL*$(G
M\*;"WPCKX8;F5RZG\74],,U39:#1(:;!XR+A";VLK*]M,SM5JTIY4_"-MAT&
M)Z;\7C,]]AAGI@ >   &>0  _>/+:BS=2)O)OWZZXN*_"?O?$_I_W7MVUTVV
M*G_ GO(GOTQAW[S/]I/Y8F<$#[&0^'EMD6]_+\\8&J) ,$B_YG$J2E/LOW4\
MN0Z#9B3.IT5]5?H/08P^(Y. !78 9'06Y[.K\*?+Z'&3I22$R9M^1Q%).3B+
M<QGWSVI*_$GP_P#S1C-(T\_TP-2E<)S/Q/79\'A&[H.YS[YC\SM$O4>'ZXG3
MH/ ?3#]34IN@<*;6.5A;ERMW.UEC5(VY9C:8U\<8ZK)Y"9,QK)G??$G:;;M^
MXC1/]U/3RVMP.@]!C"K6OF/QJV_K'IXX#*0C@5]A/+^Z.GEL*@.4V'H.N)V5
M*E'Q*N;W-[G##'2GVEK"U[VL+7LG.VU5&I\/S&,HZ3R$R9Y3??4X>FDI(-P#
MF.0ZIVMH_"/O<XQBR9U.G4]^+'0. Y#GR'0["O;S_+#M$\PN?4]1B.3 +'(?
MO*&@TOIY=MJ3FBO'\\9=DFU_[/SU]=\0VH)26U7 .1U /+;!UP',;#\(V'16
M,Y2$\VO]4'SC7&/4(0JH+"D)4!PD I! /$<\QMA,9'4&;P+3XIQ.(*$"P"$@
M<.@2!I>V@VR%,E, \HF4W@3MOBD^I5[G4[GJ,2*(E).8!R.H!Z[9MH#E%A]@
M8QCI/Q7.V_6)]</K24\ R'P'0;6D@2;#[4K%-PFUSZ](C!.%/099C(:]=CQ'
M)ZGUPZL@%&8O:]KYVS&G3TVMI A5MOUQ0<)"A!B=8WLK7KC>.,I2?H]%E*E)
M/^%R@7!(-OZ)5Y7'+;=&[^SU<W_[<1K?_P "C'GYX _W2XD _P#<56;C?^F:
M;XTTD..<!_K%Z'^^KMWVU#'<FTI*Q*4G38=1B/3">I_=OJ=?M9^>0^&U9S17
MC^>,M3 =!^(#0:=,,"G%W/VUZG^\?SVJJ)@W/];?_.&+X O8:=.\8"Y]H&^?
MGGS'7:.2=23YX)!(( ,#IY8:GLM,L@<NM]=JE1;2WPD^?7QQ?;ORS>1?OMOB
MT:#R&T+5^6;ZZWZX1U/B?KBX\O+\3M,H""8$P;QW8;".6!P$V%[#/GSVHN@?
M%;I^6)V=O$_3$3FY.(MEGRR_O'IMC%$R;G^MO_F@_6^+J=8VY08[X3?!$*5_
MG'^]S/\ H_F?CLR"9U.O4]%?H/3#;>1^B_T'H,.]-)*B223QD7))ROIGM=IB
M>?4V%N[$3^A&W3;\)VQ,H6C?K_[[MLC.B?$?08PKVO\ RC_\\,2N+H/-/W#:
MZC4#;IY'&(J )-MC] ?K?#FD#A5D.?W;38I80R2;',ZCGVVC<V\_RQ98 D6'
MI_G8BT_0^0^\;4'=?,_+3TQF6-1]_P!88Q]5B4O-$$@W(N"0;7&5QRVU][\?
MD,9IK\ \OH,$B*474 J)!&8N;'+GLS)/.D28E6_3FC!+_"?+ZXF,0D)%B190
MMF<L]M@8)Y1<_B_,8Q#P$FVX^8OZ[XD\92OLBYL2+BYSR&UU!,BY_$=_\XXQ
MKH$+,"1,&!(OAX43P:_YWW#:?&+&H\1]<,TI2OM?:.2A;,Y;1KV\_P L9-@"
M18:#8=#B*3B;:G,F^??;&U/X5?\ *^HQF*8"UA]\V,8XA)N<SKU/5>V&<U5X
M?EBX;B#<=#IB.14I*@2D$\0U /+OM$DDD2?ZI_\ GL0P.68OS1.\1IB9Q&T!
M*"$(!LG,)%^?.U]I1TV@VVT.)8$FVP^JL2:,!PHR&@Y?Z(/WY[6FM^XV[KG
M$F]SH?\ Y^/IA0L #( 9]//:0Z'P.$@DDR2;=>\8O9)O:YMTOV.QMD_#<Z=>
)["6!:W7\L?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
